PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hagerty, L; Weitzel, DH; Chambers, J; Fortner, CN; Brush, MH; Loiselle, D; Hosoya, H; Haystead, TAJ				Hagerty, Laura; Weitzel, Douglas H.; Chambers, Jenica; Fortner, Christopher N.; Brush, Matthew H.; Loiselle, David; Hosoya, Hiroshi; Haystead, Timothy A. J.			ROCK1 phosphorylates and activates zipper-interacting protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT-CHAIN; RHO-ASSOCIATED KINASE; SMOOTH-MUSCLE CONTRACTION; PHOSPHATASE-ASSOCIATED KINASE; GTP-BINDING PROTEIN; CA2+ SENSITIZATION; IN-VIVO; REGULATORY SUBUNIT; GAMMA-S; CELLS	Zipper-interacting protein kinase (ZIPK) regulates Ca2+-independent phosphorylation of both smooth muscle (to regulate contraction) and non-muscle myosin (to regulate non-apoptotic cell death) through either phosphorylation and inhibition of myosin phosphatase, the myosin phosphatase inhibitor CPI17, or direct phosphorylation of myosin light chain. ZIPK is regulated by multisite phosphorylation. Phosphorylation at least three sites Thr-180, Thr-225, and Thr-265 has been shown to be essential for full activity, whereas phosphorylation at Thr-299 regulates its intracellular localization. Herein we utilized an unbiased proteomics screen of smooth muscle extracts with synthetic peptides derived from the sequence of the regulatory phosphorylation sites of the enzyme to identify the protein kinases that might regulate ZIPK activity in vivo. Discrete kinase activities toward Thr-265 and Thr-299 were defined and identified by mass spectrometry as Rho kinase 1 (ROCK1). In vitro, ROCK1 showed a high degree of substrate specificity toward native ZIPK, both stoichiometrically phosphorylating the enzyme at Thr-265 and Thr-299 as well as bringing about activation. In HeLa cells, coexpression of ZIPK with ROCK1 altered the ROCK-induced phenotype of focused stress fiber pattern to a Rho-like phenotype of parallel stress fiber pattern. This effect was also dependent upon phosphorylation at Thr-265. Our findings provide a new regulatory pathway in smooth muscle and non-muscle cells whereby ROCK1 phosphorylates and regulates ZIP kinase.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Hiroshima 7398526, Japan	Duke University; Hiroshima University	Haystead, TAJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	hayst001@mc.duke.edu			NHLBI NIH HHS [R01 HL07895] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Borman MA, 2002, J BIOL CHEM, V277, P23441, DOI 10.1074/jbc.M201597200; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Croft DR, 2005, J CELL BIOL, V168, P245, DOI 10.1083/jcb.200409049; Endo A, 2004, J BIOL CHEM, V279, P42055, DOI 10.1074/jbc.M403676200; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Fu XH, 1998, FEBS LETT, V440, P183, DOI 10.1016/S0014-5793(98)01455-0; FUJITA A, 1995, J PHARMACOL EXP THER, V274, P555; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Gong MC, 1997, J BIOL CHEM, V272, P10704; Graves PR, 2005, J BIOL CHEM, V280, P9363, DOI 10.1074/jbc.M412538200; Graves PR, 2002, MOL PHARMACOL, V62, P1364, DOI 10.1124/mol.62.6.1364; Hartshorne DJ, 2004, J BIOL CHEM, V279, P37211, DOI 10.1074/jbc.R400018200; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; Haystead TAJ, 2005, CELL SIGNAL, V17, P1313, DOI 10.1016/j.cellsig.2005.05.008; Hickson GRX, 2006, CURR BIOL, V16, P359, DOI 10.1016/j.cub.2005.12.043; Hirano M, 1999, BIOCHEM BIOPH RES CO, V254, P490, DOI 10.1006/bbrc.1998.9973; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Leung T, 1996, MOL CELL BIOL, V16, P5313; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lontay B, 2005, CELL SIGNAL, V17, P1265, DOI 10.1016/j.cellsig.2005.01.008; Lubomirov LT, 2006, CIRC RES, V98, P1159, DOI 10.1161/01.RES.0000219904.43852.3e; Miyazaki K, 2002, J BIOL CHEM, V277, P725, DOI 10.1074/jbc.M108568200; Muranyi A, 2005, FEBS LETT, V579, P6611, DOI 10.1016/j.febslet.2005.10.055; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Murata-Hori M, 2001, ONCOGENE, V20, P8175, DOI 10.1038/sj.onc.1205055; Murthy KS, 2006, ANNU REV PHYSIOL, V68, P345, DOI 10.1146/annurev.physiol.68.040504.094707; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Niiro N, 2003, BIOCHEM J, V369, P117, DOI 10.1042/BJ20021040; Niiro N, 2001, J BIOL CHEM, V276, P29567, DOI 10.1074/jbc.M102753200; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sato N, 2006, IMMUNOL LETT, V103, P127, DOI 10.1016/j.imlet.2005.10.015; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Sebbagh M, 2005, J EXP MED, V201, P465, DOI 10.1084/jem.20031877; Shani G, 2004, MOL CELL BIOL, V24, P8611, DOI 10.1128/MCB.24.19.8611-8626.2004; Shimizu Y, 2005, J CELL BIOL, V168, P941, DOI 10.1083/jcb.200411179; Shin HM, 2002, CIRC RES, V90, P546, DOI 10.1161/01.RES.0000012822.23273.EC; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Takizawa N, 2002, BIOCHEM BIOPH RES CO, V297, P773, DOI 10.1016/S0006-291X(02)02302-1; Thumkeo D, 2003, MOL CELL BIOL, V23, P5043, DOI 10.1128/MCB.23.14.5043-5055.2003; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; Ueda K, 2002, ONCOGENE, V21, P5852, DOI 10.1038/sj.onc.1205747; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Velasco G, 2002, FEBS LETT, V527, P101, DOI 10.1016/S0014-5793(02)03175-7; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wooldridge AA, 2004, J BIOL CHEM, V279, P34496, DOI 10.1074/jbc.M405957200; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056	57	67	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4884	4893		10.1074/jbc.M609990200	http://dx.doi.org/10.1074/jbc.M609990200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158456	hybrid			2022-12-27	WOS:000244482000071
J	Kaileh, M; Vanden Berghe, W; Heyerick, A; Horion, J; Piette, J; Libert, C; De Keukeleire, D; Essawi, T; Haegeman, G				Kaileh, Mary; Vanden Berghe, Wim; Heyerick, Arne; Horion, Julie; Piette, Jacques; Libert, Claude; De Keukeleire, Denis; Essawi, Tamer; Haegeman, Guy			Withaferin A strongly elicits I kappa B kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; WITHANIA-SOMNIFERA; TRANSCRIPTION FACTOR; GENE-EXPRESSION; IKK-BETA; POSITIVE REGULATION; MAPK PHOSPHATASE; ACTIVATION; APOPTOSIS; ALPHA	The transcription factor NF kappa B plays a critical role in normal and pathophysiological immune responses. Therefore, NF kappa B and the signaling pathways that regulate its activation have become a major focus of drug development programs. Withania somnifera (WS) is a medicinal plant that is widely used in Palestine for the treatment of various inflammatory disorders. In this study we show that the leave extract of WS, as well as its major constituent withaferin A (WA), potently inhibits NF kappa B activation by preventing the tumor necrosis factor-induced activation of I kappa B kinase beta via a thicialkylation-sensitive redox mechanism, whereas other WS-derived steroidal lactones, such as withanolide A and 12-deoxywithastramonolide, are far less effective. To our knowledge, this is the first communication of I kappa B kinase beta inhibition by a plant-derived inhibitor, coinciding with MEK1/ERK-dependent Ser-181 hyperphosphorylation. This prevents I kappa B phosphorylation and degradation, which subsequently blocks NF kappa B translocation, NF kappa B/DNA binding, and gene transcription. Taken together, our results indicate that pure WA or WA-enriched WS extracts can be considered as a novel class of NF kappa B inhibitors, which hold promise as novel anti-inflammatory agents for treatment of various inflammatory disorders and/or cancer.	Univ Ghent, Dept Mol Biol, LEGEST, B-9000 Ghent, Belgium; Birzeit Univ, Master Program Clin Lab Sci, Birzeit, Israel; CBIG, Virol & Immunol Unit, Inst Pathol, B-4000 Liege, Belgium; Inst Pathol, Virol & Immunol Unit, CBIG, B-4000 Liege, Belgium; Flanders Interuniv Biotechnol, Dept Mol Biomed Res, B-9052 Zwijnaarde, Belgium; Univ Ghent, Lab Pharmacognosy & Phytochem, B-9000 Ghent, Belgium	Ghent University; Birzeit University; Ghent University	Haegeman, G (corresponding author), Univ Ghent, Dept Mol Biol, LEGEST, B-9000 Ghent, Belgium.	Guy.Haegeman@UGent.be	Berghe, Wim Vanden/S-6425-2018; Libert, Claude/A-6504-2010; Heyerick, Arne/A-9633-2008; Vanden Berghe, Wim/HGE-4696-2022	Berghe, Wim Vanden/0000-0003-0161-7355; Heyerick, Arne/0000-0001-6159-8040				Adams DG, 2005, J BIOL CHEM, V280, P42644, DOI 10.1074/jbc.M502464200; Aggarwal BB, 2006, EXPERT OPIN THER TAR, V10, P87, DOI 10.1517/14728222.10.1.87; Ali-Shtayeh MS, 1998, J ETHNOPHARMACOL, V60, P265, DOI 10.1016/S0378-8741(97)00153-0; Ali-Shtayeh MS, 1999, MYCOSES, V42, P665, DOI 10.1046/j.1439-0507.1999.00499.x; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; [Anonymous], 2004, Altern Med Rev, V9, P211; Archana R, 1999, J ETHNOPHARMACOL, V64, P91, DOI 10.1016/S0378-8741(98)00107-X; ASCHER KRS, 1984, PHYTOPARASITICA, V12, P147, DOI 10.1007/BF02981166; Azaizeh H, 2003, FITOTERAPIA, V74, P98, DOI 10.1016/S0367-326X(02)00285-X; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; Bernier M, 2006, J BIOL CHEM, V281, P2551, DOI 10.1074/jbc.M511878200; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen F, 1999, CLIN CHEM, V45, P7; Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103; Codreanu SG, 2006, BIOCHEMISTRY-US, V45, P10020, DOI 10.1021/bi060551n; Davis L, 2001, J ETHNOPHARMACOL, V75, P165, DOI 10.1016/S0378-8741(00)00404-9; De Bosscher K, 2005, P NATL ACAD SCI USA, V102, P15827, DOI 10.1073/pnas.0505554102; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Essawi T, 2000, J ETHNOPHARMACOL, V70, P343, DOI 10.1016/S0378-8741(99)00187-7; Foley TD, 2004, BIOCHEM BIOPH RES CO, V315, P568, DOI 10.1016/j.bbrc.2004.01.096; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; FUSKA J, 1984, NEOPLASMA, V31, P31; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GLOTTER E, 1973, TETRAHEDRON, V29, P1353, DOI 10.1016/S0040-4020(01)83156-2; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hertlein E, 2005, MOL CELL BIOL, V25, P4956, DOI 10.1128/MCB.25.12.4956-4968.2005; Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Humphries KM, 2005, J BIOL CHEM, V280, P2750, DOI 10.1074/jbc.M410242200; Jayaprakasam B, 2003, LIFE SCI, V74, P125, DOI 10.1016/j.lfs.2003.07.007; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; KIRSON I, 1977, ISRAEL J CHEM, V16, P20; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kray AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Liang MC, 2006, BIOCHEM PHARMACOL, V71, P634, DOI 10.1016/j.bcp.2005.11.013; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Maeng YS, 2006, CELL SIGNAL, V18, P994, DOI 10.1016/j.cellsig.2005.08.007; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Mishra L C, 2000, Altern Med Rev, V5, P334; Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456-004-1026-3; Na HK, 2006, MOL CARCINOGEN, V45, P368, DOI 10.1002/mc.20225; NICHOLAS AW, 1976, BIOORG CHEM, V5, P367, DOI 10.1016/0045-2068(76)90021-3; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Pasparakis M, 2006, CELL DEATH DIFFER, V13, P861, DOI 10.1038/sj.cdd.4401870; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Peyregne VP, 2005, MOL CANCER THER, V4, P595, DOI 10.1158/1535-7163.MCT-04-0274; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Prajapati S, 2004, J BIOL CHEM, V279, P1739, DOI 10.1074/jbc.M306273200; Rahmouni S, 2006, NAT CELL BIOL, V8, P524, DOI 10.1038/ncb1398; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; Reynaert NL, 2006, P NATL ACAD SCI USA, V103, P13086, DOI 10.1073/pnas.0603290103; Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899; Sandur SK, 2006, J BIOL CHEM, V281, P17023, DOI 10.1074/jbc.M601595200; Schirmer A, 2006, P NATL ACAD SCI USA, V103, P4234, DOI 10.1073/pnas.0600445103; Seth D, 2006, BIOCHEMISTRY-US, V45, P8476, DOI 10.1021/bi060157p; Shin HM, 2006, INT IMMUNOPHARMACOL, V6, P916, DOI 10.1016/j.intimp.2006.01.006; Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200; Takada Y, 2005, BLOOD, V106, P641, DOI 10.1182/blood-2004-12-4589; Takada Y, 2006, J BIOL CHEM, V281, P5612, DOI 10.1074/jbc.M507213200; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Ueda K, 2002, FEBS LETT, V525, P48, DOI 10.1016/S0014-5793(02)03065-X; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vanden Berghe W, 1999, MOL PHARMACOL, V56, P797; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Vanden Berghe W, 2006, CANCER RES, V66, P4852, DOI 10.1158/0008-5472.CAN-05-2957; Vasudevan SA, 2005, BIOCHEM BIOPH RES CO, V330, P511, DOI 10.1016/j.bbrc.2005.03.028; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Wei HC, 2003, J NUTR, V133, p3811S, DOI 10.1093/jn/133.11.3811S; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yokota Y, 2006, BIOORG MED CHEM LETT, V16, P2603, DOI 10.1016/j.bmcl.2006.02.039; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	81	230	237	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4253	4264		10.1074/jbc.M606728200	http://dx.doi.org/10.1074/jbc.M606728200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17150968	hybrid			2022-12-27	WOS:000244482000005
J	Yamamoto, N; Sawada, H; Izumi, Y; Kume, T; Katsuki, H; Shimohama, S; Akaike, A				Yamamoto, Noriyuki; Sawada, Hideyuki; Izumi, Yasuhiko; Kume, Toshiaki; Katsuki, Hiroshi; Shimohama, Shun; Akaike, Akinori			Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress - Relevance to Parkinson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ANTIOXIDANT RESPONSE ELEMENT; NERVE GROWTH-FACTOR; NF-KAPPA-B; GENE-EXPRESSION; SUBSTANTIA-NIGRA; DOPAMINERGIC-NEURONS; NF-E2-RELATED FACTOR-2; HEME OXYGENASE-1; SUBUNIT GENE	The cause of selective dopaminergic neuronal degeneration in Parkinson disease has still not been resolved, but it has been hypothesized that oxidative stress and the ubiquitin-proteasome system are important in the pathogenesis. In this report, we investigated the effect of proteasome inhibition on oxidative stress-induced cytotoxicity in PC12 cells, an in vitro model of Parkinson disease. Treatment with proteasome inhibitors provided significant protection against toxicity by 6-hydroxydopamine and H2O2 in a concentration-dependent manner. The measurement of intracellular reactive oxygen species using 2',7'-dichlorofluorescein diacetate demonstrated that lactacystin, a proteasome inhibitor, significantly reduced 6-hydroxydopamine- and H2O2-induced reactive oxygen species production. Proteasome inhibitors elevated the amount of glutathione and phosphorylated p38 mitogen-activated protein kinase (MAPK) prior to glutathione elevation. The treatment with lactacystin induced the nuclear translocation of NF-E2-related factor 2 (Nrf2) and increased the level of mRNA for gamma-glutamylcysteine synthetase, a rate-limiting enzyme in glutathione synthesis. Furthermore, SB203580, an inhibitor of p38 MAPK, abolished glutathione elevation and cytoprotection by lacta-cystin. These data suggest that proteasome inhibition afforded cyto-protection against oxidative stress by the elevation of glutathione content, and its elevation was mediated by p38 MAPK phosphorylation.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sakyo, Kyoto 6068501, Japan; Utano Natl Hosp, Ctr Neurol Dis, Dept Neurol & Clin Res Ctr, Ukyo Ku, Kyoto 6165152, Japan; Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Akaike, A (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sakyo, 46-29 Shimoadachi Cho, Kyoto 6068501, Japan.	aakaike@pharm.kyoto-u.ac.jp		Sawada, Hideyuki/0000-0002-5909-3366; Katsuki, Hiroshi/0000-0001-7595-3154				Alam ZI, 1997, J NEUROCHEM, V69, P1326; Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; AMBANI LM, 1975, ARCH NEUROL-CHICAGO, V32, P114, DOI 10.1001/archneur.1975.00490440064010; Bush KT, 1997, J BIOL CHEM, V272, P9086; Cao C, 2003, BIOCHEMISTRY-US, V42, P10348, DOI 10.1021/bi035023f; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Dick LR, 1997, J BIOL CHEM, V272, P182; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Ding QX, 2001, FREE RADICAL BIO MED, V31, P574, DOI 10.1016/S0891-5849(01)00635-9; Dorion S, 1999, J BIOL CHEM, V274, P37591, DOI 10.1074/jbc.274.53.37591; Floor E, 1998, J NEUROCHEM, V70, P268; Galindo MF, 2003, J NEUROCHEM, V84, P1066, DOI 10.1046/j.1471-4159.2003.01592.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Huang HC, 2001, P NATL ACAD SCI USA, V98, P379; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Ibi M, 1999, J NEUROCHEM, V73, P1696, DOI 10.1046/j.1471-4159.1999.731696.x; Inden M, 2005, J PHARMACOL SCI, V97, P203, DOI 10.1254/jphs.FP0040525; Izumi Y, 2005, J NEUROSCI RES, V79, P849, DOI 10.1002/jnr.20382; Izumi Y, 2005, J NEUROSCI RES, V82, P126, DOI 10.1002/jnr.20595; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jenner P, 1998, MOVEMENT DISORD, V13, P24; JENNER P, 1993, ACTA NEUROL SCAND, V87, P6; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kitazawa M, 2001, FREE RADICAL BIO MED, V31, P1473, DOI 10.1016/S0891-5849(01)00726-2; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; LIANG YO, 1977, J MED CHEM, V20, P581, DOI 10.1021/jm00214a026; McNaught KS, 2003, ANN NEUROL, V53, pS73, DOI 10.1002/ana.10512; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; NAPPI AJ, 1994, BBA-GEN SUBJECTS, V1201, P498, DOI 10.1016/0304-4165(94)90082-5; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003; Orimo S, 1999, J NEUROL NEUROSUR PS, V67, P189, DOI 10.1136/jnnp.67.2.189; Pearce RKB, 1997, J NEURAL TRANSM, V104, P661, DOI 10.1007/BF01291884; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Phillips JB, 2000, STROKE, V31, P1686, DOI 10.1161/01.STR.31.7.1686; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; Sawada H, 2005, JAMA-J AM MED ASSOC, V293, P932, DOI 10.1001/jama.293.8.932-c; Sawada H, 2004, J BIOL CHEM, V279, P10710, DOI 10.1074/jbc.M308434200; SEEGAL RF, 1989, NEUROTOXICOLOGY, V10, P757; Sekhar KR, 2000, BIOCHEM BIOPH RES CO, V270, P311, DOI 10.1006/bbrc.2000.2419; Sekhar KR, 2002, ONCOGENE, V21, P6829, DOI 10.1038/sj.onc.1205905; SHAFER TJ, 1991, NEUROTOXICOLOGY, V12, P473; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimizu E, 2002, NEUROPHARMACOLOGY, V43, P434, DOI 10.1016/S0028-3908(02)00108-9; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; van Leyen K, 2005, J NEUROCHEM, V92, P824, DOI 10.1111/j.1471-4159.2004.02915.x; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wojcik C, 2004, STROKE, V35, P1506, DOI 10.1161/01.STR.0000126891.93919.4e; Wu WT, 2004, BIOCHEM J, V379, P587, DOI 10.1042/BJ20031579; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zipper LM, 2000, BIOCHEM BIOPH RES CO, V278, P484, DOI 10.1006/bbrc.2000.3830; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	62	121	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4364	4372		10.1074/jbc.M603712200	http://dx.doi.org/10.1074/jbc.M603712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158454	hybrid			2022-12-27	WOS:000244482000016
J	Harhaj, NS; Sun, SC; Harhaj, EW				Harhaj, Nicole S.; Sun, Shao-Cong; Harhaj, Edward W.			Activation of NF-kappa B by the human T cell leukemia virus type I tax oncoprotein is associated with ubiquitin-dependent relocalization of I kappa B kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I; IKK-GAMMA; TRANSFORMING PROTEIN; MEDIATED ACTIVATION; PERIPHERAL-BLOOD; SUMOYLATION; LYMPHOCYTES; NF-KAPPA-B2; MUTANTS; SUBUNIT	Human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell leukemia. HTLV-1 encodes a trans-activating protein, Tax, which is largely responsible for the oncogenic properties of the virus. Tax promotes T cell transformation by deregulating the activity of various cellular factors, including the transcription factor NF-kappa B. Tax activates the I kappa B kinase (IKK) via physical interaction with the regulatory subunit, IKK gamma, although it is unknown precisely how Tax activates the IKK complex. Here we show that Tax modulates the cellular localization of the IKK complex. The IKKs relocalize from a broad distribution in the cytoplasm to concentrated perinuclear "hot spots" in both HTLV-1-transformed lines and in Tax-expressing Jurkat cells. Relocalization of IKK is not observed with Tax mutants unable to activate NF-kappa B, suggesting that only activated forms of IKK are relocalized. However, relocalization of IKK is strictly dependent on Tax expression because it does not occur in ATL cell lines that lack Tax expression or in Jurkat cells treated with phorbol 12-myristate 13-acetate and ionomycin. Furthermore, IKK gamma is required for redistribution because cells lacking IKK gamma were unable to relocalize IKK alpha upon expression of Tax. We also find that Tax ubiquitination likely regulates IKK relocalization because mutation of three critical lysine residues in Tax renders it unable to relocalize IKK and activate the canonical and noncanonical NF-kappa B pathways. Finally, we have observed that the perinuclear IKK in Tax-expressing cells colocalizes with the Golgi, and disruption of Golgi with either nocodazole or brefeldin A leads to a redistribution of IKK to the cytoplasm. Together, these results demonstrate that Tax induces relocalization of the IKK complex in a ubiquitin-dependent manner, and dynamic changes in the subcellular localization of the IKK complex may be critical for Tax function.	Penn State Univ, Coll Med, Hershey Med Ctr, Dept Microbiol & Immunol, Hershey, PA 17033 USA; Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Microbiol & Immunol, Miami, FL 33136 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Miami	Sun, SC (corresponding author), Penn State Univ, Coll Med, Hershey Med Ctr, Dept Microbiol & Immunol, Hershey, PA 17033 USA.	sxs70@psu.edu; eharhaj@med.miami.edu			NCI NIH HHS [R01 CA68471, R01 CA99926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471, R01CA099926] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Alefantis T, 2005, J BIOL CHEM, V280, P17353, DOI 10.1074/jbc.M409851200; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Beraud C, 1996, J ACQ IMMUN DEF SYND, V13, pS76, DOI 10.1097/00042560-199600001-00014; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Grant C, 2002, J CELL PHYSIOL, V190, P133, DOI 10.1002/JCP.10053; Hall WW, 2005, ONCOGENE, V24, P5965, DOI 10.1038/sj.onc.1208975; Harhaj EW, 2005, IUBMB LIFE, V57, P83, DOI 10.1080/15216540500078715; Harhaj EW, 2005, VIROLOGY, V333, P145, DOI 10.1016/j.virol.2004.12.008; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; He HT, 2005, SEMIN IMMUNOL, V17, P23, DOI 10.1016/j.smim.2004.09.001; Hemelaar J, 2001, J VIROL, V75, P11106, DOI 10.1128/JVI.75.22.11106-11115.2001; Huang GJ, 2002, FEBS LETT, V531, P494, DOI 10.1016/S0014-5793(02)03590-1; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M., 1999, SCI SIGNAL TRANSDUCT, V5, P1; Lamsoul I, 2005, MOL CELL BIOL, V25, P10391, DOI 10.1128/MCB.25.23.10391-10406.2005; Miura H, 2005, EXP CELL RES, V308, P29, DOI 10.1016/j.yexcr.2005.04.005; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Mor A, 2006, ANNU REV IMMUNOL, V24, P771, DOI 10.1146/annurev.immunol.24.021605.090723; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182/blood-2005-09-3572; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nejmeddine M, 2005, J BIOL CHEM, V280, P29653, DOI 10.1074/jbc.M502639200; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Rios RM, 2003, CURR OPIN CELL BIOL, V15, P60, DOI 10.1016/S0955-0674(02)00013-3; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Schwamborn K, 2000, J BIOL CHEM, V275, P22780, DOI 10.1074/jbc.M001500200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	44	60	60	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4185	4192		10.1074/jbc.M611031200	http://dx.doi.org/10.1074/jbc.M611031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17145747	hybrid			2022-12-27	WOS:000244481900081
J	Nakamura, Y; Umehara, T; Nakano, K; Jang, MK; Shirouzu, M; Morita, S; Uda-Tochio, H; Hamana, H; Terada, T; Adachi, N; Matsumoto, T; Tanaka, A; Horikoshi, M; Ozato, K; Padmanabhan, B; Yokoyama, S				Nakamura, Yoshihiro; Umehara, Takashi; Nakano, Kazumi; Jang, Moon Kyoo; Shirouzu, Mikako; Morita, Satoshi; Uda-Tochio, Hiroko; Hamana, Hiroaki; Terada, Takaho; Adachi, Naruhiko; Matsumoto, Takehisa; Tanaka, Akiko; Horikoshi, Masami; Ozato, Keiko; Padmanabhan, Balasundaram; Yokoyama, Shigeyuki			Crystal structure of the human BRD2 bromodomain - Insights into dimerization and recognition of acetylated histone H4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CHROMOSOMES; MYELOID-LEUKEMIA; RING3 GENE; CHROMATIN; PROTEIN; DROSOPHILA; MITOSIS; CBP; DNA; ACETYLTRANSFERASES	The BET (bromodomains and extra terminal domain) family proteins recognize acetylated chromatin through their bromodomain and act as transcriptional activators. One of the BET proteins, BRD2, associates with the transcription factor E2F, the mediator components CDK8 and TRAP220, and RNA polymerase II, as well as with acetylated chromatin during mitosis. BRD2 contains two bromodomains (BD1 and BD2), which are considered to be responsible for binding to acetylated chromatin. The BRD2 protein specifically recognizes the histone H4 tail acetylated at Lys(12). Here, we report the crystal structure of the N-terminal bromodomain (BD1, residues 74-194) of human BRD2. Strikingly, the BRD2 BD1 protein forms an intact dimer in the crystal. This is the first observation of a homodimer among the known bromodomain structures, through the buried hydrophobic core region at the interface. Biochemical studies also demonstrated BRD2 BD1 dimer formation in solution. The two acetyllysine-binding pockets and a negatively charged secondary binding pocket, produced at the dimer interface in BRD2 BD I, may be the unique features that allow BRD2 BD1 to selectively bind to the acetylated H4 tail.	RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Japan Sci & Technol Corp, Horikoshi Gene Selector Project Exploratory Res A, Tsukuba, Ibaraki 3002635, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Lab Dev Biol, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	RIKEN; Japan Science & Technology Agency (JST); University of Tokyo; University of Tokyo; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Padmanabhan, B (corresponding author), RIKEN, Genom Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	paddy@gsc.riken.jp; yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016; Umehara, Takashi/N-5683-2015; Umehara, Takashi/AHB-1730-2022	Yokoyama, Shigeyuki/0000-0003-3133-7338; Umehara, Takashi/0000-0003-3464-2960; Umehara, Takashi/0000-0003-3464-2960; Jang, Moon Kyoo/0000-0002-1657-2877	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008815] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008815] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beck S, 1992, DNA Seq, V2, P203, DOI 10.3109/10425179209020804; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coleman RA, 1999, MOL CELL, V4, P451, DOI 10.1016/S1097-2765(00)80453-0; Denis GV, 1996, GENE DEV, V10, P261, DOI 10.1101/gad.10.3.261; Dey A, 2000, MOL CELL BIOL, V20, P6537, DOI 10.1128/MCB.20.17.6537-6549.2000; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Hudson BP, 2000, J MOL BIOL, V304, P355, DOI 10.1006/jmbi.2000.4207; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jones DT, 1996, CURR OPIN STRUC BIOL, V6, P210, DOI 10.1016/S0959-440X(96)80076-5; Jones MH, 1997, GENOMICS, V45, P529, DOI 10.1006/geno.1997.5000; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanno T, 2004, MOL CELL, V13, P33, DOI 10.1016/S1097-2765(03)00482-9; Kigawa T, 1999, FEBS LETT, V442, P15, DOI 10.1016/S0014-5793(98)01620-2; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Liedman D, 2001, CURR OPIN HEMATOL, V8, P218, DOI 10.1097/00062752-200107000-00007; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Mujtaba S, 2004, MOL CELL, V13, P251, DOI 10.1016/S1097-2765(03)00528-8; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Ohshima T, 2001, BIOCHEM BIOPH RES CO, V281, P569, DOI 10.1006/bbrc.2001.4389; OKAMOTO N, 1991, HUM IMMUNOL, V32, P221, DOI 10.1016/0198-8859(91)90059-I; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thorpe KL, 1997, GENE, V200, P177, DOI 10.1016/S0378-1119(97)00415-0; Thorpe KL, 1996, IMMUNOGENETICS, V44, P391, DOI 10.1007/s002510050142; You J, 2004, CELL, V117, P349, DOI 10.1016/S0092-8674(04)00402-7; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	48	85	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4193	4201		10.1074/jbc.M605971200	http://dx.doi.org/10.1074/jbc.M605971200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148447	hybrid			2022-12-27	WOS:000244481900082
J	Oguariri, RM; Brann, TW; Imamichi, T				Oguariri, Raphael M.; Brann, Terrence W.; Imamichi, Tomozumi			Hydroxyurea and interleukin-6 synergistically reactivate HIV-1 replication in a latently infected promonocytic cell line via SP1/SP3 transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; NF-KAPPA-B; TUMOR NECROSIS FACTOR; LONG TERMINAL REPEAT; CD4(+) T-CELLS; IN-VIVO; HIV-1-INFECTED PATIENTS; PROMOTER ACTIVITY; ACTINOMYCIN-D	The existence of viral latency limits the success of highly active antiretroviral therapy. With the therapeutic intention of reactivating latent virus to induce a cure, in this study we assessed the impact of cell synchronizers on HIV gene activation in latently infected U1 cells and investigated the molecular mechanisms responsible for such effect. Latently infected U1 cells were treated with 10 drugs including hydroxyurea (HU) and HIV-1 replication monitored using a p24 antigen capture assay. We found that HU was able to induce HIV-1 replication by 5-fold. HU has been used in the clinical treatment of HIV-1-infected patients in combination with didanosine; therefore, we investigated the impact of HU on HIV-1 activation in the presence of the proinflammatory cytokines, interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha). IL-6 or TNF-alpha alone induced HIV replication by 18- and similar to 500-fold, respectively. Of interest, in the presence of HU, IL-6-mediated HIV-1 activation was enhanced by > 90-fold, whereas TNF-alpha-mediated activation was inhibited by > 30%. A reporter gene assay showed that HU and IL-6 synergized to activate HIV promoter activity via the Sp1 binding site. Electrophoretic mobility shift and supershift assays revealed increased binding of the Sp1 and Sp3 transcription factors to this region. Western blot analysis showed that HU and IL-6 co-stimulation resulted in increased levels of Sp1 and Sp3 proteins. In contrast, treatment with HU plus TNF-alpha down-regulated the expression of NF-kappa B. These findings suggest that Sp1/Sp3 is involved in controlling the HU/IL-6-induced reactivation of HIV-1 in latently infected cells.	SAIC Frederick Inc, Clin Serv Program, Lab Human Retrovirol, NCI Frederick,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Imamichi, T (corresponding author), SAIC Frederick Inc, Clin Serv Program, Lab Human Retrovirol, NCI Frederick,NIH, POB B,Bldg 550,Rm 126, Frederick, MD 21702 USA.	timamichi@mail.nih.gov		Imamichi, Tomozumi/0000-0002-1474-1796	NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; ANTONI BA, 1994, VIROLOGY, V202, P684, DOI 10.1006/viro.1994.1390; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; Barreiro P, 2003, HIV CLIN TRIALS, V4, P361, DOI 10.1310/4GMU-AG3T-Q3CC-GE5D; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; CANNON P, 1994, J VIROL, V68, P1993, DOI 10.1128/JVI.68.3.1993-1997.1994; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cohen J, 1998, SCIENCE, V279, P1854, DOI 10.1126/science.279.5358.1854; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Emiliani S, 1996, P NATL ACAD SCI USA, V93, P6377, DOI 10.1073/pnas.93.13.6377; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Foli A, 1997, Antivir Ther, V2, P31; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOLKS TM, 1988, J IMMUNOL, V140, P1117; Frank I, 1999, J BIOL REG HOMEOS AG, V13, P186; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; GAO WY, 1994, MOL PHARMACOL, V46, P767; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAREL J, 1981, VIROLOGY, V110, P202, DOI 10.1016/0042-6822(81)90022-2; Havlir DV, 2001, AIDS, V15, P1379, DOI 10.1097/00002030-200107270-00007; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; Imamichi T, 2005, JAIDS-J ACQ IMM DEF, V40, P388, DOI 10.1097/01.qai.0000179466.25700.2f; Imamichi T, 2003, J VIROL, V77, P1011, DOI 10.1128/JVI.77.2.1011-1020.2003; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; Johns DG, 1998, BIOCHEM PHARMACOL, V55, P1551, DOI 10.1016/S0006-2952(97)00664-3; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Loeffler S, 2005, INT J CANCER, V115, P202, DOI 10.1002/ijc.20871; Lori F, 2000, J BIOL REG HOMEOS AG, V14, P45; Lori F, 1998, ANTIVIR THER, V3, P81; Lori F, 1997, AIDS RES HUM RETROV, V13, P1403, DOI 10.1089/aid.1997.13.1403; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; Lori Franco, 2004, Expert Opin Drug Saf, V3, P279, DOI 10.1517/14740338.3.4.279; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALLEY SD, 1994, LANCET, V343, P1292, DOI 10.1016/S0140-6736(94)92182-2; Marcello A, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-7; MCCUNE JM, 1995, CELL, V82, P183, DOI 10.1016/0092-8674(95)90305-4; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; Quivy V, 2002, J VIROL, V76, P11091, DOI 10.1128/JVI.76.21.11091-11103.2002; Romanelli F, 2006, CURR PHARM DESIGN, V12, P1121, DOI 10.2174/138161206776055868; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; Rutschmann OT, 1998, ANTIVIR THER, V3, P65; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; Siliciano Robert F, 2005, Top HIV Med, V13, P96; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200	62	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3594	3604		10.1074/jbc.M608150200	http://dx.doi.org/10.1074/jbc.M608150200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150965	hybrid			2022-12-27	WOS:000244481900021
J	Kondoh, K; Sunadome, K; Nishida, E				Kondoh, Kunio; Sunadome, Kazunori; Nishida, Eisuke			Notch signaling suppresses p38 MAPK activity via induction of MKP-1 in myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; SATELLITE CELL; RBP-J; PATHWAY; PHOSPHATASES; MYOD; TRANSCRIPTION; PHOSPHORYLATION	Cross-talks among intracellular signaling pathways are important for the regulation of cell fate decisions and cellular responses to extracellular signals. Both the Notch pathway and the MAPK pathways play important roles in many biological processes, and the Notch pathway has been shown to interact with the ERK-type MAPK pathway. However, its interaction with the other MAPK pathways is unknown. Here we show that Notch signaling activation in C2C12 cells suppresses the activity of p38 MAPK to inhibit myogenesis. Our results show that Notch specifically induces expression of MKP-1, a member of the dual-specificity MAPK phosphatase, which directly inactivates p38 to negatively regulate C2C12 myogenesis. The Notch-induced expression of MKP-1 is shown to depend on RBP-J. Moreover, inhibition of MKP-1 expression by short interfering RNA suppresses p38 inactivation and partially rescues the negative regulation of myogenesis. These results reveal a novel cross-talk between the Notch pathway and the p38 MAPK pathway that is mediated by Notch induction of MKP-1.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp		Kondoh, Kunio/0000-0002-1139-328X				Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHARLES CH, 1992, ONCOGENE, V7, P187; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dinev D, 2001, EMBO REP, V2, P829, DOI 10.1093/embo-reports/kve177; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jones NC, 2005, J CELL BIOL, V169, P105, DOI 10.1083/jcb.200408066; Kato H, 1997, DEVELOPMENT, V124, P4133; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; Nakagawa S, 1998, DEVELOPMENT, V125, P2963; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Penn BH, 2004, GENE DEV, V18, P2348, DOI 10.1101/gad.1234304; Shawber C, 1996, DEVELOPMENT, V122, P3765; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	37	66	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3058	3065		10.1074/jbc.M607630200	http://dx.doi.org/10.1074/jbc.M607630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17158101	hybrid			2022-12-27	WOS:000243793900032
J	Luthra, R; Kerr, SC; Harreman, MT; Apponi, LH; Fasken, MB; Ramineni, S; Chaurasia, S; Valentini, SR; Corbett, AH				Luthra, Roopa; Kerr, Shana C.; Harreman, Michelle T.; Apponi, Luciano H.; Fasken, Milo B.; Ramineni, Suneela; Chaurasia, Shyam; Valentini, Sandro R.; Corbett, Anita H.			Actively transcribed GAL genes can be physically linked to the nuclear pore by the SAGA chromatin modifying complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; IN-VIVO; CHROMOSOME TERRITORIES; NUCLEOSOME ACETYLATION; YEAST; RECRUITMENT; ORGANIZATION; COACTIVATOR; COMPONENTS; EXPRESSION	Recent work has demonstrated that some actively transcribed genes closely associate with nuclear pore complexes (NPC) at the nuclear periphery. The Saccharomyces cerevisiae Mlp1 and Mlp2 proteins are components of the inner nuclear basket of the nuclear pore that mediate interactions with these active genes. To investigate the physical link between the NPC and active loci, we identified proteins that interact with the carboxyl-terminal globular domain of Mlp1 by tandem affinity purification coupled with mass spectrometry. This analysis led to the identification of several components of the Spt-Ada-Gcn5-acetyltransferase ( SAGA) histone acetyltransferase complex, Gcn5, Ada2, and Spt7. We utilized co-immunoprecipitation and in vitro binding assays to confirm the interaction between the Mlp proteins and SAGA components. Chromatin immunoprecipitation experiments revealed that Mlp1 and SAGA components associate with the same region of the GAL promoters. Critically, this Mlp-promoter interaction depends on the integrity of the SAGA complex. These results identify a physical association between SAGA and the NPC, and support previous results that relied upon visualization of GAL loci at the nuclear periphery by microscopy ( Cabal, G. G. Genovesio, A., Rodriguez-Navarro, S., Zimmer, C., Gadal, O., Lesne, A., Buc, H., Feuerbach- Fournier, F., Olivo-Marin, J.-C., Hurt, E. C., and Nehrbass, U. ( 2006) Nature 441, 770-773). We propose that a physical interaction between nuclear pore components and the SAGA complex can link the actively transcribed GAL genes to the nuclear pore.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA; Univ Estadual Paulista, Sao Paulo State Univ, Sch Pharmaceut Sci, Dept Biol Sci, BR-14801902 Sao Paulo, Brazil	Emory University; Emory University; Emory University; Universidade Estadual Paulista	Corbett, AH (corresponding author), 1510 Clifton Rd NE, Atlanta, GA 30322 USA.	acorbe2@emory.edu	Corbett, Anita/AAH-6106-2021; Chaurasia, Shyam/AAB-4709-2019; Fasken, Milo/K-2177-2019; Valentini, Sandro R/C-4353-2012; Apponi, Luciano H/A-4081-2013	Corbett, Anita/0000-0002-0461-6895; Chaurasia, Shyam/0000-0001-8725-676X; Fasken, Milo/0000-0003-4317-7909; Valentini, Sandro Roberto/0000-0003-4453-5413	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058728] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058728] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; Baxter J, 2002, CURR OPIN CELL BIOL, V14, P372, DOI 10.1016/S0955-0674(02)00339-3; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brickner JH, 2004, PLOS BIOL, V2, P1843, DOI 10.1371/journal.pbio.0020342; Bryant GO, 2003, MOL CELL, V11, P1301, DOI 10.1016/S1097-2765(03)00144-8; Cabal GG, 2006, NATURE, V441, P770, DOI 10.1038/nature04752; Casolari JM, 2005, GENE DEV, V19, P1188, DOI 10.1101/gad.1307205; Casolari JM, 2004, CELL, V117, P427, DOI 10.1016/S0092-8674(04)00448-9; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Cremer T, 2006, CURR OPIN CELL BIOL, V18, P307, DOI 10.1016/j.ceb.2006.04.007; Dieppois G, 2006, MOL CELL BIOL, V26, P7858, DOI 10.1128/MCB.00870-06; Drubin DA, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-19; Galy V, 2004, CELL, V116, P63, DOI 10.1016/S0092-8674(03)01026-2; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Green DM, 2003, P NATL ACAD SCI USA, V100, P1010, DOI 10.1073/pnas.0336594100; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Larschan E, 2005, MOL CELL BIOL, V25, P114, DOI 10.1128/MCB.25.1.114-123.2005; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lei EP, 2003, MOL BIOL CELL, V14, P836, DOI 10.1091/mbc.E02-08-0520; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Menon BB, 2005, P NATL ACAD SCI USA, V102, P5749, DOI 10.1073/pnas.0501768102; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmid M, 2006, MOL CELL, V21, P379, DOI 10.1016/j.molcel.2005.12.012; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; Sterner DE, 2002, J BIOL CHEM, V277, P8178, DOI 10.1074/jbc.M108601200; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Strambio-de-Castillia C, 1999, J CELL BIOL, V144, P839, DOI 10.1083/jcb.144.5.839; Taddei A, 2006, NATURE, V441, P774, DOI 10.1038/nature04845; Vinciguerra P, 2005, EMBO J, V24, P813, DOI 10.1038/sj.emboj.7600527; Williams RRE, 2003, TRENDS GENET, V19, P298, DOI 10.1016/S0168-9525(03)00109-4; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wu PYJ, 2004, MOL CELL, V15, P199, DOI 10.1016/j.molcel.2004.06.005; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002	49	102	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3042	3049		10.1074/jbc.M608741200	http://dx.doi.org/10.1074/jbc.M608741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17158105	hybrid			2022-12-27	WOS:000243793900030
J	Orth, JHC; Aktories, K; Kubatzky, KF				Orth, Joachim H. C.; Aktories, Klaus; Kubatzky, Katharina F.			Modulation of host cell gene expression through activation of STAT transcription factors by Pasteurella multocida toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICOBACTER-PYLORI; ALPHA-INTERFERON; CYCLE PROGRESSION; BACTERIAL TOXINS; GAMMA-INTERFERON; JAK/STAT PATHWAY; TYROSINE KINASE; GROWTH; RECEPTOR; G-ALPHA(Q)	The Pasteurella multocida toxin (PMT) is highly mitogenic and has potential carcinogenic properties. PMT causes porcine atrophic rhinitis that is characterized by bone resorption and loss of nasal turbinates, but experimental nasal infection also leads to excess proliferation of bladder epithelial cells. PMT acts intracellularly and activates phospholipase C-linked signals and MAPK pathways via the heterotrimeric G alpha(q) and G alpha(12/13) proteins. We found that PMT induces activation of STAT proteins, and we identified STAT1, STAT3, and STAT5 as new targets of PMT-induced G alpha q signaling. Inhibition of Janus kinases completely abolished STAT activation. PMT-dependent STAT phosphorylation remained constitutive for at least 18 h. PMT caused down-regulation of the expression of the suppressor of cytokine signaling-3, indicating a novel mechanism to maintain activation of STATs. Moreover, stimulation of Swiss 3T3 cells with PMT increased transcription of the cancer-associated STAT-dependent gene cyclooxygenase-2. Because constitutive activation of STATs has been found in a number of cancers, our findings offer a new mechanism for a carcinogenic role of PMT.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Kubatzky, KF (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Albertstr 25, D-79104 Freiburg, Germany.	kubatzky@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Kubatzky, Katharina F./0000-0003-3739-9329				Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Busch C, 2001, INFECT IMMUN, V69, P3628, DOI 10.1128/IAI.69.6.3628-3634.2001; Court M, 2002, J INFECT DIS, V186, P1348, DOI 10.1086/344321; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dudet LI, 1996, J CELL PHYSIOL, V168, P173; Dumoutier L, 2004, J BIOL CHEM, V279, P32269, DOI 10.1074/jbc.M404789200; FERRAND A, 1995, J BIOL CHEM, V280, P10710; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Gilsbach R, 2006, BIOTECHNIQUES, V40, P173, DOI 10.2144/000112052; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; Juttner S, 2003, CELL MICROBIOL, V5, P821, DOI 10.1046/j.1462-5822.2003.00324.x; KIMMAN TG, 1987, INFECT IMMUN, V55, P2110, DOI 10.1128/IAI.55.9.2110-2116.1987; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; Lax AJ, 2005, NAT REV MICROBIOL, V3, P343, DOI 10.1038/nrmicro1130; Lax AJ, 2004, INT J MED MICROBIOL, V293, P505, DOI 10.1078/1438-4221-00287; Lax AJ, 2002, TRENDS MICROBIOL, V10, P293, DOI 10.1016/S0966-842X(02)02360-0; Lax AJ, 2001, INT J MED MICROBIOL, V291, P261, DOI 10.1078/1438-4221-00129; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Nardone G, 2004, ALIMENT PHARM THER, V20, P261, DOI 10.1111/j.1365-2036.2004.02075.x; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Offermanns S, 1998, ONCOGENE, V17, P1375, DOI 10.1038/sj.onc.1202173; Orth JHC, 2005, J BIOL CHEM, V280, P36701, DOI 10.1074/jbc.M507203200; Orth JHC, 2004, J BIOL CHEM, V279, P34150, DOI 10.1074/jbc.M405353200; Oswald E, 2005, CURR OPIN MICROBIOL, V8, P83, DOI 10.1016/j.mib.2004.12.011; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; Sabri A, 2002, CIRC RES, V90, P850, DOI 10.1161/01.RES.0000016165.23795.1F; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Stross C, 2006, J BIOL CHEM, V281, P8458, DOI 10.1074/jbc.M511212200; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Thompson JE, 2002, BIOORG MED CHEM LETT, V12, P1219, DOI 10.1016/S0960-894X(02)00106-3; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Ward PN, 1998, INFECT IMMUN, V66, P5636, DOI 10.1128/IAI.66.12.5636-5642.1998; Wilson BA, 2000, INFECT IMMUN, V68, P4531, DOI 10.1128/IAI.68.8.4531-4538.2000; Wilson BA, 1999, INFECT IMMUN, V67, P80, DOI 10.1128/IAI.67.1.80-87.1999; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zywietz A, 2001, J BIOL CHEM, V276, P3840, DOI 10.1074/jbc.M007819200	49	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3050	3057		10.1074/jbc.M609018200	http://dx.doi.org/10.1074/jbc.M609018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17150962	hybrid			2022-12-27	WOS:000243793900031
J	Birkenkamp, KU; Essafi, A; van der Vos, KE; da Costa, M; Hui, RCY; Holstege, F; Koenderman, L; Lam, EWF; Coffer, PJ				Birkenkamp, Kim U.; Essafi, Abdelkader; van der Vos, Kristan E.; da Costa, Marco; Hui, Rosaline C. -Y; Holstege, Frank; Koenderman, Leo; Lam, Eric W. -F.; Coffer, Paul J.			FOXO3a induces differentiation of Bcr-Abl- transformed cells through transcriptional down-regulation of Id1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM-CELLS; ERYTHROID-DIFFERENTIATION; EXPRESSION; KINASE; PROTEINS; MECHANISMS; SURVIVAL; GROWTH; IDENTIFICATION	Leukemic transformation often requires activation of protein kinase B (PKB/c-Akt) and is characterized by increased proliferation, decreased apoptosis, and a differentiation block. PKB phosphorylates and inactivates members of the FOXO subfamily of Forkhead transcription factors. It has been suggested that hyperactivation of PKB maintains the leukemic phenotype through actively repressing FOXO-mediated regulation of specific genes. We have found expression of the transcriptional repressor Id1 (inhibitor of DNA binding 1) to be abrogated by FOXO3a activation. Inhibition of PKB activation or growth factor deprivation also resulted in strong down-regulation of Id1 promoter activity, Id1 mRNA, and protein expression. Id1 is highly expressed in Bcr-Abl-transformed K562 cells, correlating with high PKB activation and FOXO3a phosphorylation. Inhibition of Bcr-Abl by the chemical inhibitor STI571 resulted in activation of FOXO3a and down-regulation of Id1 expression. By performing chromatin immunoprecipitation assays and promoter-mutation analysis, we demonstrate that FOXO3a acts as a transcriptional repressor by directly binding to the Id1 promoter. STI571 treatment, or expression of constitutively active FOXO3a, resulted in erythroid differentiation of K562 cells, which was inhibited by ectopic expression of Id1. Taken together our data strongly suggest that high expression of Id1, through PKB-mediated inhibition of FOXO3a, is critical for maintenance of the leukemic phenotype.	Univ Utrecht, Med Ctr, Mol Immunol Lab, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Med Genet, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands; Hammersmith Hosp, Canc Res UK Labs, London W12 0NN, England; Hammersmith Hosp, Sect Canc Cell Biol, Dept Canc Med, Imperial Coll,Sch Med, London W12 0NN, England	Utrecht University; Utrecht University; Utrecht University; Cancer Research UK; Imperial College London; Imperial College London	Coffer, PJ (corresponding author), Univ Utrecht, Med Ctr, Mol Immunol Lab, Dept Immunol, KC 02-085-2,Lundiaan 6, NL-3584 CX Utrecht, Netherlands.	P.J.Coffer@umcutrecht.nl	Lam, Eric W-F/AAW-8566-2020; Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009; Essafi, Abdelkader/A-6602-2009; Hui, Rosaline/E-7287-2010; Holstege, Frank/AAM-9944-2021; Koenderman, Leo/AAE-7870-2020	Lam, Eric W-F/0000-0003-1274-3576; Koenderman, Leo/0000-0002-5636-6453; Coombes, Raoul Charles/0000-0002-4811-1100	Engineering and Physical Sciences Research Council [GR/S45713/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; Barreda DR, 2004, DEV COMP IMMUNOL, V28, P509, DOI 10.1016/j.dci.2003.09.010; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; BLOOMFIELD CD, 1987, SEMIN ONCOL, V14, P372; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buitenhuis M, 2005, BLOOD, V105, P4272, DOI 10.1182/blood-2004-12-4883; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; EAVES CJ, 1992, BLOOD CELLS, V18, P301; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; HUMPHRIES RK, 1981, P NATL ACAD SCI-BIOL, V78, P3629, DOI 10.1073/pnas.78.6.3629; KAIHO SI, 1985, ANAL BIOCHEM, V149, P117, DOI 10.1016/0003-2697(85)90483-X; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kawauchi K, 2003, BLOOD CELL MOL DIS, V31, P11, DOI 10.1016/S1079-9796(03)00070-6; Kharas MG, 2004, BLOOD, V103, P4268, DOI 10.1182/blood-2003-07-2193; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; Kim D, 1999, MOL CELL BIOL, V19, P8240; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Kops GJPL, 2000, J ANAT, V197, P571, DOI 10.1046/j.1469-7580.2000.19740571.x; Kreuzer KA, 1999, CLIN CHEM, V45, P297; Kruse JJCM, 2004, RADIAT RES, V161, P28, DOI 10.1667/RR3097; Kuzelova K, 2005, J CELL BIOCHEM, V95, P268, DOI 10.1002/jcb.20407; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Nigten J, 2005, LEUKEMIA, V19, P799, DOI 10.1038/sj.leu.2403699; Norton JD, 2000, J CELL SCI, V113, P3897; OGAWA M, 1983, BLOOD, V61, P823; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Oudijk EJD, 2005, THORAX, V60, P538, DOI 10.1136/thx.2004.034009; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Ren RB, 2002, ONCOGENE, V21, P8629, DOI 10.1038/sj.onc.1206090; Salesse S, 2002, ONCOGENE, V21, P8605, DOI 10.1038/sj.onc.1206088; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shapiro L H, 1995, Curr Opin Hematol, V2, P3; Shi C, 2004, J CLIN INVEST, V114, P408, DOI 10.1172/jci200421100; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; Tauchi T, 2004, LEUKEMIA RES, V28, pS39, DOI 10.1016/j.leukres.2003.10.007; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310	56	68	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2211	2220		10.1074/jbc.M606669200	http://dx.doi.org/10.1074/jbc.M606669200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17132628	hybrid			2022-12-27	WOS:000243593200012
J	Krzewska, J; Tanaka, M; Burston, SG; Melki, R				Krzewska, Joanna; Tanaka, Motomasa; Burston, Steven G.; Melki, Ronald			Biochemical and functional analysis of the assembly of full-length Sup35p and its prion-forming domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; CHAIN RELEASE FACTOR; TRANSLATION TERMINATION; IN-VITRO; FACTORS ERF1; PROTEIN; DETERMINANT; PROPAGATION; PSI+; GTP	The protein Sup35 has prion properties. Its aggregation is at the origin of the [PSI+] trait in Saccharomyces cerevisiae. In vitro, the N-terminal domain of Sup35p alone or with the middle domain assembles into fibrils that exhibit the characteristics of amyloids. The vast majority of in vitro studies on the assembly of Sup35p have been performed using Sup35pNM, as fibrils made of Sup35pNM assembled in vitro propagate [PSI+] when reintroduced into yeast cells. Little is known about the assembly of full-length Sup35p and the role of the functional C-terminal domain of the protein. Here we report a systematic comparison of the biochemical and assembly properties of full-length Sup35p and Sup35pNM. We show that the native structure of the C-terminal domain is retained within the fibrils. We determined the size of Sup35p nuclei and the critical concentration for assembly that both differ from that of Sup35pNM. We demonstrate that Sup35pNM co-assembles with the full-length protein and that fibrils made of Sup35p or Sup35pNM seed the assembly of soluble Sup35pNM and Sup35p with different efficiencies. Finally, we show that fibrils made of full-length Sup35p induce with higher efficiency [PSI+] appearance as compared with those made of Sup35pNM. Our findings reveal differences and similarities in the assembly of Sup35p and its NM fragment and validate the use of Sup35pNM in studying some aspects of Sup35p aggregation but also underline the importance of using full-length Sup35p in studying prion propagation both in vivo and in vitro.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; RIKEN, Brain Sci Inst, Mol Neuropathol Grp, Wako, Saitama 3510198, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; RIKEN; Japan Science & Technology Agency (JST); Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Bristol	Melki, R (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse, F-91198 Gif Sur Yvette, France.	melki@lebs.cnrs-gif.fr	Tanaka, Motomasa/N-5064-2015	Tanaka, Motomasa/0000-0002-2994-7703; Wolak, Joanna/0000-0003-1068-1770; Burston, Steven/0000-0003-1848-1853				Alkalaeva EZ, 2006, CELL, V125, P1125, DOI 10.1016/j.cell.2006.04.035; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Collins SR, 2004, PLOS BIOL, V2, P1582, DOI 10.1371/journal.pbio.0020321; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; Derkatch IL, 1996, GENETICS, V144, P1375; Frolova L, 1996, RNA, V2, P334; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; Gidalevitz T, 2006, SCIENCE, V311, P1471, DOI 10.1126/science.1124514; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Hoshino S, 1998, J BIOL CHEM, V273, P22254, DOI 10.1074/jbc.273.35.22254; Ito K, 1998, RNA, V4, P958, DOI 10.1017/S1355838298971874; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Kobayashi T, 2004, J BIOL CHEM, V279, P45693, DOI 10.1074/jbc.M405163200; Krzewska J, 2006, EMBO J, V25, P822, DOI 10.1038/sj.emboj.7600985; Kushnirov VV, 2000, CURR BIOL, V10, P1443, DOI 10.1016/S0960-9822(00)00802-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN SW, 1979, J BACTERIOL, V139, P1068, DOI 10.1128/JB.139.3.1068-1071.1979; Liu JJ, 2002, P NATL ACAD SCI USA, V99, P16446, DOI 10.1073/pnas.252652099; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; MELKI R, 1990, BIOCHEMISTRY-US, V29, P8921, DOI 10.1021/bi00490a007; Merkulova TI, 1999, FEBS LETT, V443, P41, DOI 10.1016/S0014-5793(98)01669-X; OOSAWA F, 1975, THERMODYNAMICS POLYM, P41; Padrick SB, 2002, BIOCHEMISTRY-US, V41, P4694, DOI 10.1021/bi0160462; Salas-Marco J, 2004, MOL CELL BIOL, V24, P7769, DOI 10.1128/MCB.24.17.7769-7778.2004; Scheibel T, 2001, NAT STRUCT BIOL, V8, P958, DOI 10.1038/nsb1101-958; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Shorter J, 2006, MOL CELL, V23, P425, DOI 10.1016/j.molcel.2006.05.042; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; Tuite MF, 2003, NAT REV MOL CELL BIO, V4, P878, DOI 10.1038/nrm1247; Uptain SM, 2001, EMBO J, V20, P6236, DOI 10.1093/emboj/20.22.6236; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Xu SH, 2001, BIOPHYS J, V81, P446, DOI 10.1016/S0006-3495(01)75712-8; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x; [No title captured]	39	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1679	1686		10.1074/jbc.M608110200	http://dx.doi.org/10.1074/jbc.M608110200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121860	hybrid			2022-12-27	WOS:000243451300019
J	Wang, X; Wang, Y; Kim, HP; Nakahira, K; Ryter, SW; Choi, AMK				Wang, Xue; Wang, Yong; Kim, Hong Pyo; Nakahira, Kiichi; Ryter, Stefan W.; Choi, Augustine M. K.			Carbon monoxide protects against hyperoxia-induced endothelial cell apoptosis by inhibiting reactive oxygen species formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR PROTECTS; KINASE PATHWAY; HEME OXYGENASE; VIVO EXPOSURE; LUNG; DEATH; INJURY; BAX; ACTIVATION; COMPLEX	Hyperoxia causes cell injury and death associated with reactive oxygen species formation and inflammatory responses. Recent studies show that hyperoxia-induced cell death involves apoptosis, necrosis, or mixed phenotypes depending on cell type, although the underlying mechanisms remain unclear. Using murine lung endothelial cells, we found that hyperoxia caused cell death by apoptosis involving both extrinsic (Fas-dependent) and intrinsic (mitochondria-dependent) pathways. Hyperoxia-dependent activation of the extrinsic apoptosis pathway and formation of the death-inducing signaling complex required NADPH oxidase-dependent reactive oxygen species production, because this process was attenuated by chemical inhibition, as well as by genetic deletion of the p47(phox) subunit, of the oxidase. Overexpression of heme oxygenase-1 prevented hyperoxia-induced cell death and cytochrome c release. Likewise, carbon monoxide, at low concentrations, markedly inhibited hyperoxia-induced endothelial cell death by inhibiting cytochrome c release and caspase-9/3 activation. Carbon monoxide, by attenuating hyperoxia-induced reactive oxygen species production, inhibited extrinsic apoptosis signaling initiated by death-inducing signal complex trafficking from the Golgi apparatus to the plasma membrane and downstream activation of caspase-8. We also found that carbon monoxide inhibited the hyperoxia-induced activation of Bcl-2-related proteins involved in both intrinsic and extrinsic apoptotic signaling. Carbon monoxide inhibited the activation of Bid and the expression and mitochondrial translocation of Bax, whereas promoted Bcl-X-L/Bax interaction and increased Bad phosphorylation. We also show that carbon monoxide promoted an interaction of heme oxygenase-1 with Bax. These results define novel mechanisms underlying the antiapoptotic effects of carbon monoxide during hyperoxic stress.	Univ Pittsburgh, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Choi, AMK (corresponding author), Univ Pittsburgh, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, 3459 5th Ave,MUH 628NW, Pittsburgh, PA 15213 USA.	choiam@upmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070807, R01HL055330, R01HL060234, R01HL079904] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL55330, P01-HL70807, R01-HL079904, R01-HL60234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amersi F, 2002, HEPATOLOGY, V35, P815, DOI 10.1053/jhep.2002.32467; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Barazzone C, 1998, AM J RESP CELL MOL, V19, P573, DOI 10.1165/ajrcmb.19.4.3173; Barazzone C, 1999, AM J PATHOL, V154, P1479, DOI 10.1016/S0002-9440(10)65402-8; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; Eberle A, 2005, HEPATOLOGY, V41, P315, DOI 10.1002/hep.20564; FREEMAN BA, 1982, ARCH BIOCHEM BIOPHYS, V216, P477, DOI 10.1016/0003-9861(82)90236-3; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; HOROWITZ S, 1997, LUNG GROWTH DEV, P577; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; Kim HP, 2006, ANNU REV PHARMACOL, V46, P411, DOI 10.1146/annurev.pharmtox.46.120604.141053; Li J, 2004, FREE RADICAL BIO MED, V36, P1460, DOI 10.1016/j.freeradbiomed.2004.03.005; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Liu XM, 2002, CARDIOVASC RES, V55, P396, DOI 10.1016/S0008-6363(02)00410-8; Mantell LL, 1999, ANN NY ACAD SCI, V887, P171, DOI 10.1111/j.1749-6632.1999.tb07931.x; Mantell LL, 2000, MOL GENET METAB, V71, P359, DOI 10.1006/mgme.2000.3046; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Morita T, 1997, J BIOL CHEM, V272, P32804, DOI 10.1074/jbc.272.52.32804; Nakahira K, 2006, J EXP MED, V203, P2377, DOI 10.1084/jem.20060845; O'Reilly MA, 2003, AM J PHYSIOL-LUNG C, V284, pL368, DOI 10.1152/ajplung.00299.2002; O'Reilly MA, 2001, AM J RESP CELL MOL, V24, P703, DOI 10.1165/ajrcmb.24.6.4355; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, AM J PATHOL, V163, P2555, DOI 10.1016/S0002-9440(10)63610-3; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; OTTERBEIN LE, 1998, AM J PHYSIOL, V75, pL14; Parinandi NL, 2003, AM J PHYSIOL-LUNG C, V284, pL26, DOI 10.1152/ajplung.00123.2002; Petrache I, 1999, AM J PHYSIOL-LUNG C, V277, pL589, DOI 10.1152/ajplung.1999.277.3.L589; Reinehr R, 2003, FASEB J, V17, P731, DOI 10.1096/fj.02-0915fje; Roper JM, 2004, AM J PHYSIOL-LUNG C, V286, pL1045, DOI 10.1152/ajplung.00376.2003; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Sawle P, 2005, BRIT J PHARMACOL, V145, P800, DOI 10.1038/sj.bjp.0706241; Song RP, 2003, AM J PATHOL, V163, P231, DOI 10.1016/S0002-9440(10)63646-2; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Terrones O, 2004, J BIOL CHEM, V279, P30081, DOI 10.1074/jbc.M313420200; Walsh CM, 2003, J CLIN IMMUNOL, V23, P333, DOI 10.1023/A:1025313415487; Wang X, 2004, FASEB J, V18, P1826, DOI 10.1096/fj.04-2047com; Wang X, 2005, MOL CELL BIOL, V25, P4742, DOI 10.1128/MCB.25.11.4742-4751.2005; Wang X, 2003, J BIOL CHEM, V278, P29184, DOI 10.1074/jbc.M301624200; Wang X, 2004, J BIOL CHEM, V279, P5237, DOI 10.1074/jbc.M309271200; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	50	168	188	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1718	1726		10.1074/jbc.M607610200	http://dx.doi.org/10.1074/jbc.M607610200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17135272	hybrid			2022-12-27	WOS:000243451300023
J	Goldstrohm, AC; Seay, DJ; Hook, BA; Wickens, M				Goldstrohm, Aaron C.; Seay, Daniel J.; Hook, Brad A.; Wickens, Marvin			PUF protein-mediated deadenylation is catalyzed by Ccr4p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEADENYLASE; YEAST HOMOLOG; TRANSLATION; TRANSCRIPT; COMPLEX; FAMILY; DECAY; CAF1; DEGRADATION; RECRUITMENT	PUF proteins control gene expression by binding to the 3'-untranslated regions of specific mRNAs and triggering mRNA decay or translational repression. Here we focus on the mechanism of PUF-mediated regulation. The yeast PUF protein, Mpt5p, regulates HO mRNA and stimulates removal of its poly(A) tail (i.e. deadenylation). Mpt5p repression in vivo is dependent on POP2, a component of the cytoplasmic Ccr4p-Pop2p-Not complex that deadenylates mRNAs. In this study, we elucidate the individual roles of the Ccr4p and Pop2p deadenylases in Mpt5p-regulated deadenylation. Both in vivo and in vitro, Pop2p and Ccr4p proteins are required for Mpt5p-regulated deadenylation of HO. However, the requirements for the two proteins differ dramatically: the enzymatic activity of Ccr4p is essential, whereas that of Pop2p is dispensable. We conclude that Pop2p is a bridge through which the PUF protein recruits the Ccr4p enzyme to the target mRNA, thereby stimulating deadenylation. Our data suggest that PUF proteins may enhance mRNA degradation and repress expression by both deadenylation-dependent and -independent mechanisms, using the same Pop2p bridge to recruit a multifunctional Pop2p complex to the mRNA.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Wickens, M (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	wickens@biochem.wisc.edu			NIGMS NIH HHS [GM50942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aviv T, 2003, NAT STRUCT BIOL, V10, P614, DOI 10.1038/nsb956; Behm-Ansmant I, 2006, GENE DEV, V20, P1885, DOI 10.1101/gad.1424106; Bianchin C, 2005, RNA, V11, P487, DOI 10.1261/rna.7135305; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Chagnovich D, 2001, P NATL ACAD SCI USA, V98, P11359, DOI 10.1073/pnas.201284398; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Chou CF, 2006, MOL CELL BIOL, V26, P3695, DOI 10.1128/MCB.26.10.3695-3706.2006; Coller J, 2005, CELL, V122, P875, DOI 10.1016/j.cell.2005.07.012; Coller JM, 2001, RNA, V7, P1717, DOI 10.1017/S135583820101994X; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; Denis CL, 2003, PROG NUCLEIC ACID RE, V73, P221, DOI 10.1016/S0079-6603(03)01007-9; Dupressoir A, 2001, BMC Genomics, V2, P9, DOI 10.1186/1471-2164-2-9; Duttagupta R, 2003, MOL CELL BIOL, V23, P2623, DOI 10.1128/MCB.23.8.2623-2632.2003; Gerber AP, 2004, PLOS BIOL, V2, P342, DOI 10.1371/journal.pbio.0020079; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Goldstrohm AC, 2006, NAT STRUCT MOL BIOL, V13, P533, DOI 10.1038/nsmb1100; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Hata H, 1998, GENETICS, V148, P571; Jackson JS, 2004, RNA, V10, P1625, DOI 10.1261/rna.7270204; Kuhn U, 2004, BBA-GENE STRUCT EXPR, V1678, P67, DOI 10.1016/j.bbaexp.2004.03.008; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Moraes KCM, 2006, RNA, V12, P1084, DOI 10.1261/rna.59606; Olivas W, 2000, EMBO J, V19, P6602, DOI 10.1093/emboj/19.23.6602; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; Seay D, 2006, RNA, V12, P1594, DOI 10.1261/rna.145306; Semotok JL, 2005, CURR BIOL, V15, P284, DOI 10.1016/j.cub.2005.01.048; Tadauchi T, 2001, EMBO J, V20, P552, DOI 10.1093/emboj/20.3.552; Thore S, 2003, EMBO REP, V4, P1150, DOI 10.1038/sj.embor.7400020; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Viswanathan P, 2004, J BIOL CHEM, V279, P23988, DOI 10.1074/jbc.M402803200; Viswanathan P, 2003, J BIOL CHEM, V278, P14949, DOI 10.1074/jbc.M211794200; Weston A, 2006, NUCLEIC ACIDS RES, V34, P3082, DOI 10.1093/nar/gkl409; Wickens M, 2002, TRENDS GENET, V18, P150, DOI 10.1016/S0168-9525(01)02616-6; Wickens M, 2000, COLD SPRING HARBOR M, V39, P295; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103	39	123	123	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					109	114		10.1074/jbc.M609413200	http://dx.doi.org/10.1074/jbc.M609413200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17090538	hybrid			2022-12-27	WOS:000243166500013
J	Burgis, NE; Cunningham, RP				Burgis, Nicholas E.; Cunningham, Richard P.			Substrate specificity of RdgB protein, a deoxyribonucleoside triphosphate pyrophosphohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; METHANOCOCCUS-JANNASCHII; GENE; 6-N-HYDROXYLAMINOPURINE; IDENTIFICATION; PYROPHOSPHATASE; SUPPRESSION; MUTAGENESIS; PRODUCTS; MUTANTS	We have previously reported the identification of a DNA repair system in Escherichia coli for the prevention of the stable incorporation of noncanonical purine dNTPs into DNA. We hypothesized that the RdgB protein is active on 2'-deoxy-N-6-hydroxylaminopurine triphosphate (dHAPTP) as well as deoxyinosine triphosphate. Here we show that RdgB protein and RdgB homologs from Saccharomyces cerevisiae, mouse, and human all possess deoxyribonucleoside triphosphate pyrophosphohydrolase activity and that all four RdgB homologs have high specificity for dHAPTP and deoxyinosine triphosphate compared with the four canonical dNTPs and several other noncanonical (d)NTPs. Kinetic analysis reveals that the major source of the substrate specificity lies in changes in K. for the various substrates. The expression of these enzymes in E. coli complements defects that are caused by the incorporation of HAP and an endogenous noncanonical purine into DNA. Our data support a preemptive role for the RdgB homologs in excluding endogenous and exogenous modified purine dNTPs from incorporation into DNA.	SUNY Albany, Dept Biol Sci, Albany, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany	Cunningham, RP (corresponding author), SUNY Albany, Dept Biol Sci, 1400 Washington Ave, Albany, NY 12222 USA.	moose@albany.edu	Burgis, Nicholas E./AAR-4733-2020	Burgis, Nicholas E./0000-0002-8279-7193	NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015464] Funding Source: NIH RePORTER; NCRR NIH HHS [1 C06 RR015464] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABDULMASIH MT, 1986, J BIOL CHEM, V261, P2020; AMES BN, 1960, J BIOL CHEM, V235, P769; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradshaw JS, 2003, MOL MICROBIOL, V48, P1711, DOI 10.1046/j.1365-2958.2003.03540.x; Burgis NE, 2003, J BACTERIOL, V185, P3101, DOI 10.1128/JB.185.10.3101-3110.2003; Chung JH, 2002, J BIOCHEM MOL BIOL, V35, P403, DOI 10.5483/BMBRep.2002.35.4.403; Chung JH, 2001, NUCLEIC ACIDS RES, V29, P3099, DOI 10.1093/nar/29.14.3099; CLEMENT B, 1990, BIOCHEM PHARMACOL, V39, P925, DOI 10.1016/0006-2952(90)90209-4; CLYMAN J, 1991, J BACTERIOL, V173, P1360, DOI 10.1128/jb.173.3.1360-1362.1991; CLYMAN J, 1987, J BACTERIOL, V169, P4203, DOI 10.1128/jb.169.9.4203-4210.1987; CSONKA LN, 1980, J BACTERIOL, V143, P529, DOI 10.1128/JB.143.1.529-530.1980; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Guo GM, 1998, J BACTERIOL, V180, P46, DOI 10.1128/JB.180.1.46-51.1998; Hasona A, 1998, J BACTERIOL, V180, P1466, DOI 10.1128/JB.180.6.1466-1472.1998; HOLMES SL, 1979, CLIN CHIM ACTA, V97, P143, DOI 10.1016/0009-8981(79)90410-8; Hwang KY, 1999, NAT STRUCT BIOL, V6, P691; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Kozmin SG, 2000, J BACTERIOL, V182, P3361, DOI 10.1128/JB.182.12.3361-3367.2000; Lin SR, 2001, J BIOL CHEM, V276, P18695, DOI 10.1074/jbc.M011084200; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Noskov VN, 1996, YEAST, V12, P17, DOI 10.1002/(SICI)1097-0061(199601)12:1<17::AID-YEA875>3.0.CO;2-I; PAVLOV YI, 1986, SOVIET GENETICS, V22, P1099; SAMBROOK J., 1989, MOL CLONING LAB MANU; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SHAPIRO R, 1968, BIOCHEMISTRY-US, V7, P448, DOI 10.1021/bi00841a057; VANDERHEIDEN BS, 1970, BIOCHIM BIOPHYS ACTA, V215, P555, DOI 10.1016/0304-4165(70)90109-1; Wheeler LJ, 2005, DNA REPAIR, V4, P1450, DOI 10.1016/j.dnarep.2005.09.003; ZALKIN H, 1996, ESCHERICHIA COLI SAL, P561	29	37	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3531	3538		10.1074/jbc.M608708200	http://dx.doi.org/10.1074/jbc.M608708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17090528	hybrid			2022-12-27	WOS:000244481900015
J	Wei, Y; Tang, CH; Kim, Y; Robillard, L; Zhang, F; Kugler, MC; Chapman, HA				Wei, Ying; Tang, Chi-Hui; Kim, Young; Robillard, Liliane; Zhang, Feng; Kugler, Matthias C.; Chapman, Harold A.			Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; SMOOTH-MUSCLE-CELLS; PLASMINOGEN-ACTIVATOR; GENE-EXPRESSION; FIBROSARCOMA CELLS; ANTISENSE UPAR; OVARIAN-CANCER; GELATINASE B; IN-VIVO; FIBRONECTIN	Up-regulation of urokinase receptors is common during tumor progression and thought to promote invasion and metastasis. Urokinase receptors bind urokinase and a set of beta 1 integrins, but it remains unclear to what degree urokinase receptor/integrin binding is important to beta 1 integrin signaling. Using site-directed mutagenesis, single amino acid mutants of the urokinase receptor were identified that fail to associate with either alpha 3 beta 1 (D262A) or alpha 5 beta 1 (H249A) but associate normally with urokinase. To study the effects of these mutations on beta 1 integrin function, endogenous urokinase receptors were first stably silenced in tumor cell lines HT1080 and H1299, and then wild type or mutant receptors were expressed. Knockdown of urokinase receptors resulted in markedly reduced fibronectin and alpha 5 beta 1-dependent ERK activation and metalloproteinase MMP-9 expression. Re-expression of wild type or D262A mutant receptors but not the alpha 5 beta 1 binding-deficient H249A mutant reconstituted fibronectin responses. Because urokinase receptor-alpha 5 beta 1 complexes bind in the fibronectin heparin-binding domain (Type III 12-14) whereas alpha 5 beta 1 primarily binds in the RGD-containing domain (Type III 7-10), signaling pathways leading to ERK and MMP-9 responses were dissected. Binding to III 7-10 led to Src/focal adhesion kinase activation, whereas binding to III 7-14 caused Rac 1 activation. Tumor cells engaging fibronectin required both Type III 7-10- and 12-14-initiated signals to activate ERK and up-regulate MMP-9. Thus urokinase receptor binding to alpha 5 beta 1 is required for maximal responses to fibronectin and tumor cell invasion, and this operates through an enhanced Src/Rac/ERK signaling pathway.	Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Wei, Y (corresponding author), Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, 513 Parnassus Ave,HSE201, San Francisco, CA 94143 USA.	ying.wei@ucsf.edu; hal.chapman@ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044712] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL044712, HL44712] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Ahmed N, 2003, BRIT J CANCER, V89, P374, DOI 10.1038/sj.bjc.6601098; Ahmed N, 2002, J CELL BIOCHEM, V84, P675, DOI 10.1002/jcb.10080; Alberts AS, 2005, J BIOL CHEM, V280, P12152, DOI 10.1074/jbc.M405073200; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; Carriero MV, 1999, CANCER RES, V59, P5307; Chaurasia P, 2006, J BIOL CHEM, V281, P14852, DOI 10.1074/jbc.M512311200; Costa G L, 1996, Methods Mol Biol, V57, P239; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; de Bock CE, 2004, MED RES REV, V24, P13, DOI 10.1002/med.10054; Degryse B, 2005, J BIOL CHEM, V280, P24792, DOI 10.1074/jbc.M413954200; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Gardsvoll H, 2006, J BIOL CHEM, V281, P19260, DOI 10.1074/jbc.M513583200; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; Ghosh S, 2006, J BIOL CHEM, V281, P13021, DOI 10.1074/jbc.M508526200; Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216; Gondi CS, 2003, ONCOGENE, V22, P5967, DOI 10.1038/sj.onc.1206535; Hahn-Dantona E, 1999, ANN NY ACAD SCI, V878, P372, DOI 10.1111/j.1749-6632.1999.tb07696.x; Hamelers IHL, 2005, J CELL BIOL, V171, P871, DOI 10.1083/jcb.200509172; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Inuzuka K, 2000, J SURG RES, V93, P211, DOI 10.1006/jsre.2000.5952; Jeong J, 2001, BIOCHEM J, V356, P531, DOI 10.1042/0264-6021:3560531; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kim J, 2001, BIOCHEM J, V360, P239, DOI 10.1042/0264-6021:3600239; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Kugler MC, 2003, CURR PHARM DESIGN, V9, P1565, DOI 10.2174/1381612033454658; Lakka SS, 2001, CLIN CANCER RES, V7, P1087; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; Loeser RF, 2003, J BIOL CHEM, V278, P24577, DOI 10.1074/jbc.M304530200; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; Mao Y, 2005, MATRIX BIOL, V24, P389, DOI 10.1016/j.matbio.2005.06.008; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Mazzieri R, 2006, MOL BIOL CELL, V17, P367, DOI 10.1091/mbc.E05-07-0635; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Rao JS, 2005, MOL CANCER THER, V4, P1399, DOI 10.1158/1535-7163.MCT-05-0082; Schedin P, 2000, J CELL SCI, V113, P795; Schmitz U, 2001, J BIOL CHEM, V276, P22003, DOI 10.1074/jbc.M102450200; Segarra M, 2005, FASEB J, V19, P1875, DOI 10.1096/fj.04-3574fje; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Shibata K, 1997, CANCER RES, V57, P5416; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; Stanton H, 2002, BIOCHEM J, V364, P181, DOI 10.1042/bj3640181; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; Wang XF, 2001, CHINESE J ASTRON AST, V1, P257, DOI 10.1088/1009-9271/1/3/257; Wang Y, 2001, MED RES REV, V21, P146, DOI 10.1002/1098-1128(200103)21:2<146::AID-MED1004>3.0.CO;2-B; Wei Y, 2005, J CELL BIOL, V168, P501, DOI 10.1083/jcb.200404112; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; Xue W, 1997, CANCER RES, V57, P1682; Yasuda T, 2003, ARTHRITIS RHEUM, V48, P1271, DOI 10.1002/art.10951; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Zhang F, 2003, J CELL BIOL, V163, P177, DOI 10.1083/jcb.200304065; Zhou H, 2005, J BIOL CHEM, V280, P10624, DOI 10.1074/jbc.M411900200	78	88	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3929	3939		10.1074/jbc.M607989200	http://dx.doi.org/10.1074/jbc.M607989200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17145753	hybrid			2022-12-27	WOS:000244481900057
J	Zhou, MY; Xia, L; Engel, K; Wang, J				Zhou, Mingyan; Xia, Li; Engel, Karen; Wang, Joanne			Molecular determinants of substrate selectivity of a novel organic cation transporter (PMAT) in the SLC29 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; MONOAMINE TRANSPORTER; CHIMERIC CONSTRUCTS; AMINO-ACIDS; NUCLEOSIDE; IDENTIFICATION; ADENOSINE; AFFINITY; REVEAL; KIDNEY	Plasma membrane monoamine transporter (PMAT or ENT4) is a newly cloned transporter assigned to the equilibrative nucleoside transporter (ENT) family (SLC29). Unlike ENT1-3, PMAT mainly functions as a polyspecific organic cation transporter. In this study, we investigated the molecular mechanisms underlying the unique substrate selectivity of PMAT. By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine ( a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. To identify residues important for the cation selectivity of PMAT, 10 negatively charged residues were chosen and substituted with alanine. Five of the alanine mutants retained PMAT activity, and four were non-functional due to impaired targeting to the plasma membrane. However, alanine substitution at Glu(206) in TM5 abolished PMAT activity without affecting cell surface expression. Eliminating the charge at Glu206 (E206Q) resulted in loss of organic cation transport activity, whereas conserving the negative charge (E206D) restored transporter function. Interestingly, mutant E206Q, which possesses the equivalent residue in ENT1, gained uridine transport activity. Thr(220), another residue in TM5, also showed an effect on PMAT activity. Helical wheel analysis of TM5 revealed a distinct amphipathic pattern with Glu206 and Thr220 clustered in the center of the hydrophilic face. In summary, our results suggest that Glu206 functions as a critical charge sensor for cationic substrates and TM5 forms part of the substrate permeation pathway in PMAT.	Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Wang, J (corresponding author), H272J,Hlth Sci Bldg, Seattle, WA 98195 USA.	jowang@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066233] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; Alberts B., 2008, MOL BIOL CEL, V5th ed.; Baldwin SA, 2005, J BIOL CHEM, V280, P15880, DOI 10.1074/jbc.M414337200; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; Barnes K, 2006, CIRC RES, V99, P510, DOI 10.1161/01.RES.0000238359.18495.42; EISENBERG D, 1986, J CELL BIOCHEM, V31, P11, DOI 10.1002/jcb.240310103; Engel K, 2005, MOL PHARMACOL, V68, P1397, DOI 10.1124/mol.105.016832; Engel K, 2004, J BIOL CHEM, V279, P50042, DOI 10.1074/jbc.M407913200; Fujita T, 2006, J PHARM SCI-US, V95, P25, DOI 10.1002/jps.20536; Gorboulev V, 2005, MOL PHARMACOL, V67, P1612, DOI 10.1124/mol.104.008821; Hediger MA, 2004, PFLUG ARCH EUR J PHY, V447, P465, DOI 10.1007/s00424-003-1192-y; Koepsell H, 2004, PFLUG ARCH EUR J PHY, V447, P666, DOI 10.1007/s00424-003-1089-9; Kong W, 2004, CURR DRUG METAB, V5, P63, DOI 10.2174/1389200043489162; Lai YR, 2002, J BIOL CHEM, V277, P37711, DOI 10.1074/jbc.M204986200; Popp C, 2005, MOL PHARMACOL, V67, P1600, DOI 10.1124/mol.104.008839; Saier MH, 2000, MICROBIOL MOL BIOL R, V64, P354, DOI 10.1128/MMBR.64.2.354-411.2000; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Wang J, 1997, J BIOL CHEM, V272, P28845, DOI 10.1074/jbc.272.46.28845; Wang J, 1999, J BIOL CHEM, V274, P2298, DOI 10.1074/jbc.274.4.2298; Wright EM, 2004, PHYSIOLOGY, V19, P370, DOI 10.1152/physiol.00026.2004; Wright SH, 2004, PHYSIOL REV, V84, P987, DOI 10.1152/physrev.00040.2003; XIA L, 2006, IN PRESS AM J PHYSL; Xu W, 2006, J BIOL CHEM, V281, P31178, DOI 10.1074/jbc.M605664200; Yao SYM, 2002, J BIOL CHEM, V277, P24938, DOI 10.1074/jbc.M200966200; Zhang L, 1998, ANNU REV PHARMACOL, V38, P431, DOI 10.1146/annurev.pharmtox.38.1.431; Zhang XH, 2005, J BIOL CHEM, V280, P34813, DOI 10.1074/jbc.M506342200; Zhou MY, 2007, BIOCHEM PHARMACOL, V73, P147, DOI 10.1016/j.bcp.2006.09.008	28	34	38	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3188	3195		10.1074/jbc.M609421200	http://dx.doi.org/10.1074/jbc.M609421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17121826	Green Accepted, hybrid			2022-12-27	WOS:000243793900045
J	Sidhu, ABS; Sun, QG; Nkrumah, LJ; Dunne, MW; Sacchettini, JC; Fidock, DA				Sidhu, Amar Bir Singh; Sun, Qingan; Nkrumah, Louis J.; Dunne, Michael W.; Sacchettini, James C.; Fidock, David A.			In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM MALARIA; RIBOSOMAL-PROTEIN L4; MUTATIONS CONFERRING RESISTANCE; STREPTOCOCCUS-PNEUMONIAE; MACROLIDE RESISTANCE; ERYTHROMYCIN RESISTANCE; CHLOROQUINE RESISTANCE; TOXOPLASMA-GONDII; ANTIMALARIAL ACTIVITY; DIGESTIVE VACUOLE	Azithromycin (AZ), a broad-spectrum antibacterial macrolide that inhibits protein synthesis, also manifests reasonable efficacy as an antimalarial. Its mode of action against malarial parasites, however, has remained undefined. Our in vitro investigations with the human malarial parasite Plasmodium falciparum document a remarkable increase in AZ potency when exposure is prolonged from one to two generations of intraerythrocytic growth, with AZ producing 50% inhibition of parasite growth at concentrations in the mid to low nanomolar range. In our culture-adapted lines, AZ displayed no synergy with chloroquine (CQ), amodiaquine, or artesunate. AZ activity was also unaffected by mutations in the pfcrt (P. falciparum chloroquine resistance transporter) or pfmdr1 (P. falciparum multidrug resistance-1) drug resistance loci, as determined using transgenic lines. We have selected mutant, AZ-resistant 7G8 and Dd2 parasite lines. In the AZ-resistant 7G8 line, the bacterial-like apicoplast large subunit ribosomal RNA harbored a U438C mutation in domain I. Both AZ-resistant lines revealed a G76V mutation in a conserved region of the apicoplast-encoded P. falciparum ribosomal protein L4 (PfRpl4). This protein is predicted to associate with the nuclear genome-encoded P. falciparum ribosomal protein L22 (PfRpl22) and the large subunit rRNA to form the 50 S ribosome polypeptide exit tunnel that can be occupied by AZ. The PfRpl22 sequence remained unchanged. Molecular modeling of mutant PfRpl4 with AZ suggests an altered orientation of the L75 side chain that could preclude AZ binding. These data imply that AZ acts on the apicoplast bacterial-like translation machinery and identify Pfrpl4 as a potential marker of resistance.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Pfizer Inc, Pfizer Global Res & Dev, New London, CT 06320 USA	Yeshiva University; Albert Einstein College of Medicine; Texas A&M University System; Texas A&M University College Station; Pfizer	Fidock, DA (corresponding author), Forchheimer 403,1300 Morris Pk Ave, Bronx, NY 10461 USA.	dfidock@aecom.yu.edu	Dunne, Michael W/AAD-7418-2020	Dunne, Michael W/0000-0001-6186-5196; Fidock, David/0000-0001-6753-8938				ANDERSEN SL, 1995, AM J TROP MED HYG, V52, P159, DOI 10.4269/ajtmh.1995.52.159; ANDERSON SL, 1995, ANN INTERN MED, V123, P771, DOI 10.7326/0003-4819-123-10-199511150-00005; Baird JK, 2005, NEW ENGL J MED, V352, P1565, DOI 10.1056/NEJMra043207; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Banerjee Ritu, 2001, P43; Camps M, 2002, MOL MICROBIOL, V43, P1309, DOI 10.1046/j.1365-2958.2002.02825.x; Canu A, 2002, ANTIMICROB AGENTS CH, V46, P125, DOI 10.1128/AAC.46.1.125-131.2002; CHITTUM HS, 1994, J BACTERIOL, V176, P6192, DOI 10.1128/jb.176.20.6192-6198.1994; Clark C, 2002, ANTIMICROB AGENTS CH, V46, P2956, DOI 10.1128/AAC.46.9.2956-2962.2002; Cooper RA, 2002, MOL PHARMACOL, V61, P35, DOI 10.1124/mol.61.1.35; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; Dahl EL, 2006, ANTIMICROB AGENTS CH, V50, P3124, DOI 10.1128/AAC.00394-06; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; Doktor SZ, 2004, DIAGN MICR INFEC DIS, V49, P47, DOI 10.1016/S0732-8893(03)00130-5; Douthwaite S, 2000, MOL MICROBIOL, V36, P183, DOI 10.1046/j.1365-2958.2000.01841.x; Dunne MW, 2005, AM J TROP MED HYG, V73, P1108; Dunne MW, 2005, J INFECT DIS, V191, P1582, DOI 10.1086/429343; Edelstein PH, 2004, CLIN INFECT DIS, V38, pS322, DOI 10.1086/382687; EGEBJERG J, 1989, EMBO J, V8, P607, DOI 10.1002/j.1460-2075.1989.tb03415.x; Farrell DJ, 2004, ANTIMICROB AGENTS CH, V48, P3169, DOI 10.1128/AAC.48.8.3169-3171.2004; FICHERA ME, 1995, ANTIMICROB AGENTS CH, V39, P1530, DOI 10.1128/AAC.39.7.1530; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; Fidock DA, 1998, MOL PHARMACOL, V54, P1140, DOI 10.1124/mol.54.6.1140; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Foley M, 1998, PHARMACOL THERAPEUT, V79, P55, DOI 10.1016/S0163-7258(98)00012-6; Foth BJ, 2003, SCIENCE, V299, P705, DOI 10.1126/science.1078599; Frank M, 2004, PROG COMPUT FLUID DY, V4, P191, DOI 10.1504/PCFD.2004.004087; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; GARDNER MJ, 1993, NUCLEIC ACIDS RES, V21, P1067, DOI 10.1093/nar/21.5.1067; GINGRAS BA, 1992, AM J TROP MED HYG, V47, P378, DOI 10.4269/ajtmh.1992.47.378; GINGRAS BA, 1993, AM J TROP MED HYG, V49, P101, DOI 10.4269/ajtmh.1993.49.101; GIRARD AE, 1987, ANTIMICROB AGENTS CH, V31, P1948, DOI 10.1128/AAC.31.12.1948; Goodyer ID, 1997, EXP PARASITOL, V86, P158, DOI 10.1006/expr.1997.4156; Gregory ST, 1999, J MOL BIOL, V289, P827, DOI 10.1006/jmbi.1999.2839; GULLE H, 1988, NUCLEIC ACIDS RES, V16, P815, DOI 10.1093/nar/16.3.815; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; Hansen LH, 1999, MOL MICROBIOL, V31, P623, DOI 10.1046/j.1365-2958.1999.01202.x; Johnson DJ, 2004, MOL CELL, V15, P867, DOI 10.1016/j.molcel.2004.09.012; Kain KC, 2001, CLIN INFECT DIS, V33, P226, DOI 10.1086/321817; KUSCHNER RA, 1994, LANCET, V343, P1396, DOI 10.1016/S0140-6736(94)92526-7; Lakshmanan V, 2005, EMBO J, V24, P2294, DOI 10.1038/sj.emboj.7600681; Leclercq R, 2002, CLIN INFECT DIS, V34, P482, DOI 10.1086/324626; Lell B, 2002, ANTIMICROB AGENTS CH, V46, P2315, DOI 10.1128/AAC.46.8.2315-2320.2002; Looareesuwan S, 1996, AM J TROP MED HYG, V54, P62, DOI 10.4269/ajtmh.1996.54.62; McConkey GA, 1997, J BIOL CHEM, V272, P2046, DOI 10.1074/jbc.272.4.2046; McLeod R, 2001, INT J PARASITOL, V31, P109, DOI 10.1016/S0020-7519(01)00111-4; Melo F, 2002, PROTEIN SCI, V11, P430, DOI 10.1002/pro.110430; Nagai K, 2002, ANTIMICROB AGENTS CH, V46, P546, DOI 10.1128/AAC.46.2.546-549.2002; Ng LK, 2002, ANTIMICROB AGENTS CH, V46, P3020, DOI 10.1128/AAC.46.9.3020-3025.2002; Nkrumah LJ, 2006, NAT METHODS, V3, P615, DOI 10.1038/NMETH904; Noedl H, 2006, CLIN INFECT DIS, V43, P1264, DOI 10.1086/508175; O'Neill PM, 1998, PHARMACOL THERAPEUT, V77, P29, DOI 10.1016/S0163-7258(97)00084-3; Oehler R, 1997, NUCLEIC ACIDS RES, V25, P1219, DOI 10.1093/nar/25.6.1219; Ohrt C, 2002, ANTIMICROB AGENTS CH, V46, P2518, DOI 10.1128/AAC.46.8.2518-2524.2002; Ohrt C, 1997, ANN INTERN MED, V126, P963, DOI 10.7326/0003-4819-126-12-199706150-00006; Perozzo R, 2002, J BIOL CHEM, V277, P13106, DOI 10.1074/jbc.M112000200; PFEFFERKORN ER, 1994, ANTIMICROB AGENTS CH, V38, P31, DOI 10.1128/AAC.38.1.31; Pihlajamaki M, 2002, ANTIMICROB AGENTS CH, V46, P654, DOI 10.1128/AAC.46.3.654-658.2002; Poehlsgaard J, 2005, NAT REV MICROBIOL, V3, P870, DOI 10.1038/nrmicro1265; Prunier AL, 2003, J INFECT DIS, V187, P1709, DOI 10.1086/374937; Ralph SA, 2004, NAT REV MICROBIOL, V2, P203, DOI 10.1038/nrmicro843; RASMUSSEN B, 1991, ANTIMICROB AGENTS CH, V35, P2306, DOI 10.1128/AAC.35.11.2306; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Reinert RR, 2005, ANTIMICROB AGENTS CH, V49, P2903, DOI 10.1128/AAC.49.7.2903-2913.2005; Reinert RR, 2003, ANTIMICROB AGENTS CH, V47, P2319, DOI 10.1128/AAC.47.7.2319-2322.2003; RETSEMA J, 1987, ANTIMICROB AGENTS CH, V31, P1939, DOI 10.1128/AAC.31.12.1939; Retsema J, 2001, INT J ANTIMICROB AG, V18, pS3, DOI 10.1016/S0924-8579(01)00401-0; Rogers MJ, 1997, RNA, V3, P815; ROSENDAHL G, 1994, NUCLEIC ACIDS RES, V22, P357, DOI 10.1093/nar/22.3.357; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Saliba KJ, 1998, BIOCHEM PHARMACOL, V56, P313, DOI 10.1016/S0006-2952(98)00140-3; Schlunzen F, 2003, STRUCTURE, V11, P329, DOI 10.1016/S0969-2126(03)00022-4; Sidhu ABS, 2005, MOL MICROBIOL, V57, P913, DOI 10.1111/j.1365-2958.2005.04729.x; Sidhu ABS, 2002, SCIENCE, V298, P210, DOI 10.1126/science.1074045; Sidhu ABS, 2006, J INFECT DIS, V194, P528, DOI 10.1086/507115; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; Tait-Kamradt A, 2000, ANTIMICROB AGENTS CH, V44, P2118, DOI 10.1128/AAC.44.8.2118-2125.2000; Tait-Kamradt A, 2000, ANTIMICROB AGENTS CH, V44, P3395, DOI 10.1128/AAC.44.12.3395-3401.2000; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toler S, 2005, MED HYPOTHESES, V65, P683, DOI 10.1016/j.mehy.2005.05.011; Tu D, 2005, CELL, V121, P257, DOI 10.1016/j.cell.2005.02.005; Uhlemann AC, 2005, MOLECULAR APPROACHES TO MALARIA, P429; Vester B, 2001, ANTIMICROB AGENTS CH, V45, P1, DOI 10.1128/AAC.45.1.1-12.2001; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WEISBLUM B, 1995, ANTIMICROB AGENTS CH, V39, P577, DOI 10.1128/AAC.39.3.577; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; Wolter N, 2005, ANTIMICROB AGENTS CH, V49, P3554, DOI 10.1128/AAC.49.8.3554-3557.2005; Worbs M, 2000, EMBO J, V19, P807, DOI 10.1093/emboj/19.5.807; YEO AET, 1995, INT J PARASITOL, V25, P531, DOI 10.1016/0020-7519(94)00119-9; Yonath A, 2005, ANNU REV BIOCHEM, V74, P649, DOI 10.1146/annurev.biochem.74.082803.133130	94	118	118	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2494	2504		10.1074/jbc.M608615200	http://dx.doi.org/10.1074/jbc.M608615200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17110371	hybrid			2022-12-27	WOS:000243593200041
J	Yoshizawa-Sugata, N; Masai, H				Yoshizawa-Sugata, Naoko; Masai, Hisao			Human Tim/Timeless-interacting protein, Tipin, is required for efficient progression of S phase and DNA replication checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; FORK PROTECTION COMPLEX; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; RESPONSE PATHWAY; EUKARYOTIC DNA; HUMAN CLASPIN; DAMAGE; ATR	Tipin was originally isolated as a protein interacting with Timeless/Tim1/Tim (Tim), which is known to be involved in both circadian rhythm and cell cycle checkpoint regulation. The endogenous Tim and Tipin proteins in human cells, interacting through the N-terminal segment of each molecule, form a complex throughout the cell cycle. Tipin and Tim are expressed in the interphase nuclei mostly at constant levels during the cell cycle, and small fractions are recovered in the chromatin-enriched fractions during S phase. Depletion of endogenous Tipin results in reduced growth rate, and this may be due in part to inefficient progression of S phase and DNA synthesis. Knockdown of Tipin induces radioresistant DNA synthesis and inhibits phosphorylation of Chk1 kinase caused by replication stress, as was observed with that of Tim. Knockdown of Tipin or Tim results in reduced protein level and relocation to the cytoplasm of the respective binding partner, suggesting that the complex formation may be required for stabilization and nuclear accumulation of both proteins. Furthermore, both Tipin and Tim may facilitate the accumulation of Claspin in the nuclei under replication stress, whereas nuclear localization of Tipin and Tim is unaffected by Claspin. Our results indicate that mammalian Tipin is a checkpoint mediator that cooperates with Tim and may regulate the nuclear relocation of Claspin in response to replication checkpoint.	Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Bunkyo Ku, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Bunkyo Ku, 3-18-22 Hon Komagome, Tokyo 1138613, Japan.	hmasai@rinshoken.or.jp		Yoshizawa-Sugata, Naoko/0000-0001-8792-8669				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Calzada A, 2005, GENE DEV, V19, P1905, DOI 10.1101/gad.337205; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Dalgaard JZ, 2000, CELL, V102, P745, DOI 10.1016/S0092-8674(00)00063-5; EGEL R, 1984, P NATL ACAD SCI-BIOL, V81, P3481, DOI 10.1073/pnas.81.11.3481; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Foss EJ, 2001, GENETICS, V157, P567; Gambus A, 2006, NAT CELL BIOL, V8, P358, DOI 10.1038/ncb1382; Gotter AL, 2003, J MOL BIOL, V331, P167, DOI 10.1016/S0022-2836(03)00633-8; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kim JE, 2005, MOL CELL BIOL, V25, P10907, DOI 10.1128/MCB.25.24.10907-10915.2005; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Koike N, 1998, FEBS LETT, V441, P427, DOI 10.1016/S0014-5793(98)01597-X; Krings G, 2004, P NATL ACAD SCI USA, V101, P14085, DOI 10.1073/pnas.0406037101; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Lee BS, 2004, MOL CELL BIOL, V24, P9813, DOI 10.1128/MCB.24.22.9813-9822.2004; Lee J, 2005, MOL BIOL CELL, V16, P5269, DOI 10.1091/mbc.E05-07-0671; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu QH, 2000, GENE DEV, V14, P1448; Matsumoto S, 2005, J BIOL CHEM, V280, P42536, DOI 10.1074/jbc.M510575200; Mayer ML, 2004, MOL BIOL CELL, V15, P1736, DOI 10.1091/mbc.E03-08-0619; Montagnoli A, 2004, CANCER RES, V64, P7110, DOI 10.1158/0008-5472.CAN-04-1547; Noguchi E, 2004, MOL CELL BIOL, V24, P8342, DOI 10.1128/MCB.24.19.8342-8355.2004; Noguchi E, 2003, MOL CELL BIOL, V23, P7861, DOI 10.1128/MCB.23.21.7861-7874.2003; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Redon C, 2006, GENETICS, V172, P67, DOI 10.1534/genetics.105.046128; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Sommariva E, 2005, MOL CELL BIOL, V25, P2770, DOI 10.1128/MCB.25.7.2770-2784.2005; Sugata N, 2000, HUM MOL GENET, V9, P2919, DOI 10.1093/hmg/9.19.2919; Szyjka SJ, 2005, MOL CELL, V19, P691, DOI 10.1016/j.molcel.2005.06.037; Takai H, 2000, GENE DEV, V14, P1439; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tsao CC, 2004, EMBO J, V23, P4660, DOI 10.1038/sj.emboj.7600463; Unsal-Kacmaz K, 2005, MOL CELL BIOL, V25, P3109, DOI 10.1128/MCB.25.8.3109-3116.2005; Wang X, 2006, MOL CELL, V23, P331, DOI 10.1016/j.molcel.2006.06.022; Yoo HY, 2006, GENE DEV, V20, P772, DOI 10.1101/gad.1398806; Yoshizawa-Sugata N, 2005, J BIOL CHEM, V280, P13062, DOI 10.1074/jbc.M411653200; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	50	99	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2729	2740		10.1074/jbc.M605596200	http://dx.doi.org/10.1074/jbc.M605596200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17102137	hybrid			2022-12-27	WOS:000243593200065
J	Alwan, HAJ; van Leeuwen, JEM				Alwan, Husam A. J.; van Leeuwen, Jeroen E. M.			UBPY-mediated epidermal growth factor receptor (EGFR) de-ubiquitination promotes EGFR degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOA4 DEUBIQUITINATING ENZYME; MULTIVESICULAR BODY PATHWAY; ERBB SIGNALING NETWORK; DOWN-REGULATION; TYROSINE KINASES; PROTEIN; ENDOCYTOSIS; ISOPEPTIDASE; YEAST; DOMAIN	Whereas poly-ubiquitination targets protein substrates for proteasomal degradation, mono-ubiquitination is known to regulate protein trafficking in the endosomal system and to target cargo proteins for lysosomal degradation. The role of the de-ubiquitinating enzymes AMSH and UBPY in endosomal trafficking of cargo proteins such as the epidermal growth factor receptor (EGFR) has only very recently been the subject of study and is already a matter of debate. Although one report (Mizuno, E., Iura, T., Mukai, A., Yoshimori, T., Kitamura, N., and Komada, M. (2005) Mol. Biol. Cell 16, 5163 - 5174) concludes that UBPY negatively regulates EGFR degradation by de-ubiquitinating the EGFR on endosomes, another report (Row, P. E., Prior, I. A., McCullough, J., Clague, M. J., and Urbe, S. (2006) J. Biol. Chem. 281, 12618 - 12624) concludes that UBPY-mediated EGFR de-ubiquitination is essential for EGFR degradation. Here, we demonstrate that Usp8/UBPY, the mammalian ortholog of budding yeast Ubp4/Doa4, constitutively co-precipitates in a bivalent manner with the EGFR. Moreover, UBPY is a substrate for Src-family tyrosine kinases that are activated after ligand-induced EGFR activation. Using overexpression of three different recombinant dominant negative UBPY mutants (UBPY C748A mutant, UBPY 1-505, and UBPY 640 - 1080) in NIH3T3 and HEK293 cells, we demonstrate that UBPY affects both constitutive and ligand-induced (i) EGFR ubiquitination, (ii) EGFR expression levels, and (iii) the appearance of intermediate EGFR degradation products as well as (iv) downstream mitogen-activated protein kinase signal transduction. Our findings provide further evidence in favor of the model that UBPY-mediated EGFR de-ubiquitination promotes EGFR degradation.	Radboud Univ Nijmegen, Fac Nat Sci, Inst Neurosci, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	van Leeuwen, JEM (corresponding author), Radboud Univ Nijmegen, Fac Nat Sci, Inst Neurosci, Dept Cell Biol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	j.vanleeuwen@science.ru.nl	van Leeuwen, Jeroen/G-3555-2010					Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bordo D, 2002, EMBO REP, V3, P741, DOI 10.1093/embo-reports/kvf150; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; Gnesutta N, 2001, J BIOL CHEM, V276, P39448, DOI 10.1074/jbc.M103454200; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Huang FT, 2003, J BIOL CHEM, V278, P43411, DOI 10.1074/jbc.M306072200; Kario E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Luhtala N, 2004, J CELL BIOL, V166, P717, DOI 10.1083/jcb.200403139; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Nicholson SE, 2005, P NATL ACAD SCI USA, V102, P2328, DOI 10.1073/pnas.0409675102; Nikko E, 2003, J BIOL CHEM, V278, P50732, DOI 10.1074/jbc.M306953200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Row PE, 2006, J BIOL CHEM, V281, P12618, DOI 10.1074/jbc.M512615200; SORKIN A, 1998, FRONT BIOSCI, V3, P729; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Wu XL, 2004, MOL CELL BIOL, V24, P7748, DOI 10.1128/MCB.24.17.7748-7757.2004; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	39	110	111	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1658	1669		10.1074/jbc.M604711200	http://dx.doi.org/10.1074/jbc.M604711200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121848	hybrid, Green Published			2022-12-27	WOS:000243451300017
J	Sampey, BP; Stewart, BJ; Petersen, DR				Sampey, Brante P.; Stewart, Benjamin J.; Petersen, Dennis R.			Ethanol-induced modulation of hepatocellular extracellular signal-regulated kinase-1/2 activity via 4-hydroxynonenal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION PRODUCTS; ISOLATED RAT HEPATOCYTES; ACTIVATED PROTEIN-KINASE; ALCOHOLIC LIVER-DISEASE; HEPATIC STELLATE CELLS; KAPPA-B ACTIVATION; IN-SITU DETECTION; OXIDATIVE STRESS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CARBON-TETRACHLORIDE	Modulation of the extracellular signal-regulated kinases (ERK-1/2), a signaling pathway directly associated with cell proliferation, survival, and homeostasis, has been implicated in several pathologies, including alcoholic liver disease. However, the underlying mechanism of ethanol-induced ERK-1/2 modulation remains unknown. This investigation explored the effects of ethanol-associated oxidative stress on constitutive hepatic ERK-1/2 activity and assessed the contribution of the lipid peroxidation product 4-hydroxynonenal (4-HNE) to the observations made in vivo. Constitutive ERK-1/2 phosphorylation was suppressed in hepatocytes isolated from rats chronically consuming ethanol for 45 days. This observation was associated with an increase in 4-HNE-ERK monomer adduct concentration and a hepatic cellular and lobular redistribution of ERK-1/2 that correlated with 4-HNE-protein adduct accumulation. Chronic ethanol consumption was also associated with a decrease in hepatocyte nuclear ELK-1 phosphorylation, independent of changes in total nuclear ELK-1 protein. Primary hepatocytes treated with concentrations of 4-HNE consistent with those occurring during oxidative stress displayed a concentration-dependent decrease in constitutive ERK-1/2 phosphorylation, activity, and nuclear localization that negatively correlated with 4-HNE-ERK-1/2 monomer adduct accumulation. These data paralleled the decreased phosphorylation of the downstream kinase ELK-1. Molar ratios of purified ERK-2 to 4-HNE consistent with pathologic ratios found in vivo resulted in protein monomer-adduct formation across a range of concentrations. Collectively, these data demonstrate a novel association between ethanol-induced lipid peroxidation and the inhibition of constitutive ERK-1/2, and suggest an inhibitory mechanism mediated by the lipid peroxidation product 4-hydroxynonenal.	Univ Colorado Denver & Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, Denver, CO 80262 USA; Univ N Carolina, Sch Med, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Petersen, DR (corresponding author), Univ Colorado Denver & Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, SOP Rm 434,Box C 238,4200 E 9th Ave, Denver, CO 80262 USA.	Dennis.Petersen@uchsc.edu		Sampey, Brante/0000-0001-7765-0667	NIAAA NIH HHS [R56 AA009300, R01 AA009300-11, R01 AA009300, R37 AA009300, AA009300] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009300, R56AA009300, R37AA009300] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aroor AR, 2004, LIFE SCI, V74, P2339, DOI 10.1016/j.lfs.2003.11.001; Bae MA, 2000, FASEB J, V14, pA1516; BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; BENEDETTI A, 1979, BIOCHEM J, V180, P303, DOI 10.1042/bj1800303; Bruckner SR, 2002, J NEUROSCI RES, V70, P665, DOI 10.1002/jnr.10437; Camandola S, 2000, J NEUROCHEM, V74, P159, DOI 10.1046/j.1471-4159.2000.0740159.x; Camandola S, 1997, BIOFACTORS, V6, P173, DOI 10.1002/biof.5520060211; CANUTO RA, 1994, CARCINOGENESIS, V15, P1359, DOI 10.1093/carcin/15.7.1359; Carbone DL, 2005, J PHARMACOL EXP THER, V315, P8, DOI 10.1124/jpet.105.088088; Carbone DL, 2005, CHEM RES TOXICOL, V18, P1324, DOI 10.1021/tx050078z; Carbone DL, 2004, FREE RADICAL BIO MED, V37, P1430, DOI 10.1016/j.freeradbiomed.2004.07.016; Carbone DL, 2004, CHEM RES TOXICOL, V17, P1459, DOI 10.1021/tx049838g; Chandler LJ, 2005, ALCOHOL CLIN EXP RES, V29, P672, DOI 10.1097/01.ALC.0000158935.53360.5F; Chen JP, 1998, BIOCHEM J, V334, P669, DOI 10.1042/bj3340669; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; Davis MI, 1999, NEUROSCI LETT, V272, P95, DOI 10.1016/S0304-3940(99)00572-8; Doorn JA, 2002, CHEM RES TOXICOL, V15, P1445, DOI 10.1021/tx025590o; DUGUAY L, 1982, GUT, V23, P8, DOI 10.1136/gut.23.1.8; ESTERBAUER H, 1986, BIOCHIM BIOPHYS ACTA, V876, P154, DOI 10.1016/0005-2760(86)90329-2; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GRUNE T, 1993, FREE RADICAL BIO MED, V15, P125, DOI 10.1016/0891-5849(93)90051-U; Hall PDM, 2001, ALCOHOL CLIN EXP RES, V25, p254S, DOI 10.1111/j.1530-0277.2001.tb02405.x; Hamilton RF, 1996, AM J RESP CELL MOL, V15, P275, DOI 10.1165/ajrcmb.15.2.8703485; Hartley DP, 1997, ALCOHOL CLIN EXP RES, V21, P298, DOI 10.1111/j.1530-0277.1997.tb03764.x; Hartley DP, 1997, CHEM RES TOXICOL, V10, P895, DOI 10.1021/tx960181b; Hartley DP, 1999, TOXICOL APPL PHARM, V161, P23, DOI 10.1006/taap.1999.8788; Hendrickson RJ, 1998, EUR J PHARMACOL, V362, P251, DOI 10.1016/S0014-2999(98)00771-7; Herbst U, 1999, J CELL PHYSIOL, V181, P295, DOI 10.1002/(SICI)1097-4652(199911)181:2<295::AID-JCP11>3.0.CO;2-I; Iles KE, 2005, FREE RADICAL BIO MED, V38, P547, DOI 10.1016/j.freeradbiomed.2004.11.012; Iles KE, 2003, FREE RADICAL BIO MED, V35, pS67; Ishii H, 1996, ALCOHOL CLIN EXP RES, V20, pA162, DOI 10.1111/j.1530-0277.1996.tb01768.x; Ishii T, 2003, BIOCHEMISTRY-US, V42, P3474, DOI 10.1021/bi027172o; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Ji C, 2001, CHEM RES TOXICOL, V14, P1090, DOI 10.1021/tx000186f; Ji C, 2001, J BIOL CHEM, V276, P18223, DOI 10.1074/jbc.M101266200; KAMIMURA S, 1992, HEPATOLOGY, V16, P448, DOI 10.1002/hep.1840160225; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Kono H, 2001, FREE RADICAL BIO MED, V30, P403, DOI 10.1016/S0891-5849(00)00490-1; KRUMAN T, 1997, J NEUROSCI, V17, P5089; Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483; Li L, 1996, TOXICOL APPL PHARM, V139, P135, DOI 10.1006/taap.1996.0152; Lindros KO, 1998, ALCOHOL ALCOHOLISM, V33, P347; Liu W, 2000, J CELL SCI, V113, P635; Liu W, 1999, J CELL SCI, V112, P2409; Luckey SW, 2002, J PHARMACOL EXP THER, V302, P296, DOI 10.1124/jpet.102.033522; Luckey SW, 1999, ADV EXP MED BIOL, V463, P71; Malecki A, 2000, J NEUROCHEM, V74, P2278, DOI 10.1046/j.1471-4159.2000.0742278.x; Meagher EA, 1999, J CLIN INVEST, V104, P805, DOI 10.1172/JCI5584; MITCHELL DY, 1991, HEPATOLOGY, V13, P728, DOI 10.1016/0270-9139(91)92572-P; Mooradian AD, 2001, NUTRITION, V17, P619, DOI 10.1016/S0899-9007(01)00580-9; NIEMELA O, 1995, HEPATOLOGY, V22, P1208, DOI 10.1016/0270-9139(95)90630-4; Niemela O, 2001, FREE RADICAL BIO MED, V31, P1533, DOI 10.1016/S0891-5849(01)00744-4; Niemela O, 2001, HEPATOLOGY, V34, p694A; NORDMANN R, 1990, ALCOHOL ALCOHOLISM, V25, P231, DOI 10.1093/oxfordjournals.alcalc.a044996; OHYA T, 1994, BIOL PHARM BULL, V17, P1411; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; Page S, 1999, ATHEROSCLEROSIS, V144, P10, DOI 10.1016/S0021-9150(99)80032-X; Paradis V, 1997, HEPATOLOGY, V26, P135; Paradis V, 1997, J CLIN PATHOL, V50, P401, DOI 10.1136/jcp.50.5.401; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; POLI G, 1985, BIOCHEM J, V227, P629, DOI 10.1042/bj2270629; Poli G, 2000, IUBMB LIFE, V50, P315, DOI 10.1080/15216540051081092; Robino G, 1997, HEPATOLOGY, V26, P973; Ronis MJJ, 2005, FREE RADICAL BIO MED, V39, P619, DOI 10.1016/j.freeradbiomed.2005.04.011; Ruef J, 1998, CIRCULATION, V97, P1071, DOI 10.1161/01.CIR.97.11.1071; Sampey BP, 2003, ALCOHOL CLIN EXP RES, V27, P1015, DOI 10.1097/01.ALC.0000071928.16732.26; SCHAUR RJ, 1991, MEMBRANE LIPID OXIDA, V3, P141; TEARE JP, 1994, GUT, V35, P1644, DOI 10.1136/gut.35.11.1644; Tjalkens RB, 1998, ARCH BIOCHEM BIOPHYS, V359, P42, DOI 10.1006/abbi.1998.0895; TSUKAMOTO H, 1995, J CLIN INVEST, V96, P620, DOI 10.1172/JCI118077; TUMA DJ, 1995, HEPATOLOGY, V22, P479; Tuma DJ, 2002, FREE RADICAL BIO MED, V32, P303, DOI 10.1016/S0891-5849(01)00742-0; Tyagi A, 2003, ONCOGENE, V22, P1302, DOI 10.1038/sj.onc.1206265; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; WANDS JR, 1979, GASTROENTEROLOGY, V77, P528; Watanabe T, 2001, ATHEROSCLEROSIS, V155, P37, DOI 10.1016/S0021-9150(00)00526-8; Weng YI, 2003, ALCOHOL, V29, P83, DOI 10.1016/S0741-8329(02)00325-7; ZARKOVIC N, 1993, CELL BIOCHEM FUNCT, V11, P279, DOI 10.1002/cbf.290110409	82	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1925	1937		10.1074/jbc.M610602200	http://dx.doi.org/10.1074/jbc.M610602200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17107949	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000243451300043
J	Splingard, A; Menetrey, J; Perderiset, M; Cicolari, J; Regazzoni, K; Hamoudi, F; Cabanie, L; El Marjou, A; Wells, A; Houdusse, A; de Gunzburg, J				Splingard, Anne; Menetrey, Julie; Perderiset, Mylene; Cicolari, Jerome; Regazzoni, Karine; Hamoudi, Fatima; Cabanie, Lucien; El Marjou, Ahmed; Wells, Amber; Houdusse, Anne; de Gunzburg, Jean			Biochemical and structural characterization of the gem GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BINDING-PROTEINS; CHANNEL ACTIVITY; CELL-SHAPE; FAMILY; EXPRESSION; RESOLUTION; INTERACTS; TERMINUS; P21	RGK proteins, encompassing Rad, Gem, Rem1, and Rem2, constitute an intriguing branch of the Ras superfamily; their expression is regulated at the transcription level, they exhibit atypical nucleotide binding motifs, and they carry both large Nand C-terminal extensions. Biochemical and structural studies are required to better understand how such proteins function. Here, we report the first structure for a RGK protein: the crystal structure of a truncated form of the human Gem protein (G domain plus the first part of the C-terminal extension) in complex with Mg center dot GDP at 2.1 angstrom resolution. It reveals that the G-domain fold and Mg center dot GDP binding site of Gem are similar to those found for other Ras family GTPases. The first part of the C-terminal extension adopts an alpha-helical conformation that extends along the alpha 5 helix and interacts with the tip of the interswitch. Biochemical studies show that the affinities of Gem for GDP and GTP are considerably lower (micromolar range) compared with H-Ras, independent of the presence or absence of N- and C-terminal extensions, whereas its GTPase activity is higher than that of H-Ras and regulated by both extensions. We show how the bulky DXWEX motif, characteristic of the switch II of RGK proteins, affects the conformation of switch I and the phosphate-binding site. Altogether, our data reveal that Gem is a bona fide GTPase that exhibits striking structural and biochemical features that should impact its regulation and cellular activities.	Inst Curie, INSERM, U528, F-75248 Paris 05, France; Inst Curie, Ctr Rech, F-75248 Paris, France; CNRS, UMR 144, F-75248 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Houdusse, A (corresponding author), Inst Curie, INSERM, U528, 26 Rue Ulm, F-75248 Paris 05, France.	anne.houdusse@curie.fr; gunzburg@curie.fr	Ménétrey, Julie/AAM-6408-2021	houdusse, anne/0000-0002-8566-0336	MRC [G0500367] Funding Source: UKRI; Medical Research Council [G0500367] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Amor JC, 2001, J BIOL CHEM, V276, P42477, DOI 10.1074/jbc.M106660200; Aresta S, 2002, BIOCHEM J, V367, P57, DOI 10.1042/BJ20020829; Bahloul A, 2004, P NATL ACAD SCI USA, V101, P4787, DOI 10.1073/pnas.0306892101; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beguin P, 2005, J CELL SCI, V118, P1923, DOI 10.1242/jcs.02321; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; Finlin BS, 2005, J BIOL CHEM, V280, P41864, DOI 10.1074/jbc.M414261200; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; Hillig RC, 2000, STRUCTURE, V8, P1239, DOI 10.1016/S0969-2126(00)00531-1; Huang MD, 2001, J CELL BIOL, V155, P937, DOI 10.1083/jcb.200106039; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; Kelly K, 2005, TRENDS CELL BIOL, V15, P640, DOI 10.1016/j.tcb.2005.10.002; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Menetrey J, 2000, NAT STRUCT BIOL, V7, P466; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Piddini E, 2001, EMBO J, V20, P4076, DOI 10.1093/emboj/20.15.4076; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Ward Y, 2002, J CELL BIOL, V157, P291, DOI 10.1083/jcb.200111026	33	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1905	1915		10.1074/jbc.M604363200	http://dx.doi.org/10.1074/jbc.M604363200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17107948	hybrid			2022-12-27	WOS:000243451300041
J	Horstmann, N; Seidel, G; Aung-Hilbrich, LM; Hillen, W				Horstmann, Nicola; Seidel, Gerald; Aung-Hilbrich, Lwin-Mar; Hillen, Wolfgang			Residues His-15 and Arg-17 of HPr participate differently in catabolite signal processing via CcpA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOCARRIER PROTEIN HPR; REQUIRES SEQUENCES UPSTREAM; GRAM-POSITIVE BACTERIA; BACILLUS-SUBTILIS; TRANSCRIPTIONAL ACTIVATION; STREPTOMYCES-COELICOLOR; CARBON CATABOLISM; DNA-BINDING; REPRESSION; HISTIDINE	The carbon catabolite control protein A (CcpA) senses the physiological state of the cell by binding several effectors and responds with differential regulation of many genes in Bacilli. HPr-Ser46-P or Crh-Ser46-P interact with CcpA and stimulate binding to catabolite responsive elements. In addition, the glycolytic intermediates fructose 1,6-bisphosphate (FBP) and glucose 6-phosphate (Glc-6-P) stimulate HPr-Ser46-P but not CrhSer46-P binding to CcpA. The mechanisms by which coeffector binding to CcpA is linked to differential gene expression are unclear. To address this question we mutated residues participating in the interaction between HPr-Ser46-P or Crh-Ser46-P and CcpA and analyzed their effects on CcpA binding and stimulation of cre binding by surface plasmon resonance. The HPrH15A and CcpAD297A mutations do not affect complex formation but abolish FBP and Glc-6-P stimulation. Likewise, the CrhQ15H mutant becomes sensitive to these glycolytic intermediates. Hence, the contact of HPrHis-15 to Asp-297 in CcpA is a determinant for HPr specific FBP and Glc-6-P stimulation. The HPrR17A and -K mutants are both strongly impaired in stimulation of CcpA binding to cre, but only HPrR17A is defect in binding to CcpA indicating that these residues affect allostery of CcpA. Mutations of the residues of CcpA, which contact Arg-17 of HPr, exhibit differential effects on regulation of catabolic genes. Taken together, His-15 of HPr processes sensing information, while Arg-17 is involved in determining the genetic output.	Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Hillen, W (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, Staudtstr 5, D-91058 Erlangen, Germany.	whillen@biologie.uni-erlangen.de		Horstmann, Nicola/0000-0002-3620-5169				ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; Aung-Hilbrich LM, 2002, J MOL BIOL, V319, P77, DOI 10.1016/S0022-2836(02)00245-0; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bruckner R, 2002, FEMS MICROBIOL LETT, V209, P141; DEUTSCHER J, 1995, MOL MICROBIOL, V15, P1049, DOI 10.1111/j.1365-2958.1995.tb02280.x; Fernandez-Ballester G, 2003, EUR J BIOCHEM, V270, P2254, DOI 10.1046/j.1432-1033.2003.03594.x; Galinier A, 1999, J MOL BIOL, V286, P307, DOI 10.1006/jmbi.1998.2492; Galinier A, 1997, P NATL ACAD SCI USA, V94, P8439, DOI 10.1073/pnas.94.16.8439; Gorke B, 2004, J BACTERIOL, V186, P2992, DOI 10.1128/JB.186.10.2992-2995.2004; Gosseringer R, 1997, J MOL BIOL, V266, P665, DOI 10.1006/jmbi.1996.0820; GRUNDY FJ, 1993, J BACTERIOL, V175, P7348, DOI 10.1128/JB.175.22.7348-7355.1993; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Henkin TM, 1996, FEMS MICROBIOL LETT, V135, P9; HERZBERG O, 1992, J BIOL CHEM, V267, P24819; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; Jones BE, 1997, PROTEIN SCI, V6, P2107; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Moir-Blais TR, 2001, J BACTERIOL, V183, P2389, DOI 10.1128/JB.183.7.2389-2393.2001; Moreno MS, 2001, MOL MICROBIOL, V39, P1366, DOI 10.1046/j.1365-2958.2001.02328.x; Parche S, 1999, EUR J BIOCHEM, V265, P308, DOI 10.1046/j.1432-1327.1999.00727.x; Poncet S, 2004, BBA-PROTEINS PROTEOM, V1697, P123, DOI 10.1016/j.bbapap.2003.11.018; Reizer J, 1996, J BACTERIOL, V178, P5480, DOI 10.1128/jb.178.18.5480-5486.1996; Reizer J, 1998, MOL MICROBIOL, V27, P1157, DOI 10.1046/j.1365-2958.1998.00747.x; RENNA MC, 1993, J BACTERIOL, V175, P3863, DOI 10.1128/JB.175.12.3863-3875.1993; RYGUS T, 1991, APPL MICROBIOL BIOT, V35, P594; Schumacher MA, 2006, J BIOL CHEM, V281, P6793, DOI 10.1074/jbc.M509977200; Schumacher MA, 2004, CELL, V118, P731, DOI 10.1016/j.cell.2004.08.027; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; Seidel G, 2005, FEBS J, V272, P2566, DOI 10.1111/j.1742-4658.2005.04682.x; Stulke J, 2000, ANNU REV MICROBIOL, V54, P849, DOI 10.1146/annurev.micro.54.1.849; Tobisch S, 1999, J BACTERIOL, V181, P6996, DOI 10.1128/JB.181.22.6996-7004.1999; Turinsky AJ, 1998, J BACTERIOL, V180, P5961, DOI 10.1128/JB.180.22.5961-5967.1998; Van Nuland NAJ, 1998, BIOCHEMISTRY-US, V37, P622, DOI 10.1021/bi9717946; Wagner A, 2000, J MOL MICROB BIOTECH, V2, P587; Warner JB, 2000, J BACTERIOL, V182, P6099, DOI 10.1128/JB.182.21.6099-6105.2000; Warner JB, 2003, FEMS MICROBIOL LETT, V220, P277, DOI 10.1016/S0378-1097(03)00126-5; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869	38	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1175	1182		10.1074/jbc.M605854200	http://dx.doi.org/10.1074/jbc.M605854200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17085448	hybrid			2022-12-27	WOS:000243295200043
J	Hopkins, EJ; Layfield, S; Ferraro, T; Bathgate, RAD; Gooley, PR				Hopkins, Emma J.; Layfield, Sharon; Ferraro, Tania; Bathgate, Ross A. D.; Gooley, Paul R.			The NMR solution structure of the relaxin (RXFP1) receptor lipoprotein receptor class A module and identification of key residues in the N-terminal region of the module that mediate receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH REPEAT; TORSION ANGLE DYNAMICS; LIGAND-BINDING MODULES; LDL RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; 3-DIMENSIONAL STRUCTURE; PROTEIN STRUCTURES; CALCIUM-BINDING; DOMAIN; LGR7	The receptors for the peptide hormones relaxin and insulin-like peptide 3 (INSL3) are the leucine-rich repeat-containing G-protein-coupled receptors LGR7 and LGR8 recently renamed as the relaxin family peptide (RXFP) receptors, RXFP1 and RXFP2, respectively. These receptors differ from other LGRs by the addition of an N-terminal low density lipoprotein receptor class A (LDLa) module and are the only human G-protein-coupled receptors to contain such a domain. Recently it was shown that the LDLa module of the RXFP1 and RXFP2 receptors is essential for ligand-stimulated cAMP signaling. The mechanism by which the LDLa module modulates receptor signaling is unknown; however, it represents a unique paradigm in understanding G-protein-coupled receptor signaling. Here we present the structure of the RXFP1 receptor LDLa module determined by solution NMR spectroscopy. The structure is similar to other LDLa modules but shows small differences in side chain orientations and inter-residue packing. Interchange of the module with the second ligand binding domain of the LDL receptor, LB2, results in a receptor that binds relaxin with full affinity but is unable to signal. Furthermore, we demonstrate via structural studies on mutated LDLa modules and functional studies on mutated full-length receptors that a hydrophobic surface within the N-terminal region of the module is essential for activation of RXFP1 receptor signal in response to relaxin stimulation. This study has highlighted the necessity to understand the structural effects of single amino acid mutations on the LDLa module to fully interpret the effects of these mutations on receptor activity.	Univ Melbourne, Dept Biochem & Mol Biol, Bio21 Mol Sci & Biotechnol Inst, Parkville, Vic 3010, Australia; Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia	University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Gooley, PR (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Bio21 Mol Sci & Biotechnol Inst, 30 Flemington Rd, Parkville, Vic 3010, Australia.	prg@unimelb.edu.au	Bathgate, Ross/ABE-6471-2020	Bathgate, Ross/0000-0001-6301-861X; Petrie, Emma/0000-0002-9827-3378; Gooley, Paul/0000-0002-0323-449X				Abdul-Aziz D, 2005, BIOCHEMISTRY-US, V44, P5075, DOI 10.1021/bi047575j; ADHAM IM, 1993, J BIOL CHEM, V268, P26668; Andersen Olav M, 2003, BMC Biochem, V4, P7, DOI 10.1186/1471-2091-4-7; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bani D, 1997, B CANCER, V84, P179; Bathgate RA, 2006, PHARMACOL REV, V58, P7, DOI 10.1124/pr.58.1.9; Bieri S, 1998, BIOCHEMISTRY-US, V37, P10994, DOI 10.1021/bi980452c; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; Bogatcheva NV, 2003, MOL ENDOCRINOL, V17, P2639, DOI 10.1210/me.2003-0096; BURKHARDT E, 1994, HUM GENET, V94, P91, DOI 10.1007/BF02272850; Cai ML, 1998, J BIOMOL NMR, V11, P97, DOI 10.1023/A:1008222131470; CASTEN GG, 1958, JAMA-J AM MED ASSOC, V166, P319, DOI 10.1001/jama.1958.02990040005002; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dolmer K, 1998, BIOCHEMISTRY-US, V37, P17016, DOI 10.1021/bi982022s; Dolmer K, 2000, J BIOL CHEM, V275, P3264, DOI 10.1074/jbc.275.5.3264; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; GIDDARD TD, 2004, SPARKY 3; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hisaw FL, 1926, P SOC EXP BIOL MED, V23, P661; Hopkins EJ, 2005, ANN NY ACAD SCI, V1041, P27, DOI 10.1196/annals.1282.006; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; Huang W, 1999, J BIOL CHEM, V274, P14130, DOI 10.1074/jbc.274.20.14130; JOHNSON B, 1994, J BIOMOL NMR, V5, P603; Kawamura K, 2004, P NATL ACAD SCI USA, V101, P7323, DOI 10.1073/pnas.0307061101; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Mertens HDT, 2005, FEBS LETT, V579, P5542, DOI 10.1016/j.febslet.2005.09.017; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; North CL, 2000, BIOCHEMISTRY-US, V39, P2564, DOI 10.1021/bi992087a; Pusch W, 1996, ENDOCRINOLOGY, V137, P3009, DOI 10.1210/en.137.7.3009; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Scott DJ, 2006, J BIOL CHEM, V281, P34942, DOI 10.1074/jbc.M602728200; Scott DJ, 2004, CLIN EXP PHARMACOL P, V31, P828, DOI 10.1111/j.1440-1681.2004.04075.x; Simonovic M, 2001, BIOCHEMISTRY-US, V40, P15127, DOI 10.1021/bi015688m; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; Tonelli M, 2001, FEBS LETT, V509, P161, DOI 10.1016/S0014-5793(01)03086-1; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; Wang QY, 2002, J VIROL, V76, P2848, DOI 10.1128/JVI.76.6.2848-2856.2002; Wang QY, 2001, J VIROL, V75, P2051, DOI 10.1128/JVI.75.5.2051-2058.2001; Wilkinson TN, 2005, ANN NY ACAD SCI, V1041, P534, DOI 10.1196/annals.1282.080; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	52	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4172	4184		10.1074/jbc.M609526200	http://dx.doi.org/10.1074/jbc.M609526200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148455	hybrid			2022-12-27	WOS:000244481900080
J	Napier, SL; Healy, ZR; Schnaar, RL; Konstantopoulos, K				Napier, Susan L.; Healy, Zachary R.; Schnaar, Ronald L.; Konstantopoulos, Konstantinos			Selectin ligand expression regulates the initial vascular interactions of colon carcinoma cells - The roles of CD44V and alternative sialofucosylated selectin ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-SELECTIN; IMMOBILIZED PLATELETS; TUMOR-METASTASIS; DYNAMIC FLOW; ADHESION; CANCER; HEPARIN; GLYCOPROTEINS; VARIANT; SEQUENCES	Selectin-mediated binding of tumor cells to platelets, leukocytes, and vascular endothelium may regulate their hematogenous spread in the microvasculature. We recently reported that CD44 variant isoforms (CD44v) on LS174T colon carcinoma cells possess selectin binding activity. Here we extended those findings by showing that T84 and Colo205 colon carcinoma cells bind selectins via sialidase-sensitive O-linked glycans presented on CD44v, independent of heparan and chondroitin sulfate. To assess the functional role of CD44v in selectin-mediated binding, we quantified the adhesion to selectins of T84 cell subpopulations sorted based on their CD44 expression levels and stable LS174T cell lines generated using CD44 short hairpin RNA. High versus low CD44-expressing T84 cells tethered more efficiently to P- and L-selectin, but not E-selectin, and rolled more slowly on P- and E-selectin. Knocking down CD44 expression on LS174T cells inhibited binding to P-selectin and increased rolling velocities over P- and L-selectin relative to control-transfected cells, without affecting tethering and rolling on E-selectin, however. Blot rolling analysis revealed the presence of alternative sialylated glycoproteins with molecular masses of similar to 170 and similar to 130 kDa, which can mediate selectin binding in CD44-knockdown cells. Heparin diminishes the avidity of colon carcinoma cells for P- and L-selectin, which may compromise integrin-mediated firm adhesion to host cells and mitigate metastasis. Our finding that CD44v is a functional P-selectin ligand on colon carcinoma provides a novel perspective on the enhanced metastatic potential associated with tumor CD44v overexpression and the role of selectins in metastasis.	Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Pharmacol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Konstantopoulos, K (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	kkonsta1@jhu.edu	Konstantopoulos, Konstantinos/A-7045-2011; Thomas, Susan/A-9947-2009; Schnaar, Ronald L/S-8967-2016; Thomas, Susan/B-4592-2016	Thomas, Susan/0000-0003-4651-232X; Schnaar, Ronald L/0000-0002-7701-5484; 	NCI NIH HHS [R01 CA101135] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101135] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Borsig L, 2004, NEWS PHYSIOL SCI, V19, P16, DOI 10.1152/nips.01450.2003; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Brodt P, 1997, INT J CANCER, V71, P612, DOI 10.1002/(SICI)1097-0215(19970516)71:4<612::AID-IJC17>3.0.CO;2-D; Burdick MM, 2004, AM J PHYSIOL-CELL PH, V287, pC539, DOI 10.1152/ajpcell.00450.2003; Burdick MM, 2003, AM J PHYSIOL-CELL PH, V284, pC977, DOI 10.1152/ajpcell.00423.2002; Burdick MM, 2006, J BIOL CHEM, V281, P13899, DOI 10.1074/jbc.M513617200; Dimitroff CJ, 2000, P NATL ACAD SCI USA, V97, P13841, DOI 10.1073/pnas.250484797; Fuhlbrigge RC, 2002, J IMMUNOL, V168, P5645, DOI 10.4049/jimmunol.168.11.5645; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hanley WD, 2005, CANCER RES, V65, P5812, DOI 10.1158/0008-5472.CAN-04-4557; Hanley WD, 2006, FASEB J, V20, P337, DOI 10.1096/fj.05-4574fje; Harada N, 2001, INT J CANCER, V91, P67, DOI 10.1002/1097-0215(20010101)91:1<67::AID-IJC1011>3.0.CO;2-D; HOFMANN M, 1991, CANCER RES, V51, P5292; IZUMI Y, 1995, EXP CELL RES, V216, P215, DOI 10.1006/excr.1995.1027; Jadhav S, 2002, AM J PHYSIOL-CELL PH, V283, pC1133, DOI 10.1152/ajpcell.00104.2002; Jadhav S, 2001, J IMMUNOL, V167, P5986, DOI 10.4049/jimmunol.167.10.5986; Kannagi R, 1997, GLYCOCONJUGATE J, V14, P577, DOI 10.1023/A:1018532409041; Kim HR, 2004, CANCER RES, V64, P4569, DOI 10.1158/0008-5472.CAN-04-0202; Kim YJ, 1997, GLYCOCONJUGATE J, V14, P569, DOI 10.1023/A:1018580324971; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Konstantopoulos K, 1998, ADV DRUG DELIVER REV, V33, P141, DOI 10.1016/S0169-409X(98)00024-6; MANNORI G, 1995, CANCER RES, V55, P4425; McCarty OJT, 2000, BLOOD, V96, P1789, DOI 10.1182/blood.V96.5.1789.h8001789_1789_1797; McCarty OJT, 2002, BIOPHYS J, V83, P836, DOI 10.1016/S0006-3495(02)75212-0; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; Nieswandt B, 1999, CANCER RES, V59, P1295; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Sackstein R, 2000, BLOOD, V96, P2765, DOI 10.1182/blood.V96.8.2765.h8002765_2765_2774; Simon SI, 2005, ANNU REV BIOMED ENG, V7, P151, DOI 10.1146/annurev.bioeng.7.060804.100423; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; TOZEREN A, 1995, INT J CANCER, V60, P426; VARKI A, 1997, J CLIN INVEST, V100, P31; Wei M, 2004, J BIOL CHEM, V279, P29202, DOI 10.1074/jbc.M312951200; WIELENGA VJM, 1993, CANCER RES, V53, P4754	37	93	98	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3433	3441		10.1074/jbc.M607219200	http://dx.doi.org/10.1074/jbc.M607219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17135256	hybrid			2022-12-27	WOS:000244481900005
J	Orr, SJ; Morgan, NM; Buick, RJ; Boyd, CR; Elliott, J; Burrows, JF; Jefferies, CA; Crocker, PR; Johnston, JA				Orr, Selinda J.; Morgan, Nuala M.; Buick, Richard J.; Boyd, Caroline R.; Elliott, Joanne; Burrows, James F.; Jefferies, Caroline A.; Crocker, Paul R.; Johnston, James A.			SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIC MYELOID CELLS; PROLIFERATION; PHOSPHORYLATION; P75/AIRM1; RECEPTOR; CD33; INTERLEUKIN-2; INFLAMMATION; DEFICIENCY; ENGAGEMENT	CD33-related Siglecs (sialic acid-binding immunoglobulin-like lectins) 5-11 are inhibitory receptors that contain a membrane proximal ITIM (immunoreceptor tyrosine-based inhibitory motif) (I/V/L/)XYXX(L/V), which can recruit SHP-1/2. However, little is known about the regulation of these receptors. SOCS3 (suppressor of cytokine signaling 3) is up-regulated during inflammation and competes with SHP-1/2 for binding to ITIM-like motifs on various cytokine receptors resulting in inhibition of signaling. We show that SOCS3 binds the phosphorylated ITIM of Siglec 7 and targets it for proteasomal-mediated degradation, suggesting that Siglec 7 is a novel SOCS target. Following ligation, the ECS E3 ligase is recruited by SOCS3 to target Siglec 7 for proteasomal degradation, and SOCS3 expression is decreased concomitantly. In addition, we found that SOCS3 expression blocks Siglec 7-mediated inhibition of cytokine-induced proliferation. This is the first time that a SOCS target has been reported to degrade simultaneously with the SOCS protein and that inhibitory receptors have been shown to be degraded in this way. This may be a mechanism by which the inflammatory response is potentiated during infection.	Queens Univ Belfast, Div Infect & Immun, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; Royal Coll Surgeons Ireland, Dept Mol & Cellular Therapeut, Dublin 2, Ireland; Univ Dundee, Div Cell Biol & Immunol, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	Queens University Belfast; Royal College of Surgeons - Ireland; University of Dundee	Johnston, JA (corresponding author), Queens Univ Belfast, Div Infect & Immun, Ctr Canc Res & Cell Biol, 2nd Fl Whitla Med Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	jim.johnston@qub.ac.uk	Jefferies, Caroline/AAI-1543-2021	Jefferies, Caroline/0000-0002-8879-6722; Crocker, Paul/0000-0001-6230-0293; Orr, Selinda/0000-0001-8539-7825	Wellcome Trust [07034/Z/03/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Avril T, 2004, J IMMUNOL, V173, P6841, DOI 10.4049/jimmunol.173.11.6841; Billadeau DD, 2002, J CLIN INVEST, V109, P161, DOI 10.1172/JCI14843; Burrows JF, 2004, J BIOL CHEM, V279, P13993, DOI 10.1074/jbc.M311291200; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Crespo A, 2000, BIOCHEM J, V349, P99, DOI 10.1042/0264-6021:3490099; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; Elliott J, 2004, TRENDS IMMUNOL, V25, P434, DOI 10.1016/j.it.2004.05.012; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Hortner M, 2002, EUR J BIOCHEM, V269, P2516, DOI 10.1046/j.1432-1033.2002.02916.x; Ikehara Y, 2004, J BIOL CHEM, V279, P43117, DOI 10.1074/jbc.M403538200; Johnston JA, 2003, NAT IMMUNOL, V4, P507, DOI 10.1038/ni0603-507; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Mingari MC, 2001, IMMUNOL REV, V181, P260, DOI 10.1034/j.1600-065X.2001.1810122.x; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Tannahill GM, 2005, MOL CELL BIOL, V25, P9115, DOI 10.1128/MCB.25.20.9115-9126.2005; Vitale C, 2001, P NATL ACAD SCI USA, V98, P5764, DOI 10.1073/pnas.091097198; Vitale C, 1999, P NATL ACAD SCI USA, V96, P15091, DOI 10.1073/pnas.96.26.15091	24	48	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3418	3422		10.1074/jbc.C600216200	http://dx.doi.org/10.1074/jbc.C600216200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17138568	hybrid			2022-12-27	WOS:000244481900002
J	Reinhold, MI; Naski, MC				Reinhold, Martina I.; Naski, Michael C.			Direct interactions of Runx2 and canonical Wnt signaling induce FGF18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TCF TRANSCRIPTION FACTORS; FACTOR RECEPTOR-3 GENE; BETA-CATENIN; CHONDROCYTE PROLIFERATION; NEGATIVE REGULATOR; ENDOCHONDRAL BONE; OSTEOBLAST; DIFFERENTIATION; EXPRESSION; OSTEOGENESIS	Canonical Wnt signaling is clearly required for skeletal development and bone formation. However, the targets of Wnt signaling that convert this signal into bone are unclear. Identification of these targets will yield insight into normal bone physiology and suggest new therapeutics for treatment of bone disease. Here we show that an essential regulator of bone development, FGF18, is a direct target of canonical Writ signaling. A single DNA binding site for the Wnt-dependent transcription factors TCF/Lef accounted for the stimulation of fgf18 promoter in response to Wnt signaling. Additionally, targeted disruption of beta cat blocked fgf18 expression in vivo. Partially overlapping the TCF/Lef binding site is a Runx2 binding site and experiments showed that Runx2 and TCF/Lef work cooperatively to induced fgf18 expression. RNA interference knockdown of Runx2 inhibited and Runx2 forced expression augmented the induction of fgf18 by canonical Writ signaling. Significantly, Runx2 formed a complex with Lef1 or TCF4 and this complex bound the composite binding site in the fgf18 promoter. These results demonstrate that two transcription pathways that are essential for bone, physically and functionally converge at the fgf18 promoter.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Naski, MC (corresponding author), 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	naski@uthscsa.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050024] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR050024] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brault V, 2001, DEVELOPMENT, V128, P1253; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Hinoi E, 2006, GENE DEV, V20, P2937, DOI 10.1101/gad.1482906; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; James MJ, 2006, J BONE MINER RES, V21, P1034, DOI 10.1359/JBMR.060413; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200; Kapadia RA, 2005, DEV BIOL, V285, P496, DOI 10.1016/j.ydbio.2005.07.029; Kim S, 2006, J BIOL CHEM, V281, P14066, DOI 10.1074/jbc.M602696200; Mak KK, 2006, DEVELOPMENT, V133, P3695, DOI 10.1242/dev.02546; Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; McEwen DG, 1999, J BIOL CHEM, V274, P30934, DOI 10.1074/jbc.274.43.30934; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Naski MC, 1998, DEVELOPMENT, V125, P4977; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; Reinhold MI, 2004, MOL ENDOCRINOL, V18, P241, DOI 10.1210/me.2003-0312; Reinhold MI, 2004, J BIOL CHEM, V279, P38209, DOI 10.1074/jbc.M404855200; Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Shimokawa T, 2003, CANCER RES, V63, P6116; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324; Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491	47	84	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3653	3663		10.1074/jbc.M608995200	http://dx.doi.org/10.1074/jbc.M608995200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158875	hybrid			2022-12-27	WOS:000244481900027
J	Schneider, HP; Broeer, S; Broeer, A; Deitmer, JW				Schneider, Hans-Peter; Broeer, Stefan; Broeer, Angelika; Deitmer, Joachim W.			Heterologous expression of the glutamine transporter SNAT3 in Xenopus oocytes is associated with four modes of uncoupled transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; MAMMALIAN SEROTONIN TRANSPORTER; CHLORIDE CHANNEL ACTIVITY; PERFUSED-RAT-LIVER; LAEVIS OOCYTES; NEUROTRANSMITTER TRANSPORTERS; GLIAL-CELLS; SYSTEM; PH; PROTEOLYSIS	The glutamine transporter SNAT3 (SLC38A3, former SN1) plays a major role in glutamine release from brain astrocytes and in glutamine uptake into hepatocytes and kidney epithelial cells. Here we expressed rat SNAT3 in oocytes of Xenopus laevis and reinvestigated its transport modes using two-electrode voltage clamp and pH-sensitive microelectrodes. In addition to the established coupled Na+-glutamine-cotransport/H+ antiport, we found that there are three conductances associated with SNAT3, two dependent and one independent of the amino acid substrate. The glutamine-dependent conductance is carried by cations at pH 7.4, whereas at pH 8.4 the inward currents are still dependent on the presence of external Na+ but are carried by H+. Mutation of threonine 380 to alanine abolishes the cation conductance but leaves the proton conductance intact. Under Na+-free conditions, where the substrate - dependent conductance is suppressed, a substrate-independent, outwardly rectifying current becomes apparent at pH 8.4 that is carried by K+ and H+. In addition, we identified a glutamine-dependent uncoupled Na+/H+ exchange activity that becomes apparent upon removal of Na+ in the presence of glutamine. In conclusion, our results suggest that, in addition to coupled transport, SNAT3 mediates four modes of uncoupled ion movement across the membrane.	Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia; TU Kaiserslautern, Fachbereich Biol, Abt Allgemeine Zool, D-67653 Kaiserslautern, Germany	Australian National University; University of Kaiserslautern	Broeer, S (corresponding author), Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia.	stefan.broeer@anu.edu.au; deitmer@biologie.uni-ki.de	Broer, Stefan/A-1286-2008	Broer, Stefan/0000-0002-8040-1634				Becker HM, 2004, BIOPHYS J, V86, P235, DOI 10.1016/S0006-3495(04)74099-0; Blakely RD, 2005, PHYSIOLOGY, V20, P225, DOI 10.1152/physiol.00013.2005; Boll M, 2004, PFLUG ARCH EUR J PHY, V447, P776, DOI 10.1007/s00424-003-1073-4; Broer A, 2000, BIOCHEM J, V346, P705, DOI 10.1042/0264-6021:3460705; Broer A, 2002, J PHYSIOL-LONDON, V539, P3, DOI 10.1013/jphysiol.2001.013303; Broer S, 2002, PFLUG ARCH EUR J PHY, V444, P457, DOI 10.1007/s00424-002-0840-y; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; Broer Stefan, 2003, Methods Mol Biol, V227, P245, DOI 10.1385/1-59259-387-9:245; Cao YW, 1997, J NEUROSCI, V17, P2257; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Fei YJ, 2000, J BIOL CHEM, V275, P23707, DOI 10.1074/jbc.M002282200; Galli A, 1996, P NATL ACAD SCI USA, V93, P8671, DOI 10.1073/pnas.93.16.8671; Gasnier B, 2004, PFLUG ARCH EUR J PHY, V447, P756, DOI 10.1007/s00424-003-1091-2; Gouaux E, 2005, SCIENCE, V310, P1461, DOI 10.1126/science.1113666; Gu SM, 2000, P NATL ACAD SCI USA, V97, P3230, DOI 10.1073/pnas.050318197; HAUSSINGER D, 1990, EUR J BIOCHEM, V188, P689, DOI 10.1111/j.1432-1033.1990.tb15451.x; HAUSSINGER D, 1990, BIOCHEM J, V272, P239, DOI 10.1042/bj2700039; Hill, 2001, ION CHANNELS EXCITAB, P441; Ingram SL, 2002, NAT NEUROSCI, V5, P971, DOI 10.1038/nn920; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MATHISEN J, 2001, EMBO J, V20, P7041; MUNSCH T, 1994, J PHYSIOL-LONDON, V474, P43, DOI 10.1113/jphysiol.1994.sp020001; Nelson N, 2002, NAT REV MOL CELL BIO, V3, P876, DOI 10.1038/nrm955; Ryan RM, 2005, CLIN EXP PHARMACOL P, V32, P1, DOI 10.1111/j.1440-1681.2005.04164.x; Ryan RM, 2002, J BIOL CHEM, V277, P13494, DOI 10.1074/jbc.M109970200; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Stegen C, 2000, BBA-BIOMEMBRANES, V1467, P91, DOI 10.1016/S0005-2736(00)00209-1; Sulzer D, 2003, TRENDS NEUROSCI, V26, P173, DOI 10.1016/S0166-2236(03)00063-8; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991	36	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3788	3798		10.1074/jbc.M609452200	http://dx.doi.org/10.1074/jbc.M609452200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148440	hybrid			2022-12-27	WOS:000244481900042
J	Tresini, M; Lorenzini, A; Torres, C; Cristofalo, VJ				Tresini, Maria; Lorenzini, Antonello; Torres, Claudio; Cristofalo, Vincent J.			Modulation of replicative senescence of diploid human cells by nuclear ERK signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TERNARY COMPLEX-FORMATION; OF-FUNCTION MUTATION; SINGLE-STEP METHOD; MAP-KINASE; IN-VITRO; REGULATED KINASE; RNA ISOLATION; CYCLE ARREST; PHOSPHORYLATION	Normal somatic cells have a limited replicative lifespan, and serial subcultivation ultimately results in senescence. Senescent cells are irreversibly growth-arrested and show impaired responses to mitogens. Activation of the ERK signaling pathway, an absolute requirement for cell proliferation, results in nuclear relocalization of active ERKs, an event impaired in senescent fibroblasts. This impairment coincides with increased activity of the nuclear ERK phosphatase MKP2. Here we show that replicative lifespan can be altered by changes in nuclear ERK activity. Ectopic expression of MKP2 results in premature senescence. In contrast, knock-down of MKP2 expression, through transduction of MKP2 sequence-specific short hairpin RNA, or expression of the phosphatase resistant ERK2(D319N) mutant, abrogates the effects of increased endogenous MKP2 levels and senescence is postponed. Nuclear targeting of ERK2(D319N) significantly augments its effects and the transduced cultures show higher than 60% increase in replicative lifespan compared with cultures transduced with wt ERK2. Long-lived cultures senesce with altered molecular characteristics and retain the ability to express c-fos, and Rb is maintained in its inactive form. Our results support that MKP2-mediated inactivation of nuclear ERK2 represents a key event in the establishment of replicative senescence. Although it is evident that senescence can be imposed through multiple mechanisms, restoration of nuclear ERK activity can bypass a critical senescence checkpoint and, thus, extend replicative lifespan.	Lankenau Inst Med Res, Wynnewood, PA 19106 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19101 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University	Tresini, M (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19106 USA.	tresini@netscape.net	LORENZINI, ANTONELLO/E-6582-2016; Lorenzini, Antonello/G-4463-2012	LORENZINI, ANTONELLO/0000-0001-9615-9697; Tresini, Maria/0000-0001-7711-3204	NIA NIH HHS [AG20955] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG020955] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHYFLICK L, 1977, HDB BIOL AGING, P159; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; Bose C, 2004, J GERONTOL A-BIOL, V59, P126; Bost F, 2005, DIABETES, V54, P402, DOI 10.2337/diabetes.54.2.402; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Burack WR, 2005, J BIOL CHEM, V280, P3832, DOI 10.1074/jbc.M410031200; Cadalbert L, 2005, CELL SIGNAL, V17, P1254, DOI 10.1016/j.cellsig.2005.01.003; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Cristofalo VJ, 2004, MECH AGEING DEV, V125, P827, DOI 10.1016/j.mad.2004.07.010; CRISTOFALO VJ, 1976, GERONTOLOGY, V22, P9, DOI 10.1159/000212122; CRISTOFALO VJ, 1998, METHODS AGING, P77; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Echeverria V, 2004, NEUROSCIENCE, V129, P583, DOI 10.1016/j.neuroscience.2004.07.036; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Gaumont-Leclerc MF, 2004, J BIOL CHEM, V279, P46802, DOI 10.1074/jbc.M403893200; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; Hatano N, 2003, GENES CELLS, V8, P847, DOI 10.1046/j.1365-2443.2003.00680.x; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Katagiri C, 2005, J BIOL CHEM, V280, P14716, DOI 10.1074/jbc.M500200200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim-Kaneyama JR, 2000, J BIOL CHEM, V275, P20685, DOI 10.1074/jbc.M908723199; Kohno Michiaki, 2003, Prog Cell Cycle Res, V5, P219; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lim IK, 2000, MECH AGEING DEV, V119, P113, DOI 10.1016/S0047-6374(00)00167-6; Lim IK, 2001, ANN NY ACAD SCI, V928, P176; Lips DJ, 2004, CIRCULATION, V109, P1938, DOI 10.1161/01.CIR.0000127126.73759.23; Marais R, 1996, CANCER SURV, V27, P101; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Mazzucchelli C, 2002, NEURON, V34, P807, DOI 10.1016/S0896-6273(02)00716-X; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Pages G, 2000, ANN NY ACAD SCI, V902, P187; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Saba-El-Leil MK, 2003, EMBO REP, V4, P964, DOI 10.1038/sj.embor.embor939; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Severino J, 2000, EXP CELL RES, V257, P162, DOI 10.1006/excr.2000.4875; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Stewart SA, 2002, ONCOGENE, V21, P627, DOI 10.1038/sj.onc.1205062; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Tarrega C, 2005, J BIOL CHEM, V280, P37885, DOI 10.1074/jbc.M504366200; Thomas DM, 2003, CANCER BIOL THER, V2, P124, DOI 10.4161/cbt.2.2.235; Tombes RM, 1998, BIOCHEM J, V330, P1451; Torres C, 2003, EXP CELL RES, V290, P195, DOI 10.1016/S0014-4827(03)00309-4; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tresini M, 2001, EXP CELL RES, V269, P287, DOI 10.1006/excr.2001.5334; Venter DJ, 2005, CANCER GENET CYTOGEN, V160, P134, DOI 10.1016/j.cancergencyto.2004.12.007; Vial E, 2004, ANN NY ACAD SCI, V1030, P208, DOI 10.1196/annals.1329.027; Volmat V, 2001, J CELL SCI, V114, P3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Yao Y, 2003, P NATL ACAD SCI USA, V100, P12759, DOI 10.1073/pnas.2134254100; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	95	49	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4136	4151		10.1074/jbc.M604955200	http://dx.doi.org/10.1074/jbc.M604955200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17145763	hybrid			2022-12-27	WOS:000244481900077
J	Wu, CY; Huang, JT				Wu, Chengyu; Huang, Jiaoti			Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; LNCAP CELLS; PROTEIN-KINASE; IN-VIVO; AKT; PROGRESSION; TRANSDIFFERENTIATION; GROWTH; SUPPRESSOR; EXPRESSION	Hormonal therapy of prostate cancer, by inhibiting androgen production and/or androgen function, is the treatment of choice for advanced prostate cancer. Although most patients respond initially, the effect is only temporary, and the tumor cells win resume proliferation in an androgen-deprived environment. The mechanism for androgen-independent proliferation of cancer cells is unclear. Hormonal therapy induces neuroendocrine differentiation of prostate cancer cells, which is hypothesized to contribute to tumor recurrence by a paracrine mechanism. We studied signal transduction pathways of neuroendocrine differentiation in LNCaP cells after androgen withdrawal, and we showed that both the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway and ERK are activated, but only the former is required for neuroendocrine differentiation. A constitutively active AKT promotes neuroendocrine differentiation and a dominant negative AKT inhibits it. Activation of AKT by IGF-1 leads to neuroendocrine differentiation, and neuroendocrine differentiation induced by epinephrine requires AKT activation. We also show that the AKT pathway is likely responsible for neuroendocrine differentiation in DU145, an androgen-independent prostate cancer cell line. Therefore, our study demonstrated a novel function of the AKT pathway in prostate cancer progression and identified potential targets that may be explored for the treatment of androgen-independent cancer.	Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA	University of Rochester	Huang, JT (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, Box 626,601 Elmwood Ave, Rochester, NY 14642 USA.	Jiaoti_Huang@urmc.rochester.edu		Huang, Jiaoti/0000-0003-1195-1998				Adam RM, 2002, ENDOCRINOLOGY, V143, P4599, DOI 10.1210/en.2002-220561; Ayala G, 2004, CLIN CANCER RES, V10, P6572, DOI 10.1158/1078-0432.CCR-04-0477; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Burchardt T, 1999, J UROLOGY, V162, P1800, DOI 10.1016/S0022-5347(05)68241-9; Chan JM, 2002, J NATL CANCER I, V94, P1099; Cinar B, 2005, CANCER RES, V65, P2547, DOI 10.1158/0008-5472.CAN-04-3411; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Culig Z, 2005, ENDOCR-RELAT CANCER, V12, P229, DOI 10.1677/erc.1.00775a; DISANTAGNESE PA, 1985, ARCH PATHOL LAB MED, V109, P607; Evangelou AI, 2004, J CELL BIOCHEM, V91, P671, DOI 10.1002/jcb.10771; Gregory CW, 2001, CANCER RES, V61, P2892; HUANG J, 2002, ADV ONCOLOGY EXPANDI, P243; Huang JT, 2006, PROSTATE, V66, P1399, DOI 10.1002/pros.20434; Huang JT, 2005, AM J PATHOL, V166, P1807, DOI 10.1016/S0002-9440(10)62490-X; Huss WJ, 2004, PROSTATE, V60, P91, DOI 10.1002/pros.20032; Jin RJ, 2004, CANCER RES, V64, P5489, DOI 10.1158/0008-5472.CAN-03-3117; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kim J, 2002, CANCER RES, V62, P1549; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Lei QY, 2006, CANCER CELL, V9, P367, DOI 10.1016/j.ccr.2006.03.031; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li L, 2005, PROSTATE CANCER P D, V8, P108, DOI 10.1038/sj.pcan.4500776; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Quinn M, 2002, BJU INT, V90, P162, DOI 10.1046/j.1464-410X.2002.2822.x; Sharifi N, 2005, JAMA-J AM MED ASSOC, V294, P238, DOI 10.1001/jama.294.2.238; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stern DF, 2004, CLIN CANCER RES, V10, P6407, DOI 10.1158/1078-0432.CCR-04-1783; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; Thomas GV, 2004, CLIN CANCER RES, V10, P8351, DOI 10.1158/1078-0432.CCR-04-0130; Uchida K, 2005, PROSTATE, V62, P40, DOI 10.1002/pros.20111; Vashchenko N, 2005, EUR UROL, V47, P147, DOI 10.1016/j.eururo.2004.09.007; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Webber MM, 1997, PROSTATE, V30, P136, DOI 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Wu CY, 2006, PROSTATE, V66, P1125, DOI 10.1002/pros.20412; Wyszomierski SL, 2005, CANCER CELL, V8, P437, DOI 10.1016/j.ccr.2005.11.006; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Yang X, 2006, ONCOGENE, V25, P3436, DOI 10.1038/sj.onc.1209366; Yang XZ, 2005, CANCER RES, V65, P5263, DOI 10.1158/0008-5472.CAN-05-0162; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986; Zelivianski S, 2001, BBA-MOL CELL RES, V1539, P28, DOI 10.1016/S0167-4889(01)00087-8; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764; ZHUANG S, 2006, IN PRESS AM J PHYSL	51	66	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3571	3583		10.1074/jbc.M608487200	http://dx.doi.org/10.1074/jbc.M608487200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148458	hybrid			2022-12-27	WOS:000244481900019
J	Hambrock, A; Franz, CBD; Hiller, S; Grenz, A; Ackermann, S; Schulze, DU; Drews, G; Osswald, H				Hambrock, Annette; de Oliveira Franz, Claudia Bernardo; Hiller, Sabrina; Grenz, Almut; Ackermann, Stefanie; Schulze, Dorothea U.; Drews, Gisela; Osswald, Hartmut			Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNEL; BETA-CELL APOPTOSIS; INSULIN-SECRETION; PHYTOALEXIN RESVERATROL; POTASSIUM CHANNELS; TRANS-RESVERATROL; HIGH-AFFINITY; HUMAN ISLETS; CA2+ INFLUX; GLIBENCLAMIDE	Sulfonylurea receptors (SURs) constitute the regulatory subunits of ATP-sensitive K+ channels (K-ATP channels). SUR binds nucleotides and synthetic KATP channel modulators, e. g. the antidiabetic sulfonylurea glibenclamide, which acts as a channel blocker. However, knowledge about naturally occurring ligands of SUR is very limited. In this study, we show that the plant phenolic compound trans-resveratrol can bind to SUR and displace binding of glibenclamide. Electrophysiological measurements revealed that resveratrol is a blocker of pancreatic SUR1/K(IR)6.2 K-ATP channels. We further demonstrate that, like glibenclamide, resveratrol induces enhanced apoptosis. This was shown by analyzing different apoptotic parameters (cell detachment, nuclear condensation and fragmentation, and activities of different caspase enzymes). The observed apoptotic effect was specific to cells expressing the SUR1 isoform and was not mediated by the electrical activity of K-ATP channels, as it was observed in human embryonic kidney 293 cells expressing SUR1 alone. Enhanced susceptibility to resveratrol was not observed in pancreatic beta-cells from SUR1 knock-out mice or in cells expressing the isoform SUR2A or SUR2B or the mutant SUR1(M1289T). Resveratrol was much more potent than glibenclamide in inducing SUR1-specific apoptosis. Treatment with etoposide, a classical inducer of apoptosis, did not result in SUR isoform-specific apoptosis. In conclusion, resveratrol is a natural SUR ligand that can induce apoptosis in a SUR isoform-specific manner. Considering the tissue-specific expression patterns of SUR isoforms and the possible effects of SUR mutations on susceptibility to apoptosis, these observations could be important for diabetes and/or cancer research.	Univ Tubingen, Fac Med, Dept Pharmacol & Toxicol, D-72074 Tubingen, Germany; Univ Tubingen, Inst Pharm, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Hambrock, A (corresponding author), Univ Tubingen, Fac Med, Dept Pharmacol & Toxicol, Wilhelmstr 56, D-72074 Tubingen, Germany.	annette.hambrock@uni-tuebingen.de						Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Ahren B, 2005, CURR MOL MED, V5, P275, DOI 10.2174/1566524053766004; Ansar MM, 2006, NITRIC OXIDE-BIOL CH, V14, P39, DOI 10.1016/j.niox.2005.09.002; Ashcroft SJH, 2000, J MEMBRANE BIOL, V176, P187, DOI 10.1007/s002320001095; Ashfield R, 1999, DIABETES, V48, P1341, DOI 10.2337/diabetes.48.6.1341; Bataille D, 1999, CELL MOL LIFE SCI, V56, P78, DOI 10.1007/s000180050008; BRAY KM, 1992, J BIOL CHEM, V267, P11689; Bryan J, 2004, DIABETES, V53, pS104, DOI 10.2337/diabetes.53.suppl_3.S104; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Christopoulos A, 1998, TRENDS PHARMACOL SCI, V19, P351, DOI 10.1016/S0165-6147(98)01240-1; Cnop M, 2005, DIABETES, V54, pS97, DOI 10.2337/diabetes.54.suppl_2.S97; Cooray HC, 2004, BIOCHEM BIOPH RES CO, V317, P269, DOI 10.1016/j.bbrc.2004.03.040; de la Lastra CA, 2005, MOL NUTR FOOD RES, V49, P405; Delmas D, 2006, CURR DRUG TARGETS, V7, P423, DOI 10.2174/138945006776359331; Donath MY, 2005, DIABETES, V54, pS108, DOI 10.2337/diabetes.54.suppl_2.S108; Doyle ME, 2003, PHARMACOL REV, V55, P105, DOI 10.1124/pr.55.1.7; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; FURUKAWA T, 1993, J MEMBRANE BIOL, V136, P289; Gojkovic-Bukarica L, 2002, BRIT J PHARMACOL, V137, P429, DOI 10.1038/sj.bjp.0704905; Granados-Soto V, 2002, NEUROPHARMACOLOGY, V43, P917, DOI 10.1016/S0028-3908(02)00130-2; Gribble FM, 2003, DIABETOLOGIA, V46, P875, DOI 10.1007/s00125-003-1143-3; Hambrock A, 2006, J PHARMACOL EXP THER, V316, P1031, DOI 10.1124/jpet.105.097501; Hambrock A, 2004, DIABETES, V53, pS128, DOI 10.2337/diabetes.53.suppl_3.S128; Hambrock A, 2001, MOL PHARMACOL, V60, P190, DOI 10.1124/mol.60.1.190; Henquin JC, 2004, DIABETES, V53, pS48, DOI 10.2337/diabetes.53.suppl_3.S48; Henry C, 2005, J AGR FOOD CHEM, V53, P798, DOI 10.1021/jf048909e; Illek B, 2000, AM J PHYSIOL-CELL PH, V279, pC1838, DOI 10.1152/ajpcell.2000.279.6.C1838; Iwakura T, 2000, BIOCHEM BIOPH RES CO, V271, P422, DOI 10.1006/bbrc.2000.2616; Klein A, 2005, BRIT J PHARMACOL, V145, P907, DOI 10.1038/sj.bjp.0706252; Li HF, 2000, CARDIOVASC RES, V45, P1035, DOI 10.1016/S0008-6363(99)00397-1; Maedler K, 2005, J CLIN ENDOCR METAB, V90, P501, DOI 10.1210/jc.2004-0699; Maedler K, 2004, DIABETES, V53, P1706, DOI 10.2337/diabetes.53.7.1706; Mandrup-Poulsen T, 2001, DIABETES, V50, pS58, DOI 10.2337/diabetes.50.2007.S58; Moreau C, 2000, EMBO J, V19, P6644, DOI 10.1093/emboj/19.24.6644; Nakaune R, 2002, MOL GENET GENOMICS, V267, P179, DOI 10.1007/s00438-002-0649-6; Novakovic A, 2006, J PHARMACOL SCI, V101, P85, DOI 10.1254/jphs.FP0050863; Pervaiz S, 2004, DRUG RESIST UPDATE, V7, P333, DOI 10.1016/j.drup.2004.11.001; Proks P, 2001, BRIT J PHARMACOL, V132, P973, DOI 10.1038/sj.bjp.0703916; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Russ U, 1997, BRIT J PHARMACOL, V122, P1119, DOI 10.1038/sj.bjp.0701514; Rustenbeck I, 2004, BIOCHEM PHARMACOL, V67, P1733, DOI 10.1016/j.bcp.2004.01.016; Schoonbeek H, 2001, MOL PLANT MICROBE IN, V14, P562, DOI 10.1094/MPMI.2001.14.4.562; SCHWANSTECHER M, 1992, BRIT J PHARMACOL, V106, P295, DOI 10.1111/j.1476-5381.1992.tb14331.x; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Sergent T, 2005, TOXICOL LETT, V159, P60, DOI 10.1016/j.toxlet.2005.04.013; Simard JM, 2004, J NEUROSURG ANESTH, V16, P98, DOI 10.1097/00008506-200401000-00021; Szkudelski T, 2001, PHYSIOL RES, V50, P537; Wenzel E, 2005, MOL NUTR FOOD RES, V49, P472, DOI 10.1002/mnfr.200500010; Zhou SF, 2004, LIFE SCI, V74, P935, DOI 10.1016/j.lfs.2003.09.035; Zwiers LH, 2003, MOL GENET GENOMICS, V269, P499, DOI 10.1007/s00438-003-0855-x	50	60	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3347	3356		10.1074/jbc.M608216200	http://dx.doi.org/10.1074/jbc.M608216200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17138562	hybrid			2022-12-27	WOS:000243793900061
J	Kim, WS; Rahmanto, AS; Kamili, A; Rye, KA; Guillemin, GJ; Gelissen, IC; Jessup, W; Hill, AF; Garner, B				Kim, Woojin Scott; Rahmanto, Aldwin Suryo; Kamili, Alvin; Rye, Kerry-Anne; Guillemin, Gilles J.; Gelissen, Ingrid C.; Jessup, Wendy; Hill, Andrew F.; Garner, Brett			Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; HIGH-DENSITY-LIPOPROTEIN; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; CELLULAR CHOLESTEROL; CEREBROSPINAL-FLUID; GENE-EXPRESSION; LIPID RAFTS	Maintenance of an adequate supply of cholesterol is important for neuronal function, whereas excess cholesterol promotes amyloid precursor protein (APP) cleavage generating toxic amyloid-beta (A beta) peptides. To gain insights into the pathways that regulate neuronal cholesterol level, we investigated the potential for reconstituted apolipoprotein E (apoE) discs, resembling nascent lipoprotein complexes in the central nervous system, to stimulate neuronal [H-3] cholesterol efflux. ApoE discs potently accelerated cholesterol efflux from primary human neurons and cell lines. The process was saturable (17.5 mu g of apoE/ml) and was not influenced by APOE genotype. High performance liquid chromatography analysis of cholesterol and cholesterol metabolites effluxed from neurons indicated that < 25% of the released cholesterol was modified to polar products (e.g. 24-hydroxycholesterol) that diffuse from neuronal membranes. Thus, most cholesterol (similar to 75%) appeared to be effluxed from neurons in a native state via a transporter pathway. ATP-binding cassette transporters ABCA1, ABCA2, and ABCG1 were detected in neurons and neuroblastoma cell lines and expression of these cDNAs revealed that ABCA1 and ABCG1 stimulated cholesterol efflux to apoE discs. In addition, ABCA1 and ABCG1 expression in Chinese hamster ovary cells that stably express human APP significantly reduced A beta generation, whereas ABCA2 did not modulate either cholesterol efflux or A beta generation. These data indicate that ABCA1 and ABCG1 play a significant role in the regulation of neuronal cholesterol efflux to apoE discs and in suppression of APP processing to generate A beta peptides.	Prince Wales Med Res Inst, Sydney, NSW 2031, Australia; Heart Res Inst, Sydney, NSW 2050, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia; Univ New S Wales, Sch Med Sci, Sydney, NSW 2052, Australia; Univ Melbourne, Bio21 Mol Sci & Biotechnol Inst, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia; Univ Melbourne, Bio21 Mol Sci & Biotechnol Inst, Dept Pathol, Melbourne, Vic 3010, Australia	Prince Wales Medical Research Institute; University of Sydney; Heart Research Institute; St Vincents Hospital Sydney; University of New South Wales Sydney; University of New South Wales Sydney; University of Melbourne; University of Melbourne	Garner, B (corresponding author), Prince Wales Med Res Inst, Sydney, NSW 2031, Australia.	brett.garner@unsw.edu.au	Hill, Andrew F/B-4527-2009; Guillemin, Gilles J/C-3878-2015; Hill, Andrew F./AAH-2854-2020; Hill, Andrew F./GZL-4124-2022	Hill, Andrew F/0000-0001-5581-2354; Guillemin, Gilles J/0000-0001-8105-4470; Hill, Andrew F./0000-0001-5581-2354; Kamili, Alvin/0000-0002-4864-1195				Abildayeva K, 2006, J BIOL CHEM, V281, P12799, DOI 10.1074/jbc.M601019200; Alexandrov P, 2005, NEUROREPORT, V16, P909, DOI 10.1097/00001756-200506210-00007; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Burns MP, 2006, J NEUROCHEM, V98, P792, DOI 10.1111/j.1471-4159.2006.03925.x; Chroni A, 2005, BIOCHEMISTRY-US, V44, P13132, DOI 10.1021/bi051029o; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Danik M, 1999, CRIT REV NEUROBIOL, V13, P357, DOI 10.1615/CritRevNeurobiol.v13.i4.20; Demeester N, 2000, J LIPID RES, V41, P963; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Engel T, 2006, FEBS LETT, V580, P4551, DOI 10.1016/j.febslet.2006.07.006; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; Gelissen IC, 2006, ARTERIOSCL THROM VAS, V26, P534, DOI 10.1161/01.ATV.0000200082.58536.e1; Ghribi O, 2006, EXP NEUROL, V200, P460, DOI 10.1016/j.expneurol.2006.03.019; Glaros EN, 2005, J BIOL CHEM, V280, P24515, DOI 10.1074/jbc.M413862200; Gong JS, 2002, J BIOL CHEM, V277, P29919, DOI 10.1074/jbc.M203934200; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Hirsch-Reinshagen V, 2005, J BIOL CHEM, V280, P43243, DOI 10.1074/jbc.M508781200; Ito J, 1999, J NEUROCHEM, V72, P2362, DOI 10.1046/j.1471-4159.1999.0722362.x; Jessup W, 2006, CURR OPIN LIPIDOL, V17, P247, DOI 10.1097/01.mol.0000226116.35555.eb; Johansson C, 2001, NEUROBIOL DIS, V8, P351, DOI 10.1006/nbdi.2000.0373; Kalvodova L, 2005, J BIOL CHEM, V280, P36815, DOI 10.1074/jbc.M504484200; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Karten B, 2006, J BIOL CHEM, V281, P4049, DOI 10.1074/jbc.M508915200; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Kim WS, 2006, NEUROREPORT, V17, P891, DOI 10.1097/01.wnr.0000221833.41340.cd; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Kobayashi A, 2006, J LIPID RES, V47, P1791, DOI 10.1194/jlr.M500546-JLR200; Koch S, 2001, J LIPID RES, V42, P1143; Koldamova R, 2005, J BIOL CHEM, V280, P43224, DOI 10.1074/jbc.M504513200; Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200; Kolsch H, 1999, BRAIN RES, V818, P171, DOI 10.1016/S0006-8993(98)01274-8; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Meaney S, 2002, J LIPID RES, V43, P2130, DOI 10.1194/jlr.M200293-JLR200; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Nakamura K, 2004, J BIOL CHEM, V279, P45980, DOI 10.1074/jbc.M408652200; Oram JF, 2001, J LIPID RES, V42, P1173; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Pfrieger FW, 2003, CELL MOL LIFE SCI, V60, P1158, DOI 10.1007/s00018-003-3018-7; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Pohl A, 2005, BBA-MOL CELL BIOL L, V1733, P29, DOI 10.1016/j.bbalip.2004.12.007; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Raftery M, 2005, BIOCHEMISTRY-US, V44, P7346, DOI 10.1021/bi0504052; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; Rye K, 2006, J LIPID RES, V47, P1025, DOI 10.1194/jlr.M500525-JLR200; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Shan H, 2003, STEROIDS, V68, P221, DOI 10.1016/S0039-128X(02)00185-X; Shobab LA, 2005, LANCET NEUROL, V4, P841, DOI 10.1016/S1474-4422(05)70248-9; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; Tachikawa M, 2005, J NEUROCHEM, V95, P294, DOI 10.1111/j.1471-4159.2005.03369.x; Thilakawardhana S, 2005, NEUROBIOL AGING, V26, P813, DOI 10.1016/j.neurobiolaging.2004.08.004; Tokuda T, 2000, BIOCHEM J, V348, P359, DOI 10.1042/0264-6021:3480359; Tun H, 2002, J MOL NEUROSCI, V19, P31, DOI 10.1007/s12031-002-0007-5; Vaughan AM, 2005, J BIOL CHEM, V280, P30150, DOI 10.1074/jbc.M505368200; Vaughan AM, 2006, J LIPID RES, V47, P2433, DOI 10.1194/jlr.M600218-JLR200; Vetrivel KS, 2005, J BIOL CHEM, V280, P25892, DOI 10.1074/jbc.M503570200; Wahrle SE, 2005, J BIOL CHEM, V280, P43236, DOI 10.1074/jbc.M508780200; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; White AR, 2006, J BIOL CHEM, V281, P17670, DOI 10.1074/jbc.M602487200; Wolozin B, 2004, NEURON, V41, P7, DOI 10.1016/S0896-6273(03)00840-7; Xu Q, 2000, J BIOL CHEM, V275, P31770, DOI 10.1074/jbc.M002796200; Zhang J, 1997, BIOCHEM J, V322, P175, DOI 10.1042/bj3220175	74	146	152	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2851	2861		10.1074/jbc.M607831200	http://dx.doi.org/10.1074/jbc.M607831200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17121837	hybrid			2022-12-27	WOS:000243793900011
J	Marchand, B; Tchesnokov, EP; Gotte, M				Marchand, Bruno; Tchesnokov, Egor P.; Gotte, Matthias			The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T7 RNA-POLYMERASE; DNA-POLYMERASE; NONNUCLEOSIDE INHIBITORS; ZIDOVUDINE RESISTANCE; PHOSPHONOFORMIC ACID; PRIMER UNBLOCKING; KINETIC MECHANISM; DRUG-RESISTANCE; MUTATIONS	The pyrophosphate (PPi) analogue phosphonoformic acid (PFA or foscarnet) inhibits the reverse transcriptase (RT) of the human immunodeficiency virus type 1 (HIV-1); however, the mechanisms of drug action and resistance remain elusive. Here we studied the effects of the translocational status of HIV-1 RT on drug binding and inhibition of DNA synthesis. We identified "hot spots" for inhibition during active elongation. Site-specific footprinting analyses revealed that the corresponding complexes exist predominantly in the pre-translocational state. The sensitivity to PFA is significantly reduced with sequences that show a bias toward the post-translocational state. Binding studies showed that PFA stabilizes selectively the complex in the pre-translocated configuration. These findings are consistent with a Brownian ratchet model of polymerase translocation. The enzyme can rapidly shuttle between pre-and post-translocated states. The bound inhibitor acts like a pawl of a ratchet and prevents the forward motion of HIV-1 RT, whereas the bound nucleotide binds to the post-translocated complex and prevents the reverse motion. The proposed mechanisms of RT translocation and drug action are consistent with the PFA-resistant phenotypes. We show that certain sequences and the PFA-resistant E89K mutant diminishes the stability of the pre-translocated complex. Inthesecases, the enzyme is seen at multiple positions around the 3' end of the primer, which provides a novel mechanism for resistance. These findings validate the pre-translocated complex as a target for the development of novel, perhaps less toxic and more potent inhibitors that block HIV-1 RT translocation.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Gotte, M (corresponding author), Duff Med Bldg D-6,3775 Univ St, Montreal, PQ H3A 2B4, Canada.	matthias.gotte@mcgill.ca						Abbondanzieri EA, 2005, NATURE, V438, P460, DOI 10.1038/nature04268; Arion D, 2000, J BIOL CHEM, V275, P9251, DOI 10.1074/jbc.275.13.9251; Bar-Nahum G, 2005, CELL, V120, P183, DOI 10.1016/j.cell.2004.11.045; Cruchaga C, 2006, J BIOL CHEM, V281, P27744, DOI 10.1074/jbc.M603360200; CRUMPACKER CS, 1992, AM J MED, V92, pS3, DOI 10.1016/0002-9343(92)90329-A; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jcv.2004.02.009; De Clercq Erik, 2005, Expert Opin Emerg Drugs, V10, P241, DOI 10.1517/14728214.10.2.241; DERSE D, 1982, J BIOL CHEM, V257, P251; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Gotte M, 2006, CURR PHARM DESIGN, V12, P1867, DOI 10.2174/138161206776873626; Gotte M, 2001, J BIOL CHEM, V276, P6711, DOI 10.1074/jbc.M009097200; Guajardo R, 1998, J MOL BIOL, V281, P777, DOI 10.1006/jmbi.1998.1988; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Guo Q, 2006, J MOL BIOL, V358, P241, DOI 10.1016/j.jmb.2006.02.001; Hammond JL, 2001, ANTIMICROB AGENTS CH, V45, P1621, DOI 10.1128/AAC.45.6.1621-1628.2001; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; Ignatov ME, 2005, BIOCHEMISTRY-US, V44, P5346, DOI 10.1021/bi048000p; KATI WM, 1992, J BIOL CHEM, V267, P25988; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Marchand B, 2004, INT J BIOCHEM CELL B, V36, P1823, DOI 10.1016/j.biocel.2004.02.029; Marchand B, 2003, J BIOL CHEM, V278, P35362, DOI 10.1074/jbc.M304262200; Mathiesen S, 2004, AIDS, V18, P1076, DOI 10.1097/00002030-200404300-00020; MELLORS JW, 1995, ANTIMICROB AGENTS CH, V39, P1087, DOI 10.1128/AAC.39.5.1087; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 2003, J VIROL, V77, P6127, DOI 10.1128/JVI.77.11.6127-6137.2003; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Nedialkov YA, 2003, J BIOL CHEM, V278, P18303, DOI 10.1074/jbc.M301103200; OBERG B, 1982, PHARMACOL THERAPEUT, V19, P387, DOI 10.1016/0163-7258(82)90074-2; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Rigourd M, 2000, J BIOL CHEM, V275, P26944; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; Sarafianos SG, 2003, J BIOL CHEM, V278, P16280, DOI 10.1074/jbc.M212911200; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; Spence RA, 1996, BIOCHEMISTRY-US, V35, P1054, DOI 10.1021/bi952058+; Tachedjian G, 1998, AIDS RES HUM RETROV, V14, P1059, DOI 10.1089/aid.1998.14.1059; TACHEDJIAN G, 1995, VIROLOGY, V212, P58, DOI 10.1006/viro.1995.1453; Tachedjian G, 1996, J VIROL, V70, P7171, DOI 10.1128/JVI.70.10.7171-7181.1996; Tchesnokov EP, 2006, J VIROL, V80, P1440, DOI 10.1128/JVI.80.3.1440-1450.2006; Tong WJ, 1997, BIOCHEMISTRY-US, V36, P5749, DOI 10.1021/bi962410z; Tuske S, 2005, CELL, V122, P541, DOI 10.1016/j.cell.2005.07.017; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5	44	63	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3337	3346		10.1074/jbc.M607710200	http://dx.doi.org/10.1074/jbc.M607710200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145704	hybrid			2022-12-27	WOS:000243793900060
J	Venegas-Caleron, M; Beaudoin, F; Sayanova, O; Napier, JA				Venegas-Caleron, Monica; Beaudoin, Frederic; Sayanova, Olga; Napier, Johnathan A.			Co-transcribed genes for long chain polyunsaturated fatty acid biosynthesis in the protozoon Perkinsus marinus include a plant-like FAE1 3-ketoacyl coenzyme A synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE; DESATURASES; SPECIFICITY; MICROALGA; PATHWAY	The marine parasitic protozoon Perkinus marinus synthesizes the polyunsaturated fatty acid arachidonic acid via the unusual alternative Delta 8 pathway in which elongation of C-18 fatty acids generates substrate for two sequential desaturations. Here we have shown that genes encoding the three P. marinus activities responsible for arachidonic acid biosynthesis (C-18 Delta 9-elongating activity, C-20 Delta 8 desaturase, C-20 Delta 5 desaturase) are genomically clustered and co-transcribed as an operon. The acyl elongation reaction, which underpins this pathway, is catalyzed by a FAE1 (fatty acid elongation 1)-like 3-ketoacyl-CoA synthase class of condensing enzyme previously only reported in higher plants and algae. This is the first example of an elongating activity involved in the biosynthesis of a polyunsaturated fatty acid that is not a member of the ELO/SUR4 family. The P. marinus FAE1-like elongating activity is sensitive to the herbicide flufenacet, similar to some higher plant 3-ketoacyl-CoA synthases, but unable to rescue the yeast elo2 Delta/elo3 Delta mutant consistent with a role in the elongation of polyunsaturated fatty acids. P. marinus represents a key organism in the taxonomic separation of the single-celled eukaryotes collectively known as the alveolates, and our data imply a lineage in which ancestral acquisition of plant-like genes, such as FAE1-like 3-ketoacyl-CoA synthases, occurred via endosymbiosis. The P. marinus FAE1-like elongating activity is also indicative of the independent evolution of the alternative Delta 8 pathway, distinct from ELO/SUR4-dependent examples.	Rothamsted Res, Crop Performance & Improvement Div, Harpenden AL5 2JQ, Herts, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Napier, JA (corresponding author), Rothamsted Res, Crop Performance & Improvement Div, Harpenden AL5 2JQ, Herts, England.	johnathan.napier@bbsrc.ac.uk	Venegas-Calerón, Mónica/ABC-7074-2020; Venegas-Calerón, Mónica/M-8529-2013	Venegas-Calerón, Mónica/0000-0002-1562-5025; Napier, Johnathan/0000-0003-3580-3607	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004156] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Andrews JD, 1996, J SHELLFISH RES, V15, P13; Azachi M, 2002, PLANT PHYSIOL, V129, P1320, DOI 10.1104/pp.001909; Blacklock BJ, 2006, BIOCHEM BIOPH RES CO, V346, P583, DOI 10.1016/j.bbrc.2006.05.162; Chen Q, 2000, LIPIDS, V35, P871, DOI 10.1007/S11745-000-0596-9; Chu FLE, 2004, MOL BIOCHEM PARASIT, V133, P45, DOI 10.1016/j.molbiopara.2003.08.012; Chu FLE, 2002, MOL BIOCHEM PARASIT, V119, P179, DOI 10.1016/S0166-6851(01)00413-3; Domergue F, 2005, BIOCHEM J, V389, P483, DOI 10.1042/BJ20050111; Domergue F, 2005, TRENDS PLANT SCI, V10, P112, DOI 10.1016/j.tplants.2005.01.003; El-Sayed NM, 2005, SCIENCE, V309, P404, DOI 10.1126/science.1112181; Gaffney PM, 1996, J SHELLFISH RES, V15, P135; JAMES DW, 1995, PLANT CELL, V7, P309, DOI 10.2307/3869853; Leander BS, 2003, TRENDS ECOL EVOL, V18, P395, DOI 10.1016/S0169-5347(03)00152-6; Lechelt-Kunze C, 2003, PEST MANAG SCI, V59, P847, DOI 10.1002/ps.714; LEES AM, 1966, BIOCHEMISTRY-US, V5, P1475, DOI 10.1021/bi00869a005; Leonard AE, 2004, PROG LIPID RES, V43, P36, DOI 10.1016/S0163-7827(03)00040-7; Loftus B, 2005, NATURE, V433, P865, DOI 10.1038/nature03291; Lund ED, 2005, DIS AQUAT ORGAN, V67, P217, DOI 10.3354/dao067217; Lund ED, 2002, MOL BIOCHEM PARASIT, V121, P245, DOI 10.1016/S0166-6851(02)00046-4; Millar AA, 1997, PLANT J, V12, P121, DOI 10.1046/j.1365-313X.1997.12010121.x; Napier JA, 2004, LIPIDS, V39, P1067, DOI 10.1007/s11745-004-1332-1; Napier JA, 2003, PROSTAG LEUKOTR ESS, V68, P135, DOI 10.1016/S0952-3278(02)00263-6; Paul S, 2006, J BIOL CHEM, V281, P9018, DOI 10.1074/jbc.M507723200; Qi BX, 2004, NAT BIOTECHNOL, V22, P739, DOI 10.1038/nbt972; Qi BX, 2002, FEBS LETT, V510, P159, DOI 10.1016/S0014-5793(01)03247-1; RAY SM, 1954, J PARASITOL, V40, P235, DOI 10.2307/3274312; Saldarriaga JF, 2003, INT J SYST EVOL MICR, V53, P355, DOI 10.1099/ijs.0.02328-0; Sayanova O, 2006, FEBS LETT, V580, P1946, DOI 10.1016/j.febslet.2006.02.062; Sayanova OV, 2004, PHYTOCHEMISTRY, V65, P147, DOI 10.1016/j.phytochem.2003.10.017; Sperling P, 2003, PROSTAG LEUKOTR ESS, V68, P73, DOI 10.1016/S0952-3278(02)00258-2; Trenkamp S, 2004, P NATL ACAD SCI USA, V101, P11903, DOI 10.1073/pnas.0404600101; Tripodi KEJ, 2006, FEBS J, V273, P271, DOI 10.1111/j.1742-4658.2005.05049.x	31	26	31	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2996	3003		10.1074/jbc.M607051200	http://dx.doi.org/10.1074/jbc.M607051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17092943	hybrid, Green Published			2022-12-27	WOS:000243793900026
J	Rasbach, KA; Schnellmann, RG				Rasbach, Kyle A.; Schnellmann, Rick G.			Signaling of mitochondrial biogenesis following oxidant injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE; FACTOR RECEPTOR; RENAL ISCHEMIA; P38 MAPK; COACTIVATOR PGC-1; PROXIMAL TUBULES; NITRIC-OXIDE; AMP KINASE	Mitochondrial dysfunction is a common consequence of ischemia-reperfusion and drug injuries. For example, sublethal injury of renal proximal tubular cells (RPTCs) with the model oxidant tert-butylhydroperoxide (TBHP) causes mitochondrial injury that recovers over the course of six days. Although regeneration of mitochondrial function is integral to cell repair and function, the signaling pathway of mitochondrial biogenesis following oxidant injury has not been examined. A 10-fold overexpression of the mitochondrial biogenesis regulator PPAR-gamma cofactor-1 alpha (PGC-1 alpha) in control RPTCs resulted in a 52% increase in mitochondrial number, a 27% increase in respiratory capacity, and a 30% increase in mitochondrial protein markers, demonstrating that PGC-1 alpha mediates mitochondrial biogenesis in RPTCs. RPTCs sublethally injured with TBHP exhibited a 50% decrease in mitochondrial function and increased mitochondrial autophagy. Compared with the controls, PGC-1 alpha levels increased 12-fold on days 1, 2, and 3 post-injury and returned to base line on day 4 as mitochondrial function returned. Inhibition p38 MAPK blocked the up-regulation of PGC-1 alpha following oxidant injury, whereas inhibition of calcium-calmodulin-dependent protein kinase, calcineurin A, nitric-oxide synthase, and phosphoinositol 3-kinase had no effect. The epidermal growth factor receptor (EGFR) was activated following TBHP exposure, and the EGFR inhibitor AG1478 blocked the up-regulation of PGC-1 alpha. Additional inhibitor studies revealed that the sequential activation of Src, p38 MAPK, EGFR, and p38 MAPK regulate the expression of PGC-1 alpha following oxidant injury. In contrast, although Akt was activated following oxidant injury, it did not play a role in PGC-1 alpha expression. We suggest that mitochondrial biogenesis following oxidant injury is mediated by p38 and EGFR activation of PGC-1 alpha.	Med Univ S Carolina, Dept Pharmaceut Res, Charleston, SC 29425 USA	Medical University of South Carolina	Schnellmann, RG (corresponding author), Med Univ S Carolina, Dept Pharmaceut Res, 280 Calhoun St, Charleston, SC 29425 USA.				NHLBI NIH HHS [T32 HL007260] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007260] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimoto T, 2005, J BIOL CHEM, V280, P19587, DOI 10.1074/jbc.M408862200; Baris O, 2004, J CLIN ENDOCR METAB, V89, P994, DOI 10.1210/jc.2003-031238; Chakrabarti SK, 1998, TOXICOL APPL PHARM, V151, P123, DOI 10.1006/taap.1998.8414; Clement E, 2005, COMP BIOCHEM PHYS A, V142, P102, DOI 10.1016/j.cbpb.2005.04.022; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cummings BS, 2000, TOXICOLOGY, V150, P83, DOI 10.1016/S0300-483X(00)00252-3; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Feldkamp T, 2005, AM J PHYSIOL-RENAL, V288, pF1092, DOI 10.1152/ajprenal.00443.2004; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Hardiek K, 2001, AM J PHYSIOL-RENAL, V280, pF61, DOI 10.1152/ajprenal.2001.280.1.F61; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Jung K, 2001, ADV DRUG DELIVER REV, V49, P87, DOI 10.1016/S0169-409X(01)00128-4; KAYS SE, 1995, TOXICOL APPL PHARM, V132, P273, DOI 10.1006/taap.1995.1108; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Leary SC, 2003, BIOESSAYS, V25, P538, DOI 10.1002/bies.10298; Lee WJ, 2006, BIOCHEM BIOPH RES CO, V340, P291, DOI 10.1016/j.bbrc.2005.12.011; Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3; Li J, 2005, CIRC RES, V97, P872, DOI 10.1161/01.RES.0000187458.77026.10; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; McGee SL, 2006, CLIN EXP PHARMACOL P, V33, P395, DOI 10.1111/j.1440-1681.2006.04362.x; Mount PF, 2005, AM J PHYSIOL-RENAL, V289, pF1103, DOI 10.1152/ajprenal.00458.2004; Nath KA, 1998, KIDNEY INT, V53, P100, DOI 10.1046/j.1523-1755.1998.00731.x; Nisoli E, 2004, PROSTAG OTH LIPID M, V73, P9, DOI 10.1016/j.prostaglandins.2004.01.005; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Nisoli E, 2004, BIOCHEM PHARMACOL, V67, P1, DOI 10.1016/j.bcp.2003.10.015; Nowak G, 1998, AM J PHYSIOL-RENAL, V274, pF509, DOI 10.1152/ajprenal.1998.274.3.F509; Nowak G, 1996, AM J PHYSIOL-CELL PH, V271, pC2072, DOI 10.1152/ajpcell.1996.271.6.C2072; Ojuka EO, 2004, P NUTR SOC, V63, P275, DOI 10.1079/PNS2004339; Pelletier A, 2005, ENDOCRINOLOGY, V146, P2285, DOI 10.1210/en.2004-1565; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Priault M, 2005, CELL DEATH DIFFER, V12, P1613, DOI 10.1038/sj.cdd.4401697; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RIVERA MI, 1994, TOXICOL APPL PHARM, V128, P239, DOI 10.1006/taap.1994.1203; SAFIRSTEIN R, 1990, KIDNEY INT, V37, P1515, DOI 10.1038/ki.1990.143; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Schaeffer PJ, 2004, J BIOL CHEM, V279, P39593, DOI 10.1074/jbc.M403649200; SCHNELLMANN RG, 1988, AM J PHYSIOL, V255, P28; Sriwijitkamol A, 2006, AM J PHYSIOL-ENDOC M, V290, pE925, DOI 10.1152/ajpendo.00429.2005; Suliman HB, 2004, CARDIOVASC RES, V64, P279, DOI 10.1016/j.cardiores.2004.07.005; Suwa M, 2003, J APPL PHYSIOL, V95, P960, DOI 10.1152/japplphysiol.00349.2003; Suwa M, 2006, J APPL PHYSIOL, V101, P1685, DOI 10.1152/japplphysiol.00255.2006; Taira T, 1996, VIRCHOWS ARCH, V427, P583; Weinberg JM, 1997, KIDNEY INT, V52, P140, DOI 10.1038/ki.1997.313; Weinberg JM, 2000, P NATL ACAD SCI USA, V97, P2826, DOI 10.1073/pnas.97.6.2826; Yano T, 1999, NEPHRON, V81, P230, DOI 10.1159/000045281; Zhuang SG, 2005, J BIOL CHEM, V280, P21036, DOI 10.1074/jbc.M413300200; Zhuang SG, 2004, AM J PHYSIOL-RENAL, V287, pF365, DOI 10.1152/ajprenal.00035.2004; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	50	134	142	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2355	2362		10.1074/jbc.M608009200	http://dx.doi.org/10.1074/jbc.M608009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17116659	hybrid			2022-12-27	WOS:000243593200027
J	Fiete, D; Mi, YL; Oats, EL; Beranek, MC; Baenziger, JU				Fiete, Dorothy; Mi, Yiling; Oats, Edward L.; Beranek, Mary C.; Baenziger, Jacques U.			N-linked oligosaccharides on the low density lipoprotein receptor homolog SorLA/LR11 are modified with terminal GalNAc-4-SO4 in kidney and brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; APOLIPOPROTEIN-E RECEPTOR; CIRCULATORY HALF-LIFE; BETA 1,4GLCNAC BETA; MOLECULAR-CLONING; SIALYLATED OLIGOSACCHARIDES; MANNOSE RECEPTOR; MANNOSE/N-ACETYLGALACTOSAMINE-4-SO4 RECEPTOR; SULFATED OLIGOSACCHARIDES; DIFFERENTIAL EXPRESSION	Sorting protein-related receptor (SorLA/LR11) is a highly conserved mosaic receptor that is expressed by cells in a number of different tissues including principal cells of the collecting ducts in the kidney and neurons in the central and peripheral nervous systems. SorLA/LR11 has features that indicate it serves as a sorting receptor shuttling between the plasma membrane, endosomes, and the Golgi. We have found that a fraction of SorLA/LR11 that is synthesized in the kidney and the brain bears N-linked oligosaccharides that are modified with terminal beta 1,4-linked GalNAc-4-SO4. Oligosaccharides located in the vacuolar sorting (Vps) 10p domain (Vps10p domain) are modified with beta 1,4-linked GalNAc when the Vps10p domain is expressed in cells along with either of two recently cloned protein-specific beta 1,4GalNAc-transferases, GalNAcTIII and GalNAcTIV. Either of two sequences with basic amino acids located within the Vps10p domain is able to mediate recognition by these beta 1,4GalNAc-transferases. The highly specific modification of oligosaccharides in the Vps10p domain of SorLA/LR11 with terminal GalNAc-4-SO4 suggests that this unusual modification may modulate the interaction of SorLA/LR11 with proteins and influence their trafficking.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL)	Baenziger, JU (corresponding author), 4940 Parkview Pl, St Louis, MO 63110 USA.	Baenziger@Pathology.wustl.edu	Baenziger, Jacques U/E-9430-2012		NATIONAL CANCER INSTITUTE [R37CA021923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA21923] Funding Source: Medline; NIDDK NIH HHS [R01-DK41738] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen OM, 2005, P NATL ACAD SCI USA, V102, P13461, DOI 10.1073/pnas.0503689102; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; Boregowda RK, 2005, GLYCOBIOLOGY, V15, P1349, DOI 10.1093/glycob/cwj024; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; Evers MR, 2001, J BIOL CHEM, V276, P36344, DOI 10.1074/jbc.M105848200; Fiete D, 1997, J BIOL CHEM, V272, P14629, DOI 10.1074/jbc.272.23.14629; Fiete D, 1997, P NATL ACAD SCI USA, V94, P11256, DOI 10.1073/pnas.94.21.11256; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; Gotoh M, 2004, FEBS LETT, V562, P134, DOI 10.1016/S0014-5793(04)00219-4; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; Hampe W, 2000, J CELL SCI, V113, P4475; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; Hermans-Borgmeyer I, 1998, MECH DEVELOP, V70, P65, DOI 10.1016/S0925-4773(97)00177-9; Hermey G, 1999, BIOCHEM BIOPH RES CO, V266, P347, DOI 10.1006/bbrc.1999.1822; Hiraoka N, 2001, GLYCOBIOLOGY, V11, P495, DOI 10.1093/glycob/11.6.495; HOOPER LV, 1995, J BIOL CHEM, V270, P5985, DOI 10.1074/jbc.270.11.5985; Jacobsen L, 2002, FEBS LETT, V511, P155, DOI 10.1016/S0014-5793(01)03299-9; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; Jacobsen L, 2001, J BIOL CHEM, V276, P22788, DOI 10.1074/jbc.M100857200; Kamsteeg EJ, 2000, EXP NEPHROL, V8, P326; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; MANZELLA SM, 1995, J BIOL CHEM, V270, P21665, DOI 10.1074/jbc.270.37.21665; Martinez-Pomares L, 1999, J BIOL CHEM, V274, P35211, DOI 10.1074/jbc.274.49.35211; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; MENGELING BJ, 1991, ANAL BIOCHEM, V199, P286, DOI 10.1016/0003-2697(91)90103-Z; Mi YL, 2002, J CLIN INVEST, V109, P269, DOI 10.1172/JCI13997; Motoi Y, 1999, BRAIN RES, V833, P209, DOI 10.1016/S0006-8993(99)01542-5; NYAME K, 1989, J BIOL CHEM, V264, P3235; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Riedel IB, 2002, HISTOCHEM CELL BIOL, V118, P183, DOI 10.1007/s00418-002-0445-8; Roseman DS, 2001, J BIOL CHEM, V276, P17052, DOI 10.1074/jbc.M101027200; Sato T, 2003, J BIOL CHEM, V278, P47534, DOI 10.1074/jbc.M308857200; Scherzer CR, 2004, ARCH NEUROL-CHICAGO, V61, P1200, DOI 10.1001/archneur.61.8.1200; SICILIANO RA, 1993, GLYCOBIOLOGY, V3, P225, DOI 10.1093/glycob/3.3.225; SICILIANO RA, 1994, J BIOL CHEM, V269, P910; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1990, J BIOL CHEM, V265, P874; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; Van Rooijen JJM, 1998, EUR J BIOCHEM, V256, P471, DOI 10.1046/j.1432-1327.1998.2560471.x; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; Woodworth A, 2004, J BIOL CHEM, V279, P10413, DOI 10.1074/jbc.M312466200; Woodworth A, 2002, J BIOL CHEM, V277, P50941, DOI 10.1074/jbc.M209876200; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597	52	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1873	1881		10.1074/jbc.M606455200	http://dx.doi.org/10.1074/jbc.M606455200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121844	hybrid			2022-12-27	WOS:000243451300038
J	Zhao, X; Chang, AY; Toh-e, A; Arvan, P				Zhao, Xiang; Chang, Amy Y.; Toh-e, Akio; Arvan, Peter			A role for Lte1p (a low temperature essential protein involved in mitosis) in proprotein processing in the yeast secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; MITOTIC EXIT; BUD CORTEX; GTPASES; GENES; RAS; CLATHRIN; DNA; PHOSPHORYLATION	We previously identified six single gene disruptions in Saccharomyces cerevisiae that allow enhanced immunoreactive insulin secretion primarily because of defective Kex2p-mediated endoproteolytic processing. Five eis mutants disrupted established VPS (vacuolar protein sorting) genes, The sixth, LTE1, is a (L) under bar ow (T) under bar emperature (< 15 degrees C) (E) under bar ssential gene encoding a large protein with potential guanine nucleotide exchange (GEF) domains. Lte1p functions as a positive regulator of the mitotic GTPase Tem1p, and overexpression of Tem1p suppresses the low temperature mitotic defect of lte1. By sequence analysis, Tem1p has highest similarity to Vps21p (yeast homolog of mammalian Rab5). Unlike TEM1, LTE1 is not restricted to mitosis but is expressed throughout the cell cycle. Lte1p function in interphase cells is largely unknown. Here we confirm the eis phenotype of lte1 mutant cells and demonstrate a defect in proalpha factor processing that is rescued by expression of full-length Lte1p but not a C-terminally truncated Lte1p lacking its GEF homology domain. Neither overexpression of Tem1p nor 13 other structurally related GTPases can suppress the secretory proprotein processing defect. However, overexpression of Vps21p selectively restores proprotein processing in a manner dependent upon the active GTP-bound form of the GTPase. By contrast, a vps21 mutant produces a synthetic defect with lte1 in proprotein processing, as well as a synthetic growth defect. Together, the data underscore a link between the mitotic regulator, Lte1p, and protein processing and trafficking in the secretory/endosomal system.	Univ Michigan, Sch Med, Div Endocrinol Diabet & Metab, Ann Arbor, MI 48109 USA; Yeshiva Univ Albert Einstein Coll Med, Sue Golding Grad Div, Bronx, NY 10461 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Tokyo, Dept Biol Sci, Tokyo 1130033, Japan	University of Michigan System; University of Michigan; Yeshiva University; Albert Einstein College of Medicine; University of Michigan System; University of Michigan; University of Tokyo	Arvan, P (corresponding author), Univ Michigan, Sch Med, Div Endocrinol Diabet & Metab, 5560 MSRB2,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	parvan@umich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280, P30DK020572, P60DK020572] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK020572, DK20572, P60 DK020572, DK48280, R01 DK048280, R01 DK048280-13] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Bensen ES, 2000, GENETICS, V154, P83; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; Carney DS, 2006, TRENDS CELL BIOL, V16, P27, DOI 10.1016/j.tcb.2005.11.001; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; Ha SA, 2003, MOL BIOL CELL, V14, P1319, DOI 10.1091/mbc.E02-10-0686; Hofken T, 2002, EMBO J, V21, P4851, DOI 10.1093/emboj/cdf481; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; Jensen S, 2004, CELL CYCLE, V3, P817; Jensen S, 2002, J CELL SCI, V115, P4977, DOI 10.1242/jcs.00189; Johnston HD, 2005, MOL BIOL CELL, V16, P1456, DOI 10.1091/mbc.E04-07-0642; Li BJ, 1996, J BIOL CHEM, V271, P16813, DOI 10.1074/jbc.271.28.16813; Lord M, 2000, J CELL BIOL, V151, P1501, DOI 10.1083/jcb.151.7.1501; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; MARSH L, 1992, MOL CELL BIOL, V12, P3959, DOI 10.1128/MCB.12.9.3959; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; Molk JN, 2004, MOL BIOL CELL, V15, P1519, DOI 10.1091/mbc.E03-09-0708; OHYA Y, 1993, MOL BIOL CELL, V4, P1017, DOI 10.1091/mbc.4.10.1017; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Seshan A, 2005, CELL CYCLE, V4, P940, DOI 10.4161/cc.4.7.1785; SHERMAN F, 1986, LAB MANUAL; SHIRAYAMA M, 1994, YEAST, V10, P451, DOI 10.1002/yea.320100404; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGERKRUGER B, 1995, J CELL SCI, V108, P3509; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; WARNER JR, 1991, METHODS ENZYMOL, V194, P423; WICKNER RB, 1987, YEAST, V3, P51, DOI 10.1002/yea.320030108; Yeung BG, 1999, MOL BIOL CELL, V10, P3643, DOI 10.1091/mbc.10.11.3643; Yoshida S, 2003, J CELL BIOL, V161, P889, DOI 10.1083/jcb.200301128; Zhang BY, 2003, J BIOL CHEM, V278, P3687, DOI 10.1074/jbc.M209474200; Zhang BY, 2001, J CELL BIOL, V153, P1187, DOI 10.1083/jcb.153.6.1187	37	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1670	1678		10.1074/jbc.M610500200	http://dx.doi.org/10.1074/jbc.M610500200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121813	Green Accepted, hybrid			2022-12-27	WOS:000243451300018
J	Gowda, ASP; Madhunapantula, SV; Achur, RN; Valiyaveettil, M; Bhavanandan, VP; Gowda, DC				Gowda, A. S. Prakasha; Madhunapantula, SubbaRao V.; Achur, Rajeshwara N.; Valiyaveettil, Manojkumar; Bhavanandan, Veer P.; Gowda, D. Channe			Structural basis for the adherence of plasmodium falciparum-infected erythrocytes to chondroitin 4-sulfate and design of novel photoactivable reagents for the identification of parasite adhesive proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; PREGNANCY-ASSOCIATED MALARIA; SULFATE-A; HUMAN PLACENTA; ANTIGENIC VARIATION; MEMBRANE PROTEIN-1; BIRTH-WEIGHT; RECEPTOR; VAR2CSA; PROTEOGLYCANS	A dodecasaccharide motif of the low-sulfated chondroitin 4-sulfate (C4S) mediate the binding of Plasmodium falciparum-infected red blood cells (IRBCs) in human placenta. Here we studied the detailed C4S structural requirements by assessing the ability of chemically modified C4S to inhibit IRBC binding to the placental chondroitin sulfate proteoglycan. Replacement of the N-acetyl groups with bulky N-acyl or N-benzoyl substituents had no effect on the inhibitory activity of C4S, whereas reduction of the carboxyl groups abrogated the activity. Dermatan sulfates showed similar to 50% inhibitory activity when compared with C4Ss with similar sulfate contents. These data demonstrate that the C4S carboxyl groups and their equatorial orientation but not the N-acetyl groups are critical for IRBC binding. Conjugation of bulky substituents to the reducing end N-acetylgalactosamine residues of C4S dodecasaccharide had no effect on its inhibitory activity. Based on these results, we prepared photoaffinity reagents for the identification of the parasite proteins involved in C4S binding. Cross-linking of the IRBCs with a radioiodinated photoactivable C4S dodecasaccharide labeled a similar to 22-kDa novel parasite protein, suggesting strongly for the first time that a low molecular weight IRBC surface protein rather than a 200-400-kDa PfEMP1 is involved in C4S binding. Conjugation of biotin to the C4S dodecasaccharide photoaffinity probe afforded a strategy for the isolation of the labeled protein by avidin affinity precipitation, facilitating efforts to identify the C4S-adherent IRBC protein(s). Our results also have broader implications for designing oligosaccharide-based photoaffinity probes for the identification of proteins involved in glycosaminoglycan-dependent attachment of microbes to hosts.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Gowda, DC (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr, Hershey, PA 17033 USA.	gowda@psu.edu	Madhunapantula, SubbaRao V./B-1590-2015	Madhunapantula, SubbaRao V./0000-0001-9167-9271; Gowda, Channe/0000-0002-6860-5108; ALADAHALLI SANNE GOWDA, PRAKASHA GOWDA/0000-0002-0055-7103; Achur, Rajeshwara/0000-0001-9867-8917	NIAID NIH HHS [AI45086] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045086, R21AI045086] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achur RN, 2003, J BIOL CHEM, V278, P11705, DOI 10.1074/jbc.M211015200; Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200; Alkhalil A, 2000, J BIOL CHEM, V275, P40357, DOI 10.1074/jbc.M006399200; Barfod L, 2006, INFECT IMMUN, V74, P4357, DOI 10.1128/IAI.01617-05; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; Beeson JG, 2005, CURR TOP MICROBIOL, V297, P187; Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743; Bull PC, 2005, J INFECT DIS, V192, P1119, DOI 10.1086/432761; CARRUTHERS VB, 2000, INFECT IMMUN, V125, P21; Chai WG, 2002, J BIOL CHEM, V277, P22438, DOI 10.1074/jbc.M111401200; CIFONELLI JA, 1976, METHODS CARBOHYDR CH, V8, P139; Cooke BM, 2000, PARASITOL TODAY, V16, P416, DOI 10.1016/S0169-4758(00)01753-1; COWMAN MK, 1984, BIOCHEM J, V221, P707, DOI 10.1042/bj2210707; Elliott SR, 2005, INFECT IMMUN, V73, P2848, DOI 10.1128/IAI.73.5.2848-2856.2005; FINNE J, 1982, METHOD ENZYMOL, V83, P269; Fried M, 2000, EXP PARASITOL, V95, P75, DOI 10.1006/expr.2000.4510; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fuzesi M, 2005, J BIOL CHEM, V280, P18291, DOI 10.1074/jbc.M500080200; Gamain B, 2005, J INFECT DIS, V191, P1010, DOI 10.1086/428137; Gamain B, 2002, P NATL ACAD SCI USA, V99, P10020, DOI 10.1073/pnas.152321599; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; Gowda DC, 1999, BIOSCIENCE REP, V19, P261, DOI 10.1023/A:1020542206916; Heddini A, 2001, INFECT IMMUN, V69, P5849, DOI 10.1128/IAI.69.9.5849-5856.2001; HOWARD RJ, 1984, J CELL BIOCHEM, V24, P297, DOI 10.1002/jcb.240240310; JACKSON P, 1990, BIOCHEM J, V270, P705, DOI 10.1042/bj2700705; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; Mackintosh CL, 2004, TRENDS PARASITOL, V20, P597, DOI 10.1016/j.pt.2004.09.006; Matsubayashi Y, 2000, J BIOL CHEM, V275, P15520, DOI 10.1074/jbc.275.20.15520; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; Menendez C, 2000, J INFECT DIS, V181, P1740, DOI 10.1086/315449; Muthusamy A, 2004, GLYCOBIOLOGY, V14, P635, DOI 10.1093/glycob/cwh077; Muthusamy A, 2004, AM J PATHOL, V164, P2013, DOI 10.1016/S0002-9440(10)63761-3; Ndam NGT, 2005, J INFECT DIS, V192, P331, DOI 10.1086/430933; Oonuki Y, 2005, ANAL BIOCHEM, V343, P212, DOI 10.1016/j.ab.2005.05.039; PASLOSKE BL, 1994, ANNU REV MED, V45, P283; Recker M, 2004, NATURE, V429, P555, DOI 10.1038/nature02486; Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198; Ridley BL, 1997, ANAL BIOCHEM, V249, P10, DOI 10.1006/abio.1997.2165; Rogerson SJ, 1997, PARASITOL TODAY, V13, P70, DOI 10.1016/S0169-4758(96)10081-8; Romaniouk AV, 2004, GLYCOBIOLOGY, V14, P301, DOI 10.1093/glycob/cwh044; Rostand KS, 1997, INFECT IMMUN, V65, P1; Rowe JA, 2004, MOL MICROBIOL, V53, P1011, DOI 10.1111/j.1365-2958.2004.04256.x; Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; Sherman IW, 2003, MICROBES INFECT, V5, P897, DOI 10.1016/S1286-4579(03)00162-X; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Taylor R. L., 1976, METHODS CARBOHYDRATE, V7, P149; Trang DTX, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-7; Wadstrom T, 1999, J MED MICROBIOL, V48, P223, DOI 10.1099/00222615-48-3-223; Weatherall David J, 2002, Hematology Am Soc Hematol Educ Program, P35	53	23	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					916	928		10.1074/jbc.M604741200	http://dx.doi.org/10.1074/jbc.M604741200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17085451	hybrid			2022-12-27	WOS:000243295200014
J	Amelot, AA; Tagzirt, M; Ducouret, G; Kuen, RL; Le Bonniec, BF				Amelot, Aymeric A.; Tagzirt, Madjid; Ducouret, Guylaine; Kuen, Rene Lai; Le Bonniec, Bernard F.			Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET FACTOR-IV; ACTIVATED PROTEIN-C; ARG-PRO-AMIDE; CRYSTAL-STRUCTURE; LATERAL AGGREGATION; FRAGMENT-D; PROTOFIBRIL FORMATION; EXTRA GLYCOSYLATION; BOVINE FIBRINOGEN; CALCIUM-BINDING	Platelet factor-4 (PF4/CXCL4) is an orphan chemokine released in large quantities in the vicinity of growing blood clots. Coagulation of plasma supplemented with a matching amount of PF4 results in a translucent jelly-like clot. Saturating amounts of PF4 reduce the porosity of the fibrin network 4.4-fold and decrease the values of the elastic and loss moduli by 31- and 59-fold, respectively. PF4 alters neither the cleavage of fibrinogen by thrombin nor the cross-linking of protofibrils by activated factor XIII but binds to fibrin and dramatically transforms the structure of the ensuing network. Scanning electron microscopy showed that PF4 gives rise to a previously unreported pattern of polymerization where fibrin assembles to form a sealed network. The subunits constituting PF4 form a tetrahedron having at its corners a RPRH motif that mimics (in reverse orientation) the Gly-His-Arg-Pro-amide peptides that co-crystallize with fibrin. Molecular modeling showed that PF4 could be docked to fibrin with remarkable complementarities and absence of steric clashes, allowing the assembly of irregular polymers. Consistent with this hypothesis, as little as 50 mu M the QVRPRHIT peptide derived from PF4 affects the polymerization of fibrin.	Univ Paris Descartes, INSERM, U765, F-75270 Paris 06, France; Ecole Super Phys & Chim Ind Ville Paris, CNRS, Lab Physicochim Polymeres & Milieux Disperses, F-75231 Paris 05, France; Univ Paris Descartes, Serv Imagerie Cellulaire & Mol, F-75270 Paris 06, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); UDICE-French Research Universities; Universite Paris Cite	Le Bonniec, BF (corresponding author), Univ Paris Descartes, INSERM, U765, 4 Av Observ, F-75270 Paris 06, France.	bernard.le-bonniec@univ-paris5.fr	Le Bonniec, Bernard/S-5756-2016; TAGZIRT, Madjid MT/R-8048-2018; Le Bonniec, Bernard/ABA-1366-2020	Le Bonniec, Bernard/0000-0002-8432-7363; TAGZIRT, Madjid MT/0000-0001-7914-0695; Le Bonniec, Bernard/0000-0002-8432-7363				Ariens RAS, 2002, BLOOD, V100, P743, DOI 10.1182/blood.V100.3.743; BALE MD, 1985, P NATL ACAD SCI USA, V82, P1410, DOI 10.1073/pnas.82.5.1410; BALE MD, 1986, J BIOL CHEM, V261, P862; Bikfalvi A, 2004, SEMIN THROMB HEMOST, V30, P379, DOI 10.1055/s-2004-831051; Blomback B, 2004, BIOPHYS CHEM, V112, P147, DOI 10.1016/j.bpc.2004.07.013; BLOMBACK B, 1989, BIOCHIM BIOPHYS ACTA, V997, P96, DOI 10.1016/0167-4838(89)90140-4; Brown JH, 2000, P NATL ACAD SCI USA, V97, P85, DOI 10.1073/pnas.97.1.85; CARR ME, 1989, BIOCHEMISTRY-US, V28, P1384, DOI 10.1021/bi00429a066; CARR ME, 1987, THROMB RES, V45, P539, DOI 10.1016/0049-3848(87)90316-1; CHEN MJ, 1991, BIOCHEMISTRY-US, V30, P6402, DOI 10.1021/bi00240a009; Chong BH, 2003, J THROMB HAEMOST, V1, P1471, DOI 10.1046/j.1538-7836.2003.00270.x; Collet JP, 1996, BIOPHYS J, V70, P500, DOI 10.1016/S0006-3495(96)79596-6; Collet JP, 2002, CIRC RES, V90, P428, DOI 10.1161/hh0402.105095; Coughlin SR, 2001, THROMB HAEMOSTASIS, V86, P298; DHALL TZ, 1983, THROMB HAEMOSTASIS, V49, P42; Doolittle RF, 2006, BIOCHEMISTRY-US, V45, P2657, DOI 10.1021/bi0524767; Doolittle RF, 2003, J THROMB HAEMOST, V1, P1559, DOI 10.1046/j.1538-7836.2003.00278.x; Doolittle RF, 2003, BLOOD REV, V17, P33, DOI 10.1016/S0268-960X(02)00060-7; Dudek AZ, 1997, J BIOL CHEM, V272, P31785, DOI 10.1074/jbc.272.50.31785; Eslin DE, 2004, BLOOD, V104, P3173, DOI 10.1182/blood-2003-11-3994; Everse SJ, 1999, BIOCHEMISTRY-US, V38, P2941, DOI 10.1021/bi982626w; EVERSE SJ, 1995, PROTEIN SCI, V4, P1013; Gorkun OV, 1998, BIOCHEMISTRY-US, V37, P15434, DOI 10.1021/bi981551t; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; Hirota-Kawadobora M, 2005, J THROMB HAEMOST, V3, P983, DOI 10.1111/j.1538-7836.2005.01294.x; JANMEY PA, 1983, J RHEOL, V27, P135, DOI 10.1122/1.549722; Kostelansky MS, 2004, BIOCHEMISTRY-US, V43, P2475, DOI 10.1021/bi0359978; Kostelansky MS, 2002, BIOCHEMISTRY-US, V41, P12124, DOI 10.1021/bi0261894; LANGER BG, 1988, J BIOL CHEM, V263, P15056; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; Lorand L, 2005, J THROMB HAEMOST, V3, P1337, DOI 10.1111/j.1538-7836.2005.01213.x; Lounes KC, 2002, BIOCHEMISTRY-US, V41, P5291, DOI 10.1021/bi011988s; Lu Q, 2005, J THROMB HAEMOST, V3, P1791, DOI 10.1111/j.1538-7836.2005.01358.x; Lundblad RL, 2004, THROMB HAEMOSTASIS, V91, P851, DOI 10.1160/TH-03-12-0792; Madrazo J, 2001, P NATL ACAD SCI USA, V98, P11967, DOI 10.1073/pnas.211439798; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Mann KG, 2003, J THROMB HAEMOST, V1, P1504, DOI 10.1046/j.1538-7836.2003.00298.x; Marchi R, 2004, J THROMB HAEMOST, V2, P940, DOI 10.1111/j.1538-7836.2004.00730.x; Marque PE, 2000, J BIOL CHEM, V275, P809, DOI 10.1074/jbc.275.2.809; MAYO KH, 1995, BIOCHEMISTRY-US, V34, P11399, DOI 10.1021/bi00036a012; Mihalyi E, 2004, BIOPHYS CHEM, V112, P131, DOI 10.1016/j.bpc.2004.07.012; Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538-7836.2005.01365.x; Mullin JL, 2000, BIOCHEMISTRY-US, V39, P9843, DOI 10.1021/bi000045c; Ryan EA, 1999, BIOPHYS J, V77, P2813, DOI 10.1016/S0006-3495(99)77113-4; Scheiner T, 2003, J THROMB HAEMOST, V1, P2594, DOI 10.1111/j.1538-7836.2003.00521.x; Slungaard A, 2003, BLOOD, V102, P146, DOI 10.1182/blood-2002-11-3529; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; Sugo T, 1999, BLOOD, V94, P3806, DOI 10.1182/blood.V94.11.3806.423a17_3806_3813; Sugo T, 2000, BLOOD, V96, P3779, DOI 10.1182/blood.V96.12.3779.h8003779_3779_3785; VANGELDER JM, 1993, THROMB RES, V72, P339, DOI 10.1016/0049-3848(93)90143-C; WEISEL JW, 1993, J MOL BIOL, V232, P285, DOI 10.1006/jmbi.1993.1382; WEISEL JW, 1992, BIOPHYS J, V63, P111, DOI 10.1016/S0006-3495(92)81594-1; Woodhead JL, 1996, J BIOL CHEM, V271, P4946; Yang Z, 2002, BIOCHEMISTRY-US, V41, P15610, DOI 10.1021/bi026666i; Yang Z, 2002, BIOCHEMISTRY-US, V41, P10218, DOI 10.1021/bi020299t; Yang Z, 2000, P NATL ACAD SCI USA, V97, P14156, DOI 10.1073/pnas.97.26.14156; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P693	61	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					710	720		10.1074/jbc.M606650200	http://dx.doi.org/10.1074/jbc.M606650200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17090548	hybrid			2022-12-27	WOS:000243166500076
J	Martin, T; Sharma, R; Sippel, C; Waegemann, K; Soll, J; Vothknecht, UC				Martin, Torsten; Sharma, Rita; Sippel, Claudia; Waegemann, Karin; Soll, Juergen; Vothknecht, Ute C.			A protein kinase family in Arabidopsis phosphorylates chloroplast precursor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIT PEPTIDE; OUTER ENVELOPE; IMPORT; TRANSLOCATION; BIOGENESIS; INTEGRATION	A serine/threonine protein kinase that is able to phosphorylate chloroplast-destined precursor proteins was purified from leaf extract of Arabidopsis thaliana and was identified by mass spectrometry. The protein kinase, encoded by AT2G17700, belongs to a small protein family comprising in addition AT4G35780 and AT4G38470. All three proteins were expressed heterologously in Escherichia coli and characterized with regard to their properties in precursor protein phosphorylation. They were able to phosphorylate several chloroplast-destined precursor proteins within their cleavable presequences. In contrast, a mitochondria-destined precursor protein was not a substrate for these kinases. For all three enzymes, the phosphorylation reaction was specific for ATP with apparent K-m values between 14 and 67 mu M. They did not utilize other NTPs nor were those able to compete for ATP in the reaction. An excess of ADP was able to inhibit ATP-dependent phosphorylation. Furthermore, all three kinases exhibited autophosphorylation. The protein kinases described here could represent subunits of a regulatory network involved in the cytosolic events of chloroplast protein import.	Univ Munich, Dept Biol 1, D-80638 Munich, Germany	University of Munich	Soll, J (corresponding author), Univ Munich, Dept Biol 1, Menzinger Str 67, D-80638 Munich, Germany.	soll@lmu.de	Vothknecht, Ute C/F-4678-2014	Vothknecht, Ute C/0000-0002-8930-0127				Abdallah F, 2000, TRENDS PLANT SCI, V5, P141, DOI 10.1016/S1360-1385(00)01574-0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Baier M, 2005, J EXP BOT, V56, P1449, DOI 10.1093/jxb/eri161; Bauer J, 2001, CELL MOL LIFE SCI, V58, P420, DOI 10.1007/PL00000867; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; Chigri F, 2005, PLANT J, V42, P821, DOI 10.1111/j.1365-313X.2005.02414.x; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GAMBORG OL, 1976, IN VITRO CELL DEV B, V12, P473; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Hormann F, 2004, J BIOL CHEM, V279, P34756, DOI 10.1074/jbc.M402817200; Jarvis P, 2003, CURR BIOL, V13, pR314, DOI 10.1016/S0960-9822(03)00235-5; JOHN CG, 2003, PHILOS T R SOC LON B, V358, P135; Koop HU, 1996, PLANTA, V199, P193, DOI 10.1007/BF00196559; Kuchler M, 2002, EMBO J, V21, P6136, DOI 10.1093/emboj/cdf621; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez-Juez E, 2005, INT J DEV BIOL, V49, P557, DOI 10.1387/ijdb.051997el; May T, 2000, PLANT CELL, V12, P53, DOI 10.1105/tpc.12.1.53; Mollier P, 2002, CURR GENET, V40, P405, DOI 10.1007/s00294-002-0271-5; Nakrieko KA, 2004, EUR J BIOCHEM, V271, P509, DOI 10.1046/j.1432-1033.2003.03950.x; Rial DV, 2003, J BIOL CHEM, V278, P46473, DOI 10.1074/jbc.M306684200; Rudrabhatla P, 2006, PLANT MOL BIOL, V60, P293, DOI 10.1007/s11103-005-4109-7; Schleiff E, 2003, P NATL ACAD SCI USA, V100, P4604, DOI 10.1073/pnas.0730860100; Schleiff E, 2002, BIOCHEMISTRY-US, V41, P1934, DOI 10.1021/bi011361+; Vothknecht UC, 2005, GENE, V354, P99, DOI 10.1016/j.gene.2005.04.021; Waegemann K, 1996, J BIOL CHEM, V271, P6545, DOI 10.1074/jbc.271.11.6545; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; Zhang XL, 2006, J BIOL CHEM, V281, P13949, DOI 10.1074/jbc.M601384200	31	54	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40216	40223		10.1074/jbc.M606580200	http://dx.doi.org/10.1074/jbc.M606580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17090544	hybrid			2022-12-27	WOS:000243033900052
J	Chrestensen, CA; Shuman, JK; Eschenroeder, A; Worthington, M; Gram, H; Sturgil, TW				Chrestensen, Carol A.; Shuman, Jacquelyn K.; Eschenroeder, Andrew; Worthington, Mark; Gram, Hermann; Sturgil, Thomas W.			MNK1 and MNK2 regulation in HER2-overexpressing breast cancer lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INITIATION-FACTOR 4E; PHOSPHORYLATION SITES; FACTOR EIF4E; CELL-LINES; MOLECULAR CHARACTERIZATION; TRANSCRIPTION FACTOR; NUCLEAR EXPORT; N-TERMINI; C-TERMINI	MAPK-interacting protein kinases 1 and 2 (MNK1 and MNK2) function downstream of p38 and ERK MAPK, but there are large gaps in our knowledge of how MNKs are regulated and function. As proteins activated in the HER2/Ras/Raf/ERK pathway, the MNKs are of potential interest in HER2-overexpressing cancers. We utilized a panel of breast cell lines (HCC1419, AU565, SKBR3, MCF7, and MCF10A), three of which overexpress HER2, to characterize the amounts and activation status of MNKs and other pathway enzymes (ERKs and RSKs) in these cells. We generated a phosphospecific antibody to Thr(P)-214 in the T-loop of MNKs and found that phosphorylations of both Thr-209 and Thr-214 in human MNK1 are required for activation. Increased phosphorylation and activity of the MNKs correlate with HER2 overexpression, and inhibition of the MNKs reduces colony formation in soft agar. Our work identifies the MNKs as potential therapeutic targets for breast cancer treatments.	Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Digeset Hlth Ctr Excellence, Charlottesville, VA 22908 USA; Novartis Pharma AG, Arthritis & Bone Metab, CH-4002 Basel, Switzerland	University of Virginia; University of Virginia; Novartis	Sturgil, TW (corresponding author), Univ Virginia, Sch Med, Dept Pharmacol, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	Thomas_Sturgill@virginia.edu			NIGMS NIH HHS [GM62890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson K, 2006, CYTOKINE, V33, P52, DOI 10.1016/j.cyto.2005.11.017; Arquier N, 2005, CURR BIOL, V15, P19, DOI 10.1016/j.cub.2004.12.037; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Baselga J, 2002, CANCER CELL, V1, P319, DOI 10.1016/S1535-6108(02)00066-1; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; Chrestensen CA, 2004, J BIOL CHEM, V279, P10176, DOI 10.1074/jbc.M310486200; Chrestensen CA, 2002, J BIOL CHEM, V277, P27733, DOI 10.1074/jbc.M202663200; Cowell JK, 2005, CANCER GENET CYTOGEN, V163, P23, DOI 10.1016/j.cancergencyto.2005.04.019; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Dyer JR, 2003, NAT NEUROSCI, V6, P219, DOI 10.1038/nn1018; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fujita T, 2006, BRIT J CANCER, V94, P247, DOI 10.1038/sj.bjc.6602926; Fujita T, 2006, ANTI-CANCER DRUG, V17, P455, DOI 10.1097/01.cad.0000198910.90819.06; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; He YW, 2005, J CELL SCI, V118, P3173, DOI 10.1242/jcs.02448; Hoffmann J, 2004, J NATL CANCER I, V96, P210, DOI 10.1093/jnci/djh022; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; Jauch R, 2005, STRUCTURE, V13, P1559, DOI 10.1016/j.str.2005.07.013; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Lee AWM, 1999, ONCOGENE, V18, P7477, DOI 10.1038/sj.onc.1203123; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; Liscovitch M, 2007, CANCER LETT, V245, P350, DOI 10.1016/j.canlet.2006.01.013; McCoy CE, 2005, BIOCHEM J, V387, P507, DOI 10.1042/BJ20041501; Meng Z, 2005, NUCLEIC ACIDS RES, V33, P2962, DOI 10.1093/nar/gki603; Morley SJ, 2003, CELL SIGNAL, V15, P741, DOI 10.1016/S0898-6568(03)00008-1; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Neve RM, 2001, ANN ONCOL, V12, P9, DOI 10.1023/A:1011199404516; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Nikolcheva T, 2002, J CLIN INVEST, V110, P119, DOI 10.1172/JCI200215336; O'Loghlen A, 2004, EXP CELL RES, V299, P343, DOI 10.1016/j.yexcr.2004.06.006; Parra-Palau JL, 2003, J BIOL CHEM, V278, P44197, DOI 10.1074/jbc.M302398200; Patry C, 2004, MOL CANCER THER, V3, P1193; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Ross G, 2006, J NEUROCHEM, V97, P79, DOI 10.1111/j.1471-4159.2006.03704.x; Scheper GC, 2003, MOL CELL BIOL, V23, P5692, DOI 10.1128/MCB.23.16.5692-5705.2003; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Slentz-Kesler K, 2000, GENOMICS, V69, P63, DOI 10.1006/geno.2000.6299; Smith JA, 2005, CANCER RES, V65, P1027; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Tschopp C., 2000, Molecular Cell Biology Research Communications, V3, P205, DOI 10.1006/mcbr.2000.0217; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Ushigome M, 2005, INT J ONCOL, V26, P635; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Worch J, 2004, ONCOGENE, V23, P9162, DOI 10.1038/sj.onc.1208164	58	43	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4243	4252		10.1074/jbc.M607368200	http://dx.doi.org/10.1074/jbc.M607368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17130135	hybrid			2022-12-27	WOS:000244482000004
J	Donkor, J; Sariahmetoglu, M; Dewald, J; Brindley, DN; Reue, K				Donkor, Jimmy; Sariahmetoglu, Meltem; Dewald, Jay; Brindley, David N.; Reue, Karen			Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-GAMMA; RAT-LIVER; SUBCELLULAR-LOCALIZATION; INSULIN-RESISTANCE; ADIPOSE-TISSUE; FATTY-ACIDS; PHOSPHOHYDROLASE; PHOSPHORYLATION; LIPODYSTROPHY; GENE	We previously identified mutations in the Lpin1 gene, encoding lipin-1, as the underlying cause of lipodystrophy in the fatty liver dystrophy (fld) mutant mouse. Lipin-1 is normally expressed at high levels in adipose tissue and skeletal muscle, and deficiency in the fld mouse causes impaired adipose tissue development, insulin resistance, and altered energy expenditure. We also identified two additional lipin protein family members of unknown function, lipin-2 and lipin-3. Han et al. (Han, G. S., Wu, W. I., and Carman, G. M. (2006) J. Biol. Chem. 281,9210-9218) recently demonstrated that the single lipin homolog in yeast, Smp2, exhibits phosphatidate phosphatase type-1 (PAP1) activity, which has a key role in glycerolipid synthesis. Here we demonstrate that lipin-1 accounts for all of the PAPI activity in white and brown adipose tissue and skeletal muscle. However, livers of lipin-1-deficient mice exhibited normal PAP1 activity, indicating that other members of the lipin protein family could have PAPI activity. Consistent with this possibility, recombinant lipin-2 and lipin-3 possess PAPI activity. Each of the three lipin family members showed Mg2+-dependent activity that was specific for phosphatidate under the conditions employed. The different lipins showed distinct tissue expression patterns. Our results establish the three mammalian lipin proteins as PAP I enzymes and explain the biochemical basis for lipodystrophy in the lipin-1-deficient fld mouse.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Alberta, Dept Biochem, Signal Transduct Res Grp, Edmonton, AB T6G 2S2, Canada	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Alberta	Reue, K (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Gonda 6506A,695 Charles E Young Dr S, Los Angeles, CA 90095 USA.	reuek@ucla.edu			NHGRI NIH HHS [S-T32-HG002536, T32 HG002536] Funding Source: Medline; NHLBI NIH HHS [HL-28481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG002536] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Brindley D N, 1974, Biomembranes, V4B, P621; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Brindley DN, 2004, J CELL BIOCHEM, V92, P900, DOI 10.1002/jcb.20126; BRINDLEY DN, 1988, PHOSPHATIDATE PHOSPH, P21; BUTTERWITH SC, 1984, BIOCHEM J, V220, P825, DOI 10.1042/bj2200825; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Finck BN, 2006, CELL METAB, V4, P199, DOI 10.1016/j.cmet.2006.08.005; GOMEZMUNOZ A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P49, DOI 10.1016/0005-2760(92)90200-F; Han GS, 2006, J BIOL CHEM, V281, P9210, DOI 10.1074/jbc.M600425200; Harris TE, 2007, J BIOL CHEM, V282, P277, DOI 10.1074/jbc.M609537200; Hegele RA, 2005, AM J PHYSIOL-REG I, V289, pR663, DOI 10.1152/ajpregu.00275.2005; Huffman TA, 2002, P NATL ACAD SCI USA, V99, P1047, DOI 10.1073/pnas.022634399; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; LINDEGAARD B, 2007, IN PRESS INT J OBES; MARTIN A, 1991, METHOD ENZYMOL, V197, P553; MARTINSANZ P, 1984, FEBS LETT, V175, P284, DOI 10.1016/0014-5793(84)80752-8; O'Hara L, 2006, J BIOL CHEM, V281, P34537, DOI 10.1074/jbc.M606654200; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; Peterfy M, 2005, J BIOL CHEM, V280, P32883, DOI 10.1074/jbc.M503885200; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Petersen KF, 2006, AM J MED, V119, p10S, DOI 10.1016/j.amjmed.2006.01.009; Phan J, 2005, CELL METAB, V1, P73, DOI 10.1016/j.cmet.2004.12.002; Phan J, 2004, J BIOL CHEM, V279, P29558, DOI 10.1074/jbc.M403506200; Reue K, 2000, J LIPID RES, V41, P1067; Reue K, 2006, CURR OPIN CLIN NUTR, V9, P436, DOI 10.1097/01.mco.0000232904.82038.db; Reue K, 2006, FUTURE LIPIDOL, V1, P91, DOI 10.2217/17460875.1.1.91; SAGGERSON ED, 1988, PHOSPHATIDATE PHOSPH, P79; Suviolahti E, 2006, HUM MOL GENET, V15, P377, DOI 10.1093/hmg/ddi448; van Harmelen V, 2007, J LIPID RES, V48, P201, DOI 10.1194/jlr.M600272-JLR200; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; Yao-Borengasser A, 2006, DIABETES, V55, P2811, DOI 10.2337/db05-1688	34	276	299	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3450	3457		10.1074/jbc.M610745200	http://dx.doi.org/10.1074/jbc.M610745200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158099	hybrid			2022-12-27	WOS:000244481900007
J	Fazal, F; Minhajuddin, M; Bijli, KM; McGrath, JL; Rahman, A				Fazal, Fabeha; Minhajuddin, Mohd; Bijli, Kaiser M.; McGrath, James L.; Rahman, Arshad			Evidence for actin cytoskeleton-dependent and -independent pathways for RelA/p65 nuclear translocation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERCELLULAR-ADHESION MOLECULE-1; GENE-EXPRESSION; ACTIVATION; THROMBIN; PROTEIN; PHOSPHORYLATION; KINASE; ALPHA; TRANSCRIPTION	Activation of the transcription factor NF-kappa B involves its release from the inhibitory protein I kappa B alpha in the cytoplasm and subsequently, its translocation to the nucleus. Whereas the events responsible for its release have been elucidated, mechanisms regulating the nuclear transport of NF-kappa B remain elusive. We now provide evidence for actin cytoskeleton-dependent and-independent mechanisms of RelA/p65 nuclear transport using the proinflammatory mediators, thrombin and tumor necrosis factor a, respectively. We demonstrate that thrombin alters the actin cytoskeleton in endothelial cells and interfering with these alterations, whether by stabilizing or destabilizing the actin filaments, prevents thrombin-induced NF-kappa B activation and consequently, expression of its target gene, ICAM-1. The blockade of NF-kappa B activation occurs downstream of I kappa B alpha degradation and is associated with impaired RelA/p65 nuclear translocation. Importantly, thrombin induces association of RelA/p65 with actin and this interaction is sensitive to stabilization/destabilization of the actin filaments. In parallel studies, stabilizing or destabilizing the actin filaments fails to inhibit RelA/p65 nuclear accumulation and ICAM-1 expression by tumor necrosis factor a, consistent with its inability to induce actin filament formation comparable with thrombin. Thus, these studies reveal the existence of actin cytoskeleton-dependent and-independent pathways that may be engaged in a stimulus-specific manner to facilitate RelA/p65 nuclear import and thereby ICAM-1 expression in endothelial cells.	Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biomed Engn, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Rahman, A (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pediat, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.	Arshad_Rahman@urmc.rochester.edu		McGrath, James/0000-0003-2017-8335	NHLBI NIH HHS [HL67424, R01 HL067424] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067424] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965; Are AF, 2000, EXP CELL RES, V256, P533, DOI 10.1006/excr.2000.4830; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Bourgarel-Rey V, 2000, EUR J CANCER, V36, P1043, DOI 10.1016/S0959-8049(00)00042-3; Bourgarel-Rey V, 2001, MOL PHARMACOL, V59, P1165, DOI 10.1124/mol.59.5.1165; BUBB MR, 1994, J BIOL CHEM, V269, P14869; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Doerschuk CM, 2000, AM J RESP CELL MOL, V23, P133, DOI 10.1165/ajrcmb.23.2.f193; Fazal F, 2005, MOL CELL BIOL, V25, P6259, DOI 10.1128/MCB.25.14.6259-6266.2005; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; Geiger RC, 2006, GENE THER, V13, P725, DOI 10.1038/sj.gt.3302693; Ghisletti S, 2005, MOL CELL BIOL, V25, P2957, DOI 10.1128/MCB.25.8.2957-2968.2005; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawkitinarong K, 2004, AM J RESP CELL MOL, V31, P517, DOI 10.1165/rcmb.2003-0432OC; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Mackenzie GG, 2002, J BIOL CHEM, V277, P34610, DOI 10.1074/jbc.M203616200; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Minhajuddin M, 2005, J IMMUNOL, V174, P5823, DOI 10.4049/jimmunol.174.9.5823; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Qiao J, 2003, AM J PHYSIOL-LUNG C, V284, pL972, DOI 10.1152/ajplung.00429.2002; Rahman A, 1999, J IMMUNOL, V162, P5466; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Rivas FV, 2004, MOL CELL BIOL, V24, P1628, DOI 10.1128/MCB.24.4.1628-1639.2004; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spencer W, 1999, ONCOGENE, V18, P495, DOI 10.1038/sj.onc.1202335; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VALLEE R, 1993, P NATL ACAD SCI USA, V90, P8769, DOI 10.1073/pnas.90.19.8769; VandenBerg E, 2004, J CELL BIOCHEM, V91, P926, DOI 10.1002/jcb.20011; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003	58	53	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3940	3950		10.1074/jbc.M608074200	http://dx.doi.org/10.1074/jbc.M608074200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158457	hybrid			2022-12-27	WOS:000244481900058
J	Hofacker, M; Gompf, S; Zutz, A; Presenti, C; Haase, W; van der Does, C; Model, K; Tampe, R				Hofacker, Matthias; Gompf, Simone; Zutz, Ariane; Presenti, Chiara; Haase, Winfried; van der Does, Chris; Model, Kirstin; Tampe, Robert			Structural and functional fingerprint of the mitochondrial ATP-binding cassette transporter Mdl1 from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINATORIAL PEPTIDE LIBRARIES; ABC TRANSPORTER; ESCHERICHIA-COLI; LACTOCOCCUS-LACTIS; NUCLEOTIDE-BINDING; MEMBRANE-PROTEIN; ELECTRON-MICROSCOPY; BACILLUS-SUBTILIS; 3-DIMENSIONAL RECONSTRUCTION; HYDROLYSIS CYCLE	The ATP-binding cassette half-transporter Mdl1 from Saccharomyces cerevisiae has been proposed to be involved in the quality control of misassembled respiratory chain complexes by exporting degradation products generated by the m-AAA proteases from the matrix. Direct functional or structural data of the transport complex are, however, not known so far. After screening expression in various hosts, Mdl1 was overexpressed 100-fold to 1% of total mitochondrial membrane protein in S. cerevisiae. Based on detergent screens, Mdl1 was solubilized and purified to homogeneity. Mdl1 showed a high binding affinity for MgATP (K-d = 0.26 mu M) and an ATPase activity with a K. of 0.86 mM (Hill coefficient of 0.98) and a turnover rate of 2.6 ATP/s. Mutagenesis of the conserved glutamate downstream of the Walker B motif (E599Q) or the conserved histidine of the H-loop (H631A) abolished ATP hydrolysis, whereas ATP binding was not affected. Mdl1 reconstituted into liposomes showed an ATPase activity similar to the solubilized complex. By single particle electron microscopy, a first three-dimensional structure of the mitochondrial ATP-binding cassette transporter was derived at 2.3-nm resolution, revealing a homodimeric complex in an open conformation.	Goethe Univ Frankfurt, Inst Biochem, Bioctr, D-60438 Frankfurt, Germany; Max Planck Inst Biophys, D-60438 Frankfurt, Germany; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Goethe University Frankfurt; Max Planck Society; MRC Laboratory Molecular Biology	Tampe, R (corresponding author), Goethe Univ Frankfurt, Inst Biochem, Bioctr, Max Von Laue Str 9, D-60438 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; Awayn NH, 2005, BIOCHEM SOC T, V33, P996, DOI 10.1042/BST0330996; BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; Brachmann CB, 1998, YEAST, V14, P115; Chami M, 2002, J MOL BIOL, V315, P1075, DOI 10.1006/jmbi.2001.5309; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chloupkova M, 2003, J MOL BIOL, V331, P155, DOI 10.1016/S0022-2836(03)00666-1; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; DEAN M, 1994, YEAST, V10, P377, DOI 10.1002/yea.320100310; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Detmers FJM, 2000, P NATL ACAD SCI USA, V97, P12487, DOI 10.1073/pnas.220308797; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doeven MK, 2004, J BIOL CHEM, V279, P32301, DOI 10.1074/jbc.M404343200; Ferreira-Pereira A, 2003, J BIOL CHEM, V278, P11995, DOI 10.1074/jbc.M212198200; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hogue DL, 1999, J MOL BIOL, V285, P379, DOI 10.1006/jmbi.1998.2259; Horn C, 2003, J MOL BIOL, V334, P403, DOI 10.1016/j.jmb.2003.09.079; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; JOBLING MG, 1990, NUCLEIC ACIDS RES, V18, P5315, DOI 10.1093/nar/18.17.5315; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Kuhnke G, 2006, MOL MEMBR BIOL, V23, P173, DOI 10.1080/09687860500473630; Kunji ERS, 2003, BBA-BIOMEMBRANES, V1610, P97, DOI 10.1016/S0005-2736(02)00712-5; Lapinski PE, 2003, J BIOL CHEM, V278, P8229, DOI 10.1074/jbc.M208930200; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; Ravaud S, 2006, BIOCHEM J, V395, P345, DOI 10.1042/BJ20051719; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shirihai OS, 2000, EMBO J, V19, P2492, DOI 10.1093/emboj/19.11.2492; Sorzano COS, 2004, J STRUCT BIOL, V148, P194, DOI 10.1016/j.jsb.2004.06.006; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; UEBEL S, 1995, J BIOL CHEM, V270, P18512, DOI 10.1074/jbc.270.31.18512; van der Does C, 2006, J BIOL CHEM, V281, P5694, DOI 10.1074/jbc.M511730200; van der Does C, 2004, BIOL CHEM, V385, P927, DOI 10.1515/BC.2004.121; van der Does C, 2003, METHOD ENZYMOL, V372, P86; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; van der Sluis EO, 2002, FEBS LETT, V527, P159, DOI 10.1016/S0014-5793(02)03202-7; Velarde G, 2001, J BIOL CHEM, V276, P46054, DOI 10.1074/jbc.M108435200; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wada S, 2002, J BIOL CHEM, V277, P46809, DOI 10.1074/jbc.M207817200; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3; Wolters JC, 2005, J BIOL CHEM, V280, P23631, DOI 10.1074/jbc.M503231200; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957; Zhang F, 2000, FEBS LETT, V478, P89, DOI 10.1016/S0014-5793(00)01823-8	64	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3951	3961		10.1074/jbc.M609899200	http://dx.doi.org/10.1074/jbc.M609899200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150958	Green Published, hybrid			2022-12-27	WOS:000244481900059
J	Yang, W; Zhang, Y; Li, YF; Wu, ZG; Zhu, DH				Yang, Wei; Zhang, Yong; Li, Yanfeng; Wu, Zhenguo; Zhu, Dahai			Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 beta pathway and is antagonized by insulin-like growth factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; IGF-I; SUPERFAMILY MEMBER; EPITHELIAL-CELLS; SKELETAL-MUSCLE; PROTEIN-KINASE; CANCER CELLS; EXPRESSION; INHIBITION; PROLIFERATION	Myostatin is a transforming growth factor 13 superfamil member and is known as an inhibitor of skeletal muscle cell proliferation and differentiation. Exposure to myostatin induces G, phase cell cycle arrest. In this study, we demonstrated that myostatin down-regulates Cdk4 activity via promotion of cyclin D1 degradation. Overexpression of cyclin D1 significantly blocked myostatin-induced proliferation inhibition. We further showed that phosphorylation at threonine 286 by GSK-3 beta was required for myostatin-stimulated cyclin D1 nuclear export and degradation. This process is dependent upon the activin receptor IIB and the phosphatidylinositol 3-kinase/ Akt pathway but not Smad3. Insulin-like growth factor I (IGF-1) treatment or Akt activation attenuated the myostatin-stimulated cyclin D1 degradation as well as the associated cell proliferation repression. In contrast, attenuation of IGF-1 signaling caused C2C12 cells to undergo apoptosis in response to myostatin treatment. The observation that IGF-1 treatment increases myostatin expression through a phosphatidylinositol 3-kinase pathway suggests a possible feedback regulation between IGF-1 and myostatin. These findings uncover a novel role for myostatin in the regulation of cell growth and cell death in concert with IGF-1.	Chinese Acad Med Sci, Natl Lab Med Mol Biol, Inst Basic Med Sci, Beijing 10005, Peoples R China; Peking Union Med Coll, Beijing 10005, Peoples R China; Harbin Inst Technol, Mol & Cellular Dev Biol Lab, Harbin 150001, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon 999077, Hong Kong, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Harbin Institute of Technology; Hong Kong University of Science & Technology	Zhu, DH (corresponding author), Chinese Acad Med Sci, Natl Lab Med Mol Biol, Inst Basic Med Sci, 5 Dong Dan San Tiao, Beijing 10005, Peoples R China.	dhzhu@pumc.edu.cn	Chen, Runsheng/S-9834-2017; Wu, Zhenguo/AAB-8679-2021; li, yan/GTI-4638-2022; Zhu, Dahai/ABA-5315-2021	Chen, Runsheng/0000-0001-6049-8347; Yang, Wei/0000-0003-0162-4221				BULLOUGH WS, 1967, NATURE, V214, P578, DOI 10.1038/214578a0; Carro E, 2003, MOL NEUROBIOL, V27, P153, DOI 10.1385/MN:27:2:153; Chen B, 2005, MOL ENDOCRINOL, V19, P1978, DOI 10.1210/me.2004-0274; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Danielpour D, 2006, CYTOKINE GROWTH F R, V17, P59, DOI 10.1016/j.cytogfr.2005.09.007; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fernandez AM, 2002, J CLIN INVEST, V109, P347, DOI 10.1172/JCI200213503; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Gonzalez-Cadavid NF, 2004, CURR OPIN CLIN NUTR, V7, P451, DOI 10.1097/01.mco.0000134365.99523.7f; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; Ji SQ, 1998, AM J PHYSIOL-REG I, V275, pR1265, DOI 10.1152/ajpregu.1998.275.4.R1265; Jong HS, 2002, BIOCHEM BIOPH RES CO, V292, P383, DOI 10.1006/bbrc.2002.6666; Kassouf W, 2005, CANCER RES, V65, P10524, DOI 10.1158/0008-5472.CAN-05-1536; Kim IY, 1998, CLIN CANCER RES, V4, P1625; Kim JS, 2005, AM J PHYSIOL-ENDOC M, V288, pE1110, DOI 10.1152/ajpendo.00464.2004; Kim WK, 2004, J IMMUNOL, V172, P7015, DOI 10.4049/jimmunol.172.11.7015; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Kuemmerle JF, 2004, AM J PHYSIOL-GASTR L, V286, pG412, DOI 10.1152/ajpgi.00403.2003; Langley B, 2004, ONCOGENE, V23, P524, DOI 10.1038/sj.onc.1207144; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Martinez LA, 2000, ONCOGENE, V19, P315, DOI 10.1038/sj.onc.1203301; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McCroskery S, 2005, J CELL SCI, V118, P3531, DOI 10.1242/jcs.02482; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Morissette MR, 2006, CIRC RES, V99, P15, DOI 10.1161/01.RES.0000231290.45676.d4; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Philip B, 2005, CELL SIGNAL, V17, P365, DOI 10.1016/j.cellsig.2004.08.003; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Sharma M, 1999, J CELL PHYSIOL, V180, P1; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Taniyama Y, 2003, MOL CELL BIOL, V23, P8019, DOI 10.1128/MCB.23.22.8019-8029.2003; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; Van der Poel HG, 2004, J UROLOGY, V172, P1333, DOI 10.1097/01.ju.0000138829.97838.19; von Wichert T, 2005, ONCOGENE, V24, P1284, DOI 10.1038/sj.onc.1208264; Wilkes MC, 2005, CANCER RES, V65, P10431, DOI 10.1158/0008-5472.CAN-05-1522; Yang JZ, 2001, MOL REPROD DEV, V60, P351, DOI 10.1002/mrd.1097; Yang W, 2006, CANCER RES, V66, P1320, DOI 10.1158/0008-5472.CAN-05-3060; Yang W, 2005, BIOCHEM BIOPH RES CO, V326, P660, DOI 10.1016/j.bbrc.2004.11.096; Yang W, 2003, ACTA BIOCH BIOPH SIN, V35, P1016; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200; Zhao BQ, 2005, BIOCHEM BIOPH RES CO, V337, P248, DOI 10.1016/j.bbrc.2005.09.044	49	166	179	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3799	3808		10.1074/jbc.M610185200	http://dx.doi.org/10.1074/jbc.M610185200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17130121	hybrid			2022-12-27	WOS:000244481900043
J	Allen, KD; Chernova, TA; Tennant, EP; Wilkinson, KD; Chernoff, YO				Allen, Kim D.; Chernova, Tatiana A.; Tennant, E. Paula; Wilkinson, Keith D.; Chernoff, Yury O.			Effects of ubiquitin system alterations on the formation and loss of a yeast prion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATOR; PROTEIN; DEGRADATION; PROTEASOME; CHAPERONE; HSP104; TOXICITY; HSP70; PSI+; MUTATION	The yeast prion [PSI+] is a self-propagating amyloidogenic isoform of the translation termination factor Sup35. Overproduction of the chaperone protein Hsp104 results in loss of [PSI+]. Here we demonstrate that this effect is decreased by deletion of either the gene coding for one of the major yeast ubiquitin-conjugating enzymes, Ubc4, or the gene coding for the ubiquitin-recycling enzyme, Ubp6. The effect of ubc4 Delta on [PSI+] loss was increased by depletion of the Hsp70 chaperone Ssb but was not influenced by depletion of Ubp6. This indicates that Ubc4 affects [PSI+] loss via a pathway that is the same as the one affected by Ubp6 but not by Ssb. In the presence of Rnq1 protein, ubc4 Delta also facilitates spontaneous de novo formation of [PSI+]. This stimulation is independent of [PIN+], the prion isoform of Rnq1. Numerous attempts failed to detect ubiquitinated Sup35 in the yeast extracts. While ubc4 Delta and other alterations of ubiquitin system used in this work cause slight induction of some Hsps, these changes are insufficient to explain their effect on [PSI+]. However, ubc4 Delta increases the proportion of the Hsp70 chaperone Ssa bound to Sup35, suggesting that mis-folded Sup35 is either more abundant or more accessible to the chaperones in the absence of Ubc4. The proportion of [PSI+] cells containing large aggregated Sup35 structures is also increased by ubc4 Delta. We propose that UPS alterations induce an adaptive response, resulting in accumulation of the large "aggresome" like aggregates that promote de novo prion generation and prion recovery from the chaperone treatment.	Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Georgia Inst Technol, Inst Bioengn & Biosci, Atlanta, GA 30332 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Emory University	Chernoff, YO (corresponding author), Georgia Inst Technol, Sch Biol, M-C 0230,310 Ferst Dr, Atlanta, GA 30332 USA.	yury.chernoff@biology.gatech.edu	Chernova, Tatiana/AAR-5007-2020; Chernoff, Yury O/J-2833-2014	Chernova, Tatiana/0000-0003-1966-0159; Chernoff, Yury/0000-0002-8934-9051; Allen, Kim D/0000-0001-9774-5014	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058763, R01GM030308] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58763, R01 GM030308, GM30308] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen KD, 2005, GENETICS, V169, P1227, DOI 10.1534/genetics.104.037168; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Apodaca J, 2006, BIOCHEM BIOPH RES CO, V347, P319, DOI 10.1016/j.bbrc.2006.06.078; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Chernoff Y, 2004, CURR OPIN CHEM BIOL, V8, P665, DOI 10.1016/j.cbpa.2004.09.002; Chernoff YO, 2000, MOL MICROBIOL, V35, P865, DOI 10.1046/j.1365-2958.2000.01761.x; Chernoff YO, 1999, MOL CELL BIOL, V19, P8103; Chernoff YO, 2002, METHOD ENZYMOL, V351, P499; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Chernoff YO, 2001, MUTAT RES-REV MUTAT, V488, P39, DOI 10.1016/S1383-5742(00)00060-0; Chernova TA, 2003, J BIOL CHEM, V278, P52102, DOI 10.1074/jbc.M310283200; Derkatch IL, 1997, GENETICS, V147, P507; Derkatch IL, 2001, CELL, V106, P171, DOI 10.1016/S0092-8674(01)00427-5; Derkatch IL, 2000, EMBO J, V19, P1942, DOI 10.1093/emboj/19.9.1942; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; Dupre S, 2004, BBA-MOL CELL RES, V1695, P89, DOI 10.1016/j.bbamcr.2004.09.024; Ganusova EE, 2006, MOL CELL BIOL, V26, P617, DOI 10.1128/MCB.26.2.617-629.2006; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gokhale KC, 2005, J BIOL CHEM, V280, P22809, DOI 10.1074/jbc.M500390200; Hanna J, 2003, MOL CELL BIOL, V23, P9251, DOI 10.1128/MCB.23.24.9251-9261.2003; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200; Jung G, 2000, GENETICS, V156, P559; Kaiser C., 1994, METHODS YEAST GENETI; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Lindquist S, 1996, P NATL ACAD SCI USA, V93, P5301, DOI 10.1073/pnas.93.11.5301; LIU HP, 1992, GENETICS, V132, P665; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Mayer RJ, 2003, DRUG NEWS PERSPECT, V16, P103, DOI 10.1358/dnp.2003.16.2.829327; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Nakayashiki T, 2005, P NATL ACAD SCI USA, V102, P10575, DOI 10.1073/pnas.0504882102; Newnam GP, 1999, MOL CELL BIOL, V19, P1325; OHBA M, 1994, FEBS LETT, V351, P263; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Resende CG, 2003, MOL MICROBIOL, V49, P1005, DOI 10.1046/j.1365-2958.2003.03608.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Serio TR, 1999, METHOD ENZYMOL, V309, P649; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Sondheimer N, 2001, EMBO J, V20, P2435, DOI 10.1093/emboj/20.10.2435; Song YT, 2005, EUKARYOT CELL, V4, P289, DOI 10.1128/EC.4.2.289-297.2005; Soto C, 2006, TRENDS BIOCHEM SCI, V31, P150, DOI 10.1016/j.tibs.2006.01.002; TUITE MF, 1981, GENETICS, V98, P691; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Wegrzyn RD, 2001, MOL CELL BIOL, V21, P4656, DOI 10.1128/MCB.21.14.4656-4669.2001; Wickner RB, 2004, COLD SPRING HARB SYM, V69, P489, DOI 10.1101/sqb.2004.69.489; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383	59	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3004	3013		10.1074/jbc.M609597200	http://dx.doi.org/10.1074/jbc.M609597200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17142456	hybrid			2022-12-27	WOS:000243793900027
J	Liu, YL; Tarsounas, M; O'Regan, P; West, SC				Liu, Yilun; Tarsounas, Madalena; O'Regan, Paul; West, Stephen C.			Role of RAD51C and XRCC3 in genetic recombination and DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTION; ESCHERICHIA-COLI; MAMMALIAN-CELLS; CROSSING-OVER; HOMOLOGOUS RECOMBINATION; MOUSE SPERMATOCYTES; MISMATCH REPAIR; OKADAIC-ACID; IN-VIVO; PROTEINS	In germ line cells, recombination is required for gene reassortment and proper chromosome segregation at meiosis, whereas in somatic cells it provides an important mechanism for the repair of DNA double-strand breaks. Five proteins ( RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3) that share homology with RAD51 recombinase and are known as the RAD51 paralogs are important for recombinational repair, as paralog- defective cell lines exhibit spontaneous chromosomal aberrations, defective DNA repair, and reduced gene targeting. The paralogs form two distinct protein complexes, RAD51B-RAD51C-RAD51D-XRCC2 and RAD51C-XRCC3, but their precise cellular roles remain unknown. Here, we show that, like MLH1, RAD51C localized to mouse meiotic chromosomes at pachytene/diplotene. Using immunoprecipitation and gel filtration analyses, we found that Holliday junction resolvase activity associated tightly and co-eluted with the 80-kDa RAD51C-XRCC3 complex. Taken together, these data indicate that the RAD51C-XRCC3-associated Holliday junction resolvase complex associates with crossovers and may play an essential role in the resolution of recombination intermediates prior to chromosome segregation.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	West, SC (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	stephen.west@cancer.org.uk	liu, yi/GXE-9662-2022	West, Stephen/0000-0001-8848-9418	Breast Cancer Now [2004NOV03, 2002:445] Funding Source: Medline	Breast Cancer Now		Alsheimer M, 1996, EXP CELL RES, V228, P181, DOI 10.1006/excr.1996.0315; Anderson LK, 1999, GENETICS, V151, P1569; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Bleuyard JY, 2005, PLANT J, V41, P533, DOI 10.1111/j.1365-313X.2004.02318.x; Braybrooke JP, 2003, J BIOL CHEM, V278, P48357, DOI 10.1074/jbc.M308838200; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; BURGOYNE PS, 1982, HUM GENET, V61, P85, DOI 10.1007/BF00274192; CARPENTER ATC, 1994, CELL, V77, P959, DOI 10.1016/0092-8674(94)90434-0; Ciccia A, 2003, J BIOL CHEM, V278, P25172, DOI 10.1074/jbc.M302882200; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Deans B, 2000, EMBO J, V19, P6675, DOI 10.1093/emboj/19.24.6675; Eggleston AK, 1997, CELL, V89, P607, DOI 10.1016/S0092-8674(00)80242-1; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; French CA, 2002, J BIOL CHEM, V277, P19322, DOI 10.1074/jbc.M201402200; Garcia PL, 2004, EMBO J, V23, P2882, DOI 10.1038/sj.emboj.7600301; Gasior SL, 2001, P NATL ACAD SCI USA, V98, P8411, DOI 10.1073/pnas.121046198; Godthelp BC, 2002, NUCLEIC ACIDS RES, V30, P2172, DOI 10.1093/nar/30.10.2172; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; HYDE H, 1994, J BIOL CHEM, V269, P5202; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Li WX, 2005, PLANT PHYSIOL, V138, P965, DOI 10.1104/pp.104.058347; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu YL, 2004, SCIENCE, V303, P243, DOI 10.1126/science.1093037; Marcon E, 2003, GENETICS, V165, P2283; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Masson JY, 2001, P NATL ACAD SCI USA, V98, P8440, DOI 10.1073/pnas.111005698; May CA, 2002, NAT GENET, V31, P272, DOI 10.1038/ng918; Palmer S, 1997, P NATL ACAD SCI USA, V94, P12030, DOI 10.1073/pnas.94.22.12030; Perry J, 2001, GENOME RES, V11, P1826, DOI 10.1101/gr.203001; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pittman DL, 2000, GENESIS, V26, P167, DOI 10.1002/(SICI)1526-968X(200003)26:3<167::AID-GENE1>3.0.CO;2-M; Rafferty JB, 1998, J MOL BIOL, V278, P105, DOI 10.1006/jmbi.1998.1697; Rodrigue A, 2006, EMBO J, V25, P222, DOI 10.1038/sj.emboj.7600914; Shu ZG, 1999, MOL CELL BIOL, V19, P8686; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Tarsounas M, 1999, J CELL SCI, V112, P423; Tarsounas M, 2004, CELL, V117, P337, DOI 10.1016/S0092-8674(04)00337-X; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Yonetani Y, 2005, NUCLEIC ACIDS RES, V33, P4544, DOI 10.1093/nar/gki766	44	88	95	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1973	1979		10.1074/jbc.M609066200	http://dx.doi.org/10.1074/jbc.M609066200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17114795	hybrid			2022-12-27	WOS:000243451300048
J	Cesena, TI; Cardinaux, JR; Kwok, R; Schwartz, J				Cesena, Teresa I.; Cardinaux, Jean-Rene; Kwok, Roland; Schwartz, Jessica			CCAAT/enhancer-binding protein (C/EBP) beta is acetylated at multiple lysines - Acetylation of C/EBP beta at lysine 39 modulates its ability to activate transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; GROWTH-HORMONE; GENE-EXPRESSION; C-FOS; ADIPOCYTE DIFFERENTIATION; DNA-BINDING; HISTONE H3; FAMILY-MEMBERS; IN-VITRO; REVERSIBLE ACETYLATION	Transcription factor function can be modulated by post-translational modifications. Because the transcription factor CCAAT/enhancer-binding protein (C/EBP) beta associates with the nuclear coactivator p300, which contains acetyltransferase activity, acetylation of C/EBP beta was examined to understand its regulation and function. C/EBP beta is acetylated by acetyltransferases p300 and p300/CREB-binding protein associated factor. Endogenous C/EBP beta in 3T3-F442A preadipocytes is also recognized by an acetyl-lysine-specific antibody. Analysis of truncations of C/EBP beta and peptides based on C/EBP beta sequences identified multiple lysines within C/EBP beta that can be acetylated. Among these, a novel acetylation site at lysine 39 of C/EBP beta was identified. Mutation of Lys-39 to arginine or alanine impairs its acetylation and the ability of C/EBP beta to activate transcription at the promoters for C/EBP beta and c-fos. Different C/EBP beta-responsive promoters require different patterns of acetylated lysines in C/EBP beta for transcription activation. Furthermore, C/EBP beta acetylation was increased by growth hormone, and mutation of Lys-39 impaired growth hormone-stimulated c-fos promoter activation. These data suggest that acetylation of Lys-39 of C/EBP beta, alone or in combination with acetylation at other lysines, may play a role in C/EBP beta-mediated transcriptional activation.	Univ Michigan, Program Mol & Cell Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Obstet Gynecol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Lausanne, Dept Psychiat, Ctr Psychiat Neurosci, CH-1008 Prilly, Switzerland	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Lausanne	Schwartz, J (corresponding author), Univ Michigan, Program Mol & Cell Biol, Ann Arbor, MI 48109 USA.	jeschwar@umich.edu	Cardinaux, Jean-René/G-5391-2012	Cardinaux, Jean-René/0000-0001-6423-0014	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [R03TW008143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F31DK074377, R01DK046072, P60DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW008143] Funding Source: Medline; NICHD NIH HHS [T32-HD07505] Funding Source: Medline; NIDDK NIH HHS [5P60 DK20572, DK074377-01, DK46072] Funding Source: Medline; NIGMS NIH HHS [T32-GM07315] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Cui TX, 2005, MOL ENDOCRINOL, V19, P2175, DOI 10.1210/me.2004-0502; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Ghosh AK, 2006, J CELL PHYSIOL, V207, P251, DOI 10.1002/jcp.20559; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; HARVAT BL, 1995, CELL GROWTH DIFFER, V6, P955; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Herrera JE, 1997, J BIOL CHEM, V272, P27253, DOI 10.1074/jbc.272.43.27253; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Huo XF, 2005, J CELL MOL MED, V9, P103, DOI 10.1111/j.1582-4934.2005.tb00340.x; Joo M, 2004, J BIOL CHEM, V279, P6658, DOI 10.1074/jbc.M306267200; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kovacs KA, 2003, J BIOL CHEM, V278, P36959, DOI 10.1074/jbc.M303147200; Kovacs KA, 2006, J NEUROCHEM, V98, P1390, DOI 10.1111/j.1471-4159.2006.03957.x; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Liao J, 1999, J BIOL CHEM, V274, P31597, DOI 10.1074/jbc.274.44.31597; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lu Q, 2003, J BIOL CHEM, V278, P15727, DOI 10.1074/jbc.M300546200; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; METZ R, 1991, ONCOGENE, V6, P2165; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MOLLER C, 1992, J BIOL CHEM, V267, P23403; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; Pilipuk GP, 2003, J BIOL CHEM, V278, P35668, DOI 10.1074/jbc.M305182200; Piwien-Pilipuk G, 2002, J PEDIATR ENDOCR MET, V15, P771; Piwien-Pilipuk G, 2002, J BIOL CHEM, V277, P44557, DOI 10.1074/jbc.M206886200; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; PIWIENPILIPUK G, 2004, 86 ANN M END SOC NEW, P498; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Raymond L, 2006, J CELL PHYSIOL, V207, P683, DOI 10.1002/jcp.20608; Rosen JM, 1998, BIOCHEM SOC SYMP, P101; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Santos-Rosa H, 2003, NUCLEIC ACIDS RES, V31, P4285, DOI 10.1093/nar/gkg655; SCOTT LM, 1992, BLOOD, V80, P1725; Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang QQ, 2004, BIOCHEM BIOPH RES CO, V318, P213, DOI 10.1016/j.bbrc.2004.04.017; Tang QQ, 2005, P NATL ACAD SCI USA, V102, P9766, DOI 10.1073/pnas.0503891102; Tang QQ, 1997, P NATL ACAD SCI USA, V94, P13571, DOI 10.1073/pnas.94.25.13571; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; TRAUTWEIN C, 1995, J BIOL CHEM, V270, P15130, DOI 10.1074/jbc.270.25.15130; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; WANG XY, 1993, J BIOL CHEM, V268, P3573; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	81	76	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					956	967		10.1074/jbc.M511451200	http://dx.doi.org/10.1074/jbc.M511451200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17110376	hybrid, Green Submitted			2022-12-27	WOS:000243295200018
J	Chaturvedi, LS; Marsh, HM; Shang, X; Zheng, Y; Basscon, MD				Chaturvedi, Lakshmi S.; Marsh, H. Michael; Shang, Xun; Zheng, Yi; Basscon, Marc D.			Repetitive deformation activates focal adhesion kinase and ERK mitogenic signals in human caco-2 intestinal epithelial cells through Src and Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; STIMULATES TYROSINE PHOSPHORYLATION; MEMBRANE TESTOSTERONE RECEPTORS; EXTRACELLULAR-MATRIX PROTEINS; EPIDERMAL-GROWTH-FACTOR; RHO-FAMILY GTPASES; MECHANICAL STRAIN; CYCLIC STRETCH; SHEAR-STRESS; IN-VITRO	Intestinal epithelial cells are subject to repetitive deformation during peristalsis and villous motility, whereas the mucosa atrophies during sepsis or ileus when such stimuli are abnormal. Such repetitive deformation stimulates intestinal epithelial proliferation via focal adhesion kinase (FAK) and extracellular signal-regulated kinases (ERK). However, the upstream mediators of these effects are unknown. We investigated whether Src and Rac1 mediate deformation-induced FAK and ERK phosphorylation and proliferation in human Caco-2 and rat IEC-6 intestinal epithelial cells. Cells cultured on collagen-I were subjected to an average 10% cyclic strain at 10 cycles/min. Cyclic strain activated Rac1 and induced Rac1 translocation to cell membranes. Mechanical strain also induced rapid sustained phosphorylation of c-Src at Tyr(418), Rac1 at Ser(71), FAK at Tyr(397) and Tyr(576), and ERK1/2 at Thr(202)/Tyr(204). The mitogenic effect of cyclic strain was blocked by inhibition of Src (PP2 or short interfering RNA) or Rac1 (NSC23766). Src or Rac1 inhibition also prevented strain-induced FAK phosphorylation at Tyr(576) and ERK phosphorylation but not FAK phosphorylation at Tyr(397). Reducing FAK using short interfering RNA blocked strain-induced mitogenicity and attenuated ERK phosphorylation but not Src or Rac1 phosphorylation. Src inhibition blocked strain-induced Rac1 phosphorylation, but Rac inhibition did not alter Src phosphorylation. Transfection of a two-tyrosine phosphorylation-deficient FAK mutant Y576F/Y577F prevented activation of cotransfected myc-ERK2 by cyclic strain. Repetitive deformation induced by peristalsis or villus motility may support the gut mucosa by a pathway involving Src, Rac 1, FAK, and ERK. This pathway may present important targets for interventions to prevent mucosal atrophy during prolonged iIeus or fasting.	John D Dingel Vet Affairs Med Ctr, Surg Serv 11S, Detroit, MI 48201 USA; Wayne State Univ, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Dept Anesthesiol, Detroit, MI 48201 USA; Wayne State Univ, Dept Anat & Cell Biol, Detroit, MI 48201 USA; Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA	Wayne State University; Wayne State University; Wayne State University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Basscon, MD (corresponding author), John D Dingel Vet Affairs Med Ctr, Surg Serv 11S, 4646 John R St, Detroit, MI 48201 USA.	marc.basson@va.gov	Zheng, Yi/J-7235-2015; /AAL-3363-2020	Zheng, Yi/0000-0001-7089-6074; 	NIDDK NIH HHS [R01 DK067257] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067257] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Alexander LD, 2004, KIDNEY INT, V65, P551, DOI 10.1111/j.1523-1755.2004.00405.x; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Barone M, 2002, SCAND J GASTROENTERO, V37, P88, DOI 10.1080/003655202753387419; BARRY ST, 1994, J CELL SCI, V107, P2033; Basson MD, 1996, J CELL PHYSIOL, V168, P476, DOI 10.1002/(SICI)1097-4652(199608)168:2<476::AID-JCP26>3.0.CO;2-#; Basson MD, 1996, EXP CELL RES, V225, P301, DOI 10.1006/excr.1996.0180; Basson MD, 2003, DIGESTION, V68, P217, DOI 10.1159/000076385; Basson MD, 2002, METABOLISM, V51, P1525, DOI 10.1053/meta.2002.36303; BASSON MD, 1992, J CLIN INVEST, V90, P15, DOI 10.1172/JCI115828; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CARR KE, 1991, J SUBMICR CYTOL PATH, V23, P569; Cary LA, 1996, J CELL SCI, V109, P1787; Chen QH, 2003, J VASC SURG, V37, P660, DOI 10.1067/mva.2003.95; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Cohen LA, 2005, CURR CANCER DRUG TAR, V5, P629, DOI 10.2174/156800905774932798; Faraone D, 2006, BLOOD, V107, P1896, DOI 10.1182/blood-2005-04-1524; Fenton JI, 2005, CANCER EPIDEM BIOMAR, V14, P1646, DOI 10.1158/1055-9965.EPI-04-0916; Fera E, 2004, J BIOL CHEM, V279, P35573, DOI 10.1074/jbc.M400711200; Fitzgerald AJ, 2001, ALIMENT PHARM THERAP, V15, P1077, DOI 10.1046/j.1365-2036.2001.01025.x; Flinn HM, 1996, J CELL SCI, V109, P1133; FRIEDMAN HI, 1977, ANAT RECORD, V188, P77, DOI 10.1002/ar.1091880109; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; Granet C, 2002, CELL SIGNAL, V14, P679, DOI 10.1016/S0898-6568(02)00008-6; Gutierrez JA, 1999, AM J PHYSIOL-GASTR L, V277, pG1074, DOI 10.1152/ajpgi.1999.277.5.G1074; Han B, 2004, J BIOL CHEM, V279, P54793, DOI 10.1074/jbc.M406880200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han O, 1998, BIOCHEM BIOPH RES CO, V250, P668, DOI 10.1006/bbrc.1998.9372; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Haussinger D, 2003, GASTROENTEROLOGY, V124, P1476, DOI 10.1016/S0016-5085(03)00274-9; Hornberger TA, 2005, AM J PHYSIOL-CELL PH, V288, pC185, DOI 10.1152/ajpcell.00207.2004; Huang Q, 2005, CELL MOL LIFE SCI, V62, P1167, DOI 10.1007/s00018-005-5050-2; Hwang SY, 2006, INT J CANCER, V118, P2056, DOI 10.1002/ijc.21574; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jiang K, 2003, BLOOD, V101, P236, DOI 10.1182/blood-2002-04-1251; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; John GR, 2004, J NEUROSCI, V24, P2837, DOI 10.1523/JNEUROSCI.4789-03.2004; Jung ID, 2004, EUR J BIOCHEM, V271, P1557, DOI 10.1111/j.1432-1033.2004.04066.x; Kaeffer B, 1997, CELL BIOL INT, V21, P303, DOI 10.1006/cbir.1997.0141; Kallergi G, 2003, EXP CELL RES, V288, P94, DOI 10.1016/S0014-4827(03)00210-6; Kampa M, 2004, EXP CELL RES, V294, P434, DOI 10.1016/j.yexcr.2003.11.027; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200; Kumar A, 2004, FASEB J, V18, P1524, DOI 10.1096/fj.04-2414com; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Laboureau J, 2004, EXP DERMATOL, V13, P70, DOI 10.1111/j.0906-6705.2004.00117.x; Lee HS, 2000, J BONE MINER RES, V15, P1501, DOI 10.1359/jbmr.2000.15.8.1501; Lee J, 2005, EXP CELL RES, V307, P315, DOI 10.1016/j.yexcr.2005.03.028; Lehoux S, 2005, CIRCULATION, V111, P643, DOI 10.1161/01.CIR.0000154548.16191.2F; Li, 2000, Arterioscler Thromb Vasc Biol, V20, pE1; Li LF, 2003, AM J PHYSIOL-LUNG C, V285, pL464, DOI 10.1152/ajplung.00031.2003; Li S, 1999, J CLIN INVEST, V103, P1141, DOI 10.1172/JCI5367; Li W, 2001, AM J PHYSIOL-GASTR L, V280, pG75, DOI 10.1152/ajpgi.2001.280.1.G75; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; MCNEIL PL, 1989, GASTROENTEROLOGY, V96, P1238, DOI 10.1016/S0016-5085(89)80010-1; MOORE R, 1989, AM J PHYSIOL, V257, pG274, DOI 10.1152/ajpgi.1989.257.2.G274; Murnin M, 2000, J GASTROINTEST SURG, V4, P435, DOI 10.1016/S1091-255X(00)80025-6; Naruse K, 1998, FEBS LETT, V441, P111, DOI 10.1016/S0014-5793(98)01528-2; Osada T, 1999, GUT, V45, P508, DOI 10.1136/gut.45.4.508; Pan J, 2005, J CELL PHYSIOL, V202, P536, DOI 10.1002/jcp.20151; Papakonstanti EA, 2003, MOL ENDOCRINOL, V17, P870, DOI 10.1210/me.2002-0253; PETERSON MD, 1993, J CELL SCI, V105, P461; Plotkin LI, 2005, AM J PHYSIOL-CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004; Potoka DA, 2003, AM J PHYSIOL-GASTR L, V285, pG861, DOI 10.1152/ajpgi.00412.2002; Putnam AJ, 2003, AM J PHYSIOL-CELL PH, V284, pC627, DOI 10.1152/ajpcell.00137.2002; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Rice DC, 2002, HYPERTENSION, V39, P502, DOI 10.1161/hy0202.102834; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Sai XR, 1999, J CELL SCI, V112, P1365; Sanders MA, 2000, J BIOL CHEM, V275, P38040, DOI 10.1074/jbc.M003871200; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlegel TF, 2006, AM J SPORT MED, V34, P275, DOI 10.1177/0363546505279912; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; Seko Y, 1999, BIOCHEM BIOPH RES CO, V259, P8, DOI 10.1006/bbrc.1999.0720; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Shikata Y, 2005, EXP CELL RES, V304, P40, DOI 10.1016/j.yexcr.2004.11.001; Smith PG, 1998, EXP CELL RES, V239, P353, DOI 10.1006/excr.1997.3905; SPENCER AU, 2006, J SURG RES, V130, P189; Thamilselvan V, 2004, GASTROENTEROLOGY, V126, P8, DOI 10.1053/j.gastro.2003.10.078; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; van Zyp JV, 2006, CANCER BIOL THER, V5, P1169; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Wang JG, 2001, BIOCHEM BIOPH RES CO, V288, P356, DOI 10.1006/bbrc.2001.5775; Wang JK, 2005, DEV BIOL, V286, P299, DOI 10.1016/j.ydbio.2005.07.035; WOMACK WA, 1987, AM J PHYSIOL, V252, pG250, DOI 10.1152/ajpgi.1987.252.2.G250; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yu CF, 2000, AM J PHYSIOL-GASTR L, V278, pG952, DOI 10.1152/ajpgi.2000.278.6.G952; Zhang JH, 2003, BIOCHEM BIOPH RES CO, V306, P746, DOI 10.1016/S0006-291X(03)01044-1; Zhang JH, 2003, FASEB J, V17, P926, DOI 10.1096/fj.02-0663fje; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	94	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					14	28		10.1074/jbc.M605817200	http://dx.doi.org/10.1074/jbc.M605817200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17088251	hybrid			2022-12-27	WOS:000243166500003
J	Yin, L; Kharbanda, S; Kufe, D				Yin, Li; Kharbanda, Surender; Kufe, Donald			Mucin 1 oncoprotein blocks hypoxia-inducible factor 1 alpha activation in a survival response to hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED ANTIGEN; GROWTH-FACTOR RECEPTOR; MUC1 ONCOPROTEIN; C-SRC; PROLYL-HYDROXYLASES; GENE-TRANSCRIPTION; BETA-CATENIN; HIF-ALPHA; PROTEIN; CELLS	Resistance of carcinoma cells to hypoxic stress is of importance to the growth of solid tumors. The mucin 1 (MUC1) oncoprotein is aberrantly overexpressed by most human carcinomas; however, there is no known relationship between MUC1 and the hypoxic stress response. The present work has demonstrated that MUC1. attenuates activation of hypoxia-inducible factor-1 alpha (HIF-1 alpha), a regulator of gene transcription in the response of cells to hypoxic stress. In cells with stable gain and loss of MUC1 function, we have shown that MUC1 up-regulates prolyl hydroxylase 3 (PHD3) expression and promotes HIF-1 alpha degradation. PHD activity is attenuated by increases in reactive oxygen species (ROS) generated in the hypoxic stress response. Our results further demonstrate that MUC1 blocks hypoxia-induced increases in ROS and thereby potentiates PHD-mediated HIF-1 alpha suppression. Importantly, MUC1. also blocks hypoxia-induced apoptosis and necrosis by suppressing accumulation of ROS. These findings indicate that MUC1 attenuates HIF-1 alpha activation in a survival response to hypoxic stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA097098, R01CA098628] Funding Source: NIH RePORTER; NCI NIH HHS [CA98628, CA97098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; BENEZRA J, 1991, J HISTOCHEM CYTOCHEM, V39, P351, DOI 10.1177/39.3.1704393; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huang L, 2003, CANCER BIOL THER, V2, P702; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; MERLO GR, 1989, CANCER RES, V49, P6966; Nakashima I, 2002, ANTIOXID REDOX SIGN, V4, P517, DOI 10.1089/15230860260196326; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Nicotera P, 1998, TOXICOL LETT, V103, P139; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2006, ONCOGENE, V25, P20, DOI 10.1038/sj.onc.1209012; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Sowter HM, 2001, CANCER RES, V61, P6669; Steinbach JP, 2004, CANCER RES, V64, P1575, DOI 10.1158/0008-5472.CAN-03-3775; Vaupel P, 1998, ADV EXP MED BIOL, V454, P591; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Wouters BG, 1997, RADIAT RES, V147, P541, DOI 10.2307/3579620; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yin L, 2004, J BIOL CHEM, V279, P45721, DOI 10.1074/jbc.M408027200; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	55	56	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					257	266		10.1074/jbc.M610156200	http://dx.doi.org/10.1074/jbc.M610156200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17102128	hybrid			2022-12-27	WOS:000243166500030
J	Hur, S; Stroud, RM; Finer-Moore, J				Hur, Sun; Stroud, Robert M.; Finer-Moore, Janet			Substrate recognition by RNA 5-methyluridine methyltransferases and pseudouridine synthases: A structural perspective	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; TRUD REVEALS; COMPLEX; FOLD; HOMOLOGS; ENZYMES; RUMA		Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Finer-Moore, J (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	finer@msg.ucsf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051232] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwalla S, 2002, J BIOL CHEM, V277, P8835, DOI 10.1074/jbc.M111825200; Aravind L, 1999, J MOL EVOL, V48, P291, DOI 10.1007/PL00006472; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; Ericsson UB, 2004, FEBS LETT, V565, P59, DOI 10.1016/j.febslet.2004.03.085; Foster PG, 2000, NAT STRUCT BIOL, V7, P23; Gu XR, 1998, BIOCHEMISTRY-US, V37, P339, DOI 10.1021/bi971590p; Gu XR, 1996, BIOCHEMISTRY-US, V35, P11652, DOI 10.1021/bi9612125; Gustafsson C, 1996, NUCLEIC ACIDS RES, V24, P3756, DOI 10.1093/nar/24.19.3756; Hamma T, 2005, NAT STRUCT MOL BIOL, V12, P1101, DOI 10.1038/nsmb1036; Hoang C, 2001, CELL, V107, P929, DOI 10.1016/S0092-8674(01)00618-3; Hoang C, 2004, RNA, V10, P1026, DOI 10.1261/rna.7240504; Ishitani R, 2003, CELL, V113, P383, DOI 10.1016/S0092-8674(03)00280-0; Kaya Y, 2003, RNA, V9, P711, DOI 10.1261/rna.5230603; Kaya Y, 2004, J BIOL CHEM, V279, P18107, DOI 10.1074/jbc.C400072200; KEALEY JT, 1994, BIOCHIMIE, V76, P1133, DOI 10.1016/0300-9084(94)90042-6; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; Lee TT, 2005, CELL, V120, P599, DOI 10.1016/j.cell.2004.12.037; Lee TT, 2004, STRUCTURE, V12, P397, DOI 10.1016/j.str.2004.02.009; Li L, 2006, NATURE, V443, P302, DOI 10.1038/nature05151; Meier UT, 2005, CHROMOSOMA, V114, P1, DOI 10.1007/s00412-005-0333-9; Ofengand J, 2002, FEBS LETT, V514, P17, DOI 10.1016/S0014-5793(02)02305-0; Pan H, 2003, P NATL ACAD SCI USA, V100, P12648, DOI 10.1073/pnas.2135585100; PATTON JR, 1993, BIOCHEM J, V290, P595, DOI 10.1042/bj2900595; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Phannachet K, 2004, NUCLEIC ACIDS RES, V32, P1422, DOI 10.1093/nar/gkh287; Rashid R, 2006, MOL CELL, V21, P249, DOI 10.1016/j.molcel.2005.11.017; SAMUELSSON T, 1990, J BIOL CHEM, V265, P8782; Sivaraman J, 2002, NAT STRUCT BIOL, V9, P353, DOI 10.1038/nsb788; Watanabe Y, 2000, NUCLEIC ACIDS RES, V28, P2342, DOI 10.1093/nar/28.12.2342	29	29	31	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					38969	38973		10.1074/jbc.R600034200	http://dx.doi.org/10.1074/jbc.R600034200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17085441	hybrid			2022-12-27	WOS:000242898700002
J	Martinez-Caballero, S; Grigoriev, SM; Herrmann, JM; Campo, ML; Kinnally, KW				Martinez-Caballero, Sonia; Grigoriev, Sell M.; Herrmann, Johannes M.; Campo, Maria Luisa; Kinnally, Kathleen W.			Tim17p regulates the twin pore structure and voltage gating of the mitochondrial protein import complex TIM23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE CONDUCTANCE CHANNEL; INNER MEMBRANE; PREPROTEIN TRANSLOCASE; PRESEQUENCE TRANSLOCASE; OUTER-MEMBRANE; MOTOR; MACHINERY; COMPONENT; TIM50; PERMEABILITY	The TIM23 complex mediates import of preproteins into mitochondria, but little is known of the mechanistic properties of this translocase. Here patch clamping reconstituted inner membranes allowed for first time insights into the structure and function of the preprotein translocase. Our findings indicate that the TIM23 channel has "twin pores" (two equal sized pores that cooperatively gate) thereby strikingly resembling TOM, the translocase of the outer membrane. Tim17p and Tim23p are homologues, but their functions differ. Tim23p acts as receptor for preproteins and may largely constitute the preprotein- conducting passageway. Conversely depletion of Tim17p induces a collapse of the twin pores into a single pore, whereas N terminus deletion or C terminus truncation results in variable sized pores that cooperatively gate. Further analysis of Tim17p mutants indicates that the N terminus is vital for both voltage sensing and protein sorting. These results suggest that although Tim23p is the main structural unit of the pore Tim17p is required for twin pore structure and provides the voltage gate for the TIM23 channel.	NYU, Coll Dent, Dept Basic Sci, New York, NY 10010 USA; Univ Extremadura, Dept Bioquim & Biol Mol & Genet, Caceres 10071, Spain; Univ Kaiserslautern, Inst Cell Biol, D-67663 Kaiserslautern, Germany	New York University; Universidad de Extremadura; University of Kaiserslautern	Kinnally, KW (corresponding author), NYU, Coll Dent, Dept Basic Sci, 345 E 24th St, New York, NY 10010 USA.	kck1@nyu.edu	Martínez-Caballero, Sonia/AAB-8481-2022; Caballero, Sonia Martinez/B-7583-2013; Campo, Maria Luisa/L-5211-2014	Martínez-Caballero, Sonia/0000-0002-4401-6165; 	NIGMS NIH HHS [GM57249] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057249] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bezrukov SM, 1997, EUR BIOPHYS J BIOPHY, V26, P471, DOI 10.1007/s002490050101; Chacinska A, 2005, CELL, V120, P817, DOI 10.1016/j.cell.2005.01.011; Colombini M, 1996, Ion Channels, V4, P169; D'Silva PD, 2003, P NATL ACAD SCI USA, V100, P13839, DOI 10.1073/pnas.1936150100; DECKER GL, 1977, J ULTRA MOL STRUCT R, V59, P44, DOI 10.1016/S0022-5320(77)80027-0; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; Frazier AE, 2004, NAT STRUCT MOL BIOL, V11, P226, DOI 10.1038/nsmb735; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; Grigoriev SM, 2004, INT REV CYTOL, V238, P227, DOI 10.1016/S0074-7696(04)38005-8; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 2001, IONIC CHANNELS EXCIT, P351; Kozany C, 2004, NAT STRUCT MOL BIOL, V11, P234, DOI 10.1038/nsmb734; KRASILNIKOV OV, 1992, FEMS MICROBIOL IMMUN, V105, P93; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Kushnareva YE, 1999, ARCH BIOCHEM BIOPHYS, V366, P107, DOI 10.1006/abbi.1999.1190; Kushnareva YE, 2001, ARCH BIOCHEM BIOPHYS, V386, P251, DOI 10.1006/abbi.2000.2201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YF, 2004, J BIOL CHEM, V279, P38047, DOI 10.1074/jbc.M404319200; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; LOHRET TA, 1995, J BIOL CHEM, V270, P15950, DOI 10.1074/jbc.270.27.15950; Lohret TA, 1996, J BIOL CHEM, V271, P4846; LOHRET TA, 1995, BIOPHYS J, V68, P2299, DOI 10.1016/S0006-3495(95)80412-1; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; MARTINEZCABALLE.S, 2007, IN PRESS ANAL BIOCH; Meier S, 2005, J BIOL CHEM, V280, P7777, DOI 10.1074/jbc.M412158200; Meinecke M, 2006, SCIENCE, V312, P1523, DOI 10.1126/science.1127628; Milisav I, 2001, J BIOL CHEM, V276, P25856, DOI 10.1074/jbc.M102132200; Moczydlowski E., 1986, ION CHANNEL RECONSTI, P75; Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Muro C, 2003, BIOPHYS J, V84, P2981, DOI 10.1016/S0006-3495(03)70024-1; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Peixoto PM, 2004, RECENT RES DEV BIOPH, V3, P413; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pfanner N, 2002, BBA-MOL CELL RES, V1592, P15, DOI 10.1016/S0167-4889(02)00260-4; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Reichert AS, 2004, TRENDS GENET, V20, P555, DOI 10.1016/j.tig.2004.08.012; Ryan KR, 1998, MOL CELL BIOL, V18, P178, DOI 10.1128/MCB.18.1.178; SABIROV RZ, 1993, GEN PHYSIOL BIOPHYS, V12, P95; Sobko AA, 2006, J BIOL CHEM, V281, P14408, DOI 10.1074/jbc.M513634200; SZABO I, 1992, J BIOL CHEM, V267, P2940; Taylor RD, 2004, BBA-BIOENERGETICS, V1658, P37, DOI 10.1016/j.bbabio.2004.04.017; Truscott KN, 2003, J CELL BIOL, V163, P707, DOI 10.1083/jcb.200308004; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	52	88	88	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3584	3593		10.1074/jbc.M607551200	http://dx.doi.org/10.1074/jbc.M607551200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148445	hybrid			2022-12-27	WOS:000244481900020
J	Sakai, K; Kimata, K; Sato, T; Gotoh, M; Narimatsu, H; Shinomiya, K; Watanabe, H				Sakai, Kenichiro; Kimata, Koji; Sato, Takashi; Gotoh, Masanori; Narimatsu, Hisashi; Shinomiya, Kenichi; Watanabe, Hideto			Chondroitin sulfate N-acetylgalactosaminyltransferase-1 plays a critical role in chondroitin sulfate synthesis in cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; LOW-BACK-PAIN; MOLECULAR-CLONING; N-ACETYLGALACTOSAMINYLTRANSFERASE; DISC DEGENERATION; INTERVERTEBRAL DISC; RAT CHONDROSARCOMA; AGGRECAN TURNOVER; GLUCURONIC-ACID; ASPARTIC-ACID	Cartilage destruction leads to severe joint diseases, such as osteoarthritis and spinal disorders with back pain, and cartilage regeneration is very inefficient. A major component of the cartilage extracellular matrix is the proteoglycan aggrecan that contains approximately 100 chondroitin sulfate (CS) chains, which impart water absorption and resistance to compression. Here, we demonstrate that chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGaINAcT-1) plays a critical role in CS biosynthesis in cartilage. By in situ hybridization and real time reverse transcription-PCR of developing cartilage, CSGal-NAcT-1 exhibited the highest level of expression. Its expression in chondrogenic ATDC5 cells correlated well with that of aggrecan core protein. In heterozygote and homozygote aggrecan-null cartilage where aggrecan transcription is decreased, CSGal-NAcT-1 transcription diminished accordingly. Overexpression of the enzyme in chondrocytic cells further enhanced CS biosynthesis but not that of the aggrecan core protein, indicating that the enzyme activity is not saturated in the cells and that aggrecan synthesized in the overexpressing cells is heavier than the native molecule. Analysis of the CS chains synthesized in the overexpressing cells by gel chromatography and that of disaccharide composition revealed that the CS chains had similar length and sulfation patterns. Furthermore, adenoviral gene delivery of the enzyme into intervertebral discs displayed a substantial increase in the level of CS biosynthesis. These observations indicate that CSGaINAcT-1 overexpression increases the number of CS chains attached to aggrecan core protein. Our studies may lead to a new therapeutic intervention, ameliorating the outcome of cartilage degenerative diseases.	Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Tokyo Med & Dent Univ, Dept Orthoped Surg, Bunkyo Ku, Tokyo 1138519, Japan; Natl Inst Adv Ind Sci & Technol, Ctr Glycosci, Tsukuba, Ibaraki 3058568, Japan	Aichi Medical University; Tokyo Medical & Dental University (TMDU); National Institute of Advanced Industrial Science & Technology (AIST)	Watanabe, H (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan.	wannabee@aichi-med-u.ac.jp	Narimatsu, Hisashi/M-4757-2018; Sato, Takashi/M-2577-2018	Narimatsu, Hisashi/0000-0002-8402-133X; Sato, Takashi/0000-0002-9973-8923; Watanabe, Hideto/0000-0001-5291-0696				Anderson DG, 2005, SPINE, V30, pS14, DOI 10.1097/01.brs.0000175174.50235.ba; Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; BAYLISS MT, 1990, BIOCHEM SOC T, V18, P799, DOI 10.1042/bst0180799; CHOI HU, 1971, P NATL ACAD SCI USA, V68, P877, DOI 10.1073/pnas.68.5.877; Creamer P, 1997, LANCET, V350, P503, DOI 10.1016/S0140-6736(97)07226-7; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140-6736(05)71086-2; DOEGE KJ, 1994, J BIOL CHEM, V269, P29232; Gotoh M, 2002, J BIOL CHEM, V277, P38189, DOI 10.1074/jbc.M203619200; Gotoh M, 2002, J BIOL CHEM, V277, P38179, DOI 10.1074/jbc.M202601200; Kamiya N, 2002, J BONE MINER RES, V17, P1832, DOI 10.1359/jbmr.2002.17.10.1832; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kuo CK, 2006, CURR OPIN RHEUMATOL, V18, P64, DOI 10.1097/01.bor.0000198005.88568.df; Luoma K, 2000, SPINE, V25, P487, DOI 10.1097/00007632-200002150-00016; Maroudas A, 1998, ARCH BIOCHEM BIOPHYS, V350, P61, DOI 10.1006/abbi.1997.0492; MAROUDAS A, 1975, PHILOS T ROY SOC B, V271, P293, DOI 10.1098/rstb.1975.0054; Martinek V, 2003, J BONE JOINT SURG BR, V85B, P782, DOI 10.1302/0301-620X.85B6.14351; Masuda K, 2004, SPINE, V29, P2757, DOI 10.1097/01.brs.0000146048.14946.af; Matsumoto K, 2006, J BIOL CHEM, V281, P18257, DOI 10.1074/jbc.M510330200; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Nogami K, 2004, J BIOL CHEM, V279, P8219, DOI 10.1074/jbc.M307304200; OEGEMA TR, 1975, J BIOL CHEM, V250, P6151; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; Roughley P, 2006, EUR CELLS MATER, V11, P1; Sato T, 2003, J BIOL CHEM, V278, P3063, DOI 10.1074/jbc.M208886200; Shibata S, 2003, J ANAT, V203, P425, DOI 10.1046/j.1469-7580.2003.00226.x; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Silbert JE, 1996, GLYCOCONJUGATE J, V13, P907, DOI 10.1007/BF01053185; SILBERT JE, 1980, BIOCHEM J, V190, P307, DOI 10.1042/bj1900307; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Sivan SS, 2006, J BIOL CHEM, V281, P13009, DOI 10.1074/jbc.M600296200; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Uyama T, 2003, J BIOL CHEM, V278, P3072, DOI 10.1074/jbc.M209446200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; Venkatesan N, 2004, P NATL ACAD SCI USA, V101, P18087, DOI 10.1073/pnas.0404504102; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P6943, DOI 10.1073/pnas.94.13.6943; Watanabe H, 1998, J BIOCHEM, V124, P687, DOI 10.1093/oxfordjournals.jbchem.a022166; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; Yada T, 2003, J BIOL CHEM, V278, P39711, DOI 10.1074/jbc.M304421200; Yada T, 2003, J BIOL CHEM, V278, P30235, DOI 10.1074/jbc.M303657200	45	34	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4152	4161		10.1074/jbc.M606870200	http://dx.doi.org/10.1074/jbc.M606870200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17145758	hybrid			2022-12-27	WOS:000244481900078
J	Vingadassalom, D; Kolb, A; Mayer, C; Collatz, E; Podglajen, I				Vingadassalom, Didier; Kolb, Annie; Mayer, Claudine; Collatz, Ekkehard; Podglajen, Isabelle			Probing the importance of selected phylum-specific amino acids in sigma(A) of Bacteroides fragilis, a primary or factor naturally devoid of an N-terminal acidic region 1.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL RNA-POLYMERASE; ESCHERICHIA-COLI SIGMA(70); TRANSCRIPTION INITIATION; CONSERVED REGION-3; DNA-BINDING; RECOGNITION; HOLOENZYME; SUBUNIT; GENE; RESISTANCE	The sigma(A) factor of Bacteroides fragilis is the prototype of a novel subgroup of primary or factors that are essential for growth and ensure the initiation of transcription of the housekeeping genes. This subgroup is confined to the phyla Bacteroidetes and Chlorobi. Its members carry a specific amino acid signature and are notably characterized by a short, basic N-terminal segment instead of the typical acidic region 1.1. Using in vitro mutagenesis, we investigated the importance of this basic segment and of several residues of the signature for the function of sigma(A). We have shown that the conserved residues Phe-61 and Lys-265, located in the core binding and DNA binding subregions 2.1 and 4.2, respectively, are critical for full function of the B.fragilis holoenzyme. With respect to the unusual subregion composition of sigma(A), we have shown that truncation of the basic N-terminal segment, or reversion of its charge, strongly affects the overall transcriptional activity of B.fragilis RNA polymerase in vitro. Our results indicate that the presence of the intact basic segment is required for the formation of RNA polymerase (RNAP)promoter open complexes, the correct architecture of the transcription bubble, and efficient promoter clearance.	Univ Paris 06, Fac Med, F-75006 Paris, France; INSERM, Lab Rech Mol Antibiot, U655, F-75006 Paris, France; Inst Pasteur, CNRS, Unite Regulat Transcriptionnelles, URA 2172, F-75724 Paris, France; Hop Europeen Georges Pompidou, AP HP, F-75015 Paris, France	UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Kolb, A (corresponding author), 25 Rue Dr Roux, F-75724 Paris 15, France.	akolb@pasteur.fr						Andre E, 2004, ASSAY DRUG DEV TECHN, V2, P629, DOI 10.1089/adt.2004.2.629; Baldwin NE, 2001, MOL MICROBIOL, V42, P427, DOI 10.1046/j.1365-2958.2001.02642.x; Barne KA, 1997, EMBO J, V16, P4034, DOI 10.1093/emboj/16.13.4034; Bayley DP, 2000, FEMS MICROBIOL LETT, V193, P149, DOI 10.1111/j.1574-6968.2000.tb09417.x; Borukhov S, 2003, CURR OPIN MICROBIOL, V6, P93, DOI 10.1016/S1369-5274(03)00036-5; BREUIL J, 1989, PLASMID, V21, P151, DOI 10.1016/0147-619X(89)90060-7; Camarero JA, 2002, P NATL ACAD SCI USA, V99, P8536, DOI 10.1073/pnas.132033899; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Cashel M, 2003, J BIOL CHEM, V278, P5539, DOI 10.1074/jbc.M211430200; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; Dupuy B, 2006, RES MICROBIOL, V157, P201, DOI 10.1016/j.resmic.2005.11.004; Feklistov A, 2006, MOL CELL, V23, P97, DOI 10.1016/j.molcel.2006.06.010; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Gopal V, 1997, EUR J BIOCHEM, V244, P613, DOI 10.1111/j.1432-1033.1997.00613.x; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; Gruber TM, 2003, ANNU REV MICROBIOL, V57, P441, DOI 10.1146/annurev.micro.57.030502.090913; Gruber TM, 1997, J BACTERIOL, V179, P1734, DOI 10.1128/jb.179.5.1734-1747.1997; Haugen SP, 2006, CELL, V125, P1069, DOI 10.1016/j.cell.2006.04.034; Helmann JD, 2002, ADV MICROB PHYSIOL, V46, P47; HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536; Hernandez VJ, 1996, J BIOL CHEM, V271, P18775, DOI 10.1074/jbc.271.31.18775; Hinton DM, 2006, J BACTERIOL, V188, P1279, DOI 10.1128/JB.188.4.1279-1285.2006; Hsu HH, 2004, J BACTERIOL, V186, P2366, DOI 10.1128/JB.186.8.2366-2375.2004; Imashimizu M, 2006, FEBS LETT, V580, P3439, DOI 10.1016/j.febslet.2006.05.017; Iyer LM, 2004, GENE, V335, P73, DOI 10.1016/j.gene.2004.03.017; Kuwahara T, 2004, P NATL ACAD SCI USA, V101, P14919, DOI 10.1073/pnas.0404172101; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Marschall C, 1998, J MOL BIOL, V276, P339, DOI 10.1006/jmbi.1997.1533; Martinez-Argudo I, 2004, P NATL ACAD SCI USA, V101, P16316, DOI 10.1073/pnas.0405312101; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; Paget MSB, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-203; Podglajen I, 2001, J BACTERIOL, V183, P3531, DOI 10.1128/JB.183.11.3531-3535.2001; Susa M, 2006, MOL MICROBIOL, V59, P1807, DOI 10.1111/j.1365-2958.2006.05058.x; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Vingadassalom D, 2005, MOL MICROBIOL, V56, P888, DOI 10.1111/j.1365-2958.2005.04590.x; Vuthoori S, 2001, J MOL BIOL, V309, P561, DOI 10.1006/jmbi.2001.4690; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029	41	1	1	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3442	3449		10.1074/jbc.M608855200	http://dx.doi.org/10.1074/jbc.M608855200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150963	hybrid			2022-12-27	WOS:000244481900006
J	Xie, J; Burz, DS; He, W; Bronstein, IB; Lednev, I; Shekhtman, A				Xie, Jingjing; Burz, David S.; He, Wei; Bronstein, Igor B.; Lednev, Igor; Shekhtman, Alexander			Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; CELL-SURFACE RECEPTOR; SOLUBLE RECEPTOR; CALCIUM; PROTEINS; ACTIVATION; DOMAIN; MECHANISM; COMPLEX; STATES	Calgranulin C (S100A12) is a member of the S100 family of proteins that undergoes a conformational change upon calcium binding allowing them to interact with target molecules and initiate biological responses; one such target is the receptor for advanced glycation products (RAGE). The RAGE-calgranulin C interaction mediates a pro-inflammatory response to cellular stress and can contribute to the pathogenesis of inflammatory lesions. The soluble extracellular part of RAGE (sRAGE) was shown to decrease the inflammation response possibly by scavenging RAGE-activating ligands. Here, by using high resolution NMR spectroscopy, we identified the sRAGE-calgranulin C interaction surface. Ca2+ binding creates two symmetric hydrophobic surfaces on Ca2+-calgranulin C that allow calgranulin C to bind to the C-type immunoglobulin domain of RAGE. Apo-calgranulin C also binds to sRAGE using a completely different surface and with substantially lower affinity, thus underscoring the role of Ca2+ binding to S100 proteins as a molecular switch. By using native gel electrophoresis, chromatography, and fluorescence spectroscopy, we established that sRAGE forms tetramers that bind to hexamers of Ca2+-calgranulin C. This arrangement creates a large platform for effectively transmitting RAGE-dependent signals from extracellular S100 proteins to the cytoplasmic signaling complexes.	SUNY Albany, Dept Chem, Albany, NY 12222 USA; Natl Inst Med Res, London NW7 1AA, England	State University of New York (SUNY) System; State University of New York (SUNY) Albany; MRC National Institute for Medical Research	Shekhtman, A (corresponding author), SUNY Albany, Dept Chem, Albany, NY 12222 USA.	ashekhta@albany.edu	Lednev, Igor K/J-8387-2017	Lednev, Igor K/0000-0002-6504-531X; Shekhtman, Alexander/0000-0003-2649-2675				ABRAGAM A, 1961, PRINCIPLES NUCLEAR M, P427; BAUDIER J, 1983, BIOCHEMISTRY-US, V22, P3360, DOI 10.1021/bi00283a009; Bhattacharya S, 2004, BBA-MOL CELL RES, V1742, P69, DOI 10.1016/j.bbamcr.2004.09.002; Bhattacharya S, 2003, BIOCHEMISTRY-US, V42, P14416, DOI 10.1021/bi035089a; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; BOLLAG DM, 1996, PROTEIN METHODS, P155; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CAVANAGH J, 1996, PROTEIN NMR SPECTROS, P478; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; DELATORRE JG, 1994, BIOPHYS J, V67, P530, DOI 10.1016/S0006-3495(94)80512-0; Dempsey AC, 2003, STRUCTURE, V11, P887, DOI 10.1016/S0969-2126(03)00126-6; Ding QX, 2005, BBA-MOL CELL RES, V1746, P18, DOI 10.1016/j.bbamcr.2005.08.006; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Drohat AC, 1996, BIOCHEMISTRY-US, V35, P11577, DOI 10.1021/bi9612226; Dutta K, 2002, BIOCHEMISTRY-US, V41, P4239, DOI 10.1021/bi012061v; Eghbalnia HR, 2005, J BIOMOL NMR, V32, P71, DOI 10.1007/s10858-005-5705-1; Eisner DA, 2005, EXP PHYSIOL, V90, P3, DOI 10.1113/expphysiol.2004.029231; Ferrage F, 2003, J AM CHEM SOC, V125, P2541, DOI 10.1021/ja0211407; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hadding A, 2004, BBA-MOL CELL RES, V1691, P67, DOI 10.1016/j.bbamcr.2004.01.003; Hanford LE, 2004, J BIOL CHEM, V279, P50019, DOI 10.1074/jbc.M409782200; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hsieh HL, 2004, BIOCHEM BIOPH RES CO, V316, P949, DOI 10.1016/j.bbrc.2004.02.135; Inman KG, 2002, J MOL BIOL, V324, P1003, DOI 10.1016/S0022-2836(02)01152-X; Ishihara K, 2003, FEBS LETT, V550, P107, DOI 10.1016/S0014-5793(03)00846-9; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; LANE AN, 1994, METHOD ENZYMOL, V239, P596; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; Masse JE, 2005, J MAGN RESON, V174, P133, DOI 10.1016/j.jmr.2005.01.017; Matsuo H, 1999, J AM CHEM SOC, V121, P9903, DOI 10.1021/ja991881g; MCCLURE WO, 1966, BIOCHEMISTRY-US, V5, P1908, DOI 10.1021/bi00870a018; Moroz OV, 2002, ACTA CRYSTALLOGR D, V58, P407, DOI 10.1107/S0907444901021278; Moroz OV, 2003, MICROSC RES TECHNIQ, V60, P581, DOI 10.1002/jemt.10300; Moroz OV, 2001, ACTA CRYSTALLOGR D, V57, P20, DOI 10.1107/S090744490001458X; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Otterbein LR, 2002, STRUCTURE, V10, P557, DOI 10.1016/S0969-2126(02)00740-2; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Rintala AC, 2002, J BIOMOL NMR, V22, P191, DOI 10.1023/A:1014256512514; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Rustandi RR, 2002, BIOCHEMISTRY-US, V41, P788, DOI 10.1021/bi0118308; SCHIMMEL PR, 1980, BIOPHYS CHEM TECHNIQ, P549; Schmidt AM, 1996, DIABETES, V45, pS77, DOI 10.2337/diab.45.3.S77; SCHMIDT AM, 1997, CIRCULATION S, V1, P37; Shekhtman A, 2001, J MOL BIOL, V314, P129, DOI 10.1006/jmbi.2001.5126; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; Sousa MM, 2000, LAB INVEST, V80, P1101, DOI 10.1038/labinvest.3780116; Srikrishna G, 2002, J NEUROCHEM, V80, P998, DOI 10.1046/j.0022-3042.2002.00796.x; Strupat K, 2000, J AM SOC MASS SPECTR, V11, P780, DOI 10.1016/S1044-0305(00)00150-1; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; Vallely KM, 2002, BIOCHEMISTRY-US, V41, P12670, DOI 10.1021/bi020365r; Walters KJ, 1999, P NATL ACAD SCI USA, V96, P7877, DOI 10.1073/pnas.96.14.7877; Walters KJ, 2001, METHOD ENZYMOL, V339, P238, DOI 10.1016/S0076-6879(01)39316-3; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; Williams RJP, 1996, CELL CALCIUM, V20, P87, DOI 10.1016/S0143-4160(96)90054-8; Wright NT, 2005, J MOL BIOL, V353, P410, DOI 10.1016/j.jmb.2005.08.027; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	67	136	143	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4218	4231		10.1074/jbc.M608888200	http://dx.doi.org/10.1074/jbc.M608888200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158877	hybrid			2022-12-27	WOS:000244481900085
J	Chew, AGM; Bryant, DA				Chew, Aline Gomez Maqueo; Bryant, Donald A.			Characterization of a plant-like protochlorophyllide a divinyl reductase in green sulfur bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROBIUM-TEPIDUM; BACTERIOCHLOROPHYLL-C; RHODOBACTER-CAPSULATUS; ARABIDOPSIS-THALIANA; REACTION CENTERS; CHLOROPHYLL; MUTANT; GENE; PROCHLOROCOCCUS; IDENTIFICATION	The green sulfur bacterium Chlorobium tepidum synthesizes three types of (bacterio) chlorophyll ((B) Chl): BChl a(p), Chl a(PD), and BChl c(F). During the synthesis of all three molecules, a C-8 vinyl substituent is reduced to an ethyl group, and in the case of BChl c(F), the C-82 carbon of this ethyl group is subsequently methylated once or twice by the radical S-adenosylmethionine enzyme BchQ. The C. tepidum genome contains homologs of two genes, bchJ (CT2014) and CT1063, that are highly homologous to genes, bchJ and AT5G18660, and that have been reported to encode C-8 vinyl reductases in Rhodobacter capsulatus and Arabidopsis thaliana, respectively. To determine which gene product actually encodes a C-8 vinyl reductase activity, the bchJ and CT1063 genes were insertionally inactivated in C. tepidum. All three Ch1s synthesized by the CT1063 mutant of C. tepidum have a C-8 vinyl group. Using NADPH but not NADH as reductant, recombinant BciA reduces the C-8 vinyl group of 3,8-divinyl-protochlorophyllide in vitro. These data demonstrate that CT1063, renamed bciA, encodes a C-8 divinyl reductase in C. tepidum. The bchJ mutant produces detectable amounts of Chl a(PD), BChl a(P), and BChl c(F), all of which have reduced C-8 substituents, but the mutant cells secrete large amounts of 3,8-divinyl-protochlorophyllide a into the growth medium and have a greatly reduced BChl c(F) content. The results suggest that BchJ may play an important role in substrate channeling and/ or regulation of Chl biosynthesis but show that it is not a vinyl reductase. Because only some Ch1-synthesizing organisms possess homologs of bciA, at least two types of C-8 vinyl reductases must occur.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Bryant, DA (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	dab14@psu.edu	Gomez Maqueo Chew, Aline/D-8631-2016	Gomez Maqueo Chew, Aline/0000-0001-6075-2907				Allen JP, 1998, FEBS LETT, V438, P5, DOI 10.1016/S0014-5793(98)01245-9; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BACHMANN BJ, 1980, MICROBIOL REV, V44, P1; BAZZAZ MB, 1981, PHOTOBIOCH PHOTOBIOP, V2, P199; BOBE FW, 1990, BIOCHEMISTRY-US, V29, P4340, DOI 10.1021/bi00470a012; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; BROCKMANN H, 1976, PHILOS T ROY SOC B, V273, P277, DOI 10.1098/rstb.1976.0013; DEMEREC M, 1966, GENETICS, V54, P61; Eckhardt U, 2004, PLANT MOL BIOL, V56, P1, DOI 10.1007/s11103-004-2331-3; Eisen JA, 2002, P NATL ACAD SCI USA, V99, P9509, DOI 10.1073/pnas.132181499; Frigaard Niels-Ulrik, 2006, V25, P201; Frigaard NU, 1997, ARCH MICROBIOL, V167, P343, DOI 10.1007/s002030050453; Frigaard NU, 2002, J BACTERIOL, V184, P3368, DOI 10.1128/JB.184.12.3368-3376.2002; Frigaard NU, 2001, APPL ENVIRON MICROB, V67, P2538, DOI 10.1128/AEM.67.6.2538-2544.2001; GOLBECK JH, 1993, P NATL ACAD SCI USA, V90, P1642, DOI 10.1073/pnas.90.5.1642; GREEN BR, 2004, ADV PHOTOSYNTHESIS R, V13; Helfrich M, 1999, BBA-BIOENERGETICS, V1410, P262, DOI 10.1016/S0005-2728(99)00004-3; Kim JS, 1996, J BIOCHEM MOL BIOL, V29, P327; Kolossov VL, 2006, ANAL BIOCHEM, V348, P192, DOI 10.1016/j.ab.2005.07.031; Kolossov VL, 2001, ANAL BIOCHEM, V295, P214, DOI 10.1006/abio.2001.5195; Mizoguchi T, 2000, PHOTOCHEM PHOTOBIOL, V71, P596, DOI 10.1562/0031-8655(2000)071<0596:STATAF>2.0.CO;2; Nagata N, 2005, PLANT CELL, V17, P233, DOI 10.1105/tpc.104.027276; Nakanishi H, 2005, PLANT CELL PHYSIOL, V46, P467, DOI 10.1093/pcp/pci053; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; Permentier HP, 2000, PHOTOSYNTH RES, V64, P27, DOI 10.1023/A:1026515027824; STANIER RY, 1960, BIOCHIM BIOPHYS ACTA, V41, P478, DOI 10.1016/0006-3002(60)90045-7; SUZUKI JY, 1995, J BIOL CHEM, V270, P3732, DOI 10.1074/jbc.270.8.3732; WAHLUND TM, 1995, J BACTERIOL, V177, P2583, DOI 10.1128/jb.177.9.2583-2588.1995; WAHLUND TM, 1991, ARCH MICROBIOL, V156, P81, DOI 10.1007/BF00290978	30	53	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2967	2975		10.1074/jbc.M609730200	http://dx.doi.org/10.1074/jbc.M609730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148453	hybrid			2022-12-27	WOS:000243793900023
J	Ferrer, P; Asensi, M; Priego, S; Benlloch, M; Mena, S; Ortega, A; Obrador, E; Esteve, JM; Estrela, JM				Ferrer, Paula; Asensi, Miguel; Priego, Sonia; Benlloch, Maria; Mena, Salvador; Ortega, Angel; Obrador, Elena; Esteve, Juan M.; Estrela, Jose M.			Nitric oxide mediates natural polyphenol-induced Bcl-2 down-regulation and activation of cell death in metastatic B16 melanoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC SINUSOIDAL ENDOTHELIUM; TUMOR-CYTOTOXICITY; GUANYLATE-CYCLASE; INDUCED APOPTOSIS; IN-VITRO; HUMAN-LYMPHOCYTES; SYNTHASE; RESVERATROL; CERAMIDE; GLUTATHIONE	Intravenous administration to mice of trans-pterostilbene (t-PTER; 3,5-dimethoxy-4'-hydroxystilbene) and quercetin (QUER; 3,3',4',5,6-pentahydroxyflavone), two structurally related and naturally occurring small polyphenols, inhibits metastatic growth of highly malignant B16 melanoma F10 (B16M-F10) cells. t-PTER and QUER inhibit bcl-2 expression in metastatic cells, which sensitizes them to vascular endothelium-induced cytotoxicity. However, the molecular mechanism(s) linking polyphenol signaling and bcl-2 expression are unknown. NO is a potential bioregulator of apoptosis with controversial effects on Bcl-2 regulation. Polyphenols may affect NO generation. Short-term exposure (60 min/day) to t-PTER (40 mu M) and QUER (20 mu M) (approximate mean values of the plasma concentrations measured within the first hour after intravenous administration of 20 mg of each polyphenol/kg) down-regulated inducible NO synthetase in B16M-F10 cells and up-regulated endothelial NO synthetase in the vascular endothelium and thereby facilitated endothelium-induced tumor cytotoxicity. Very low and high NO levels down-regulated bcl-2 expression in B16M-F10 cells. t-PTER and QUER induced a NO shortage-dependent decrease in cAMP-response element-binding protein phosphorylation, a positive regulator of bcl-2 expression, inB16M-F10 cells. On the other hand, during cancer and endothelial cell interaction, t-PTER- and QUER-induced NO release from the vascular endothelium up-regulated neutral sphingomyelinase activity and ceramide generation in B16M-F10 cells. Direct NO-induced cytotoxicity and ceramide-induced mitochondrial permeability transition and apoptosis activation can explain the increased endothelium-induced death of Bcl-2-depleted B16M-F10 cells.	Univ Valencia, Fac Med & Odontol, Dept Physiol, Valencia 46010, Spain	University of Valencia	Estrela, JM (corresponding author), Univ Valencia, Fac Med & Odontol, Dept Physiol, 17 Av Blasco Ibanez, Valencia 46010, Spain.	jose.m.estrela@uv.es	OBRADOR, ELENA/H-4069-2015; Miralles, Miguel A Asensi/I-2756-2015; Mena, Salvador/F-6696-2016; Estrela, Jose/H-4449-2015; Mena, Salvador/L-8780-2014; Ortega, Angel L./A-4113-2014	OBRADOR, ELENA/0000-0002-5934-5543; Miralles, Miguel A Asensi/0000-0003-1922-7777; Estrela, Jose/0000-0002-2540-9190; Mena, Salvador/0000-0002-6423-4741; Ortega, Angel L./0000-0002-9901-3383				Anasagasti MJ, 1997, HEPATOLOGY, V25, P840, DOI 10.1002/hep.510250410; Anasagasti MJ, 1998, HEPATOLOGY, V27, P1249, DOI 10.1002/hep.510270510; Anter E, 2004, J BIOL CHEM, V279, P46637, DOI 10.1074/jbc.M405547200; Asensi M, 2002, FREE RADICAL BIO MED, V33, P387, DOI 10.1016/S0891-5849(02)00911-5; Billard C, 2002, LEUKEMIA LYMPHOMA, V43, P1991, DOI 10.1080/1042819021000015952; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMAN RS, 1989, ANAL CHEM, V61, P2715, DOI 10.1021/ac00199a007; Brockhaus F, 1998, EXP CELL RES, V238, P33, DOI 10.1006/excr.1997.3778; Carretero J, 2001, J BIOL CHEM, V276, P25775, DOI 10.1074/jbc.M101148200; CHAN SY, 2006, IN PRESS EXP MOL PAT; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; Conkright MD, 2005, TRENDS CELL BIOL, V15, P457, DOI 10.1016/j.tcb.2005.07.007; de Pascual-Teresa S, 2004, J NUTR, V134, P552, DOI 10.1093/jn/134.3.552; DEGUCHI T, 1976, J NEUROCHEM, V27, P1027, DOI 10.1111/j.1471-4159.1976.tb00304.x; Dragsted LO, 2003, INT J VITAM NUTR RES, V73, P112, DOI 10.1024/0300-9831.73.2.112; Eissa S, 1998, CLIN CHEM, V44, P1423; Estrela JM, 2006, CRIT REV CL LAB SCI, V43, P143, DOI 10.1080/10408360500523878; Ferrer P, 2005, NEOPLASIA, V7, P37, DOI 10.1593/neo.04337; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Goldberg DA, 2003, CLIN BIOCHEM, V36, P79, DOI 10.1016/S0009-9120(02)00397-1; Haynes V, 2004, J BIOENERG BIOMEMBR, V36, P341, DOI 10.1023/B:JOBB.0000041765.27145.08; Hsieh TC, 1999, CANCER RES, V59, P2596; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Kim SS, 2002, ONCOGENE, V21, P2020, DOI 10.1038/sj.onc.1205037; Kolb JP, 2000, LEUKEMIA, V14, P1685, DOI 10.1038/sj.leu.2401896; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroon PA, 2004, AM J CLIN NUTR, V80, P15; Lamson D W, 2000, Altern Med Rev, V5, P196; MAEDA H, 1994, J LEUKOCYTE BIOL, V56, P588, DOI 10.1002/jlb.56.5.588; Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nijveldt RJ, 2001, AM J CLIN NUTR, V74, P418; Obrador E, 2002, HEPATOLOGY, V35, P74, DOI 10.1053/jhep.2002.30277; Obrador E, 2001, FREE RADICAL BIO MED, V31, P642, DOI 10.1016/S0891-5849(01)00622-0; OHIGASHI H, 1989, JPN J CANCER RES, V80, P818, DOI 10.1111/j.1349-7006.1989.tb01720.x; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Ortega A, 2003, J BIOL CHEM, V278, P39591, DOI 10.1074/jbc.M303753200; Ortega AL, 2003, J BIOL CHEM, V278, P13888, DOI 10.1074/jbc.M207140200; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Quiney C, 2004, LEUKEMIA RES, V28, P851, DOI 10.1016/j.leukres.2003.12.003; Rao CV, 1999, CARCINOGENESIS, V20, P641, DOI 10.1093/carcin/20.4.641; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; Rimando AM, 2002, J AGR FOOD CHEM, V50, P3453, DOI 10.1021/jf0116855; Roman V, 2002, BRIT J HAEMATOL, V117, P842, DOI 10.1046/j.1365-2141.2002.03520.x; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; Rui M, 2002, LIFE SCI, V71, P1771, DOI 10.1016/S0024-3205(02)01943-4; Salvucci O, 2001, CANCER RES, V61, P318; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Siskind LJ, 2005, J BIOENERG BIOMEMBR, V37, P143, DOI 10.1007/s10863-005-6567-7; Soeda S, 2001, BBA-MOL CELL RES, V1538, P234, DOI 10.1016/S0167-4889(01)00073-8; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Takeda Y, 1999, J BIOL CHEM, V274, P10654, DOI 10.1074/jbc.274.15.10654; VIDALVANACLOCHA F, 1993, HEPATOLOGY, V18, P328; WALDMAN SA, 1984, J BIOL CHEM, V259, P4038; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Xie KP, 1996, J LEUKOCYTE BIOL, V59, P797, DOI 10.1002/jlb.59.6.797; Xie KP, 1997, ONCOGENE, V15, P771, DOI 10.1038/sj.onc.1201239; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381	68	33	36	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2880	2890		10.1074/jbc.M605934200	http://dx.doi.org/10.1074/jbc.M605934200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135264	hybrid			2022-12-27	WOS:000243793900014
J	Kulangara, K; Kropf, M; Glauser, L; Magnin, S; Alberi, S; Yersin, A; Hirling, H				Kulangara, Karina; Kropf, Michel; Glauser, Liliane; Magnin, Sarah; Alberi, Stefano; Yersin, Alexandre; Hirling, Harald			Phosphorylation of glutamate receptor interacting protein 1 regulates surface expression of glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM DEPRESSION; MEDIATED SYNAPTIC-TRANSMISSION; ENRICHED ENDOSOMAL PROTEIN; DOMAIN-CONTAINING PROTEINS; ATOMIC-FORCE MICROSCOPY; AMPA RECEPTOR; DIFFERENTIAL PALMITOYLATION; HIPPOCAMPAL-NEURONS; CARBOXYL-TERMINUS; PICK1 INTERACTS	The number of synaptic alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-type glutamate receptors (AMPARs) controls the strength of excitatory transmission. AMPARs cycle between internal endosomal compartments and the plasma membrane. Interactions between the AMPAR subunit GluR2, glutamate receptor interacting protein 1 (GRIP1), and the endosomal protein NEEP21 are essential for correct GluR2 recycling. Here we show that an about 85-kDa protein kinase phosphorylates GRIP1 on serine 917. This kinase is present in NEEP21 immunocomplexes and is activated in okadaic acid-treated neurons. Pulldown assays and atomic force microscopy indicate that phosphorylated GRIP shows reduced binding to NEEP21. AMPA or N-methyl-D-aspartate stimulation of hippocampal neurons induces delayed phosphorylation of the same serine 917. A wild type carboxy-terminal GRIP1 fragment expressed in hippocampal neurons interferes with GluR2 surface expression. On the contrary, a S917D mutant fragment does not interfere with GluR2 surface expression. Likewise, coexpression of GluR2 together with full-length wild type GRIP1 enhances GluR2 surface expression in fibroblasts, whereas full-length GRIP1-S917D had no effect. This indicates that this serine residue is implicated in AMPAR cycling. Our results identify an important regulatory mechanism in the trafficking of AMPAR subunits between internal compartments and the plasma membrane.	Ecole Polytech Fed Lausanne, Fac Sci Vie, Brain Mind Inst, CH-1015 Lausanne, Switzerland; Univ Geneva, Ctr Med Univ Geneva, Dept Neurosci Fondamentales, CH-1211 Geneva, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Geneva	Hirling, H (corresponding author), Ecole Polytech Fed Lausanne, Fac Sci Vie, Brain Mind Inst, CH-1015 Lausanne, Switzerland.	harald.hirling@epfl.ch						Adesnik H, 2005, NEURON, V48, P977, DOI 10.1016/j.neuron.2005.11.030; Alberi S, 2005, MOL CELL NEUROSCI, V29, P313, DOI 10.1016/j.mcn.2005.03.011; Allen S, 1997, BIOCHEMISTRY-US, V36, P7457, DOI 10.1021/bi962531z; Barry MF, 2002, CURR OPIN NEUROBIOL, V12, P279, DOI 10.1016/S0959-4388(02)00329-X; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Charych EI, 2004, J BIOL CHEM, V279, P38978, DOI 10.1074/jbc.M405786200; Choquet D, 2003, NAT REV NEUROSCI, V4, P251, DOI 10.1038/nrn1077; Chung HJ, 2000, J NEUROSCI, V20, P7258; Chung HJ, 2003, SCIENCE, V300, P1751, DOI 10.1126/science.1082915; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Debaigt C, 2004, J BIOL CHEM, V279, P35687, DOI 10.1074/jbc.M402751200; DeSouza S, 2002, J NEUROSCI, V22, P3493; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Hoogenraad CC, 2005, NAT NEUROSCI, V8, P906, DOI 10.1038/nn1487; Kasas S, 2000, REV SCI INSTRUM, V71, P2082, DOI 10.1063/1.1150583; Launey T, 2004, P NATL ACAD SCI USA, V101, P676, DOI 10.1073/pnas.0302914101; Lee SH, 2004, NEURON, V43, P221, DOI 10.1016/j.neuron.2004.06.015; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Lin SHS, 2001, MOL PHARMACOL, V60, P916, DOI 10.1124/mol.60.5.916; Lu W, 2005, NEURON, V47, P407, DOI 10.1016/j.neuron.2005.07.006; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Matsuda S, 1999, J NEUROCHEM, V73, P1765, DOI 10.1046/j.1471-4159.1999.731765.x; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Song I, 2002, TRENDS NEUROSCI, V25, P578, DOI 10.1016/S0166-2236(02)02270-1; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Steiner P, 2005, EMBO J, V24, P2873, DOI 10.1038/sj.emboj.7600755; Steiner P, 2002, J CELL BIOL, V157, P1197, DOI 10.1083/jcb.200202022; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Yamazaki M, 2001, NEUROSCI LETT, V304, P81, DOI 10.1016/S0304-3940(01)01766-9; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8; Yersin A, 2003, P NATL ACAD SCI USA, V100, P8736, DOI 10.1073/pnas.1533137100	48	30	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2395	2404		10.1074/jbc.M606471200	http://dx.doi.org/10.1074/jbc.M606471200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121843	hybrid			2022-12-27	WOS:000243593200031
J	Pontier, D; Albrieux, C; Joyard, J; Lagrange, T; Block, MA				Pontier, Dominique; Albrieux, Catherine; Joyard, Jacques; Lagrange, Thierry; Block, Maryse A.			Knock-out of the magnesium protoporphyrin IX methyltransferase gene in Arabidopsis - Effects on chloroplast development and on chloroplast-to-nucleus signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MG-CHELATASE; PROTOCHLOROPHYLLIDE REDUCTASE; SPINACH-CHLOROPLASTS; THYLAKOID MEMBRANES; ENVELOPE MEMBRANES; LOCALIZATION; EXPRESSION; TOBACCO; SUBUNIT; SEQUENCE	Protoporphyrin IX is the last common intermediate between the heme and chlorophyll biosynthesis pathways. The addition of magnesium directs this molecule toward chlorophyll biosynthesis. The first step downstream from the branchpoint is catalyzed by the magnesium chelatase and is a highly regulated process. The corresponding product, magnesium protoporphyrin IX, has been proposed to play an important role as a signaling molecule implicated in plastid-to-nucleus communication. To get more information on the chlorophyll biosynthesis pathway and on magnesium protoporphyrin IX derivative functions, we have identified an magnesium protoporphyrin IX methyltransferase (CHLM) knock-out mutant in Arabidopsis in which the mutation induces a blockage downstream from magnesium protoporphyrin IX and an accumulation of this chlorophyll biosynthesis intermediate. Our results demonstrate that the CHLM gene is essential for the formation of chlorophyll and subsequently for the formation of photosystems I and II and cytochrome b6f complexes. Analysis of gene expression in the chlm mutant provides an independent indication that magnesium protoporphyrin IX is a negative effector of nuclear photo-synthetic gene expression, as previously reported. Moreover, it suggests the possible implication of magnesium protoporphyrin IX methyl ester, the product of CHLM, in chloroplast-to-nucleus signaling. Finally, post-transcriptional up-regulation of the level of the CHLH subunit of the magnesium chelatase has been detected in the chlm mutant and most likely corresponds to specific accumulation of this protein inside plastids. This result suggests that the CHLH subunit might play an important regulatory role when the chlorophyll biosynthetic pathway is disrupted at this particular step.	Univ Grenoble 1, DRDC PCV, CEA,Lab Physiol Cellulaire Vegetale, INRA,CNRS, F-38054 Grenoble 9, France; Univ Perpignan, Lab Genome & Dev Plantes, CNRS, Inst Rech Dev, F-66000 Perpignan, France	INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Perpignan Via Domitia	Block, MA (corresponding author), Univ Grenoble 1, DRDC PCV, CEA,Lab Physiol Cellulaire Vegetale, INRA,CNRS, 17 Rue Martyrs, F-38054 Grenoble 9, France.	mblock@cea.fr		Pontier, Dominique/0000-0001-9032-4620; Lagrange, Thierry/0000-0003-3090-0918				Alawady A, 2005, PLANT MOL BIOL, V57, P679, DOI 10.1007/s11103-005-1427-8; Alawady AE, 2005, PLANT J, V41, P282, DOI 10.1111/j.1365-313X.2004.02291.x; Barthelemy X, 2000, PHOTOSYNTH RES, V64, P63, DOI 10.1023/A:1026576319029; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; Block MA, 2002, EUR J BIOCHEM, V269, P240, DOI 10.1046/j.0014-2956.2001.02643.x; Eichacker LA, 1996, J BIOL CHEM, V271, P32174, DOI 10.1074/jbc.271.50.32174; Gadjieva R, 2005, PLANT PHYSIOL BIOCH, V43, P901, DOI 10.1016/j.plaphy.2005.08.003; GIBSON LCD, 1995, P NATL ACAD SCI USA, V92, P1941, DOI 10.1073/pnas.92.6.1941; GORCHEIN A, 1972, BIOCHEM J, V127, P97, DOI 10.1042/bj1270097; Hinchigeri SB, 1997, FEBS LETT, V407, P337, DOI 10.1016/S0014-5793(97)00371-2; Hoober JK, 1999, PHOTOSYNTH RES, V61, P197; HURKMAN WJ, 1986, PLANT PHYSIOL, V81, P802, DOI 10.1104/pp.81.3.802; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; JOYARD J, 1990, J BIOL CHEM, V265, P21820; Kropat J, 2000, PLANT J, V24, P523, DOI 10.1046/j.1365-313x.2000.00898.x; Larkin RM, 2003, SCIENCE, V299, P902, DOI 10.1126/science.1079978; LOGEMANN J, 1988, P NATL ACAD SCI USA, V85, P1136, DOI 10.1073/pnas.85.4.1136; MATRINGE M, 1992, J BIOL CHEM, V267, P4646; MAYFIELD SP, 1984, EUR J BIOCHEM, V144, P79, DOI 10.1111/j.1432-1033.1984.tb08433.x; Millar AJ, 1996, P NATL ACAD SCI USA, V93, P15491, DOI 10.1073/pnas.93.26.15491; MITTLER R, 1995, PLANT CELL, V7, P1951, DOI 10.1105/tpc.7.11.1951; Mochizuki N, 2001, P NATL ACAD SCI USA, V98, P2053, DOI 10.1073/pnas.98.4.2053; MORAN R, 1980, PLANT PHYSIOL, V65, P478, DOI 10.1104/pp.65.3.478; NAGY F, 1987, EMBO J, V6, P2537, DOI 10.1002/j.1460-2075.1987.tb02541.x; Nakayama M, 1998, PLANT CELL PHYSIOL, V39, P275, DOI 10.1093/oxfordjournals.pcp.a029368; Papenbrock J, 1997, PLANT J, V12, P981, DOI 10.1046/j.1365-313X.1997.12050981.x; Paulsen H, 2001, ADV PHOTOSYNTH, V11, P219; Pierre Y, 2003, BIOCHEMISTRY-US, V42, P1031, DOI 10.1021/bi026934c; Ravanel S, 2004, J BIOL CHEM, V279, P22548, DOI 10.1074/jbc.M313250200; Reinbothe C, 2006, P NATL ACAD SCI USA, V103, P4777, DOI 10.1073/pnas.0511066103; Rzeznicka K, 2005, P NATL ACAD SCI USA, V102, P5886, DOI 10.1073/pnas.0501784102; Samson F, 2002, NUCLEIC ACIDS RES, V30, P94, DOI 10.1093/nar/30.1.94; Strand A, 2003, NATURE, V421, P79, DOI 10.1038/nature01204; SUSEK RE, 1993, CELL, V74, P787, DOI 10.1016/0092-8674(93)90459-4; Tottey S, 2003, P NATL ACAD SCI USA, V100, P16119, DOI 10.1073/pnas.2136793100; White RA, 1996, PHOTOSYNTH RES, V47, P267, DOI 10.1007/BF02184287; Willows RD, 1996, EUR J BIOCHEM, V235, P438, DOI 10.1111/j.1432-1033.1996.00438.x; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	39	104	119	4	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2297	2304		10.1074/jbc.M610286200	http://dx.doi.org/10.1074/jbc.M610286200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135235	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000243593200021
J	Korkmaz, B; Hajjar, E; Kalupov, T; Reuter, N; Brillard-Bourdet, M; Moreau, T; Juliano, L; Gauthier, F				Korkmaz, Brice; Hajjar, Eric; Kalupov, Timofey; Reuter, Nathalie; Brillard-Bourdet, Michele; Moreau, Thierry; Juliano, Luiz; Gauthier, Francis			Influence of charge distribution at the active site surface on the substrate specificity of human neutrophil protease 3 and elastase - A kinetic and molecular modeling analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; NECROSIS-FACTOR-ALPHA; MONOCYTIC CELL-LINE; WEGENERS-GRANULOMATOSIS; SERINE PROTEINASE; BINDING-PROTEIN; CATHEPSIN-G; INHIBITOR; CLEAVAGE; DIFFERENTIATION	The biological functions of human neutrophil protease 3 ( Pr3) differ from those of neutrophil elastase despite their close structural and functional resemblance. Although both proteases are strongly cationic, their sequences differ mainly in the distribution of charged residues. We have used these differences in electrostatic surface potential in the vicinity of their active site to produce fluorescence resonance energy transfer ( FRET) peptide substrates for investigating individual Pr3 subsites. The specificities of subsites S5 to S3' were investigated both kinetically and by molecular dynamic simulations. Subsites S2, S1', and S2' were the main definers of Pr3 specificity. Combinations of results for each subsite were used to deduce a consensus sequence that was complementary to the extended Pr3 active site and was not recognized by elastase. Similar sequences were identified in natural protein substrates such as NF kappa B and p21 that are specifically cleaved by Pr3. FRET peptides derived from these natural sequences were specifically hydrolyzed by Pr3 with specificity constants k(cat)/K-m in the 10(6) M-1 S-1 range. The consensus Pr3 sequence may also be used to predict cleavage sites within putative protein targets like the proform of interleukin-18, or to develop specific Pr3 peptide-derived inhibitors, because none is available for further studies on the physiopathological function of this protease.	Fac Med Tours, INSERM, U618, F-37032 Tours, France; Univ Tours, F-37000 Tours, France; Univ Bergen, Bergen Ctr Computat Sci, Computat Biol Unit, N-5008 Bergen, Norway; Univ Fed Sao Paulo, Escola Paulista Med, Dept Biofis, BR-0404420 Sao Paulo, Brazil	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; University of Bergen; Universidade Federal de Sao Paulo (UNIFESP)	Gauthier, F (corresponding author), Fac Med Tours, INSERM, U618, 10 Bd Tonnelle, F-37032 Tours, France.	gauthier@univ-tours.fr	Reuter, Nathalie/G-2037-2012; Juliano, Luiz/D-7204-2012	Reuter, Nathalie/0000-0002-3649-7675; Juliano, Luiz/0000-0002-5589-2822; KORKMAZ, BRICE/0000-0002-5159-8706				Akita K, 1997, J BIOL CHEM, V272, P26595, DOI 10.1074/jbc.272.42.26595; Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Benson KF, 2003, NAT GENET, V35, P90, DOI 10.1038/ng1224; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BRUBAKER MJ, 1992, BIOCHEM BIOPH RES CO, V188, P1318, DOI 10.1016/0006-291X(92)91375-Z; Campbell EJ, 2000, J IMMUNOL, V165, P3366, DOI 10.4049/jimmunol.165.6.3366; Coeshott C, 1999, P NATL ACAD SCI USA, V96, P6261, DOI 10.1073/pnas.96.11.6261; DENGLER R, 1995, BRIT J HAEMATOL, V89, P250, DOI 10.1111/j.1365-2141.1995.tb03297.x; Duan ZJ, 2004, MOL CELL BIOL, V24, P58, DOI 10.1128/MCB.24.1.58-70.2004; Dublet B, 2005, J BIOL CHEM, V280, P30242, DOI 10.1074/jbc.M414609200; Fantuzzi G, 1999, J CLIN IMMUNOL, V19, P1, DOI 10.1023/A:1020506300324; Fujinaga M, 1996, J MOL BIOL, V261, P267, DOI 10.1006/jmbi.1996.0458; GOLDSCHMEDING R, 1989, J CLIN INVEST, V84, P1577, DOI 10.1172/JCI114335; Hajjar E, 2006, J MED CHEM, V49, P1248, DOI 10.1021/jm051018t; HECK LW, 1990, AM J PATHOL, V136, P1267; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; KAM CM, 1992, FEBS LETT, V297, P119, DOI 10.1016/0014-5793(92)80340-M; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; Koehl C, 2003, J BIOL CHEM, V278, P12609, DOI 10.1074/jbc.M210074200; Korkmaz B, 2002, J BIOL CHEM, V277, P39074, DOI 10.1074/jbc.M202918200; Korkmaz B, 2005, AM J RESP CELL MOL, V32, P553, DOI 10.1165/rcmb.2004-0374OC; Korkmaz B, 2004, AM J RESP CELL MOL, V30, P801, DOI 10.1165/rcmb.2003-0139OC; LESTIENNE P, 1980, J BIOL CHEM, V255, P9289; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; Pendergraft WF, 2004, KIDNEY INT, V65, P75, DOI 10.1111/j.1523-1755.2004.00364.x; PIPOLY DJ, 1987, BIOCHEMISTRY-US, V26, P5748, DOI 10.1021/bi00392a025; Preston GA, 2002, J AM SOC NEPHROL, V13, P2840, DOI 10.1097/01.ASN.0000034911.03334.C3; RAO NV, 1991, J BIOL CHEM, V266, P9540; RAO NV, 1993, AM J RESP CELL MOL, V8, P612, DOI 10.1165/ajrcmb/8.6.612; Rarok AA, 2003, J LEUKOCYTE BIOL, V74, P3, DOI 10.1189/jlb.1202611; ROBACHEGALLEA S, 1995, J BIOL CHEM, V270, P23688, DOI 10.1074/jbc.270.40.23688; SALVESEN G, 1991, BIOMED BIOCHIM ACTA, V50, P665; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SERVEAU C, 1992, FEBS LETT, V309, P405, DOI 10.1016/0014-5793(92)80817-Z; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P2238, DOI 10.1021/bi00382a025; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Sugawara S, 2005, CRIT REV IMMUNOL, V25, P343, DOI 10.1615/CritRevImmunol.v25.i5.10; VANDERWOUDE FJ, 1985, LANCET, V2, P48; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; Wiedow O, 2005, J INTERN MED, V257, P319, DOI 10.1111/j.1365-2796.2005.01476.x; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Witko-Sarsat V, 2002, J BIOL CHEM, V277, P47338, DOI 10.1074/jbc.M202789200	44	48	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1989	1997		10.1074/jbc.M608700200	http://dx.doi.org/10.1074/jbc.M608700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17088257	hybrid			2022-12-27	WOS:000243451300050
J	Kulinski, A; Vance, JE				Kulinski, Agnes; Vance, Jean E.			Lipid homeostasis and lipoprotein secretion in Niemann-Pick C1-deficient hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; DISEASE TYPE-C; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; APOLIPOPROTEIN-B SECRETION; ELEMENT-BINDING PROTEIN-1; CDP-CHOLINE PATHWAY; CHOLESTEROL HOMEOSTASIS; ENDOPLASMIC-RETICULUM; PHOSPHATIDYLCHOLINE SYNTHESIS	Niemann-Pick C (NPC) disease is a fatal inherited disorder characterized by an accumulation of cholesterol and other lipids in late endosomes/lysosomes. Although this disease is considered to be primarily a neurodegenerative disorder, many NPC patients suffer from liver disease. We have investigated alterations that occur in hepatic lipid homeostasis using primary hepatocytes isolated from NPC1-deficient mice. The cholesterol content of Npc1(-/-) hepatocytes was 5-fold higher than that of Npc1(-/-) hepatocytes; phospholipids and cholesteryl esters also accumulated. In contrast, the triacylglycerol content of Npc1(-/-) hepatocytes was 50% lower than of Npc1(+/+) hepatocytes. We hypothesized that the cholesterol sequestration induced by NPC1 deficiency might inhibit very low density lipoprotein secretion. However, this process was enhanced by NPC1 deficiency and the secreted particles were enriched in cholesteryl esters. We investigated the mechanisms responsible for these changes. The synthesis of phosphatidylcholine, cholesteryl esters, and cholesterol in hepatocytes was increased by NPC1 deficiency and the amount of the mature form of sterol response element-binding protein-1 was also increased. These observations indicate that the enhanced secretion of lipoproteins from NPC1-deficient hepatocytes is due, at least in part, to increased lipid synthesis.	Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada.	jean.vance@ualberta.ca						Amigo L, 2002, HEPATOLOGY, V36, P819, DOI 10.1053/jhep.2002.35617; Beltroy EP, 2005, HEPATOLOGY, V42, P886, DOI 10.1002/hep.20868; Boadu E, 2006, J BIOL CHEM, V281, P37081, DOI 10.1074/jbc.M606890200; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BREMER J, 1961, BIOCHIM BIOPHYS ACTA, V46, P205, DOI 10.1016/0006-3002(61)90745-4; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; Choi HY, 2003, J BIOL CHEM, V278, P32569, DOI 10.1074/jbc.M304553200; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; CUI Z, 1993, J BIOL CHEM, V268, P16655; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DAVIS RA, 1985, J BIOL CHEM, V260, P4137; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; Du XM, 2004, J BIOL CHEM, V279, P47010, DOI 10.1074/jbc.M408690200; ELOVSON J, 1988, J LIPID RES, V29, P1461; Folch J., 1959, J BIOL CHEM, V226, P495; Frolov A, 2003, J BIOL CHEM, V278, P25517, DOI 10.1074/jbc.M302588200; GOLDIN E, 1992, BIOCHIM BIOPHYS ACTA, V1127, P303, DOI 10.1016/0005-2760(92)90236-O; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Holtta-Vuori M, 2002, MOL BIOL CELL, V13, P3107, DOI 10.1091/mbc.E02-01-0025; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jacobs RL, 2004, J BIOL CHEM, V279, P47402, DOI 10.1074/jbc.M404027200; Karten B, 2002, J NEUROCHEM, V83, P1154, DOI 10.1046/j.1471-4159.2002.01220.x; Karten B, 2005, BIOCHEM J, V387, P779, DOI 10.1042/BJ20041694; Karten B, 2003, J BIOL CHEM, V278, P4168, DOI 10.1074/jbc.M205406200; KELLY DA, 1993, J PEDIATR-US, V123, P242, DOI 10.1016/S0022-3476(05)81695-6; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kulinski A, 2004, J BIOL CHEM, V279, P23916, DOI 10.1074/jbc.M312676200; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Mari M, 2006, CELL METAB, V4, P185, DOI 10.1016/j.cmet.2006.07.006; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; PATSCH W, 1983, J CLIN INVEST, V72, P371, DOI 10.1172/JCI110977; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PENTCHEV PG, 1995, METABOLIC MOL BASES; PITTMAN RC, 1984, J LIPID RES, V25, P1577; Puri V, 2003, J BIOL CHEM, V278, P20961, DOI 10.1074/jbc.M300304200; Ridgway ND, 2003, BIOCHEM J, V372, P811, DOI 10.1042/BJ20030252; ROFF CF, 1992, AM J MED GENET, V42, P593, DOI 10.1002/ajmg.1320420433; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; SOKOL J, 1988, J BIOL CHEM, V263, P3411; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE DE, 1979, TRENDS BIOCHEM SCI, V4, P145, DOI 10.1016/0968-0004(79)90001-X; VANCE JE, 2002, BIOCH LIPIDS LIPOPRO, P505; Vanier MT, 2003, CLIN GENET, V64, P269, DOI 10.1034/j.1399-0004.2003.00147.x; VANIER MT, 1983, BIOCHIM BIOPHYS ACTA, V750, P178, DOI 10.1016/0005-2760(83)90218-7; Wang SL, 1997, J BIOL CHEM, V272, P19351, DOI 10.1074/jbc.272.31.19351; Wang Y, 2005, J BIOL CHEM, V280, P11876, DOI 10.1074/jbc.M414676200; Watanabe Y, 1998, BRAIN DEV-JPN, V20, P95, DOI 10.1016/S0387-7604(97)00113-7; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805; Watari H, 1999, J BIOL CHEM, V274, P21861, DOI 10.1074/jbc.274.31.21861; Xie CL, 1999, P NATL ACAD SCI USA, V96, P11992, DOI 10.1073/pnas.96.21.11992; YAO ZM, 1988, J BIOL CHEM, V263, P2998; Yerushalmi B, 2002, J PEDIATR GASTR NUTR, V35, P44, DOI 10.1097/00005176-200207000-00011; Yu WX, 2005, J BIOL CHEM, V280, P11731, DOI 10.1074/jbc.M412898200; Zervas M, 2001, CURR BIOL, V11, P1283, DOI 10.1016/S0960-9822(01)00396-7; ZHOU X, 1992, J LIPID RES, V33, P1233	66	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1627	1637		10.1074/jbc.M610001200	http://dx.doi.org/10.1074/jbc.M610001200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17107950	hybrid			2022-12-27	WOS:000243451300014
J	Liao, JJ; Huang, MC; Graler, M; Huang, Y; Qiu, H; Goetzl, EJ				Liao, Jia-Jun; Huang, Mei-Chuan; Graler, Markus; Huang, Yong; Qiu, Hong; Goetzl, Edward J.			Distinctive T cell-suppressive signals from nuclearized type 1 sphingosine 1-phosphate G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CUTTING EDGE; SPHINGOSINE-1-PHOSPHATE; EXPRESSION; ENDOCYTOSIS; SPHINGOLIPIDS; CHEMOTAXIS; MODULATION; ACTIVATION; ROLES	Sphingosine 1-phosphate ( S1P) generated by cells of innate immunity and the type 1 S1P G protein-coupled receptor ( S1P(1)) on mobile T cells constitute a major system for control of lymphoid organ traffic and tissue migration of T cells. Now we show that T cell activation mediated by the T cell antigen receptor translocates plasma membrane S1P1 to nuclear envelope membranes for association there with G(i/o), Erk 1/2, and other proteins that plasma membrane S1P(1) uses to signal T cell proliferation. However, nuclear S1P(1) and plasma membrane S1P(1) transduce opposite effects of S1P on T cell proliferation and relevant signaling as exemplified by respective decreases and increases in T cell nuclear concentrations of both phospho-Erk and active ( phosphorylated) c-Jun. T cell antigen receptor-mediated activation of T cells therefore both eliminates migration responses to S1P by down-regulation of plasma membrane S1P(1) and translocates the S1P-S1P(1) axis into the nuclear domain where signals are directed to transcriptional control of immune functions other than migration.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Hannover Med Sch, Inst Immunol, D-30625 Hannover, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Hannover Medical School	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med, Rm UB8B,UC Box 0711,533 Parnassus 4th Ave, San Francisco, CA 94143 USA.	edward.goetzl@ucsf.edu	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809, P01HL068738] Funding Source: NIH RePORTER; NHLBI NIH HHS [P0-1 HL68738, R0-1 HL31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albi E, 2004, BIOL CELL, V96, P657, DOI 10.1016/j.biolcel.2004.05.004; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Dorsam G, 2003, J IMMUNOL, V171, P3500, DOI 10.4049/jimmunol.171.7.3500; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fieger CB, 2005, FASEB J, V19, P1926, DOI 10.1096/fj.05-4476fje; Fischer AM, 2005, IMMUNITY, V23, P431, DOI 10.1016/j.immuni.2005.08.013; Gobeil F, 2003, J BIOL CHEM, V278, P38875, DOI 10.1074/jbc.M212481200; Gobeil F, 2006, J BIOL CHEM, V281, P16058, DOI 10.1074/jbc.M602219200; Goetzl EJ, 2004, J CLIN INVEST, V114, P1531, DOI 10.1172/JCI200423704; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Graeler MH, 2003, J BIOL CHEM, V278, P27737, DOI 10.1074/jbc.C300147200; Grahler MH, 2005, J IMMUNOL, V174, P1997; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Ledeen RW, 2006, BBA-MOL CELL BIOL L, V1761, P588, DOI 10.1016/j.bbalip.2006.04.010; Lee DK, 2004, J BIOL CHEM, V279, P7901, DOI 10.1074/jbc.M306377200; Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; Nekrasova T, 2005, J IMMUNOL, V175, P2374, DOI 10.4049/jimmunol.175.4.2374; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; Reif K, 2004, J IMMUNOL, V173, P2236, DOI 10.4049/jimmunol.173.4.2236; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640; Shida D, 2004, FEBS LETT, V577, P333, DOI 10.1016/j.febslet.2004.10.024; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Tanimoto T, 2004, CIRC RES, V94, P1050, DOI 10.1161/01.RES.0000126404.41421.BE; Zhang ZX, 2004, J BIOL CHEM, V279, P33937, DOI 10.1074/jbc.M403404200	31	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1964	1972		10.1074/jbc.M608597200	http://dx.doi.org/10.1074/jbc.M608597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121832	hybrid			2022-12-27	WOS:000243451300047
J	Mandicourt, G; Iden, S; Ebnet, K; Aurrand-Lions, M; Imhof, BA				Mandicourt, Guillaume; Iden, Sandra; Ebnet, Klaus; Aurrand-Lions, Michel; Imhof, Beat A.			JAM-C regulates tight junctions and integrin-mediated cell adhesion and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; PROTEIN-KINASE-C; IMMUNOGLOBULIN SUPERFAMILY; MOLECULE JAM; ENDOTHELIAL-CELLS; FAMILY-MEMBERS; POLARITY; COMPLEX; LIGAND; RECRUITMENT	Junctional Adhesion Molecules (JAMs) have been described as major components of tight junctions in endothelial and epithelial cells. Tight junctions are crucial for the establishment and maintenance of cell polarity. During tumor development, they are remodeled, enabling neoplastic cells to escape from constraints imposed by intercellular junctions and to adopt a migratory behavior. Using a carcinoma cell line we tested whether JAM-C could affect tight junctions and migratory properties of tumor cells. We show that transfection of JAM-C improves the tight junctional barrier in tumor cells devoid of JAM-C expression. This is dependent on serine 281 in the cytoplasmic tail of JAM-C because serine mutation into alanine abolishes the specific localization of JAM-C in tight junctions and establishment of cell polarity. More importantly, the same mutation stimulates integrin-mediated cell migration and adhesion via the modulation of beta 1 and beta 3 integrin activation. These results highlight an unexpected function for JAM-C in controlling epithelial cell conversion from a static, polarized state to a pro-migratory phenotype.	Univ Geneva, Med Ctr, Dept Pathol & Immunol, CH-1211 Geneva 4, Switzerland; Univ Munster, Inst Med Biochem, Ctr Mol Biol Inflammat, D-48149 Munster, Germany	University of Geneva; University of Munster	Imhof, BA (corresponding author), Univ Geneva, Med Ctr, Dept Pathol & Immunol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	beat.imhof@medecine.unige.ch	Ebnet, Klaus T/C-8314-2009; Iden, Sandra/I-1585-2012; Iden, Sandra/ABB-2698-2021; Aurrand-Lions, Michel/O-9953-2016	Ebnet, Klaus T/0000-0002-0417-7888; Iden, Sandra/0000-0003-2333-9827; Aurrand-Lions, Michel/0000-0002-8361-3034				Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Birchmeier C, 1996, ACTA ANAT, V156, P217; Chavakis T, 2003, THROMB HAEMOSTASIS, V89, P13; Cunningham SA, 2002, J BIOL CHEM, V277, P27589, DOI 10.1074/jbc.C200331200; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Forteza R, 2005, AM J RESP CELL MOL, V32, P462, DOI 10.1165/rcmb.2004-0302OC; Gliki G, 2004, NATURE, V431, P320, DOI 10.1038/nature02877; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hay ED, 1995, ACTA ANAT, V154, P8; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; KANEKO T, 1980, IN VITRO CELL DEV B, V16, P884, DOI 10.1007/BF02619426; Lamagna C, 2005, MOL BIOL CELL, V16, P4992, DOI 10.1091/mbc.E05-04-0310; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Ostermann G, 2005, ARTERIOSCL THROM VAS, V25, P729, DOI 10.1161/01.ATV.0000157154.14474.3b; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Ozaki H, 1999, J IMMUNOL, V163, P553; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Rehder D, 2006, EXP CELL RES, V312, P3389, DOI 10.1016/j.yexcr.2006.07.004; Roh MH, 2002, J BIOL CHEM, V277, P27501, DOI 10.1074/jbc.M201177200; Santoso S, 2005, J BIOL CHEM, V280, P36326, DOI 10.1074/jbc.M505059200; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wehrle-Haller B, 2002, TRENDS CELL BIOL, V12, P382, DOI 10.1016/S0962-8924(02)02321-8; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; Zegers MMP, 2003, TRENDS CELL BIOL, V13, P169, DOI 10.1016/S0962-8924(03)00036-9; Zen K, 2004, MOL BIOL CELL, V15, P3926, DOI 10.1091/mbc.E04-04-0317	45	67	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1830	1837		10.1074/jbc.M605666200	http://dx.doi.org/10.1074/jbc.M605666200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17099249	hybrid			2022-12-27	WOS:000243451300034
J	Abaffy, T; Malhotra, A; Luetje, CW				Abaffy, Tatjana; Malhotra, Arun; Luetje, Charles W.			The molecular basis for ligand specificity in a mouse olfactory receptor - A network of functionally important residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ODORANT-BINDING-SITE; STRUCTURAL BASIS; DISULFIDE BOND; RHODOPSIN; PREDICTION; SYSTEM; IDENTIFICATION; RECOGNITION; MECHANISMS	Sequence differences between members of the mouse olfactory receptor MOR42 subfamily (MOR42-3 and MOR42-1) are likely to be the basis for variation in ligand binding preference among these receptors. We investigated the specificity of MOR42-3 for a variety of dicarboxylic acids. We used site-directed mutagenesis, guided by homology modeling and ligand docking studies, to locate functionally important residues. Receptors were expressed in Xenopus oocytes and assayed using high throughput electrophysiology. The importance of the Val-113 residue, located deep within the receptor, was analyzed in the context of interhelical interactions. We also screened additional residues predicted to be involved in ligand binding site, based on comparison of ortholog/paralog pairs from the mouse and human olfactory receptor genomes (Man, O., Gilad, Y., and Lancet, D. (2004) Protein Sci. 13, 240 - 254). A network of 8 residues in transmembrane domains III, V, and VI was identified. These residues form part of the ligand binding pocket of MOR42-3. C12 dicarboxylic acid did not activate the receptor in our functional assay, yet our docking simulations predicted its binding site in MOR42-3. Binding without activation implied that C12 dicarboxylic acid might act as an antagonist. In our functional assay, C12 dicarboxylic acid did indeed act as an antagonist of MOR42-3, in agreement with molecular docking studies. Our results demonstrate a powerful approach based on the synergy between computational predictions and physiological assays.	Univ Miami, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA; Univ Miami, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami; University of Miami	Abaffy, T (corresponding author), Univ Miami, Dept Mol & Cellular Pharmacol, POB 016189, Miami, FL 33101 USA.	tabaffy@med.miami.edu	Malhotra, Arun/A-3916-2008; Abaffy, Tatjana/C-2071-2015; Malhotra, Arun/Z-5140-2019	Malhotra, Arun/0000-0001-6656-7841; Malhotra, Arun/0000-0001-6656-7841	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH066038] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM69972] Funding Source: Medline; NIMH NIH HHS [MH66038] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abaffy T, 2006, J NEUROCHEM, V97, P1506, DOI 10.1111/j.1471-4159.2006.03859.x; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; DeLano W.L, PYMOL MOL GRAPHICS S; Dima RI, 2006, PROTEIN SCI, V15, P258, DOI 10.1110/ps.051767306; DuchampViret P, 1997, PROG NEUROBIOL, V53, P561, DOI 10.1016/S0301-0082(97)00049-X; Firestein S, 2001, NATURE, V413, P211, DOI 10.1038/35093026; Floriano WB, 2004, CHEM SENSES, V29, P269, DOI 10.1093/chemse/bjh030; Floriano WB, 2000, P NATL ACAD SCI USA, V97, P10712, DOI 10.1073/pnas.97.20.10712; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Hall SE, 2004, CHEM SENSES, V29, P595, DOI 10.1093/chemse/bjh063; Hobrath JV, 2006, J MED CHEM, V49, P4470, DOI 10.1021/jm0501634; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; Javitch JA, 1995, BIOCHEMISTRY-US, V34, P16433, DOI 10.1021/bi00050a026; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katada S, 2005, J NEUROSCI, V25, P1806, DOI 10.1523/jneurosci.4723-04.2005; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewcock JW, 2004, P NATL ACAD SCI USA, V101, P1069, DOI 10.1073/pnas.0307986100; Madabushi S, 2002, J MOL BIOL, V316, P139, DOI 10.1006/jmbi.2001.5327; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Man O, 2004, PROTEIN SCI, V13, P240, DOI 10.1110/ps.03296404; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Mombaerts P, 1999, ANNU REV NEUROSCI, V22, P487, DOI 10.1146/annurev.neuro.22.1.487; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Oka Y, 2004, EMBO J, V23, P120, DOI 10.1038/sj.emboj.7600032; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Oliveira L, 2002, CHEMBIOCHEM, V3, P1010, DOI 10.1002/1439-7633(20021004)3:10<1010::AID-CBIC1010>3.0.CO;2-T; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pilpel Y, 1999, PROTEIN SCI, V8, P969, DOI 10.1110/ps.8.5.969; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schild D, 1998, PHYSIOL REV, V78, P429, DOI 10.1152/physrev.1998.78.2.429; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Serizawa S, 2000, NAT NEUROSCI, V3, P687, DOI 10.1038/76641; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Shirokova E, 2005, J BIOL CHEM, V280, P11807, DOI 10.1074/jbc.M411508200; Singer MS, 2000, CHEM SENSES, V25, P155, DOI 10.1093/chemse/25.2.155; SINGER MS, 1995, RECEPTOR CHANNEL, V3, P89; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; Tsai J, 1999, J MOL BIOL, V290, P253, DOI 10.1006/jmbi.1999.2829; Vaidehi N, 2002, P NATL ACAD SCI USA, V99, P12622, DOI 10.1073/pnas.122357199; VANGUNSTEREN WF, 1992, EUR J BIOCHEM, V204, P947; Varady J, 2003, J MED CHEM, V46, P4377, DOI 10.1021/jm030085p; Vullo A, 2004, BIOINFORMATICS, V20, P653, DOI 10.1093/bioinformatics/btg463; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Zelano C, 2005, NEURON, V48, P431, DOI 10.1016/j.neuron.2005.10.009; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800; Zozulya S, 2001, GENOME BIOL, V2	50	77	78	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1216	1224		10.1074/jbc.M609355200	http://dx.doi.org/10.1074/jbc.M609355200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17114180	hybrid			2022-12-27	WOS:000243295200047
J	Bignone, PA; King, MDA; Pinder, JC; Baines, AJ				Bignone, Paola A.; King, Mikayala D. A.; Pinder, Jennifer C.; Baines, Anthony J.			Phosphorylation of a threonine unique to the short C-terminal isoform of beta II-spectrin links regulation of alpha-beta spectrin interaction to neuritogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL SPECTRIN; SELF-ASSOCIATION; ERYTHROCYTE SPECTRIN; PROTEIN-KINASES; AXON OUTGROWTH; GROWTH-FACTOR; SITE; IDENTIFICATION; MEMBRANE; BRAIN	Spectrin tetramers are cytoskeletal proteins required in the formation of complex animal tissues. Mammalian alpha II- and beta II-spectrin subunits form dimers that associate head to head with high affinity to form tetramers, but it is not known if this interaction is regulated. We show here that the short C-terminal splice variant of beta II-spectrin (beta II Sigma 2) is a substrate for phosphorylation. In vitro, protein kinase CK2 phosphorylates Ser-2110 and Thr-2159; protein kinase A phosphorylates Thr-2159. Anti-phospho-Thr-2159 peptide antibody detected phosphorylated beta II Sigma 2 in Cos-1 cells. Immunoreactivity was increased in Cos-1 cells by treatment with forskolin, indicating that phosphorylation is promoted by elevated cAMP. The effect of forskolin was counteracted by the cAMP-dependent kinase inhibitor, H89. In vitro, protein kinase A phosphorylation of an active fragment of beta II Sigma 2 greatly reduced its interaction with beta II-spectrin at the tetramerization site. Mutation of Thr-2159 to alanine eliminated inhibition by phosphorylation. Among the processes that require spectrin in mammals is the formation of neurites (incipient nerve axons). We tested the relationship of spectrin phosphorylation to neuritogenesis by transfecting the neuronal cell line, PC12, with enhanced green fluorescent protein-coupled fragments of beta II Sigma 2-spectrin predicted to act as inhibitors of spectrin tetramer formation. Both wild-type and T2159E mutant fragments allowed normal neuritogenesis in PC12 cells in response to nerve growth factor. The mutant T2159A inhibited neuritogenesis. Because the T2159A mutant represents a high affinity inhibitor of tetramer formation, we conclude that tetramers are requisite for neuritogenesis. Furthermore, because both the T2159E mutant and the wild-type allow neuritogenesis, we conclude that the short C-terminal beta II-spectrin is phosphorylated during this process.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Kings Coll London, Randal Ctr Mol Mech Cell Funct, London SE1 1UL, England	University of Kent; University of London; King's College London	Baines, AJ (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.	A.J.Baines@kent.ac.uk	Bignone, Paola/K-3797-2012	Baines, Anthony/0000-0003-3068-7811; Bignone, Paola/0000-0003-2296-7039; King, Mikayala/0000-0001-5191-4679	Biotechnology and Biological Sciences Research Council [C18062] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		An XL, 2002, J BIOL CHEM, V277, P31796, DOI 10.1074/jbc.M204567200; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bignone PA, 2003, BIOCHEM J, V374, P613, DOI 10.1042/BJ20030507; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; Chierzi S, 2005, EUR J NEUROSCI, V21, P2051, DOI 10.1111/j.1460-9568.2005.04066.x; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hammarlund M, 2000, J CELL BIOL, V149, P931, DOI 10.1083/jcb.149.4.931; HARLOW E, 1988, ANTIBODIES LABORATOR, P312; Hayes NVL, 2000, J CELL SCI, V113, P2023; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kersey PJ, 2004, PROTEOMICS, V4, P1985, DOI 10.1002/pmic.200300721; KOTULA L, 1993, J BIOL CHEM, V268, P14788; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; Nishimura K, 2003, J CELL BIOL, V163, P1077, DOI 10.1083/jcb.200303060; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Porter GA, 1997, CELL MOTIL CYTOSKEL, V37, P7, DOI 10.1002/(SICI)1097-0169(1997)37:1<7::AID-CM2>3.0.CO;2-7; ROACH PJ, 1984, METHOD ENZYMOL, V107, P81; Rodger J, 2005, MOL CELL NEUROSCI, V30, P452, DOI 10.1016/j.mcn.2005.08.009; Salomao M, 2006, P NATL ACAD SCI USA, V103, P643, DOI 10.1073/pnas.0507661103; SHAHBAKHTI F, 1986, BIOCHEMISTRY-US, V25, P5969, DOI 10.1021/bi00368a020; Sihag RK, 1998, J NEUROCHEM, V71, P2220; Sihag RK, 1996, J NEUROSCI RES, V44, P430, DOI 10.1002/(SICI)1097-4547(19960601)44:5<430::AID-JNR3>3.0.CO;2-G; Snider WD, 2002, NEURON, V35, P13, DOI 10.1016/S0896-6273(02)00762-6; SOBUE K, 1989, NEURON, V3, P311, DOI 10.1016/0896-6273(89)90255-9; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; Tang HY, 2004, BIOCHEMISTRY-US, V43, P4251, DOI 10.1021/bi036092x; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2002, ONCOGENE, V21, P5255, DOI 10.1038/sj.onc.1205548; Taylor-Harris PM, 2005, CELL MOL BIOL LETT, V10, P135; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; UNGEWICKELL E, 1978, EUR J BIOCHEM, V88, P379, DOI 10.1111/j.1432-1033.1978.tb12459.x; Ursitti JA, 2001, DEV BRAIN RES, V129, P81, DOI 10.1016/S0165-3806(01)00160-2; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; VIEL A, 1994, P NATL ACAD SCI USA, V91, P10839, DOI 10.1073/pnas.91.23.10839; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	42	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					888	896		10.1074/jbc.M605920200	http://dx.doi.org/10.1074/jbc.M605920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17088250	hybrid			2022-12-27	WOS:000243295200011
J	Leung, KF; Baron, R; Ali, BR; Magee, AI; Seabra, MC				Leung, Ka Fai; Baron, Rudi; Ali, Bassam R.; Magee, Anthony I.; Seabra, Miguel C.			Rab GTPases containing a CAAX motif are processed post-geranylgeranylation by proteolysis and methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL METHYLTRANSFERASE; PROTEINS; GERANYLGERANYLTRANSFERASE; TRANSFERASE; ACTIVATION; TARGETS; GENE	Post-translational modification by protein prenylation is required for membrane targeting and biological function of monomeric GTPases. Ras and Rho proteins possess a C-terminal CAAX motif (C is cysteine, A is usually an aliphatic residue, and X is any amino acid), in which the cysteine is prenylated, followed by proteolytic cleavage of the AAX peptide and carboxyl methylation by the Rce1 CAAX protease and Icmt methyltransferase, respectively. Rab GTPases usually undergo double geranylgeranylation within CC or CXC motifs. However, very little is known about processing and membrane targeting of Rabs that naturally contain a CAAX motif. We show here that a variety of Rab-CAAX proteins undergo carboxyl methylation, both in vitro and in vivo, with one exception. Rab38(CAKS) is not methylated in vivo, presumably because of the inhibitory action of the lysine residue within the AAX motif for cleavage by Rce1. Unlike farnesylated Ras proteins, we observed no targeting defects of overexpressed Rab-CAAX proteins in cells deficient in Rce1 or Icmt, as reported for geranylgeranylated Rho proteins. However, endogenous geranylgeranylated non-methylated Rab-CAAX and Rab-CXC proteins were significantly redistributed to the cytosol at steady-state levels and redistribution correlates with higher affinity of RabGDI for non-methylated Rabs in Icmt-deficient cells. Our data suggest a role for methylation in Rab function by regulating the cycle of Rab membrane recruitment and retrieval. Our findings also imply that those Rabs that undergo post-prenylation processing follow an indirect targeting pathway requiring initial endoplasmic reticulum membrane association prior to specific organelle targeting.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Mol & Cellular Med Sect, London SW7 2AZ, England	Imperial College London	Seabra, MC (corresponding author), Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	kfl28@cam.ac.uk; m.seabra@imperial.ac.uk	Seabra, Miguel/AAC-3099-2019; Ali, Bassam/J-7014-2012; Magee, Anthony/V-8345-2019; Seabra, Miguel C/M-3280-2013	Seabra, Miguel C/0000-0002-6404-4892; Ali, Bassam R/0000-0003-1306-6618	MRC [G0100471] Funding Source: UKRI; Medical Research Council [G0100471] Funding Source: Medline; Wellcome Trust [075498] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		ANDO S, 1992, J BIOL CHEM, V267, P25709; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; Armstrong J, 1996, J CELL SCI, V109, P1265; ARMSTRONG SA, 1995, METHOD ENZYMOL, V257, P30; Backlund PS, 1997, J BIOL CHEM, V272, P33175, DOI 10.1074/jbc.272.52.33175; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; Chiu VK, 2004, J BIOL CHEM, V279, P7346, DOI 10.1074/jbc.M311602200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; Gomes AQ, 2003, MOL BIOL CELL, V14, P1882, DOI 10.1091/mbc.E02-10-0639; JOBERTY G, 1993, FEBS LETT, V330, P323, DOI 10.1016/0014-5793(93)80897-4; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Lane KT, 2006, J LIPID RES, V47, P681, DOI 10.1194/jlr.R600002-JLR200; Leung KF, 2006, J LIPID RES, V47, P467, DOI 10.1194/jlr.R500017-JLR200; Michaelson D, 2005, MOL BIOL CELL, V16, P1606, DOI 10.1091/mbc.e04-11-0960; NEWMAN CMH, 1992, J BIOL CHEM, V267, P11329; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; Seabra MC, 2004, CURR OPIN CELL BIOL, V16, P451, DOI 10.1016/j.ceb.2004.06.014; Seabra MC, 1998, METH MOL B, V84, P251; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; SMELAND TE, 1994, P NATL ACAD SCI USA, V91, P10712, DOI 10.1073/pnas.91.22.10712; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Thoma NH, 2001, J BIOL CHEM, V276, P48637, DOI 10.1074/jbc.M108241200; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Wright LP, 2006, J LIPID RES, V47, P883, DOI 10.1194/jlr.R600004-JLR200	29	62	67	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1487	1497		10.1074/jbc.M605557200	http://dx.doi.org/10.1074/jbc.M605557200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17114793	hybrid			2022-12-27	WOS:000243295200073
J	Olave, IA; Doneanu, C; Fang, XD; Stamatoyannopoulos, G; Li, QL				Olave, Ivan A.; Doneanu, Catalin; Fang, Xiangdong; Stamatoyannopoulos, George; Li, Qiliang			Purification and identification of proteins that bind to the hereditary persistence of fetal hemoglobin - 198 mutation in the gamma-globin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; DNA AFFINITY-CHROMATOGRAPHY; TRANSCRIPTION FACTORS; POLYACRYLAMIDE-GELS; MASS-SPECTROMETRY; REPLICATION FOCI; TRANSGENIC MICE; METHYLATION; COMPLEX; DNMT1	Expression of the gamma-globin gene is silenced in adult humans. However, certain point mutations in the gamma-globin gene promoter are capable of maintaining expression of this gene during adult erythropoiesis, a condition called non-deletion hereditary persistence of fetal hemoglobin (HPFH). Among these, the British form of HPFH carrying a T -> C point mutation at position -198 of the A gamma-globin gene promoter results in 4-10% fetal hemoglobin in heterozygotes. In this study, we used nuclear extracts from murine erythroleukemia cells to purify a protein complex that binds the HPFH -198 gamma-globin gene promoter. Members of this protein complex were identified by mass spectrometry and include DNMT1, the transcriptional coactivator p52, the protein SNEV, and RAP74 (the largest subunit of the general transcription factor IIF). Sp1, which was previously considered responsible for HPFH similar to 198 gamma-globin gene activation, was not identified. The potential role of these proteins in the reactivation and/or maintenance of gamma-globin gene expression in the adult transcriptional environment is discussed.	Univ Washington, Div Med Genet, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Med Chem, Mass Spectrometry Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Li, QL (corresponding author), Univ Washington, Div Med Genet, Dept Med, POB 357720, Seattle, WA 98195 USA.	li111640@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045365, R56DK045365, R01DK045365, R01DK061805] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL73439, R01 HL073439] Funding Source: Medline; NIDDK NIH HHS [DK45365, R37 DK045365, DK61805, R56 DK045365, R01 DK045365-06S1, R37 DK045365-07S1, R01 DK061805, R01 DK045365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ajuh P, 2000, EMBO J, V19, P6569, DOI 10.1093/emboj/19.23.6569; Bernstein HS, 1997, J BIOL CHEM, V272, P5833, DOI 10.1074/jbc.272.9.5833; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brand M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/nsmb713; CHANG CH, 1993, J BIOL CHEM, V268, P20482; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; FISCHER KD, 1990, NUCLEIC ACIDS RES, V18, P5685, DOI 10.1093/nar/18.19.5685; FLORES O, 1989, J BIOL CHEM, V264, P8913; Forget BG, 1998, ANN NY ACAD SCI, V850, P38, DOI 10.1111/j.1749-6632.1998.tb10460.x; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fujita N, 2003, MOL CELL BIOL, V23, P2834, DOI 10.1128/MCB.23.8.2834-2843.2003; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Gadgil H, 2001, ANAL BIOCHEM, V290, P147, DOI 10.1006/abio.2000.4912; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; Gotzmann J, 2000, EXP CELL RES, V261, P166, DOI 10.1006/excr.2000.5025; GUMUCIO DL, 1991, BLOOD, V78, P1853; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; Hirayama T, 1996, P NATL ACAD SCI USA, V93, P13371, DOI 10.1073/pnas.93.23.13371; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; KERRIGAN LA, 1996, CURRENT PROTOCOLS MO; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Lei L, 1998, MOL CELL BIOL, V18, P2130, DOI 10.1128/MCB.18.4.2130; Li QL, 2001, EMBO J, V20, P157, DOI 10.1093/emboj/20.1.157; Liu LR, 2005, J BIOL CHEM, V280, P7452, DOI 10.1074/jbc.M411407200; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Milutinovic S, 2004, J BIOL CHEM, V279, P27915, DOI 10.1074/jbc.M312823200; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; OLAVE I, 1997, MRNA METABOLISM POST, P23; PETERSON KR, 1995, P NATL ACAD SCI USA, V92, P5655, DOI 10.1073/pnas.92.12.5655; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; RONCHI A, 1989, NUCLEIC ACIDS RES, V17, P10231, DOI 10.1093/nar/17.24.10231; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Singh DP, 2000, GENE, V242, P265, DOI 10.1016/S0378-1119(99)00506-5; STAMATOYANNOPOU.G, 2001, HEMOGLOBIN SWITCHI 2; Sun ZJ, 1999, CANCER-AM CANCER SOC, V86, P689, DOI 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO;2-P; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	49	8	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					853	862		10.1074/jbc.M610404200	http://dx.doi.org/10.1074/jbc.M610404200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17114178	Green Accepted, hybrid			2022-12-27	WOS:000243295200007
J	Prohinar, P; Re, F; Widstrom, R; Zhang, DS; Teghanemt, A; Weiss, JP; Gioannini, TL				Prohinar, Polonca; Re, Fabio; Widstrom, Richard; Zhang, DeSheng; Teghanemt, Athmane; Weiss, Jerrold P.; Gioannini, Theresa L.			Specific high affinity interactions of monomeric endotoxin center dot protein complexes with Toll-like receptor 4 ectodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING; NEISSERIA-MENINGITIDIS; RECEPTOR 4-MD-2; MD-2 BINDS; CD14; TLR4; LPS; RESPONSIVENESS; RECOGNITION; CONFERS	Potent Toll-like receptor 4 (TLR4) activation by endotoxin has been intensely studied, but the molecular requirements for endotoxin interaction with TLR4 are still incompletely defined. Ligand-receptor interactions involving endotoxin and TLR4 were characterized using monomeric endotoxin(.)protein complexes of high specific radioactivity. The binding of endotoxin(.)MD-2 to the TLR4 ectodomain (TLR4(ECD)) and transfer of endotoxin from CD14 to MD-2/TLR4(ECD) were demonstrated using HEK293T-conditioned medium containing TLR4(ECD)+/- MD-2. These interactions are specific, of high affinity (K-D < 300 pM), and consistent with the molecular requirements for potent cell activation by endotoxin. Both reactions result in the formation of a M-r similar to 190,000 complex composed of endotoxin, MD-2, and TLR4(ECD). CD14 facilitates transfer of endotoxin to MD-2(TLR4) but is not a stable component of the endotoxin(.)MD-2/TLR4 complex. The ability to assay specific high affinity interactions of monomeric endotoxin(.)protein complexes with TLR4(ECD) should allow better definition of the structural requirements for endotoxin-induced TLR4 activation.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Inflammat Program, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52246 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Tennessee System; University of Tennessee Health Science Center	Gioannini, TL (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, 2501 Crosspk Rd, Coralville, IA 52241 USA.	theresa-gioannini@uiowa.edu		Weiss, Jerrold/0000-0003-1476-4485	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054665, R01AI059372] Funding Source: NIH RePORTER; NIAID NIH HHS [AI59372, R21 AI54665] Funding Source: Medline; PHS HHS [P0144642] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abreu MT, 2002, J BIOL CHEM, V277, P20431, DOI 10.1074/jbc.M110333200; Akashi S, 2000, BIOCHEM BIOPH RES CO, V268, P172, DOI 10.1006/bbrc.2000.2089; Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; Beutler B, 2003, ANNU REV PHARMACOL, V43, P609, DOI 10.1146/annurev.pharmtox.43.100901.135729; Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552; Coats SR, 2005, J IMMUNOL, V175, P4490, DOI 10.4049/jimmunol.175.7.4490; Dauphinee SM, 2006, LAB INVEST, V86, P9, DOI 10.1038/labinvest.3700366; Dunzendorfer S, 2004, FASEB J, V18, P1117, DOI 10.1096/fj.03-1263fje; Fitzgerald KA, 2004, MICROBES INFECT, V6, P1361, DOI 10.1016/j.micinf.2004.08.015; Gay NJ, 2006, NAT REV IMMUNOL, V6, P693, DOI 10.1038/nri1916; Giardina PC, 2001, J BIOL CHEM, V276, P5883, DOI 10.1074/jbc.M009273200; Gioannini TL, 2005, J ENDOTOXIN RES, V11, P117, DOI 10.1179/096805105X35198; Gioannini TL, 2002, J BIOL CHEM, V277, P47818, DOI 10.1074/jbc.M206404200; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Hyakushima N, 2004, J IMMUNOL, V173, P6949, DOI 10.4049/jimmunol.173.11.6949; Jia HP, 2004, AM J PHYSIOL-LUNG C, V287, pL428, DOI 10.1152/ajplung.00377.2003; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; Kennedy MN, 2004, J BIOL CHEM, V279, P34698, DOI 10.1074/jbc.M405444200; Miyake K, 2003, INT IMMUNOPHARMACOL, V3, P119, DOI 10.1016/S1567-5769(02)00258-8; MUNFORD RS, 1992, METHOD ENZYMOL, V209, P485; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Nakata T, 2006, CELL MICROBIOL, V8, P1899, DOI 10.1111/j.1462-5822.2006.00756.x; Ohnishi T, 2003, CLIN DIAGN LAB IMMUN, V10, P405, DOI 10.1128/CDLI.10.3.405-410.2003; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Saitoh S, 2004, INT IMMUNOL, V16, P961, DOI 10.1093/intimm/dxh097; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Shuto T, 2005, BIOCHEM BIOPH RES CO, V338, P1402, DOI 10.1016/j.bbrc.2005.10.102; Teghanemt A, 2005, J IMMUNOL, V175, P4669, DOI 10.4049/jimmunol.175.7.4669; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; Viriyakosol S, 2000, J BIOL CHEM, V275, P3144, DOI 10.1074/jbc.275.5.3144; Viriyakosol S, 1996, INFECT IMMUN, V64, P653, DOI 10.1128/IAI.64.2.653-656.1996; Viriyakosol S, 2000, J ENDOTOXIN RES, V6, P489, DOI 10.1179/096805100101532379; Visintin A, 2005, J IMMUNOL, V175, P6465, DOI 10.4049/jimmunol.175.10.6465; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Yu WM, 1998, J IMMUNOL, V161, P4244; Zughaier SM, 2004, INFECT IMMUN, V72, P371, DOI 10.1128/IAI.72.1.371-380.2004	39	76	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1010	1017		10.1074/jbc.M609400200	http://dx.doi.org/10.1074/jbc.M609400200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17121827	hybrid			2022-12-27	WOS:000243295200024
J	Chen, Y; Whetstone, HC; Youn, A; Nadesan, P; Chow, ECY; Lin, AC; Alman, BA				Chen, Yan; Whetstone, Heather C.; Youn, Andrew; Nadesan, Puviindran; Chow, Edwin C. Y.; Lin, Alvin C.; Alman, Benjamin A.			beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE-SPECIFIC ENHANCER; WNT/BETA-CATENIN; OSTEOBLAST DIFFERENTIATION; ENDOCHONDRAL OSSIFICATION; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; NEGATIVE REGULATOR; WNT; GENE; EXPRESSION	Endochondral ossification is recapitulated during bone morphogenetic protein (BMP)-induced ectopic bone formation. Although BMP and beta-catenin have been investigated in bone development and in mesenchymal cells, how they interact in this process is not clear. We implanted recombinant BMP-2 into the muscle of mice to investigate the effect of beta-catenin signaling on BMP-induced in vivo endochondral bone formation. BMP-2 induced expression of several Wnt ligands and their receptors and also activated beta-catenin-mediated T cell factor-dependent transcriptional activity. An adenovirus expressing Dickkopf-1 (Dkk-1, an inhibitor of canonical Writ pathway) inhibited beta-catenin signaling and endochondral bone formation. Interestingly, Dkk-1 inhibited both chondrogenesis and osteogenesis. Likewise, mice expressing conditional beta-catenin null alleles also displayed an inhibition of BMP-induced chondrogenesis and osteogenesis. This is in contrast to studies of embryonic skeletogenesis, which demonstrate that beta-catenin is required for osteogenesis but is dispensable for chondrogenesis. These findings suggest that embryonic development pathways are not always recapitulated during post-natal regenerative processes, and the biochemical pathways utilized to regulate cell differentiation may be different. During in vivo ectopic bone formation, BMP-2 induces beta-catenin-mediated signaling through Writ ligands, and beta-catenin is required for both chondrogenesis and osteogenesis.	Univ Toronto, Hosp Sick Children, Program Dev Biol, Inst Res, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Alman, BA (corresponding author), Univ Toronto, Hosp Sick Children, Program Dev Biol, Inst Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	benjamin.alman@sickkids.ca	, Edwin/H-8789-2019					Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359-6101(00)00011-3; Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006-291X(02)02951-0; Behrens J, 2000, J CELL SCI, V113, P911; Brault V, 2001, DEVELOPMENT, V128, P1253; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; Cheon SS, 2006, FASEB J, V20, P692, DOI 10.1096/fj.05-4759com; Cheon SS, 2004, EXP CELL RES, V293, P267, DOI 10.1016/j.yexcr.2003.09.029; Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399; Clancy BM, 2003, BONE, V33, P46, DOI 10.1016/S8756-3282(03)00116-9; Cohen MM, 2000, J CRAN GENET DEV BIO, V20, P84; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Dong YF, 2006, J CELL PHYSIOL, V208, P77, DOI 10.1002/jcp.20656; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Ebara S, 2002, SPINE, V27, pS10, DOI 10.1097/00007632-200208151-00004; Enomoto-Iwamoto M, 2002, DEV BIOL, V251, P142, DOI 10.1006/dbio.2002.0802; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Gaur T, 2006, J CELL PHYSIOL, V208, P87, DOI 10.1002/jcp.20637; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Hinoi E, 2002, BIOCHEM BIOPH RES CO, V294, P1177, DOI 10.1016/S0006-291X(02)00578-8; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Karsenty G, 1998, DEV GENET, V22, P301, DOI 10.1002/(SICI)1520-6408(1998)22:4&lt;301::AID-DVG1&gt;3.0.CO;2-A; Kolpakova E, 2005, DEV CELL, V8, P626, DOI 10.1016/j.devcel.2005.04.008; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Liu ZY, 2006, J BIOL CHEM, V281, P17156, DOI 10.1074/jbc.M513812200; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253; Nakashima A, 2005, J BIOL CHEM, V280, P37660, DOI 10.1074/jbc.M504612200; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; Reinhold MI, 2006, J BIOL CHEM, V281, P1381, DOI 10.1074/jbc.M504875200; Ryu JH, 2006, J BIOL CHEM, V281, P22039, DOI 10.1074/jbc.M601804200; Sakou T, 1998, BONE, V22, P591, DOI 10.1016/S8756-3282(98)00053-2; Tamamura Y, 2005, J BIOL CHEM, V280, P19185, DOI 10.1074/jbc.M414275200; Tiet TD, 2006, AM J PATHOL, V168, P321, DOI 10.2353/ajpath.2006.050001; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Westfall TA, 2003, J CELL BIOL, V162, P889, DOI 10.1083/jcb.200303107; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Yang Yingzi, 2003, Birth Defects Research, V69, P305, DOI 10.1002/bdrc.10026; Yano F, 2005, BIOCHEM BIOPH RES CO, V333, P1300, DOI 10.1016/j.bbrc.2005.06.041; Zhang WV, 2004, CELL COMMUN ADHES, V11, P89, DOI 10.1080/15419060490951790	48	152	170	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					526	533		10.1074/jbc.M602700200	http://dx.doi.org/10.1074/jbc.M602700200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17085452	hybrid			2022-12-27	WOS:000243166500058
J	Junemann, C; Song, YT; Bassili, G; Goergen, D; Henke, J; Niepmann, M				Juenemann, Christiane; Song, Yutong; Bassili, Gergis; Goergen, Dagmar; Henke, Jura; Niepmann, Michael			Picornavirus internal ribosome entry site elements can stimulate translation of upstream genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; MOUTH-DISEASE VIRUS; INITIATION-FACTOR EIF4B; CAP-INDEPENDENT TRANSLATION; MESSENGER-RNA; 3'-UNTRANSLATED REGION; NONTRANSLATED REGION; RETROVIRAL VECTORS; PROTEIN-SYNTHESIS; CELL-FREE	Certain viral and cellular mRNAs initiate translation cap-independently at internal ribosome entry site (IRES) elements. Picornavirus IRES elements are widely used in dicistronic or multicistronic vectors in gene therapy, virus replicon systems, and analysis of IRES function. In such vectors, expression of the upstream gene often serves as internal control to standardize the readings of IRES-driven downstream reporter activity. Picornaviral IRES elements translate optimally at up to 120 mm K+ concentration, whereas genes used as upstream reporters usually have lower salt optima when present in monocistronic mRNAs. However, here we show that such reporter genes are efficiently translated at higher K+ concentrations when placed upstream of a functional picornavirus IRES. This translation enhancement occurs in cis, is independent of the nature of the first reporter and of second reporter translation, and is conferred by the IRESs of picornaviruses but not of hepatitis C virus. A defective picornavirus IRES with a deletion killing IRES activity but leaving the binding site for initiation factor eIF4G intact retains translation enhancement activity. Translation enhancement on a capped mRNA is disabled by m(7) GDP. In addition, the C-terminal fragment of eIF4G can confer translation enhancement also on uncapped mRNA. We conclude that whenever eIF4F has been captured to a dicistronic mRNA by binding to a picornavirus IRES via its eIF4G moiety, it can be provided in cis to the 5'-end of the RNA and there stimulate translation initiation, either by binding to the cap nucleotide using its eIF4E moiety or by binding to the RNA cap-independently using its eIF4G moiety.	Univ Giessen, Fac Med, Inst Biochem, D-35392 Giessen, Germany	Justus Liebig University Giessen	Niepmann, M (corresponding author), Univ Giessen, Fac Med, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	michael.niepmann@biochemie.med.uni-giessen.de						ALEXANDER L, 1994, P NATL ACAD SCI USA, V91, P1406, DOI 10.1073/pnas.91.4.1406; Bassili G, 2004, J GEN VIROL, V85, P2555, DOI 10.1099/vir.0.80106-0; Bergamini G, 2000, RNA, V6, P1781, DOI 10.1017/S1355838200001679; Bordeleau ME, 2006, NAT CHEM BIOL, V2, P213, DOI 10.1038/nchembio776; BORMAN A, 1992, VIROLOGY, V188, P685, DOI 10.1016/0042-6822(92)90523-R; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; Bradrick SS, 2006, NUCLEIC ACIDS RES, V34, P1293, DOI 10.1093/nar/gkl019; CARRASCO L, 1976, NATURE, V264, P807, DOI 10.1038/264807a0; de Felipe P., 2002, Current Gene Therapy, V2, P355, DOI 10.2174/1566523023347742; De Gregorio E, 1998, RNA, V4, P828, DOI 10.1017/S1355838298980372; De Quinto SL, 2000, RNA, V6, P1380, DOI 10.1017/S1355838200000753; DILDINE SL, 1991, VIROLOGY, V182, P742, DOI 10.1016/0042-6822(91)90615-I; Douin V, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-16; Friebe P, 2002, J VIROL, V76, P5326, DOI 10.1128/JVI.76.11.5326-5338.2002; GLASS MJ, 1993, VIROLOGY, V193, P842, DOI 10.1006/viro.1993.1193; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Jackson Richard J., 2002, P171; JACKSON RJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P345, DOI 10.1016/0167-4781(91)90124-5; Jackson RJ, 1995, RNA, V1, P985; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Kolupaeva VG, 1998, J BIOL CHEM, V273, P18599, DOI 10.1074/jbc.273.29.18599; Kolupaeva VG, 2003, MOL CELL BIOL, V23, P687, DOI 10.1128/MCB.23.2.687-698.2003; KUHN R, 1990, J VIROL, V64, P4625; Lee H, 2004, J VIROL, V78, P10865, DOI 10.1128/JVI.78.20.10865-10877.2004; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; MEYER K, 1995, J VIROL, V69, P2819, DOI 10.1128/JVI.69.5.2819-2824.1995; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; Ngoi SM, 2004, CURR GENE THER, V4, P15, DOI 10.2174/1566523044578095; Niepmann M, 1997, J VIROL, V71, P8330, DOI 10.1128/JVI.71.11.8330-8339.1997; Niepmann M, 2003, VIRUS RES, V93, P71, DOI 10.1016/S0168-1702(03)00067-4; Ochs K, 2003, J VIROL, V77, P115, DOI 10.1128/JVI.77.1.115-122.2003; Ochs K, 2002, J VIROL, V76, P2113, DOI 10.1128/JVI.76.5.2113-2122.2002; Ochs K, 1999, J VIROL, V73, P7505, DOI 10.1128/JVI.73.9.7505-7514.1999; PELLETIER J, 1988, MOL CELL BIOL, V8, P1103, DOI 10.1128/MCB.8.3.1103; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; PETERSEN A, THESIS U GIESSEN GER; PILIPENKO EV, 1994, J MOL BIOL, V241, P398, DOI 10.1006/jmbi.1994.1516; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Prevot D, 2003, EMBO J, V22, P1909, DOI 10.1093/emboj/cdg175; Rust RC, 1999, J VIROL, V73, P6111, DOI 10.1128/JVI.73.7.6111-6113.1999; Saleh L, 2001, J GEN VIROL, V82, P757, DOI 10.1099/0022-1317-82-4-757; SANGAR DV, 1977, J GEN VIROL, V35, P281, DOI 10.1099/0022-1317-35-2-281; Schmidt-Brauns J, 2003, ACTA VIROL, V47, P65; Sokolic RA, 1996, BLOOD, V87, P42, DOI 10.1182/blood.V87.1.42.bloodjournal87142; Song YT, 2006, J VIROL, V80, P11579, DOI 10.1128/JVI.00675-06; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; Tarun SZ, 1997, MOL CELL BIOL, V17, P6876, DOI 10.1128/MCB.17.12.6876; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; Varaklioti A, 1998, BIOCHEM BIOPH RES CO, V253, P678, DOI 10.1006/bbrc.1998.9842; Yi MK, 2003, J VIROL, V77, P3557, DOI 10.1128/JVI.77.6.3557-3568.2003; Zhu YH, 2001, MOL THER, V4, P375, DOI 10.1006/mthe.2001.0469; ZITVOGEL L, 1994, HUM GENE THER, V5, P1493, DOI 10.1089/hum.1994.5.12-1493	55	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					132	141		10.1074/jbc.M608750200	http://dx.doi.org/10.1074/jbc.M608750200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17095505	hybrid			2022-12-27	WOS:000243166500016
J	Lauer-Fields, JL; Minond, D; Sritharan, T; Kashiwagi, M; Nagase, H; Fields, GB				Lauer-Fields, Janelle L.; Minond, Dmitriy; Sritharan, Thilaka; Kashiwagi, Masahide; Nagase, Hideaki; Fields, Gregg B.			Substrate conformation modulates aggrecanase (ADAMTS-4) affinity and sequence specificity - Suggestion of a common topological specificity for functionally diverse proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE INHIBITORS; AMYLOID PRECURSOR PROTEIN; NECROSIS-FACTOR-ALPHA; FIBROBLAST COLLAGENASE; PROTEOLYTIC-ENZYMES; TISSUE INHIBITOR; MICROPLATE ASSAY; DISINTEGRIN-LIKE; TERMINAL DOMAIN; N-PROTEINASE	Protease-substrate interactions are governed by a variety of structural features. Although the substrate sequence specificities of numerous proteases have been established, "topological specificities," whereby proteases may be classified based on recognition of distinct three-dimensional structural motifs, have not. The aggrecanase members of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family cleave a variety of proteins but do not seem to possess distinct sequence specificities. In the present study, the topological substrate specificity of ADAMTS-4 (aggrecanase-1) was examined using triple-helical or single-stranded poly(Pro) II helical peptides. Substrate topology modulated the affinity and sequence specificity of ADAMTS-4 with K. values indicating a preference for triple-helical structure. In turn, non-catalytic ADAMTS-4 domains were critical for hydrolysis of triple-helical and poly(Pro) II helical substrates. Comparison of ADAMTS-4 with MMP-1 (collagenase 1), MMP-13 (collagenase 3), trypsin, and thermolysin using triple-helical peptide (THP) and single-stranded peptide (SSP) substrates demonstrated that all five proteases possessed efficient "triple-helical peptidase" activity and fell into one of two categories: (k(cat)/K-m)(SSP) > (k(cat)/K-m)(THP) (thermolysin, trypsin, and MMP-13) or (k(cat)/K-m)(THP) >= (k(cat)/ K-m)(SSP) and (K-m)(SSP) > (K-m)(THP) (MMP-1 and ADAMTS-4). Overall these results suggest that topological specificity may be a guiding principle for protease behavior and can be utilized to design specific substrates and inhibitors. The triplehelical and single-stranded poly(Pro) II helical peptides represent the first synthetic substrates successfully designed for aggrecanases.	Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA; Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, Div Rheumatol, London W6 8LH, England	State University System of Florida; Florida Atlantic University; Imperial College London; University of Oxford	Fields, GB (corresponding author), Florida Atlantic Univ, Dept Chem & Biochem, 777 Glades Rd, Boca Raton, FL 33431 USA.	fieldsg@fau.edu		Minond, Dmitriy/0000-0003-2473-5944	NCI NIH HHS [CA 77402, R01 CA098799] Funding Source: Medline; NIAMS NIH HHS [AR 39189] Funding Source: Medline; NIBIB NIH HHS [EB 000289] Funding Source: Medline; Wellcome Trust [057508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098799, R01CA077402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; Arnold WV, 1998, J BIOL CHEM, V273, P31822, DOI 10.1074/jbc.273.48.31822; Arribas J, 2003, CURR TOP DEV BIOL, V54, P125, DOI 10.1016/S0070-2153(03)54007-8; BARRETT AJ, 2004, HDB PROTEOLYTIC ENZY, V1, P472; BIRKEDALHANSEN H, 1985, J BIOL CHEM, V260, P6411; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; Canals F, 2006, PROTEOMICS, V6, pS28, DOI 10.1002/pmic.200500446; Cawston TE, 1996, PHARMACOL THERAPEUT, V70, P163, DOI 10.1016/0163-7258(96)00015-0; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Chung LD, 2004, EMBO J, V23, P3020, DOI 10.1038/sj.emboj.7600318; Das C, 2003, J AM CHEM SOC, V125, P11794, DOI 10.1021/ja037131v; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dickinson SC, 2003, MATRIX BIOL, V22, P267, DOI 10.1016/S0945-053X(03)00034-9; Engel J, 1997, SCIENCE, V277, P1785, DOI 10.1126/science.277.5333.1785; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FIELDS GB, 2001, SYNTHETIC PEPTIDES U, P93; Flannery CR, 2006, FRONT BIOSCI-LANDMRK, V11, P544, DOI 10.2741/1818; Forns P, 2000, BIOPOLYMERS, V54, P531, DOI 10.1002/1097-0282(200012)54:7<531::AID-BIP60>3.0.CO;2-X; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Gore T, 2001, LANGMUIR, V17, P5352, DOI 10.1021/la010223i; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Henkel W, 1999, BIOCHEMISTRY-US, V38, P13610, DOI 10.1021/bi9905157; Horber C, 2000, MATRIX BIOL, V19, P533, DOI 10.1016/S0945-053X(00)00113-X; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 2001, EUR J BIOCHEM, V268, P1888, DOI 10.1046/j.1432-1033.2001.02062.x; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lauer-Fields JL, 2000, J CHROMATOGR A, V890, P117, DOI 10.1016/S0021-9673(00)00396-4; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; Lauer-Fields JL, 2003, J BIOL CHEM, V278, P18140, DOI 10.1074/jbc.M211330200; Lauer-Fields JL, 2002, BIOL CHEM, V383, P1095, DOI 10.1515/BC.2002.118; Lauer-Fields JL, 2001, BIOCHEMISTRY-US, V40, P5795, DOI 10.1021/bi0101190; Lind T, 2006, MOL CELL BIOCHEM, V281, P95, DOI 10.1007/s11010-006-0637-y; Locardi E, 1999, J PHYS CHEM A, V103, P10561, DOI 10.1021/jp9925435; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Melching LI, 2006, OSTEOARTHR CARTILAGE, V14, P1147, DOI 10.1016/j.joca.2006.05.014; MILLER EJ, 1976, ARCH BIOCHEM BIOPHYS, V173, P631, DOI 10.1016/0003-9861(76)90300-3; Miller JA, 2003, ANAL BIOCHEM, V314, P260, DOI 10.1016/S0003-2697(02)00638-3; Millichip MI, 1998, BIOCHEM BIOPH RES CO, V245, P594, DOI 10.1006/bbrc.1998.8485; Minond D, 2004, BIOCHEMISTRY-US, V43, P11474, DOI 10.1021/bi048938i; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MYERS D, 1988, SURFACTANT SCI TECHN, P81; Nagase H, 2003, ARTHRITIS RES THER, V5, P94, DOI 10.1186/ar630; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Nakamura H, 2000, J BIOL CHEM, V275, P38885, DOI 10.1074/jbc.M003875200; Ottl J, 2000, CHEM BIOL, V7, P119, DOI 10.1016/S1074-5521(00)00077-6; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Overall CM, 2006, BRIT J CANCER, V94, P941, DOI 10.1038/sj.bjc.6603043; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Pan WJ, 2003, J BIOL CHEM, V278, P27820, DOI 10.1074/jbc.M304436200; Peppard J, 2003, J BIOMOL SCREEN, V8, P149, DOI 10.1177/1087057103252308; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Rao BG, 2005, CURR PHARM DESIGN, V11, P295, DOI 10.2174/1381612053382115; Roberge M, 2001, BIOCHEMISTRY-US, V40, P9522, DOI 10.1021/bi010592d; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; RUBEN GC, 1988, J BIOL CHEM, V263, P2861; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sugimoto K, 1999, J BIOCHEM, V126, P449, DOI 10.1093/oxfordjournals.jbchem.a022471; Suzuki K, 1998, BIOL CHEM, V379, P185, DOI 10.1515/bchm.1998.379.2.185; Tanaka K, 2000, ENDOCRINOLOGY, V141, P3573, DOI 10.1210/en.141.10.3573; TANZAWA K, 1985, J BIOL CHEM, V260, P1120; Thomas M, 2006, MATRIX BIOL, V25, P261, DOI 10.1016/j.matbio.2005.12.003; Torres-Collado AX, 2006, J BIOL CHEM, V281, P17827, DOI 10.1074/jbc.M513465200; Tortorella MD, 2004, J BIOL CHEM, V279, P17554, DOI 10.1074/jbc.M313041200; Tsakadze NL, 2006, J BIOL CHEM, V281, P3157, DOI 10.1074/jbc.M510797200; UPADHYE S, 1995, BIOCHEM BIOPH RES CO, V215, P474, DOI 10.1006/bbrc.1995.2489; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; WANG HM, 1978, BIOCHIM BIOPHYS ACTA, V533, P270, DOI 10.1016/0005-2795(78)90571-8; Westling J, 2002, J BIOL CHEM, V277, P16059, DOI 10.1074/jbc.M108607200; Will Horst, 2005, J Biomol Tech, V16, P459; Woessner J.F., 2000, PROTEIN PROFILE SER; Woessner JF, 1998, BIOL EXTRAC, P1; Xu Y, 2002, J BIOL CHEM, V277, P27312, DOI 10.1074/jbc.M201163200; Yu YC, 1998, J AM CHEM SOC, V120, P9979, DOI 10.1021/ja981654z; Yu YC, 1999, BIOCHEMISTRY-US, V38, P1659, DOI 10.1021/bi982315l; Yu YC, 1996, J AM CHEM SOC, V118, P12515, DOI 10.1021/ja9627656; Zhou Q, 1996, BIOCHEM BIOPH RES CO, V219, P720, DOI 10.1006/bbrc.1996.0301	90	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					142	150		10.1074/jbc.M605236200	http://dx.doi.org/10.1074/jbc.M605236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17095512	hybrid			2022-12-27	WOS:000243166500017
J	Shinohara, H; Ogawa, M; Sakagami, Y; Matsubayashi, Y				Shinohara, Hidefumi; Ogawa, Mari; Sakagami, Youji; Matsubayashi, Yoshikatsu			Identification of ligand binding site of phytosulfokine receptor by on-column photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE GROWTH-FACTOR; STIMULATES SOMATIC EMBRYOGENESIS; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; SULFATED PEPTIDE; MESOPHYLL-CELLS; GENE ENCODES; KINASE; ALPHA; ARABIDOPSIS	Phytosulfokine (PSK), an endogenous 5-amino-acid-secreted peptide in plants, affects cellular potential for growth via binding to PSKR1, a member of the leucine-rich repeat receptor kinase (LRR-RK) family. PSK interacts with PSKR1 in a highly specific manner with a nanomolar dissociation constant. However, it is not known which residues in the PSKR1 extracellular domain constitute the ligand binding pocket. Here, we have identified the PSK binding domain of carrot PSKR1 (DcPSKR1) by photoaffinity labeling. We cross-linked the photoactivatable PSK analog [I-125]-[N-epsilon-(4-azidosalicyl)Lys(5)]PSK with DcPSKR1 using UV irradiation and mapped the cross-linked region using chemical and enzymatic fragmentation. We also established a novel "on-column photoaffinity labeling" methodology that allows repeated incorporation of the photoaffinity label to increase the efficiency of the photoaffinity cross-linking reactions. We purified a labeled DcPSKR1 tryptic fragment using anti-PSK antibodies and identified a peptide fragment that corresponds to the 15-amino-acid Glu(503)-Lys(517) region of DcPSKR1 by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Deletion of Glu(503)-Lys(517) completely abolishes the ligand binding activity of DcPSKR1. This region is in the island domain flanked by extracellular LRRs, indicating that this domain forms a ligand binding pocket that directly interacts with PSK.	Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Nagoya University	Matsubayashi, Y (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.	matsu@agr.nagoya-u.ac.jp	MATSUBAYASHI, Yoshikatsu/AAA-9705-2019	Matsubayashi, Yoshikatsu/0000-0002-2669-2119; Ogawa-Ohnishi, Mari/0000-0002-7581-2607				ALI SA, 1995, BIOTECHNIQUES, V18, P746; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; AN GH, 1985, PLANT PHYSIOL, V79, P568, DOI 10.1104/pp.79.2.568; Bixel MG, 2001, J BIOL CHEM, V276, P6151, DOI 10.1074/jbc.M008467200; Chen YF, 2000, PLANTA, V211, P752, DOI 10.1007/s004250000370; Chinchilla D, 2006, PLANT CELL, V18, P465, DOI 10.1105/tpc.105.036574; Dong MQ, 2004, J BIOL CHEM, V279, P2894, DOI 10.1074/jbc.M310407200; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Gros E., 1967, METHOD ENZYMOL, V11, P238; Guermeur Y, 1999, BIOINFORMATICS, V15, P413, DOI 10.1093/bioinformatics/15.5.413; Hasegawa M, 1999, J BIOL CHEM, V274, P31713, DOI 10.1074/jbc.274.44.31713; Igasaki T, 2003, PLANT CELL PHYSIOL, V44, P1412, DOI 10.1093/pcp/pcg161; Jeong S, 1999, PLANT CELL, V11, P1925, DOI 10.1105/tpc.11.10.1925; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; Kinoshita T, 2005, NATURE, V433, P167, DOI 10.1038/nature03227; Kobayashi T, 1999, J EXP BOT, V50, P1123, DOI 10.1093/jexbot/50.336.1123; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Matsubayashi Y, 2002, SCIENCE, V296, P1470, DOI 10.1126/science.1069607; Matsubayashi Y, 2000, J BIOL CHEM, V275, P15520, DOI 10.1074/jbc.275.20.15520; Matsubayashi Y, 1999, EUR J BIOCHEM, V262, P666, DOI 10.1046/j.1432-1327.1999.00409.x; Matsubayashi Y, 1999, PLANTA, V207, P559, DOI 10.1007/s004250050518; Matsubayashi Y, 1999, PLANT PHYSIOL, V120, P1043, DOI 10.1104/pp.120.4.1043; Matsubayashi Y, 1996, P NATL ACAD SCI USA, V93, P7623, DOI 10.1073/pnas.93.15.7623; Matsubayashi Y, 2006, PLANT PHYSIOL, V142, P45, DOI 10.1104/pp.106.081109; Mizel SB, 2003, J BIOL CHEM, V278, P23624, DOI 10.1074/jbc.M303481200; Nadeau JA, 2002, SCIENCE, V296, P1697, DOI 10.1126/science.1069596; Ron M, 2004, PLANT CELL, V16, P1604, DOI 10.1105/tpc.022475; Scheer JM, 2002, P NATL ACAD SCI USA, V99, P9585, DOI 10.1073/pnas.132266499; Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; Tan YV, 2004, J BIOL CHEM, V279, P38889, DOI 10.1074/jbc.M404460200; Torii KU, 2004, INT REV CYTOL, V234, P1, DOI 10.1016/S0074-7696(04)34001-5; van der Hoorn RAL, 2005, PLANT CELL, V17, P1000, DOI 10.1105/tpc.104.028118; Wen B, 2005, ARCH BIOCHEM BIOPHYS, V444, P100, DOI 10.1016/j.abb.2005.09.010; Wen B, 2005, BIOCHEMISTRY-US, V44, P1833, DOI 10.1021/bi048228c; Yamakawa S, 1998, J PLANT RES, V111, P453, DOI 10.1007/BF02507810; Yang G, 1999, PLANT BIOTECHNOL-NAR, V16, P231; Yang HP, 1999, P NATL ACAD SCI USA, V96, P13560, DOI 10.1073/pnas.96.23.13560; Yang HP, 2001, PLANT PHYSIOL, V127, P842, DOI 10.1104/pp.010452	39	33	36	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					124	131		10.1074/jbc.M604558200	http://dx.doi.org/10.1074/jbc.M604558200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17092941	hybrid			2022-12-27	WOS:000243166500015
J	Tracy, BS; Avci, FY; Linhardt, RJ; DeAngelis, PL				Tracy, Breca S.; Avci, Fikri Y.; Linhardt, Robert J.; DeAngelis, Paul L.			Acceptor specificity of the Pasteurella hyaluronan and chondroitin synthases and production of chimeric glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 ACTIVE-SITES; MOLECULAR-CLONING; ENZYMATIC RECONSTRUCTION; CHEMOENZYMATIC SYNTHESIS; HEPAROSAN SYNTHASE; DERMATAN SULFATE; MULTOCIDA; HEPARIN; OLIGOSACCHARIDES; IDENTIFICATION	The hyaluronan (HA) synthase, PmHAS, and the chondroitin synthase, PmCS, from the Gram-negative bacterium Pasteurella multocida polymerize the glycosaminoglycan (GAG) sugar chains HA or chondroitin, respectively. The recombinant Escherichia coli-derived enzymes were shown previously to elongate exogenously supplied oligosaccharides of their cognate GAG (e.g. HA elongated by PmHAS). Here we show that oligosaccharides and polysaccharides of certain noncognate GAGs (including sulfated and iduronic acid-containing forms) are elongated by PmHAS (e.g. chondroitin elongated by PmHAS) or PmCS. Various acceptors were tested in assays where the synthase extended the molecule with either a single monosaccharide or a long chain (similar to 10(2-4) sugars). Certain GAGs were very poor acceptors in comparison to the cognate molecules, but elongated products were detected nonetheless. Overall, these findings suggest that for the interaction between the acceptor and the enzyme (a) the orientation of the hydroxyl at the C-4 position of the hexosamine is not critical, (b) the conformation of C-5 of the hexuronic acid (glucuronic versus iduronic) is not crucial, and (c) additional negative sulfate groups are well tolerated in certain cases, such as on C-6 of the hexosamine, but others, including C-4 sulfates, were not or were poorly tolerated. In vivo, the bacterial enzymes only process unsulfated polymers; thus it is not expected that the PmCS and PmHAS catalysts would exhibit such relative relaxed sugar specificity by acting on a variety of animal-derived sulfated or epimerized GAGs. However, this feature allows the chemoenzymatic synthesis of a variety of chimeric GAG polymers, including mimics of proteoglycan complexes.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Rensselaer Polytech Inst, Dept Chem & Biol Chem, Ctr Biotechnol, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Biol & Chem, Ctr Biotechnol, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Biol Engn, Ctr Biotechnol, Troy, NY 12180 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	paul-deangelis@ouhsc.edu		Avci, Fikri/0000-0002-1902-7532	NCRR NIH HHS [R41 RR023764, R41 RR023764-02] Funding Source: Medline; NHLBI NIH HHS [R01 HL052622-09, R01 HL052622, R01 HL062244-07, R01 HL062244] Funding Source: Medline; NIAID NIH HHS [R01 AI065786-02, R01 AI065786] Funding Source: Medline; NIGMS NIH HHS [GM38060, R01 GM038060-19, R24 GM061894, R24-GM61894, R01 GM038060] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R41RR023764] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062244, R01HL052622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM061894, R01GM038060] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avci FY, 2003, CARBOHYD RES, V338, P2101, DOI 10.1016/S0008-6215(03)00348-3; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; DeAngelis PL, 2000, J BIOL CHEM, V275, P24124, DOI 10.1074/jbc.M003385200; DeAngelis PL, 2004, J BACTERIOL, V186, P8529, DOI 10.1128/JB.186.24.8529-8532.2004; Deangelis PL, 2003, J BIOL CHEM, V278, P35199, DOI 10.1074/jbc.M306431200; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; DeAngelis PL, 2002, GLYCOBIOLOGY, V12, p9R, DOI 10.1093/glycob/12.1.9R; DeAngelis PL, 2002, CARBOHYD RES, V337, P1547, DOI 10.1016/S0008-6215(02)00219-7; DeAngelis PL, 2002, J BIOL CHEM, V277, P7209, DOI 10.1074/jbc.M112130200; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; Jing W, 2004, J BIOL CHEM, V279, P42345, DOI 10.1074/jbc.M402744200; Jing W, 2003, GLYCOBIOLOGY, V13, P661, DOI 10.1093/glycob/cwg085; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Kobayashi S, 2006, CHEM-EUR J, V12, P5962, DOI 10.1002/chem.200600191; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Ninomiya T, 2002, J BIOL CHEM, V277, P21567, DOI 10.1074/jbc.M201719200; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; SAITOH H, 1995, J BIOL CHEM, V270, P3741, DOI 10.1074/jbc.270.8.3741; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Sudo M, 2001, ANAL BIOCHEM, V297, P42, DOI 10.1006/abio.2001.5296; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; Takagaki K, 2000, J BIOCHEM, V127, P695, DOI 10.1093/oxfordjournals.jbchem.a022659; Thanawiroon C, 2003, J CHROMATOGR A, V1014, P215, DOI 10.1016/S0021-9673(03)00779-9; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; Williams KJ, 2006, J BIOL CHEM, V281, P5391, DOI 10.1074/jbc.M510439200; Yang HO, 2000, GLYCOBIOLOGY, V10, P1033, DOI 10.1093/glycob/10.10.1033	30	25	27	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					337	344		10.1074/jbc.M607569200	http://dx.doi.org/10.1074/jbc.M607569200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17099217	hybrid, Green Accepted			2022-12-27	WOS:000243166500038
J	Wang, YH; Chiu, WT; Wang, YK; Wu, CC; Chen, TL; Teng, CF; Chang, WT; Chang, HC; Tang, MJ				Wang, Yao-Hsien; Chiu, Wen-Tai; Wang, Yang-Kao; Wu, Ching-Chou; Chen, Tsu-Ling; Teng, Chiao-Feng; Chang, Wen-Tsan; Chang, Hsien- Chang; Tang, Ming-Jer			Deregulation of AP-1 proteins in collagen gel-induced epithelial cell apoptosis mediated by low substratum rigidity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; JUN ACTIVATION DOMAIN; C-JUN; EXTRACELLULAR-MATRIX; TERMINAL PHOSPHORYLATION; FIBRONECTIN DEPOSITION; MECHANICAL-PROPERTIES; SIGNAL-TRANSDUCTION; FOCAL ADHESIONS; DOWN-REGULATION	In this study, we established that collagen gel, but not collagen gel coating, induced apoptosis exclusively in epithelial cell lines, which indicated that low substratum rigidity might trigger cell apoptosis. To confirm this, we used collagen gels with different rigidities due to cross-linking or physical disruption of collagen fibrils caused by sonication. We found that collagen gel-induced apoptosis was inversely correlated with substratum rigidity. Low substratum rigidity collagen gel-induced apoptosis was neither prevented by Bcl-2 overexpression nor preceded by mitochondrial release of cytochrome c. This suggested that the mitochondrial pathway was not involved in low substratum rigidity-induced apoptosis. Low substratum rigidity activated c-jun N-terminal kinase (JNK) within 4 h, but it also rapidly down-regulated c-jun within I h and triggered persistent aberrant expression of c-Fos for at least 24 h. Either reduced c-jun expression or c-Fos overexpression induced apoptosis in several epithelial cells. Inhibiting low substratum rigidity-induced JNK activation prevented aberrant c-Fos expression but only partially blocked low substratum rigidity-induced apoptosis. Taking these results together, we conclude that low substratum rigidity collagen gel induced apoptosis in epithelial cells and that deregulated AP-1 proteins mediated that apoptosis, at least in part.	Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 701, Taiwan; Natl Cheng Kung Univ, Dept Physiol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Dept Biochem & Mol Biol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Ctr Gene Regulat & Signal Transduct, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Engn, Inst Biomed Engn, Tainan 701, Taiwan; Natl Chung Hsing Univ, Dept Bioind Mechatron Engn, Taichung 402, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Chung Hsing University	Tang, MJ (corresponding author), Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 701, Taiwan.	mjtang1@mail.ncku.edu.tw	Wang, Yang-Kao/Y-4550-2019; Teng, Chiao-Fang/L-6679-2013; Wu, ChingChou/AAT-5096-2020	Wang, Yang-Kao/0000-0003-4887-5562; Wu, ChingChou/0000-0002-8683-3796; Tang, Ming-Jer/0000-0002-0883-4363; Teng, Chiao-Fang/0000-0002-5218-0571				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; Barnes H.A., 1989, INTRO RHEOLOGY; BAROCAS VH, 1995, J BIOMECH ENG, V11, P164; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bernstein Lori R., 1994, Current Opinion in Oncology, V6, P106, DOI 10.1097/00001622-199401000-00015; BETSCH DF, 1980, BIORHEOLOGY, V17, P83; Bhoumik A, 2004, P NATL ACAD SCI USA, V101, P4222, DOI 10.1073/pnas.0400195101; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Dembo M, 1999, BIOPHYS J, V76, P2307, DOI 10.1016/S0006-3495(99)77386-8; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; GIRAUDGUILLE MM, 1989, BIOL CELL, V67, P97, DOI 10.1111/j.1768-322X.1989.tb03014.x; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HSU S, 1994, BIORHEOLOGY, V31, P21; INGBER DE, 1993, J CELL SCI, V104, P613; Jiang ST, 2000, KIDNEY INT, V57, P1539, DOI 10.1046/j.1523-1755.2000.00998.x; Jiang ST, 1999, KIDNEY INT, V56, P92, DOI 10.1046/j.1523-1755.1999.00520.x; Jiang ST, 2000, KIDNEY INT, V57, P1860, DOI 10.1046/j.1523-1755.2000.00035.x; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEE MS, 1993, ONCOGENE, V8, P387; Lin HH, 1999, KIDNEY INT, V55, P168, DOI 10.1046/j.1523-1755.1999.00249.x; LOWRY OH, 1951, J BIOL CHEM, V193, P165; MacLaren A, 2004, MOL CELL BIOL, V24, P9006, DOI 10.1128/MCB.24.20.9006-9018.2004; MCATEER JA, 1982, J TISSUE CULT METHOD, V7, P117; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; MOONEY DJ, 1995, J CELL SCI, V108, P2311; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Oshitari T, 2002, INVEST OPHTH VIS SCI, V43, P2442; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; POKHARNA HK, 1995, J ORTHOPAED RES, V13, P13, DOI 10.1002/jor.1100130105; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rich KA, 1997, J NEUROBIOL, V32, P593, DOI 10.1002/(SICI)1097-4695(19970605)32:6<593::AID-NEU5>3.0.CO;2-V; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Storm C, 2005, NATURE, V435, P191, DOI 10.1038/nature03521; Tan JL, 2003, P NATL ACAD SCI USA, V100, P1484, DOI 10.1073/pnas.0235407100; Tang MJ, 1998, AM J PHYSIOL-CELL PH, V275, pC921, DOI 10.1152/ajpcell.1998.275.4.C921; Wang HB, 2000, AM J PHYSIOL-CELL PH, V279, pC1345, DOI 10.1152/ajpcell.2000.279.5.C1345; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Wang YK, 2003, J BIOL CHEM, V278, P21886, DOI 10.1074/jbc.M300092200; Wang YK, 2001, AM J PHYSIOL-CELL PH, V280, pC1440, DOI 10.1152/ajpcell.2001.280.6.C1440; Watson A, 1998, J NEUROSCI, V18, P751; Wenzel A, 2000, J NEUROSCI, V20, P81, DOI 10.1523/JNEUROSCI.20-01-00081.2000; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wu CC, 2005, J BIOMAT SCI-POLYM E, V16, P1261, DOI 10.1163/156856205774269494; YANG J, 1997, SCIENCE, V275, P1132; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792	72	27	27	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					752	763		10.1074/jbc.M604801200	http://dx.doi.org/10.1074/jbc.M604801200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17085440	hybrid			2022-12-27	WOS:000243166500080
J	Penheiter, AR; Bogoger, M; Ellison, PA; Oswald, B; Perkins, WJ; Jones, KA; Cremo, CR				Penheiter, Alan R.; Bogoger, Michelle; Ellison, Patricia A.; Oswald, Barbara; Perkins, William J.; Jones, Keith A.; Cremo, Christine R.			H2O2-induced kinetic and chemical modifications of smooth muscle myosin - Correlation to effects of H2O2 on airway smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAIN; PHOSPHORYLATION-DEPENDENT REGULATION; HYDROGEN-PEROXIDE; HEAVY-MEROMYOSIN; CA2+ SENSITIVITY; ATP HYDROLYSIS; CALCIUM SENSITIVITY; N-ETHYLMALEIMIDE; RABBIT AORTA; MECHANISM	The effect of H2O2 on smooth muscle heavy meromyosin (HMM) and subfragment 1 (S1) was examined. The number of molecules that retained the ability to bind ATP and the actin-activated rate of P-i release were measured by single-turnover kinetics. H2O2 treatment caused a decrease in HMM regulation from 800- to 27-fold. For unphosphorylated and phosphorylated heavy meromyosin and for S1, -50% of the molecules lost the ability to bind to ATP. H2O2 treatment in the presence of EDTA protected against ATPase inactivation and against the loss of total ATP binding. Inactivation of S1 versus time correlated to a loss of reactive thiols. Treatment of H2O2-inactivated phosphorylated HMM or S1 with dithiothreitol partially reactivated the ATPase but had no effect on total ATP binding. H2O2-inactivated S1 contained a prominent cross-link between the N-terminal 65-kDa and C-terminal 26-kDa heavy chain regions. Mass spectral studies revealed that at least seven thiols in the heavy chain and the essential light chain were oxidized to cysteic acid. In thiophosphorylated porcine tracheal muscle strips at pCa 9 + 2.1 mM ATP, H2O2 caused a similar to 50% decrease in the amplitude but did not alter the rate of force generation, suggesting that H2O2 directly affects the force generating complex. Dithiothreitol treatment reversed the H2O2 inhibition of the maximal force by similar to 50%. These data, when compared with the in vitro kinetic data, are consistent with a H2O2-induced loss of functional myosin heads in the muscle.	Univ Nevada, Sch Med, Dept Biochem & Mol Biol, Reno, NV 89557 USA; Mayo Clin, Dept Anesthesiol, Rochester, MN 55905 USA; Univ Alabama, Birmingham, AL 35249 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Mayo Clinic; University of Alabama System; University of Alabama Birmingham	Cremo, CR (corresponding author), Univ Nevada, Sch Med, Dept Biochem & Mol Biol, 330,1664 N Virginia ST, Reno, NV 89557 USA.	cremo@unr.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018751] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040917, R29AR040917] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20 RR 018751] Funding Source: Medline; NHLBI NIH HHS [HL 54757] Funding Source: Medline; NIAMS NIH HHS [AR 40917] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abe MK, 1998, AM J RESP CELL MOL, V18, P562, DOI 10.1165/ajrcmb.18.4.2958; ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; Aikawa K, 2003, J UROLOGY, V170, P2082, DOI 10.1097/01.ju.0000081461.73156.48; Bevington P. R., 2003, DATA REDUCTION ERROR, DOI 10.2307/2284752; Boardman KC, 2004, J CELL PHYSIOL, V199, P57, DOI 10.1002/jcp.10451; CHANDRA TS, 1985, J BIOL CHEM, V260, P202; Chitaley K, 2001, Curr Hypertens Rep, V3, P139, DOI 10.1007/s11906-001-0028-4; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Cremo CR, 2001, J BIOL CHEM, V276, P41465, DOI 10.1074/jbc.M107103200; DASH PK, 1991, BIOCHEM INT, V25, P1013; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Ellison PA, 2000, J BIOL CHEM, V275, P15142, DOI 10.1074/jbc.275.20.15142; Ellison PA, 2003, J BIOL CHEM, V278, P4410, DOI 10.1074/jbc.M211016200; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ENGLISH AM, 2001, METAL IONS BIOL SYST; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; GAO YS, 1992, AM J PHYSIOL, V263, pL402, DOI 10.1152/ajplung.1992.263.3.L402; GAO YS, 1993, J APPL PHYSIOL, V74, P2105, DOI 10.1152/jappl.1993.74.5.2105; Giese KC, 1997, BIOCHEMISTRY-US, V36, P8465, DOI 10.1021/bi963141f; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; GUPTA JB, 1992, AM J PHYSIOL, V263, pL714, DOI 10.1152/ajplung.1992.263.6.L714; Hiramoto K, 2002, BIOL PHARM BULL, V25, P1467, DOI 10.1248/bpb.25.1467; Iesaki T, 1996, CARDIOVASC RES, V31, P820, DOI 10.1016/S0008-6363(96)00022-3; IESAKI T, 1994, CARDIOVASC RES, V28, P963, DOI 10.1093/cvr/28.7.963; IKEBE M, 1994, J BIOL CHEM, V269, P28173; IKEBE M, 1994, P NATL ACAD SCI USA, V91, P9096, DOI 10.1073/pnas.91.19.9096; IKEBE M, 1991, J BIOL CHEM, V266, P21339; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; Kojima S, 1999, BIOCHEMISTRY-US, V38, P11670, DOI 10.1021/bi990081f; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Lorenz RR, 1999, AM J PHYSIOL-LUNG C, V277, pL816, DOI 10.1152/ajplung.1999.277.4.L816; Mazhari SM, 2004, J BIOL CHEM, V279, P39905, DOI 10.1074/jbc.M407062200; Mian KB, 1997, BRIT J PHARMACOL, V121, P813, DOI 10.1038/sj.bjp.0701187; NATH N, 1986, BIOCHEMISTRY-US, V25, P6169, DOI 10.1021/bi00368a051; Ohashi T, 2006, J PHARMACOL EXP THER, V318, P296, DOI 10.1124/jpet.106.102541; Olsen JV, 2004, P NATL ACAD SCI USA, V101, P13417, DOI 10.1073/pnas.0405549101; ONISHI H, 1985, J BIOCHEM, V98, P81, DOI 10.1093/oxfordjournals.jbchem.a135276; OSTAP EM, 1993, BIOCHEMISTRY-US, V32, P6712, DOI 10.1021/bi00077a026; Pandya HC, 2002, AM J PHYSIOL-LUNG C, V283, pL1220, DOI 10.1152/ajplung.00268.2001; Pelaia G, 2004, J CELL BIOCHEM, V93, P142, DOI 10.1002/jcb.20124; PEMRICK S, 1976, BIOCHEMISTRY-US, V15, P5193, DOI 10.1021/bi00668a038; Perkins WJ, 2003, AM J PHYSIOL-LUNG C, V284, pL324, DOI 10.1152/ajplung.00159.2002; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RABE KF, 1995, AM J PHYSIOL-LUNG C, V269, pL332, DOI 10.1152/ajplung.1995.269.3.L332; Reeve HL, 2001, J PHYSIOL-LONDON, V533, P253, DOI 10.1111/j.1469-7793.2001.0253b.x; Saurin AT, 2004, P NATL ACAD SCI USA, V101, P17982, DOI 10.1073/pnas.0404762101; Savineau JP, 1997, FUNDAM CLIN PHARM, V11, P289, DOI 10.1111/j.1472-8206.1997.tb00841.x; SLEEP JA, 1981, J MUSCLE RES CELL M, V2, P373, DOI 10.1007/BF00711966; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Syka JEP, 2004, J PROTEOME RES, V3, P621, DOI 10.1021/pr0499794; SZAREK JL, 1990, AM J PHYSIOL, V258, pL232, DOI 10.1152/ajplung.1990.258.4.L232; Tiago T, 2006, BIOCHEMISTRY-US, V45, P3794, DOI 10.1021/bi0518500; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; WHITE HD, 1985, J BIOL CHEM, V260, P982	58	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4336	4344		10.1074/jbc.M609499200	http://dx.doi.org/10.1074/jbc.M609499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17121824	hybrid			2022-12-27	WOS:000244482000013
J	Bist, P; Madhusoodanan, UK; Rao, DN				Bist, Pradeep; Madhusoodanan, Urulangodi Kunhiraman; Rao, Desirazu N.			A mutation in the mod subunit of EcoP151 restriction enzyme converts the DNA methyltransferase to a site-specific endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION SITES; ESCHERICHIA-COLI; ATP HYDROLYSIS; CLEAVAGE; TRANSLOCATION	A closer inspection of the amino acid sequence of EcoP15I DNA methyltransferase revealed a region of similarity to the PDXn(D/E)XK catalytic site of type II restriction endonucleases, except for methionine in EcoP15I DNA methyltransferase instead of proline. Substitution of methionine at position 357 by proline converts EcoP15I DNA methyltransferase to a site-specific endonuclease. EcoP15I-M357P DNA methyltransferase specifically binds to the recognition sequence 5'-CAGCAG-3' and cleaves DNA asymmetrically EcoP151-M357P(.)DNA methyltransferase specifically binds to the recognition sequence 5'-CAGCAG-3' and cleaves DNA asymmetrically, 5'-CAGCAG(N)(10)-3', as indicated by the arrows, in presence of magnesium ions.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rao, DN (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	dnrao@biochem.iisc.ernet.in	BIST, PRADEEP/AAG-7986-2019					AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; AHAMD I, 1994, J MOL BIOL, V242, P378, DOI 10.1006/jmbi.1994.1588; Bath AJ, 2002, J BIOL CHEM, V277, P4024, DOI 10.1074/jbc.M108441200; Bist P, 2003, J BIOL CHEM, V278, P41837, DOI 10.1074/jbc.M307053200; Bitinaite J, 1998, P NATL ACAD SCI USA, V95, P10570, DOI 10.1073/pnas.95.18.10570; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bujnicki JM, 2000, J MOL EVOL, V50, P39, DOI 10.1007/s002399910005; Dryden DTF, 2001, NUCLEIC ACIDS RES, V29, P3728, DOI 10.1093/nar/29.18.3728; Dupureur CM, 2001, BIOCHEMISTRY-US, V40, P387, DOI 10.1021/bi001680l; ENDLICH B, 1985, J BIOL CHEM, V260, P5729; Fuxreiter M, 2002, PROTEIN SCI, V11, P1978, DOI 10.1110/ps.4980102; JO K, 1995, SCIENCE, V267, P1817, DOI 10.1126/science.7892605; Kingston IJ, 2003, NUCLEIC ACIDS RES, V31, P5221, DOI 10.1093/nar/gkg743; Kosinski J, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-172; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lagunavicius A, 2003, J MOL BIOL, V326, P1051, DOI 10.1016/S0022-2836(03)00020-2; MEISEL A, 1995, EMBO J, V14, P2958, DOI 10.1002/j.1460-2075.1995.tb07296.x; MEISEL A, 1992, NATURE, V355, P467, DOI 10.1038/355467a0; MEISEL A, 1991, NUCLEIC ACIDS RES, V19, P3997, DOI 10.1093/nar/19.14.3997; Peakman LJ, 2004, NUCLEIC ACIDS RES, V32, P4166, DOI 10.1093/nar/gkh762; Pingoud A, 2005, CELL MOL LIFE SCI, V62, P685, DOI 10.1007/s00018-004-4513-1; Raghavendra NK, 2004, NUCLEIC ACIDS RES, V32, P5703, DOI 10.1093/nar/gkh899; RAO DN, 1989, J MOL BIOL, V209, P599, DOI 10.1016/0022-2836(89)90597-4; Reddy YVR, 1998, J BIOL CHEM, V273, P23866, DOI 10.1074/jbc.273.37.23866; Roberts RJ, 2005, NUCLEIC ACIDS RES, V33, pD230; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P1805, DOI 10.1093/nar/gkg274; SAHA S, 1995, J MOL BIOL, V247, P559, DOI 10.1016/S0022-2836(05)80137-8; Sambrook J., 2001, MOL CLONING LAB MANU; SEGEL IH, 1975, BIOCH CALCULATIONS, P208; Vipond IB, 1995, MOL BIOTECHNOL, V4, P259, DOI 10.1007/BF02779019; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101	31	3	3	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3520	3530		10.1074/jbc.M603250200	http://dx.doi.org/10.1074/jbc.M603250200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148461	hybrid			2022-12-27	WOS:000244481900014
J	Kuniyeda, K; Okuno, T; Terawaki, K; Miyano, M; Yokomizo, T; Shimizu, T				Kuniyeda, Kanako; Okuno, Toshiaki; Terawaki, Kan; Miyano, Masashi; Yokomizo, Takehiko; Shimizu, Takao			Identification of the intracellular region of the leukotriene B-4 receptor type 1 that is specifically involved in G(i) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; B-4 RECEPTOR; STRUCTURAL DETERMINANTS; BINDING-SITE; IN-VITRO; RHODOPSIN; CLONING; MUTANT; CRYSTALLOGRAPHY; RECONSTITUTION	Many G-protein-coupled receptors can activate more than one G-protein subfamily member. Leukotriene B-4 receptor type 1 (BLT1) is a high affinity G-protein-coupled receptors for leukotriene B-4 functioning in host defense, inflammation, and immunity. Previous studies have shown that BLT1 utilizes different G-proteins (the G(i) family and G(16) G-proteins) in mediating diverse cellular events and that truncation of the cytoplasmic tail of BLT1 does not impair activation of Gi and G16 proteins. To determine responsive regions of BLT1 for G-protein coupling, we performed an extensive mutagenesis study of its intracellular loops. Three intracellular loops (i1, i2, and i3) of BLT1 were found to be important for both Gi and G16 coupling, as judged by G(i)-dependent guanosine 5'-(gamma-thio)triphosphate (GTP gamma S) binding and G(16)-dependent inositol phosphate accumulation assays. The i3-1 mutant, with a mutation at the i3 amino terminus, exhibited greatly reduced GTP gamma S binding but intact inositol phosphate accumulation triggered by leukotriene B, stimulation. These results suggest that the i3-1 region is required only for Gi activation. Moreover, in the i3-1 mutant, the deficiency in Gi activation was accompanied by a loss of the high affinity leukotriene B4 binding state seen with the wild type receptor. A three-dimensional model of BLT1 constructed based on the structure of bovine rhodopsin suggests that the i3-1 region may consist of the cytoplasmic end of the transmembrane helix V, which protrudes the helix into the cytoplasm. From mutational studies and three-dimensional modeling, we propose that the extended cytoplasmic helix connected to the transmembrane helix V of BLT1 might be a key region for selective activation of Gi proteins.	Univ Tokyo, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Metabolome, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Japan Sci & Technol Agcy, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Harima Inst, Struct Biophys Lab, Sayo, Hyogo 6795148, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; RIKEN	Yokomizo, T (corresponding author), Kyushu Univ, Dept Med Biochem, Fac Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yokomizo-tky@umin.ac.jp	Yokomizo, Takehiko/P-5673-2016; Shimizu, Takao/AAV-7052-2021; Miyano, Masashi/R-2785-2016	Yokomizo, Takehiko/0000-0002-5219-1553; Miyano, Masashi/0000-0003-2253-6175; Kuniyeda, Kanako/0000-0002-4466-0145				Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; Fukunaga K, 2001, J BIOL CHEM, V276, P43025, DOI 10.1074/jbc.M108288200; Gaudreau R, 2004, J BIOL CHEM, V279, P10338, DOI 10.1074/jbc.M309207200; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; GOLDMAN DW, 1984, J ALLERGY CLIN IMMUN, V74, P373, DOI 10.1016/0091-6749(84)90133-7; Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; Igarashi T, 1999, EUR J BIOCHEM, V259, P419, DOI 10.1046/j.1432-1327.1999.00054.x; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Jala VR, 2004, TRENDS IMMUNOL, V25, P315, DOI 10.1016/j.it.2004.04.003; Janz JM, 2004, J BIOL CHEM, V279, P29767, DOI 10.1074/jbc.M402567200; Johnston CA, 2005, STRUCTURE, V13, P1069, DOI 10.1016/j.str.2005.04.007; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; Kamohara M, 2000, J BIOL CHEM, V275, P27000; Katada S, 2005, J NEUROSCI, V25, P1806, DOI 10.1523/jneurosci.4723-04.2005; Kusunoki H, 1998, BIOCHEMISTRY-US, V37, P4782, DOI 10.1021/bi972756p; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Luster AD, 2004, NAT REV IMMUNOL, V4, P711, DOI 10.1038/nri1438; Masuda K, 2003, J BIOL CHEM, V278, P24552, DOI 10.1074/jbc.M302801200; MIKI I, 1990, BIOCHEM BIOPH RES CO, V166, P342, DOI 10.1016/0006-291X(90)91951-N; Miyano M, 2005, STRUCTURE, V13, P946, DOI 10.1016/j.str.2005.06.002; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; NEGISHI M, 1993, J BIOL CHEM, V268, P26067; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Shi LC, 1996, J NEUROCHEM, V67, P1478; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Showell HJ, 1996, BRIT J PHARMACOL, V117, P1127, DOI 10.1111/j.1476-5381.1996.tb16706.x; SHOWELL HJ, 1995, J PHARMACOL EXP THER, V273, P176; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Tryselius Y, 2000, BIOCHEM BIOPH RES CO, V274, P377, DOI 10.1006/bbrc.2000.3152; Ulfers AL, 2002, PROTEIN SCI, V11, P2526, DOI 10.1110/ps.0218402; Wang SK, 2000, J BIOL CHEM, V275, P40686, DOI 10.1074/jbc.M004512200; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200	44	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3998	4006		10.1074/jbc.M610540200	http://dx.doi.org/10.1074/jbc.M610540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158791	hybrid			2022-12-27	WOS:000244481900064
J	Ottolia, M; John, S; Ren, XY; Philipson, KD				Ottolia, Michela; John, Scott; Ren, Xiaoyan; Philipson, Kenneth D.			Fluorescent Na+-Ca+ exchangers - Electrophysiological and optical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGE; NA+/CA2+ EXCHANGER; CA2+-BINDING DOMAIN; DYNAMIC PROPERTIES; MEMBRANE PATCHES; STEADY-STATE; XIP REGION; PROTEIN; CA2+	The cardiac sarcolemmal Na+-Ca2+ exchanger (NCX1) influences cardiac contractility by extruding Ca2+ from myocytes. As a Ca2+ efflux mechanism, the exchanger plays a prominent role in Ca2+ homeostasis. To track NCX1 and study changes in conformation, NCX1 was tagged with derivatives of green fluorescent protein. Cyan (CFP) and yellow (YFP) fluorescent proteins were used for both visualization of the protein in HEK cells and fluorescent resonance energy transfer (FRET). CFP or YFP was inserted at position 266, 371, 467, or 548 of the large intracellular loop of NCX1 located between transmembrane segments 5 and 6. These constructs were tested for functional activity and visualized for cell surface expression. All constructs were targeted to the plasma membrane. Transport properties were assessed by both Ca-45(2+) uptake and electrophysiological measurements. The fluorescent-tagged exchangers had similar biophysical proper-ties to the wild type NCX1. Unexpectedly, all constructs retain their sensitivity to regulation by cytoplasmic Na+ and Ca2+ ions. FRET analysis indicates the proximity of NCX1 to plasma membrane phosphatidylinositol 4,5-bisphosphate. These results indicate that insertion of CFP or YFP into the large intracellular loop of NCX1 protein does not impair exchanger proper-ties. These constructs will be useful to further characterize the biological properties of the exchanger in intact cells.	Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Philipson, KD (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Lab, MRL 3-645, Los Angeles, CA 90095 USA.	kphilipson@mednet.ucla.edu		John, Scott/0000-0002-1232-9140	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49101] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; Fujioka Y, 2000, J PHYSIOL-LONDON, V529, P611, DOI 10.1111/j.1469-7793.2000.00611.x; He ZP, 2000, AM J PHYSIOL-CELL PH, V278, pC661, DOI 10.1152/ajpcell.2000.278.4.C661; Hilge M, 2006, MOL CELL, V22, P15, DOI 10.1016/j.molcel.2006.03.008; Hilgemann DW, 1998, METHOD ENZYMOL, V293, P267; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; Kasir J, 1999, J BIOL CHEM, V274, P24873, DOI 10.1074/jbc.274.35.24873; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Nicoll DA, 2006, J BIOL CHEM, V281, P21577, DOI 10.1074/jbc.C600117200; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Philipson KD, 2002, ANN NY ACAD SCI, V976, P1; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509	23	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3695	3701		10.1074/jbc.M610425200	http://dx.doi.org/10.1074/jbc.M610425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158867	hybrid			2022-12-27	WOS:000244481900032
J	Hanyaloglu, AC; von Zastrow, M				Hanyaloglu, Aylin C.; von Zastrow, Mark			A novel sorting sequence in the beta(2)-adrenergic receptor switches recycling from default to the Hrs-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; POSTENDOCYTOTIC TRAFFICKING; CLATHRIN; SIGNAL; ENDOCYTOSIS; ENDOSOMES; BINDING; SUFFICIENT; COMPLEX	Plasma membrane recycling of G protein-coupled receptors can occur by at least two distinct mechanisms as follows: a "default" mechanism that occurs nonselectively, and a specifically sorted mechanism that requires the endosome-associated protein Hrs. In this study we have defined a sequence in the beta(2)-adrenergic receptor cytoplasmic tail that confers Hrs dependence on receptor recycling. This sequence resembles acidic dileucine class motifs found in other membrane proteins but is structurally and functionally distinct from previously identified sorting sequences. Mutation of the novel sorting sequence rendered plasma membrane recycling independent of Hrs and independent of a distal PDZ ligand required for Hrs-dependent recycling. We propose that the novel sorting sequence functions to "switch" endocytic trafficking between mechanistically distinct recycling modes, thereby explaining failure of the wild type beta(2)-adrenergic receptor to recycle efficiently by default.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA	University of California System; University of California San Francisco	von Zastrow, M (corresponding author), Univ Calif San Francisco, Dept Psychiat, MC 2140,Genentech Hall,Rm N212E,600 16th St, San Francisco, CA USA.	zastrow@itsa.ucsf.edu		/0000-0003-4206-737X				Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Gage RM, 2005, J BIOL CHEM, V280, P3305, DOI 10.1074/jbc.M406934200; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Galet C, 2004, MOL ENDOCRINOL, V18, P434, DOI 10.1210/me.2003-0293; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Hanyaloglu AC, 2005, EMBO J, V24, P2265, DOI 10.1038/sj.emboj.7600688; Hislop JN, 2004, J BIOL CHEM, V279, P22522, DOI 10.1074/jbc.M311062200; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Krishnamurthy H, 2003, MOL ENDOCRINOL, V17, P2162, DOI 10.1210/me.2003-0118; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Raiborg C, 2006, J CELL SCI, V119, P2414, DOI 10.1242/jcs.02978; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; Vargas GA, 2004, J BIOL CHEM, V279, P37461, DOI 10.1074/jbc.M401034200; Yan Q, 2005, MOL BIOL CELL, V16, P2470, DOI 10.1091/mbc.e04-11-1014	28	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3095	3104		10.1074/jbc.M605398200	http://dx.doi.org/10.1074/jbc.M605398200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17138565	hybrid			2022-12-27	WOS:000243793900036
J	Panupinthu, N; Zhao, L; Possmayer, F; Ke, HZ; Sims, SM; Dixon, SJ				Panupinthu, Nattapon; Zhao, Lin; Possmayer, Fred; Ke, Hua Z.; Sims, Stephen M.; Dixon, S. Jeffrey			P2X7 nucleotide receptors mediate blebbing in osteoblasts through a pathway involving lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVATION; LARGE-PORE FORMATION; P2X(7) RECEPTOR; EXTRACELLULAR ATP; PROTEIN-KINASE; CELL-SURFACE; PURINERGIC RECEPTORS; G(I) PROTEINS; DUCTAL CELLS; ROCK-I	Extracellular nucleotides, released in response to mechanical or inflammatory stimuli, signal through P2 receptors in many cell types, including osteoblasts. P2X7 receptors are ATP-gated cation channels that can induce formation of large membrane pores. Disruption of the gene encoding the P2X7 receptor leads to decreased periosteal bone formation and insensitivity of the skeleton to mechanical stimulation. Our purpose was to investigate signaling pathways coupled to P2X7 activation in osteoblasts. Live cell imaging showed that ATP or 2', 3'-O-(4-benzoylbenzoyl)-ATP (BzATP), but not UTP, UDP, or 2-methylthio-ADP, induced dynamic membrane blebbing in calvarial osteoblasts. Blebbing was observed in calvarial cells from wildtype but not P2X7 knock-out mice. P2X7 receptors coupled to activation of phospholipase D and A2, inhibition of which suppressed BzATP-induced blebbing. Activation of these phospholipases leads to production of lysophosphatidic acid (LPA). LPA caused dynamic blebbing in osteoblasts from both wild-type and P2X7 knock-out mice, similar to that induced by BzATP in wildtype cells. However, LPA-induced blebbing was more rapid in onset and was not affected by inhibition of phospholipase D or A2. Blockade or desensitization of LPA receptors suppressed blebbing in response to LPA and BzATP, without affecting P2X7-stimulated pore formation. Thus, LPA functions downstream of P2X7 receptors to induce membrane blebbing. Furthermore, inhibition of Rho-associated kinase abolished blebbing induced by both BzATP and LPA. In summary, we propose a novel signaling axis that links P2X7 receptors through phospholipases to production of LPA and activation of Rho-associated kinase. This pathway may contribute to P2X7-stimulated osteogenesis during skeletal development and mechanotransduction.	Univ Western Ontario, Dept Physiol & Pharmacol, Schulich Sch Med & Dent, Canadian Inst Hlth,Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Obstet & Gynaecol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Pfizer Global Res & Dev, Groton, CT 06340 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Pfizer	Dixon, SJ (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Schulich Sch Med & Dent, Canadian Inst Hlth,Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada.	jeff.dixon@schulich.uwo.ca	Dixon, S. Jeffrey/G-3657-2013; Sims, Stephen/G-4510-2013	Dixon, S. Jeffrey/0000-0001-9162-1686; 				Alzola E, 1998, J BIOL CHEM, V273, P30208, DOI 10.1074/jbc.273.46.30208; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boucharaba A, 2006, P NATL ACAD SCI USA, V103, P9643, DOI 10.1073/pnas.0600979103; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dixon SJ, 2000, DRUG DEVELOP RES, V49, P187, DOI 10.1002/(SICI)1098-2299(200003)49:3<187::AID-DDR9>3.0.CO;2-F; Dziak R, 2003, PROSTAG LEUKOTR ESS, V68, P239, DOI 10.1016/S0952-3278(02)00277-6; Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; Gargett CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/bj3130529; Gartland A, 2001, J BONE MINER RES, V16, P846, DOI 10.1359/jbmr.2001.16.5.846; Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009; Gesta S, 2002, J LIPID RES, V43, P904; GODMAN GC, 1975, J CELL BIOL, V64, P644, DOI 10.1083/jcb.64.3.644; Grey A, 2002, ENDOCRINOLOGY, V143, P4755, DOI 10.1210/en.2002-220347; Grey A, 2001, ENDOCRINOLOGY, V142, P1098, DOI 10.1210/en.142.3.1098; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Heasley BH, 2004, BIOORG MED CHEM LETT, V14, P4069, DOI 10.1016/j.bmcl.2004.05.023; Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165-6147(03)00123-8; Hoebertz A, 2000, BONE, V27, P503, DOI 10.1016/S8756-3282(00)00351-3; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003-0021; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Klein J, 2005, J NEUROCHEM, V94, P1473, DOI 10.1111/j.1471-4159.2005.03315.x; Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Le Stunff H, 2004, J BIOL CHEM, V279, P16918, DOI 10.1074/jbc.M313064200; Leverrier Y, 2001, NAT CELL BIOL, V3, pE91, DOI 10.1038/35070151; Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200; Liang LH, 2005, AM J PHYSIOL-CELL PH, V288, pC240, DOI 10.1152/ajpcell.00532.2004; Ma YF, 1995, BONE, V17, P549, DOI 10.1016/8756-3282(95)00387-8; Mackenzie AB, 2005, J BIOL CHEM, V280, P33968, DOI 10.1074/jbc.M502705200; Masiello LM, 2006, BONE, V39, P72, DOI 10.1016/j.bone.2005.12.013; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Morelli A, 2003, MOL BIOL CELL, V14, P2655, DOI 10.1091/mbc.02-04-0061; NICOTERA P, 1986, FEBS LETT, V209, P139, DOI 10.1016/0014-5793(86)81099-7; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Olmedo ML, 1999, J ORTHOP TRAUMA, V13, P356, DOI 10.1097/00005131-199906000-00006; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Pfeiffer ZA, 2004, J LEUKOCYTE BIOL, V75, P1173, DOI 10.1189/jlb.1203648; Pochet S, 2003, CELL SIGNAL, V15, P927, DOI 10.1016/S0898-6568(03)00053-6; Ralevic V, 1998, PHARMACOL REV, V50, P413; Seman M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Sun SH, 1999, J NEUROCHEM, V73, P334, DOI 10.1046/j.1471-4159.1999.0730334.x; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Turner CH, 2004, CURR PHARM DESIGN, V10, P2629, DOI 10.2174/1381612043383755; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Verhoef PA, 2003, J IMMUNOL, V170, P5728, DOI 10.4049/jimmunol.170.11.5728; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279; Zheng XJ, 2003, BBA-MOL CELL RES, V1643, P25, DOI 10.1016/j.bbamcr.2003.08.006	58	94	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3403	3412		10.1074/jbc.M605620200	http://dx.doi.org/10.1074/jbc.M605620200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135244	hybrid			2022-12-27	WOS:000243793900066
J	Rasimas, JJ; Kar, SR; Pegg, AE; Fried, MG				Rasimas, Joseph J.; Kar, Sambit R.; Pegg, Anthony E.; Fried, Michael G.			Interactions of human O-6-alkylguanine-DNA alkyltransferase (AGT) with short single-stranded DNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; PROTEIN INTERACTIONS; BINDING MECHANISM; REPAIR PROTEIN; ALKYLATION; COMPLEX; INACTIVATION; INHIBITOR; RELEVANCE; TRIAL	The O-6-alkylguanine-DNA alkyltransferase (AGT) repairsO(6)-alkylguanine and O-4-alkylthymine adducts in single-stranded and duplex DNAs. Here we characterize the binding of AGT to single-stranded DNAs ranging in length from 5 to 78 nucleotides (nt). Binding is moderately cooperative (37.9 +/- 3.0 <= omega <= 89.8 +/- 8.9), resulting in an all-or-nothing association pattern on short templates. This cooperativity contrasts with the isolated binding seen in recent crystal structures of AGT-DNA complexes. The statistical binding site size S (mean = 5.2 +/- 0.1) oscillates with increasing template length. The oscillation period (4.10 +/- 0.02 nt/protein) is nearly identical to the binding site size obtained at the highest known binding density (S = 4 nt/protein) and is significantly smaller than the contour length (similar to 8 bp) occupied in crystalline complexes. A model in which AGT proteins overlap along the DNA contour is proposed to account for these features. Oscillations in intrinsic binding constant K-i and cooperativity factor omega have the same frequency but are of opposite phase to S with the result that the most stable protein-protein and protein-DNA interactions occur at the highest packing densities. We hypothesize that modest binding cooperativity and high binding densities are adaptations that allow AGT to efficiently search for lesions in the context of chromatin remodeling and DNA replication.	Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Ctr Struct Biol, Lexington, KY 40536 USA; Penn State Univ, Coll Med, Dept Mol Physiol, Hershey, PA 17033 USA	University of Kentucky; University of Kentucky; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Fried, MG (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, 741 S Limestone, Lexington, KY 40536 USA.	michael.fried@uky.edu			NATIONAL CANCER INSTITUTE [R01CA097209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008601, R01GM070662] Funding Source: NIH RePORTER; NCI NIH HHS [CA-97209, R01 CA097209] Funding Source: Medline; NIGMS NIH HHS [T32 GM008601, GM-070662, 5 T32 GM-08601-05, R01 GM070662] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS C, 2006, IN PRESS PROTEIN INT; Bender K, 1996, NUCLEIC ACIDS RES, V24, P2087, DOI 10.1093/nar/24.11.2087; BHATTACHARYYA D, 1990, EUR J BIOCHEM, V193, P337, DOI 10.1111/j.1432-1033.1990.tb19343.x; BURINGTON RS, 1973, HDB MATH TABLES FORM, P226; CANTOR CR, 1965, J MOL BIOL, V13, P65, DOI 10.1016/S0022-2836(65)80080-8; Cavaluzzi MJ, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh015; CHAN CL, 1993, ARCH BIOCHEM BIOPHYS, V300, P193, DOI 10.1006/abbi.1993.1027; COHEN G, 1968, BIOPOLYMERS, V6, P1077, DOI 10.1002/bip.1968.360060805; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Daniels DS, 2000, MUTAT RES-DNA REPAIR, V460, P151, DOI 10.1016/S0921-8777(00)00024-0; Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791; Daugherty MA, 2005, ANALYTICAL ULTRACENTRIFUGATION: TECHNIQUES AND METHODS, P195; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Duguid EM, 2005, J MOL BIOL, V350, P657, DOI 10.1016/j.jmb.2005.05.028; Dyckman D, 2002, J BIOL CHEM, V277, P19064, DOI 10.1074/jbc.M110554200; EKER APM, 1992, MUTAT RES, V274, P211, DOI 10.1016/0921-8777(92)90067-D; Encell LP, 2000, CARCINOGENESIS, V21, P1397, DOI 10.1093/carcin/21.7.1397; Fang QM, 2005, BIOCHEMISTRY-US, V44, P15396, DOI 10.1021/bi051460d; Fanning E, 2006, NUCLEIC ACIDS RES, V34, P4126, DOI 10.1093/nar/gkl550; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Fried MG, 1996, BIOCHEMISTRY-US, V35, P15295, DOI 10.1021/bi960971k; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; Fried MG, 1998, ELECTROPHORESIS, V19, P1247, DOI 10.1002/elps.1150190804; Gajewski TF, 2005, CLIN CANCER RES, V11, P7861, DOI 10.1158/1078-0432.CCR-05-0060; Gerson SL, 2002, J CLIN ONCOL, V20, P2388, DOI 10.1200/JCO.2002.06.110; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KANUGULA S, 1995, BIOCHEMISTRY-US, V34, P7113, DOI 10.1021/bi00021a024; Kar SR, 2001, BIOCHEMISTRY-US, V40, P13378, DOI 10.1021/bi011289f; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIEM LK, 1993, J MOL BIOL, V231, P950, DOI 10.1006/jmbi.1993.1344; LOVELESS A, 1969, NATURE, V223, P206, DOI 10.1038/223206a0; Luu KX, 2002, BIOCHEMISTRY-US, V41, P8689, DOI 10.1021/bi025857i; Maluf NK, 2003, J MOL BIOL, V325, P889, DOI 10.1016/S0022-2836(02)01276-7; Marenstein DR, 2004, DNA REPAIR, V3, P527, DOI 10.1016/j.dnarep.2004.01.010; Margison GP, 2002, BIOESSAYS, V24, P255, DOI 10.1002/bies.10063; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5; Panjkovich A, 2005, NUCLEIC ACIDS RES, V33, pW570, DOI 10.1093/nar/gki379; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; Pegg AE, 2001, J PHARMACOL EXP THER, V296, P958; PEGG AE, 1990, CANCER RES, V50, P6119; Pegg AE, 1998, J BIOL CHEM, V273, P10863, DOI 10.1074/jbc.273.18.10863; Rabik CA, 2006, CANCER TREAT REV, V32, P261, DOI 10.1016/j.ctrv.2006.03.004; Ranson M, 2006, CLIN CANCER RES, V12, P1577, DOI 10.1158/1078-0432.CCR-05-2198; Rasimas JJ, 2004, PROTEIN SCI, V13, P301, DOI 10.1110/ps.03319404; Rasimas JJ, 2003, BIOCHEMISTRY-US, V42, P980, DOI 10.1021/bi026970b; Rasimas JJ, 2003, J BIOL CHEM, V278, P7973, DOI 10.1074/jbc.M211854200; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; Rippe K, 1998, J MOL BIOL, V278, P915, DOI 10.1006/jmbi.1998.1746; ROY R, 1995, CARCINOGENESIS, V16, P405, DOI 10.1093/carcin/16.2.405; Scaramozzino N, 2003, NUCLEIC ACIDS RES, V31, P4950, DOI 10.1093/nar/gkg672; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SNOW ET, 1987, CANCER INVEST, V5, P119, DOI 10.3109/07357908709018466; Tsodikov OV, 2001, BIOPHYS J, V81, P1960, DOI 10.1016/S0006-3495(01)75847-X; Xu-Welliver M, 2002, CARCINOGENESIS, V23, P823, DOI 10.1093/carcin/23.5.823; Zeman SM, 2001, METHOD ENZYMOL, V340, P51	61	40	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3357	3366		10.1074/jbc.M608876200	http://dx.doi.org/10.1074/jbc.M608876200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17138560	Green Accepted, hybrid, Green Submitted			2022-12-27	WOS:000243793900062
J	Brown, NM; Martin, SM; Maurice, N; Kuwana, T; Knudson, CM				Brown, Nicholas M.; Martin, Sean M.; Maurice, Nick; Kuwana, Tomomi; Knudson, C. Michael			Caspase inhibition blocks cell death and results in cell cycle arrest in cytokine-deprived hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; FACTOR-INDEPENDENT SURVIVAL; CYTOCHROME-C RELEASE; HUMAN TUMOR-CELLS; BCL-X-L; APOPTOTIC PATHWAYS; BH3-ONLY PROTEINS; BH3 DOMAINS; BAX; CANCER	Cytokine deprivation has been classically used to study molecular processes of apoptosis. Following interleukin (IL)-3 withdrawal in FL5.12 cells, Bax undergoes a conformational change that results in its mitochondria targeting, cytochrome c release, activation of caspase-9, and apoptosis. Cells overexpressing Casp9DN (dominant negative caspase-9) or treated with the caspase inhibitor Q-VD-OPh increased viability but failed to increase clonogenic survival. We find that caspase-inhibited cells had a significant fraction of viable cells (herein termed "rescued" cells) that failed to initiate cell division after IL-3 add back. The "rescued" cells had reduced mitochondrial potential, stained for active Bax, and had reduced staining with dihydroethidium, an agent sensitive to superoxide levels. Readdition of IL-3 after deprivation demonstrated that Bax activation was reversed, whereas altered 5,5', 6,6'-tetrachloro-1,1', 3,3'-tetraethylbenzimidazolylcarbocyanine iodide and dihydroethidium staining persisted for days. Furthermore, the "rescued" cells were resistant to rotenone, an inhibitor of mitochondrial respiration. The cells were highly sensitive to 2-deoxyglucose, an inhibitor of glycolysis and proposed anti-cancer agent. We conclude that the inhibition of caspase-9 allows cells to retain viability, but cells have prolonged mitochondrial dysfunction and enter a unique nondividing state that shares some properties with malignant cells.	Univ Iowa, Dept Pathol, Div Mol Biol, Roy J & Lucille P Carver Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Div Immunol, Roy J & Lucille P Carver Coll Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Knudson, CM (corresponding author), Univ Iowa, Dept Pathol, Div Mol Biol, Roy J & Lucille P Carver Coll Med, 200 Hawkins Dr,1171 ML, Iowa City, IA 52242 USA.	c-knudson@uiowa.edu		Knudson, Charles Michael/0000-0003-3964-5466	NCI NIH HHS [CA88967, CA104694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anel A, 1997, J IMMUNOL, V158, P1999; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cheng NL, 2004, ONCOGENE, V23, P3770, DOI 10.1038/sj.onc.1207478; Cheung HH, 2006, CLIN CANCER RES, V12, P3238, DOI 10.1158/1078-0432.CCR-06-0817; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Elhasid R, 2004, ONCOGENE, V23, P5468, DOI 10.1038/sj.onc.1207725; Emerson DK, 2005, J BIOL CHEM, V280, P3233, DOI 10.1074/jbc.M411672200; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Hasegawa J, 1996, CANCER RES, V56, P1713; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Knudson CM, 2001, CANCER RES, V61, P659; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li JL, 2000, BIOL SIGNAL RECEPT, V9, P122; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lugli E, 2005, CYTOM PART A, V68A, P28, DOI 10.1002/cyto.a.20188; Luke JJ, 2003, CELL DEATH DIFFER, V10, P740, DOI 10.1038/sj.cdd.4401233; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mandic A, 2001, MOL CELL BIOL, V21, P3684, DOI 10.1128/MCB.21.11.3684-3691.2001; Marsden VS, 2006, BLOOD, V107, P1872, DOI 10.1182/blood-2005-05-2160; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; Murahashi H, 2003, J LEUKOCYTE BIOL, V73, P399, DOI 10.1189/jlb.0702335; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Rokhlin OW, 2004, CANCER BIOL THER, V3, P761, DOI 10.4161/cbt.3.8.970; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schafer FQ, 2002, BIOL CHEM, V383, P671, DOI 10.1515/BC.2002.069; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	48	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2144	2155		10.1074/jbc.M607961200	http://dx.doi.org/10.1074/jbc.M607961200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17102131	hybrid			2022-12-27	WOS:000243593200005
J	Cho, SY; Shin, ES; Park, PJ; Shin, DW; Chang, HK; Kim, D; Lee, HH; Lee, JH; Kim, SH; Song, MJ; Chang, IS; Lee, OS; Lee, TR				Cho, Si Young; Shin, Eui Seok; Park, Pil Joon; Shin, Dong Wook; Chang, Hui Kyoung; Kim, Daegun; Lee, Hyoung Ho; Lee, Jeong Ho; Kim, Shin Hyoung; Song, Min Jung; Chang, Ih-Seop; Lee, Ok Sub; Lee, Tae Ryong			Identification of mouse Prp19p as a lipid droplet-associated protein and its possible involvement in the biogenesis of lipid droplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HORMONE-SENSITIVE LIPASE; STEAROYL-COA DESATURASE; PERILIPIN-A; DNA-REPAIR; LIPOLYSIS; MICE; MODULATION; RESISTANCE; CAVEOLIN-1	Prp19p is an integral component of the heteromeric protein complex (the NineTeen complex) in the nucleus, and it is essential for the structural integrity of NineTeen complex and its subsequent activation of the spliceosome. We identified Prp19p, which has never been reported in relation to any function outside of the nucleus, as a member of proteins associated with lipid droplets. Down-regulation of Prp19p expression with RNA interference in 3T3-L1 cells repressed lipid droplet formation with the reduction in the level of expression of perilipin and S3-12. The levels of expression of SCD1 (stearoyl-CoA desaturase-1), DGAT-1 (acyl-CoA diacylglycerol acyltransferase-1), and glycerol-3-phosphate acyltransferase were also reduced in Prp19p down-regulated cells, and a significant decrease in triglycerides was observed. Unlike perilipin, which is one of the most extensively studied lipid droplet-associated proteins, Prp19p is not essential for cAMP- and hormone-sensitive lipase-dependent lipolysis pathways, even though Prp19p is a component of the lipid droplet phospholipid monolayer, and down-regulation of Prp19p represses fat accretion significantly. These results suggest that Prp19p or Prp19-interacting proteins during lipid droplet biogenesis in adipocytes may be considered as another class of potential targets for attacking obesity and obesity-related problems.	AmorePacific Corp, R&D Ctr, Yongin 446729, Gyeonggi Do, South Korea	Samsung	Lee, TR (corresponding author), AmorePacific Corp, R&D Ctr, 314-1 Bora Dong, Yongin 446729, Gyeonggi Do, South Korea.	trlee@amorepacific.com		Lee, Tae Ryong/0000-0002-6914-1237				Atshaves BP, 2001, J BIOL CHEM, V276, P25324, DOI 10.1074/jbc.M100560200; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Castro-Chavez F, 2003, DIABETES, V52, P2666, DOI 10.2337/diabetes.52.11.2666; Chan SP, 2005, J BIOL CHEM, V280, P31190, DOI 10.1074/jbc.M505060200; Chan SP, 2003, SCIENCE, V302, P279, DOI 10.1126/science.1086602; Chen CH, 2002, NUCLEIC ACIDS RES, V30, P1029, DOI 10.1093/nar/30.4.1029; Cohen AW, 2004, DIABETES, V53, P1261, DOI 10.2337/diabetes.53.5.1261; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Dobrzyn A, 2005, PROSTAG LEUKOTR ESS, V73, P35, DOI 10.1016/j.plefa.2005.04.011; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; Grey M, 1996, NUCLEIC ACIDS RES, V24, P4009, DOI 10.1093/nar/24.20.4009; Igal RA, 1997, J PEDIATR GASTR NUTR, V25, P541, DOI 10.1097/00005176-199711000-00011; Jiang GQ, 2005, J CLIN INVEST, V115, P1030, DOI 10.1172/JCI200523962; Kim YC, 2000, J LIPID RES, V41, P1310; Le Lay S, 2004, BIOCHEM SOC T, V32, P103, DOI 10.1042/BST0320103; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Londos C, 2005, BIOCHIMIE, V87, P45, DOI 10.1016/j.biochi.2004.12.010; Mahajan KN, 2003, P NATL ACAD SCI USA, V100, P10746, DOI 10.1073/pnas.1631060100; Makarova OV, 2004, EMBO J, V23, P2381, DOI 10.1038/sj.emboj.7600241; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Ohi MD, 2005, MOL CELL BIOL, V25, P451, DOI 10.1128/MCB.25.1.451-460.2005; Robenek MJ, 2004, FASEB J, V18, P866, DOI 10.1096/fj.03-0782fje; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2004, IUBMB LIFE, V56, P379, DOI 10.1080/15216540400009968; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Than NG, 2003, EUR J BIOCHEM, V270, P1176, DOI 10.1046/j.1432-1033.2003.03475.x; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; Wolins NE, 2005, J BIOL CHEM, V280, P19146, DOI 10.1074/jbc.M500978200; Yamaguchi T, 2004, J BIOL CHEM, V279, P30490, DOI 10.1074/jbc.M403920200; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	38	56	58	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2456	2465		10.1074/jbc.M608042200	http://dx.doi.org/10.1074/jbc.M608042200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17118936	hybrid			2022-12-27	WOS:000243593200037
J	Zhuang, GL; Hunter, S; Hwang, Y; Chen, J				Zhuang, Guanglei; Hunter, Sonja; Hwang, Yoonha; Chen, Jin			Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-kinase-dependent Rac1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; 5-PHOSPHATASE SHIP2; CELL BEHAVIOR; SAM DOMAIN; C-CBL; PROTEIN; VAV; MECHANISM; TUMOR	Endocytosis of Eph receptors is critical for a number of biological processes, including modulating axon growth cone collapse response and regulating cell surface levels of receptor in epithelial cells. In particular, ephrin-A ligand stimulation of tumor cells induces EphA2 receptor internalization and degradation, a process that has been explored as a means to reduce tumor malignancy. However, the mechanism and regulation of ligand-induced Eph receptor internalization are not well understood. Here we show that SHIP2 (Src homology 2 domain-containing phosphoinositide 5-phosphatase 2) is recruited to activated EphA2 via a heterotypic sterile alpha motif (SAM)-SAM domain interaction, leading to regulation of EphA2 internalization. Overexpression of SHIP2 inhibits EphA2 receptor endocytosis, whereas suppression of SHIP2 expression by small interfering RNA-mediated gene silencing promotes ligand-induced EphA2 internalization and degradation. SHIP2 regulates EphA2 endocytosis via phosphatidylinositol 3-kinase-dependent Rac1 activation. Phosphatidylinositol 3,4,5-trisphosphate levels are significantly elevated in SHIP2 knockdown cells, phosphatidylinositol 3-kinase inhibitor decreases phosphatidylinositol 3,4,5-trisphosphate levels and suppresses increased EphA2 endocytosis. Ephrin-A1 stimulation activates Rac1 GTPase, and the Rac1-GTP levels are further increased in SHIP2 knockdown cells. A dominant negative Rac1 GTPase effectively inhibited ephrin-A1-induced EphA2 endocytosis. Together, our findings provide evidence that recruitment of SHIP2 to EphA2 attenuates a positive signal to receptor endocytosis mediated by phosphatidylinositol 3-kinase and Rac1 GTPase.	Vanderbilt Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, A-4323 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jin.chen@vanderbilt.edu	Zhuang, Guanglei/K-6097-2013	Chen, Jin/0000-0002-5557-2079; Zhuang, Guanglei/0000-0001-8141-5096; Hwang, Yoonha/0000-0001-7420-4477	NCI NIH HHS [CA114301, CA95004] Funding Source: Medline; NIGMS NIH HHS [GM072461] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114301, R01CA095004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM072461] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Aoki K, 2005, MOL BIOL CELL, V16, P2207, DOI 10.1091/mbc.e04-10-0904; Brantley-Sieders D, 2004, CURR PHARM DESIGN, V10, P3431, DOI 10.2174/1381612043383160; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Chen RY, 2002, J HISTOCHEM CYTOCHEM, V50, P697, DOI 10.1177/002215540205000511; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Cowan CW, 2005, NEURON, V46, P205, DOI 10.1016/j.neuron.2005.03.019; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hunter SG, 2006, MOL CELL BIOL, V26, P4830, DOI 10.1128/MCB.02215-05; Irie F, 2005, NAT CELL BIOL, V7, P501, DOI 10.1038/ncb1252; Jurney WM, 2002, J NEUROSCI, V22, P6019; Koolpe M, 2002, J BIOL CHEM, V277, P46974, DOI 10.1074/jbc.M208495200; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Liu L, 1997, J BIOL CHEM, V272, P8983; Marston DJ, 2003, NAT CELL BIOL, V5, P879, DOI 10.1038/ncb1044; NOBLITT LW, 2004, CANCER GENE THER, P1; PANDEY A, 1994, J BIOL CHEM, V269, P30154; Parker M, 2004, BIOCHEM BIOPH RES CO, V323, P17, DOI 10.1016/j.bbrc.2004.07.209; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Paternotte N, 2005, FEBS J, V272, P6052, DOI 10.1111/j.1742-4658.2005.04996.x; Pesesse X, 2001, J BIOL CHEM, V276, P28348, DOI 10.1074/jbc.M103537200; Prasad NK, 2005, J BIOL CHEM, V280, P13129, DOI 10.1074/jbc.M410289200; Qiao Feng, 2005, Sci STKE, V2005, pre7, DOI 10.1126/stke.2862005re7; Rohrschneider LR, 2000, GENE DEV, V14, P505; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Schurmans S, 1999, GENOMICS, V62, P260, DOI 10.1006/geno.1999.5995; Sleeman MW, 2005, NAT MED, V11, P199, DOI 10.1038/nm1178; Smalla M, 1999, PROTEIN SCI, V8, P1954, DOI 10.1110/ps.8.10.1954; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Thanos CD, 1999, J BIOL CHEM, V274, P37301, DOI 10.1074/jbc.274.52.37301; Vandenbroere I, 2003, BIOCHEM BIOPH RES CO, V300, P494, DOI 10.1016/S0006-291X(02)02894-2; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vedham V, 2005, MOL CELL BIOL, V25, P4211, DOI 10.1128/MCB.25.10.4211-4220.2005; Walker-Daniels J, 2002, MOL CANCER RES, V1, P79; Wang YJ, 2002, BIOCHEM BIOPH RES CO, V296, P214, DOI 10.1016/S0006-291X(02)00806-9; Zimmer M, 2003, NAT CELL BIOL, V5, P869, DOI 10.1038/ncb1045	47	107	113	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2683	2694		10.1074/jbc.M608509200	http://dx.doi.org/10.1074/jbc.M608509200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135240	hybrid			2022-12-27	WOS:000243593200061
J	Adle, DJ; Sinani, D; Kim, H; Lee, J				Adle, David J.; Sinani, Devis; Kim, Heejeong; Lee, Jaekwon			A cadmium-transporting P-1B-type ATPase in yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; AFFINITY COPPER TRANSPORTER; HEAVY-METAL DETOXIFICATION; TRANSCRIPTION FACTOR MTF-1; WILSON-DISEASE GENE; BINDING DOMAIN; SUPEROXIDE-DISMUTASE; METALLOTHIONEIN GENE; EXPRESSION; ARABIDOPSIS	Detoxification and homeostatic acquisition of metal ions are vital for all living organisms. We have identified PCA1 in yeast Saccharomyces cerevisiae as an overexpression suppressor of copper toxicity. PCA1 possesses signatures of a P-1B-type heavy metal-transporting ATPase that is widely distributed from bacteria to humans. Copper resistance conferred by PCA1 is not dependent on catalytic activity, but it appears that a cysteine-rich region located in the N terminus sequesters copper. Unexpectedly, when compared with two independent natural isolates and an industrial S. cerevisiae strain, the PCA1 allele of the common laboratory strains we have examined possesses a missense mutation in a predicted ATP-binding residue conserved in P-1B-type ATPases. Consistent with a previous report that identifies an equivalent mutation in a copper-transporting P-1B-type ATPase of a Wilson disease patient, the PCA1 allele found in laboratory yeast strains is nonfunctional. Overexpression or deletion of the functional allele in yeast demonstrates that PCA1 is a cadmium efflux pump. Cadmium as well as copper and silver, but not other metals examined, dramatically increase PCA1 protein expression through post-transcriptional regulation and promote subcellular localization to the plasma membrane. Our study has revealed a novel metal detoxification mechanism in yeast mediated by a P-1B-type ATPase that is unique in structure, substrate specificity, and mode of regulation.	Univ Nebraska, Dept Biochem, Redox Biol Ctr, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Lee, J (corresponding author), Univ Nebraska, Dept Biochem, Beadle Ctr N210, Lincoln, NE 68588 USA.	jlee7@unlnotes.unl.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016337] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR-17675, P20 RR017675] Funding Source: Medline; NIEHS NIH HHS [R01 ES016337] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andres-Colas N, 2006, PLANT J, V45, P225, DOI 10.1111/j.1365-313X.2005.02601.x; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Axelsen KB, 2001, PLANT PHYSIOL, V126, P696, DOI 10.1104/pp.126.2.696; Ballatori N, 2002, ENVIRON HEALTH PERSP, V110, P689, DOI 10.1289/ehp.02110s5689; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Cobbett C, 2002, ANNU REV PLANT BIOL, V53, P159, DOI 10.1146/annurev.arplant.53.100301.135154; Darbre PD, 2006, J APPL TOXICOL, V26, P191, DOI 10.1002/jat.1135; De Freitas JM, 2004, J BIOL CHEM, V279, P4450, DOI 10.1074/jbc.M212308200; Dmitriev O, 2006, P NATL ACAD SCI USA, V103, P5302, DOI 10.1073/pnas.0507416103; Ercal Nuran, 2001, Current Topics in Medicinal Chemistry, V1, P529, DOI 10.2174/1568026013394831; Eren E, 2004, PLANT PHYSIOL, V136, P3712, DOI 10.1104/pp.104.046292; Eren E, 2006, J BIOL CHEM, V281, P33881, DOI 10.1074/jbc.M605218200; Gatti D, 2000, J BIOL CHEM, V275, P34009, DOI 10.1074/jbc.R000012200; GEITZ RD, 1995, YEAST, V11, P355; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; HALL BH, 1990, BROOKINGS PAP ECO AC, P85; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; Henson MC, 2004, EXP BIOL MED, V229, P383, DOI 10.1177/153537020422900506; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hussain D, 2004, PLANT CELL, V16, P1327, DOI 10.1105/tpc.020487; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Lee J, 2002, J BIOL CHEM, V277, P40253, DOI 10.1074/jbc.M208002200; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Lichtlen P, 2001, BIOESSAYS, V23, P1010, DOI 10.1002/bies.1146; LIU HP, 1992, GENETICS, V132, P665; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; McMurray CT, 2003, NAT GENET, V34, P239, DOI 10.1038/ng0703-239; Mills RF, 2005, FEBS LETT, V579, P783, DOI 10.1016/j.febslet.2004.12.040; Mills RF, 2003, PLANT J, V35, P164, DOI 10.1046/j.1365-313X.2003.01790.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; Nies DH, 1999, APPL MICROBIOL BIOT, V51, P730, DOI 10.1007/s002530051457; Palmgren MG, 2001, ANNU REV PLANT PHYS, V52, P817, DOI 10.1146/annurev.arplant.52.1.817; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Papoyan A, 2004, PLANT PHYSIOL, V136, P3814, DOI 10.1104/pp.104.044503; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Portillo F, 2000, BBA-REV BIOMEMBRANES, V1469, P31, DOI 10.1016/S0304-4157(99)00011-8; RAD MR, 1994, YEAST, V10, P1217, DOI 10.1002/yea.320100910; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; RYMOND BC, 1983, GENE, V25, P249, DOI 10.1016/0378-1119(83)90229-9; Sazinsky MH, 2006, J BIOL CHEM, V281, P11161, DOI 10.1074/jbc.M510708200; Shiraishi E, 2000, CURR GENET, V37, P79, DOI 10.1007/s002940050013; SIKORSKI RS, 1989, GENETICS, V122, P19; Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753; SINGHAL RK, 1987, FASEB J, V1, P220, DOI 10.1096/fasebj.1.3.2887478; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Stoica A, 2000, MOL ENDOCRINOL, V14, P545, DOI 10.1210/me.14.4.545; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; Tao TY, 2003, HEPATOLOGY, V37, P1241, DOI 10.1053/jhep.2003.50281; TAWFIK OW, 1989, J CLIN MICROBIOL, V27, P1689, DOI 10.1128/JCM.27.7.1689-1691.1989; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; VALLEE BL, 1972, ANNU REV BIOCHEM, V41, P91, DOI 10.1146/annurev.bi.41.070172.000515; Verret F, 2004, FEBS LETT, V576, P306, DOI 10.1016/j.febslet.2004.09.023; Wang Y, 2004, FASEB J, V18, P1071, DOI 10.1096/fj.03-1282com; Williams LE, 2005, TRENDS PLANT SCI, V10, P491, DOI 10.1016/j.tplants.2005.08.008; Wimmer U, 2005, NUCLEIC ACIDS RES, V33, P5715, DOI 10.1093/nar/gki881; Wunderli-Ye H, 1999, ADV EXP MED BIOL, V448, P255; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zalups RK, 2003, TOXICOL APPL PHARM, V186, P163, DOI 10.1016/S0041-008X(02)00021-2; ZHOU PB, 1993, BIOFACTORS, V4, P105	73	59	62	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					947	955		10.1074/jbc.M609535200	http://dx.doi.org/10.1074/jbc.M609535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17107946	hybrid, Green Accepted			2022-12-27	WOS:000243295200017
J	Scott, GK; Goga, A; Bhaumik, D; Berger, CE; Sullivan, CS; Benz, CC				Scott, Gary K.; Goga, Andrei; Bhaumik, Dipa; Berger, Crystal E.; Sullivan, Christopher S.; Benz, Christopher C.			Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; GENES; CELLS; INTERFERENCE; BIOGENESIS; RECEPTOR; GROWTH	Deregulation of micro-RNAs (miRNAs) is emerging as a major aspect of cancer etiology because their capacity to direct the translation and stability of targeted transcripts can dramatically influence cellular physiology. To explore the potential of exogenously applied miRNAs to suppress oncogenic proteins, the ERBB oncogene family was chosen with a bioinformatics search identifying targeting seed sequences for miR-125a and miR-125b within the 3'-untranslated regions of both ERBB2 and ERBB3. Using the human breast cancer cell line SKBR3 as a model for ERBB2 and ERBB3 dependence, infection of these cells with retroviral constructs expressing either miR-125a or miR-125b resulted in suppression of ERBB2 and ERBB3 at both the transcript and protein level. Luciferase constructs containing the 3' 3'-untranslated regions of ERBB2 and ERBB3 demonstrated similar to 35% less activity in miR-125a- and miR-125b-expressing cells relative to controls. Additionally, phosphorylation of ERK1/2 and AKT was suppressed in SKBR3 cells overexpressing either miR-125a or miR-125b. Consistent with suppression of both ERBB2 and ERBB3 signaling, miR-125a- or miR-125b-overexpressing SKBR3 cells were impaired in their anchorage-dependent growth and exhibited reduced migration and invasion capacities. Parallel studies performed on MCF10A cells demonstrated that miR-125a or miR- 125b overexpression produced only marginal influences on the growth and migration of these non-transformed human mammary epithelial cells. These results illustrate the feasibility of using miRNAs as a therapeutic strategy to suppress oncogene expression and function.	Buck Inst Age Res, Novato, CA 94945 USA; Univ Calif San Francisco, GW Hooper Res Fdn, San Francisco, CA 94143 USA	Buck Institute for Research on Aging; University of California System; University of California San Francisco	Benz, CC (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	cbenz@buckinstitute.org	Huang, H/E-9490-2010		NATIONAL CANCER INSTITUTE [P50CA058207, K08CA104032, R01CA036773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022868] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA058207, K08-CA104032, K08 CA104032, R01 CA036773, P50-CA58207, R01-CA36773] Funding Source: Medline; NIA NIH HHS [R01 AG022868, R01-AG22868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Bennasser Y, 2006, J BIOL CHEM, V281, P27674, DOI 10.1074/jbc.C600072200; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chung KH, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl143; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Michael MZ, 2003, MOL CANCER RES, V1, P882; Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632; SCOTT GK, 2002, MOL CANCER THER, V2, P971; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Weiler J, 2006, GENE THER, V13, P496, DOI 10.1038/sj.gt.3302654; Wu LG, 2005, MOL CELL BIOL, V25, P9198, DOI 10.1128/MCB.25.21.9198-9208.2005; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444	31	500	547	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1479	1486		10.1074/jbc.M609383200	http://dx.doi.org/10.1074/jbc.M609383200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17110380	hybrid			2022-12-27	WOS:000243295200072
J	Ulyanova, NP; Schnitzler, GR				Ulyanova, Natalia P.; Schnitzler, Gavin R.			Inverted factor access and slow reversion characterize SWI/SNF-altered nucleosome dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SWI-SNF; TRANSCRIPTIONAL ACTIVATORS; RETINOBLASTOMA PROTEIN; BINDING; COMPLEX; DNA; ACETYLATION; DISRUPTION; FAMILY; FORM	Human SWI/SNF (hSWI/SNF) is an ATP-dependent chromatin remodeling complex with important functions in activation and repression of cellular genes. Previously, we showed that hSWI/SNF creates structurally altered dimers from mononucleosome cores. More recently we found that hSWI/SNF also generates abundant structurally altered dinucleosomes, called altosomes, on polynucleosomal templates. Here, we find that dimers revert to normal nucleosomes at a similar rate as altosomes and can also be cleaved to yield nucleosomal particles with mobilities similar to mononucleosomes. Using these and other shared properties we propose a single model for both types of hSWI/SNF product. In addition, we further characterize the accessibility of altered dimers to transcription factors, and find that the DNA in dimers is most accessible in the middle and least accessible at the ends, directly opposite the profile of normal mononucleosomes. We also find that transcription factor binding can influence the ratio of normal nucleosomes and dimers as hSWI/SNF products. Implications for the interplay between hSWI/SNF products and transcription factors are discussed.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University	Schnitzler, GR (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA.	gavin.schnitzler@tufts.edu						ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; Aoyagi S, 2002, MOL CELL BIOL, V22, P7484, DOI 10.1128/MCB.22.21.7484-7490.2002; Cloutier TE, 2004, MOL CELL, V14, P355, DOI 10.1016/S1097-2765(04)00210-2; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fan HY, 2003, MOL CELL, V11, P1311, DOI 10.1016/S1097-2765(03)00192-8; Flaus A, 2003, MOL CELL BIOL, V23, P7767, DOI 10.1128/MCB.23.21.7767-7779.2003; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; Guyon JR, 2001, MOL CELL BIOL, V21, P1132, DOI 10.1128/MCB.21.4.1132-1144.2001; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Kassabov SR, 2003, MOL CELL, V11, P391, DOI 10.1016/S1097-2765(03)00039-X; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Narlikar GJ, 2001, MOL CELL, V8, P1219, DOI 10.1016/S1097-2765(01)00412-9; Phelan ML, 2000, MOL CELL BIOL, V20, P6380, DOI 10.1128/MCB.20.17.6380-6389.2000; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; Ramachandran A, 2003, J BIOL CHEM, V278, P48590, DOI 10.1074/jbc.M309033200; RAMACHANDRAN A, 2004, RECENT RES DEV MOL C, V5, P149; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Schnitzler GR, 2001, MOL CELL BIOL, V21, P8504, DOI 10.1128/MCB.21.24.8504-8511.2001; Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Ulyanova NP, 2005, MOL CELL BIOL, V25, P11156, DOI 10.1128/MCB.25.24.11156-11170.2005; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; Wang W, 2003, CURR TOP MICROBIOL, V274, P143	32	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1018	1028		10.1074/jbc.M609473200	http://dx.doi.org/10.1074/jbc.M609473200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17121825	hybrid			2022-12-27	WOS:000243295200025
J	Pang, T; Xiong, B; Li, JY; Qiu, BY; Jin, GZ; Shen, JK; Li, J				Pang, Tao; Xiong, Bing; Li, Jing-Ya; Qiu, Bei-Ying; Jin, Guo-Zhang; Shen, Jin-Kang; Li, Jia			Conserved alpha-helix acts as autoinhibitory sequence in AMP-activated protein kinase alpha subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; FATTY-ACID OXIDATION; YEAST SNF1; NONCATALYTIC BETA; CATALYTIC DOMAIN; CELLULAR-ENERGY; RAT-LIVER; GLUCOSE; ISOFORMS; PHOSPHORYLATION	AMP-activated protein kinase (AMPK) acts as an energy sensor, being activated by metabolic stresses and regulating cellular metabolism. AMPK is a heterotrimer consisting of a catalytic a subunit and two regulatory subunits, beta and gamma. It had been reported that the mammalian AMPK a subunit contained an autoinhibitory domain (alpha 1: residues 313-392) and had little kinase activity. We have found that a conserved short segment of the a subunit (alpha 1-(313-335)), which includes a predicted a-helix, is responsible for a subunit autoinhibition. The role of the residues in this segment for autoinhibition was further investigated by systematic site-directed mutation. Several hydrophobic and charged residues, in particular Leu-328, were found to be critical for alpha 1 autoinhibition. An autoinhibitory structural model of human AMPK alpha 1-(1-335) was constructed and revealed that Val-298 interacts with Leu-328 through hydrophobic bonding at a distance of about 4 A and may stabilize the autoinhibitory conformation. Further mutation analysis showed that V298G mutation significantly activated the kinase activity. Moreover, the phosphorylation level of acetyl-CoA carboxylase, the AMPK downstream substrate, was significantly increased in COS7 cells overexpressing AMPK alpha 1-(1-394) with deletion of residues 313-335 (Delta alpha 394) and a V298G or L328Q mutation, and the glucose uptake was also significantly enhanced in HepG2 cells transiently transfected with Delta alpha 394, V298G, or L328Q mutants, which indicated that these AMPK al mutants are constitutively active in mammalian cells and that interaction between Leu-328 and Val-298 plays an important role in AMPK alpha autoinhibitor-gamma function.	Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, Shanghai Inst Biol Sci,Grah Sch, Shanghai 201203, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS	Li, J (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, Shanghai Inst Biol Sci,Grah Sch, 189 Guo Shou Jing Rd, Shanghai 201203, Peoples R China.	jli@mail.shcnc.ac.cn	li, jia/GVT-7587-2022; Xiong, Bing/B-8849-2008; Li, Jia/F-9116-2011	Xiong, Bing/0000-0001-9776-8136; 				Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Elbing K, 2006, J BIOL CHEM, V281, P26170, DOI 10.1074/jbc.M603811200; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; GAO G, 1995, BBA-MOL CELL RES, V1266, P73, DOI 10.1016/0167-4889(94)00222-Z; Gao G, 1996, J BIOL CHEM, V271, P8675, DOI 10.1074/jbc.271.15.8675; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Halse R, 2003, DIABETES, V52, P9, DOI 10.2337/diabetes.52.1.9; Hamilton SR, 2002, BIOCHEM BIOPH RES CO, V293, P892, DOI 10.1016/S0006-291X(02)00312-1; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Hutber CA, 1997, AM J PHYSIOL-ENDOC M, V272, pE262, DOI 10.1152/ajpendo.1997.272.2.E262; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Iseli TJ, 2005, J BIOL CHEM, V280, P13395, DOI 10.1074/jbc.M412993200; Jaleel M, 2006, BIOCHEM J, V394, P545, DOI 10.1042/BJ20051844; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Lee K, 2005, ENDOCRINOLOGY, V146, P3, DOI 10.1210/en.2004-0968; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Nayak V, 2006, STRUCTURE, V14, P477, DOI 10.1016/j.str.2005.12.008; Neumann D, 2003, PROTEIN EXPRES PURIF, V30, P230, DOI 10.1016/S1046-5928(03)00126-8; Panneerselvam S, 2006, STRUCTURE, V14, P173, DOI 10.1016/j.str.2005.09.022; PoteetSmith CE, 1997, J BIOL CHEM, V272, P379; Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200; Rosenberg OS, 2005, CELL, V123, P849, DOI 10.1016/j.cell.2005.10.029; Scott JW, 2002, J MOL BIOL, V317, P309, DOI 10.1006/jmbi.2001.5316; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yun H, 2005, J BIOL CHEM, V280, P9963, DOI 10.1074/jbc.M412994200; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	53	86	90	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					495	506		10.1074/jbc.M605790200	http://dx.doi.org/10.1074/jbc.M605790200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17088252	hybrid			2022-12-27	WOS:000243166500055
J	Wang, J; Caruano-Yzermans, A; Rodriguez, A; Scheurmann, JP; Slunt, HH; Cao, XH; Gitlin, J; Hart, PJ; Borchelt, DR				Wang, Jiou; Caruano-Yzermans, Amy; Rodriguez, Angela; Scheurmann, Jonathan P.; Slunt, Hilda H.; Cao, Xiaohang; Gitlin, Jonathan; Hart, P. John; Borchelt, David R.			Disease-associated mutations at copper ligand histidine residues of superoxide dismutase 1 diminish the binding of copper and compromise dimer stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU,ZN SUPEROXIDE-DISMUTASE; MOTOR-NEURON DEGENERATION; TRANSGENIC MICE; FAMILIAL ALS; CHAPERONE CCS; WILD-TYPE; SOD1; AGGREGATION; GENE	A subset of superoxide dismutase 1 (Cu/Zn-SOD1) mutants that cause familial amyotrophic lateral sclerosis (FALS) have heightened reactivity with -ONOO and H2O2 in vitro. This reactivity requires a copper ion bound in the active site and is a suggested mechanism of motor neuron injury. However, we have found that transgenic mice that express SOD1-H46R/ H48Q, which combines natural FALS mutations at ligands for copper and which is inactive, develop motor neuron disease. Using a direct radioactive copper incorporation assay in transfected cells and the established tools of single crystal x-ray diffraction, we now demonstrate that this variant does not stably bind copper. We find that single mutations at copper ligands, including H46R, H48Q, and a quadruple mutant H46R/H48Q/H63G/H120G, also diminish the binding of radioactive copper. Further, using native polyacrylamide gel electrophoresis and a yeast two-hybrid assay, the binding of copper was found to be related to the formation of the stable dimeric enzyme. Collectively, our data demonstrate a relationship between copper and assembly of SOD1 into stable dimers and also define disease-causing SOD1 mutants that are unlikely to robustly produce toxic radicals via copper-mediated chemistry.	Univ Florida, Dept Neurosci, Santa Fe Hlth Alzheimers Dis Res Ctr, McKnight Brain Inst, Gainesville, FL 32610 USA; Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA; Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Univ Texas, San Antonio Hlth Sci Ctr, Dept Biochem, Xray Crystallog Core Lab, San Antonio, TX 78229 USA; Univ Texas, San Antonio Hlth Sci Ctr, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs,S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA	State University System of Florida; University of Florida; Johns Hopkins University; Johns Hopkins University; Washington University (WUSTL); University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Borchelt, DR (corresponding author), Univ Florida, Dept Neurosci, Santa Fe Hlth Alzheimers Dis Res Ctr, McKnight Brain Inst, 100 Newell Dr,Room L1-100H,POB 100244, Gainesville, FL 32610 USA.	Borchelt@mbi.ufl.edu			NATIONAL CANCER INSTITUTE [R24CA086307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039912, P01NS049134, R01NS039112] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA86307, R24 CA086307] Funding Source: Medline; NINDS NIH HHS [R01 NS039112, P01 NS049134, R01 NS039912, R01 NS39912, R01 NS039112-07] Funding Source: Medline; PHS HHS [44464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSEN PM, 2000, AMYOTROPHIC LATERAL, P223; Antonyuk S, 2005, PROTEIN SCI, V14, P1201, DOI 10.1110/ps.041256705; AOKI M, 1994, J NEUROL SCI, V126, P77, DOI 10.1016/0022-510X(94)90097-3; Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Bergemalm D, 2006, J NEUROSCI, V26, P4147, DOI 10.1523/JNEUROSCI.5461-05.2006; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Brown NM, 2004, P NATL ACAD SCI USA, V101, P5518, DOI 10.1073/pnas.0401175101; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carroll MC, 2004, P NATL ACAD SCI USA, V101, P5964, DOI 10.1073/pnas.0308298101; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; DENG HX, P NATL ACAD SCI US, V103, P7142; Doucette PA, 2004, J BIOL CHEM, V279, P54558, DOI 10.1074/jbc.M409744200; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FRIDOVICH I, 1974, ADV ENZYMOL RAMB, V41, P35; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hart PJ, 2006, CURR OPIN CHEM BIOL, V10, P131, DOI 10.1016/j.cbpa.2006.02.034; Hart PJ, 1998, PROTEIN SCI, V7, P545; HARTZ JW, 1972, J BIOL CHEM, V247, P7043; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Jonsson PA, 2004, BRAIN, V127, P73, DOI 10.1093/brain/awh005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V346, P263, DOI 10.1006/abbi.1997.0298; MALINOWSKI DP, 1979, BIOCHEMISTRY-US, V18, P237, DOI 10.1021/bi00568a037; OGASAWARA M, 1993, NAT GENET, V5, P323, DOI 10.1038/ng1293-323; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; Ray SS, 2004, BIOCHEMISTRY-US, V43, P4899, DOI 10.1021/bi030246r; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; Rodriguez JA, 2005, P NATL ACAD SCI USA, V102, P10516, DOI 10.1073/pnas.0502515102; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rumfeldt JAO, 2006, J MOL BIOL, V355, P106, DOI 10.1016/j.jmb.2005.10.042; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Vassall KA, 2006, BIOCHEMISTRY-US, V45, P7366, DOI 10.1021/bi0600953; Wang J, 2003, HUM MOL GENET, V12, P2753, DOI 10.1093/hmg/ddg312; Wang J, 2005, HUM MOL GENET, V14, P2335, DOI 10.1093/hmg/ddi236; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7	48	40	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					345	352		10.1074/jbc.M604503200	http://dx.doi.org/10.1074/jbc.M604503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17092942	hybrid, Green Accepted			2022-12-27	WOS:000243166500039
J	Webster, RB; Rodriguez, Y; Klimecki, WT; Vercelli, D				Webster, Robin B.; Rodriguez, Yelitza; Klimecki, Wait T.; Vercelli, Donata			The human IL-13 locus in neonatal CD4(+) T cells is refractory to the acquisition of a repressive chromatin architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RANGE INTRACHROMOSOMAL INTERACTIONS; CYTOKINE GENE-EXPRESSION; HYPERSENSITIVE SITE; ATOPIC-DERMATITIS; CONTROL REGION; SUBSEQUENT DEVELOPMENT; POSITIONED NUCLEOSOME; COORDINATE REGULATOR; HISTONE ACETYLATION; LINEAGE COMMITMENT	The Th2 cytokine IL-13 is a major effector molecule in human allergic inflammation. Notably, IL-13 expression at birth correlates with subsequent susceptibility to atopic disease. In order to characterize the chromatin-based mechanisms that regulate IL-13 expression in human neonatal CD4(+) T cells, we analyzed patterns of DNase I hypersensitivity and epigenetic modifications within the IL-13 locus in cord blood CD4(+) T cells, naive or differentiated in vitro under Th1- or Th2-polarizing conditions. In naive CD4(+) T cells, hypersensitivity associated with DNA hypomethylation was limited to the distal promoter. Unexpectedly, during both Th1 and Th2 differentiation, the locus was extensively remodeled, as revealed by the formation of numerous HS sites and decreased DNA methylation. Obvious differences in chromatin architecture were limited to the proximal promoter, where strong hypersensitivity, hypomethylation, and permissive histone modifications were found selectively in Th2 cells. In addition to revealing the locations of putative cis-regulatory elements that may be required to control IL-13 expression in neonatal CD4(+) T cells, our results suggest that differential IL-13 expression may depend on the acquisition of a permissive chromatin architecture at the proximal promoter in Th2 cells rather than the formation of locus-wide repressive chromatin in Th1 cells.	Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ 85724 USA; Univ Arizona, Funct Genom Lab, Tucson, AZ 85724 USA; Univ Arizona, Coll Med, Dept Cell Biol, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona	Vercelli, D (corresponding author), Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, Room 2349,1501 N Campbell Ave, Tucson, AZ 85724 USA.	donata@arc.arizona.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066391] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL66391] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Akdis CA, 1999, J INVEST DERMATOL, V113, P628, DOI 10.1046/j.1523-1747.1999.00720.x; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Ansel KM, 2004, NAT IMMUNOL, V5, P1251, DOI 10.1038/ni1135; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; Arnosti DN, 1996, EMBO J, V15, P3659, DOI 10.1002/j.1460-2075.1996.tb00735.x; Attema JL, 2002, J IMMUNOL, V169, P2466, DOI 10.4049/jimmunol.169.5.2466; Baguet A, 2004, P NATL ACAD SCI USA, V101, P11410, DOI 10.1073/pnas.0403334101; Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Dolganov G, 1996, BLOOD, V87, P3316, DOI 10.1182/blood.V87.8.3316.bloodjournal8783316; ELDER JT, 1990, MOL CELL BIOL, V10, P1382, DOI 10.1128/MCB.10.4.1382; Fields PE, 2004, IMMUNITY, V21, P865, DOI 10.1016/j.immuni.2004.10.015; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; Gray S, 1996, GENE DEV, V10, P700, DOI 10.1101/gad.10.6.700; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hsieh CL, 1999, MOL CELL BIOL, V19, P46; Im SH, 2004, J BIOL CHEM, V279, P46818, DOI 10.1074/jbc.M401722200; Kang JG, 2002, EMBO J, V21, P1406, DOI 10.1093/emboj/21.6.1406; Kishikawa H, 2001, J IMMUNOL, V167, P4414, DOI 10.4049/jimmunol.167.8.4414; Koyanagi M, 2005, J BIOL CHEM, V280, P31470, DOI 10.1074/jbc.M504766200; Lange J, 2003, CLIN EXP ALLERGY, V33, P1537, DOI 10.1046/j.1365-2222.2003.01789.x; Lanone S, 2002, J CLIN INVEST, V110, P463, DOI 10.1172/JCI200214136; Lavenu-Bombled C, 2002, J BIOL CHEM, V277, P18313, DOI 10.1074/jbc.M110013200; Lazo GR, 2001, BIOTECHNIQUES, V30, P1300, DOI 10.2144/01306bc03; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; Lee GR, 2005, NAT IMMUNOL, V6, P42, DOI 10.1038/ni1148; Lee GR, 2003, IMMUNITY, V19, P145, DOI 10.1016/S1074-7613(03)00179-1; Lee GR, 2001, IMMUNITY, V14, P447, DOI 10.1016/S1074-7613(01)00125-X; Lee JH, 2001, AM J RESP CELL MOL, V25, P474, DOI 10.1165/ajrcmb.25.4.4522; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Martinez FD, 2003, NEW ENGL J MED, V349, P1473, DOI 10.1056/NEJMe030041; Martinez Fernando D, 2002, Paediatr Respir Rev, V3, P193, DOI 10.1016/S1526-0542(02)00188-4; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Mohrs M, 2001, NAT IMMUNOL, V2, P842, DOI 10.1038/ni0901-842; Monticelli S, 2005, INT IMMUNOL, V17, P1513, DOI 10.1093/intimm/dxh329; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ohshima Y, 2002, PEDIATR RES, V51, P195, DOI 10.1203/00006450-200202000-00012; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; Ribeiro-do-Couto LM, 2001, EUR J IMMUNOL, V31, P3394, DOI 10.1002/1521-4141(200111)31:11<3394::AID-IMMU3394>3.0.CO;2-B; Rozen S, 2000, Methods Mol Biol, V132, P365; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santangelo S, 2002, J IMMUNOL, V169, P1893, DOI 10.4049/jimmunol.169.4.1893; Schubeler D, 2000, MOL CELL BIOL, V20, P9103, DOI 10.1128/MCB.20.24.9103-9112.2000; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; Takemoto N, 1998, INT IMMUNOL, V10, P1981, DOI 10.1093/intimm/10.12.1981; van der Velden VHJ, 2001, CLIN EXP ALLERGY, V31, P997, DOI 10.1046/j.1365-2222.2001.01176.x; Vercelli D, 2002, CURR OPIN ALLERGY CL, V2, P389, DOI 10.1097/00130832-200210000-00004; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wilson CB, 2005, SEMIN IMMUNOL, V17, P105, DOI 10.1016/j.smim.2005.01.005; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458	64	63	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					700	709		10.1074/jbc.M609501200	http://dx.doi.org/10.1074/jbc.M609501200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17090525	hybrid			2022-12-27	WOS:000243166500075
J	Qiao, LP; Shao, JH				Qiao, Liping; Shao, Jianhua			SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; BINDING-PROTEIN; ADIPOSE-TISSUE; FACTOR FOXO1; PROMOTER; DIFFERENTIATION; METABOLISM; INDUCTION; MUSCLE	Adiponectin is an adipose-derived hormone that plays an important role in maintaining energy homeostasis. Adiponectin gene expression is diminished in both obesity and type 2 diabetes. However, the mechanism underlying the impaired adiponectin gene expression remains poorly understood. Recent studies have indicated that forkhead transcription factor O1 (Foxo1) and silent information regulator 2 mammalian ortholog SIRT1 are involved in adipogenesis. Here we have shown that Foxo1 up-regulates adiponectin gene transcription through a Foxo1-responsive region in the mouse adiponectin promoter that contains two adjacent Foxo1 binding sites. Foxo1 interacts with CCAAT/enhancer-binding protein alpha (C/EBP alpha) to form a transcription complex at the mouse adiponectin promoter and up-regulates adiponectin gene transcription. Our study has revealed that C/EBP alpha accesses the adiponectin promoter through two Foxo1 binding sites and acts as a co-activator. Further, SIRT1 increases adiponectin transcription in adipocytes by activating Foxo1 and enhancing Foxo1 and C/EBP alpha interaction. Importantly, both Foxo1 and SIRT1 protein levels were significantly lower in epididymal fat tissues from db/db and high fat diet-induced obese mice compared with normal mice. We propose that low expression of SIRT1 and Foxo1 leads to impaired Foxo1-C/EBP alpha complex formation, which contributes to the diminished adiponectin expression in obesity and type 2 diabetes.	Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40536 USA	University of Kentucky	Shao, JH (corresponding author), Univ Kentucky, Grad Ctr Nutr Sci, 900 S Limestone, Lexington, KY 40536 USA.	JianhuaShao@uky.edu						Altomonte J, 2004, J CLIN INVEST, V114, P1493, DOI 10.1172/JCI200419992; Barth N, 2002, DIABETOLOGIA, V45, P1425, DOI 10.1007/s00125-002-0895-5; Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cariou B, 2004, ENDOCRINOLOGY, V145, P1926, DOI 10.1210/en.2003-0882; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Das K, 2001, BIOCHEM BIOPH RES CO, V280, P1120, DOI 10.1006/bbrc.2001.4217; Davis KE, 2004, J BIOL CHEM, V279, P42453, DOI 10.1074/jbc.M402197200; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Iglseder B, 2005, STROKE, V36, P2577, DOI 10.1161/01.STR.0000190834.00284.fd; Imae M, 2003, J MOL ENDOCRINOL, V30, P253, DOI 10.1677/jme.0.0300253; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005; Li JP, 2002, AM J PHYSIOL-ENDOC M, V282, pE1334, DOI 10.1152/ajpendo.00516.2001; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Matsumoto M, 2005, CELL METAB, V1, P215, DOI 10.1016/j.cmet.2005.03.008; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; OBrien RM, 1995, J CLIN INVEST, V96, P2546, DOI 10.1172/JCI118317; Onuma H, 2006, MOL ENDOCRINOL, V20, P2831, DOI 10.1210/me.2006-0085; Orlicky DJ, 2001, J LIPID RES, V42, P910; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; Park SK, 2004, DIABETES, V53, P2757, DOI 10.2337/diabetes.53.11.2757; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Qiao LP, 2005, DIABETES, V54, P1744, DOI 10.2337/diabetes.54.6.1744; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Saito K, 1999, BIOL PHARM BULL, V22, P1158; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Seo JB, 2004, J BIOL CHEM, V279, P22108, DOI 10.1074/jbc.M400238200; Ulrich S, 2006, CANCER RES, V66, P7348, DOI 10.1158/0008-5472.CAN-05-2777; van der Heide LP, 2005, TRENDS BIOCHEM SCI, V30, P81, DOI 10.1016/j.tibs.2004.12.002; Vander Kooi BT, 2003, J BIOL CHEM, V278, P11782, DOI 10.1074/jbc.M212570200; Wolfrum C, 2003, J CLIN INVEST, V112, P345, DOI 10.1172/JCI18698; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	40	267	288	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39915	39924		10.1074/jbc.M607215200	http://dx.doi.org/10.1074/jbc.M607215200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17090532	hybrid			2022-12-27	WOS:000243033900019
J	Nam, YJ; Mani, K; Wu, L; Peng, CF; Calvert, JW; Foo, RSY; Krishnamurthy, B; Miao, WF; Ashton, AW; Lefer, DJ; Kitsis, RN				Nam, Young-Jae; Mani, Kartik; Wu, Lily; Peng, Chang-Fu; Calvert, John W.; Foo, Roger S. -Y.; Krishnamurthy, Barath; Miao, Wenfeng; Ashton, Anthony W.; Lefer, David J.; Kitsis, Richard N.			The apoptosis inhibitor ARC undergoes ubiquitin-proteasomal-mediated degradation in response to death stimuli - Identification of a degradation-resistant mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE RECRUITMENT DOMAIN; RAT VENTRICULAR MYOCYTES; CELL-DEATH; REPERFUSION INJURY; PROTEIN ARC; REPRESSOR; ACTIVATION; LOCALIZES; RECEPTOR; PATHWAY	Efficient induction of apoptosis requires not only the activation of death-promoting proteins but also the inactivation of inhibitors of cell death. ARC (apoptosis repressor with caspase recruitment domain) is an endogenous inhibitor of apoptosis that antagonizes both central apoptosis pathways. Despite its potent inhibition of cell death, cells that express abundant ARC eventually succumb. A possible explanation is that ARC protein levels decrease dramatically in response to death stimuli. The mechanisms that mediate decreases in ARC protein levels during apoptosis and whether these decreases initiate the subsequent cell death are not known. Here we show that endogenous ARC protein levels decrease in response to death stimuli in a variety of cell contexts as well as in a model of myocardial ischemia reperfusion in intact mice. Decreases in ARC protein levels are not explained by alterations in the abundance of ARC transcripts. Rather, pulse-chase experiments show that decreases in steady state ARC protein levels during apoptosis result from marked destabilization of ARC protein. ARC protein destabilization, in turn, is mediated by the ubiquitin-proteasomal pathway, as mutation of ARC ubiquitin acceptor residues stabilizes ARC protein and preserves its steady state levels during apoptosis. In addition, this degradation-resistant ARC mutant exhibits improved cytoprotection. We conclude that decreases in ARC protein levels in response to death stimuli are mediated by increased ARC protein degradation via the ubiquitin-proteasomal pathway. Moreover, these data demonstrate that decreases in ARC protein levels are a trigger, and not merely a consequence, of the ensuing cell death.	Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Cardiovasc Res Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Canc, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Kitsis, RN (corresponding author), Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	kitsis@aecom.yu.edu	Lefer, David/A-6372-2012; Mani, Kartik/B-8121-2011; Calvert, John W/F-4497-2014	Mani, Kartik/0000-0002-4951-3478; Calvert, John W/0000-0001-6858-6042; Lefer, David/0000-0003-2293-7278; Foo, Roger/0000-0002-8079-4618	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061550, R01HL080607, R01HL060665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL61550, R01HL60665, R01HL80607] Funding Source: Medline; NIDDK NIH HHS [P60DK020541] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; Chatterjee S, 2003, J THORAC CARDIOV SUR, V125, P1461, DOI 10.1016/S0022-5223(02)73229-7; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Donath S, 2006, CIRCULATION, V113, P1203, DOI 10.1161/CIRCULATIONAHA.105.576785; Ekhterae D, 1999, CIRC RES, V85, pE70; Foo RSY, 2007, J BIOL CHEM, V282, P5529, DOI 10.1074/jbc.M609046200; Geertman R, 1996, BBA-GENE STRUCT EXPR, V1306, P147, DOI 10.1016/0167-4781(96)00036-X; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gustafsson AB, 2002, CIRCULATION, V106, P735, DOI 10.1161/01.CIR.0000023943.50821.F7; Gustafsson AB, 2004, J BIOL CHEM, V279, P21233, DOI 10.1074/jbc.M400695200; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Lee P, 2003, AM J PHYSIOL-HEART C, V284, pH456, DOI 10.1152/ajpheart.00777.2002; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Mercier I, 2005, CELL DEATH DIFFER, V12, P682, DOI 10.1038/sj.cdd.4401631; Nam YJ, 2004, MOL CELL, V15, P901, DOI 10.1016/j.molcel.2004.08.020; Neuss M, 2001, J BIOL CHEM, V276, P33915, DOI 10.1074/jbc.M104080200; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Peter Marcus E, 2004, Biochem J, V382, pe1; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Potts MB, 2005, J CELL BIOL, V171, P925, DOI 10.1083/jcb.200504082; Potts PR, 2003, J CELL BIOL, V163, P789, DOI 10.1083/jcb.200307130; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Tarzami ST, 2003, CIRCULATION, V108, P2387, DOI 10.1161/01.CIR.0000093192.72099.9A; Wang M, 2005, FEBS LETT, V579, P2411, DOI 10.1016/j.febslet.2005.03.040; Yaniv G, 2005, BIOCHEM BIOPH RES CO, V336, P740, DOI 10.1016/j.bbrc.2005.08.167; Yaniv G, 2002, CARDIOVASC RES, V54, P611, DOI 10.1016/S0008-6363(02)00264-X	28	47	49	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5522	5528		10.1074/jbc.M609186200	http://dx.doi.org/10.1074/jbc.M609186200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17142452	hybrid			2022-12-27	WOS:000244482300047
J	Estey, T; Cantore, M; Weston, PA; Carpenter, JF; Petrash, JM; Vasiliou, V				Estey, Tia; Cantore, Miriam; Weston, Philip A.; Carpenter, John F.; Petrash, J. Mark; Vasiliou, Vasilis			Mechanisms involved in the protection of UV-induced protein inactivation by the corneal crystallin ALDH3A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCULAR ALDEHYDE DEHYDROGENASE; HEAT-SHOCK PROTEINS; ULTRAVIOLET-LIGHT; ALPHA-CRYSTALLIN; CHAPERONE FUNCTION; EXPRESSION; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; LENS; SENSITIVITY; IRRADIATION	Various lines of evidence have shown that ALDH3A1 (aldehyde dehydrogenase 3A1) plays a critical and multifaceted role in protecting the cornea from UV-induced oxidative stress. ALDH3A1 is a corneal crystallin, which is defined as a protein recruited into the cornea for structural purposes without losing its primary function (i.e. metabolism). Although the primary role of ALDH3A1 in the metabolism of toxic aldehydes has been clearly demonstrated, including the detoxification of aldehydes produced during UV-induced lipid peroxidation, the structural role of ALDH3A1 in the cornea remains elusive. We therefore examined the potential contribution of ALDH3A1 in maintaining the optical integrity of the cornea by suppressing the aggregation and/or inactivation of other proteins through chaperone-like activity and other protective mechanisms. We found that ALDH3A1 underwent a structural transition near physiological temperatures to form a partially unfolded conformation that is suggestive of chaperone activity. Although this structural transition alone did not correlate with any protection, ALDH3A1 substantially reduced the inactivation of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal and malondialdehyde when co-incubated with NADP(+), reinforcing the importance of the metabolic function of this corneal enzyme in the detoxification of toxic aldehydes. A large excess of ALDH3A1 also protected glucose-6-phosphate dehydrogenase from inactivation because of direct exposure to UVB light, which suggests that ALDH3A1 may shield other proteins from damaging UV rays. Collectively, these data demonstrate that ALDH3A1 can reduce protein inactivation and/or aggregation not only by detoxification of reactive aldehydes but also by directly absorbing UV energy. This study provides for the first time mechanistic evidence supporting the structural role of the corneal crystallin ALDH3A1 as a UV-absorbing constituent of the cornea.	Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Ctr Pharmaceut Biotechnol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Mol Toxicol & Environm Hlth Sci Program, Denver, CO 80262 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63119 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Washington University (WUSTL)	Vasiliou, V (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Ctr Pharmaceut Biotechnol, Denver, CO 80262 USA.	vasilis.vasiliou@uchsc.edu		vasiliou, vasilis/0000-0003-2552-3118	NATIONAL EYE INSTITUTE [R01EY011490, R29EY011490] Funding Source: NIH RePORTER; NEI NIH HHS [EY11490, EY13987] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; Bulteau AL, 2002, FREE RADICAL BIO MED, V32, P1157, DOI 10.1016/S0891-5849(02)00816-X; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Davies MJ, 2004, PHOTOCH PHOTOBIO SCI, V3, P17, DOI 10.1039/b307576c; Davies MJ, 2001, J PHOTOCH PHOTOBIO B, V63, P114, DOI 10.1016/S1011-1344(01)00208-1; DOWNES JE, 1994, CORNEA, V13, P67, DOI 10.1097/00003226-199401000-00011; DOWNES JE, 1993, CORNEA, V12, P241, DOI 10.1097/00003226-199305000-00010; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Estey T, 2007, EXP EYE RES, V84, P3, DOI 10.1016/j.exer.2006.04.010; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; Ganea E, 2006, CURR EYE RES, V31, P1, DOI 10.1080/02713680500477347; Ganea E, 2000, BBA-MOL BASIS DIS, V1500, P49, DOI 10.1016/S0925-4439(99)00087-3; Ganea E, 1996, BIOCHEM BIOPH RES CO, V222, P626, DOI 10.1006/bbrc.1996.0794; HAHN DW, 2005, ROLE KERATOCYTES COR; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Jester JV, 2005, INVEST OPHTH VIS SCI, V46, P2369, DOI 10.1167/iovs.04-1225; Jester JV, 1999, J CELL SCI, V112, P613; King G, 1998, J EXP ZOOL, V282, P12; Kolozsvari L, 2002, INVEST OPHTH VIS SCI, V43, P2165; Koteiche HA, 2003, J BIOL CHEM, V278, P10361, DOI 10.1074/jbc.M211851200; Kueltzo LA, 2003, J PHARM SCI-US, V92, P1805, DOI 10.1002/jps.10439; Kumar MS, 2005, BIOCHEM J, V391, P335, DOI 10.1042/BJ20050506; LINDAHL R, 1991, BIOCHEM PHARMACOL, V41, P1583, DOI 10.1016/0006-2952(91)90157-Z; MACH H, 1994, ANAL BIOCHEM, V222, P323, DOI 10.1006/abio.1994.1499; Manzer R, 2003, DNA CELL BIOL, V22, P329, DOI 10.1089/104454903322216671; Manzer R, 2003, CHEM-BIOL INTERACT, V143, P45, DOI 10.1016/S0009-2797(02)00171-0; MITCHELL J, 1995, CORNEA, V14, P266, DOI 10.1097/00003226-199505000-00007; MUROV SL, 1992, HDB PHOTOCHEMISTRY, P298; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Pappa A, 2003, BIOCHEM J, V376, P615, DOI 10.1042/BJ20030810; Pappa A, 2003, FREE RADICAL BIO MED, V34, P1178, DOI 10.1016/S0891-5849(03)00070-4; Pappa A, 2001, CHEM-BIOL INTERACT, V130, P181, DOI 10.1016/S0009-2797(00)00233-7; Piatigorsky J, 2000, J OCUL PHARMACOL TH, V16, P173, DOI 10.1089/jop.2000.16.173; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; Piatigorsky J, 1998, ANN NY ACAD SCI, V842, P7, DOI 10.1111/j.1749-6632.1998.tb09626.x; Piatigorsky J, 2001, CORNEA, V20, P853, DOI 10.1097/00003226-200111000-00015; PITTS DG, 1993, ENV VISION, P2; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; Reddy GB, 2001, BIOCHEM BIOPH RES CO, V282, P712, DOI 10.1006/bbrc.2001.4642; Ringvold A, 1998, ACTA OPHTHALMOL SCAN, V76, P149, DOI 10.1034/j.1600-0420.1998.760205.x; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Shashidharamurthy R, 2005, J BIOL CHEM, V280, P5281, DOI 10.1074/jbc.M407236200; Shiao T, 1999, PHARMACOGENETICS, V9, P145; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; Uma L, 1996, EXP EYE RES, V63, P117, DOI 10.1006/exer.1996.0098; Uma L, 1996, CURR EYE RES, V15, P685, DOI 10.3109/02713689609008910; VANKUIJK FJGM, 1991, ENVIRON HEALTH PERSP, V96, P177, DOI 10.2307/3431229; Vasiliou V, 2004, DRUG METAB REV, V36, P279, DOI 10.1081/DMR-120034001; ZIGMAN S, 1993, PHOTOCHEM PHOTOBIOL, V57, P1060, DOI 10.1111/j.1751-1097.1993.tb02972.x	50	44	47	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4382	4392		10.1074/jbc.M607546200	http://dx.doi.org/10.1074/jbc.M607546200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158879	hybrid			2022-12-27	WOS:000244482000018
J	Yong, WD; Yang, ZC; Periyasamy, S; Chen, HY; Yucel, S; Li, W; Lin, LY; Wolf, IM; Cohn, MJ; Baskin, LS; Sanchez, ER; Shou, WN				Yong, Weidong; Yang, Zuocheng; Periyasamy, Sumudra; Chen, Hanying; Yucel, Selcul; Li, Wei; Lin, Leanne Y.; Wolf, Irene M.; Cohn, Martin J.; Baskin, Laurence S.; Sanchez, Edwin R.; Shou, Weinian			Essential role for co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLPROLYL ISOMERASE DOMAIN; TETRATRICOPEPTIDE REPEAT DOMAIN; HSP56 IMMUNOPHILIN COMPONENT; STEROID-HORMONE RECEPTORS; HEAT-SHOCK-PROTEIN; GLUCOCORTICOID-RECEPTOR; DYNEIN INTERACTION; INSENSITIVITY SYNDROME; FK506-BINDING PROTEIN; PROGESTERONE-RECEPTOR	Fkbp52 and Fkbp51 are tetratricopeptide repeat proteins found in steroid receptor complexes, and Fkbp51 is an androgen receptor (AR) target gene. Although in vitro studies suggest that Fkbp52 and Fkbp51 regulate hormone binding and/or subcellular trafficking of receptors, the roles of Fkbp52 and Fkbp51 in vivo have not been extensively investigated. Here, we evaluate their physiological roles in Fkbp52-deficient and Fkbp51-deficient mice. Fkbp52-deficient males developed defects in select reproductive organs (e.g. penile hypospadias and prostate dysgenesis but normal testis), pointing to a role for Fkbp52 in AR-mediated signaling and function. Surprisingly, ablation of Fkbp52 did not affect AR hormone binding or nuclear translocation in vivo and in vitro. Molecular studies in mouse embryonic fibroblast cells uncovered that Fkbp52 is critical to AR transcriptional activity. Interestingly, Fkbp51 expression was down-regulated in Fkbp52-deficient males but only in affected tissues, providing further evidence of tissue-specific loss of AR activity and suggesting that Fkbp51 is an AR target gene essential to penile and prostate development. However, Fkbp51-deficient mice were normal, showing no defects in AR-mediated reproductive function. Our work demonstrates that Fkbp52 but not Fkbp51 is essential to AR-mediated signaling and provides evidence for an unprecedented Fkbp52 function, direct control of steroid receptor transcriptional activity.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Pediat Cardiol Sect,Dept Pediat, Indianapolis, IN 46202 USA; Cent S Univ, Xiang Ya Sch Med, Dept Pediat, Xiang Ya Hosp 3, Changsha 410013, Peoples R China; Univ Toledo, Coll Med, Dept Physiol & Pharmacol, Toledo, OH 43614 USA; Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA; Univ Florida, Dept Zool, Gainesville, FL 32611 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Central South University; University System of Ohio; University of Toledo; University of California System; University of California San Francisco; State University System of Florida; University of Florida	Shou, WN (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Pediat Cardiol Sect,Dept Pediat, R4-368,1044 W Walnut, Indianapolis, IN 46202 USA.	wshou@iupui.edu	Yucel, Selcuk/AAA-9434-2021; Yucel, Selcuk/D-5153-2016	Yucel, Selcuk/0000-0001-9837-5510; Lin, Leanne/0000-0002-4132-3055	NIDDK NIH HHS [DK70127, R01 DK073402, DK43867, R01 DK043867, R01 DK070127, DK73402, R01 DK073402-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043867, R01DK070127, R01DK073402, R29DK043867] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATCH JA, 1992, HUM MOL GENET, V1, P497, DOI 10.1093/hmg/1.7.497; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; CHAREST NJ, 1991, MOL ENDOCRINOL, V5, P573, DOI 10.1210/mend-5-4-573; Chen HY, 2004, DEVELOPMENT, V131, P2219, DOI 10.1242/dev.01094; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Cheung-Flynn J, 2005, MOL ENDOCRINOL, V19, P1654, DOI 10.1210/me.2005-0071; Cheung-Flynn J, 2003, J BIOL CHEM, V278, P17388, DOI 10.1074/jbc.M300955200; COLE TJ, 1995, STEROIDS, V60, P93, DOI 10.1016/0039-128X(94)00009-2; CZAR MJ, 1994, MOL ENDOCRINOL, V8, P1731, DOI 10.1210/me.8.12.1731; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Davies TH, 2005, BIOCHEMISTRY-US, V44, P2030, DOI 10.1021/bi048503v; Davies TH, 2005, INT J BIOCHEM CELL B, V37, P42, DOI 10.1016/j.biocel.2004.03.013; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Febbo PG, 2005, J UROLOGY, V173, P1772, DOI 10.1097/01.ju.0000155845.44729.ba; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Huang ZQ, 2002, MOL ENDOCRINOL, V16, P924, DOI 10.1210/me.16.5.924; Hubler TR, 2003, ENDOCRINOLOGY, V144, P2380, DOI 10.1210/en.2003-0092; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; Magee JA, 2006, ENDOCRINOLOGY, V147, P590, DOI 10.1210/en.2005-1001; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Pratt WB, 2004, ESSAYS BIOCHEM, V40, P41, DOI 10.1042/bse0400041; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; RUFF VA, 1992, J BIOL CHEM, V267, P21285; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sinars CR, 2003, P NATL ACAD SCI USA, V100, P868, DOI 10.1073/pnas.0231020100; SONG CS, 1993, BIOCHEM J, V294, P779, DOI 10.1042/bj2940779; Stanford WL, 2001, NAT REV GENET, V2, P756, DOI 10.1038/35093548; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; Tan KAL, 2005, ENDOCRINOLOGY, V146, P2674, DOI 10.1210/en.2004-1630; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Vanaja DK, 2002, CELL STRESS CHAPERON, V7, P55, DOI 10.1379/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P742, DOI 10.1021/bi00147a029; Wise SC, 1998, ONCOGENE, V16, P2001, DOI 10.1038/sj.onc.1201697; Wochnik GM, 2005, J BIOL CHEM, V280, P4609, DOI 10.1074/jbc.M407498200; Yang ZC, 2006, MOL ENDOCRINOL, V20, P2682, DOI 10.1210/me.2006-0024; Yeager MP, 2004, ACTA ANAESTH SCAND, V48, P799, DOI 10.1111/j.1399-6576.2004.00434.x; Yeh SY, 2002, P NATL ACAD SCI USA, V99, P13498, DOI 10.1073/pnas.212474399; YEM AW, 1992, J BIOL CHEM, V267, P2868; Yucel S, 2003, BJU INT, V92, P1016, DOI 10.1111/j.1464-410X.2003.04511.x; Zhu W, 2001, CARCINOGENESIS, V22, P1399, DOI 10.1093/carcin/22.9.1399	58	116	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					5026	5036		10.1074/jbc.M609360200	http://dx.doi.org/10.1074/jbc.M609360200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17142810	Green Accepted, hybrid			2022-12-27	WOS:000244482000085
J	Praetorius-Ibba, M; Hausmann, CD; Paras, M; Rogers, TE; Ibba, M				Praetorius-Ibba, Mette; Hausmann, Corinne D.; Paras, Molly; Rogers, Theresa E.; Ibba, Michael			Functional association between three archaeal aminoacyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIENZYME COMPLEX; PROTEIN; DOMAIN; SEQUENCE; ARC1P	Aminoacyl-tRNA synthetases (aaRSs) are responsible for attaching amino acids to their cognate tRNAs during protein synthesis. In eukaryotes aaRSs are commonly found in multienzyme complexes, although the role of these complexes is still not completely clear. Associations between aaRSs have also been reported in archaea, including a complex between prolyl-(ProRS) and leucyl-tRNA synthetases (LeuRS) in Methanothermobacter thermautotrophicus that enhances tRNA(Pro) aminoacylation. Yeast two-hybrid screens suggested that lysyl-tRNA synthetase (LysRS) also associates with LeuRS in M. thermautotrophicus. Co-purification experiments confirmed that LeuRS, LysRS, and ProRS associate in cell-free extracts. LeuRS bound LysRS and ProRS with a comparable K-D of about 0.3-0.9 mu m, further supporting the formation of a stable multi-synthetase complex. The steady-state kinetics of aminoacylation by LysRS indicated that LeuRS specifically reduced the K-m for tRNA(Lys) over 3-fold, with no additional change seen upon the addition of ProRS. No significant changes in aminoacylation by LeuRS or ProRS were observed upon the addition of LysRS. These findings, together with earlier data, indicate the existence of a functional complex of three aminoacyl-tRNA synthetases in archaea in which LeuRS improves the catalytic efficiency of tRNA aminoacylation by both LysRS and ProRS.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Ibba, M (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.	ibba.1@osu.edu		Paras, Molly/0000-0001-6658-8634; Rogers, Theresa/0000-0002-9741-5768	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065183] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 65183] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An S, 2005, J BIOL CHEM, V280, P34465, DOI 10.1074/jbc.M507550200; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; Dagkessamanskaia A, 2001, FEMS MICROBIOL LETT, V200, P53, DOI 10.1016/S0378-1097(01)00203-8; de Pouplana LR, 2001, CELL, V104, P191, DOI 10.1016/S0092-8674(01)00204-5; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Fukunaga R, 2005, NAT STRUCT MOL BIOL, V12, P915, DOI 10.1038/nsmb985; Galani K, 2005, FEBS LETT, V579, P969, DOI 10.1016/j.febslet.2004.11.112; Galani K, 2001, EMBO J, V20, P6889, DOI 10.1093/emboj/20.23.6889; GOLDGUR Y, 1994, BIOCHEM MOL BIOL INT, V32, P1075; Hsu JL, 2006, J BIOL CHEM, V281, P23075, DOI 10.1074/jbc.M601606200; Ibba M., 2005, AMINOACYL TRNA SYNTH; JAKUBOWSKI H, 1984, J BACTERIOL, V158, P769, DOI 10.1128/JB.158.3.769-776.1984; Kovaleski BJ, 2006, J BIOL CHEM, V281, P19449, DOI 10.1074/jbc.M601189200; Lee SW, 2004, J CELL SCI, V117, P3725, DOI 10.1242/jcs.01342; Ling C, 2005, J BIOL CHEM, V280, P34755, DOI 10.1074/jbc.M413511200; Lipman RSA, 2003, BIOCHEMISTRY-US, V42, P7487, DOI 10.1021/bi0344533; MIRANDE M, 2005, AMINOACYL TRNA SYNTH, P298; Negrutskii BS, 1999, J BIOL CHEM, V274, P4545, DOI 10.1074/jbc.274.8.4545; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; Park SG, 2005, TRENDS BIOCHEM SCI, V30, P569, DOI 10.1016/j.tibs.2005.08.004; Polycarpo C, 2003, MOL CELL, V12, P287, DOI 10.1016/S1097-2765(03)00280-6; Praetorius-Ibba M, 2005, J BIOL CHEM, V280, P26099, DOI 10.1074/jbc.M503539200; Robinson JC, 2000, J MOL BIOL, V304, P983, DOI 10.1006/jmbi.2000.4242; Rocak S, 2002, FEMS MICROBIOL LETT, V214, P101, DOI 10.1111/j.1574-6968.2002.tb11331.x; Sampath P, 2004, CELL, V119, P195, DOI 10.1016/j.cell.2004.09.030; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Wang LN, 2005, RNA, V11, P1291, DOI 10.1261/rna.2060405; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Wolfe CL, 2005, J BIOL CHEM, V280, P38870, DOI 10.1074/jbc.M502759200; Wolfson A, 2005, FEBS LETT, V579, P3467, DOI 10.1016/j.febslet.2005.05.038; Xia QW, 2006, MOL CELL PROTEOMICS, V5, P868, DOI 10.1074/mcp.M500369-MCP200; Zhang CM, 2006, J MOL BIOL, V361, P300, DOI 10.1016/j.jmb.2006.06.015	36	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3680	3687		10.1074/jbc.M609988200	http://dx.doi.org/10.1074/jbc.M609988200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158871	Green Published, hybrid			2022-12-27	WOS:000244481900030
J	Scola, AM; Higginbottom, A; Partridge, LJ; Reid, RC; Woodruff, T; Taylor, SM; Fairlie, DP; Monk, PN				Scola, Anne-Marie; Higginbottom, Adrian; Partridge, Lynda J.; Reid, Robert C.; Woodruff, Trent; Taylor, Stephen M.; Fairlie, David P.; Monk, Peter N.			The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C5A RECEPTOR; HUMAN C3A RECEPTOR; AMINO-TERMINUS; PROTEIN; ANAPHYLATOXIN; IDENTIFICATION; SITE; ANTAGONISTS; ACTIVATION; ANTIBODIES	C5L2 is a new cellular receptor found to interact with the human anaphylatoxins complement factor C5a and its C-terminal cleavage product C5a des Arg. The classical human C5a receptor (CSaR) preferentially binds C5a, with a 10-100-fold lower affinity for C5a des Arg. In contrast, C5L2 binds both ligands with nearly equal affinity. C5aR presents acidic and tyrosine residues in its N terminus that interact with the core of C5a while a hydrophobic pocket formed by the transmembrane helices interacts with residues in the C terminus of C5a. Here, we have investigated the molecular basis for the increased affinity of C5L2 for C5a des Arg. Rat and mouse C5L2 preferentially bound C5a des Arg, whereas rodent C5aR showed much higher affinity for intact C5a. Effective peptidic and non-peptidic ligands for the transmembrane hydrophobic pocket of C5aR were poor inhibitors of ligand binding to C5L2. An antibody raised against the N terminus of human C5L2 did not affect the binding of C5a to C5L2 but did inhibit C5a des Arg binding. A chimeric C5L2, containing the N terminus of C5aR, had little effect on the affinity for C5a des Arg. Mutation of acidic and tyrosine residues in the N terminus of human C5L2 revealed that 3 residues were critical for C5a des Arg binding but had little involvement in C5a binding. C5L2 thus appears to bind C5a and C5a des Arg by different mechanisms, and, unlike C5aR, C5L2 uses critical residues in its N-terminal domain for binding only to C5a des Arg.	Univ Sheffield, Sch Med, Acad Neurol Unit, Sheffield S10 2RX, S Yorkshire, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2RX, S Yorkshire, England; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Biomed Sci, Brisbane, Qld 4072, Australia	University of Sheffield; University of Sheffield; University of Queensland; University of Queensland	Monk, PN (corresponding author), Univ Sheffield, Sch Med, Acad Neurol Unit, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	p.monk@shef.ac.uk	Woodruff, Trent M/B-4861-2009; Woodruff, Trent/AAS-4629-2020; Reid, Robert/D-8041-2012; Monk, Peter/C-6155-2008; Fairlie, David P/F-8865-2014	Woodruff, Trent M/0000-0003-1382-911X; Woodruff, Trent/0000-0003-1382-911X; Reid, Robert/0000-0002-0829-239X; Monk, Peter/0000-0003-4637-3059; Fairlie, David P/0000-0002-7856-8566	Wellcome Trust [072231] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; Cain SA, 2001, BIOCHEMISTRY-US, V40, P14047, DOI 10.1021/bi011055w; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; Chen ZG, 1998, J BIOL CHEM, V273, P10411, DOI 10.1074/jbc.273.17.10411; Crass T, 1999, J BIOL CHEM, V274, P8367, DOI 10.1074/jbc.274.13.8367; deLaszlo SE, 1997, BIOORG MED CHEM LETT, V7, P213, DOI 10.1016/S0960-894X(96)00606-3; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; Eglite S, 2000, J IMMUNOL, V165, P2183, DOI 10.4049/jimmunol.165.4.2183; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Gao HW, 2005, FASEB J, V19, P1003, DOI 10.1096/fj.04-3424fje; Gavrilyuk V, 2005, J NEUROCHEM, V92, P1140, DOI 10.1111/j.1471-4159.2004.02942.x; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gerard NP, 2005, J BIOL CHEM, V280, P39677, DOI 10.1074/jbc.C500287200; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; HIGGINBOTTOM A, 2005, J BIOL CHEM; Kalant D, 2003, J BIOL CHEM, V278, P11123, DOI 10.1074/jbc.M206169200; LANZA TJ, 1992, J MED CHEM, V35, P252, DOI 10.1021/jm00080a008; MERY L, 1994, J BIOL CHEM, V269, P3457; MERY L, 1993, EUR J HAEMATOL, V51, P282; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; MORGAN EL, 1993, J IMMUNOL, V151, P377; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; Otto M, 2004, J BIOL CHEM, V279, P142, DOI 10.1074/jbc.M310078200; Paczkowski NJ, 1999, BRIT J PHARMACOL, V128, P1461, DOI 10.1038/sj.bjp.0702938; PEASE JE, 1993, BIOCHEM MOL BIOL INT, V31, P719; Postma B, 2005, J BIOL CHEM, V280, P2020, DOI 10.1074/jbc.M412230200; Sun JZ, 1999, PROTEIN SCI, V8, P2304; Wilken HC, 1999, IMMUNOL LETT, V67, P141, DOI 10.1016/S0165-2478(99)00002-4; Wilken HC, 1999, J IMMUNOL METHODS, V226, P139, DOI 10.1016/S0022-1759(99)00064-2	32	43	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3664	3671		10.1074/jbc.M609178200	http://dx.doi.org/10.1074/jbc.M609178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158873	Green Accepted, hybrid			2022-12-27	WOS:000244481900028
J	Kinukawa, M; Nomura, M; Vacquier, VD				Kinukawa, Masashi; Nomura, Mamoru; Vacquier, Victor D.			A sea urchin sperm flagellar adenylate kinase with triplicated catalytic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CREATINE-KINASE; PHOSPHOCREATINE SHUTTLE; PROTEOMIC ANALYSIS; ENERGY-TRANSPORT; OUTER ARM; MOTILITY; SPERMATOZOA; MOVEMENT; DYNEIN	The mitochondrion of sea urchin sperm is located at the base of the sperm head, and the flagellum extends from the mitochondrion for similar to 40 mu m. These sperm have two known flagellar, non-mitochondrial, enzymatic systems to rephosphorylate ADP. The first involves the phosphocreatine shuttle, where flagellar creatine kinase (Sp-CK) uses phosphocreatine to rephosphorylate ADP. The second system, studied in this report, is adenylate kinase (Sp-AK), which uses 2 ADP to make ATP + AMP. Cloning of Sp-AK shows that, like Sp-CK, Sp-AK has three catalytic domains. Sp-AK localizes along the entire flagellum, and most of it is tightly bound to the axoneme. Sp-AK activity and flagellar motility were studied using demembranated sperm. The specific Sp-AK inhibitor Ap5A blocks enzyme activity with an IC50 of 0.41 mu M. In 1 mM ADP, flagella reactivate motility in 5 min; 1 mu M Ap5A completely inhibits this reactivation. No inhibition of motility occurs in Ap5A when 1 mM ATP is added to the reactivation buffer. The pH optimum for Sp-AK is 7.7, an internal pH at which sperm are fully motile. The pH optimum for Sp-CK is 6.7, an internal pH at which sperm are immotile. In isolated, detergent-permeabilized flagella, assayed at pH 7.6, the K-m for Sp-AK is 0.32 mM and the V-max is 2.80 mu M ATP formed/min/mg of protein. When assayed at pH 7.6, the Sp-CK K-m is 0.25 mM and the V-max 5.25. At the measured in vivo concentrations of ADP of 114 mu M, at pH 7.6, the axonemal Sp-AK could contribute similar to 31%, and Sp-CK 69%, of the total non-mitochondrial ATP synthesis associated with the demembranated axoneme. Thus, Sp-AK could contribute substantially to ATP synthesis utilized for motility. Alternatively, Sp-AK could function in the removal of ADP, which is a potent inhibitor of dynein ATPase.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA; Univ Tsukuba, Shimoda Marine Res Ctr, Shizuoka 4150025, Japan	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Tsukuba	Kinukawa, M (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA.	makinukawa@ucsd.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012986, R01HD012986] Funding Source: NIH RePORTER; NICHD NIH HHS [HD12986] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BROKAW CJ, 1961, EXP CELL RES, V22, P151, DOI 10.1016/0014-4827(61)90094-5; BROKAW CJ, 1973, J CELL SCI, V13, P1; CHRISTEN R, 1983, J BIOL CHEM, V258, P5392; GIBBONS BH, 1972, J CELL BIOL, V54, P75, DOI 10.1083/jcb.54.1.75; GIBBONS IR, 1965, J CELL BIOL, V25, P400, DOI 10.1083/jcb.25.2.400; Gibbons IR, 1996, CELL STRUCT FUNCT, V21, P331, DOI 10.1247/csf.21.331; Ginger ML, 2005, J BIOL CHEM, V280, P11781, DOI 10.1074/jbc.M413821200; Inaba K, 2003, ZOOL SCI, V20, P1043, DOI 10.2108/zsj.20.1043; KAMIMURA S, 1981, NATURE, V293, P566, DOI 10.1038/293566a0; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; Miki K, 2004, P NATL ACAD SCI USA, V101, P16501, DOI 10.1073/pnas.0407708101; Mitchell BF, 2005, MOL BIOL CELL, V16, P4509, DOI 10.1091/mbc.E05-04-0347; Nakamura K, 1999, COMP BIOCHEM PHYS B, V124, P195, DOI 10.1016/S0305-0491(99)00114-5; Nakano I, 2003, J CELL SCI, V116, P1627, DOI 10.1242/jcs.00336; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; Ogawa K, 1996, MOL BIOL CELL, V7, P1895, DOI 10.1091/mbc.7.12.1895; OKUNO M, 1979, J CELL SCI, V38, P105; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Ostrowski LE, 2002, MOL CELL PROTEOMICS, V1, P451, DOI 10.1074/mcp.M200037-MCP200; Patel-King RS, 2002, J BIOL CHEM, V277, P34271, DOI 10.1074/jbc.M204137200; Pazour GJ, 2005, J CELL BIOL, V170, P103, DOI 10.1083/jcb.200504008; Pullen TJ, 2004, MOL BIOL CELL, V15, P3257, DOI 10.1091/mbc.E04-03-0217; Quest AFG, 1997, BIOCHEMISTRY-US, V36, P6993, DOI 10.1021/bi9629337; QUEST AFG, 1992, J BIOL CHEM, V267, P15080; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Saudrais C, 1998, CELL MOTIL CYTOSKEL, V41, P91; SCHOFF PK, 1989, J BIOL CHEM, V264, P6086; Su YH, 2005, DEV BIOL, V285, P116, DOI 10.1016/j.ydbio.2005.06.007; TANG WJY, 1982, J BIOL CHEM, V257, P508; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOMBES RM, 1987, BIOPHYS J, V52, P75, DOI 10.1016/S0006-3495(87)83190-9; TOMBES RM, 1989, J EXP ZOOL, V251, P82, DOI 10.1002/jez.1402510110; TOMBES RM, 1987, J BIOL CHEM, V262, P16011; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; TOMBES RM, 1988, EXP CELL RES, V178, P307, DOI 10.1016/0014-4827(88)90401-6; Vacquier VD, 2004, METHOD CELL BIOL, V74, P523; vanDorsten FA, 1997, BIOCHEM J, V325, P411, DOI 10.1042/bj3250411; WATANABE T, 1976, J BIOL CHEM, V251, P182; Wirschell M, 2004, MOL BIOL CELL, V15, P2729, DOI 10.1091/mbc.E03-11-0820; WOTHE DD, 1990, P NATL ACAD SCI USA, V87, P5203, DOI 10.1073/pnas.87.13.5203; Zhang H, 2004, J CELL SCI, V117, P4179, DOI 10.1242/jcs.01297	43	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2947	2955		10.1074/jbc.M607972200	http://dx.doi.org/10.1074/jbc.M607972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145754	hybrid			2022-12-27	WOS:000243793900021
J	Koropatkin, NM; Koppenaal, DW; Pakrasi, HB; Smith, TJ				Koropatkin, Nicole M.; Koppenaal, David W.; Pakrasi, Himadri B.; Smith, Thomas J.			The structure of a cyanobacterial bicarbonate transport protein, CmpA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-LIGAND INTERACTIONS; BINDING-PROTEIN; CRYSTAL-STRUCTURE; ACTIVE-TRANSPORT; SPECIFICITY; GEOMETRY; RECEPTOR; CALCIUM	Cyanobacteria, blue-green algae, are the most abundant autotrophs in aquatic environments and form the base of the food chain by fixing carbon and nitrogen into cellular biomass. To compensate for the low selectivity of Rubisco for CO2 over O-2, cyanobacteria have developed highly efficient CO2-concentrating machinery of which the ABC transport system CmpABCD from Synechocystis PCC 6803 is one component. Here, we have described the structure of the bicarbonatebinding protein CmpA in the absence and presence of bicarbonate and carbonic acid. CmpA is highly homologous to the nitrate transport protein NrtA. CmpA binds carbonic acid at the entrance to the ligand-binding pocket, whereas bicarbonate binds in nearly an identical location compared with nitrate binding to NrtA. Unexpectedly, bicarbonate binding is accompanied by a metal ion, identified as Ca2+ via inductively coupled plasma optical emission spectrometry. The binding of bicarbonate and metal appears to be highly cooperative and suggests that CmpA may co-transport bicarbonate and calcium or that calcium acts a cofactor in bicarbonate transport.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; Pacific NW Natl Lab, Richland, WA 99352 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA	Donald Danforth Plant Science Center; United States Department of Energy (DOE); Pacific Northwest National Laboratory; Washington University (WUSTL)	Smith, TJ (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	tsmith@danforthcenter.org	Smith, Thomas J/K-9086-2013	Smith, Thomas J/0000-0003-3528-6793	NIGMS NIH HHS [GM078800] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM078800] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Badger MR, 2003, J EXP BOT, V54, P609, DOI 10.1093/jxb/erg076; Banerjee S, 2003, J MOL BIOL, V333, P1061, DOI 10.1016/j.jmb.2003.09.008; BERKELMAN T, 1994, J BACTERIOL, V176, P4430, DOI 10.1128/jb.176.14.4430-4436.1994; Bruns CM, 1997, NAT STRUCT BIOL, V4, P919, DOI 10.1038/nsb1197-919; Bruns CM, 2001, BIOCHEMISTRY-US, V40, P15631, DOI 10.1021/bi0156759; Dwyer MA, 2004, CURR OPIN STRUC BIOL, V14, P495, DOI 10.1016/j.sbi.2004.07.004; Gould S. J., 2001, BOOK LIFE ILLUSTRATE; Guo ML, 2003, J BIOL CHEM, V278, P2490, DOI 10.1074/jbc.M208776200; Harding MM, 2000, ACTA CRYSTALLOGR D, V56, P857, DOI 10.1107/S0907444900005849; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Holland H. D., 1978, CHEM ATMOSPHERE OCEA; Homann PH, 2002, PHOTOSYNTH RES, V73, P169, DOI 10.1023/A:1020486729283; Hu YL, 1997, NAT STRUCT BIOL, V4, P703, DOI 10.1038/nsb0997-703; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koropatkin NM, 2006, P NATL ACAD SCI USA, V103, P9820, DOI 10.1073/pnas.0602517103; Lawson DM, 1998, STRUCTURE, V6, P1529, DOI 10.1016/S0969-2126(98)00151-8; Livingston D.A., 1963, 440 US GEOL SURV; Maeda S, 2000, J BIOL CHEM, V275, P20551, DOI 10.1074/jbc.M003034200; NOWALK AJ, 1994, BIOCHEMISTRY-US, V33, P12769, DOI 10.1021/bi00209a007; OMATA T, 1986, PLANT PHYSIOL, V80, P525, DOI 10.1104/pp.80.2.525; Omata T, 1999, P NATL ACAD SCI USA, V96, P13571, DOI 10.1073/pnas.96.23.13571; OMATA T, 1995, PLANT CELL PHYSIOL, V36, P207, DOI 10.1093/oxfordjournals.pcp.a078751; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; Shouldice SR, 2003, BIOCHEMISTRY-US, V42, P11908, DOI 10.1021/bi035389s; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Vyas NK, 2003, STRUCTURE, V11, P765, DOI 10.1016/S0969-2126(03)00109-6; WANG ZM, 1994, J BIOL CHEM, V269, P25091; Whitton B.A., 2000, ECOLOGY CYANOBACTERI; Zhao YH, 2005, P NATL ACAD SCI USA, V102, P5744, DOI 10.1073/pnas.0501782102	32	65	66	5	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2606	2614		10.1074/jbc.M610222200	http://dx.doi.org/10.1074/jbc.M610222200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121816	hybrid			2022-12-27	WOS:000243593200053
J	St Maurice, M; Mera, PE; Taranto, MP; Sesma, F; Escalante-Semerena, JC; Rayment, I				St. Maurice, Martin; Mera, Paola E.; Taranto, Maria P.; Sesma, Fernando; Escalante-Semerena, Jorge C.; Rayment, Ivan			Structural characterization of the active site of the PduO-type ATP : Co(I)rrinoid adenosyltransferase from Lactobacillus reuteri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-CORRINOID ADENOSYLTRANSFERASE; ATP-COB(I)ALAMIN ADENOSYLTRANSFERASE; SALMONELLA-TYPHIMURIUM; METHYLMALONIC ACIDURIA; TEV PROTEASE; COBALAMIN ADENOSYLTRANSFERASE; INITIAL-CHARACTERIZATION; ENZYMATIC CONVERSION; CRYSTAL-STRUCTURE; FUSION PROTEINS	The three-dimensional crystal structure of the PduO-type corrinoid adenosyltransferase from Lactobacillus reuteri (LrPduO) has been solved to 1.68-angstrom resolution. The functional assignment of LrPduO as a corrinoid adenosyltransferase was confirmed by in vivo and in vitro evidence. The enzyme has an apparent K-m(ATP) of 2.2 mu M and K-m(Cobalamin) of 0.13 mu M and a k(cat) of 0.025 s(-1). Co-crystallization of the enzyme with Mg-ATP resulted in well-defined electron density for an N-terminal loop that had been disordered in other PduO-type enzyme structures. This newly defined N-terminal loop makes up the lower portion of the enzyme active site with the other half being contributed from an adjacent subunit. These results provide the first detailed description of the enzyme active site for a PduO-type adenosyltransferase and identify a unique ATP binding motif at the protein N terminus. The molecular architecture at the active site offers valuable new insight into the role of various residues responsible for the human disease methylmalonic aciduria.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Consejo Nacl Invest Cient & Tecn, CERELA, RA-4000 San Miguel De Tucuman, Argentina	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	escalante@bact.wisc.edu; Ivan_Rayment@biochem.wisc.edu	St. Maurice, Martin/AGJ-6319-2022; rayment, ivan/A-2720-2008; St.Maurice, Martin/AAL-5054-2021	St. Maurice, Martin/0000-0002-6507-9528; rayment, ivan/0000-0001-9279-7835; 	NIAMS NIH HHS [AR35186, R01 AR035186] Funding Source: Medline; NIGMS NIH HHS [R37 GM040313, R01 GM040313, T32 GM008505-13, GM40313] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008505, R37GM040313, R01GM040313] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AILION M, 1993, J BACTERIOL, V175, P7200, DOI 10.1128/JB.175.22.7200-7208.1993; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bandarian V., 1999, Chemistry and biochemistry of B12., P811; Banerjee R., 1999, Chemistry and biochemistry of B12., P707; Bauer CB, 2001, BIOCHEMISTRY-US, V40, P361, DOI 10.1021/bi002145o; BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; Bertani G, 2004, J BACTERIOL, V186, P595, DOI 10.1128/JB.186.3.595-600.2004; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; Buan NR, 2006, J BIOL CHEM, V281, P16971, DOI 10.1074/jbc.M603069200; Buan NR, 2006, J BACTERIOL, V188, P3543, DOI 10.1128/JB.188.10.3543-3550.2006; Buan NR, 2005, J BIOL CHEM, V280, P40948, DOI 10.1074/jbc.M506713200; Buan NR, 2004, J BACTERIOL, V186, P5708, DOI 10.1128/JB.186.17.5708-5714.2004; Buckel W., 1999, Chemistry and biochemistry of B12., P757; Ciani F, 2000, CRIT CARE MED, V28, P2119, DOI 10.1097/00003246-200006000-00078; Dobson CM, 2002, HUM MOL GENET, V11, P3361, DOI 10.1093/hmg/11.26.3361; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; Fonseca MV, 2001, J BIOL CHEM, V276, P32101, DOI 10.1074/jbc.M102510200; Fonseca MV, 2002, J BIOL CHEM, V277, P33127, DOI 10.1074/jbc.M203893200; Fontecave M, 1998, CELL MOL LIFE SCI, V54, P684, DOI 10.1007/s000180050195; Fontecave M., 1999, Chemistry and biochemistry of B12., P731; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; Haspel J, 2001, BIOTECHNIQUES, V30, P60, DOI 10.2144/01301st01; HUENNEKENS FM, 1982, B12, V1, P145; Johnson CLV, 2001, J BACTERIOL, V183, P1577, DOI 10.1128/JB.183.5.1577-1584.2001; Johnson CLV, 2004, J BACTERIOL, V186, P7881, DOI 10.1128/JB.186.23.7881-7887.2004; Kapust RB, 2000, PROTEIN EXPRES PURIF, V19, P312, DOI 10.1006/prep.2000.1251; Komoto J, 2004, BIOCHEMISTRY-US, V43, P1821, DOI 10.1021/bi035611t; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leal NA, 2004, J BIOL CHEM, V279, P47536, DOI 10.1074/jbc.M405449200; Leal NA, 2003, J BIOL CHEM, V278, P9227, DOI 10.1074/jbc.M212739200; Lerner-Ellis JP, 2006, MOL GENET METAB, V87, P219, DOI 10.1016/j.ymgme.2005.11.011; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; POSPIECH A, 1995, TRENDS GENET, V11, P217, DOI 10.1016/S0168-9525(00)89052-6; Reczkowski RS, 1998, BIOCHEMISTRY-US, V37, P13499, DOI 10.1021/bi9811011; Saridakis V, 2004, J BIOL CHEM, V279, P23646, DOI 10.1074/jbc.M401395200; SASSE J, 1991, CURRENT PROTOCOLS MO, V1, DOI DOI 10.6.1-10.6.8; SHEPPARD DE, 1994, J BACTERIOL, V176, P1287, DOI 10.1128/jb.176.5.1287-1296.1994; Shih YP, 2005, PROTEIN SCI, V14, P936, DOI 10.1110/ps.041129605; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Stich TA, 2005, J AM CHEM SOC, V127, P7660, DOI 10.1021/ja050546r; Stich TA, 2005, J AM CHEM SOC, V127, P8710, DOI 10.1021/ja042142p; SUH SJ, 1995, J BACTERIOL, V177, P921, DOI 10.1128/jb.177.4.921-925.1995; Taranto MP, 2003, J BACTERIOL, V185, P5643, DOI 10.1128/JB.185.18.5643-5647.2003; Toraya T., 1999, Chemistry and biochemistry of B12., P783; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VITOLS E, 1966, J BIOL CHEM, V241, P1455; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Warren MJ, 2002, NAT PROD REP, V19, P390, DOI 10.1039/B108967F; Wohlfarth G., 1999, Chemistry and biochemistry of B12., P871; Yamanishi M, 2005, J AM CHEM SOC, V127, P526, DOI 10.1021/ja044365l; Zhang J, 2006, MOL GENET METAB, V87, P315, DOI 10.1016/j.ymgme.2005.12.003	56	49	50	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2596	2605		10.1074/jbc.M609557200	http://dx.doi.org/10.1074/jbc.M609557200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121823	hybrid, Green Accepted			2022-12-27	WOS:000243593200052
J	Zawacka-Pankau, J; Issaeva, N; Hossain, S; Pramanik, A; Selivanova, G; Podhajska, AJ				Zawacka-Pankau, Joanna; Issaeva, Natalia; Hossain, Shakil; Pramanik, Aladdin; Selivanova, Galina; Podhajska, Anna J.			Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and -independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-MDM2 FEEDBACK LOOP; PHOTODYNAMIC THERAPY; TUMOR-SUPPRESSOR; DNA-DAMAGE; GENE; APOPTOSIS; PATHWAY; MDM2; BAX; PHOSPHORYLATION	Photodynamic therapy (PDT) of cancer is an alternative treatment for tumors resistant to chemo- and radiotherapy. It induces cancer cell death mainly through generation of reactive oxygen species by a laser light-activated photosensitizer. It has been suggested that the p53 tumor suppressor protein sensitizes some human cancer cells to PDT. However, there is still no direct evidence for this. We have demonstrated here for the first time that the photosensitizer protoporphyrin IX (PpIX) binds to p53 and disrupts the interaction between p53 tumor suppressor protein and its negative regulator HDM2 in vitro and in cells. Moreover, HCT116 colon cancer cells exhibited a p53-dependent sensitivity to PpIX in a dose-dependent manner, as was demonstrated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and fluorescence-activated cell sorter (FACS) analysis of cell cycle profiles. We have also observed induction of p53 target pro-apoptotic genes, e. g. puma (p53-upregulated modulator of apoptosis), and bak in PpIX-treated cells. In addition, p53-independent growth suppression by PpIX was detected in p53-negative cells. PDT treatment (2 J/cm(2)) of HCT116 cells induced p53-dependent activation of pro-apoptotic gene expression followed by growth suppression and induction of apoptosis.	Univ Gdansk, Intercollegiate Fac Biotechnol, Div Mol Diagnost, Dept Biotechnol, PL-80822 Gdansk, Poland; Med Univ Gdansk, PL-80822 Gdansk, Poland; Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Fahrenheit Universities; University of Gdansk; Fahrenheit Universities; Medical University Gdansk; Karolinska Institutet; Karolinska Institutet	Zawacka-Pankau, J (corresponding author), Univ Gdansk, Intercollegiate Fac Biotechnol, Div Mol Diagnost, Dept Biotechnol, Kladki 24, PL-80822 Gdansk, Poland.	jzawacka@biotech.ug.gda.pl	Issaeva, Natalia/K-4577-2019; Zawacka-Pankau, Joanna/AAE-4600-2019	Zawacka-Pankau, Joanna/0000-0002-7415-2942; Selivanova, Galina/0000-0002-8698-4332; Issaeva, Natalia/0000-0001-5483-6610				Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; Barberi-Heyob M, 2004, INT J ONCOL, V24, P951; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Brown SB, 2004, LANCET ONCOL, V5, P497, DOI 10.1016/S1470-2045(04)01529-3; Chene P, 2000, J MOL BIOL, V299, P245, DOI 10.1006/jmbi.2000.3738; Collister M, 1998, CARCINOGENESIS, V19, P2115, DOI 10.1093/carcin/19.12.2115; Dahle J, 1999, PHOTOCHEM PHOTOBIOL, V70, P363, DOI 10.1111/j.1751-1097.1999.tb08150.x; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Evans HH, 1997, PHOTOCHEM PHOTOBIOL, V66, P690, DOI 10.1111/j.1751-1097.1997.tb03208.x; Fisher AMR, 1997, PHOTOCHEM PHOTOBIOL, V66, P265, DOI 10.1111/j.1751-1097.1997.tb08653.x; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gupta S, 2001, LIFE SCI, V69, P2957, DOI 10.1016/S0024-3205(01)01404-7; Heinzelmann-Schwarz V, 2003, LASER SURG MED, V33, P182, DOI 10.1002/lsm.10213; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KASTAN MB, 1991, CANCER RES, V51, P6304; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LEE HB, 2005, CANCER CHEMOTH PHARM, V7, P1; Lim DS, 2006, HUM GENE THER, V17, P347, DOI 10.1089/hum.2006.17.347; Luo Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P528, DOI 10.1111/j.1751-1097.1996.tb03079.x; Marine JC, 2005, BIOCHEM BIOPH RES CO, V331, P750, DOI 10.1016/j.bbrc.2005.03.151; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Ohnishi T, 1999, RADIAT RES, V151, P368, DOI 10.2307/3579950; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pramanik A, 2004, CURR PHARM BIOTECHNO, V5, P205, DOI 10.2174/1389201043377002; PRAMANIK A, 2004, ENCY MOL CELL BIOL M, P461; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; SELIVANOVA G, 2001, TUMOR SUPPRESSING VI, P397; SELIVANOVA G, 2001, CURR OPIN INVESTIG D, V8, P1136; Srivastava M, 2001, J BIOL CHEM, V276, P15481, DOI 10.1074/jbc.M006920200; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tong ZM, 2000, PHOTOCHEM PHOTOBIOL, V71, P201, DOI 10.1562/0031-8655(2000)071<0201:TROTPT>2.0.CO;2; Uehlinger P, 2000, J PHOTOCH PHOTOBIO B, V54, P72, DOI 10.1016/S1011-1344(99)00159-1; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yakovleva T, 2001, J BIOL CHEM, V276, P15650, DOI 10.1074/jbc.M100482200; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zawacka-Pankau J, 2007, J PHOTOCH PHOTOBIO B, V86, P35, DOI 10.1016/j.jphotobiol.2006.08.005	50	50	51	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2466	2472		10.1074/jbc.M608906200	http://dx.doi.org/10.1074/jbc.M608906200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135250	hybrid			2022-12-27	WOS:000243593200038
J	Abida, WM; Nikolaev, A; Zhao, WH; Zhang, WZ; Gu, W				Abida, Wassim M.; Nikolaev, Anatoly; Zhao, Wenhui; Zhang, Wenzhu; Gu, Wei			FBXO11 promotes the neddylation of p53 and inhibits its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCF UBIQUITIN LIGASE; LEUCINE-RICH REPEAT; KAPPA-B-ALPHA; DEPENDENT DEGRADATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; NEDD8; PHOSPHORYLATION; ACETYLATION; CONJUGATION	The p53 tumor suppressor is regulated by post-translational modification, including ubiquitination, phosphorylation and acetylation. It has previously been shown that the ubiquitin ligase Mdm2 also promotes the conjugation of Nedd8, a ubiquitin-like protein, to p53, inhibiting its transcriptional activity. We report the identification of FBXO11, a member of the F-box protein family and a component of the Skp1 center dot Cullin1 center dot F-box (SCF) complex, as a new p53-interacting protein. We show that FBXO11 promotes the neddylation of p53 both in vitro and in vivo. In addition to the C-terminal lysine residues, FBXO11 can also promote Nedd8 conjugation to Lys-320 and Lys-321, and neddylation of p53 leads to suppression of p53 function. This is consistent with recent studies showing that a lysine to arginine mutation at Lys-320 significantly enhances p53 function, although Lys-320 was originally identified as an acetylation site involving PCAF-mediated activation of p53. Our study provides an example of an F-box protein acting as an adaptor protein that can mediate the neddylation of a non-cullin substrate.	Columbia Univ, Inst Canc Genet, Irving Camc Res Ctr, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Gu, W (corresponding author), Columbia Univ, Inst Canc Genet, Irving Camc Res Ctr, Coll Phys & Surg, Rm 609A,1130 St Nicholas Ave, New York, NY 10032 USA.	wg8@columbia.edu		ZHAO, WENHUI/0000-0002-7703-7106; Nikolaev, Anatoly/0000-0003-2818-5839	NCI NIH HHS [R01 CA129627, R01 CA104843, R01 CA131439, R01 CA098821, R01 CA085533, R01 CA118561] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA131439, R01CA118561, R01CA098821, R01CA104843, R01CA129627, R01CA085533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Chehab NH, 2000, GENE DEV, V14, P278; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Ciccarelli FD, 2002, TRENDS BIOCHEM SCI, V27, P59, DOI 10.1016/S0968-0004(01)02046-1; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Enkhbayar P, 2004, PROTEINS, V54, P394, DOI 10.1002/prot.10605; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Le Poole IC, 2001, PIGM CELL RES, V14, P475, DOI 10.1034/j.1600-0749.2001.140608.x; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; LUNA RMD, 1995, NATURE, V378, P203; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marine JC, 2005, BIOCHEM BIOPH RES CO, V331, P750, DOI 10.1016/j.bbrc.2005.03.151; Morimoto M, 2003, BIOCHEM BIOPH RES CO, V301, P392, DOI 10.1016/S0006-291X(02)03051-6; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Nikolaev AY, 2004, BIOCHEM BIOPH RES CO, V323, P1216, DOI 10.1016/j.bbrc.2004.08.227; Oved S, 2006, J BIOL CHEM, V281, P21640, DOI 10.1074/jbc.M513034200; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Shieh SY, 2000, GENE DEV, V14, P289; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tasaki T, 2005, MOL CELL BIOL, V25, P7120, DOI 10.1128/MCB.25.16.7120-7136.2005; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; ZUMFT WG, 1990, EUR J BIOCHEM, V192, P591, DOI 10.1111/j.1432-1033.1990.tb19265.x	52	139	151	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1797	1804		10.1074/jbc.M609001200	http://dx.doi.org/10.1074/jbc.M609001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17098746	hybrid, Green Accepted			2022-12-27	WOS:000243451300031
J	Adkins, MW; Carson, JJ; English, CM; Ramey, CJ; Tyler, JK				Adkins, Melissa W.; Carson, Joshua J.; English, Christine M.; Ramey, Christopher J.; Tyler, Jessica K.			The histone chaperone anti-silencing function 1 stimulates the acetylation of newly synthesized histone H3 in S-phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; LYSINE-56 ACETYLATION; CHROMATIN; YEAST; ASF1; H4; ACETYLTRANSFERASE; COMPLEX; DEACETYLATION; DEPOSITION	Anti- silencing function 1 (Asf1) is a highly conserved chaperone of histones H3/H4 that assembles or disassembles chromatin during transcription, replication, and repair. We have found that budding yeast lacking Asf1 has greatly reduced levels of histone H3 acetylated at lysine 9. Lysine 9 is acetylated on newly synthesized budding yeast histone H3 prior to its assembly onto newly replicated DNA. Accordingly, we found that the vast majority of H3 Lys-9 acetylation peaked in S-phase, and this S-phase peak of H3 lysine 9 acetylation was absent in yeast lacking Asf1. By contrast, deletion of ASF1 has no effect on the S-phase specific peak of H4 lysine 12 acetylation; another modification carried by newly synthesized histones prior to chromatin assembly. We show that Gcn5 is the histone acetyltransferase responsible for the S-phase-specific peak of H3 lysine 9 acetylation. Strikingly, overexpression of Asf1 leads to greatly increased levels of H3 on acetylation on lysine 56 and Gcn5-dependent acetylation on lysine 9. Analysis of a panel of Asf1 mutations that modulate the ability of Asf1 to bind to histones H3/H4 demonstrates that the histone binding activity of Asf1 is required for the acetylation of Lys-9 and Lys-56 on newly synthesized H3. These results demonstrate that Asf1 does not affect the stability of the newly synthesized histones per se, but instead histone binding by Asf1 promotes the efficient acetylation of specific residues of newly synthesized histone H3.	Univ Colorado, Dept Biochem & Mol Genet, Sch Med, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Tyler, JK (corresponding author), Univ Colorado, Dept Biochem & Mol Genet, Sch Med, Aurora, CO 80045 USA.	jessica.tyler@uchsc.edu		Tyler, Jessica/0000-0001-9765-1659	NIGMS NIH HHS [R01 GM064475, GM064475] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064475] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adkins MW, 2004, J BIOL CHEM, V279, P52069, DOI 10.1074/jbc.M406113200; Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; Celic I, 2006, CURR BIOL, V16, P1280, DOI 10.1016/j.cub.2006.06.023; Chimura T, 2002, P NATL ACAD SCI USA, V99, P9334, DOI 10.1073/pnas.142627899; Donaldson AD, 2005, TRENDS GENET, V21, P444, DOI 10.1016/j.tig.2005.05.012; English CM, 2006, CELL, V127, P495, DOI 10.1016/j.cell.2006.08.047; English CM, 2005, BIOCHEMISTRY-US, V44, P13673, DOI 10.1021/bi051333h; Glowczewski L, 2004, MOL CELL BIOL, V24, P10180, DOI 10.1128/MCB.24.23.10180-10192.2004; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ma XJ, 1998, P NATL ACAD SCI USA, V95, P6693, DOI 10.1073/pnas.95.12.6693; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Mellor J, 2005, MOL CELL, V19, P147, DOI 10.1016/j.molcel.2005.06.023; Moshkin YM, 2002, GENE DEV, V16, P2621, DOI 10.1101/gad.231202; Osada S, 2001, GENE DEV, V15, P3155, DOI 10.1101/gad.907201; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Poveda A, 2004, J BIOL CHEM, V279, P16033, DOI 10.1074/jbc.M314228200; Recht J, 2006, P NATL ACAD SCI USA, V103, P6988, DOI 10.1073/pnas.0601676103; Robert F, 2004, MOL CELL, V16, P199, DOI 10.1016/j.molcel.2004.09.021; Schulz LL, 2006, FASEB J, V20, P488, DOI 10.1096/fj.05-5020fje; Sklenar Amy R., 2004, BMC Biochemistry, V5, P11, DOI 10.1186/1471-2091-5-11; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Sutton A, 2003, J BIOL CHEM, V278, P16887, DOI 10.1074/jbc.M210709200; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; van Holde KE., 1989, SPRINGER SERIES MOL; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Zabaronick SR, 2005, MOL CELL BIOL, V25, P652, DOI 10.1128/MCB.25.2.652-660.2005	36	71	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1334	1340		10.1074/jbc.M608025200	http://dx.doi.org/10.1074/jbc.M608025200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17107956	hybrid			2022-12-27	WOS:000243295200059
J	Jang, SJ; Imlay, JA				Jang, Soojin; Imlay, James A.			Micromolar intracellular hydrogen peroxide disrupts metabolism by damaging iron-sulfur enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ACONITASE; DNA-BINDING PROTEIN; FE-S CLUSTER; SUPEROXIDE SENSITIVITY; TRANSCRIPTION FACTOR; OXIDATIVE DAMAGE; FUMARASE-A; INACTIVATION; DEHYDRATASE; RESISTANCE	An Escherichia coli strain that cannot scavenge hydrogen peroxide has been used to identify the cell processes that are most sensitive to this oxidant. Low micromolar concentrations of H2O2 completely blocked the biosynthesis of leucine. The defect was tracked to the inactivation of isopropylmalate isomerase. This enzyme belongs to a family of [4Fe-4S] dehydratases that are notoriously sensitive to univalent oxidation, and experiments confirmed that other members were also inactivated. In vitro and in vivo analyses showed that H2O2 directly oxidized their solvent-exposed clusters in a Fenton-like reaction. The oxidized cluster then degraded to a catalytically inactive [3Fe-4S] form. Experiments indicated that H2O2 accepted two consecutive electrons during the oxidation event. As a consequence, hydroxyl radicals were not released; the polypeptide was undamaged; and the enzyme was competent for reactivation by repair processes. Strikingly, in scavenger-deficient mutants, the H2O2 that was generated as an adventitious by-product of metabolism (< 1 mu M) was sufficient to damage these [4Fe-4S] enzymes. This result demonstrates that aerobic organisms must synthesize H2O2 scavengers to avoid poisoning their own pathways. The extreme vulnerability of these enzymes may explain why many organisms, including mammals, deploy H2O2 to suppress microbial growth.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Imlay, JA (corresponding author), Univ Illinois, Dept Microbiol, 601 S Goodwin Ave, Urbana, IL 61801 USA.	jimlay@uiuc.edu	Matin, AC/A-1315-2007	Matin, AC/0000-0003-4468-980X	NIGMS NIH HHS [R01 GM049640, R37 GM049640, GM49640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049640, R01GM049640] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Brown NM, 2002, J BIOL CHEM, V277, P7246, DOI 10.1074/jbc.M110282200; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Djaman O, 2004, J BIOL CHEM, V279, P44590, DOI 10.1074/jbc.M406487200; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FLINT DH, 1994, ARCH BIOCHEM BIOPHYS, V311, P509, DOI 10.1006/abbi.1994.1269; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; Griffiths SW, 2002, BIOCHEMISTRY-US, V41, P6245, DOI 10.1021/bi025599p; HALL BH, 1990, BROOKINGS PAP ECO AC, P85; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Inbaraj JJ, 2004, CHEM RES TOXICOL, V17, P55, DOI 10.1021/tx034132s; Ito A, 2003, CURR MICROBIOL, V47, P231, DOI 10.1007/s00284-002-3993-1; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; KLEBANOFF SJ, 1983, CIBA F SYMP, V99, P92; KOHLHAW GB, 1988, METHOD ENZYMOL, V166, P423; KUO CF, 1987, J BIOL CHEM, V262, P4724; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; Lee JW, 2006, NATURE, V440, P363, DOI 10.1038/nature04537; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; MASON EC, 1963, J CLIN PATHOL, V16, P604, DOI 10.1136/jcp.16.6.604-b; MASSEY V, 1955, METHOD ENZYMOL, V1, P729, DOI 10.1016/0076-6879(55)01127-0; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P2480; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Park S, 2005, P NATL ACAD SCI USA, V102, P9317, DOI 10.1073/pnas.0502051102; Pericone CD, 2003, J BACTERIOL, V185, P6815, DOI 10.1128/JB.185.23.6815-6825.2003; Ran HM, 2003, P NATL ACAD SCI USA, V100, P14315, DOI 10.1073/pnas.2332354100; RUSH JD, 1990, FEBS LETT, V261, P121, DOI 10.1016/0014-5793(90)80651-X; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Seaver LC, 2001, J BACTERIOL, V183, P7182, DOI 10.1128/JB.183.24.7182-7189.2001; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; Varghese S, 2003, J BACTERIOL, V185, P221, DOI 10.1128/JB.185.1.221-230.2003; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; Wojtaszek P, 1997, BIOCHEM J, V322, P681, DOI 10.1042/bj3220681; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	46	233	240	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					929	937		10.1074/jbc.M607646200	http://dx.doi.org/10.1074/jbc.M607646200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17102132	Green Accepted, hybrid			2022-12-27	WOS:000243295200015
J	Radeff-Huang, J; Seasholtz, TM; Chang, JW; Smith, JM; Walsh, CT; Brown, JH				Radeff-Huang, Julie; Seasholtz, Tammy M.; Chang, Jenny W.; Smith, Jeffrey M.; Walsh, Colin T.; Heller Brown, Joan			Tumor necrosis factor-alpha-stimulated cell proliferation is mediated through sphingosine kinase-dependent akt activation and cyclin D expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; BINDING PROTEIN-RHO; GROWTH-FACTOR; CALCIUM MOBILIZATION; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; APOPTOSIS; RECEPTOR; SURVIVAL; PHOSPHORYLATION	Tumor necrosis factor-alpha(TNF-alpha) has been shown to activate sphingosine kinase (SphK) in a variety of cell types. The extent to which SphK signaling mediates the pleiotropic effects of TNF-alpha is not entirely clear. The current study examined the role of SphK activity in TNF-alpha-stimulated cell proliferation in 1321N1 glioblastoma cells. We first demonstrated that pharmacological inhibitors of SphK markedly decrease TNF-alpha-stimulated DNA synthesis. Signaling mechanisms through which SphK mediated the effect of TNF-alpha on DNA synthesis were then examined. Inhibition of Rho proteins with C3 exoenzyme or of Rho kinase with Y27632 attenuated TNF-alpha-stimulated DNA synthesis. However, RhoA activation by TNF-alpha was not blocked by SphK inhibition. ERK activation was also required for TNF-alpha-stimulated DNA synthesis but likewise TNF-alpha-induced ERK activation was not blocked by inhibition of SphK. Thus, neither RhoA nor ERK activation are the SphK-dependent transducers of TNF-alpha-induced proliferation. In contrast, TNF-alpha-stimulated Akt phosphorylation, which was also required for DNA synthesis, was attenuated by SphK inhibition or SphK1 knockdown by small interfering RNA. Furthermore, cyclin D expression was increased by TNF-alpha in a SphK- and Akt-dependent manner. Additional studies demonstrated that TNF-alpha effects on DNA synthesis, ERK, and Akt phosphorylation are not mediated through cell surface G(i)-coupled S1P receptors, because none of these responses were inhibited by pertussis toxin. We conclude that SphK- dependent Akt activation plays a significant role in TNF-alpha-induced cyclin D expression and cell proliferation.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jhbrown@ucsd.edu			NIGMS NIH HHS [GM36927] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM036927, R01GM036927] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; BARNA BP, 1990, J NEUROIMMUNOL, V30, P239, DOI 10.1016/0165-5728(90)90108-Y; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Choi OH, 1996, NATURE, V380, P634; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ferrajoli A, 2002, BLOOD, V100, P1215, DOI 10.1182/blood.V100.4.1215.h81602001215_1215_1219; French KJ, 2003, CANCER RES, V63, P5962; Itagaki K, 2003, J BIOL CHEM, V278, P27540, DOI 10.1074/jbc.M301763200; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Johnstone ED, 2005, PLACENTA, V26, P548, DOI 10.1016/j.placenta.2004.08.012; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; KIRSTEIN M, 1988, J CELL PHYSIOL, V134, P479, DOI 10.1002/jcp.1041340321; Knobbe CB, 2002, NEURO-ONCOLOGY, V4, P196; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Liu RY, 2000, J BIOL CHEM, V275, P21086, DOI 10.1074/jbc.M001281200; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Narita Y, 2002, CANCER RES, V62, P6764; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, FASEB J, V13, P1593, DOI 10.1096/fasebj.13.12.1593; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Sarkar S, 2005, FEBS LETT, V579, P5313, DOI 10.1016/j.febslet.2005.08.055; Seasholtz TM, 2004, J NEUROCHEM, V91, P501, DOI 10.1111/j.1471-4159.2004.02749.x; SELMAJ KW, 1990, J IMMUNOL, V144, P129; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Vann LR, 2002, J BIOL CHEM, V277, P12649, DOI 10.1074/jbc.M109111200; WU S, 1993, CANCER RES, V53, P1939; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; Young KW, 2000, J BIOL CHEM, V275, P38532, DOI 10.1074/jbc.M006631200; Zaslavsky A, 2005, FEBS LETT, V579, P3899, DOI 10.1016/j.febslet.2005.06.006; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	49	61	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					863	870		10.1074/jbc.M601698200	http://dx.doi.org/10.1074/jbc.M601698200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17114809	hybrid			2022-12-27	WOS:000243295200008
J	Yochum, GS; Cleland, R; McWeeney, S; Goodman, RH				Yochum, Gregory S.; Cleland, Ryan; McWeeney, Shannon; Goodman, Richard H.			An antisense transcript induced by Wnt/beta-catenin signaling decreases E2F4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-SITES; BETA-CATENIN; DOWNSTREAM TARGET; IN-VIVO; ACTIVATION; IDENTIFICATION; CHROMATIN; GENE; EXPRESSION; MUTATIONS	Wnt signaling induces the nuclear accumulation of beta-catenin and transcription of specific target genes via the DNA-binding proteins TCF/Lef. Although all known beta-catenin target genes encode proteins, genome-wide RNA profiling studies indicate that many transcripts do not have this capability. Transcription factor-binding sites associated with these noncoding transcripts can be identified using unbiased techniques such as serial analysis of chromatin occupancy (SACO). We used this method to identify a beta-catenin-regulated antisense RNA expressed in HCT116 colorectal carcinoma cells, a cellular model of activated beta-catenin signaling. Genomic signature tags designating putative beta-catenin-binding sites mapped to the 3'-untranslated region (3'-UTR) of the E2F4 gene. We showed that both beta-catenin and TCF4 bind to the E2F4 3'-UTR site in vivo, inducing expression of an E2F4 antisense transcript. LiCl, which mimics Wnt signaling, also induced expression of the E2F4 antisense transcript and decreased E2F4 protein levels. This effect was blocked by a cDNA expressing the E2F4 3'-UTR sense strand. The antisense-mediated decrease in E2F4 protein was reflected by reduced E2F4 association with specific target genes, including CCNA2, CDC2, PCNA, and Rad54. We propose that Wnt/beta-catenin signaling may contribute to colorectal carcinogenesis by reducing the level of the E2F4 cell cycle repressor via an antisense mechanism.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Div Biostat, Dept Publ Hlth & Preventat Med, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Yochum, GS (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 Sam Jackson Pk Rd, Portland, OR 97239 USA.	yochumg@ohsu.edu		McWeeney, Shannon/0000-0001-8333-6607				Balciunaite E, 2005, MOL CELL BIOL, V25, P8166, DOI 10.1128/MCB.25.18.8166-8178.2005; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Dahary D, 2005, GENOME RES, V15, P364, DOI 10.1101/gr.3308405; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Gustincich S, 2006, J PHYSIOL-LONDON, V575, P321, DOI 10.1113/jphysiol.2006.115568; Hanlon SE, 2004, CURR OPIN GENET DEV, V14, P697, DOI 10.1016/j.gde.2004.09.008; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Johnson R, 2006, NUCLEIC ACIDS RES, V34, P3862, DOI 10.1093/nar/gkl525; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Kim JW, 2005, NAT METHODS, V2, P47, DOI 10.1038/NMETH726; Kim TH, 2005, GENOME RES, V15, P830, DOI 10.1101/gr.3430605; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nelson JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj004; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Polakis P, 2000, GENE DEV, V14, P1837; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Rizvi AZ, 2005, STEM CELLS, V23, P150, DOI 10.1634/stemcells.2004-0096; Roh TY, 2004, NAT BIOTECHNOL, V22, P1013, DOI 10.1038/nbt990; Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Siddiqui AS, 2005, P NATL ACAD SCI USA, V102, P18485, DOI 10.1073/pnas.0509455102; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Takahashi Y, 2000, GENE DEV, V14, P804; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103	50	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					871	878		10.1074/jbc.M609391200	http://dx.doi.org/10.1074/jbc.M609391200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17121828	hybrid			2022-12-27	WOS:000243295200009
J	Lemaire, R; Bayle, J; Mecham, RP; Lafyatis, R				Lemaire, Raphael; Bayle, Julie; Mecham, Robert P.; Lafyatis, Robert			Microfibril-associated MAGP-2 stimulates elastic fiber assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRILLIN-CONTAINING MICROFIBRILS; EXTRACELLULAR MICROFIBRILS; DEVELOPMENTAL EXPRESSION; MOLECULAR-INTERACTIONS; TERNARY COMPLEX; I COLLAGEN; MATRIX; GLYCOPROTEIN-2; TROPOELASTIN; INTERACTS	Elastic fibers are complex structures composed of a tropoelastin inner core and microfibril outer mantle guiding tropoelastin deposition. Microfibrillar proteins mainly include fibrillins and microfibril-associated glycoproteins (MAGPs). MAGP-2 exhibits developmental expression peaking at elastic fiber onset, suggesting that MAGP-2 mediates elastic fiber assembly. To determine whether MAGP-2 regulates elastic fiber assembly, we used an in vitro model featuring doxycycline-regulated cells conditionally overexpressing exogenous MAGP-2 and constitutively expressing enhanced green fluorescent protein-tagged tropoelastin. Analysis by immunofluorescent staining showed that MAGP-2 overexpression dramatically increased elastic fibers levels, independently of extracellular levels of soluble tropoelastin, indicating that MAGP-2 stimulates elastic fiber assembly. This was associated with increased levels of matrix-associated MAGP-2. Electron microscopy showed that MAGP-2 specifically associates with microfibrils and that elastin globules primarily colocalize with MAGP-2-associated microfibrils, suggesting that microfibril-associated MAGP-2 facilitates elastic fiber assembly. MAGP-2 overexpression did not change levels of matrix-associated fibrillin-1, MAGP-1, fibulin-2, fibulin-5, or emilin-1, suggesting that microfibrils and other elastic fiber-associated proteins known to regulate elastogenesis do not mediate MAGP-2-induced elastic fiber assembly. Moreover, mutation analysis showed that MAGP-2 does not stimulate elastic fiber assembly through its RGD motif, suggesting that integrin receptor binding does not mediate MAGP-2-induced elastic fiber assembly. Because MAGP-2 interacts with Jagged-1 that controls cell-matrix interaction and cell motility, two key factors in elastic fiber macroassembly, microfibril-associated MAGP-2 may stimulate elastic fiber macroassembly by targeting the release of elastin globules from the cell membrane onto developing elastic fibers.	Boston Univ, Sch Med, Ctr Arthritis, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Boston University; Boston University; Washington University (WUSTL)	Lemaire, R (corresponding author), Boston Univ, Sch Med, Ctr Arthritis, Bldg E-5,715 Albany St, Boston, MA 02118 USA.	riemaire@bu.edu		Lafyatis, Robert/0000-0002-9398-5034	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051089] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01AR051089-02] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHU M, 2004, 2 NAT M AM SOC MATR; Clarke AW, 2005, BIOCHEMISTRY-US, V44, P10271, DOI 10.1021/bi050530d; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; COX BA, 1974, J BIOL CHEM, V249, P997; Czirok A, 2006, J CELL PHYSIOL, V207, P97, DOI 10.1002/jcp.20573; Finnis ML, 1997, J BIOL CHEM, V272, P22817, DOI 10.1074/jbc.272.36.22817; Gayraud B, 2000, J CELL BIOL, V150, P667, DOI 10.1083/jcb.150.3.667; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENLEE TK, 1966, J CELL BIOL, V30, P59, DOI 10.1083/jcb.30.1.59; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; Hanssen E, 2004, J BIOL CHEM, V279, P29185, DOI 10.1074/jbc.M313672200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Kielty CM, 2002, J CELL SCI, V115, P2817; Kissin EY, 2002, ARTHRITIS RHEUM, V46, P3000, DOI 10.1002/art.10621; Kozel BA, 2006, J CELL PHYSIOL, V207, P87, DOI 10.1002/jcp.20546; Kozel BA, 2004, MATRIX BIOL, V23, P23, DOI 10.1016/j.matbio.2004.02.004; Lemaire R, 2005, ARTHRITIS RHEUM-US, V52, P1812, DOI 10.1002/art.21059; Lemaire R, 2004, J INVEST DERMATOL, V123, P1063, DOI 10.1111/j.0022-202X.2004.23471.x; Lemaire R, 2004, ARTHRITIS RHEUM-US, V50, P915, DOI 10.1002/art.20053; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MARIENCHECK MC, 1995, CONNECT TISSUE RES, V31, P87, DOI 10.3109/03008209509028396; Milewicz DM, 2000, MATRIX BIOL, V19, P471, DOI 10.1016/S0945-053X(00)00099-8; Nehring LC, 2005, J BIOL CHEM, V280, P20349, DOI 10.1074/jbc.M500273200; Penner AS, 2002, J BIOL CHEM, V277, P35044, DOI 10.1074/jbc.M206363200; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; RAGHUNATH M, 1995, J MOL BIOL, V248, P901, DOI 10.1006/jmbi.1995.0270; Reinboth B, 2002, J BIOL CHEM, V277, P3950, DOI 10.1074/jbc.M109540200; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; Zanetti M, 2004, MOL CELL BIOL, V24, P638, DOI 10.1128/MCB.24.2.638-650.2004; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	38	43	48	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					800	808		10.1074/jbc.M609692200	http://dx.doi.org/10.1074/jbc.M609692200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17099216	hybrid			2022-12-27	WOS:000243166500085
J	Drozina, G; Kohoutek, J; Nishiya, T; Peterlin, BM				Drozina, Gorazd; Kohoutek, Jiri; Nishiya, Tadashi; Peterlin, B. Matija			Sequential modifications in class II transactivator isoform 1 induced by lipopolysaccharide stimulate major histocompatibility complex class II transcription in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-B; UBIQUITIN-MEDIATED PROTEOLYSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; CREB BINDING-PROTEIN; TOLL-LIKE RECEPTORS; ACTIVATE TRANSCRIPTION; DIFFERENTIAL USAGE; DENDRITIC CELLS; CIITA FUNCTION; IFN-GAMMA	By presenting antigenic peptides on major histocompatibility complex class (MHC) II determinants to CD4(+) T cells, macrophages help to direct the establishment of adaptive immunity. We found that in these cells, lipopolysaccharide stimulates the expression of MHC II genes via the activation of Erk1/2, which is mediated by Toll-like receptor 4. Erk1/2 then phosphorylates the serine at position 357, which is located in a degron of CIITA isoform 1 that leads to its monoubiquitylation. Thus modified, CIITA isoform 1 binds P-TEFb, which mediates the elongation of RNA polymerase II and co-transcriptional processing of nascent transcripts. This induction leads to the expression of MHC II genes. Subsequent polyubiquitylation results in the degradation of CIITA isoform 1. Thus, the signaling cascade from Toll-like receptor 4 to CIITA isoform 1 represents one connection between innate and adaptive immunity in macrophages.	Univ Calif San Francisco, Rosalind Russell Med Res Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Rosalind Russell Med Res Ctr, Dept Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Rosalind Russell Med Res Ctr, Dept Immunol, San Francisco, CA 94143 USA; Univ Med Ctr Ljubljana, Dept Internal Med, Div Gastroenterol, Ljubljana 1000, Slovenia; Univ Calif San Francisco, George Williams Hooper Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University Medical Centre Ljubljana; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Peterlin, BM (corresponding author), Box 0703 UCSF,3rd & Parnassus Aves, San Francisco, CA 94143 USA.	matija.peterlin@ucsf.edu			NIAID NIH HHS [R01 AI050770] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050770] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; FIGUEIREDO F, 1989, J IMMUNOL, V143, P3781; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1996, J EXP MED, V183, P2517, DOI 10.1084/jem.183.6.2517; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Giroux M, 2003, J IMMUNOL, V171, P4187, DOI 10.4049/jimmunol.171.8.4187; Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985; Greer SF, 2004, J IMMUNOL, V173, P376, DOI 10.4049/jimmunol.173.1.376; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jiang HM, 2005, MOL CELL BIOL, V25, P10675, DOI 10.1128/MCB.25.24.10675-10683.2005; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kohoutek J, 2006, P NATL ACAD SCI USA, V103, P17349, DOI 10.1073/pnas.0603079103; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Kurosu T, 2004, CURR BIOL, V14, P1112, DOI 10.1016/j.cub.2004.06.020; LeibundGut-Landmann S, 2004, NAT IMMUNOL, V5, P899, DOI 10.1038/ni1109; Li GX, 2001, MOL CELL BIOL, V21, P4626, DOI 10.1128/MCB.21.14.4626-4635.2001; Lin X, 2003, J VIROL, V77, P8227, DOI 10.1128/JVI.77.15.8227-8236.2003; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; Mudhasani R, 2002, MOL CELL BIOL, V22, P5019, DOI 10.1128/MCB.22.14.5019-5026.2002; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nickerson K, 2001, J BIOL CHEM, V276, P19089, DOI 10.1074/jbc.M101295200; Nikcevich KM, 1999, J NEUROIMMUNOL, V99, P195, DOI 10.1016/S0165-5728(99)00117-4; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Schnappauf F, 2003, EUR J IMMUNOL, V33, P2337, DOI 10.1002/eji.200323490; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Sisk TJ, 2003, INT IMMUNOL, V15, P1195, DOI 10.1093/intimm/dxg116; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Takeuchi O, 2003, J AM SOC NEPHROL, V14, P2823, DOI 10.1097/01.ASN.0000094084.18567.CC; Tosi G, 2002, EMBO J, V21, P5467, DOI 10.1093/emboj/cdf557; WENTWORTH PA, 1987, J IMMUNOL, V138, P3167; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	40	16	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39963	39970		10.1074/jbc.M608538200	http://dx.doi.org/10.1074/jbc.M608538200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17095509	hybrid			2022-12-27	WOS:000243033900024
J	Sapkota, G; Knockaert, M; Alarcon, C; Montalvo, E; Brivanlou, AH; Massague, J				Sapkota, Gopal; Knockaert, Marie; Alarcon, Claudio; Montalvo, Ermelinda; Brivanlou, Ali H.; Massague, Joan			Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY MEDIATOR SMAD1; TGF-BETA; RECEPTOR; BMP; PHOSPHORYLATION; INTEGRATION; MECHANISM; SMURF1; DEGRADATION; EXPRESSION	Smad proteins transduce bone morphogenetic protein ( BMP) and transforming growth factor-beta ( TGF beta) signals upon phosphorylation of their C-terminal SXS motif by receptor kinases. The activity of Smad1 in the BMP pathway and Smad2/3 in the TGF beta pathway is restricted by pathway cross- talk and feedback through protein kinases, including MAPK, CDK2/4, p38MAPK, JNK, and others. These kinases phosphorylate Smads 1-3 at the region that links the N-terminal DNA- binding domain and the C- terminal transcriptional domain. Phosphatases that dephosphorylate the linker region are therefore likely to play an integral part in the regulation of Smad activity. We reported previously that small C-terminal domain phosphatases 1, 2, and 3 (SCP1-3) dephosphorylate Smad1 C-terminal tail, thereby attenuating BMP signaling. Here we provide evidence that SCP1-3 also dephosphorylate the linker regions of Smad1 and Smad2/3 in vitro, in mammalian cells and in Xenopus embryos. Overexpression of SCP 1, 2, or 3 decreased linker phosphorylation of Smads 1, 2 and 3. Moreover, RNA interference-mediated knockdown of SCP1/2 increased the BMP- dependent phosphorylation of the Smad1 linker region as well as the C terminus. In contrast, SCP1/2 knockdown increased the TGF beta-dependent linker phosphorylation of Smad2/3 but not the C- terminal phosphorylation. Consequently, SCP1/2 knockdown inhibited TGF beta transcriptional responses, but it enhanced BMP transcriptional responses. Thus, by dephosphorylating Smad2/3 at the linker ( inhibitory) but not the C-terminal ( activating) site, the SCPs enhance TGF beta signaling, and by dephosphorylating Smad1 at both sites, the SCPs reset Smad1 to the basal unphosphorylated state.	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Canc Biol & Genet Program, New York, NY 10021 USA; Rockefeller Univ, Mol Vertebrate Embryol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Rockefeller University	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Canc Biol & Genet Program, Box 116,1275 York Ave, New York, NY 10021 USA.	j-massague@ski.mskcc.org	Sapkota, Gopal/C-7300-2014	Sapkota, Gopal/0000-0001-9931-3338; Massague, Joan/0000-0001-9324-8408	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD032105, R01HD032105] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R37CA034610, R01CA034610] Funding Source: NIH RePORTER; NCI NIH HHS [CA34610] Funding Source: Medline; NICHD NIH HHS [HD32105] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRIVANLOU AH, 1989, DEVELOPMENT, V106, P611; Chen HB, 2006, GENE DEV, V20, P648, DOI 10.1101/gad.1384706; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DUAN X, 2006, J BIOL CHEM; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Grimm OH, 2002, NAT CELL BIOL, V4, P519, DOI 10.1038/ncb812; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Knockaert M, 2006, P NATL ACAD SCI USA, V103, P11940, DOI 10.1073/pnas.0605133103; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Pera EM, 2003, GENE DEV, V17, P3023, DOI 10.1101/gad.1153603; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Su YA, 1997, ONCOGENE, V15, P1289, DOI 10.1038/sj.onc.1201294; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; WRIGHTON KH, 2006, J BIOL CHEM; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Yeo M, 2005, SCIENCE, V307, P596, DOI 10.1126/science.1100801; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069	29	129	135	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40412	40419		10.1074/jbc.M610172200	http://dx.doi.org/10.1074/jbc.M610172200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17085434	hybrid			2022-12-27	WOS:000243033900071
J	Huang, YC; Lin, YM; Chang, TW; Wu, SJ; Lee, YS; Chang, MDT; Chen, C; Wu, SH; Liao, YD				Huang, Yu-Chie; Lin, Yu-Min; Chang, Ting-Wei; Wu, Shih-Jung; Lee, Yan-Shin; Chang, Margaret Dah-Tsyr; Chen, Chinpan; Wu, Shih-Hsiung; Liao, You-Di			The flexible and clustered lysine residues of human ribonuclease 7 are critical for membrane permeability and antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL-DERIVED NEUROTOXIN; BULLFROG RANA-CATESBEIANA; CATIONIC PROTEIN; PEPTIDE; PURIFICATION; INDOLICIDIN; ANGIOGENIN; EVOLUTION; RNASE-7; CLONING	The ubiquitous ribonucleases (RNases) play important roles in RNA metabolism, angiogenesis, neurotoxicity, and antitumor or antimicrobial activity. Only the antimicrobial RNases possess high positively charged residues, although their mechanisms of action remain unclear. Here, we report on the role of cationic residues of human RNase7 (hRNase7) in its antimicrobial activity. It exerted antimicrobial activity against bacteria and yeast, even at 4 degrees C. The bacterial membrane became permeable to the DNA-binding dye SYTOX Green in only a few minutes after bactericidal RNase treatment. NMR studies showed that the 22 positively charged residues (Lys(18) and Arg(4)) are distributed into three clusters on the surface of hRNase7. The first cluster, K-1,K-3,K-111,K-112, was located at the flexible coil near the N terminus, whereas the other two, K-32,K-35 and K-96,R-97,K-100, were located on rigid secondary structures. Mutagenesis studies showed that the flexible cluster K-1,K-3,K-111,K-112, rather than the catalytic residues His(15), Lys(38), and His(123) or other clusters such as K-32,K-35 and K-96,R-97,K-100, is critical for the bactericidal activity. We suggest that the hRNase7 binds to bacterial membrane and renders the membrane permeable through the flexible and clustered Lys residues K-1,K-3,K-111,K-112. The conformation of hRNase7 can be adapted for pore formation or disruption of bacterial membrane even at 4 degrees C.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan; Natl Yang Ming Univ, Inst Pharmacol, Taipei 112, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Tsing Hua University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Wu, SH (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	shwu@gate.sinica.edu.tw; ydliao@ibms.sinica.edu.tw	Chang, Tse Wen/H-5955-2011; Liao, You-Di/S-7018-2018; Chen, Chinpan/O-4202-2018	Liao, You-Di/0000-0001-5527-4736; 				ALASKOWSKI RA, 1996, J BIOMOL NMR, V8, P477; Carreras E, 2003, BIOCHEMISTRY-US, V42, P6636, DOI 10.1021/bi0273011; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Harder J, 2002, J BIOL CHEM, V277, P46779, DOI 10.1074/jbc.M207587200; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Holloway DE, 2001, PROTEIN EXPRES PURIF, V22, P307, DOI 10.1006/prep.2001.1434; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Hsu CH, 2005, NUCLEIC ACIDS RES, V33, P4053, DOI 10.1093/nar/gki725; Hsu CH, 2003, J MOL BIOL, V326, P1189, DOI 10.1016/S0022-2836(02)01472-9; Huang HC, 1998, J BIOL CHEM, V273, P6395, DOI 10.1074/jbc.273.11.6395; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Liao YD, 2000, NUCLEIC ACIDS RES, V28, P4097, DOI 10.1093/nar/28.21.4097; LIAO YD, 1994, EUR J BIOCHEM, V222, P215, DOI 10.1111/j.1432-1033.1994.tb18859.x; MCLAREN DJ, 1981, PARASITE IMMUNOL, V3, P359, DOI 10.1111/j.1365-3024.1981.tb00414.x; Nekhotiaeva N, 2003, FASEB J, V17, P394, DOI 10.1096/fj.03-0449fje; Nitto T, 2006, J BIOL CHEM, V281, P25622, DOI 10.1074/jbc.M604313200; Powers JPS, 2003, PEPTIDES, V24, P1681, DOI 10.1016/j.peptides.2003.08.023; Robinson WE, 1998, J LEUKOCYTE BIOL, V63, P94, DOI 10.1002/jlb.63.1.94; ROSENBERG HF, 1995, J BIOL CHEM, V270, P21539, DOI 10.1074/jbc.270.37.21539; Zhang JZ, 2003, NUCLEIC ACIDS RES, V31, P602, DOI 10.1093/nar/gkg157	29	94	100	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4626	4633		10.1074/jbc.M607321200	http://dx.doi.org/10.1074/jbc.M607321200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17150966	hybrid, Green Published			2022-12-27	WOS:000244482000043
J	Pollok-Kopp, B; Huttenrauch, F; Rethorn, S; Oppermann, M				Pollok-Kopp, Beatrix; Huettenrauch, Friederike; Rethorn, Stephanie; Oppermann, Martin			Dynamics of protein kinase C-mediated phosphorylation of the complement C5a receptor on serine 334	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II RECEPTOR; 5 CCR5 PHOSPHORYLATION; COUPLED RECEPTOR; BETA-ARRESTIN; ANAPHYLATOXIN RECEPTOR; CHEMOATTRACTANT RECEPTORS; TERMINAL DOMAIN; HL-60 CELLS; INTERNALIZATION; BINDING	Upon agonist binding, the C5a anaphylatoxin receptor (C5aR) is rapidly phosphorylated on phosphorylation sites that are located within the C-terminal domain of the receptor. Previous studies suggested that C5aR phosphorylation proceeds in a hierarchical manner with serine 334 presenting a highly accessible priming site that controls subsequent phosphorylation at other positions. To better understand the dynamics of Ser-334 phosphorylation, we generated site-specific monoclonal antibodies that specifically react with phosphoserine 334. In differentiated U937 cells, which endogenously express C5aR, stimulation with low C5a concentrations resulted in a very rapid (t2/1 similar to 20 s), albeit transient, receptor phosphorylation. Whole cell phosphorylation assays with specific inhibitors as well as in vitro phosphorylation assays with recombinant enzymes and peptide substrates revealed that phosphorylation of Ser-334 is regulated by protein kinase C-beta and a calyculin A-sensitive protein phosphatase. Surprisingly, at high concentrations (> 10 nM) of C5a, the protein kinase C-mediated phosphorylation of Ser-334 was essentially blocked. This could be attributed to the even faster (t2/1 < 5 s) binding of beta-arrestin to the receptor. Analysis of C5aR Ser/Ala mutants that possess a single intact serine residue either at position 334 or at neighboring positions 327, 332, or 338 revealed functional redundancy of C-terminal phosphorylation sites since all 4 serine residues could individually support C5aR internalization and desensitization. This study is among the first to analyze in a detailed manner, using a non-mutational approach, modifications of a defined phosphorylation site in a G protein-coupled receptor and to correlate these findings with functional parameters of receptor deactivation.	Univ Gottingen, Dept Cellular & Mol Immunol, D-37073 Gottingen, Germany	University of Gottingen	Oppermann, M (corresponding author), Univ Gottingen, Dept Cellular & Mol Immunol, Humboldtallee 34, D-37073 Gottingen, Germany.	mopperm@gwdg.de						ALI H, 1993, J BIOL CHEM, V268, P24247; Balasubramanian N, 2002, LEUKEMIA RES, V26, P67, DOI 10.1016/S0145-2126(01)00098-4; BARKER MD, 1986, BIOCHEM J, V236, P621, DOI 10.1042/bj2360621; Bennett TA, 2001, J BIOL CHEM, V276, P49195, DOI 10.1074/jbc.M106414200; Braun L, 2003, J BIOL CHEM, V278, P4277, DOI 10.1074/jbc.M210120200; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Christophe T, 2000, J BIOL CHEM, V275, P1656, DOI 10.1074/jbc.275.3.1656; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; Gurevich VV, 2006, PHARMACOL THERAPEUT, V110, P465, DOI 10.1016/j.pharmthera.2005.09.008; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Jala VR, 2005, J BIOL CHEM, V280, P4880, DOI 10.1074/jbc.M409821200; Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Langkabel P, 1999, EUR J IMMUNOL, V29, P3035, DOI 10.1002/(SICI)1521-4141(199909)29:09<3035::AID-IMMU3035>3.0.CO;2-Z; MONTZ H, 1990, CELL IMMUNOL, V127, P337, DOI 10.1016/0008-8749(90)90137-G; Naik N, 1997, J CELL SCI, V110, P2381; OGITA K, 1991, METHOD ENZYMOL, V200, P228; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Pollok-Kopp B, 2003, J BIOL CHEM, V278, P2190, DOI 10.1074/jbc.M209844200; Potter RM, 2006, J IMMUNOL, V176, P5418, DOI 10.4049/jimmunol.176.9.5418; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Rothermel E, 1997, BBA-GENE STRUCT EXPR, V1351, P9, DOI 10.1016/S0167-4781(97)00006-7; TARDIF M, 1993, J IMMUNOL, V150, P3534; WERFEL T, 1992, BLOOD, V79, P152, DOI 10.1182/blood.V79.1.152.bloodjournal791152; Zwirner J, 1999, MOL IMMUNOL, V36, P877, DOI 10.1016/S0161-5890(99)00109-1	32	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4345	4353		10.1074/jbc.M601317200	http://dx.doi.org/10.1074/jbc.M601317200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17145764	hybrid			2022-12-27	WOS:000244482000014
J	Sarto-Jackson, I; Furtmueller, R; Ernst, M; Huck, S; Sieghart, W				Sarto-Jackson, Isabella; Furtmueller, Roman; Ernst, Margot; Huck, Sigismund; Sieghart, Werner			Spontaneous cross-link of mutated alpha 1 subunits during GABA(A) receptor assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; BETA-SUBUNITS; QUANTITATIVE IMPORTANCE; INTERSUBUNIT CONTACTS; A RECEPTORS; IDENTIFICATION; STOICHIOMETRY; EXPRESSION; SIGNALS; PROTEIN	gamma-Aminobutyric acid, type A (GABA(A)) receptor alpha 1 subunits containing a cysteine mutation at a position in the channel mouth (H109C) surprisingly formed a spontaneous cross-link with each other in receptors composed of alpha 1H109C, beta 3, and gamma 2 subunits. Cross-linking of two alpha 1H109C subunits did not significantly change the affinity of [H-3]muscimol or [H-3]Ro15-1788 binding in alpha 1H109C beta 3 gamma 2 receptors, but GABA displayed a reduced potency for activating chloride currents. On reduction of the disulfide bond, however, GABA activation as well as diazepam modulation was similar in mutated and wild-type receptors, suggesting that these receptors exhibited the same subunit stoichiometry and arrangement. Disulfide bonds could not be reoxidized by copper phenanthroline after having been reduced in completely assembled receptors, suggesting that cross-linking can only occur at an early stage of assembly. The cross-link of alpha 1H109C subunits and the subsequent transport of the resulting homodimers to the cell surface caused a reduction of the intracellular pool of alpha 1H109C subunits and a reduced formation of completely assembled receptors. The formation of alpha 1H109C homodimers as well as of correctly assembled GABAA receptors containing cross-linked alpha 1H109C subunits could indicate that homodimerization of alpha 1 subunits via contacts located in the channel mouth might be one starting point of GABA, receptor assembly. Alternatively the assembly mechanism might have started with the formation of heterodimers followed by a cross-link of mutated alpha 1 subunits at the hetero trimeric stage. The formation of cross-linked alpha 1H109C homodimers would then have occurred independently in a separate pathway.	Med Univ Vienna, Ctr Brain Res, Div Biochem & Mol Biol, A-1090 Vienna, Austria; Univ Clin Psychiat, Sect Biochem Psychiat, A-1090 Vienna, Austria	Medical University of Vienna	Sieghart, W (corresponding author), Med Univ Vienna, Ctr Brain Res, Div Biochem & Mol Biol, Spitalgasse 4, A-1090 Vienna, Austria.	werner.sieghart@meduniwien.ac.at	Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302; Huck, Sigismund/0000-0003-2022-5680; Ernst, Margot/0000-0002-9809-2649				Amato A, 1999, J PHYSIOL-LONDON, V517, P35, DOI 10.1111/j.1469-7793.1999.0035z.x; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; Bollan K, 2003, BIOCHEM SOC T, V31, P875, DOI 10.1042/bst0310875; Bollan K, 2003, J BIOL CHEM, V278, P4747, DOI 10.1074/jbc.M210229200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Chang YC, 1996, J NEUROSCI, V16, P5415; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; Ehya N, 2003, J NEUROCHEM, V84, P127, DOI 10.1046/j.1471-4159.2003.01509.x; Ernst M, 2005, MOL PHARMACOL, V68, P1291, DOI 10.1124/mol.105.015982; Ernst M, 2003, NEUROSCIENCE, V119, P933, DOI 10.1016/S0306-4522(03)00288-4; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Klausberger T, 2000, J BIOL CHEM, V275, P8921, DOI 10.1074/jbc.275.12.8921; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; NAYEEM N, 1994, J NEUROCHEM, V62, P815; Neville D M Jr, 1974, Methods Enzymol, V32, P92; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; PAULSON HL, 1990, J CELL BIOL, V110, P1705, DOI 10.1083/jcb.110.5.1705; Poltl A, 2003, J NEUROCHEM, V87, P1444, DOI 10.1046/j.1471-4159.2003.02135.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sarto I, 2002, J BIOL CHEM, V277, P30656, DOI 10.1074/jbc.M203597200; Sarto I, 2002, NEUROPHARMACOLOGY, V43, P482, DOI 10.1016/S0028-3908(02)00160-0; Sarto-Jackson I, 2006, J NEUROCHEM, V96, P983, DOI 10.1111/j.1471-4159.2005.03626.x; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Taylor PM, 2000, J NEUROSCI, V20, P1297; Taylor PM, 1999, J NEUROSCI, V19, P6360; Tretter V, 1997, J NEUROSCI, V17, P2728; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	36	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4354	4363		10.1074/jbc.M609676200	http://dx.doi.org/10.1074/jbc.M609676200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17148454	hybrid			2022-12-27	WOS:000244482000015
J	Jin, XH; Okamoto, Y; Morishita, J; Tsuboi, K; Tonai, T; Ueda, N				Jin, Xing-Hua; Okamoto, Yasuo; Morishita, Jun; Tsuboi, Kazuhito; Tonai, Takeharu; Ueda, Natsuo			Discovery and characterization of Ca2+-independent phosphatidylethanolarnine N-acyltransferase generating the anandarnide precursor and its congeners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-RETINOL ACYLTRANSFERASE; ACID AMIDE HYDROLASE; CANNABINOID-RECEPTOR-LIGAND; HYDROLYZING PHOSPHOLIPASE-D; ISCHEMIC RAT-BRAIN; ETHANOLAMINE PHOSPHOLIPIDS; ACYLETHANOLAMINE PHOSPHOLIPIDS; INFARCTED MYOCARDIUM; DOWN-REGULATION; ANANDAMIDE	N-Acylphosphatidylethanolamines (NAPEs) are precursors of bioactive N-acylethanolamines, including the endocannabinoid anandamide. In animal tissues, NAPE is formed by transfer of a fatty acyl chain at the sn-1 position of glycerophospholipids to the amino group of phosphatidylethanolamine (PE), and this reaction is believed to be the principal rate-limiting step in N-acylethanolamine synthesis. However, the Ca2+-dependent, membrane-associated N-acyltransferase (NAT) responsible for this reaction has not yet been cloned. In this study, on the basis of the functional similarity of NAT to lecithin-retinol acyltransferase (LRAT), we examined a possible PE N-acylation activity in two rat LRAT homologous proteins. Upon overexpression in COS-7 cells, one protein, named rat LRAT-like protein (RLP)-1, catalyzed transfer of a radioactive acyl group from phosphatidylicholine (PC) to PE, resulting in the formation of radioactive NAPE. However, the RLP-1 activity was detected mainly in the cytosolic rather than membrane fraction and was little stimulated by Ca2+. Moreover, RLP-1 did not show selectivity with respect to the sn-1 and sn-2 positions of PC as an acyl donor and therefore could generate N-arachidonoyl-PE (anandamide precursor) from 2-arachidonoyl-PC and PE. In contrast, under the same assay conditions, partially purified NAT from rat brain was highly Ca2+-dependent, membrane-associated, and specific for the sn-1-acyl group of PC. RLP-1 mRNA was expressed predominantly in testis among various rat tissues, and the testis cytosol exhibited an RLP-1-like activity. These results reveal that RLP-1 can function as a PE N-acyltransferase, catalytically distinguishable from the known Ca2+-dependent NAT.	Kagawa Univ, Sch Med, Dept Biochem, Miki, Kagawa 7610793, Japan; Natl Zentsuji Hosp, Dept Orthoped Surg, Kagawa 7650001, Japan; Natl Zentsuji Hosp, Clin Res Inst, Kagawa 7650001, Japan	Kagawa University	Ueda, N (corresponding author), Kagawa Univ, Sch Med, Dept Biochem, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	nueda@med.kagawa-u.ac.jp	Jin, Xinghua/K-1142-2015; OKAMOTO, Yasuo/J-8438-2015	Jin, Xinghua/0000-0002-8883-5234; 				Akiyama H, 1999, J BIOL CHEM, V274, P32192, DOI 10.1074/jbc.274.45.32192; Anantharaman V, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r11; ARAI H, 1985, J BIOCHEM-TOKYO, V97, P1525, DOI 10.1093/oxfordjournals.jbchem.a135209; Berdyshev EV, 2000, BIOCHEM J, V346, P369, DOI 10.1042/0264-6021:3460369; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadas H, 1997, J NEUROSCI, V17, P1226; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; EPPS DE, 1979, BIOCHEM BIOPH RES CO, V90, P628, DOI 10.1016/0006-291X(79)91281-6; EPPS DE, 1980, BIOCHIM BIOPHYS ACTA, V618, P420, DOI 10.1016/0005-2760(80)90260-X; Golczak M, 2005, J BIOL CHEM, V280, P42263, DOI 10.1074/jbc.M509351200; Guo Y, 2005, J BIOL CHEM, V280, P23429, DOI 10.1074/jbc.C500168200; HANJNAL A, 1994, ONCOGENE, V9, P479; HANSEN HS, 1995, BBA-LIPID LIPID MET, V1258, P303, DOI 10.1016/0005-2760(95)00134-X; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Jahng WJ, 2003, BIOCHEMISTRY-US, V42, P12805, DOI 10.1021/bi035370p; KERWIN JL, 1994, J LIPID RES, V35, P1102; Kondo S, 1998, ARCH BIOCHEM BIOPHYS, V354, P303, DOI 10.1006/abbi.1998.0688; Kurahashi Y, 1997, BIOCHEM BIOPH RES CO, V237, P512, DOI 10.1006/bbrc.1997.7180; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; Maccarrone M, 2005, J CELL SCI, V118, P4393, DOI 10.1242/jcs.02536; McKinney MK, 2005, ANNU REV BIOCHEM, V74, P411, DOI 10.1146/annurev.biochem.74.082803.133450; Moesgaard B, 2000, J LIPID RES, V41, P985; NATARAJAN V, 1986, BIOCHIM BIOPHYS ACTA, V878, P32, DOI 10.1016/0005-2760(86)90341-3; NATARAJAN V, 1983, J NEUROCHEM, V41, P1303, DOI 10.1111/j.1471-4159.1983.tb00825.x; NATARAJAN V, 1982, BIOCHIM BIOPHYS ACTA, V712, P342, DOI 10.1016/0005-2760(82)90352-6; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Rando RR, 2002, BIOCHEM BIOPH RES CO, V292, P1243, DOI 10.1006/bbrc.2001.2021; REDDY PV, 1983, BIOCHIM BIOPHYS ACTA, V751, P241, DOI 10.1016/0005-2760(83)90178-9; REDDY PV, 1983, BIOCHIM BIOPHYS ACTA, V750, P472, DOI 10.1016/0005-2760(83)90187-X; REDDY PV, 1984, BIOCHIM BIOPHYS ACTA, V795, P130, DOI 10.1016/0005-2760(84)90113-9; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; Schmid HHO, 2002, PROSTAG LEUKOTR ESS, V66, P363, DOI 10.1054/plef.2001.0348; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V218, P113, DOI 10.1006/bbrc.1996.0020; Sun YX, 2004, BIOCHEM J, V380, P749, DOI 10.1042/BJ20040031; Terrazzino S, 2004, FASEB J, V18, P1580, DOI 10.1096/fj.03-1080fje; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UEDA N, 1995, BBA-LIPID LIPID MET, V1254, P127, DOI 10.1016/0005-2760(94)00170-4; Ueda N, 2000, CHEM PHYS LIPIDS, V108, P107, DOI 10.1016/S0009-3084(00)00190-0; Ueda N, 2005, CURR MED CHEM, V12, P1413, DOI 10.2174/0929867054020918; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Wang J, 2006, J BIOL CHEM, V281, P12325, DOI 10.1074/jbc.M512359200; Zolfaghari R, 2000, J LIPID RES, V41, P2024	53	117	125	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3614	3623		10.1074/jbc.M606369200	http://dx.doi.org/10.1074/jbc.M606369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158102	hybrid			2022-12-27	WOS:000244481900023
J	Tanio, M; Kondo, S; Sugio, S; Kohno, T				Tanio, Michikazu; Kondo, Shin; Sugio, Shigetoshi; Kohno, Toshiyuki			Trivalent recognition unit of innate immunity system - Crystal structure of trimeric human M-ficolin fibrinogen-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECTIN-COMPLEMENT PATHWAY; MANNOSE-BINDING LECTIN; CARBOHYDRATE-RECOGNITION; LIGAND-BINDING; GAMMA-CHAIN; PROTEIN; PATTERN; CLONING; PURIFICATION; COLLECTINS	Ficohins are a kind of pathogen-recognition molecule in the innate immune systems. To investigate the discrimination mechanism between self and non-self by ficolins, we determined the crystal structure of the human M-ficolin fibrinogen-like domain (FD1), which is the ligand-binding domain, at 1.9 angstrom resolution. Although the FD1 monomer shares a common fold with the fibrinogen gamma fragment and tachylectin-SA, the Asp-282-Cys-283 peptide bond, which is the predicted ligand-binding site on the C-terminal P domain, is a normal trans bond, unlike the cases of the other two proteins. The trimeric formation of FD1 results in the separation of the three P domains, and the spatial arrangement of the three predicted ligand-binding sites on the trimer is very similar to that of the trimeric collectin, indicating that such an arrangement is generally required for pathogen-recognition. The ligand binding study of FD1 in solution indicated that the recombinant protein binds to N-acetyl-D-glucosamine and the peptide Gly-Pro-Arg-Pro and suggested that the ligand-binding region exhibits a conformational equilibrium involving cis-trans isomerization of the Asp-282-Cys-283 peptide bond. The crystal structure and the ligand binding study of FD1 provide an insight of the self- and non-self discrimination mechanism by ficolins.	ZOEGENE Corp, Aoba Ku, Yokohama, Kanagawa 2278502, Japan; Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS)	Sugio, S (corresponding author), ZOEGENE Corp, Aoba Ku, 1000 Kamoshida, Yokohama, Kanagawa 2278502, Japan.	ssugio@rc.m-kagaku.co.jp	Tanio, Michikazu/F-2857-2013	Tanio, Michikazu/0000-0001-5652-4952				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barton WA, 2005, STRUCTURE, V13, P825, DOI 10.1016/j.str.2005.03.009; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Endo Y, 1996, GENOMICS, V36, P515, DOI 10.1006/geno.1996.0497; Frederiksen PD, 2005, SCAND J IMMUNOL, V62, P462, DOI 10.1111/j.1365-3083.2005.01685.x; Fujita T, 2004, MOL IMMUNOL, V41, P103, DOI 10.1016/j.molimm.2004.03.026; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; Fujita T, 2004, IMMUNOL REV, V198, P185, DOI 10.1111/j.0105-2896.2004.0123.x; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Head JF, 2003, J BIOL CHEM, V278, P43254, DOI 10.1074/jbc.M305628200; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; ICHIJO H, 1991, J BIOL CHEM, V266, P22459; IOBST ST, 1994, J BIOL CHEM, V269, P15505; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x; Kairies N, 2001, P NATL ACAD SCI USA, V98, P13519, DOI 10.1073/pnas.201523798; Kawabata S, 2002, BBA-GEN SUBJECTS, V1572, P414, DOI 10.1016/S0304-4165(02)00322-7; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Krarup A, 2005, INFECT IMMUN, V73, P1052, DOI 10.1128/IAI.73.2.1052-1060.2005; Krarup A, 2004, J BIOL CHEM, V279, P47513, DOI 10.1074/jbc.M407161200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Le Y, 1998, FEBS LETT, V425, P367, DOI 10.1016/S0014-5793(98)00267-1; Le Y, 1997, J IMMUNOL METHODS, V204, P43, DOI 10.1016/S0022-1759(97)00029-X; LEE RT, 1991, J BIOL CHEM, V266, P4810; Liu Y, 2005, J IMMUNOL, V175, P3150, DOI 10.4049/jimmunol.175.5.3150; Lu J, 1996, IMMUNOLOGY, V89, P289, DOI 10.1046/j.1365-2567.1996.d01-732.x; Lu JH, 1996, BIOCHEM J, V313, P473, DOI 10.1042/bj3130473; Lu JH, 2002, BBA-GEN SUBJECTS, V1572, P387, DOI 10.1016/S0304-4165(02)00320-3; Lynch NJ, 2004, J IMMUNOL, V172, P1198, DOI 10.4049/jimmunol.172.2.1198; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; Matsushita M, 2001, INT IMMUNOPHARMACOL, V1, P359, DOI 10.1016/S1567-5769(00)00045-X; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; Matsushita M, 2002, IMMUNOBIOLOGY, V205, P490, DOI 10.1078/0171-2985-00149; Matsushita M, 2002, J IMMUNOL, V168, P3502, DOI 10.4049/jimmunol.168.7.3502; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; Ohashi T, 2004, J BIOL CHEM, V279, P6534, DOI 10.1074/jbc.M310555200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pratt KP, 1997, P NATL ACAD SCI USA, V94, P7176, DOI 10.1073/pnas.94.14.7176; Sano H, 2005, MOL IMMUNOL, V42, P279, DOI 10.1016/j.molimm.2004.07.014; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Shrive AK, 2003, J MOL BIOL, V331, P509, DOI 10.1016/S0022-2836(03)00761-7; Sugimoto R, 1998, J BIOL CHEM, V273, P20721, DOI 10.1074/jbc.273.33.20721; Tanio M, 2006, ACTA CRYSTALLOGR F, V62, P652, DOI 10.1107/S1744309106019786; Teh C, 2000, IMMUNOLOGY, V101, P225, DOI 10.1046/j.1365-2567.2000.00099.x; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Yang IA, 2004, GENES IMMUN, V5, P41, DOI 10.1038/sj.gene.6364037; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	53	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3889	3895		10.1074/jbc.M608627200	http://dx.doi.org/10.1074/jbc.M608627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148457	hybrid			2022-12-27	WOS:000244481900053
J	Shi, XB; Kachirskaia, I; Walter, KL; Kuo, JHA; Lake, A; Davrazou, F; Chan, SM; Martin, DGE; Fingerman, IM; Briggs, SD; Howe, L; Utz, PJ; Kutateladze, TG; Lugovskoy, AA; Bedford, MT; Gozani, O				Shi, Xiaobing; Kachirskaia, Ioulia; Walter, Kay L.; Kuo, Jen-Hao A.; Lake, Aimee; Davrazou, Foteini; Chan, Steve M.; Martin, David G. E.; Fingerman, Ian M.; Briggs, Scott D.; Howe, LeAnn; Utz, Paul J.; Kutateladze, Tatiana G.; Lugovskoy, Alexey A.; Bedford, Mark T.; Gozani, Or			Proteome-wide analysis in Saccharomyces cerevisiae identifies several PHD fingers as novel direct and selective binding modules of histone H3 methylated at either lysine 4 or lysine 36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT HOMEODOMAIN; CODE; CHROMATIN; H3K4ME3; NURF; READ; ING2; MARK	The PHD finger motif is a signature chromatin-associated motif that is found throughout eukaryotic proteomes. Here we have determined the histone methyl-lysine binding activity of the PHD fingers present within the Saccharomyces cerevisiae proteome. We provide evidence on the genomic scale that PHD fingers constitute a general class of effector modules for histone H3 trimethylated at lysine 4 (H3K4me3) and histone H3 trimethylated at lysine 36 (H3K36me3). Structural modeling of PHD fingers demonstrates a conserved mechanism for recognizing the trimethyl moiety and provides insight into the molecular basis of affinity for the different methyl-histone ligands. Together, our study suggests that a common function for PHD fingers is to transduce methyl-lysine events and sheds light on how a single histone modification can be linked to multiple biological outcomes.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Texas, MD Anderson Canc Ctr, Smithville, TX 78957 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA; Stanford Univ, Sch Med, Div Immunol & Rheumatol, Dept Med, Stanford, CA 94305 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Stanford University; University of Texas System; UTMD Anderson Cancer Center; University of Colorado System; University of Colorado Anschutz Medical Campus; Stanford University; University of British Columbia; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Harvard University; Harvard Medical School	Gozani, O (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	ogozani@stanford.edu	Mareček, Vladimír/G-7287-2014; Gozani, Or P/I-6157-2013; Bedford, Mark T/E-7856-2011	Gozani, Or/0000-0002-1365-4463; Kutateladze, Tatiana/0000-0001-7375-6990; Briggs, Scott D/0000-0003-2852-3594; Shi, Xiaobing/0000-0001-5242-8189	NIGMS NIH HHS [R01 GM074183, R01 GM074183-03, R01 GM074183-02, R01 GM074183-04, R01 GM074183-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2004, METHOD ENZYMOL, V376, P269; Becker PB, 2006, NATURE, V442, P31, DOI 10.1038/442031a; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Daniel JA, 2005, CELL CYCLE, V4, P919, DOI 10.4161/cc.4.7.1824; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; DeLano W.L, PYMOL MOL GRAPHICS S; Eberharter A, 2004, EMBO J, V23, P4029, DOI 10.1038/sj.emboj.7600382; Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Martin DGE, 2006, MOL CELL BIOL, V26, P7871, DOI 10.1128/MCB.00573-06; Martin DGE, 2006, MOL CELL BIOL, V26, P3018, DOI 10.1128/MCB.26.8.3018-3028.2006; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Ragvin A, 2004, J MOL BIOL, V337, P773, DOI 10.1016/j.jmb.2004.01.051; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Zhang K, 2005, CELL, V122, P723, DOI 10.1016/j.cell.2005.06.021; Zhang Y, 2006, NAT STRUCT MOL BIOL, V13, P572, DOI 10.1038/nsmb0706-572	23	197	207	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2450	2455		10.1074/jbc.C600286200	http://dx.doi.org/10.1074/jbc.C600286200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17142463	hybrid, Green Accepted			2022-12-27	WOS:000243593200036
J	Wicovsky, A; Muller, N; Daryab, N; Marienfeld, R; Kneitz, C; Kavuri, S; Leverkus, M; Baumann, B; Wajant, H				Wicovsky, Andreas; Mueller, Nicole; Daryab, Neda; Marienfeld, Ralf; Kneitz, Christian; Kavuri, Shyam; Leverkus, Martin; Baumann, Bernd; Wajant, Harald			Sustained JNK activation in response to tumor necrosis factor is mediated by caspases in a cell type-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ALPHA-INDUCED APOPTOSIS; TNF-ALPHA; SIGNAL-TRANSDUCTION; MAP KINASES; IKK-GAMMA; DEATH; INHIBITOR; PATHWAY; RIP	In most cell types, tumor necrosis factor (TNF) induces a transient activation of the JNK pathway. However, in NF kappa B-inhibited cells, TNF stimulates also a second sustained phase of JNK activation, which has been implicated in cell death induction. In the present study, we have analyzed the relationship of cell death induction, caspase activity, JNK, and NF kappa B stimulation in the context of TNF signaling in four different cellular systems. In all cases, NF kappa B inhibition enhanced TNF-induced cell death and primed most, but not all, cells for sustained JNK activation. The caspase inhibitor Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VAD-fmk) and overexpression of the antiapoptotic proteins FLIP-L and Bcl2 differentially blocked transient and sustained JNK activation in NF kappa B-inhibited KB and HaCaT cells, indicating that the two phases of TNF-induced JNK activation occur at least in these cellular models by different pathways. Although the broad range caspase inhibitor Z-VAD-fmk and the antioxidant butylated hydroxyanisole interfered with TNF-induced cell death to a varying extent in a cell type-specific manner, inhibition of JNK signaling had no or only a very moderate effect. Notably, the JNK inhibitory effect of neither Z-VAD-fmk nor butylated hydroxyanisole was strictly correlated with the capability of these compounds to rescue cells from TNF-induced cell death. Thus, sustained JNK activation by TNF has no obligate role in TNF-induced cell death and is mediated by caspases and reactive oxygen species in a cell type-specific manner.	Univ Wurzburg, Dept Mol Internal Med, Med Clin & Polyclin 2, D-97070 Wurzburg, Germany; Univ Ulm, D-89081 Ulm, Germany; Otto Von Guericke Univ, Lab Expt Dermatol, Dept Dermatol & Venerol, D-39120 Magdeburg, Germany	University of Wurzburg; Ulm University; Otto von Guericke University	Wajant, H (corresponding author), Univ Wurzburg, Dept Mol Internal Med, Med Clin & Polyclin 2, Roentgenring 11, D-97070 Wurzburg, Germany.	wajant@mail.uni-wuerzburg.de	Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949; Muller-Sienerth, Nicole/0000-0002-7527-5127				Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Ham YM, 2003, J BIOL CHEM, V278, P50330, DOI 10.1074/jbc.M302997200; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Herr I, 2000, ONCOGENE, V19, P4255, DOI 10.1038/sj.onc.1203776; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Nakano H, 2004, TRENDS IMMUNOL, V25, P402, DOI 10.1016/j.it.2004.05.007; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Wachter T, 2004, J BIOL CHEM, V279, P52824, DOI 10.1074/jbc.M409554200; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wajant H, 2003, CYTOKINE GROWTH F R, V14, P53, DOI 10.1016/S1359-6101(02)00072-2; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	33	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2174	2183		10.1074/jbc.M606167200	http://dx.doi.org/10.1074/jbc.M606167200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121845	hybrid			2022-12-27	WOS:000243593200008
J	Woods, K; Thomson, JM; Hammond, SM				Woods, Keith; Thomson, J. Michael; Hammond, Scott M.			Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTERS	Micro-RNAs (miRNAs) are a class of non-coding RNAs that post-transcriptionally regulate gene expression via the RNA interference pathway. In addition to roles in normal development, miRNAs have recently been implicated in a range of human diseases, including cancer. We recently demonstrated that a polycistronic cluster of miRNAs, miR-17 - 92, is oncogenic in a mouse model for Burkitt's lymphoma. This is due, in part, to a reduced apoptotic program. In an effort to understand the regulation of miR-17 - 92, we have studied the promoter structure of this miRNA cluster. The primary transcript initiates from a consensus initiator sequence downstream of a nonconsensus TATA box. The core promoter region contains two functional E2F transcription factor binding sites. Chromatin immunoprecipitation demonstrates that E2F3 is the primary E2F family member that occupies the promoter. These data place miR-17 - 92 in a regulatory loop between E2F3 and the miR-17 target E2F1. We propose a model whereby miR-17 - 92 promotes cell proliferation by shifting the E2F transcriptional balance away from the pro-apoptotic E2F1 and toward the proliferative E2F3 transcriptional network.	Univ N Carolina, Dept Cell & Dev Biol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Hammond, SM (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	hammond@med.unc.edu						BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Fang ZH, 2006, HISTOL HISTOPATHOL, V21, P403, DOI 10.14670/HH-21.403; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Humbert PO, 2000, GENE DEV, V14, P690; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Moore PA, 1999, MOL CELL BIOL, V19, P7610; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ponjavic J, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-r78; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; WASYLYK B, 1983, EMBO J, V2, P1605, DOI 10.1002/j.1460-2075.1983.tb01631.x; Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	24	399	417	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2130	2134		10.1074/jbc.C600252200	http://dx.doi.org/10.1074/jbc.C600252200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135268	Green Published, hybrid			2022-12-27	WOS:000243593200003
J	Silkstone, G; Jasaitis, A; Wilson, MT; Vos, MH				Silkstone, Gary; Jasaitis, Audrius; Wilson, Michael T.; Vos, Marten H.			Ligand dynamics in an electron transfer protein - Picosecond geminate recombination of carbon monoxide to heme in mutant forms of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURALLY ENGINEERED CYTOCHROMES; FEMTOSECOND MID-IR; NITRIC-OXIDE; YEAST ISO-1-CYTOCHROME-C; SACCHAROMYCES-CEREVISIAE; MOLECULAR-DYNAMICS; FLASH-PHOTOLYSIS; BINDING KINETICS; MET80X MUTANTS; DOCKING SITE	Substitution of the heme coordination residue Met-80 of the electron transport protein yeast iso-1-cytochrome c allows external ligands like CO to bind and thus increase the effective redox potential. This mutation, in principle, turns the protein into a quasi-native photoactivable electron donor. We have studied the kinetic and spectral characteristics of geminate recombination of heme and CO in a series of single M80X (X = Ala, Ser, Asp, Arg) mutants, using femtosecond transient absorption spectroscopy. In these proteins, all geminate recombination occurs on the picosecond and early nanosecond time scale, in a multiphasic manner, in which heme relaxation takes place on the same time scale. The extent of geminate recombination varies from > 99% (Ala, Ser) to similar to 70% (Arg), the latter value being in principle low enough for electron injection studies. The rates and extent of the CO geminate recombination phases are much higher than in functional ligand-binding proteins like myoglobin, presumably reflecting the rigid and hydrophobic properties of the heme environment, which are optimized for electron transfer. Thus, the dynamics of CO recombination in cytochrome c are a tool for studying the heme pocket, in a similar way as NO in myoglobin. We discuss the differences in the CO kinetics between the mutants in terms of the properties of the heme environment and strategies to enhance the CO escape yield. Experiments on double mutants in which Phe-82 is replaced by Asp or Gly as well as the M80D substitution indicate that such steric changes substantially increase the motional freedom-dissociated CO.	Ecole Polytech, CNRS, INSERM, Lab Opt Biosci, F-91128 Palaiseau, France; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; University of Essex	Vos, MH (corresponding author), Ecole Polytech, CNRS, INSERM, Lab Opt Biosci, F-91128 Palaiseau, France.	marten.vos@polytechnique.edu		Vos, Marten/0000-0003-0493-4831				ANTONINI E, 1965, PHYSIOL REV, V45, P123, DOI 10.1152/physrev.1965.45.1.123; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Arcovito A, 2001, J BIOL CHEM, V276, P41073, DOI 10.1074/jbc.M105183200; BANCI L, 1995, BIOCHEMISTRY-US, V34, P11385, DOI 10.1021/bi00036a011; BOELENS R, 1982, BIOCHIM BIOPHYS ACTA, V682, P264, DOI 10.1016/0005-2728(82)90107-4; BREN KL, 1995, J AM CHEM SOC, V117, P8067, DOI 10.1021/ja00136a003; BREN KL, 1993, J AM CHEM SOC, V115, P10382, DOI 10.1021/ja00075a073; BRUNORI M, 1973, P NATL ACAD SCI USA, V70, P3141, DOI 10.1073/pnas.70.11.3141; Brunori M, 2001, EMBO REP, V2, P674, DOI 10.1093/embo-reports/kve159; Brunori M, 2000, BIOPHYS CHEM, V86, P221, DOI 10.1016/S0301-4622(00)00142-3; Brzezinski P, 1997, P NATL ACAD SCI USA, V94, P6176, DOI 10.1073/pnas.94.12.6176; Cao WX, 2004, BIOCHEMISTRY-US, V43, P7017, DOI 10.1021/bi0497291; CARLSON ML, 1994, BIOCHEMISTRY-US, V33, P10597, DOI 10.1021/bi00201a005; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; CIANETTI S, 2004, BIOCHIM BIOPHYS ACTA, V1658, P218; Cohen J, 2006, BIOPHYS J, V91, P1844, DOI 10.1529/biopbysj.106.085746; Flynn PF, 2001, BIOCHEMISTRY-US, V40, P6559, DOI 10.1021/bi0102252; Franzen S, 2002, P NATL ACAD SCI USA, V99, P16754, DOI 10.1073/pnas.252590999; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; Ionascu D, 2005, J AM CHEM SOC, V127, P16921, DOI 10.1021/ja054249y; Karpefors M, 1998, BBA-BIOENERGETICS, V1364, P385, DOI 10.1016/S0005-2728(98)00063-2; Kim S, 2005, J AM CHEM SOC, V127, P8908, DOI 10.1021/ja0502270; Kim S, 2005, J AM CHEM SOC, V127, P5786, DOI 10.1021/ja050734h; Kim S, 2004, J PHYS CHEM B, V108, P20366, DOI 10.1021/jp0489020; Kumazaki S, 2000, J BIOL CHEM, V275, P38378, DOI 10.1074/jbc.M005533200; Larsen RW, 2003, BBA-GEN SUBJECTS, V1619, P15, DOI 10.1016/S0304-4165(02)00436-1; Liebl U, 2003, BIOCHEMISTRY-US, V42, P6527, DOI 10.1021/bi027359f; Liebl U, 2002, P NATL ACAD SCI USA, V99, P12771, DOI 10.1073/pnas.192311699; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; Lim MH, 1997, J BIOL INORG CHEM, V2, P531, DOI 10.1007/s007750050167; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; LO TP, 1995, BIOCHEMISTRY-US, V34, P5259, DOI 10.1021/bi00015a041; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; LU Y, 1993, P NATL ACAD SCI USA, V90, P11456, DOI 10.1073/pnas.90.24.11456; MARTIN JL, 1994, METHOD ENZYMOL, V232, P416; MORGAN JE, 1995, BIOCHEMISTRY-US, V34, P15633, DOI 10.1021/bi00048a005; Muegge I, 1997, J PHYS CHEM B, V101, P825, DOI 10.1021/jp962478o; Negrerie M, 2001, J BIOL CHEM, V276, P46815, DOI 10.1074/jbc.M102224200; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; Nienhaus K, 2003, J BIOL CHEM, V278, P42532, DOI 10.1074/jbc.M306888200; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PEARCE LL, 1989, BIOCHEMISTRY-US, V28, P3152, DOI 10.1021/bi00434a006; PETRICH JW, 1994, J MOL BIOL, V238, P437, DOI 10.1006/jmbi.1994.1302; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; Pilet E, 2004, P NATL ACAD SCI USA, V101, P16198, DOI 10.1073/pnas.0405032101; PROVENCHER SW, 1983, PROGR SCI COMPUTING, V2, P304; Puranik M, 2004, J BIOL CHEM, V279, P21096, DOI 10.1074/jbc.M400613200; Rosell FI, 2000, BIOCHEMISTRY-US, V39, P9047, DOI 10.1021/bi001095k; Rubtsov IV, 2001, J AM CHEM SOC, V123, P10056, DOI 10.1021/ja011023w; Schmidt M, 2005, P NATL ACAD SCI USA, V102, P11704, DOI 10.1073/pnas.0504932102; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; Silkstone G, 2005, DALTON T, P3489, DOI 10.1039/b508183c; Silkstone G, 2002, BIOPHYS CHEM, V98, P65, DOI 10.1016/S0301-4622(02)00085-6; SILKSTONE G, 2000, BIOPHYS STUDIES METH; Silkstone Gary, 1998, Biochemical Society Transactions, V26, pS348; Silkstone GG, 2005, J AM CHEM SOC, V127, P92, DOI 10.1021/ja045719b; Simonson T, 2002, P NATL ACAD SCI USA, V99, P6544, DOI 10.1073/pnas.082657099; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; Sugimoto T, 1998, BIOPHYS J, V75, P2188, DOI 10.1016/S0006-3495(98)77662-3; TIAN WD, 1993, J MOL BIOL, V233, P155, DOI 10.1006/jmbi.1993.1491; TUCKER PW, 1978, P NATL ACAD SCI USA, V75, P1076, DOI 10.1073/pnas.75.3.1076; Vitkup D, 1997, NAT STRUCT BIOL, V4, P202, DOI 10.1038/nsb0397-202; Vos MH, 1999, BBA-BIOENERGETICS, V1411, P1, DOI 10.1016/S0005-2728(99)00035-3; WALDA KN, 1994, BIOCHEMISTRY-US, V33, P2198, DOI 10.1021/bi00174a029; WEISS RF, 1970, DEEP-SEA RES, V17, P721, DOI 10.1016/0011-7471(70)90037-9; WOOD PM, 1984, BIOCHIM BIOPHYS ACTA, V768, P293, DOI 10.1016/0304-4173(84)90020-X; Yao Y, 2002, J BIOL INORG CHEM, V7, P539, DOI 10.1007/s00775-001-0334-y; Ye X, 2002, J AM CHEM SOC, V124, P5914, DOI 10.1021/ja017359n	75	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1638	1649		10.1074/jbc.M605760200	http://dx.doi.org/10.1074/jbc.M605760200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17114183	hybrid			2022-12-27	WOS:000243451300015
J	Zhang, JH; Wang, SB; Kern, S; Cui, XL; Danner, RL				Zhang, Jianhua; Wang, Shuibang; Kern, Steven; Cui, Xiaolin; Danner, Robert L.			Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLO-LIKE KINASE; ACTIVATED-PROTEIN-KINASE; CANCER-CELLS; MITOSIS; PROLIFERATION; TRANSCRIPTION; REPRESSION; EXPRESSION; APOPTOSIS; DEPLETION	Polo-like kinase 1 (PLK1) is an evolutionarily conserved serine/threonine kinase essential for cell mitosis. As a master cell cycle regulator, p21/Waf1 plays a critical role in cell cycle progression. Nitric oxide (NO center dot) has been shown to down-regulate PLK1 and up-regulate p21/Waf1 independent of cGMP. Here, the respective roles of p38 MAPK and p21/Waf1 in NO center dot-mediated PLK1 repression were investigated using differentiated U937 cells that lack soluble guanylate cyclase. NO center dot was shown to down-regulate both PLK1 mRNA and protein. Nuclear run-on assays and mRNA stability studies demonstrated that the effect of NO center dot on PLK1 expression was associated with decreased transcription without changes in transcript stability. SB202190, a p38 MAPK inhibitor, prevented transcriptional repression of PLK1 by NO center dot. Transfection with dominant-negative p38 MAPK mutant eliminated the NO center dot effect on both p21/Waf1 and PLK1 gene expression. Knockdown of p21/Waf1 with siRNA also substantially reduced the regulatory effect of NO center dot on PLK1. Reporter gene experiments showed that NO center dot decreased activity of the PLK1 proximal promoter, an effect that was blocked by p38 MAPK inhibitor. Deletion or mutation of the CDE/CHR promoter site, an element regulated by p21/Waf1, increased base-line promoter activity and abolished NO center dot repression of the PLK1 promoter. Likewise, electrophoretic mobility shift assays with CDE/CHR probe revealed a NO center dot-mediated change in protein-probe complex formation. Competition with various unlabeled CDE/CHR mutant sequences showed that NO center dot increased nuclear protein binding to intact CHR. These results demonstrate that a NO center dot-p38 MAPK-p21/Waf1 signal transduction pathway represses PLK1 through a canonical CDE/CHR promoter element.	NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Danner, RL (corresponding author), NIH, Dept Crit Care Med, Ctr Clin, Bldg 10,Rm 2C145, Bethesda, MD 20892 USA.	rdanner@nih.gov			CLINICAL CENTER [Z01CL000188, Z01CL001164, ZIACL000188, ZIACL001158, Z01CL001158, ZIACL001164] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	CLINICAL CENTER; Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bauer PM, 2001, P NATL ACAD SCI USA, V98, P12802, DOI 10.1073/pnas.211443198; Brune B, 2003, CELL DEATH DIFFER, V10, P864, DOI 10.1038/sj.cdd.4401261; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Cui XL, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-151; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hsu YL, 2005, J PHARMACOL EXP THER, V313, P333, DOI 10.1124/jpet.104.078808; Hussain SP, 2004, CANCER RES, V64, P6849, DOI 10.1158/0008-5472.CAN-04-2201; Ignarro LJ, 2001, P NATL ACAD SCI USA, V98, P4202, DOI 10.1073/pnas.071054698; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Ishida A, 1999, MOL PHARMACOL, V56, P938, DOI 10.1124/mol.56.5.938; Janssens S, 1998, CIRCULATION, V97, P1274, DOI 10.1161/01.CIR.97.13.1274; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Ma PL, 2004, J LEUKOCYTE BIOL, V76, P278, DOI 10.1189/jlb.1203653; Muller C, 1999, J BIOL CHEM, V274, P11220, DOI 10.1074/jbc.274.16.11220; Reagan-Shaw S, 2005, FASEB J, V19, P611, DOI 10.1096/fj.04-2910fje; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tanner FC, 2000, CIRCULATION, V101, P1982, DOI 10.1161/01.CIR.101.16.1982; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190; Wang SB, 2006, NUCLEIC ACIDS RES, V34, P3044, DOI 10.1093/nar/gkl386; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wasner M, 2003, FEBS LETT, V536, P66, DOI 10.1016/S0014-5793(03)00028-0; Winkles JA, 2005, ONCOGENE, V24, P260, DOI 10.1038/sj.onc.1208219; Zhang JH, 2003, J BIOL CHEM, V278, P29192, DOI 10.1074/jbc.M213043200; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906; Zhu HM, 2002, CELL CYCLE, V1, P59, DOI 10.4161/cc.1.1.101; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	40	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1003	1009		10.1074/jbc.M607609200	http://dx.doi.org/10.1074/jbc.M607609200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17121839	hybrid			2022-12-27	WOS:000243295200023
J	Bruzzone, S; Dodoni, G; Kaludercic, N; Basile, G; Millo, E; De Flora, A; Di Lisa, F; Zocchi, E				Bruzzone, Santina; Dodoni, Giuliano; Kaludercic, Nina; Basile, Giovanna; Millo, Enrico; De Flora, Antonio; Di Lisa, Fabio; Zocchi, Elena			Mitochondrial dysfunction induced by a cytotoxic adenine dinucleotide produced by ADP-ribosyl cyclases from cADPR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; CALCIUM; IDENTIFICATION; REPERFUSION; ACTIVATION; APOPTOSIS; GRANULES; CHANNELS; RELEASE; CA2+	ADP-ribosyl cyclases were previously shown to produce three new adenine dinucleotides, P1,P2 diadenosine 5'-diphosphate (Ap2A) and two isomers thereof (P18 and P24), from cyclic ADP-ribose (cADPR) and adenine (Basile, G., TaglialatelaScafati, O., Damonte, G., Armirotti, A., Bruzzone, S., Guida, L., Franco, L., Usai, C., Fattorusso, E., De Flora, A., and Zocchi, E. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 14509-14514). The Ap2A isomer P24, containing an unusual C1'-N3 N-glycosidic bond, is shown here to affect mitochondrial function through (i) opening of the permeability transition pore complex (and consequent proton gradient dissipation) and (ii) inhibition of Complex I of the respiratory chain. Whereas proton gradient dissipation is dependent upon the extracellular Ca2+ influx triggered by P24, the effect on oxygen consumption is Ca2+ independent. The proton gradient dissipation induces apoptosis in HeLa cells and thus appears to be responsible for the already described potent cytotoxic effect of P24 on several human cell types. The other products of ADP-ribosyl cyclase activity, Ap2A and cADPR, antagonize P24-induced proton gradient dissipation and cytotoxicity, suggesting that the relative concentration of P24, cADPR, and Ap2A in cyclase-positive cells may affect the balance between cell life and death.	Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy; Univ Padua, Dept Biochem, I-35121 Padua, Italy	University of Genoa; University of Genoa; University of Padua	Zocchi, E (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Via Benedetto XV1, I-16132 Genoa, Italy.	ezocchi@unige.it	Millo, Enrico/K-3218-2018	Millo, Enrico/0000-0002-4019-0051; Di Lisa, Fabio/0000-0001-9757-8818				Almofti MR, 2003, J BIOCHEM, V134, P43, DOI 10.1093/jb/mvg111; Basile G, 2005, P NATL ACAD SCI USA, V102, P14509, DOI 10.1073/pnas.0503691102; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Carafoli E, 2005, FEBS J, V272, P1073, DOI 10.1111/j.1742-4658.2005.04546.x; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; DeFlora A, 1997, J BIOL CHEM, V272, P12945, DOI 10.1074/jbc.272.20.12945; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Di Lisa F, 2006, CARDIOVASC RES, V70, P191, DOI 10.1016/j.cardiores.2006.01.016; Gasser A, 2006, J BIOL CHEM, V281, P2489, DOI 10.1074/jbc.M506525200; Guse AH, 2005, FEBS J, V272, P4590, DOI 10.1111/j.1742-4658.2005.04863.x; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Heiner I, 2006, BIOCHEM J, V398, P225, DOI 10.1042/BJ20060183; Jankowski J, 2001, J BIOL CHEM, V276, P8904, DOI 10.1074/jbc.M009527200; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 2005, J BIOL CHEM, V280, P33693, DOI 10.1074/jbc.R500012200; LEE HC, 2002, CYCLIC ADP RIBOSE NA; Luo J, 1999, FASEB J, V13, P695, DOI 10.1096/fasebj.13.6.695; Malkevitch NV, 1997, FEBS LETT, V412, P173, DOI 10.1016/S0014-5793(97)00666-2; Masuda W, 1997, FEBS LETT, V405, P104, DOI 10.1016/S0014-5793(97)00168-3; ORMEROD MG, 1993, ACTA ONCOL, V32, P417, DOI 10.3109/02841869309093620; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Podesta M, 2005, J BIOL CHEM, V280, P5343, DOI 10.1074/jbc.M408085200; Rossi L, 1998, AIDS RES HUM RETROV, V14, P435, DOI 10.1089/aid.1998.14.435; RYFFEL B, 1991, J RECEPTOR RES, V11, P675, DOI 10.3109/10799899109066435; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Szabadkai G, 2003, J BIOL CHEM, V278, P15153, DOI 10.1074/jbc.M300180200; Walseth TF, 2005, P NATL ACAD SCI USA, V102, P14941, DOI 10.1073/pnas.0507258102; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126	35	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					5045	5052		10.1074/jbc.M609802200	http://dx.doi.org/10.1074/jbc.M609802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158448	hybrid			2022-12-27	WOS:000244482000087
J	Smallwood, PM; Williams, J; Xu, Q; Leahy, DJ; Nathans, J				Smallwood, Philip M.; Williams, John; Xu, Qiang; Leahy, Daniel J.; Nathans, Jeremy			Mutational analysis of Norrin-Frizzled4 recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL EXUDATIVE VITREORETINOPATHY; FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; HUMAN CHORIONIC-GONADOTROPIN; LIGAND-RECEPTOR INTERACTIONS; WNT SIGNALING PATHWAY; CRYSTAL-STRUCTURE; NORRIE-DISEASE; CELL-SURFACE; CYSTINE KNOT	Norrin and Frizzled4 (Fz4) function as a ligand-receptor pair to control vascular development in the retina and inner ear. In mice and humans, mutations in either of the corresponding genes lead to defects in vascular development. The present work is aimed at defining the sequence determinants of binding specificity between Norrin and the Fz4 amino-terminal ligand-binding domain (the "cysteine-rich domain" (CRD)). The principal conclusions are as follows: 1) Norrin binds to the Fz4 CRD and does not detectably bind to the 14 other mammalian Frizzled and secreted Frizzled-related protein CRDs; 2) Norrin and Xenopus Wnt8 recognize largely overlapping regions of the Fz4 CRD; 3) surface determinants on the Fz4 and Fz8 CRDs that allow Norrin to distinguish between these two CRDs reside within several small regions on one face of the CRD; 4) Norrin function depends critically on three pairs of cysteines that form the highly conserved trio of disulfide bonds shared among all cystine knot proteins, but the remaining two putative disulfide bonds are less important; 5) Norrin-CRD binding depends on a largely contiguous group of amino acids in the extended beta-sheet domain of Norrin that are predicted to face away from the interface between the two monomers in the Norrin homodimer; 6) Norrin-CRD binding is strongly modulated by interactions involving charged amino acid side chains; and 7) Norrin-CRD binding is enhanced similar to 10-fold by the addition of heparin. These observations are discussed in the context of Frizzled signaling and the structure and function of other cystine knot proteins.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 805 PCTB,725 N Wolfe St, Baltimore, MD 21205 USA.	jnathans@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460				Allendorph GP, 2006, P NATL ACAD SCI USA, V103, P7643, DOI 10.1073/pnas.0602558103; Belenkaya TY, 2004, CELL, V119, P231, DOI 10.1016/j.cell.2004.09.031; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; BERGER W, 2001, METABOLIC MOL BASES, P5977; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Binari RC, 1997, DEVELOPMENT, V124, P2623; Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575; Chen CM, 1999, DEVELOPMENT, V126, P5441; CHEN ZY, 1992, NAT GENET, V1, P204, DOI 10.1038/ng0692-204; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; FURUHASHI M, 1994, J BIOL CHEM, V269, P25543; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; Guo N, 2004, P NATL ACAD SCI USA, V101, P9277, DOI 10.1073/pnas.0402802101; Han C, 2005, DEVELOPMENT, V132, P667, DOI 10.1242/dev.01636; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Luhmann UFO, 2005, INVEST OPHTH VIS SCI, V46, P3372, DOI 10.1167/iovs.05-0174; Lyuksyutova AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/science.1089610; McLellan JS, 2006, P NATL ACAD SCI USA, V103, P17208, DOI 10.1073/pnas.0606738103; MEINDL A, 1992, NAT GENET, V2, P139, DOI 10.1038/ng1092-139; MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; Mohammadi M, 2005, CURR OPIN STRUC BIOL, V15, P506, DOI 10.1016/j.sbi.2005.09.002; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Perez-Vilar J, 1997, J BIOL CHEM, V272, P33410, DOI 10.1074/jbc.272.52.33410; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; Povelones M, 2005, EMBO J, V24, P3493, DOI 10.1038/sj.emboj.7600817; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rehm HL, 2002, J NEUROSCI, V22, P4286, DOI 10.1523/JNEUROSCI.22-11-04286.2002; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Richter M, 1998, INVEST OPHTH VIS SCI, V39, P2450; Rider CC, 2006, BIOCHEM SOC T, V34, P458, DOI 10.1042/BST0340458; Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957; Sato A, 1997, J BIOL CHEM, V272, P18098, DOI 10.1074/jbc.272.29.18098; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; Toomes C, 2004, AM J HUM GENET, V74, P721, DOI 10.1086/383202; Toomes C, 2004, INVEST OPHTH VIS SCI, V45, P2083, DOI 10.1167/iovs.03-1044; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Wang YS, 2002, J NEUROSCI, V22, P8563; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	60	83	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4057	4068		10.1074/jbc.M609618200	http://dx.doi.org/10.1074/jbc.M609618200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158104	hybrid			2022-12-27	WOS:000244481900069
J	Sylvestre, Y; De Guire, V; Querido, E; Mukhopadhyay, UK; Bourdeau, V; Major, F; Ferbeyre, G; Chartrand, P				Sylvestre, Yannick; De Guire, Vincent; Querido, Emmanuelle; Mukhopadhyay, Utpal K.; Bourdeau, Veronique; Major, Francois; Ferbeyre, Gerardo; Chartrand, Pascal			An E2F/miR-20a autoregulatory feedback loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F FAMILY; CELL-CYCLE; DNA-DAMAGE; EXPRESSION; TRANSCRIPTION; GENE; MYC; PROLIFERATION; MICRORNAS; ACTIVATION	The E2F family of transcription factors is essential in the regulation of the cell cycle and apoptosis. While the activity of E2F1-3 is tightly controlled by the retinoblastoma family of proteins, the expression of these factors is also regulated at the level of transcription, post-translational modifications and protein stability. Recently, a new level of regulation of E2Fs has been identified, where micro-RNAs (miRNAs) from the mir-17 - 92 cluster influence the translation of the E2F1 mRNA. We now report that miR-20a, a member of the mir-17 - 92 cluster, modulates the translation of the E2F2 and E2F3 mRNAs via binding sites in their 3'-untranslated region. We also found that the endogenous E2F1, E2F2, and E2F3 directly bind the promoter of the mir-17 - 92 cluster activating its transcription, suggesting an autoregulatory feedback loop between E2F factors and miRNAs from the mir-17 - 92 cluster. Our data also point toward an antiapoptotic role for miR-20a, since overexpression of this miRNA decreased apoptosis in a prostate cancer cell line, while inhibition of miR-20a by an antisense oligonucleotide resulted in increased cell death after doxorubicin treatment. This anti-apoptotic role of miR-20a may explain some of the oncogenic capacities of the mir-17 - 92 cluster. Altogether, these results suggest that the autoregulation between E2F1-3 and miR-20a is important for preventing an abnormal accumulation of E2F1-3 and may play a role in the regulation of cellular proliferation and apoptosis.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Inst Rech Immunol & Canc, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Informat & Rech Operat, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Ferbeyre, G (corresponding author), Univ Montreal, Dept Biochim, 2900 Edouard Montpetit, Montreal, PQ H3C 3J7, Canada.	g.ferbeyre@umontreal.ca; p.chartrand@umontreal.ca	Ferbeyre, Gerardo/A-1569-2010	Querido, Emmanuelle/0000-0002-8027-3732; Chartrand, Pascal/0000-0002-3006-7279				Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lin WC, 2001, GENE DEV, V15, P1833; Mangan S, 2003, P NATL ACAD SCI USA, V100, P11980, DOI 10.1073/pnas.2133841100; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Mukhopadhyay UK, 2005, CANCER RES, V65, P2872, DOI 10.1158/0008-5472.CAN-04-2502; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Plasterk RHA, 2006, CELL, V124, P877, DOI 10.1016/j.cell.2006.02.030; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; White J, 2005, MOL BIOL CELL, V16, P2018, DOI 10.1091/mbc.e04-12-1056; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	43	477	516	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2135	2143		10.1074/jbc.M608939200	http://dx.doi.org/10.1074/jbc.M608939200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135249	hybrid			2022-12-27	WOS:000243593200004
J	Wang, ZQ; Lawson, RJ; Buddha, MR; Wei, CC; Crane, BR; Munro, AW; Stuehr, DJ				Wang, Zhi-Qiang; Lawson, Rachel J.; Buddha, Madhavan R.; Wei, Chin-Chuan; Crane, Brian R.; Munro, Andrew W.; Stuehr, Dennis J.			Bacterial flavodoxins support nitric oxide production by bacillus subtilis nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ELECTRON-TRANSFER; ISOLATED OXYGENASE; REDUCTASE DOMAINS; NO; TETRAHYDROBIOPTERIN; PROTEIN; COMPLEX; EXPRESSION; TRYPTOPHAN	Unlike animal nitric-oxide synthases (NOSs), the bacterial NOS enzymes have no attached flavoprotein domain to reduce their heme and so must rely on unknown bacterial proteins for electrons. We tested the ability of two Bacillus subtilis flavodoxins (YkuN and YkuP) to support catalysis by purified B. subtilis NOS (bsNOS). When an NADPH-utilizing bacterial flavodoxin reductase (FLDR) was added to reduce YkuP or YkuN, both supported NO synthesis from either L-arginine or N-hydroxyarginine and supported a linear nitrite accumulation over a 30-min reaction period. Rates of nitrite production were directly dependent on the ratio of YkuN or YkuP to bsNOS. However, the V/Km value for YkuN (5.2 x 10(5)) was about 20 times greater than that of YkuP (2.6 x 10(4)), indicating YkuN is more efficient in supporting bsNOS catalysis. YkuN that was either photo-reduced or prereduced by FLDR transferred an electron to the bsNOS ferric heme at rates similar to those measured for heme reduction in the animal NOSs. YkuN supported a similar NO synthesis activity by a different bacterial NOS (Deinococcus radiodurans) but not by any of the three mammalian NOS oxygenase domains nor by an insect NOS oxygenase domain. Our results establish YkuN as a kinetically competent redox partner for bsNOS and suggest that FLDR/flavodoxin proteins could function physiologically to support catalysis by bacterial NOSs.	Cleveland Clin Fdn, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44195 USA; Univ Manchester, Sch Chem Engn & Analyt Sci, Manchester Interdisciplinary Bioctr, Manchester M1 7ND, Lancs, England; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; So Illinois Univ, Dept Chem, Edwardsville, IL 62026 USA	Cleveland Clinic Foundation; University of Manchester; Cornell University; Southern Illinois University System; Southern Illinois University Edwardsville	Stuehr, DJ (corresponding author), Cleveland Clin, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org	Munro, Andrew/G-5639-2019	Munro, Andrew/0000-0002-4642-180X; Wei, Chin-Chuan/0000-0001-6453-9409	NCI NIH HHS [CA53914] Funding Source: Medline; NHLBI NIH HHS [HL76491] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2001, J BIOL CHEM, V276, P23246, DOI 10.1074/jbc.M102509200; Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bird LE, 2002, STRUCTURE, V10, P1687, DOI 10.1016/S0969-2126(02)00911-5; Buddha MR, 2004, J BIOL CHEM, V279, P49567, DOI 10.1074/jbc.C400418200; CHEN YJ, 1995, J BACTERIOL, V177, P5122, DOI 10.1128/jb.177.17.5122-5128.1995; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Degtyarenko KN, 2001, BIOCHEM SOC T, V29, P139, DOI 10.1042/BST0290139; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P11316, DOI 10.1021/bi00036a003; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; GORETSKI J, 1990, J BIOL CHEM, V265, P11535; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; Kers JA, 2004, NATURE, V429, P79, DOI 10.1038/nature02504; Konas DW, 2004, J BIOL CHEM, V279, P35412, DOI 10.1074/jbc.M400872200; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Lawson RJ, 2004, BIOCHEMISTRY-US, V43, P12390, DOI 10.1021/bi049131t; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; Mansuy D, 2002, DRUG METAB REV, V34, P593, DOI 10.1081/DMR-120005661; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; McIver L, 1998, EUR J BIOCHEM, V257, P577, DOI 10.1046/j.1432-1327.1998.2570577.x; Midha S, 2005, BIOCHEM BIOPH RES CO, V336, P346, DOI 10.1016/j.bbrc.2005.08.083; MONCADA S, 1994, J HYPERTENS, V12, pS35; Munro AW, 1996, MOL MICROBIOL, V20, P1115, DOI 10.1111/j.1365-2958.1996.tb02632.x; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; Rozhkova EA, 2002, J BIOL CHEM, V277, P16888, DOI 10.1074/jbc.M200642200; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; Stohr C, 2002, J EXP BOT, V53, P2293, DOI 10.1093/jxb/erf110; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Sudhamsu J, 2006, J BIOL CHEM, V281, P9623, DOI 10.1074/jbc.M510062200; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; Wang ZQ, 2004, J BIOL CHEM, V279, P19018, DOI 10.1074/jbc.M311663200; Wang ZQ, 2005, BIOCHEMISTRY-US, V44, P4676, DOI 10.1021/bi047508p; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571	42	74	77	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2196	2202		10.1074/jbc.M608206200	http://dx.doi.org/10.1074/jbc.M608206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17127770	hybrid			2022-12-27	WOS:000243593200010
J	Yaklichkin, S; Steiner, AB; Lu, Q; Kessler, DS				Yaklichkin, Sergey; Steiner, Aaron B.; Lu, Qun; Kessler, Daniel S.			FoxD3 and Grg4 physically interact to repress transcription and induce mesoderm in Xenopus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUCHO-RELATED GENE; NEURAL CREST; DIFFERENTIAL EXPRESSION; ZEBRAFISH FOXD3; COREPRESSOR; PROTEINS; ECTODERM; DOMAIN; SEGMENTATION; NEUROGENESIS	FoxD3 is a forkhead-related transcriptional regulator that is essential for multiple developmental processes in the vertebrate embryo, including neural crest development and maintenance of mammalian stem cell lineages. Recent results demonstrate a requirement for FoxD3 in Xenopus mesodermal development. In the gastrula, FoxD3 functions as a transcriptional repressor in the Spemann organizer to maintain the expression of Nodal-related members of the transforming growth factor-beta superfamily that induce dorsal mesoderm formation. Here we report that the function of FoxD3 in mesoderm induction is dependent on the recruitment of transcriptional corepressors of the TLE/Groucho family. Structure-function analyses indicate that the transcriptional repression and mesoderm induction activities of FoxD3 are dependent on a C-terminal domain, as well as specific DNA-binding activity conferred by the forkhead domain. The C-terminal domain contains a heptapeptide similar to the eh1/GEH Groucho interaction motif. Deletion and point mutagenesis demonstrated that the FoxD3 eh1/GEH motif is required for both repression of transcription and induction of mesoderm, as well as the direct physical interaction of FoxD3 and Grg4 (Groucho-related gene-4). Consistent with a functional interaction of FoxD3 and Grg4, the transcriptional repression activity of FoxD3 is enhanced by Grg4, and reduced by Grg5, a dominant inhibitory Groucho protein. The results indicate that FoxD3 recruitment of Groucho corepressors is essential for the transcriptional repression of target genes and induction of mesoderm in Xenopus.	Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Kessler, DS (corresponding author), 421 Curie Blvd, Philadelphia, PA 19104 USA.	kesslerd@mail.med.upenn.edu		KESSLER, DANIEL/0000-0002-3557-2434; Steiner, Aaron/0000-0002-6120-9671	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064768] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM064768, GM64768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adell T, 2004, GENE, V334, P35, DOI 10.1016/j.gene.2004.02.036; Agius E, 2000, DEVELOPMENT, V127, P1173; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brugmann SA, 2004, DEVELOPMENT, V131, P5871, DOI 10.1242/dev.01516; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Cheung M, 2005, DEV CELL, V8, P179, DOI 10.1016/j.devcel.2004.12.010; Courey AJ, 2001, GENE DEV, V15, P2786; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; DECELIS JF, 1995, DEVELOPMENT, V121, P3467; DEHNI G, 1995, MECH DEVELOP, V53, P369, DOI 10.1016/0925-4773(95)00452-1; DIRKSEN ML, 1995, DEV GENET, V17, P107, DOI 10.1002/dvg.1020170203; Dottori M, 2001, DEVELOPMENT, V128, P4127; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Freyaldenhoven BS, 1997, CANCER RES, V57, P123; Freyaldenhoven BS, 1997, ONCOGENE, V15, P483, DOI 10.1038/sj.onc.1201189; Guo Y, 2002, P NATL ACAD SCI USA, V99, P3663, DOI 10.1073/pnas.062041099; Hanna LA, 2002, GENE DEV, V16, P2650, DOI 10.1101/gad.1020502; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Heasman J, 2006, DEVELOPMENT, V133, P1205, DOI 10.1242/dev.02304; Imai KS, 2002, DEVELOPMENT, V129, P3441; Jennings BH, 2006, MOL CELL, V22, P645, DOI 10.1016/j.molcel.2006.04.024; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Jin CW, 1999, J MOL BIOL, V289, P683, DOI 10.1006/jmbi.1999.2819; Kaestner KH, 2000, GENE DEV, V14, P142; Kelsh RN, 2000, MECH DEVELOP, V93, P161, DOI 10.1016/S0925-4773(00)00250-1; Koop KE, 1996, MECH DEVELOP, V59, P73, DOI 10.1016/0925-4773(96)00582-5; Kos R, 2001, DEVELOPMENT, V128, P1467; Labosky PA, 1998, MECH DEVELOP, V76, P185, DOI 10.1016/S0925-4773(98)00105-1; Lee HC, 2006, DEV BIOL, V290, P359, DOI 10.1016/j.ydbio.2005.11.032; Lef J, 1996, INT J DEV BIOL, V40, P245; Lehmann OJ, 2003, TRENDS GENET, V19, P339, DOI 10.1016/S0168-9525(03)00111-2; Leon C, 1997, DEV DYNAM, V208, P11, DOI 10.1002/(SICI)1097-0177(199701)208:1<11::AID-AJA2>3.0.CO;2-4; Lister JA, 2006, DEV BIOL, V290, P92, DOI 10.1016/j.ydbio.2005.11.014; Mariani FV, 1998, DEVELOPMENT, V125, P5019; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Molenaar M, 2000, MECH DEVELOP, V91, P311, DOI 10.1016/S0925-4773(99)00259-2; NIEUWKOOP PD, 1967, NORMAL TABLE XENOPUS, P576; Odenthal J, 1998, DEV GENES EVOL, V208, P245, DOI 10.1007/s004270050179; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pera MF, 2000, J CELL SCI, V113, P5; Pohl BS, 2005, GENE, V344, P21, DOI 10.1016/j.gene.2004.09.037; Pohl BS, 2001, MECH DEVELOP, V103, P93, DOI 10.1016/S0925-4773(01)00334-3; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Sasai N, 2001, DEVELOPMENT, V128, P2525; Satou Y, 2003, DEV GENES EVOL, V213, P213, DOI 10.1007/s00427-003-0319-7; SCHEUCHER M, 1995, ROUX ARCH DEV BIOL, V204, P203, DOI 10.1007/BF00241274; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Smith ST, 1996, DEVELOPMENT, V122, P3141; Steiner AB, 2006, DEVELOPMENT, V133, P4827, DOI 10.1242/dev.02663; Stewart RA, 2006, DEV BIOL, V292, P174, DOI 10.1016/j.ydbio.2005.12.035; Sullivan SA, 2001, DEV BIOL, V232, P439, DOI 10.1006/dbio.2001.0191; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Tompers DM, 2005, DEV BIOL, V285, P126, DOI 10.1016/j.ydbio.2005.06.008; Umbhauer M, 2001, MECH DEVELOP, V109, P61, DOI 10.1016/S0925-4773(01)00517-2; Watanabe M, 1999, DEVELOPMENT, V126, P5621; Whitlock KE, 2005, DEVELOPMENT, V132, P5491, DOI 10.1242/dev.02158; Whitman M, 2001, DEV CELL, V1, P605, DOI 10.1016/S1534-5807(01)00076-4; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; Yaklichkin S, 2004, VERTEBRATE ORGANIZER, P113; Yamagata M, 1998, NEUROSCI LETT, V249, P33, DOI 10.1016/S0304-3940(98)00385-1; Yan H, 2003, BIOPHYS J, V85, P3248, DOI 10.1016/S0006-3495(03)74742-0; YAO J, 1999, METHODS MOL BIOL DEV, V3; Yu JK, 2002, DEV DYNAM, V225, P289, DOI 10.1002/dvdy.10173	71	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2548	2557		10.1074/jbc.M607412200	http://dx.doi.org/10.1074/jbc.M607412200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17138566	hybrid, Green Accepted			2022-12-27	WOS:000243593200047
J	Manavathi, B; Kumar, R				Manavathi, Bramanandam; Kumar, Rakesh			Metastasis tumor antigens, an emerging family of multifaceted master coregulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ESTROGEN-RECEPTOR-ALPHA; TRANSCRIPTIONAL REPRESSION; CRYSTAL-STRUCTURE; PROTEIN-1 MTA1; CELL FATE; COMPLEX; NURD; MI-2/NURD; CANCER; GROWTH	Regulation of fundamental genetic processes demands dynamic participation of transcription factors, their coregulators, and multiprotein chromatin remodeling activities at target genes. One family of chromatin modifiers that is ubiquitously expressed is the metastasis tumor antigens (MTA), which are integral parts of nucleosome remodeling and histone deacetylation ( NuRD) complexes. MTA family members exist in distinct NuRD complexes, and functional redundancy is lacking among MTA family members. MTA proteins regulate divergent cellular pathways, including hormonal action, epithelial-to-mesenchymal transitions, differentiation, protein stability and development, and cell fate programs by modifying the acetylation status of crucial target genes. Intriguingly, at least one member of this family, MTA1, itself undergoes acetylation and acts as a coactivator in certain contexts. We discuss the roles of the MTA family of chromatin modifiers, with an emphasis on their physiologic functions.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Kumar, Rakesh/ABD-1065-2020	Kumar, Rakesh/0000-0001-7664-0803; Manavathi, Bramanandam/0000-0002-1797-398X	NCI NIH HHS [CA98823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Bagheri-Yarmand R, 2004, DEVELOPMENT, V131, P3469, DOI 10.1242/dev.01213; Balasenthil S, 2005, CAN META BIO TREAT, V7, P215; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Brackertz M, 2002, J BIOL CHEM, V277, P40958, DOI 10.1074/jbc.M207467200; Chen Z, 2001, DEVELOPMENT, V128, P4911; Cismasiu VB, 2005, ONCOGENE, V24, P6753, DOI 10.1038/sj.onc.1208904; COHEN T, 2004, SCI STKE, pE42; Cui YK, 2006, MOL ENDOCRINOL, V20, P2020, DOI 10.1210/me.2005-0063; Fujita N, 2004, MOL ENDOCRINOL, V18, P2937, DOI 10.1210/me.2004-0258; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gong ZH, 2006, MOL CELL BIOL, V26, P4519, DOI 10.1128/MCB.00409-06; Grune T, 2003, MOL CELL, V12, P449, DOI 10.1016/S1097-2765(03)00273-9; Gururaj AE, 2006, P NATL ACAD SCI USA, V103, P6670, DOI 10.1073/pnas.0601989103; Herman MA, 1999, DEVELOPMENT, V126, P1055; Kleene R, 1999, J CELL SCI, V112, P2539; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Kumar R, 2003, CELL, V113, P142, DOI 10.1016/S0092-8674(03)00274-5; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Mersfelder EL, 2006, NUCLEIC ACIDS RES, V34, P2653, DOI 10.1093/nar/gkl338; Mishra SK, 2004, J BIOL CHEM, V279, P32709, DOI 10.1074/jbc.M402942200; Mishra SK, 2004, ONCOGENE, V23, P4422, DOI 10.1038/sj.onc.1207569; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Moon WS, 2004, HUM PATHOL, V35, P424, DOI 10.1016/j.humpath.2003.11.007; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Oliver AW, 2005, BIOCHEM J, V389, P657, DOI 10.1042/BJ20050310; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Singh RR, 2006, J BIOL CHEM, V281, P25612, DOI 10.1074/jbc.M604444200; Singh RR, 2005, CANCER RES, V65, P10594, DOI 10.1158/0008-5472.CAN-05-2268; Solari F, 1999, DEVELOPMENT, V126, P2483; Staudt LM, 2004, NATURE, V431, P919, DOI 10.1038/431919a; Talukder AH, 2004, MOL CELL BIOL, V24, P6581, DOI 10.1128/mcb.24.15.6581-6591.2004; Talukder AH, 2003, J BIOL CHEM, V278, P11676, DOI 10.1074/jbc.M209570200; TOH Y, 1994, J BIOL CHEM, V269, P22958; von Zelewsky T, 2000, DEVELOPMENT, V127, P5277; Xia L, 2001, GENE, V268, P77, DOI 10.1016/S0378-1119(01)00429-2; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yaguchi M, 2005, BBA-GENE STRUCT EXPR, V1732, P8, DOI 10.1016/j.bbaexp.2005.12.001; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Zhang H, 2006, GENE DEV, V20, P2943, DOI 10.1101/gad.1461706; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	48	116	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1529	1533		10.1074/jbc.R600029200	http://dx.doi.org/10.1074/jbc.R600029200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17142453	hybrid			2022-12-27	WOS:000243451300002
J	Vitrenko, YA; Gracheva, EO; Richmond, JE; Liebman, SW				Vitrenko, Yakov A.; Gracheva, Elena O.; Richmond, Janet E.; Liebman, Susan W.			Visualization of aggregation of the Rnq1 prion domain and cross-seeding interactions with Sup35NM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PRION; SACCHAROMYCES-CEREVISIAE; PSI+ PRION; IN-VITRO; INFECTIOUS PROTEIN; AMYLOID FIBRILS; DETERMINANT; SPECIFICITY; CONVERSION; MECHANISM	Factors triggering the de novo appearance of prions are still poorly understood. In yeast, the appearance of one prion, [PSI+], is enhanced by the presence of another prion, [PIN+]. The [PSI+] and [PIN+] prion-forming proteins are, respectively, the translational termination factor Sup35 and the yet poorly characterized Rnq1 protein that is rich in glutamines and asparagines. The prion domain of Rnq1 (RnqPD) polymerizes more readily in vitro than the full-length protein. As is typical for amyloidogenic proteins, the reaction begins with a lag phase, followed by exponential growth. Seeding with pre-formed aggregates significantly shortens the lag. A generic antibody against pre-amyloid oligomer inhibits the unseeded but not the self-seeded reaction. As revealed by electron microscopy, RnqPD polymerizes predominantly into spherical species that eventually agglomerate. We observed infrequent fiber-like structures in samples taken at 4 h of polymerization, but in overnight samples SDS treatment was required to reveal fibers among agglomerates. Polymerization reactions in which RnqPD and the prion domain of Sup35 (Sup35NM) cross-seed each other proceeded with a shortened lag that only depends weakly on the protein concentration. Cross-seeded Sup35NM fibers appear to sprout from globular RnqPD aggregates as seen by electron microscopy. RnqPD spherical aggregates appear to associate with and, later occlude, Sup35NM seed fibers. Our kinetic and morphological analyses suggest that, upon cross-seeding, the aggregate provides the surface on which oligomers of the heterologous protein nucleate their subsequent amyloid formation.	Univ Illinois, Dept Biol Sci, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Liebman, SW (corresponding author), Univ Illinois, Dept Biol Sci, 900 S Ashland Ave,M-C 567, Chicago, IL 60607 USA.	sueL@uic.edu		Gracheva, Elena O/0000-0002-0846-3427; Vitrenko, Yakov/0000-0002-5704-6443	NIGMS NIH HHS [GM56350, R01 GM056350] Funding Source: Medline; NIMH NIH HHS [R01 MH073156-02, R01 MH073156] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH073156] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bagriantsev S, 2004, J BIOL CHEM, V279, P51042, DOI 10.1074/jbc.M410611200; Bagriantsev SN, 2006, METHOD ENZYMOL, V412, P33, DOI 10.1016/S0076-6879(06)12003-0; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2005, BIOCHEMISTRY-US, V44, P2339, DOI 10.1021/bi048322t; Bradley ME, 2003, GENETICS, V165, P1675; Catharino S, 2005, BIOL CHEM, V386, P633, DOI 10.1515/BC.2005.074; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; Collins SR, 2004, PLOS BIOL, V2, P1582, DOI 10.1371/journal.pbio.0020321; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Derkatch IL, 2004, P NATL ACAD SCI USA, V101, P12934, DOI 10.1073/pnas.0404968101; Derkatch IL, 1997, GENETICS, V147, P507; Derkatch IL, 2001, CELL, V106, P171, DOI 10.1016/S0092-8674(01)00427-5; DERKATCH IL, 2006, IN PRESS PROTEIN BAS; Ganusova EE, 2006, MOL CELL BIOL, V26, P617, DOI 10.1128/MCB.26.2.617-629.2006; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jones GW, 2005, BIOESSAYS, V27, P823, DOI 10.1002/bies.20267; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim JR, 2004, PROTEIN SCI, V13, P2888, DOI 10.1110/ps.04847404; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Krebs MRH, 2004, PROTEIN SCI, V13, P1933, DOI 10.1110/ps.04707004; Kryndushkin DS, 2003, J BIOL CHEM, V278, P49636, DOI 10.1074/jbc.M307996200; O'Nuallain B, 2004, J BIOL CHEM, V279, P17490, DOI 10.1074/jbc.M311300200; Osherovich LZ, 2002, DEV CELL, V2, P143, DOI 10.1016/S1534-5807(02)00118-1; PATEL BK, 2006, IN PRESS J MOL BIOL; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ross ED, 2005, NAT CELL BIOL, V7, P1039, DOI 10.1038/ncb1105-1039; Salnikova AB, 2005, J BIOL CHEM, V280, P8808, DOI 10.1074/jbc.M410150200; Scheibel T, 2004, P NATL ACAD SCI USA, V101, P2287, DOI 10.1073/pnas.0308754101; Schwimmer C, 2002, MOL CELL BIOL, V22, P3590, DOI 10.1128/MCB.22.11.3590-3598.2002; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Serio TR, 1999, METHOD ENZYMOL, V309, P649; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Souillac PO, 2002, J BIOL CHEM, V277, P12666, DOI 10.1074/jbc.M109229200; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; TERAVANESYAN MD, 1994, GENETICS, V137, P671; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 2004, ANNU REV GENET, V38, P681, DOI 10.1146/annurev.genet.38.072902.092200; Wickner Reed B., 2004, VVolume 41, P305; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	44	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1779	1787		10.1074/jbc.M609269200	http://dx.doi.org/10.1074/jbc.M609269200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121829	hybrid			2022-12-27	WOS:000243451300029
J	Tompkins, VS; Hagen, J; Frazier, AA; Lushnikova, T; Fitzgerald, MP; di Tommaso, A; Ladeveze, V; Domann, FE; Eischen, CM; Quelle, DE				Tompkins, Van S.; Hagen, Jussara; Frazier, April A.; Lushnikova, Tamara; Fitzgerald, Matthew P.; di Tommaso, Anne; Ladeveze, Veronique; Domann, Frederick E.; Eischen, Christine M.; Quelle, Dawn E.			A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PATTERNS; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR PROTEIN; NF-KAPPA-B; DNA-DAMAGE; TGF-BETA; NUCLEOLAR-LOCALIZATION; MAMMALIAN-CELLS; MOUSE EMBRYO; P53	The ARF tumor suppressor signals through p53 and other poorly defined anti- proliferative pathways to block carcinogenesis. In a search for new regulators of ARF signaling, we discovered a novel nuclear protein that we named NIAM (nuclear interactor of ARF and MDM2) for its ability to bind both ARF and the p53 antagonist MDM2. NIAM protein is normally expressed at low to undetectable levels in cells because of, at least in part, MDM2-mediated ubiquitination and proteasomal degradation. When reintroduced into cells, NIAM activated p53, caused a G(1) phase cell cycle arrest, and collaborated with ARF in an additive fashion to suppress proliferation. Notably, NIAM retains growth inhibitory activity in cells lacking ARF and/or p53, and knockdown experiments revealed that it is not essential for ARF-mediated growth inhibition. Thus, NIAM and ARF act in separate anti-proliferative pathways that intersect mechanistically and suppress growth more effectively when jointly activated. Intriguingly, silencing of NIAM accelerated chromosomal instability, and microarray analyses showed reduced NIAM mRNA expression in numerous primary human tumors. This study identifies a novel protein with tumor suppressor-like behaviors and functional links to ARF-MDM2-p53 signaling.	Univ Iowa, Dept Pharmacol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiat Oncol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Poitiers, UPRES EA2622, Lab Genet Cellulaire & Mol, F-86022 Poitiers, France; Ctr Hosp Univ Poitiers, F-86022 Poitiers, France	University of Iowa; University of Iowa; University of Nebraska System; University of Nebraska Medical Center; Universite de Poitiers; CHU Poitiers; Universite de Poitiers	Quelle, DE (corresponding author), Univ Iowa, Dept Pharmacol, Roy J & Lucille A Carver Coll Med, 51 Newton Rd, Iowa City, IA 52242 USA.	dawn-quelle@uiowa.edu	Tompkins, Van/A-5757-2018	Tompkins, Van/0000-0003-1279-8075; Domann, Frederick/0000-0002-0489-2179; Quelle, Dawn/0000-0001-8776-0122	NCI NIH HHS [R01 CA090367, CA98139, CA90367, CA73612] Funding Source: Medline; NHLBI NIH HHS [T32 HL007344] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA073612, R01CA098139, R01CA090367, R01CA073612, R29CA073612] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007344] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; BABALOLA GO, 1995, MOL REPROD DEV, V41, P133, DOI 10.1002/mrd.1080410203; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Eischen CM, 2002, CANCER RES, V62, P2184; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Eymin B, 2006, MOL CELL BIOL, V26, P4339, DOI 10.1128/MCB.02240-05; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Groth A, 2000, J BIOL CHEM, V275, P27473; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hasan MK, 2002, J BIOL CHEM, V277, P37765, DOI 10.1074/jbc.M204177200; Henry MK, 2001, BLOOD, V98, P834, DOI 10.1182/blood.V98.3.834; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Jackson MW, 2001, J BIOL CHEM, V276, P25336, DOI 10.1074/jbc.M010685200; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Lee C, 2005, CANCER RES, V65, P9834, DOI 10.1158/0008-5472.CAN-05-1759; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Michor F, 2005, SEMIN CANCER BIOL, V15, P43, DOI 10.1016/j.semcancer.2004.09.007; Modestou M, 2001, CANCER RES, V61, P3145; Moller MB, 1999, LEUKEMIA, V13, P453, DOI 10.1038/sj.leu.2401315; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nicholson SA, 2001, CANCER RES, V61, P5636; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Pihan GA, 1998, CANCER RES, V58, P3974; Pollice A, 2004, J BIOL CHEM, V279, P6345, DOI 10.1074/jbc.M310957200; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tompkins V, 2006, CELL CYCLE, V5, P641; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang P, 2006, ONCOGENE, V25, P3708, DOI 10.1038/sj.onc.1209411; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhao L, 2003, MOL CANCER RES, V1, P195	76	33	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1322	1333		10.1074/jbc.M609612200	http://dx.doi.org/10.1074/jbc.M609612200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17110379	hybrid			2022-12-27	WOS:000243295200058
J	Wang, GL; Shi, XR; Salisbury, E; Sun, YX; Albrecht, JH; Smith, RG; Timchenko, NA				Wang, Guo-Li; Shi, Xiurong; Salisbury, Elizabeth; Sun, Yuxiang; Albrecht, Jeffrey H.; Smith, Roy G.; Timchenko, Nikolai A.			Growth hormone corrects proliferation and transcription of phosphoenolpyruvate carboxykinase in livers of old mice via elimination of CCAAT/enhancer-binding protein alpha-Brm complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-ALPHA; CELL-PROLIFERATION; REGENERATING LIVER; AGE; EXPRESSION; DNA; IDENTIFICATION; ARREST; BETA	Growth hormone (GH), which is reduced with age, corrects the impaired proliferative capacity of livers of old animals. In this paper, we present a mechanism by which GH eliminates age-dependent negative control of proliferation and increases transcription of liver-specific genes in livers of old mice. The reduced proliferative capacities of the liver of old animals are associated with the CCAAT/enhancer-binding protein alpha (C/EBP alpha)-Brm complex, which inhibits E2F-dependent promoters. We found that a sequestration of C/EBP alpha into complexes with Brm leads to a weak interaction of C/EBP alpha with promoters of liver-specific genes, expression of which is reduced in old animals. Injection of either GH or the regulator of the amplitude of endogenous GH release, ghrelin, reduces the C/EBP alpha-Brm complex in livers of old mice, leading to a derepression of E2F targets, to increased interactions of C/EBP alpha with promoters of liver-specific genes, and to correction of their expression. GH-dependent elimination of the complex is mediated by the inhibition of cyclin D3-CDK4 activity and by elevation of a phosphatase, protein phosphatase 2A, which dephosphorylates C/EBP alpha and dissociates the complex.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Cellular Biol, Houston, TX 77030 USA; Hennepin Cty Med Ctr, Div Gastroenterol, Minneapolis, MN 55415 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Hennepin County Medical Center	Timchenko, NA (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	nikolait@bcm.tmc.edu		Salisbury, Elizabeth/0000-0003-3607-2367	NCI NIH HHS [CA10070] Funding Source: Medline; NIA NIH HHS [AG19230, AG18895, AG025477] Funding Source: Medline; NIDDK NIH HHS [DK54921] Funding Source: Medline; NIGMS NIH HHS [GM55188] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025477, R56AG019230, R01AG019230, R01AG018895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BUCHER NLR, 1964, CANCER RES, V24, P509; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Fausto N, 2006, HEPATOLOGY, V43, pS45, DOI 10.1002/hep.20969; FRY M, 1984, J CELL PHYSIOL, V118, P225, DOI 10.1002/jcp.1041180302; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; Inoue Y, 2004, J BIOL CHEM, V279, P44740, DOI 10.1074/jbc.M405177200; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Krupczak-Hollis K, 2003, HEPATOLOGY, V38, P1552, DOI 10.1016/j.hep.2003.08.052; Lawlor MA, 2001, J CELL SCI, V114, P2903; McFie PJ, 2006, J BIOL CHEM, V281, P18069, DOI 10.1074/jbc.M512734200; Miller M, 2003, J BIOL CHEM, V278, P15178, DOI 10.1074/jbc.M300417200; Pennisi PA, 2004, ENDOCRINOLOGY, V145, P4748, DOI 10.1210/en.2004-0655; Rastegar M, 2000, ENDOCRINOLOGY, V141, P1686, DOI 10.1210/en.141.5.1686; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Smith RG, 1997, ENDOCR REV, V18, P621, DOI 10.1210/er.18.5.621; Tan EH, 2005, CANCER RES, V65, P10330, DOI 10.1158/0008-5472.CAN-04-4486; Timchenko LT, 2006, J BIOL CHEM, V281, P32806, DOI 10.1074/jbc.M605701200; Timchenko NA, 1998, NUCLEIC ACIDS RES, V26, P3293, DOI 10.1093/nar/26.13.3293; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Wang GL, 2006, MOL CELL BIOL, V26, P2570, DOI 10.1128/MCB.26.7.2570-2582.2006; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; WIMONWATWATEE T, 1994, AM J PHYSIOL, V267, pG201, DOI 10.1152/ajpgi.1994.267.2.G201; Yamasaki H, 2006, DEVELOPMENT, V133, P4233, DOI 10.1242/dev.02591; Yang JQ, 2005, J BIOL CHEM, V280, P38689, DOI 10.1074/jbc.M503486200	30	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1468	1478		10.1074/jbc.M608226200	http://dx.doi.org/10.1074/jbc.M608226200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17107955	hybrid			2022-12-27	WOS:000243295200071
J	Han, GS; Gable, K; Yan, LY; Allen, MJ; Wilson, WH; Moitra, P; Harmon, JM; Dunn, TM				Han, Gongshe; Gable, Kenneth; Yan, Lianying; Allen, Michael J.; Wilson, William H.; Moitra, Prasun; Harmon, Jeffrey M.; Dunn, Teresa M.			Expression of a novel marine viral single-chain serine palmitoyltransferase and construction of yeast and mammalian single-chain chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPATHY TYPE-I; 5-AMINOLEVULINATE SYNTHASE; CIRCULAR PERMUTATION; SPHINGOLIPID BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; MUTATIONS; ENZYME; CHROMATOGRAPHY; PURIFICATION; SUBUNIT	The genus Coccolithovirus is a recently discovered group of viruses that infect the globally important marine calcifying microalga Emiliania huxleyi. Surprisingly, the viral genome contains a cluster of putative sphingolipid biosynthetic genes not found in other viral genus. To address the role of these genes in viral pathogenesis, the ehv050 gene predicted to encode a serine palmitoyltransferase (SPT), the first and rate-limiting enzyme of sphingolipid biosynthesis, was expressed and characterized in Saccharomyces cerevisiae. We show that the encoded protein is indeed a fully functional, endoplasmic reticulum-localized, single-chain SPT. In eukaryotes SPT is a heterodimer comprised of long chain base 1 (LCB1) and LCB2 subunits. Sequence alignment and mutational analysis showed that the N-terminal domain of the viral protein most closely resembled the LCB2 subunit and the C-terminal domain most closely resembled the LCB1 subunit. Regardless of whether the viral protein was expressed as a single polypeptide or as two independent domains, it exhibited an unusual preference for myristoyl-CoA rather than palmitoyl-CoA. This preference was reflected by the increased presence of C16-sphingoid bases in yeast cells expressing the viral protein. The occurrence of a single-chain SPT suggested to us that it might be possible to create other fusion SPTs with unique properties. Remarkably, when the two subunits of the yeast SPT were thus expressed, the single-chain chimera was functional and displayed a novel substrate preference. This suggests that expression of other multi-subunit membrane proteins as single-chain chimera could provide a powerful approach to the characterization of integral membrane proteins.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20184 USA; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20184 USA; Plymouth Marine Lab, Plymouth PL1 3DH, Devon, England; Bigelow Lab Ocean Sci, Boothbay Harbor, ME 04575 USA	Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA; Plymouth Marine Laboratory; Bigelow Laboratory for Ocean Sciences	Dunn, TM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20184 USA.	tdunn@usuhs.mil	Allen, Michael J/C-1248-2011	Allen, Michael J/0000-0001-8504-7171; Harmon, Jeffrey/0000-0001-7833-931X	NINDS NIH HHS [NS47717] Funding Source: Medline; NERC [NE/D001455/1] Funding Source: UKRI; Natural Environment Research Council [NE/D001455/1] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047717] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen MJ, 2006, J VIROL, V80, P7699, DOI 10.1128/JVI.00491-06; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Bejaoui K, 2002, J CLIN INVEST, V110, P1301, DOI 10.1172/JCI200216450; Cheltsov AV, 2001, J BIOL CHEM, V276, P19141, DOI 10.1074/jbc.M100329200; Cheltsov AV, 2003, J BIOL CHEM, V278, P27945, DOI 10.1074/jbc.M207011200; Dawkins JL, 2001, NAT GENET, V27, P309, DOI 10.1038/85879; Ferreira GC, 2002, CELL MOL BIOL, V48, P11; Fuhrman JA, 1999, NATURE, V399, P541, DOI 10.1038/21119; Gable K, 2002, J BIOL CHEM, V277, P10194, DOI 10.1074/jbc.M107873200; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Garcia-Campayo V, 2004, J BIOL CHEM, V279, P44286, DOI 10.1074/jbc.M408386200; Han GS, 2004, J BIOL CHEM, V279, P53707, DOI 10.1074/jbc.M410014200; Hanada K, 2003, BBA-MOL CELL BIOL L, V1632, P16, DOI 10.1016/S1388-1981(03)00059-3; HANADA K, 1990, J BIOL CHEM, V265, P22137; Hanada Kentaro, 2003, Methods Mol Biol, V228, P163, DOI 10.1385/1-59259-400-X:163; Hofer M, 2005, EXP PARASITOL, V110, P178, DOI 10.1016/j.exppara.2005.03.018; Ikushiro H, 2001, J BIOL CHEM, V276, P18249, DOI 10.1074/jbc.M101550200; Lester RL, 2001, ANAL BIOCHEM, V298, P283, DOI 10.1006/abio.2001.5368; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; MERRILL AH, 1984, J LIPID RES, V25, P185; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Sherman F., 1986, METHODS YEAST GENETI; Wilson WH, 2005, SCIENCE, V309, P1090, DOI 10.1126/science.1113109; Wilson WH, 2002, J MAR BIOL ASSOC UK, V82, P369, DOI 10.1017/S002531540200560X	24	44	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39935	39942		10.1074/jbc.M609365200	http://dx.doi.org/10.1074/jbc.M609365200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17090526	Green Published, hybrid			2022-12-27	WOS:000243033900021
J	Johnston, D; Tavano, C; Wickner, S; Trun, N				Johnston, Danielle; Tavano, Christine; Wickner, Sue; Trun, Nancy			Specificity of DNA binding and dimerization by CspE from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SHOCK PROTEIN; BACILLUS-SUBTILIS; TRANSCRIPTION COMPLEXES; CRYSTAL-STRUCTURE; RNA; FAMILY; GENE; IDENTIFICATION; REPLICATION	The CspE protein from Escherichia coli K12 is a single-stranded nucleic acid-binding protein that plays a role in chromosome condensation in vivo. We report here that CspE binds to single-stranded DNA containing 6 or more contiguous dT residues with high affinity (K-D < 30 nM). The interactions are predominantly through base-specific contacts. When an oligonucleotide contains fewer than 6 contiguous dT residues, the CspE interactions with single-stranded DNA are primarily electrostatic. The minimal length of single-stranded DNA to which CspE binds in a salt-resistant manner is eight nucleotides. We also show that CspE exists as a dimer in solution. We present a possible mechanism to explain the role of CspE in chromosome condensation in vivo by CspE binding to distant DNA regions in the chromosome and dimerizing, thereby condensing the intervening DNA.	Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA; NCI, Mol Biol Lab, NIH, Bethesda, MD 20895 USA	Duquesne University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Trun, N (corresponding author), Duquesne Univ, Dept Biol Sci, 600 Forbes Ave,256 Mellon Hall, Pittsburgh, PA 15282 USA.	trun@duq.edu			Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM65121-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM065121] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae WH, 2000, P NATL ACAD SCI USA, V97, P7784, DOI 10.1073/pnas.97.14.7784; Bae WH, 1999, MOL MICROBIOL, V31, P1429, DOI 10.1046/j.1365-2958.1999.01284.x; Falsone SF, 2002, J BIOL CHEM, V277, P16512, DOI 10.1074/jbc.M200833200; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; Graumann P, 1996, J BACTERIOL, V178, P4611, DOI 10.1128/jb.178.15.4611-4619.1996; Graumann P, 1997, MOL MICROBIOL, V25, P741, DOI 10.1046/j.1365-2958.1997.5121878.x; Hanna MM, 1998, J MOL BIOL, V282, P227, DOI 10.1006/jmbi.1998.2005; Hu KH, 1996, GENETICS, V143, P1521; IYER VN, 1971, BIOCHIM BIOPHYS ACTA, V228, P117, DOI 10.1016/0005-2787(71)90551-X; Jiang WN, 1997, J BIOL CHEM, V272, P196; Jiang WN, 1996, J BACTERIOL, V178, P4919, DOI 10.1128/jb.178.16.4919-4925.1996; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; Kreuzer KN, 2005, ANNU REV MICROBIOL, V59, P43, DOI 10.1146/annurev.micro.59.030804.121255; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LOHMAN TM, 1991, METHOD ENZYMOL, V208, P258; Lopez MM, 2000, BBA-PROTEIN STRUCT M, V1479, P196, DOI 10.1016/S0167-4838(00)00048-0; Lopez MM, 2001, J BIOL CHEM, V276, P15511, DOI 10.1074/jbc.M010474200; Lopez MM, 1999, J BIOL CHEM, V274, P33601, DOI 10.1074/jbc.274.47.33601; Max KEA, 2006, J MOL BIOL, V360, P702, DOI 10.1016/j.jmb.2006.05.044; NEWKIRK K, 1994, P NATL ACAD SCI USA, V91, P5114, DOI 10.1073/pnas.91.11.5114; Ohta K, 1999, NUCLEIC ACIDS RES, V27, P2175, DOI 10.1093/nar/27.10.2175; PANAYOTATOS N, 1985, J BIOL CHEM, V260, P3173; Phadtare S, 1999, MOL MICROBIOL, V33, P1004, DOI 10.1046/j.1365-2958.1999.01541.x; Phadtare S, 2002, J BIOL CHEM, V277, P7239, DOI 10.1074/jbc.M111496200; Phadtare S, 2001, J BACTERIOL, V183, P1205, DOI 10.1128/JB.183.4.1205-1214.2001; Phadtare S, 2005, NUCLEIC ACIDS RES, V33, P5583, DOI 10.1093/nar/gki859; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Sand O, 2003, MICROBIOL-SGM, V149, P2107, DOI 10.1099/mic.0.26363-0; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; TANABE H, 1992, J BACTERIOL, V174, P3867, DOI 10.1128/jb.174.12.3867-3873.1992; Trun N, 2003, CURR TOP DEV BIOL, V55, P173, DOI 10.1016/S0070-2153(03)01004-4; Wang BD, 2005, MOL CELL BIOL, V25, P7216, DOI 10.1128/MCB.25.16.7216-7225.2005; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YAMANAKA K, 1994, MOL MICROBIOL, V13, P301, DOI 10.1111/j.1365-2958.1994.tb00424.x; Yamanaka K, 2001, MOL MICROBIOL, V39, P1572, DOI 10.1046/j.1365-2958.2001.02345.x; YAMANAKA K, 1994, FEMS MICROBIOL LETT, V123, P27, DOI 10.1016/0378-1097(94)90269-0	40	9	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40208	40215		10.1074/jbc.M606414200	http://dx.doi.org/10.1074/jbc.M606414200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17088256	hybrid			2022-12-27	WOS:000243033900051
J	Kunnimalaiyaan, M; Vaccaro, AM; Ndiaye, MA; Chen, H				Kunnimalaiyaan, Muthusamy; Vaccaro, Abram M.; Ndiaye, Mary A.; Chen, Herbert			Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACHAETE-SCUTE HOMOLOG-1; CARCINOID-TUMOR CELLS; ENDOCRINE DEVELOPMENT; TRANSCRIPTION FACTOR; NERVOUS-SYSTEM; HORMONE-LEVELS; CYCLE ARREST; LUNG-CANCER; DIFFERENTIATION; EXPRESSION	The role of NOTCH1 as an oncogene or tumor suppressor appears to be cell type-specific. Medullary thyroid cancer (MTC) cells characteristically express the transcription factor ASCL1 (achaete-scute complex-like 1) as well as high levels of the neuroendocrine (NE) markers calcitonin and chromogranin A (CgA). In this study, we show that the active NOTCH1 intracellular domain is absent in human MTC tumor tissue samples and MTC-TT cells. To determine the effects of NOTCH1 expression, we created a doxycycline-inducible NOTCH1 intracellular domain in MTC cells (TT-NOTCH cells). Treatment of TT-NOTCH cells with doxycycline led to dose-dependent induction of NOTCH1 protein with corresponding decreases in ASCL1 protein and NE hormones. ASCL1 promoter-reporter assay and Northern analysis revealed that ASCL1 reduction by NOTCH1 activation is predominantly via silencing of ASCL1 gene transcription. Overexpression of ASCL1 in MTC cells indicated that CgA expression is highly dependent on the levels of ASCL1. This was further confirmed by experiments using small interfering RNA against ASCL1, in which reduction in ASCL1 led to reduction in both CgA and calcitonin. Furthermore, we demonstrate that NOTCH1 signaling activation leads to ERK1/2 phosphorylation, but that reduction in NE markers is independent of ERK1/2 activation. Activation of NOTCH1 resulted in significant MTC cell growth inhibition. Notably, reduction in MTC cell growth was dependent on the level of NOTCH1 protein present. Moreover, no increase in growth upon expression of ASCL1 in NOTCH1-activated cells was observed, indicating that the growth suppression observed upon NOTCH1 activation is independent of ASCL1 reduction. Mechanistically, we show that MTC cell growth inhibition by NOTCH1 is mediated by cell cycle arrest associated with up-regulation of p21.	Univ Wisconsin, Sch Med & Publ Hlth, Endocrine Surg Res Labs, Dept Surg, Madison, WI 53792 USA; Univ Wisconsin, Sch Med & Publ Hlth, Univ Wisconsin Paul P Carbone Comprehens Canc Ctr, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Chen, H (corresponding author), Univ Wisconsin, Dept Surg, Ctr Clin Sci, 600 Highland Ave, Madison, WI 53792 USA.	chen@surgery.wisc.edu			NATIONAL CANCER INSTITUTE [R01CA109053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK064735, R21DK066169, R21DK063015] Funding Source: NIH RePORTER; NCI NIH HHS [CA109053] Funding Source: Medline; NIDDK NIH HHS [DK066169, DK064735, DK063015] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Bae SK, 2000, DEVELOPMENT, V127, P2933; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Chen H, 1996, SURGERY, V120, P168, DOI 10.1016/S0039-6060(96)80284-4; Chen H, 2005, THYROID, V15, P511, DOI 10.1089/thy.2005.15.511; Chen H, 1997, ONCOL REP, V4, P775; Chen H, 1997, CELL GROWTH DIFFER, V8, P677; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; Chen HB, 1998, ANN SURG, V227, P887, DOI 10.1097/00000658-199806000-00012; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Hald J, 2003, DEV BIOL, V260, P426, DOI 10.1016/S0012-1606(03)00326-9; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; Joseph J, 2004, ONCOGENE, V23, P6304, DOI 10.1038/sj.onc.1207852; Kadesch T, 2004, CURR OPIN GENET DEV, V14, P506, DOI 10.1016/j.gde.2004.07.007; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; Kunnimalaiyaan M, 2005, AM J PHYSIOL-GASTR L, V289, pG636, DOI 10.1152/ajpgi.00146.2005; Kunnimalaiyaan M, 2005, SURGERY, V138, P1137, DOI 10.1016/j.surg.2005.05.027; Kunnimalaiyaan M, 2006, ANTI-CANCER DRUG, V17, P139, DOI 10.1097/00001813-200602000-00004; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; Lanigan TM, 1998, J NEUROBIOL, V34, P126, DOI 10.1002/(SICI)1097-4695(19980205)34:2<126::AID-NEU3>3.0.CO;2-4; LO LC, 1994, PERSPECT DEV NEUROBI, V2, P191; Maillard I, 2003, CANCER CELL, V3, P203, DOI 10.1016/S1535-6108(03)00052-7; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Moley JF, 1999, CURR PROB SURG, V36, P658, DOI 10.1016/S0011-3840(99)80001-X; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Murtaugh LC, 2003, P NATL ACAD SCI USA, V100, P14920, DOI 10.1073/pnas.2436557100; Nakakura EK, 2005, J CLIN ENDOCR METAB, V90, P4350, DOI 10.1210/jc.2005-0540; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Oishi K, 2004, DEV BIOL, V276, P172, DOI 10.1016/j.ydbio.2004.08.039; Park JI, 2003, MOL CELL BIOL, V23, P543, DOI 10.1128/MCB.23.2.543-554.2003; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Ronchini C, 2000, ONCOGENE, V19, P3914, DOI 10.1038/sj.onc.1203719; Shou JY, 2001, CANCER RES, V61, P7291; Sippel RS, 2003, AM J PHYSIOL-GASTR L, V285, pG245, DOI 10.1152/ajpgi.00420.2002; Sippel RS, 2003, SURGERY, V134, P866, DOI 10.1016/S0039-6060(03)00418-5; Sriuranpong V, 2002, MOL CELL BIOL, V22, P3129, DOI 10.1128/MCB.22.9.3129-3139.2002; Sriuranpong V, 2001, CANCER RES, V61, P3200; Van Gompel JJ, 2005, MOL CANCER THER, V4, P910, DOI 10.1158/1535-7163.MCT-04-0334; Yoon K, 2005, NAT NEUROSCI, V8, P709, DOI 10.1038/nn1475	42	102	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39819	39830		10.1074/jbc.M603578200	http://dx.doi.org/10.1074/jbc.M603578200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17090547	hybrid			2022-12-27	WOS:000243033900009
J	Detarsio, E; Alvarez, CE; Saigo, M; Andreo, CS; Drincovich, MF				Detarsio, Enrique; Alvarez, Clarisa E.; Saigo, Mariana; Andreo, Carlos S.; Drincovich, Maria F.			Identification of domains involved in tetramerization and malate inhibition of maize C-4-NADP-malic enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADP-MALIC ENZYME; C4 PHOSPHOENOLPYRUVATE CARBOXYLASE; OXIDATIVE DECARBOXYLASES; SUBSTRATE-INHIBITION; PIGEON LIVER; FLAVERIA; SITES; BINDING; MECHANISM; EVOLUTION	C-4 photosynthetic NADP-malic enzyme (ME) has evolved from non-C-4 isoforms and gained unique kinetic and structural properties during this process. To identify the domains responsible for the structural and kinetic differences between maize C4 and non-C-4-NADP-ME several chimeras between these isoforms were constructed and analyzed. By using this approach, we found that the region flanked by amino acid residues 102 and 247 is critical for the tetrameric state of C-4-NADP-ME. In this way, the oligomerization strategy of these NADP-ME isoforms differs markedly from the one that present non-plant NADP-ME with known crystal structures. On the other hand, the region from residue 248 to the C-terminal end of the C-4 isoform is involved in the inhibition by high malate concentrations at pH 7.0. The inhibition pattern of the C-4-NADP-ME and some of the chimeras suggested an allosteric site responsible for such behavior. This pH-dependent inhibition could be important for regulation of the C-4 isoform in vivo, with the enzyme presenting maximum activity while photosynthesis is in progress.	Univ Nacl Rosario, Ctr Estudios Fotosintet & Bioquim, RA-2000 Rosario, Argentina	National University of Rosario	Andreo, CS (corresponding author), Univ Nacl Rosario, Ctr Estudios Fotosintet & Bioquim, Suipacha 531, RA-2000 Rosario, Argentina.	candreo@fbioyf.unr.edu.ar	Drincovich, Maria F/Q-4195-2019; Drincovich, Maria F/F-3902-2017	Drincovich, Maria F/0000-0003-4897-3285; Drincovich, Maria F/0000-0003-4897-3285; Saigo, Mariana/0000-0002-2312-8782				Ashton AR, 1997, ARCH BIOCHEM BIOPHYS, V345, P251, DOI 10.1006/abbi.1997.0260; Chang GG, 2003, BIOCHEMISTRY-US, V42, P12721, DOI 10.1021/bi035251+; Chang HC, 2003, J BIOL CHEM, V278, P23996, DOI 10.1074/jbc.M213242200; Detarsio E, 2003, J BIOL CHEM, V278, P13757, DOI 10.1074/jbc.M212530200; Dixon M., 1979, ENZYMES, Vthird; DRINCOVICH MF, 1991, PHYSIOL PLANTARUM, V81, P462; Drincovich MF, 2001, FEBS LETT, V490, P1, DOI 10.1016/S0014-5793(00)02331-0; EDWARDS GE, 1992, PHYTOCHEMISTRY, V31, P1845, DOI 10.1016/0031-9422(92)80322-6; Fridlyand LE, 1998, ARCH BIOCHEM BIOPHYS, V349, P290, DOI 10.1006/abbi.1997.0482; HSU RY, 1980, BIOCHEMISTRY-US, V19, P962, DOI 10.1021/bi00546a021; Hsu WC, 2004, BIOCHEMISTRY-US, V43, P7382, DOI 10.1021/bi049600r; Hung HC, 2005, BIOCHEM J, V392, P39, DOI 10.1042/BJ20050641; IGLESIAS AA, 1990, PLANT PHYSIOL, V92, P66, DOI 10.1104/pp.92.1.66; Karsten WE, 2003, BIOCHEMISTRY-US, V42, P9712, DOI 10.1021/bi034101w; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai LB, 2002, PLANT PHYSIOL, V128, P140, DOI 10.1104/pp.010449; Lai LB, 2002, PLANT PHYSIOL, V128, P125, DOI 10.1104/pp.010448; Lara MV, 2006, PLANT PHYSIOL, V142, P673, DOI 10.1104/pp.106.085829; Maurino VG, 2001, PLANT MOL BIOL, V45, P409, DOI 10.1023/A:1010665910095; PRY TA, 1980, BIOCHEMISTRY-US, V19, P951, DOI 10.1021/bi00546a020; REYNOLDS CH, 1978, ARCH BIOCHEM BIOPHYS, V189, P309, DOI 10.1016/0003-9861(78)90217-5; Saigo M, 2004, PLANT MOL BIOL, V55, P97, DOI 10.1007/s11103-004-0472-z; Svensson P, 2003, ARCH BIOCHEM BIOPHYS, V414, P180, DOI 10.1016/S0003-9861(03)00165-6; Tausta SL, 2002, PLANT MOL BIOL, V50, P635, DOI 10.1023/A:1019998905615; Westhoff P, 2004, ANN BOT-LONDON, V93, P13, DOI 10.1093/aob/mch003; Wheeler MCG, 2005, PLANT PHYSIOL, V139, P39, DOI 10.1104/pp.105.065953; Xu YW, 1999, STRUCT FOLD DES, V7, P877, DOI 10.1016/S0969-2126(99)80115-4; Yang ZR, 2002, PROTEIN SCI, V11, P332, DOI 10.1110/ps.38002; Yang ZR, 2002, STRUCTURE, V10, P951, DOI 10.1016/S0969-2126(02)00788-8	29	24	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6053	6060		10.1074/jbc.M609436200	http://dx.doi.org/10.1074/jbc.M609436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17150960	hybrid			2022-12-27	WOS:000244867200010
J	Chen, HQ; Khan, AA; Liu, F; Gilligan, DM; Peters, LL; Messick, J; Haschek-Hock, WM; Li, XR; Ostafin, AE; Chishti, AH				Chen, Huiqing; Khan, Anwar A.; Liu, Fei; Gilligan, Diana M.; Peters, Luanne L.; Messick, Joanne; Haschek-Hock, Wanda M.; Li, Xuerong; Ostafin, Agnes E.; Chishti, Athar H.			Combined deletion of mouse dematin-head piece and beta-adducin exerts a novel effect on the spectrin-actin junctions leading to erythrocyte fragility and hemolytic anemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; MEMBRANE SKELETON; TARGETED DISRUPTION; BUNDLING PROTEIN; BINDING; BAND-3; CYTOSKELETON; DOMAIN; MICE; SPHEROCYTOSIS	Dematin and adducin are actin-binding proteins of the erythrocyte "junctional complex." Individually, they exert modest effects on erythrocyte shape and membrane stability, and their homologues are expressed widely in non-erythroid cells. Here we report generation and characterization of double knock-out mice lacking beta-adducin and the headpiece domain of dematin. The combined mutations result in altered erythrocyte morphology, increased membrane instability, and severe hemolysis. Peripheral blood analysis shows evidence of severe hemolytic anemia with reduced number of erythrocytes/hematocrit/hemoglobin and an similar to 12-fold increase in the number of circulating reticulocytes. The presence of a variety of misshapen and fragmented erythrocytes correlates with increased osmotic fragility and reduced in vivo life span. Despite the apparently normal protein composition of the mutant erythrocyte membrane, the retention of the spectrin-actin complex in the membrane under low ionic strength conditions is significantly reduced by the double mutation. Atomic force microscopy reveals an increase in grain size and a decrease in filament number of the mutant membrane cytoskeleton, although the volume parameter is similar to wild type erythrocytes. Aggregated, disassembled, and irregular features are visualized in the mutant membrane, consistent with the presence of large protein aggregates. Importantly, purified dematin binds to the stripped inside-out vesicles in a saturable manner, and dematin-membrane binding is abolished upon pretreatment of membrane vesicles with trypsin. Together, these results reveal an essential role of dematin and adducin in the maintenance of erythrocyte shape and membrane stability, and they suggest that the dematin-membrane interaction could link the junctional complex to the plasma membrane in erythroid cells.	Univ Illinois, Dept Pharmacol, Coll Med, Ctr Canc, Chicago, IL 60612 USA; Univ Notre Dame, Dept Chem Engn, Notre Dame, IN 46556 USA; Univ Washington, Sch Med, Puget Sound Blood Ctr, Seattle, WA 98104 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Illinois, Dept Comparat Pathol, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Notre Dame; Puget Sound Blood Center; University of Washington; University of Washington Seattle; Jackson Laboratory; University of Illinois System; University of Illinois Urbana-Champaign	Chishti, AH (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, Ctr Canc, 909 S Wolcott Ave,Rm 5097, Chicago, IL 60612 USA.	chishti@uic.edu		Peters, Luanne/0000-0002-0784-0534	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075714, R56HL051445, R01HL051445] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL075714, R01 HL075714, HL051445] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPELL KC, 1982, BIOCHEMISTRY-US, V21, P2151, DOI 10.1021/bi00538a026; AZIM AC, 1995, J BIOL CHEM, V270, P17407, DOI 10.1074/jbc.270.29.17407; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; CHASIS JA, 1992, BLOOD, V80, P1869; Chishti A H, 1998, Curr Opin Hematol, V5, P116; CHISHTI AH, 1989, J BIOL CHEM, V264, P8985; CHISHTI AH, 1988, NATURE, V334, P718; COHEN CM, 1992, SEMIN HEMATOL, V29, P244; DERICK LH, 1992, EUR J CELL BIOL, V57, P317; Eber S, 2004, SEMIN HEMATOL, V41, P118, DOI 10.1053/j.seminhematol.2004.01.002; ELGSAETER A, 1986, SCIENCE, V234, P1217, DOI 10.1126/science.3775380; Fowler VM, 1996, CURR OPIN CELL BIOL, V8, P86, DOI 10.1016/S0955-0674(96)80052-4; Gallagher Patrick G, 2004, Curr Hematol Rep, V3, P85; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GARDNER K, 1986, J BIOL CHEM, V261, P1339; Gilligan DM, 1999, P NATL ACAD SCI USA, V96, P10717, DOI 10.1073/pnas.96.19.10717; GILLIGAN DM, 1993, SEMIN HEMATOL, V30, P74; Hassoun H, 1998, BLOOD, V91, P2146, DOI 10.1182/blood.V91.6.2146.2146_2146_2151; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; Khanna R, 2002, P NATL ACAD SCI USA, V99, P6637, DOI 10.1073/pnas.052155999; KORSGREN C, 1986, J BIOL CHEM, V261, P5536; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN DC, 1978, J BIOL CHEM, V253, P1415; Liu F, 2005, J STRUCT BIOL, V150, P200, DOI 10.1016/j.jsb.2005.02.001; Liu F, 2003, CELL BIOCHEM BIOPHYS, V38, P251, DOI 10.1385/CBB:38:3:251; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; MISCHE SM, 1987, J CELL BIOL, V105, P2837, DOI 10.1083/jcb.105.6.2837; Muro AF, 2000, BLOOD, V95, P3978; Nunomura W, 2000, J BIOL CHEM, V275, P24540, DOI 10.1074/jbc.M002492200; PETERS LL, 1992, BLOOD, V80, P2122; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; SCARAMUZZINO DA, 1993, P NATL ACAD SCI USA, V90, P3398, DOI 10.1073/pnas.90.8.3398; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SIEGEL DL, 1985, J CELL BIOL, V100, P775, DOI 10.1083/jcb.100.3.775; Southgate CD, 1996, NAT GENET, V14, P227, DOI 10.1038/ng1096-227; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; Swihart AH, 2001, J MICROSC-OXFORD, V204, P212, DOI 10.1046/j.1365-2818.2001.00960.x; URSITTI JA, 1991, CELL MOTIL CYTOSKEL, V19, P227, DOI 10.1002/cm.970190402	43	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4124	4135		10.1074/jbc.M610231200	http://dx.doi.org/10.1074/jbc.M610231200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17142833	hybrid			2022-12-27	WOS:000244481900076
J	Waldron, KJ; Tottey, S; Yanagisawa, S; Dennison, C; Robinson, NJ				Waldron, Kevin J.; Tottey, Stephen; Yanagisawa, Sachiko; Dennison, Christopher; Robinson, Nigel J.			A periplasmic iron-binding protein contributes toward inward copper supply	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; THYLAKOID MEMBRANE; TRANSPORT PROTEIN; TERMINAL DOMAIN; SYNECHOCYSTIS; PLASTOCYANIN; IDENTIFICATION; GENE; PHOTOSYNTHESIS; EXPRESSION	Periplasmic substrate binding proteins are known for iron, zinc, manganese, nickel, and molybdenum but not copper. Synechocystis PCC 6803 requires copper for thylakoid-localized plastocyanin and cytochrome oxidase. Here we show that mutants deficient in a periplasmic substrate binding protein FutA2 have low cytochrome oxidase activity and produce cytochrome c(6) when grown under copper conditions (150 nM) in which wild-type cells use plastocyanin rather than cytochrome c6. Anaerobic separation of extracts by two-dimensional native liquid chromatography followed by metal analysis and peptide mass-fingerprinting establish that accumulation of copper-plastocyanin is impaired, but iron-ferredoxin is unaffected in Delta futA2 grown in 150 nM copper. However, recombinant FutA2 binds iron in preference to copper in vitro with an apparent Fe(III) affinity similar to that of its paralog FutA1, the principal substrate binding protein for iron import. FutA2 is also associated with iron and not copper in periplasm extracts, and this Fe(III)-protein complex is absent in Delta futA2. There are differences in the soluble protein and small-molecule complexes of copper and iron, and the total amount of both elements increases in periplasm extracts of Delta futA2 relative to wild type. Changes in periplasm protein and small-molecule complexes for other metals are also observed in Delta futA2. It is proposed that FutA2 contributes to metal partitioning in the periplasm by sequestering Fe(III), which limits aberrant Fe(III) associations with vital binding sites for other metals, including copper.	Univ Newcastle, Sch Med, ICaMB, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robinson, NJ (corresponding author), Univ Newcastle, Sch Med, ICaMB, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.j.robinson@ncl.ac.uk	Waldron, Kevin/J-2368-2016; Robinson, Nigel J/J-6363-2012; Waldron, Kevin John/HHM-8983-2022	Waldron, Kevin/0000-0002-5577-7357; Robinson, Nigel J/0000-0001-5586-1092; Waldron, Kevin John/0000-0002-5577-7357; Dennison, Christopher/0000-0001-8665-052X	Biotechnology and Biological Sciences Research Council [BBS/B/02576] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALGE D, 1994, GENE, V138, P127, DOI 10.1016/0378-1119(94)90794-3; Banci L, 2004, J BIOL CHEM, V279, P27502, DOI 10.1074/jbc.M402005200; Banci L, 2006, P NATL ACAD SCI USA, V103, P8320, DOI 10.1073/pnas.0600142103; Banerjee S, 2003, J MOL BIOL, V333, P1061, DOI 10.1016/j.jmb.2003.09.008; BARTSEVICH VV, 1995, EMBO J, V14, P1845, DOI 10.1002/j.1460-2075.1995.tb07176.x; Bartsevich VV, 1996, J BIOL CHEM, V271, P26057, DOI 10.1074/jbc.271.42.26057; Borrelly GPM, 2004, MOL MICROBIOL, V53, P217, DOI 10.1111/j.1365-2958.2004.04106.x; Borrelly GPM, 2004, BIOCHEM J, V378, P293, DOI 10.1042/BJ20031669; BOTTIN H, 1992, BIOCHIM BIOPHYS ACTA, V1101, P48, DOI 10.1016/0167-4838(92)90465-P; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; CHEN CY, 1993, MOL MICROBIOL, V10, P311, DOI 10.1111/j.1365-2958.1993.tb01957.x; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; da Silva J. J. R. Frausto, 2001, BIOL CHEM ELEMENTS; Fulda S, 1999, ARCH MICROBIOL, V171, P214, DOI 10.1007/s002030050702; Fulda S, 2000, EUR J BIOCHEM, V267, P5900, DOI 10.1046/j.1432-1327.2000.01642.x; Gabricevic M, 2004, BIOCHEMISTRY-US, V43, P5811, DOI 10.1021/bi036217y; Herald VL, 2003, FEBS LETT, V537, P96, DOI 10.1016/S0014-5793(03)00101-7; Huang F, 2006, PROTEOMICS, V6, P910, DOI 10.1002/pmic.200500114; Huang F, 2002, MOL CELL PROTEOMICS, V1, P956, DOI 10.1074/mcp.M200043-MCP200; KANAMARU K, 1994, MOL MICROBIOL, V13, P369, DOI 10.1111/j.1365-2958.1994.tb00430.x; Katoh H, 2001, PLANT CELL PHYSIOL, V42, P823, DOI 10.1093/pcp/pce106; Katoh H, 2001, J BACTERIOL, V183, P2779, DOI 10.1128/JB.183.9.2779-2784.2001; Keren N, 2004, PLANT PHYSIOL, V135, P1666, DOI 10.1104/pp.104.042770; Keren N, 2002, BIOCHEMISTRY-US, V41, P15085, DOI 10.1021/bi026892s; Liberton M, 2006, PROTOPLASMA, V227, P129, DOI 10.1007/s00709-006-0145-7; Manna P, 1997, PLANT MOL BIOL, V35, P407, DOI 10.1023/A:1005875124387; MERCHANT S, 1987, EMBO J, V6, P2531, DOI 10.1002/j.1460-2075.1987.tb02540.x; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; Molina-Heredia FP, 2003, NATURE, V424, P33, DOI 10.1038/424033b; Moseley J, 2000, EMBO J, V19, P2139, DOI 10.1093/emboj/19.10.2139; PHUNG LT, 1994, P NATL ACAD SCI USA, V91, P9651, DOI 10.1073/pnas.91.20.9651; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Rosenzweig AC, 2002, CHEM BIOL, V9, P673, DOI 10.1016/S1074-5521(02)00156-4; Rukhman V, 2005, J MOL BIOL, V348, P961, DOI 10.1016/j.jmb.2005.03.006; Simon WJ, 2002, PROTEOMICS, V2, P1735, DOI 10.1002/1615-9861(200212)2:12<1735::AID-PROT1735>3.0.CO;2-K; Spence E, 2003, MOL MICROBIOL, V48, P1481, DOI 10.1046/j.1365-2958.2003.03519.x; Srivastava R, 2005, PROTEOMICS, V5, P4905, DOI 10.1002/pmic.200500111; Tolle J, 2002, MICROBIOL-SGM, V148, P3293, DOI 10.1099/00221287-148-10-3293; Tottey S, 2005, ACCOUNTS CHEM RES, V38, P775, DOI 10.1021/ar0300118; Tottey S, 2002, J BIOL CHEM, V277, P5490, DOI 10.1074/jbc.M105857200; Tottey S, 2001, J BIOL CHEM, V276, P19999, DOI 10.1074/jbc.M011243200; van de Meene AML, 2006, ARCH MICROBIOL, V184, P259, DOI 10.1007/s00203-005-0027-y; Wang HL, 2002, MOL MICROBIOL, V44, P1493, DOI 10.1046/j.1365-2958.2002.02983.x; Weigel M, 2003, J BIOL CHEM, V278, P31286, DOI 10.1074/jbc.M302876200; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350; ZHANG L, 1992, J BIOL CHEM, V267, P19054	47	37	42	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3837	3846		10.1074/jbc.M609916200	http://dx.doi.org/10.1074/jbc.M609916200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148438	hybrid			2022-12-27	WOS:000244481900047
J	Kopp, JL; Wilder, PJ; Desler, M; Kinarsky, L; Rizzino, A				Kopp, Janel L.; Wilder, Phillip J.; Desler, Michelle; Kinarsky, Leo; Rizzino, Angie			Different domains of the transcription factor ELF3 are required in a promoter-specific manner and multiple domains control its binding to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; BETA RECEPTOR GENE; ETS-FAMILY MEMBER; NF-KAPPA-B; AUTOINHIBITORY DOMAINS; II RECEPTOR; FUNCTIONAL-ANALYSIS; EPITHELIAL-CELLS; FACTOR ELK-1; EXPRESSION	Elf3 is an epithelially restricted member of the ETS transcription factor family, which is involved in a wide range of normal cellular processes. Elf3 is also aberrantly expressed in several cancers, including breast cancer. To better understand the molecular mechanisms by which Elf3 regulates these processes, we created a large series of Elf3 mutant proteins with specific domains deleted or targeted by point mutations. The modified forms of Elf3 were used to analyze the contribution of each domain to DNA binding and the activation of gene expression. Our work demonstrates that three regions of Elf3, in addition to its DNA binding domain ( ETS domain), influence Elf3 binding to DNA, including the transactivation domain that behaves as an autoinhibitory domain. Interestingly, disruption of the transactivation domain relieves the autoinhibition of Elf3 and enhances Elf3 binding to DNA. On the basis of these studies, we suggest a model for autoinhibition of Elf3 involving intramolecular interactions. Importantly, this model is consistent with our finding that the N-terminal region of Elf3, which contains the transactivation domain, interacts with its C terminus, which contains the ETS domain. In parallel studies, we demonstrate that residues flanking the N- and C-terminal sides of the ETS domain of Elf3 are crucial for its binding to DNA. Our studies also show that an AT-hook domain, as well as the serine- and aspartic acid-rich domain but not the pointed domain, is necessary for Elf3 activation of promoter activity. Unexpectedly, we determined that one of the AT-hook domains is required in a promoter-specific manner.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Rizzino, A (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	arizzino@unmc.edu			NCI NIH HHS [CA009476, CA36727] Funding Source: Medline; NCRR NIH HHS [RR16469] Funding Source: Medline; NIGMS NIH HHS [GM80751] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, T32CA009476] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER RR, 1990, DEVELOPMENT, V110, P211; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Asada S, 2003, J AM CHEM SOC, V125, P4992, DOI 10.1021/ja0292703; Asada S, 2002, P NATL ACAD SCI USA, V99, P12747, DOI 10.1073/pnas.202162199; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Brembeck FH, 2000, ONCOGENE, V19, P1941, DOI 10.1038/sj.onc.1203441; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Buttice G, 1996, ONCOGENE, V13, P2297; Cabral A, 2003, J BIOL CHEM, V278, P17792, DOI 10.1074/jbc.M300508200; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; De Haro L, 2002, NUCLEIC ACIDS RES, V30, P2972; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Do HJ, 2006, FEBS LETT, V580, P1865, DOI 10.1016/j.febslet.2006.02.049; Eckel KL, 2003, DNA CELL BIOL, V22, P79, DOI 10.1089/104454903321515896; Feldman RJ, 2003, ANTICANCER RES, V23, P2125; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Grall FT, 2005, FEBS J, V272, P1676, DOI 10.1111/j.1742-4658.2005.04592.x; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Kelly D, 1998, J BIOL CHEM, V273, P21115, DOI 10.1074/jbc.273.33.21115; Kim JH, 2002, J BIOL CHEM, V277, P17520, DOI 10.1074/jbc.M110434200; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kopp JL, 2004, J BIOL CHEM, V279, P19407, DOI 10.1074/jbc.M314115200; Kwon JH, 2003, J BIOL CHEM, V278, P875, DOI 10.1074/jbc.M208241200; Laget MP, 1996, ONCOGENE, V12, P1325; Lamb KA, 1998, MOL REPROD DEV, V51, P218; Lee HJ, 2003, J EXP CLIN CANC RES, V22, P477; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Neve RM, 2002, ONCOGENE, V21, P3934, DOI 10.1038/sj.onc.1205503; Ng AYN, 2002, GASTROENTEROLOGY, V122, P1455, DOI 10.1053/gast.2002.32990; Nowling T, 2002, MOL REPROD DEV, V63, P309, DOI 10.1002/mrd.90014; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Perrella MA, 1999, J BIOL CHEM, V274, P9045, DOI 10.1074/jbc.274.13.9045; Prescott JD, 2004, MOL CELL BIOL, V24, P5548, DOI 10.1128/MCB.24.12.5548-5564.2004; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310; Rizzino A, 2002, VITAM HORM, V64, P1, DOI 10.1016/S0083-6729(02)64001-4; Rudders S, 2001, J BIOL CHEM, V276, P3302, DOI 10.1074/jbc.M006507200; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sieweke Michael H., 1997, Leukemia (Basingstoke), V11, P486; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Wang YZ, 2005, BIOCHEMISTRY-US, V44, P7095, DOI 10.1021/bi047352t; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Wiebe MS, 2003, J BIOL CHEM, V278, P17901, DOI 10.1074/jbc.M212211200; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Zhang XM, 1999, J BIOL CHEM, V274, P20235, DOI 10.1074/jbc.274.29.20235	72	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3027	3041		10.1074/jbc.M609907200	http://dx.doi.org/10.1074/jbc.M609907200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148437	hybrid			2022-12-27	WOS:000243793900029
J	Li, FC; Shetty, AK; Sugahara, K				Li, Fuchuan; Shetty, Ajaya Kumar; Sugahara, Kazuyuki			Neuritogenic activity of chondroitin/dermatan sulfate hybrid chains of embryonic pig brain and their mimicry from shark liver - Involvement of the pleiotrophin and hepatocyte growth factor signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-SCATTER FACTOR; ANAPLASTIC LYMPHOMA KINASE; PROTEIN LINKAGE REGION; L-IDURONIC ACID; NEURITE OUTGROWTH; DERMATAN SULFATE; FUNCTIONAL-CHARACTERIZATION; HIPPOCAMPAL-NEURONS; BINDING ACTIVITIES; HEPARAN-SULFATE	Accumulating evidence suggests the involvement of chondroitin sulfate (CS) and dermatan sulfate (DS) hybrid chains in the brain's development and critical roles for oversulfated disaccharides and IdoUA residues in the growth factor-binding and neuritogenic activities of these chains. In the pursuit of sources of CS/DS with unique structures, neuritogenic activity, and therapeutic potential, two novel CS/DS preparations were isolated from shark liver by anion exchange chromatography. The major (80%) low sulfated and minor (20%) highly sulfated fractions had an average molecular mass of 3.8-38.9 and 75.7 kDa, respectively. Digestion with various chondroitinases (CSases) revealed a large panel of disaccharides with either GlcUA or IdoUA scattered along the polysaccharide chains in both of the fractions. The higher M-r fraction, richer in IdoUA(2-O-sulfate) alpha 1-3GalNAc(4-O-sulfate) and GlcUA beta/IdoUA alpha 1-3GalNAc(4,6-O-disulfate) units, exerted greater neurite outgrowth-promoting (NOP) activity and better promoted the binding of various heparin-binding growth factors, including pleiotrophin (PTN), midkine, recombinant human heparin-binding epidermal growth factor-like growth factor, VEGF(165), fibroblast growth factor-2, fibroblast growth factor-7, and hepatocyte growth factor (HGF). These activities were largely abolished by digestion with CSase ABC or B but only moderately affected by a mixture of CSases AC-I and AC-II. In addition, the NOP activity of the larger fraction was markedly reduced by desulfation with alkali, suggesting a role for the 2-O-sulfate of IdoUA(2-O-sulfate) alpha 1-3GalNAc(4-O-sulfate). The NOP activity of the higher molecular weight fraction and that of the embryonic pig brain-derived CS/DS fraction were also suppressed to a large extent by antibodies against HGF, PTN, and their individual receptors cMet and anaplastic lymphoma kinase, revealing the involvement of the HGF and PTN signaling pathways in the activity.	Hokkaido Univ, Grad Sch Life Sci, Lab Proteoglycan Signaling & Therapeut, Frontier Res Ctr PostGenom Sci & Technol,Kita Ku, Sapporo, Hokkaido 0010021, Japan; Kobe Pharmaceut Univ, Dept Biochem, Kobe, Hyogo 6588558, Japan	Hokkaido University; Kobe Pharmaceutical University	Sugahara, K (corresponding author), Hokkaido Univ, Grad Sch Life Sci, Lab Proteoglycan Signaling & Therapeut, Frontier Res Ctr PostGenom Sci & Technol,Kita Ku, Nishi 11 Choume,Kita 21 Jo, Sapporo, Hokkaido 0010021, Japan.	k-sugar@sci.hokudai.ac.jp						Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bao XF, 2005, J BIOL CHEM, V280, P35318, DOI 10.1074/jbc.M507304200; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; Bergefall K, 2005, J BIOL CHEM, V280, P32193, DOI 10.1074/jbc.M503645200; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; BOHLEN P, 1991, Progress in Growth Factor Research, V3, P143, DOI 10.1016/S0955-2235(05)80005-5; CACERES A, 1986, J NEUROSCI, V6, P714; CHANDRASEKHAR S, 1987, ANAL BIOCHEM, V161, P103, DOI 10.1016/0003-2697(87)90658-0; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Deakin JA, 1999, J CELL SCI, V112, P1999; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; ERNFORS P, 1990, J NEUROSCI RES, V27, P10, DOI 10.1002/jnr.490270103; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FERRO DR, 1986, J AM CHEM SOC, V108, P6773, DOI 10.1021/ja00281a052; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; HAYNES LW, 1988, MOL NEUROBIOL, V2, P263, DOI 10.1007/BF02935635; Helmbacher F, 2003, NEURON, V39, P767, DOI 10.1016/S0896-6273(03)00493-8; Hienola A, 2006, J CELL BIOL, V174, P569, DOI 10.1083/jcb.200602043; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Hsiao JC, 1999, J VIROL, V73, P8750, DOI 10.1128/JVI.73.10.8750-8761.1999; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Kluppel M, 2005, DEVELOPMENT, V132, P3989, DOI 10.1242/dev.01948; LAFONT F, 1992, DEVELOPMENT, V114, P17; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maina F, 1998, NEURON, V20, P835, DOI 10.1016/S0896-6273(00)80466-3; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MICHELACCI YM, 1975, BIOCHEM J, V151, P121, DOI 10.1042/bj1510121; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nandi S, 2006, BLOOD, V107, P786, DOI 10.1182/blood-2005-05-1822; Nandini CD, 2005, J BIOL CHEM, V280, P4058, DOI 10.1074/jbc.M412074200; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; POOLE AR, 1986, BIOCHEM J, V236, P1; Properzi F, 2005, EUR J NEUROSCI, V21, P378, DOI 10.1111/j.1460-9568.2005.03876.x; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; RAUVALA H, 1994, DEV BRAIN RES, V79, P157, DOI 10.1016/0165-3806(94)90121-X; REJ R, 1989, THROMB HAEMOSTASIS, V61, P540; RODEN L, 1980, BIOCH GLYCOPROTEINS, P491; SCOTT JE, 1995, BIOCHEMISTRY-US, V34, P15467, DOI 10.1021/bi00047a011; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Taylor KR, 2006, FASEB J, V20, P9, DOI 10.1096/fj.05-4682rev; Thompson J, 2004, MOL CELL NEUROSCI, V27, P441, DOI 10.1016/j.mcn.2004.07.007; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; White J, 2003, CURR BIOL, V13, pR717, DOI 10.1016/j.cub.2003.08.048; Williams RK, 1997, J VIROL, V71, P1375, DOI 10.1128/JVI.71.2.1375-1380.1997; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yang XM, 1998, J NEUROSCI, V18, P8369; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	67	64	66	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2956	2966		10.1074/jbc.M609296200	http://dx.doi.org/10.1074/jbc.M609296200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145750	hybrid			2022-12-27	WOS:000243793900022
J	Pedelini, L; Marquina, M; Arino, J; Casamayor, A; Sanz, L; Bollen, M; Sanz, P; Garcia-Gimeno, MA				Pedelini, Leda; Marquina, Maribel; Arino, Joaquin; Casamayor, Antonio; Sanz, Libia; Bollen, Mathieu; Sanz, Pascual; Garcia-Gimeno, Maria Adelaida			YPI1 and SDS22 proteins regulate the nuclear localization and function of yeast type 1 phosphatase Glc7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; CATALYTIC SUBUNIT; KINASE; BINDING; HOMOLOG; GENE; INACTIVATION; ORGANIZATION; PP1-GAMMA-2	We have recently characterized Ypi1 as an inhibitory subunit of yeast Glc7 PP1 protein phosphatase. In this work we demonstrate that Ypi1 forms a complex with Glc7 and Sds22, another Glc7 regulatory subunit that targets the phosphatase to substrates involved in cell cycle control. Interestingly, the combination of equimolar amounts of Ypi1 and Sds22 leads to an almost full inhibition of Glc7 activity. Because YPI1 is an essential gene, we have constructed conditional mutants that demonstrate that depletion of Ypi1 leads to alteration of nuclear localization of Glc7 and cell growth arrest in mid-mitosis with aberrant mitotic spindle. These phenotypes mimic those produced upon inactivation of Sds22. The fact that progressive depletion of either Ypi1 or Sds22 resulted in similar physiological phenotypes and that both proteins inhibit the phosphatase activity of Glc7 strongly suggest a common role of these two proteins in regulating Glc7 nuclear localization and function.	CSIC, Inst Biomed Valencia, Valencia 46010, Spain; Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Catholic Univ Louvain, Fac Med, Dept Mol Cell Biol, B-3000 Louvain, Belgium	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Autonomous University of Barcelona; Universite Catholique Louvain	Sanz, P (corresponding author), CSIC, Inst Biomed Valencia, Jaime Roig 11, Valencia 46010, Spain.	sanz@ibv.csic.es	Arino, Joaquin/D-3756-2011; Casamayor, Antonio/C-2509-2017; García-Gimeno, María Adelaida/K-9855-2014; Casamayor, Antonio/A-3190-2012; Sanz, Pascual/K-2751-2014	Arino, Joaquin/0000-0002-6774-2987; García-Gimeno, María Adelaida/0000-0002-6483-3912; Casamayor, Antonio/0000-0003-2788-7329; Sanz, Pascual/0000-0002-2399-4103; Marquina Rodriguez, Maribel/0000-0002-7798-5528; Sanz, Libia/0000-0003-4991-9598; PEDELINI, LEDA/0000-0001-5437-0013; Arino Carmona, Joaquin/0000-0002-0390-4270				Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; CANNON JF, 1994, GENETICS, V136, P485; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Ceulemans H, 2002, J BIOL CHEM, V277, P47331, DOI 10.1074/jbc.M206838200; Chang JS, 2002, J BIOL CHEM, V277, P48002, DOI 10.1074/jbc.M208471200; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLOTET J, 1991, CURR GENET, V19, P339, DOI 10.1007/BF00309593; Cohen PTW, 2002, J CELL SCI, V115, P241; Daher W, 2006, BIOCHEM J, V395, P433, DOI 10.1042/BJ20051597; Dinischiotu A, 1997, FEBS LETT, V402, P141, DOI 10.1016/S0014-5793(96)01514-1; Dombradi V, 2004, TOP CURR GENET, V5, P21; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; Fashena SJ, 2000, GENE, V250, P1, DOI 10.1016/S0378-1119(00)00182-7; FENG ZH, 1991, J BIOL CHEM, V266, P23796; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Garcia-Gimeno MA, 2003, J BIOL CHEM, V278, P47744, DOI 10.1074/jbc.M306157200; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; HISAMOTO N, 1995, MOL CELL BIOL, V15, P3767; Hong G, 2000, ARCH BIOCHEM BIOPHYS, V376, P288, DOI 10.1006/abbi.2000.1715; Huang ZH, 2002, BIOL REPROD, V67, P1936, DOI 10.1095/biolreprod.102.004093; Kim J, 1998, GENETICS, V149, P795; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; Mayordomo I, 2003, FEBS LETT, V544, P160, DOI 10.1016/S0014-5793(03)00498-8; Mayordomo I, 2001, YEAST, V18, P1309, DOI 10.1002/yea.780; Mishra S, 2003, BIOL REPROD, V69, P1572, DOI 10.1095/biolreprod.103.018739; Peggie MW, 2002, J CELL SCI, V115, P195; Pinsky BA, 2006, MOL CELL BIOL, V26, P2648, DOI 10.1128/MCB.26.7.2648-2660.2006; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Ramaswamy NT, 1998, GENETICS, V149, P57; Rose MD., 1990, METHODS YEAST GENETI; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; Song WJ, 1998, EMBO J, V17, P5757, DOI 10.1093/emboj/17.19.5757; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; Suter B, 2006, BIOTECHNIQUES, V40, P625, DOI 10.2144/000112151; Tachikawa H, 2001, J CELL BIOL, V155, P797, DOI 10.1083/jcb.200107008; TU JL, 1994, MOL CELL BIOL, V14, P6789, DOI 10.1128/MCB.14.10.6789; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; Walsh EP, 2002, BIOCHEMISTRY-US, V41, P2409, DOI 10.1021/bi015815e; Williams-Hart T, 2002, GENETICS, V160, P1423; Wu XL, 2001, BIOCHEMISTRY-US, V40, P7410, DOI 10.1021/bi002796k; Yen KY, 2003, YEAST, V20, P1255, DOI 10.1002/yea.1037; Zhang K, 2005, CELL, V122, P723, DOI 10.1016/j.cell.2005.06.021; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	57	40	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3282	3292		10.1074/jbc.M607171200	http://dx.doi.org/10.1074/jbc.M607171200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17142459	hybrid			2022-12-27	WOS:000243793900055
J	Raje, CI; Kumar, S; Harle, A; Nanda, JS; Raje, M				Raje, Chaaya Iyengar; Kumar, Santosh; Harle, Arti; Nanda, Jagpreet Singh; Raje, Manoj			The macrophage cell surface glyceraldehyde-3-phosphate dehydrogenase is a novel transferrin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; IRON-METABOLISM; MACROMOLECULAR SUBSTRATE; ACTIVATOR COMPLEX; BINDING PROTEIN; NITRIC-OXIDE; PROLIFERATION; EXPRESSION; FUSION; DIFFERENTIATION	The reticuloendothelial system plays a major role in iron metabolism. Despite this, the manner in which macrophages handle iron remains poorly understood. Mammalian cells utilize transferrin-dependent mechanisms to acquire iron via transferrin receptors 1 and 2 (TfR1 and TfR2) by receptor-mediated endocytosis. Here, we show for the first time that the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is localized on human and murine macrophage cell surface. The expression of this surface GAPDH is regulated by the availability of iron in the medium. We further demonstrate that this GAPDH interacts with transferrin and the GAPDH-transferrin complex is subsequently internalized into the early endosomes. Our work sheds new light on the mechanisms involved in regulation of iron, vital for controlling numerous diseases and maintaining normal immune function. Thus, we propose an entirely new avenue for investigation with respect to transferrin uptake and regulation mechanisms in macrophages.	Inst Microbial Technol, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Raje, M (corresponding author), Inst Microbial Technol, Sector 39-A, Chandigarh 160036, India.	manoj@imtech.res.in	Nanda, Jagpreet/F-9833-2011; Raje, Chaaya Iyengar/AAU-2651-2021	Nanda, Jagpreet/0000-0002-6629-4641; Iyengar, Chaaya/0000-0003-4434-0536; Kumar, Santosh/0000-0002-9363-3530				BREKELMANS P, 1994, EUR J IMMUNOL, V24, P2896, DOI 10.1002/eji.1830241147; Brock Jeremy H., 1993, Journal of Nutritional Immunology, V2, P47, DOI 10.1300/J053v02n03_06; Brock JH, 2000, P NUTR SOC, V59, P537, DOI 10.1017/S002966510000077X; CHAN RYY, 1992, EXP CELL RES, V202, P326, DOI 10.1016/0014-4827(92)90082-J; CHITAMBAR CR, 1983, J CLIN INVEST, V72, P1314, DOI 10.1172/JCI111087; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; DASS SV, 1996, J BIOL CHEM, V270, P1; Dhar J, 2002, J BIOL CHEM, V277, P13257, DOI 10.1074/jbc.M108422200; DIAZ R, 1988, J BIOL CHEM, V263, P6093; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Fuchs H, 1998, STRUCTURE, V6, P1235, DOI 10.1016/S0969-2126(98)00124-5; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Ikuta K, 2004, INT J BIOCHEM CELL B, V36, P340, DOI 10.1016/S1357-2725(03)00258-9; JANDL JH, 1959, J CLIN INVEST, V38, P161, DOI 10.1172/JCI103786; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Jeffery CJ, 2003, ANN MED, V35, P28, DOI 10.1080/07853890310004101; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kim JW, 2005, TRENDS BIOCHEM SCI, V30, P142, DOI 10.1016/j.tibs.2005.01.005; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; Knutson M, 2003, CRIT REV BIOCHEM MOL, V38, P61, DOI 10.1080/713609210; Kuvibidila SR, 1998, J NUTR, V128, P1077, DOI 10.1093/jn/128.7.1077; Kuvibidila SR, 1999, J CELL BIOCHEM, V74, P468, DOI 10.1002/(SICI)1097-4644(19990901)74:3<468::AID-JCB14>3.3.CO;2-7; Kwok JC, 2002, CRIT REV ONCOL HEMAT, V42, P65, DOI 10.1016/S1040-8428(01)00213-X; Laurent O, 1998, J BIOL CHEM, V273, P793, DOI 10.1074/jbc.273.2.793; LEDERMAN HM, 1984, BLOOD, V64, P748; Levy JE, 1999, NAT GENET, V21, P396, DOI 10.1038/7727; Mazzola JL, 2003, BBA-GEN SUBJECTS, V1622, P50, DOI 10.1016/S0304-4165(03)00117-X; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; Mittal J, 2002, FOLIA MICROBIOL, V47, P709, DOI 10.1007/BF02818676; Modun B, 1999, INFECT IMMUN, V67, P1086, DOI 10.1128/IAI.67.3.1086-1092.1999; Modun B, 2000, TRENDS MICROBIOL, V8, P231, DOI 10.1016/S0966-842X(00)01728-5; MORGAN EH, 1981, MOL ASPECTS MED, V4, P1, DOI 10.1016/0098-2997(81)90003-0; Mukherjee K, 2000, J CELL BIOL, V148, P741, DOI 10.1083/jcb.148.4.741; Mulero V, 1999, BLOOD, V94, P2383, DOI 10.1182/blood.V94.7.2383.419k20_2383_2389; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Pancholi V, 2003, INT J MED MICROBIOL, V293, P391, DOI 10.1078/1438-4221-00283; Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9; QUAIL EA, 1995, FEBS LETT, V359, P126, DOI 10.1016/0014-5793(95)00023-3; RASO V, 1984, J BIOL CHEM, V259, P1143; Sirover MA, 2005, J CELL BIOCHEM, V95, P45, DOI 10.1002/jcb.20399; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Sojar HT, 2005, FEMS IMMUNOL MED MIC, V45, P25, DOI 10.1016/j.femsim.2005.01.006; Sundram V, 2003, J BIOL CHEM, V278, P30569, DOI 10.1074/jbc.M303799200; Taylor JM, 2002, MOL MICROBIOL, V43, P1603, DOI 10.1046/j.1365-2958.2002.02850.x; Terao Y, 2006, J BIOL CHEM, V281, P14215, DOI 10.1074/jbc.M513408200; Tribble GD, 2006, P NATL ACAD SCI USA, V103, P11027, DOI 10.1073/pnas.0509813103; Trinder D, 1996, HEPATOLOGY, V23, P1512, DOI 10.1002/hep.510230631; Trinder D, 2003, INT J BIOCHEM CELL B, V35, P292, DOI 10.1016/S1357-2725(02)00258-3; West AP, 2000, J BIOL CHEM, V275, P38135, DOI 10.1074/jbc.C000664200; Yamaji R, 2005, BBA-GEN SUBJECTS, V1726, P261, DOI 10.1016/j.bbagen.2005.07.013	51	96	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3252	3261		10.1074/jbc.M608328200	http://dx.doi.org/10.1074/jbc.M608328200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17121833	hybrid			2022-12-27	WOS:000243793900052
J	Haraguchi, N; Andoh, T; Frendewey, D; Tani, T				Haraguchi, Noriko; Andoh, Tomoko; Frendewey, David; Tani, Tokio			Mutations in the SF1-U2AF(59)-U2AF(23) complex cause exon skipping in schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; FISSION YEAST; SPLICING FACTOR; GENE; MECHANISMS; ENCODES; INTRON; DEFINITION; FIDELITY; PROTEIN	To identify genes involved in the mechanism to ensure ordered 5' to 3' exon joining in constitutively spliced pre-mRNAs, we screened for mutants that cause exon skipping in the fission yeast Schizosaccharomyces pombe using a reporter plasmid, which contains the ura4(+) gene with the nda3 intron 1-exon 2-intron 2 sequence. The reporter plasmid was designed to produce the functional ura4(+) mRNA, when the central nda3 exon is skipped during the splicing reaction. We mutagenized cells harboring the plasmid by UV irradiation and isolated 34 ura(+) mutants that grew on minimal medium. Of those, eight mutants were found to be temperature sensitive (ts) for growth. Complementation analyses revealed that the ts mutants belong to three distinct complementation groups named ods (ordered splicing) 1, 2, and 3. RT-PCR analyses showed that products of exon skipping were actually generated in the ods mutants. We cloned the genes responsible for the ods mutations, and found that ods1(+), ods2(+), and ods3(+) encode splicing factors Prp2p/ U2AF(59), U2AF(23), and SF1, respectively, which form a SF1-U2AF(59)-U2AF23 complex involved in recognition of the branchpoint and 3' splice site sequences in a pre-mRNA. We also showed that mutations in the SF1-U2AF(59)-U2AF(23) binding sequences in the reporter plasmid result in exon skipping in wild-type S. pombe cells. In addition, drugs that decrease the rate of transcription elongation were found to suppress the exon skipping in the ods mutants. These results suggest that co-transcriptional recognition of a nascent pre-mRNA by the SF1-U2AF(59)- U2AF23 complex is essential for ordered exon joining in constitutive splicing in S. pombe.	Kumamoto Univ, Grad Sch Sci & Technol, Dept Biol Sci, Kumamoto 8608555, Japan; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Kumamoto University; Regeneron	Tani, T (corresponding author), Kumamoto Univ, Grad Sch Sci & Technol, Dept Sci, Kumamoto 8608555, Japan.	ttani@sci.kumamoto-u.ac.jp		Frendewey, David/0000-0003-2305-3490				Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; AEBI M, 1987, TRENDS GENET, V3, P102, DOI 10.1016/0168-9525(87)90193-4; Alfa C., 1993, EXPT FISSION YEAST; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blandin G, 2000, FEBS LETT, V487, P31, DOI 10.1016/S0014-5793(00)02275-4; Brow DA, 2002, ANNU REV GENET, V36, P333, DOI 10.1146/annurev.genet.36.043002.091635; GATERMANN KB, 1989, MOL CELL BIOL, V9, P1526, DOI 10.1128/MCB.9.4.1526; Gutz H, 1974, HDB GENETICS, P395, DOI 10.1007/978-1-4899-1710-2_25; Habara Y, 1998, NUCLEIC ACIDS RES, V26, P5662, DOI 10.1093/nar/26.24.5662; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; Howe KJ, 2003, RNA, V9, P993, DOI 10.1261/rna.5390803; Huang T, 2002, EMBO J, V21, P5516, DOI 10.1093/emboj/cdf555; HUMPHREY T, 1991, EMBO J, V10, P3503, DOI 10.1002/j.1460-2075.1991.tb04914.x; Kuhn AN, 2003, CURR GENET, V42, P241, DOI 10.1007/s00294-002-0355-2; Kupfer DM, 2004, EUKARYOT CELL, V3, P1088, DOI 10.1128/EC.3.5.1088-1100.2004; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Morris DP, 2000, J BIOL CHEM, V275, P39935, DOI 10.1074/jbc.M004118200; Okazaki K, 2000, DNA RES, V7, P27, DOI 10.1093/dnares/7.1.27; POTASHKIN J, 1993, SCIENCE, V262, P573, DOI 10.1126/science.8211184; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; Romfo CM, 1999, RNA, V5, P49, DOI 10.1017/S1355838299981323; Romfo CM, 2000, MOL CELL BIOL, V20, P7955, DOI 10.1128/MCB.20.21.7955-7970.2000; SAMBROOK J, 1989, MOL CLONING LAB MANU, P568; Sherman F, 1986, METHODS YEAST GENETI, P61; Urushiyama S, 1997, GENETICS, V147, P101; Webb CJ, 2004, MOL CELL BIOL, V24, P4229, DOI 10.1128/MCB.24.10.4229-4240.2004; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724	30	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2221	2228		10.1074/jbc.M609430200	http://dx.doi.org/10.1074/jbc.M609430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17130122	hybrid			2022-12-27	WOS:000243593200013
J	Xiang, S; Usunow, G; Lange, G; Busch, M; Tong, L				Xiang, Song; Usunow, Gerlinde; Lange, Gudrun; Busch, Marco; Tong, Liang			Crystal structure of 1-deoxy-d-xylulose 5-phosphate synthase, a crucial enzyme for isoprenoids biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-MEVALONATE PATHWAY; ESCHERICHIA-COLI; MACROMOLECULAR STRUCTURES; SACCHAROMYCES-CEREVISIAE; ANOMALOUS DIFFRACTION; THIAMIN; TRANSKETOLASE; DIPHOSPHATE; DEHYDROGENASE; PYRIDOXOL	Isopentenyl pyrophosphate (IPP) is a common precursor for the synthesis of all isoprenoids, which have important functions in living organisms. IPP is produced by the mevalonate pathway in archaea, fungi, and animals. In contrast, IPP is synthesized by a mevalonate-independent pathway in most bacteria, algae, and plant plastids. 1-Deoxy-D-xylulose 5-phosphate synthase (DXS) catalyzes the first and the rate-limiting step of the mevalonate-independent pathway and is an attractive target for the development of novel antibiotics, antimalarials, and herbicides. We report here the first structural information on DXS, from Escherichia coli and Deinococcus radiodurans, in complex with the coenzyme thiamine pyrophosphate (TPP). The structure contains three domains (I, II, and III), each of which bears homology to the equivalent domains in transketolase and the E1 subunit of pyruvate dehydrogenase. However, DXS has a novel arrangement of these domains as compared with the other enzymes, such that the active site of DXS is located at the interface of domains I and II in the same monomer, whereas that of transketolase is located at the interface of the dimer. The coenzyme TPP is mostly buried in the complex, but the C-2 atom of its thiazolium ring is exposed to a pocket that is the substrate-binding site. The structures identify residues that may have important roles in catalysis, which have been confirmed by our mutagenesis studies.	Columbia Univ, Dept Sci Biol, New York, NY 10027 USA; Bayer CropSci GmbH, D-65926 Frankfurt, Germany	Columbia University; Bayer AG; Bayer CropScience	Tong, L (corresponding author), Columbia Univ, Dept Sci Biol, New York, NY 10027 USA.	ltong@columbia.edu	Xiang, Song/AAF-6422-2019	Xiang, Song/0000-0001-9314-4684; Tong, Liang/0000-0002-0563-6468				AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; BAI Y, 2007, IN PRESS ACTA CRYSTA; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; Bouvier F, 1998, PLANT PHYSIOL, V117, P1423, DOI 10.1104/pp.117.4.1423; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W, 2002, PYMOL 0 99; Dubey VS, 2003, J BIOSCIENCES, V28, P637, DOI 10.1007/BF02703339; Eisenreich W, 2004, CELL MOL LIFE SCI, V61, P1401, DOI 10.1007/s00018-004-3381-z; Estevez JM, 2001, J BIOL CHEM, V276, P22901, DOI 10.1074/jbc.M100854200; Fiedler E, 2002, P NATL ACAD SCI USA, V99, P591, DOI 10.1073/pnas.022510999; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hahn FM, 2001, J BACTERIOL, V183, P1, DOI 10.1128/JB.183.1.1-11.2001; Harker M, 1999, FEBS LETT, V448, P115, DOI 10.1016/S0014-5793(99)00360-9; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hill RE, 1996, J BIOL CHEM, V271, P30426, DOI 10.1074/jbc.271.48.30426; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kuzuyama T, 2000, J BACTERIOL, V182, P891, DOI 10.1128/JB.182.4.891-897.2000; Lange BM, 2000, P NATL ACAD SCI USA, V97, P13172, DOI 10.1073/pnas.240454797; Lange BM, 1998, P NATL ACAD SCI USA, V95, P2100, DOI 10.1073/pnas.95.5.2100; Lichtenthaler HK, 2000, BIOCHEM SOC T, V28, P785, DOI 10.1042/BST0280785; Lois LM, 2000, PLANT J, V22, P503, DOI 10.1046/j.1365-313x.2000.00764.x; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; Mandel CR, 2006, ACTA CRYSTALLOGR F, V62, P1041, DOI 10.1107/S1744309106038152; Mandel MA, 1996, PLANT J, V9, P649, DOI 10.1046/j.1365-313X.1996.9050649.x; Matthews PD, 2000, APPL MICROBIOL BIOT, V53, P396, DOI 10.1007/s002530051632; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NIKKOLA M, 1994, J MOL BIOL, V238, P387, DOI 10.1006/jmbi.1994.1299; Nilsson U, 1997, J BIOL CHEM, V272, P1864, DOI 10.1074/jbc.272.3.1864; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLETCHER J, 1977, J AM CHEM SOC, V99, P1396, DOI 10.1021/ja00447a019; Querol J, 2001, BIOCHEM BIOPH RES CO, V289, P155, DOI 10.1006/bbrc.2001.5957; Rodriguez-Concepcion M, 2002, PLANT PHYSIOL, V130, P1079, DOI 10.1104/pp.007138; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; Sauret-Gueto S, 2006, FEBS LETT, V580, P736, DOI 10.1016/j.febslet.2005.12.092; Schellenberger A, 1998, BBA-PROTEIN STRUCT M, V1385, P177, DOI 10.1016/S0167-4838(98)00067-3; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780	44	120	145	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2676	2682		10.1074/jbc.M610235200	http://dx.doi.org/10.1074/jbc.M610235200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135236	hybrid			2022-12-27	WOS:000243593200060
J	Zhu, H; Zhou, HL; Hasman, RA; Lou, H				Zhu, Hui; Zhou, Hua-Lin; Hasman, Robert A.; Lou, Hua			Hu proteins regulate polyadenylation by blocking sites containing U-rich sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TRACT-BINDING-PROTEIN; CLEAVAGE STIMULATION FACTOR; LAST-INTRON REMOVAL; ALTERNATIVE POLYADENYLATION; PROCESSING EFFICIENCY; GENE-EXPRESSION; FACTOR CSTF-64; ELEMENTS; MECHANISM	A recent genome-wide bioinformatic analysis indicated that 54% of human genes undergo alternative polyadenylation. Although it is clear that differential selection of poly(A) sites can alter gene expression, resulting in significant biological consequences, the mechanisms that regulate polyadenylation are poorly understood. Here we report that the neuron-specific members of a family of RNA-binding proteins, Hu proteins, known to regulate mRNA stability and translation in the cytoplasm, play an important role in polyadenylation regulation. Hu proteins are homologs of the Drosophila embryonic lethal abnormal visual protein and contain three RNA recognition motifs. Using an in vitro polyadenylation assay with HeLa cell nuclear extract and recombinant Hu proteins, we have shown that Hu proteins selectively block both cleavage and poly(A) addition at sites containing U-rich sequences. Hu proteins have no effect on poly(A) sites that do not contain U-rich sequences or sites in which the U-rich sequences are mutated. All three RNA recognition motifs of Hu proteins are required for this activity. Overexpression of HuR in HeLa cells also blocks polyadenylation at a poly(A) signal that contains U-rich sequences. Hu proteins block the interaction between the polyadenylation cleavage stimulation factor 64-kDa subunit and RNA most likely through direct interaction with poly(A) cleavage stimulation factor 64-kDa subunit and cleavage and polyadenylation specificity factor 160-kDa subunit. These studies identify a novel group of mammalian polyadenylation regulators. Furthermore, they define a previously unknown nuclear function of Hu proteins.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44122 USA; Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44122 USA; Case Western Reserve Univ, Ctr RNA Mol Biol, Sch Med, Cleveland, OH 44122 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Lou, H (corresponding author), Case Western Reserve Univ, Dept Genet, 10900 Euclid Ave, Cleveland, OH 44122 USA.	hxl47@case.edu			NINDS NIH HHS [NS-049103-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049103, R56NS049103] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; Arhin GK, 2002, NUCLEIC ACIDS RES, V30, P1842, DOI 10.1093/nar/30.8.1842; Ashiya M, 1997, RNA, V3, P996; Brackenridge S, 2000, MOL CELL BIOL, V20, P2660, DOI 10.1128/MCB.20.8.2660-2669.2000; Brown KM, 2003, MOL CELL, V12, P1467, DOI 10.1016/S1097-2765(03)00453-2; Castelo-Branco P, 2004, MOL CELL BIOL, V24, P4174, DOI 10.1128/MCB.24.10.4174-4183.2004; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Cooke C, 1999, MOL CELL BIOL, V19, P4971; Cooke C, 2002, MOL CELL BIOL, V22, P4579, DOI 10.1128/MCB.22.13.4579-4586.2002; Edmonds M, 2002, PROG NUCLEIC ACID RE, V71, P285, DOI 10.1016/S0079-6603(02)71046-5; Gao FB, 1996, J CELL SCI, V109, P579; Hall-Pogar T, 2005, NUCLEIC ACIDS RES, V33, P2565, DOI 10.1093/nar/gki544; Hu J, 2005, RNA, V11, P1485, DOI 10.1261/rna.2107305; Kaufmann I, 2004, EMBO J, V23, P616, DOI 10.1038/sj.emboj.7600070; Kyburz A, 2006, MOL CELL, V23, P195, DOI 10.1016/j.molcel.2006.05.037; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Lisbin MJ, 2001, GENE DEV, V15, P2546, DOI 10.1101/gad.903101; Lou H, 1999, MOL CELL BIOL, V19, P78; Lou H, 1998, MOL CELL BIOL, V18, P4977, DOI 10.1128/MCB.18.9.4977; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; Lou H, 2001, ENDOCR REV, V22, P205, DOI 10.1210/er.22.2.205; MacDonald CC, 2002, MOL CELL ENDOCRINOL, V190, P1, DOI 10.1016/S0303-7207(02)00044-8; MOREIRA A, 1995, EMBO J, V14, P3809, DOI 10.1002/j.1460-2075.1995.tb00050.x; Moreira A, 1998, GENE DEV, V12, P2522, DOI 10.1101/gad.12.16.2522; Natalizio BJ, 2002, J BIOL CHEM, V277, P42733, DOI 10.1074/jbc.M208070200; Okano HJ, 1997, J NEUROSCI, V17, P3024; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Sachchithananthan M, 2005, NUCLEIC ACIDS RES, V33, P1010, DOI 10.1093/nar/gki245; Shell SA, 2005, J BIOL CHEM, V280, P39950, DOI 10.1074/jbc.M508848200; Soller M, 2003, GENE DEV, V17, P2526, DOI 10.1101/gad.1106703; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; Venkataraman K, 2005, GENE DEV, V19, P1315, DOI 10.1101/gad.1298605; Veraldi KL, 2001, MOL CELL BIOL, V21, P1228, DOI 10.1128/MCB.21.4.1228-1238.2001; Wallace AM, 1999, P NATL ACAD SCI USA, V96, P6763, DOI 10.1073/pnas.96.12.6763; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhao XM, 2005, J VIROL, V79, P4270, DOI 10.1128/JVI.79.7.4270-4288.2005; ZHOU HL, 2006, IN PRESS MOL CELL BI; Zhu H, 2003, MOL CELL BIOL, V23, P5959, DOI 10.1128/MCB.23.17.5959-5971.2003; ZHU H, 2006, MOL BIOL CELL	43	103	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2203	2210		10.1074/jbc.M609349200	http://dx.doi.org/10.1074/jbc.M609349200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17127772	hybrid			2022-12-27	WOS:000243593200011
J	Basu, S; Pathak, SK; Banerjee, A; Pathak, S; Bhattacharyya, A; Yang, ZH; Talarico, S; Kundu, M; Basu, J				Basu, Sanchita; Pathak, Sushil Kumar; Banerjee, Anirban; Pathak, Shresh; Bhattacharyya, Asima; Yang, Zhenhua; Talarico, Sarah; Kundu, Manikuntala; Basu, Joyoti			Execution of macrophage apoptosis by PE_PGRS33 of mycobacterium tuberculosis is mediated by toll-like receptor 2-dependent release of tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PE-PGRS PROTEINS; GRANULOMA-FORMATION; TNF-ALPHA; SIGNALING PATHWAYS; DEFICIENT MICE; CYTOCHROME-C; INFECTION; EXPRESSION; ACTIVATION; GENE	Combating tuberculosis requires a detailed understanding of how mycobacterial effectors modulate the host immune response. The role of the multigene PE family of proteins unique to mycobacteria in the pathogenesis of tuberculosis is still poorly understood, although certain PE_PGRS genes have been linked to virulence. Tumor necrosis factor-alpha(TNF-alpha) is essential for successfully combating tuberculosis. In this study we provide evidence that PE_PGRS33, a surface exposed protein, elicits TNF-alpha release from macrophages in a TLR2 (Toll-like receptor 2)-dependent manner. ASK1 (apoptosis signal-regulating kinase 1) is activated downstream of TLR2. ASK1 activates the MAPKs p38 and JNK. PE_PGRS33-induced signaling leads to enhanced expression of TNF-alpha and TNF receptor I (TNFRI) genes. Mycobacterium smegmatis expressing PE_PGRS33 elicits the same effects as purified PE_PGRS33. TNF-alpha release occurs even when internalization of the bacteria is blocked by cytochalasin D, suggesting that interaction of PE_PGRS33 with TLR2 is sufficient to trigger the effects described. Release of TNF-alpha plays the determining role in triggering apoptosis in macrophages challenged with PE_PGRS33. The death receptor-dependent signals are amplified through classical caspase 8-dependent mitochondrial release of cytochrome c, leading to the activation of caspases 9 and 3. An important aspect of our findings is that deletions within the PGRS domain (simulating those occurring in clinical strains) attenuate the TNF-alpha-inducing ability of PE_PGRS33. These results provide the first evidence that variations in the polymorphic repeats of the PGRS domain modulate the innate immune response.	Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48105 USA	Department of Science & Technology (India); Bose Institute; University of Michigan System; University of Michigan	Basu, J (corresponding author), Bose Inst, Dept Chem, 93-1 Acharya Prafulla Chandra Rd, Kolkata 700009, W Bengal, India.	joyoti@vsnl.com	PATHAK, SHRESH/I-6938-2012	PATHAK, SHRESH/0000-0001-5275-1816; Banerjee, Anirban/0000-0001-7678-1868; Bhattacharyya, Asima/0000-0001-7292-6644				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Balcewicz-Sablinska MK, 1998, J IMMUNOL, V161, P2636; Banu S, 2002, MOL MICROBIOL, V44, P9, DOI 10.1046/j.1365-2958.2002.02813.x; Bean AGD, 1999, J IMMUNOL, V162, P3504; Bhattacharyya A, 2003, J BIOL CHEM, V278, P26517, DOI 10.1074/jbc.M300852200; Brennan MJ, 2001, INFECT IMMUN, V69, P7326, DOI 10.1128/IAI.69.12.7326-7333.2001; Choudhuri BS, 2002, BIOCHEM J, V367, P279, DOI 10.1042/BJ20020615; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Delogu G, 2004, MOL MICROBIOL, V52, P725, DOI 10.1111/j.1365-2958.2004.04007.x; Dheenadhayalan V, 2006, MICROBES INFECT, V8, P262, DOI 10.1016/j.micinf.2005.06.021; Drennan MB, 2004, AM J PATHOL, V164, P49, DOI 10.1016/S0002-9440(10)63095-7; Ehlers S, 1999, INFECT IMMUN, V67, P3571, DOI 10.1128/IAI.67.7.3571-3579.1999; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; Garcia I, 1997, EUR J IMMUNOL, V27, P3182, DOI 10.1002/eji.1830271215; Gardam MA, 2003, LANCET INFECT DIS, V3, P148, DOI 10.1016/S1473-3099(03)00545-0; GODDETTE DW, 1986, J BIOL CHEM, V261, P5974; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Into T, 2005, CELL MICROBIOL, V7, P1305, DOI 10.1111/j.1462-5822.2005.00558.x; Kaneko H, 1999, LAB INVEST, V79, P379; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Leemans JC, 2005, J INFECT DIS, V191, P65, DOI 10.1086/426395; Lopez M, 2003, J IMMUNOL, V170, P2409, DOI 10.4049/jimmunol.170.5.2409; MANOR E, 1986, INFECT IMMUN, V54, P90, DOI 10.1128/IAI.54.1.90-95.1986; Mohan AK, 2004, CLIN INFECT DIS, V39, P295, DOI 10.1086/421494; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pathak SK, 2004, J BIOL CHEM, V279, P55127, DOI 10.1074/jbc.M409885200; Rahman Masmudur M, 2006, PLoS Pathog, V2, pe4; Ramakrishnan L, 2000, SCIENCE, V288, P1436, DOI 10.1126/science.288.5470.1436; Reiling N, 2002, J IMMUNOL, V169, P3480, DOI 10.4049/jimmunol.169.7.3480; Roach DR, 2002, J IMMUNOL, V168, P4620, DOI 10.4049/jimmunol.168.9.4620; Rojas M, 1999, J IMMUNOL, V162, P6122; Sampson SL, 2001, TUBERCULOSIS, V81, P305, DOI 10.1054/tube.2001.0304; Stenger S, 2005, ANN RHEUM DIS, V64, P24, DOI 10.1136/ard.2005.042531; Talarico S, 2005, J CLIN MICROBIOL, V43, P4954, DOI 10.1128/JCM.43.10.4954-4960.2005; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; VANSOOLINGEN D, 1993, J CLIN MICROBIOL, V31, P1987, DOI 10.1128/JCM.31.8.1987-1995.1993; Voskuil MI, 2004, TUBERCULOSIS, V84, P256, DOI 10.1016/j.tube.2003.12.014; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang XD, 2001, GENE DEV, V15, P2922; Winau F, 2006, IMMUNITY, V24, P105, DOI 10.1016/j.immuni.2005.12.001; Yang CS, 2006, CELL MICROBIOL, V8, P1158, DOI 10.1111/j.1462-5822.2006.00699.x; Zganiacz A, 2004, J CLIN INVEST, V113, P401, DOI 10.1172/JCI200418991	46	160	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1039	1050		10.1074/jbc.M604379200	http://dx.doi.org/10.1074/jbc.M604379200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17095513	hybrid			2022-12-27	WOS:000243295200027
J	Belenghi, B; Romero-Puertas, MC; Vercammen, D; Brackenier, A; Inze, D; Delledonne, M; Van Breusegem, F				Belenghi, Beatrice; Romero-Puertas, Maria C.; Vercammen, Dominique; Brackenier, Anouk; Inze, Dirk; Delledonne, Massimo; Van Breusegem, Frank			Metacaspase activity of Arabidopsis thaliana is regulated by S-nitrosylation of a critical cysteine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; IDENTIFICATION; CASPASE-3; PROTEINS; PLAYS; DEATH; NO	Nitric oxide (NO) regulates a number of signaling functions in both animals and plants under several physiological and pathophysiological conditions. S-Nitrosylation linking a nitrosothiol on cysteine residues mediates NO signaling functions of a broad spectrum of mammalian proteins, including caspases, the main effectors of apoptosis. Metacaspases are suggested to be the ancestors of metazoan caspases, and plant metacaspases have previously been shown to be genuine cysteine proteases that autoprocess in a manner similar to that of caspases. We show that S-nitrosylation plays a central role in the regulation of the proteolytic activity of Arabidopsis thaliana metacaspase 9 (AtMC9) and hypothesize that this S-nitrosylation affects the cellular processes in which metacaspases are involved. We found that AtMC9 zymogens are S-nitrosylated at their active site cysteines in vivo and that this posttranslational modification suppresses both AtMC9 autoprocessing and proteolytic activity. However, the mature processed form is not prone to NO inhibition due to the presence of a second S-nitrosylation-insensitive cysteine that can replace the S-nitrosylated cysteine residue within the catalytic center of the processed AtMC9. This cysteine is absent in caspases and paracaspases but is conserved in all reported metacaspases.	Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; Univ Ghent VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium	University of Verona; Flanders Institute for Biotechnology (VIB); Ghent University	Van Breusegem, F (corresponding author), Univ Verona, Dipartimento Sci & Tecnol, Str Grazie,15, I-37134 Verona, Italy.	frank.vanbreusegem@psb.ugent.be	Delledonne, Massimo/O-8685-2017; Van Breusegem, Frank/AAJ-2647-2020; Puertas, Maria Romero/S-2845-2019; Romero-Puertas, Maria C/H-4724-2015; Vercammen, Dominique/A-4237-2008; Inzé, Dirk/AAW-6381-2021; Van Breusegem, Frank/Y-2999-2019	Van Breusegem, Frank/0000-0002-3147-0860; Puertas, Maria Romero/0000-0002-4854-896X; Romero-Puertas, Maria C/0000-0002-4854-896X; Inzé, Dirk/0000-0002-3217-8407; Delledonne, Massimo/0000-0002-7100-4581				Bethke PC, 2004, PLANT CELL, V16, P332, DOI 10.1105/tpc.017822; Bozhkov PV, 2005, P NATL ACAD SCI USA, V102, P14463, DOI 10.1073/pnas.0506948102; Brune B, 2001, CURR PROTEIN PEPT SC, V2, P61, DOI 10.2174/1389203013381206; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Colosimo A, 1999, BIOTECHNIQUES, V26, P870, DOI 10.2144/99265bm15; Correa-Aragunde N, 2004, PLANTA, V218, P900, DOI 10.1007/s00425-003-1172-7; Crawford NM, 2006, J EXP BOT, V57, P471, DOI 10.1093/jxb/erj050; DeLano W.L., 2000, PYMOL MOL GRAPHICS S; Delledonne M, 2005, CURR OPIN PLANT BIOL, V8, P390, DOI 10.1016/j.pbi.2005.05.002; Gabaldon C, 2005, NEW PHYTOL, V165, P121, DOI 10.1111/j.1469-8137.2004.01230.x; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Karimi M, 2002, TRENDS PLANT SCI, V7, P193, DOI 10.1016/S1360-1385(02)02251-3; Lindermayr C, 2006, J BIOL CHEM, V281, P4285, DOI 10.1074/jbc.M511635200; Lindermayr C, 2005, PLANT PHYSIOL, V137, P921, DOI 10.1104/pp.104.058719; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Mannick JB, 2004, FREE RADICAL RES, V38, P1, DOI 10.1080/10715760310001629065; Mitchell DA, 2005, NAT CHEM BIOL, V1, P154, DOI 10.1038/nchembio720; Mottram JC, 2003, TRENDS PARASITOL, V19, P182, DOI 10.1016/S1471-4922(03)00038-2; Perazzolli M, 2004, PLANT CELL, V16, P2785, DOI 10.1105/tpc.104.025379; Planchet E, 2005, PLANT J, V41, P732, DOI 10.1111/j.1365-313X.2005.02335.x; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Szallies A, 2002, FEBS LETT, V517, P144, DOI 10.1016/S0014-5793(02)02608-X; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Vercammen D, 2004, J BIOL CHEM, V279, P45329, DOI 10.1074/jbc.M406329200; Vercammen D, 2006, J MOL BIOL, V364, P625, DOI 10.1016/j.jmb.2006.09.010; Woltering EJ, 2002, PLANT PHYSIOL, V130, P1764, DOI 10.1104/pp.006338	31	168	178	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1352	1358		10.1074/jbc.M608931200	http://dx.doi.org/10.1074/jbc.M608931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17110382	hybrid			2022-12-27	WOS:000243295200061
J	Clarke, CJ; Truong, TG; Hannun, YA				Clarke, Christopher J.; Truong, Thach-Giao; Hannun, Yusuf A.			Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (VCAM) in lung epithelial cells - p38 MAPK is an upstream regulator of nSMase2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SPHINGOSINE KINASE PATHWAY; ACTIVATED PROTEIN-KINASE; VEIN ENDOTHELIAL-CELLS; SIGNALING PATHWAYS; ICAM-1 EXPRESSION; INDUCED APOPTOSIS; CERAMIDE; INVOLVEMENT; PHOSPHORYLATION	Neutral sphingomyelinases (N-SMases) are major candidates for stress-induced ceramide production. However, there is little information on the physiological regulation and roles of the cloned N-SMase enzyme, nSMase2. In this study, nSMase2 was found to translocate acutely to the plasma membrane of A549 epithelial cells in response to tumor necrosis factor alpha(TNF-alpha) in a time- and dose-dependent manner. Additionally, TNF-alpha increased N-SMase activity rapidly and transiently both endogenously and in cells overexpressing nSMase2. Furthermore, the translocation of nSMase2 was regulated by p38-alpha MAPK, but not ERK or JNK, and the increase in endogenous N-SMase activity was abrogated by p38 MAPK inhibition. In addition, both p38-alpha MAPK and nSMase2 were implicated in the TNF-alpha-stimulated up-regulation of the adhesion proteins vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM), but this was largely independent of NF-kappa B activation. These data reveal p38 MAPK as an upstream regulator of nSMase2 and indicate a role for nSMase2 in pro- inflammatory responses induced by TNF-alpha as a regulator of adhesion proteins.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	hannun@musc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; Billich A, 2005, CELL SIGNAL, V17, P1203, DOI 10.1016/j.cellsig.2004.12.005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen CC, 2001, CELL SIGNAL, V13, P543, DOI 10.1016/S0898-6568(01)00171-1; Chen CC, 2001, MOL PHARMACOL, V59, P493, DOI 10.1124/mol.59.3.493; De Palma C, 2006, ARTERIOSCL THROM VAS, V26, P99, DOI 10.1161/01.ATV.0000194074.59584.42; Grethe S, 2004, EXP CELL RES, V298, P632, DOI 10.1016/j.yexcr.2004.05.007; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Holden NS, 2004, EUR J BIOCHEM, V271, P785, DOI 10.1111/j.1432-1033.2004.03982.x; Jain RG, 1998, ADV ENZYME REGUL, V38, P333, DOI 10.1016/S0065-2571(97)00007-1; Kang JS, 2006, MOL PHARMACOL, V69, P941, DOI 10.1124/mol.105.017442; Karakashian AA, 2004, FASEB J, V18, P968, DOI 10.1096/fj.03-0875fje; Katan M, 2003, ADV ENZYME REGUL, V43, P77, DOI 10.1016/S0065-2571(02)00027-4; Kong JY, 2005, MOL CELL BIOCHEM, V278, P39, DOI 10.1007/s11010-005-1979-6; Kronke M, 1999, CHEM PHYS LIPIDS, V102, P157, DOI 10.1016/S0009-3084(99)00084-5; Krut O, 2006, J BIOL CHEM, V281, P13784, DOI 10.1074/jbc.M511306200; Lee CW, 2006, J CELL PHYSIOL, V207, P174, DOI 10.1002/jcp.20549; Levy M, 2006, BIOCHEM BIOPH RES CO, V344, P900, DOI 10.1016/j.bbrc.2006.04.013; Mallampalli RK, 1999, AM J PHYSIOL-LUNG C, V276, pL481, DOI 10.1152/ajplung.1999.276.3.L481; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Neumeyer J, 2006, EXP CELL RES, V312, P2142, DOI 10.1016/j.yexcr.2006.03.014; Pettersen CA, 2002, CHEST, V121, p142S, DOI 10.1378/chest.121.5_suppl.142S; Radi ZA, 2001, J VET INTERN MED, V15, P516, DOI 10.1892/0891-6640(2001)015&lt;0516:CAMLTA&gt;2.3.CO;2; Rosette C, 2005, CARCINOGENESIS, V26, P943, DOI 10.1093/carcin/bgi070; Shafer LM, 2005, BBA-MOL CELL RES, V1745, P393, DOI 10.1016/j.bbamcr.2005.07.002; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHERN JA, 1991, J GEN VIROL, V72, P1551, DOI 10.1099/0022-1317-72-7-1551; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Willaime S, 2001, EUR J NEUROSCI, V13, P2037, DOI 10.1046/j.0953-816x.2001.01581.x; Woo CH, 2005, AM J PHYSIOL-LUNG C, V288, pL307, DOI 10.1152/ajplung.00105.2004; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499	38	81	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1384	1396		10.1074/jbc.M609216200	http://dx.doi.org/10.1074/jbc.M609216200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17085432	hybrid			2022-12-27	WOS:000243295200064
J	Leipold, MD; Kaniuk, NA; Whitfield, C				Leipold, Michael D.; Kaniuk, Natalia A.; Whitfield, Chris			The C-terminal domain of the Escherichia coli WaaJ glycosyltransferase is important for catalytic activity and membrane association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; CORE OLIGOSACCHARIDE; SALMONELLA LIPOPOLYSACCHARIDE; NEISSERIA-MENINGITIDIS; POLYACRYLAMIDE GELS; CRYSTAL-STRUCTURE; OUTER-MEMBRANE; ENZYMES; COMPLEX; PURIFICATION	The waaJ gene encodes an alpha-1,2-glucosyltransferase involved in the synthesis of the outer core region of the lipopolysaccharide of some Escherichia coli and Salmonella isolates. WaaJ belongs to glycosyltransferase CAZy family 8, characterized by the GT-A fold, a DXD motif, and by retention of configuration at the anomeric carbon of the donor sugar. Detailed kinetic and structural information for bacterial family 8 glycosyltransferases has resulted from studies of Neisseria meningitidis LgtC. As many as 28 amino acids could be deleted from the C terminus of LgtC without affecting its in vitro catalytic behavior. This C-terminal domain has a high ratio of positively charged and hydrophobic residues, a feature conserved in WaaJ and some other family 8 representatives. Unexpectedly, deletion of as few as five residues from the C terminus of WaaJ resulted in substantially reduced in vivo activity. With deletions of 15 residues or less, activity was only detected when levels of expression were elevated. No in vivo activity was detected after the removal of 20 amino acids, regardless of expression levels. Longer deletions (20 residues and greater) compromised the ability of WaaJ to associate with the membrane. However, the reduced in vivo activity in enzymes lacking 5-12 C-terminal residues also reflected a dramatic drop in catalytic activity in vitro (a 294-fold decrease in the apparent k(cat)/K-m,(LPS)). Deletions removing 20 or more residues resulted in a protein showing no detectable in vitro activity. Therefore, the C-terminal domain of WaaJ plays a critical role in enzyme function.	Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of Guelph	Whitfield, C (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca	Leipold, Michael/A-9452-2013	Leipold, Michael/0000-0001-5389-0906				ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; Amor K, 2000, INFECT IMMUN, V68, P1116, DOI 10.1128/IAI.68.3.1116-1124.2000; Boix E, 2001, J BIOL CHEM, V276, P48608, DOI 10.1074/jbc.M108828200; Doerrler WT, 2006, MOL MICROBIOL, V60, P542, DOI 10.1111/j.1365-2958.2006.05130.x; ENDO A, 1969, BIOCHEMISTRY-US, V8, P3508, DOI 10.1021/bi00837a004; GALANOS C, 1993, METHODS CARBOHYDR CH, V9, P11; Gibbons BJ, 2002, J MOL BIOL, V319, P463, DOI 10.1016/S0022-2836(02)00305-4; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAISHIMA Y, 1992, EUR J BIOCHEM, V203, P127, DOI 10.1111/j.1432-1033.1992.tb19837.x; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; KADAM SK, 1985, J BACTERIOL, V161, P277, DOI 10.1128/JB.161.1.277-284.1985; Kaniuk NA, 2004, J BIOL CHEM, V279, P31237, DOI 10.1074/jbc.M401879200; Kaniuk NA, 2002, MOL MICROBIOL, V46, P1305, DOI 10.1046/j.1365-2958.2002.03243.x; KARKHANIS YD, 1978, ANAL BIOCHEM, V85, P595, DOI 10.1016/0003-2697(78)90260-9; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lairson LL, 2004, J BIOL CHEM, V279, P28339, DOI 10.1074/jbc.M400451200; LEVY SB, 1970, J BIOL CHEM, V245, P585; Lougheed B, 1999, J BIOL CHEM, V274, P37717, DOI 10.1074/jbc.274.53.37717; MULLER E, 1972, J BIOL CHEM, V247, P2614; Olsthoorn MMA, 1998, J BIOL CHEM, V273, P3817, DOI 10.1074/jbc.273.7.3817; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; SCHMIDT G, 1969, EUR J BIOCHEM, V10, P501, DOI 10.1111/j.1432-1033.1969.tb00717.x; SCHMIDT G, 1970, EUR J BIOCHEM, V14, P357, DOI 10.1111/j.1432-1033.1970.tb00297.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Wakarchuk WW, 1998, PROTEIN ENG, V11, P295, DOI 10.1093/protein/11.4.295; WEISER MM, 1968, J BIOL CHEM, V243, P1320; Zhang YN, 2003, BIOCHEMISTRY-US, V42, P13512, DOI 10.1021/bi035430r	32	18	18	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1257	1264		10.1074/jbc.M608164200	http://dx.doi.org/10.1074/jbc.M608164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17090541	hybrid			2022-12-27	WOS:000243295200051
J	Sun, JJ; Vernier, G; Wigelsworth, DJ; Collier, RJ				Sun, Jianjun; Vernier, Gregory; Wigelsworth, Darran J.; Collier, R. John			Insertion of anthrax protective antigen into liposomal membranes - Effects of a receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; PROTEIN TRANSLOCATION; CRYSTAL-STRUCTURE; CHELATING LIPIDS; LETHAL FACTOR; FRAGMENT-B; LOW-PH; PORE; CELLS; CONVERSION	Protective antigen (PA), the receptor-binding component of anthrax toxin, heptamerizes and inserts into the endosomal membrane at acidic pH, forming a pore that mediates translocation of the enzymic components of the toxin to the cytosol. When the heptameric pre-insertion form of PA (the prepore) is acidified in solution, it rapidly loses the ability to insert into membranes. To maximize insertion into model membranes, we examined two ways to bind the protein to large unilamellar vesicles (LUV). One involved attaching a His tag to the von Willebrand factor A domain of one of the PA receptors, ANTXR2, and using this protein as a bridge to bind PA to LUV containing a nickel-chelating lipid. The other involved using a His tag fused to the C terminus of PA to bind the protein directly to LUV containing the same lipid. Both ways enhanced pore formation at pH 5.0 strongly and about equally, as measured by the release of K+. Controls showed that pore formation in this system faithfully reproduced that in vivo. We also showed that binding unmodified ANTXR2 von Willebrand factor A to the prepore in solution enhanced its pore forming activity by slowing its inactivation at acidic pH. These findings indicate that an important role of PA receptors is to promote partitioning of PA into the bilayer by maintaining the prepore close to the target membrane and presumably in the optimal orientation as it undergoes the acidic pH-dependent conformational transition to the pore.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Collier, RJ (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	jcollier@hms.harvard.edu	Sun, Jianjun/B-1525-2009	Collier, R John/0000-0002-2427-4239	NIAID NIH HHS [P01 AI 56013, AI 48489, R01 AI 22021] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI056013, R01AI048489, R01AI022021] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barth H, 2004, MICROBIOL MOL BIOL R, V68, P373, DOI 10.1128/MMBR.68.3.373-402.2004; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BOQUET P, 1979, EUR J BIOCHEM, V100, P483, DOI 10.1111/j.1432-1033.1979.tb04192.x; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Bubeck D, 2005, NAT STRUCT MOL BIOL, V12, P615, DOI 10.1038/nsmb955; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CABIAUX V, 1984, BIOCHIM BIOPHYS ACTA, V775, P31, DOI 10.1016/0005-2736(84)90231-1; Chikh GG, 2002, BBA-BIOMEMBRANES, V1567, P204, DOI 10.1016/S0005-2736(02)00618-1; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Dalla Serra M, 2003, METHOD ENZYMOL, V372, P99; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; FALMAGNE P, 1982, TOXICON, V20, P243, DOI 10.1016/0041-0101(82)90209-4; JANSONS VK, 1983, BIOCHIM BIOPHYS ACTA, V735, P433, DOI 10.1016/0005-2736(83)90159-1; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; Krantz BA, 2006, J MOL BIOL, V355, P968, DOI 10.1016/j.jmb.2005.11.030; Krantz BA, 2005, SCIENCE, V309, P777, DOI 10.1126/science.1113380; KUBALEK EW, 1994, J STRUCT BIOL, V113, P117, DOI 10.1006/jsbi.1994.1039; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P13147, DOI 10.1073/pnas.0405405101; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Nguyen TL, 2004, J BIOMOL STRUCT DYN, V22, P253, DOI 10.1080/07391102.2004.10531226; Nieba L, 1997, ANAL BIOCHEM, V252, P217, DOI 10.1006/abio.1997.2326; Pack DW, 1997, CHEM PHYS LIPIDS, V86, P135, DOI 10.1016/S0009-3084(97)02662-5; PAPINI E, 1987, EUR J BIOCHEM, V169, P629, DOI 10.1111/j.1432-1033.1987.tb13654.x; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Qa'dan M, 2005, MOL CELL BIOL, V25, P5492, DOI 10.1128/MCB.25.13.5492-5498.2005; Rainey GJA, 2005, P NATL ACAD SCI USA, V102, P13278, DOI 10.1073/pnas.0505865102; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Sellman BR, 2001, J BIOL CHEM, V276, P8371, DOI 10.1074/jbc.M008309200; Sellman BR, 2001, SCIENCE, V292, P695, DOI 10.1126/science.109563; Tuthill TJ, 2006, J VIROL, V80, P172, DOI 10.1128/JVI.80.1.172-180.2006; Wigelsworth DJ, 2004, J BIOL CHEM, V279, P23349, DOI 10.1074/jbc.M401292200; Wolfe JT, 2005, J BIOL CHEM, V280, P39417, DOI 10.1074/jbc.M509049200; Zhang S, 2004, BIOPHYS J, V87, P3842, DOI 10.1529/biophysj.104.050864	38	42	42	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1059	1065		10.1074/jbc.M609869200	http://dx.doi.org/10.1074/jbc.M609869200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17107945	hybrid			2022-12-27	WOS:000243295200029
J	Ahn, KS; Sethi, G; Krishnan, K; Aggarwal, BB				Ahn, Kwang Seok; Sethi, Gautam; Krishnan, Koyamangalath; Aggarwal, Bharat B.			gamma-tocotrienol inhibits nuclear factor-kappa B signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and Potentiation of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; BREAST-CANCER CELLS; MAMMARY EPITHELIAL-CELLS; ALPHA KINASE ACTIVATION; PALM-OIL TOCOTRIENOLS; VITAMIN-E; PROSTATE-CANCER; IN-VITRO; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS	Unlike the tocopherols, the tocotrienols, also members of the vitamin E family, have an unsaturated isoprenoid side chain. In contrast to extensive studies on tocopherol, very little is known about tocotrienol. Because the nuclear factor-kappa B (NF-kappa B) pathway has a central role in tumorigenesis, we investigated the effect of gamma-tocotrienol on the NF-kappa B pathway. Although gamma-tocotrienol completely abolished tumor necrosis factor alpha (TNF)-induced NF-kappa B activation, a similar dose of gamma-tocopherol had no effect. Besides TNF, gamma-tocotrienol also abolished NF-kappa B activation induced by phorbol myristate acetate, okadaic acid, lipopolysaccharide, cigarette smoke, interleukin-1 beta, and epidermal growth factor. Constitutive NF-kappa B activation expressed by certain tumor cells was also abrogated by gamma-tocotrienol. Reducing agent had no effect on the gamma-tocotrienol-induced down-regulation of NF-kappa B. Mevalonate reversed the NF-kappa B inhibitory effect of gamma-tocotrienol, indicating the role of hydroxymethylglutaryl-CoA reductase. gamma-Tocotrienol blocked TNF-induced phosphorylation and degradation of I kappa B alpha through the inhibition of I kappa B alpha kinase activation, thus leading to the suppression of the phosphorylation and nuclear translocation of p65. gamma-Tocotrienol also suppressed NF-kappa B-dependent reporter gene transcription induced by TNF, TNFR1, TRADD, TRAF2, TAK1, receptor-interacting protein, NIK, and I kappa B alpha kinase but not that activated by p65. Additionally, the expressions of NF-kappa B-regulated gene products associated with antiapoptosis (IAP1, IAP2, Bcl-xL, Bcl-2, cFLIP, XIAP, Bfl-1/A1, TRAF1, and Survivin), proliferation (cyclin D1, COX2, and c-Myc), invasion (MMP-9 and ICAM-1), and angiogenesis (vascular endothelial growth factor) were down-regulated by gamma-tocotrienol. This correlated with potentiation of apoptosis induced by TNF, paclitaxel, and doxorubicin. Overall, our results demonstrate that gamma-tocotrienol inhibited the NF-kappa B activation pathway, leading to down-regulation of various gene products and potentiation of apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Sect, Houston, TX 77030 USA; E Tennessee State Univ, Dept Internal Med, Div Hematol Oncol, Johnson City, TN 37614 USA	University of Texas System; UTMD Anderson Cancer Center; East Tennessee State University	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Sect, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013; Sethi, Gautam/F-2372-2011; Ahn, Kwang Seok/G-4249-2013	Sethi, Gautam/0000-0002-8677-8475; 	NATIONAL CANCER INSTITUTE [P50CA097007, P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA97007, P01 CA91844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal MK, 2004, CELL CYCLE, V3, P205; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; AHN KS, 2006, IN PRESS J IMMUNOL; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; Azlina MFN, 2005, ASIA PAC J CLIN NUTR, V14, P358; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Birringer M, 2002, J NUTR, V132, P3113, DOI 10.1093/jn/131.10.3113; Black TM, 2000, J NUTR, V130, P2420, DOI 10.1093/jn/130.10.2420; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Chiang YM, 2005, BRIT J PHARMACOL, V146, P352, DOI 10.1038/sj.bjp.0706343; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cominacini L, 2005, J AM COLL CARDIOL, V46, P799, DOI 10.1016/j.jacc.2005.05.063; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Eitsuka T, 2006, BIOCHEM BIOPH RES CO, V348, P170, DOI 10.1016/j.bbrc.2006.07.029; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Galli F, 2004, ARCH BIOCHEM BIOPHYS, V423, P97, DOI 10.1016/j.abb.2003.11.014; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; GOH SH, 1994, INT J CANCER, V57, P529, DOI 10.1002/ijc.2910570415; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOULD MN, 1991, AM J CLIN NUTR, V53, pS1068, DOI 10.1093/ajcn/53.4.1068S; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guthrie N, 1997, J NUTR, V127, pS544, DOI 10.1093/jn/127.3.544S; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HAYES KC, 1993, P SOC EXP BIOL MED, V202, P353, DOI 10.3181/00379727-202-43546; He L, 1997, J NUTR, V127, P668, DOI 10.1093/jn/127.5.668; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Iqbal J, 2004, EUR J CANCER PREV, V13, P515, DOI 10.1097/00008469-200412000-00009; JACKSONBERNITSA.DG, 2006, IN PRESS ONCOGENE; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; John Anitha, 2001, Pathology and Oncology Research, V7, P14; KamalEldin A, 1996, LIPIDS, V31, P671, DOI 10.1007/BF02522884; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kumar KS, 2006, LIFE SCI, V78, P2099, DOI 10.1016/j.lfs.2005.12.005; Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McIntyre BS, 2000, P SOC EXP BIOL MED, V224, P292, DOI 10.1046/j.1525-1373.2000.22434.x; Miyazawa T, 2004, BIOCHEMISTRY-MOSCOW+, V69, P67, DOI 10.1023/B:BIRY.0000016353.18007.39; Naito Y, 2005, ATHEROSCLEROSIS, V180, P19, DOI 10.1016/j.atherosclerosis.2004.11.017; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nesaretnam K, 2000, INT J FOOD SCI NUTR, V51, pS95, DOI 10.1080/096374800750049611; NGAH WZW, 1991, AM J CLIN NUTR, V53, pS1076, DOI 10.1093/ajcn/53.4.1076S; Noguchi N, 2003, FREE RADICAL BIO MED, V34, P1614, DOI 10.1016/S0891-5849(03)00216-8; Ozes ON, 1999, NATURE, V401, P82; Pacifico F, 2006, BIOCHEM PHARMACOL, V72, P1142, DOI 10.1016/j.bcp.2006.07.032; PARKER RA, 1993, J BIOL CHEM, V268, P11230; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Prabhu KS, 2002, BIOCHEM J, V366, P203, DOI 10.1042/BJ20020256; QURESHI AA, 1991, AM J CLIN NUTR, V53, pS1021, DOI 10.1093/ajcn/53.4.1021S; QURESHI AA, 1991, AM J CLIN NUTR, V53, pS1042, DOI 10.1093/ajcn/53.4.1042S; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sandur SK, 2006, J BIOL CHEM, V281, P17023, DOI 10.1074/jbc.M601595200; Sen CK, 2006, LIFE SCI, V78, P2088, DOI 10.1016/j.lfs.2005.12.001; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Shah S, 2003, NUTR CANCER, V45, P236, DOI 10.1207/S15327914NC4502_14; Shah S, 2004, EXP BIOL MED, V229, P745, DOI 10.1177/153537020422900806; Shah SJ, 2005, EXP BIOL MED, V230, P235; Shain KH, 1999, J CELL BIOCHEM, V73, P237, DOI 10.1002/(SICI)1097-4644(19990501)73:2<237::AID-JCB10>3.0.CO;2-H; Shishodia S, 2004, J BIOL CHEM, V279, P47148, DOI 10.1074/jbc.M408093200; Shishodia S, 2005, BIOCHEM PHARMACOL, V70, P700, DOI 10.1016/j.bcp.2005.04.043; Shun MC, 2004, NUTR CANCER, V48, P95, DOI 10.1207/s15327914nc4801_13; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Song BL, 2006, J BIOL CHEM, V281, P25054, DOI 10.1074/jbc.M605575200; Srivastava JK, 2006, BIOCHEM BIOPH RES CO, V346, P447, DOI 10.1016/j.bbrc.2006.05.147; SUZUKI Y, 1993, BIOCHEMISTRY-US, V32, P10692, DOI 10.1021/bi00091a020; Sylvester PW, 2005, ASIA PAC J CLIN NUTR, V14, P366; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Theriault A, 2002, ATHEROSCLEROSIS, V160, P21, DOI 10.1016/S0021-9150(01)00540-8; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wada S, 2005, CANCER LETT, V229, P181, DOI 10.1016/j.canlet.2005.06.036; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamoto Yumi, 2001, Current Molecular Medicine (Hilversum), V1, P287; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Yu WP, 1999, NUTR CANCER, V33, P26, DOI 10.1080/01635589909514744; Zhang WJ, 2001, FASEB J, V15, P2423, DOI 10.1096/fj.01-0260com; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8	93	203	213	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					809	820		10.1074/jbc.M610028200	http://dx.doi.org/10.1074/jbc.M610028200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17114179	hybrid, Green Published			2022-12-27	WOS:000243166500086
J	Pilkinton, M; Sandoval, R; Song, J; Ness, SA; Colamonici, OR				Pilkinton, Mark; Sandoval, Raudel; Song, Julie; Ness, Scott A.; Colamonici, Oscar R.			Mip/LIN-9 regulates the expression of B-Myb and the induction of cyclin A, cyclin B, and CDK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; C-MYB; TRANSCRIPTION; ACTIVATION; PROTEIN; PHOSPHORYLATION; DIFFERENTIATION; IDENTIFICATION; REPRESSION; DROSOPHILA	Members of the novel family of proteins that include Drosophila Mip130, Caenorhabditis elegans LIN-9, and mammalian LIN-9 intervene in different cellular functions such as regulation of transcription, differentiation, transformation, and cell cycle progression. Here we demonstrate that LIN-9, designated as Mip/LIN-9, interacts with B-Myb but not with c-Myb or A-Myb. Mip/LIN-9 regulates the expression of B-Myb in a post-transcriptional manner, and its depletion not only decreases the level of the B-Myb protein but also affects the expression of S phase and mitotic genes (i.e. cyclin A, CDK1, and cyclin B). The critical role of Mip/LIN-9 on the expression of S and G(2)/M genes is further supported by the finding that coexpression of Mip/ LIN-9 and B-Myb results in the activation of cyclin A and cyclin B promoter-luciferase reporters, and both proteins are detected on the cyclin A and B promoters. Interestingly, although Mip/ LIN-9 promoter occupancy peaks earlier than B-Myb, the highest levels of expression of cyclins A and B correlate with the maximum binding of B-Myb to these promoters. These data support the concept that Mip/LIN-9 is required for the expression of B-Myb, and both proteins collaborate in the control of the cell cycle progression via the regulation of S phase and mitotic cyclins.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of New Mexico; University of New Mexico's Health Sciences Center	Colamonici, OR (corresponding author), Univ Illinois, Dept Pharmacol, 835 S wolcott,Rm E403,MC 869, Chicago, IL 60612 USA.	ocolamon@uic.edu	Ness, Scott/AAV-4009-2020	Ness, Scott/0000-0001-6965-8909	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32DK07739] Funding Source: Medline; NIGMS NIH HHS [GM54709] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlbory DR, 2005, ONCOGENE, V24, P7127, DOI 10.1038/sj.onc.1208869; ARAP W, 1995, CANCER RES, V55, P1351; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; Beall EL, 2004, GENE DEV, V18, P1667, DOI 10.1101/gad.1206604; Beitel GJ, 2000, GENE, V254, P253, DOI 10.1016/S0378-1119(00)00296-1; Bhatt AM, 2004, GENE, V336, P219, DOI 10.1016/j.gene.2004.03.033; FERGUSON EL, 1989, GENETICS, V123, P109; Gagrica S, 2004, EMBO J, V23, P4627, DOI 10.1038/sj.emboj.7600470; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Lei WL, 2005, BLOOD, V105, P3855, DOI 10.1182/blood-2004-08-3342; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Masselink H, 2001, CANCER LETT, V171, P87, DOI 10.1016/S0304-3835(01)00631-0; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Robinson C, 1996, ONCOGENE, V12, P1855; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1999, J CELL PHYSIOL, V179, P245; Sandoval R, 2006, EXP CELL RES, V312, P2465, DOI 10.1016/j.yexcr.2006.04.002; Santilli G, 2005, J BIOL CHEM, V280, P15628, DOI 10.1074/jbc.M411747200; Saville MK, 1998, ADV CANCER RES, V72, P109; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; White-Cooper H, 1998, DEVELOPMENT, V125, P125; White-Cooper H, 2000, DEVELOPMENT, V127, P5463; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	41	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					168	175		10.1074/jbc.M609924200	http://dx.doi.org/10.1074/jbc.M609924200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17098733	hybrid			2022-12-27	WOS:000243166500020
J	Kedde, M; Sage, CI; Duursma, A; Zlotorynski, E; van Leeuwen, B; Nijkamp, W; Beijersbergen, R; Agami, R				Kedde, Martijn; Sage, Carlos Ie; Duursma, Anja; Zlotorynski, Eitan; van Leeuwen, Bart; Nijkamp, Wouter; Beijersbergen, Roderick; Agami, Reuven			Telomerase-independent regulation of ATR by human telomerase RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMORTAL HUMAN-CELLS; DNA-DAMAGE; MULTISTAGE PATHOGENESIS; REVERSE-TRANSCRIPTASE; PROLIFERATION INDEX; CYCLE ARREST; EXPRESSION; COMPONENT; INHIBITION; LENGTH	The human telomerase RNA ( hTR), together with the telomerase reverse transcriptase, hTERT, constitute the core components of telomerase that is essential for telomere maintenance. While hTR is ubiquitously expressed, hTERT is normally restricted to germ cells and certain stem cells, but both are often deregulated during tumorigenesis. Here, we investigated the effects of changes in hTR cellular levels. Surprisingly, while inhibition of hTR expression triggers a rapid, telomerase- independent, growth arrest associated with p53 and CHK1 activation, its increased expression neutralizes activation of these pathways in response to genotoxic stress. These hTR effects are mediated through ATR and are sufficiently strong to impair ATR- mediated DNA- damage checkpoint responses. Furthermore, in response to low UV radiation, which activates ATR, endogenous hTR levels increase irrespective of telomerase status. Thus, we uncovered a novel, telomerase- independent, function of hTR that restrains ATR activity and participates in the recovery of cells from UV radiation.	Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Agami, R (corresponding author), Netherlands Canc Inst, Div Tumor Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.agami@nki.nl	Kedde, Martijn/F-9716-2016; agami, reuven/GOG-8289-2022	Beijersbergen, Roderick/0000-0003-0116-4130; Agami, Reuven/0000-0002-2848-2473				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Brown DF, 1997, J NEUROPATH EXP NEUR, V56, P1349, DOI 10.1097/00005072-199712000-00009; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Busby EC, 2000, CANCER RES, V60, P2108; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Chiang YJ, 2004, MOL CELL BIOL, V24, P7024, DOI 10.1128/MCB.24.16.7024-7031.2004; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; di Fagagna FD, 2004, GENE DEV, V18, P1781, DOI 10.1101/gad.1214504; Dome JS, 2005, J CLIN ONCOL, V23, P9138, DOI 10.1200/JCO.2005.00.562; Duursma A, 2005, MOL CELL BIOL, V25, P6937, DOI 10.1128/MCB.25.16.6937-6947.2005; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Li S, 2005, J BIOL CHEM, V280, P23709, DOI 10.1074/jbc.M502782200; Li S, 2004, CANCER RES, V64, P4833, DOI 10.1158/0008-5472.CAN-04-0953; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Maitra A, 1999, CANCER-AM CANCER SOC, V85, P741, DOI 10.1002/(SICI)1097-0142(19990201)85:3<741::AID-CNCR25>3.0.CO;2-6; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Morales CP, 1998, CANCER, V83, P652, DOI 10.1002/(SICI)1097-0142(19980815)83:4<652::AID-CNCR4>3.0.CO;2-M; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; Rushing EJ, 1997, J NEUROPATH EXP NEUR, V56, P1142, DOI 10.1097/00005072-199710000-00008; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Scheel C, 2001, ONCOGENE, V20, P3835, DOI 10.1038/sj.onc.1204493; Scherr M, 2005, GENE THER, V12, P12, DOI 10.1038/sj.gt.3302328; Schwartz M, 2006, CANCER LETT, V232, P13, DOI 10.1016/j.canlet.2005.07.039; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Takata H, 2005, MOL CELL, V17, P573, DOI 10.1016/j.molcel.2005.01.014; Takata H, 2004, MOL CELL, V14, P515, DOI 10.1016/S1097-2765(04)00262-X; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Vespa L, 2005, GENE DEV, V19, P2111, DOI 10.1101/gad.1333805; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Wright WE, 1996, DEV GENET, V18, P173; Yashima K, 1998, CLIN CANCER RES, V4, P229; Yashima K, 1997, CANCER RES, V57, P2373; Yi XM, 1999, MOL CELL BIOL, V19, P3989; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	71	59	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40503	40514		10.1074/jbc.M607676200	http://dx.doi.org/10.1074/jbc.M607676200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17098743	hybrid			2022-12-27	WOS:000243033900080
J	Zihni, C; Mitsopoulos, C; Tavares, IA; Baum, B; Ridley, AJ; Morris, JDH				Zihni, Ceniz; Mitsopoulos, Costas; Tavares, Ignatius A.; Baum, Buzz; Ridley, Anne J.; Morris, Jonathan D. H.			Prostate-derived sterile 20-like kinase 1-alpha induces apoptosis - JNK- and caspase-dependent nuclear localization is a requirement for membrane blebbing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; N-TERMINAL KINASE; PROTEIN-KINASE; STE20-RELATED KINASE; MEDIATED ACTIVATION; SCAFFOLD PROTEINS; HISTONE H2B; ROCK-I; CLEAVAGE; PHOSPHORYLATION	We have demonstrated previously that full-length prostate-derived sterile 20-like kinase 1-alpha (PSK1-alpha) binds to microtubules via its C terminus and regulates their organization and stability independently of its catalytic activity. Here we have shown that apoptotic and microtubule-disrupting agents promote catalytic activation, C-terminal cleavage, and nuclear translocation of endogenous phosphoserine 181 PSK1-a and activated N-terminal PSK1-alpha-induced apoptosis. PSK1-a, unlike its novel isoform PSK1-beta, stimulated the c-jun N-terminal kinase (JNK) pathway, and the nucleajr localization of PSK1-alpha and its induction of cell contraction, membrane blebbing, and apoptotic body formation were dependent on JNK activity. PSK1-alpha was also a caspase substrate, and the broad spectrum caspase inhibitor benzyloxycarbonyl-VAD-fluoromethyl ketone or mutation of a putative caspase recognition motif ((916)DPGD(919)) blocked nuclear localization of PSK1-a and its induction of membrane blebs. Additional inhibition of caspase 9 was needed to prevent cell contraction. PSK1-a is therefore a bifunctional kinase that associates with microtubules, and JNK-and caspase-mediated removal of its C-terminal microtubule-binding domain permits nuclear translocation of the N-terminal region of PSK1-alpha and its induction of apoptosis.	Kings Coll London, Rayne Inst, London SE5 9NU, England; UCL Branch, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; King's College London; Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Morris, JDH (corresponding author), Kings Coll London, Rayne Inst, 123 Coldharbour Lane, London SE5 9NU, England.	jonathan.morris@kcl.ac.uk		Baum, Buzz/0000-0002-9201-6186; Mitsopoulos, Costas/0000-0002-9116-5921; Ridley, Anne/0000-0001-8186-5708				Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Dan I, 2002, J BIOL CHEM, V277, P5929, DOI 10.1074/jbc.M110882200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de la Barre AE, 2001, EMBO J, V20, P6383, DOI 10.1093/emboj/20.22.6383; Deng Y, 2003, J BIOL CHEM, V278, P11760, DOI 10.1074/jbc.M211085200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Flygare J, 1998, FEBS LETT, V427, P247, DOI 10.1016/S0014-5793(98)00433-5; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Huang CYF, 2002, J BIOL CHEM, V277, P34367, DOI 10.1074/jbc.M202468200; Kelkar N, 2005, MOL CELL BIOL, V25, P2733, DOI 10.1128/MCB.25.7.2733-2743.2005; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Leverrier Y, 2001, NAT CELL BIOL, V3, pE91, DOI 10.1038/35070151; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Mitsopoulos C, 2003, J BIOL CHEM, V278, P18085, DOI 10.1074/jbc.M213064200; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Schwab BL, 1998, EXP CELL RES, V238, P415, DOI 10.1006/excr.1997.3850; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhou TJ, 2004, STRUCTURE, V12, P1891, DOI 10.1016/j.str.2004.07.021; Zihni C, 2006, J BIOL CHEM, V281, P7317, DOI 10.1074/jbc.M513769200	44	26	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6484	6493		10.1074/jbc.M608336200	http://dx.doi.org/10.1074/jbc.M608336200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17158878	hybrid			2022-12-27	WOS:000244867200056
J	Ghosh, M; Meiss, G; Pingoud, AM; London, RE; Pedersen, LC				Ghosh, Mahua; Meiss, Gregor; Pingoud, Alfred M.; London, Robert E.; Pedersen, Lars C.			The nuclease A-inhibitor complex is characterized by a novel metal ion bridge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL EXTRACELLULAR TRAPS; TORSION ANGLE DYNAMICS; DNA-BINDING; STREPTOCOCCUS-PNEUMONIAE; SERRATIA-MARCESCENS; ENZYME-INHIBITORS; CRYSTAL-STRUCTURE; ACTIVE-SITE; PROTEIN; MECHANISM	Nonspecific, extracellular nucleases have received enhanced attention recently as a consequence of the critical role that these enzymes can play in infectivity by overcoming the host neutrophil defense system. The activity of the cyanobacterial nuclease NucA, a member of the beta beta alpha Me superfamily, is controlled by the specific nuclease inhibitor, NuiA. Here we report the 2.3-angstrom resolution crystal structure of the NucA-NuiA complex, showing that NucA inhibition by NuiA involves an unusual divalent metal ion bridge that connects the nuclease with its inhibitor. The C-terminal Thr-135(NuiA) hydroxyl oxygen is directly coordinated with the catalytic Mg2+ of the nuclease active site, and Glu-24(NuiA) also extends into the active site, mimicking the charge of a scissile phosphate. NuiA residues Asp-75 and Trp-76 form a second interaction site, contributing to the strength and specificity of the interaction. The crystallographically defined interface is shown to be consistent with results of studies using site-directed NuiA mutants. This mode of inhibition differs dramatically from the exosite mechanism of inhibition seen with the DNase colicins E7/E9 and from other nuclease-inhibitor complexes that have been studied. The structure of this complex provides valuable insights for the development of inhibitors for related nonspecific nucleases that share the DRGH active site motif such as the Streptococcus pneumoniae nuclease EndA, which mediates infectivity of this pathogen, and mitochondrial EndoG, which is involved in recombination and apoptosis.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Giessen, Inst Biochem FB08, D-35392 Giessen, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Justus Liebig University Giessen	London, RE (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	london@niehs.nih.gov	Pedersen, Lars/C-6173-2019; London, Robert E/F-7990-2019	Pedersen, Lars/0000-0002-4488-4077; London, Robert E/0000-0001-9108-8463	Intramural NIH HHS [Z99 ES999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALL TK, 1992, NUCLEIC ACIDS RES, V20, P4971, DOI 10.1093/nar/20.19.4971; Banci L, 2006, NAT CHEM BIOL, V2, P367, DOI 10.1038/nchembio797; Beiter K, 2006, CURR BIOL, V16, P401, DOI 10.1016/j.cub.2006.01.056; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchanan JT, 2006, CURR BIOL, V16, P396, DOI 10.1016/j.cub.2005.12.039; BUCKLE AM, 1994, BIOCHEMISTRY-US, V33, P8878, DOI 10.1021/bi00196a004; COTE J, 1989, J BIOL CHEM, V264, P3301; D'Alessio G., 1997, RIBONUCLEASES STRUCT; Dryden DTF, 2006, BIOCHEM SOC T, V34, P317, DOI 10.1042/BST0340317; Flick KE, 1998, NATURE, V394, P96, DOI 10.1038/27952; Ghosh M, 2005, J BIOL CHEM, V280, P27990, DOI 10.1074/jbc.M501798200; GUILLET V, 1993, STRUCTURE, V1, P165, DOI 10.1016/0969-2126(93)90018-C; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hannan JP, 1999, PROTEIN SCI, V8, P1711, DOI 10.1110/ps.8.8.1711; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Ho HC, 1998, EUR J BIOCHEM, V256, P112, DOI 10.1046/j.1432-1327.1998.2560112.x; Ho HC, 1999, BIOCHEM J, V339, P261, DOI 10.1042/0264-6021:3390261; Hsia KC, 2004, STRUCTURE, V12, P205, DOI 10.1016/j.str.2004.01.004; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kirby TW, 2002, J MOL BIOL, V320, P771, DOI 10.1016/S0022-2836(02)00460-6; Klarmann George J., 2002, AIDS Reviews, V4, P183; Kleanthous C, 1999, BIOCHEM SOC T, V27, P63, DOI 10.1042/bst0270063; Kleanthous C, 2001, TRENDS BIOCHEM SCI, V26, P624, DOI 10.1016/S0968-0004(01)01941-7; Ko TP, 1999, STRUCT FOLD DES, V7, P91, DOI 10.1016/S0969-2126(99)80012-4; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; KRUPP G, 1979, NUCLEIC ACIDS RES, V6, P3481, DOI 10.1093/nar/6.11.3481; Kuhlmann UC, 1999, FEBS LETT, V463, P1, DOI 10.1016/S0014-5793(99)01499-4; Kuzmic P, 2000, ANAL BIOCHEM, V286, P45, DOI 10.1006/abio.2000.4685; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li CL, 2003, EMBO J, V22, P4014, DOI 10.1093/emboj/cdg377; Linn S.M., 1993, NUCLEASES; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Loverix S, 2003, CURR MED CHEM, V10, P779, DOI 10.2174/0929867033457845; Mate MJ, 2004, J BIOL CHEM, V279, P34763, DOI 10.1074/jbc.M403719200; Meiss G, 2000, J MOL BIOL, V297, P521, DOI 10.1006/jmbi.2000.3586; Miller MD, 1999, J MOL BIOL, V288, P975, DOI 10.1006/jmbi.1999.2729; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MUROPASTOR AM, 1992, MOL MICROBIOL, V6, P3021, DOI 10.1111/j.1365-2958.1992.tb01760.x; NESTLE M, 1969, J BIOL CHEM, V244, P5213; PUYET A, 1990, J MOL BIOL, V213, P727, DOI 10.1016/S0022-2836(05)80259-1; Rangarajan ES, 2001, FEMS MICROBIOL REV, V25, P583, DOI 10.1111/j.1574-6976.2001.tb00593.x; Schein, 2001, NUCLEASE METHODS PRO; Shen BW, 2004, J MOL BIOL, V342, P43, DOI 10.1016/j.jmb.2004.07.032; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VINCENT RD, 1988, NUCLEIC ACIDS RES, V16, P3297, DOI 10.1093/nar/16.8.3297; Williams J W, 1979, Methods Enzymol, V63, P437	48	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5682	5690		10.1074/jbc.M605986200	http://dx.doi.org/10.1074/jbc.M605986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17138564	Green Accepted, hybrid			2022-12-27	WOS:000244482300065
J	Povirk, LF; Zhou, T; Zhou, RZ; Cowan, MJ; Yannone, SM				Povirk, Lawrence F.; Zhou, Tong; Zhou, Ruizhe; Cowan, Morton J.; Yannone, Steven M.			Processing of 3 '-phosphoglycolate-terminated DNA double strand breaks by artemis nuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; REPAIR; TERMINI; CELLS; NEOCARZINOSTATIN; ENDONUCLEASE; DEFICIENCY; MECHANISMS; BLEOMYCIN; RECOMBINATION	The Artemis nuclease is required for V(D)J recombination and for repair of an as yet undefined subset of radiation-induced DNA double strand breaks. To assess the possibility that Artemis acts on oxidatively modified double strand break termini, its activity toward model DNA substrates, bearing either 3'-hydroxyl or 3'-phosphoglycolate moieties, was examined. A 3'-phosphoglycolate had little effect on Artemis-mediated trimming of long 3' overhangs (>= 9 nucleotides), which were efficiently trimmed to 4-5 nucleotides. However, 3'-phosphoglycolates on overhangs of 4-5 bases promoted Artemis-mediated removal of a single 3'-terminal nucleotide, while at least 2 nucleotides were trimmed from identical hydroxyl-terminated substrates. Artemis also efficiently removed a single nucleotide from a phosphoglycolate-terminated 3-base 3' overhang, while leaving an analogous hydroxyl-terminated overhang largely intact. Such removal was completely dependent on DNA-dependent protein kinase and ATP and was largely dependent on Ku, which markedly stimulated Artemis activity toward all 3' overhangs. Together, these data suggest that efficient Artemis-mediated cleavage of 3' overhangs requires a minimum of 2 nucleotides, or a nucleotide plus a phosphoglycolate, 3' to the cleavage site, as well as 2 unpaired nucleotides 5' to the cleavage site. Shorter 3'-phosphoglycolate-terminated overhangs and blunt ends were also processed by Artemis but much more slowly. Consistent with a role for Artemis in repair of terminally blocked double strand breaks in vivo, human cells lacking Artemis exhibited hypersensitivity to x-rays, bleomycin, and neocarzinostatin, which all induce 3'-phosphoglycolate-terminated double strand breaks.	Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mol Biol, Div Life Sci, Berkeley, CA 94720 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Virginia Commonwealth University; University of California System; University of California San Francisco	Yannone, SM (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mol Biol, Div Life Sci, Mail Stop 74-157,1 Cyclotron Rd, Berkeley, CA 94720 USA.	SMYannone@lbl.gov	Yannone, Steven/ABA-3524-2021; Yannone, Steven/G-1927-2011		NATIONAL CANCER INSTITUTE [R01CA040615] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028339] Funding Source: NIH RePORTER; NCI NIH HHS [CA40615] Funding Source: Medline; NHLBI NIH HHS [HL58842] Funding Source: Medline; NIAID NIH HHS [AI28339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bennett RAO, 1996, INT J RADIAT BIOL, V70, P623; BERTONCINI CRA, 1995, NUCLEIC ACIDS RES, V23, P2995, DOI 10.1093/nar/23.15.2995; Chen S, 2001, ANAL BIOCHEM, V289, P274, DOI 10.1006/abio.2000.4936; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; DEDON PC, 1990, J BIOL CHEM, V265, P14713; Goodarzi AA, 2006, EMBO J, V25, P3880, DOI 10.1038/sj.emboj.7601255; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HENNER WD, 1983, J BIOL CHEM, V258, P711; Inamdar KV, 2002, J BIOL CHEM, V277, P27162, DOI 10.1074/jbc.M204688200; Jeggo PA, 2006, DNA REPAIR, V5, P1192, DOI 10.1016/j.dnarep.2006.05.011; Lee JW, 2003, ENVIRON MOL MUTAGEN, V42, P279, DOI 10.1002/em.10197; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; Li LY, 2002, J IMMUNOL, V168, P6323, DOI 10.4049/jimmunol.168.12.6323; Ma YM, 2005, DNA REPAIR, V4, P845, DOI 10.1016/j.dnarep.2005.04.013; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nicolas N, 1996, EUR J IMMUNOL, V26, P1118, DOI 10.1002/eji.1830260524; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Suh D, 1997, NUCLEIC ACIDS RES, V25, P2495, DOI 10.1093/nar/25.12.2495; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Zhou T, 2005, NUCLEIC ACIDS RES, V33, P289, DOI 10.1093/nar/gki170	27	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3547	3558		10.1074/jbc.M607745200	http://dx.doi.org/10.1074/jbc.M607745200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17121861	hybrid, Green Submitted			2022-12-27	WOS:000244481900017
J	Suzuki, H; Ueda, T; Taguchi, H; Takeuchi, N				Suzuki, Hiroaki; Ueda, Takuya; Taguchi, Hideki; Takeuchi, Nono			Chaperone properties of mammalian mitochondrial translation elongation factor Tu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EF-TU; HEREDITARY SPASTIC PARAPLEGIA; GREEN FLUORESCENT PROTEIN; FACTOR 1A; HEAT-SHOCK; MOLECULAR CHAPERONE; ACTIN CYTOSKELETON; FACTOR-TS; F-ACTIN; RNA	The main function of the prokaryotic translation elongation factor Tu (EF-Tu) and its eukaryotic counterpart eEF1A is to deliver aminoacyl-tRNA to the A-site on the ribosome. In addition to this primary function, it has been reported that EF-Tu from various sources has chaperone activity. At present, little information is available about the chaperone activity of mitochondrial EF-Tu. In the present study, we have examined the chaperone function of mammalian mitochondrial EF-Tu (EF-Tumt). We demonstrate that recombinant EF-Tumt prevents thermal aggregation of proteins and enhances protein refolding in vitro and that this EF-Tumt chaperone activity proceeds in a GTP-independent manner. We also demonstrate that, under heat stress, the newly synthesized peptides from the mitochondrial ribosome specifically co-immunoprecipitate with EF-Tumt and are destabilized in EF-Tumt-overexpressing cells. We show that most of the EF-Tumt localizes on the mitochondrial inner membrane where most mitochondrial ribosomes are found. We discuss the possible role of EF-Tumt chaperone activity in protein quality control in mitochondria, with regard to the recently reported in vivo chaperone function of eEF1A.	Univ Tokyo, Dept Med Genome Sci, Grad Sch Frontier Sci, Kashiwa, Chiba 2778562, Japan	University of Tokyo	Takeuchi, N (corresponding author), Univ Tokyo, Dept Med Genome Sci, Grad Sch Frontier Sci, Bldg FSB-401,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	nono@k.u-tokyo.ac.jp	Ueda, Takuya/K-5217-2014; Suzuki, Hiroaki/T-8989-2019; Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021	Ueda, Takuya/0000-0002-7760-8271; Suzuki, Hiroaki/0000-0002-8899-0955; Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339				Abel K, 1996, STRUCTURE, V4, P229, DOI 10.1016/S0969-2126(96)00027-5; Bross P, 2004, TOP CURR GENET, V8, P97; Cai YC, 2000, PROTEIN SCI, V9, P1791; Caldas TD, 1998, J BIOL CHEM, V273, P11478, DOI 10.1074/jbc.273.19.11478; CHANG R, 2006, IN PRESS J CELL BIOC; Chuang SM, 2005, MOL CELL BIOL, V25, P403, DOI 10.1128/MCB.25.1.403-413.2005; DHARMAWARDHANE S, 1991, CELL MOTIL CYTOSKEL, V20, P279, DOI 10.1002/cm.970200404; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; Enoki S, 2004, BIOCHEMISTRY-US, V43, P14238, DOI 10.1021/bi048733+; Gottlieb RA, 2000, METHOD ENZYMOL, V322, P213; Gross SR, 2005, NAT STRUCT MOL BIOL, V12, P772, DOI 10.1038/nsmb979; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; Hotokezaka Y, 2002, J BIOL CHEM, V277, P18545, DOI 10.1074/jbc.M201022200; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Kambacheld M, 2005, J BIOL CHEM, V280, P20132, DOI 10.1074/jbc.M500398200; Kudlicki W, 1997, J BIOL CHEM, V272, P32206, DOI 10.1074/jbc.272.51.32206; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Liu G, 2002, MOL BIOL CELL, V13, P579, DOI 10.1091/mbc.01-03-0140; Liu G, 1996, J CELL BIOL, V135, P953, DOI 10.1083/jcb.135.4.953; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; Major T, 2006, MOL CELL BIOL, V26, P762, DOI 10.1128/MCB.26.3.762-776.2006; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; Malki A, 2005, J BIOL CHEM, V280, P14420, DOI 10.1074/jbc.M408296200; MILLER DL, 1970, ARCH BIOCHEM BIOPHYS, V141, P26, DOI 10.1016/0003-9861(70)90102-5; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; Munshi R, 2001, GENETICS, V157, P1425; Nolden M, 2005, CELL, V123, P277, DOI 10.1016/j.cell.2005.08.003; Rao D, 2004, EUR J BIOCHEM, V271, P3684, DOI 10.1111/j.1432-1033.2004.04309.x; Richarme G, 1998, BIOCHEM BIOPH RES CO, V252, P156, DOI 10.1006/bbrc.1998.9591; Rugarli EI, 2006, TRENDS MOL MED, V12, P262, DOI 10.1016/j.molmed.2006.04.002; Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; Shamovsky I, 2006, NATURE, V440, P556, DOI 10.1038/nature04518; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; TAGUCHI H, 1994, J BIOL CHEM, V269, P8529; TRAVERS AA, 1970, NATURE, V228, P748, DOI 10.1038/228748a0; Turner C, 2001, ADV EXP MED BIOL, V487, P229; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WEISSBACH H, 1970, ARCH BIOCHEM BIOPHYS, V137, P262, DOI 10.1016/0003-9861(70)90433-9; Woriax VL, 1995, BBA-GENE STRUCT EXPR, V1264, P347, DOI 10.1016/0167-4781(95)00176-X; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; Zipfel C, 2006, CELL, V125, P749, DOI 10.1016/j.cell.2006.03.037	45	57	61	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4076	4084		10.1074/jbc.M608187200	http://dx.doi.org/10.1074/jbc.M608187200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17130126	hybrid			2022-12-27	WOS:000244481900071
J	Jennemann, R; Sandhoff, R; Langbein, L; Kaden, S; Rothermel, U; Gallala, H; Sandhoff, K; Wiegandt, H; Grone, HJ				Jennemann, Richard; Sandhoff, Roger; Langbein, Lutz; Kaden, Sylvia; Rothermel, Ulrike; Gallala, Hichem; Sandhoff, Konrad; Wiegandt, Herbert; Groene, Hermann-Josef			Integrity and barrier function of the epidermis critically depend on glucosylceramide synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; HUMAN HAIR FOLLICLE; STRATUM-CORNEUM; GLYCOSPHINGOLIPID SYNTHESIS; LIPID-COMPOSITION; TIGHT JUNCTIONS; HUMAN GLIOMAS; MICE; SKIN; PROTEINS	Ceramides are vital components of the water barrier in mammalian skin. Epidermis-specific, a major ceramide portion contains omega-hydroxy very long chain fatty acids (C30-C36). These omega-hydroxy ceramides (Cers) are found in the extracellular lamellae of the stratum corneum either as linoleic acyl esters or protein bound. Glucosylceramide is the major glycosphingolipid of the epidermis. Synthesized from ceramide and UDPglucose, it is thought to be itself an intracellular precursor and carrier for extracellular omega-hydroxy ceramides. To investigate whether GlcCer is an obligatory intermediate in ceramide metabolism to maintain epidermal barrier function, a mouse with an epidermis-specific glucosylceramide synthase (Ugcg) deficiency has been generated. Four days after birth animals devoid of GlcCer synthesis in keratinocytes showed a pronounced desquamation of the stratum corneum and extreme transepidermal water loss leading to death. The stratum corneum appeared as a thick unstructured mass. Lamellar bodies of the stratum granulosum did not display the usual ordered inner structure and were often irregularly arranged. Although the total amount of epidermal protein-bound ceramides remained unchanged, epidermal-free omega-hydroxy ceramides increased 4-fold and omega-hydroxy sphingomyelins, almost not detectable in wild type epidermis, emerged in quantities comparable with lost GlcCer. We conclude that the transient formation of GlcCer is vital for a regular arrangement of lipids and proteins in lamellar bodies and for the maintenance of the epidermal barrier.	German Canc Res Ctr, Dept Cellular & Mol Pathol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Cell Biol, D-69120 Heidelberg, Germany; Univ Bonn, LIMES, Membrane Biol & Lipid Biochem Unit, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Bonn	Jennemann, R (corresponding author), German Canc Res Ctr, Dept Cellular & Mol Pathol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	r.jennemann@dkfz.de; h.-j.groene@dkfz.de						Bouwstra JA, 2003, PROG LIPID RES, V42, P1, DOI 10.1016/S0163-7827(02)00028-0; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Chujor CSN, 1998, J LIPID RES, V39, P277; DIAZ LA, 1977, J INVEST DERMATOL, V68, P36, DOI 10.1111/1523-1747.ep12485156; Doering T, 1999, J BIOL CHEM, V274, P11038, DOI 10.1074/jbc.274.16.11038; Doering T, 1999, FEBS LETT, V447, P167, DOI 10.1016/S0014-5793(99)00274-4; Doering T, 2002, J LIPID RES, V43, P1727, DOI 10.1194/jlr.M200208-JLR200; ELIAS PM, 1979, J INVEST DERMATOL, V73, P339, DOI 10.1111/1523-1747.ep12550377; FREINKEL RK, 1985, J INVEST DERMATOL, V85, P295, DOI 10.1111/1523-1747.ep12276831; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; GRAYSON S, 1985, J INVEST DERMATOL, V85, P289, DOI 10.1111/1523-1747.ep12276826; Hanley K, 1997, J LIPID RES, V38, P576; Herrmann T, 2003, J CELL BIOL, V161, P1105, DOI 10.1083/jcb.200207080; HOLLERAN WM, 1993, J CLIN INVEST, V91, P1656, DOI 10.1172/JCI116374; HOLLERAN WM, 1994, J CLIN INVEST, V93, P1756, DOI 10.1172/JCI117160; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Indra AK, 2000, HORM RES, V54, P296, DOI 10.1159/000053275; JECKEL D, 1992, J CELL BIOL, V259, P267; Jennemann R, 2005, P NATL ACAD SCI USA, V102, P12459, DOI 10.1073/pnas.0500893102; JENNEMANN R, 1990, CANCER RES, V50, P7444; JENNEMANN R, 1994, ACTA NEUROCHIR, V126, P170, DOI 10.1007/BF01476429; Kirfel J, 2003, CELL MOL LIFE SCI, V60, P56, DOI 10.1007/s000180300004; Ku NO, 2002, P NATL ACAD SCI USA, V99, P4373, DOI 10.1073/pnas.072624299; Langbein L, 2005, INT REV CYTOL, V243, P1, DOI 10.1016/S0074-7696(05)43001-6; Langbein L, 2003, J INVEST DERMATOL, V120, P512, DOI 10.1046/j.1523-1747.2003.12087.x; Langbein L, 2002, EUR J CELL BIOL, V81, P419, DOI 10.1078/0171-9335-00270; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Madison KC, 2003, J INVEST DERMATOL, V121, P231, DOI 10.1046/j.1523-1747.2003.12359.x; MADISON KC, 1986, J INVEST DERMATOL, V87, P253, DOI 10.1111/1523-1747.ep12696636; Marekov LN, 1998, J BIOL CHEM, V273, P17763, DOI 10.1074/jbc.273.28.17763; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; Mertens AEE, 2005, J CELL BIOL, V170, P1029, DOI 10.1083/jcb.200502129; Potten C S, 1981, Int Rev Cytol, V69, P271; Sandhoff R, 2002, J BIOL CHEM, V277, P20386, DOI 10.1074/jbc.M110641200; Schuette CG, 1999, BIOL CHEM, V380, P759, DOI 10.1515/BC.1999.096; Schweizer J, 2006, J CELL BIOL, V174, P169, DOI 10.1083/jcb.200603161; Sprong H, 2001, J CELL BIOL, V155, P369, DOI 10.1083/jcb.200106104; Tamboli IY, 2005, J BIOL CHEM, V280, P28110, DOI 10.1074/jbc.M414525200; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Uchida Y, 2000, J LIPID RES, V41, P2071; Vielhaber G, 2001, J INVEST DERMATOL, V117, P1126, DOI 10.1046/j.0022-202x.2001.01527.x; Yamashita T, 2005, GENESIS, V43, P175, DOI 10.1002/gene.20167; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142	48	88	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3083	3094		10.1074/jbc.M610304200	http://dx.doi.org/10.1074/jbc.M610304200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145749	hybrid			2022-12-27	WOS:000243793900035
J	Mahieu, F; Owsianik, G; Verbert, L; Janssens, A; De Smedt, H; Nilius, B; Voets, T				Mahieu, Frank; Owsianik, Grzegorz; Verbert, Leen; Janssens, Annelies; De Smedt, Humbert; Nilius, Bernd; Voets, Thomas			TRPM8-independent menthol-induced Ca2+ release from endoplasmic reticulum and Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-AMINOETHOXYDIPHENYL BORATE 2-APB; PROSTATE-CANCER; CALCIUM-RELEASE; XESTOSPONGIN-C; HELA-CELLS; CHANNEL; RECEPTOR; STORE; TRPM8; SUBCOMPARTMENTS	Menthol, a secondary alcohol produced by the peppermint herb, Mentha piperita, is widely used in the food and pharmaceutical industries as a cooling/ soothing compound and odorant. It induces Ca2+ influx in a subset of sensory neurons from dorsal root and trigeminal ganglia, due to activation of TRPM8, a Ca2+-permeable, cold-activated member of the TRP superfamily of cation channels. Menthol also induces Ca2+ release from intracellular stores in several TRPM8-expressing cell types, which has led to the suggestion that TRPM8 can function as an intracellular Ca2+-release channel. Here we show that menthol induces Ca2+ release from intracellular stores in four widely used cell lines (HEK293, lymph node carcinoma of the prostate (LNCaP), Chinese hamster ovary (CHO), and COS), and provide several lines of evidence indicating that this release pathway is TRPM8-independent: 1) menthol-induced Ca2+ release was potentiated at higher temperatures, which contrasts to the cold activation of TRPM8; 2) overexpression of TRPM8 did not enhance the menthol-induced Ca2+ release; 3) menthol-induced Ca2+ release was mimicked by geraniol and linalool, which are structurally related to menthol, but not by the more potent TRPM8 agonists icilin or eucalyptol; and 4) TRPM8 expression in HEK293 cells was undetectable at the protein and mRNA levels. Moreover, using a novel TRPM8-specific antibody we demonstrate that both heterologously expressed TRPM8 (in HEK293 cells) and endogenous TRPM8 (in LNCaP cells) are mainly localized in the plasma membrane, which contrast to previous localization studies using commercial anti-TRPM8 antibodies. Finally, aequorin-based measurements demonstrate that the TRPM8-independent menthol-induced Ca2+ release originates from both endoplasmic reticulum and Golgi compartments.	Katholieke Univ Leuven, Div Physiol, Dept Mol Cell Biol, Lab Ion Channel Res, B-3000 Louvain, Belgium	KU Leuven	Voets, T (corresponding author), Katholieke Univ Leuven, Div Physiol, Dept Mol Cell Biol, Lab Ion Channel Res, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	thomas.voets@med.kuleuven.be	Voets, Thomas/E-2466-2012; Voets, Thomas/AAD-4389-2019	Voets, Thomas/0000-0001-5526-5821; Voets, Thomas/0000-0001-5526-5821; Janssens, Annelies/0000-0002-6735-8248				Behrendt HJ, 2004, BRIT J PHARMACOL, V141, P737, DOI 10.1038/sj.bjp.0705652; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Bose DD, 2006, NEUROPHARMACOLOGY, V50, P532, DOI 10.1016/j.neuropharm.2005.10.011; Cao LS, 2005, BIOCHEM BIOPH RES CO, V331, P503, DOI 10.1016/j.bbrc.2005.03.201; De Smet P, 1999, CELL CALCIUM, V26, P9; ECCLES R, 1994, J PHARM PHARMACOL, V46, P618, DOI 10.1111/j.2042-7158.1994.tb03871.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haeseler G, 2002, EUR J ANAESTH, V19, P571, DOI 10.1017/S0265021502000923; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Missiaen L, 2004, CELL CALCIUM, V36, P479, DOI 10.1016/j.ceca.2004.04.007; Montero M, 1997, J CELL BIOL, V139, P601, DOI 10.1083/jcb.139.3.601; Nealen ML, 2003, J NEUROPHYSIOL, V90, P515, DOI 10.1152/jn.00843.2002; PALADE P, 1987, J BIOL CHEM, V262, P6142; PaltaufDoburzynska J, 1997, CELL CALCIUM, V21, P43, DOI 10.1016/S0143-4160(97)90095-6; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Qian F, 2005, PFLUG ARCH EUR J PHY, V451, P277, DOI 10.1007/s00424-005-1469-4; Querfurth HW, 1998, BIOCHEM J, V334, P79, DOI 10.1042/bj3340079; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Solovyova N, 2002, CELL CALCIUM, V32, P49, DOI 10.1016/S0143-4160(02)00094-5; TAKEUCHI S, 1994, BIOCHEM BIOPH RES CO, V201, P1333, DOI 10.1006/bbrc.1994.1850; Takezawa R, 2004, P NATL ACAD SCI USA, V101, P6009, DOI 10.1073/pnas.0307565101; Thebault S, 2005, J BIOL CHEM, V280, P39423, DOI 10.1074/jbc.M503544200; Tsavaler L, 2001, CANCER RES, V61, P3760; Tsuzuki K, 2004, J NEUROSCI, V24, P762, DOI 10.1523/JNEUROSCI.4658-03.2004; Turner H, 2003, BIOCHEM J, V371, P341, DOI 10.1042/BJ20021381; Vriens J, 2005, CIRC RES, V97, P908, DOI 10.1161/01.RES.0000187474.47805.30; Zhang L, 2004, CANCER RES, V64, P8365, DOI 10.1158/0008-5472.CAN-04-2146	27	101	105	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3325	3336		10.1074/jbc.M605213200	http://dx.doi.org/10.1074/jbc.M605213200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17142461	hybrid, Green Published			2022-12-27	WOS:000243793900059
J	Chiba, S; Coleman, K; Pogliano, K				Chiba, Shinobu; Coleman, Kristina; Pogliano, Kit			Impact of membrane fusion and proteolysis on SpoIIQ dynamics and interaction with SpoIIIAH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED INTRAMEMBRANE PROTEOLYSIS; BACILLUS-SUBTILIS; GENE-EXPRESSION; ESCHERICHIA-COLI; SPORULATION; ENGULFMENT; FORESPORE; PRO-SIGMA(K); PROTEIN; TRANSCRIPTION	The onset of engulfment-dependent gene expression during Bacillus subtilis sporulation requires the forespore membrane protein SpoIIQ, which recruits mother cell proteins involved in late gene expression to the outer forespore membrane. Engulfment activates the late forespore transcription factor sigma(G), which produces high levels of the secreted SpoIVB protease that is required for activation of the late mother cell transcription factor sigma(K). Engulfment also triggers the proteolytic cleavage of SpoIIQ, an event that depends on the SpoIVB protease but not on sigma(G) activity. To determine if SpoIVB directly cleaves SpoIIQ and to determine if this event participates in the onset of late gene expression, we purified SpoIVB, SpoIIQ, and SpoIVFA ( another SpoIVB substrate). SpoIVB directly cleaved SpoIIQ at the same site in vitro and in vivo and cleaved SpoIVFA in at least three different locations. SpoIIQ cleavage depends on membrane fusion, but not on sigma(G) activity, suggesting that the ability of SpoIVB to cleave substrates is regulated by membrane fusion. We isolated SpoIVB-resistant SpoIIQ proteins by random mutagenesis of codons at the cleavage site and demonstrated that SpoIIQ processing is dispensable for spore formation and for activation of late forespore and mother cell gene expression. Fluorescence recovery after photobleaching analysis demonstrated that membrane fusion releases SpoIIQ from an immobile complex, an event that could allow SpoIVB to cleave SpoIIQ. We propose that this membrane fusion-dependent reorganization in the complex, rather than SpoIIQ proteolysis itself, is necessary for the onset of late transcription.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Pogliano, K (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	kpogliano@ucsd.edu		Chiba, Shinobu/0000-0003-3485-3477; Pogliano, Kit/0000-0002-7868-3345	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057045] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM057045-10, GM 57045, R01 GM057045] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abanes-De Mello A, 2002, GENE DEV, V16, P3253, DOI 10.1101/gad.1039902; Blaylock B, 2004, GENE DEV, V18, P2916, DOI 10.1101/gad.1252704; Broder DH, 2006, CELL, V126, P917, DOI 10.1016/j.cell.2006.06.053; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Campo N, 2006, MOL CELL, V23, P25, DOI 10.1016/j.molcel.2006.05.019; CUTTING S, 1991, GENE DEV, V5, P456, DOI 10.1101/gad.5.3.456; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; Doan T, 2005, MOL MICROBIOL, V55, P1767, DOI 10.1111/j.1365-2958.2005.04501.x; Dong TC, 2003, MOL MICROBIOL, V49, P1425, DOI 10.1046/j.1365-2958.2003.03651.x; DUBNAU D, 1971, J MOL BIOL, V56, P209, DOI 10.1016/0022-2836(71)90460-8; Ehrmann M, 2004, ANNU REV GENET, V38, P709, DOI 10.1146/annurev.genet.38.072902.093416; Errington J, 2003, NAT REV MICROBIOL, V1, P117, DOI 10.1038/nrmicro750; Gomez M, 1996, MICROBIOL-UK, V142, P3453, DOI 10.1099/13500872-142-12-3453; Jiang X, 2005, MOL MICROBIOL, V58, P102, DOI 10.1111/j.1365-2958.2005.04811.x; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kroos L, 2000, CURR OPIN MICROBIOL, V3, P553, DOI 10.1016/S1369-5274(00)00140-5; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Liu NJL, 2006, MOL MICROBIOL, V59, P1097, DOI 10.1111/j.1365-2958.2005.05004.x; LondonoVallejo JA, 1997, MOL MICROBIOL, V24, P29, DOI 10.1046/j.1365-2958.1997.3181680.x; Perez AR, 2000, J BACTERIOL, V182, P1096, DOI 10.1128/JB.182.4.1096-1108.2000; Piggot PJ, 2004, CURR OPIN MICROBIOL, V7, P579, DOI 10.1016/j.mib.2004.10.001; Pogliano K, 1997, J BACTERIOL, V179, P3331, DOI 10.1128/jb.179.10.3331-3341.1997; RICCA E, 1992, J BACTERIOL, V174, P3177, DOI 10.1128/jb.174.10.3177-3184.1992; Rubio A, 2005, J BACTERIOL, V187, P5000, DOI 10.1128/JB.187.14.5000-5002.2005; Rubio A, 2004, EMBO J, V23, P1636, DOI 10.1038/sj.emboj.7600171; Rudner DZ, 1999, P NATL ACAD SCI USA, V96, P14765, DOI 10.1073/pnas.96.26.14765; Rudner DZ, 2001, DEV CELL, V1, P733, DOI 10.1016/S1534-5807(01)00094-6; Rudner DZ, 2002, GENE DEV, V16, P1007, DOI 10.1101/gad.977702; Saikawa N, 2004, J STRUCT BIOL, V146, P123, DOI 10.1016/j.jsb.2003.09.020; SAWANO A, 2000, NUCLEIC ACIDS RES, V28, P78, DOI DOI 10.1093/NAR/28.16.E78; Sharp MD, 1999, P NATL ACAD SCI USA, V96, P14553, DOI 10.1073/pnas.96.25.14553; STERLINI JM, 1969, BIOCHEM J, V113, P29, DOI 10.1042/bj1130029; Sun YL, 2000, J BACTERIOL, V182, P2919, DOI 10.1128/JB.182.10.2919-2927.2000; Wakeley PR, 2000, MOL MICROBIOL, V36, P1336, DOI 10.1046/j.1365-2958.2000.01946.x; YOUNGMAN P, 1984, MOL GEN GENET, V195, P424, DOI 10.1007/BF00341443; Yu YTN, 2000, J BACTERIOL, V182, P3305, DOI 10.1128/JB.182.11.3305-3309.2000; Zhang B, 1998, J BACTERIOL, V180, P2434, DOI 10.1128/JB.180.9.2434-2441.1998; Zhou RB, 2005, MOL MICROBIOL, V58, P835, DOI 10.1111/j.1365-2958.2005.04870.x; Zhou RB, 2004, P NATL ACAD SCI USA, V101, P6385, DOI 10.1073/pnas.0307709101	39	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2576	2586		10.1074/jbc.M606056200	http://dx.doi.org/10.1074/jbc.M606056200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121846	Green Accepted, hybrid			2022-12-27	WOS:000243593200050
J	Maas, C; Hermeling, S; Bouma, B; Jiskoot, W; Gebbink, MFBG				Maas, Coen; Hermeling, Suzanne; Bouma, Barend; Jiskoot, Wim; Gebbink, Martijn F. B. G.			A role for protein misfolding in immunogenicity of biopharmaceuticals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-BETA-STRUCTURE; IMMUNE TOLERANT MICE; RED-CELL APLASIA; WILD-TYPE; ANTIBODIES; THERAPEUTICS; AGGREGATION; FORMULATION; ACTIVATION; STABILITY	For largely unknown reasons, biopharmaceuticals evoke potentially harmful antibody formation. Such antibodies can inhibit drug efficacy and, when directed against endogenous proteins, cause life-threatening complications. Insight into the mechanisms by which biopharmaceuticals break tolerance and induce an immune response will contribute to finding solutions to prevent this adverse effect. Using a transgenic mouse model, we here demonstrate that protein misfolding, detected with the use of tissue-type plasminogen activator and thioflavin T, markers of amyloid-like properties, results in breaking of tolerance. In wild-type mice, misfolding enhances protein immunogenicity. Several commercially available biopharmaceutical products were found to contain misfolded proteins. In some cases, the level of misfolded protein was found to increase upon storage under conditions prescribed by the manufacturer. Our results indicate that misfolding of therapeutic proteins is an immunogenic signal and a risk factor for immunogenicity. These findings offer novel possibilities to detect immunogenic protein entities with tPA and reduce immunogenicity of biopharmaceuticals.	Univ Utrecht, Med Ctr, Lab Thrombosis & Haemostasis, Dept Clin Chem & Haematol, NL-3584 CH Utrecht, Netherlands; Inst Biomembranes, NL-3584 CH Utrecht, Netherlands; Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, NL-3508 TB Utrecht, Netherlands; Univ Utrecht, Cent Lab Anim Inst, NL-3508 TD Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University	Gebbink, MFBG (corresponding author), POB 85500, NL-3508 GA Utrecht, Netherlands.	m.gebbink@umcutrecht.nl	Jiskoot, Wim/A-6877-2016	Jiskoot, Wim/0000-0002-1012-3456; Maas, Coen/0000-0003-4593-0976				Azakami H, 2005, J AGR FOOD CHEM, V53, P1254, DOI 10.1021/jf049325f; Belz GT, 2002, J IMMUNOL, V168, P6066, DOI 10.4049/jimmunol.168.12.6066; Bouma B, 2003, J BIOL CHEM, V278, P41810, DOI 10.1074/jbc.M303925200; Boven K, 2005, KIDNEY INT, V67, P2346, DOI 10.1111/j.1523-1755.2005.00340.x; Braun A, 1997, PHARMACEUT RES, V14, P1472, DOI 10.1023/A:1012193326789; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Bunn HF, 2002, NEW ENGL J MED, V346, P522, DOI 10.1056/NEJM200202143460711; Casadevall N, 2002, NEW ENGL J MED, V346, P469, DOI 10.1056/NEJMoa011931; Casadevall N, 2002, NEPHROL DIAL TRANSPL, V17, P42, DOI 10.1093/ndt/17.suppl_5.42; Chirino AJ, 2004, DRUG DISCOV TODAY, V9, P82, DOI 10.1016/S1359-6446(03)02953-2; Frokjaer S, 2005, NAT REV DRUG DISCOV, V4, P298, DOI 10.1038/nrd1695; Frost H, 2005, TOXICOLOGY, V209, P155, DOI 10.1016/j.tox.2004.12.028; Galantai R, 2006, BIOCHEM BIOPH RES CO, V341, P736, DOI 10.1016/j.bbrc.2006.01.027; Ge JB, 2005, ARTERIOSCL THROM VAS, V25, P2157, DOI 10.1161/01.ATV.0000181744.58265.63; Goudemand J, 2006, BLOOD, V107, P46, DOI 10.1182/blood-2005-04-1371; Grudena MA, 2004, DEMENT GERIATR COGN, V18, P165, DOI 10.1159/000079197; Hermeling S, 2006, J PHARM SCI-US, V95, P1084, DOI 10.1002/jps.20599; Hermeling S, 2005, PHARM RES-DORDR, V22, P1997, DOI 10.1007/s11095-005-8177-9; Hermeling S, 2003, PHARM RES, V20, P1903, DOI 10.1023/B:PHAM.0000008034.61317.02; Koren E., 2002, Current Pharmaceutical Biotechnology, V3, P349, DOI 10.2174/1389201023378175; Kranenburg O, 2002, CURR BIOL, V12, P1833, DOI 10.1016/S0960-9822(02)01224-1; Kromminga A, 2005, ANN NY ACAD SCI, V1050, P257, DOI 10.1196/annals.1313.027; Machovich R, 1997, ARCH BIOCHEM BIOPHYS, V344, P343, DOI 10.1006/abbi.1997.0221; Nilsson MR, 2003, PROTEIN SCI, V12, P2637, DOI 10.1110/ps.0360403; Obrenovich M.E., 2004, SCI AGING KNOWL ENV, V2004, pE3; Oldenburg J, 2004, SEMIN HEMATOL, V41, P82, DOI 10.1053/j.seminhematol.2003.11.016; Pavlou AK, 2004, NAT BIOTECHNOL, V22, P1513, DOI 10.1038/nbt1204-1513; Ruiz L, 2005, J PHARM PHARM SCI, V8, P207; Schellekens H, 2002, CLIN THER, V24, P1720, DOI 10.1016/S0149-2918(02)80075-3; Schellekens H, 2002, NAT REV DRUG DISCOV, V1, P457, DOI 10.1038/nrd818; Shacter E, 2000, DRUG METAB REV, V32, P307, DOI 10.1081/DMR-100102336; Soenderkaer S, 2004, EUR J PHARM SCI, V21, P597, DOI 10.1016/j.ejps.2003.12.010; Stathopulos PB, 2004, PROTEIN SCI, V13, P3017, DOI 10.1110/ps.04831804; Stewart CR, 2005, BIOCHEMISTRY-US, V44, P9108, DOI 10.1021/bi050497v; Townsend KP, 2005, EUR J IMMUNOL, V35, P901, DOI 10.1002/eji.200425585; Wang W, 2005, INT J PHARMACEUT, V289, P1, DOI 10.1016/j.ijpharm.2004.11.014; Wang W, 2000, INT J PHARMACEUT, V203, P1, DOI 10.1016/S0378-5173(00)00423-3; Zhao HX, 2004, BIOCHEMISTRY-US, V43, P10302, DOI 10.1021/bi049002c; Zhu M, 2002, J BIOL CHEM, V277, P50914, DOI 10.1074/jbc.M207225200	39	124	137	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2229	2236		10.1074/jbc.M605984200	http://dx.doi.org/10.1074/jbc.M605984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135263	hybrid			2022-12-27	WOS:000243593200014
J	Uchida, T; Iwashita, N; Ohara-Imaizumi, M; Ogihara, T; Nagai, S; Choi, JB; Tamura, Y; Tada, N; Kawamori, R; Nakayama, KI; Nagamatsu, S; Watada, H				Uchida, Toyoyoshi; Iwashita, Noseki; Ohara-Imaizumi, Mica; Ogihara, Takeshi; Nagai, Shintaro; Choi, Jong Bock; Tamura, Yoshifumi; Tada, Norihiro; Kawamori, Ryuzo; Nakayama, Keiichi I.; Nagamatsu, Shinya; Watada, Hirotaka			Protein kinase C delta plays a non-redundant role in insulin secretion in pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE STIMULATION; GK RAT; EXOCYTOSIS; ISLETS; PHOSPHORYLATION; GRANULES; RELEASE; EXPRESSION; SYNTAXIN; LOCALIZATION	Protein kinase C (PKC) is considered to modulate glucose-stimulated insulin secretion. Pancreatic beta cells express multiple isoforms of PKCs; however, the role of each isoform in glucose-stimulated insulin secretion remains controversial. In this study we investigated the role of PKC delta, a major isoform expressed in pancreatic beta cells on beta cell function. Here, we showed that PKC delta null mice manifested glucose intolerance with impaired insulin secretion. Insulin tolerance test showed no decrease in insulin sensitivity in PKC delta null mice. Studies using islets isolated from these mice demonstrated decreased glucose- and KCl-stimulated insulin secretion. Perifusion studies indicated that mainly the second phase of insulin secretion was decreased. On the other hand, glucose- induced influx of Ca2+ into beta cells was not altered. Immunohistochemistry using total internal reflection fluorescence microscopy and electron microscopic analysis showed an increased number of insulin granules close to the plasma membrane in beta cells of PKC delta null mice. Although PKC is thought to phosphorylate Munc18-1 and facilitate soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptors complex formation, the phosphorylation of Munc18-1 by glucose stimulation was decreased in islets of PKC delta null mice. We conclude that PKC delta plays a non-redundant role in glucose-stimulated insulin secretion. The impaired insulin secretion in PKC delta null mice is associated with reduced phosphorylation of Munc18-1.	Juntendo Univ, Sch Med, Dept Med Metab & Endocrinol, Tokyo 1138421, Japan; Kyorin Univ, Sch Med, Dept Biochem, Mitaka, Tokyo 1818611, Japan; Juntendo Univ, Sch Med, Div Biomed Res Resources, Tokyo 1138421, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan	Juntendo University; Kyorin University; Juntendo University; Kyushu University	Watada, H (corresponding author), Juntendo Univ, Sch Med, Dept Med Metab & Endocrinol, 2-1-1, Tokyo 1138421, Japan.	hwatada@med.juntendo.ac.jp	Tamura, Yoshifumi/AFK-2430-2022	Tamura, Yoshifumi/0000-0002-1685-7821; Watada, Hirotaka/0000-0001-5961-1816				Barbu AR, 2002, MOL MED, V8, P733, DOI 10.1007/BF03402037; Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; BLACHIER F, 1989, BIOCHIM BIOPHYS ACTA, V1013, P144, DOI 10.1016/0167-4889(89)90042-6; Bratanova-Tochkova TK, 2002, DIABETES, V51, pS83, DOI 10.2337/diabetes.51.2007.S83; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Carpenter L, 2004, DIABETES, V53, P53, DOI 10.2337/diabetes.53.1.53; Cheviet S, 2004, MOL ENDOCRINOL, V18, P117, DOI 10.1210/me.2003-0300; Choi JB, 2003, DIABETOLOGIA, V46, P1366, DOI 10.1007/s00125-003-1182-9; Craig TJ, 2003, J NEUROCHEM, V86, P1450, DOI 10.1046/j.1471-4159.2003.01955.x; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Fukui K, 2005, CELL METAB, V2, P373, DOI 10.1016/j.cmet.2005.11.003; GANESAN S, 1990, P NATL ACAD SCI USA, V87, P9893, DOI 10.1073/pnas.87.24.9893; Gao ZY, 2000, J BIOL CHEM, V275, P36079, DOI 10.1074/jbc.M004284200; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; Gomi H, 2005, J CELL BIOL, V171, P99, DOI 10.1083/jcb.200505179; Gonelle-Gispert C, 2002, BIOCHEM J, V368, P223, DOI 10.1042/BJ20020896; Gorogawa S, 2004, BIOCHEM BIOPH RES CO, V319, P1159, DOI 10.1016/j.bbrc.2004.05.095; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; HELLMAN B, 1971, BIOCHEM J, V123, P513, DOI 10.1042/bj1230513; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Idris I, 2001, DIABETOLOGIA, V44, P659, DOI 10.1007/s001250051675; Jones PM, 1998, ENDOCR REV, V19, P429, DOI 10.1210/er.19.4.429; Kaneto H, 2002, J BIOL CHEM, V277, P3680, DOI 10.1074/jbc.M109647200; Kasai K, 2005, J CLIN INVEST, V115, P388, DOI 10.1172/JCI200522955; Knutson KL, 1996, J CELL BIOCHEM, V60, P130, DOI 10.1002/(SICI)1097-4644(19960101)60:1<130::AID-JCB15>3.0.CO;2-T; Knutson KL, 1997, BIOCHEM MOL MED, V62, P50, DOI 10.1006/bmme.1997.2613; KOMATSU M, 1995, P NATL ACAD SCI USA, V92, P10728, DOI 10.1073/pnas.92.23.10728; Lammert E, 2003, CURR BIOL, V13, P1070, DOI 10.1016/S0960-9822(03)00378-6; Lilja L, 2004, J BIOL CHEM, V279, P29534, DOI 10.1074/jbc.M312711200; Liu Y, 2006, J BIOL CHEM, V281, P12102, DOI 10.1074/jbc.M600508200; Mica OI, 2004, BIOCHEM J, V381, P13, DOI 10.1042/BJ20040434; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Morgan A, 2005, BIOCHEM SOC T, V33, P1341, DOI 10.1042/BST0331341; Nagamatsu S, 1999, DIABETES, V48, P2367, DOI 10.2337/diabetes.48.12.2367; Nesher R, 2002, DIABETES, V51, pS68, DOI 10.2337/diabetes.51.2007.S68; Nomiyama T, 2004, BIOCHEM BIOPH RES CO, V320, P639, DOI 10.1016/j.bbrc.2004.06.019; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; Regazzi R, 1996, J CELL SCI, V109, P2265; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Sheu L, 2003, J BIOL CHEM, V278, P27556, DOI 10.1074/jbc.M303203200; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; Tian YM, 1996, MOL CELL ENDOCRINOL, V119, P185, DOI 10.1016/0303-7207(96)03811-7; Warwar N, 2006, DIABETES, V55, P590, DOI 10.2337/diabetes.55.03.06.db05-0001; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Yu W, 2000, DIABETES, V49, P945, DOI 10.2337/diabetes.49.6.945; ZAITSEV SV, 1995, P NATL ACAD SCI USA, V92, P9712, DOI 10.1073/pnas.92.21.9712; Zawalich WS, 2001, MOL CELL ENDOCRINOL, V177, P95, DOI 10.1016/S0303-7207(01)00422-1; Zhang W, 2000, J BIOL CHEM, V275, P41521, DOI 10.1074/jbc.M005479200	55	57	58	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2707	2716		10.1074/jbc.M610482200	http://dx.doi.org/10.1074/jbc.M610482200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135234	hybrid			2022-12-27	WOS:000243593200063
J	Uhlmann, T; Boeing, S; Lehmbacher, M; Meisterernst, M				Uhlmann, Thomas; Boeing, Stefan; Lehmbacher, Michael; Meisterernst, Michael			The VP16 activation domain establishes an active mediator lacking CDK8 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; HISTONE ACETYLTRANSFERASE COMPLEXES; TRANSCRIPTION FACTOR-TFIIB; GENE-EXPRESSION; BASAL TRANSCRIPTION; COACTIVATOR COMPLEX; COFACTOR COMPLEX; MAMMALIAN-CELLS; CHROMATIN; BINDING	VP16 has been widely used to unravel the mechanisms underlying gene transcription. Much of the previous work has been conducted in reconstituted in vitro systems. Here we study the formation of transcription complexes at stable reporters under the control of an inducible Tet-VP16 activator in living cells. In this simplified model for gene activation VP16 recruits the general factors and the cofactors Mediator, GCN5, CBP, and PC4, within minutes to the promoter region. Activation is accompanied by only minor changes in histone acetylation and H3K4 methylation but induces a marked promoter-specific increase in H3K79 methylation. Mediated through contacts with VP16 several subunits of the cleavage and polyadenylation factor (CPSF/CstF) are concentrated at the promoter region. We provide in vitro and in vivo evidence that VP16 activates transcription through a specific MED25-associated Mediator, which is deficient in CDK8.	Natl Res Ctr Environm & Hlth, D-81377 Munich, Germany	University of Munich	Meisterernst, M (corresponding author), Natl Res Ctr Environm & Hlth, Marchioninistr 25, D-81377 Munich, Germany.	Meisterernst@gsf.de						Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Andrau JC, 2006, MOL CELL, V22, P179, DOI 10.1016/j.molcel.2006.03.023; Baek HJ, 2006, J BIOL CHEM, V281, P15172, DOI 10.1074/jbc.M601983200; Blazek E, 2005, CHROMOSOMA, V113, P399, DOI 10.1007/s00412-005-0329-5; Calvo O, 2005, EMBO J, V24, P1009, DOI 10.1038/sj.emboj.7600575; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; CHOY B, 1993, COLD SPRING HARB SYM, V58, P199, DOI 10.1101/SQB.1993.058.01.024; Conaway RC, 2005, TRENDS BIOCHEM SCI, V30, P250, DOI 10.1016/j.tibs.2005.03.002; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; Elmlund H, 2006, P NATL ACAD SCI USA, V103, P15788, DOI 10.1073/pnas.0607483103; Fivaz J, 2000, METH MOL B, V133, P167; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Fukuda A, 2004, MOL CELL BIOL, V24, P6525, DOI 10.1128/MCB.24.14.6525-6535.2004; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gilfillan S, 2005, J BIOL CHEM, V280, P6222, DOI 10.1074/jbc.M406343200; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOSSEN M, 1995, BIOTECHNIQUES, V19, P213; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Hallberg M, 2004, P NATL ACAD SCI USA, V101, P3370, DOI 10.1073/pnas.0400221101; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; Hardy S, 2002, J BIOL CHEM, V277, P32875, DOI 10.1074/jbc.M205860200; Ikeda K, 2002, GENES CELLS, V7, P49, DOI 10.1046/j.1356-9597.2001.00492.x; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Johnson KM, 2004, METHOD ENZYMOL, V380, P207; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Malik S, 2005, MOL CELL BIOL, V25, P2117, DOI 10.1128/MCB.25.6.2117-2129.2005; Mittler G, 2003, EMBO J, V22, P6494, DOI 10.1093/emboj/cdg619; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Ryu SJ, 1999, P NATL ACAD SCI USA, V96, P7137, DOI 10.1073/pnas.96.13.7137; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sato S, 2004, MOL CELL, V14, P685, DOI 10.1016/j.molcel.2004.05.006; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; SEIPEL K, 1994, BIOL CHEM H-S, V375, P463, DOI 10.1515/bchm3.1994.375.7.463; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; Taatjes DJ, 2004, MOL CELL, V14, P675, DOI 10.1016/j.molcel.2004.05.014; Taatjes DJ, 2004, NAT REV MOL CELL BIO, V5, P403, DOI 10.1038/nrm1369; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Wang G, 2005, MOL CELL, V17, P683, DOI 10.1016/j.molcel.2005.02.010; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; Xie J, 2000, EMBO J, V19, P672, DOI 10.1093/emboj/19.4.672; Zeisig BB, 2003, LEUKEMIA, V17, P359, DOI 10.1038/sj.leu.2402804; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015; Zhou J, 2005, EMBO J, V24, P1406, DOI 10.1038/sj.emboj.7600609; Zhu XF, 2006, MOL CELL, V22, P169, DOI 10.1016/j.molcel.2006.03.032	65	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2163	2173		10.1074/jbc.M608451200	http://dx.doi.org/10.1074/jbc.M608451200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135252	hybrid			2022-12-27	WOS:000243593200007
J	Bredemeier, R; Schlegel, T; Ertel, F; Vojta, A; Borissenko, L; Bohnsack, MT; Groll, M; Von Haeseler, A; Schleiff, E				Bredemeier, Rolf; Schlegel, Thomas; Ertel, Franziska; Vojta, Aleksandar; Borissenko, Ljudmila; Bohnsack, Markus T.; Groll, Michael; Von Haeseler, Arndt; Schleiff, Enrico			Functional and phylogenetic properties of the pore-forming beta-barrel transporters of the Omp85 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; CONSERVED BACTERIAL PROTEIN; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; ASSEMBLY MACHINERY; CELL VIABILITY; CHANNEL TOC75; LIPID EXPORT; YAET OMP85; ENVELOPE	beta-Barrel-shaped channels of the Omp85 family are involved in the translocation or assembly of proteins of bacterial, mitochondrial, and plastidic outer membranes. We have compared these proteins to understand the evolutionary development of the translocators. We have demonstrated that the proteins from proteobacteria and mitochondria have a pore diameter that is at least five times smaller than found for the Omp85 in cyanobacteria and plastids. This finding can explain why Omp85 from cyanobacteria (but not the homologous protein from proteobacteria) was remodeled to become the protein translocation pore after endosymbiosis. Further, the pore-forming region of the Omp85 proteins is restricted to the C terminus. Based on a phylogenetic analysis we have shown that the pore-forming domain displays a different evolutionary relationship than the N-terminal domain. In line with this, the affinity of the N-terminal domain to the C-terminal region of the Omp85 from plastids and cyanobacteria differs, even though the N-terminal domain is involved in gating of the pore in both groups. We have further shown that the N-terminal domain of nOmp85 takes part in homo-oligomerization. Thereby, the differences in the phylogeny of the two domains are explained by different functional constraints acting on the regions. The pore-forming domain, however, is further divided into two functional regions, where the distal C terminus itself forms a dimeric pore. Based on functional and phylogenetic analysis, we suggest an evolutionary scenario that explains the origin of the contemporary translocon.	Univ Munich, Dept Biol 1, VW Res Grp, D-80638 Munich, Germany; Univ Dusseldorf, Inst Informat, D-40225 Dusseldorf, Germany; Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany; Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Med Univ Vienna, Max F Perutz Labs, Ctr Integrat Bioinformat Vienna, A-1030 Vienna, Austria; Vet Univ Vienna, A-1030 Vienna, Austria	University of Munich; Heinrich Heine University Dusseldorf; University of Munich; University of Edinburgh; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); University of Veterinary Medicine Vienna	Schleiff, E (corresponding author), Univ Munich, Dept Biol 1, VW Res Grp, Menzinger Str 67, D-80638 Munich, Germany.	schleiff@lrz.uni-muenchen.de	Groll, Michael/C-1174-2010; Bohnsack, Markus T./D-3076-2011; Groll, Michael/F-5572-2015; Vojta, Aleksandar/S-2086-2017; von Haeseler, Arndt/HCI-9958-2022; Schleiff, Enrico/C-5105-2017	Bohnsack, Markus T./0000-0001-7063-5456; Vojta, Aleksandar/0000-0002-4627-1821; von Haeseler, Arndt/0000-0002-3366-4458; Schleiff, Enrico/0000-0002-0518-3489				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arora A, 2001, NAT STRUCT BIOL, V8, P334, DOI 10.1038/86214; Cavalier-Smith T, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-19; Doerrler WT, 2005, J BIOL CHEM, V280, P27679, DOI 10.1074/jbc.M504796200; Dyall SD, 2004, SCIENCE, V304, P253, DOI 10.1126/science.1094884; Ertel F, 2005, J BIOL CHEM, V280, P28281, DOI 10.1074/jbc.M503035200; Faraldo-Gomez JD, 2003, NAT REV MOL CELL BIO, V4, P105, DOI 10.1038/nrm1015; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Fitzpatrick DA, 2005, J MOL EVOL, V60, P268, DOI 10.1007/s00239-004-0194-5; Genevrois S, 2003, EMBO J, V22, P1780, DOI 10.1093/emboj/cdg174; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; Gentle IE, 2005, MOL MICROBIOL, V58, P1216, DOI 10.1111/j.1365-2958.2005.04906.x; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Hertle R, 1997, MOL MICROBIOL, V26, P853, DOI 10.1046/j.1365-2958.1997.6031978.x; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; Inoue K, 2004, PLANT J, V39, P354, DOI 10.1111/j.1365-313X.2004.02135.x; Ishikawa D, 2004, J CELL BIOL, V166, P621, DOI 10.1083/jcb.200405138; Jacob-Dubuisson F, 1999, J BIOL CHEM, V274, P37731, DOI 10.1074/jbc.274.53.37731; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Kikuchi S, 2006, PLANT CELL PHYSIOL, V47, P363, DOI 10.1093/pcp/pcj002; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Malinverni JC, 2006, MOL MICROBIOL, V61, P151, DOI 10.1111/j.1365-2958.2006.05211.x; Milenkovic D, 2004, J BIOL CHEM, V279, P22781, DOI 10.1074/jbc.C400120200; Moslavac S, 2005, FEBS J, V272, P1367, DOI 10.1111/j.1742-4658.2005.04569.x; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Schleiff E, 2005, EMBO REP, V6, P1023, DOI 10.1038/sj.embor.7400563; Schleiff E, 2003, PROTEIN SCI, V12, P748, DOI 10.1110/ps.0237503; Schleiff E, 2003, J CELL BIOL, V160, P541, DOI 10.1083/jcb.200210060; Stegmeier JF, 2006, J BIOCHEM, V140, P275, DOI 10.1093/jb/mvj147; Steiner JM, 2005, MOL MEMBR BIOL, V22, P123, DOI 10.1080/09687860500041411; Surana NK, 2004, P NATL ACAD SCI USA, V101, P14497, DOI 10.1073/pnas.0404679101; Vinh LS, 2004, MOL BIOL EVOL, V21, P1565, DOI 10.1093/molbev/msh176; Voulhoux R, 2004, RES MICROBIOL, V155, P129, DOI 10.1016/j.resmic.2003.11.007; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Werner J, 2005, MOL MICROBIOL, V57, P1450, DOI 10.1111/j.1365-2958.2005.04775.x; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; Wirth A, 2003, MOL CELL, V12, P261, DOI 10.1016/S1097-2765(03)00283-1; Wu T, 2005, CELL, V121, P235, DOI 10.1016/j.cell.2005.02.015; Yen MR, 2002, BBA-BIOMEMBRANES, V1562, P6, DOI 10.1016/S0005-2736(02)00359-0	41	74	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1882	1890		10.1074/jbc.M609598200	http://dx.doi.org/10.1074/jbc.M609598200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17088246	hybrid			2022-12-27	WOS:000243451300039
J	Glerup, S; Kloverpris, S; Laursen, LS; Dagnaes-Hansen, F; Thiel, S; Conover, CA; Oxvig, C				Glerup, Simon; Kloverpris, Sren; Laursen, Lisbeth S.; Dagnaes-Hansen, Frederik; Thiel, Steffen; Conover, Cheryl A.; Oxvig, Claus			Cell surface detachment of pregnancy-associated plasma protein-A requires the formation of intermolecular proteinase-inhibitor disulfide bonds and glycosaminoglycan covalently bound to the inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR BASIC-PROTEIN; MESSENGER-RIBONUCLEIC-ACID; PAPP-A; TERNARY COMPLEX; PROFORM; BINDING; PROTEOLYSIS; SPECIFICITY; EXPRESSION; MECHANISM	The metzincin metalloproteinase pregnancy-associated plasma protein-A (PAPP-A, pappalysin-1) promotes cell growth by proteolytic cleavage of insulin-like growth factor-binding proteins 4 and 5, causing the release of bound insulin-like growth factors. PAPP-A binds an unknown cell-surface heparan sulfate proteoglycan, suggesting that it controls insulin-like growth factor signaling spatially. In human pregnancy, the majority of PAPP-A circulates as a disulfide-bonded complex with its inhibitor, the proform of eosinophil major basic protein (proMBP). Interestingly, Ser-62 of proMBP is substituted with a glycosaminoglycan ( GAG) chain, possibly a heparan sulfate type, and the PAPP-A center dot proMBP complex is unable to bind to the cell surface. We show here that proMBP detaches surface-bound PAPP-A in a process that depends on the proMBP GAG and also on the formation of intermolecular disulfide bonds between PAPP-A and proMBP. Unlike what was expected, we demonstrate that the GAG of proMBP is not required for PAPP-A center dot proMBP complex formation and that proMBP residues His-137, Ser-178, Arg-179, and Asn-181 are important for the recognition of PAPP-A. Using a mouse model, we find that the half-life of circulating PAPP-A and proMBP in complex is severalfold higher than both of the uncomplexed proteins, further suggesting that the PAPP-A center dot proMBP complex is formed at the cell surface in vivo rather than in the circulation. Further supporting this, we show that formation of the PAPP-A center dot proMBP complex at the cell surface proceeds rapidly compared with the slow rate of complex formation in solution. Because both PAPP-A and proMBP are expressed ubiquitously, this model may be applicable to many tissues in which insulin-like growth factor bioavailability is locally regulated.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Immunol & Med Microbiol, DK-8000 Aarhus C, Denmark; Mayo Clin & Mayo Fdn, Coll Med, Dept Internal Med, Div Metab Endocrinol & Nutr, Rochester, MN 55905 USA	Aarhus University; Aarhus University; Mayo Clinic	Oxvig, C (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	co@mb.au.dk		Thiel, Steffen/0000-0002-4817-155X; Laursen, Lisbeth Schmidt/0000-0002-8676-5869; Oxvig, Claus/0000-0002-4715-9719; Dagnaes-Hansen, Frederik/0000-0002-6622-0853				Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Boldt HB, 2001, BIOCHEM J, V358, P359, DOI 10.1042/0264-6021:3580359; BONNO M, 1994, LAB INVEST, V71, P560; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; Chen BK, 2003, J CLIN ENDOCR METAB, V88, P4465, DOI 10.1210/jc.2003-030193; Conover CA, 2004, DEVELOPMENT, V131, P1187, DOI 10.1242/dev.00997; Conover CA, 2001, ENDOCRINOLOGY, V142, P2155, DOI 10.1210/en.142.5.2155; Dementiev A, 2004, NAT STRUCT MOL BIOL, V11, P863, DOI 10.1038/nsmb810; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Ganesh VK, 2004, P NATL ACAD SCI USA, V101, P8924, DOI 10.1073/pnas.0400744101; GIUDICE LC, 2002, J CLIN ENDOCR METAB, V87, P2329; Glerup S, 2005, J BIOL CHEM, V280, P9823, DOI 10.1074/jbc.M413228200; Glerup S, 2006, J BIOL CHEM, V281, P31509, DOI 10.1074/jbc.M605824200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hogg PJ, 2003, TRENDS BIOCHEM SCI, V28, P210, DOI 10.1016/S0968-0004(03)00057-4; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Laursen LS, 2002, J BIOL CHEM, V277, P47225, DOI 10.1074/jbc.M209155200; Laursen LS, 2002, BIOCHEM J, V367, P31, DOI 10.1042/BJ20020831; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; Overgaard MT, 2000, J BIOL CHEM, V275, P31128, DOI 10.1074/jbc.M001384200; Overgaard MT, 1999, BIOL REPROD, V61, P1083, DOI 10.1095/biolreprod61.4.1083; Overgaard MT, 2004, FEBS LETT, V560, P147, DOI 10.1016/S0014-5793(04)00095-X; Overgaard MT, 2003, J BIOL CHEM, V278, P2106, DOI 10.1074/jbc.M208777200; OXVIG C, 1994, BIOCHEM MOL BIOL INT, V33, P329; OXVIG C, 1993, J BIOL CHEM, V268, P12243; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PIZZO SV, 1989, AM J MED, V87, pS10, DOI 10.1016/0002-9343(89)80524-8; Qin QP, 1997, CLIN CHEM, V43, P2323; Smith GCS, 2002, NATURE, V417, P916, DOI 10.1038/417916a; SOTTRUPJENSEN L, 1993, BIOCHEM MOL BIOL INT, V30, P789; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; Swaminathan GJ, 2001, J BIOL CHEM, V276, P26197, DOI 10.1074/jbc.M100848200; Wald NJ, 1999, NEW ENGL J MED, V341, P461, DOI 10.1056/NEJM199908123410701; Weyer K, 2004, EUR J BIOCHEM, V271, P1525, DOI 10.1111/j.1432-1033.2004.04061.x; Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200	39	14	14	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1769	1778		10.1074/jbc.M608454200	http://dx.doi.org/10.1074/jbc.M608454200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17145752	hybrid			2022-12-27	WOS:000243451300028
J	Li, QP; Qi, XM; Pramanik, R; Pohl, NM; Loesch, M; Chen, G				Li, Qing-Ping; Qi, Xiaomei; Pramanik, Rocky; Pohl, Nicole M.; Loesch, Mathew; Chen, Guan			Stress-induced c-Jun-dependent vitamin D receptor (VDR) activation dissects the non-classical VDR pathway from the classical VDR activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; RETINOID-X-RECEPTOR; CHEMOTHERAPY-INDUCED ALOPECIA; TRANSCRIPTIONAL ACTIVATION; GROWTH-INHIBITION; CARCINOMA-CELLS; 1,25-DIHYDROXYVITAMIN D-3; SIGNALING PATHWAY; NUCLEAR RECEPTORS; PROTEIN-KINASES	Vitamin D receptor (VDR) is a ligand-dependent transcription factor that mediates vitamin D-3-induced gene expression. Our previous work has established that stress MAPK signaling stimulates VDR expression (Qi, X., Pramank, R., Wang, J., Schultz, R. M., Maitra, R. K., Han, J., DeLuca, H. F., and Chen, G. (2002) J. Biol. Chem. 277, 25884-25892) and VDR inhibits cell death in response to p38 MAPK activation (Qi, X., Tang, J., Pramanik, R., Schultz, R. M., Shirasawa, S., Sasazuki, T., Han, J., and Chen, G. (2004) J. Biol. Chem. 279, 22138-22144). Here we show that c-Jun is essential for VDR expression and VDR in turn inhibits c-Jun-dependent cell death by non-classical mechanisms. In response to stress c-Jun is recruited to the Vdr promoter before VDR protein expression is induced. The necessary and sufficient role of c-Jun in VDR expression was established by the fact that c-Jun knock-out decreases VDR expression, whereas c-Jun restoration recovers its activity. Existence of the non-classical VDR pathway was suggested by a requirement of both c-Jun and VDR in stress-induced VDR activity and further demonstrated by VDR inhibiting c-Jun-dependent cell death independent of its classical transcriptional activity and independent of vitamin D3. c-Jun is also required for vitamin D3-induced classical VDR transcriptional activity by a mechanism likely involving physical interactions between c-Jun and VDR proteins. These results together reveal a non-classical mechanism by which VDR acts as a c-Jun/AP-1 target gene to modify c-Jun activity in stress response through increased protein expression independent of classical transcriptional regulations.	Med Coll Wisconsin, Dept Pharmacol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Toxicol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Zablocki Vet Adm Med Ctr, Milwaukee, WI 53226 USA; Loyola Univ, Dept Radiat Oncol, Maywood, IL 60153 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Loyola University Chicago	Chen, G (corresponding author), Med Coll Wisconsin, Dept Pharmacol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	gchen@mcw.edu			NCI NIH HHS [2R01 CA91576] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091576] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; ALROY I, 1995, MOL CELL BIOL, V15, P5789; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bao BY, 2004, ONCOGENE, V23, P3350, DOI 10.1038/sj.onc.1207461; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Chen G, 1998, INT J CANCER, V75, P303, DOI 10.1002/(SICI)1097-0215(19980119)75:2<303::AID-IJC21>3.0.CO;2-C; Chen LF, 2005, J IMMUNOL, V174, P6144, DOI 10.4049/jimmunol.174.10.6144; CHEN TL, 1981, J BIOL CHEM, V256, P5561; Daniel C, 2004, BIOCHEM BIOPH RES CO, V324, P1220, DOI 10.1016/j.bbrc.2004.09.191; Diaz GD, 2000, CANCER RES, V60, P2304; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Gilad LA, 2005, J ENDOCRINOL, V185, P577, DOI 10.1677/joe.1.05770; Guzey M, 2004, J CELL BIOCHEM, V93, P133, DOI 10.1002/jcb.20172; Hershberger PA, 1999, CANCER RES, V59, P2644; Hewison M, 1996, J IMMUNOL, V156, P4391; Hsieh JC, 2003, J BIOL CHEM, V278, P38665, DOI 10.1074/jbc.M304886200; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; Jehan F, 1997, P NATL ACAD SCI USA, V94, P10138, DOI 10.1073/pnas.94.19.10138; JIMENEZ JJ, 1992, CANCER RES, V52, P5123; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kane KF, 1996, CANCER RES, V56, P623; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Konta T, 2001, J BIOL CHEM, V276, P12697, DOI 10.1074/jbc.M011000200; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Lee H, 2000, MOL ENDOCRINOL, V14, P1882, DOI 10.1210/me.14.11.1882; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Maruyama R, 2006, CANCER RES, V66, P4574, DOI 10.1158/0008-5472.CAN-05-2562; Mathiasen IS, 2002, J BIOL CHEM, V277, P30738, DOI 10.1074/jbc.M201558200; McGuire TF, 2001, J BIOL CHEM, V276, P26365, DOI 10.1074/jbc.M010101200; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Pedigo NG, 2005, ONCOGENE, V24, P2654, DOI 10.1038/sj.onc.1208336; Pinzone JJ, 2004, MOL CELL BIOL, V24, P4605, DOI 10.1128/MCB.24.11.4605-4612.2004; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Qi XM, 2004, J BIOL CHEM, V279, P22138, DOI 10.1074/jbc.M313964200; Qi XM, 2004, J BIOL CHEM, V279, P6769, DOI 10.1074/jbc.M311492200; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; Ravid A, 2002, J ENDOCRINOL, V173, DOI 10.1677/joe.0.1730525; Schilli MB, 1998, J INVEST DERMATOL, V111, P598, DOI 10.1046/j.1523-1747.1998.00350.x; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; STUDZINSKI GP, 1995, CANCER RES, V55, P4014; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tang J, 2005, J BIOL CHEM, V280, P23910, DOI 10.1074/jbc.M500699200; Tolon RM, 2000, MOL CELL BIOL, V20, P8793, DOI 10.1128/MCB.20.23.8793-8802.2000; Towers TL, 1999, MOL CELL BIOL, V19, P4191; VINKVANWIJNGAARDEN T, 1994, CANCER RES, V54, P5711; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WIESE RJ, 1992, J BIOL CHEM, V267, P20082; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU HM, 1993, EXP CELL RES, V209, P367, DOI 10.1006/excr.1993.1322; Yang LM, 2001, J CELL PHYSIOL, V188, P383, DOI 10.1002/jcp.1125; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	68	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1544	1551		10.1074/jbc.M604052200	http://dx.doi.org/10.1074/jbc.M604052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121851	hybrid			2022-12-27	WOS:000243451300005
J	Fu, J; Astarita, G; Gaetani, S; Kim, J; Cravatt, BF; Mackie, K; Piomelli, D				Fu, Jin; Astarita, Giuseppe; Gaetani, Silvana; Kim, Janet; Cravatt, Benjamin F.; Mackie, Ken; Piomelli, Daniele			Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D; MOLECULAR CHARACTERIZATION; ACID AMIDASE; BODY-WEIGHT; ANANDAMIDE; RECEPTOR; RAT; MODULATION; PHOSPHATIDYLETHANOLAMINE; BIOSYNTHESIS	Oleoylethanolamide (OEA) is a lipid mediator that inhibits food intake by activating the nuclear receptor peroxisome proliferator-activated receptor-alpha. In the rodent small intestine OEA levels decrease during food deprivation and increase upon refeeding, suggesting that endogenous OEA may participate in the regulation of satiety. Here we show that feeding stimulates OEA mobilization in the mucosal layer of rat duodenum and jejunum but not in the serosal layer from the same intestinal segments in other sections of the gastrointestinal tract (stomach, ileum, colon) or in a broad series of internal organs and tissues (e.g. liver, brain, heart, plasma). Feeding also increases the levels of other unsaturated fatty acid ethanolamides (FAEs) (e.g. linoleoylethanolamide) without affecting those of saturated FAEs (e.g. palmitoylethanolamide). Feeding-induced OEA mobilization is accompanied by enhanced accumulation of OEA-generating N-acylphos-phatidylethanolamines (NAPEs) increased activity and expression of the OEA-synthesizing enzyme NAPE-phospholipase D, and decreased activity and expression of the OEA-degrading enzyme fatty acid amide hydrolase. Immunostaining studies revealed that NAPE-phospholipase D and fatty acid amide hydrolase are expressed in intestinal enterocytes and lamina propria cells. Collectively, these results indicate that nutrient availability controls OEA mobilization in the mucosa of the proximal intestine through a concerted regulation of OEA biosynthesis and degradation.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Drug Discovery, Irvine, CA 92697 USA; Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, I-00185 Rome, Italy; Scripps Res Inst, Dept Cell Biol & Chem, La Jolla, CA 92037 USA; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Sapienza University Rome; Scripps Research Institute; University of Washington; University of Washington Seattle	Piomelli, D (corresponding author), Univ Calif Irvine, Dept Pharmacol, 360 MSRII, Irvine, CA 92697 USA.	piomelli@uci.edu	Fu, Jin/A-3510-2012; Gaetani, Silvana/D-3455-2009; Mackie, Ken/E-3715-2013; Mackie, Kenneth P/B-7358-2011; Astarita, Giuseppe/AAD-1239-2019; Astarita, Giuseppe/N-7346-2014	Mackie, Ken/0000-0001-8501-6199; Astarita, Giuseppe/0000-0001-6700-301X	NIDA NIH HHS [R01 DA011322, K02 DA000286] Funding Source: Medline; NIDDK NIH HHS [R01 DK073955] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011322, K02DA000286] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ahern GP, 2003, J BIOL CHEM, V278, P30429, DOI 10.1074/jbc.M305051200; Astarita G, 2006, AM J PHYSIOL-REG I, V290, pR1407, DOI 10.1152/ajpregu.00664.2005; Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bocher V, 2002, ANN NY ACAD SCI, V967, P7; Broberger C, 2005, J INTERN MED, V258, P301, DOI 10.1111/j.1365-2796.2005.01553.x; Cadas H, 1997, J NEUROSCI, V17, P1226; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; Gaetani S, 2003, NEUROPSYCHOPHARMACOL, V28, P1311, DOI 10.1038/sj.npp.1300166; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Gomez R, 2002, J NEUROSCI, V22, P9612; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Kersten S, 2000, EXS, V89, P141; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; Little TJ, 2005, OBES REV, V6, P297, DOI 10.1111/j.1467-789X.2005.00212.x; Lo Verme J, 2005, CELL MOL LIFE SCI, V62, P708, DOI 10.1007/s00018-004-4494-0; LoVerme J, 2006, J BIOL CHEM, V281, P22815, DOI 10.1074/jbc.M604751200; Lowe ME, 1997, ANNU REV NUTR, V17, P141, DOI 10.1146/annurev.nutr.17.1.141; McKinney MK, 2005, ANNU REV BIOCHEM, V74, P411, DOI 10.1146/annurev.biochem.74.082803.133450; Mor M, 2004, J MED CHEM, V47, P4998, DOI 10.1021/jm031140x; Nielsen MJ, 2004, J LIPID RES, V45, P1027, DOI 10.1194/jlr.C300008-JLR200; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Onaga T, 2002, PEPTIDES, V23, P279, DOI 10.1016/S0196-9781(01)00609-X; Overton HA, 2006, CELL METAB, V3, P167, DOI 10.1016/j.cmet.2006.02.004; Petersen G, 2006, BBA-MOL CELL BIOL L, V1761, P143, DOI 10.1016/j.bbalip.2005.12.011; Proulx K, 2005, AM J PHYSIOL-REG I, V289, pR729, DOI 10.1152/ajpregu.00029.2005; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Shi YG, 2004, NAT REV DRUG DISCOV, V3, P695, DOI 10.1038/nrd1469; Strader AD, 2005, GASTROENTEROLOGY, V128, P175, DOI 10.1053/j.gastro.2004.10.043; Tsuboi K, 2005, J BIOL CHEM, V280, P11082, DOI 10.1074/jbc.M413473200; Tsuboi K, 2004, BIOCHEM J, V379, P99, DOI 10.1042/BJ20031695; Twitchell W, 1997, J NEUROPHYSIOL, V78, P43, DOI 10.1152/jn.1997.78.1.43; Wang J, 2006, J BIOL CHEM, V281, P12325, DOI 10.1074/jbc.M512359200; Wang XB, 2005, J PHYSIOL-LONDON, V564, P541, DOI 10.1113/jphysiol.2004.081844; YANG Y, 2006, IN PRESS AM J PHYSL	38	191	200	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1518	1528		10.1074/jbc.M607809200	http://dx.doi.org/10.1074/jbc.M607809200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17121838	hybrid, Green Accepted, Green Submitted			2022-12-27	WOS:000243295200076
J	Hogg, M; Aller, P; Konigsberg, W; Wallace, SS; Doublie, S				Hogg, Matthew; Aller, Pierre; Konigsberg, William; Wallace, Susan S.; Doublie, Sylvie			Structural and biochemical investigation of the role in proofreading of a beta hairpin loop found in the exonuclease domain of a replicative DNA polymerase of the B family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DEOXYRIBONUCLEIC-ACID; APYRIMIDINIC SITES; FIDELITY; INSIGHTS; COMPLEX; PROCESSIVITY; DYNAMICS; KINETICS; FRAGMENT	Replicative DNA polymerases, as exemplified by the B family polymerases from bacteriophages T4 and RB69, not only replicate DNA but also have the ability to proofread misincorporated nucleotides. Because the two activities reside in separate protein domains, polymerases must employ a mechanism that allows for efficient switching of the primer strand between the two active sites to achieve fast and accurate replication. Prior mutational and structural studies suggested that a beta hairpin structure located in the exonuclease domain of family B polymerases might play an important role in active site switching in the event of a nucleotide misincorporation. We show that deleting the beta hairpin loop in RB69 gp43 affects neither polymerase nor exonuclease activities. Single binding event studies with mismatched primer termini, however, show that the beta hairpin plays a role in maintaining the stability of the polymerase/DNA interactions during the binding of the primer DNA in the exonuclease active site but not on the return of the corrected primer to the polymerase active site. In addition, the deletion variant showed a more stable incorporation of a nucleotide opposite an abasic site. Moreover, in the 2.4 angstrom crystal structure of the beta hairpin deletion variant incorporating an A opposite a templating furan, all four molecules in the crystal asymmetric unit have DNA in the polymerase active site, despite the presence of DNA distortions because of the misincorporation, confirming that the primer strand is not stably bound within the exonuclease active site in the absence of the beta hairpin loop.	Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Burlington, VT 05405 USA; Yale Univ, Dept Biochem & Mol Biophys, New Haven, CT 06510 USA	University of Vermont; Yale University	Wallace, SS (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Stafford Hall,95 Carrigan Dr, Burlington, VT 05405 USA.	swallace@uvm.edu; sdoublie@uvm.edu		Wallace, Susan S./0000-0002-3906-0321; Aller, Pierre/0000-0002-1793-7030; Doublie, Sylvie/0000-0002-6294-5304	NATIONAL CANCER INSTITUTE [R01CA052040] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA052040-16, CA52040] Funding Source: Medline; NIGMS NIH HHS [Y1-GM-1104] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bebenek A, 2001, J BIOL CHEM, V276, P10387, DOI 10.1074/jbc.M007707200; Berdis AJ, 2001, BIOCHEMISTRY-US, V40, P7180, DOI 10.1021/bi0101594; BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6746, DOI 10.1021/bi00269a020; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W.L, PYMOL MOL GRAPHICS S; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; DRAKE JW, 1969, NATURE, V221, P1132, DOI 10.1038/2211132a0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Freisinger E, 2004, EMBO J, V23, P1494, DOI 10.1038/sj.emboj.7600158; Hashimoto H, 2001, J MOL BIOL, V306, P469, DOI 10.1006/jmbi.2000.4403; Hogg M, 2004, EMBO J, V23, P1483, DOI 10.1038/sj.emboj.7600150; Hogg M, 2006, NUCLEIC ACIDS RES, V34, P2528, DOI 10.1093/nar/gkl300; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; Kamtekar S, 2004, MOL CELL, V16, P609, DOI 10.1016/j.molcel.2004.10.019; KUNKEL TA, 1984, J BIOL CHEM, V259, P1539; Liu SP, 2006, J BIOL CHEM, V281, P18193, DOI 10.1074/jbc.M602414200; Marquez LA, 1996, J BIOL CHEM, V271, P28903, DOI 10.1074/jbc.271.46.28903; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perez-Arnaiz P, 2006, NUCLEIC ACIDS RES, V34, P3107, DOI 10.1093/nar/gkl402; REDDY MK, 1992, J BIOL CHEM, V267, P14157; Reha-Krantz LJ, 1998, GENETICS, V148, P1551; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; Rodriguez AC, 2000, J MOL BIOL, V299, P447, DOI 10.1006/jmbi.2000.3728; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; Savino C, 2004, STRUCTURE, V12, P2001, DOI 10.1016/j.str.2004.09.007; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P438; STOCKI SA, 1995, J MOL BIOL, V254, P15, DOI 10.1006/jmbi.1995.0595; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; WANG CC, 1995, J BIOL CHEM, V270, P26558, DOI 10.1074/jbc.270.44.26558; Wang CX, 2004, BIOCHEMISTRY-US, V43, P3853, DOI 10.1021/bi0302292; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r; Zhao YX, 1999, STRUCTURE, V7, P1189, DOI 10.1016/S0969-2126(00)80053-2	39	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1432	1444		10.1074/jbc.M605675200	http://dx.doi.org/10.1074/jbc.M605675200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17098747	hybrid			2022-12-27	WOS:000243295200068
J	Liu, CL; Yu, IS; Pan, HW; Lin, SW; Hsu, HC				Liu, Chao-Lien; Yu, I-Shing; Pan, Hung-Wei; Lin, Shu-Wha; Hsu, Hey-Chi			L2dtl is essential for cell survival and nuclear division in early mouse embryonic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; DIFFERENTIAL DISPLAY; EARLY RECURRENCE; GENE-EXPRESSION; RETINOIC ACID; P53 MUTATION; BOX C/D; PROTEIN; REPEAT; MICE	l(2)dtl(lethal(2)denticleless), is an embryonic lethal homozygous mutation initially identified in Drosophila melanogaster that produces embryos that lack ventral denticle belts. In addition to nucleotide sequence, bioinformatic analysis has revealed a conservation of critical functional motifs among the human L2DTL, mouse L2dtl, and Drosophila l(2) dtl proteins. The function of the L2DTL protein in the development of mammalian embryos was studied using targeted disruption of the L2dtl gene in mice. The knock-out resulted in early embryonic lethality. L2dtl(-/-) embryos were deformed and terminated development at the 4-8-cell stage. Microinjection of a small interfering RNA (siRNA) vector (siRNA-L2dtl) into the two-cell stage nuclei of wild-type mouse embryos led to cell cycle progression failure, termination of cell division, and, eventually, embryonic death during the preimplantation stage. Morphological studies of the embryos 54 h after injection showed fragmentation of mitotic chromosomes and chromosomal lagging, hallmarks of mitotic catastrophe. The siRNA-L2dtl-treated embryos eventually lysed and failed to develop into blastocysts after 72 h of in vitro culturing. However, the embryos developed normally after they were microinjected into one nucleus of the two-celled embryos. The siRNA studies in HeLa cells showed that L2dtl protein depletion results in multinucleation and down-regulation of phosphatidylinositol 3-kinase, proliferating cell nuclear antigen, and PTTG1/securin, which might partially explain the mitotic catastrophe observed in L2dtl-depleted mouse embryos. Based on these findings, we conclude that L2dtl gene expression is essential for very early mouse embryonic development.	Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei 100, Taiwan; Natl Taiwan Univ, Grad Inst Pathol, Taipei 100, Taiwan; Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 100, Taiwan; Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Lin, SW (corresponding author), Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei 100, Taiwan.	swlin@ha.mc.ntu.edu.tw; heychi@ha.mc.ntu.edu.tw		LIN, SHU-WHA/0000-0001-6748-5581; Liu, Chao Lien/0000-0002-9574-0305				ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; Burton JL, 2005, MOL CELL, V18, P533, DOI 10.1016/j.molcel.2005.04.022; Cheung WMW, 2001, J BIOL CHEM, V276, P17083, DOI 10.1074/jbc.M010802200; CHOI WJ, 1990, BIOCHEM BIOPH RES CO, V172, P1324, DOI 10.1016/0006-291X(90)91594-I; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; d'Orval BC, 2001, NUCLEIC ACIDS RES, V29, P4518, DOI 10.1093/nar/29.22.4518; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; Evsikov AV, 2004, CYTOGENET GENOME RES, V105, P240, DOI 10.1159/000078195; Gratenstein K, 2005, GENOMICS, V85, P762, DOI 10.1016/j.ygeno.2005.02.010; Haraguchi S, 2004, MOL REPROD DEV, V68, P17, DOI 10.1002/mrd.20047; Hsu HC, 1997, CANCER RES, V57, P5179; HUANG LR, 1995, CANCER RES, V55, P4717; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; KurzikDumke U, 1996, GENE, V171, P163, DOI 10.1016/0378-1119(95)00885-3; LAWITTS JA, 1993, METHOD ENZYMOL, V225, P153; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lievens S, 2001, NUCLEIC ACIDS RES, V29, P3459, DOI 10.1093/nar/29.17.3459; Liu SH, 2002, AM J PATHOL, V160, P1831, DOI 10.1016/S0002-9440(10)61129-7; Morham SG, 1996, MOL CELL BIOL, V16, P6804; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Pan HW, 2003, CANCER-AM CANCER SOC, V98, P119, DOI 10.1002/cncr.11487; Pfleger CM, 2000, GENE DEV, V14, P655; Rinaudo P, 2004, REPRODUCTION, V128, P301, DOI 10.1530/rep.1.00297; Roers A, 1998, EUR J IMMUNOL, V28, P2424; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SHAW DR, 1989, MOL GEN GENET, V218, P453, DOI 10.1007/BF00332409; Sibon OCM, 1999, CURR BIOL, V9, P302, DOI 10.1016/S0960-9822(99)80138-9; Silva FP, 2005, NEOPLASIA, V7, P348, DOI 10.1593/neo.04544; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Tran E, 2005, RNA, V11, P285, DOI 10.1261/rna.7223405; van Nocker S, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-50; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; Xie P, 1997, NEUROREPORT, V8, P1067, DOI 10.1097/00001756-199703240-00001; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; Yamaguchi S, 1997, MOL BIOL CELL, V8, P2475, DOI 10.1091/mbc.8.12.2475; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; Yu IS, 2000, THROMB HAEMOSTASIS, V84, P865, DOI 10.1055/s-0037-1614129; Zhang XM, 2000, EXP HEMATOL, V28, P1286, DOI 10.1016/S0301-472X(00)00539-7	41	21	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1109	1118		10.1074/jbc.M606535200	http://dx.doi.org/10.1074/jbc.M606535200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17107960	Green Submitted, hybrid			2022-12-27	WOS:000243295200035
J	Minopoli, G; Stante, M; Napolitano, F; Telese, F; Aloia, L; De Felice, M; Di Lauro, R; Pacelli, R; Brunetti, A; Zambrano, N; Russo, T				Minopoli, Giuseppina; Stante, Maria; Napolitano, Francesco; Telese, Francesca; Aloia, Luigi; De Felice, Mario; Di Lauro, Roberto; Pacelli, Roberto; Brunetti, Arturo; Zambrano, Nicola; Russo, Tommaso			Essential roles for Fe65, Alzheimer amyloid precursor-binding protein, in the cellular response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; INTRACELLULAR DOMAIN; APP; PROGRESSION; INTERACTS; BREAKS; CELLS	Fe65 interacts with the cytosolic domain of the Alzheimer amyloid precursor protein (APP). The functions of the Fe65 are still unknown. To address this point we generated Fe65 knockout (KO) mice. These mice do not show any obvious phenotype; however, when fibroblasts (mouse embryonic fibroblasts), isolated from Fe65 KO embryos, were exposed to low doses of DNA damaging agents, such as etoposide or H2O2, an increased sensitivity to genotoxic stress, compared with wild type animals, clearly emerged. Accordingly, brain extracts from Fe65 KO mice, exposed to non-lethal doses of ionizing radiations, showed high levels of gamma-H2AX and p53, thus demonstrating a higher sensitivity to X-rays than wild type mice. Nuclear Fe65 is necessary to rescue the observed phenotype, and few minutes after the exposure of MEFs to DNA damaging agents, Fe65 undergoes phosphorylation in the nucleus. With a similar timing, the proteolytic processing of APP is rapidly affected by the genotoxic stress: in fact, the cleavage of the APP COOH-terminal fragments by gamma-secretase is induced soon after the exposure of cells to etoposide, in a Fe65-dependent manner. These results demonstrate that Fe65 plays an essential role in the response of the cells to DNA damage.	CEINGE Biotecnol Avanzate, I-80145 Naples, Italy; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; BioGeM Scarl CEINGE, I-80145 Naples, Italy; Univ Naples Federico II, CNR, Ist Biostrutture & Bioimmagini, Dipartimento Diangost Immagini & Radioterapia, I-80131 Naples, Italy	CEINGE Biotecnologie Avanzate; University of Naples Federico II; CEINGE Biotecnologie Avanzate; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); University of Naples Federico II	Russo, T (corresponding author), CEINGE Biotecnol Avanzate, Via Comunal Margherita 482, I-80145 Naples, Italy.	russot@dbbm.unina.it	Di Lauro, Roberto/A-2746-2012; Zambrano, Nicola/B-9352-2014; Russo, Tommaso/K-1331-2016; Brunetti, Arturo/AAE-5261-2019; Pacelli, Roberto/AFS-0333-2022; Napolitano, Francesco/F-8691-2012	Di Lauro, Roberto/0000-0001-9493-3036; Zambrano, Nicola/0000-0001-9395-3481; Russo, Tommaso/0000-0003-4426-0106; Brunetti, Arturo/0000-0001-7057-3494; Pacelli, Roberto/0000-0002-2048-7675; Aloia, Luigi/0000-0003-4509-2730; Telese, Francesca/0000-0003-3877-0628; Napolitano, Francesco/0000-0003-0884-1851				Adamec E, 1999, BRAIN RES, V849, P67, DOI 10.1016/S0006-8993(99)02004-1; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bruni P, 2002, J BIOL CHEM, V277, P35481, DOI 10.1074/jbc.M205227200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Guenette S, 2006, EMBO J, V25, P420, DOI 10.1038/sj.emboj.7600926; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Herms J, 2004, EMBO J, V23, P4106, DOI 10.1038/sj.emboj.7600390; Herrup K, 2004, J NEUROSCI, V24, P9232, DOI 10.1523/JNEUROSCI.3347-04.2004; Hoe HS, 2006, J BIOL CHEM, V281, P24521, DOI 10.1074/jbc.M600728200; Holway AH, 2006, J CELL BIOL, V172, P999, DOI 10.1083/jcb.200512136; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Nakaya T, 2006, GENES CELLS, V11, P633, DOI 10.1111/j.1365-2443.2006.00968.x; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Parshad R, 1996, P NATL ACAD SCI USA, V93, P5146, DOI 10.1073/pnas.93.10.5146; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Reddy PH, 2006, J NEUROCHEM, V96, P1, DOI 10.1111/j.1471-4159.2005.03530.x; Rolig RL, 2000, TRENDS NEUROSCI, V23, P417, DOI 10.1016/S0166-2236(00)01625-8; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sabo SL, 2003, J NEUROSCI, V23, P5407; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Telese F, 2005, EMBO REP, V6, P77, DOI 10.1038/sj.embor.7400309; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Wang BP, 2004, J NEUROSCI RES, V75, P12, DOI 10.1002/jnr.10834; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128; Zambrano N, 2002, J CELL SCI, V115, P1411; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200	36	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					831	835		10.1074/jbc.C600276200	http://dx.doi.org/10.1074/jbc.C600276200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17121854	hybrid			2022-12-27	WOS:000243295200004
J	Miyoshi, H; Perfield, JW; Souza, SC; Shen, WJ; Zhang, HH; Stancheva, ZS; Kraemer, FB; Obin, MS; Greenberg, AS				Miyoshi, Hideaki; Perfield, James W., II; Souza, Sandra C.; Shen, Wen-Jun; Zhang, Hui-Hong; Stancheva, Zlatina S.; Kraemer, Fredric B.; Obin, Martin S.; Greenberg, Andrew S.			Control of adipose triglyceride lipase action by serine 517 of perilipin A globally regulates protein kinase A-stimulated lipolysis in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; MEDIATED LIPOLYSIS; LIPID DROPLETS; EXPRESSION; TISSUE; PHOSPHORYLATION; METABOLISM; OBESITY; STORAGE; CGI-58	Phosphorylation of the lipid droplet-associated protein perilipin A (Peri A) mediates the actions of cyclic AMP-dependent protein kinase A (PKA) to stimulate triglyceride hydrolysis (lipolysis) in adipocytes. Studies addressing how Peri A PKA sites regulate adipocyte lipolysis have relied on non-adipocyte cell models, which express neither adipose triglyceride lipase (ATGL), the rate-limiting enzyme for triglyceride catabolism in mice, nor the "downstream" lipase, hormone-sensitive lipase (HSL). ATGL and HSL are robustly expressed by adipocytes that we generated from murine embryonic fibroblasts of perilipin knock-out mice. Adenoviral expression of Peri A PKA site mutants in these cells reveals that mutation of serine 517 alone is sufficient to abrogate 95% of PKA (forskolin)-stimulated fatty acid (FA) and glycerol release. Moreover, a "phosphomimetic" (aspartic acid) substitution at serine 517 enhances PKA-stimulated FA release over levels obtained with wild type Peri A. Studies with ATGL- and HSL-directed small hairpin RNAs demonstrate that 1) ATGL activity is required for all PKA-stimulated FA and glycerol release in murine embryonic fibroblast adipocytes and 2) all PKA-stimulated FA release in the absence of HSL activity requires serine 517 phosphorylation. These results provide the first demonstration that Peri A regulates ATGL- dependent lipolysis and identify serine 517 as the Peri A PKA site essential for this regulation. The contributions of other PKA sites to PKA-stimulated lipolysis are manifested only in the presence of phosphorylated or phosphomimetic serine 517. Thus, serine 517 is a novel "master regulator" of PKA-stimulated adipocyte lipolysis.	Tufts Univ, JMUSDA, HNRCA Tufts, Boston, MA 02111 USA; Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan; Stanford Univ, Palo Alto, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94305 USA	Tufts University; United States Department of Agriculture (USDA); Hokkaido University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Obin, MS (corresponding author), Tufts Univ, JMUSDA, HNRCA Tufts, 711 Washington St, Boston, MA 02111 USA.	martin.obin@tufts.edu; andrew.greenberg@tufts.edu	MIYOSHI, HIDEAKI/G-3971-2012; Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807; Shen, Wen-Jun/0000-0001-5150-1698	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928, R01DK050647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG024635] Funding Source: NIH RePORTER; NIA NIH HHS [AG024635] Funding Source: Medline; NIDDK NIH HHS [DK-50647, P30 DK-34928] Funding Source: Medline; NINDS NIH HHS [P30 NS047243] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arner P, 2005, BEST PRACT RES CL EN, V19, P471, DOI 10.1016/j.beem.2005.07.004; ARNER P, 1995, INT J OBES RELAT S4, V19, P18; Belfrage P, 1982, Prog Clin Biol Res, V102 Pt C, P213; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; COPPACK SW, 1994, J LIPID RES, V35, P177; Corella D, 2005, J CLIN ENDOCR METAB, V90, P5121, DOI 10.1210/jc.2005-0576; Dodt C, 2003, ACTA PHYSIOL SCAND, V177, P351, DOI 10.1046/j.1365-201X.2003.01077.x; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Haemmerle G, 2002, J BIOL CHEM, V277, P12946, DOI 10.1074/jbc.M108640200; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; Lake AC, 2005, J LIPID RES, V46, P2477, DOI 10.1194/jlr.M500290-JLR200; Lass A, 2006, CELL METAB, V3, P309, DOI 10.1016/j.cmet.2006.03.005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Londos C, 2005, BIOCHIMIE, V87, P45, DOI 10.1016/j.biochi.2004.12.010; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Marcinkiewicz A, 2006, J BIOL CHEM, V281, P11901, DOI 10.1074/jbc.M600171200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Miyoshi H, 2006, J BIOL CHEM, V281, P15837, DOI 10.1074/jbc.M601097200; Moore HPH, 2005, J BIOL CHEM, V280, P43109, DOI 10.1074/jbc.M506336200; Qi L, 2004, OBES RES, V12, P1758, DOI 10.1038/oby.2004.218; Robidoux J, 2004, ANNU REV PHARMACOL, V44, P297, DOI 10.1146/annurev.pharmtox.44.101802.121659; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; SOKAL RR, 1969, BIOMETRY, P607; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Subramanian V, 2004, J BIOL CHEM, V279, P42062, DOI 10.1074/jbc.M407462200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2004, IUBMB LIFE, V56, P379, DOI 10.1080/15216540400009968; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Wang J, 2005, BIOCHEMISTRY-US, V44, P1953, DOI 10.1021/bi049206t; Wyne KL, 2003, AM J MED, V115, P29, DOI 10.1016/j.amjmed.2003.09.004; Yeaman SJ, 2004, BIOCHEM J, V379, P11, DOI 10.1042/BJ20031811; Zechner R, 2005, CURR OPIN LIPIDOL, V16, P333, DOI 10.1097/01.mol.0000169354.20395.1c; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	41	220	237	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					996	1002		10.1074/jbc.M605770200	http://dx.doi.org/10.1074/jbc.M605770200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17114792	Green Published, hybrid			2022-12-27	WOS:000243295200022
J	Boekema, EJ; Braun, HP				Boekema, Egbert J.; Braun, Hans-Peter			Supramolecular structure of the mitochondrial oxidative phosphorylation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NADH-UBIQUINONE OXIDOREDUCTASE; RESPIRATORY COMPLEX-I; ACYL-CARRIER PROTEIN; DIMERIC ATP SYNTHASE; CYTOCHROME-C-OXIDASE; CHAIN; SUPERCOMPLEX; YEAST; ORGANIZATION; CARDIOLIPIN	The protein complexes of the mitochondrial oxidative phosphorylation system were recently reported to form supramo lecular assemblies termed respiratory supercomplexes or respirasomes. These supercomplexes are considered to be of great functional importance. Here we review new insights into supercomplex structure and physiology.	Leibniz Univ Hannover, Fac Nat Sci, Inst Plant Genet, D-30419 Hannover, Germany; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	Leibniz University Hannover; University of Groningen	Braun, HP (corresponding author), Leibniz Univ Hannover, Fac Nat Sci, Inst Plant Genet, Herrenhauser Str 2, D-30419 Hannover, Germany.	braun@genetik.uni-hannover.de	Braun, Hans-Peter/E-7149-2011	Braun, Hans-Peter/0000-0002-4459-9727				Acin-Perez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8; ALLEN RD, 1995, PROTOPLASMA, V189, P1, DOI 10.1007/BF01280286; ALLEN RD, 1989, J CELL BIOL, V108, P2233, DOI 10.1083/jcb.108.6.2233; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BERRY EA, 1985, J BIOL CHEM, V260, P2458; Bianchi C, 2003, BIOFACTORS, V18, P3, DOI 10.1002/biof.5520180202; Bianchi C, 2004, J BIOL CHEM, V279, P36562, DOI 10.1074/jbc.M405135200; Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872; Brandt U, 2006, ANNU REV BIOCHEM, V75, P69, DOI 10.1146/annurev.biochem.75.103004.142539; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; Dickson VK, 2006, EMBO J, V25, P2911, DOI 10.1038/sj.emboj.7601177; Dudkina NV, 2006, FEBS LETT, V580, P3427, DOI 10.1016/j.febslet.2006.04.097; Dudkina NV, 2005, FEBS LETT, V579, P5769, DOI 10.1016/j.febslet.2005.09.065; Dudkina NV, 2005, P NATL ACAD SCI USA, V102, P3225, DOI 10.1073/pnas.0408870102; Eubel H, 2003, PLANT PHYSIOL, V133, P274, DOI 10.1104/pp.103.024620; Gavin PD, 2004, J CELL SCI, V117, P2333, DOI 10.1242/jcs.01074; Giraud MF, 2002, BBA-BIOENERGETICS, V1555, P174, DOI 10.1016/S0005-2728(02)00274-8; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; HATEFI Y, 1967, METHOD ENZYMOL, V10, P225; HEINEMEYER J, 2007, PLANT MITOCHONDRIA; Horsefield R, 2004, CURR PROTEIN PEPT SC, V5, P107, DOI 10.2174/1389203043486847; Krause F, 2005, BIOCHEM BIOPH RES CO, V329, P583, DOI 10.1016/j.bbrc.2005.02.010; Krause F, 2004, J BIOL CHEM, V279, P26453, DOI 10.1074/jbc.M402756200; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; Lenaz G, 2001, FEBS LETT, V509, P151, DOI 10.1016/S0014-5793(01)03172-6; Millar AH, 2004, PLANT MOL BIOL, V56, P77, DOI 10.1007/s11103-004-2316-2; Minauro-Sanmiguel F, 2005, P NATL ACAD SCI USA, V102, P12356, DOI 10.1073/pnas.0503893102; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; RAGAN CI, 1978, BIOCHEM J, V174, P783, DOI 10.1042/bj1740783; Rasmusson AG, 2004, ANNU REV PLANT BIOL, V55, P23, DOI 10.1146/annurev.arplant.55.031903.141720; Rich PR, 2003, BIOCHEM SOC T, V31, P1095; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; Richter OMH, 2003, REV PHYSIOL BIOCH P, V147, P47, DOI 10.1007/s10254-003-0006-0; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SACKMANN U, 1991, EUR J BIOCHEM, V200, P463, DOI 10.1111/j.1432-1033.1991.tb16205.x; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Schafer E, 2006, J BIOL CHEM, V281, P15370, DOI 10.1074/jbc.M513525200; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; Sunderhaus S, 2006, J BIOL CHEM, V281, P6482, DOI 10.1074/jbc.M511542200; van Lis R, 2003, PLANT PHYSIOL, V132, P318, DOI 10.1104/pp.102.018325; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; Wittig I, 2005, PROTEOMICS, V5, P4338, DOI 10.1002/pmic.200500081; Wittig I, 2006, BBA-BIOENERGETICS, V1757, P1066, DOI 10.1016/j.bbabio.2006.05.006; Zhang M, 2005, J BIOL CHEM, V280, P29403, DOI 10.1074/jbc.M504955200; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200	49	172	177	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					1	4		10.1074/jbc.R600031200	http://dx.doi.org/10.1074/jbc.R600031200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17102127	Green Published, hybrid			2022-12-27	WOS:000243166500001
J	Lee, MJ; Yang, RZ; Gong, DW; Fried, SK				Lee, Mi-Jeong; Yang, Rong-Ze; Gong, Da-Wei; Fried, Susan K.			Feeding and insulin increase leptin translation - Importance of the leptin mRNA untranslated regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-LIPASE ACTIVITY; HUMAN ADIPOSE-TISSUE; OB GENE-EXPRESSION; OBESE GENE; 5'-UNTRANSLATED REGION; RAT ADIPOCYTES; DEXAMETHASONE; MECHANISMS; SECRETION; ELEMENTS	The post-transcriptional mechanisms by which feeding and insulin increase leptin production are poorly understood. Starvation of 6-7-week-old rats for 14 h decreased leptin mRNA level by only 22% but decreased plasma levels, adipose tissue leptin content, and release by over 75%. The decreased leptin with starvation was explained by > 85% decrease in relative rates of leptin biosynthesis measured by metabolic labeling and immunoprecipitation. In vitro insulin treatment of adipose tissue from fed or starved rats for 2 h increased relative rates of leptin biosynthesis by 2-3-fold, and the effect was blocked by inhibition of phosphatidylinositol 3-kinase or mammalian target of rapamycin. Consistent with the hypothesis that feeding/insulin increases leptin translation, more leptin mRNA was associated with polysomes in adipose tissue of fed than starved rats and in vitro incubation of adipose tissue of starved rats with insulin shifted leptin mRNA into polysomes. To assess the mechanisms regulating leptin translation, chimeric human leptin untranslated region (UTR) reporter constructs were transiently transfected into differentiated 3T3-L1 adipocytes. The 5'-UTR of leptin mRNA increased luciferase reporter activity 2-3-fold, whereas the full-length 3'-UTR (nucleotides 1-2804) was inhibitory (-65%). Sequences between nucleotides 462 and 1130 of the leptin 3'-UTR conferred most of the inhibitory effect. Insulin stimulated the expression of constructs that included both the full-length 5'-UTR and the inhibitory 3'-UTR, and the effect was blocked by inhibition of phosphatidylinositol 3-kinase or mammalian target of rapamycin. Our data suggest that insulin derepresses leptin translation by a mechanism that requires both the 5'-UTR and the 3'-UTR and may contribute to the increase in leptin production with feeding.	Univ Maryland, Div Endocrinol Diabet & Nutr, Dept Med, Baltimore, MD 21201 USA; Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Baltimore Vet Affairs Med Ctr, Geriatr Res & Educ Clin Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Rutgers State University New Brunswick; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Fried, SK (corresponding author), Univ Maryland, Div Endocrinol Diabet & Nutr, Dept Med, 660 W Redwood St, Baltimore, MD 21201 USA.	sfried@medicine.umaryland.edu	Lee, Mi-Jeong/ABE-1084-2020; Lee, Mi-Jeong/GXV-9843-2022	Lee, Mi-Jeong/0000-0002-8171-7913; Lee, Mi-Jeong/0000-0002-8171-7913; Fried, Susan K./0000-0003-1101-9332	NIDDK NIH HHS [R01 DK52398] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052398] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attoub S, 1999, ENDOCRINOLOGY, V140, P4406, DOI 10.1210/en.140.10.4406; BECKER DJ, 1995, FEBS LETT, V371, P324, DOI 10.1016/0014-5793(95)00943-4; Bradley RL, 1999, DIABETES, V48, P272, DOI 10.2337/diabetes.48.2.272; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gong DW, 1996, J BIOL CHEM, V271, P3971; Kraemer FB, 1998, METABOLISM, V47, P555, DOI 10.1016/S0026-0495(98)90239-6; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; Lee JJ, 1998, J NUTR, V128, P940, DOI 10.1093/jn/128.6.940; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MARONI BJ, 1990, J LIPID RES, V31, P1703; Pico C, 2002, OBES RES, V10, P932, DOI 10.1038/oby.2002.127; Pontrelli L, 2004, BIOCHEMISTRY-US, V43, P6734, DOI 10.1021/bi049887s; Ricci MR, 2005, AM J PHYSIOL-ENDOC M, V288, pE798, DOI 10.1152/ajpendo.00446.2004; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; Roh C, 2003, AM J PHYSIOL-ENDOC M, V284, pE322, DOI 10.1152/ajpendo.00230.2002; Russell CD, 2001, AM J PHYSIOL-ENDOC M, V280, pE399, DOI 10.1152/ajpendo.2001.280.3.E399; Russell CD, 1998, AM J PHYSIOL-ENDOC M, V275, pE507, DOI 10.1152/ajpendo.1998.275.3.E507; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Vivinus S, 2001, EUR J BIOCHEM, V268, P1908, DOI 10.1046/j.1432-1327.2001.02064.x; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	23	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					72	80		10.1074/jbc.M609518200	http://dx.doi.org/10.1074/jbc.M609518200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17085442	hybrid			2022-12-27	WOS:000243166500009
J	Nemetski, SM; Gardner, LB				Nemetski, S. Maureen; Gardner, Lawrence B.			Hypoxic regulation of Id-1 and activation of the unfolded protein response are aberrant in neuroblastoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; GENE-EXPRESSION; ENDOPLASMIC-RETICULUM; STRESS-RESPONSE; TRANSCRIPTIONAL REPRESSION; TRANSLATIONAL CONTROL; COMPLEX-FORMATION; MESSENGER-RNA; CELLS; ID1	The Id proteins play an important role in proliferation, differentiation and tumorigenesis. Many tumors are hypoxic, but it is unknown if expression of Id proteins is regulated in hypoxic cells. Here we show that Id-1 is down-regulated in multiple primary, immortalized, and neoplastic hypoxic cell lines, and the transcriptional repressor ATF-3 is both necessary and sufficient for this hypoxia-induced repression of Id-1. Hypoxic up-regulation of ATF-3 is due in part to activation of the unfolded protein response, a cellular stress response. Remarkably, we observe that the unfolded protein response is de-regulated in all neuroblastoma cell lines tested. Indeed, in the absence of ATF-3 the hypoxia-induced transcription factor HIF-1 up-regulates Id-1 in hypoxic neuroblastoma cells. Hypoxic neuroblastoma cells diminish expression of some neuronal differentiation markers, and forced expression of ATF-3 in hypoxic neuroblastoma cells represses Id-1 and prevents the loss of these markers. The divergent regulation of Id proteins in distinct hypoxic cells may explain some of the varied effects hypoxia has on cellular differentiation and proliferation.	NYU, Sch Med, Dept Med Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University	Gardner, LB (corresponding author), NYU, Sch Med, Div Hematol, Dept Med, Tisch 401,550 1st Ave, New York, NY 10016 USA.	lawrence.gardner@med.nyu.edu		Gardner, Lawrence/0000-0003-0191-0172	NCI NIH HHS [CA89265] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA089265] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Axelson H, 2005, SEMIN CELL DEV BIOL, V16, P554, DOI 10.1016/j.semcdb.2005.03.007; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Caldwell CC, 2001, J IMMUNOL, V167, P6140, DOI 10.4049/jimmunol.167.11.6140; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Cheung M, 2003, DEVELOPMENT, V130, P5681, DOI 10.1242/dev.00808; Covello KL, 2004, CURR TOP DEV BIOL, V62, P37; Danet GH, 2003, J CLIN INVEST, V112, P126, DOI 10.1172/JCI200317669; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Gardner LB, 2003, MOL CELL BIOL, V23, P9032, DOI 10.1128/MCB.23.24.9032-9045.2003; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Hai T, 1999, GENE EXPRESSION, V7, P321; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Jogi A, 2002, J BIOL CHEM, V277, P9118, DOI 10.1074/jbc.M107713200; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; KANTOR L, 2005, HUM GENET, P1; Kitamuro T, 2003, J BIOL CHEM, V278, P9125, DOI 10.1074/jbc.M209939200; Koritzinsky M, 2006, EMBO J, V25, P1114, DOI 10.1038/sj.emboj.7600998; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2002, CANCER RES, V62, P301; Lofstedt T, 2004, J BIOL CHEM, V279, P39223, DOI 10.1074/jbc.M402904200; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Manotham K, 2004, KIDNEY INT, V65, P871, DOI 10.1111/j.1523-1755.2004.00461.x; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Mazure NM, 1996, CANCER RES, V56, P3436; Moeller BJ, 2005, CANCER CELL, V8, P99, DOI 10.1016/j.ccr.2005.06.016; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Pahlman S, 2004, SEMIN CANCER BIOL, V14, P365, DOI 10.1016/j.semcancer.2004.04.016; Ramirez-Bergeron DL, 2004, DEVELOPMENT, V131, P4623, DOI 10.1242/dev.01310; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sudhakar A, 2000, BIOCHEMISTRY-US, V39, P12929, DOI 10.1021/bi0008682; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Uittenbogaard M, 2003, J NEUROCHEM, V84, P678, DOI 10.1046/j.1471-4159.2003.01572.x; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4	48	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					240	248		10.1074/jbc.M607275200	http://dx.doi.org/10.1074/jbc.M607275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17102133	hybrid			2022-12-27	WOS:000243166500028
J	Shen, YG; Lee, G; Choe, Y; Zoltewicz, JS; Peterson, AS				Shen, Yiguo; Lee, Gena; Choe, Youngshik; Zoltewicz, J. Susie; Peterson, Andrew S.			Functional architecture of atrophins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; GENE-PRODUCT; INTERACTS; POLYGLUTAMINE; POLARITY; DOMAIN; PML	Vertebrate genomes harbor two Atrophin genes, Atrophin-1 (Atn1) and Atrophin-2 (Atn2). The Atnl locus produces a single polypeptide, whereas two different protein products are expressed from the Atn2 (also known as Rere) locus. A long, or full-length, form contains an amino-terminal MTA-2-homologous domain followed by an Atrophin-1-related domain. A short form, expressed via an internal promoter, consists solely of the Atrophin domain. Atrophin-1 can be co-immunoprecipitated along with Atrophin-2, suggesting that the Atrophins ordinarily function together. Mutations that disrupt the expression of the long form of Atrophin-2 disrupt early embryonic development. To determine the requirement for Atrophin-1 during development we generated a null allele. Somewhat surprisingly we found that Atrophin-1 function is dispensable. To gain a better understanding of the requirement for Atrophin function during development, an analysis of the functional domains of the three different gene products was carried out. Taken together, these data suggest that Atrophins function as bifunctional transcriptional regulators. The long form of Atrophin-2 has a transcriptional repression activity that is not found in the other Atrophin polypeptides and that is required for normal embryogenesis. Atrophin-1 and the short form of Atrophin-2, on the other hand, can act as potent and evolutionarily conserved transcriptional activators.	Univ Calif San Francisco, Gallo Ctr, Oakland, CA 94608 USA; Univ Calif San Francisco, Dept Neurol, Oakland, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco	Peterson, AS (corresponding author), Genentech Inc, Dept Mol Biol, MS-37,1 DNA Way, San Francisco, CA 94080 USA.	Peterson.Andrew@gene.com			NIDA NIH HHS [7R01DA017627-09] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA017627] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Asai Y, 2006, P NATL ACAD SCI USA, V103, P9069, DOI 10.1073/pnas.0603453103; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Charroux B, 2006, DEV BIOL, V291, P278, DOI 10.1016/j.ydbio.2005.12.012; Fanto M, 2003, DEVELOPMENT, V130, P763, DOI 10.1242/dev.00304; Herman MA, 1999, DEVELOPMENT, V126, P1055; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Okamura-Oho Y, 1999, HUM MOL GENET, V8, P947, DOI 10.1093/hmg/8.6.947; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Takahashi J, 2003, NEUROBIOL DIS, V13, P230, DOI 10.1016/S0969-9961(03)00080-9; Waerner T, 2001, CELL GROWTH DIFFER, V12, P201; Wang L, 2006, GENE DEV, V20, P525, DOI 10.1101/gad.1393506; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Yamada M, 2001, ANN NEUROL, V49, P14, DOI 10.1002/1531-8249(200101)49:1<14::AID-ANA5>3.0.CO;2-X; Yanagisawa H, 2000, HUM MOL GENET, V9, P1433, DOI 10.1093/hmg/9.9.1433; Zhang S, 2002, CELL, V108, P45, DOI 10.1016/S0092-8674(01)00630-4; Zoltewicz JS, 2004, DEVELOPMENT, V131, P3, DOI 10.1242/dev.00908	18	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					5037	5044		10.1074/jbc.M610274200	http://dx.doi.org/10.1074/jbc.M610274200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17150957	hybrid			2022-12-27	WOS:000244482000086
J	Venteclef, N; Delerive, P				Venteclef, Nicolas; Delerive, Philippe			Interleukin-1 receptor antagonist induction as an additional mechanism for liver receptor homolog-1 to negatively regulate the hepatic acute phase response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; STEROIDOGENIC FACTOR-I; IL-1 RECEPTOR; CHOLESTEROL-METABOLISM; LRH-1; EXPRESSION; GENE; MICE; IDENTIFICATION; INFLAMMATION	The liver receptor homolog-1 (LRH-1) is an orphan nuclear receptor believed to play a key role in bile acid metabolism, cholesterol homeostasis, and intestinal cell crypt renewal. LRH-1 has recently been reported to negatively regulate the hepatic acute phase response by antagonizing, at least in part, the CCAAT/enhancer-binding protein signaling pathway. Here we have shown, using adenovirus-mediated LRH-1 overexpression and gene-silencing experiments, that the interleukin-1 receptor antagonist (IL-1RA) gene is a novel LRH-1 target gene in hepatic cells. Promoter mapping and chromatin immunoprecipitation experiments revealed that LRH-1 regulates IL-1RA gene expression under inflammatory conditions at the transcriptional level via the binding to an LRH-1 response element. Interestingly, IL-1RA induction by an intraperitoneal injection of lipopolysaccharide is significantly lower in LRH-1 heterozygous compared with wild-type mice, demonstrating the contribution of LRH-1 in IL-1RA gene regulation. Finally, RNA interference experiments indicate that LRH-1 blocks the hepatic acute phase response by, at least in part, inducing IL-1RA expression. Taken together, these results lead to the identification of IL-1RA as a novel LRH-1 target gene and demonstrate the existence of multiple mechanisms contributing to the overall anti-inflammatory properties of LRH-1 in hepatic cells.	GlaxoSmithKline R&D, Cardiovasc & Urogenital Ctr Excellence Drug Disco, F-91951 Les Ulis, France	GlaxoSmithKline	Delerive, P (corresponding author), GlaxoSmithKline R&D, Cardiovasc & Urogenital Ctr Excellence Drug Disco, 25 Ave Quebec, F-91951 Les Ulis, France.	pxd14884@gsk.com	Venteclef, Nicolas/K-8484-2017	Venteclef, Nicolas/0000-0002-6313-1214				Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; Arend WP, 2000, ARTHRITIS RES, V2, P245, DOI 10.1186/ar94; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; CASTILLOOLIVARE.A, 2000, J BIOL CHEM, V275, P17793; Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8; Clyne CD, 2002, J BIOL CHEM, V277, P20591, DOI 10.1074/jbc.M201117200; Delerive P, 2004, MOL ENDOCRINOL, V18, P2378, DOI 10.1210/me.2004-0132; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; Fayard E, 2003, J BIOL CHEM, V278, P35725, DOI 10.1074/jbc.M302370200; Fayard E, 2004, TRENDS CELL BIOL, V14, P250, DOI 10.1016/j.tcb.2004.03.008; Francois M, 2006, ARTHRITIS RHEUM-US, V54, P1233, DOI 10.1002/art.21728; Freeman LA, 2004, J LIPID RES, V45, P1197, DOI 10.1194/jlr.C400002-JLR200; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gabay C, 1997, J CLIN INVEST, V99, P2930, DOI 10.1172/JCI119488; Gabay C, 2001, EUR J IMMUNOL, V31, P490, DOI 10.1002/1521-4141(200102)31:2<490::AID-IMMU490>3.0.CO;2-H; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748; Gu PL, 2005, MOL CELL BIOL, V25, P3492, DOI 10.1128/MCB.25.9.3492-3505.2005; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; Horai R, 1998, J EXP MED, V187, P1463, DOI 10.1084/jem.187.9.1463; Isoda K, 2005, J BIOL CHEM, V280, P7002, DOI 10.1074/jbc.M412220200; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Josephs MD, 2000, AM J PHYSIOL-REG I, V278, pR824, DOI 10.1152/ajpregu.2000.278.4.R824; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; Li Y, 2005, MOL CELL, V17, P491, DOI 10.1016/j.molcel.2005.02.002; Luo Y, 2001, J BIOL CHEM, V276, P24767, DOI 10.1074/jbc.M100912200; Matsuki T, 2003, J EXP MED, V198, P877, DOI 10.1084/jem.20030299; MORRONE G, 1988, J BIOL CHEM, V263, P12554; Mueller M, 2006, J EXP MED, V203, P2057, DOI 10.1084/jem.20060357; Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Ortlund EA, 2005, NAT STRUCT MOL BIOL, V12, P357, DOI 10.1038/nsmb910; Pare JF, 2004, J BIOL CHEM, V279, P21206, DOI 10.1074/jbc.M401523200; Schoonjans K, 2002, EMBO REP, V3, P1181, DOI 10.1093/embo-reports/kvf238; SMITH MF, 1992, J IMMUNOL, V149, P2000; Venteclef N, 2006, MOL CELL BIOL, V26, P6799, DOI 10.1128/MCB.00579-06; Wang W, 2005, P NATL ACAD SCI USA, V102, P7505, DOI 10.1073/pnas.0409482102; Wegrzyn P, 2006, BBA-MOL BASIS DIS, V1762, P319, DOI 10.1016/j.bbadis.2005.11.001	39	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4393	4399		10.1074/jbc.M608993200	http://dx.doi.org/10.1074/jbc.M608993200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158876	hybrid			2022-12-27	WOS:000244482000019
J	Feinberg, H; Castelli, R; Drickamer, K; Seeberger, PH; Weis, WI				Feinberg, Hadar; Castelli, Riccardo; Drickamer, Kurt; Seeberger, Peter H.; Weis, William I.			Multiple modes of binding enhance the affinity of DC-SIGN for high mannose N-linked glycans found on viral glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; ANTIBODY 2G12; RECOGNITION; RECEPTORS; VIRUS; OLIGOSACCHARIDES; MECHANISM; CLUSTER	The dendritic cell surface receptor DC-SIGN and the closely related endothelial cell receptor DC-SIGNR specifically recognize high mannose N-linked carbohydrates on viral pathogens. Previous studies have shown that these receptors bind the outer trimannose branch Man alpha 1-3[Manal-6]Man alpha present in high mannose structures. Although the trimannoside binds to DC-SIGN or DC-SIGNR more strongly than mannose, additional affinity enhancements are observed in the presence of one or more Man alpha 1-2Man alpha moieties on the nonreducing termini of oligomannose structures. The molecular basis of this enhancement has been investigated by determining crystal structures of DC-SIGN bound to a synthetic six-mannose fragment of a high mannose N-linked oligosaccharide, Man alpha 1-2Man alpha 1-3[Man alpha 1-2Man alpha 1-6]Man alpha-6Man and to the disaccharide Man alpha 1-2Man. The structures reveal mixtures of two binding modes in each case. Each mode features typical C-type lectin binding at the principal Ca2+-binding site by one mannose residue. In addition, other sugar residues form contacts unique to each binding mode. These results suggest that the affinity enhancement displayed toward oligosaccharides decorated with the Mana1-2Mana structure is due in part to multiple binding modes at the primary Ca 21 site, which provide both additional contacts and a statistical (entropic) enhancement of binding.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Cellular Physiol, Stanford, CA 94305 USA; ETH, Swiss Fed Inst Technol, Lab Organ Chem, CH-8093 Zurich, Switzerland; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England	Stanford University; Stanford University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Imperial College London	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, 299 Campus Dr W, Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150	NIGMS NIH HHS [GM50569] Funding Source: Medline; Wellcome Trust [075565] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102; Cambi A, 2003, CURR OPIN CELL BIOL, V15, P539, DOI 10.1016/j.ceb.2003.08.004; Ding XL, 1997, CARBOHYD RES, V303, P445, DOI 10.1016/S0008-6215(97)00190-0; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Feinberg H, 2005, J BIOL CHEM, V280, P1327, DOI 10.1074/jbc.M409925200; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; Pohlmann S, 2001, TRENDS IMMUNOL, V22, P643, DOI 10.1016/S1471-4906(01)02081-6; Ratner DM, 2004, CHEMBIOCHEM, V5, P379, DOI 10.1002/cbic.200300804; Ratner DM, 2002, EUR J ORG CHEM, V2002, P826; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730; SONDHEIMER SJ, 1978, CARBOHYD RES, V60, P187, DOI 10.1016/S0008-6215(00)83477-1; Steinman RM, 2000, CELL, V100, P491, DOI 10.1016/S0092-8674(00)80684-4; Tong L, 1996, ACTA CRYSTALLOGR A, V52, P782, DOI 10.1107/S010876739600548X; van Kooyk Y, 2003, TRENDS MOL MED, V9, P153, DOI 10.1016/S1471-4914(03)00027-3; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Woods RJ, 1998, EUR J BIOCHEM, V258, P372, DOI 10.1046/j.1432-1327.1998.2580372.x	28	123	131	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4202	4209		10.1074/jbc.M609689200	http://dx.doi.org/10.1074/jbc.M609689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150970	Green Accepted, hybrid			2022-12-27	WOS:000244481900083
J	He, JQ; Saha, SK; Kang, JR; Zarnegar, B; Cheng, GH				He, Jeannie Q.; Saha, Supriya K.; Kang, Jason R.; Zarnegar, Brian; Cheng, Genhong			Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; RING FINGER; SIGNAL TRANSDUCER; ADAPTER PROTEINS; ACTIVATION; KINASE; MICE; CD40; NF-KAPPA-B2; FAMILY	Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are critical signaling adaptors downstream of many receptors in the TNF receptor and interleukin-1 receptor/Toll-like receptor superfamilies. Whereas TRAF2, 5, and 6 are activators of the canonical NF-kappa B signaling pathway, TRAF3 is an inhibitor of the noncanonical NF-kappa B pathway. The contribution of the different domains in TRAFs to their respective functions remains unclear. To elucidate the structural and functional specificities of TRAF3, we reconstituted TRAF3-deficient cells with a series of TRAF3 mutants and assessed their abilities to restore TRAF3-mediated inhibition of the noncanonical NF-kappa B pathway as measured by NF-kappa B-inducing kinase (NIK) protein levels and processing of p100 to p52. We found that a structurally intact RING finger domain of TRAF3 is required for inhibition of the noncanonical NF-kappa B pathway. In addition, the three N-terminal domains, but not the C-terminal TRAF domain, of the highly homologous TRAF5 can functionally replace the corresponding domains of TRAF3 in suppression of the noncanonical NF-kappa B pathway. This functional specificity correlates with the specific binding of TRAF3, but not TRAF5, to the previously reported TRAF3 binding motif in NIK. Our studies suggest that both the RING finger domain activity and the specific binding of the TRAF domain to NIK are two critical components of TRAF3 suppression of NIK protein levels and the processing of p100 to p52.	Univ Calif Los Angeles, Dept Microbiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Med Scientist Training Program, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Cheng, GH (corresponding author), Univ Calif Los Angeles, Dept Microbiol, 8-240 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	gcheng@mednet.ucla.edu	Saha, Supriya/AAC-5365-2019		NATIONAL CANCER INSTITUTE [R01CA087924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057559] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA87924] Funding Source: Medline; NIAID NIH HHS [AI07126-30, R01 AI056154] Funding Source: Medline; NIGMS NIH HHS [GM 08042, R01 GM57559] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Brink R, 1998, J BIOL CHEM, V273, P4129, DOI 10.1074/jbc.273.7.4129; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chung JY, 2002, J CELL SCI, V115, P679; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dadgostar H, 1998, J BIOL CHEM, V273, P24775, DOI 10.1074/jbc.273.38.24775; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Grech A, 2000, MOL IMMUNOL, V37, P721, DOI 10.1016/S0161-5890(00)00098-5; Grech AP, 2004, IMMUNITY, V21, P629, DOI 10.1016/j.immuni.2004.09.011; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; He JQ, 2006, J EXP MED, V203, P2413, DOI 10.1084/jem.20061166; Hu WH, 2004, J BIOL CHEM, V279, P35975, DOI 10.1074/jbc.M405699200; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kim YS, 2005, MOL CELL BIOL, V25, P2130, DOI 10.1128/MCB.25.6.2130-2137.2005; Li CL, 2002, STRUCTURE, V10, P403, DOI 10.1016/S0969-2126(02)00733-5; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Qian YC, 2004, IMMUNITY, V21, P575, DOI 10.1016/j.immuni.2004.09.001; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Saha SK, 2006, EMBO J, V25, P3257, DOI 10.1038/sj.emboj.7601220; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tsitsikov EN, 2001, IMMUNITY, V15, P647, DOI 10.1016/S1074-7613(01)00207-2; Wajant H, 1998, J MOL EVOL, V47, P656, DOI 10.1007/PL00006423	38	83	88	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3688	3694		10.1074/jbc.M610271200	http://dx.doi.org/10.1074/jbc.M610271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158868	hybrid			2022-12-27	WOS:000244481900031
J	Stopak, KS; Chiu, YL; Kropp, J; Grant, RM; Greene, WC				Stopak, Kim S.; Chiu, Ya-Lin; Kropp, Jerry; Grant, Robert M.; Greene, Warner C.			Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INDUCED CYTIDINE DEAMINASE; ACTIVATED KILLER-CELLS; VIRAL VIF PROTEIN; HIV-1 VIF; T-LYMPHOCYTES; ANTIRETROVIRAL DEFENSE; ANTIVIRAL ACTIVITY; ENZYME APOBEC3G; HOST FACTORS	Human APOBEC3G (A3G), a deoxycytidine deaminase, is a broadly acting antiretroviral factor expressed in a variety of cells. Mitogen activation of CD4 T cells enhances A3G expression and leads to recruitment of low molecular mass (LMM) A3G, which functions as a post-entry human immunodeficiency virus (HIV) restriction factor, into enzymatically inactive, high molecular mass (HMM) RNA-protein complexes that include Staufen RNA-transporting granules. We now report that interleukin-2 (IL-2), IL-15 and, to a lesser extent, IL-7 enhance the expression of A3G in peripheral blood lymphocytes and that this effect is blocked by inhibitors of the JAK and MAPK signaling pathways. In mixed cultures of CD4+ T cells containing either HMM or LMM A3G, HIV preferentially infected cells containing HMM A3G. A3G shifted into a HMM complex when IL-2,-7, or -15 was added to resting T cells, likely explaining how cytokine treatment renders resting CD4+ T cells permissive to HIV infection. Similarly, poly(I:C)/tumor necrosis factor-alpha-induced maturation of dendritic cells was associated with a sharp increase in A3G expression; however, this induction led to the accumulation of LMM A3G. Together, these results highlight the distinct inductive effects of select cytokines on A3G gene expression and A3G complex assembly that occur in natural cellular targets of HIV infection.	Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Greene, WC (corresponding author), Gladstone Inst Virol & Immunol, 1650 Owens St, San Francisco, CA 94158 USA.	wgreene@gladstone.ucsf.edu		Grant, Robert/0000-0002-0851-7085	NIAID NIH HHS [R01 AI065329] Funding Source: Medline; NICHD NIH HHS [P01 HD40543] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD040543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065329] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Bishop KN, 2006, J VIROL, V80, P8450, DOI 10.1128/JVI.00839-06; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; Chiu YL, 2006, P NATL ACAD SCI USA, V103, P15588, DOI 10.1073/pnas.0604524103; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Cohen OJ, 1997, IMMUNOL REV, V159, P31, DOI 10.1111/j.1600-065X.1997.tb01005.x; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Delebecque F, 2006, J VIROL, V80, P605, DOI 10.1128/JVI.80.2.605-614.2006; Ducrey-Rundquist O, 2002, J VIROL, V76, P9103, DOI 10.1128/JVI.76.18.9103-9111.2002; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kobayashi M, 2004, J VIROL, V78, P8238, DOI 10.1128/JVI.78.15.8238-8244.2004; Kreisberg JF, 2006, J EXP MED, V203, P865, DOI 10.1084/jem.20051856; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Peng G, 2006, J EXP MED, V203, P41, DOI 10.1084/jem.20051512; Pomerantz RJ, 2003, CELL MOL LIFE SCI, V60, P2017, DOI 10.1007/s00018-003-3192-7; Rose KM, 2005, AIDS RES HUM RETROV, V21, P611, DOI 10.1089/aid.2005.21.611; Rose KM, 2004, J BIOL CHEM, V279, P41744, DOI 10.1074/jbc.M406760200; Rosler C, 2005, HEPATOLOGY, V42, P301, DOI 10.1002/hep.20801; Rush JS, 2005, P NATL ACAD SCI USA, V102, P13242, DOI 10.1073/pnas.0502779102; Russell RA, 2005, J VIROL, V79, P8724, DOI 10.1128/JVI.79.14.8724-8731.2005; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sasada A, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-32; Seppen J, 2004, J HEPATOL, V41, P1068, DOI 10.1016/j.jhep.2004.10.008; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Spisek R, 2003, CANCER IMMUNOL IMMUN, V52, P445, DOI 10.1007/s00262-002-0368-1; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; Suspene R, 2005, P NATL ACAD SCI USA, V102, P8321, DOI 10.1073/pnas.0408223102; Unutmaz D, 1999, J EXP MED, V189, P1735, DOI 10.1084/jem.189.11.1735; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhou C, 2003, J IMMUNOL, V170, P1887, DOI 10.4049/jimmunol.170.4.1887	48	128	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3539	3546		10.1074/jbc.M610138200	http://dx.doi.org/10.1074/jbc.M610138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17110377	hybrid			2022-12-27	WOS:000244481900016
J	Youn, H; Kerby, RL; Koh, J; Roberts, GP				Youn, Hwan; Kerby, Robert L.; Koh, Junseock; Roberts, Gary P.			A C-helix residue, Arg-123, has important roles in both the active and inactive forms of the cAMP receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CYCLIC-NUCLEOTIDE; TRANSCRIPTION ACTIVATION; ALLOSTERIC REGULATION; CRYSTAL-STRUCTURE; BINDING; DNA; MUTATIONS; CAP; CRP	The cAMP receptor protein I of Escherichia coli exists in an equilibrium between active and inactive forms, and the effector, cAMP, shifts that equilibrium to the active form, thereby allowing DNA binding. For this equilibrium shift, a C-helix repositioning around the C-helix residues Thr-127 and Ser-128 has been reported as a critical local event along with proper beta 4/beta 5 positioning. Here we show that another C-helix residue, Arg-123, has a unique role in cAMP-dependent CRP activation in two different ways. First, Arg-123 is important for proper cAMP affinity, although it is not critical for the conformational change with saturating amounts of cAMP. Second, Arg-123 is optimal for stabilizing the inactive conformation of CRP when cAMP is absent, thereby allowing a maximal range of regulation by cAMP. However, Arg-123 does not appear to be critical for a functional response to cAMP, as has been proposed previously (Berman, H. M., Ten Eyck, L. F., Goodsell, D. S., Haste, N. M., Korney, A., and Taylor, S. S. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 45-50). Based on mutagenic evidence, we also propose the basis for the stabilization of the inactive form to be through a salt interaction between Asp-68 and Arg-123.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Roberts, GP (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.	groberts@bact.wisc.edu			NIGMS NIH HHS [GM53228, R01 GM053228, GM23467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023467, R01GM053228, R37GM023467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1985, EMBO J, V4, P3329, DOI 10.1002/j.1460-2075.1985.tb04084.x; BELDUZ AO, 1993, NUCLEIC ACIDS RES, V21, P1827, DOI 10.1093/nar/21.8.1827; Berman HM, 2005, P NATL ACAD SCI USA, V102, P45, DOI 10.1073/pnas.0408579102; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CHENG XD, 1994, J BIOL CHEM, V269, P30781; Chiang L W, 1993, PCR Methods Appl, V2, P210; GARGES S, 1985, CELL, V41, P745, DOI 10.1016/S0092-8674(85)80055-6; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; HARMAN JG, 1986, J BIOL CHEM, V261, P6332; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Lin SH, 2002, BIOCHEMISTRY-US, V41, P14935, DOI 10.1021/bi026756n; Lin SH, 2002, BIOCHEMISTRY-US, V41, P11857, DOI 10.1021/bi026099z; Malecki J, 2000, J BIOL CHEM, V275, P8480, DOI 10.1074/jbc.275.12.8480; Marvin JS, 2001, NAT STRUCT BIOL, V8, P795, DOI 10.1038/nsb0901-795; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MOORE J, 1992, J BACTERIOL, V174, P8030, DOI 10.1128/JB.174.24.8030-8035.1992; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Savery NJ, 2002, J BACTERIOL, V184, P2273, DOI 10.1128/JB.184.8.2273-2280.2002; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Shi Y, 2000, BIOCHEMISTRY-US, V39, P7300, DOI 10.1021/bi000225m; TAKAHASHI M, 1989, J MOL BIOL, V207, P783, DOI 10.1016/0022-2836(89)90244-1; Youn H, 2006, J BIOL CHEM, V281, P1119, DOI 10.1074/jbc.M509421200	27	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3632	3639		10.1074/jbc.M606602200	http://dx.doi.org/10.1074/jbc.M606602200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158453	hybrid			2022-12-27	WOS:000244481900025
J	Picha, KM; Patel, SS; Mandiyan, S; Koehn, J; Wennogle, LP				Picha, Kristen M.; Patel, Smita S.; Mandiyan, Sreekala; Koehn, James; Wennogle, Lawrence P.			The role of the C-terminal domain of protein tyrosine phosphatase-1B in phosphatase activity and substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-BASED DESIGN; INSULIN-RECEPTOR; NEGATIVE REGULATOR; STRUCTURAL BASIS; DOWN-REGULATION; 1B; DEPHOSPHORYLATION; PHOSPHORYLATION; PTP-1B; PTP1B	Protein tyrosine phosphatase 1B (PTP-1B) has been implicated in the regulation of the insulin receptor. Dephosphorylation of the insulin receptor results in decreased insulin signaling and thus decreased glucose uptake. PTP-1B(-/-) mice have increased insulin sensitivity and are resistant to weight gain when fed a high fat diet, validating PTP-1B as a potential target for the treatment of type 2 diabetes. Many groups throughout the world have been searching for selective inhibitors for PTP-1B, and most of them target inhibitors to PTP-1B-(1-298), the N-terminal catalytic domain of the enzyme. However, the C-terminal domain is quite large and could influence the activity of the enzyme. Using two constructs of PTP-1B and a phosphopeptide as substrate, steady state assays showed that the presence of the C-terminal domain decreased both the K-m and the k(cat) 2-fold. Pre-steady state kinetic experiments showed that the presence of the C-terminal domain improved the affinity of the enzyme for a phosphopeptide 2-fold, primarily because the off-rate was slower. This suggests that the C-terminal domain of PTP-1B may contact the phosphopeptide in some manner, allowing it to remain at the active site longer. This could be useful when screening libraries of compounds for inhibitors of PTP-1B. A compound that is able to make contacts with the C-terminal domain of PTP-1B would not only have a modest improvement in affinity but may also provide for specificity over other phosphatases.	Novartis Inst Biomed Res, Cambridge, MA 02139 USA	Novartis	Wennogle, LP (corresponding author), Intra Cellular Therapies Inc ITI, Audubon Biomed Sci & Technol Pk,3960 Broadway, New York, NY 10032 USA.	lwennogle@intracellulartherapies.com		Wennogle, Lawrence/0000-0002-3795-409X	NIGMS NIH HHS [R37 GM051966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD F, 1995, BBA-PROTEIN STRUCT M, V1248, P57, DOI 10.1016/0167-4838(95)00003-D; Ahmad F, 1997, J CLIN INVEST, V100, P449, DOI 10.1172/JCI119552; AHMAD F, 1995, AM J PHYSIOL-ENDOC M, V268, pE932, DOI 10.1152/ajpendo.1995.268.5.E932; AHMAD F, 1995, METABOLISM, V44, P1175, DOI 10.1016/0026-0495(95)90012-8; AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bleasdale JE, 2001, BIOCHEMISTRY-US, V40, P5642, DOI 10.1021/bi002865v; Burke TR, 1998, BIOPOLYMERS, V47, P225, DOI 10.1002/(SICI)1097-0282(1998)47:3<225::AID-BIP3>3.0.CO;2-O; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; Caselli A, 2002, BIOCHEM BIOPH RES CO, V296, P692, DOI 10.1016/S0006-291X(02)00928-2; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Cohen J, 2004, BIOCHEM J, V377, P517, DOI 10.1042/BJ20031420; Dadke S, 2000, J BIOL CHEM, V275, P23642, DOI 10.1074/jbc.M001063200; Egawa K, 2001, J BIOL CHEM, V276, P10207, DOI 10.1074/jbc.M009489200; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Fersht A., 1985, ENZYME STRUCTURE MEC; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; Groves MR, 1998, BIOCHEMISTRY-US, V37, P17773, DOI 10.1021/bi9816958; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; Iversen LF, 2001, BIOCHEMISTRY-US, V40, P14812, DOI 10.1021/bi011389l; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kennedy BP, 2000, BIOCHEM PHARMACOL, V60, P877, DOI 10.1016/S0006-2952(00)00305-1; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; LEREA KM, 1989, BIOCHEMISTRY-US, V28, P9286, DOI 10.1021/bi00450a008; Li LW, 2000, SEMIN IMMUNOL, V12, P75, DOI 10.1006/smim.2000.0209; Liang FB, 2005, J BIOL CHEM, V280, P24857, DOI 10.1074/jbc.M502780200; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Lund IK, 2005, J MOL ENDOCRINOL, V34, P339, DOI 10.1677/jme.1.01694; Montalibet J, 2006, J BIOL CHEM, V281, P5258, DOI 10.1074/jbc.M511546200; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Pellegrini MC, 1998, BIOCHEMISTRY-US, V37, P15598, DOI 10.1021/bi981427+; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; Romsicki Y, 2004, J BIOL CHEM, V279, P12868, DOI 10.1074/jbc.M309600200; Rondinone CM, 2002, DIABETES, V51, P2405, DOI 10.2337/diabetes.51.8.2405; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Shi K, 2004, J BIOCHEM, V136, P89, DOI 10.1093/jb/mvh094; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; Taylor SD, 2004, EXPERT OPIN INV DRUG, V13, P199, DOI 10.1517/eoid.13.3.199.27347; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Ukkola O, 2002, J INTERN MED, V251, P467, DOI 10.1046/j.1365-2796.2002.00992.x; Wang WQ, 2003, CURR TOP MED CHEM, V3, P739, DOI 10.2174/1568026033452302; Wiesmann C, 2004, NAT STRUCT MOL BIOL, V11, P730, DOI 10.1038/nsmb803; Wu XD, 2001, J CLIN ENDOCR METAB, V86, P5973, DOI 10.1210/jc.86.12.5973; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang ZY, 2006, J BIOL CHEM, V281, P1746, DOI 10.1074/jbc.M509590200; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; Zinker BA, 2002, P NATL ACAD SCI USA, V99, P11357, DOI 10.1073/pnas.142298199	65	20	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2911	2917		10.1074/jbc.M610096200	http://dx.doi.org/10.1074/jbc.M610096200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135270	hybrid			2022-12-27	WOS:000243793900017
J	Ringgaard, S; Ebersbach, G; Borch, J; Gerdes, K				Ringgaard, Simon; Ebersbach, Gitte; Borch, Jonas; Gerdes, Kenn			Regulatory cross-talk in the double par locus of plasmid pB171E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; PARTITION COMPLEX; BACTERIAL MITOSIS; DNA SEGREGATION; PROTEIN; PROMOTER; ACTIN; R1; SUPERFAMILY	The double par locus of Escherichia coli virulence factor pB171 consists of two adjacent and oppositely oriented par loci of different types, called par1 and par2. par1 encodes an actin ATPase (ParM), and par2 encodes an oscillating, MinD-like ATPase (ParA). The par loci share a central cis-acting region of approximate to 200 bp, called parC1, located between the two par loci. An additional cis-acting region, parC2, is located downstream of the parAB operon of par2. Here we show that ParR of par1 and ParB of par2 bind cooperatively to unrelated sets of direct repeats in parC1 to form the cognate partition and promoter repression complexes. Surprisingly, ParB repressed transcription of the noncognate par operon, indicating cross-talk and possibly epistasis between the two systems. The par promoters, P1 and P2, affected each other negatively. The DNA binding activities of ParR and ParB correlated well with the observed transcriptional regulation of the par operons in vivo and in vitro. Integration host factor (IHF) was identified as a novel factor involved in par2-mediated plasmid partitioning.	Univ Newcastle Upon Tyne, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Newcastle University - UK; University of Southern Denmark; Yale University	Gerdes, K (corresponding author), Univ Newcastle Upon Tyne, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	kenn.gerdes@ncl.ac.uk	Gerdes, Kenn/AAS-5548-2021; Gerdes, Kenn/M-2420-2014	Gerdes, Kenn/0000-0002-7462-4612; Gerdes, Kenn/0000-0002-7462-4612; Ringgaard, Simon/0000-0002-4980-5964				BECK CF, 1988, MICROBIOL REV, V52, P318, DOI 10.1128/MMBR.52.3.318-326.1988; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Ebersbach G, 2005, ANNU REV GENET, V39, P453, DOI 10.1146/annurev.genet.38.072902.091252; Ebersbach G, 2004, MOL MICROBIOL, V52, P385, DOI 10.1111/j.1365-2958.2004.04002.x; Ebersbach G, 2001, P NATL ACAD SCI USA, V98, P15078, DOI 10.1073/pnas.261569598; Ebersbach G, 2006, MOL MICROBIOL, V61, P1428, DOI 10.1111/j.1365-2958.2006.05322.x; Fothergill TJG, 2005, J BACTERIOL, V187, P2651, DOI 10.1128/JB.187.8.2651-2661.2005; FUNNELL BE, 1993, J BIOL CHEM, V268, P3616; FUNNELL BE, 1991, J BIOL CHEM, V266, P14328; Garner EC, 2004, SCIENCE, V306, P1021, DOI 10.1126/science.1101313; Gerdes K, 2004, CELL, V116, P359, DOI 10.1016/S0092-8674(04)00116-3; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hayes F, 2000, MOL MICROBIOL, V37, P528, DOI 10.1046/j.1365-2958.2000.02030.x; Hayes F, 2006, TRENDS BIOCHEM SCI, V31, P247, DOI 10.1016/j.tibs.2006.03.002; JENSEN RB, 1994, J MOL BIOL, V236, P1299, DOI 10.1016/0022-2836(94)90059-0; Jensen RB, 1998, P NATL ACAD SCI USA, V95, P8550, DOI 10.1073/pnas.95.15.8550; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; Koonin EV, 2000, CELL, V101, P573, DOI 10.1016/S0092-8674(00)80867-3; Koonin EV, 1996, TRENDS GENET, V12, P334, DOI 10.1016/0168-9525(96)20010-1; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LARSEN JEL, 1984, GENE, V28, P45, DOI 10.1016/0378-1119(84)90086-6; Lawley TD, 2003, J BACTERIOL, V185, P3060, DOI 10.1128/JB.185.10.3060-3067.2003; Moller-Jensen J, 2003, MOL CELL, V12, P1477, DOI 10.1016/S1097-2765(03)00451-9; Opel ML, 2001, MOL MICROBIOL, V39, P1109, DOI 10.1046/j.1365-2958.2001.02309.x; Strainic MG, 2000, J BACTERIOL, V182, P216, DOI 10.1128/JB.182.1.216-220.2000	28	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3134	3145		10.1074/jbc.M609092200	http://dx.doi.org/10.1074/jbc.M609092200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17092933	hybrid			2022-12-27	WOS:000243793900039
J	Baldassa, S; Gnesutta, N; Fascio, U; Sturani, E; Zippel, R				Baldassa, Simona; Gnesutta, Nerina; Fascio, Umberto; Sturani, Emmapaola; Zippel, Renata			SCLIP, a microtubule-destabilizing factor, interacts with RasGRF1 and inhibits its ability to promote Rac activation and neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; GROWTH-ASSOCIATED PROTEIN; LONG-TERM POTENTIATION; STATHMIN FAMILY; NEURONAL GROWTH; NERVOUS-SYSTEM; PHOSPHOPROTEIN STATHMIN; GLUTAMATE RECEPTORS; SCG10-LIKE PROTEIN; ALZHEIMERS-DISEASE	RasGRF1 is a neuron-specific guanine nucleotide exchange factor for the small GTPases Ras and Rac. It is implicated in the regulation of memory formation and in the development of tolerance to drug abuse, although the mechanisms have been elucidated only in part. Here we report the isolation, by the yeast two-hybrid screen, of the microtubule-destabilizing factor SCLIP (SCG10-like protein) as a novel RasGRF1-interacting protein. This interaction requires the region spanning the Dbl-homology domain of RasGRF1, endowed with catalytic activity on Rac. In search for a possible function we found by biochemical means that SCLIP influences the signaling properties of RasGRF1, greatly reducing its ability to activate the Rac/p38 MAPK pathway, while the Ras/Erk one remains unaffected. Moreover, a potential role is suggested by transfection studies in neuronal PC12 cells in which RasGRF1 induces neurite outgrowth, and coexpression of SCLIP counteracts this effect, causing a dramatic decrease in the percentage of cells bearing neurites, which also appear significantly shortened. This study unveils a physical and functional interaction between RasGRF1 and SCLIP. We suggest that this novel interplay may have possible implications in mechanisms that regulate neuronal morphology and structural plasticity.	Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy; Univ Milan, Interdept Ctr Adv Microscopy, I-20133 Milan, Italy	University of Milan; University of Milan	Baldassa, S (corresponding author), Univ Milan, Dept Biomol Sci & Biotechnol, Via Celoria 26, I-20133 Milan, Italy.	simona.baldassa@unimi.it	Gnesutta, Nerina/I-5432-2015	Gnesutta, Nerina/0000-0002-2465-8881				Antonsson B, 1998, J BIOL CHEM, V273, P8439, DOI 10.1074/jbc.273.14.8439; Baldassa S, 2003, MOL BRAIN RES, V119, P111, DOI 10.1016/j.molbrainres.2003.08.020; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Baouz S, 2001, J BIOL CHEM, V276, P1742, DOI 10.1074/jbc.M005770200; Beilharz EJ, 1998, J NEUROSCI, V18, P9780; Bieche I, 2003, GENOMICS, V81, P400, DOI 10.1016/S0888-7543(03)00031-4; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Chakrabarti K, 2005, MOL CELL BIOL, V25, P5106, DOI 10.1128/MCB.25.12.5106-5118.2005; Charbaut E, 2005, J CELL SCI, V118, P2313, DOI 10.1242/jcs.02349; Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; Forlani G, 2006, FEBS J, V273, P2127, DOI 10.1111/j.1742-4658.2006.05226.x; Gavet O, 1998, J CELL SCI, V111, P3333; Gavet O, 2002, J NEUROSCI RES, V68, P535, DOI 10.1002/jnr.10234; Giese KP, 2001, NEUROPHARMACOLOGY, V41, P791, DOI 10.1016/S0028-3908(01)00096-X; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; Grenningloh G, 2004, J NEUROBIOL, V58, P60, DOI 10.1002/neu.10279; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Innocenti M, 1999, FEBS LETT, V460, P357, DOI 10.1016/S0014-5793(99)01374-5; Jin LW, 1996, NEUROBIOL AGING, V17, P331, DOI 10.1016/0197-4580(96)00021-8; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Kang SW, 2005, EXP CELL RES, V309, P305, DOI 10.1016/j.yexcr.2005.06.012; Krapivinsky G, 2003, NEURON, V40, P775, DOI 10.1016/S0896-6273(03)00645-7; Kubo T, 2002, J NEUROSCI, V22, P8504; Kunda P, 2001, J NEUROSCI, V21, P2361, DOI 10.1523/JNEUROSCI.21-07-02361.2001; Li SM, 2006, J NEUROSCI, V26, P1721, DOI 10.1523/JNEUROSCI.3990-05.2006; Liu ZY, 2002, J BIOL CHEM, V277, P37832, DOI 10.1074/jbc.M205908200; MacDonald JIS, 1999, J MOL NEUROSCI, V13, P141, DOI 10.1385/JMN:13:1-2:141; Matsuo N, 1998, GENE, V215, P477, DOI 10.1016/S0378-1119(98)00324-2; Matsuo N, 2002, J BIOL CHEM, V277, P2860, DOI 10.1074/jbc.M106186200; Mori N, 2002, J NEUROSCI RES, V70, P264, DOI 10.1002/jnr.10353; Morii H, 2006, NEUROSCI LETT, V396, P241, DOI 10.1016/j.neulet.2005.11.043; OKAZAKI T, 1995, NEUROBIOL AGING, V16, P883, DOI 10.1016/0197-4580(95)02001-2; Ozon S, 1998, J NEUROCHEM, V70, P2386; Ozon S, 1997, EUR J BIOCHEM, V248, P794, DOI 10.1111/j.1432-1033.1997.t01-2-00794.x; Peng HX, 2003, J NEUROSCI, V23, P6617; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; Robinson KN, 2005, J BIOL CHEM, V280, P225, DOI 10.1074/jbc.M410454200; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Rubino T, 2005, J NEUROCHEM, V93, P984, DOI 10.1111/j.1471-4159.2005.03101.x; Rubino T, 2004, MOL CELL NEUROSCI, V25, P355, DOI 10.1016/j.mcn.2003.11.003; SOBEL A, 1989, J BIOL CHEM, V264, P3765; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Sugiura Y, 1995, DEV BRAIN RES, V90, P73, DOI 10.1016/0165-3806(96)83488-2; Tararuk T, 2006, J CELL BIOL, V173, P265, DOI 10.1083/jcb.200511055; Tian XJ, 2006, J BIOL CHEM, V281, P7578, DOI 10.1074/jbc.M512060200; Tian XJ, 2004, EMBO J, V23, P1567, DOI 10.1038/sj.emboj.7600151; Tonini R, 1999, EUR J NEUROSCI, V11, P959, DOI 10.1046/j.1460-9568.1999.00504.x; Tonini R, 2006, J NEUROSCI, V26, P5810, DOI 10.1523/JNEUROSCI.5469-05.2006; Wittmann T, 2003, J CELL BIOL, V161, P845, DOI 10.1083/jcb.200303082; Wyttenbach A, 2006, MOL CELL PROTEOMICS, V5, P553, DOI 10.1074/mcp.T500028-MCP200; Yang HB, 2006, MOL BIOL CELL, V17, P2177, DOI 10.1091/mbc.E05-10-0913; Zippel R, 1997, MOL BRAIN RES, V48, P140	57	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2333	2345		10.1074/jbc.M604495200	http://dx.doi.org/10.1074/jbc.M604495200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135267	hybrid			2022-12-27	WOS:000243593200025
J	Sampath, H; Miyazaki, M; Dobrzyn, A; Ntambi, JM				Sampath, Harini; Miyazaki, Makoto; Dobrzyn, Agnieszka; Ntambi, James M.			Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN-1C; CORONARY-HEART-DISEASE; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; LIPID-METABOLISM; HEPATIC STEATOSIS; SKELETAL-MUSCLE; GENE-EXPRESSION; RECEPTOR-ALPHA	Dietary saturated fats have often been implicated in the promotion of obesity and related disorders. It has been shown recently that saturated fats act through the transcription factor SREBP-1c (sterol regulatory element-binding protein-1c) and its requisite coactivator, peroxisome proliferator-activated receptor-gamma coactivator-1 beta (PGC-1 beta), to exert their pro-lipogenic effects. We show here that a diet high in the saturated fat stearate induces lipogenic genes in wild-type mice, with the induction of the Scd1 (stearoyl-CoA desaturase-1) gene preceding that of other lipogenic genes. However, in Scd1(-/-) mice, stearate does not induce lipogenesis, and Srebp-1c and Pgc-1 beta levels are markedly reduced. Instead, genes of fatty acid oxidation such as Cpt-1 (carnitine palmitoyltransferase-1) as well as Pgc-1 alpha are induced. Mitochondrial fatty acid oxidation is increased, and white adipose tissue and hepatic glycogen stores are depleted in stearate-fed Scd1(-/-) mice. Furthermore, AMP-activated protein kinase is also induced by stearate feeding in Scd1(-/-) mice. These results indicate that the desaturation of saturated fats such as stearate by SCD is an essential step mediating their induction of lipogenesis. In the absence of SCD1, stearate promotes oxidation, leading to protection from saturated fat-induced obesity. SCD1 thus serves as a molecular switch in the promotion or prevention of lipid-induced disorders brought on by consumption of excess saturated fat.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutrit Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ntambi, JM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ntambi@biochem.wisc.edu	Dobrzyn, Agnieszka/R-4073-2016	Dobrzyn, Agnieszka/0000-0002-6331-9460	PHS HHS [NIDDK R0162388] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Biddinger SB, 2005, DIABETES, V54, P1314, DOI 10.2337/diabetes.54.5.1314; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Chakravarthy MV, 2005, CELL METAB, V1, P309, DOI 10.1016/j.cmet.2005.04.002; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Corpeleijn E, 2006, DIABETOLOGIA, V49, P2392, DOI 10.1007/s00125-006-0383-4; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Dobrzyn A, 2005, J BIOL CHEM, V280, P23356, DOI 10.1074/jbc.M502436200; Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101; Griel AE, 2006, ARTERIOSCL THROM VAS, V26, P1958, DOI 10.1161/01.ATV.0000233384.97125.bd; Hardie DG, 2006, PHYSIOLOGY, V21, P48, DOI 10.1152/physiol.00044.2005; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Hulver MW, 2005, CELL METAB, V2, P251, DOI 10.1016/j.cmet.2005.09.002; Ikemoto S, 1996, METABOLISM, V45, P1539, DOI 10.1016/S0026-0495(96)90185-7; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kris-Etherton PM, 2005, LIPIDS, V40, P1193, DOI 10.1007/s11745-005-1485-y; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Miyazaki M, 2006, J LIPID RES, V47, P700, DOI 10.1194/jlr.C500025-JLR200; Miyazaki M, 2004, J BIOL CHEM, V279, P25164, DOI 10.1074/jbc.M402781200; Miyazaki M, 2003, PROSTAG LEUKOTR ESS, V68, P113, DOI 10.1016/S0952-3278(02)00261-2; Miyazaki M, 2003, J BIOL CHEM, V278, P33904, DOI 10.1074/jbc.M304724200; Miyazaki M, 2001, J LIPID RES, V42, P1018; Mulligan JD, 2005, J GERONTOL A-BIOL, V60, P21, DOI 10.1093/gerona/60.1.21; Muoio DM, 2006, ANNU REV BIOCHEM, V75, P367, DOI 10.1146/annurev.biochem.75.103004.142512; Ntambi JM, 2004, PROG LIPID RES, V43, P91, DOI 10.1016/S0163-7827(03)00039-0; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; Rahman SM, 2005, AM J PHYSIOL-ENDOC M, V288, pE381, DOI 10.1152/ajpendo.00314.2004; Rahman SM, 2003, P NATL ACAD SCI USA, V100, P11110, DOI 10.1073/pnas.1934571100; Reaven G, 2004, RECENT PROG HORM RES, V59, P207, DOI 10.1210/rp.59.1.207; ROEHRIG KL, 1974, ANAL BIOCHEM, V58, P414, DOI 10.1016/0003-2697(74)90210-3; Rudel LL, 1997, J CLIN INVEST, V100, P74, DOI 10.1172/JCI119524; Sacks FM, 2002, AM J MED, V113, P13, DOI 10.1016/S0002-9343(01)00987-1; Sampath H, 2006, CURR OPIN CLIN NUTR, V9, P84, DOI 10.1097/01.mco.0000214564.59815.af; Sampath H, 2005, LIPIDS, V40, P1187, DOI 10.1007/s11745-005-1484-z; Sampath H, 2005, ANNU REV NUTR, V25, P317, DOI 10.1146/annurev.nutr.25.051804.101917; Scaglia N, 2005, J BIOL CHEM, V280, P25339, DOI 10.1074/jbc.M501159200; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Thewke D, 2000, BIOCHEM BIOPH RES CO, V273, P1, DOI 10.1006/bbrc.2000.2826; Utzschneider KM, 2006, J CLIN ENDOCR METAB, V91, P4753, DOI 10.1210/jc.2006-0587; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang D, 2006, ENDOCRINOLOGY, V147, P943, DOI 10.1210/en.2005-0570; Wanten GJ, 2004, MINI-REV MED CHEM, V4, P847, DOI 10.2174/1389557043403503; Warensjo E, 2005, DIABETOLOGIA, V48, P1999, DOI 10.1007/s00125-005-1897-x; Weindruch R, 2002, NES NUTR WS, V6, P17, DOI 10.1159/000061853; Xu JQ, 2006, AM J CLIN NUTR, V84, P894, DOI 10.1093/ajcn/84.4.894; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200	51	169	177	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2483	2493		10.1074/jbc.M610158200	http://dx.doi.org/10.1074/jbc.M610158200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17127673	hybrid			2022-12-27	WOS:000243593200040
J	Bourguignon, LYW; Peyrollier, K; Gilad, E; Brightman, A				Bourguignon, Lilly Y. W.; Peyrollier, Karine; Gilad, Eli; Brightman, Amy			Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-BINDING DOMAIN; C-MYC GENE; ARP2/3 COMPLEX; TYROSINE KINASES; CD44 INTERACTION; E-CADHERIN; CYCLIN D1; CYTOSKELETAL REARRANGEMENT; DEPOLYMERIZING PROTEIN; POOR SURVIVAL	In this study we have investigated the interaction of hyaluronan (HA) and CD44 with the neuronal Wiskott-Aldrich syndrome protein (N-WASP) in regulating actin polymerization and ErbB2/beta-catenin signaling in human ovarian tumor cells (SK-OV-3.ipl cells). Biochemical and immunological analyses indicate that N-WASPis expressed in SK-OV-3.ipl cells and that the binding of HA stimulates N-WASP association with CD44 and Arp2/Arp3 leading to filamentous actin formation and ovarian tumor cell migration. In addition, HA binding promotes CD44-N-WASP association with ErbB2 and activates ErbB2 kinase activity that in turn increases phosphorylation of the cytoskeletal protein, beta-catenin. Subsequently, phosphorylated beta-catenin is transported into the nucleus leading to beta-catenin-mediated TCF/LEF-transcriptional co-activation. Because HA-induced beta-catenin phosphorylation, nuclear translocation, and TCF/LEF transcriptional activation is effectively blocked by the ErbB2 inhibitor, AG825, we conclude that HA/CD44-N-WASP-associated ErbB2 activation is required for beta-catenin-mediated signaling events. Transfection of SK-OV-3.ipl cells with N-WASP-VCA ((v) under bar erpolin homology, cofilin homology, and acidic domain) fragment cDNA not only blocks HA/CD44-induced N-WASP-Arp2/3 complex formation but also inhibits actin polymerization/F-actin assembly and tumor cell migration. Overexpression of the N-WASP-VCA domain also significantly reduces HA-induced ErbB2 recruitment to CD44, diminishes beta-catenin phosphorylation/nuclear translocation, and abrogates TCF/LEF-specific transcriptional co-activation by beta-catenin. Taken together, our findings strongly suggest that N- WASP plays a pivotal role in regulating HA-mediated CD44-ErbB2 interaction, beta-catenin signaling, and actin cytoskeleton functions that are required for tumor-specific behaviors and ovarian cancer progression.	[Bourguignon, Lilly Y. W.; Peyrollier, Karine; Gilad, Eli; Brightman, Amy] Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, Vet Affairs Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.	lilly.bourguignon@ucsf.edu			NCI NIH HHS [R01 CA66163, R01 CA 78633] Funding Source: Medline; NIAMS NIH HHS [P01 AR39448] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066163, R01CA078633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Barbieri F, 2004, ONCOLOGY-BASEL, V66, P310, DOI 10.1159/000078332; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERCHUCK A, 1990, CANCER RES, V50, P4087; Boerboom D, 2005, CANCER RES, V65, P9206, DOI 10.1158/0008-5472.CAN-05-1024; Bourguignon LYW, 2006, J BIOL CHEM, V281, P14026, DOI 10.1074/jbc.M507734200; Bourguignon LYW, 2005, J BIOL CHEM, V280, P11961, DOI 10.1074/jbc.M411985200; Bourguignon LYW, 2004, J BIOL CHEM, V279, P29654, DOI 10.1074/jbc.M403608200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Chen CH, 2005, INT J GYNECOL CANCER, V15, P878, DOI 10.1111/j.1525-1438.2005.00150.x; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; FOX H, 1990, CLIN GYNAECOLOGICAL, P188; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; HOSKINS WJ, 1993, CANCER, V71, P1534, DOI 10.1002/cncr.2820710420; HOWARD TH, 1984, J CELL BIOL, V98, P1265, DOI 10.1083/jcb.98.4.1265; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; Iba T, 2004, CANCER SCI, V95, P418, DOI 10.1111/j.1349-7006.2004.tb03225.x; JIANG WG, 1994, BRIT J SURG, V81, P1576, DOI 10.1002/bjs.1800811107; JONES LMH, 1995, CLIN EXP METASTAS, V13, P373; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOLINA IJ, 1992, J EXP MED, V176, P867, DOI 10.1084/jem.176.3.867; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Saegusa M, 2003, CANCER SCI, V94, P103, DOI 10.1111/j.1349-7006.2003.tb01360.x; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shibata T, 1996, ONCOGENE, V13, P883; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; UNDERHILL C, 1992, J CELL SCI, V103, P293; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329; Zhu D, 2000, J CELL PHYSIOL, V183, P182, DOI 10.1002/(SICI)1097-4652(200005)183:2<182::AID-JCP5>3.0.CO;2-O; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	81	74	79	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1265	1280		10.1074/jbc.M604672200	http://dx.doi.org/10.1074/jbc.M604672200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17092940	hybrid			2022-12-27	WOS:000243295200052
J	Chen, SH; Smolka, MB; Zhou, HL				Chen, Sheng-hong; Smolka, Marcus B.; Zhou, Huilin			Mechanism of Dun1 activation by Rad53 phosphorylation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; REDUCTASE INHIBITOR SML1; BUDDING YEAST RAD9; PROTEIN-PHOSPHORYLATION; REPLICATION STRESS; KINASE; PATHWAYS; MRC1; DOMAIN; MEC1	Despite extensive studies, the molecular mechanism of DNA damage checkpoint activation remains incompletely understood. To better dissect this mechanism, we developed an activity-based assay for Dun1, a downstream DNA damage checkpoint kinase in yeast, using its physiological substrate Sml1. Using this assay, we confirmed the genetic basis of Dun1 activation. Rad53 was found to be directly responsible for Dun1 activation. We reconstituted the activation of Dun1 by Rad53 and found that phosphorylation of Thr-380 in the activation loop of Dun1 by Rad53 is responsible for Dun1 activation. Interestingly, phosphorylation of the evolutionarily conserved Thr-354 in the activation loop of Rad53 is also important for the regulation of Rad53 activity. Thus, this conserved mode of activation loop phosphorylation appears to be a general mechanism for the activation of Chk2 family kinases.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Zhou, HL (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, 9500 Gilman Dr,CMM E,Rm 3050, La Jolla, CA 92093 USA.	huzhou@ucsd.edu	Chen, Sheng-hong/AAU-4018-2021	Chen, Sheng-hong/0000-0002-7722-2221; Zhou, Huilin/0000-0002-1350-4430	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K22HG002604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080469] Funding Source: NIH RePORTER; NHGRI NIH HHS [K22 HG002604] Funding Source: Medline; NIGMS NIH HHS [R01 GM080469, R01 GM080469-01] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Bashkirov VI, 2003, MOL CELL BIOL, V23, P1441, DOI 10.1128/MCB.23.4.1441-1452.2003; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee SJ, 2003, MOL CELL BIOL, V23, P6300, DOI 10.1128/MCB.23.17.6300-6314.2003; Lee YD, 2006, GENE DEV, V20, P334, DOI 10.1101/gad.1380506; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Ma JL, 2006, J BIOL CHEM, V281, P3954, DOI 10.1074/jbc.M507508200; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Pan XW, 2006, CELL, V124, P1069, DOI 10.1016/j.cell.2005.12.036; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Smolka MB, 2005, MOL CELL PROTEOMICS, V4, P1358, DOI 10.1074/mcp.M500115-MCP200; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Sweeney FD, 2005, CURR BIOL, V15, P1364, DOI 10.1016/j.cub.2005.06.063; Szyjka SJ, 2005, MOL CELL, V19, P691, DOI 10.1016/j.molcel.2005.06.037; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Uchiki T, 2004, J BIOL CHEM, V279, P11293, DOI 10.1074/jbc.M309751200; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Xu YJ, 2006, GENE DEV, V20, P990, DOI 10.1101/gad.1406706; Zhang Z, 2006, P NATL ACAD SCI USA, V103, P1422, DOI 10.1073/pnas.0510516103; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhao XL, 2002, P NATL ACAD SCI USA, V99, P3746, DOI 10.1073/pnas.062502299; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	33	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					986	995		10.1074/jbc.M609322200	http://dx.doi.org/10.1074/jbc.M609322200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17114794	Green Accepted, hybrid			2022-12-27	WOS:000243295200021
J	Ito, T; Fujio, Y; Takahashi, K; Azuma, J				Ito, Takashi; Fujio, Yasushi; Takahashi, Kyoko; Azuma, Junichi			Degradation of NFAT5, a transcriptional regulator of osmotic stress-related genes, is a critical event for doxorubicin-induced cytotoxicity in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; HEAT-SHOCK PROTEINS; RESPONSE ELEMENT; STIMULATES TRANSCRIPTION; ORNITHINE-DECARBOXYLASE; INDUCED CARDIOTOXICITY; TAURINE TRANSPORTER; INDUCED APOPTOSIS; NUCLEAR-FACTOR; MUSCLE-CELLS	Nuclear factor-activated T cell 5 (NFAT5), a novel member of the NFAT family of proteins, was originally identified as a transcriptional factor responsible for adaptation to hyperosmotic stress. Though NFAT5 is ubiquitously expressed, the biological functions of NFAT5 remain to be clarified, especially in the tissues that are not exposed to hypertonicity, including hearts. In the present study, we focused on the cardioprotective roles of NFAT5 against the cardiotoxic anti-tumor agent doxorubicin (Dox). In cultured cardiomyocytes, transcripts of the hypertonicity-inducible genes, such as taurine transporter (TauT) and sodium/myo-inositol transporter, were down-regulated by Dox. Interestingly, NFAT5 protein, but not mRNA, was decreased in cardiomyocytes exposed to Dox. Treatment of proteasome inhibitors, MG-132 or proteasome-specific inhibitor 1, prevented the Dox-mediated decrease of NFAT5 protein. Further, ubiquitin-conjugated NFAT5 was not detected in cultured cardiomyocytes treated with MG-132 and/or Dox, as assessed by immunoprecipitation assay, suggesting Dox-induced degradation through ubiquitin-independent proteasome pathway. Importantly, inhibition of NFAT5 with overexpression of dominantnegative NFAT5 decreased cell viability and increased creatine kinase leakage into culture medium. Consistently, small interfering RNA targeting NFAT5 gene enhanced myocyte death. These findings suggest that Dox promoted the degradation of NFAT5 protein, reducing cell viability in cardiomyocytes. This is the first demonstration that NFAT5 is a positive regulator of cardiomyocyte survival.	Osaka Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol & Clin Pharmacogenom, Suita, Osaka 5650871, Japan	Osaka University	Azuma, J (corresponding author), Osaka Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol & Clin Pharmacogenom, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan.	azuma@phs.osaka-u.ac.jp	Fujio, Yasushi/H-3421-2017	Fujio, Yasushi/0000-0003-0828-2930				Aihara Y, 2000, J MOL CELL CARDIOL, V32, P1401, DOI 10.1006/jmcc.2000.1173; Anwar A, 2003, J BIOL CHEM, V278, P10368, DOI 10.1074/jbc.M211981200; Arai M, 1998, J MOL CELL CARDIOL, V30, P243, DOI 10.1006/jmcc.1997.0588; Asher G, 2005, MOL CELL, V17, P645, DOI 10.1016/j.molcel.2005.01.020; AZUMA J, 1982, INT J CARDIOL, V2, P303, DOI 10.1016/0167-5273(82)90052-3; BOSMAN DK, 1992, J NEUROCHEM, V59, P591, DOI 10.1111/j.1471-4159.1992.tb09410.x; Chesney R W, 1985, Adv Pediatr, V32, P1; Craig SAS, 2004, AM J CLIN NUTR, V80, P539; Dahl SC, 2001, AM J PHYSIOL-CELL PH, V280, pC248, DOI 10.1152/ajpcell.2001.280.2.C248; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P16800, DOI 10.1073/pnas.222659799; Fujio Y, 2004, FEBS LETT, V573, P202, DOI 10.1016/j.febslet.2004.07.082; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HAMAGUCHI T, 1988, RES COMMUN CHEM PATH, V59, P21; HAMAGUCHI T, 1989, PHARMACOL RES, V21, P729, DOI 10.1016/1043-6618(89)90232-6; Ho SN, 2003, ARCH BIOCHEM BIOPHYS, V413, P151, DOI 10.1016/S0003-9861(03)00130-9; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; Irarrazabal CE, 2004, P NATL ACAD SCI USA, V101, P8809, DOI 10.1073/pnas.0403062101; Ito H, 1999, LIFE SCI, V64, P755, DOI 10.1016/S0024-3205(98)00617-1; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; Ito T, 2004, BIOCHEM J, V382, P177, DOI 10.1042/BJ20031838; Kalivendi SV, 2005, BIOCHEM J, V389, P527, DOI 10.1042/BJ20050285; Kitamura H, 1998, KIDNEY INT, V53, P146, DOI 10.1046/j.1523-1755.1998.00747.x; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Ko BCB, 2002, J BIOL CHEM, V277, P46085, DOI 10.1074/jbc.M208138200; Kojima R, 2004, BIOCHEM J, V380, P783, DOI 10.1042/BJ20040313; Kukan M, 2004, J PHYSIOL PHARMACOL, V55, P3; Kumarapeli ARK, 2005, FASEB J, V19, P2051, DOI 10.1096/fj.05-3973fje; Latchman DS, 2001, CARDIOVASC RES, V51, P637, DOI 10.1016/S0008-6363(01)00354-6; Lee SD, 2002, BIOCHEM BIOPH RES CO, V294, P968, DOI 10.1016/S0006-291X(02)00572-7; Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Lou H, 2005, AM J PHYSIOL-HEART C, V288, pH1925, DOI 10.1152/ajpheart.01054.2004; Maouyo D, 2002, AM J PHYSIOL-RENAL, V282, pF802, DOI 10.1152/ajprenal.00123.2001; Matsuda T, 2006, J MOL CELL CARDIOL, V40, P495, DOI 10.1016/j.yjmcc.2005.12.010; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Poizat C, 2005, MOL CELL BIOL, V25, P2673, DOI 10.1128/MCB.25.7.2673-2687.2005; Poizat C, 2000, MOL CELL BIOL, V20, P8643, DOI 10.1128/MCB.20.23.8643-8654.2000; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; Soti C, 2005, BRIT J PHARMACOL, V146, P769, DOI 10.1038/sj.bjp.0706396; Spallarossa P, 2006, CARDIOVASC RES, V69, P736, DOI 10.1016/j.cardiores.2005.08.009; Takahashi K, 2003, J CARDIOVASC PHARM, V41, P726, DOI 10.1097/00005344-200305000-00009; Takatani T, 2004, BIOCHEM BIOPH RES CO, V316, P484, DOI 10.1016/j.bbrc.2004.02.066; TAKIHARA K, 1986, AM HEART J, V112, P1278, DOI 10.1016/0002-8703(86)90360-1; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; Trama J, 2002, J IMMUNOL, V169, P5477, DOI 10.4049/jimmunol.169.10.5477; Uozumi Y, 2006, BIOCHEM J, V394, P699, DOI 10.1042/BJ20051303; Wang SW, 2002, BIOCHEM J, V367, P729, DOI 10.1042/BJ20020752; Wang Y, 2005, J BIOL CHEM, V280, P19986, DOI 10.1074/jbc.M501689200; Woo SK, 2002, PFLUG ARCH EUR J PHY, V444, P579, DOI 10.1007/s00424-002-0849-2; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002; Zhang Z, 2003, AM J PHYSIOL-RENAL, V285, pF688, DOI 10.1152/ajprenal.00028.2003	58	37	39	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1152	1160		10.1074/jbc.M609547200	http://dx.doi.org/10.1074/jbc.M609547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17105721	hybrid			2022-12-27	WOS:000243295200040
J	Saraf, A; Virshup, DM; Strack, S				Saraf, Amit; Virshup, David M.; Strack, Stefan			Differential expression of the B ' beta regulatory subunit of protein phosphatase 2A modulates tyrosine hydroxylase phosphorylation and catecholamine synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; SITE-DIRECTED MUTAGENESIS; SERINE/THREONINE PHOSPHATASES; NEURODEGENERATIVE-DISEASES; DEPENDENT PHOSPHORYLATION; SUBCELLULAR-LOCALIZATION; DEVELOPMENTAL REGULATION; PARKINSONS-DISEASE; 2A HETEROTRIMERS; SUBSTANTIA-NIGRA	Tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis, is stimulated by N-terminal phosphorylation by several kinases and inhibited by protein serine/threonine phosphatase 2A (PP2A). PP2A is a family of heterotrimeric holoenzymes containing one of more than a dozen different regulatory subunits. In comparison with rat forebrain extracts, adrenal gland extracts exhibited TH hyperphosphorylation at Ser(19), Ser(31), and Ser(40), as well as reduced phosphatase activity selectively toward phosphorylated TH. Because the B'beta regulatory subunit of PP2A is expressed in brain but not in adrenal glands, we tested the hypothesis that PP2A/B'beta is a specific TH phosphatase. In catecholamine-secreting PC12 cells, inducible expression of B'beta decreased both N-terminal Ser phosphorylation and in situ TH activity, whereas inducible silencing of endogenous B'beta had the opposite effect. Furthermore, PP2A/B'beta directly dephosphorylated TH in vitro. As to specificity, other PP2A regulatory subunits had negligible effects on TH activity and phosphorylation in situ and in vitro. Whereas B'beta was highly expressed in doparninergic cell bodies in the substantia nigra, the PP2A regulatory subunit was excluded from TH-positive terminal fields in the striatum and failed to colocalize with presynaptic markers in general. Consistent with a model in which B'beta enrichment in neuronal cell bodies helps confine catecholamine synthesis to axon terminals, TH phosphorylation was higher in processes than in somata of dopaminergic neurons. In summary, we show that B'beta recruits PP2A to modulate TH activity in a tissue- and cell compartment-specific fashion.	Univ Iowa, Carver Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Utah, Ctr Children, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA	University of Iowa; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Strack, S (corresponding author), Univ Iowa, Carver Coll Med, Dept Pharmacol, 2-432 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	stefan-strack@uiowa.edu	Saraf, amit/GZL-0533-2022; Virshup, David M/C-1449-2009	Saraf, amit/0000-0002-0823-2266; Virshup, David M/0000-0001-6976-850X; Strack, Stefan/0000-0002-6175-7280	NATIONAL CANCER INSTITUTE [R01CA080809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043254] Funding Source: NIH RePORTER; NCI NIH HHS [CA80809] Funding Source: Medline; NINDS NIH HHS [NS43254] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; BERRESHEIM U, 1994, BRAIN RES, V637, P273, DOI 10.1016/0006-8993(94)91244-0; Bobrovskaya L, 2004, J NEUROCHEM, V90, P857, DOI 10.1111/j.1471-4159.2004.02550.x; Burke WJ, 2004, NEUROTOXICOLOGY, V25, P101, DOI 10.1016/S0161-813X(03)00090-1; Cheah TB, 1999, J NEUROSCI METH, V87, P167, DOI 10.1016/S0165-0270(99)00002-3; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Dagda RK, 2005, J BIOL CHEM, V280, P27375, DOI 10.1074/jbc.M503693200; Dagda RK, 2003, J BIOL CHEM, V278, P24976, DOI 10.1074/jbc.M302832200; Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dunkley PR, 2004, J NEUROCHEM, V91, P1025, DOI 10.1111/j.1471-4159.2004.02797.x; Firulli BA, 2003, MOL CELL, V12, P1225, DOI 10.1016/S1097-2765(03)00425-8; Fukunaga K, 2000, J NEUROCHEM, V74, P807, DOI 10.1046/j.1471-4159.2000.740807.x; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAAVIK J, 1989, FEBS LETT, V251, P36, DOI 10.1016/0014-5793(89)81424-3; HAYCOCK JW, 1989, ANAL BIOCHEM, V181, P259, DOI 10.1016/0003-2697(89)90240-6; Haycock JW, 1998, J NEUROCHEM, V71, P1670; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HAYCOCK JW, 1992, J NEUROCHEM, V58, P57, DOI 10.1111/j.1471-4159.1992.tb09276.x; HOKFELT T, 1973, HISTOCHEMISTRY, V33, P231; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kumer SC, 1996, J NEUROCHEM, V67, P443; Leal RB, 2002, NEUROCHEM RES, V27, P207, DOI 10.1023/A:1014880403970; Lehmann IT, 2006, J BIOL CHEM, V281, P17644, DOI 10.1074/jbc.M512194200; LEVITT M, 1965, J PHARMACOL EXP THER, V148, P1; Lew JY, 1999, MOL PHARMACOL, V55, P202, DOI 10.1124/mol.55.2.202; Li XH, 2002, EUR J BIOCHEM, V269, P546, DOI 10.1046/j.0014-2956.2001.02680.x; Lim IA, 2003, NEUROPHARMACOLOGY, V45, P738, DOI 10.1016/S0028-3908(03)00276-4; MARKEY KA, 1980, MOL PHARMACOL, V17, P79; Martens E, 2004, J MOL BIOL, V336, P971, DOI 10.1016/j.jmb.2003.12.047; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moy LY, 2004, J BIOL CHEM, V279, P54487, DOI 10.1074/jbc.M406636200; Nishi A, 2000, P NATL ACAD SCI USA, V97, P12840, DOI 10.1073/pnas.220410397; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Ramsey AJ, 2000, BIOCHEMISTRY-US, V39, P773, DOI 10.1021/bi991901r; Salvatore MF, 2000, J NEUROCHEM, V75, P225, DOI 10.1046/j.1471-4159.2000.0750225.x; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SKAGERBERG G, 1988, NEUROSCIENCE, V24, P605, DOI 10.1016/0306-4522(88)90354-5; Strack S, 1999, J COMP NEUROL, V413, P373; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Strack S, 1998, J COMP NEUROL, V392, P515; Sura GR, 2004, J NEUROCHEM, V90, P970, DOI 10.1111/j.1471-4159.2004.02566.x; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Usui H, 1998, FEBS LETT, V430, P312, DOI 10.1016/S0014-5793(98)00684-X; Van Kanegan MJ, 2005, J BIOL CHEM, V280, P36029, DOI 10.1074/jbc.M506986200; WAYMIRE JC, 1991, J NEUROCHEM, V57, P1313, DOI 10.1111/j.1471-4159.1991.tb08296.x; Yohrling GJ, 2003, MOL BRAIN RES, V119, P28, DOI 10.1016/j.molbrainres.2003.08.009; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	58	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					573	580		10.1074/jbc.M607407200	http://dx.doi.org/10.1074/jbc.M607407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17085438	hybrid			2022-12-27	WOS:000243166500063
J	Takeji, M; Moriyama, T; Oseto, S; Kawada, N; Hori, M; Imai, E; Miwa, T				Takeji, Masanobu; Moriyama, Toshiki; Oseto, Susumu; Kawada, Noritaka; Hori, Masatsugu; Imai, Enyu; Miwa, Takeshi			Smooth muscle alpha-actin deficiency in myofibroblasts leads to enhanced renal tissue fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; UNILATERAL URETERAL OBSTRUCTION; HEPATIC STELLATE CELL; TUBULOINTERSTITIAL FIBROSIS; MESANGIAL CELLS; LIVER FIBROSIS; IN-VIVO; DIFFERENTIATION; FIBROBLASTS; EXPRESSION	Myofibroblasts are a major source of proinflammatory cytokines and extracellular matrix in progressive tissue fibrosis leading to chronic organ failure. Myofibroblasts are characterized by de novo expression of smooth muscle alpha-actin (SM alpha A), which correlates with the extent of disease progression, although their exact role is unknown. In vitro cultured myofibroblasts from kidney of SM alpha A knock-out mice demonstrate significantly more prominent cell motility, proliferation, and type-I procollagen expression than those of wild-type myofibroblasts. These pro-fibrotic properties are suppressed by adenovirus-mediated SM alpha A re-expression, accompanied by down-regulation of focal adhesion proteins. In interstitial fibrosis model, tissue fibrosis area, proliferating interstitial cell number, and type-I procollagen expression are enhanced under SM alpha A deficiency. In mesangioproliferative glomerulonephritis model, cell proliferation in the mesangial area is also enhanced in SM alpha A knock-out mice. Adenoviral SM alpha A introduction into renal interstitium obviously ameliorates tissue fibrosis in interstitial fibrosis model. These results indicate that SM alpha A suppresses the pro-fibrotic properties of myofibroblasts, highlighting the significance of smooth muscle-related proteins in moderating chronic organ fibrosis under pathological conditions.	Osaka Univ, Genom Informat Res Ctr, Microbial Dis Res Inst, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Nephrol, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Hlth Care Ctr, Toyonaka, Osaka 5600043, Japan	Osaka University; Osaka University; Osaka University	Miwa, T (corresponding author), Osaka Univ, Genom Informat Res Ctr, Microbial Dis Res Inst, Grad Sch Med, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	miwa@gen-info.osaka-u.ac.jp						Badid C, 2001, RENAL FAILURE, V23, P543, DOI 10.1081/JDI-100104736; Bettinger BT, 2004, NAT REV MOL CELL BIO, V5, P410, DOI 10.1038/nrm1370; Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Crawford K, 2002, MOL CELL BIOL, V22, P5887, DOI 10.1128/MCB.22.16.5887-5896.2002; DIAMOND JR, 1995, AM J PATHOL, V146, P121; Direkze NC, 2003, STEM CELLS, V21, P514, DOI 10.1634/stemcells.21-5-514; Forbes SJ, 2004, GASTROENTEROLOGY, V126, P955, DOI 10.1053/j.gastro.2004.02.025; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Govindarajan G, 2000, CIRC RES, V87, P710, DOI 10.1161/01.RES.87.8.710; Graham F L, 1992, Biotechnology, V20, P363; Grotendorst GR, 2004, FASEB J, V18, P469, DOI 10.1096/fj.03-0699com; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Holderman MT, 2002, MOL PHARMACOL, V61, P1174, DOI 10.1124/mol.61.5.1174; ISHIDOYA S, 1995, KIDNEY INT, V47, P1285, DOI 10.1038/ki.1995.183; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; JOHNSON RJ, 1992, J AM SOC NEPHROL, V2, pS190; KANETO H, 1994, KIDNEY INT, V45, P1637, DOI 10.1038/ki.1994.215; Kawada N, 1999, KIDNEY INT, V55, P2338, DOI 10.1046/j.1523-1755.1999.00475.x; Klahr S, 2002, AM J PHYSIOL-RENAL, V283, pF861, DOI 10.1152/ajprenal.00362.2001; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; Liu Q, 2003, GENE THER, V10, P935, DOI 10.1038/sj.gt.3302036; Mano T, 1999, CIRC RES, V84, P647, DOI 10.1161/01.RES.84.6.647; McCrudden R, 2000, HISTOL HISTOPATHOL, V15, P1159, DOI 10.14670/HH-15.1159; Menke A, 2002, J GASTROINTEST CANC, V31, P41, DOI 10.1385/IJGC:31:1-3:41; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; MORIYAMA T, 1995, J AM SOC NEPHROL, V6, P95; Nagatoya K, 2002, KIDNEY INT, V61, P1684, DOI 10.1046/j.1523-1755.2002.00328.x; Okada H, 2000, KIDNEY INT, V58, P587, DOI 10.1046/j.1523-1755.2000.00205.x; Okamoto-Inoue M, 1999, CANCER LETT, V142, P173, DOI 10.1016/S0304-3835(99)00150-0; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; Phan SH, 2002, CHEST, V122, p286S, DOI 10.1378/chest.122.6_suppl.286S; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Reif S, 2003, J BIOL CHEM, V278, P8083, DOI 10.1074/jbc.M212927200; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schildmeyer LA, 2000, FASEB J, V14, P2213, DOI 10.1096/fj.99-0927com; Sundberg LJ, 2003, J BIOL CHEM, V278, P29783, DOI 10.1074/jbc.M303771200; Takeji M, 2004, J AM SOC NEPHROL, V15, P2383, DOI 10.1097/01.ASN.0000136426.01160.2F; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Wang DZ, 2004, CURR OPIN GENET DEV, V14, P558, DOI 10.1016/j.gde.2004.08.003; Witzenbichler B, 1999, J CLIN INVEST, V104, P1469, DOI 10.1172/JCI7251	45	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40193	40200		10.1074/jbc.M602182200	http://dx.doi.org/10.1074/jbc.M602182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17090535	hybrid			2022-12-27	WOS:000243033900049
J	Winterburn, TJ; Wyatt, DM; Phylip, LH; Bur, D; Harrison, RJ; Berry, C; Kay, J				Winterburn, Tim J.; Wyatt, David M.; Phylip, Lowri H.; Bur, Daniel; Harrison, Rebecca J.; Berry, Colin; Kay, John			Key features determining the specificity of aspartic proteinase inhibition by the helix-forming IA(3) polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The 68-residue IA(3) polypeptide from Saccharomyces cerevisiae is essentially unstructured. It inhibits its target aspartic proteinase through an unprecedented mechanism whereby residues 2-32 of the polypeptide adopt an amphipathic alpha-helical conformation upon contact with the active site of the enzyme. This potent inhibitor (K-i < 0.1 nM) appears to be specific for a single target proteinase, saccharopepsin. Mutagenesis of IA(3) from S. cerevisiae and its ortholog from Saccharomyces castellii was coupled with quantitation of the interaction for each mutant polypeptide with saccharopepsin and closely related aspartic proteinases from Pichia pastoris and Aspergillus fumigatus. This identified the charged K18/D22 residues on the otherwise hydrophobic face of the amphipathic helix as key selectivity-determining residues within the inhibitor and implicated certain residues within saccharopepsin as being potentially crucial. Mutation of these amino acids established Ala-213 as the dominant specificity-governing feature in the proteinase. The side chain of Ala-213 in conjunction with valine 26 of the inhibitor marshals Tyr-189 of the enzyme precisely into a position in which its side-chain hydroxyl is interconnected via a series of water-mediated contacts to the key K18/D22 residues of the inhibitor. This extensive hydrogen bond network also connects K18/D22 directly to the catalytic Asp-32 and Tyr-75 residues of the enzyme, thus deadlocking the inhibitor in position. In most other aspartic proteinases, the amino acid at position 213 is a larger hydrophobic residue that prohibits this precise juxtaposition of residues and eliminates these enzymes as targets of IA(3). The exquisite specificity exhibited by this inhibitor in its interaction with its cognate folding partner proteinase can thus be readily explained.	Cardiff Univ, Sch Biosci, Cardiff CF10 3US, Wales; Actelion Pharmaceut Ltd, CH-4123 Allschwil, Switzerland	Cardiff University; Actelion Pharmaceuticals Ltd	Kay, J (corresponding author), Cardiff Univ, Sch Biosci, Museum Ave, Cardiff CF10 3US, Wales.	KayJ@cardiff.ac.uk	Berry, Colin/A-4338-2010	Berry, Colin/0000-0002-9943-548X; Plummer, Beverley/0000-0002-6559-7237	Wellcome Trust [VS/04/CAR/A1/OA/AM/F] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguilar CF, 1997, J MOL BIOL, V267, P899, DOI 10.1006/jmbi.1996.0880; Dunn BM, 2002, CHEM REV, V102, P4431, DOI 10.1021/cr010167q; Green TB, 2004, BIOCHEMISTRY-US, V43, P4071, DOI 10.1021/bi034823n; Li M, 2000, NAT STRUCT BIOL, V7, P113, DOI 10.1038/72378; Phylip LH, 2001, J BIOL CHEM, V276, P2023, DOI 10.1074/jbc.M008520200; Reichard U, 2000, INT J MED MICROBIOL, V290, P85; SIBANDA BL, 1984, FEBS LETT, V174, P102, DOI 10.1016/0014-5793(84)81086-8; Tigue NJ, 1998, J BIOL CHEM, V273, P26441, DOI 10.1074/jbc.273.41.26441; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; Winterburn TJ, 2006, BIOL CHEM, V387, P1139, DOI 10.1515/BC.2006.140; WINTHER JR, 2004, HDB PROTEOLYTIC ENZY, P87	11	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6508	6516		10.1074/jbc.M610503200	http://dx.doi.org/10.1074/jbc.M610503200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17145748	hybrid			2022-12-27	WOS:000244867200058
J	Foo, RSY; Chan, LKW; Kitsis, RN; Bennett, MR				Foo, Roger S. -Y.; Chan, Lennard K. W.; Kitsis, Richard N.; Bennett, Martin R.			Ubiquitination and degradation of the anti-apoptotic protein ARC by MDM2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE RECRUITMENT DOMAIN; CELL-DEATH; CARDIAC-HYPERTROPHY; OXIDATIVE STRESS; DOWN-REGULATION; OXIDANT STRESS; HUMAN P53; REPRESSOR; HEART; PHOSPHORYLATION	Current evidence shows that cardiomyocyte apoptosis plays a central role in the pathogenesis of myocardial disease and that reactive oxygen species is critically responsible for mediating cardiomyocyte apoptosis in both ischernia-reperfusion injury and dilated cardiomyopathy. ARC (Apoptosis Repressor with Caspase recruitment domain) is an anti-apoptotic protein that is found abundantly in terminally differentiated cells such as cardiomyocytes. The ARC knock-out mouse developed larger infarct in response to ischemia-reperfusion and transitioned more rapidly and severely to dilated cardiomyopathy following aortic constriction. In addition, ARC protein levels are decreased in human dilated cardiomyopathy and when cardiomyocytes are exposed to oxidative stress in vitro, but the mechanisms regulating ARC protein levels are not known. Here we show that degradation of ARC is dependent on the p53-induced ubiquitin E3 ligase, MDM2. Oxidative stress reduced ARC levels and up-regulated MDM2. MDM2 directly accelerated ARC protein turnover via ubiquitination and proteasomal-dependent degradation. This activity requires a functioning MDM2 ring finger domain because the MDM2(C464A) mutant was unable to direct ARC degradation. Furthermore, ARC degradation requires MDM2, because MDM2 knock-out fibroblasts showed defective ARC degradation that could be rescued by MDM2. Proteasomal inhibitors rescued both MDM2 and H2O2-induced degradation of ARC and inhibited cardiomyocyte apoptosis. Dilated cardiomyopathic hearts from mice that have undergone transverse aortic banding have increased MDM2 levels associated with decreased ARC levels. We conclude that MDM2 is a critical regulator of ARC levels in cardiomyocytes. Prevention of MDM2-induced degradation of ARC represents a potential therapeutic target to prevent cardiomyocyte apoptosis.	Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, Cambridge CB2 2QQ, England; Royal Hosp Sick Children, Dept Plast & Reconstruct Surg, Edinburgh EH9 1LF, Midlothian, Scotland; Albert Einstein Coll Med, Cardiovasc Res Ctr, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Cardiovasc Res Ctr, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Canc, Bronx, NY 10461 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Foo, RSY (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, ACCI Bldg,Level 6,Box 110,Hills Rd, Cambridge CB2 2QQ, England.	rsyf2@cam.ac.uk		Bennett, Martin/0000-0002-2565-1825; Foo, Roger/0000-0002-8079-4618	NHLBI NIH HHS [HL60665, HL61550, HL80607] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080607, R01HL060665, R01HL061550] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Donath S, 2006, CIRCULATION, V113, P1203, DOI 10.1161/CIRCULATIONAHA.105.576785; Dumaz N, 2001, BIOCHEM J, V359, P459, DOI 10.1042/0264-6021:3590459; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Foo RSY, 2005, J CLIN INVEST, V115, P565, DOI 10.1172/JCI200524569; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Gustafsson AB, 2002, CIRCULATION, V106, P735, DOI 10.1161/01.CIR.0000023943.50821.F7; Gustafsson AB, 2004, J BIOL CHEM, V279, P21233, DOI 10.1074/jbc.M400695200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; LUNA RMD, 1995, NATURE, V378, P203; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Meiners S, 2004, HYPERTENSION, V44, P471, DOI 10.1161/01.HYP.0000142772.71367.65; Nam YJ, 2004, MOL CELL, V15, P901, DOI 10.1016/j.molcel.2004.08.020; Neuss M, 2001, J BIOL CHEM, V276, P33915, DOI 10.1074/jbc.M104080200; Sarkar S, 2004, J BIOL CHEM, V279, P52630, DOI 10.1074/jbc.M402037200; Sawyer DB, 2002, J MOL CELL CARDIOL, V34, P379, DOI 10.1006/jmcc.2002.1526; Sorescu Dan, 2002, Congest Heart Fail, V8, P132, DOI 10.1111/j.1527-5299.2002.00717.x; Tachibana H, 2005, CIRCULATION, V111, P591, DOI 10.1161/01.CIR.0000142291.70954.DF; Takimoto E, 2005, J CLIN INVEST, V115, P1221, DOI 10.1172/JCI200521968; Toth A, 2006, J BIOL CHEM, V281, P3679, DOI 10.1074/jbc.M509630200; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; van Empel VPM, 2005, CIRC RES, V96, pE92, DOI 10.1161/01.RES.0000172081.30327.28; von Harsdorf R, 2004, CIRC RES, V95, P554, DOI 10.1161/01.RES.0000143717.70275.8f; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664	33	66	71	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5529	5535		10.1074/jbc.M609046200	http://dx.doi.org/10.1074/jbc.M609046200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17142834	hybrid			2022-12-27	WOS:000244482300048
J	Chou, TF; Wagner, CR				Chou, Tsui-Fen; Wagner, Carston R.			Lysyl-tRNA synthetase-generated lysyl-adenylate is a substrate for histidine triad nucleotide binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-INTERACTING PROTEIN-1; TRANSCRIPTIONAL ACTIVITY; ACTIVE-SITE; HIT FAMILY; HIV-1 GAG; HINT; FHIT; MECHANISM; ENZYME; GENE	Histidine triad nucleotide binding proteins (Hints) are the most ancient members of the histidine triad protein superfamily of nucleotidyltransferases and hydrolyases. Protein-protein interaction studies have found that complexes of the transcription factors MITE or USF2 and lysyl-tRNA synthetase (LysRS) are associated with human Hintl. Therefore, we hypothesized that lysyl-AMP or the LysRS center dot lysyl-AMP may be a native substrate for Hints. To explore the biochemical relationship between Hintl and LysRS, a series of catalytic radiolabeling, mutagenesis, and kinetic experiments was conducted with purified LysRSs and Hints from human and Escherichia coli. After incubation of the E. coli or human LysRS with Hints and [alpha-P-32]ATP, but not [alpha-P-32]GTP, P-32-labeled Hints were observed. By varying time and the concentrations of lysine, Mg2+, or LysRS, the adenylation of Hint was found to be dependent on the formation of lysyl-AMP. Site-directed mutagenesis studies of the active site histidine triad revealed that Hint labeling could be abolished by substitution of either His-101 of E. coli hinT or His-112 of human Hintl by either alanine or glycine. Ap(4)A, believed to be synthesized by LysRS in vivo, and Zn2+ were shown to inhibit the formation of Hint-AMP with an IC50 value in the low micromolar range. Consistent with pyrophosphate being an inhibitor for aminoacyl-tRNA synthetase, incubations in the presence of pyrophosphatase resulted in enhanced formation of Hint-AMP. These results demonstrate that the lysyl-AMP intermediate formed by LysRS is a natural substrate for Hints and suggests a potential highly conserved regulatory role for Hints on LysRS and possibly other aminoacyl-tRNA synthetases.	Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Wagner, CR (corresponding author), Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA.	wagne003@umn.edu						Ahel I, 2006, NATURE, V443, P713, DOI 10.1038/nature05164; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BREVET A, 1995, J BIOL CHEM, V270, P14439, DOI 10.1074/jbc.270.24.14439; BREVET A, 1989, P NATL ACAD SCI USA, V86, P8275, DOI 10.1073/pnas.86.21.8275; Bullock TL, 2003, J MOL BIOL, V328, P395, DOI 10.1016/S0022-2836(03)00305-X; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; Chou TF, 2005, J BIOL CHEM, V280, P15356, DOI 10.1074/jbc.M500434200; CHOU TF, 2006, IN PRESS MOL PHARM; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Desogus G, 2000, BIOCHEMISTRY-US, V39, P8418, DOI 10.1021/bi0006722; FREY PA, 1982, METHOD ENZYMOL, V87, P20; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; Geeganage S, 1998, BIOCHEMISTRY-US, V37, P14500, DOI 10.1021/bi9815546; Hati S, 2006, J BIOL CHEM, V281, P27862, DOI 10.1074/jbc.M605856200; Howard OMZ, 2002, J EXP MED, V196, P781, DOI 10.1084/jem.20020186; Huang K, 2004, BIOCHEMISTRY-US, V43, P7637, DOI 10.1021/bi049762n; Huang KS, 2005, EUR J ORG CHEM, V2005, P5198, DOI 10.1002/ejoc.200500499; Hughes SJ, 2006, PROTEINS, V62, P649, DOI 10.1002/prot.20609; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Jakubowski H, 1999, BIOCHEMISTRY-US, V38, P8088, DOI 10.1021/bi990629i; Javanbakht H, 2003, J BIOL CHEM, V278, P27644, DOI 10.1074/jbc.M301840200; Khvorova A, 1999, NUCLEIC ACIDS RES, V27, P4451, DOI 10.1093/nar/27.22.4451; Kijas AW, 2006, J BIOL CHEM, V281, P13939, DOI 10.1074/jbc.M507946200; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Kovaleski BJ, 2006, J BIOL CHEM, V281, P19449, DOI 10.1074/jbc.M601189200; Krakowiak A, 2004, J BIOL CHEM, V279, P18711, DOI 10.1074/jbc.M314271200; Kwasnicka DA, 2003, J BIOL CHEM, V278, P39051, DOI 10.1074/jbc.M306355200; LEDNEVA RK, 1967, DOKL AKAD NAUK SSSR+, V172, P977; Lee YN, 2005, MOL CELL BIOL, V25, P8904, DOI 10.1128/MCB.25.20.8904-8912.2005; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Li H, 2006, ONCOGENE, V25, P713, DOI 10.1038/sj.onc.1209111; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; Martin J, 2006, GASTROENTEROLOGY, V130, P2179, DOI 10.1053/j.gastro.2006.03.024; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Park SG, 2005, TRENDS BIOCHEM SCI, V30, P569, DOI 10.1016/j.tibs.2005.08.004; Parks KP, 2004, PHYSIOL GENOMICS, V20, P12, DOI 10.1152/physiolgenomics.00204.2004; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; Stark LA, 1998, J VIROL, V72, P3037, DOI 10.1128/JVI.72.4.3037-3044.1998; Steer BA, 1999, BIOCHEMISTRY-US, V38, P4965, DOI 10.1021/bi990038s; THEOCLITOU ME, 1996, J CHEM SOC P1, V16, P123; Weiske J, 2006, J BIOL CHEM, V281, P27356, DOI 10.1074/jbc.M513452200; Wolfson AD, 2002, P NATL ACAD SCI USA, V99, P5965, DOI 10.1073/pnas.092152799; Yuan BZ, 2004, NEOPLASIA, V6, P412, DOI 10.1593/neo.03490; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3	51	50	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4719	4727		10.1074/jbc.M610530200	http://dx.doi.org/10.1074/jbc.M610530200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158446	hybrid, Green Accepted			2022-12-27	WOS:000244482000053
J	Pearson, LA; Barrow, KD; Neilan, BA				Pearson, Leanne A.; Barrow, Kevin D.; Neilan, Brett A.			Characterization of the 2-hydroxy-acid dehydrogenase Mcyl, encoded within the microcystin biosynthesis gene cluster of Microcystis aeruginosa PCC7806	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-LACTATE DEHYDROGENASE; ESCHERICHIA-COLI; PEPTIDE SYNTHETASE; D-3-PHOSPHOGLYCERATE DEHYDROGENASE; 3-PHOSPHOGLYCERATE DEHYDROGENASE; ENZYME; EVOLUTION; SEQUENCE; PATHWAY	The cyanobacterium Microcystis aeruginosa is widely known for its production of the potent hepatotoxin microcystin. This cyclic heptapeptide is synthesized non-ribosomally by the thio-template function of a large modular enzyme complex encoded within the 55-kb microcystin synthetase gene (mcy) cluster. The mcy gene cluster also encodes several stand-alone enzymes, putatively involved in the tailoring and export of microcystin. This study describes the characterization of the 2-hydroxy-acid dehydrogenase McyI, putatively involved in the production of D-methyl aspartate at position 3 within the microcystin cyclic structure. A combination of bioinformatics, molecular, and biochemical techniques was used to elucidate the structure, function, regulation, and evolution of this unique enzyme. The recombinant McyI enzyme was overexpressed in Escherichia coli and enzymatically characterized. The hypothesized native activity of McyI, the interconversion of 3-methyl malate to 3-methyl oxalacetate, was demonstrated using an in vitro spectrophotometric assay. The enzyme was also able to reduce a-ketoglutarate to 2-hydroxyglutarate and to catalyze the interconversion of malate and oxalacetate. Although NADP(H) was the preferred cofactor of the McyI-catalyzed reactions, NAD(H) could also be utilized, although rates of catalysis were significantly lower. The combined results of this study suggest that hepatotoxic cyanobacteria such as M. aeruginosa PCC7806 are capable of producing methyl aspartate via a novel glutamate mutase-independent pathway, in which McyI plays a pivotal role.	Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Neilan, BA (corresponding author), Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia.	b.neilan@unsw.edu.au	Neilan, Brett A/I-5767-2012; Pearson, Leanne/AAZ-3326-2020; Pearson, Leanne/E-3845-2013	Neilan, Brett A/0000-0001-6113-772X; Pearson, Leanne/0000-0002-7091-9763				Ali V, 2004, EUR J BIOCHEM, V271, P2670, DOI 10.1111/j.1432-1033.2004.04195.x; Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; BAHT KS, 1985, INDIAN J CHEM, V24, P509; Bell JK, 2002, EUR J BIOCHEM, V269, P4176, DOI 10.1046/j.1432-1033.2002.03075.x; BOTES DP, 1985, J CHEM SOC PERK T 1, P2747, DOI 10.1039/p19850002747; Buckel W, 2001, APPL MICROBIOL BIOT, V57, P263, DOI 10.1007/s002530100773; CAMPBELL HD, 1984, EUR J BIOCHEM, V144, P367, DOI 10.1111/j.1432-1033.1984.tb08473.x; Christiansen G, 2003, J BACTERIOL, V185, P564, DOI 10.1128/JB.185.2.564-572.2003; Dittmann E, 1997, MOL MICROBIOL, V26, P779, DOI 10.1046/j.1365-2958.1997.6131982.x; GOLDBERG JD, 1994, J MOL BIOL, V236, P1123, DOI 10.1016/0022-2836(94)90016-7; Grant GA, 1999, J BIOL CHEM, V274, P5357, DOI 10.1074/jbc.274.9.5357; Grant GA, 2000, ARCH BIOCHEM BIOPHYS, V375, P171, DOI 10.1006/abbi.1999.1652; Grant GA, 2001, J BIOL CHEM, V276, P1078, DOI 10.1074/jbc.M007512200; Heinzelmann E, 2003, ANTIMICROB AGENTS CH, V47, P447, DOI 10.1128/AAC.47.2.447-457.2003; HENNING M, 1991, INT REV GES HYDROBIO, V76, P37, DOI 10.1002/iroh.19910760105; HERDMAN M, 2001, BERGEYS MANUAL SYSTE, V1, P776; Herter S, 2002, J BIOL CHEM, V277, P20277, DOI 10.1074/jbc.M201030200; Ho CL, 1999, J BIOL CHEM, V274, P397, DOI 10.1074/jbc.274.1.397; JACKSON ARB, 1984, VET PATHOL, V21, P102, DOI 10.1177/030098588402100117; Kaebernick M, 2002, APPL ENVIRON MICROB, V68, P449, DOI 10.1128/AEM.68.2.449-455.2002; Kaebernick M, 2001, ENVIRON MICROBIOL, V3, P669, DOI 10.1046/j.1462-2920.2001.00241.x; Kaebernick M, 2000, APPL ENVIRON MICROB, V66, P3387, DOI 10.1128/AEM.66.8.3387-3392.2000; KAKINUMA K, 1993, BIOSCI BIOTECH BIOCH, V57, P1916, DOI 10.1271/bbb.57.1916; Kato Y, 1997, ARCH MICROBIOL, V168, P457, DOI 10.1007/s002030050522; Kim AD, 2002, J BACTERIOL, V184, P4134, DOI 10.1128/JB.184.15.4134-4140.2002; KOCHHAR S, 1992, BIOCHEM BIOPH RES CO, V184, P60, DOI 10.1016/0006-291X(92)91157-L; Moffitt MC, 2004, APPL ENVIRON MICROB, V70, P6353, DOI 10.1128/AEM.70.11.6353-6362.2004; Moffitt MC, 2001, FEMS MICROBIOL LETT, V196, P207, DOI 10.1111/j.1574-6968.2001.tb10566.x; Moore BS, 1999, NAT PROD REP, V16, P653, DOI 10.1039/a805873c; MOORE RE, 1991, J AM CHEM SOC, V113, P5083, DOI 10.1021/ja00013a066; NAMIKOSHI M, 1992, CHEM RES TOXICOL, V5, P661, DOI 10.1021/tx00029a011; Neilan BA, 1997, INT J SYST BACTERIOL, V47, P693, DOI 10.1099/00207713-47-3-693; Nishizawa T, 1999, J BIOCHEM-TOKYO, V126, P520, DOI 10.1093/oxfordjournals.jbchem.a022481; RENAUD P, 1987, HELV CHIM ACTA, V70, P292, DOI 10.1002/hlca.19870700204; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; RIPPKA R., 1992, PASTEUR CULTURE COLL, V1; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; Sen AK, 1999, EUR J BIOCHEM, V261, P524, DOI 10.1046/j.1432-1327.1999.00303.x; SIVONEN K, 1992, APPL ENVIRON MICROB, V58, P2495, DOI 10.1128/AEM.58.8.2495-2500.1992; SIVONEN K, 1999, TOXIC CYANOBACTERIA, P42; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STARR RC, 1993, J PHYCOL, V29, P1, DOI 10.1111/j.0022-3646.1993.00001.x; TAGUCHI H, 1991, J BIOL CHEM, V266, P12588; Tillett D, 2000, J PHYCOL, V36, P251, DOI 10.1046/j.1529-8817.2000.99079.x; Tillett D, 2000, CHEM BIOL, V7, P753, DOI 10.1016/S1074-5521(00)00021-1; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	46	22	26	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4681	4692		10.1074/jbc.M606986200	http://dx.doi.org/10.1074/jbc.M606986200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17142460	hybrid			2022-12-27	WOS:000244482000049
J	Wenz, T; Covian, R; Hellwig, P; MacMillan, F; Meunier, B; Trumpower, BL; Hunte, C				Wenz, Tina; Covian, Raul; Hellwig, Petra; MacMillan, Fraser; Meunier, Brigitte; Trumpower, Bernard L.; Hunte, Carola			Mutational analysis of cytochrome b at the ubiquinol oxidation site of yeast complex III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BC(1) COMPLEX; SACCHAROMYCES-CEREVISIAE; Q(O) SITE; QUINOL OXIDATION; MOLECULAR-BASIS; Q-CYCLE; RESISTANCE; INHIBITORS; PROTEIN; UBIHYDROQUINONE	The cytochrome bc(1) complex is a dimeric enzyme of the inner mitochondrial membrane that links electron transfer from ubiquinol to cytochrome c by a protonmotive Q cycle mechanism in which ubiquinol is oxidized at one center in the enzyme, referred to as center P, and ubiquinone is rereduced at a second center, referred to as center N. To better understand the mechanism of ubiquinol oxidation, we have examined catalytic activities and pre-steady-state reduction kinetics of yeast cytochrome bc(1) complexes with mutations in cytochrome b that we expected would affect oxidation of ubiquinol. We mutated two residues thought to be involved in proton conduction linked to ubiquinol oxidation, Tyr(132) and Glu(272), and two residues proposed to be involved in docking ubiquinol into the center P pocket, Phe(129) and Tyr(279). Substitution of Phe(129) by lysine or arginine yielded a respiration-deficient phenotype and lipid-dependent catalytic activity. Increased bypass reactions were detectable for both variants, with F129K showing the more severe effects. Substitution with lysine leads to a disturbed coordination of a b heme as deduced from changes in the midpoint potential and the EPR signature. Removal of the aromatic side chain in position Tyr(279) lowers the catalytic activity accompanied by a low level of bypass reactions. Pre-steady-state kinetics of the enzymes modified at Glu(272) and Tyr(132) confirmed the importance of their functional groups for electron transfer. Altered center N kinetics and activation of ubiquinol oxidation by binding of cytochrome c in the Y132F and E272D enzymes indicate long range effects of these mutations.	Max Planck Inst Biophys, Dept Mol Membrane Biol, D-60438 Frankfurt, Germany; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Univ Strasbourg 1, Inst Chim, UMR 7177, LC3, F-67000 Strasbourg, France; Univ Frankfurt, Inst Phys & Theoret Chem, D-60439 Frankfurt, Germany; Univ Frankfurt, Ctr Biomol Magnet Resonance, D-60439 Frankfurt, Germany; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Max Planck Society; Dartmouth College; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Goethe University Frankfurt; Goethe University Frankfurt; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Hunte, C (corresponding author), Max Planck Inst Biophys, Dept Mol Membrane Biol, Max Von Laue Str 3, D-60438 Frankfurt, Germany.	Carola.Hunte@mpibp-frankfurt.mpg.de	Hunte, Carola/E-4071-2015; MacMillan, Fraser/AAM-4483-2020; MacMillan, Fraser/B-7619-2011	Hunte, Carola/0000-0002-0826-3986; MacMillan, Fraser/0000-0002-2410-4790; MacMillan, Fraser/0000-0002-2410-4790; hellwig, petra/0000-0001-6294-5163; Meunier, Brigitte/0000-0002-6988-4663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; Covian R, 2005, J BIOL CHEM, V280, P22732, DOI 10.1074/jbc.M413592200; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DIRAGO JP, 1989, J BIOL CHEM, V264, P14543; Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065; Fisher N, 2005, PEST MANAG SCI, V61, P973, DOI 10.1002/ps.1066; Fisher N, 2004, J BIOL CHEM, V279, P12951, DOI 10.1074/jbc.M313866200; GEIER BM, 1992, EUR J BIOCHEM, V208, P375, DOI 10.1111/j.1432-1033.1992.tb17197.x; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Hunte C, 2003, FEBS LETT, V545, P39, DOI 10.1016/S0014-5793(03)00391-0; Jordan DB, 1999, PESTIC SCI, V55, P105, DOI 10.1002/(SICI)1096-9063(199902)55:2&lt;105::AID-PS879&gt;3.0.CO;2-D; Kessl JJ, 2004, J BIOL CHEM, V279, P2817, DOI 10.1074/jbc.M309984200; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; Lebrun E, 2006, MOL BIOL EVOL, V23, P1180, DOI 10.1093/molbev/msk010; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Muller F, 2002, BIOCHEMISTRY-US, V41, P7866, DOI 10.1021/bi025581e; Osyczka A, 2005, TRENDS BIOCHEM SCI, V30, P176, DOI 10.1016/j.tibs.2005.02.001; Palsdottir H, 2004, BBA-BIOMEMBRANES, V1666, P2, DOI 10.1016/j.bbamem.2004.06.012; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; SARBIAS AS, 1992, BIOCHEMISTRY-US, V34, P16004; Silkstone GG, 2005, J AM CHEM SOC, V127, P92, DOI 10.1021/ja045719b; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Wenz T, 2006, BIOCHEMISTRY-US, V45, P9042, DOI 10.1021/bi060280g; Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224	30	52	55	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3977	3988		10.1074/jbc.M606482200	http://dx.doi.org/10.1074/jbc.M606482200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17145759	hybrid			2022-12-27	WOS:000244481900062
J	Beach, D; Gonen, R; Bogin, Y; Reischl, IG; Yablonski, D				Beach, Dvora; Gonen, Ronnie; Bogin, Yaron; Reischl, Ilona G.; Yablonski, Deborah			Dual role of SLP-76 in mediating T cell receptor-induced activation of phospholipase C-gamma 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; ANTIGEN RECEPTOR; DIFFERENTIAL ROLE; PROTEIN NETWORKS; LIPID RAFTS; LAT LINKER; C-GAMMA; PLC-GAMMA-1; DOMAIN	Phospholipase C-gamma 1 (PLC-gamma 1) activation depends on a heterotrimeric complex of adaptor proteins composed of LAT, Gads, and SLP-76. Upon T cell receptor stimulation, a portion of PLC-gamma 1 is recruited to a detergent-resistant membrane fraction known as the glycosphingolipid-enriched membrane microdomains (GEMs), or lipid rafts, to which LAT is constitutively localized. In addition to LAT, PLC-gamma 1 GEM recruitment depended on SLP-76, and, in particular, required the Gads-binding domain of SLP-76. The N-terminal tyrosine phosphorylation sites and P-I region of SLP-76 were not required for PLC-gamma 1 GEM recruitment, but were required for PLC-gamma 1 phosphorylation at Tyr(783). Thus, GEM recruitment can be insufficient for full activation of PLC-gamma 1 in the absence of a second SLP-76-mediated event. Indeed, a GEM-targeted derivative of PLC-gamma 1 depended on SLP-76 for T cell receptor-induced phosphorylation at Tyr(783) and subsequent NFAT activation. On a biochemical level, SLP-76 inducibly associated with both Vav and catalytically active ITK, which efficiently phosphorylated a PLC-gamma 1 fragment at Tyr(783) in vitro. Both associations were disrupted upon mutation of the N-terminal tyrosine phosphorylation sites of SLP-76. The P-I region deletion disrupted Vav association and reduced SLP-76-associated kinase activity. A smaller deletion within the P-I region, which does not impair PLC-gamma 1 activation, did not impair the association with Vav, but reduced SLP-76-associated kinase activity. These results provide new insight into the multiple roles of SLP-76 and the functional importance of its interactions with other signaling proteins.	Technion Israel Inst Technol, Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; US FDA, Immunobiol Lab, Div Monoclonal Antibodies, Off Biotechnol Prod,Ctr Drug Evaluat & Res, Bethesda, MD 20892 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; US Food & Drug Administration (FDA)	Yablonski, D (corresponding author), Technion Israel Inst Technol, Rappaport Fac Med, Rappaport Family Inst Res Med Sci, POB 9649 Bat Galim, IL-31096 Haifa, Israel.	debya@tx.technion.ac.il		Yablonski, Deborah/0000-0003-2979-0440; Blecher, Ronnie/0000-0003-2847-1149				Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Braiman A, 2006, EMBO J, V25, P774, DOI 10.1038/sj.emboj.7600978; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Douglass AD, 2005, CELL, V121, P937, DOI 10.1016/j.cell.2005.04.009; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Gonen R, 2005, J BIOL CHEM, V280, P8364, DOI 10.1074/jbc.M409437200; Harder T, 2004, CURR OPIN IMMUNOL, V16, P353, DOI 10.1016/j.coi.2004.03.013; Hartgroves LC, 2003, J BIOL CHEM, V278, P20389, DOI 10.1074/jbc.M301212200; Houtman JCD, 2004, BIOCHEMISTRY-US, V43, P4170, DOI 10.1021/bi0357311; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; Jia CYH, 2005, MOL CELL PROTEOMICS, V4, P1155, DOI 10.1074/mcp.M500108-MCP200; Jordan MS, 2006, J IMMUNOL, V176, P2430, DOI 10.4049/jimmunol.176.4.2430; Kettner A, 2003, MOL CELL BIOL, V23, P2395, DOI 10.1128/MCB.23.7.2395-2406.2003; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Koretzky GA, 2006, NAT REV IMMUNOL, V6, P67, DOI 10.1038/nri1750; Kumar L, 2002, P NATL ACAD SCI USA, V99, P884, DOI 10.1073/pnas.022619199; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; Liu SKW, 2001, ONCOGENE, V20, P6284, DOI 10.1038/sj.onc.1204771; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Myung PS, 2001, IMMUNITY, V15, P1011, DOI 10.1016/S1074-7613(01)00253-9; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Paz PE, 2001, BIOCHEM J, V356, P461, DOI 10.1042/0264-6021:3560461; Poulin B, 2005, P NATL ACAD SCI USA, V102, P4276, DOI 10.1073/pnas.0409590102; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Schneider H, 2000, J BIOL CHEM, V275, P3835, DOI 10.1074/jbc.275.6.3835; Sekiya F, 2004, J BIOL CHEM, V279, P32181, DOI 10.1074/jbc.M405116200; Serrano CJ, 2005, J IMMUNOL, V174, P6233, DOI 10.4049/jimmunol.174.10.6233; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Singer AL, 2004, J BIOL CHEM, V279, P15481, DOI 10.1074/jbc.M313339200; Stoica B, 1998, J IMMUNOL, V160, P1059; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Wonerow P, 2002, BIOCHEM J, V364, P755, DOI 10.1042/BJ20020128; Wong J, 2000, J BIOL CHEM, V275, P33116, DOI 10.1074/jbc.M004467200; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Xu Z, 2002, CELL GROWTH DIFFER, V13, P285; Yablonski D, 2001, ADV IMMUNOL, V79, P93, DOI 10.1016/S0065-2776(01)79003-7; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu MH, 2005, J IMMUNOL, V174, P31, DOI 10.4049/jimmunol.174.1.31; Zhu NH, 2003, J IMMUNOL, V170, P325, DOI 10.4049/jimmunol.170.1.325	57	36	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2937	2946		10.1074/jbc.M606697200	http://dx.doi.org/10.1074/jbc.M606697200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148460	hybrid			2022-12-27	WOS:000243793900020
J	Bennett, RD; Mauer, AS; Strehler, EE				Bennett, Richard D.; Mauer, Amy S.; Strehler, Emanuel E.			Calmodulin-like protein increases filopodia-dependent cell motility via up-regulation of myosin-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL MYOSIN; EPITHELIAL-CELLS; MOTOR; GENE	Human calmodulin-like protein (CLP) is an epithelial-specific protein that is expressed during cell differentiation but down-regulated in primary cancers and transformed cell lines. Using stably transfected and inducible HeLa cell lines, we found that CLP expression did not alter the proliferation rate and colony-forming potential of these cells. However, remarkable phenotypic changes were observed in CLP-expressing compared with control cells. Soft agar colonies of CLP-expressing cells had rough boundaries, with peripheral cells migrating away from the colony. Cells expressing CLP displayed a striking increase in the number and length of myosin-10-positive filopodia and showed increased mobility in a wound healing assay. This increase in wound healing capacity was prevented by small interference RNA-mediated down-regulation of myosin-10. Fluorescence microscopy and Western blotting revealed that CLP expression results in up-regulation of its target protein, myosin-10. This up-regulation occurs at the protein level by stabilization of myosin-10. Thus, CLP functions by increasing the stability of myosin-10, leading to enhanced myosin-10 function and a subsequent increase in filopodial dynamics and cell migration. In stratified epithelia, CLP may be required during terminal differentiation to increase myosin-10 function as cells migrate toward the upper layers and establish new adhesive contacts.	Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Cell Biol & Genet Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Strehler, EE (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	strehler.emanuel@mayo.edu						Berg JS, 2000, J CELL SCI, V113, P3439; Berg JS, 2002, NAT CELL BIOL, V4, P246, DOI 10.1038/ncb762; Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X; EDMAN CF, 1994, EUR J BIOCHEM, V226, P725, DOI 10.1111/j.1432-1033.1994.tb20101.x; GALLAGHER S, 1998, CURRENT PROTOCOLS MO; Han BG, 2002, FEBS LETT, V521, P24, DOI 10.1016/S0014-5793(02)02780-1; Homma K, 2001, J BIOL CHEM, V276, P34348, DOI 10.1074/jbc.M104785200; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; KOLLER M, 1988, FEBS LETT, V239, P121, DOI 10.1016/0014-5793(88)80558-1; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; RHYNER JA, 1992, BIOCHEMISTRY-US, V31, P12826, DOI 10.1021/bi00166a017; Rogers Michael S., 1999, Neoplasia (New York), V1, P220, DOI 10.1038/sj.neo.7900029; Rogers MS, 2001, EXP CELL RES, V267, P216, DOI 10.1006/excr.2001.5254; Rogers MS, 2001, J BIOL CHEM, V276, P12182, DOI 10.1074/jbc.M010056200; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Sousa AD, 2005, TRENDS CELL BIOL, V15, P533, DOI 10.1016/j.tcb.2005.08.006; Tokuo H, 2004, BIOCHEM BIOPH RES CO, V319, P214, DOI 10.1016/j.bbrc.2004.04.167; Weber KL, 2004, NATURE, V431, P325, DOI 10.1038/nature02834; YASWEN P, 1992, CELL GROWTH DIFFER, V3, P335; YASWEN P, 1990, P NATL ACAD SCI USA, V87, P7360, DOI 10.1073/pnas.87.19.7360; Zhang HQ, 2004, NAT CELL BIOL, V6, P523, DOI 10.1038/ncb1136	22	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3205	3212		10.1074/jbc.M607174200	http://dx.doi.org/10.1074/jbc.M607174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17130134	hybrid			2022-12-27	WOS:000243793900047
J	Chattopadhyay, S; Tracy, E; Liang, P; Robledo, O; Rose-John, S; Baumann, H				Chattopadhyay, Souvik; Tracy, Erin; Liang, Ping; Robledo, Olivier; Rose-John, Stefan; Baumann, Heinz			Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; T-CELLS; ALPHA(1)-PROTEINASE INHIBITOR; FIBRINOGEN BIOSYNTHESIS; STIMULATING FACTOR; GROWTH-INHIBITION; DESIGNER CYTOKINE; PLASMA-PROTEINS; IN-VIVO; RECEPTOR	Lung epithelial cells are primary targets of oncostatin M (OSM) and, to a lower degree, of interleukin (IL)-6 and IL-31, all members of the IL-6 cytokine family. The OSM receptor (OSMR) signals through activation of STAT and mitogen-activated protein kinase pathways to induce genes encoding differentiated cell functions, reduce cell-cell interaction, and suppress cell proliferation. IL-31 functions through the heteromeric IL-31 receptor, which shares with OSMR the OSMR beta subunit, but does not engage gp130, the common subunit of all other IL-6 cytokine receptors. Because the response of epithelial cells to IL-31 is unknown, the action of IL-31 was characterized in the human alveolar epithelial cell line A549 in which the expression of the ligand-binding IL-31R alpha subunit was increased. IL-31 initiated signaling that differed from other IL-6 cytokines by the particularly strong recruitment of the STAT3, ERK, JNK, and Akt pathways. IL-31 was highly effective in suppressing proliferation by altering expression of cell cycle proteins, including up-regulation of p27(Kip1) and down regulation of cyclin B1, CDC2, CDK6, MCM4, and retinoblastoma. A single STAT3 recruitment site (Tyr-721) in the cytoplasmic domain of IL-31R alpha exerts a dominant function in the entire receptor complex and is critical for gene induction, morphological changes, and growth inhibition. The data suggest that inflammatory and immune reactions involving activated T-cells regulate functions of epithelial cells by IL-6 cytokines through receptor-defined signaling reactions.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Univ Kiel, Dept Biochem, D-24098 Kiel, Germany	Roswell Park Cancer Institute; Roswell Park Cancer Institute; University of Kiel	Baumann, H (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	heinz.baumann@roswellpark.org	Rose-John, Stefan/A-7998-2010; Liang, Ping/D-2709-2009; Liang, Ping/S-3790-2018	Rose-John, Stefan/0000-0002-7519-3279; Liang, Ping/0000-0003-4423-0636; Liang, Ping/0000-0003-4423-0636	NATIONAL CANCER INSTITUTE [R01CA085580, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056, CA085580] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bando T, 2006, NEUROSCIENCE, V142, P1263, DOI 10.1016/j.neuroscience.2006.07.009; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; Bihl M, 1998, AM J RESP CELL MOL, V19, P606, DOI 10.1165/ajrcmb.19.4.3247; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; Boutten A, 1998, AM J RESP CELL MOL, V18, P511, DOI 10.1165/ajrcmb.18.4.2772; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cichy J, 1998, BIOCHEM J, V329, P335, DOI 10.1042/bj3290335; de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; DeMiguel F, 2002, PROSTATE, V52, P123, DOI 10.1002/pros.10110; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Diveu C, 2003, J BIOL CHEM, V278, P49850, DOI 10.1074/jbc.M307286200; Diveu C, 2004, EUR CYTOKINE NETW, V15, P291; Dreuw A, 2004, J BIOL CHEM, V279, P36112, DOI 10.1074/jbc.M401122200; duPont NC, 2005, J REPROD IMMUNOL, V66, P175, DOI 10.1016/j.jri.2005.03.005; Finelt N, 2005, CYTOKINE, V31, P305, DOI 10.1016/j.cyto.2005.05.005; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FULLER GM, 1985, J CELL BIOL, V101, P1481, DOI 10.1083/jcb.101.4.1481; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; Gao LF, 2005, CLIN CANCER RES, V11, P6333, DOI 10.1158/1078-0432.CCR-05-0148; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Grant SL, 2001, GROWTH FACTORS, V19, P153, DOI 10.3109/08977190109001083; Greenberg AK, 2002, AM J RESP CELL MOL, V27, P320, DOI 10.1165/rcmb.4710; Haidaris PJS, 1997, BLOOD, V89, P873; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Huising MO, 2006, J ENDOCRINOL, V189, P1, DOI 10.1677/joe.1.06591; Ishimi Y, 2003, J BIOL CHEM, V278, P24644, DOI 10.1074/jbc.M213252200; Jones SA, 2005, J INTERF CYTOK RES, V25, P241, DOI 10.1089/jir.2005.25.241; Kaido T, 2004, HEPATO-GASTROENTEROL, V51, P1667; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kawada M, 2006, CANCER RES, V66, P2913, DOI 10.1158/0008-5472.CAN-05-3460; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Klein C, 2005, J CLIN INVEST, V115, P860, DOI 10.1172/JCI200523640; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Krebs DL, 2000, J CELL SCI, V113, P2813; Lai CF, 1999, J BIOL CHEM, V274, P7793, DOI 10.1074/jbc.274.12.7793; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Loewen GM, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-145; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Nakamura K, 2004, HEPATOLOGY, V39, P635, DOI 10.1002/hep.20086; Peters M, 1998, J IMMUNOL, V161, P3575; PIQUETPELLORCE C, 1994, EXP CELL RES, V213, P340, DOI 10.1006/excr.1994.1208; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674; Sallenave JM, 1997, J INTERF CYTOK RES, V17, P337, DOI 10.1089/jir.1997.17.337; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Stross C, 2006, J BIOL CHEM, V281, P8458, DOI 10.1074/jbc.M511212200; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Viswanathan S, 2002, STEM CELLS, V20, P119, DOI 10.1634/stemcells.20-2-119; Wahl AF, 2001, ANN RHEUM DIS, V60, pIII75; Wallace PM, 1999, J IMMUNOL, V162, P5547; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	66	85	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3014	3026		10.1074/jbc.M609655200	http://dx.doi.org/10.1074/jbc.M609655200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148439	hybrid			2022-12-27	WOS:000243793900028
J	Oertel, J; Villmann, C; Kettenmann, H; Kirchhoff, F; Becker, CM				Oertel, Jana; Villmann, Carmen; Kettenmann, Helmut; Kirchhoff, Frank; Becker, Cord-Michael			A novel glycine receptor beta subunit splice variant predicts an unorthodox transmembrane topology - Assembly into heteromeric receptor complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SPINAL-CORD; GLIAL-CELLS; NEUROTRANSMITTER RECEPTORS; NICOTINIC RECEPTORS; CHLORIDE CHANNELS; GABA RECEPTORS; MESSENGER-RNA; SPASTIC MOUSE; GEPHYRIN; EXPRESSION	The inhibitory glycine receptor is a ligand-gated ion channel with a pentameric assembly from ligand binding alpha and structural beta subunits. In addition to alpha subunit gene variants (alpha 1-alpha 4) and developmental alterations in subunit composition of the receptor protein complex, alternative splicing of alpha subunits has been found to contribute to glycine receptor heterogeneity. Here, we describe a novel splice variant of the glycine receptor beta subunit from mouse central nervous system, prevailing in macroglial cells, predominantly in astrocytes and extraneural tissues. As predicted by its cDNA sequence, the novel subunit beta Delta 7 lacks amino acid positions 251-302 encoded by exon 7 of the Glrb gene. Transcripts and antigen of beta Delta 7 were detected in cerebral cortex, liver, and heart. Lack of exon 7 results in a profoundly altered prediction of transmembrane topology as beta Delta 7 lacks TM1 and TM2 present in the full-length variant. Despite these topological alterations, in vitro studies showed that the beta Delta 7 polypeptide integrates into the plasma membrane, forming receptor complexes with the alpha 1 subunit and gephyrin. Our data demonstrate that a topology deviating from the classical four transmembrane-fold is compatible with formation of glycine receptor protein complexes. However, co-expression of alpha 1 with beta Delta 7 subunits did not change glycine receptor channel properties. Rather, the high level of expression in non- neuronal cells having intimate contact with synaptic regions may account for a yet unknown function of this splice variant beta Delta 7 in glycinergic neurotransmission.	Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, D-91054 Erlangen, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Max Planck Inst Expt Med, D-37075 Gottingen, Germany	University of Erlangen Nuremberg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society	Becker, CM (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Fahrstr 17, D-91054 Erlangen, Germany.	cmb@biochem.uni-erlangen.de	Oertel, Jana/T-1048-2017; Kirchhoff, Frank/B-9335-2008; Kettenmann, Helmut/AAJ-5142-2021	Kirchhoff, Frank/0000-0002-2324-2761; Kettenmann, Helmut/0000-0001-8208-0291				AKAGI H, 1991, NEUROSCI RES, V11, P28, DOI 10.1016/0168-0102(91)90064-6; BECKER CM, 1992, NEURON, V8, P283, DOI 10.1016/0896-6273(92)90295-O; BECKER CM, 1988, EMBO J, V7, P3717, DOI 10.1002/j.1460-2075.1988.tb03255.x; BETZ H, 1991, TRENDS NEUROSCI, V14, P458, DOI 10.1016/0166-2236(91)90045-V; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; FRASER DD, 1994, GLIA, V11, P83, DOI 10.1002/glia.440110203; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Grudzinska J, 2005, NEURON, V45, P727, DOI 10.1016/j.neuron.2005.01.028; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hawthorne R, 2005, J BIOL CHEM, V280, P35836, DOI 10.1074/jbc.M506645200; JACKSON PS, 1993, AM J PHYSIOL, V265, pC1489, DOI 10.1152/ajpcell.1993.265.6.C1489; KIM EY, 2006, IN PRESS EMBO J; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; Kirchhoff F, 1996, J NEUROCHEM, V66, P1383; Kirsch J, 1996, MOL CELL NEUROSCI, V8, P93, DOI 10.1006/mcne.1996.0048; KIRSCH J, 1995, J NEUROSCI, V15, P4148; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; Kneussel M, 1999, J NEUROCHEM, V72, P1323, DOI 10.1046/j.1471-4159.1999.0721323.x; Kneussel M, 2000, J PHYSIOL-LONDON, V525, P1, DOI 10.1111/j.1469-7793.2000.t01-4-00001.x; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUHSE J, 1990, NEURON, V5, P867, DOI 10.1016/0896-6273(90)90346-H; KUHSE J, 1990, J BIOL CHEM, V265, P22317; Kumar DV, 2002, J NEUROBIOL, V52, P156, DOI 10.1002/neu.10072; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; Makara JK, 2001, GLIA, V34, P52, DOI 10.1002/glia.1039; MALOSIO ML, 1991, EMBO J, V10, P2401, DOI 10.1002/j.1460-2075.1991.tb07779.x; Matthias K, 2003, J NEUROSCI, V23, P1750; Meier J, 2004, J NEUROSCI, V24, P1398, DOI 10.1523/JNEUROSCI.4260-03.2004; Meier J, 2001, NAT NEUROSCI, V4, P253, DOI 10.1038/85099; Meier JC, 2005, NAT NEUROSCI, V8, P736, DOI 10.1038/nn1467; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; MULHARDT C, 1994, NEURON, V13, P1003, DOI 10.1016/0896-6273(94)90265-8; Nikolic Z, 1998, J BIOL CHEM, V273, P19708, DOI 10.1074/jbc.273.31.19708; PASTOR A, 1995, EUR J NEUROSCI, V7, P1188, DOI 10.1111/j.1460-9568.1995.tb01109.x; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Rees MI, 2003, J BIOL CHEM, V278, P24688, DOI 10.1074/jbc.M301070200; Rees MI, 2002, HUM MOL GENET, V11, P853, DOI 10.1093/hmg/11.7.853; Ren Z, 2003, J BIOL CHEM, V278, P52700, DOI 10.1074/jbc.M309585200; Ross ED, 2005, NAT CELL BIOL, V7, P1039, DOI 10.1038/ncb1105-1039; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Rouzaire-Dubois B, 2000, PFLUG ARCH EUR J PHY, V440, P881, DOI 10.1007/s004240000371; SASSOEPOGNETTO M, 1995, J COMP NEUROL, V357, P1, DOI 10.1002/cne.903570102; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; Sola M, 2004, EMBO J, V23, P2510, DOI 10.1038/sj.emboj.7600256; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; Todd AJ, 1996, EUR J NEUROSCI, V8, P2492, DOI 10.1111/j.1460-9568.1996.tb01543.x; Unwin N, 2003, FEBS LETT, V555, P91, DOI 10.1016/S0014-5793(03)01084-6; van Zundert B, 2005, BRAIN RES, V1050, P40, DOI 10.1016/j.brainres.2005.05.014; Wassle H, 1998, VISION RES, V38, P1411, DOI 10.1016/s0042-6989(97)00300-3; Zhang XD, 2004, GLIA, V47, P46, DOI 10.1002/glia.20024	57	30	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2798	2807		10.1074/jbc.M608941200	http://dx.doi.org/10.1074/jbc.M608941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145751	Green Submitted, hybrid			2022-12-27	WOS:000243793900006
J	Jiang, M; Pabla, N; Murphy, RF; Yang, TX; Yin, XM; Degenhardt, K; White, E; Dong, Z				Jiang, Man; Pabla, Navjotsin; Murphy, Robert F.; Yang, Tianxin; Yin, Xiao-Ming; Degenhardt, Kurt; White, Eileen; Dong, Zheng			Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE ANTAGONISTS; CYTOCHROME-C RELEASE; MDM2 ANTAGONISTS; EMBRYONIC LETHALITY; P53 ACTIVATION; APOPTOSIS; PATHWAY; BAX; INHIBITOR; DEATH	Nutlins, the newly developed small molecule antagonists of MDM2, activate p53 and induce apoptosis in cancer cells, offering a novel strategy of chemotherapy. Recent studies have further suggested synergistic effects of nutlins with other chemotherapeutic drugs. However, it is unclear whether nutlins increase or decrease the side effects of these drugs in normal non-malignant cells or tissues. Cisplatin is a widely used chemotherapy drug, which has a major side effect of kidney injury. Here we show that Nutlin-3 protected kidney cells against cis-platin-induced apoptosis. The cytoprotective effects of Nutlin-3 were not related to its regulation of p53 or consequent gene expression during cisplatin treatment. Moreover, the protective effects were shown in MDM2-, MDM4-, or p53-deficient cells. On the other hand, Nutlin-3 suppressed mitochondrial events of apoptosis during cisplatin incubation, including Bax activation and cytochrome c release. Nutlin-3 attenuated cisplatin-induced oligomerization of Bax and Bak but not their interactions with Bcl-XL. In isolated mitochondria, Nutlin-3 inhibited cytochrome c release induced by Ca2+, Bim peptide, and recombinant tBid. Importantly, it blocked both Bax and Bak oligomerization under these conditions. Together, the results have uncovered a new pharmacological function of nutlins, i.e. suppression of Bax and Bak, two critical mediators of apoptosis.	Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Vet Affairs Med Ctr, Augusta, GA 30912 USA; NCI, NIH, Bethesda, MD 20892 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84148 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Rutgers State Univ, Canc Inst New Jersey, Dept Mol Biol & Biochem, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA	University System of Georgia; Augusta University; US Department of Veterans Affairs; Veterans Health Administration (VHA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Dong, Z (corresponding author), Med Coll Georgia, Dept Cellular Biol & Anat, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	zdong@mail.mcg.edu	White, Eileen/ABD-6745-2021; Pabla, Navjotsingh/H-3568-2011	White, Eileen/0000-0003-2961-3065; Pabla, Navjot/0000-0001-9408-0539; Livingston, Man/0000-0001-8638-0902	NCI NIH HHS [R37 CA053370-17, R37 CA053370-16, R37 CA053370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arany I, 2003, SEMIN NEPHROL, V23, P460, DOI 10.1016/S0270-9295(03)00089-5; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Cao C, 2006, MOL CANCER THER, V5, P411, DOI 10.1158/1535-7163.MCT-05-0356; Carvajal D, 2005, CANCER RES, V65, P1918, DOI 10.1158/0008-5472.CAN-04-3576; Coll-Mulet L, 2006, BLOOD, V107, P4109, DOI 10.1182/blood-2005-08-3273; Cummings BS, 2002, J PHARMACOL EXP THER, V302, P8, DOI 10.1124/jpet.302.1.8; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Dong Z, 2000, BIOCHEM J, V347, P669, DOI 10.1042/0264-6021:3470669; Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200; Fischer PM, 2004, TRENDS PHARMACOL SCI, V25, P343, DOI 10.1016/j.tips.2004.04.011; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Jiang M, 2006, ONCOGENE, V25, P4056, DOI 10.1038/sj.onc.1209440; Jiang M, 2004, AM J PHYSIOL-RENAL, V287, pF1140, DOI 10.1152/ajprenal.00262.2004; Jordan P, 2000, CELL MOL LIFE SCI, V57, P1229, DOI 10.1007/PL00000762; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Kojima K, 2006, BLOOD, V108, P993, DOI 10.1182/blood-2005-12-5148; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; LUNA RMD, 1995, NATURE, V378, P203; Megyesi J, 1998, J CLIN INVEST, V101, P777, DOI 10.1172/JCI1497; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Park MS, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134858; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Perez JM, 2000, CRIT REV ONCOL HEMAT, V35, P109, DOI 10.1016/S1040-8428(00)00053-6; Ribas J, 2006, EXP CELL RES, V312, P2394, DOI 10.1016/j.yexcr.2006.04.021; Scoumanne A, 2006, CANCER RES, V66, P6271, DOI 10.1158/0008-5472.CAN-06-0121; Secchiero P, 2006, BLOOD, V107, P4122, DOI 10.1182/blood-2005-11-4465; Seth R, 2005, J BIOL CHEM, V280, P31230, DOI 10.1074/jbc.M503305200; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Stuhmer T, 2005, BLOOD, V106, P3609, DOI 10.1182/blood-2005-04-1489; Taguchi T, 2005, CONTRIB NEPHROL, V148, P107, DOI 10.1159/000086055; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Vassilev LT, 2004, CELL CYCLE, V3, P419; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200	44	84	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2636	2645		10.1074/jbc.M606928200	http://dx.doi.org/10.1074/jbc.M606928200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17130128	Green Accepted, hybrid			2022-12-27	WOS:000243593200056
J	Lindsey, S; Huang, WQ; Wang, H; Horvath, E; Zhu, CL; Eklund, EA				Lindsey, Stephan; Huang, Weiqi; Wang, Hao; Horvath, Elizabeth; Zhu, Chunliu; Eklund, Elizabeth A.			Activation of SHP2 protein-tyrosine phosphatase increases HoxA10-induced repression of the genes encoding gp91(PHOX) and p67(PHOX)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; LEUKEMIC TRANSFORMATION; MYELOID PROGENITORS; FUSION GENE; HOX GENES; EXPRESSION; MUTATIONS	The CYBB and NCF2 genes encode the phagocyte oxidase proteins gp91(PHOX) and p67(PHOX), respectively. These genes are transcribed after the promyelocyte stage of differentiation, and transcription continues until cell death. In undifferentiated myeloid cells, homologous cis-elements in the CYBB and NCF2 genes are repressed by the homeodomain transcription factor HoxA10. During cytokine-induced myelopoiesis, tyrosine phosphorylation of HoxA10 decreases binding affinity for the CYBB and NCF2 cis-elements. This abrogates HoxA10-induced transcriptional repression as differentiation proceeds. Therefore, mechanisms involved in differentiation stage-specific HoxA10 tyrosine phosphorylation are of interest because HoxA10 phosphorylation modulates myeloid-specific gene transcription. In this study, we found that HoxA10 is a substrate for SHP2 protein-tyrosine phosphatase in undifferentiated myeloid cells. In contrast, HoxA10 is a substrate for a constitutively active mutant form of SHP2 in both undifferentiated and differentiating myeloid cells. Expression of such SHP2 mutants results in persistent HoxA10 repression of CYBB and NCF2 transcription during myelopoiesis. Both HoxA10 overexpression and activating SHP2 mutations have been described in human myeloid malignancies. Therefore, our results suggest that these mutations could cooperate, leading to decreased myeloid-specific gene transcription and functional differentiation block in myeloid cells with both defects.	Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Jesse Brown Vet Affairs Med Ctr, Lakeside Div, Chicago, IL 60612 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Eklund, EA (corresponding author), Northwestern Univ, Feinberg Sch Med, Olson Pavil,Rm 8524,710 N Fairbanks Ct, Chicago, IL 60611 USA.	e-eklund@northwestern.edu	Huang, Weiqi/E-4341-2010; Lindsey, Stephan/E-4358-2012	Wang, Hao/0000-0003-2131-0377				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; AYNTON PM, 2003, GENE DEV, V17, P2298; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Chen F, 1997, DEV BIOL, V181, P186, DOI 10.1006/dbio.1996.8440; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; Dong Q, 1999, J IMMUNOL, V162, P3220; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Eklund EA, 2002, J BIOL CHEM, V277, P36878, DOI 10.1074/jbc.M203917200; Eklund EA, 1996, J IMMUNOL, V157, P2418; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Eklund EA, 2006, CURR OPIN HEMATOL, V13, P67, DOI 10.1097/01.moh.0000208467.63861.d6; EZEKOWITZ RAB, 1987, J CLIN INVEST, V80, P1009, DOI 10.1172/JCI113153; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; FromentalRamain C, 1996, DEVELOPMENT, V122, P461; Huang WQ, 2006, MOL CELL BIOL, V26, P6311, DOI 10.1128/MCB.00036-06; Kakar R, 2005, J LEUKOCYTE BIOL, V77, P120, DOI 10.1189/jlb.0704429; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kautz B, 2001, J BIOL CHEM, V276, P37868; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; KhannaGupta A, 1997, BLOOD, V90, P2784, DOI 10.1182/blood.V90.7.2784.2784_2784_2795; KHWAJA A, 1991, BRIT J HAEMATOL, V77, P25, DOI 10.1111/j.1365-2141.1991.tb07943.x; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kumar AR, 2004, BLOOD, V103, P1823, DOI 10.1182/blood-2003-07-2582; LARRICK JW, 1980, J IMMUNOL, V125, P6; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; Lindsey S, 2005, J IMMUNOL, V175, P5269, DOI 10.4049/jimmunol.175.8.5269; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; LOWNEY P, 1991, NUCLEIC ACIDS RES, V19, P3443, DOI 10.1093/nar/19.12.3443; Lu YF, 2003, J BIOL CHEM, V278, P47792, DOI 10.1074/jbc.M305885200; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SATOKATA I, 1995, NATURE, V374, P460, DOI 10.1038/374460a0; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; Schubbert S, 2005, BLOOD, V106, P311, DOI 10.1182/blood-2004-11-4207; So CW, 2004, BLOOD, V103, P3192, DOI 10.1182/blood-2003-10-3722; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Zhu CL, 2004, J BIOL CHEM, V279, P50874, DOI 10.1074/jbc.M405736200	50	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2237	2249		10.1074/jbc.M608642200	http://dx.doi.org/10.1074/jbc.M608642200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17138561	hybrid			2022-12-27	WOS:000243593200015
J	Tang, CH; Hsu, TL; Lin, WW; Lai, MZ; Yang, RS; Hsieh, SL; Fu, WM				Tang, Chih-Hsin; Hsu, Tsui-Ling; Lin, Wan-Wan; Lai, Ming-Zong; Yang, Rong-Sen; Hsieh, Shie-Liang; Fu, Wen-Mei			Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; RAT OSTEOBLASTS; GROWTH-FACTOR; FAS LIGAND; CELLS; DIFFERENTIATION; EXPRESSION; RESORPTION; PATHWAY	Decoy receptor 3 (DcR3), a soluble receptor for FasL, LIGHT, and TL1A, induces osteoclast formation from monocyte, macrophage, and bone stromal marrow cells. However, the function of DcR3 on bone formation remains largely unknown. To understand the function of DcR3 in bone formation in vivo, transgenic mice overexpressing DcR3 were generated. Bone mineral density (BMD) and bone mineral content (BMC) of total body were significantly lower in DcR3 transgenic mice as compared with wild-type controls. The difference in BMD and BMC between DcR3 transgenic and control mice was confirmed by histomorphometric analysis, which showed a 35.7% decrease in trabecular bone volume in DcR3 transgenic mice in comparison with wild-type controls. The number of osteoclasts increased in DcR3 transgenic mice. In addition, local administration of DcR3 (30 mu g/ml, 10 mu l, once/day) into the metaphysis of the tibia via the implantation of a needle cannula significantly decreased the BMD, BMC, and bone volume of secondary spongiosa in tibia. Local injection of DcR3 also increased osteoclast numbers around trabecular bone in tibia. Furthermore, coadminstration of soluble tumor necrosis factor receptor inhibitor/Fc chimera (TNFRSF1A) but not osteoprotegerin inhibited the action of DcR3. In addition, in an assay of osteoclast activity on substrate plates, DcR3 significantly increased the resorption activity of mature osteoclasts. Treatment with higher concentrations of DcR3 slightly increased nodule formation and alkaline phosphatase activity of primary cultured osteoblasts. These results indicate that DcR3 may play an important role in osteoporosis or other bone diseases.	Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei 100, Taiwan; Natl Taiwan Univ, Dept Orthopaed, Coll Med, Taipei 100, Taiwan; Natl Yang Ming Univ, Dept Microbiol & Immunol, Taipei 112, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; China Med Univ, Dept Pharmacol, Taichung 404, Taiwan	National Taiwan University; National Taiwan University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; China Medical University Taiwan	Hsieh, SL (corresponding author), Natl Taiwan Univ, Dept Pharmacol, Coll Med, 1,Sec 1,Jen Ai Rd, Taipei 100, Taiwan.	slhsieh@ym.edu.tw; wenmei@ha.mc.ntu.edu.tw	Hsu, Tsui-Ling/H-6704-2015; Lai, Ming-Zong/AAA-4408-2021; Hsu, Tsui-Ling/AAE-8821-2019; Hsieh, Shie-Liang Edmond/ABA-9184-2021	Hsu, Tsui-Ling/0000-0002-2912-3261; Yang, Rong-Sen/0000-0002-0553-4779; Lin, Wan Wan/0000-0002-3207-734X; FU, WEN-MEI/0000-0003-4157-8987				Abu-Amer Y, 2000, J BIOL CHEM, V275, P27307; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Bai C, 2000, P NATL ACAD SCI USA, V97, P1230, DOI 10.1073/pnas.97.3.1230; David JP, 1998, J BONE MINER RES, V13, P1730, DOI 10.1359/jbmr.1998.13.11.1730; Fujikawa Y, 2001, BONE, V28, P261, DOI 10.1016/S8756-3282(00)00453-1; Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Hsu MJ, 2004, EXP CELL RES, V292, P241, DOI 10.1016/j.yexcr.2003.09.019; Hsu TL, 2005, J IMMUNOL, V175, P5135, DOI 10.4049/jimmunol.175.8.5135; Kim S, 2004, INFECT IMMUN, V72, P89, DOI 10.1128/IAI.72.1.89-93.2004; Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Otsuki T, 2000, CLIN EXP IMMUNOL, V119, P323; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; Tang CH, 2005, J BIOL CHEM, V280, P22907, DOI 10.1074/jbc.M500130200; Tang CH, 2004, MOL PHARMACOL, V66, P440; Tang CH, 2003, J BONE MINER RES, V18, P502, DOI 10.1359/jbmr.2003.18.3.502; Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160; Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756-3282(01)00685-8; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952; Tsuji S, 2003, INT J CANCER, V106, P17, DOI 10.1002/ijc.11170; UY HL, 1995, J BONE MINER RES, V10, P295; Yang CR, 2004, CELL DEATH DIFFER, V11, pS97, DOI 10.1038/sj.cdd.4401403; Yang CR, 2004, CANCER RES, V64, P1122, DOI 10.1158/0008-5472.CAN-03-0609; Yang RS, 2005, ULTRASOUND MED BIOL, V31, P431, DOI 10.1016/j.ultrasmedbio.2004.11.010; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733; Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200	33	38	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2346	2354		10.1074/jbc.M603070200	http://dx.doi.org/10.1074/jbc.M603070200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17099218	hybrid			2022-12-27	WOS:000243593200026
J	Ramsey, JE; Daugherty, MA; Kelm, RJ				Ramsey, Jon E.; Daugherty, Margaret A.; Kelm, Robert J., Jr.			Hydrodynamic studies on the quaternary structure of recombinant mouse Pur beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESTROGEN-RECEPTOR DIMERIZATION; SEDIMENTATION-VELOCITY DATA; ALPHA-ACTIN PROMOTER; MYOSIN HEAVY-CHAIN; BINDING PROTEINS; LIGHT-SCATTERING; GENE-EXPRESSION; RNA; ASSOCIATION	Pur beta is a gene regulatory factor belonging to a family of highly conserved nucleic acid-binding proteins related by their ability to preferentially bind single-stranded DNA or RNA sequences rich in purine nucleotides. In conjunction with Pur alpha, Pur beta has been implicated in transcriptional and translational repression of genes encoding contractile proteins found in the heart and vasculature. Although several models of sequence-specific DNA recognition, strand separation, and activator inhibition by oligomeric Pur alpha and Pur beta have been proposed, it is currently unclear whether protein-protein interaction is a prerequisite to, or a consequence of nucleic acid binding. In this study, a recombinant protein purification scheme was devised to yield homogenous mouse Pur beta devoid of nucleic acid. Recombinant Pur beta was then subjected to light scattering and analytical ultracentrifugation analyses to assess the size, shape, and oligomeric state of the purified protein in solution. Results of laser light scattering and sedimentation velocity experiments indicated that Pur beta reversibly self-associates in the absence of nucleic acid. Both approaches independently showed that the hydrodynamic shape of the Pur beta homodimer is markedly asymmetric and non-spherical. Sedimentation velocity analyses indicated that dimeric Pur beta has a sedimentation coefficient of 3.96 Svedberg, a frictional coefficient ratio (f/f(0)) of 1.60, and a hydrodynamic radius of 4.43 nm. These values were consistent with those determined by independent dynamic light scattering studies. Sedimentation equilibrium analyses confirmed that Pur beta self-associates in a reversible monomer-dimer equilibrium characterized by a K-d = 1.13 +/- 0.27 mu M.	Univ Vermont, Coll Med, Dept Biochem, Inst Cardiovasc Res, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Med, Inst Cardiovasc Res, Burlington, VT 05405 USA; Middlebury Coll, Dept Chem & Biochem, Middlebury, VT 05753 USA	University of Vermont; University of Vermont	Kelm, RJ (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Inst Cardiovasc Res, Burlington, VT 05405 USA.	Robert.Kelm@uvm.edu			NHLBI NIH HHS [HL54281] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ban CG, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh109; Barr SM, 2001, J CELL BIOCHEM, V81, P621, DOI 10.1002/jcb.1099; Becker NA, 2000, J BIOL CHEM, V275, P15384, DOI 10.1074/jbc.M909687199; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; Cavaluzzi MJ, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh015; Chepenik LG, 1998, GENE, V210, P37, DOI 10.1016/S0378-1119(98)00033-X; Cole JL, 2004, METHOD ENZYMOL, V384, P212; Darbinian N, 1999, ONCOGENE, V18, P6398, DOI 10.1038/sj.onc.1203011; Darbinian N, 2001, J CELL BIOCHEM, V80, P589, DOI 10.1002/1097-4644(20010315)80:4<589::AID-JCB1013>3.0.CO;2-0; Darbinian N, 2001, J CELL PHYSIOL, V189, P334, DOI 10.1002/jcp.10029; Daugherty MA, 2005, ANALYTICAL ULTRACENTRIFUGATION: TECHNIQUES AND METHODS, P195; Desmouliere A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x; Ding Y, 1997, NEUROCHEM INT, V31, P45, DOI 10.1016/S0197-0186(96)00127-1; Engelse MA, 2002, CIRC RES, V90, P1128, DOI 10.1161/01.RES.0000021044.53156.F5; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; Folta-Stogniew E, 1999, J Biomol Tech, V10, P51; Gallia GL, 1999, J CELL BIOCHEM, V74, P334, DOI 10.1002/(SICI)1097-4644(19990901)74:3<334::AID-JCB3>3.0.CO;2-O; Gallia GL, 2001, J CELL BIOCHEM, V83, P355, DOI 10.1002/jcb.1247; Gallia GL, 2000, NUCLEIC ACIDS RES, V28, P3197, DOI 10.1093/nar/28.17.3197; Gupta M, 2003, J BIOL CHEM, V278, P44935, DOI 10.1074/jbc.M307696200; HARDING SE, 1995, BIOPHYS CHEM, V55, P69, DOI 10.1016/0301-4622(94)00143-8; Hebenstreit D, 2005, DRUG NEWS PERSPECT, V18, P243, DOI 10.1358/dnp.2005.18.4.908658; Itoh H, 1998, CELL GROWTH DIFFER, V9, P651; Itoh S, 2002, CIRCULATION, V105, P2288, DOI 10.1161/01.CIR.0000015607.33345.1F; Jameson DM, 1999, METHODS, V19, P222, DOI 10.1006/meth.1999.0853; Johnson EM, 2003, ANTICANCER RES, V23, P2093; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kelm RJ, 2003, J BIOL CHEM, V278, P38749, DOI 10.1074/jbc.M306163200; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kelm RJ, 1999, J BIOL CHEM, V274, P38268, DOI 10.1074/jbc.274.53.38268; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Khalili K, 2003, MOL CELL BIOL, V23, P6857, DOI 10.1128/MCB.23.19.6857-6875.2003; Knapp AM, 2006, J BIOL CHEM, V281, P7907, DOI 10.1074/jbc.M509682200; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; KUNTZ ID, 1971, J AM CHEM SOC, V93, P514, DOI 10.1021/ja00731a036; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAUER TM, 1992, TECHNICAL APPL INFOR; Liu H, 2005, BIOCHEM BIOPH RES CO, V328, P851, DOI 10.1016/j.bbrc.2005.01.038; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; Schildmeyer LA, 2000, FASEB J, V14, P2213, DOI 10.1096/fj.99-0927com; Stacey DW, 1999, ONCOGENE, V18, P4254, DOI 10.1038/sj.onc.1202795; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stafford WF, 2004, BIOPHYS CHEM, V108, P231, DOI 10.1016/j.bpc.2003.10.028; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; Subramanian SV, 2002, CARDIOVASC RES, V54, P539, DOI 10.1016/S0008-6363(02)00270-5; TAKAGI T, 1990, J CHROMATOGR, V506, P409, DOI 10.1016/S0021-9673(01)91596-1; Tamrazi A, 2002, MOL ENDOCRINOL, V16, P2706, DOI 10.1210/me.2002-0250; WANG H, 1995, J BIOL CHEM, V270, P23322, DOI 10.1074/jbc.270.40.23322; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; Wortman MJ, 2005, BBA-MOL CELL RES, V1743, P64, DOI 10.1016/j.bbamcr.2004.08.010	56	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1552	1560		10.1074/jbc.M609356200	http://dx.doi.org/10.1074/jbc.M609356200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121857	hybrid			2022-12-27	WOS:000243451300006
J	Wang, XJ; Dolan, PT; Dang, Y; Zheng, YH				Wang, Xiaojun; Dolan, Patrick T.; Dang, Ying; Zheng, Yong-Hui			Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; POLYNUCLEOTIDE (DEOXY)CYTIDINE DEAMINASES; VIRUS-LIKE PARTICLES; RNA EDITING PROTEIN; CYTIDINE DEAMINATION; VIF PROTEIN; ANTIRETROVIRAL FACTOR; RETROVIRAL INFECTION; ANTIVIRAL ACTIVITY; AID/APOBEC FAMILY	APOBEC3G and APOBEC3F are cytidine deaminase with duplicative cytidine deaminase motifs that restrict HIV-1 replication by catalyzing C-to-U transitions on nascent viral cDNA. Despite 60% protein sequence similarity, APOBEC3F and APOBEC3G have a different target consensus sequence for editing, and importantly, APOBEC3G has 10-fold higher anti-HIV activity than APOBEC3F. Thus, APOBEC3F and APOBEC3G may have distinctive characteristics that account for their functional differences. Here, we have biochemically characterized human APOBEC3F and APOBEC3G protein complexes as a function of the HIV-1 life cycle. APOBEC3G was previously shown to form RNase-sensitive, enzymatically inactive, high molecular mass complexes in immortalized cells, which are converted into enzymatically active, low molecular mass complexes by RNase digestion. We found that APOBEC3F also formed high molecular mass complexes in these cells, but these complexes were resistant to RNase treatment. Further, the N-terminal half determined RNase sensitivity and was necessary for the high molecular mass complex assembly of APOBEC3G but not APOBEC3F. Unlike APOBEC3F, APOBEC3G strongly interacted with cellular proteins via disulfide bonds. Inside virions, both APOBEC3F and APOBEC3G were found in viral cores, but APOBEC3G was associated with low molecular mass, whereas APOBEC3F was still retained in high molecular mass complexes. After cell entry, both APOBEC3F and APOBEC3G were localized in low molecular mass complexes associated with viral reverse transcriptional machinery. These results demonstrate that APOBEC3F and APOBEC3G complexes undergo dynamic conversion during HIV-1 infection and also reveal biochemical differences that likely determine their different anti-HIV-1 activity.	Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA	Michigan State University	Zheng, YH (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.	zhengyo@msu.edu	Dolan, Patrick T./AAE-6508-2021; Zheng, Yong-Hui/AAP-4492-2021	Dolan, Patrick T./0000-0002-4169-0058; Zheng, Yong-Hui/0000-0002-1098-7385; Wang, Xiaojun/0000-0003-4521-4099	NIAID NIH HHS [R01 AI063944, AI063944, R56 AI063944] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI063944, R01AI063944] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200; Bishop KN, 2006, J VIROL, V80, P8450, DOI 10.1128/JVI.00839-06; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Cullen BR, 2006, J VIROL, V80, P1067, DOI 10.1128/JVI.80.3.1067-1076.2006; Dang Y, 2006, J VIROL, V80, P10522, DOI 10.1128/JVI.01123-06; Doehle BP, 2005, VIROLOGY, V339, P281, DOI 10.1016/j.virol.2005.06.005; Douaisi M, 2004, BIOCHEM BIOPH RES CO, V321, P566, DOI 10.1016/j.bbrc.2004.07.005; Forshey BM, 2002, J VIROL, V76, P5667, DOI 10.1128/JVI.76.11.5667-5677.2002; Hache G, 2005, J BIOL CHEM, V280, P10920, DOI 10.1074/jbc.M500382200; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Huthoff H, 2005, VIROLOGY, V334, P147, DOI 10.1016/j.virol.2005.01.038; Iwatani Y, 2006, J VIROL, V80, P5992, DOI 10.1128/JVI.02680-05; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Khan MA, 2005, J VIROL, V79, P5870, DOI 10.1128/JVI.79.9.5870-5874.2005; Kotov A, 1999, J VIROL, V73, P8824, DOI 10.1128/JVI.73.10.8824-8830.1999; Kremer M, 2005, VIROLOGY, V337, P175, DOI 10.1016/j.virol.2005.04.006; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Liu BD, 2005, J VIROL, V79, P9579, DOI 10.1128/JVI.79.15.9579-9587.2005; Luo K, 2005, P NATL ACAD SCI USA, V102, P11444, DOI 10.1073/pnas.0502440102; Luo K, 2004, J VIROL, V78, P11841, DOI 10.1128/JVI.78.21.11841-11852.2004; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Mehle A, 2006, J BIOL CHEM, V281, P17259, DOI 10.1074/jbc.M602413200; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Opi S, 2006, J VIROL, V80, P4673, DOI 10.1128/JVI.80.10.4673-4682.2006; Pinter A, 1997, J VIROL, V71, P8073, DOI 10.1128/JVI.71.10.8073-8077.1997; PINTER A, 1978, VIROLOGY, V91, P345, DOI 10.1016/0042-6822(78)90382-3; Rogozin IB, 2005, CELL CYCLE, V4, P1281, DOI 10.4161/cc.4.9.1994; Schafer A, 2004, VIROLOGY, V328, P163, DOI 10.1016/j.virol.2004.08.006; Schultz SJ, 2006, J BIOL CHEM, V281, P1943, DOI 10.1074/jbc.M510504200; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Xiao ZX, 2006, VIROLOGY, V349, P290, DOI 10.1016/j.virol.2006.02.002; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204; Zennou W, 2004, J VIROL, V78, P12058, DOI 10.1128/JVI.78.21.12058-12061.2004; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	51	48	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1585	1594		10.1074/jbc.M610150200	http://dx.doi.org/10.1074/jbc.M610150200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17142455	Green Accepted, hybrid			2022-12-27	WOS:000243451300010
J	Yanagawa, M; Tsukuba, T; Nishioku, T; Okamoto, Y; Okamoto, K; Takii, R; Terada, Y; Nakayama, KI; Kadowaki, T; Yamamoto, K				Yanagawa, Michiyo; Tsukuba, Takayuki; Nishioku, Tsuyoshi; Okamoto, Yoshiko; Okamoto, Kuniaki; Takii, Ryosuke; Terada, Yoshihiro; Nakayama, Keiichi I.; Kadowaki, Tomoko; Yamamoto, Kenji			Cathepsin E deficiency induces a novel form of lysosomal storage disorder showing the accumulation of lysosomal membrane sialoglycoproteins and the elevation of lysosomal pH in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC PROTEINASES; ACID; INVOLVEMENT; BIOGENESIS; EXPRESSION; MARKER; CANCER; ASSAY; LUNG	Cathepsin E, an endolysosomal aspartic proteinase predominantly expressed in cells of the immune system, has an important role in immune responses. However, little is known about the precise roles of cathepsin E in this system. Here we report that cathepsin E deficiency (CatE(-/-)) leads to a novel form of lysosome storage disorder in macrophages, exhibiting the accumulation of the two major lysosomal membrane sialoglycoproteins LAMP-1 and LAMP-2 and the elevation of lysosomal pH. These striking features were also found in wild-type macrophages treated with pepstatin A and Ascaris inhibitor. Whereas there were no obvious differences in their expression, biosynthesis, and trafficking between wild-type and CatE(-/-) macrophages, the degradation rates of these two membrane proteins were apparently decreased as a result of cathepsin E deficiency. Because there was no difference in the vacuolar-type H+ -ATPase activity in both cell types, the elevated lysosomal pH in CatE(-/-) macrophages is most likely due to the accumulation of these lysosomal membrane glycoproteins highly modified with acidic monosaccharides, thereby leading to the disruption of non-proton factors controlling lysosomal pH. Furthermore, the selective degradation of LAMP-1 and LAMP-2, as well as LIMP-2, was also observed by treatment of the lysosomal membrane fraction isolated from wild-type macrophages with purified cathepsin E at pH 5. Our results thus suggest that cathepsin E is important for preventing the accumulation of these lysosomal membrane sialoglycoproteins that can induce a new form of lysosomal storage disorder.	Kyushu Univ, Grad Sch Dent Sci, Dept Pharmacol, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Dent Sci, Dept Fixed Prosthodont, Fukuoka 8128582, Japan; Daiichi Univ, Coll Pharmaceut Sci, Dept Biochem, Fukuoka 8158511, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dent Pharmacol, Nagasaki 8528588, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan	Kyushu University; Kyushu University; Nagasaki University; Kyushu University	Yamamoto, K (corresponding author), Kyushu Univ, Grad Sch Dent Sci, Dept Pharmacol, Fukuoka 8128582, Japan.	kyama@dent.kyushu-u.ac.jp	Tsukuba, Takayuki/I-9542-2018	Tsukuba, Takayuki/0000-0003-3322-1339				ARBUSTINI E, 1994, AM J PATHOL, V145, P310; Bach G, 1999, CLIN CHIM ACTA, V280, P173, DOI 10.1016/S0009-8981(98)00183-1; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; BOSI F, 1993, AM J RESP CELL MOL, V8, P626, DOI 10.1165/ajrcmb/8.6.626; BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; Busquets L, 2006, TUMOR BIOL, V27, P36, DOI 10.1159/000090154; CAPONY F, 1994, EXP CELL RES, V215, P154, DOI 10.1006/excr.1994.1327; Chen QR, 2002, NUCLEIC ACIDS RES, V30, P1338, DOI 10.1093/nar/30.6.1338; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Fukushima N, 2004, ONCOGENE, V23, P9042, DOI 10.1038/sj.onc.1208117; Futerman AH, 2004, NAT REV MOL CELL BIO, V5, P554, DOI 10.1038/nrm1423; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Holopainen JM, 2001, EUR J BIOCHEM, V268, P5851, DOI 10.1046/j.0014-2956.2001.02530.x; Hua CT, 1998, CLIN CHEM, V44, P2094; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Lewis BC, 2005, MOL CELL BIOL, V25, P1228, DOI 10.1128/MCB.25.4.1228-1237.2005; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; Matsuo K, 1996, HUM PATHOL, V27, P184, DOI 10.1016/S0046-8177(96)90373-1; Medd PG, 2000, SEMIN CELL DEV BIOL, V11, P203, DOI 10.1006/scdb.2000.0162; Meikle PJ, 1997, CLIN CHEM, V43, P1325; MORIYAMA Y, 1992, FEBS LETT, V302, P18, DOI 10.1016/0014-5793(92)80274-K; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; NAKANISHI H, 1994, EXP NEUROL, V126, P119, DOI 10.1006/exnr.1994.1048; Nishioku T, 2002, J BIOL CHEM, V277, P4816, DOI 10.1074/jbc.M108382200; ODA K, 1991, BIOCHEM BIOPH RES CO, V178, P369, DOI 10.1016/0006-291X(91)91823-U; OHSUMI Y, 1983, J BIOCHEM, V93, P547; PETERS C, 1994, FEBS LETT, V346, P108, DOI 10.1016/0014-5793(94)00499-4; Ramirez-Montealegre D, 2005, HUM MOL GENET, V14, P3759, DOI 10.1093/hmg/ddi406; ROBINS E, 1968, J BIOL CHEM, V243, P4246; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Sastradipura DF, 1998, J NEUROCHEM, V70, P2045; Schmid JA, 1999, J BIOL CHEM, V274, P19063, DOI 10.1074/jbc.274.27.19063; Sun-Wada GH, 2003, CELL STRUCT FUNCT, V28, P455, DOI 10.1247/csf.28.455; Tsukuba T, 2006, FEBS J, V273, P219, DOI 10.1111/j.1742-4658.2005.05062.x; Tsukuba T, 2003, J BIOCHEM, V134, P893, DOI 10.1093/jb/mvg216; Tyynela J, 2000, EMBO J, V19, P2786, DOI 10.1093/emboj/19.12.2786; Ullmann R, 2004, J PATHOL, V203, P798, DOI 10.1002/path.1584; Weisz OA, 2003, TRAFFIC, V4, P57, DOI 10.1034/j.1600-0854.2003.40201.x; YAMAMOTO K, 1978, EUR J BIOCHEM, V92, P499, DOI 10.1111/j.1432-1033.1978.tb12772.x; Yamamoto K, 1999, MCBU, P59; Yasuda Y, 1999, J BIOCHEM-TOKYO, V125, P1137, DOI 10.1093/oxfordjournals.jbchem.a022396	48	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1851	1862		10.1074/jbc.M604143200	http://dx.doi.org/10.1074/jbc.M604143200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17095504	hybrid			2022-12-27	WOS:000243451300036
J	Dikeakos, JD; Lacombe, MJ; Mercure, C; Mireuta, M; Reudelhuber, TL				Dikeakos, Jimmy D.; Lacombe, Marie-Josee; Mercure, Chantal; Mireuta, Matei; Reudelhuber, Timothy L.			A hydrophobic patch in a charged alpha-helix is sufficient to target proteins to dense core secretory granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; CARBOXYPEPTIDASE-E; SORTING RECEPTOR; ATT-20 CELLS; HYDROPHILIC BALANCE; CPE(FAT) MICE; PATHWAY; PEPTIDES; BINDING; PROSOMATOSTATIN	Many endocrine and neuroendocrine cells contain specialized secretory organelles called dense core secretory granules. These organelles are the repository of proteins and peptides that are secreted in a regulated manner when the cell receives a physiological stimulus. The targeting of proteins to these secretory granules is crucial for the generation of certain peptide hormones, including insulin and ACTH. Although previous work has demonstrated that proteins destined to a variety of cellular locations, including secretory granules, contain targeting sequences, no single consensus sequence for secretory granulesorting signals has emerged. We have shown previously that alpha-helical domains in the C-terminal tail of the prohormone convertase PC1/3 play an important role in the ability of this region of the protein to direct secretory granule targeting (Jutras, I. Seidah, N.G., and Reudelhuber, T. L. (2000) J. Biol. Chem. 275, 40337-40343). In this study, we show that a variety of alpha-helical domains are capable of directing a heterologous secretory protein to granules. By testing a series of synthetic alpha-helices, we also demonstrate that the presence of charged (either positive or negative) amino acids spatially segregated from a hydrophobic patch in the alpha-helices of secretory proteins likely plays a critical role in the ability of these structures to direct secretory granule sorting.	Inst Rech Clin Montreal, Lab Mol Biochem Hypertens, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Reudelhuber, TL (corresponding author), Inst Rech Clin Montreal, Lab Mol Biochem Hypertens, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.	reudelt@ircm.qc.ca						Arnaoutova I, 2003, BIOCHEMISTRY-US, V42, P10445, DOI 10.1021/bi034277y; Assadi M, 2004, BIOCHEMISTRY-US, V43, P7798, DOI 10.1021/bi036331g; Beuret N, 2004, J BIOL CHEM, V279, P20242, DOI 10.1074/jbc.M310613200; Boulatnikov I, 2004, J BIOL CHEM, V279, P40918, DOI 10.1074/jbc.M406213200; BRAKCH N, 1994, BIOCHEM BIOPH RES CO, V205, P221, DOI 10.1006/bbrc.1994.2653; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; Bundgaard JR, 2004, J BIOL CHEM, V279, P5488, DOI 10.1074/jbc.M310547200; Cool DR, 1998, MOL CELL ENDOCRINOL, V139, P7, DOI 10.1016/S0303-7207(98)00081-1; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Dannies PS, 2001, MOL CELL ENDOCRINOL, V177, P87, DOI 10.1016/S0303-7207(01)00437-3; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Dhanvantari S, 2002, BIOCHEMISTRY-US, V41, P52, DOI 10.1021/bi015698n; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Furuya T, 2003, BIOPHYS J, V84, P1950, DOI 10.1016/S0006-3495(03)75003-6; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Garcia AL, 2005, J BIOL CHEM, V280, P41595, DOI 10.1074/jbc.M509122200; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; HEINRIKSON RL, 1989, AM J HYPERTENS, V2, P367, DOI 10.1093/ajh/2.5.367; Jutras I, 2000, J BIOL CHEM, V275, P40337, DOI 10.1074/jbc.M004757200; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; Kitamura A, 1999, BIOPHYS J, V76, P1457, DOI 10.1016/S0006-3495(99)77306-6; Kiyota T, 1996, BIOCHEMISTRY-US, V35, P13196, DOI 10.1021/bi961289t; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Lee MCS, 2005, CELL, V122, P605, DOI 10.1016/j.cell.2005.07.025; Lee S, 2001, J BIOL CHEM, V276, P41224, DOI 10.1074/jbc.M104705200; MITRA A, 1994, J BIOL CHEM, V269, P19876; Mouchantaf R, 2001, J BIOL CHEM, V276, P26308, DOI 10.1074/jbc.M102514200; O'Donnell PJ, 2003, J MOL CELL CARDIOL, V35, P915, DOI 10.1016/S0022-2828(03)00171-8; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Shen FS, 1997, P NATL ACAD SCI USA, V94, P5314, DOI 10.1073/pnas.94.10.5314; Tanaka S, 1997, J HISTOCHEM CYTOCHEM, V45, P425, DOI 10.1177/002215549704500310; Ueda K, 2003, P NATL ACAD SCI USA, V100, P5622, DOI 10.1073/pnas.0631617100; Wasmeier C, 2002, TRAFFIC, V3, P654, DOI 10.1034/j.1600-0854.2002.30907.x	37	20	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1136	1143		10.1074/jbc.M605718200	http://dx.doi.org/10.1074/jbc.M605718200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17092937	hybrid			2022-12-27	WOS:000243295200038
J	Fabrichniy, IP; Lehtio, L; Tammenkoski, M; Zyryanov, AB; Oksanen, E; Baykov, AA; Lahti, R; Goldman, A				Fabrichniy, Igor P.; Lehtio, Lari; Tammenkoski, Marko; Zyryanov, Anton B.; Oksanen, Esko; Baykov, Alexander A.; Lahti, Reijo; Goldman, Adrian			A trimetal site and substrate distortion in a family II inorganic pyrophosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-LIGAND INTERACTIONS; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; DIFFRACTION DATA; PROTEIN; ION; IMIDODIPHOSPHATE; REQUIREMENT; HYDROLYSIS; GEOMETRY	We report the first crystal structures of a family II pyrophosphatase complexed with a substrate analogue, imidodiphosphate (PNP). These provide new insights into the catalytic reaction mechanism of this enzyme family. We were able to capture the substrate complex both by fluoride inhibition and by site-directed mutagenesis providing complementary snapshots of the Michaelis complex. Structures of both the fluoride-inhibited wild type and the H98Q variant of the PNP-Bacillus subtilis pyrophosphatase complex show a unique trinuclear metal center. Each metal ion coordinates a terminal oxygen on the electrophilic phosphate and a lone pair on the putative nucleophile, thus placing it in line with the scissile bond without any coordination by protein. The nucleophile moves further away from the electrophilic phosphorus site, to the opposite side of the trimetal plane, upon binding of substrate. In comparison with earlier product complexes, the side chain of Lys(296) has swung in and so three positively charged side chains, His(98), Lys(205) and Lys(296), now surround the bridging nitrogen in PNP. Finally, one of the active sites in the wild-type structure appears to show evidence of substrate distortion. Binding to the enzyme may thus strain the substrate and thus enhance the catalytic rate.	Univ Helsinki, Inst Biotechnol, Program Struct Biol & Biophys, Bioctr 3, FIN-00014 Helsinki, Finland; Univ Turku, Dept Biochem, Natl Grad Sch Informat & Struct Biol, FIN-20014 Turku, Finland; Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Moscow MV Lomonosov State Univ, Sch Chem, Moscow 119899, Russia	University of Helsinki; Finland National Institute for Health & Welfare; University of Turku; Lomonosov Moscow State University; Lomonosov Moscow State University	Goldman, A (corresponding author), Univ Helsinki, Inst Biotechnol, Program Struct Biol & Biophys, Bioctr 3, POB 65, FIN-00014 Helsinki, Finland.	adrian.goldman@helsinki.fi	Baykov, Alexander A/C-7981-2012; Oksanen, Esko/D-4639-2009; Baykov, Alexander/AAH-5301-2021	Oksanen, Esko/0000-0002-1841-4813; Lehtio, Lari/0000-0001-7250-832X; Baykov, Alexander/0000-0002-2495-8200; Goldman, Adrian/0000-0001-8032-9700				ADMIRAAL SJ, 1995, CHEM BIOL, V2, P729, DOI 10.1016/1074-5521(95)90101-9; Ahn S, 2001, J MOL BIOL, V313, P797, DOI 10.1006/jmbi.2001.5070; Allen KN, 2004, TRENDS BIOCHEM SCI, V29, P495, DOI 10.1016/j.tibs.2004.07.008; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baykov A A, 1999, Prog Mol Subcell Biol, V23, P127; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cannon WR, 1996, NAT STRUCT BIOL, V3, P821, DOI 10.1038/nsb1096-821; CHANLEY JD, 1963, J AM CHEM SOC, V85, P1181, DOI 10.1021/ja00891a033; CHATANI Y, 1987, MACROMOLECULES, V20, P1042, DOI 10.1021/ma00171a028; CRUICKSHANK DWJ, 1964, ACTA CRYSTALLOGR, V17, P671, DOI 10.1107/S0365110X64001633; Fabrichniy IP, 2004, BIOCHEMISTRY-US, V43, P14403, DOI 10.1021/bi0484973; Halonen P, 2005, BIOCHEMISTRY-US, V44, P4004, DOI 10.1021/bi047926u; Harding MM, 2000, ACTA CRYSTALLOGR D, V56, P857, DOI 10.1107/S0907444900005849; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; Heikinheimo P, 2001, P NATL ACAD SCI USA, V98, P3121, DOI 10.1073/pnas.061612498; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kornberg A., 1962, HORIZONS BIOCH, P251; Kuhn NJ, 2000, ARCH BIOCHEM BIOPHYS, V379, P292, DOI 10.1006/abbi.2000.1860; LARSEN M, 1969, SCIENCE, V166, P1510, DOI 10.1126/science.166.3912.1510; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merckel MC, 2001, STRUCTURE, V9, P289, DOI 10.1016/S0969-2126(01)00587-1; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parfenyev AN, 2001, J BIOL CHEM, V276, P24511, DOI 10.1074/jbc.M101829200; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rajagopalan PTR, 2002, CHEM REC, V2, P24, DOI 10.1002/tcr.10009; SALMINEN T, 1995, BIOCHEMISTRY-US, V34, P782, DOI 10.1021/bi00003a011; Shintani T, 1998, FEBS LETT, V439, P263, DOI 10.1016/S0014-5793(98)01381-7; SMIRNOVA IN, 1986, FEBS LETT, V206, P121, DOI 10.1016/0014-5793(86)81352-7; Yamagata A, 2002, P NATL ACAD SCI USA, V99, P5908, DOI 10.1073/pnas.092547099; Young TW, 1998, MICROBIOL-SGM, V144, P2563, DOI 10.1099/00221287-144-9-2563; Zyryanov AB, 2005, BIOCHEMISTRY-MOSCOW+, V70, P908, DOI 10.1007/s10541-005-0201-5; Zyryanov AB, 2004, BIOCHEMISTRY-US, V43, P14395, DOI 10.1021/bi048470j; Zyryanov AB, 2004, BIOCHEMISTRY-US, V43, P1065, DOI 10.1021/bi0357513; Zyryanov AB, 2002, BIOCHEM J, V367, P901, DOI 10.1042/BJ20020880	40	41	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1422	1431		10.1074/jbc.M513161200	http://dx.doi.org/10.1074/jbc.M513161200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17095506	hybrid			2022-12-27	WOS:000243295200067
J	Wilhelm, M; Xu, ZH; Kukekov, NV; Gire, S; Greene, LA				Wilhelm, Michael; Xu, Zhiheng; Kukekov, Nickolay V.; Gire, Stephen; Greene, Lloyd A.			Proapoptotic Nix activates the JNK pathway by interacting with POSH and mediates death in a Parkinson disease model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CEREBRAL-ISCHEMIA; BH3 DOMAIN; APOPTOSIS; MITOCHONDRIAL; BNIP3; PROTEIN; KINASE; FAMILY; TRANSLOCATION	Nix, a pro-apoptotic BH3- only protein, promotes apoptosis of non-neuronal cells, although the mechanisms involved remain incompletely understood. Using a yeast two-hybrid screen with POSH (plenty of SH3 domains, a scaffold involved in activation of the apoptotic JNK/c-Jun pathway) as the bait, we identified an interaction between POSH and Nix. Co-immunoprecipitation and in vitro binding studies confirmed a direct interaction between POSH and Nix in mammalian cells. When overexpressed in HEK293 cells, Nix promotes apoptosis along with enhanced phosphorylation/activation of JNKs and their target c-Jun. These effects appear to be dependent on POSH because Nix does not promote either JNK/c-Jun phosphorylation or apoptosis of 293 cells that do not express POSH. Nix and POSH appear to mutually stabilize one another and this effect could contribute to their promotion of death. Past work showed induction of Nix transcripts in a cellular model of Parkinson disease based on neuronal PC12 cells exposed to 6-hydroxydopamine. Here, we confirm elevation of Nix protein in this model and that Nix overexpression causes apoptotic death of PC12 cells by a mechanism dependent on c-Jun activation. Expression of s-Nix, a dominant-negative form of Nix, protects neuronal PC12 cells from 6-hydroxydopamine but not from nerve growth factor deprivation. These results indicate that Nix promotes cell death via interaction with POSH and activation of the JNK/c-Jun pathway and that Nix protein is induced and contributes to cell death in a cellular model of Parkinson disease.	Columbia Univ Hlth Sci, Dept Pediat, New York, NY 10032 USA; Columbia Univ Hlth Sci, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Wilhelm, M (corresponding author), Columbia Univ Hlth Sci, Dept Pediat, 3959 Broadway,BHN 10-24, New York, NY 10032 USA.	mw2025@columbia.edu		Xu, Zhiheng/0000-0002-4809-2851	NICHD NIH HHS [K12-HD043389-02, K12-HD00850] Funding Source: Medline; NINDS NIH HHS [5R01 NS033689, 5P01 NS38370-06] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000850] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD043389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033689, P50NS038370] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Birse-Archbold JLA, 2005, J CEREBR BLOOD F MET, V25, P1356, DOI 10.1038/sj.jcbfm.9600133; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Farooq M, 2001, EXP MOL MED, V33, P169, DOI 10.1038/emm.2001.29; Galvez AS, 2006, J BIOL CHEM, V281, P1442, DOI 10.1074/jbc.M509056200; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kuan CY, 2005, CNS NEUROL DISORD-DR, V4, P63, DOI 10.2174/1568007053005145; Kuan CY, 2003, P NATL ACAD SCI USA, V100, P15184, DOI 10.1073/pnas.2336254100; Kukekov NV, 2006, J BIOL CHEM, V281, P15517, DOI 10.1074/jbc.M601056200; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Ryu EJ, 2005, NEUROBIOL DIS, V18, P54, DOI 10.1016/j.nbd.2004.08.016; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Sowter HM, 2001, CANCER RES, V61, P6669; Thomadaki H, 2006, CRIT REV CL LAB SCI, V43, P1, DOI 10.1080/10408360500295626; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu ZH, 2005, MOL CELL BIOL, V25, P9949, DOI 10.1128/MCB.25.22.9949-9959.2005; Xu ZH, 2006, J BIOL CHEM, V281, P303, DOI 10.1074/jbc.M509060200; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Yussman MG, 2002, NAT MED, V8, P725, DOI 10.1038/nm719; Zhang QG, 2005, J NEUROCHEM, V95, P784, DOI 10.1111/j.1471-4159.2005.03435.x	31	33	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1288	1295		10.1074/jbc.M607038200	http://dx.doi.org/10.1074/jbc.M607038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17095503	hybrid			2022-12-27	WOS:000243295200054
J	Askari, N; Diskin, R; Avitzour, M; Capone, R; Livnah, O; Engelberg, D				Askari, Nadav; Diskin, Ron; Avitzour, Michal; Capone, Ricardo; Livnah, Oded; Engelberg, David			Hyperactive variants of p38 alpha induce, whereas hyperactive variants of p38 gamma suppress, activating protein 1-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE PATHWAYS; C-JUN; P38 MAPK; DUAL PHOSPHORYLATION; CELL-PROLIFERATION; REGULATED KINASE; DNA-BINDING; PC12 CELLS; AP-1	The p38 family of kinases is a subgroup of the mitogen-activated protein kinase family. It is composed of four isoforms and is involved in critical biological processes as well as in inflammatory diseases. The exact unique role of each p38 isoform in these processes is not understood well. To approach this question we have been developing intrinsically active variants of p38s. Recently we described a series of mutants of the human p38 alpha, which were spontaneously active as recombinant proteins purified from Escherichia coli cells. We show here that some of these mutants are spontaneously active in several mammalian cells in culture. The spontaneous activity of some mutants is higher than the activity of the fully activated wild type counterpart. We further produced mutants of the other p38 isoforms and found that p38 beta(D176A), p38 gamma(D179A), p38 delta(DI76A), and p38 delta(F324S) are spontaneously active in vivo. The active mutants are also spontaneously phosphorylated. To test whether the mutants actually fulfill downstream duties of p38 proteins, we tested their effect on activating protein 1 (AP-1)-mediated transcription. Active mutants of p38 alpha induced AP-1-driven reporter genes, as well as the c-jun and c-fos promoters. An active variant of p38 gamma suppressed AP-1-mediated transcription. When active variants of p38 alpha and p38-gamma were co-expressed, AP-1 activity was not induced, showing that p38 gamma is dominant over p38 alpha with respect to AP-1 activation. Thus, intrinsically active variants that are spontaneously active in vivo have been obtained for all p38 isoforms. These variants have disclosed different effects of each isoform on AP-1 activity.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Engelberg, D (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	engelber@cc.huji.ac.il	Capone, Ricardo F/D-1943-2010	Capone, Ricardo F/0000-0002-7327-9837				Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Aebersold DM, 2004, MOL CELL BIOL, V24, P10000, DOI 10.1128/MCB.24.22.10000-10015.2004; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Askari N, 2006, MOL CELL ENDOCRINOL, V252, P231, DOI 10.1016/j.mce.2006.03.015; Beardmore VA, 2005, MOL CELL BIOL, V25, P10454, DOI 10.1128/MCB.25.23.10454-10464.2005; Bell M, 2003, J BIOL CHEM, V278, P14603, DOI 10.1074/jbc.C300006200; Bell M, 2001, J BIOL CHEM, V276, P25351, DOI 10.1074/jbc.M101818200; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DECESARE D, 1995, ONCOGENE, V11, P365; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Diskin R, 2004, J BIOL CHEM, V279, P47040, DOI 10.1074/jbc.M404595200; DISKIN R, 2006, IN PRESS J MOL BIOL; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Eilers A, 1998, J NEUROSCI, V18, P1713; Engelberg D, 2004, SEMIN CANCER BIOL, V14, P271, DOI 10.1016/j.semcancer.2004.04.006; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Faccio L, 2000, AM J PHYSIOL-CELL PH, V278, pC781, DOI 10.1152/ajpcell.2000.278.4.C781; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Haq RW, 1998, CANCER METAST REV, V17, P233, DOI 10.1023/A:1006075007857; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jackson Paul F., 2002, Current Topics in Medicinal Chemistry, V2, P1011, DOI 10.2174/1568026023393372; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kuma Y, 2004, BIOCHEM J, V379, P133, DOI 10.1042/BJ20031559; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RANGEAUD J, 1996, MOL CELL BIOL, V16, P1247; Recio JA, 2002, ONCOGENE, V21, P1000, DOI 10.1038/sj.onc.1205150; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; RYSECK RP, 1991, ONCOGENE, V6, P533; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Salvador JM, 2005, NAT IMMUNOL, V6, P390, DOI 10.1038/ni1177; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Stanhill A, 2006, ONCOGENE, V25, P1485, DOI 10.1038/sj.onc.1209193; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Williams NG, 1998, J BIOL CHEM, V273, P24624, DOI 10.1074/jbc.273.38.24624; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yaakov G, 2003, MOL CELL BIOL, V23, P4826, DOI 10.1128/MCB.23.14.4826-4840.2003; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; Yung YV, 2000, J BIOL CHEM, V275, P15799, DOI 10.1074/jbc.M910060199; Zhang CC, 2000, J BIOL CHEM, V275, P479, DOI 10.1074/jbc.275.1.479; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966; Zhu XW, 2002, NEUROSIGNALS, V11, P270, DOI 10.1159/000067426	73	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					91	99		10.1074/jbc.M608012200	http://dx.doi.org/10.1074/jbc.M608012200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17088247	hybrid			2022-12-27	WOS:000243166500011
J	Itoh, Y; Masuyama, N; Nakayama, K; Nakayama, KI; Gotoh, Y				Itoh, Yasuhiro; Masuyama, Norihisa; Nakayama, Keiko; Nakayama, Keiichi I.; Gotoh, Yukiko			The cyclin-dependent kinase inhibitors p57 and p27 regulate neuronal migration in the developing mouse neocortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; CELL-CYCLE; P57(KIP2); P27(KIP1); DIFFERENTIATION; HYPERPLASIA; EXPRESSION; BINDING; GROWTH	Neuronal precursors remain in the proliferative zone of the developing mammalian neocortex until after they have undergone neuronal differentiation and cell cycle arrest. The newborn neurons then migrate away from the proliferative zone and enter the cortical plate. The molecules that coordinate migration with neuronal differentiation have been unclear. We have proposed in this study that the cdk inhibitors p57 and p27 play a role in this coordination. We have found that p57 and p27 mRNA increase upon neuronal differentiation of neocortical neuroepithelial cells. Knockdown of p57 by RNA interference resulted in a significant delay in the migration of neurons that entered the cortical plate but did not affect neuronal differentiation. Knockdown of p27 also inhibits neuronal migration in the intermediate zone as well as in the cortical plate, as reported by others. We have also found that knockdown of p27 increases p57 mRNA levels. These results suggest that both p57 and p27 play essential roles in neuronal migration and may, in concert, coordinate the timing of neuronal differentiation, migration, and possibly cell cycle arrest in neocortical development.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Tohoku Univ, Dept Dev Biol, Ctr Translat & Adv Anim Res Human Dis, Grad Sch Med,Aoba Ku, Sendai, Miyagi 9808575, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan	University of Tokyo; Tohoku University; Kyushu University	Gotoh, Y (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ygotoh@iam.u-tokyo.ac.jp		Ito, Yasuhiro/0000-0001-8590-9122				Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Ge WH, 2006, P NATL ACAD SCI USA, V103, P1319, DOI 10.1073/pnas.0510419103; Gupta A, 2002, NAT REV GENET, V3, P342, DOI 10.1038/nrg799; Hand R, 2005, NEURON, V48, P45, DOI 10.1016/j.neuron.2005.08.032; Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Kawauchi T, 2006, NAT CELL BIOL, V8, P17, DOI 10.1038/ncb1338; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Nagahama H, 2001, ANAT EMBRYOL, V203, P77, DOI 10.1007/s004290000146; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; NGUYEN L, 2000, GENE DEV, V20, P1511; Sakakibara S, 1997, J NEUROSCI, V17, P8300; Tabata H, 2001, NEUROSCIENCE, V103, P865, DOI 10.1016/S0306-4522(01)00016-1; Takahashi T, 1999, J NEUROSCI, V19, P10357; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yokoo T, 2003, J BIOL CHEM, V278, P52919, DOI 10.1074/jbc.M309334200; Yoshimatsu T, 2006, DEVELOPMENT, V133, P2553, DOI 10.1242/dev.02419; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	24	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					390	396		10.1074/jbc.M609944200	http://dx.doi.org/10.1074/jbc.M609944200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17092932	hybrid			2022-12-27	WOS:000243166500044
J	Kuballa, P; Matentzoglu, K; Scheffner, M				Kuballa, Petric; Matentzoglu, Konstantin; Scheffner, Martin			The role of the ubiquitin ligase E6-AP in human papillomavirus E6-mediated degradation of PDZ domain-containing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E6 PROTEINS; MEDIATED DEGRADATION; P53; BINDING; EXPRESSION; CANCER; ONCOPROTEIN; INVOLVEMENT; SUPPRESSION; RECOGNITION	The E6 oncoprotein of human papillomaviruses associated with cervical cancer targets the tumor suppressor p53 and several other cellular proteins including the human homologs of Dlg and Scribble for degradation via the ubiquitin-proteasome system. Similar to p53 degradation, E6-induced degradation of Scribble is mediated by the ubiquitin ligase E6-AP. In contrast, degradation of Dlg in vitro and within cells has been reported to be independent of E6-AP, suggesting that the E6 oncoprotein has the ability to interact with ubiquitin ligases other than E6-AP. Furthermore, the ability of the E6 oncoprotein to interact with these yet unidentified ubiquitin ligases may be shared by the E6 protein of so-called low risk human papillomaviruses that are not associated with cervical cancer. In this study, we used the RNA interference technology and mouse embryo fibroblasts derived from E6-AP-deficient mice to obtain information about the identity of the ubiquitin ligase(s) involved in E6-mediated degradation of Dlg. We report that, within cells, E6-mediated degradation of Dlg depends on the presence of functional E6-AP and provide evidence that the E6 protein of low risk human papillomaviruses functionally interacts with E6-AP. Based on these data, we propose that, in general, the proteolytic properties of human papillomavirus E6 proteins are mediated by interaction with E6-AP.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Scheffner, M (corresponding author), Univ Konstanz, Dept Biol, Box M642, D-78457 Constance, Germany.	martin.scheffner@uni-konstanz.de	Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; Blot V, 2004, J CELL SCI, V117, P3983, DOI 10.1242/jcs.01266; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Grm HS, 2004, J GEN VIROL, V85, P2815, DOI 10.1099/vir.0.80035-0; Hengstermann A, 1998, ONCOGENE, V17, P2933, DOI 10.1038/sj.onc.1202282; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Kim Y, 2003, CANCER GENE THER, V10, P707, DOI 10.1038/sj.cgt.7700623; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Matsumoto Y, 2006, J MED VIROL, V78, P501, DOI 10.1002/jmv.20568; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 2002, ONCOGENE, V21, P8140, DOI 10.1038/sj.onc.1206026; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scheffner M, 2003, SEMIN CANCER BIOL, V13, P59, DOI 10.1016/S1044-579X(02)00100-1; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Simonson SJS, 2005, CANCER RES, V65, P8266, DOI 10.1158/0008-5472.CAN-05-1651; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thomas M, 1999, J GEN VIROL, V80, P1513, DOI 10.1099/0022-1317-80-6-1513; Varshavsky A, 2005, METHOD ENZYMOL, V399, P777, DOI 10.1016/S0076-6879(05)99051-4; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Wegmann F, 2004, EXP CELL RES, V300, P121, DOI 10.1016/j.yexcr.2004.07.010; Yamamoto Y, 1997, GENOMICS, V41, P263, DOI 10.1006/geno.1997.4617; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	36	52	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					65	71		10.1074/jbc.M605117200	http://dx.doi.org/10.1074/jbc.M605117200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17085449	Green Published, hybrid			2022-12-27	WOS:000243166500008
J	Sanbe, A; Yamauchi, J; Miyamoto, Y; Fujiwara, Y; Murabe, M; Tanoue, A				Sanbe, Atsushi; Yamauchi, Junji; Miyamoto, Yuki; Fujiwara, Yoko; Murabe, Mayu; Tanoue, Akito			Interruption of CryAB-Amyloid oligomer formation by HSP22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; DESMIN-RELATED CARDIOMYOPATHY; PROTEIN-PROTEIN INTERACTIONS; UBIQUITIN-PROTEASOME SYSTEM; INCLUSION-BODY FORMATION; COMMON MECHANISM; DISEASE; GENE; LENS; NEURODEGENERATION	An R120G missense mutation in a-B-crystallin (CryAB), a small heat-shock protein (HSP), causes a desmin-related cardiomyopathy (DRM) that is characterized by the formation of aggregates containing CryAB and desmin. The mutant CryAB protein leads to the formation of inclusion bodies, which contain amyloid oligomer intermediates (amyloid oligomer) in the cardiornyocytes. To further address the underlying mechanism(s) of amyloid oligomer formation in DRM linked to the CryAB R120G, a recombinant CryAB R120G protein was generated. The purified CryAB R120G protein can form a toxic amyloid oligomer, whereas little immunoreactivity was observed in the wild-type CryAB protein. A native PAGE showed that the oligomerized form was present in the CryAB R120G protein, whereas only a high molecular mass was detected in the wildtype CryAB. The oligomerized CryAB R120G of around 240480 kDa showed strong positive immunoreactivity against an anti-oligomer antibody. The CryAB R120G amyloid oligomer was unstable and easily lost its conformation by beta-mercaptoethanol and SDS. Recombinant HSP25 or HSP22 proteins can directly interrupt oligomer formation by the CryAB R120G protein, whereas the amyloid oligomer is still present in the mixture of the wild-type CryAB and CryAB R120G proteins. This interruption by HSP25 and HSP22 was confirmed in a cardiomyocyte-based study using an adenoviral transfection system. Blockade of amyloid oligomer formation by HSP25 and HSP22 recovered the ubiquitin proteosomal activity and cellular viability. Blockade of oligomer formation by small HSP may be a new therapeutic strategy for treating DRM as well as other types of amyloid-based degenerative diseases.	Natl Res Inst Child Hlth & Dev, Dept Pharmacol, Setagaya Ku, Tokyo 1578535, Japan	National Center for Child Health & Development - Japan	Sanbe, A (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Pharmacol, Setagaya Ku, 2-10-1,Okura, Tokyo 1578535, Japan.	asanbe@nch.go.jp						Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bence NF, 2005, METHOD ENZYMOL, V399, P481, DOI 10.1016/S0076-6879(05)99033-2; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chen QH, 2005, CIRC RES, V97, P1018, DOI 10.1161/01.RES.0000189262.92896.0b; DUBIN RA, 1990, GENOMICS, V7, P594, DOI 10.1016/0888-7543(90)90204-8; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Fu L, 2003, INVEST OPHTH VIS SCI, V44, P1155, DOI 10.1167/iovs.02-0950; Fu L, 2002, J BIOL CHEM, V277, P4255, DOI 10.1074/jbc.M110027200; Glabe CG, 2006, NEUROBIOL AGING, V27, P570, DOI 10.1016/j.neurobiolaging.2005.04.017; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Horwitz J, 1998, INT J BIOL MACROMOL, V22, P263, DOI 10.1016/S0141-8130(98)00024-5; Ito H, 1996, J CELL PHYSIOL, V166, P332, DOI 10.1002/(SICI)1097-4652(199602)166:2<332::AID-JCP11>3.0.CO;2-D; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lee JS, 1998, BIOCHEM BIOPH RES CO, V244, P379, DOI 10.1006/bbrc.1998.8272; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Miller RJ, 2003, TRENDS PHARMACOL SCI, V24, P18, DOI 10.1016/S0165-6147(02)00011-1; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; Richard Irene H, 2004, Cogn Behav Neurol, V17, P201; Sanbe A, 2005, P NATL ACAD SCI USA, V102, P13592, DOI 10.1073/pnas.0503324102; Sanbe A, 2004, P NATL ACAD SCI USA, V101, P10132, DOI 10.1073/pnas.0401900101; Sanbe A, 2003, CIRC RES, V92, P609, DOI 10.1161/01.RES.0000065442.64694.9F; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Taylor RP, 2005, J MOL CELL CARDIOL, V38, P433, DOI 10.1016/j.yjmcc.2004.12.014; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Wang XJ, 2001, CIRC RES, V89, P84, DOI 10.1161/hh1301.092688; Zobel ATC, 2003, HUM MOL GENET, V12, P1609, DOI 10.1093/hmg/ddg173	33	58	62	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					555	563		10.1074/jbc.M605481200	http://dx.doi.org/10.1074/jbc.M605481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17092938	hybrid			2022-12-27	WOS:000243166500061
J	Venkitasubramanian, P; Daniels, L; Rosazza, JPN				Venkitasubramanian, Padmesh; Daniels, Lacy; Rosazza, John P. N.			Reduction of carboxylic acids by Nocardia aldehyde oxidoreductase requires a phosphopantetheinylated enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; AMP PHOSPHOTRANSFERASE; MICROBIAL REDUCTION; ATP REGENERATION; IN-VITRO; TRANSFERASE; POLYPHOSPHATE; STREPTOMYCES; ALIGNMENT	Aldehyde oxidoreductase (carboxylic acid reductase (Car)) catalyzes the magnesium-, ATP-, and NADPH-dependent reduction of carboxylic acids to their corresponding aldehydes. Heterologous expression of the car gene in Escherichia coli afforded purified recombinant enzyme with a specific activity nearly 50-fold lower than that of purified native Nocardia sp. enzyme. The 5-fold increase in specific activity obtained by incubating purified recombinant Car with CoA and Nocardia cell-free extracts indicated that post-translational phosphopantetheinylation of Car is required for maximum enzyme activity. Nocardia phosphopantetheine transferase (PPTase) expressed in E coli was isolated and characterized. When incubated with [H-3]acetyl-CoA and Nocardia PPTase, the labeled acetylphosphopantetheine moiety was incorporated into recombinant Car. Coexpression of Nocardia Car and PPTase in E. coli gave a reductase with nearly 20-fold higher specific activity. Site-directed mutagenesis in which Ser(689) was replaced with Ala resulted in an inactive Car mutant. The results show that Car expressed in Escherichia coli is an apoenzyme that is converted to a holoenzyme by post-translational modification via phosphopantetheinylation. Doubly recombinant resting E. coli cells efficiently reduce vanillic acid to vanillin.	Univ Iowa, Ctr Biocatalysis & Bioproc, Iowa City, IA 52242 USA; Univ Iowa, Div Med & Nat Prod Chem, Coll Pharm, Iowa City, IA 52242 USA; Texas A&M Univ, Hlth Sci Ctr, Irma Lerma Rangel Coll Pharm, Kingsville, TX 78363 USA	University of Iowa; University of Iowa; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University Kingsville	Rosazza, JPN (corresponding author), Univ Iowa, Ctr Biocatalysis & Bioproc, Oakdale Res Pk,2501 Crosspk Rd,Suite C100, Iowa City, IA 52242 USA.	john-rosazza@uiowa.edu						Admiraal SJ, 2001, BIOCHEMISTRY-US, V40, P6116, DOI 10.1021/bi010080z; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARFMANN HA, 1993, Z NATURFORSCH C, V48, P52; BACHMAN DM, 1960, ARCH BIOCHEM BIOPHYS, V91, P326, DOI 10.1016/0003-9861(60)90508-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YJ, 1994, APPL ENVIRON MICROB, V60, P1292, DOI 10.1128/AEM.60.4.1292-1296.1994; COLE HA, 1967, BIOCHIM BIOPHYS ACTA, V143, P445, DOI 10.1016/0005-2728(67)90050-3; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; He AM, 2004, APPL ENVIRON MICROB, V70, P1874, DOI 10.1128/AEM.70.3.1874-1881.2004; Ishikawa J, 2004, P NATL ACAD SCI USA, V101, P14925, DOI 10.1073/pnas.0406410101; JEZO I, 1986, CHEM PAP, V40, P279; Kameda A, 2001, J BIOSCI BIOENG, V91, P557, DOI 10.1263/jbb.91.557; KATO N, 1988, AGR BIOL CHEM TOKYO, V52, P1885; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Li T, 1997, J BACTERIOL, V179, P3482, DOI 10.1128/jb.179.11.3482-3487.1997; Li T, 1998, J BIOL CHEM, V273, P34230, DOI 10.1074/jbc.273.51.34230; NAKANO MM, 1992, MOL GEN GENET, V232, P313, DOI 10.1007/BF00280011; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; RAMAN TS, 1962, J BACTERIOL, V84, P1339, DOI 10.1128/JB.84.6.1339-1340.1962; Resnick SM, 2000, APPL ENVIRON MICROB, V66, P2045, DOI 10.1128/AEM.66.5.2045-2051.2000; SAMBROOK J, 2000, MOL CLONING LAB MANU; Sanchez C, 2001, CHEM BIOL, V8, P725, DOI 10.1016/S1074-5521(01)00047-3; Seidle HF, 2006, ARCH BIOCHEM BIOPHYS, V446, P167, DOI 10.1016/j.abb.2005.12.007; Tang LJ, 1997, J BACTERIOL, V179, P3697, DOI 10.1128/jb.179.11.3697-3705.1997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van der Donk WA, 2003, CURR OPIN BIOTECH, V14, P421, DOI 10.1016/S0958-1669(03)00094-6; Venkitasubramanian P, 2006, BIOCATALYSIS PHARM B, P425; WHITE H, 1989, EUR J BIOCHEM, V184, P89, DOI 10.1111/j.1432-1033.1989.tb14993.x; Wichmann R, 2005, ADV BIOCHEM ENG BIOT, V92, P225, DOI 10.1007/b98911; Yun H, 2005, BIOTECHNOL PROGR, V21, P366, DOI 10.1021/bp049694w	30	99	152	2	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					478	485		10.1074/jbc.M607980200	http://dx.doi.org/10.1074/jbc.M607980200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17102130	hybrid			2022-12-27	WOS:000243166500053
J	Wright, DC; Han, DH; Garcia-Roves, PM; Geiger, PC; Jones, TE; Holloszy, JO				Wright, David C.; Han, Dong-Ho; Garcia-Roves, Pablo M.; Geiger, Paige C.; Jones, Terry E.; Holloszy, John O.			Exercise-induced mitochondrial biogenesis begins before the increase in muscle PGC-1 alpha expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATOR PGC-1; HUMAN SKELETAL-MUSCLE; GLUCOSE-TRANSPORT CAPACITY; PPAR-GAMMA COACTIVATOR-1; BIOCHEMICAL ADAPTATIONS; EPITROCHLEARIS MUSCLE; 1-ALPHA PGC-1-ALPHA; RECEPTOR-ALPHA; ERR-ALPHA; P38 MAPK	Exercise results in rapid increases in expression of the transcription coactivator peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) and in mitochondrial biogenesis in skeletal muscle. PGC-1a regulates and coordinates mitochondrial biogenesis, and overexpression of PGC-1 alpha in muscle cells results in increases in mitochondrial content. In this context, it has been proposed that the increase in PGC-1 alpha protein expression mediates the exercise-induced increase in mitochondrial biogenesis. However, we found that mitochondrial proteins with a short half-life increase as rapidly as, or more rapidly than, PGC-1 alpha protein. This finding led us to hypothesize that activation, rather than increased expression, of PGC-1 alpha mediates the initial phase of the exercise-induced increase in mitochondria. In this study, we found that most of the PGC-1 alpha in resting skeletal muscle is in the cytosol. Exercise resulted in activation of p38 MAPK and movement of PGC-1 alpha into the nucleus. In support of our hypothesis, binding of the transcription factor nuclear respiratory factor 1 (NRF-1) to the cytochrome c promoter and NRF-2 to the cytochrome oxidase subunit 4 promoter increased in response to exercise prior to an increase in PGC-1 alpha protein. Furthermore, exercise-induced increases in the mRNAs of cytochrome c, delta-aminolevulinate synthase, and citrate synthase also occurred before an increase in PGC-1 protein. Thus, it appears that activation of PGC-1 alpha may mediate the initial phase of the exercise-induced adaptive increase in muscle mitochondria, whereas the subsequent increase in PGC-1 alpha protein sustains and enhances the increase in mitochondrial biogenesis.	Washington Univ, Sch Med, Sect Appl Physiol, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Sect Appl Physiol, Dept Med, Campus Box 8113,4566 Scott Ave, St Louis, MO 63110 USA.	jhollosz@im.wustl.edu	Roves, Pablo Garcia/A-7113-2015; Garcia-Roves, Pablo M./X-4585-2018	Wright, David/0000-0003-3867-8901; Garcia-Roves, Pablo M./0000-0002-8371-2067	NIA NIH HHS [AG00078, AG00425] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-06, DK070425, P30 DK056341-07, P30 DK056341] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK070425, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG000425, R56AG000425, R01AG000425] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akimoto T, 2005, J BIOL CHEM, V280, P19587, DOI 10.1074/jbc.M408862200; Baar K, 2003, FASEB J, V17, P1666, DOI 10.1096/fj.03-0049com; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; BALDWIN KM, 1972, AM J PHYSIOL, V222, P373, DOI 10.1152/ajplegacy.1972.222.2.373; BOOTH FW, 1997, HDB PHYSL 12, P1075; Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Garcia-Roves P, 2003, AM J PHYSIOL-ENDOC M, V285, pE729, DOI 10.1152/ajpendo.00216.2003; Garcia-Roves PM, 2006, AM J PHYSIOL-ENDOC M, V290, pE1172, DOI 10.1152/ajpendo.00633.2005; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; HOLLOSZY JO, 1970, BIOCHEM BIOPH RES CO, V40, P1368, DOI 10.1016/0006-291X(70)90017-3; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOLE PA, 1971, J CLIN INVEST, V50, P2323, DOI 10.1172/JCI106730; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; OSCAI LB, 1971, J BIOL CHEM, V246, P6968; Otani K, 2004, J BIOL CHEM, V279, P20915, DOI 10.1074/jbc.M400213200; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; PLOUG T, 1990, AM J PHYSIOL, V259, P778; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; REN JM, 1994, J BIOL CHEM, V269, P14396; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Terada S, 2006, AM J PHYSIOL-ENDOC M, V290, pE607, DOI 10.1152/ajpendo.00430.2005; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	41	346	367	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					194	199		10.1074/jbc.M606116200	http://dx.doi.org/10.1074/jbc.M606116200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17099248	hybrid, Green Published			2022-12-27	WOS:000243166500023
J	Criddle, DN; Gillies, S; Baumgartner-Wilson, HK; Jaffar, M; Chinje, EC; Passmore, S; Chvanov, M; Barrow, S; Gerasimenko, OV; Tepikin, AV; Sutton, R; Petersen, OH				Criddle, David N.; Gillies, Stuart; Baumgartner-Wilson, Heidi K.; Jaffar, Mohammed; Chinje, Edwin C.; Passmore, Sarah; Chvanov, Michael; Barrow, Stephanie; Gerasimenko, Oleg V.; Tepikin, Alexei V.; Sutton, Robert; Petersen, Ole H.			Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; FREE RADICAL PRODUCTION; DT-DIAPHORASE; OXIDATIVE STRESS; NADH DEHYDROGENASE; DUCT OBSTRUCTION; CANCER CELLS; KAPPA-B; NAD(P)H; ACID	Oxidative stress may be an important determinant of the severity of acute pancreatitis. One- electron reduction of oxidants generates reactive oxygen species ( ROS) via redox cycling, whereas two-electron detoxification, e. g. by NAD( P) H: quinone oxidoreductase, does not. The actions of menadione on ROS production and cell fate were compared with those of a non- cycling analogue ( 2,4- dimethoxy- 2- methylnaphthalene ( DMN)) using real-time confocal microscopy of isolated perfused murine pancreatic acinar cells. Menadione generatedROS with a concomitant decrease of NAD( P) H, consistent with redox cycling. The elevation of ROS was prevented by the antioxidant N-acetyl-L-cysteine but not by the NADPH oxidase inhibitor diphenyliodonium. DMN produced no change in reactive oxygen species per se but significantly potentiated menadione- induced effects, probably via enhancement of one- electron reduction, since DMN was found to inhibit NAD( P) H: quinone oxidoreductase detoxification. Menadione caused apoptosis of pancreatic acinar cells that was significantly potentiated by DMN, whereasDMNalone had no effect. Furthermore, bile acid ( taurolithocholic acid 3-sulfate)-induced caspase activation was also greatly increased by DMN, whereas DMN had no effect per se. These results suggest that acute generation of ROS by menadione occurs via redox cycling, the net effect of which is induction of apoptotic pancreatic acinar cell death. Two-electron detoxifying enzymes such as NAD( P) H: quinone oxidoreductase, which are elevated in pancreatitis, may provide protection against excessive ROS and exert an important role in determining acinar cell fate.	Univ Liverpool, MRC Secretory Res Grp, Dept Physiol, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Div Surg & Oncol, Liverpool L69 3BX, Merseyside, England; Morvus Technol Ltd, Salisbury SP4 0JQ, Wilts, England; Univ Manchester, Dept Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England	University of Liverpool; University of Liverpool; University of Manchester	Criddle, DN (corresponding author), Univ Liverpool, MRC Secretory Res Grp, Dept Physiol, Liverpool L69 3BX, Merseyside, England.	criddle@liverpool.ac.uk	Sutton, Robert/I-3587-2016; Petersen, Ole H/E-8708-2010; Gerasimenko, Oleg/A-6622-2010	Sutton, Robert/0000-0001-6600-562X; Gerasimenko, Oleg/0000-0003-2573-8258; Petersen, Ole/0000-0002-6998-0380; Chvanov, Michael/0000-0003-1747-650X; Tepikin, Alexei/0000-0002-8172-7513	MRC [G0300076] Funding Source: UKRI; Medical Research Council [G0300076] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Altomare E, 1996, GUT, V38, P742, DOI 10.1136/gut.38.5.742; Bai JX, 2006, J BIOL CHEM, V281, P5128, DOI 10.1074/jbc.M510484200; Bhatia M, 1998, BIOCHEM BIOPH RES CO, V246, P476, DOI 10.1006/bbrc.1998.8519; Bhatia M, 2004, J CELL MOL MED, V8, P402, DOI 10.1111/j.1582-4934.2004.tb00330.x; Chen YR, 2005, J BIOL CHEM, V280, P37339, DOI 10.1074/jbc.M503936200; Chernyak BV, 1997, BIOSCIENCE REP, V17, P293, DOI 10.1023/A:1027384628678; Chiou TJ, 1999, TOXICOLOGY, V139, P103, DOI 10.1016/S0300-483X(99)00109-2; Chvanov M, 2005, PHILOS T R SOC B, V360, P2273, DOI 10.1098/rstb.2005.1757; Colell A, 2004, FEBS LETT, V560, P63, DOI 10.1016/S0014-5793(04)00071-7; Criddle DN, 2004, P NATL ACAD SCI USA, V101, P10738, DOI 10.1073/pnas.0403431101; Criddle DN, 2006, GASTROENTEROLOGY, V130, P781, DOI 10.1053/j.gastro.2005.12.031; Danson S, 2004, CANCER TREAT REV, V30, P437, DOI 10.1016/j.ctrv.2004.01.002; Dinkova-Kostova LT, 2000, FREE RADICAL BIO MED, V29, P231, DOI 10.1016/S0891-5849(00)00300-2; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Gerasimenko JV, 2002, J CELL SCI, V115, P485; Graf D, 2002, GASTROENTEROLOGY, V122, P1411, DOI 10.1053/gast.2002.32976; Gukovskaya AS, 2004, PANCREATOLOGY, V4, P567, DOI 10.1159/000082182; Gukovskaya AS, 2002, GASTROENTEROLOGY, V122, P974, DOI 10.1053/gast.2002.32409; HAMMONS GJ, 1995, CANCER LETT, V96, P9, DOI 10.1016/0304-3835(95)03911-F; Ito T, 2003, TETRAHEDRON-ASYMMETR, V14, P3525, DOI 10.1016/S0957-4166(03)00580-9; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; Lewis A, 2004, CLIN CANCER RES, V10, P4550, DOI 10.1158/1078-0432.CCR-03-0667; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Lyn-Cook BD, 2006, CELL BIOL TOXICOL, V22, P73, DOI 10.1007/s10565-006-0156-3; Mareninova OA, 2006, J BIOL CHEM, V281, P3370, DOI 10.1074/jbc.M511276200; Mochizuki T, 2006, ONCOGENE, V25, P3699, DOI 10.1038/sj.onc.1209406; NIEDERAU C, 1990, GASTROENTEROLOGY, V99, P1120, DOI 10.1016/0016-5085(90)90633-C; NORDBACK IH, 1991, ANN SURG, V213, P341, DOI 10.1097/00000658-199104000-00009; Oh SH, 2006, TOXICOLOGY, V220, P1, DOI 10.1016/j.tox.2005.08.025; Petersen OH, 2006, TRENDS PHARMACOL SCI, V27, P113, DOI 10.1016/j.tips.2005.12.006; Phillips RM, 1999, BIOCHEM PHARMACOL, V58, P303, DOI 10.1016/S0006-2952(99)00092-1; Qanungo S, 2004, J BIOL CHEM, V279, P50455, DOI 10.1074/jbc.M406749200; Reinehr R, 2005, GASTROENTEROLOGY, V129, P2009, DOI 10.1053/j.gastro.2005.09.023; ROBERTSON N, 1992, BIOCHEM PHARMACOL, V44, P409, DOI 10.1016/0006-2952(92)90429-M; SANFEY H, 1986, ACTA PHYSIOL SCAND, V126, P109; SANFEY H, 1984, ANN SURG, V200, P405, DOI 10.1097/00000658-198410000-00003; Sevillano S, 2003, BBA-MOL BASIS DIS, V1639, P177, DOI 10.1016/j.bbadis.2003.09.003; SIEGEL D, 1990, CANCER RES, V50, P7293; Sutton R, 2003, PANCREATOLOGY, V3, P497, DOI 10.1159/000075581; Thomsen R, 2006, J MED CHEM, V49, P3315, DOI 10.1021/jm051197e; THOR H, 1982, J BIOL CHEM, V257, P2419; Tsai K, 1998, GUT, V42, P850, DOI 10.1136/gut.42.6.850; TSUJI N, 1994, GUT, V35, P1659, DOI 10.1136/gut.35.11.1659; Urunuela A, 2002, BBA-MOL BASIS DIS, V1588, P159, DOI 10.1016/S0925-4439(02)00160-6; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Voronina S, 2002, J PHYSIOL-LONDON, V539, P41, DOI 10.1113/jphysiol.2001.013134; Yu JH, 2005, INT J BIOCHEM CELL B, V37, P1458, DOI 10.1016/j.biocel.2005.02.004	48	249	252	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40485	40492		10.1074/jbc.M607704200	http://dx.doi.org/10.1074/jbc.M607704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17088248	hybrid			2022-12-27	WOS:000243033900078
J	Rashid, UJ; Paterok, D; Koglin, A; Gohlke, H; Piehler, J; Chen, JCH				Rashid, Umar Jan; Paterok, Dirk; Koglin, Alexander; Gohlke, Holger; Piehler, Jacob; Chen, Julian C-H.			Structure of Aquifex aeolicus Argonaute highlights conformational flexibility of the PAZ domain as a potential regulator of RNA-induced silencing complex function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-CORRELATION ANALYSIS; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; CITRATE SYNTHASE; SIRNA; MOTIONS; RECOGNITION; PROTEINS; FLUCTUATION; INSIGHTS	Gene silencing mediated by RNA interference requires the sequence-specific recognition of target mRNA by the endonuclease Argonaute, the primary enzymatic component of the RNA-induced silencing complex. We report the crystal structure of Aquifex aeolicus Argonaute, refined at 3.2 angstrom resolution. Relative to recent Argonaute structures, a 24 degrees reorientation of the PAZ domain in our structure opens a basic cleft between the N-terminal and PAZ domains, exposing the guide strand binding pocket of PAZ. This rearrangement leads to a branched, Y-shaped system of grooves that extends through the molecule and merges in a central channel containing the catalytic residues. A 5.5-ns molecular dynamics simulation of Argonaute shows a strong tendency of the PAZ and N-terminal domains to be mobile. Binding of single-stranded DNA to Argonaute monitored by total internal reflection fluorescence spectroscopy shows biphasic kinetics, also indicative of domain rearrangement upon DNA binding. Conformational rearrangement of the PAZ domain may therefore be critical for the catalytic cycle of Argonaute and the RNA-induced silencing complex.	JW Goethe Univ Frankfurt, Inst Biophys Chem, D-60438 Frankfurt, Germany; JW Goethe Univ Frankfurt, Inst Biochem, D-60438 Frankfurt, Germany; JW Goethe Univ Frankfurt, Inst Cell Biol & Neurosci, D-60438 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt	Chen, JCH (corresponding author), JW Goethe Univ Frankfurt, Inst Biophys Chem, Max Von Laue Str 9, D-60438 Frankfurt, Germany.	chen@chemie.uni-frankfurt.de						AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Bahar I, 2005, CURR OPIN STRUC BIOL, V15, P586, DOI 10.1016/j.sbi.2005.08.007; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; DeLaBarre B, 2006, ACTA CRYSTALLOGR D, V62, P923, DOI 10.1107/S0907444906012650; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Filipowicz W, 2005, CELL, V122, P17, DOI 10.1016/j.cell.2005.06.023; Gavutis M, 2005, BIOPHYS J, V88, P4289, DOI 10.1529/biophysj.104.055855; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; HAYWARD S, 1995, ANNU REV PHYS CHEM, V46, P223, DOI 10.1146/annurev.pc.46.100195.001255; HUNENBERGER PH, 1995, J MOL BIOL, V252, P492, DOI 10.1006/jmbi.1995.0514; ICHIYE T, 1991, PROTEINS, V11, P205, DOI 10.1002/prot.340110305; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Karplus M, 1996, J MOL BIOL, V263, P120, DOI 10.1006/jmbi.1996.0562; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Lai LH, 2000, STRUCTURE, V8, P897, DOI 10.1016/S0969-2126(00)00179-9; Lata S, 2005, ANAL CHEM, V77, P1096, DOI 10.1021/ac048813j; Ling H, 1998, BIOCHEMISTRY-US, V37, P1777, DOI 10.1021/bi971806n; Lingel A, 2004, NAT STRUCT MOL BIOL, V11, P576, DOI 10.1038/nsmb777; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; MacRae IJ, 2006, SCIENCE, V311, P195, DOI 10.1126/science.1121638; Marques O, 1995, PROTEINS, V23, P557, DOI 10.1002/prot.340230410; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Parker JS, 2005, NATURE, V434, P663, DOI 10.1038/nature03462; Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020; Rivas FV, 2005, NAT STRUCT MOL BIOL, V12, P340, DOI 10.1038/nsmb918; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Simmerling C, 2002, J AM CHEM SOC, V124, P11258, DOI 10.1021/ja0273851; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Tahbaz N, 2004, EMBO REP, V5, P189, DOI 10.1038/sj.embor.7400070; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Yuan YR, 2005, MOL CELL, V19, P405, DOI 10.1016/j.molcel.2005.07.011	45	37	42	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13824	13832		10.1074/jbc.M608619200	http://dx.doi.org/10.1074/jbc.M608619200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17130125	hybrid			2022-12-27	WOS:000246060300072
J	Chan, JYH; Cheng, HL; Chou, JLJ; Li, FCH; Dai, KY; Chan, SHH; Chang, AYW				Chan, Julie Y. H.; Cheng, Hsiao-Lei; Chou, Jimmy L. J.; Li, Faith C. H.; Dai, Kuang-Yu; Chan, Samuel H. H.; Chang, Alice Y. W.			Heat shock protein 60 or 70 activates nitric-oxide synthase (NOS) I- and inhibits NOSII-associated signaling and depresses the mitochondrial apoptotic cascade during brain stem death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROSTRAL VENTROLATERAL MEDULLA; SYSTEMIC ARTERIAL-PRESSURE; HEAT-SHOCK PROTEINS; ACUTE MEVINPHOS INTOXICATION; KAPPA-B ACTIVATION; CARDIOVASCULAR-RESPONSES; MESSENGER-RNA; GLUTAMATERGIC TRANSMISSION; NEURONAL APOPTOSIS; SPECTRAL-ANALYSIS	The cellular and molecular basis of brain stem death remains an enigma. As the origin of a "life-and-death" signal that reflects the progression toward brain stem death, the rostral ventrolateral medulla (RVLM) is a suitable neural substrate for mechanistic delineation of this phenomenon. Here, we evaluated the hypothesis that heat shock proteins (HSPs) play a neuroprotective role in the RVLM during brain stem death and delineated the underlying mechanisms, using a clinically relevant animal model that employed the organophosphate pesticide mev-inphos (Mev) as the experimental insult. In Sprague-Dawley rats, proteomic, Western blot, and real-time PCR analyses demonstrated that Mev induced de novo synthesis of HSP60 or HSP70 in the RVLM without affecting HSP90 level. Loss-of-function manipulations of HSP60 or HSP70 in the RVLM using antiserum or antisense oligonucleotide potentiated Mev-elicited cardiovascular depression alongside reduced nitric-oxide synthase (NOS) I/protein kinase G signaling, enhanced NOS II/peroxynitrite cascade, intensified nucleosomal DNA fragmentation, elevated cytoplasmic histone-associated DNA fragments or activated caspase-3, and augmented the cytochrome c/caspase-3 cascade of apoptotic signaling in the RVLM. Co-immunoprecipitation experiments further revealed a progressive increase in the complex formed between HSP60 and mitochondrial or cytosolic Bax or mitochondrial Bcl-2 during Mev intoxication, alongside a dissociation of the cytosolic HSP60-Bcl-2 complex. We conclude that HSP60 and HSP70 confer neuroprotection against Mev intoxication by ameliorating cardiovascular depression via an anti-apoptotic action in the RVLM. The possible underlying intracellular processes include enhancing NOS I/protein kinase G signaling and inhibiting the NOS II/peroxynitrite cascade. In addition, HSP60 exerts its effects against apoptosis by blunting Mev-induced activation of the Bax/cytochrome c/caspase-3 cascade.	Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung 80424, Taiwan; Kaohsiung Vet Gen hosp, Dept Med Educ & Res, Kaohsiung 81346, Taiwan; Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct Res, Tainan 70101, Taiwan	National Sun Yat Sen University; Kaohsiung Veterans General Hospital; National Cheng Kung University	Chang, AYW (corresponding author), Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung 80424, Taiwan.	achang@mail.nsysu.edu.tw	Chan, Julie/X-5253-2019					BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; Chan JYH, 2005, PROG NEUROBIOL, V77, P396, DOI 10.1016/j.pneurobio.2005.11.004; Chan JYH, 2005, NEUROPHARMACOLOGY, V48, P161, DOI 10.1016/j.neuropharm.2004.08.012; Chan JYH, 2004, CIRCULATION, V110, P3560, DOI 10.1161/01.CIR.0000143082.63063.33; Chan JYH, 2004, NEUROPHARMACOLOGY, V46, P1184, DOI 10.1016/j.neuropharm.2004.01.017; Chan SHH, 2005, CIRC RES, V97, P772, DOI 10.1161/01.RES.0000185804.79157.C0; Chan SHH, 2005, FREE RADICAL BIO MED, V39, P603, DOI 10.1016/j.freeradbiomed.2005.04.012; Chan SHH, 2001, BRIT J PHARMACOL, V133, P606, DOI 10.1038/sj.bjp.0704105; Chang AYW, 2003, J BIOMED SCI, V10, P285, DOI 10.1159/000070093; Ciani E, 2002, J BIOL CHEM, V277, P49896, DOI 10.1074/jbc.M206177200; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; CORRERAS MC, 2004, MOL ASPECTS MED, V25, P125; Deans Z, 1996, J BIOL CHEM, V271, P32153, DOI 10.1074/jbc.271.50.32153; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Emrich Thomas, 2002, Methods Mol Biol, V191, P99; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; Fernando LP, 2000, SHOCK, V14, P128, DOI 10.1097/00024382-200014020-00009; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Flohe SB, 2003, J IMMUNOL, V170, P2340, DOI 10.4049/jimmunol.170.5.2340; GENG Y, 1992, CIRC RES, V71, P1268, DOI 10.1161/01.RES.71.5.1268; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Gupta RC, 2001, ARCH TOXICOL, V75, P346, DOI 10.1007/s002040100249; Hauser GJ, 1996, AM J PHYSIOL-HEART C, V271, pH2529, DOI 10.1152/ajpheart.1996.271.6.H2529; Hirvonen MR, 1996, BIOCHEM J, V315, P845, DOI 10.1042/bj3150845; Hou Q, 2005, AM J PHYSIOL-HEART C, V289, pH477, DOI 10.1152/ajpheart.00879.2004; Huang CC, 2004, MOL PHARMACOL, V66, P492, DOI 10.1124/mol.104.000554; Huang CC, 2003, MOL PHARMACOL, V64, P521, DOI 10.1124/mol.64.2.521; Huang YH, 2002, PROTEOMICS, V2, P1220, DOI 10.1002/1615-9861(200209)2:9<1220::AID-PROT1220>3.0.CO;2-3; HUNG TP, 1995, J NEUROL NEUROSUR PS, V58, P75, DOI 10.1136/jnnp.58.1.75; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Kaetsu A, 2001, J APPL TOXICOL, V21, P425, DOI 10.1002/jat.774; Kirchhoff SR, 2002, CIRCULATION, V105, P2899, DOI 10.1161/01.CIR.0000019403.35847.23; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kuo TBJ, 1997, AM J PHYSIOL-HEART C, V272, pH485, DOI 10.1152/ajpheart.1997.272.1.H485; Kuo TBJ, 1997, AM J PHYSIOL-HEART C, V273, pH1291, DOI 10.1152/ajpheart.1997.273.3.H1291; Li FCH, 2005, MOL PHARMACOL, V68, P179, DOI 10.1124/mol.105.011684; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Lossi L, 2003, PROG NEUROBIOL, V69, P287, DOI 10.1016/S0301-0082(03)00051-0; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; Martinus RD, 1996, EUR J BIOCHEM, V240, P98, DOI 10.1111/j.1432-1033.1996.0098h.x; Meldrum KK, 2003, CIRC RES, V92, P293, DOI 10.1161/01.RES.0000057754.35180.99; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Oksala N, 2004, EUR SURG RES, V36, P67, DOI 10.1159/000076645; Pallis CA, 1983, ABC BRAIN STEM DEATH; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; PODCROSO JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85; Ramachandran A, 2002, FREE RADICAL BIO MED, V33, P1465, DOI 10.1016/S0891-5849(02)01142-5; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; Robertson JD, 1999, BIOCHEM J, V344, P477, DOI 10.1042/0264-6021:3440477; ROSS CA, 1984, J NEUROSCI, V4, P474; Ryan MT, 1997, GENE, V196, P9, DOI 10.1016/S0378-1119(97)00111-X; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Saur D, 2002, J BIOL CHEM, V277, P25798, DOI 10.1074/jbc.M109802200; Shan YX, 2003, J MOL CELL CARDIOL, V35, P1135, DOI 10.1016/S0022-2828(03)00229-3; Soltys BJ, 1996, EXP CELL RES, V222, P16, DOI 10.1006/excr.1996.0003; Szabo C, 1996, EUR J PHARMACOL, V315, P221, DOI 10.1016/S0014-2999(96)00628-0; Thippeswamy T, 2001, EUR J NEUROSCI, V14, P1229, DOI 10.1046/j.0953-816x.2001.01752.x; Todryk SM, 2000, IMMUNOLOGY, V99, P334, DOI 10.1046/j.1365-2567.2000.00002.x; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Wu KLH, 2003, NEUROBIOL DIS, V14, P19, DOI 10.1016/S0969-9961(03)00078-0; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Yang CH, 1995, J PHARMACOL EXP THER, V275, P1568; Yen DHT, 2004, SHOCK, V21, P358, DOI 10.1097/00024382-200404000-00011; Yen DHT, 2001, SHOCK, V15, P35, DOI 10.1097/00024382-200115010-00006; Yen DHT, 2000, CRIT CARE MED, V28, P2805, DOI 10.1097/00003246-200008000-00021; Yien HW, 1997, CRIT CARE MED, V25, P258, DOI 10.1097/00003246-199702000-00011; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445; Zucchi I, 2002, P NATL ACAD SCI USA, V99, P8660, DOI 10.1073/pnas.132259399	75	58	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4585	4600		10.1074/jbc.M603394200	http://dx.doi.org/10.1074/jbc.M603394200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17150954	hybrid			2022-12-27	WOS:000244482000040
J	Debrincat, MA; Zhang, JG; Willson, TA; Silke, J; Connolly, LM; Simpson, RJ; Alexander, WS; Nicola, NA; Kile, BT; Hilton, DJ				Debrincat, Marlyse A.; Zhang, Jian-Guo; Willson, Tracy A.; Silke, John; Connolly, Lisa M.; Simpson, Richard J.; Alexander, Warren S.; Nicola, Nicos A.; Kile, Benjamin T.; Hilton, Douglas J.			Ankyrin repeat and suppressors of cytokine signaling box protein Asb-9 targets creatine kinase B for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOCS-BOX; ENERGY HOMEOSTASIS; MASS-SPECTROMETRY; UBIQUITIN LIGASE; IN-VIVO; GENE; CELLS; IDENTIFICATION; INHIBITION; LEUKEMIA	The suppressors of cytokine signaling (SOCS) proteins inhibit cytokine action by direct interaction with Janus kinases or activated cytokine receptors. In addition to the N-terminal and Src homology 2 domains that mediate these interactions, SOCS proteins contain a C-terminal SOCS box. DNA data base searches have identified a number of other protein families that possess a SOCS box, of which the ankyrin repeat and SOCS box-containing (Asb) proteins constitute the largest. Although it is known that the SOCS proteins are involved in the negative regulation of cytokine signaling, the biological and biochemical functions of the Asbs are largely undefined. Using a proteomics approach, we demonstrate that creatine kinase B (CKB) interacts with Asb-9 in a specific, SOCS box-independent manner. This interaction increases the polyubiquitylation of CKB and decreases total CKB levels within the cell. The targeting of CKB for degradation by Asb-9 was primarily SOCS box-dependent and suggests that Asb-9 acts as a specific ubiquitin ligase regulating levels of this evolutionarily conserved enzyme.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haematol, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Mol Med, Parkville, Vic 3050, Australia; Univ Melbourne, Dept Med Biol, Parkville, Vic 3050, Australia; La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Joint Proteom Lab, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne; La Trobe University; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Hilton, DJ (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haematol, 1G Royal Parade, Parkville, Vic 3050, Australia.	hilton@wehi.edu.au	Silke, John/B-7622-2008; Simpson, Richard/A-6947-2012; Nicola, Nicos/D-2989-2011; Kile, Benjamin T/F-6593-2011; Hilton, Douglas J/C-7250-2013; Kile, Benjamin/GNP-3246-2022	Silke, John/0000-0002-7611-5774; Nicola, Nicos/0000-0003-1054-7889; Kile, Benjamin T/0000-0002-8836-8947; Hilton, Douglas J/0000-0002-7698-2392; Kile, Benjamin/0000-0002-8836-8947; Simpson, Richard/0000-0002-9834-0796				ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Boengler K, 2003, BIOCHEM BIOPH RES CO, V302, P17, DOI 10.1016/S0006-291X(03)00095-0; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Chen JS, 2001, BLOOD, V97, P2115, DOI 10.1182/blood.V97.7.2115; CHNG JLC, 1994, J BIOL CHEM, V269, P2336; Chung AS, 2005, MOL CELL BIOL, V25, P4716, DOI 10.1128/MCB.25.11.4716-4726.2005; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Diks SH, 2006, J CELL BIOL, V174, P581, DOI 10.1083/jcb.200601081; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Guibal FC, 2002, J BIOL CHEM, V277, P218, DOI 10.1074/jbc.M108476200; Haan S, 2003, J BIOL CHEM, V278, P31972, DOI 10.1074/jbc.M303170200; Heuze ML, 2005, J BIOL CHEM, V280, P5468, DOI 10.1074/jbc.M413040200; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Jost CR, 2002, EUR J NEUROSCI, V15, P1692, DOI 10.1046/j.1460-9568.2002.02001.x; KADDURAHDAOUK R, 1990, MOL CELL BIOL, V10, P1476, DOI 10.1128/MCB.10.4.1476; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kile BT, 2001, MOL CELL BIOL, V21, P6189, DOI 10.1128/MCB.21.18.6189-6197.2001; Kile BT, 2000, GENE, V258, P31, DOI 10.1016/S0378-1119(00)00402-9; Kohroki J, 2001, FEBS LETT, V505, P223, DOI 10.1016/S0014-5793(01)02829-0; Liu YZ, 2003, BIOCHEM BIOPH RES CO, V300, P972, DOI 10.1016/S0006-291X(02)02971-6; McDaneld TG, 2006, AM J PHYSIOL-REG I, V290, pR1672, DOI 10.1152/ajpregu.00239.2005; McDaneld TG, 2004, PHYSIOL GENOMICS, V16, P275, DOI 10.1152/physiolgenomics.00127.2003; MORITZ RL, 1992, J CHROMATOGR, V599, P119; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Silke J, 2005, P NATL ACAD SCI USA, V102, P16182, DOI 10.1073/pnas.0502828102; Silke J, 2004, J BIOL CHEM, V279, P4313, DOI 10.1074/jbc.M305661200; Simpson RJ, 2000, ELECTROPHORESIS, V21, P1707, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1707::AID-ELPS1707>3.0.CO;2-Q; SOMJEN D, 1989, P NATL ACAD SCI USA, V86, P3361, DOI 10.1073/pnas.86.9.3361; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tachikawa M, 2004, EUR J NEUROSCI, V20, P144, DOI 10.1111/j.1460-9568.2004.03478.x; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Vasilescu J, 2004, PROTEOMICS, V4, P3845, DOI 10.1002/pmic.200400856; WALLIMANN T, 1994, MOL CELL BIOCHEM, V133, P193, DOI 10.1007/BF01267955; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wang F, 2002, J CELL BIOCHEM, V84, P156, DOI 10.1002/jcb.1276; Wilcox A, 2004, J BIOL CHEM, V279, P38881, DOI 10.1074/jbc.M406101200; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	50	41	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4728	4737		10.1074/jbc.M609164200	http://dx.doi.org/10.1074/jbc.M609164200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17148442	hybrid			2022-12-27	WOS:000244482000054
J	Ding, WX; Ni, HM; Gao, WT; Hou, YF; Melan, MA; Chen, XY; Stolz, DB; Shao, ZM; Yin, XM				Ding, Wen-Xing; Ni, Hong-Min; Gao, Wentao; Hou, Yi-Feng; Melan, Melissa A.; Chen, Xiaoyun; Stolz, Donna B.; Shao, Zhi-Ming; Yin, Xiao-Ming			Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISFOLDED PROTEINS; DEATH; APOPTOSIS; INHIBITION; DISSECTION; DISEASE; ABSENCE; ROLES; BAX	Autophagy is a cellular response to adverse environment and stress, but its significance in cell survival is not always clear. Here we show that autophagy could be induced in the mammalian cells by chemicals, such as A23187, tunicamycin, thapsigargin, and brefeldin A, that cause endoplasmic reticulum stress. Endoplasmic reticulum stress-induced autophagy is important for clearing polyubiquitinated protein aggregates and for reducing cellular vacuolization in HCT116 colon cancer cells and DU145 prostate cancer cells, thus mitigating endoplasmic reticulum stress and protecting against cell death. In contrast, autophagy induced by the same chemicals does not confer protection in a normal human colon cell line and in the non-transformed murine embryonic fibroblasts but rather contributes to cell death. Thus the impact of autophagy on cell survival during endoplasmic reticulum stress is likely contingent on the status of cells, which could be explored for tumor-specific therapy.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Fudan Univ, Dept Surg, Canc Hosp, Shanghai 200032, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fudan University	Yin, XM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA.	xmyin@pitt.edu	Chen, Xiaoyun/K-4786-2019	Melan, Melissa/0000-0001-6088-7801	NCI NIH HHS [CA111456, CA83817] Funding Source: Medline; NINDS NIH HHS [NS45252] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111456, R01CA083817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045252] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Chandra D, 2005, J BIOL CHEM, V280, P19051, DOI 10.1074/jbc.M501391200; Ding WX, 2004, HEPATOLOGY, V40, P403, DOI 10.1002/hep.20310; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73; Kamimoto T, 2006, J BIOL CHEM, V281, P4467, DOI 10.1074/jbc.M509409200; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; KOUROKU Y, 2006, CELL DEATH DIFF 0623; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Ohsumi Y, 2004, SEMIN CELL DEV BIOL, V15, P231, DOI 10.1016/j.semcdb.2003.12.004; Perlmutter DH, 1999, LAB INVEST, V79, P623; Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Shibata M, 2006, J BIOL CHEM, V281, P14474, DOI 10.1074/jbc.M600364200; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V279, pG961, DOI 10.1152/ajpgi.2000.279.5.G961; Yoneda T, 2002, GENE DEV, V16, P1307, DOI 10.1101/gad.1000902; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	40	393	421	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4702	4710		10.1074/jbc.M609267200	http://dx.doi.org/10.1074/jbc.M609267200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17135238	hybrid			2022-12-27	WOS:000244482000051
J	Luka, Z; Pakhomova, S; Loukachevitch, LV; Egli, M; Newcomer, ME; Wagner, C				Luka, Zigmund; Pakhomova, Svetlana; Loukachevitch, Lioudmila V.; Egli, Martin; Newcomer, Marcia E.; Wagner, Conrad			5-methyltetrahydrofolate is bound in intersubunit areas of rat liver folate-binding protein glycine N-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; DIHYDROFOLATE-REDUCTASE; CATALYTIC MECHANISM; FOLIC-ACID; INHIBITION; DEFICIENCY; METABOLISM; ENZYMES; METHYLENETETRAHYDROFOLATE; PURIFICATION	Glycine N-methyltransferase (GNMT) is a key regulatory enzyme in methyl group metabolism. It is abundant in the liver, where it uses excess S-adenosylmethionine (AdoMet) to methylate glycine to N-methylglycine (sarcosine) and produces S-adenosylhomocysteine (AdoHcy), thereby controlling the methylating potential of the cell. GNMT also links utilization of preformed methyl groups, in the form of methionine, to their de novo synthesis, because it is inhibited by a specific form of folate, 5-methyltetrahydrofolate. Although the structure of the enzyme has been elucidated by x-ray crystallography of the apoenzyme and in the presence of the substrate, the location of the folate inhibitor in the tetrameric structure has not been identified. We report here for the first time the crystal structure of rat GNMT complexed with 5-methyltetrahydrofolate. In the GNMT-folate complex, two folate binding sites were located in the intersubunit areas of the tetramer. Each folate binding site is formed primarily by two 1-7 N-terminal regions of one pair of subunits and two 205-218 regions of the other pair of subunits. Both the pteridine and p-aminobenzoyl rings are located in the hydrophobic cavities formed by Tyr(5), Leu(207), and Met(215) residues of all subunits. Binding experiments in solution also confirm that one GNMT tetramer binds two folate molecules. For the enzymatic reaction to take place, the N-terminal fragments of GNMT must have a significant degree of conformational freedom to provide access to the active sites. The presence of the folate in this position provides a mechanism for its inhibition.	Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37212 USA; Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Louisiana State University System; Louisiana State University	Wagner, C (corresponding author), Vanderbilt Univ, Med Ctr, Dept Biochem, 620 Light Hall, Nashville, TN 37232 USA.	Conrad.Wagner@vanderbilt.edu			NIDDK NIH HHS [DK15289] Funding Source: Medline; NIGMS NIH HHS [GM55237] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015289, R01DK015289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055237] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BALAGHI M, 1993, AM J CLIN NUTR, V58, P198, DOI 10.1093/ajcn/58.2.198; Blakley R.L., 1969, N HOLLAND RES MONOGR, P1; BLUMENSTEIN J, 1960, BIOCHEM BIOPH RES CO, V3, P259, DOI 10.1016/0006-291X(60)90235-7; Brautigam CA, 2004, P NATL ACAD SCI USA, V101, P12142, DOI 10.1073/pnas.0404851101; CANTONI GL, 1978, TRANSMETHYLATION, P155; Chen SY, 2004, CANCER RES, V64, P3617, DOI 10.1158/0008-5472.CAN-03-3726; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; Cody V, 2004, ACTA CRYSTALLOGR D, V60, P646, DOI 10.1107/S0907444904002094; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; Evans JC, 2004, P NATL ACAD SCI USA, V101, P3729, DOI 10.1073/pnas.0308082100; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; GUPTA VS, 1967, ARCH BIOCHEM BIOPHYS, V120, P712, DOI 10.1016/0003-9861(67)90536-X; HEADY JE, 1973, J BIOL CHEM, V248, P69; HORNE DW, 1988, CLIN CHEM, V34, P2357; Huang Y, 2000, J MOL BIOL, V298, P149, DOI 10.1006/jmbi.2000.3637; Hyatt DC, 1997, BIOCHEMISTRY-US, V36, P4585, DOI 10.1021/bi962936j; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLOTZ IM, 1946, ARCH BIOCHEM, V9, P109; Luka Z, 2003, PROTEIN EXPRES PURIF, V28, P280, DOI 10.1016/S1046-5928(02)00710-6; Luka Z, 2002, HUM GENET, V110, P68, DOI 10.1007/s00439-001-0648-4; Luka Z, 2006, TRANSGENIC RES, V15, P393, DOI 10.1007/s11248-006-0008-1; MATTHEWS DA, 1977, SCIENCE, V197, P452, DOI 10.1126/science.17920; Moreland JL, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-21; Mudd SH, 2001, J INHERIT METAB DIS, V24, P448, DOI 10.1023/A:1010577512912; OGAWA H, 1993, COMP BIOCHEM PHYS B, V106, P601, DOI 10.1016/0305-0491(93)90137-T; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pakhomova S, 2004, PROTEINS, V57, P331, DOI 10.1002/prot.20209; Pattanayek R, 1998, PROTEIN SCI, V7, P1326, DOI 10.1002/pro.5560070608; Pejchal R, 2005, BIOCHEMISTRY-US, V44, P11447, DOI 10.1021/bi050533q; POE M, 1980, BIOCHEMISTRY-US, V19, P4576, DOI 10.1021/bi00561a006; SUZUKI N, 1980, ARCH BIOCHEM BIOPHYS, V199, P236, DOI 10.1016/0003-9861(80)90277-5; Takata Y, 2003, BIOCHEMISTRY-US, V42, P8394, DOI 10.1021/bi034245a; Thomas AH, 2001, HELV CHIM ACTA, V84, P3849, DOI 10.1002/1522-2675(20011219)84:12<3849::AID-HLCA3849>3.0.CO;2-F; Thomas AH, 2002, HELV CHIM ACTA, V85, P2300, DOI 10.1002/1522-2675(200208)85:8<2300::AID-HLCA2300>3.0.CO;2-B; WAGNER C, 1985, BIOCHEM BIOPH RES CO, V127, P746, DOI 10.1016/S0006-291X(85)80006-1; Yeo EJ, 1999, J BIOL CHEM, V274, P37559, DOI 10.1074/jbc.274.53.37559; ZAMIEROWSKI MM, 1977, J BIOL CHEM, V252, P933	38	24	26	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4069	4075		10.1074/jbc.M610384200	http://dx.doi.org/10.1074/jbc.M610384200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158459	hybrid, Green Published			2022-12-27	WOS:000244481900070
J	Johansson, C; Kavanagh, KL; Gileadi, O; Oppermann, U				Johansson, Catrine; Kavanagh, Kathryn L.; Gileadi, Opher; Oppermann, Udo			Reversible sequestration of active site cysteines in a 2Fe-2S-bridged dimer provides a mechanism for glutaredoxin 2 regulation in human mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRX5 MONOTHIOL GLUTAREDOXIN; LIPOIC ACID; LIPID-PEROXIDATION; ESCHERICHIA-COLI; PROTEIN; THIOREDOXIN; GLUTATHIONE; ASSIGNMENTS; PROTECTION; CLUSTERS	Human mitochondrial glutaredoxin 2 (GLRX2), which controls intracellular redox balance and apoptosis, exists in a dynamic equilibrium of enzymatically active monomers and quiescent dimers. Crystal structures of both monomeric and dimeric forms of human GLRX2 reveal a distinct glutathione binding mode and show a 2Fe-2S-bridged dimer. The iron-sulfur cluster is coordinated through the N-terminal active site cysteine, Cys-37, and reduced glutathione. The structures indicate that the enzyme can be inhibited by a high GSH/GSSG ratio either by forming a 2Fe-2S-bridged dimer that locks away the N-terminal active site cysteine or by binding non-covalently and blocking the active site as seen in the monomer. The properties that permit GLRX2, and not other glutaredoxins, to form an iron-sulfur-containing dimer are likely due to the proline-to-serine substitution in the active site motif, allowing the main chain more flexibility in this area and providing polar interaction with the stabilizing glutathione. This appears to be a novel use of an iron-sulfur cluster in which binding of the cluster inactivates the protein by sequestering active site residues and where loss of the cluster through changes in subcellular redox status creates a catalytically active protein. Under oxidizing conditions, the dimers would readily separate into iron-free active monomers, providing a structural explanation for glutaredoxin activation under oxidative stress.	Univ Oxford, Botnar Res Ctr, Struct Genom Consortium, Oxford OX3 7LD, England	University of Oxford	Kavanagh, KL (corresponding author), Univ Oxford, Botnar Res Ctr, Struct Genom Consortium, Oxford OX3 7LD, England.	kate.kavanagh@sgc.ox.ac.uk; udo.oppermann@sgc.ox.ac.uk	Gileadi, Opher/F-1105-2013	Gileadi, Opher/0000-0001-6886-898X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arivazhagan P, 2001, J NUTR BIOCHEM, V12, P2, DOI 10.1016/S0955-2863(00)00138-8; Aslund F, 1996, J BIOL CHEM, V271, P6736, DOI 10.1074/jbc.271.12.6736; BAST A, 1988, BIOCHIM BIOPHYS ACTA, V963, P558, DOI 10.1016/0005-2760(88)90326-8; Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624; Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200; Belli G, 2002, J BIOL CHEM, V277, P37590, DOI 10.1074/jbc.M201688200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Enoksson M, 2005, BIOCHEM BIOPH RES CO, V327, P774, DOI 10.1016/j.bbrc.2004.12.067; Feng YG, 2006, BIOCHEMISTRY-US, V45, P7998, DOI 10.1021/bi060444t; Holmgren A, 2005, BIOCHEM SOC T, V33, P1375, DOI 10.1042/BST0331375; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hurd TR, 2005, ANTIOXID REDOX SIGN, V7, P999, DOI 10.1089/ars.2005.7.999; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Lillig CH, 2004, P NATL ACAD SCI USA, V101, P13227, DOI 10.1073/pnas.0401896101; Lundberg M, 2006, PROTEIN EXPRES PURIF, V45, P37, DOI 10.1016/j.pep.2005.07.001; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Molina-Navarro MM, 2006, FEBS LETT, V580, P2273, DOI 10.1016/j.febslet.2006.03.037; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Porras P, 2002, BIOCHEM BIOPH RES CO, V295, P1046, DOI 10.1016/S0006-291X(02)00771-4; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Singh KK, 2006, ANN NY ACAD SCI, V1067, P182, DOI 10.1196/annals.1354.022; SODANO P, 1991, J MOL BIOL, V221, P1311; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Storz P., 2006, SCI STKE, V2006, pre3, DOI DOI 10.1126/STKE.3322006RE3; Tamarit J, 2003, J BIOL CHEM, V278, P25745, DOI 10.1074/jbc.M303477200; Wingert RA, 2005, NATURE, V436, P1035, DOI 10.1038/nature03887; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504; Yi XW, 2005, MOL CELL BIOL, V25, P8387, DOI 10.1128/MCB.25.18.8387-8392.2005	31	114	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3077	3082		10.1074/jbc.M608179200	http://dx.doi.org/10.1074/jbc.M608179200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17121859	Green Published, hybrid			2022-12-27	WOS:000243793900034
J	Luria, A; Weldon, SM; Kabcenell, AK; Ingraham, RH; Matera, D; Jiang, HP; Gill, R; Morisseau, C; Newman, JW; Hammock, BD				Luria, Ayala; Weldon, Steven M.; Kabcenell, Alisa K.; Ingraham, Richard H.; Matera, Damian; Jiang, Huiping; Gill, Rajan; Morisseau, Christophe; Newman, John W.; Hammock, Bruce D.			Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE EPOXIDE HYDROLASE; OMEGA-HYDROXYLASE ACTIVITY; ARACHIDONIC-ACID; EPOXYEICOSATRIENOIC ACIDS; CYTOCHROME-P450 EPOXYGENASE; 20-HYDROXYEICOSATETRAENOIC ACID; PHOSPHATASE-ACTIVITY; TARGETED DISRUPTION; LIPID-METABOLISM; HYPERTENSION	Arachidonic acid-derived epoxides, epoxyeicosatrienoic acids, are important regulators of vascular homeostasis and inflammation, and therefore manipulation of their levels is a potentially useful pharmacological strategy. Soluble epoxide hydrolase converts epoxyeicosatrienoic acids to their corresponding diols, dihydroxyeicosatrienoic acids, modifying or eliminating the function of these oxylipins. To better understand the phenotypic impact of Ephx2 disruption, two independently derived colonies of soluble epoxide hydrolase-null mice were compared. We examined this genotype evaluating protein expression, biofluid oxylipin profile, tissue oxylipin production capacity, and blood pressure. Ephx2 gene disruption eliminated soluble epoxide hydrolase protein expression and activity in liver, kidney, and heart from each colony. Plasma levels of epoxy fatty acids were increased, and fatty acid diols levels were decreased, while measured levels of lipoxygenase-and cyclooxygenase-dependent oxylipins were unchanged. Liver and kidney homogenates also show elevated epoxide fatty acids. However, in whole kidney homogenate a 4-fold increase in the formation of 20-hydroxyeicosatetraenoic acid was measured along with a 3-fold increase in lipoxygenase-derived hydroxylation and prostanoid production. Unlike previous reports, however, neither Ephx2-null colony showed alterations in basal blood pressure. Finally, the soluble epoxide hydrolase-null mice show a survival advantage following acute systemic inflammation. The data suggest that blood pressure homeostasis may be achieved by increasing production of the vasoconstrictor, 20-hydroxyeicosatetraenoic acid in the kidney of the Ephx2-null mice. This shift in renal metabolism is likely a metabolic compensation for the loss of the soluble epoxide hydrolase gene.	Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Univ Calif Davis, Canc Res Ctr, Davis, CA 95616 USA; Boehringer Ingelheim Pharmaceut Inc, Dept Translat Sci, Ridgefield, CT 06877 USA; Boehringer Ingelheim Pharmaceut Inc, Dept Cardiovasc Dis, Ridgefield, CT 06877 USA; USDA, ARS, Western Human Nutr Res Ctr, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Boehringer Ingelheim; Boehringer Ingelheim; United States Department of Agriculture (USDA)	Hammock, BD (corresponding author), Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.	bdhammock@ucdavis.edu		Newman, John/0000-0001-9632-6571	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013933, P42ES004699, P30ES005707, R37ES002710] Funding Source: NIH RePORTER; NIEHS NIH HHS [R37 ES02710, P42 ES004699, P30 ES005707, R01 ES013933, P30 ES05707, R37 ES002710] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Argiriadi MA, 1999, P NATL ACAD SCI USA, V96, P10637, DOI 10.1073/pnas.96.19.10637; BEETHAM JK, 1995, DNA CELL BIOL, V14, P61, DOI 10.1089/dna.1995.14.61; Besson V, 2005, BIOL CELL, V97, P787, DOI 10.1042/BC20040525; BORHAN B, 1995, ANAL BIOCHEM, V231, P188, DOI 10.1006/abio.1995.1520; Cronin A, 2003, P NATL ACAD SCI USA, V100, P1552, DOI 10.1073/pnas.0437829100; Dey A, 2004, OBES RES, V12, P1278, DOI 10.1038/oby.2004.162; DuTeaux SB, 2004, TOXICOL SCI, V78, P187, DOI 10.1093/toxsci/kfh066; Enayetallah AE, 2006, BIOCHEM BIOPH RES CO, V341, P254, DOI 10.1016/j.bbrc.2005.12.180; Enayetallah AE, 2004, J HISTOCHEM CYTOCHEM, V52, P447, DOI 10.1177/002215540405200403; Gomez GA, 2004, BIOCHEMISTRY-US, V43, P4716, DOI 10.1021/bi036189j; Harder DR, 2002, NEWS PHYSIOL SCI, V17, P27, DOI 10.1152/physiologyonline.2002.17.1.27; HEIZER ML, 1991, STROKE, V22, P1389, DOI 10.1161/01.STR.22.11.1389; Holla VR, 1999, J CLIN INVEST, V104, P751, DOI 10.1172/JCI7013; Holla VR, 2001, P NATL ACAD SCI USA, V98, P5211, DOI 10.1073/pnas.081627898; Imig JD, 2005, HYPERTENSION, V46, P975, DOI 10.1161/01.HYP.0000176237.74820.75; Imig JD, 1996, J AM SOC NEPHROL, V7, P2364; Imig JD, 2002, HYPERTENSION, V39, P690, DOI 10.1161/hy0202.103788; Imig JD, 1999, BRIT J PHARMACOL, V127, P1399, DOI 10.1038/sj.bjp.0702662; Kroetz DL, 2002, CURR OPIN LIPIDOL, V13, P273, DOI 10.1097/00041433-200206000-00007; Lee CR, 2006, HUM MOL GENET, V15, P1640, DOI 10.1093/hmg/ddl085; MAKITA K, 1994, J CLIN INVEST, V94, P2414, DOI 10.1172/JCI117608; Messer-Letienne I, 1999, EUR J PHARMACOL, V378, P291, DOI 10.1016/S0014-2999(99)00470-7; Newman JW, 2005, PROG LIPID RES, V44, P1, DOI 10.1016/j.plipres.2004.10.001; Newman JW, 2004, ENDOCRINOLOGY, V145, P5097, DOI 10.1210/en.2004-0710; Newman JW, 2003, P NATL ACAD SCI USA, V100, P1558, DOI 10.1073/pnas.0437724100; Newman JW, 2002, J LIPID RES, V43, P1563, DOI 10.1194/jlr.D200018-JLR200; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Node K, 2001, J BIOL CHEM, V276, P15983, DOI 10.1074/jbc.M100439200; ODonnell VB, 1997, BIOCHEM J, V327, P203, DOI 10.1042/bj3270203; Parlakian A, 2005, CIRCULATION, V112, P2930, DOI 10.1161/CIRCULATIONAHA.105.533778; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Sandberg M, 1996, BIOCHEM BIOPH RES CO, V221, P333, DOI 10.1006/bbrc.1996.0596; Sarkis A, 2004, CURR OPIN NEPHROL HY, V13, P205, DOI 10.1097/00041552-200403000-00009; Scarff KL, 2004, MOL CELL BIOL, V24, P4075, DOI 10.1128/MCB.24.9.4075-4082.2004; SCHMELZER K, 2005, P NATL ACAD SCI US; Sellers KW, 2005, FASEB J, V19, P626, DOI 10.1096/fj.04-3128fje; Seubert JM, 2006, CIRC RES, V99, P442, DOI 10.1161/01.RES.0000237390.92932.37; Sinal CJ, 2000, J BIOL CHEM, V275, P40504, DOI 10.1074/jbc.M008106200; Smith KR, 2005, P NATL ACAD SCI USA, V102, P2186, DOI 10.1073/pnas.0409591102; Spector AA, 2004, PROG LIPID RES, V43, P55, DOI 10.1016/S0163-7827(03)00049-3; Su P, 1998, AM J PHYSIOL-REG I, V275, pR426, DOI 10.1152/ajpregu.1998.275.2.R426; Takahashi N, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133604; Tran KL, 2005, BIOCHEMISTRY-US, V44, P12179, DOI 10.1021/bi050842g; Wang MH, 2003, HYPERTENSION, V42, P594, DOI 10.1161/01.HYP.0000090123.55365.BA; Xu FY, 2002, AM J PHYSIOL-REG I, V283, pR710, DOI 10.1152/ajpregu.00522.2001; Yu ZG, 2000, CIRC RES, V87, P992, DOI 10.1161/01.RES.87.11.992; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; Zhao XY, 2004, J AM SOC NEPHROL, V15, P1244	48	121	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2891	2898		10.1074/jbc.M608057200	http://dx.doi.org/10.1074/jbc.M608057200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135253	Green Accepted, hybrid			2022-12-27	WOS:000243793900015
J	Ronni, T; Payne, KJ; Ho, S; Bradley, MN; Dorsam, G; Dovat, S				Ronni, Tapani; Payne, Kimberly J.; Ho, Sam; Bradley, Michelle N.; Dorsam, Glenn; Dovat, Sinisa			Human Ikaros function in activated T cells is regulated by coordinated expression of its largest isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR IKAROS; ACUTE LYMPHOBLASTIC-LEUKEMIA; ALPHA-SATELLITE DNA; GENE-EXPRESSION; CENTROMERIC HETEROCHROMATIN; POINT MUTATIONS; DOWN-REGULATION; SEQUENCE; BINDING; DIFFERENTIATION	The Ikaros gene is alternately spliced to generate multiple zinc finger proteins involved in gene regulation and chromatin remodeling. Whereas murine studies have provided important information regarding the role of Ikaros in the mouse, little is known of Ikaros function in human. We report functional analyses of the two largest human Ikaros (hIK) isoforms, hIK-VI and hIK-H, in T cells. Abundant expression of hIK-H, the largest described isoform, is restricted to human hematopoietic cells. We find that the DNA binding affinity of hIK-H differs from that of hIK-VI. Co-expression of hIk-H with hIk-VI alters the ability of Ikaros complexes to bind DNA motifs found in pericentromeric heterochromatin (PC-HC). In the nucleus, hIK-VI is localized solely in PC-HC, whereas the hIK-H protein exhibits dual centromeric and noncentromeric localization. Mutational analysis defined the amino acids responsible for the distinct DNA binding ability of hIK-H, as well as the sequence required for the specific subcellular localization of this isoform. In proliferating cells, the binding of hIK-H to the upstream regulatory region of known Ikaros target genes correlates with their positive regulation by Ikaros. Results suggest that expression of hIK-H protein restricts affinity of Ikaros protein complexes toward specific PC-HC repeats. We propose a model, whereby the binding of hIK-H-deficient Ikaros complexes to the regulatory sequence of target genes would recruit these genes to the restrictive pericentromeric compartment, resulting in their repression. The presence of hIK-H in the Ikaros complex would alter its affinity for PC-HC, leading to chromatin remodeling and activation of target genes.	Univ Wisconsin, Dept Pediat, Div Pediat Hematol Oncol, Madison, WI 53792 USA; Univ Calif Los Angeles, Mattel Childrens Hosp, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; N Dakota State Univ, Dept Chem & Mol Biol, Fargo, ND 58105 USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Children's Hospital Los Angeles; North Dakota State University Fargo	Dovat, S (corresponding author), Univ Wisconsin, Dept Pediat, Div Pediat Hematol Oncol, 600 Highland Ave,H4-431 CSC, Madison, WI 53792 USA.	dovat@wisc.edu	Payne, Kimberly/AAS-6814-2020; Dorsam, Glenn/GYD-8815-2022	Payne, Kimberly/0000-0002-7025-5821; Dovat, Sinisa/0000-0003-3906-6165	NATIONAL CANCER INSTITUTE [K22CA111392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK066163, F32DK010101] Funding Source: NIH RePORTER; NCI NIH HHS [K22 CA 111392] Funding Source: Medline; NIDDK NIH HHS [5K01 DK066163, 1F32DK10101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arco PGD, 2005, MOL CELL BIOL, V25, P2688, DOI 10.1128/MCB.25.7.2688-2697.2005; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; CHOO KH, 1991, NUCLEIC ACIDS RES, V19, P1179, DOI 10.1093/nar/19.6.1179; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Dorsam G, 2002, J BIOL CHEM, V277, P13488, DOI 10.1074/jbc.M107922200; Dovat S, 2002, GENE DEV, V16, P2985, DOI 10.1101/gad.1040502; Dumortier A, 2003, BLOOD, V101, P2219, DOI 10.1182/blood-2002-05-1336; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Gomez-del Arco P, 2004, MOL CELL BIOL, V24, P2797, DOI 10.1128/MCB.24.7.2797-2807.2004; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Karlsson A, 2002, CANCER RES, V62, P2650; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Kwan M, 2005, EUR J IMMUNOL, V35, P1267, DOI 10.1002/eji.200425619; LEE C, 1995, CHROMOSOMA, V104, P103, DOI 10.1007/BF00347692; Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508; Liberg D, 2003, TRENDS IMMUNOL, V24, P567, DOI 10.1016/j.it.2003.09.008; LIN CC, 1993, CHROMOSOMA, V102, P333, DOI 10.1007/BF00661276; Lopez RA, 2002, P NATL ACAD SCI USA, V99, P602, DOI 10.1073/pnas.022412699; Maccarrone M, 2003, J BIOL CHEM, V278, P32726, DOI 10.1074/jbc.M302123200; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Nakayama H, 1999, CANCER RES, V59, P3931; Nakayama H, 2000, EXP HEMATOL, V28, P1232, DOI 10.1016/S0301-472X(00)00530-0; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; Olivero S, 2000, BRIT J HAEMATOL, V110, P826, DOI 10.1046/j.1365-2141.2000.02297.x; Papathanasiou P, 2003, IMMUNITY, V19, P131, DOI 10.1016/S1074-7613(03)00168-7; Payne KJ, 2003, J IMMUNOL, V170, P3091, DOI 10.4049/jimmunol.170.6.3091; Payne KJ, 2001, J IMMUNOL, V167, P1867, DOI 10.4049/jimmunol.167.4.1867; PROSSER J, 1986, J MOL BIOL, V187, P145, DOI 10.1016/0022-2836(86)90224-X; Rebollo A, 2003, IMMUNOL CELL BIOL, V81, P171, DOI 10.1046/j.1440-1711.2003.01159.x; Romanova LY, 1996, J MOL BIOL, V261, P334, DOI 10.1006/jmbi.1996.0466; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Sun L, 1999, J CLIN ONCOL, V17, P3753, DOI 10.1200/JCO.1999.17.12.3753; Sun P, 2002, J BIOL CHEM, V277, P12854, DOI 10.1074/jbc.M112268200; Tonnelle C, 2002, LEUKEMIA LYMPHOMA, V43, P29, DOI 10.1080/10428190210186; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wargnier A, 1998, J BIOL CHEM, V273, P35326, DOI 10.1074/jbc.273.52.35326; WAYE JS, 1989, P NATL ACAD SCI USA, V86, P6250, DOI 10.1073/pnas.86.16.6250; WILLARD HF, 1987, J MOL EVOL, V25, P207, DOI 10.1007/BF02100014; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Yap WH, 2005, FEBS LETT, V579, P4470, DOI 10.1016/j.febslet.2005.07.018	47	32	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2538	2547		10.1074/jbc.M605627200	http://dx.doi.org/10.1074/jbc.M605627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135265	hybrid			2022-12-27	WOS:000243593200046
J	Nagahara, N; Yoshii, T; Abe, Y; Matsumura, T				Nagahara, Noriyuki; Yoshii, Taro; Abe, Yasuko; Matsumura, Tomohiro			Thioredoxin-dependent enzymatic activation of mercaptopyruvate sulfurtransferase - An intersubunit disulfide bond serves as a redox swith for activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; SITE-DIRECTED MUTAGENESIS; CHLOROPLAST FRUCTOSE-1,6-BISPHOSPHATASE; 3-MERCAPTOPYRUVATE SULFURTRANSFERASE; REDUCTIVE ACTIVATION; LIVER RHODANESE; ACTIVE-SITE; RAT-LIVER; PROTEIN; SEQUENCE	Rat 3-mercaptopyruvate sulfurtransferase (MST) contains three exposed cysteines as follows: a catalytic site cysteine, Cys(247), in the active site and Cys(154) and Cys(263) on the surface of MST. The corresponding cysteine to Cys(263) is conserved in mammalian MSTs, and Cys(154) is a unique cysteine. MST has monomer-dimer equilibrium with the assistance of oxidants and reductants. The monomer to dimer ratio is maintained at similar to 92:8 in 0.2M potassium phosphate buffer containing no reductants under air-saturated conditions; the dimer might be symmetrical via an intersubunit disulfide bond between Cys(154) and Cys(154) and between Cys(263) and Cys(263), or asymmetrical via an intersubunit disulfide bond between Cys(154) and Cys(263). Escherichia coli reduced thioredoxin (Trx) cleaved the intersubunit disulfide bond to activate MST to 2.3- and 4.9-fold the levels of activation of dithiothreitol (DTT)-treated and DTT-untreated MST, respectively. Rat Trx also activated MST. On the other hand, reduced glutathione did not affect MST activity. E. coli C35S Trx, in which Cys(35) was replaced with Ser, formed some adducts with MST and activated MST after treatment with DTT. Thus, Cys(32) of E. coli Trx reacted with the redox-active cysteines, Cys(154) and Cys(263), by forming an intersubunit disulfide bond and a sulfenyl Cys(247). A consecutively formed disulfide bond between Trx and MST must be cleaved for the activation. E. coli C32S Trx, however, did not activate MST. Reduced Trx turns on a redox switch for the enzymatic activation of MST, which contributes to the maintenance of cellular redox homeostasis.	Nippon Med Coll, Dept Environm Med, Bunkyo Ku, Tokyo 1138602, Japan; Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan	Nippon Medical School; Nippon Medical School	Nagahara, N (corresponding author), Nippon Med Coll, Dept Environm Med, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.	noriyuki@nms.ac.jp						Buhrman G, 2005, BIOCHEMISTRY-US, V44, P5307, DOI 10.1021/bi047449f; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; CHEN ZQ, 1995, J BIOL CHEM, V270, P19246, DOI 10.1074/jbc.270.33.19246; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Guyton A.C., 2006, TXB MED PHYSL; HAMA H, 1994, J BIOCHEM-TOKYO, V115, P1135, DOI 10.1093/oxfordjournals.jbchem.a124469; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KOBAYASHI F, 1995, HUM REPROD, V10, P1603, DOI 10.1093/HUMREP/10.6.1603; Kondo N, 2004, J IMMUNOL, V172, P442, DOI 10.4049/jimmunol.172.1.442; LARSSON A, 1973, EUR J BIOCHEM, V35, P346, DOI 10.1111/j.1432-1033.1973.tb02845.x; Loewy A.G., 1991, CELL STRUCTURE FUNCT; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MARTINEZGALISTEO E, 1993, BIOCHIMIE, V75, P803, DOI 10.1016/0300-9084(93)90131-B; Mikkelsen R, 2005, P NATL ACAD SCI USA, V102, P1785, DOI 10.1073/pnas.0406674102; Mora-Garcia S, 1998, J BIOL CHEM, V273, P16273, DOI 10.1074/jbc.273.26.16273; Mosharov E, 2000, BIOCHEMISTRY-US, V39, P13005, DOI 10.1021/bi001088w; MUSSO R, 1977, P NATL ACAD SCI USA, V74, P106, DOI 10.1073/pnas.74.1.106; Nagahara N, 2006, CURR MED CHEM, V13, P1219, DOI 10.2174/092986706776360914; Nagahara N, 2005, J BIOL CHEM, V280, P34569, DOI 10.1074/jbc.M505643200; NAGAHARA N, 1995, J BIOL CHEM, V270, P16230, DOI 10.1074/jbc.270.27.16230; Nagahara N, 1996, J BIOL CHEM, V271, P27395, DOI 10.1074/jbc.271.44.27395; Nagahara N, 1998, HISTOCHEM CELL BIOL, V110, P243, DOI 10.1007/s004180050286; Nagahara N, 1999, HISTOL HISTOPATHOL, V14, P1277, DOI 10.14670/HH-14.1277; Nakamura H, 1996, INT IMMUNOL, V8, P603, DOI 10.1093/intimm/8.4.603; PALLINI R, 1991, BIOCHEM BIOPH RES CO, V180, P887, DOI 10.1016/S0006-291X(05)81148-9; Papenbrock J, 2000, EUR J BIOCHEM, V267, P145, DOI 10.1046/j.1432-1327.2000.00980.x; Park C, 2001, PROTEIN ENG, V14, P939, DOI 10.1093/protein/14.11.939; PARK EM, 1989, ARCH BIOCHEM BIOPHYS, V272, P25, DOI 10.1016/0003-9861(89)90190-2; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Reynolds CM, 2001, BIOCHEMISTRY-US, V40, P3912, DOI 10.1021/bi002766h; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Sasaki Y, 1997, P NATL ACAD SCI USA, V94, P11096, DOI 10.1073/pnas.94.20.11096; Sevier CS, 2006, MOL BIOL CELL, V17, P2256, DOI 10.1091/mbc.E05-05-0417; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Suzuki T, 2000, J BIOL CHEM, V275, P37902, DOI 10.1074/jbc.M007075200; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; Wang YL, 2002, J BIOL CHEM, V277, P26496, DOI 10.1074/jbc.M202133200; Williams RAM, 2003, J BIOL CHEM, V278, P1480, DOI 10.1074/jbc.M209395200; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	45	77	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1561	1569		10.1074/jbc.M605931200	http://dx.doi.org/10.1074/jbc.M605931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17130129	hybrid			2022-12-27	WOS:000243451300007
J	Thoden, JB; Sellick, CA; Reece, RJ; Holden, HM				Thoden, James B.; Sellick, Christopher A.; Reece, Richard J.; Holden, Hazel M.			Understanding a transcriptional paradigm at the molecular level - The structure of yeast Gal80p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; KLUYVEROMYCES-LACTIS; CRYSTAL-STRUCTURE; REGULATORY PROTEIN; GAL4 PROTEIN; AMINO-ACIDS; GENE; GALACTOKINASE; ACTIVATION; SWITCH	In yeast, the GAL genes encode the enzymes required for normal galactose metabolism. Regulation of these genes in response to the organism being challenged with galactose has served as a paradigm for eukaryotic transcriptional control over the last 50 years. Three proteins, the activator Gal4p, the repressor Gal80p, and the ligand sensor Gal3p, control the switch between inert and active gene expression. Gal80p, the focus of this investigation, plays a pivotal role both in terms of repressing the activity of Gal4p and allowing the GAL switch to respond to galactose. Here we present the three-dimensional structure of Gal80p from Kluyveromyces lactis and show that it is structurally homologous to glucose-fructose oxidoreductase, an enzyme in the sorbitol-gluconate pathway. Our results clearly define the overall tertiary and quaternary structure of Gal80p and suggest that Gal4p and Gal3p bind to Gal80p at distinct but overlapping sites. In addition to providing a molecular basis for previous biochemical and genetic studies, our structure demonstrates that much of the enzymatic scaffold of the oxidoreductase has been maintained in Gal80p, but it is utilized in a very different manner to facilitate transcriptional regulation.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Wisconsin System; University of Wisconsin Madison; University of Manchester	Reece, RJ (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	Richard.Reece@manchester.ac.uk; Hazel_Holden@biochem.wisc.edu			NIDDK NIH HHS [DK47814] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047814, R01DK047814] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS BG, 1977, BIOCHEM BIOPH RES CO, V97, P27; Anders A, 2006, J BIOL CHEM, V281, P29337, DOI 10.1074/jbc.M604271200; BHAT PJ, 1990, GENETICS, V125, P281; BHAT PJ, 1992, MOL CELL BIOL, V12, P2701, DOI 10.1128/MCB.12.6.2701; El Omari K, 2005, J BIOL CHEM, V280, P18229, DOI 10.1074/jbc.M501113200; GLEASON WB, 1994, BIOCHEMISTRY-US, V33, P2078, DOI 10.1021/bi00174a014; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; JOHNSTON SA, 1986, P NATL ACAD SCI USA, V83, P6553, DOI 10.1073/pnas.83.17.6553; Kikuchi A, 2001, NAT STRUCT BIOL, V8, P221, DOI 10.1038/84955; Kingston RL, 1996, STRUCTURE, V4, P1413, DOI 10.1016/S0969-2126(96)00149-9; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Melcher K, 2005, GENETICS, V171, P469, DOI 10.1534/genetics.105.045237; MEYER J, 1991, MOL CELL BIOL, V11, P5454, DOI 10.1128/MCB.11.11.5454; Peng G, 2000, MOL CELL BIOL, V20, P5140, DOI 10.1128/MCB.20.14.5140-5148.2000; Peng G, 2002, P NATL ACAD SCI USA, V99, P8548, DOI 10.1073/pnas.142100099; Pilauri V, 2005, GENETICS, V169, P1903, DOI 10.1534/genetics.104.036723; Platt A, 2000, P NATL ACAD SCI USA, V97, P3154, DOI 10.1073/pnas.97.7.3154; Platt A, 1998, EMBO J, V17, P4086, DOI 10.1093/emboj/17.14.4086; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; ROTMAN B, 1953, J BACTERIOL, V66, P492, DOI 10.1128/JB.66.4.492-497.1953; ROWLAND P, 1994, STRUCTURE, V2, P1073, DOI 10.1016/S0969-2126(94)00110-3; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; Sellick CA, 2005, TRENDS BIOCHEM SCI, V30, P405, DOI 10.1016/j.tibs.2005.05.007; Stammers DK, 2001, EMBO J, V20, P6619, DOI 10.1093/emboj/20.23.6619; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thoden JB, 2005, J BIOL CHEM, V280, P36905, DOI 10.1074/jbc.M508446200; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WEBSTER TD, 1988, NUCLEIC ACIDS RES, V16, P8011, DOI 10.1093/nar/16.16.8011; Zenke FT, 1996, SCIENCE, V272, P1662, DOI 10.1126/science.272.5268.1662	34	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1534	1538		10.1074/jbc.C600285200	http://dx.doi.org/10.1074/jbc.C600285200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121853	hybrid			2022-12-27	WOS:000243451300003
J	Le Clainche, C; Schlaepfer, D; Ferrari, A; Klingauf, M; Grohmanova, K; Veligodskiy, A; Didry, D; Le, D; Egile, C; Carlier, MF; Kroschewski, R				Le Clainche, Christophe; Schlaepfer, Dominik; Ferrari, Aldo; Klingauf, Mirko; Grohmanova, Katarina; Veligodskiy, Alexey; Didry, Dominique; Le, Diep; Egile, Coumaran; Carlier, Marie-France; Kroschewski, Ruth			IQGAP1 stimulates actin assembly through the N-WASP-Arp2/3 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; N-WASP; ARP2/3 COMPLEX; CAPTURE MICROTUBULES; SHIGELLA-FLEXNERI; ACTOMYOSIN RING; CELL MOTILITY; CDC42; RAC1; ACTIVATION	IQGAP1 is a conserved modular protein overexpressed in cancer and involved in organizing actin and microtubules in motile processes such as adhesion, migration, and cytokinesis. A variety of proteins have been shown to interact with IQGAP1, including the small G proteins Rac1 and Cdc42, actin, calmodulin, beta-catenin, the microtubule plus end-binding proteins CLIP170 (cytoplasmic linker protein) and adenomatous polyposis coli. However, the molecular mechanism by which IQGAP 1 controls actin dynamics in cell motility is not understood. Quantitative co-localization analysis and down-regulation of IQGAP1 revealed that IQGAP1 controls the co-localization of N-WASP with the Arp2/3 complex in lamellipodia. Co-immunoprecipitation supports an in vivo link between IQGAP1 and N-WASP. Pull-down experiments and kinetic assays of branched actin polymerization with N-WASP and Arp2/3 complex demonstrated that the C-terminal half of IQGAP1 activates N-WASP by interacting with its BR-CRIB domain in a Cdc42-like manner, whereas the N-terminal half of IQGAP1 antagonizes this activation by association with a C-terminal region of IQGAP1. We propose that signal-induced relief of the autoinhibited fold of IQGAP1 allows activation of N-WASP to stimulate Arp2/3-dependent actin assembly.	CNRS, Dynam Cytoskeleton & Motil Grp, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; ETH, Inst Biochem, CH-8093 Zurich, Switzerland; Univ Zurich, Inst Mol Biol, Mol Life Sci PhD Program, CH-8057 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Carlier, MF (corresponding author), CNRS, Dynam Cytoskeleton & Motil Grp, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.	carlier@lebs.cnrs-gif.fr; ruth.kroschewski@bc.biol.ethz.ch	Le Clainche, Christophe/A-4782-2015	Le Clainche, Christophe/0000-0001-5659-677X; Kroschewski, Ruth/0000-0002-6032-2568				Adachi H, 1997, J CELL BIOL, V137, P891, DOI 10.1083/jcb.137.4.891; Anton IM, 2003, J CELL SCI, V116, P2443, DOI 10.1242/jcs.00433; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Bompard G, 2004, J CELL BIOL, V166, P957, DOI 10.1083/jcb.200403127; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Brown MD, 2006, TRENDS CELL BIOL, V16, P242, DOI 10.1016/j.tcb.2006.03.002; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Eng K, 1998, CURR BIOL, V8, P611, DOI 10.1016/S0960-9822(98)70248-9; Etienne-Manneville S, 2004, TRAFFIC, V5, P470, DOI 10.1111/j.1600-0854.2004.00196.x; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Fukata M, 2001, MOL CELL BIOL, V21, P2165, DOI 10.1128/MCB.21.6.2165-2183.2001; Golub T, 2005, J CELL BIOL, V169, P151, DOI 10.1083/jcb.200407058; Grohmanova K, 2004, J BIOL CHEM, V279, P48495, DOI 10.1074/jbc.M408113200; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Innocenti M, 2005, NAT CELL BIOL, V7, P969, DOI 10.1038/ncb1304; Jung G, 2001, J CELL BIOL, V153, P1479, DOI 10.1083/jcb.153.7.1479; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Landmann L, 2002, J MICROSC-OXFORD, V208, P134, DOI 10.1046/j.1365-2818.2002.01068.x; Lehtonen S, 2005, P NATL ACAD SCI USA, V102, P9814, DOI 10.1073/pnas.0504166102; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; Lommel S, 2001, EMBO REP, V2, P850, DOI 10.1093/embo-reports/kve197; Machesky LM, 1998, CURR BIOL, V8, pR202, DOI 10.1016/S0960-9822(98)70125-3; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; MANDERS EMM, 1992, J CELL SCI, V103, P857; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mataraza JM, 2003, BIOCHEM BIOPH RES CO, V305, P315, DOI 10.1016/S0006-291X(03)00759-9; Mateer SC, 2003, CELL MOTIL CYTOSKEL, V55, P147, DOI 10.1002/cm.10118; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Nabeshima K, 2002, CANCER LETT, V176, P101, DOI 10.1016/S0304-3835(01)00742-X; Nakagawa H, 2001, J CELL SCI, V114, P1555; Noritake J, 2005, J CELL SCI, V118, P2085, DOI 10.1242/jcs.02379; Otsuki M, 2003, J BIOL CHEM, V278, P6461, DOI 10.1074/jbc.M207433200; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Prehoda KE, 2002, CURR OPIN CELL BIOL, V14, P149, DOI 10.1016/S0955-0674(02)00307-1; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Shannon KB, 1999, MOL BIOL CELL, V10, P283, DOI 10.1091/mbc.10.2.283; Verma S, 2004, J BIOL CHEM, V279, P34062, DOI 10.1074/jbc.M404814200; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Wendland J, 2002, FUNGAL GENET BIOL, V37, P81, DOI 10.1016/S1087-1845(02)00034-8; Yamashiro S, 2003, CELL MOTIL CYTOSKEL, V55, P36, DOI 10.1002/cm.10109	55	111	112	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					426	435		10.1074/jbc.M607711200	http://dx.doi.org/10.1074/jbc.M607711200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17085436	hybrid			2022-12-27	WOS:000243166500048
J	Young, SG; Meta, M; Yang, SH; Fong, LG				Young, Stephen G.; Meta, Margarita; Yang, Shao H.; Fong, Loren G.			Prelamin A farnesylation and progeroid syndromes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NUCLEAR LAMIN-A; FARNESYLTRANSFERASE INHIBITOR; LMNA MUTATIONS; ZMPSTE24; PROTEIN; DISEASE; RAS; FIBROBLASTS; DEFICIENCY; MATURATION	Hutchinson-Gilford progeria syndrome (HGPS) is caused by a LMNA mutation that leads to the synthesis of a mutant prelamin A that is farnesylated but cannot be further processed to mature lamin A. A more severe progeroid disorder, restrictive dermopathy (RD), is caused by the loss of the prelamin A-processing enzyme, ZMPSTE24. The absence of ZMPSTE24 prevents the endoproteolytic processing of farnesyl-prelamin A to mature lamin A and leads to the accumulation of farnesyl-prelamin A. In both HGPS and RD, the farnesyl-prelamin A is targeted to the nuclear envelope, where it interferes with the integrity of the nuclear envelope and causes misshapen cell nuclei. Recent studies have shown that the frequency of misshapen nuclei can be reduced by treating cells with a farnesyltransferase inhibitor (FTI). Also, administering an FTI to mouse models of HGPS and RD ameliorates the phenotypes of progeria. These studies have prompted interest in testing the efficacy of FTIs in children with HGPS.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Young, SG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.	sgyoung@mednet.ucla.edu; lfong@mednet.ucla.edu		Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL086683, HL76839] Funding Source: Medline; NIAMS NIH HHS [AR050200, AR050966] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086683, R01HL076839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR050966, R01AR050200] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarwal AK, 2003, HUM MOL GENET, V12, P1995, DOI 10.1093/hmg/ddg213; Alsina M, 2004, BLOOD, V103, P3271, DOI 10.1182/blood-2003-08-2764; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Boyartchuk VL, 1998, GENETICS, V150, P95; Bracha K, 2002, J BIOL CHEM, V277, P29856, DOI 10.1074/jbc.M202916200; Broers JLV, 2006, PHYSIOL REV, V86, P967, DOI 10.1152/physrev.00047.2005; Capell BC, 2005, P NATL ACAD SCI USA, V102, P12879, DOI 10.1073/pnas.0506001102; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; Corrigan DP, 2005, BIOCHEM J, V387, P129, DOI 10.1042/BJ20041359; Csoka AB, 2004, AGING CELL, V3, P235, DOI 10.1111/j.1474-9728.2004.00105.x; Csoka AB, 2004, J MED GENET, V41, P304, DOI 10.1136/jmg.2003.015651; Dahl KN, 2006, P NATL ACAD SCI USA, V103, P10271, DOI 10.1073/pnas.0601058103; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; De Sandre-Giovannoli A, 2002, AM J HUM GENET, V70, P726, DOI 10.1086/339274; Delbarre E, 2006, HUM MOL GENET, V15, P1113, DOI 10.1093/hmg/ddl026; Denecke J, 2006, HUM MUTAT, V27, P524, DOI 10.1002/humu.20315; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Ferguson D, 2005, CLIN CANCER RES, V11, P3045, DOI 10.1158/1078-0432.CCR-04-2041; Fong LG, 2006, SCIENCE, V311, P1621, DOI 10.1126/science.1124875; Fong LG, 2004, P NATL ACAD SCI USA, V101, P18111, DOI 10.1073/pnas.0408558102; Fong LG, 2006, J CLIN INVEST, V116, P743, DOI 10.1172/JCI27125; Glynn MW, 2005, HUM MOL GENET, V14, P2959, DOI 10.1093/hmg/ddi326; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; HENNEKES H, 1994, J CELL SCI, V107, P1019; Izbicka E, 2005, ANTICANCER RES, V25, P3215; Izumi M, 2000, MOL BIOL CELL, V11, P4323, DOI 10.1091/mbc.11.12.4323; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Lammerding J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670; Lammerding J, 2006, J BIOL CHEM, V281, P25768, DOI 10.1074/jbc.M513511200; Leung GK, 2001, J BIOL CHEM, V276, P29051, DOI 10.1074/jbc.M102908200; LIN F, 1993, J BIOL CHEM, V268, P16321; Liu BH, 2005, NAT MED, V11, P780, DOI 10.1038/nm1266; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; Mallampalli MP, 2005, P NATL ACAD SCI USA, V102, P14416, DOI 10.1073/pnas.0503712102; Moulson CL, 2005, J INVEST DERMATOL, V125, P913, DOI 10.1111/j.0022-202X.2005.23846.x; Muchir A, 2004, MUSCLE NERVE, V30, P444, DOI 10.1002/mus.20122; Navarro CL, 2005, HUM MOL GENET, V14, P1503, DOI 10.1093/hmg/ddi159; Pendas AM, 2002, NAT GENET, V31, P94, DOI 10.1038/ng871; Raharjo WH, 2001, J CELL SCI, V114, P4447; Rusinol AE, 2006, J CELL SCI, V119, P3265, DOI 10.1242/jcs.03156; Scaffidi P, 2005, NAT MED, V11, P440, DOI 10.1038/nm1204; Shackleton S, 2005, J MED GENET, V42, DOI 10.1136/jmg.2004.029751; Shumaker DK, 2006, P NATL ACAD SCI USA, V103, P8703, DOI 10.1073/pnas.0602569103; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Toth JI, 2005, P NATL ACAD SCI USA, V102, P12873, DOI 10.1073/pnas.0505767102; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Varela I, 2005, NATURE, V437, P564, DOI 10.1038/nature04019; VARUGHAN OA, 2001, J CELL SCI, V114, P2577; WEBER K, 1989, FEBS LETT, V257, P411, DOI 10.1016/0014-5793(89)81584-4; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Yang SH, 2005, P NATL ACAD SCI USA, V102, P10291, DOI 10.1073/pnas.0504641102; Yang SH, 2006, J CLIN INVEST, V116, P2115, DOI 10.1172/JCI28968; Young SG, 2005, J LIPID RES, V46, P2531, DOI 10.1194/jlr.R500011-JLR200; YOUNG SG, 2005, ENZYMES, P273; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	58	89	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39741	39745		10.1074/jbc.R600033200	http://dx.doi.org/10.1074/jbc.R600033200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17090536	hybrid			2022-12-27	WOS:000243033900001
J	Jacobson, F; Pistorius, A; Farkas, D; De Grip, W; Hansson, O; Sjolin, L; Neutze, R				Jacobson, Frida; Pistorius, Arthur; Farkas, Daniel; De Grip, Willem; Hansson, Orjan; Sjolin, Lennart; Neutze, Richard			pH dependence of copper geometry, reduction potential, and nitrite affinity in nitrite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCALIGENES-FAECALIS S-6; X-RAY-STRUCTURE; INTRAMOLECULAR ELECTRON-TRANSFER; ATOMIC-RESOLUTION STRUCTURES; TYPE-2 COPPER; ACHROMOBACTER-CYCLOCLASTES; ACTIVE-SITE; MOLECULAR REPLACEMENT; ANGSTROM RESOLUTION; SUBSTRATE-BINDING	Many properties of copper-containing nitrite reductase are pH-dependent, such as gene expression, enzyme activity, and substrate affinity. Here we use x-ray diffraction to investigate the structural basis for the pH dependence of activity and nitrite affinity by examining the type 2 copper site and its immediate surroundings in nitrite reductase from Rhodobacter sphaeroides 2.4.3. At active pH the geometry of the substrate-free oxidized type 2 copper site shows a near perfect tetrahedral geometry as defined by the positions of its ligands. At higher pH values the most favorable copper site geometry is altered toward a more distorted tetrahedral geometry whereby the solvent ligand adopts a position opposite to that of the His-131 ligand. This pH-dependent variation in type 2 copper site geometry is discussed in light of recent computational results. When co-crystallized with substrate, nitrite is seen to bind in a bidentate fashion with its two oxygen atoms ligating the type 2 copper, overlapping with the positions occupied by the solvent ligand in the high and low pH structures. Fourier transformation infrared spectroscopy is used to assign the pH dependence of the binding of nitrite to the active site, and EPR spectroscopy is used to characterize the pH dependence of the reduction potential of the type 2 copper site. Taken together, these spectroscopic and structural observations help to explain the pH dependence of nitrite reductase, highlighting the subtle relationship between copper site geometry, nitrite affinity, and enzyme activity.	Chalmers, Dept Chem & Biol Engn, SE-40530 Gothenburg, Sweden; Radboud Univ Nijmegen, Dept Biochem, UMC 286, Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Univ Gothenburg, Dept Chem, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Dept Chem, SE-41296 Gothenburg, Sweden	Chalmers University of Technology; Radboud University Nijmegen; University of Gothenburg; University of Gothenburg	Neutze, R (corresponding author), Chalmers, Dept Chem & Biol Engn, Box 462, SE-40530 Gothenburg, Sweden.	richard.neutze@chembio.chalmers.se	Neutze, Richard/A-7573-2010; Pistorius, Arthur/ABB-1229-2021; Pistorius, Arthur MA/P-5780-2015; Sjolin, Lennart G/B-2619-2010; Hansson, Orjan/D-1282-2009; DeGrip, Willem/L-4335-2015	Neutze, Richard/0000-0003-0986-6153; Pistorius, Arthur/0000-0003-1865-4961; DeGrip, Willem/0000-0001-7637-4920				Abraham ZHL, 1997, BIOCHEM J, V324, P511, DOI 10.1042/bj3240511; ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; Antonyuk SV, 2005, P NATL ACAD SCI USA, V102, P12041, DOI 10.1073/pnas.0504207102; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett ML, 2004, BIOCHEMISTRY-US, V43, P16311, DOI 10.1021/bi048682g; Beaumont HJE, 2004, MOL MICROBIOL, V54, P148, DOI 10.1111/j.1365-2958.2004.04248.x; Boulanger MJ, 2002, J MOL BIOL, V315, P1111, DOI 10.1006/jmbi.2001.5251; Boulanger MJ, 2001, BIOCHEMISTRY-US, V40, P9132, DOI 10.1021/bi0107400; Boulanger MJ, 2000, J BIOL CHEM, V275, P23957, DOI 10.1074/jbc.M001859200; Dodd FE, 1997, ACTA CRYSTALLOGR D, V53, P406, DOI 10.1107/S0907444997002667; Ellis MJ, 2003, J MOL BIOL, V328, P429, DOI 10.1016/S0022-2836(03)00308-5; Ellis MJ, 2002, J MOL BIOL, V316, P51, DOI 10.1006/jmbi.2001.5304; Ellis MJ, 2001, ACTA CRYSTALLOGR D, V57, P1110, DOI 10.1107/S0907444901008654; Evans W, 1997, CHEM BRIT, V33, P22; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; Impagliazzo A, 2005, CHEMBIOCHEM, V6, P1648, DOI 10.1002/cbic.200500082; Inoue T, 1998, J BIOCHEM, V124, P876, DOI 10.1093/oxfordjournals.jbchem.a022201; Jacobson F, 2005, ACTA CRYSTALLOGR D, V61, P1190, DOI 10.1107/S0907444905017488; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kallrot N, 2005, INT J QUANTUM CHEM, V102, P520, DOI 10.1002/qua.20386; Kobayashi K, 1999, J BIOCHEM, V126, P408, DOI 10.1093/oxfordjournals.jbchem.a022465; Kukimoto M, 1996, J BIOL CHEM, V271, P13680, DOI 10.1074/jbc.271.23.13680; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LESLIE AGW, 1992, JNT CCP4 ESF EAMCB N, V26, P27; MURPHY MEP, 1995, BIOCHEMISTRY-US, V34, P12107, DOI 10.1021/bi00038a003; Murphy MEP, 1997, J BIOL CHEM, V272, P28455, DOI 10.1074/jbc.272.45.28455; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nurizzo D, 1997, STRUCTURE, V5, P1157, DOI 10.1016/S0969-2126(97)00267-0; Olesen K, 1998, BIOCHEMISTRY-US, V37, P6086, DOI 10.1021/bi971603z; SUZUKI S, 1994, J AM CHEM SOC, V116, P11145, DOI 10.1021/ja00103a035; Suzuki S, 1999, COORDIN CHEM REV, V190, P245, DOI 10.1016/S0010-8545(99)00069-7; Tocheva EI, 2004, SCIENCE, V304, P867, DOI 10.1126/science.1095109; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Veselov A, 1998, BIOCHEMISTRY-US, V37, P6095, DOI 10.1021/bi971604r; Wijma HJ, 2003, BIOCHEMISTRY-US, V42, P4075, DOI 10.1021/bi027270+; Zhao YW, 2002, BIOCHEMISTRY-US, V41, P7464, DOI 10.1021/bi0256274; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	40	62	61	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6347	6355		10.1074/jbc.M605746200	http://dx.doi.org/10.1074/jbc.M605746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17148448	Green Published, hybrid			2022-12-27	WOS:000244867200041
J	Gupta, A; Decaillot, FM; Gomes, I; Tkalych, O; Heimann, AS; Ferro, ES; Devi, LA				Gupta, Achla; Decaillot, Fabien M.; Gomes, Ivone; Tkalych, Oleg; Heimann, Andrea S.; Ferro, Erner S.; Devi, Lakshmi A.			Conformation state-sensitive antibodies to G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT CHANGES; DELTA-OPIOID RECEPTORS; MONOCLONAL-ANTIBODY; STRUCTURAL FEATURES; TERMINAL SEQUENCE; RHODOPSIN; BINDING; MU; AGONIST; ACTIVATION	A growing body of evidence indicates that G-protein-coupled receptors undergo complex conformational changes upon agonist activation. It is likely that the extracellular region, including the N terminus, undergoes activation-dependent conformational changes. We examined this by generating antibodies to regions within the N terminus of mu-opioid receptors. We find that antibodies to the midportion of the N-terminal tail exhibit enhanced recognition of activated receptors, whereas those to the distal regions do not. The enhanced recognition is abolished upon treatment with agents that block G-protein coupling or deglycosylate the receptor. This suggests that the N-terminal region of mu receptors undergoes conformational changes following receptor activation that can be selectively detected by these region-specific antibodies. We used these antibodies to characterize,mu receptor type-specific ligands and find that the antibodies accurately differentiate ligands with varying efficacies. Next, we examined if these antibodies can be used to investigate the extent and duration of activation of endogenous receptors. We find that peripheral morphine administration leads to a time-dependent increase in antibody binding in the striatum and prefrontal cortex with a peak at about 30 min, indicating that these antibodies can be used to probe the spatio-temporal dynamics of native mu receptors. Finally, we show that this strategy of targeting the N-terminal region to generate receptor conformation-specific antisera can be applied to other G alpha(i)-coupled (delta-opioid, CB1 cannabinoid, alpha(2A)-adrenergic) as well as G alpha(s)- (beta(2)-adrenergic) and G alpha(q)-coupled (AT1 angiotensin) receptors. Taken together, these studies describe antisera as tools that allow, for the first time, studies probing differential conformation states of G-protein-coupled receptors, which could be used to identify molecules of therapeutic interest.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; Proteimax SC, BR-06700020 Cotia, SP, Brazil; Univ Sao Paulo, Dept Cell & Dev Biol, BR-05504900 Sao Paulo, Brazil	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Universidade de Sao Paulo	Devi, LA (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, 19-84 Annenberg Bldg,1 Gustave L Levy Pl, New York, NY 10029 USA.	lakshmi.devi@mssm.edu	Devi P, Lakshmi/GXM-5982-2022; Ferro, Emer S/D-3908-2012	Devi P, Lakshmi/0000-0001-9274-4776; Ferro, Emer S/0000-0003-1651-9192	NIDA NIH HHS [DA19521, R37 DA008863, R01 DA008863, R56 DA008863, K05 DA019521, DA08863] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA008863, R56DA008863, R01DA008863, K05DA019521] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7945, DOI 10.1021/bi990014l; Archer E, 2003, TRENDS PHARMACOL SCI, V24, P36, DOI 10.1016/S0165-6147(02)00009-3; Blanpain C, 2002, MOL BIOL CELL, V13, P723, DOI 10.1091/mbc.01-03-0129; Bozon V, 2002, RECEPTOR CHANNEL, V8, P113, DOI 10.1080/10606820212394; Cha KW, 2000, P NATL ACAD SCI USA, V97, P3016, DOI 10.1073/pnas.97.7.3016; Decaillot FM, 2003, NAT STRUCT BIOL, V10, P629, DOI 10.1038/nsb950; Dhawan BN, 1996, PHARMACOL REV, V48, P567; Eitan S, 2003, J NEUROSCI, V23, P8360; Fadhil I, 2004, J BIOL CHEM, V279, P21069, DOI 10.1074/jbc.M311468200; Fang F, 1996, BRAIN RES, V722, P95, DOI 10.1016/0006-8993(96)00198-9; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fujisawa Y, 1999, J NEUROSCI, V19, P9618; GARZON J, 1994, LIFE SCI, V54, pPL191, DOI 10.1016/0024-3205(94)90167-8; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101; Gomes I, 2002, METHODS, V27, P358, DOI 10.1016/S1046-2023(02)00094-4; Gomes I, 1999, FEBS LETT, V456, P126, DOI 10.1016/S0014-5793(99)00878-9; Gouarderes C, 2000, EUR J PHARMACOL, V406, P391, DOI 10.1016/S0014-2999(00)00716-0; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lebesgue D, 1998, EUR J PHARMACOL, V348, P123, DOI 10.1016/S0014-2999(98)00136-8; Lecat S, 2002, J BIOL CHEM, V277, P42034, DOI 10.1074/jbc.M203606200; Levin MC, 2002, J BIOL CHEM, V277, P30429, DOI 10.1074/jbc.M200681200; Lu J, 1998, J IMMUNOL, V160, P1782; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MORGAN EL, 1993, J IMMUNOL, V151, P377; Mouledous L, 2000, J BIOL CHEM, V275, P29268, DOI 10.1074/jbc.M004971200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Peter JC, 2003, J BIOL CHEM, V278, P36740, DOI 10.1074/jbc.M306877200; Salle L, 2001, J MOL CELL CARDIOL, V33, P405, DOI 10.1006/jmcc.2000.1312; Scherrer G, 2004, EUR J NEUROSCI, V19, P2239, DOI 10.1111/j.0953-816X.2004.03339.x; Schmidt A, 2001, J BIOL CHEM, V276, P23373, DOI 10.1074/jbc.M100057200; Silve C, 2005, J BIOL CHEM, V280, P37917, DOI 10.1074/jbc.M506263200; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Takao M, 2002, ZOOL SCI, V19, P651, DOI 10.2108/zsj.19.651; Trapaidze N, 2000, DNA CELL BIOL, V19, P195, DOI 10.1089/104454900314465; Vaidehi N, 2002, P NATL ACAD SCI USA, V99, P12622, DOI 10.1073/pnas.122357199; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Wang DX, 2004, J PHARMACOL EXP THER, V308, P512, DOI 10.1124/jpet.103.054049; Xu W, 2001, BIOCHEMISTRY-US, V40, P8018, DOI 10.1021/bi002490d; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u	43	81	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5116	5124		10.1074/jbc.M609254200	http://dx.doi.org/10.1074/jbc.M609254200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17148456	hybrid, Green Accepted			2022-12-27	WOS:000244482300005
J	Fardeau, V; Lelandais, G; Oldfield, A; Salin, H; Lemoine, S; Garcia, M; Tanty, V; Le Crom, S; Jacq, C; Devaux, F				Fardeau, Vivienne; Lelandais, Gaelle; Oldfield, Andrew; Salin, Helene; Lemoine, Sophie; Garcia, Mathilde; Tanty, Veronique; Le Crom, Stephane; Jacq, Claude; Devaux, Frederic			The central role of PDR1 in the foundation of yeast drug resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION DATA; SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; TRANSCRIPTION FACTOR; GENOME-WIDE; NUCLEAR-LOCALIZATION; CANDIDA-ALBICANS; ABC TRANSPORTERS; IN-VIVO; STRESS	The widespread pleiotropic drug resistance (PDR) phenomenon is well described as the long term selection of genetic variants expressing constitutively high levels of membrane transporters involved in drug efflux. However, the transcriptional cascades leading to the PDR phenotype in wild-type cells are largely unknown, and the first steps of this phenomenon are poorly understood. We investigated the transcriptional mechanisms underlying the establishment of an efficient PDR response in budding yeast. We show that within a few minutes of drug sensing yeast elicits an effective PDR response, involving tens of PDR genes. This early PDR response (ePDR) is highly dependent on the Pdr1p transcription factor, which is also one of the major genetic determinants of long term PDR acquisition. The activity of Pdr1p in early drug response is not drug-specific, as two chemically unrelated drugs, benomyl and fluphenazine, elicit identical, Pdr1p-dependent, ePDR patterns. Our data also demonstrate that Pdr1p is an original stress response factor, the DNA binding properties of which do not depend on the presence of drugs. Thus, Pdr1p is a promoter-resident regulator involved in both basal expression and rapid drug-dependent induction of PDR genes.	Ecole Normale Super, Mol Genet Lab, CNRS, UMR8541, F-75230 Paris 05, France; INSERM, U368, Mol & Dev Biol Lab, F-75230 Paris 05, France; Ecole Normale Super, Plate Forme Transcriptome IFR36, F-75230 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Devaux, F (corresponding author), Ecole Normale Super, Mol Genet Lab, CNRS, UMR8541, F-75230 Paris 05, France.	devaux@biologie.ens.Fr	Oldfield, Andrew/ABF-1343-2021; Le Crom, Stéphane/P-4176-2016; DEVAUX, Frédéric/N-2288-2019; Oldfield, Andrew J./AAP-4354-2021	Oldfield, Andrew/0000-0002-5401-9909; Le Crom, Stéphane/0000-0002-0534-7797; DEVAUX, Frédéric/0000-0002-0039-9096; 				Akache B, 2002, J BIOL CHEM, V277, P21254, DOI 10.1074/jbc.M202566200; Azevedo D, 2003, FREE RADICAL BIO MED, V35, P889, DOI 10.1016/S0891-5849(03)00434-9; BALZI E, 1987, J BIOL CHEM, V262, P16871; Boorsma A, 2005, NUCLEIC ACIDS RES, V33, pW592, DOI 10.1093/nar/gki484; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; Cui Z, 1998, MOL MICROBIOL, V29, P1307, DOI 10.1046/j.1365-2958.1998.01027.x; Cyert MS, 2003, BIOCHEM BIOPH RES CO, V311, P1143, DOI 10.1016/S0006-291X(03)01552-3; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; Delahodde A, 2001, MOL MICROBIOL, V39, P304, DOI 10.1046/j.1365-2958.2001.02182.x; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Devaux F, 2002, FEBS LETT, V515, P25, DOI 10.1016/S0014-5793(02)02387-6; Devauz F, 2001, EMBO REP, V2, P493, DOI 10.1093/embo-reports/kve114; Edlind T, 2002, MOL MICROBIOL, V46, P257, DOI 10.1046/j.1365-2958.2002.03165.x; Gao C, 2004, J BIOL CHEM, V279, P42677, DOI 10.1074/jbc.M406363200; GARCIA M, 2007, YEAST MITOCHONDRIAL; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Golfier G, 2004, BIOINFORMATICS, V20, P1641, DOI 10.1093/bioinformatics/bth117; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Harismendy O, 2003, EMBO J, V22, P4738, DOI 10.1093/emboj/cdg466; Hellauer K, 2002, J BIOL CHEM, V277, P17671, DOI 10.1074/jbc.M201637200; Henry KW, 1999, ANTIMICROB AGENTS CH, V43, P1968, DOI 10.1128/AAC.43.8.1968; Hikkel I, 2003, J BIOL CHEM, V278, P11427, DOI 10.1074/jbc.M208549200; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Karababa M, 2006, MOL MICROBIOL, V59, P1429, DOI 10.1111/j.1365-2958.2005.05037.x; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Kellis M, 2004, J COMPUT BIOL, V11, P319, DOI 10.1089/1066527041410319; Kolaczkowska A, 1999, DRUG RESIST UPDATE, V2, P403, DOI 10.1054/drup.1999.0113; Kolaczkowski M, 2004, EUKARYOT CELL, V3, P880, DOI 10.1128/EC.3.4.880-892.2004; Kolaczkowski M, 1998, MICROB DRUG RESIST, V4, P143, DOI 10.1089/mdr.1998.4.143; Larochelle M, 2006, MOL CELL BIOL, V26, P6690, DOI 10.1128/MCB.02450-05; Le Crom S, 2002, MOL CELL BIOL, V22, P2642, DOI 10.1128/MCB.22.8.2642-2649.2002; Li XZ, 2004, DRUGS, V64, P159, DOI 10.2165/00003495-200464020-00004; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lucau-Danila A, 2005, MOL CELL BIOL, V25, P1860, DOI 10.1128/MCB.25.5.1860-1868.2005; Lucau-Danila A, 2003, J BIOL CHEM, V278, P52641, DOI 10.1074/jbc.M309580200; Mamnun YM, 2002, MOL MICROBIOL, V46, P1429, DOI 10.1046/j.1365-2958.2002.03262.x; Matta MAD, 2001, GENE, V272, P111, DOI 10.1016/S0378-1119(01)00558-3; Motohashi Noboru, 2000, Current Drug Targets, V1, P237, DOI 10.2174/1389450003349191; Moye-Rowley WS, 2003, PROG NUCLEIC ACID RE, V73, P251, DOI 10.1016/S0079-6603(03)01008-0; Onda M, 2004, GENE, V332, P51, DOI 10.1016/j.gene.2004.02.003; Owsianik G, 2002, MOL MICROBIOL, V43, P1295, DOI 10.1046/j.1365-2958.2002.02823.x; Prasad R, 2005, INT REV CYTOL, V242, P215; Sanglard D, 2003, MOL MICROBIOL, V48, P959, DOI 10.1046/j.1365-2958.2003.03495.x; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Souid AK, 2006, GENETICS, V173, P1919, DOI 10.1534/genetics.106.057596; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Teixeira MC, 2002, BIOCHEM BIOPH RES CO, V292, P530, DOI 10.1006/bbrc.2002.6691; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tutulan-Cunita AC, 2005, BIOSCI BIOTECH BIOCH, V69, P857, DOI 10.1271/bbb.69.857; Vaquerizas JM, 2005, NUCLEIC ACIDS RES, V33, pW616, DOI 10.1093/nar/gki500; Viladevall L, 2004, J BIOL CHEM, V279, P43614, DOI 10.1074/jbc.M403606200; Wehrschutz-Sigl E, 2004, EUR J BIOCHEM, V271, P1145, DOI 10.1111/j.1432-1033.2004.04018.x; WHITE CI, 1985, MOL GEN GENET, V201, P99, DOI 10.1007/BF00397993; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200; Zeitlinger J, 2003, CELL, V113, P395, DOI 10.1016/S0092-8674(03)00301-5; Zhang XT, 2001, J BIOL CHEM, V276, P8812, DOI 10.1074/jbc.M010686200	63	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					5063	5074		10.1074/jbc.M610197200	http://dx.doi.org/10.1074/jbc.M610197200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158869	hybrid			2022-12-27	WOS:000244482000089
J	Whitney, SM; Sharwood, RE				Whitney, Spencer M.; Sharwood, Robert E.			Linked Rubisco subunits can assemble into functional oligomers without impeding catalytic performance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; ESCHERICHIA-COLI; TOBACCO CHLOROPLASTS; KINETIC-PROPERTIES; PLASTID GENOME; RBCS GENE; PHOTOSYNTHESIS; OXYGENASE; 1,5-BISPHOSPHATE	Although transgenic manipulation in higher plants of the catalytic large subunit (L) of the photosynthetic CO2-fixing enzyme ribulose 1,5-bisphospahte carboxylase/oxygenase (Rubisco) is now possible, the manipulation of its cognate small subunit (S) is frustrated by the nuclear location of its multiple gene copies. To examine whether L and S can be engineered simultaneously by fusing them together, the subunits from Synechococcus PCC6301 Rubisco were tethered together by different linker sequences, producing variant fusion peptides. In Escherichia coli the variant PCC6301 LS fusions assembled into catalytically functional octameric ([LS](8)) and hexadecameric ([[LS](8)](2)) quaternary structures that excluded the integration of co-expressed unfused S. Assembly of the LS fusions into Rubisco complexes was impaired 50-90% relative to the assembly of unlinked L and S into L8S8. enzyme. Assembly in E. coli was not emulated using tobacco SL fusions that accumulated entirely as insoluble protein. Catalytic measurements showed the CO2/O-2 specificity, carboxylation rate, and Michaelis constants for CO2 and ribulose 1,5-bisphosphate for the cyanobacterial Rubisco complexes comprising fusions where the S was linked to the N terminus of L closely matched those of the wild-type L,S, enzyme. In contrast, the substrate affinities and carboxylation rate of the Rubisco complexes comprising fusions where L was fused to the N terminus of S or a six-histidine tag was appended to the C terminus of L were compromised. Overall this work provides a framework for implementing an alternative strategy for exploring simultaneous engineering of modified, or foreign, Rubisco L and S subunits in higher plant plastids.	Australian Natl Univ, Res Sch Biol Sci, M, Canberra, ACT 2601, Australia	Australian National University	Whitney, SM (corresponding author), Australian Natl Univ, Res Sch Biol Sci, M, POB 475, Canberra, ACT 2601, Australia.	spencer.whitney@anu.edu.au	Whitney, Spencer M/C-9266-2009	Whitney, Spencer M/0000-0003-2954-2359; Sharwood, Robert/0000-0003-4993-3816				Andrews TJ, 2003, ARCH BIOCHEM BIOPHYS, V414, P159, DOI 10.1016/S0003-9861(03)00100-0; ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; Dhingra A, 2004, P NATL ACAD SCI USA, V101, P6315, DOI 10.1073/pnas.0400981101; Duff AP, 2000, J MOL BIOL, V298, P903, DOI 10.1006/jmbi.2000.3724; Emlyn-Jones D, 2006, PLANT CELL PHYSIOL, V47, P1630, DOI 10.1093/pcp/pcl028; Farr GW, 2003, EMBO J, V22, P3220, DOI 10.1093/emboj/cdg313; GATENBY AA, 1992, PLANT MOL BIOL, V19, P677, DOI 10.1007/BF00026793; GATENBY AA, 1984, EUR J BIOCHEM, V144, P361, DOI 10.1111/j.1432-1033.1984.tb08472.x; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GUTTERIDGE S, 1986, BIOCHEM SOC T, V14, P28, DOI 10.1042/bst0140028; Houtz RL, 2003, ARCH BIOCHEM BIOPHYS, V414, P150, DOI 10.1016/S0003-9861(03)00122-X; Kane HJ, 1998, PLANT PHYSIOL, V117, P1059, DOI 10.1104/pp.117.3.1059; KANE HJ, 1994, AUST J PLANT PHYSIOL, V21, P449, DOI 10.1071/PP9940449; Kanevski I, 1999, PLANT PHYSIOL, V119, P133, DOI 10.1104/pp.119.1.133; KANEVSKI I, 1994, P NATL ACAD SCI USA, V91, P1969, DOI 10.1073/pnas.91.5.1969; KETTLEBOROUGH CA, 1990, J EXP BOT, V41, P1287, DOI 10.1093/jxb/41.10.1287; LARIMER FW, 1993, GENE, V126, P85, DOI 10.1016/0378-1119(93)90593-R; Long SP, 2006, PLANT CELL ENVIRON, V29, P315, DOI 10.1111/j.1365-3040.2005.01493.x; MORELL MK, 1994, J BIOL CHEM, V269, P8091; MORELL MK, 1992, AUST J BOT, V40, P431, DOI 10.1071/BT9920431; Parry MAJ, 2003, J EXP BOT, V54, P1321, DOI 10.1093/jxb/erg141; PAUL K, 1991, BIOCHEMISTRY-US, V30, P10019, DOI 10.1021/bi00105a029; Pearce FG, 2006, BIOCHEM J, V399, P525, DOI 10.1042/BJ20060430; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; PORTIS AR, 1990, ARCH BIOCHEM BIOPHYS, V283, P397, DOI 10.1016/0003-9861(90)90660-Q; Raines CA, 2006, PLANT CELL ENVIRON, V29, P331, DOI 10.1111/j.1365-3040.2005.01488.x; Roy Harry, 2000, VVolume 9, P53; Ruuska S, 1998, AUST J PLANT PHYSIOL, V25, P859, DOI 10.1071/PP98079; Spreitzer RJ, 2005, P NATL ACAD SCI USA, V102, P17225, DOI 10.1073/pnas.0508042102; Spreitzer RJ, 2003, ARCH BIOCHEM BIOPHYS, V414, P141, DOI 10.1016/S0003-9861(03)00171-1; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Taylor TC, 1997, J MOL BIOL, V265, P432, DOI 10.1006/jmbi.1996.0738; Tcherkez GGB, 2006, P NATL ACAD SCI USA, V103, P7246, DOI 10.1073/pnas.0600605103; Whitney SM, 1999, PLANT PHYSIOL, V121, P579, DOI 10.1104/pp.121.2.579; Whitney SM, 2003, PLANT PHYSIOL, V133, P287, DOI 10.1104/pp.103.026146; Whitney SM, 2001, P NATL ACAD SCI USA, V98, P14738, DOI 10.1073/pnas.261417298; Whitney SM, 2001, PLANT J, V26, P535, DOI 10.1046/j.1365-313x.2001.01056.x; Whitney SM, 2001, PLANT CELL, V13, P193, DOI 10.1105/tpc.13.1.193; Zhang XH, 2002, PLANT CELL PHYSIOL, V43, P1302, DOI 10.1093/pcp/pcf158; Zhu GH, 1998, PHOTOSYNTH RES, V57, P71, DOI 10.1023/A:1006020424581; Zhu XG, 2004, PLANT CELL ENVIRON, V27, P155, DOI 10.1046/j.1365-3040.2004.01142.x	42	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3809	3818		10.1074/jbc.M610479200	http://dx.doi.org/10.1074/jbc.M610479200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150955	hybrid			2022-12-27	WOS:000244481900044
J	Harris, EN; Kyosseva, SV; Weigel, JA; Weigel, PH				Harris, Edward N.; Kyosseva, Svetlana V.; Weigel, Janet A.; Weigel, Paul H.			Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ENDOTHELIAL-CELLS; CHONDROITIN SULFATE PROTEOGLYCAN; RAT-LIVER; LIGAND-BINDING; PROTEINS; TISSUE; IDENTIFICATION; STABILIN-1; HYPEROSMOLARITY; LOCALIZATION	The hyaluronic acid ( HA) receptor for endocytosis ( HARE; also designated stabilin-2 and FEEL-2) mediates systemic clearance of glycosaminoglycans from the circulatory and lymphatic systems via coated pit-mediated uptake. HARE is primarily found as two isoforms (315- and 190-kDa) in sinusoidal endothelial cells of the liver, lymph node, and spleen. Here we characterize the ligand specificity and function of the large stably expressed 315- HARE isoform in Flp-In 293 cell lines. Like human spleen sinusoidal endothelial cells, Flp-In 293 cell lines transfected with a single cDNA encoding the full-length 315- HARE express both the 315-kDa and the proteolytically truncated 190-kDa isoforms in a ratio of similar to 3-4:1. The 190-kDa HARE isoform generated from the 315-kDa HARE and the 315-kDa HARE specifically bound I-125-HA. Like the 190-kDa HARE expressed alone (Harris, E. N., Weigel, J. A., and Weigel, P. H. (2004) J. Biol. Chem. 279, 36201-36209), the 190- and 315-kDa HARE isoforms expressed in 315-HARE cell lines were recognized by anti-HARE monoclonal antibodies 30, 154, and 159. All 315-HARE cell lines could endocytose and degrade I-125-HA. Competition studies with live cells indicate that 190- HARE and 315- HARE bind HA with higher apparent affinity (Kd similar to 10-20 nM) than chondroitin sulfate (CS) types A, C, D, or E. Only slight competition of HA endocytosis was observed with CS-B (dermatan sulfate) and chondroitin. Direct binding assays with the 315-HARE ectodomain revealed high affinity HA binding, and lower binding affinities for CS-C, CS-D, and CS-E. A majority of each HARE isoform was intracellular, within the endocytic system, suggesting transient surface residency typical of an active endocytic recycling receptor.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@ouhc.edu	Harris, Edward N/A-1596-2011		NIGMS NIH HHS [GM69961] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069961] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abatangelo G., 2000, REDEFINING HYALURONA; ASARI A, 1994, J HISTOCHEM CYTOCHEM, V42, P513, DOI 10.1177/42.4.8126377; Balazs E A, 1972, Mod Probl Ophthalmol, V10, P3; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; ERIKSSON S, 1983, EXP CELL RES, V144, P223, DOI 10.1016/0014-4827(83)90458-5; Falkowski M, 2003, HISTOCHEM CELL BIOL, V120, P361, DOI 10.1007/s00418-003-0585-5; FRASER JRE, 1983, CELL TISSUE RES, V233, P285; FRASER JRE, 1981, BIOCHEM J, V200, P415, DOI 10.1042/bj2000415; FRASER JRE, 1985, CELL TISSUE RES, V242, P505; Hansen B, 2005, EXP CELL RES, V303, P160, DOI 10.1016/j.yexcr.2004.09.017; Harris EN, 2004, J BIOL CHEM, V279, P36201, DOI 10.1074/jbc.M405322200; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laurent T.C., 1991, DEGRADATION BIOACTIV, P249; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; Matsui Fumiko, 2004, Congenital Anomalies, V44, P181, DOI 10.1111/j.1741-4520.2004.00038.x; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; McGary CT, 2003, METHOD ENZYMOL, V363, P354; MCGARY CT, 1993, HEPATOLOGY, V18, P1465, DOI 10.1002/hep.1840180628; Meyer K, 1934, J BIOL CHEM, V107, P629; Moller HJ, 1998, SCAND J CLIN LAB INV, V58, P269, DOI 10.1080/00365519850186445; Nishida Y, 2005, EXP CELL RES, V307, P194, DOI 10.1016/j.yexcr.2005.03.026; OKA JA, 1989, J BIOL CHEM, V264, P12016; OKA JA, 1988, J CELL BIOCHEM, V36, P169, DOI 10.1002/jcb.240360208; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; Prevo R, 2004, J BIOL CHEM, V279, P52580, DOI 10.1074/jbc.M406897200; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; Rapp A, 2006, BIOCHIMIE, V88, P473, DOI 10.1016/j.biochi.2005.10.007; SMEDSROD B, 1990, BIOCHEM J, V266, P313, DOI 10.1042/bj2660313; Smedsrod B, 2003, GLYCOBIOLOGY, V13, p11G, DOI 10.1093/glycob/cwg056; SMEDSROD B, 1988, CELL TISSUE RES, V253, P39; Tamura Y, 2003, J BIOL CHEM, V278, P12613, DOI 10.1074/jbc.M210211200; Tonnaer ELGM, 2006, MICROBES INFECT, V8, P316, DOI 10.1016/j.micinf.2005.06.028; Toole BP, 2002, AM J PATHOL, V161, P745, DOI 10.1016/S0002-9440(10)64232-0; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; TZAICOS C, 1989, BIOCHEM J, V264, P823, DOI 10.1042/bj2640823; Ulbrich SE, 2004, MOL CELL ENDOCRINOL, V214, P9, DOI 10.1016/j.mce.2003.12.002; Weigel JA, 2003, J BIOL CHEM, V278, P42802, DOI 10.1074/jbc.M307201200; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; Weigel PH, 2003, GLYCOBIOLOGY, V13, p12G, DOI 10.1093/glycob/cwg057; Weigel PH, 2002, BBA-GEN SUBJECTS, V1572, P341, DOI 10.1016/S0304-4165(02)00318-5; WEISSMANN B, 1954, J BIOL CHEM, V208, P417; YannarielloBrown J, 1997, GLYCOBIOLOGY, V7, P15, DOI 10.1093/glycob/7.1.15; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055; YANNARIELLOBROWN J, 1992, J CELL BIOCHEM, V48, P73, DOI 10.1002/jcb.240480111; YU Q, 1995, BIOTECHNIQUES, V19, P122; Zhou B, 1999, J BIOL CHEM, V274, P33831, DOI 10.1074/jbc.274.48.33831; Zhou B, 2003, GLYCOBIOLOGY, V13, P339, DOI 10.1093/glycob/cwg029; Zhou B, 2002, MOL BIOL CELL, V13, P2853, DOI 10.1091/mbc.02-03-0048; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200	57	94	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2785	2797		10.1074/jbc.M607787200	http://dx.doi.org/10.1074/jbc.M607787200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145755	hybrid, Green Submitted			2022-12-27	WOS:000243793900005
J	Liu, YS; Jiang, N; Wu, JY; Dai, W; Rosenblum, JS				Liu, Yongsheng; Jiang, Ning; Wu, Jiangyue; Dai, Wei; Rosenblum, Jonathan S.			Polo-like kinases inhibited by Wortmannin - Labeling site and downstream effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE/THREONINE KINASE; PROGNOSTIC-SIGNIFICANCE; PLK EXPRESSION; APOPTOSIS; CARCINOMAS; PLX1; PHOSPHORYLATION	Polo-like kinases play crucial roles throughout mitosis. We previously reported that wortmannin potently inhibits Polo-like kinase 1 (Plk1). In this study, we show that wortmannin also strongly inhibits Polo-like kinase 3 (Plk3). To further characterize this inhibition, we identified the sites of labeling on Plk1 and Plk3 targeted by AX7503, a tetramethylrhodamine-wortmannin conjugate. AX7503 labeling on Plk1 and Plk3 was found to occur on a conserved ATP binding site residue. In addition, we show that wortmannin inhibits Plk3 activity in live cells at concentrations commonly used to inhibit the more well known targets of wortmannin, the phosphoinositide 3-kinases. Importantly, we found that inhibition of Plk3 by wortmannin lead to a decrease in phosphorylation of p53 on serine 20 induced by DNA damage, demonstrating the effect of wortmannin on a downstream Plk3 target. Taken together, our results suggest that wortmannin can affect multiple functions of Plk3 in cell cycle progression and at the DNA damage check point. The identification of the labeling sites of Plk1 and Plk3 by AX7503 may be useful in designing more effective compounds to target Polo-like kinases for cancer treatment and also may be useful for the structural study of Plk domains.	NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA; ActivX Biosci Inc, La Jolla, CA 92037 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	New York University; Kyorin Pharmaceutical Co Ltd; New York Medical College	Dai, W (corresponding author), NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA.	wei.dai@med.nyu.edu; jonr@activx.com		Dai, Wei/0000-0003-0169-8327; Rosenblum, Jonathan/0000-0002-7318-0896	NATIONAL CANCER INSTITUTE [R01CA074229, R44CA097462] Funding Source: NIH RePORTER; NCI NIH HHS [5R44-CA097462, R01-CA74229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Abrieu A, 1998, J CELL SCI, V111, P1751; Adam GC, 2004, J AM CHEM SOC, V126, P1363, DOI 10.1021/ja038441g; Adam GC, 2001, CHEM BIOL, V8, P81, DOI 10.1016/S1074-5521(00)90060-7; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2005, ONCOGENE, V24, P214, DOI 10.1038/sj.onc.1208270; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Liu YS, 2005, CHEM BIOL, V12, P99, DOI 10.1016/j.chembiol.2004.11.009; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Okerberg ES, 2005, P NATL ACAD SCI USA, V102, P4996, DOI 10.1073/pnas.0501205102; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; YANO H, 1993, J BIOL CHEM, V268, P25846	34	61	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2505	2511		10.1074/jbc.M609603200	http://dx.doi.org/10.1074/jbc.M609603200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135248	hybrid			2022-12-27	WOS:000243593200042
J	Malmlof, M; Roudier, E; Hogberg, J; Stenius, U				Malmlof, Maria; Roudier, Emilie; Hogberg, Johan; Stenius, Ulla			MEK-ERK-mediated phosphorylation of Mdm2 at Ser-166 in hepatocytes - Mdm2 is activated in response to inhibited Akt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-B; P53; RAF; PATHWAY; GROWTH; CELLS; UBIQUITINATION; APOPTOSIS; DIFFERENTIATION; CYTOPLASM	Mdm2 inactivates the tumor suppressor p53 and Akt has been shown to be a major activator of Mdm2 in many cell types. We have investigated the regulation of Mdm2 in hepatocytes. We found that growth factor-induced Ser-166 phosphorylation of Mdm2 was inhibited by the MEK inhibitors U0126 and PD98059 in HepG2 cells and in a rat liver cell line, TRL 1215. Also, bile acids and oxidative stress induced phosphorylation of Mdm2 at Ser-166 by an apparently MEK-ERK-dependent mechanism. In contrast, Ser-166 phosphorylation of Mdm2 in lung cells was mediated by Akt. Further studies revealed that phosphatidylinositol 3-kinase inhibitors LY294002 and wortmannin induced phosphorylated ERK Tyr-204 and pMdm2 Ser-166 phosphorylations in hepatocytes in culture and in rat hepatocytes in vivo. In HepG2 cells, this effect was inhibited by U0126 and PD98059. LY294002 also reduced the level of pRaf Ser-259. Furthermore, we have shown that myr-Akt-induced overexpression of pAkt suppressed the levels of pMdm2 Ser-166 in hepatocytes. These data indicate a reversed relationship between Akt and Mdm2 in hepatocytes and suggest that Akt is a negative regulator of Raf-MEK-ERK-Mdm2 in this cell type. Ser-166 phosphorylation of Mdm2 has been shown to increase its ubiquitin ligase activity and increase p53 degradation, and our data indicated an attenuated p53 response to DNA damage in hepatocytes exhibiting high levels of pMdm2 Ser-166. Taken together, our data indicate that Mdm2 phosphorylation is regulated via MEK-ERK in hepatocytes. This Mdm2 signaling might be important for the regeneration of hepatocytes after centrilobular cell death.	Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden	Karolinska Institutet	Stenius, U (corresponding author), Karolinska Inst, Inst Environm Med, Box 210, S-17177 Stockholm, Sweden.	ulla.stenius@ki.se						Baccarini M, 2005, FEBS LETT, V579, P3271, DOI 10.1016/j.febslet.2005.03.024; Bar J, 2005, CELL DEATH DIFFER, V12, P1578, DOI 10.1038/sj.cdd.4401677; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Dent P, 2005, HEPATOLOGY, V42, P1291, DOI 10.1002/hep.20942; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Finnberg N, 2004, CARCINOGENESIS, V25, P113, DOI 10.1093/carcin/bgg185; Galabova-Kovacs G, 2006, P NATL ACAD SCI USA, V103, P1325, DOI 10.1073/pnas.0507399103; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; He L, 2006, J BIOL CHEM, V281, P11126, DOI 10.1074/jbc.M510724200; IDOINE JB, 1976, IN VITRO CELL DEV B, V12, P541; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Moll UM, 2003, MOL CANCER RES, V1, P1001; MORNAND J, 1992, CELL, V69, P1237; Myhre O, 2004, TOXICOL SCI, V80, P296, DOI 10.1093/toxsci/kfh166; O'Neill EE, 2005, CANCER RES, V65, P5485, DOI 10.1158/0008-5472.CAN-05-1453; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Paajarvi G, 2004, FASEB J, V18, P476, DOI 10.1096/fj.04-2745fje; Paajarvi G, 2005, CARCINOGENESIS, V26, P201, DOI 10.1093/carcin/bgh289; Phelps M, 2005, J BIOL CHEM, V280, P16651, DOI 10.1074/jbc.M412334200; Phillips A, 2006, FEBS LETT, V580, P300, DOI 10.1016/j.febslet.2005.12.026; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rosseland CM, 2005, HEPATOLOGY, V42, P200, DOI 10.1002/hep.20762; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl GM, 2006, CELL DEATH DIFFER, V13, P973, DOI 10.1038/sj.cdd.4401911; Wang ZQ, 2005, J CELL PHYSIOL, V203, P510, DOI 10.1002/jcp.20243; Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	37	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2288	2296		10.1074/jbc.M604953200	http://dx.doi.org/10.1074/jbc.M604953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17107963	hybrid			2022-12-27	WOS:000243593200020
J	Wajih, N; Hutson, SM; Wallin, R				Wajih, Nadeem; Hutson, Susan M.; Wallin, Reidar			Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum - A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K-1 2,3-epoxide reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYLATION SYSTEM; EPOXIDE REDUCTASE; PROLYL 4-HYDROXYLASE; WARFARIN RESISTANCE; ACTIVE-SITE; THIOREDOXIN; INHIBITION; METABOLISM; MECHANISM; MEMBRANE	gamma-Carboxylation of vitamin K-dependent proteins is dependent on formation of reduced vitamin K-1(Vit. K1H2) in the endoplasmic reticulum (ER), where it works as an essential cofactor for gamma-carboxylase in post-translational gamma-carboxylation of vitamin K-dependent proteins. Vit. K1H2 is produced by the warfarin-sensitive enzyme vitamin K 2,3-epoxide reductase (VKOR) of the vitamin K cycle that has been shown to harbor a thiore-doxin-like CXXC center involved in reduction of vitamin K-1 2,3-epoxide (Vit. K > O). However, the cellular system providing electrons to the center is unknown. Here data are presented that demonstrate that reduction is linked to dithiol-dependent oxidative folding of proteins in the ER by protein disulfide isomerase (PDI). Oxidative folding of reduced RNase is shown to trigger reduction of Vit. K > O and gamma-carboxylation of the synthetic gamma-carboxylase peptide substrate FLEEL. In liver microsomes, reduced RNase-triggered gamma-carboxylation is inhibited by the PDI inhibitor bacitracin and also by small interfering RNA silencing of PDI in HEK 293 cells. Immunoprecipitation and two-dimensional SDS-PAGE of microsomal membrane proteins demonstrate the existence of a VKOR enzyme complex where PDI and VKORC1 appear to be tightly associated subunits. We propose that the PDI subunit of the complex provides electrons for reduction of the thioredoxin-like CXXC center in VKORC1. We can conclude that the energy required for gamma-carboxylation of proteins is provided by dithiol-dependent oxidative protein folding in the ER and thus is linked to de novo protein synthesis.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Wallin, R (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	rwallin@wfubmc.edu	Wajih, Nadeem/GMW-6625-2022		NHLBI NIH HHS [R01HL69931] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahamed J, 2006, P NATL ACAD SCI USA, V103, P13932, DOI 10.1073/pnas.0606411103; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; Dias-Gunasekara S, 2005, J BIOL CHEM, V280, P33066, DOI 10.1074/jbc.M505023200; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; FASCO MJ, 1983, BIOCHEMISTRY-US, V22, P5655, DOI 10.1021/bi00293a031; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1992, NEW ENGL J MED, V326, P800; Goodstadt L, 2004, TRENDS BIOCHEM SCI, V29, P289, DOI 10.1016/j.tibs.2004.04.004; Gross E, 2006, P NATL ACAD SCI USA, V103, P299, DOI 10.1073/pnas.0506448103; Janiszewski M, 2005, J BIOL CHEM, V280, P40813, DOI 10.1074/jbc.M509255200; Koivunen P, 2005, J BIOL CHEM, V280, P5227, DOI 10.1074/jbc.M412480200; LEE JJ, 1984, BIOCHEMISTRY-US, V23, P2246, DOI 10.1021/bi00305a024; Li T, 2004, NATURE, V427, P541, DOI 10.1038/nature02254; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; Orlandi PA, 1997, J BIOL CHEM, V272, P4591; Papp E, 2005, BIOCHEM BIOPH RES CO, V338, P938, DOI 10.1016/j.bbrc.2005.10.027; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PREUSCH PC, 1992, FEBS LETT, V305, P257, DOI 10.1016/0014-5793(92)80681-6; Rost S, 2005, THROMB HAEMOSTASIS, V94, P780, DOI 10.1160/TH05-02-0082; Rost S, 2004, NATURE, V427, P537, DOI 10.1038/nature02214; RUPP K, 1994, J BIOL CHEM, V269, P2501; RUSTAEUS P, 1988, J BIOL CHEM, V273, P5196; Schlee M, 2006, MOL THER, V14, P463, DOI 10.1016/j.ymthe.2006.06.001; SILVERMAN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1248, DOI 10.1016/S0006-291X(88)81274-9; SOUTE BAM, 1992, BIOCHEM J, V281, P255, DOI 10.1042/bj2810255; Stafford DW, 2005, J THROMB HAEMOST, V3, P1873, DOI 10.1111/j.1538-7836.2005.01419.x; THIJSSEN HHW, 1994, BIOCHEM J, V297, P277, DOI 10.1042/bj2970277; Tian G, 2006, CELL, V124, P61, DOI 10.1016/j.cell.2005.10.044; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Wajih N, 2005, J BIOL CHEM, V280, P31603, DOI 10.1074/jbc.M505373200; Wajih N, 2005, J BIOL CHEM, V280, P10540, DOI 10.1074/jbc.M413982200; Wajih N, 2004, J BIOL CHEM, V279, P43052, DOI 10.1074/jbc.M407180200; Wajih N, 2004, J BIOL CHEM, V279, P25276, DOI 10.1074/jbc.M401645200; WALLIN R, 1985, J CLIN INVEST, V76, P1879, DOI 10.1172/JCI112182; Wallin R, 2004, TRENDS MOL MED, V10, P299, DOI 10.1016/j.molmed.2004.05.003; Wallin R, 2002, THROMB RES, V108, P221, DOI 10.1016/S0049-3848(03)00060-4; Wallin R, 2001, FASEB J, V15, P2542, DOI 10.1096/fj.01-0337fje; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017	40	112	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2626	2635		10.1074/jbc.M608954200	http://dx.doi.org/10.1074/jbc.M608954200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17124179	hybrid			2022-12-27	WOS:000243593200055
J	Xu, XL; Rao, G; Quiros, RM; Kim, AW; Miao, HQ; Brunn, GJ; Platt, JL; Gattuso, P; Prinz, RA				Xu, Xiulong; Rao, Geetha; Quiros, Roderick M.; Kim, Anthony W.; Miao, Hua-Quan; Brunn, Gregory J.; Platt, Jeffrey L.; Gattuso, Paolo; Prinz, Richard A.			In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas - Loss of cell surface hs suppresses fibroblast growth factor 2-mediated cell signaling and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; CANCER-CELLS; MAMMALIAN HEPARANASE; TUMOR PROGRESSION; GENE-EXPRESSION; BREAST-CANCER; METASTASIS; ANGIOGENESIS; CARCINOMA; INVASION	Heparan sulfate proteoglycans (HSPGs) function as a co-receptor for heparin-binding growth factors, such as fibroblast growth factors (FGFs) and heparin-bound epidermal growth factor (HB-EGF). The HS side chain of HSPGs can be cleaved by HPR1 (heparanase-1), an endoglycosidase that is overexpressed in many types of malignancies. In the present study, we demonstrated that HPR1 expression in pancreatic adenocarcinomas inversely correlated with the presence of heparan sulfate (HS) in the basement membrane. In vitro cell culture study revealed that cell surface HS levels inversely correlated with HPR1 activity in five pancreatic cancer cell lysates and their conditioned media. Heparin and PI-88, two HPR1 inhibitors, were able to increase cell surface HS levels in PANC-1 cells in a dose-dependent manner. The ability of HPR1 to degrade cell surface HS was confirmed by showing that cell surface HS levels were increased in HT1080 cells stably transfected with the HPR1 antisense gene but was decreased in the cells overexpressing HPR1. Further studies showed that PI-88 and heparin were able to stimulate PANC-1 cell proliferation in the absence or presence of exogenous FGF2, whereas exogenous HPR1 was able to inhibit PANC-1 cell proliferation in a dose-dependent manner. Modulation of PANC-1 cell proliferation by HPR1 or HPR1 inhibitors corresponded with the inhibition or activation of the mitogen-activated protein kinase. Our results suggest that HPR1 expressed in pancreatic adenocarcinomas can suppress the proliferation of pancreatic tumor cells in response to the growth factors that require HSPGs as their co-receptors.	Rush Univ, Med Ctr, Dept Gen Surg, Chicago, IL 60612 USA; Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA; ImClone Syst Inc, New York, NY 10014 USA; Mayo Clin, Dept Surg, Rochester, MN 55905 USA; Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Dept Pediat, Rochester, MN 55905 USA	Rush University; Rush University; Eli Lilly; Mayo Clinic; Mayo Clinic; Mayo Clinic	Xu, XL (corresponding author), Rush Univ, Med Ctr, Dept Gen Surg, 1653 W Congress Pkwy, Chicago, IL 60612 USA.	xxu@rush.edu	Platt, Jeffrey/AHB-0480-2022	Platt, Jeffrey/0000-0002-4915-0419	NHLBI NIH HHS [HL46810] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046810] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Conejo JR, 2000, INT J CANCER, V88, P12, DOI 10.1002/1097-0215(20001001)88:1<12::AID-IJC3>3.0.CO;2-T; Delehedde M, 2000, J BIOL CHEM, V275, P33905, DOI 10.1074/jbc.M005949200; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Ellenrieder V, 1999, ANN ONCOL, V10, P46, DOI 10.1023/A:1008380501633; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Fasciano S, 2005, J BIOL CHEM, V280, P15682, DOI 10.1074/jbc.M411458200; Francis DJ, 2003, CIRC RES, V92, pE70, DOI 10.1161/01.RES.0000071345.76095.07; Garg HG, 2000, AM J PHYSIOL-LUNG C, V279, pL779, DOI 10.1152/ajplung.2000.279.5.L779; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Ihrcke NS, 1998, J CELL PHYSIOL, V175, P255, DOI 10.1002/(SICI)1097-4652(199806)175:3<255::AID-JCP3>3.0.CO;2-N; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Ishida K, 2004, MOL CANCER THER, V3, P1069; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; Joyce JA, 2005, ONCOGENE, V24, P4037, DOI 10.1038/sj.onc.1208602; Kim AW, 2002, J GASTROINTEST SURG, V6, P167, DOI 10.1016/S1091-255X(01)00087-7; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Koliopanos A, 2001, CANCER RES, V61, P4655; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Matsuda K, 2001, CANCER RES, V61, P5562; Maxhimer JB, 2005, J AM COLL SURGEONS, V200, P328, DOI 10.1016/j.jamcollsurg.2004.10.034; Maxhimer JB, 2002, SURGERY, V132, P326, DOI 10.1067/msy.2002.125719; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; Mundhenke C, 2002, AM J PATHOL, V160, P185, DOI 10.1016/S0002-9440(10)64362-3; Nackaerts K, 1997, INT J CANCER, V74, P335, DOI 10.1002/(SICI)1097-0215(19970620)74:3<335::AID-IJC18>3.3.CO;2-4; Ohkawa T, 2004, LAB INVEST, V84, P1289, DOI 10.1038/labinvest.3700159; Parish CR, 1999, CANCER RES, V59, P3433; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; Patel RC, 2002, ARTERIOSCL THROM VAS, V22, P1439, DOI 10.1161/01.ATV.0000028817.20351.FE; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Quiros RM, 2006, CANCER-AM CANCER SOC, V106, P532, DOI 10.1002/cncr.21648; Reiland J, 2004, J BIOL CHEM, V279, P8047, DOI 10.1074/jbc.M304872200; Rohloff J, 2002, BRIT J CANCER, V86, P1270, DOI 10.1038/sj.bjc.6600232; Schubert SY, 2004, LAB INVEST, V84, P535, DOI 10.1038/labinvest.3700084; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; Takaoka M, 2003, LAB INVEST, V83, P613, DOI 10.1097/01.LAB.0000067482.84946.BD; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tumova S, 1997, J BIOL CHEM, V272, P9078; Vlodavsky I, 2003, PATHOPHYSIOL HAEMO T, V33, P59, DOI 10.1159/000073296; Vlodavsky I, 2002, SEMIN CANCER BIOL, V12, P121, DOI 10.1006/scbi.2001.0420; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Xu XL, 2003, CLIN CANCER RES, V9, P5968; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	45	23	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2363	2373		10.1074/jbc.M604218200	http://dx.doi.org/10.1074/jbc.M604218200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121850	hybrid			2022-12-27	WOS:000243593200028
J	de Barros, CM; Andrade, LR; Allodi, S; Viskov, C; Mourier, PA; Cavalcante, MCM; Straus, AH; Takahashi, HK; Pomin, VH; Carvalho, VF; Martins, MA; Pavao, MSG				de Barros, Cintia M.; Andrade, Leonardo R.; Allodi, Silvana; Viskov, Christian; Mourier, Pierre A.; Cavalcante, Moises C. M.; Straus, Anita H.; Takahashi, Helio K.; Pomin, Vitor H.; Carvalho, Vinicius F.; Martins, Marco A.; Pavao, Mauro S. G.			The hemolymph of the ascidian Styela plicata (Chordata-Tunicata) contains heparin inside basophil-like cells and a unique sulfated galactoglucan in the plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHRIMP PENAEUS-BRASILIENSIS; HIGH ANTICOAGULANT ACTIVITY; PERITONEAL MAST-CELLS; HALOCYNTHIA-RORETZI; ANOMALOCARDIA-BRASILIANA; BOTRYLLID ASCIDIANS; NATIVE HEPARIN; BINDING-SITE; BONE-MARROW; BLOOD-CELLS	The hemolymph of ascidians (Chordata-Tunicata) contains different types of hemocytes embedded in a liquid plasma. In the present study, heparin and a sulfated heteropolysaccharide were purified from the hemolymph of the ascidian Styela plicata. The heteropolysaccharide occurs free in the plasma, is composed of glucose (similar to 60%) and galactose (similar to 40%), and is highly sulfated. Heparin, on the other hand, occurs in the hemocytes, and high performance liquid chromatography of the products formed by degradation with specific lyases revealed that it is composed mainly by the disaccharides Delta UA(2SO(4))-1 -> 4-beta-D-GlcN(SO4) (39.7%) and Delta UA(2SO(4))-1 -> 4-beta-D-GlcN(SO4)(6SO(4)) (38.2%). Small amounts of the 3-O-sulfated disaccharides Delta UA(2SO(4))-1 -> 4-beta-D-GlcN(SO4)(3SO(4)) (9.8%) and Delta UA(2SO(4))-1 -> 4-beta-D-GlcN(SO4)(3SO(4))(6SO(4)) (3.8%) were also detected. These 3-O-sulfated disaccharides were demonstrated to be essential for the binding of the hemocyte heparin to antithrombin III. Electron microscopy techniques were used to characterize the ultrastructure of the hemocytes and to localize heparin and histamine in these cells. At least five cell types were recognized and classified as univacuolated and multivacuolated cells, amebocytes, hemoblasts, and granulocytes. Immunocytochemistry showed that heparin and histamine co-localize in intracellular granules of only one type of hemocyte, the granulocyte. These results show for the first time that in ascidians, a sulfated galactoglucan circulates free in the plasma, and heparin occurs as an intracellular product of a circulating basophil-like cell.	Univ Fed Rio de Janeiro, Inst Bioquim Med, Ctr Ciencias Saude, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Lab Tecido Conjunt, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Programa Posgrad Ciencias Morfol, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Histol & Embriol, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Dept Bioquim, F-94400 Vitry Sur Seine, France; Fiocruz MS, Inst Oswaldo Cruz, Lab Inflamacao, BR-21045900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz	Pavao, MSG (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med, Ctr Ciencias Saude, Cidade Univ,Caixa Postal 68041, BR-21941590 Rio De Janeiro, Brazil.	mpavao@hucff.ufrj.br	Andrade, Leonardo/C-9554-2011; Pavao, Mauro Sergio Goncalves/B-1979-2010; Allodi, Silvana/G-1781-2012; de Barros, Cintia Monteiro/AAP-8834-2021; Straus, Anita H/K-7629-2013; Takahashi, Helio/J-1725-2012; Carvalho, Vinicius F/M-4762-2016; S, Allodi/AAR-7968-2020	Andrade, Leonardo/0000-0002-0004-5677; Pavao, Mauro Sergio Goncalves/0000-0002-1336-4271; Allodi, Silvana/0000-0002-3053-3866; 	FOGARTY INTERNATIONAL CENTER [R03TW005775] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW05775] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AKITA N, 1995, CELL STRUCT FUNCT, V20, P81, DOI 10.1247/csf.20.81; Arumugam M., 2004, Indian Journal of Experimental Biology, V42, P529; Azumi K, 1996, ZOOL SCI, V13, P365, DOI 10.2108/zsj.13.365; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BLAND CE, 1982, J BIOL CHEM, V257, P8661; BROWN DD, 1959, J BIOL CHEM, V234, P2948; CARDOSO LEM, 1994, BRAZ J MED BIOL RES, V27, P509; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Cavalcante MCM, 2002, J STRUCT BIOL, V137, P313, DOI 10.1016/S1047-8477(02)00007-2; Cavalcante MCM, 2000, J BIOL CHEM, V275, P36189, DOI 10.1074/jbc.M005830200; Cesaretti M, 2004, GLYCOBIOLOGY, V14, P1275, DOI 10.1093/glycob/cwh128; Chavante SF, 2000, INT J BIOL MACROMOL, V27, P49, DOI 10.1016/S0141-8130(99)00114-2; CONRAD HE, 1998, HEPARINBINDING PROTE; CORREA FMA, 1981, BRAIN RES, V205, P445, DOI 10.1016/0006-8993(81)90359-0; Demir M, 2001, CLIN APPL THROMB-HEM, V7, P44, DOI 10.1177/107602960100700110; DIETRICH CP, 1985, BIOCHIM BIOPHYS ACTA, V843, P1, DOI 10.1016/0304-4165(85)90041-8; DIETRICH CP, 1989, INT J BIOL MACROMOL, V11, P361, DOI 10.1016/0141-8130(89)90008-1; DIETRICH CP, 1976, ANAL BIOCHEM, V70, P645, DOI 10.1016/0003-2697(76)90496-6; Dietrich CP, 1999, BBA-GEN SUBJECTS, V1428, P273, DOI 10.1016/S0304-4165(99)00087-2; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FLEURY P, 1951, Ann Biol Clin (Paris), V9, P453; FUKE M, 1993, ACTA ZOOL-STOCKHOLM, V74, P61, DOI 10.1111/j.1463-6395.1993.tb01221.x; Gandra M, 2000, GLYCOBIOLOGY, V10, P1333, DOI 10.1093/glycob/10.12.1333; Green PL, 2003, DEV COMP IMMUNOL, V27, P3, DOI 10.1016/S0145-305X(02)00067-8; Hirose E, 2003, ZOOL SCI, V20, P647, DOI 10.2108/zsj.20.647; Hirose E, 2003, ZOOL SCI, V20, P387, DOI 10.2108/zsj.20.387; HORNER AA, 1971, J BIOL CHEM, V246, P231; HOVINGH P, 1982, J BIOL CHEM, V257, P9840; Kenjo A, 2001, J BIOL CHEM, V276, P19959, DOI 10.1074/jbc.M011723200; KOBAYASHI Y, 1972, ANAL BIOCHEM, V46, P85, DOI 10.1016/0003-2697(72)90397-1; KUMAZAKI T, 1990, J BIOCHEM-TOKYO, V107, P409, DOI 10.1093/oxfordjournals.jbchem.a123058; LANE DL, 1989, HEPARIN CHEM BIOL PR; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Luppi E, 2005, BIOMACROMOLECULES, V6, P1672, DOI 10.1021/bm049196b; MACDERMOTT RP, 1985, J EXP MED, V162, P1771, DOI 10.1084/jem.162.6.1771; Martinez-Silvestre A, 2005, RES VET SCI, V78, P127, DOI 10.1016/j.rvsc.2004.07.009; Menzel LP, 2002, DEV COMP IMMUNOL, V26, P505, DOI 10.1016/S0145-305X(02)00010-1; METCALFE DD, 1980, J BIOL CHEM, V255, P1753; METCALFE DD, 1979, J CLIN INVEST, V64, P1537, DOI 10.1172/JCI109613; Mourao PAS, 1997, CARBOHYD RES, V300, P315, DOI 10.1016/S0008-6215(97)00061-X; MOURAO PAS, 1995, J BIOL CHEM, V270, P3132, DOI 10.1074/jbc.270.7.3132; Mourier PAJ, 2004, ANAL BIOCHEM, V332, P299, DOI 10.1016/j.ab.2004.06.020; Nader HB, 1999, BRAZ J MED BIOL RES, V32, P529, DOI 10.1590/S0100-879X1999000500005; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; PAVAO MSG, 1989, J BIOL CHEM, V264, P9972; PAVAO MSG, 1994, BBA-GEN SUBJECTS, V1199, P229, DOI 10.1016/0304-4165(94)90001-9; Pavao MSG, 1998, J BIOL CHEM, V273, P27848, DOI 10.1074/jbc.273.43.27848; Pavao MSG, 2002, AN ACAD BRAS CIENC, V74, P105, DOI 10.1590/S0001-37652002000100007; PAVAO MSG, 1994, J EXP ZOOL, V269, P89, DOI 10.1002/jez.1402690202; PAVAO MSG, 1989, CARBOHYD RES, V189, P374, DOI 10.1016/0008-6215(89)84115-1; Pavao MSG, 1996, BRAZ J MED BIOL RES, V29, P1227; PAVAO MSG, 1990, CARBOHYD RES, V208, P153, DOI 10.1016/0008-6215(90)80095-K; Pearce S, 2001, DEV COMP IMMUNOL, V25, P377, DOI 10.1016/S0145-305X(01)00011-8; PEDDIE CM, 1994, ANN NY ACAD SCI, V712, P332, DOI 10.1111/j.1749-6632.1994.tb33587.x; PEJLER G, 1987, J BIOL CHEM, V262, P11413; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Powell AK, 2004, GLYCOBIOLOGY, V14, p17R, DOI 10.1093/glycob/cwh051; RADFORD JL, 1998, ACTA ZOOLOGICA, V79, P44; RAZIN E, 1982, J BIOL CHEM, V257, P7229; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SAITO H, 1968, J BIOL CHEM, V243, P1536; SAWADA T, 1993, BIOL BULL, V184, P87, DOI 10.2307/1542382; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; Shishikura F, 1996, COMP BIOCHEM PHYS B, V114, P1, DOI 10.1016/0305-0491(95)02110-8; Shishikura F, 1997, COMP BIOCHEM PHYS B, V118, P131, DOI 10.1016/S0305-0491(97)00217-4; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Silvestre AM, 2004, VET REC, V155, P266, DOI 10.1136/vr.155.9.266; SNYDER SH, 1966, J PHARMACOL EXP THER, V153, P544; STRAUS AH, 1992, ANAL BIOCHEM, V201, P1, DOI 10.1016/0003-2697(92)90167-6; TAKAHASHI H, 1995, EUR J BIOCHEM, V233, P778, DOI 10.1111/j.1432-1033.1995.778_3.x; Tirumalai R, 2001, MOL REPROD DEV, V58, P54, DOI 10.1002/1098-2795(200101)58:1<54::AID-MRD8>3.0.CO;2-I; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; YOKOSAWA H, 1985, J BIOCHEM, V97, P1621, DOI 10.1093/oxfordjournals.jbchem.a135219; YURT RW, 1977, J IMMUNOL, V118, P1201; YURT RW, 1977, J BIOL CHEM, V252, P518; ZUCKERFRANKLIN D, 1964, J EXP MED, V120, P569, DOI 10.1084/jem.120.4.569	80	35	38	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1615	1626		10.1074/jbc.M604056200	http://dx.doi.org/10.1074/jbc.M604056200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17114184	hybrid			2022-12-27	WOS:000243451300013
J	Moise, AR; Golczak, M; Imanishi, Y; Palczewski, K				Moise, Alexander R.; Golczak, Marcin; Imanishi, Yoshikazu; Palczewski, Krzysztof			Topology and membrane association of lecithin: Retinol acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PIGMENT EPITHELIAL MICROSOMES; RAT SMALL-INTESTINE; VITAMIN-A STATUS; VISUAL CYCLE; BINDING-PROTEINS; LIPID DROPLETS; METABOLISM; RPE65; LIVER	Fatty acid retinyl esters are the storage form of vitamin A ( all-trans-retinol) and serve as metabolic intermediates in the formation of the visual chromophore 11-cis-retinal. Lecithin: retinol acyltransferase ( LRAT), the main enzyme responsible for retinyl ester formation, acts by transferring an acyl group from the sn-1 position of phosphatidylcholine to retinol. To define the membrane association and localization of LRAT, we produced an LRAT-specific monoclonal antibody, which we used to study enzyme partition under different experimental conditions. Furthermore, we examined the membrane topology of LRAT through an N-linked glycosylation scanning approach and protease protection assays. We show that LRAT is localized to the membrane of the endoplasmic reticulum ( ER) and assumes a single membrane-spanning topology with an N-terminal cytoplasmic/C-terminal luminal orientation. In eukaryotic cells, the C-terminal transmembrane domain is essential for the activity and ER membrane targeting of LRAT. In contrast, the N-terminal hydrophobic region is not required for ER membrane targeting or enzymatic activity, and its amino acid sequence is not conserved in other species examined. We present experimental evidence of the topology and subcellular localization of LRAT, a critical enzyme in vitamin A metabolism.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Moise, AR (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, Biomed Res Bldg,10900 Euclid Ave, Cleveland, OH 44106 USA.	ram50@case.edu; kxp65@case.edu	AR, Moise/P-2474-2019; Moise, Alexander/A-7186-2008; Imanishi, Yoshikazu/E-8178-2010; Moise, Alexander R/C-9498-2009	AR, Moise/0000-0003-2307-6035; Imanishi, Yoshikazu/0000-0003-4696-4836; Moise, Alexander R/0000-0003-2307-6035	NEI NIH HHS [EY009339] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009339] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDREWS JS, 1964, J BIOL CHEM, V239, P4073; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; BLANER WS, 1990, FEBS LETT, V274, P89, DOI 10.1016/0014-5793(90)81336-M; Bok D, 2003, BIOCHEMISTRY-US, V42, P6090, DOI 10.1021/bi0342416; Borgese N, 2003, J CELL BIOL, V161, P1013, DOI 10.1083/jcb.200303069; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen QY, 2005, P NATL ACAD SCI USA, V102, P14142, DOI 10.1073/pnas.0505018102; Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Golczak M, 2005, J BIOL CHEM, V280, P42263, DOI 10.1074/jbc.M509351200; Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P11824, DOI 10.1021/bi035227w; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hellemans K, 2003, J LIPID RES, V44, P280, DOI 10.1194/jlr.M200376-JLR200; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110; Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079; Jahng WJ, 2002, BIOCHEMISTRY-US, V41, P6311, DOI 10.1021/bi015710b; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KRINSKY NI, 1958, J BIOL CHEM, V232, P881; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; MACDONALD PN, 1988, BIOCHEM BIOPH RES CO, V156, P157, DOI 10.1016/S0006-291X(88)80818-0; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Marshall R D, 1974, Biochem Soc Symp, P17; Martin S, 2005, J BIOL CHEM, V280, P42325, DOI 10.1074/jbc.M506651200; Mata NL, 1998, INVEST OPHTH VIS SCI, V39, P1312; Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200; Matsuura T, 1996, J NUTR, V126, P2474, DOI 10.1093/jn/126.10.2474; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Moise AR, 2004, J BIOL CHEM, V279, P50230, DOI 10.1074/jbc.M409130200; Moise AR, 2004, J VIROL, V78, P454, DOI 10.1128/JVI.78.1.454-463.2004; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; NILSSON I, 1993, J BIOL CHEM, V268, P5798; O'Byrne SM, 2005, J BIOL CHEM, V280, P35647, DOI 10.1074/jbc.M507924200; OLSON JA, 1984, J NATL CANCER I, V73, P1439; ONG DE, 1987, J BIOL CHEM, V262, P2729; RANDOLPH RK, 1991, J BIOL CHEM, V266, P16453; RANDOLPH RK, 1991, ARCH BIOCHEM BIOPHYS, V288, P500, DOI 10.1016/0003-9861(91)90227-A; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Ross AC, 2004, J NUTR, V134, p269S, DOI 10.1093/jn/134.1.269S; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Ruiz A, 2001, INVEST OPHTH VIS SCI, V42, P31; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1990, METHOD ENZYMOL, V190, P156; Thompson DA, 2001, NAT GENET, V28, P123, DOI 10.1038/88828; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WANG XD, 1993, J NUTR, V123, P1277, DOI 10.1093/jn/123.7.1277; Xue LL, 2004, CELL, V117, P761, DOI 10.1016/j.cell.2004.05.016; Xue LL, 2004, BIOCHEMISTRY-US, V43, P6120, DOI 10.1021/bi049556f	58	43	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					2081	2090		10.1074/jbc.M608315200	http://dx.doi.org/10.1074/jbc.M608315200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17114808	hybrid			2022-12-27	WOS:000243451300059
J	Metz, S; Wiesinger, M; Vogt, M; Lauks, H; Schmalzing, G; Heinrich, PC; Muller-Newen, G				Metz, Silke; Wiesinger, Monique; Vogt, Michael; Lauks, Heike; Schmalzing, Guenther; Heinrich, Peter C.; Mueller-Newen, Gerhard			Characterization of the interleukin (IL)-6 inhibitor IL-6-RFP fused receptor domains act as high affinity cytokine-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER; RHEUMATOID-ARTHRITIS; ESCHERICHIA-COLI; FUSION PROTEIN; GP130; EXPRESSION; PURIFICATION; RECOGNITION; COMPLEXES; CLONING	Although fusion proteins of the extracellular parts of receptor subunits termed cytokine traps turned out to be promising cytokine inhibitors for anti-cytokine therapies, their mode of action has not been analyzed. We developed a fusion protein consisting of the ligand binding domains of the IL-6 receptor subunits IL-6R alpha and gp130 that acts as a highly potent IL-6 inhibitor. Gp130 is a shared cytokine receptor also used by the IL-6-related cytokines oncostatin M and leukemia inhibitory factor. In this study, we have shown that the IL-6 receptor fusion protein (IL-6-RFP) is a specific IL-6 inhibitor that does not block oncostatin M or leukemia inhibitory factor. We characterized the complex of IL-6-RFP and fluorescently labeled IL-6 (YFP-IL6) by blue native PAGE and gel filtration. A 2-fold molar excess of IL-6-RFP over IL- 6 was sufficient to entirely bind IL- 6 in a complex with IL-6-RFP. As shown by treatment with urea and binding competition experiments, the complex of IL- 6 and IL-6-RFP is more stable than the complex of IL- 6, soluble IL-6R alpha, and soluble gp130. By live cell imaging, we have demonstrated that YFP-IL-6 bound to the surface of cells expressing gp130-CFP is removed from the plasma membrane upon the addition of IL-6-RFP. The apparent molecular mass of the IL-6 center dot IL-6-RFP complex determined by blue native PAGE and gel filtration suggests that IL- 6 is trapped in a structure analogous to the native hexameric IL- 6 receptor complex. Thus, fusion of the ligand binding domains of heteromeric receptors leads to highly specific cytokine inhibitors with superior activity compared with the separate soluble receptors.	Univ Klinikum RWTH Aachen, Inst Biochem, D-52074 Aachen, Germany; Univ Klinikum RWTH Aachen, Inst Mol Pharmakol, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Muller-Newen, G (corresponding author), Univ Klinikum RWTH Aachen, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	mueller-newen@rwth-aachen.de						AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; Ancey C, 2003, J BIOL CHEM, V278, P16968, DOI 10.1074/jbc.C300081200; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Boulanger MJ, 2003, MOL CELL, V12, P577, DOI 10.1016/S1097-2765(03)00365-4; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; BRAKENHOFF JPJ, 1989, J IMMUNOL, V143, P1175; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Choy E, 2003, ANN RHEUM DIS, V62, P68; Dinarello CA, 2003, NAT MED, V9, P20, DOI 10.1038/nm0103-20; Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Giese B, 2005, J CELL SCI, V118, P5129, DOI 10.1242/jcs.02628; Goldenberg MM, 1999, CLIN THER, V21, P75, DOI 10.1016/S0149-2918(00)88269-7; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HELLE M, 1991, J IMMUNOL METHODS, V138, P47, DOI 10.1016/0022-1759(91)90063-L; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HONDA M, 1992, J IMMUNOL, V148, P2175; Kiessig S, 2001, ELECTROPHORESIS, V22, P1428, DOI 10.1002/1522-2683(200105)22:7<1428::AID-ELPS1428>3.0.CO;2-Z; Kurth I, 1999, J IMMUNOL, V162, P1480; Matthews JM, 1998, BIOCHEMISTRY-US, V37, P10671, DOI 10.1021/bi980127p; Muller-Newen G, 1998, J IMMUNOL, V161, P6347; Muller-Newen Gerhard, 2003, Sci STKE, V2003, pPE40, DOI 10.1126/stke.2003.201.pe40; MullerNewen G, 1996, EUR J BIOCHEM, V236, P837, DOI 10.1111/j.1432-1033.1996.00837.x; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; Nishimoto N, 2005, BLOOD, V106, P2627, DOI 10.1182/blood-2004-12-4602; Sadtler S, 2003, J BIOL CHEM, V278, P16782, DOI 10.1074/jbc.M213077200; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	35	21	31	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1238	1248		10.1074/jbc.M606885200	http://dx.doi.org/10.1074/jbc.M606885200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17085445	hybrid			2022-12-27	WOS:000243295200049
J	Nossal, NG; Makhov, AM; Chastain, PD; Jones, CE; Griffith, JD				Nossal, Nancy G.; Makhov, Alexander M.; Chastain, Paul D., II; Jones, Charles E.; Griffith, Jack D.			Architecture of the bacteriophage T4 replication complex revealed with nanoscale biopointers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICASE ASSEMBLY PROTEIN; STRAND DNA-SYNTHESIS; LEADING-STRAND; LOADING PROTEIN; RNA PRIMERS; POLYMERASE GP43; LOADER PROTEIN; FORK DNA; IN-VITRO; T4	Our previous electron microscopy of DNA replicated by the bacteriophage T4 proteins showed a single complex at the fork, thought to contain the leading and lagging strand proteins, as well as the protein-covered single-stranded DNA on the lagging strand folded into a compact structure. "Trombone" loops formed from nascent lagging strand fragments were present on a majority of the replicating molecules (Chastain, P., Makhov, A. M., Nossal, N. G., and Griffith, J. D. (2003) J. Biol. Chem. 278, 21276 - 21285). Here we probe the composition of this replication complex using nanoscale DNA biopointers to show the location of biotin-tagged replication proteins. We find that a large fraction of the molecules with a trombone loop had two pointers to polymerase, providing strong evidence that the leading and lagging strand polymerases are together in the replication complex. 6% of the molecules had two loops, and 31% of these had three pointers to biotin-tagged polymerase, suggesting that the two loops result from two fragments that are being extended simultaneously. Under fixation conditions that extend the lagging strand, occasional molecules show two nascent lagging strand fragments, each being elongated by a biotin-tagged polymerase. T4 41 helicase is present in the complex on a large fraction of actively replicating molecules but on a smaller fraction of molecules with a stalled polymerase. Unexpectedly, we found that 59 helicase-loading protein remains on the fork after loading the helicase and is present on molecules with extensive replication.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; NIDDK, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Mason Farm Rd, Chapel Hill, NC 27599 USA.	jdg@med.unc.edu	Chastain, Paul/AAN-2692-2020; Jones, Charles/GVS-9497-2022	Chastain, Paul/0000-0001-6782-6788; 	Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1985, TRENDS GENET, V1, P26, DOI 10.1016/0168-9525(85)90011-3; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; Alley SC, 2001, J BIOL CHEM, V276, P39340, DOI 10.1074/jbc.M104956200; BARRY J, 1994, J BIOL CHEM, V269, P33049; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Bhagwat M, 2001, J BIOL CHEM, V276, P28516, DOI 10.1074/jbc.M103914200; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; Chastain PD, 2004, J BIOL CHEM, V279, P36354, DOI 10.1074/jbc.M403501200; Chastain PD, 2003, J BIOL CHEM, V278, P21276, DOI 10.1074/jbc.M301573200; Delagoutte E, 2005, J MOL BIOL, V347, P257, DOI 10.1016/j.jmb.2005.01.036; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dudas KC, 2005, J BIOL CHEM, V280, P21561, DOI 10.1074/jbc.m502351200; Gangisetty O, 2005, J BIOL CHEM, V280, P12876, DOI 10.1074/jbc.M414025200; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; Jing DH, 1999, J BIOL CHEM, V274, P27287, DOI 10.1074/jbc.274.38.27287; Jones CE, 2004, J BIOL CHEM, V279, P25721, DOI 10.1074/jbc.M402128200; Jones CE, 2004, J BIOL CHEM, V279, P12067, DOI 10.1074/jbc.M313840200; Jones CE, 2001, P NATL ACAD SCI USA, V98, P8312, DOI 10.1073/pnas.121009398; Jones CE, 2000, J BIOL CHEM, V275, P27145; Kadyrov FA, 2001, J BIOL CHEM, V276, P29559, DOI 10.1074/jbc.M101310200; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; Nossal NG, 2001, MOL CELL, V7, P31, DOI 10.1016/S1097-2765(01)00152-6; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pietroni P, 2001, J MOL BIOL, V309, P869, DOI 10.1006/jmbi.2001.4687; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P438; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; Stano NM, 2005, NATURE, V435, P370, DOI 10.1038/nature03615; Subramanian D, 2005, J BIOL CHEM, V280, P42568, DOI 10.1074/jbc.M506348200; Valentine AM, 2001, BIOCHEMISTRY-US, V40, P15074, DOI 10.1021/bi0108554; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; Xi J, 2005, BIOCHEMISTRY-US, V44, P12264, DOI 10.1021/bi058024b; Xi J, 2005, BIOCHEMISTRY-US, V44, P7747, DOI 10.1021/bi047296w; Yang JS, 2006, MOL CELL, V21, P153, DOI 10.1016/j.molcel.2005.11.029; Yang JS, 2004, P NATL ACAD SCI USA, V101, P8289, DOI 10.1073/pnas.0402625101; Zhang ZQ, 2005, P NATL ACAD SCI USA, V102, P3254, DOI 10.1073/pnas.0500327102	47	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1098	1108		10.1074/jbc.M606772200	http://dx.doi.org/10.1074/jbc.M606772200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17105722	Green Published, hybrid			2022-12-27	WOS:000243295200034
J	Hamra, FK; Chapman, KM; Nguyen, D; Garbers, DL				Kent Hamra, F.; Chapman, Karen M.; Nguyen, Derek; Garbers, David L.			Identification of neuregulin as a factor required for formation of aligned spermatogonia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM CELL POPULATION; LONG-TERM CULTURE; NERVOUS-SYSTEM DEVELOPMENT; IN-VITRO DIFFERENTIATION; SOMATIC SUPPORT CELLS; MALE GERM-CELLS; A SPERMATOGONIA; GROWTH-FACTORS; SELF-RENEWAL; INTERCELLULAR BRIDGES	In the absence of somatic cells, medium conditioned by the SNL fibroblast line (SNL-CM) is able to stimulate primary cultures of rat type-A single spermatogonia to develop into chains of aligned spermatogonia at the 8-, 16-, and 32-cell stages. By comparison, medium conditioned by an MSC-1 Sertoli cell line is ineffective. Glial cell line-derived neurotrophic factor (GDNF)-like molecules were identified in SNL-CM and recombinant forms of GDNF, neurturin, and artemin were shown to stimulate formation of aligned spermatogonia, but principally to only the 4- and 8-cell stages. Because SNL-CM and GDNF-like molecules stimulated the formation of spermatogonial chain length differently, we purified components of SNL-CM to identify the additional contributing factor(s). A fraction was isolated that was dependent on GDNF, but required for effective formation of 16- and 32-cell chain lengths. Sequence analysis identified the factor as mouse neuregulin-1. At picomolar concentrations, recombinant neuregulin-1 in combination with GDNF effectively stimulated formation of aligned spermatogonia up to the 32-cell stage. Neuregulin in the absence of GDNF was relatively ineffective. Soluble receptors for neuregulins blocked the effects of GDNF and SNL-CM, suggesting that both neuregulin and GDNF are required for effective formation of long spermatogonial chains. Addition of neuregulin-1 to cultures on MSC-1 feeder layers resulted in spermatogonial behavior similar to that seen on feeder layers of SNL fibroblasts. In fact, SNL cells were found to express 100-fold higher levels of neuregulin-1 transcripts than MSC-1 cells. Thus, we identify neuregulin as a factor required for spermatogonial amplification and differentiation in culture.	Univ Texas, SW Med Ctr, Cecil H & Ida Green Ctr Reprod Biol Sci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hamra, FK (corresponding author), 6001 Forest Pk Rd, Dallas, TX 75390 USA.	kent.hamra@utsouthwestern.edu						Aponte PM, 2006, THERIOGENOLOGY, V65, P1828, DOI 10.1016/j.theriogenology.2005.10.020; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; Chiarini-Garcia H, 2003, REPRODUCTION, V126, P669, DOI 10.1530/reprod/126.5.669; Chiarini-Garcia H, 2002, REPRODUCTION, V123, P567, DOI 10.1530/reprod/123.4.567; Chiarini-Garcia H, 2001, BIOL REPROD, V65, P1170, DOI 10.1095/biolreprod65.4.1170; Creemers LB, 2002, REPRODUCTION, V124, P791, DOI 10.1530/rep.0.1240791; Cronkhite JT, 2005, DEV BIOL, V284, P171, DOI 10.1016/j.ydbio.2005.05.015; de Rooij DG, 2001, REPRODUCTION, V121, P347, DOI 10.1530/rep.0.1210347; de Rooij DG, 2003, CYTOGENET GENOME RES, V103, P267, DOI 10.1159/000076812; de Rooij DG, 1998, CURR OPIN CELL BIOL, V10, P694, DOI 10.1016/S0955-0674(98)80109-9; Dirami G, 1999, BIOL REPROD, V61, P225, DOI 10.1095/biolreprod61.1.225; DYM M, 1971, BIOL REPROD, V4, P195, DOI 10.1093/biolreprod/4.2.195; Esper RM, 2006, BRAIN RES REV, V51, P161, DOI 10.1016/j.brainresrev.2005.11.006; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; FAWCETT DW, 1959, J BIOPHYS BIOCHEM CY, V5, P453, DOI 10.1083/jcb.5.3.453; Feng LX, 2002, SCIENCE, V297, P392, DOI 10.1126/science.1073162; GARBERS DL, 2004, SPERMATOGONIAL STEM; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Greenbaum MP, 2006, P NATL ACAD SCI USA, V103, P4982, DOI 10.1073/pnas.0505123103; Guan K, 2006, NATURE, V440, P1199, DOI 10.1038/nature04697; Hamra FK, 2005, P NATL ACAD SCI USA, V102, P17430, DOI 10.1073/pnas.0508780102; Hamra FK, 2002, P NATL ACAD SCI USA, V99, P14931, DOI 10.1073/pnas.222561399; Hamra FK, 2004, DEV BIOL, V269, P393, DOI 10.1016/j.ydbio.2004.01.027; Hoeben E, 1999, ENDOCRINOLOGY, V140, P2216, DOI 10.1210/en.140.5.2216; Hofmann MC, 2005, STEM CELLS, V23, P200, DOI 10.1634/stemcells.2003-0036; HUCKINS C, 1971, ANAT REC, V169, P533, DOI 10.1002/ar.1091690306; HUCKINS C, 1971, CELL TISSUE KINET, V4, P313, DOI 10.1111/j.1365-2184.1971.tb01543.x; HUCKINS C, 1971, CELL TISSUE KINET, V4, P335, DOI 10.1111/j.1365-2184.1971.tb01544.x; Izadyar F, 2003, BIOL REPROD, V68, P272, DOI 10.1095/biolreprod.102.004986; Kanatsu-Shinohara M, 2003, BIOL REPROD, V69, P612, DOI 10.1095/biolreprod.103.017012; Kanatsu-Shinohara M, 2005, BIOL REPROD, V72, P985, DOI 10.1095/biolreprod.104.036400; KIERSZENBAUM AL, 1994, ENDOCR REV, V15, P116, DOI 10.1210/er.15.1.116; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Kubota H, 2003, P NATL ACAD SCI USA, V100, P6487, DOI 10.1073/pnas.0631767100; Kubota H, 2004, P NATL ACAD SCI USA, V101, P16489, DOI 10.1073/pnas.0407063101; Kubota H, 2004, BIOL REPROD, V71, P722, DOI 10.1095/biolreprod.104.029207; Lacham-Kaplan O, 2004, REPRODUCTION, V128, P147, DOI 10.1530/rep.1.00220; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMKE G, 2006, SCI STKE, pPE11; Malkov M, 1998, BIOL REPROD, V59, P84, DOI 10.1095/biolreprod59.1.84; McLean DJ, 2002, BIOL REPROD, V66, P1374, DOI 10.1095/biolreprod66.5.1374; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Morris JK, 1999, NEURON, V23, P273, DOI 10.1016/S0896-6273(00)80779-5; OAKBERG EF, 1971, MUTAT RES, V11, P1, DOI 10.1016/0027-5107(71)90027-3; OAKBERG EF, 1971, ANAT REC, V169, P515, DOI 10.1002/ar.1091690305; Ogawa T, 1999, TISSUE CELL, V31, P461, DOI 10.1054/tice.1999.0060; Ogawa T, 2004, ARCH HISTOL CYTOL, V67, P297, DOI 10.1679/aohc.67.297; Orwig KE, 2002, BIOL REPROD, V66, P944, DOI 10.1095/biolreprod66.4.944; Pang ALY, 2006, PHYSIOL GENOMICS, V24, P75, DOI 10.1152/physiolgenomics.00215.2004; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Roy A, 2006, REPRODUCTION, V131, P207, DOI 10.1530/rep.1.00530; Ryu BY, 2005, P NATL ACAD SCI USA, V102, P14302, DOI 10.1073/pnas.0506970102; Ryu BY, 2004, DEV BIOL, V274, P158, DOI 10.1016/j.ydbio.2004.07.004; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; Schulz C, 2002, DEVELOPMENT, V129, P4523; Shinohara T, 2000, DEV BIOL, V220, P401, DOI 10.1006/dbio.2000.9655; Shinohara T, 1999, P NATL ACAD SCI USA, V96, P5504, DOI 10.1073/pnas.96.10.5504; Shinohara T, 2000, P NATL ACAD SCI USA, V97, P8346, DOI 10.1073/pnas.97.15.8346; STEINBER.A, 1966, EXP CELL RES, V44, P443, DOI 10.1016/0014-4827(66)90451-4; Steinthorsdottir V, 2004, GENE, V342, P97, DOI 10.1016/j.gene.2004.07.029; Tadokoro Y, 2002, MECH DEVELOP, V113, P29, DOI 10.1016/S0925-4773(02)00004-7; Van der Wee KS, 2001, J ANDROL, V22, P696; van Pelt AMM, 2002, ENDOCRINOLOGY, V143, P1845, DOI 10.1210/en.143.5.1845; Viglietto G, 2000, INT J ONCOL, V16, P689; Wahab-Wahlgren A, 2003, MOL CELL ENDOCRINOL, V201, P39, DOI 10.1016/S0303-7207(03)00002-9; Wang PJ, 2001, NAT GENET, V27, P422, DOI 10.1038/86927; Zhao GQ, 2002, DEV CELL, V2, P537, DOI 10.1016/S1534-5807(02)00173-9	70	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					721	730		10.1074/jbc.M608398200	http://dx.doi.org/10.1074/jbc.M608398200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17098736	hybrid			2022-12-27	WOS:000243166500077
J	Wenzel, P; Hink, U; Elze, M; Schuppan, S; Schaeuble, K; Schildknecht, S; Ho, KK; Weiner, H; Bachschmid, M; Munzel, T; Daiber, A				Wenzel, Philip; Hink, Ulrich; Elze, Matthias; Schuppan, Swaantje; Schaeuble, Karin; Schildknecht, Stefan; Ho, Kwok K.; Weiner, Henry; Bachschmid, Markus; Muenzel, Thomas; Daiber, Andreas			Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity - Implications for mitochondrial oxidative stress and nitrate tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; RAT-LIVER MITOCHONDRIA; PROTEIN-KINASE-C; NITROGLYCERIN BIOACTIVATION; HETEROZYGOUS DEFICIENCY; PROSTACYCLIN SYNTHASE; LIPID-PEROXIDATION; ORGANIC NITRATES; CROSS-TOLERANCE; NITRIC-OXIDE	Chronic therapy with nitroglycerin results in a rapid development of nitrate tolerance, which is associated with an increased production of reactive oxygen species. We have recently shown that mitochondria are an important source of nitroglycerin-induced oxidants and that the nitroglycerin-bioactivating mitochondrial aldehyde dehydrogenase is oxidatively inactivated in the setting of tolerance. Here we investigated the effect of various oxidants on aldehyde dehydrogenase activity and its restoration by dihydrolipoic acid. In vivo tolerance in Wistar rats was induced by infusion of nitroglycerin (6.6 mu g/kg/min, 4 days). Vascular reactivity was measured by isometric tension studies of isolated aortic rings in response to nitroglycerin. Chronic nitroglycerin infusion lead to impaired vascular responses to nitroglycerin and decreased dehydrogenase activity, which was corrected by dihydrolipoic acid co-incubation. Superoxide, peroxynitrite, and nitroglycerin itself were highly efficient in inhibiting mitochondrial and yeast aldehyde dehydrogenase activity, which was restored by dithiol compounds such as dihydrolipoic acid and dithiothreitol. Hydrogen peroxide and nitric oxide were rather insensitive inhibitors. Our observations indicate that mitochondrial oxidative stress (especially superoxide and peroxynitrite) in response to organic nitrate treatment may inactivate aldehyde dehydrogenase thereby leading to nitrate tolerance. Glutathionylation obviously amplifies oxidative inactivation of the enzyme providing another regulatory pathway. Furthermore, the present data demonstrate that the mitochondrial dithiol compound dihydrolipoic acid restores mitochondrial aldehyde dehydrogenase activity via reduction of a disulfide at the active site and thereby improves nitrate tolerance.	Johannes Gutenberg Univ Mainz, Univ Hosp Mainz, Med Clin 2, Dept Cardiol, D-55101 Mainz, Germany; Univ Konstanz, Dept Biol Chem, D-78457 Constance, Germany; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Johannes Gutenberg University of Mainz; University Hospital Mainz; University of Konstanz; Boston University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Daiber, A (corresponding author), Johannes Gutenberg Univ Mainz, Univ Hosp Mainz, Med Clin 2, Dept Cardiol, Verfugungsgebaude 911,Obere Zahlbacher Str 63, D-55101 Mainz, Germany.	andreas.daiber@bioredox.com	Munzel, Thomas/A-2912-2014; Wenzel, Philip/Z-1503-2019; Wenzel, Philip/HIA-0033-2022	Munzel, Thomas/0000-0001-5503-4150; Wenzel, Philip/0000-0002-5397-2781; Wenzel, Philip/0000-0002-5397-2781; Bachschmid, Markus Michael/0000-0002-0748-5528; Schauble, Karin/0000-0003-1826-0129				Abou-Mohamed G, 2004, J PHARMACOL EXP THER, V308, P289, DOI 10.1124/jpet.103.056119; ABRAMS J, 1995, ARCH INTERN MED, V155, P357, DOI 10.1001/archinte.155.4.357; Adachi T, 2004, NAT MED, V10, P1200, DOI 10.1038/nm1119; CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4; Chen ZQ, 2005, P NATL ACAD SCI USA, V102, P12159, DOI 10.1073/pnas.0503723102; Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199; Craghill J, 2004, BIOCHEM J, V379, P595, DOI 10.1042/BJ20031367; Daiber A, 2005, BIOCHEM BIOPH RES CO, V338, P1865, DOI 10.1016/j.bbrc.2005.10.106; Daiber A, 2005, MOL PHARMACOL, V68, P579, DOI 10.1124/mol.105.011585; Daiber A, 2004, MOL PHARMACOL, V66, P1372, DOI 10.1124/mol.104.002600; Daiber A, 2004, FREE RADICAL RES, V38, P259, DOI 10.1080/10715760410001659773; Daiber A, 2002, J BIOL CHEM, V277, P11882, DOI 10.1074/jbc.M111988200; Hink U, 2003, J AM COLL CARDIOL, V42, P1826, DOI 10.1016/j.jacc.2003.07.009; Li YF, 2006, J CLIN INVEST, V116, P506, DOI 10.1172/JCI26564; LOOMES KM, 1989, BIOCHEM J, V261, P281, DOI 10.1042/bj2610281; Lucas DL, 2005, J AM COLL CARDIOL, V45, P1916, DOI 10.1016/j.jacc.2005.02.075; Lynch MA, 2001, NUTR NEUROSCI, V4, P419, DOI 10.1080/1028415X.2001.11747378; Mackenzie IS, 2005, ARTERIOSCL THROM VAS, V25, P1891, DOI 10.1161/01.ATV.0000179599.71086.89; MCMICHAEL M, 1986, ALCOHOL CLIN EXP RES, V10, P323, DOI 10.1111/j.1530-0277.1986.tb05098.x; Moini H, 2002, TOXICOL APPL PHARM, V182, P84, DOI 10.1006/taap.2002.9437; Mollnau H, 2005, ARTERIOSCL THROM VAS, V25, P2554, DOI 10.1161/01.ATV.0000190673.41925.9b; Moon KH, 2005, FEBS LETT, V579, P6115, DOI 10.1016/j.febslet.2005.09.082; Munzel T, 2005, CIRC RES, V97, P618, DOI 10.1161/01.RES.0000184694.03262.6d; MUNZEL T, 1995, P NATL ACAD SCI USA, V92, P5244, DOI 10.1073/pnas.92.11.5244; MUNZEL T, 1995, J CLIN INVEST, V95, P187, DOI 10.1172/JCI117637; Murphy TC, 2005, CARDIOVASC TOXICOL, V5, P321, DOI 10.1385/CT:5:3:321; NEEDLEMAN P, 1966, MOL PHARMACOL, V2, P134; Oelze M, 2006, HYPERTENSION, V48, P677, DOI 10.1161/01.HYP.0000239207.82326.29; Raha S, 2000, FREE RADICAL BIO MED, V29, P170, DOI 10.1016/S0891-5849(00)00338-5; Schmidt P, 2003, J BIOL CHEM, V278, P12813, DOI 10.1074/jbc.M208080200; Schulz E, 2002, CIRCULATION, V105, P1170, DOI 10.1161/hc1002.105186; SENIOR DJ, 1990, BIOCHEM CELL BIOL, V68, P758, DOI 10.1139/o90-109; Strassburger M, 2005, FREE RADICAL BIO MED, V38, P1458, DOI 10.1016/j.freeradbiomed.2005.02.009; Sydow K, 2004, J CLIN INVEST, V113, P482, DOI 10.1172/JCI200419267; Takakura K, 1999, ARCH BIOCHEM BIOPHYS, V369, P197, DOI 10.1006/abbi.1999.1374; Trujillo M, 2002, ARCH BIOCHEM BIOPHYS, V397, P91, DOI 10.1006/abbi.2001.2619; TSAI CS, 1991, BIOCHEM CELL BIOL, V69, P193, DOI 10.1139/o91-028; Warnholtz A, 2002, J AM COLL CARDIOL, V40, P1356, DOI 10.1016/S0735-1097(02)02133-2; Wollin SD, 2003, J NUTR, V133, P3327	39	137	142	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					792	799		10.1074/jbc.M606477200	http://dx.doi.org/10.1074/jbc.M606477200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17102135	hybrid			2022-12-27	WOS:000243166500084
J	Basha, E; Friedrich, KL; Vierling, E				Basha, Eman; Friedrich, Kenneth L.; Vierling, Elizabeth			The N-terminal arm of small heat shock proteins is important for both chaperone activity and substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; SITE-DIRECTED MUTATIONS; IN-VIVO; FUNCTIONAL ELEMENT; UNFOLDING PROTEINS; BINDING-SITES; A-CRYSTALLIN; DOMAIN; OLIGOMERIZATION; HSP26	Small heat shock proteins (sHSPs) are a ubiquitous class of molecular chaperones that interacts with substrates to prevent their irreversible insolubilization during denaturation. How sHSPs interact with substrates remains poorly defined. To investigate the role of the conserved C-terminal alpha-crystallin domain versus the variable N-terminal arm in substrate interactions, we compared two closely related dodecameric plant sHSPs, Hsp18.1 and Hsp16.9, and four chimeras of these two sHSPs, in which all or part of the N-terminal arm was switched. The efficiency of substrate protection and formation of sHSP-substrate complexes by these sHSPs with three different model substrates, firefly luciferase, citrate synthase, and malate dehydrogenase (MDH) provide new insights into sHSP/substrate interactions. Results indicate that different substrates have varying affinities for different domains of the sHSP. For luciferase and citrate synthase, the efficiency of substrate protection was determined by the identity of the N-terminal arm in the chimeric proteins. In contrast, for MDH, efficient protection clearly required interactions with the alpha-crystallin domain in addition to the N-terminal arm. Furthermore, we show that sHSP-substrate complexes with varying stability and composition can protect substrate equally, and substrate protection is not correlated with sHSP oligomeric stability for all substrates. Protection of MDH by the dimeric chimera composed of the Hsp16.9 N-terminal arm and Hsp18.1 alpha-crystallin domain supports the model that a dimeric form of the sHSP can bind and protect substrate. In total, results demonstrate that sHSP-substrate interactions are complex, likely involve multiple sites on the sHSP, and vary depending on substrate.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	University of Arizona	Vierling, E (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, 1007 E Lowell St, Tucson, AZ 85721 USA.	vierling@u.arizona.edu		Vierling, Elizabeth/0000-0002-0066-4881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042762] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM42762] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrigo Andre-Patrick, 2002, Prog Mol Subcell Biol, V28, P171; Basha E, 2004, EUR J BIOCHEM, V271, P1426, DOI 10.1111/j.1432-1033.2004.04033.x; Basha E, 2004, J BIOL CHEM, V279, P7566, DOI 10.1074/jbc.M310684200; Bhattacharyya J, 2006, BIOCHEMISTRY-US, V45, P3069, DOI 10.1021/bi0518141; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Derham BK, 2001, EUR J BIOCHEM, V268, P713, DOI 10.1046/j.1432-1327.2001.01929.x; Friedrich KL, 2004, J BIOL CHEM, V279, P1080, DOI 10.1074/jbc.M311104200; Fu XM, 2005, J BIOL CHEM, V280, P6337, DOI 10.1074/jbc.M406319200; Ghosh JG, 2005, BIOCHEMISTRY-US, V44, P14854, DOI 10.1021/bi0503910; Giese KC, 2004, J BIOL CHEM, V279, P32674, DOI 10.1074/jbc.M404455200; Giese KC, 2005, P NATL ACAD SCI USA, V102, P18896, DOI 10.1073/pnas.0506169103; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 2004, J MOL BIOL, V343, P445, DOI 10.1016/j.jmb.2004.08.048; Haslbeck M, 2005, NAT STRUCT MOL BIOL, V12, P842, DOI 10.1038/nsmb993; Haslbeck M, 2004, EMBO J, V23, P638, DOI 10.1038/sj.emboj.7600080; Haslbeck M, 2005, J BIOL CHEM, V280, P23861, DOI 10.1074/jbc.M502697200; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Lentze N, 2003, J MOL BIOL, V328, P927, DOI 10.1016/S0022-2836(03)00356-5; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Mogk A, 2003, J BIOL CHEM, V278, P31033, DOI 10.1074/jbc.M303587200; Muchowski PJ, 1999, J MOL BIOL, V289, P397, DOI 10.1006/jmbi.1999.2759; Parcellier A, 2005, ANTIOXID REDOX SIGN, V7, P404, DOI 10.1089/ars.2005.7.404; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; Santhoshkumar P, 2001, J BIOL CHEM, V276, P47094, DOI 10.1074/jbc.M107737200; Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; Shashidharamurthy R, 2005, J BIOL CHEM, V280, P5281, DOI 10.1074/jbc.M407236200; Sobott F, 2002, J BIOL CHEM, V277, P38921, DOI 10.1074/jbc.M206060200; Stamler R, 2005, J MOL BIOL, V353, P68, DOI 10.1016/j.jmb.2005.08.025; Stromer T, 2004, J BIOL CHEM, V279, P11222, DOI 10.1074/jbc.M310149200; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; Sun Y, 2005, FEBS J, V272, P2613, DOI 10.1111/j.1742-4658.2005.04708.x; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Waters ER, 1996, J EXP BOT, V47, P325, DOI 10.1093/jxb/47.3.325	39	138	151	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39943	39952		10.1074/jbc.M607677200	http://dx.doi.org/10.1074/jbc.M607677200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17090542	hybrid, Green Published			2022-12-27	WOS:000243033900022
J	Sherrill, JD; Miller, WE				Sherrill, Joseph D.; Miller, William E.			G protein-coupled receptor (GPCR) kinase 2 regulates agonist-independent G(q/11) signaling from the mouse cytomegalovirus GPCR M33	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; MUSCLE-CELL MIGRATION; PHOSPHOLIPASE-C BETA; MURINE CYTOMEGALOVIRUS; CHEMOKINE RECEPTOR; CONSTITUTIVE ACTIVITY; SELECTIVE REGULATION; RAT CYTOMEGALOVIRUS; HOMOLOGY DOMAIN; KNOCKOUT MICE	The mouse cytomegalovirus M33 protein is highly homologous to mammalian G protein-coupled receptors (GPCRs) yet functions in an agonist-independent manner to activate a number of classical GPCR signal transduction pathways. M33 is functionally similar to the human cytomegalovirus-encoded US28 GPCR in its ability to induce inositol phosphate accumulation, activate NF-kappa B, and promote smooth muscle cell migration. This ability to promote cellular migration suggests a role for viral GPCRs like M33 in viral dissemination in vivo, and accordingly, M33 is required for efficient murine cytomegalovirus replication in the mouse. Although previous studies have identified several M33-induced signaling pathways, little is known regarding the membrane-proximal events involved in signaling and regulation of this receptor. In this study, we used recombinant retroviruses to express M33 in wild-type and G alpha(-/-)(q/11) mouse embryonic fibroblasts and show that M33 couples directly to the G(q/11) signaling pathway to induce high levels of total inositol phosphates in an agonist-independent manner. Our data also show that GRK2 is a potent regulator of M33-induced G(q/11) signaling through its ability to phosphorylate M33 and sequester G alpha(q/11) proteins. Taken together, the results from this study provide the first genetic evidence of a viral GPCR coupling to a specific G protein signaling pathway as well as identify the first viral GPCR to be regulated specifically by both the catalytic activity of the GRK2 kinase domain and the G alpha(q/11) binding activity of the GRK2 RH domain.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Miller, WE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	william.miller@uc.edu	Sherrill, Joseph/B-6662-2014	Miller, William/0000-0001-6900-4884	NIAID NIH HHS [R01 AI058159-05, R01 AI058159-02, R01 AI058159-04, R01 AI058159-03, R01 AI058159-01A2, R01 AI058159] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058159] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BLANK JL, 1992, J BIOL CHEM, V267, P23069; Burnett MS, 2001, J INFECT DIS, V183, P226, DOI 10.1086/317938; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dale LB, 2000, J BIOL CHEM, V275, P38213, DOI 10.1074/jbc.M006075200; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; Dhami GK, 2004, J BIOL CHEM, V279, P16614, DOI 10.1074/jbc.M314090200; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Flanagan CA, 2005, MOL PHARMACOL, V68, P1, DOI 10.1124/mol.105.014183; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; GAO JL, 1994, J BIOL CHEM, V269, P28539; Gruijthuijsen YK, 2002, J VIROL, V76, P1328, DOI 10.1128/JVI.76.3.1328-1338.2002; Gruijthuijsen YK, 2004, J GEN VIROL, V85, P897, DOI 10.1099/vir.0.19709-0; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hsich E, 2001, ATHEROSCLEROSIS, V156, P23, DOI 10.1016/S0021-9150(00)00608-0; Iwata K, 2005, J BIOL CHEM, V280, P2197, DOI 10.1074/jbc.M408834200; KONG GH, 1994, J BIOL CHEM, V269, P13084; Lanctot PM, 2005, BIOCHEM J, V390, P367, DOI 10.1042/BJ20050189; LEE CH, 1992, J BIOL CHEM, V267, P16044; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Melnychuk RA, 2005, J VIROL, V79, P10788, DOI 10.1128/JVI.79.16.10788-10795.2005; Miller WE, 2003, J BIOL CHEM, V278, P21663, DOI 10.1074/jbc.M303219200; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; PARIS S, 1987, J BIOL CHEM, V262, P1970; Pass R. F., 2001, FIELDS VIROLOGY; Paulsen SJ, 2005, J VIROL, V79, P536, DOI 10.1128/JVI.79.1.536-546.2005; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rawlinson WD, 1996, J VIROL, V70, P8833, DOI 10.1128/JVI.70.12.8833-8849.1996; Rigoutsos I, 2003, J VIROL, V77, P4326, DOI 10.1128/JVI.77.7.4326-4344.2003; Rosenkilde MM, 2005, MOL PHARMACOL, V68, P11, DOI 10.1124/mol.105.011239; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Tesmer VM, 2005, SCIENCE, V310, P1686, DOI 10.1126/science.1118890; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Willets JM, 2005, J BIOL CHEM, V280, P18950, DOI 10.1074/jbc.M412682200	53	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39796	39805		10.1074/jbc.M610026200	http://dx.doi.org/10.1074/jbc.M610026200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17088245	hybrid, Green Accepted			2022-12-27	WOS:000243033900007
J	Mitra, S; Holz, RC				Mitra, Sanghamitra; Holz, Richard C.			Unraveling the catalytic mechanism of nitrile hydratases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONHEME IRON; CRYSTAL-STRUCTURE; AEROMONAS-PROTEOLYTICA; INDUSTRIAL-PRODUCTION; ELECTRONIC-STRUCTURE; ACTIVE-SITE; SUBSTRATE; BIOTRANSFORMATION; AMINOPEPTIDASE; DEHYDROGENASE	To elucidate a detailed catalytic mechanism for nitrile hydratases (NHases), the pH and temperature dependence of the kinetic constants k(cat) and K-m for the cobalt-type NHase from Pseudonocardia thermophila JCM 3095 (PtNHase) were examined. PtNHase was found to exhibit a bell-shaped curve for plots of relative activity versus PH at pH 3.2-11 and was found to display maximal activity between PH 7.2 and 7.8. Fits of these data provided pK(ES1) and pK(ES2) values of 5.9 +/- 0.1 and 9.2 +/- 0.1 (k(cat)' = 130 +/- 1 s(-1)), respectively, and pK(E1) and pK(E2) values of 5.8 +/- 0.1 and 9.1 +/- 0.1 (k(cat)'/K-m' = (6.5 +/- 0.1) X 10(3)s(-1) mM(-1)), respectively. Proton inventory studies indicated that two protons are transferred in the rate-limiting step of the reaction at pH 7.6. Because PtNHase is stable at 60 degrees C, an Arrhenius plot was constructed by plotting In(k(cat)) versus 1/T, providing E-a = 23.0 +/- 1.2 kJ/mol. The thermal stability of PtNHase also allowed Delta H-0 ionization values to be determined, thus helping to identify the ionizing groups exhibiting the pK(ES1) and pK(ES2) values. Based on Delta H-ion(0) data, pK(ES1) is assigned to beta Tyr(68), whereas pK(ES2) is assigned to beta Arg(52), beta Arg(157), or alpha Ser(112) (NHases are alpha(2)beta(2)-heterotetramers). A combination of these data with those previously reported for NHases and synthetic model complexes, along with sequence comparisons of both iron- and cobalt-type NHases, allowed a novel catalytic mechanism for NHases to be proposed.	Loyola Univ, Dept Chem, Chicago, IL 60626 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Loyola University Chicago; Utah System of Higher Education; Utah State University	Mitra, S (corresponding author), Loyola Univ, Dept Chem, 1068 W Sheridan Rd, Chicago, IL 60626 USA.	rholz1@luc.edu						ALBERY WJ, 1975, PROTON TRANSFER REAC; Alfani F, 2001, J MOL CATAL B-ENZYM, V11, P687, DOI 10.1016/S1381-1177(00)00160-0; Banerjee A, 2002, APPL MICROBIOL BIOT, V60, P33, DOI 10.1007/s00253-002-1062-0; Bienvenue DL, 2002, J BIOL INORG CHEM, V7, P129, DOI 10.1007/s007750100280; Boone AJ, 2001, INORG CHEM, V40, P1837, DOI 10.1021/ic0009021; Chen GJ, 1997, BIOCHEMISTRY-US, V36, P4278, DOI 10.1021/bi9618676; Clark DD, 2004, BIOCHEMISTRY-US, V43, P6763, DOI 10.1021/bi049783h; Clark DD, 2002, BIOCHEMISTRY-US, V41, P2727, DOI 10.1021/bi0118005; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; CLELAND WW, 1982, CRC CR REV BIOCH MOL, V13, P385; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; Dadd MR, 2001, ENZYME MICROB TECH, V29, P20, DOI 10.1016/S0141-0229(01)00337-4; Desai LV, 2004, DALTON T, P872, DOI 10.1039/b313380j; Dey A, 2006, J AM CHEM SOC, V128, P533, DOI 10.1021/ja0549695; Dixon M., 1979, ENZYMES, Vthird; ELROD JP, 1980, J AM CHEM SOC, V102, P3917, DOI 10.1021/ja00531a039; Endo I, 2001, J INORG BIOCHEM, V83, P247, DOI 10.1016/S0162-0134(00)00171-9; Greene SN, 2006, INORG CHEM, V45, P17, DOI 10.1021/ic050965p; Harrop TC, 2004, ACCOUNTS CHEM RES, V37, P253, DOI 10.1021/ar0301532; Hourai S, 2003, BIOCHEM BIOPH RES CO, V312, P340, DOI 10.1016/j.bbrc.2003.10.124; Huang WJ, 1997, STRUCTURE, V5, P691, DOI 10.1016/S0969-2126(97)00223-2; IZATT RM, 1976, HEATS PROTON IONIZAT; JIN HY, 1993, J AM CHEM SOC, V115, P5290, DOI 10.1021/ja00065a048; Jones S, 2004, CURR OPIN CHEM BIOL, V8, P3, DOI 10.1016/j.cbpa.2003.11.001; KOBAYASHI M, 1992, TRENDS BIOTECHNOL, V10, P402, DOI 10.1016/0167-7799(92)90283-2; Kovacs JA, 2004, CHEM REV, V104, P825, DOI 10.1021/cr020619e; Martinkova L, 1998, BIOTECHNOL LETT, V20, P909, DOI 10.1023/A:1005306723601; Martinkova L, 2003, CURR ORG CHEM, V7, P1279, DOI 10.2174/1385272033486486; Miyanaga A, 2004, EUR J BIOCHEM, V271, P429, DOI 10.1046/j.1432-1033.2003.03943.x; Miyanaga A, 2001, BIOCHEM BIOPH RES CO, V288, P1169, DOI 10.1006/bbrc.2001.5897; NAGASAWA T, 1993, APPL MICROBIOL BIOT, V40, P189; NAGASAWA T, 1988, APPL ENVIRON MICROB, V54, P1766, DOI 10.1128/AEM.54.7.1766-1769.1988; NAGASAWA T, 1995, PURE APPL CHEM, V67, P1241, DOI 10.1351/pac199567071241; Nagashima S, 1998, NAT STRUCT BIOL, V5, P347, DOI 10.1038/nsb0598-347; Nakasako M, 1999, BIOCHEMISTRY-US, V38, P9887, DOI 10.1021/bi982753s; Padmakumar R, 1999, APPL BIOCHEM BIOTECH, V77-9, P671; Payne MS, 1997, BIOCHEMISTRY-US, V36, P5447, DOI 10.1021/bi962794t; Petrillo KL, 2005, APPL MICROBIOL BIOT, V67, P664, DOI 10.1007/s00253-004-1842-9; SALOMAA P, 1964, J AM CHEM SOC, V86, P1, DOI 10.1021/ja01055a001; Segel IH., 1993, ENZYME KINETICS BEHA; Segel IH, 1975, ENZYME KINETICS BEHA; Shaw NM, 2003, ADV SYNTH CATAL, V345, P425, DOI 10.1002/adsc.200390049; Shearer J, 2002, J AM CHEM SOC, V124, P11417, DOI 10.1021/ja012555f; Shearer J, 2001, J AM CHEM SOC, V123, P463, DOI 10.1021/ja002642s; SUGIURA Y, 1987, J AM CHEM SOC, V109, P5848, DOI 10.1021/ja00253a046; Tsujimura M, 2003, J AM CHEM SOC, V125, P11532, DOI 10.1021/ja035018z; VENKATASUBBAN KS, 1984, CRC CR REV BIOCH MOL, V17, P1, DOI 10.3109/10409238409110268; Wu ZL, 2003, CHEM COMMUN, P386, DOI 10.1039/b210743k; Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391; Yamaki T, 1997, J FERMENT BIOENG, V83, P474, DOI 10.1016/S0922-338X(97)83004-8	50	51	51	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					7397	7404		10.1074/jbc.M604117200	http://dx.doi.org/10.1074/jbc.M604117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17150969	Green Published, hybrid			2022-12-27	WOS:000245080900051
J	Eto, K; Kaur, V; Thomas, MK				Eto, Kazuhiro; Kaur, Varinderpal; Thomas, Melissa K.			Regulation of pancreas duodenum homeobox-1 expression by early growth response-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC TRANSCRIPTION; NUCLEAR FACTOR 3-BETA; INSULIN GENE-TRANSCRIPTION; PROMOTER FACTOR-I; PDX-1 GENE; TARGET GENES; BETA; EGR-1; GLUCOSE; PATHWAYS	The homeodomain transcription factor pancreas duodenum homeobox-1 (PDX-1) is a key regulator of pancreatic beta-cell development, function, and survival. Deficits in PDX-1 expression result in insulin deficiency and hyperglycemia. We previously found that the glucose-responsive transcription factor early growth response-1 (Egr-1) activates the insulin promoter in part by increasing expression levels of PDX-1. We now report that Egr-1 binds and activates multiple regulatory sites within the pdx-1 promoter. We identified consensus Egr-1 recognition sequences within proximal and distal. regions of the mouse pdx-1 promoter and demonstrated specific binding of Egr-1 by chromatin immunoprecipitation and electrophoretic mobility shift assays. Overexpression of Egr-1 increased transcriptional activation of the -4500 proximal pdx-1 promoter and of the highly conserved regulatory Areas I, II, and Ill. Mutagenesis of a specific Egr-1 binding site within Area III substantially decreased Egr-1-mediated activation. Egr-1 increased the transcriptional activation of Areas I and II, despite the absence of Egr-1 recognition sequences within this promoter segment, suggesting that Egr-1 also can regulate the pdx-1 promoter indirectly. Egr-1 increased, and a dominant-negative Egr-1 mutant repressed, the transcriptional activation of distal pdx-1 promoter sequences. Mutagenesis of a specific Egr-1 binding site within regulatory Area IV reduced basal and Egr-1-mediated transcriptional activation. Our data indicate that Egr-1 regulates expression of PDX-1 in pancreatic P-cells by both direct and indirect activation of the pdx-1 promoter. We propose that Egr-1 expression levels may act as a sensor in pancreatic P-cells to translate extracellular signals into changes in PDX-1 expression levels and pancreatic beta-cell function.	Massachusetts Gen Hosp, Mol Endocrinol Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Thomas, MK (corresponding author), Massachusetts Gen Hosp, Mol Endocrinol Lab, Thier 340,50 Blossom St, Boston, MA 02114 USA.	mthomas1@partners.org			NIDDK NIH HHS [P30DK057521] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057521] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Bae SK, 1999, CANCER RES, V59, P5989; Ben-Shushan E, 2001, J BIOL CHEM, V276, P17533, DOI 10.1074/jbc.M009088200; Bernal-Mizrachi E, 2000, J BIOL CHEM, V275, P25681, DOI 10.1074/jbc.M003424200; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; Elbein SC, 2004, DIABETES CARE, V27, P1968, DOI 10.2337/diacare.27.8.1968; Eto K, 2006, ENDOCRINOLOGY, V147, P2923, DOI 10.1210/en.2005-1336; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Fu MG, 2003, GENE, V315, P33, DOI 10.1016/S0378-1119(03)00730-3; Garnett KE, 2005, J MOL ENDOCRINOL, V35, P13, DOI 10.1677/jme.1.01792; Gerrish K, 2004, MOL ENDOCRINOL, V18, P533, DOI 10.1210/me.2003-0371; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Gerrish K, 2001, J BIOL CHEM, V276, P47775, DOI 10.1074/jbc.M109244200; Gousseva N, 2001, J CELL BIOCHEM, V81, P523, DOI 10.1002/1097-4644(20010601)81:3<523::AID-JCB1066>3.0.CO;2-E; Gragnoli C, 2005, METABOLISM, V54, P983, DOI 10.1016/j.metabol.2005.01.037; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Harada S, 2001, DNA CELL BIOL, V20, P223, DOI 10.1089/104454901750219107; Holland AM, 2002, P NATL ACAD SCI USA, V99, P12236, DOI 10.1073/pnas.192255099; JHUN BH, 1995, BIOCHEMISTRY-US, V34, P7996, DOI 10.1021/bi00025a005; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Josefsen K, 1999, DIABETOLOGIA, V42, P195, DOI 10.1007/s001250051139; Kang JH, 2006, DIABETOLOGIA, V49, P969, DOI 10.1007/s00125-006-0179-6; Keeton AB, 2003, ENDOCRINOLOGY, V144, P5402, DOI 10.1210/en.2003-0592; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; Leung-Theung-Long S, 2005, J BIOL CHEM, V280, P7976, DOI 10.1074/jbc.M407485200; LIN YL, 1995, ENDOCRINOLOGY, V136, P2922, DOI 10.1210/en.136.7.2922; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mosley AL, 2004, MOL ENDOCRINOL, V18, P2279, DOI 10.1210/me.2003-0463; Offield MF, 1996, DEVELOPMENT, V122, P983; Ohsugi M, 2004, DIABETES, V53, P1496, DOI 10.2337/diabetes.53.6.1496; Owen KR, 2004, DIABETOLOGIA, V47, P957, DOI 10.1007/s00125-004-1397-4; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Samaras SE, 2003, J BIOL CHEM, V278, P12263, DOI 10.1074/jbc.M210801200; Samaras SE, 2002, MOL CELL BIOL, V22, P4702, DOI 10.1128/MCB.22.13.4702-4713.2002; Sartipy P, 2003, J BIOL CHEM, V278, P52298, DOI 10.1074/jbc.M306922200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwitzgebel VM, 2003, J CLIN ENDOCR METAB, V88, P4398, DOI 10.1210/jc.2003-030046; Sharma S, 1996, J BIOL CHEM, V271, P2294, DOI 10.1074/jbc.271.4.2294; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; Stanojevic V, 2004, ENDOCRINOLOGY, V145, P2918, DOI 10.1210/en.2003-1188; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Taub R, 1999, SEMIN LIVER DIS, V19, P117, DOI 10.1055/s-2007-1007104; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thomas Melissa K., 2004, P552; Thomas MK, 2001, J CLIN INVEST, V108, P319, DOI 10.1172/JCI200112029; Thomas MK, 2001, ENDOCRINOLOGY, V142, P1033, DOI 10.1210/en.142.3.1033; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Tsuruzoe K, 2001, MOL CELL BIOL, V21, P26, DOI 10.1128/MCB.21.1.26-38.2001; Van Velkinburgh JC, 2005, J BIOL CHEM, V280, P38438, DOI 10.1074/jbc.M508594200; Weng JP, 2002, DIABETES CARE, V25, P68, DOI 10.2337/diacare.25.1.68; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002	64	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					5973	5983		10.1074/jbc.M607288200	http://dx.doi.org/10.1074/jbc.M607288200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17150967	hybrid			2022-12-27	WOS:000244867200002
J	Banks, CAS; Kong, SE; Spahr, H; Florens, L; Martin-Brown, S; Washburn, MP; Conaway, JW; Mushegian, A; Conaway, RC				Banks, Charles A. S.; Kong, Stephanie E.; Spahr, Henrik; Florens, Laurence; Martin-Brown, Skylar; Washburn, Michael P.; Conaway, Joan W.; Mushegian, Arcady; Conaway, Ronald C.			Identification and characterization of a Schizosaccharomyces pombe RNA polymerase II elongation factor with similarity to the metazoan transcription factor ELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; T(11-19)(Q23-P13.1); SENSITIVITY; EXPRESSION; INHIBITOR; PROTEOME; SEQUENCE; SUBUNIT; CLONING; GENE	ELL family transcription factors activate the rate of transcript elongation by suppressing transient pausing by RNA, polymerase II at many sites along the DNA. ELL-associated factors 1 and 2 (EAF1 and EAF2) bind stably to ELL family members and act as strong positive regulators of their transcription activities. Orthologs of ELL and EAF have been identified in metazoa, but it has been unclear whether such RNA polymerase II elongation factors are utilized in lower eukaryotes. Using bioinformatic and biochemical approaches, we have identified a new Schizosaccharomyces pombe RNA polymerase II elongation factor that is composed of two subunits designated SpELL and SpEAF, which share weak sequence similarity with members of the metazoan ELL and EAF families. Like mammalian ELL-EAF, SpELL-SpEAF stimulates RNA polymerase II transcription elongation and pyrophosphorolysis. In addition, like many yeast RNA polymerase II elongation factors, deletion of the SpELL gene renders S. pombe sensitive to the drug 6-azauracil. Finally, phylogenetic analyses suggest that the SpELL and SpEAF proteins are evolutionarily conserved in many fungi but not in Saccharomyces cerevisiae.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Stowers Institute for Medical Research; Stanford University; University of Kansas; University of Kansas Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Conaway, RC (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	rcc@stowers-institute.org	Mushegian, Arcady/ABF-5387-2021	Mushegian, Arcady/0000-0002-6809-9225; Banks, Charles/0000-0002-0404-2940; Conaway, Joan/0000-0002-2786-0663; Washburn, Michael/0000-0001-7568-2585; Florens, Laurence/0000-0002-9310-6650	NIGMS NIH HHS [R37GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 2000, P NATL ACAD SCI USA, V97, P11319, DOI 10.1073/pnas.200346997; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Eissenberg JC, 2002, P NATL ACAD SCI USA, V99, P9894, DOI 10.1073/pnas.152193699; Elmendorf BJ, 2001, J BIOL CHEM, V276, P23109, DOI 10.1074/jbc.M101445200; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; Gerber M, 2001, EMBO J, V20, P6104, DOI 10.1093/emboj/20.21.6104; Hamada M, 2000, J BIOL CHEM, V275, P29076, DOI 10.1074/jbc.M003980200; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hemming SA, 2000, J BIOL CHEM, V275, P35506, DOI 10.1074/jbc.M004721200; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; Jin JY, 2005, J BIOL CHEM, V280, P41207, DOI 10.1074/jbc.M509128200; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; Kong SE, 2005, P NATL ACAD SCI USA, V102, P10094, DOI 10.1073/pnas.0503017102; Li YH, 2005, J MOL BIOL, V352, P151, DOI 10.1016/j.jmb.2005.07.017; Maurus D, 2005, EMBO J, V24, P1181, DOI 10.1038/sj.emboj.7600603; Miller T, 2000, J BIOL CHEM, V275, P32052, DOI 10.1074/jbc.M005175200; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; Riles L, 2004, YEAST, V21, P241, DOI 10.1002/yea.1068; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; Simone F, 2003, BLOOD, V101, P2355, DOI 10.1182/blood-2002-06-1664; Simone F, 2001, BLOOD, V98, P201, DOI 10.1182/blood.V98.1.201; Soding J, 2005, BIOINFORMATICS, V21, P951, DOI 10.1093/bioinformatics/bti125; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Zybailov B, 2006, J PROTEOME RES, V5, P2339, DOI 10.1021/pr060161n	36	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5761	5769		10.1074/jbc.M610393200	http://dx.doi.org/10.1074/jbc.M610393200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17150956	hybrid			2022-12-27	WOS:000244482300072
J	Corzo, G; Sabo, JK; Bosmans, F; Billen, B; Villegas, E; Tytgat, J; Norton, RS				Corzo, Gerardo; Sabo, Jennifer K.; Bosmans, Frank; Billen, Bert; Villegas, Elba; Tytgat, Jan; Norton, Raymond S.			Solution structure and alanine scan of a spider toxin that affects the activation of mammalian voltage-gated sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SCORPION TOXIN; OMEGA-CONOTOXIN GVIA; NA+ CHANNELS; DOMAIN-II; RAT-BRAIN; FUNCTIONAL EXPRESSION; MOLECULAR-MECHANISMS; TITYUS-SERRULATUS; NMR-SPECTROSCOPY; MEMBRANE-PROTEIN	Magi 5, from the hexathelid spider Macrothele gigas, is a 29-residue polypeptide containing three disulfide bridges. It binds specifically to receptor site 4 on mammalian voltage-gated sodium channels and competes with scorpion beta-toxins, such as Css IV from Centruroides suffusus suffusus. As a consequence, Magi 5 shifts the activation voltage of the mammalian rNav1.2a channel to more hyperpolarized voltages, whereas the insect channel, DmNav1, is not affected. To gain insight into toxin-channel interactions, Magi 5 and 23 analogues were synthesized. The three-dimensional structure of Magi 5 in aqueous solution was determined, and its voltage-gated sodium channel-binding surfaces were mapped onto this structure using data from electrophysiological measurements on a series of Ala-substituted analogues. The structure clearly resembles the inhibitor cystine knot structural motif, although the triple-stranded beta-sheet typically found in that motif is partially distorted in Magi 5. The interactive surface of Magi 5 toward voltage-gated sodium channels resembles in some respects the Janus-faced atracotoxins, with functionally important charged residues on one face of the toxin and hydrophobic residues on the other. Magi 5 also resembles the scorpion beta-toxin Css IV, which has distinct nonpolar and charged surfaces that are critical for channel binding and has a key Glu involved in voltage sensor trapping. These two distinct classes of toxin, with different amino acid sequences and different structures, may utilize similar groups of residues on their surface to achieve the common end of modifying voltage-gated sodium channel function.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Nacl Autonoma Mexico, Inst Biotechnol, Cuernavaca 61500, Morelos, Mexico; Suntory Inst Bioorgan Res, Osaka 6188503, Japan; Univ Leuven, Toxicol Lab, B-3000 Louvain, Belgium; Univ Auton Estado mexico, Ctr Invest Biotecnol, Cuernavaca 62210, Morelos, Mexico	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Universidad Nacional Autonoma de Mexico; Suntory Holdings Ltd; KU Leuven	Norton, RS (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.	Ray.Norton@wehi.edu.au	Tytgat, Jan/F-1560-2010; Corzo, Gerardo/B-3778-2014; Bosmans, Frank/A-9660-2013; Bosmans, Frank/T-5589-2017	Corzo, Gerardo/0000-0002-9513-1622; Bosmans, Frank/0000-0002-6476-235X; Bosmans, Frank/0000-0002-6476-235X; Norton, Raymond/0000-0001-8893-0584; Bosmans, Frank/0000-0002-0451-6050; Villegas Villarreal, Elba Cristina/0000-0003-1795-0427; Tytgat, Jan/0000-0003-1778-6022				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bernard C, 2001, BIOCHEMISTRY-US, V40, P12795, DOI 10.1021/bi015537j; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2001, J GEN PHYSIOL, V118, P291, DOI 10.1085/jgp.118.3.291; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Cestele S, 2006, J BIOL CHEM, V281, P21332, DOI 10.1074/jbc.M603814200; Cohen L, 2005, J BIOL CHEM, V280, P5045, DOI 10.1074/jbc.M408427200; Cohen L, 2004, J BIOL CHEM, V279, P8206, DOI 10.1074/jbc.M307531200; Corzo G, 2003, FEBS LETT, V547, P43, DOI 10.1016/S0014-5793(03)00666-5; DINGLEY AJ, 1995, J BIOMOL NMR, V6, P321; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GIBBS SJ, 1991, J MAGN RESON, V93, P395, DOI 10.1016/0022-2364(91)90014-K; Gordon Dalia, 1997, Invertebrate Neuroscience, V3, P103, DOI 10.1007/BF02480365; Hassani O, 1999, EUR J BIOCHEM, V260, P76, DOI 10.1046/j.1432-1327.1999.00152.x; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Karbat I, 2004, FASEB J, V18, P683, DOI 10.1096/fj.03-0733com; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lew MJ, 1997, J BIOL CHEM, V272, P12014, DOI 10.1074/jbc.272.18.12014; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Little MJ, 1998, FEBS LETT, V439, P246, DOI 10.1016/S0014-5793(98)01378-7; LUDVIGSEN S, 1992, J BIOMOL NMR, V2, P227, DOI 10.1007/BF01875318; Mantegazza M, 2005, J PHYSIOL-LONDON, V568, P13, DOI 10.1113/jphysiol.2005.093484; Marcotte P, 1997, CIRC RES, V80, P363, DOI 10.1161/01.RES.80.3.363; MERUTKA G, 1995, J BIOMOL NMR, V5, P14, DOI 10.1007/BF00227466; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Pallaghy PK, 1999, J PEPT RES, V53, P343, DOI 10.1034/j.1399-3011.1999.00040.x; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Sabo JK, 2007, INFECT IMMUN, V75, P61, DOI 10.1128/IAI.01041-06; Scanlon MJ, 1997, STRUCTURE, V5, P1585, DOI 10.1016/S0969-2126(97)00307-9; Schulz G. E., 1979, PRINCIPLES PROTEIN S; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SEAVEY B R, 1991, Journal of Biomolecular NMR, V1, P217, DOI 10.1007/BF01875516; Shichor I, 2002, J NEUROSCI, V22, P4364, DOI 10.1523/JNEUROSCI.22-11-04364.2002; Tan JG, 2002, J NEUROSCI, V22, P5300; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; Tong XT, 2006, BIOCHEM BIOPH RES CO, V349, P890, DOI 10.1016/j.bbrc.2006.08.131; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Warmke JW, 1997, J GEN PHYSIOL, V110, P119, DOI 10.1085/jgp.110.2.119; Waxman SG, 2002, NOVART FDN SYMP, V241, P34; Yao SG, 2000, J BIOMOL NMR, V16, P109, DOI 10.1023/A:1008382624724; Zeng XZ, 2003, TOXICON, V41, P651, DOI 10.1016/S0041-0101(02)00361-6	51	32	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4643	4652		10.1074/jbc.M605403200	http://dx.doi.org/10.1074/jbc.M605403200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17148449	hybrid			2022-12-27	WOS:000244482000045
J	Holster, T; Pakkanen, O; Soininen, R; Sormunen, R; Nokelainen, M; Kivirikko, KI; Myllyharju, J				Holster, Tiina; Pakkanen, Outi; Soininen, Raija; Sormunen, Raija; Nokelainen, Minna; Kivirikko, Kari I.; Myllyharju, Johanna			Loss of assembly of the main basement membrane collagen, type IV, but not fibril-forming collagens and embryonic death in collagen prolyl 4-hydroxylase I null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT ISOFORM; LYSYL HYDROXYLASE-3; LETHAL MUTATION; CAENORHABDITIS-ELEGANS; ENDOPLASMIC-RETICULUM; CLONING; EXPRESSION; ENZYMES; PROTEIN; LAMININ	Collagen prolyl 4-hydroxylases (C-P4Hs) catalyze the formation of the 4-hydroxyproline residues that are essential for the generation of triple helical collagen molecules. The vertebrate C-P4Hs I, II, and III are [alpha(I)](2)beta(2), [alpha(II)](2)beta(2), and [alpha(III)](2)beta(2) tetramers with identical beta subunits. We generated mice with targeted inactivation of the P4ha1 gene encoding the catalytic alpha subunit of C-P4H I to analyze its specific functions. The null mice died after E10.5, showing an overall developmental delay and a dilated endoplasmic reticulum in their cells. The capillary walls were frequently ruptured, but the capillary density remained unchanged. The C-P4H activity level in the null embryos and fibroblasts cultured from them was 20% of that in the wild type, being evidently due to the other two isoenzymes. Collagen IV immunofluorescence was almost absent in the basement membranes of the null embryos, and electron microscopy revealed disrupted basement membranes, while immunoelectron microscopy showed a lack of collagen IV in them. The amount of soluble collagen IV was increased in the null embryos and cultured null fibroblasts, indicating a lack of assembly of collagen IV molecules into insoluble structures, probably due to their underhydroxylation and hence abnormal conformation. In contrast, the null embryos had collagen I and III fibrils with a typical cross-striation pattern but slightly increased diameters, and the null fibroblasts secreted fibril-forming collagens, although less efficiently than wild-type cells. The primary cause of death of the null embryos was thus most likely an abnormal assembly of collagen IV.	Univ Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Dept Pathol, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu; University of Oulu; University of Oulu	Myllyharju, J (corresponding author), Univ Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						Abrams EW, 2002, MECH DEVELOP, V112, P165, DOI 10.1016/S0925-4773(01)00636-0; Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; Borza DB, 2001, J BIOL CHEM, V276, P28532, DOI 10.1074/jbc.M103690200; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; ENGVALL E, 1982, CELL, V29, P475, DOI 10.1016/0092-8674(82)90164-7; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; Gould DB, 2005, SCIENCE, V308, P1167, DOI 10.1126/science.1109418; Gupta MC, 1997, J CELL BIOL, V137, P1185, DOI 10.1083/jcb.137.5.1185; Heikkinen J, 2000, J BIOL CHEM, V275, P36158, DOI 10.1074/jbc.M006203200; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; Hieta R, 2002, J BIOL CHEM, V277, P23965, DOI 10.1074/jbc.M201865200; Ishida Y, 2006, MOL BIOL CELL, V17, P2346, DOI 10.1091/mbc.E05-11-1065; JAENISCH R, 1983, CELL, V32, P209, DOI 10.1016/0092-8674(83)90511-1; Kajimura D, 2004, BIOCHEM BIOPH RES CO, V314, P11, DOI 10.1016/j.bbrc.2003.12.061; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; LEIVO I, 1980, DEV BIOL, V76, P100, DOI 10.1016/0012-1606(80)90365-6; Liu X, 1997, P NATL ACAD SCI USA, V94, P1852, DOI 10.1073/pnas.94.5.1852; LOHLER J, 1984, CELL, V38, P597, DOI 10.1016/0092-8674(84)90514-2; Marutani T, 2004, J CELL SCI, V117, P5913, DOI 10.1242/jcs.01514; Matsuoka Y, 2004, MOL BIOL CELL, V15, P4467, DOI 10.1091/mbc.E04-01-0050; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Myllyharju J, 2002, J BIOL CHEM, V277, P29187, DOI 10.1074/jbc.M203824200; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; Niederreither K, 1995, MATRIX BIOL, V14, P705, DOI 10.1016/S0945-053X(05)80013-7; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Nokelainen M, 2001, EUR J BIOCHEM, V268, P5300, DOI 10.1046/j.0014-2956.2001.02464.x; Page AP, 2003, ADV PARASIT, V53, P85, DOI 10.1016/S0065-308X(03)53003-2; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; Prockop D.J., 1976, BIOCH COLLAGENS, P163; Rautavuoma K, 2004, P NATL ACAD SCI USA, V101, P14120, DOI 10.1073/pnas.0404966101; Rautavuoma K, 2002, J BIOL CHEM, V277, P23084, DOI 10.1074/jbc.M112077200; Ruotsalainen H, 2006, J CELL SCI, V119, P625, DOI 10.1242/jcs.02780; Sasaki T, 2004, J CELL BIOL, V164, P959, DOI 10.1083/jcb.200401058; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Tajima S, 1996, J DERMATOL SCI, V13, P25, DOI 10.1016/0923-1811(95)00486-6; Takahashi S., 1999, CONNECT TISSUE, V31, P161; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; Veit G, 2006, J BIOL CHEM, V281, P3494, DOI 10.1074/jbc.M509333200; Wang CG, 2002, MATRIX BIOL, V21, P559, DOI 10.1016/S0945-053X(02)00071-9; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Yoshikawa K, 2001, J BIOCHEM-TOKYO, V129, P929, DOI 10.1093/oxfordjournals.jbchem.a002939	56	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2512	2519		10.1074/jbc.M606608200	http://dx.doi.org/10.1074/jbc.M606608200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135260	hybrid			2022-12-27	WOS:000243593200043
J	Kaur, S; Lal, L; Sassano, A; Majchrzak-Kita, B; Srikanth, M; Baker, DP; Petroulakis, E; Hay, N; Sonenberg, N; Fish, EN; Platanias, LC				Kaur, Surinder; Lal, Lakhvir; Sassano, Antonella; Majchrzak-Kita, Beata; Srikanth, Maya; Baker, Darren P.; Petroulakis, Emmanuel; Hay, Nissim; Sonenberg, Nahum; Fish, Eleanor N.; Platanias, Leonidas C.			Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-DELTA; P70 S6 KINASE; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; TRANSLATIONAL CONTROL; ALPHA; PHOSPHORYLATION; MTOR; APOPTOSIS; GROWTH	The mechanisms regulating initiation of mRNA translation for the generation of protein products that mediate interferon (IFN) responses are largely unknown. We have previously shown that both Type I and II IFNs engage the mammalian target of rapamycin (mTOR), resulting in downstream phosphorylation and deactivation of the translational repressor 4E-BP1 (eIF4E-binding protein 1). In the current study, we provide direct evidence that such regulation of 4E-BP1 by IFN alpha or IFN gamma results in sequential dissociation of 4E-BP1 from eukaryotic initiation factor-4E and subsequent formation of a functional complex between eukaryotic initiation factor-4E and eukaryotic initiation factor-4G, to allow initiation of mRNA translation. We also demonstrate that the induction of key IFN alpha- or IFN gamma-inducible proteins (ISG15 (interferon-stimulated gene 15) and CXCL10) that mediate IFN responses are enhanced in 4E-BP1 (4E-BP1(-/-)) knockout MEFs, as compared with wild-type 4E-BP1(-/-) MEFs. On the other hand, IFN-dependent transcriptional regulation of the Isg15 and Cxcl10 genes is intact in the absence of 4E-BP1, as determined by real time reverse transcriptase-PCR assays and promoter assays for ISRE and GAS, establishing that 4E-BP1 plays a selective negative regulatory role in IFN-induced mRNA translation. Interestingly, the induction of expression of ISG15 and CXCL10 proteins by IFNs was also strongly enhanced in cells lacking expression of the tuberin (TSC2(-/-)) or hamartin (TSC1(-/-)) genes, consistent with the known negative regulatory effect of the TSC1-TSC2 complex on mTOR activation. In other work, we demonstrate that the induction of an IFN-dependent antiviral response is strongly enhanced in cells lacking expression of 4E-BP1 and TSC2, demonstrating that these elements of the IFN-activated mTOR pathway exhibit important regulatory effects in the generation of IFN responses. Taken altogether, our data suggest an important role for mTOR-dependent pathways in IFN signaling and identify 4E-BP1 and TSC1-TSC2 as key components in the generation of IFN-dependent biological responses.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; Lakeside Vet Affairs Med Ctr, Chicago, IL 60611 USA; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Div Cell & Mol Biol, Toronto Res Inst, Univ Hlth Network, Toronto, ON M5G 2M1, Canada; Biogen Idec Inc, Cambridge, MA 02142 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Biogen; McGill University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 303 E Super St,Lurie 3-107, Chicago, IL 60611 USA.	l-platanias@northwestern.edu	Graham, Maya/AAC-1957-2021	Graham, Maya/0000-0003-4748-974X	NATIONAL CANCER INSTITUTE [R01CA100579, R01CA077816, R01CA094079] Funding Source: NIH RePORTER; NCI NIH HHS [CA77816, CA100579, CA94079] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersen JB, 2006, BRIT J CANCER, V94, P1465, DOI 10.1038/sj.bjc.6603099; Asselah T, 2005, J CLIN VIROL, V34, pS115, DOI 10.1016/S1386-6532(05)80020-4; Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Butterfield JH, 2005, ACTA HAEMATOL-BASEL, V114, P26, DOI 10.1159/000085560; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Deb DK, 2003, J IMMUNOL, V171, P267, DOI 10.4049/jimmunol.171.1.267; Derwenskus Joy, 2006, Adv Neurol, V98, P257; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; FRIEDMAN RM, 1972, J VIROL, V10, P1184, DOI 10.1128/JVI.10.6.1184-1198.1972; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Javed A, 2006, PHARMACOL THERAPEUT, V110, P35, DOI 10.1016/j.pharmthera.2005.08.011; Katsoulidis E, 2005, J INTERF CYTOK RES, V25, P749, DOI 10.1089/jir.2005.25.749; Kaur S, 2005, EXP HEMATOL, V33, P550, DOI 10.1016/j.exphem.2005.01.014; Kaur S, 2005, J INTERF CYTOK RES, V25, P780, DOI 10.1089/jir.2005.25.780; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lekmine F, 2004, EXP CELL RES, V295, P173, DOI 10.1016/j.yexcr.2003.12.021; Lekmine F, 2003, J BIOL CHEM, V278, P27772, DOI 10.1074/jbc.M301364200; Li YZ, 2004, J BIOL CHEM, V279, P970, DOI 10.1074/jbc.M309927200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; Martensen PM, 2004, J INTERF CYTOK RES, V24, P1, DOI 10.1089/107999004772719864; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; Meric-Bernstam F, 2004, SEMIN ONCOL, V31, P10, DOI 10.1053/j.seminoncol.2004.10.013; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Parmar S, 2005, BLOOD, V106, P2436, DOI 10.1182/blood-2004-10-4003; Parmar Simrit, 2003, Current Opinion in Oncology, V15, P431, DOI 10.1097/00001622-200311000-00005; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Ritchie KJ, 2004, NAT MED, V10, P1374, DOI 10.1038/nm1133; Ritchie KJ, 2004, SEMIN CELL DEV BIOL, V15, P237, DOI 10.1016/j.semcdb.2003.12.005; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Thyrell L, 2004, J BIOL CHEM, V279, P24152, DOI 10.1074/jbc.M312219200; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Wang CF, 2003, J VIROL, V77, P3898, DOI 10.1128/JVI.77.7.3898-3912.2003; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang HFM, 2005, MOL CELL BIOL, V25, P6247, DOI 10.1128/MCB.25.14.6247-6258.2005; Zhao KW, 2005, J BIOL CHEM, V280, P42707, DOI 10.1074/jbc.M506178200	56	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1757	1768		10.1074/jbc.M607365200	http://dx.doi.org/10.1074/jbc.M607365200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17114181	hybrid, Green Published			2022-12-27	WOS:000243451300027
J	Suh, SJ; Wang, YF; Frelet, A; Leonhardt, N; Klein, M; Forestier, C; Mueller-Roeber, B; Cho, MH; Martinoia, E; Schroeder, JI				Suh, Su Jeoung; Wang, Yong-Fei; Frelet, Annie; Leonhardt, Nathalie; Klein, Markus; Forestier, Cyrille; Mueller-Roeber, Bernd; Cho, Myeon H.; Martinoia, Enrico; Schroeder, Julian I.			The ATP binding cassette transporter AtMRP5 modulates anion and calcium channel activities in Arabidopsis guard cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RESISTANCE-RELATED PROTEIN; SENSITIVE K+ CHANNELS; ABSCISIC-ACID; PLASMA-MEMBRANE; ABC TRANSPORTER; ION CHANNELS; STOMATAL CLOSURE; CHLORIDE CHANNELS; TRANSGENIC PLANTS	Stomatal guard cells control CO2 uptake and water loss between plants and the atmosphere. Stomatal closure in response to the drought stress hormone, abscisic acid (ABA), results from anion and K+ release from guard cells. Previous studies have shown that cytosolic Ca2+ elevation and ABA activate S-type anion channels in the plasma membrane of guard cells, leading to stomatal closure. However, membrane-bound regulators of abscisic acid signaling and guard cell anion channels remain unknown. Here we show that the ATP binding cassette (ABC) protein AtMRP5 is localized to the plasma membrane. Mutation in the AtMRP5 ABC protein impairs abscisic acid and cytosolic Ca2+ activation of slow (S-type) anion channels in the plasma membrane of guard cells. Interestingly, atmrp5 insertion mutant guard cells also show impairment in abscisic acid activation of Ca2+ -permeable channel currents in the plasma membrane of guard cells. These data provide evidence that the AtMRP5 ABC transporter is a central regulator of guard cell ion channel during abscisic acid and Ca2+ signal transduction in guard cells.	Univ Zurich, Inst Pflanzenbiol, CH-8008 Zurich, Switzerland; Univ Calif San Diego, Div Biol Sci, Cell & Dev Biol Sect, La Jolla, CA 92093 USA; CEA Cadarache, CNRS, UMR 163, DEVM,Lab Echanges Membrangire & Signalisat, F-13108 St Paul Les Durance, France; Univ Potsdam, D-14476 Potsdam, Germany; Yonsei Univ, Dept Biol, Seoul 120749, South Korea	University of Zurich; University of California System; University of California San Diego; CEA; Centre National de la Recherche Scientifique (CNRS); University of Potsdam; Yonsei University	Martinoia, E (corresponding author), Univ Zurich, Inst Pflanzenbiol, Zollikerstr 107, CH-8008 Zurich, Switzerland.	enrico.martinoia@botinst.unizh.ch; julian@biomail.ucsd.edu	FORESTIER, Cyrille/B-9684-2009; Martinoia, Enrico/AAH-8712-2021; Mueller-Roeber, Bernd/Z-4052-2019; frelet barrand, annie/E-5479-2015; Frelet-Barrand, Annie/S-1951-2017; FORESTIER, Cyrille/AAX-8921-2021	FORESTIER, Cyrille/0000-0003-2141-1303; Leonhardt, Nathalie/0000-0002-5392-9732; FRELET-BARRAND, Annie/0000-0002-0849-9040; Schroeder, Julian/0000-0002-3283-5972	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060396] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM060396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen GJ, 1999, PLANT CELL, V11, P1785, DOI 10.1105/tpc.11.9.1785; Allen GJ, 2002, PLANT CELL, V14, P1649, DOI 10.1105/tpc.010448; Ando-Akatsuka Y, 2002, PFLUG ARCH EUR J PHY, V445, P177, DOI 10.1007/s00424-002-0920-z; Betz WJ, 1996, CURR OPIN NEUROBIOL, V6, P365, DOI 10.1016/S0959-4388(96)80121-8; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; Bolte S, 2004, J CELL SCI, V117, P943, DOI 10.1242/jcs.00920; Bryan J, 1999, BBA-BIOMEMBRANES, V1461, P285, DOI 10.1016/S0005-2736(99)00164-9; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; CORLISS DA, 1981, J HISTOCHEM CYTOCHEM, V29, P45, DOI 10.1177/29.1.6162881; DESILVA DLR, 1985, NEW PHYTOL, V100, P473; Gaedeke N, 2001, EMBO J, V20, P1875, DOI 10.1093/emboj/20.8.1875; Geisler M, 2004, MOL BIOL CELL, V15, P3393, DOI 10.1091/mbc.E03-11-0831; GOPALAKRISHNAN M, 1993, DRUG DEVELOP RES, V28, P95, DOI 10.1002/ddr.430280202; Grabov A, 1997, PLANT J, V12, P203, DOI 10.1046/j.1365-313X.1997.12010203.x; Grabov A, 1998, P NATL ACAD SCI USA, V95, P4778, DOI 10.1073/pnas.95.8.4778; GREGER R, 2001, PFLUGERS ARCH, V443, P3; Hamilton DWA, 2000, P NATL ACAD SCI USA, V97, P4967, DOI 10.1073/pnas.080068897; Hetherington AM, 2003, NATURE, V424, P901, DOI 10.1038/nature01843; Holland I. B., 2003, ABC PROTEINS BACTERI; Hosy E, 2003, P NATL ACAD SCI USA, V100, P5549, DOI 10.1073/pnas.0733970100; Humair D, 2001, PLANT CELL, V13, P781, DOI 10.1105/tpc.13.4.781; Jilling T, 1997, INT REV CYTOL, V172, P193, DOI 10.1016/S0074-7696(08)62361-X; Klein M, 2004, PLANT J, V39, P219, DOI 10.1111/j.1365-313X.2004.02125.x; Klein M, 2003, PLANT J, V33, P119, DOI 10.1046/j.1365-313X.2003.016012.x; Kolukisaoglu HU, 2002, PLANTA, V216, P107, DOI 10.1007/s00425-002-0890-6; Kutsuna N, 2003, PLANT CELL PHYSIOL, V44, P1045, DOI 10.1093/pcp/pcg124; Kwak JM, 2003, EMBO J, V22, P2623, DOI 10.1093/emboj/cdg277; Lasceve G, 1997, PLANT CELL ENVIRON, V20, P350, DOI 10.1046/j.1365-3040.1997.d01-71.x; Lee EK, 2004, PLANT PHYSIOL, V134, P528, DOI 10.1104/pp.103.027045; Leonhardt N, 1997, P NATL ACAD SCI USA, V94, P14156, DOI 10.1073/pnas.94.25.14156; Leonhardt N, 1999, PLANT CELL, V11, P1141; Li JX, 2000, SCIENCE, V287, P300, DOI 10.1126/science.287.5451.300; Liu GS, 2001, J BIOL CHEM, V276, P8648, DOI 10.1074/jbc.M009690200; MacRobbie EAC, 1998, PHILOS T ROY SOC B, V353, P1475, DOI 10.1098/rstb.1998.0303; Martinoia E, 2002, PLANTA, V214, P345, DOI 10.1007/s004250100661; MCAINSH MR, 1995, PLANT CELL, V7, P1207, DOI 10.1105/tpc.7.8.1207; Mori IC, 2006, PLOS BIOL, V4, P1749, DOI 10.1371/journal.pbio.0040327; Murata Y, 2001, PLANT CELL, V13, P2513, DOI 10.1105/tpc.13.11.2513; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Pei ZM, 1997, PLANT CELL, V9, P409, DOI 10.1105/tpc.9.3.409; Pei ZM, 1998, SCIENCE, V282, P287, DOI 10.1126/science.282.5387.287; Pei ZM, 1998, P NATL ACAD SCI USA, V95, P6548, DOI 10.1073/pnas.95.11.6548; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; SCHMIDANTOMARCHI H, 1987, BIOCHEM BIOPH RES CO, V146, P21, DOI 10.1016/0006-291X(87)90684-X; Schroeder JI, 2001, NATURE, V410, P327, DOI 10.1038/35066500; SCHROEDER JI, 1988, J GEN PHYSIOL, V92, P667, DOI 10.1085/jgp.92.5.667; SCHROEDER JI, 1992, P NATL ACAD SCI USA, V89, P5025, DOI 10.1073/pnas.89.11.5025; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; Song WY, 2003, NAT BIOTECHNOL, V21, P914, DOI 10.1038/nbt850; Uberlacker B, 1996, MOL BREEDING, V2, P293, DOI 10.1007/BF00564208; Wang XQ, 2001, SCIENCE, V292, P2070, DOI 10.1126/science.1059046; WARD JM, 1994, PLANT CELL, V6, P669; Young JJ, 2006, P NATL ACAD SCI USA, V103, P7506, DOI 10.1073/pnas.0602225103	57	86	96	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1916	1924		10.1074/jbc.M607926200	http://dx.doi.org/10.1074/jbc.M607926200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17098742	hybrid			2022-12-27	WOS:000243451300042
J	Maillard, AP; Lalani, S; Silva, F; Belin, D; Duong, F				Maillard, Antoine P.; Lalani, Shifana; Silva, Filo; Belin, Dominique; Duong, Franck			Deregulation of the SecYEG translocation channel upon removal of the plug domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; ESCHERICHIA-COLI; SIGNAL SEQUENCE; PREPROTEIN TRANSLOCATION; MOLECULAR-DYNAMICS; PRL MUTATIONS; SECA; EXPORT; SUPPRESSORS; PHENOTYPES	Previous studies have shown that the SecY plug is displaced from the center of the SecYEG channel during polypeptide translocation. The structural and functional consequences of the deletion of the plug are now examined. Both in vivo and in vitro observations indicate that the plug domain is not essential to the function of the translocon. In fact, deletion of the plug confers to the cell and to the membranes a Prl-like phenotype: reduced proton-motive force dependence of translocation, increased membrane insertion of SecA, diminished requirement for functional leader peptide, and weakened SecYEG subunit association. Although the plug domain does not seem essential, locking the plug in the center of the channel inactivates the translocon. Thus, the SecY plug is important to regulate the activity of the channel and to confer specificity to the translocation reaction. We propose that the plug contributes to the gating mechanism of the channel by maintaining the structure of the SecYEG complex in a compact closed state.	Univ British Columbia, Fac Med, Inst Life Sci, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ Geneva, Dept Pathol & Immunol, CH-1211 Geneva, Switzerland	University of British Columbia; University of Geneva	Duong, F (corresponding author), Univ British Columbia, Fac Med, Inst Life Sci, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	FDuong@interchange.ubc.ca	Maillard, Antoine/C-5236-2013	Maillard, Antoine/0000-0002-3658-041X				Alder NN, 2005, J CELL BIOL, V168, P389, DOI 10.1083/jcb.200409174; BEDOUELLE H, 1980, NATURE, V285, P78, DOI 10.1038/285078a0; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; Bost S, 1997, J BIOL CHEM, V272, P4087, DOI 10.1074/jbc.272.7.4087; Bostina M, 2005, J MOL BIOL, V352, P1035, DOI 10.1016/j.jmb.2005.08.005; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; Cannon KS, 2005, J CELL BIOL, V169, P219, DOI 10.1083/jcb.200412019; Clemons WM, 2004, CURR OPIN STRUC BIOL, V14, P390, DOI 10.1016/j.sbi.2004.07.006; Collinson I, 2001, EMBO J, V20, P2462, DOI 10.1093/emboj/20.10.2462; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Duong F, 1999, EMBO J, V18, P3263, DOI 10.1093/emboj/18.12.3263; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FLOWER AM, 1994, J BACTERIOL, V176, P5607, DOI 10.1128/JB.176.18.5607-5614.1994; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; Gumbart J, 2006, BIOPHYS J, V90, P2356, DOI 10.1529/biophysj.105.075291; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Harris CR, 1999, J BACTERIOL, V181, P3438, DOI 10.1128/JB.181.11.3438-3444.1999; Junne T, 2006, MOL BIOL CELL, V17, P4063, DOI 10.1091/mbc.E06-03-0200; Luirink J, 2004, BBA-MOL CELL RES, V1694, P17, DOI 10.1016/j.bbamcr.2004.03.013; Maillard AP, 2005, MOL B INT U, P19; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; MURPHY CK, 1995, GENE, V155, P1, DOI 10.1016/0378-1119(94)00920-N; Nouwen N, 1996, P NATL ACAD SCI USA, V93, P5953, DOI 10.1073/pnas.93.12.5953; PETERS EA, 1994, J BACTERIOL, V176, P4296, DOI 10.1128/jb.176.14.4296-4305.1994; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Prinz WA, 1998, J BIOL CHEM, V273, P8419, DOI 10.1074/jbc.273.14.8419; Prinz WA, 1996, EMBO J, V15, P5209, DOI 10.1002/j.1460-2075.1996.tb00906.x; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; Smith MA, 2005, J BACTERIOL, V187, P6454, DOI 10.1128/JB.187.18.6454-6465.2005; Tam PCK, 2005, EMBO J, V24, P3380, DOI 10.1038/sj.emboj.7600804; Tao H, 1999, J BACTERIOL, V181, P6425, DOI 10.1128/JB.181.20.6425-6440.1999; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; Tian P, 2006, BIOPHYS J, V90, P2718, DOI 10.1529/biophysj.105.073304; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; Vrontou E, 2004, BBA-MOL CELL RES, V1694, P67, DOI 10.1016/j.bbamcr.2004.06.003; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	43	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1281	1287		10.1074/jbc.M610060200	http://dx.doi.org/10.1074/jbc.M610060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17092931	Green Published, hybrid			2022-12-27	WOS:000243295200053
J	Cha, JY; Repa, JJ				Cha, Ji-Young; Repa, Joyce J.			The liver X receptor (LXR) and hepatic lipogenesis - The carbohydrate-response element-binding protein is a target gene of LXR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILLIAMS-BEUREN-SYNDROME; FATTY-ACID SYNTHESIS; TRANSCRIPTION FACTOR; OXYSTEROL RECEPTORS; GLUCOSE-METABOLISM; ACTIVATION; DEFICIENCY; CHOLESTEROL; SREBP-1C; CHREBP	The liver X receptors, LXR alpha (NR1H3) and LXR beta (NR1H2), are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. LXRs play a critical role in cholesterol homeostasis and bile acid metabolism. In addition, oral administration of LXR agonists to mice results in elevated hepatic fatty acid synthesis and steatosis and increased secretion of triglyceride-rich very low density lipoprotein resulting in hypertriglyceridemia. This increased hepatic lipogenesis has been largely attributed to the LXR-dependent upregulation of sterol regulatory element-binding protein 1c (SREBP-1c) expression. However, it has been reported that treating Srebp-1c null mice with the synthetic LXR agonist T0901317 still results in enhanced expression of many lipogenic genes, suggesting additional mechanisms by which LXR can enhance hepatic lipogenesis. In this report, we identify the carbohydrate response element-binding protein (ChREBP) as an LXR target that independently enhances the up-regulation of select lipogenic genes. The ChREBP promoter contains functional LXR-binding sites that confer receptor-dependent binding and transactivation. We show that T0901317 treatment of mice is associated with up-regulation of the ChREBP target gene, liver-type pyruvate kinase. Therefore, activation of LXR not only increases ChREBP mRNA via enhanced transcription but also modulates ChREBP activity. This establishes LXR as a master lipogenic transcription factor, as it directly regulates both SREBP-1c and ChREBP to enhance hepatic fatty acid synthesis.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Touchstone Ctr Diabet Res, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Repa, JJ (corresponding author), 5323 Harry Hines Blvd,Y6-322C, Dallas, TX 75390 USA.	joyce.repa@utsouthwestern.edu		Repa, Joyce/0000-0001-5740-1954; Cha, JI-Young/0000-0002-8557-6214				Cao GQ, 2003, J BIOL CHEM, V278, P1131, DOI 10.1074/jbc.M210208200; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Chisholm JW, 2003, J LIPID RES, V44, P2039, DOI 10.1194/jlr.M300135-JLR200; Chu K, 2006, MOL CELL BIOL, V26, P6786, DOI 10.1128/MCB.00077-06; de Luis O, 2000, EUR J HUM GENET, V8, P215, DOI 10.1038/sj.ejhg.5200435; Dentin R, 2005, BIOCHIMIE, V87, P81, DOI 10.1016/j.biochi.2004.11.008; Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Kalaany NY, 2005, CELL METAB, V1, P231, DOI 10.1016/j.cmet.2005.03.001; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Kawaguchi T, 2002, J BIOL CHEM, V277, P3829, DOI 10.1074/jbc.M107895200; Kurrasch DM, 2004, METHOD ENZYMOL, V389, P3; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Levin N, 2005, ARTERIOSCL THROM VAS, V25, P135, DOI 10.1161/01.ATV.0000150044.84012.68; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Ma L, 2005, J BIOL CHEM, V280, P12019, DOI 10.1074/jbc.M413063200; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Merla G, 2004, HUM MOL GENET, V13, P1505, DOI 10.1093/hmg/ddh163; Podvinec M, 2002, MOL ENDOCRINOL, V16, P1269, DOI 10.1210/me.16.6.1269; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Sandelin A, 2005, MOL ENDOCRINOL, V19, P595, DOI 10.1210/me.2004-0101; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Talukdar S, 2006, J LIPID RES, V47, P2451, DOI 10.1194/jlr.M600276-JLR200; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Uyeda K, 2006, CELL METAB, V4, P107, DOI 10.1016/j.cmet.2006.06.008; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; Wu RF, 2003, BBA-GEN SUBJECTS, V1624, P29, DOI 10.1016/j.bbagen.2003.09.002; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	39	354	384	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					743	751		10.1074/jbc.M605023200	http://dx.doi.org/10.1074/jbc.M605023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17107947	hybrid			2022-12-27	WOS:000243166500079
J	Wolde, M; Fellows, A; Cheng, J; Kivenson, A; Coutermarsh, B; Talebian, L; Karlson, K; Piserchio, A; Mierke, DF; Stanton, BA; Guggino, WB; Madden, DR				Wolde, Michael; Fellows, Abigail; Cheng, Jie; Kivenson, Aleksandr; Coutermarsh, Bonita; Talebian, Laleh; Karlson, Katherine; Piserchio, Andrea; Mierke, Dale F.; Stanton, Bruce A.; Guggino, William B.; Madden, Dean R.			Targeting CAL as a negative regulator of Delta F508-CFTR cell-surface expression - An RNA interference and structure-based muta genetic approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE-CONDUCTANCE-REGULATOR; AIRWAY EPITHELIAL-CELLS; CYSTIC-FIBROSIS GENE; PLASMA-MEMBRANE; PDZ PROTEINS; FUNCTIONAL EXPRESSION; APICAL MEMBRANE; HALF-LIFE; CFTR; DOMAIN	PDZ domains are ubiquitous peptide-binding modules that mediate protein-protein interactions in a wide variety of intracellular trafficking and localization processes. These include the pathways that regulate the membrane trafficking and endocytic recycling of the cystic fibrosis transmembrane conductance regulator (CFTR), an epithelial chloride channel mutated in patients with cystic fibrosis. Correspondingly, a number of PDZ proteins have now been identified that directly or indirectly interact with the C terminus of CFTR. One of these is CAL, whose overexpression in heterologous cells directs the lysosomal degradation of WT-CFTR in a dose-dependent fashion and reduces the amount of CFTR found at the cell surface. Here, we show that RNA interference targeting endogenous CAL specifically increases cell-surface expression of the disease-associated Delta F508-CFTR mutant and thus enhances transepithelial chloride currents in a polarized human patient bronchial epithelial cell line. We have reconstituted the CAL-CFTR interaction in vitro from purified components, demonstrating for the first time that the binding is direct and allowing us to characterize its components biochemically and biophysically. To test the hypothesis that inhibition of the binding site could also reverse CAL-mediated suppression of CFTR, a three-dimensional homology model of the CAL-CFTR complex was constructed and used to generate a CAL mutant whose binding pocket is correctly folded but has lost its ability to bind CFTR. Although produced at the same levels as wild-type protein, the mutant does not affect CFTR expression levels. Taken together, our data establish CAL as a candidate therapeutic target for correction of post-maturational trafficking defects in cystic fibrosis.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Brown Univ, Div Biol & Med, Dept Mol Pharmacol, Providence, RI 02912 USA	Dartmouth College; Dartmouth College; Johns Hopkins University; Brown University	Madden, DR (corresponding author), 7200 Vail Bldg, Hanover, NH 03755 USA.	drm0001@dartmouth.edu			NCRR NIH HHS [1 P20 RR018787] Funding Source: Medline; NHLBI NIH HHS [R01 HL47122] Funding Source: Medline; PHS HHS [R01 45881] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018787] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bebok Z, 2005, J PHYSIOL-LONDON, V569, P601, DOI 10.1113/jphysiol.2005.096669; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; Brone B, 2005, AM J PHYSIOL-CELL PH, V288, pC20, DOI 10.1152/ajpcell.00368.2004; Bruscia E, 2002, GENE THER, V9, P683, DOI 10.1038/sj.gt.3301741; Cheng J, 2005, J BIOL CHEM, V280, P3731, DOI 10.1074/jbc.M410026200; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Gruenert D C, 2004, J Cyst Fibros, V3 Suppl 2, P191, DOI 10.1016/j.jcf.2004.05.040; Guerra L, 2005, J BIOL CHEM, V280, P40925, DOI 10.1074/jbc.M505103200; Guggino WB, 2006, NAT REV MOL CELL BIO, V7, P426, DOI 10.1038/nrm1949; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Harris BZ, 2001, J CELL SCI, V114, P3219; He JQ, 2004, J BIOL CHEM, V279, P50190, DOI 10.1074/jbc.M404876200; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; KOPITO RR, 1999, PHYSIOL REV, V79, P167; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunzelmann K, 2001, NEWS PHYSIOL SCI, V16, P167; Li CY, 2005, PHARMACOL THERAPEUT, V108, P208, DOI 10.1016/j.pharmthera.2005.04.004; Li Y, 2006, AM J RESP CELL MOL, V34, P600, DOI 10.1165/rcmb.2005-0421OC; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Maliepaard M, 2001, CANCER RES, V61, P3458; Milewski MI, 2001, J CELL SCI, V114, P719; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Piserchio A, 2005, BIOCHEMISTRY-US, V44, P16158, DOI 10.1021/bi0516475; Piserchio A, 2002, J BIOL CHEM, V277, P6967, DOI 10.1074/jbc.M109453200; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Swiatecka-Urban A, 2006, AM J PHYSIOL-CELL PH, V290, pC862, DOI 10.1152/ajpcell.00108.2005; Swiatecka-Urban A, 2005, J BIOL CHEM, V280, P36762, DOI 10.1074/jbc.M508944200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Taddei A, 2004, FEBS LETT, V558, P52, DOI 10.1016/S0014-5793(04)00011-0; Tuma PL, 2002, MOL BIOL CELL, V13, P3400, DOI 10.1091/mbc.02-04-0054; Van Goor F, 2006, AM J PHYSIOL-LUNG C, V290, pL1117, DOI 10.1152/ajplung.00169.2005; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wente W, 2005, J BIOL CHEM, V280, P32419, DOI 10.1074/jbc.M507198200; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	53	55	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2007	282	11					8099	8109		10.1074/jbc.M611049200	http://dx.doi.org/10.1074/jbc.M611049200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148ND	17158866	hybrid			2022-12-27	WOS:000245081000042
J	Blume, C; Benz, PM; Walter, U; Ha, J; Kemp, BE; Renne, T				Blume, Constanze; Benz, Peter M.; Walter, Ulrich; Ha, Joohun; Kemp, Bruce E.; Renne, Thomas			AMP-activated protein kinase impairs endothelial actin cytoskeleton assembly by phosphorylating vasodilator-stimulated phosphoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTACT HUMAN PLATELETS; NITRIC-OXIDE SYNTHASE; SERUM RESPONSE FACTOR; FATTY-ACID OXIDATION; VASP IN-VITRO; ENA/VASP PROTEINS; FIBROBLAST MOTILITY; GENE-EXPRESSION; CELL-MIGRATION; DYNAMICS	Vasodilator-stimulated phosphoprotein (VASP) is an actin regulatory protein that links signaling pathways to remodeling of the cytoskeleton. VASP functions are modulated by protein kinases, which phosphorylate the sites Ser-157, Ser-239, and Thr-278. The kinase responsible for Thr-278 phosphorylation, biological functions of the phosphorylation, and association with disease states have remained enigmatic. Using VASP phosphorylation status-specific antibodies, we identified AMP-activated protein kinase (AMPK), a serine-threonine kinase and fundamental sensor of energy homeostasis, in a screen for kinases that phosphorylate the Thr-278 site of VASP in endothelial cells. Pharmacological AMPK inhibitors and activators and AMPK mutants revealed that the kinase specifically targets residue Thr-278 but not Ser-157 or Ser-239. Quantitative fluorescence-activated cell sorter analysis and serum response factor transcriptional reporter assays, which quantify the cellular F-/G-actin equilibrium, indicated that AMPK-mediated VASP phosphorylation impaired actin stress fiber formation and altered cell morphology. In the Zucker Diabetic Fatty (ZDF) rat model for type II diabetes, AMPK activity and Thr-278 phosphorylation were substantially reduced in arterial vessel walls. These findings suggest that VASP is a new AMPK substrate, that VASP Thr-278 phosphorylation translates metabolic signals into actin cytoskeleton rearrangements, and that this signaling system becomes down-regulated in diabetic vessels.	Julius Maximilians Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Kyung Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 130701, South Korea; Commonwealth Sci & Ind Res Org Mol & Hlth Technol, Parkville, Vic 3052, Australia; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	University of Wurzburg; Commonwealth Scientific & Industrial Research Organisation (CSIRO); St. Vincent's Institute of Medical Research	Renne, T (corresponding author), Julius Maximilians Univ Wurzburg, Inst Clin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	thomas@renne.net	Walter, ulrich/W-2478-2017; Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Walter, ulrich/0000-0001-6784-2307; Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082; Renne, Thomas/0000-0003-4594-5975				ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; Ahima RS, 2006, NAT MED, V12, P511, DOI 10.1038/nm0506-511; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; BUTT E, 1994, J BIOL CHEM, V269, P14509; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chen MB, 2005, J CLIN ENDOCR METAB, V90, P3665, DOI 10.1210/jc.2004-1980; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Davis BJ, 2006, DIABETES, V55, P496, DOI 10.2337/diabetes.55.02.06.db05-1064; Drew BG, 2004, P NATL ACAD SCI USA, V101, P6999, DOI 10.1073/pnas.0306266101; Foretz M, 2005, DIABETES, V54, P1331, DOI 10.2337/diabetes.54.5.1331; Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Howe AK, 2002, J BIOL CHEM, V277, P38121, DOI 10.1074/jbc.M205379200; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Loureiro JJ, 2002, MOL BIOL CELL, V13, P2533, DOI 10.1091/mbc.E01-10-0102; Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Munzel T, 2005, ARTERIOSCL THROM VAS, V25, P1551, DOI 10.1161/01.ATV.0000168896.64927.bb; Munzel T, 2003, CIRCULATION, V108, P2172, DOI 10.1161/01.CIR.0000094403.78467.C3; Pold R, 2005, DIABETES, V54, P928, DOI 10.2337/diabetes.54.4.928; Price CJ, 2000, ARTERIOSCL THROM VAS, V20, P2051, DOI 10.1161/01.ATV.20.9.2051; Profirovic J, 2005, J BIOL CHEM, V280, P32866, DOI 10.1074/jbc.M501361200; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Renne T, 2005, J IMMUNOL, V175, P3377, DOI 10.4049/jimmunol.175.5.3377; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Schirenbeck A, 2006, P NATL ACAD SCI USA, V103, P7694, DOI 10.1073/pnas.0511243103; Schulz E, 2002, CIRCULATION, V105, P1170, DOI 10.1161/hc1002.105186; Sechi AS, 2004, FRONT BIOSCI, V9, P1294, DOI 10.2741/1324; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; Wang MY, 2005, AM J PHYSIOL-ENDOC M, V288, pE216, DOI 10.1152/ajpendo.00004.2004; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Yu PK, 2005, CURR EYE RES, V30, P279, DOI 10.1080/02713680590923230; Yu X, 2004, DIABETOLOGIA, V47, P2012, DOI 10.1007/s00125-004-1570-9; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zhuang SH, 2004, J BIOL CHEM, V279, P10397, DOI 10.1074/jbc.M313048200	56	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4601	4612		10.1074/jbc.M608866200	http://dx.doi.org/10.1074/jbc.M608866200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17082196	hybrid			2022-12-27	WOS:000244482000041
J	Noureddine, H; Schmitt, C; Liu, WQ; Garbay, C; Massoulie, J; Bon, S				Noureddine, Hiba; Schmitt, Claudine; Liu, Wangqing; Garbay, Christiane; Massoulie, Jean; Bon, Suzanne			Assembly of acetylcholinesterase tetramers by peptidic motifs from the proline-rich membrane anchor, PRiMA - Competition between degradation and secretion pathways of heteromeric complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL T-PEPTIDE; COLLAGEN-TAILED FORMS; QUATERNARY ASSOCIATIONS; ATTACHMENT DOMAIN; CAUDATE-NUCLEUS; BRAIN; CHOLINESTERASES; EXPRESSION; PROTEINS; SUBUNITS	The membrane-bound form of acetylcholinesterase (AChE) constitutes the major component of this enzyme in the mammalian brain. These molecules are hetero-oligomers, composed of four AChE catalytic subunits of type T (AChE(T)), associated with a transmembrane protein of type 1, called PRiMA (proline-rich membrane anchor). PRiMA consists of a signal peptide, an extracellular domain that contains a proline-rich motif (14 prolines with an intervening leucine, P4LP10), a transmembrane domain, and a cytoplasmic domain. Expression of AChET subunits in transfected COS cells with a truncated PRiMA, without its transmembrane and cytoplasmic domains (P-stp54 mutant), produced secreted heteromeric complexes (T-4-P-stp54), instead of membrane-bound tetramers. In this study, we used a series of deletions and point mutations to analyze the interaction between the extracellular domain of PRiMA and AChET subunits. We confirmed the importance of the polyproline stretches and defined a peptidic motif (Rp(4)LP(10)RL), which induces the assembly and secretion of a heteromeric complex with four AChET subunits, nearly as efficiently as the entire extracellular domain of PRiMA. It is noteworthy that deletion of the N-terminal segment preceding the prolines had little effect. Interestingly, short PRiMA mutants, truncated within the proline-rich motif, reduced both cellular and secreted AChE activity, suggesting that their interaction with AChET subunits induces their intracellular degradation.	Ecole Normale Super, CNRS, Neurobiol Cellulaire & Mol Lab, UMR 8544, F-75005 Paris, France; INSERM, UFR Biomed St Peres, Lab Pharmacochim Mol & Cellulaire, U648, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Massoulie, J (corresponding author), Ecole Normale Super, CNRS, Neurobiol Cellulaire & Mol Lab, UMR 8544, 46 Rue DUlm, F-75005 Paris, France.	jean.massoulie@biologie.ens.fr	LIU, Wang-Qing/V-5422-2017	LIU, Wang-Qing/0000-0003-0511-3058				Belbeoc'h S, 2004, EUR J BIOCHEM, V271, P1476, DOI 10.1111/j.1432-1033.2004.04052.x; Belbeoc'h S, 2003, EMBO J, V22, P3536, DOI 10.1093/emboj/cdg360; BON S, 1991, CELL MOL NEUROBIOL, V11, P157, DOI 10.1007/BF00712807; Bon S, 2004, EUR J BIOCHEM, V271, P33, DOI 10.1046/j.1432-1033.2003.03892.x; Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; Boschetti N, 1996, FEBS LETT, V380, P133, DOI 10.1016/0014-5793(96)00041-5; BOSCHETTI N, 1994, NEUROCHEM RES, V19, P359, DOI 10.1007/BF00971586; DUVAL N, 1992, EMBO J, V11, P3255, DOI 10.1002/j.1460-2075.1992.tb05403.x; Dvir H, 2004, EMBO J, V23, P4394, DOI 10.1038/sj.emboj.7600425; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Falasca C, 2005, J BIOL CHEM, V280, P878, DOI 10.1074/jbc.M409201200; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GENNARI K, 1987, J NEUROCHEM, V49, P12, DOI 10.1111/j.1471-4159.1987.tb03386.x; GISIGER V, 1994, EUR J NEUROSCI, V6, P673, DOI 10.1111/j.1460-9568.1994.tb00979.x; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Massoulie J, 2005, CHEM-BIOL INTERACT, V157, P3, DOI 10.1016/j.cbi.2005.10.002; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morel N, 2001, J BIOL CHEM, V276, P37379, DOI 10.1074/jbc.M103192200; Perrier AL, 2000, J BIOL CHEM, V275, P34260, DOI 10.1074/jbc.M004289200; Perrier AL, 2002, NEURON, V33, P275, DOI 10.1016/S0896-6273(01)00584-0; Perrier NA, 2003, EUR J NEUROSCI, V18, P1837, DOI 10.1046/j.1460-9568.2003.02914.x; SIGLER GF, 1983, BIOPOLYMERS, V22, P2157, DOI 10.1002/bip.360221002; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; Simon S, 1998, EMBO J, V17, P6178, DOI 10.1093/emboj/17.21.6178; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Zhang DQ, 2005, PLOS COMPUT BIOL, V1, P484, DOI 10.1371/journal.pcbi.0010062	34	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3487	3497		10.1074/jbc.M607221200	http://dx.doi.org/10.1074/jbc.M607221200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158452	Green Submitted, hybrid			2022-12-27	WOS:000244481900011
J	Cruz, CM; Rinna, A; Forman, HJ; Ventura, ALM; Persechini, PM; Ojcius, DM				Cruz, Cristiane M.; Rinna, Alessandra; Forman, Henry Jay; Ventura, Ana L. M.; Persechini, Pedro M.; Ojcius, David M.			ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE 1B; REVERSIBLE INACTIVATION; P2X(7) RECEPTORS; REDOX REGULATION; MAP KINASE; PROTEIN; PHOSPHORYLATION; GLUTATHIONE; CALCIUM; PORE	Secretion of the proinflammatory cytokines, interleukin (IL)-1 beta and IL-18, usually requires two signals. The first, due to microbial products such as lipopolysaccharide, initiates transcription of the cytokine genes and accumulation of the precursor proteins. Cleavage and secretion of the cytokines is mediated by caspase-1, in association with an inflammasome containing Nalp3, which can be activated by binding of extracellular ATP to purinergic receptors. We show that treatment of macrophages with ATP results in production of reactive oxygen species (ROS), which stimulate the phosphatidylinositol 3-kinase (PI3K) pathway and subsequent Akt and ERK1/2 activation. ROS exerts its effect through glutathionylation of PTEN (phosphatase and tensin homologue deleted from chromosome 10), whose inactivation would shift the equilibrium in favor of PI3K. ATP-dependent ROS production and PI3K activation also stimulate transcription of genes required for an oxidative stress response. In parallel, ATP-mediated ROS-dependent PI3K is required for activation of caspase-1 and secretion of IL-1 beta and IL-18. Thus, an increase in ROS levels in ATP-treated macrophages results in activation of a single pathway that promotes both adaptation to subsequent exposure to oxidants or inflammation, and processing and secretion of proinflammatory cytokines.	Univ Calif, Sch Nat Sci, Merced, CA 95344 USA; Univ Fed Rio de Janeiro, IBCCF, Lab Imunobiofis, BR-21949900 Rio De Janeiro, Brazil; Univ Fed Fluminense, Inst Biol, Lab Neuroquim, BR-24030210 Niteroi, RJ, Brazil	University of California System; University of California Merced; Universidade Federal do Rio de Janeiro; Universidade Federal Fluminense	Ojcius, DM (corresponding author), POB 2039, Merced, CA 95344 USA.	dojcius@ucmerced.edu	Ojcius, David/ABE-6557-2020; Persechini, Pedro/A-9477-2009	Persechini, Pedro/0000-0002-3278-1951; Forman, Henry Jay/0000-0001-5838-2791; Ojcius, David/0000-0003-1461-4495	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37556, R01 HL037556-18, R01 HL037556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101; Auger R, 2005, J BIOL CHEM, V280, P28142, DOI 10.1074/jbc.M501290200; Bannas P, 2005, BLOOD, V105, P3663, DOI 10.1182/blood-2004-08-3325; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Bogeski I, 2006, CELL CALCIUM, V40, P1, DOI 10.1016/j.ceca.2006.03.003; Bowler JW, 2003, BRIT J PHARMACOL, V140, P567, DOI 10.1038/sj.bjp.0705459; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Colston JT, 2005, FEBS LETT, V579, P2533, DOI 10.1016/j.febslet.2005.03.057; Coutinho-Silva R, 2003, IMMUNITY, V19, P403, DOI 10.1016/S1074-7613(03)00235-8; da Cruz CM, 2006, BRIT J PHARMACOL, V147, P324, DOI 10.1038/sj.bjp.0706559; Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Forman Henry Jay, 2003, Molecular Aspects of Medicine, V24, P189, DOI 10.1016/S0098-2997(03)00013-X; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; Fratelli M, 2005, P NATL ACAD SCI USA, V102, P13998, DOI 10.1073/pnas.0504398102; Garcia-Marcos M, 2006, J LIPID RES, V47, P705, DOI 10.1194/jlr.M500408-JLR200; Gendron FP, 2003, AM J PHYSIOL-CELL PH, V284, pC571, DOI 10.1152/ajpcell.00286.2002; Gong MC, 2006, J APPL PHYSIOL, V100, P399, DOI 10.1152/japplphysiol.00873.2005; HELMKE RJ, 1987, IN VITRO CELL DEV B, V23, P567; Jacques-Silva MC, 2004, BRIT J PHARMACOL, V141, P1106, DOI 10.1038/sj.bjp.0705685; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kil IS, 2005, J BIOL CHEM, V280, P10846, DOI 10.1074/jbc.M411306200; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Lee SB, 2005, CELL SIGNAL, V17, P197, DOI 10.1016/j.cellsig.2004.07.001; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Lich JD, 2006, IMMUNITY, V24, P241, DOI 10.1016/j.immuni.2006.03.004; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946; Moellering DR, 2002, BIOCHEM J, V362, P51, DOI 10.1042/0264-6021:3620051; Monteiro HP, 2005, METHOD ENZYMOL, V396, P350, DOI 10.1016/S0076-6879(05)96029-1; Nathan C, 2003, J CLIN INVEST, V111, P769, DOI 10.1172/JCI200318174; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Pfeiffer ZA, 2004, J LEUKOCYTE BIOL, V75, P1173, DOI 10.1189/jlb.1203648; Qin SF, 2003, BIOCHEMISTRY-US, V42, P2995, DOI 10.1021/bi0205911; Rahman I, 2005, MUTAT RES-FUND MOL M, V579, P58, DOI 10.1016/j.mrfmmm.2005.02.025; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Ridnour LA, 2005, FREE RADICAL BIO MED, V38, P1361, DOI 10.1016/j.freeradbiomed.2005.01.023; Rinna A, 2006, FREE RADICAL BIO MED, V41, P86, DOI 10.1016/j.freeradbiomed.2006.03.010; Sekiyama A, 2005, IMMUNITY, V22, P669, DOI 10.1016/j.immuni.2005.04.006; Singh DK, 2005, CELL, V121, P281, DOI 10.1016/j.cell.2005.02.036; Tabner BJ, 2005, BIOCHEM SOC T, V33, P1082, DOI 10.1042/BST0331082; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Vilhardt F, 2004, EMBO J, V23, P739, DOI 10.1038/sj.emboj.7600066; Wu RF, 2005, J CELL BIOL, V171, P893, DOI 10.1083/jcb.200507004; Yamamoto M, 2004, GENES CELLS, V9, P1055, DOI 10.1111/j.1365-2443.2004.00789.x; Zhang GH, 1997, J LEUKOCYTE BIOL, V62, P341, DOI 10.1002/jlb.62.3.341; Zhuang SG, 2003, PHOTOCHEM PHOTOBIOL, V78, P361, DOI 10.1562/0031-8655(2003)078<0361:SOAOPK>2.0.CO;2; Zima AV, 2006, CARDIOVASC RES, V71, P310, DOI 10.1016/j.cardiores.2006.02.019	60	557	586	2	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2871	2879		10.1074/jbc.M608083200	http://dx.doi.org/10.1074/jbc.M608083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17132626	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000243793900013
J	Gan, HK; Walker, F; Burgess, AW; Rigopoulos, A; Scott, AM; Johns, TG				Gan, Hui K.; Walker, Francesca; Burgess, Antony W.; Rigopoulos, Angela; Scott, Andrew M.; Johns, Terrance G.			The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers - Implications for combination therapy with monoclonal antibody 806	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY CETUXIMAB; CELL-SURFACE; TUMOR XENOGRAFTS; CARCINOMA-CELLS; CYTOTOXIC DRUGS; HUMAN CANCERS; PROTEIN; RECOGNIZES; ACTIVATION; BINDING	The epidermal growth factor receptor (EGFR) has at least two fundamental conformations: an inactive tethered conformation and an active untethered, ligand-bound "back-toback" dimer, which may be part of an oligomeric complex. Monoclonal antibody (mAb) 806 is an EGFR-specific antibody that only binds a transitional form of the receptor after it untethers but before forming the back-to-back, ligated, active oligomer. We have shown that AG1478, a tyrosine kinase inhibitor of the EGFR, synergistically inhibits the growth of tumors overexpressing EGFR when used in combination with mAb 806 but the mechanism for this was not elucidated (Johns, T. G., Luwor, R. B., Murone, C., Walker, F., Weinstock, J., Vitali, A. A., Perera, R. M., Jungbluth, A. A., Stockert, E., Old, L. J., Nice, E. C., Burgess, A. W., and Scott, A. M. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 15871 15876). We now show that AG1478 increases binding of mAb 806 to the cell surface through two distinct mechanisms: an immediate effect on the conformation of EGFR and a longer term increase in cell surface under-glycosylated EGFR, an event known to increase mAb 806 reactivity. Cross-linking studies demonstrated the presence of spontaneously occurring mAb 806-reactive dimers on the surface of cells overexpressing EGFR, which are rapidly increased by AG1478. Because they react with mAb 806, these dimers must exist in a conformation distinct from the ligated back-to-back dimer. Indeed, we detected similar dimers in 293T cells expressing the EGFR lacking the small dimerization/activation arm essential to the formation of the back-to-back dimer. Thus, some of the EGFR on the cell surface of cancer cells must exist as an untethered dimer that adopts a previously unreported conformation that is inactive. This information was used to optimize the therapeutic synergy between mAb 806 and AG1478 in a xenograft model.	Austin Hosp, Ludwig Inst Canc Res, Oncogen Signalling Lab, Heidelberg, Vic 3084, Australia; Austin Hosp, Ludwig Inst Canc Res, Tumour Targeting Program, Heidelberg, Vic 3084, Australia; Royal Childrens Hosp, Epithelial Biochem Lab, Parkville, Vic 3052, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Royal Children's Hospital Melbourne	Johns, TG (corresponding author), Austin Hosp, Ludwig Inst Canc Res, Oncogen Signalling Lab, Level 6,Harold Stokes Bldg,Studley Rd, Heidelberg, Vic 3084, Australia.	terry.johns@ludwig.edu.au	Gan, Hui/C-5407-2013; Johns, Terrance/C-2441-2008	Johns, Terrance/0000-0002-8874-4543; Scott, Andrew/0000-0002-6656-295X; Gan, Hui/0000-0001-7319-8546				Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Baselga J, 2002, ONCOLOGIST, V7, P2; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Clayton AHA, 2005, J BIOL CHEM, V280, P30392, DOI 10.1074/jbc.M504770200; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; Fischel JL, 2005, BRIT J CANCER, V92, P1063, DOI 10.1038/sj.bjc.6602428; Frederick L, 2000, CANCER RES, V60, P1383; Friedman LM, 2005, P NATL ACAD SCI USA, V102, P1915, DOI 10.1073/pnas.0409610102; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GILL GN, 1984, J BIOL CHEM, V259, P7755; Hagar W, 2003, PEDIATR HEMAT ONCOL, V20, P229, DOI 10.1080/08880010390158856; Han YC, 1996, CANCER RES, V56, P3859; Hidalgo Manuel, 2003, Oncology (Williston Park), V17, P11; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; Jimeno A, 2005, CANCER RES, V65, P3003, DOI 10.1158/0008-5472.CAN-04-3586; Johns TG, 2005, FASEB J, V19, P780, DOI 10.1096/fj.04-1766fje; Johns TG, 2004, J BIOL CHEM, V279, P30375, DOI 10.1074/jbc.M401218200; Johns TG, 2003, P NATL ACAD SCI USA, V100, P15871, DOI 10.1073/pnas.2036503100; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Jungbluth AA, 2003, P NATL ACAD SCI USA, V100, P639, DOI 10.1073/pnas.232686499; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Klein P, 2004, P NATL ACAD SCI USA, V101, P929, DOI 10.1073/pnas.0307285101; KWOK TT, 1991, BRIT J CANCER, V64, P251, DOI 10.1038/bjc.1991.286; Lichtner RB, 2001, CANCER RES, V61, P5790; Luwor RB, 2001, CANCER RES, V61, P5355; Martin-Fernandez M, 2002, BIOPHYS J, V82, P2415, DOI 10.1016/S0006-3495(02)75585-9; MASUI H, 1984, CANCER RES, V44, P1002; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Mendelsohn J, 1989, Trans Am Clin Climatol Assoc, V100, P31; Mendelsohn J, 2002, J CLIN ONCOL, V20, p1S, DOI 10.1200/JCO.2002.07.121; Mishima K, 2001, CANCER RES, V61, P5349; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186; Perera RM, 2005, CLIN CANCER RES, V11, P6390, DOI 10.1158/1078-0432.CCR-04-2653; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Walker F, 1998, GROWTH FACTORS, V16, P53, DOI 10.3109/08977199809017491; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; Walker F, 2004, J BIOL CHEM, V279, P22387, DOI 10.1074/jbc.M401244200; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411	48	79	88	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2840	2850		10.1074/jbc.M605136200	http://dx.doi.org/10.1074/jbc.M605136200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17092939	hybrid			2022-12-27	WOS:000243793900010
J	Sharon, N				Sharon, Nathan			Lectins: Carbohydrate-specific reagents and biological recognition molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ERYTHRINA-CORALLODENDRON LECTIN; N-LINKED OLIGOSACCHARIDE; ESCHERICHIA-COLI; SOYBEAN AGGLUTININ; CRISTAGALLI LECTIN; CRYSTAL-STRUCTURE; CONCANAVALIN-A; PEANUT AGGLUTININ; SURFACE-MEMBRANE; CONTAINING SITES		Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Sharon, N (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	nathan.sharon@weizmann.ac.il						Adar R, 1998, PROTEIN SCI, V7, P52, DOI 10.1002/pro.5560070105; Adar R, 1996, EUR J BIOCHEM, V239, P668, DOI 10.1111/j.1432-1033.1996.0668u.x; Adar R, 1997, EUR J BIOCHEM, V249, P684, DOI 10.1111/j.1432-1033.1997.t01-3-00684.x; AGRAWAL BBL, 1965, BIOCHEM J, V96, pC23; ALLEN AK, 1973, BIOCHEM J, V131, P155, DOI 10.1042/bj1310155; ARANGO R, 1992, EUR J BIOCHEM, V205, P575, DOI 10.1111/j.1432-1033.1992.tb16815.x; ARONSON M, 1979, J INFECT DIS, V139, P329, DOI 10.1093/infdis/139.3.329; ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; ASHFORD DA, 1991, CARBOHYD RES, V213, P215, DOI 10.1016/S0008-6215(00)90610-4; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; AUB JC, 1965, P NATL ACAD SCI USA, V54, P400, DOI 10.1073/pnas.54.2.400; Aversa F, 1998, NEW ENGL J MED, V339, P1186, DOI 10.1056/NEJM199810223391702; BARKAIGOLAN R, 1978, ARCH MICROBIOL, V116, P119, DOI 10.1007/BF00406026; Bouckaert J, 2005, MOL MICROBIOL, V55, P441, DOI 10.1111/j.1365-2958.2004.04415.x; BOWLES DJ, 1986, J CELL BIOL, V102, P1284, DOI 10.1083/jcb.102.4.1284; Brinda KV, 2004, PROTEIN SCI, V13, P1735, DOI 10.1110/ps.04651004; BURGER MM, 1967, P NATL ACAD SCI USA, V57, P359, DOI 10.1073/pnas.57.2.359; Chandra NR, 2006, GLYCOBIOLOGY, V16, P938, DOI 10.1093/glycob/cwl012; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Daniels MA, 2002, NAT IMMUNOL, V3, P903, DOI 10.1038/ni1002-903; Deras IL, 1998, CARBOHYD RES, V306, P469; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; DONNELY EH, 1970, BIOCHEM J, V118, P697; DORLAND L, 1981, J BIOL CHEM, V256, P7708; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Duguid J. L., 1980, BACTERIAL ADHERENCE, V6, P185; EDELMAN GM, 1972, P NATL ACAD SCI USA, V69, P2580, DOI 10.1073/pnas.69.9.2580; FIRON N, 1983, CARBOHYD RES, V120, P235, DOI 10.1016/0008-6215(83)88019-7; FIRON N, 1987, INFECT IMMUN, V55, P472, DOI 10.1128/IAI.55.2.472-476.1987; FORIERS A, 1977, BIOCHEM BIOPH RES CO, V75, P980, DOI 10.1016/0006-291X(77)91478-4; Frederick JR, 2005, GLYCOBIOLOGY, V15, p53R, DOI 10.1093/glycob/cwj007; GILBOAGARBER N, 1981, CAN J BIOCHEM CELL B, V59, P315, DOI 10.1139/o81-044; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; GINSBURG V, 1971, STRUCTURE FUNCTION B, P439; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; HEMPERLY JJ, 1983, TRENDS BIOCHEM SCI, V8, P100, DOI 10.1016/0968-0004(83)90260-8; Hernandez JD, 2002, GLYCOBIOLOGY, V12, p127R, DOI 10.1093/glycob/cwf081; HOAGLAND MB, 1957, BIOCHIM BIOPHYS ACTA, V26, P215, DOI 10.1016/0006-3002(57)90081-1; Hughes RC, 2001, BIOCHIMIE, V83, P667; IGLESIAS JL, 1982, EUR J BIOCHEM, V123, P247, DOI 10.1111/j.1432-1033.1982.tb19760.x; INBAR M, 1969, P NATL ACAD SCI USA, V63, P1418, DOI 10.1073/pnas.63.4.1418; INBAR M, 1973, FEBS LETT, V32, P124, DOI 10.1016/0014-5793(73)80753-7; INDAPAANHEIKILA I, 1997, J INFECT DIS, V176, P704; JACOBS S, 1977, BIOCHEM BIOPH RES CO, V77, P981, DOI 10.1016/S0006-291X(77)80074-0; KABAT EA, 1978, J SUPRAMOL STR CELL, V8, P79, DOI 10.1002/jss.400080107; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Katchalski-Katzir E, 2005, J BIOL CHEM, V280, P16529, DOI 10.1074/jbc.X400013200; Kijne JW, 1997, PLANT PHYSIOL, V115, P869, DOI 10.1104/pp.115.3.869; KOBILER D, 1981, J INFECT DIS, V144, P539, DOI 10.1093/infdis/144.6.539; Koshland DE, 2004, NATURE, V432, P447, DOI 10.1038/432447a; Kulkarni KA, 2004, PROTEINS, V56, P821, DOI 10.1002/prot.20168; KYOGASHIMA M, 1989, ARCH BIOCHEM BIOPHYS, V270, P391, DOI 10.1016/0003-9861(89)90042-8; LEFFLER H, 1981, INFECT IMMUN, V34, P920, DOI 10.1128/IAI.34.3.920-929.1981; Lemieux RU, 2000, ISRAEL J CHEM, V40, P167, DOI 10.1560/KWWW-42NX-6MKR-V55W; LEVY HM, 1959, P NATL ACAD SCI USA, V45, P785, DOI 10.1073/pnas.45.6.785; LEVY HM, 1960, J BIOL CHEM, V235, P2628; Ley K, 2003, TRENDS MOL MED, V9, P263, DOI 10.1016/S1471-4914(03)00071-6; LIAV A, 1974, CARBOHYD RES, V33, P217, DOI 10.1016/S0008-6215(00)82799-8; Liener I.E., 1986, LECTINS PROPERTIES F; Liener IE, 2002, J AGR FOOD CHEM, V50, P6580, DOI 10.1021/jf020185o; LIS H, 1966, J BIOL CHEM, V241, P684; LIS H, 1969, BIOCHIM BIOPHYS ACTA, V192, P364, DOI 10.1016/0304-4165(69)90380-8; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; LIS H, 1973, ANNU REV BIOCHEM, V42, P541, DOI 10.1146/annurev.bi.42.070173.002545; LOTAN R, 1975, J BIOL CHEM, V250, P8518; LOTAN R, 1975, J BIOL CHEM, V250, P1955; LOTAN R, 1974, J BIOL CHEM, V249, P1219; Lu JH, 2002, BBA-GEN SUBJECTS, V1572, P387, DOI 10.1016/S0304-4165(02)00320-3; MARCHESI VT, 1972, P NATL ACAD SCI USA, V69, P1445, DOI 10.1073/pnas.69.6.1445; MEROMSKY L, 1986, CANCER RES, V46, P5270; MIER JW, 1982, J IMMUNOL, V128, P1122; Moreno E, 1997, BIOCHEMISTRY-US, V36, P4429, DOI 10.1021/bi962231h; Morgan WTJ, 2000, GLYCOCONJUGATE J, V17, P501, DOI 10.1023/A:1011014307683; Mysore JV, 1999, GASTROENTEROLOGY, V117, P1316, DOI 10.1016/S0016-5085(99)70282-9; NICOLSON GL, 1971, P NATL ACAD SCI USA, V68, P942, DOI 10.1073/pnas.68.5.942; NICOLSON GL, 1974, INT REV CYTOL, V39, P89, DOI 10.1016/S0074-7696(08)60939-0; NOVOGRODSKY A, 1975, J IMMUNOL, V115, P1243; NOVOGRODSKY A, 1973, P NATL ACAD SCI USA, V70, P2515, DOI 10.1073/pnas.70.9.2515; NOWELL PC, 1960, CANCER RES, V20, P462; OFEK I, 1988, INFECT IMMUN, V56, P539, DOI 10.1128/IAI.56.3.539-547.1988; OFEK I, 1977, NATURE, V265, P623, DOI 10.1038/265623a0; PEREIRA MEA, 1976, CARBOHYD RES, V51, P107; PEUMANS WJ, 1995, PLANT PHYSIOL, V109, P347, DOI 10.1104/pp.109.2.347; RAVDIN JI, 1981, J CLIN INVEST, V68, P1305, DOI 10.1172/JCI110377; RAZ A, 1981, CANCER RES, V41, P3642; REISNER Y, 1983, BLOOD, V61, P341; REISNER Y, 1978, P NATL ACAD SCI USA, V75, P2933, DOI 10.1073/pnas.75.6.2933; REISNER Y, 1976, CELL IMMUNOL, V25, P129, DOI 10.1016/0008-8749(76)90103-9; REISNER Y, 1977, DEV BIOL, V61, P20, DOI 10.1016/0012-1606(77)90338-4; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; SALIT IE, 1977, J EXP MED, V146, P1182, DOI 10.1084/jem.146.5.1182; SCHAUER R, 1973, ANGEW CHEM INT EDIT, V12, P127, DOI 10.1002/anie.197301271; SCHECHTER B, 1976, EUR J IMMUNOL, V6, P145, DOI 10.1002/eji.1830060302; SELA BA, 1970, J MEMBRANE BIOL, V3, P267, DOI 10.1007/BF01868019; SHAANAN B, 1984, J MOL BIOL, V174, P723, DOI 10.1016/0022-2836(84)90092-5; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHARON N, 1960, J BIOL CHEM, V235, P1; Sharon N, 2006, BBA-GEN SUBJECTS, V1760, P527, DOI 10.1016/j.bbagen.2005.12.008; Sharon N, 2004, GLYCOBIOLOGY, V14, p53R, DOI 10.1093/glycob/cwh122; SHARON N, 1983, ADV IMMUNOL, V34, P213, DOI 10.1016/S0065-2776(08)60380-6; SHARON N, 1993, SCI AM, V268, P82, DOI 10.1038/scientificamerican0193-82; Sharon N, 2001, ADV EXP MED BIOL, V491, P1; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SHARON N, 1972, SCIENCE, V177, P949, DOI 10.1126/science.177.4053.949; SHARON N, 1974, COLLOQ INT CENT NATL, V221, P693; SHARON N, 1997, ANTIGENS, V4, P429; SHARON N, 2000, COMPREHENSIVE BIOCH, V41, P391; Sharon N., 1975, COMPLEX CARBOHYDRATE; Sharon N., 2003, LECTINS; SHARON NATHAN, 1957, ARCH BIOCHEM AND BIOPHYS, V69, P219, DOI 10.1016/0003-9861(57)90488-5; SRINIVASAN N, 1986, CHEMTRACTS BIOCH MOL, V6, P149; STANLEY P, 1987, TRENDS GENET, V3, P77, DOI 10.1016/0168-9525(87)90180-6; Sumner JB, 1936, J BACTERIOL, V32, P227, DOI 10.1128/JB.32.2.227-237.1936; Svensson C, 2002, J MOL BIOL, V321, P69, DOI 10.1016/S0022-2836(02)00554-5; TAYLOR ME, 2006, INTRO GLYCOBOLOGY; TEICHBERG VI, 1975, P NATL ACAD SCI USA, V72, P1383, DOI 10.1073/pnas.72.4.1383; TERAO T, 1975, H-S Z PHYSIOL CHEM, V356, P1685, DOI 10.1515/bchm2.1975.356.2.1685; Turton K, 2004, GLYCOBIOLOGY, V14, P923, DOI 10.1093/glycob/cwh114; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; WADA S, 1958, J BIOL CHEM, V233, P395; WECKSLER M, 1968, ACTA CIENT VENEZ, V19, P154; Weerapana E, 2006, GLYCOBIOLOGY, V16, p91R, DOI 10.1093/glycob/cwj099; WRIGHT CS, 1977, J MOL BIOL, V111, P439, DOI 10.1016/S0022-2836(77)80063-6; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200; ZEHAVI U, 1973, J BIOL CHEM, V248, P433	126	318	338	2	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2753	2764		10.1074/JBC.X600004200	http://dx.doi.org/10.1074/JBC.X600004200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145746	hybrid			2022-12-27	WOS:000243793900002
J	Cochrane, DR; Wang, Z; Muramaki, M; Gleave, ME; Nelson, CC				Cochrane, Dawn R.; Wang, Zhou; Muramaki, Motosugu; Gleave, Martin E.; Nelson, Colleen C.			Differential regulation of clusterin and its Isoforms by androgens in prostate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRAL PROSTATE; STEROID-HORMONE RECEPTORS; BREAST-CANCER CELLS; GROWTH-FACTOR-BETA; RETE TESTIS FLUID; GENE-EXPRESSION; EPITHELIAL-CELLS; IN-VITRO; ANTISENSE OLIGONUCLEOTIDES; MEDIATED APOPTOSIS	Clusterin mRNA levels were shown to increase dramatically in rat ventral prostate following castration, and clusterin was therefore originally thought to be repressed by androgens. It was later discovered that the increased clusterin levels are most likely due to castration-induced apoptosis of the prostatic epithelium rather than direct action of the androgen receptor (AR). In the studies presented here, LNCaP cells in culture and rat prostate organ culture were treated with androgens. Clusterin mRNA and protein are shown to increase with androgen treatment in a time- and dose-dependent manner. This induction of clusterin requires AR and can be inhibited by casodex, an AR antagonist. We have found that the first intron of the clusterin gene contains putative androgen response elements. The intronic region is shown to be bound by AR in chromatin immunoprecipitation assays and is transactivated by AR in reporter assays. Two isoforms of clusterin result from alternate transcriptional start sites. Both isoforms are cytoprotective; however, Isoform 1 has the capacity to produce a splice variant that is apoptotic. Real time PCR was used to determine the response of the two isoforms to androgens. Intriguingly, these results illustrated that Isoform 2 was up-regulated, whereas Isoform 1 was down-regulated by androgens. Isoform 2 was also increased as the LNCaP xenograft tumor progressed to androgen-independence, whereas Isoform 1 was unaltered. This androgen regulation of clusterin may underline the cytoprotective role of androgens in normal prostate physiology as well as play an antiapoptotic role in prostate cancer progression.	VGH, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Genet, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Urol Sci, Vancouver, BC V6T 1Z3, Canada; Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA 15232 USA	University of British Columbia; University of British Columbia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Nelson, CC (corresponding author), VGH, Prostate Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	colleen.nelson@ubc.ca						AHUJA HS, 1994, BIOCHEM CELL BIOL, V72, P523, DOI 10.1139/o94-070; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERCHEM GJ, 1995, CANCER RES, V55, P735; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; Buchanan G, 2001, CANCER METAST REV, V20, P207, DOI 10.1023/A:1015531326689; BURKEY BF, 1992, J LIPID RES, V33, P1517; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; Caccamo AE, 2003, ANN NY ACAD SCI, V1010, P514, DOI 10.1196/annals.1299.095; Carson JP, 1999, CANCER RES, V59, P1449; Coffey RNT, 2002, PROSTATE, V53, P300, DOI 10.1002/pros.10159; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; DVERGSTEN J, 1994, KIDNEY INT, V45, P828, DOI 10.1038/ki.1994.109; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; FREEMAN AE, 1986, P NATL ACAD SCI USA, V83, P2694, DOI 10.1073/pnas.83.8.2694; FRENCH LE, 1992, J CLIN INVEST, V90, P1919, DOI 10.1172/JCI116069; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; FRITZ IB, 1983, BIOL REPROD, V28, P1173, DOI 10.1095/biolreprod28.5.1173; Gelissen IC, 1998, BIOCHEM J, V331, P231, DOI 10.1042/bj3310231; Gleave ME, 2001, UROLOGY, V58, P39, DOI 10.1016/S0090-4295(01)01241-9; Gleave ME, 2002, INVEST NEW DRUG, V20, P145, DOI 10.1023/A:1015694802521; GLEAVE ME, 1992, CANCER RES, V52, P1598; Gutacker C, 1999, BIOCHEM J, V339, P759, DOI 10.1042/0264-6021:3390759; Heikaus S, 2002, J MOL ENDOCRINOL, V29, P239, DOI 10.1677/jme.0.0290239; Hough CD, 2001, CANCER RES, V61, P3869; James SY, 1996, J STEROID BIOCHEM, V58, P395, DOI 10.1016/0960-0760(96)00048-9; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Jin G, 1999, EUR J BIOCHEM, V263, P534, DOI 10.1046/j.1432-1327.1999.00533.x; July LV, 2002, PROSTATE, V50, P179, DOI 10.1002/pros.10047; Kimura K, 2001, CANCER RES, V61, P5611; Lee C, 2000, PROSTATE, P21; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LEGER JG, 1988, PROSTATE, V13, P131, DOI 10.1002/pros.2990130205; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P1268, DOI 10.1210/endo-127-3-1268; Michel D, 1997, BIOCHEM J, V328, P45, DOI 10.1042/bj3280045; Miyake H, 2000, CANCER RES, V60, P170; Miyake H, 2001, MOL UROL, V5, P105, DOI 10.1089/10915360152559585; MONTPETIT ML, 1986, PROSTATE, V8, P25, DOI 10.1002/pros.2990080105; Pewitt EB, 1999, ENDOCRINOLOGY, V140, P2382, DOI 10.1210/en.140.5.2382; Poon S, 2000, BIOCHEMISTRY-US, V39, P15953, DOI 10.1021/bi002189x; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Reid KJ, 2001, J BIOL CHEM, V276, P2943, DOI 10.1074/jbc.M009170200; RENNIE PS, 1994, J STEROID BIOCHEM, V50, P31, DOI 10.1016/0960-0760(94)90169-4; RENNIE PS, 1988, CANCER RES, V48, P6309; RENNIE PS, 1989, MOL ENDOCRINOL, V3, P703, DOI 10.1210/mend-3-4-703; ROSEMBLIT N, 1994, J MOL ENDOCRINOL, V13, P69, DOI 10.1677/jme.0.0130069; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pW249, DOI 10.1093/nar/gkh372; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Silkensen JR, 1995, J CLIN INVEST, V96, P2646, DOI 10.1172/JCI118330; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; SYLVESTER SR, 1991, BIOL REPROD, V45, P195, DOI 10.1095/biolreprod45.1.195; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Waters KM, 2001, TOXICOL SCI, V63, P47, DOI 10.1093/toxsci/63.1.47; WONG P, 1994, EUR J BIOCHEM, V221, P917, DOI 10.1111/j.1432-1033.1994.tb18807.x; WONG P, 1993, J BIOL CHEM, V268, P5021; WONG P, 1994, BIOCHEM CELL BIOL, V72, P439, DOI 10.1139/o94-058; Wunsche W, 1998, INT J CANCER, V76, P684; Xie MJ, 2002, PANCREAS, V25, P234, DOI 10.1097/00006676-200210000-00004; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Yeung LHY, 2003, BIOCHEM J, V371, P843, DOI 10.1042/BJ20021816; Zellweger T, 2002, CLIN CANCER RES, V8, P3276; Zhang Q, 2006, BJU INT, V98, P452, DOI 10.1111/j.1464-410X.2006.06263.x; Zhu N, 1998, ENDOCRINOLOGY, V139, P4337, DOI 10.1210/en.139.10.4337	66	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2278	2287		10.1074/jbc.M608162200	http://dx.doi.org/10.1074/jbc.M608162200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17148459	Green Published, hybrid			2022-12-27	WOS:000243593200019
J	Swanson, R; Raghavendra, MP; Zhang, WQ; Froelich, C; Gettins, PGW; Olson, ST				Swanson, Richard; Raghavendra, Manikanahally P.; Zhang, Weiqing; Froelich, Christopher; Gettins, Peter G. W.; Olson, Steven T.			Serine and cysteine proteases are translocated to similar extents upon formation of covalent complexes with serpins - Fluorescence perturbation and fluorescence resonance energy transfer mapping of the protease binding site in CrmA complexes with granzyme B and caspase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; PLASMINOGEN-ACTIVATOR INHIBITOR-1; REACTIVE CENTER LOOP; CYTOKINE RESPONSE MODIFIER; CROSS-CLASS INHIBITION; CRYSTAL-STRUCTURE; ALPHA(1)-PROTEINASE INHIBITOR; PROTEINASE INHIBITION; BETA-SHEET; MECHANISM	CrmA is a "cross-class" serpin family inhibitor of the proapoptotic serine protease, granzyme B, as well as cysteine proteases of the caspase family. To determine whether crmA inhibits these structurally diverse proteases by a common conformational trapping mechanism, we mapped the position of the protease in crmA complexes with granzyme B or caspase-1 by fluorescence perturbation and fluorescence resonance energy transfer (FRET) analyses of site-specific fluorophore-labeled crmAs. A reactive loop P6 NBD label underwent similar large fluorescence enhancements (> 200%) either upon reactive loop cleavage by AspN protease or complex formation with granzyme B or caspase-1, consistent with the insertion of the cleaved reactive loop into sheet A in both types of crmA-protease complexes. NBD labels on the noninserting part of the reactive loop docking site for protease (P1' residue) or midway between the two ends of sheet A (helix F residue 101) showed no significant perturbations due to protease complexation. By contrast, labels at positions 68 and 261, lying at the end of sheet A most distal from the reactive loop, showed marked perturbations distinct from those induced by AspN cleavage and thus ascribable to granzyme B or caspase-1 proximity in the complexes. Substantial FRET between protease tryptophans and 5-dimethylaminonaphthalene-1-sulfonyl-labeled crmAs occurred in protease complexes with crmAs labeled at the 68 and 261 positions, but not the P1' position. These results suggest that granzyme B and caspase-1 are inhibited by crmA by a common mechanism involving full reactive loop insertion into sheet A and translocation of the protease to the distal end of the sheet as previously found for inhibition of other serine proteases by serpins.	Univ Illinois, Ctr Mol Biol Oral Dis, Coll Dent, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Genet, Coll Med, Chicago, IL 60612 USA; Northwestern Univ, Sch Med, Rheumatol Sect, Evanston Hosp, Evanston, IL 60201 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; NorthShore University Health System; Northwestern University	Olson, ST (corresponding author), Rm 530C,M-C 860,801 S Paulina St, Chicago, IL 60612 USA.	stolson@uic.edu			NHLBI NIH HHS [R01-HL-78827, R01-HL-79430, P01-HL-64013] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078827, R01HL079430, P01HL064013] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Backovic M, 2002, PROTEIN SCI, V11, P1182, DOI 10.1110/ps.4320102; Bjork I, 1998, BIOCHEM J, V335, P701; Dementiev A, 2006, J BIOL CHEM, V281, P3452, DOI 10.1074/jbc.M510564200; Dobo J, 2006, J BIOL CHEM, V281, P38781, DOI 10.1074/jbc.M605151200; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Irving JA, 2002, BIOCHEMISTRY-US, V41, P4998, DOI 10.1021/bi0159985; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Renatus M, 2000, STRUCT FOLD DES, V8, P789, DOI 10.1016/S0969-2126(00)00165-9; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Simonovic M, 2000, PROTEIN SCI, V9, P1423, DOI 10.1110/ps.9.8.1423; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Tesch LD, 2005, PROTEIN SCI, V14, P533, DOI 10.1110/ps.041104905; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	30	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2305	2313		10.1074/jbc.M609546200	http://dx.doi.org/10.1074/jbc.M609546200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17142451	hybrid			2022-12-27	WOS:000243593200022
J	Eoff, RL; Irimia, A; Egli, M; Guengerich, FP				Eoff, Robert L.; Irimia, Adriana; Egli, Martin; Guengerich, F. Peter			Sulfolobus solfataricus DNA polymerase Dpo4 is partially inhibited by "wobble" pairing between O-6-methylguanine and cytosine, but accurate bypass is preferred	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; CRYSTAL-STRUCTURE; TRANSLESION SYNTHESIS; NUCLEOTIDE INSERTION; MOLECULAR-STRUCTURE; Y-FAMILY; REPLICATION; LESION; FIDELITY; REPAIR	We examined the effect of a single O-6-methylguanine (O-6-MeG) template residue on catalysis by a model Y family polymerase, Dpo4 from Sulfolobus solfataricus. Mass spectral analysis of Dpo4-catalyzed extension products revealed that the enzyme accurately bypasses O-6-MeG, with C being the major product (similar to 70%) and T or A being the minor species (similar to 20% or similar to 10%, respectively), consistent with steady- state kinetic parameters. Transient- state kinetic experiments revealed that k(pol), the maximum forward rate constant describing polymerization, for dCTP incorporation opposite O-6-MeG was similar to 6-fold slower than observed for unmodified G, and no measurable product was observed for dTTP incorporation in the pre- steady state. The lack of any structural information regarding how O-6-MeG paired in a polymerase active site led us to perform x-ray crystallographic studies, which show that "wobble" pairing occurs between C and O-6-MeG. A structure containing T opposite O-6-MeG was solved, but much of the ribose and pyrimidine base density was disordered, in accordance with a much higher Km, dTTP that drives the difference in efficiency between C and T incorporation. The more stabilized C:O-6-MeG pairing reinforces the importance of hydrogen bonding with respect to nucleotide selection within a geometrically tolerant polymerase active site.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NCI NIH HHS [F32 CA119776] Funding Source: Medline; NIEHS NIH HHS [R01 ES010375, P30 ES000267, P01 ES05355] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA119776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010375, P30ES000267, P01ES005355] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bakhtina M, 2005, BIOCHEMISTRY-US, V44, P5177, DOI 10.1021/bi047664w; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi JY, 2006, J BIOL CHEM, V281, P38244, DOI 10.1074/jbc.M608369200; Christian NP, 2001, J AM SOC MASS SPECTR, V12, P744, DOI 10.1016/S1044-0305(01)00228-8; Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791; Delaney JC, 2001, BIOCHEMISTRY-US, V40, P14968, DOI 10.1021/bi015578f; DODSON LA, 1982, P NATL ACAD SCI-BIOL, V79, P7440, DOI 10.1073/pnas.79.23.7440; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P7027, DOI 10.1021/bi00242a031; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; Furge LL, 1998, BIOCHEMISTRY-US, V37, P3567, DOI 10.1021/bi9722094; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; Georgiadis P, 2000, CANCER EPIDEM BIOMAR, V9, P299; GINELL SL, 1990, BIOCHEMISTRY-US, V29, P10461, DOI 10.1021/bi00498a005; Haracska L, 2000, MOL CELL BIOL, V20, P8001, DOI 10.1128/MCB.20.21.8001-8007.2000; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; Kim TW, 2006, J BIOL CHEM, V281, P2289, DOI 10.1074/jbc.M510744200; KYRTOPOULOS SA, 1993, ENVIRON HEALTH PERSP, V99, P143, DOI 10.2307/3431470; Langston LD, 2006, MOL CELL, V23, P155, DOI 10.1016/j.molcel.2006.05.034; LAWLEY PD, 1984, CHEM CARCINOGENS, P325; LEONARD GA, 1990, P NATL ACAD SCI USA, V87, P9573, DOI 10.1073/pnas.87.24.9573; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; LOVELESS A, 1969, NATURE, V223, P206, DOI 10.1038/223206a0; Margison GP, 2002, MUTAGENESIS, V17, P483, DOI 10.1093/mutage/17.6.483; Middleton MR, 2000, INT J CANCER, V88, P469, DOI 10.1002/1097-0215(20001101)88:3<469::AID-IJC21>3.0.CO;2-7; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARTHASARATHY R, 1986, CARCINOGENESIS, V7, P221, DOI 10.1093/carcin/7.2.221; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1027, DOI 10.1021/bi00353a012; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1036, DOI 10.1021/bi00353a013; PEGG AE, 1982, P NATL ACAD SCI-BIOL, V79, P5162, DOI 10.1073/pnas.79.17.5162; PEGG AE, 1985, ENVIRON HEALTH PERSP, V62, P109, DOI 10.2307/3430101; Plosky BS, 2004, CURR OPIN GENET DEV, V14, P113, DOI 10.1016/j.gde.2004.02.002; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Singh J, 1996, J BIOL CHEM, V271, P28391, DOI 10.1074/jbc.271.45.28391; SRIRAM M, 1992, BIOCHEMISTRY-US, V31, P11823, DOI 10.1021/bi00162a022; TAN HB, 1994, BIOCHEMISTRY-US, V33, P5335, DOI 10.1021/bi00183a042; VOIGT JM, 1995, CARCINOGENESIS, V16, P1775, DOI 10.1093/carcin/16.8.1775; WHEELER GP, 1962, CANCER RES, V22, P651; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1027, DOI 10.1021/bi011495n; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1039, DOI 10.1021/bi011496f; YAMAGATA Y, 1988, NUCLEIC ACIDS RES, V16, P9307, DOI 10.1093/nar/16.19.9307; Yoshioka K, 2006, MOL CELL, V22, P501, DOI 10.1016/j.molcel.2006.04.023; Zang H, 2006, J BIOL CHEM, V281, P2358, DOI 10.1074/jbc.M510889200; Zang H, 2005, J BIOL CHEM, V280, P29750, DOI 10.1074/jbc.M504756200	49	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1456	1467		10.1074/jbc.M609661200	http://dx.doi.org/10.1074/jbc.M609661200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17105728	hybrid			2022-12-27	WOS:000243295200070
J	Kuznetsov, NA; Koval, VV; Nevinsky, GA; Douglas, KT; Zharkov, DO; Fedorova, OS				Kuznetsov, Nikita A.; Koval, Vladimir V.; Nevinsky, Georgy A.; Douglas, Kenneth T.; Zharkov, Dmitry O.; Fedorova, Olga S.			Kinetic conformational analysis of human 8-oxoguanine-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL-DNA GLYCOSYLASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUBSTRATE RECOGNITION; OGG1 PROTEIN; STRAND SCISSION; REPAIR PROTEIN; DAMAGED DNA; EXCISION; MECHANISM	7,8-Dihydro-8-oxoguanine (8-oxoG) is one of the major DNA lesions formed by reactive oxygen species that can result in transversion mutations following replication if left unrepaired. In human cells, the effects of 8-oxoG are counteracted by OGG1, a DNA glycosylase that catalyzes excision of 8-oxoguanine base followed by a much slower beta-elimination reaction at the 3'-side of the resulting abasic site. Many features of OGG1 mechanism, including its low beta-elimination activity and high specificity for a cytosine base opposite the lesion, remain poorly explained despite the availability of structural information. In this study, we analyzed the substrate specificity and the catalytic mechanism of OGG1 acting on various DNA substrates using stopped-flow kinetics with fluorescence detection. Combining data on intrinsic tryptophan fluorescence to detect conformational transitions in the enzyme molecule and 2-aminopurine reporter fluorescence to follow DNA dynamics, we defined three pre-excision steps and assigned them to the processes of (i) initial encounter with eversion of the damaged base, (ii) insertion of several enzyme residues into DNA, and (iii) enzyme isomerization to the catalytically competent form. The individual rate constants were derived for all reaction stages. Of all conformational changes, we identified the insertion step as mostly responsible for the opposite base specificity of OGG1 toward 8-oxoG:C as compared with 8-oxoG: T, 8-oxoG: G, and 8-oxoG: A. We also investigated the kinetic mechanism of OGG1 stimulation by 8-bromoguanine and showed that this compound affects the rate of beta-elimination rather than pre-excision dynamics of DNA and the enzyme.	Russian Acad Sci, Siberian Branch, Inst Chem Biol & Fundamental Med, Novosibirsk 630090, Russia; Novosibirsk State Univ, Novosibirsk 630090, Russia; Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England	Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; Novosibirsk State University; University of Manchester	Fedorova, OS (corresponding author), Russian Acad Sci, Siberian Branch, Inst Chem Biol & Fundamental Med, Novosibirsk 630090, Russia.	fedorova@niboch.nsc.ru	Nevinsky, Georgy/E-6053-2012; Kuznetsov, Nikita A/F-3245-2011; Kuznetsov, Nikita/AFU-9897-2022; Fedorova, Olga S./E-1291-2013; Kuznetsov, Nikita/CAA-3889-2022; Zharkov, Dmitry/K-2158-2012; Koval, Vladimir/G-3489-2013; Fedorova, Olga/ABE-6637-2020	Kuznetsov, Nikita A/0000-0002-4016-198X; Kuznetsov, Nikita/0000-0002-4016-198X; Fedorova, Olga S./0000-0002-4001-7187; Kuznetsov, Nikita/0000-0002-4016-198X; Zharkov, Dmitry/0000-0001-5013-0194; Koval, Vladimir/0000-0002-2577-2184; Fedorova, Olga/0000-0002-4001-7187	Wellcome Trust [070244/Z/03/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arai T, 2003, CANCER RES, V63, P4287; Banerjee A, 2005, NATURE, V434, P612, DOI 10.1038/nature03458; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bjoras M, 2002, J MOL BIOL, V317, P171, DOI 10.1006/jmbi.2002.5400; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Blainey PC, 2006, P NATL ACAD SCI USA, V103, P5752, DOI 10.1073/pnas.0509723103; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Burrows CJ, 1998, CHEM REV, V98, P1109, DOI 10.1021/cr960421s; Chen LW, 2002, CHEM BIOL, V9, P345, DOI 10.1016/S1074-5521(02)00120-5; Choi JY, 1999, FREE RADICAL BIO MED, V27, P848, DOI 10.1016/S0891-5849(99)00141-0; Chung SJ, 2004, CHEM BIOL, V11, P1643, DOI 10.1016/j.chembiol.2004.09.014; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Fedorova OS, 2002, BIOCHEMISTRY-US, V41, P1520, DOI 10.1021/bi011524u; Friedberg E. C., 2006, DNA REPAIR MUTAGENES; Fromme JC, 2003, NAT STRUCT BIOL, V10, P204, DOI 10.1038/nsb902; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Girard PM, 1998, CARCINOGENESIS, V19, P1299, DOI 10.1093/carcin/19.7.1299; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Huffman JL, 2005, MUTAT RES-FUND MOL M, V577, P55, DOI 10.1016/j.mrfmmm.2005.03.012; Jiang YL, 2002, BIOCHEMISTRY-US, V41, P11236, DOI 10.1021/bi026226r; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; Koval VV, 2004, NUCLEIC ACIDS RES, V32, P926, DOI 10.1093/nar/gkh237; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Kuznetsov NA, 2005, NUCLEIC ACIDS RES, V33, P3919, DOI 10.1093/nar/gki694; KUZNETSOV NA, 2006, IN PRESS BIOCHEMISTR; LONG RA, 1967, J ORG CHEM, V32, P2751, DOI 10.1021/jo01284a024; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; Norman DPG, 2001, J AM CHEM SOC, V123, P359, DOI 10.1021/ja003144m; Pogozelski WK, 1998, CHEM REV, V98, P1089, DOI 10.1021/cr960437i; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Verdine GL, 2003, ANNU REV BIOCHEM, V72, P337, DOI 10.1146/annurev.biochem.72.121801.161447; WARD DC, 1969, J BIOL CHEM, V244, P1228; Weiss JM, 2005, MOL CARCINOGEN, V42, P127, DOI 10.1002/mc.20067; Wong I, 2003, J BIOL CHEM, V278, P2411, DOI 10.1074/jbc.M209802200; Wong I, 2002, J BIOL CHEM, V277, P19424, DOI 10.1074/jbc.M201198200; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200; Zharkov DO, 2005, MUTAT RES-FUND MOL M, V577, P24, DOI 10.1016/j.mrfmmm.2005.03.011	45	67	72	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1029	1038		10.1074/jbc.M605788200	http://dx.doi.org/10.1074/jbc.M605788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17090545	hybrid			2022-12-27	WOS:000243295200026
J	Winger, JA; Derbyshire, ER; Marletta, MA				Winger, Jonathan A.; Derbyshire, Emily R.; Marletta, Michael A.			Dissociation of nitric oxide from soluble guanylate cyclase and heme-nitric oxide/oxygen binding domain constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; FUNCTIONAL-CHARACTERIZATION; LIGAND-BINDING; ACTIVATION; NO; YC-1; SITE; DEACTIVATION; INHIBITION; HEMOGLOBIN	Regulation of soluble guanylate cyclase (sGC), the primary NO receptor, is linked to NO binding to the prosthetic heme group. Recent studies have demonstrated that the degree and duration of sGC activation depend on the presence and ratio of purine nucleotides and on the presence of excess NO. We measured NO dissociation from full-length alpha 1 beta 1 sGC, and the constructs beta 1(1-194), beta 1(1-385), and beta 2(1-217), at 37 and 10 degrees C with and without the substrate analogue guanosine-5'-[(alpha, beta-methylene] triphosphate (GMPCPP) or the activator 3-(5'-hydroxymethyl-3'-furyl)-1-benzylindazole (YC-1). NO dissociation from each construct was complex, requiring two exponentials to fit the data. Decreasing the temperature decreased the contribution of the faster exponential for all constructs. Inclusion of YC-1 moderately accelerated NO dissociation from sGC and beta 2(1-217) at 37 degrees C and dramatically accelerated NO dissociation from sGC at 10 degrees C. The presence of GMPCPP also dramatically accelerated NO dissociation from sGC at 10 degrees C. This acceleration is due to increases in the observed rate for each exponential and in the contribution of the faster exponential. Increases in the contribution of the faster exponential correlated with higher activation of sGC by NO. These data indicate that the sGC ferrous-nitrosyl complex adopts two 5-coordinate conformations, a lower activity "closed" form, which releases NO slowly, and a higher activity "open" form, which releases NO rapidly. The ratio of these two species affects the overall rate of NO dissociation. These results have implications for the function of sGC in vivo, where there is evidence for two NO-regulated activity states.	Univ Calif Berkeley, Dept Chem, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Div Phys Biosci, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Marletta, MA (corresponding author), Univ Calif Berkeley, Dept Chem, Lawrence Berkeley Lab, 211 Lewis Hall, Berkeley, CA 94720 USA.	marletta@berkeley.edu	Winger, Jonathan/B-3885-2010	Winger, Jonathan/0000-0003-1413-3384	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boon EM, 2006, J BIOL CHEM, V281, P21892, DOI 10.1074/jbc.M600557200; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; Cary SPL, 2006, TRENDS BIOCHEM SCI, V31, P231, DOI 10.1016/j.tibs.2006.02.003; Cary SPL, 2005, P NATL ACAD SCI USA, V102, P13064, DOI 10.1073/pnas.0506289102; Chang FJ, 2005, J BIOL CHEM, V280, P11513, DOI 10.1074/jbc.M412203200; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Derbyshire ER, 2005, BIOCHEMISTRY-US, V44, P16257, DOI 10.1021/bi0515671; Friebe A, 2003, CIRC RES, V93, P96, DOI 10.1161/01.RES.0000082524.34487.31; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Friebe A, 1998, MOL PHARMACOL, V53, P123, DOI 10.1124/mol.53.1.123; Hering KW, 2006, BIOORG MED CHEM LETT, V16, P618, DOI 10.1016/j.bmcl.2005.10.093; Hoenicka M, 1999, J MOL MED-JMM, V77, P14, DOI 10.1007/s001090050292; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; IGNARRO LJ, 1989, SEMIN HEMATOL, V26, P63; Iyer LM, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-5; Karow DS, 2005, BIOCHEMISTRY-US, V44, P16266, DOI 10.1021/bi051601b; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; Kharitonov VG, 1997, BIOCHEM BIOPH RES CO, V239, P284, DOI 10.1006/bbrc.1997.7470; Koglin M, 2001, J BIOL CHEM, V276, P30737, DOI 10.1074/jbc.M102549200; Lamothe M, 2004, BIOCHEMISTRY-US, V43, P3039, DOI 10.1021/bi0360051; Lee YC, 2000, P NATL ACAD SCI USA, V97, P10763, DOI 10.1073/pnas.190333697; Lowry TM, 1910, J CHEM SOC, V97, P2634, DOI 10.1039/ct9109702634; Makino R, 2003, J BIOL CHEM, V278, P11130, DOI 10.1074/jbc.M209026200; Makino R, 1999, J BIOL CHEM, V274, P7714, DOI 10.1074/jbc.274.12.7714; Margulis A, 2000, BIOCHEMISTRY-US, V39, P1034, DOI 10.1021/bi992040p; MOORE EG, 1976, J BIOL CHEM, V251, P2788; Munzel T, 2003, CIRCULATION, V108, P2172, DOI 10.1161/01.CIR.0000094403.78467.C3; Negrerie M, 2001, J BIOL CHEM, V276, P46815, DOI 10.1074/jbc.M102224200; Nioche P, 2004, SCIENCE, V306, P1550, DOI 10.1126/science.1103596; Pellicena P, 2004, P NATL ACAD SCI USA, V101, P12854, DOI 10.1073/pnas.0405188101; Puranik M, 2004, J BIOL CHEM, V279, P21096, DOI 10.1074/jbc.M400613200; Russwurm M, 2004, EMBO J, V23, P4443, DOI 10.1038/sj.emboj.7600422; Russwurm M, 2002, J BIOL CHEM, V277, P24883, DOI 10.1074/jbc.M110570200; Smagghe BJ, 2006, BIOCHEMISTRY-US, V45, P561, DOI 10.1021/bi051902l; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Wedel BJ, 2001, ANNU REV PHYSIOL, V63, P215, DOI 10.1146/annurev.physiol.63.1.215; Yazawa S, 2006, J BIOL CHEM, V281, P21763, DOI 10.1074/jbc.M508983200; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x; Zhao YD, 2000, BIOCHEMISTRY-US, V39, P10848, DOI 10.1021/bi9929296	46	47	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					897	907		10.1074/jbc.M606327200	http://dx.doi.org/10.1074/jbc.M606327200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17098738	hybrid			2022-12-27	WOS:000243295200012
J	Jeganathan, S; Lee, JM				Jeganathan, Sujeeve; Lee, Jonathan M.			Binding of elongation factor eEF1A2 to phosphatidylinositol 4-kinase beta stimulates lipid kinase activity and phosphatidylinositol 4-phosphate generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CALCIUM SENSOR-1; FACTOR 1-ALPHA; TRANSLATION; EXPRESSION; SECRETION; PROTEIN; PIK1P; FACTOR-1-ALPHA; ACTIVATOR; ISOFORMS	Eukaryotic protein translation elongation factor 1 alpha 2 (eEF1A2) is an oncogene that transforms mammalian cell lines and increases their tumorigenicity in nude mice. Increased expression of eEF1A2 occurs during the development of breast, ovarian, and lung cancer. Here, we report that eEF1A2 directly binds to and activates phosphatidylinositol 4-kinase III beta (P14KIII beta), an enzyme that converts phosphatidylinositol to phosphatidylinositol 4-phosphate. Purified recombinant eEF1A2 increases P14KIII beta lipid kinase activity in vitro, and expression of eEF1A2 in rat and human cells is sufficient to increase overall cellular phosphatidylinositol 4-kinase activity and intracellular phosphatidylinositol 4-phosphate abundance. siRNA-mediated reduction in eEF1A2 expression concomitantly reduces phosphatidylinositol 4-kinase activity. This identifies a physical and functional relationship between eEF1A2 and P14KIII beta.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Lee, JM (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	jlee@uottawa.ca						Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Balla A, 2000, EXP BRAIN RES, V134, P279, DOI 10.1007/s002210000469; Balla A, 2006, TRENDS CELL BIOL, V16, P351, DOI 10.1016/j.tcb.2006.05.003; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; Bruns JR, 2002, J BIOL CHEM, V277, P2012, DOI 10.1074/jbc.M108571200; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Chambers DM, 1998, P NATL ACAD SCI USA, V95, P4463, DOI 10.1073/pnas.95.8.4463; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Drobak BK, 1999, INT REV CYTOL, V189, P95, DOI 10.1016/S0074-7696(08)61386-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GALLAGHER SR, 1999, CURRENT PROTOCOLS MO, V2, DOI DOI 10.12B.11-10.12B.15; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Guo J, 2003, P NATL ACAD SCI USA, V100, P3995, DOI 10.1073/pnas.0230488100; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; HARLOW E, 1999, USING ANTIBODIES LAB, P522; Heilmeyer LMG, 2003, IUBMB LIFE, V55, P59, DOI 10.1080/1521654031000090896; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; Insall RH, 2001, DEV CELL, V1, P743, DOI 10.1016/S1534-5807(01)00086-7; Kahns S, 1998, NUCLEIC ACIDS RES, V26, P1884, DOI 10.1093/nar/26.8.1884; Kapp-Barnea Y, 2003, J IMMUNOL, V171, P5320, DOI 10.4049/jimmunol.171.10.5320; KNUDSEN SM, 1993, EUR J BIOCHEM, V215, P549, DOI 10.1111/j.1432-1033.1993.tb18064.x; KULKARNI G, 2006, IN PRESS BREAST CANC; Larijani B, 2001, BIOCHEM J, V356, P495, DOI 10.1042/0264-6021:3560495; LEE S, 1993, J BIOL CHEM, V268, P24453; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Maruta H, 1999, MICROSC RES TECHNIQ, V47, P61; Meijer HJG, 2003, ANNU REV PLANT BIOL, V54, P265, DOI 10.1146/annurev.arplant.54.031902.134748; Nguyen PH, 2005, FEMS YEAST RES, V5, P363, DOI 10.1016/j.femsyr.2004.09.007; Overduin M, 2001, Mol Interv, V1, P150; Pendaries C, 2006, EMBO J, V25, P1024, DOI 10.1038/sj.emboj.7601001; Pendaries C, 2003, FEBS LETT, V546, P25, DOI 10.1016/S0014-5793(03)00437-X; Potter M, 1998, CELL IMMUNOL, V188, P111, DOI 10.1006/cimm.1998.1346; Raben DM, 2000, EUR J HISTOCHEM, V44, P67; Sciorra VA, 2005, MOL BIOL CELL, V16, P776, DOI 10.1091/mbc.e04-08-0700; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; SHULTZ LD, 1982, NATURE, V297, P402, DOI 10.1038/297402a0; Tomlinson VAL, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-113; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011; YANG W, 1994, J BIOL CHEM, V269, P3852; YANG WN, 1993, J BIOL CHEM, V268, P392; Zhao XH, 2000, J BIOL CHEM, V275, P14642, DOI 10.1074/jbc.275.19.14642; Zhao XH, 2001, J BIOL CHEM, V276, P40183, DOI 10.1074/jbc.M104048200	50	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					372	380		10.1074/jbc.M602955200	http://dx.doi.org/10.1074/jbc.M602955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17088255	hybrid			2022-12-27	WOS:000243166500042
J	Peng, XX; Pan, JA; Gong, R; Liu, Y; Kang, SL; Feng, HX; Qiu, G; Guo, DY; Tien, P; Xiao, GF				Peng, Xiaoxue; Pan, Ji'an; Gong, Rui; Liu, Yang; Kang, Shuli; Feng, Huixing; Qiu, Gang; Guo, Deyin; Tien, Po; Xiao, Gengfu			Functional characterization of syncytin-A, a newly murine endogenous virus envelope protein - Implication for its fusion mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIV GP41 CORE; CRYSTAL-STRUCTURE; MEMBRANE-FUSION; EBOLA-VIRUS; HIV-1 GP41; HERV-W; STRUCTURAL-CHARACTERIZATION; INFLUENZA HEMAGGLUTININ; POTENT INHIBITORS; RETROVIRUS-FAMILY	Trophoblast fusion in placenta is an important event for preservation of a healthy pregnancy. This process takes place throughout the pregnancy and is crucial for the formation of syncytiotrophoblast layer. Syncytin-1 and syncytin-2 are strong candidate regulators of fusion from retroviral origin. Syncytin-A and syncytin-B are other candidates from retroviral origin in Muridae. The active role of syncytin in driving fusion of trophoblast has been identified, but its fusion mechanism is still unclear. As an intact retroviral envelope protein, syncytin-A shares similar structure profiling with other viral envelope fusion proteins, especially in the regions of N- and C-terminal heptad repeats (NHR and CHR, respectively). In this paper, we showed that SynA 1 + 2 of syncytin-A (residues 445-536, including predicted NHR, CHR, and a natural linker) could form trimer and exhibited significant alpha-helix structure and high thermo-stability. Limited proteolysis result identified a stable protease-resistant core of SynA 1 + 2, which was in good agreement with computational modeling data. NHR and CHR could interact with each other in vitro, too. Different from the previous studies, the disulfide-bonded linker was apparently vital to the stability of fusion core structure. By biological assays, NHR was shown to be inhibitive to cell-cell fusion, with IC50 value about 5.4 mu m, but CHR seemed to have no inhibitory activity even at 50 mu m. From both biochemical and functional data, we first gave an explanation how syncytin-A mediated cell fusion. The insight into the mechanism of syncytin-A-mediated cell-cell fusion may provide a crucial clue to placental cytotrophoblast morphogenesis.	Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Hubei, Peoples R China; Wuhan Univ, Coll Life Sci, Modern Virol Res Ctr, Wuhan 430072, Hubei, Peoples R China	Wuhan University; Wuhan University	Xiao, GF (corresponding author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Hubei, Peoples R China.	gxiao@whu.edu.cn	Guo, Deyin/A-9498-2011; Pan, Ji-An/G-6142-2012	Guo, Deyin/0000-0002-8297-0814; 				Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; Bannert N, 2004, P NATL ACAD SCI USA, V101, P14572, DOI 10.1073/pnas.0404838101; Benit L, 2001, J VIROL, V75, P11709, DOI 10.1128/JVI.75.23.11709-11719.2001; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Blaise S, 2004, J VIROL, V78, P1050, DOI 10.1128/JVI.78.2.1050-1054.2004; Blaise S, 2003, P NATL ACAD SCI USA, V100, P13013, DOI 10.1073/pnas.2132646100; Blond JL, 2000, J VIROL, V74, P3321, DOI 10.1128/JVI.74.7.3321-3329.2000; Blond JL, 1999, J VIROL, V73, P1175, DOI 10.1128/JVI.73.2.1175-1185.1999; Boeke J. D., 1997, P343; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; BULLOUGH PA, 1994, J MOL BIOL, V236, P1262, DOI 10.1016/0022-2836(94)90027-2; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chang C, 2004, BIOL REPROD, V71, P1956, DOI 10.1095/biolreprod.104.033340; DELWART EL, 1990, AIDS RES HUM RETROV, V6, P703, DOI 10.1089/aid.1990.6.703; Dupressoir A, 2005, P NATL ACAD SCI USA, V102, P725, DOI 10.1073/pnas.0406509102; EATON B, 1993, HUMAN PLACENTA, P471; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Frendo JL, 2003, MOL CELL BIOL, V23, P3566, DOI 10.1128/MCB.23.10.3566-3574.2003; Gong R, 2005, BIOCHEM BIOPH RES CO, V331, P1193, DOI 10.1016/j.bbrc.2005.04.032; Harris JR, 1998, BIOESSAYS, V20, P307, DOI 10.1002/(SICI)1521-1878(199804)20:4<307::AID-BIES7>3.0.CO;2-M; Ji H, 2000, BIOCHEMISTRY-US, V39, P676, DOI 10.1021/bi991893e; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; JIANG SB, 1993, BIOCHEM BIOPH RES CO, V195, P533, DOI 10.1006/bbrc.1993.2078; Joshi SB, 1998, VIROLOGY, V248, P20, DOI 10.1006/viro.1998.9242; Kobe B, 1999, P NATL ACAD SCI USA, V96, P4319, DOI 10.1073/pnas.96.8.4319; Lavillette D, 2002, J VIROL, V76, P6442, DOI 10.1128/JVI.76.13.6442-6452.2002; Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Mallet F, 2004, P NATL ACAD SCI USA, V101, P1731, DOI 10.1073/pnas.0305763101; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; Potgens AJG, 2004, HUM REPROD UPDATE, V10, P487, DOI 10.1093/humupd/dmh039; RAPAPORT D, 1995, EMBO J, V14, P5524, DOI 10.1002/j.1460-2075.1995.tb00239.x; Renard M, 2005, J MOL BIOL, V352, P1029, DOI 10.1016/j.jmb.2005.07.058; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Tristem M, 2000, J VIROL, V74, P3715, DOI 10.1128/JVI.74.8.3715-3730.2000; Turner G, 2001, CURR BIOL, V11, P1531, DOI 10.1016/S0960-9822(01)00455-9; Wang EX, 2003, BIOCHEM BIOPH RES CO, V302, P469, DOI 10.1016/S0006-291X(03)00197-9; Watanabe S, 2000, J VIROL, V74, P10194, DOI 10.1128/JVI.74.21.10194-10201.2000; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Zhao X, 2000, P NATL ACAD SCI USA, V97, P14172, DOI 10.1073/pnas.260499197	50	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					381	389		10.1074/jbc.M606353200	http://dx.doi.org/10.1074/jbc.M606353200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17105734	hybrid			2022-12-27	WOS:000243166500043
J	Anderson, GR; Semenov, A; Song, JH; Martemyanov, KA				Anderson, Garret R.; Semenov, Arthur; Song, Joseph H.; Martemyanov, Kirill A.			The membrane anchor R7BP controls the proteolytic stability of the striatal specific RGS protein, RGS9-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACCELERATING PROTEIN; IN-VIVO; NERVOUS-SYSTEM; SIGNALING RGS; MICE LACKING; DEP DOMAIN; REGULATORS; R9AP; EXPRESSION; COMPLEX	A member of the RGS ((r) under bar egulators of (G) under bar protein (s) under bar ignaling) family, RGS9-2 is a critical regulator of G protein signaling pathways that control locomotion and reward signaling in the brain. RGS9-2 is specifically expressed in striatal neurons where it forms complexes with its newly discovered partner, R7BP ((R7) under bar family binding protein). Interaction with R7BP is important for the subcellular targeting of RGS9-2, which in native neurons is found in plasma membrane and its specializations, postsynaptic densities. Here we report that R7BP plays an additional important role in determining proteolytic stability of RGS9-2. We have found that co-expression with R7BP dramatically elevates the levels of RGS9-2 and its constitutive subunit, G beta 5. Measurement of the RGS9-2 degradation kinetics in cells indicates that R7BP markedly reduces the rate of RGS9-2-G beta 5 proteolysis. Lentivirus-mediated RNA interference knockdown of the R7BP expression in native striatal neurons results in the corresponding decrease in RGS9-2 protein levels. Analysis of the molecular determinants that mediate R7BP/RGS9-2 binding to result in proteolytic protection have identified that the binding site for R7BP in RGS proteins is formed by pairing of the DEP ((D) under bar isheveled, (E) under bar GL-10, Pleckstrin) domain with the R7H ((R7 h) under bar omology), a domain of previously unknown function that interacts with four putative a-helices of the R7BP core. These findings provide a mechanism for the regulation of the RGS9 protein stability in the striatal neurons.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Martemyanov, KA (corresponding author), Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA.	martemyanov@umn.edu	Anderson, Garret/B-1316-2011; Anderson, Garret/AAX-7011-2021		NIDA NIH HHS [DA011806] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Baker SA, 2006, BIOCHEMISTRY-US, V45, P10690, DOI 10.1021/bi060376a; Burchett SA, 1998, J NEUROCHEM, V70, P2216; Burns ME, 2003, NEURON, V38, P853, DOI 10.1016/S0896-6273(03)00361-1; Cabrera-Vera TM, 2004, P NATL ACAD SCI USA, V101, P16339, DOI 10.1073/pnas.0407416101; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chen CK, 2003, P NATL ACAD SCI USA, V100, P6604, DOI 10.1073/pnas.0631825100; Coleman JE, 2003, PHYSIOL GENOMICS, V12, P221, DOI 10.1152/physiolgenomics.00135.2002; Cullen BR, 2004, VIRUS RES, V102, P3, DOI 10.1016/j.virusres.2004.01.009; Drenan RM, 2005, J CELL BIOL, V169, P623, DOI 10.1083/jcb.200502007; Drenan RM, 2006, J BIOL CHEM, V281, P28222, DOI 10.1074/jbc.M604428200; Garzon J, 2001, EUR J NEUROSCI, V13, P801, DOI 10.1046/j.0953-816x.2000.01444.x; Gold SJ, 1997, J NEUROSCI, V17, P8024; Heximer SP, 2003, J CLIN INVEST, V111, P1259, DOI 10.1172/JCI200318099C; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hu G, 2003, J BIOL CHEM, V278, P14550, DOI 10.1074/jbc.M212046200; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Huang XY, 2006, MOL CELL BIOL, V26, P6870, DOI 10.1128/MCB.00314-06; Ivkovic S, 1999, J NEUROSCI, V19, P5409; Keresztes G, 2004, J BIOL CHEM, V279, P1581, DOI 10.1074/jbc.C300456200; Keresztes G, 2003, MOL CELL NEUROSCI, V24, P687, DOI 10.1016/S1044-7431(03)00231-8; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; Kovoor A, 2005, J NEUROSCI, V25, P2157, DOI 10.1523/JNEUROSCI.2840-04.2005; Krispel CM, 2006, NEURON, V51, P409, DOI 10.1016/j.neuron.2006.07.010; Krispel CM, 2003, J NEUROSCI, V23, P6965, DOI 10.1523/JNEUROSCI.23-18-06965.2003; LEFEBVRE B, 1995, BIOTECHNIQUES, V19, P186; Lishko PV, 2002, J BIOL CHEM, V277, P24376, DOI 10.1074/jbc.M203237200; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Martemyanov KA, 2005, J BIOL CHEM, V280, P5133, DOI 10.1074/jbc.C400596200; Martemyanov KA, 2003, J NEUROSCI, V23, P10175; Nishiguchi KM, 2004, NATURE, V427, P75, DOI 10.1038/nature02170; Rahman Z, 2003, NEURON, V38, P941, DOI 10.1016/S0896-6273(03)00321-0; Rojkova AM, 2003, J BIOL CHEM, V278, P12507, DOI 10.1074/jbc.M207302200; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Siderovski DP, 2005, INT J BIOL SCI, V1, P51, DOI 10.7150/ijbs.1.51; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Song JH, 2006, J BIOL CHEM, V281, P15361, DOI 10.1074/jbc.M600749200; Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415; Tekumalla PK, 2001, BIOL PSYCHIAT, V50, P813, DOI 10.1016/S0006-3223(01)01234-3; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Witherow DS, 2003, RECEPTOR CHANNEL, V9, P205, DOI 10.1080/10606820390203848; Zachariou V, 2003, P NATL ACAD SCI USA, V100, P13656, DOI 10.1073/pnas.2232594100	44	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4772	4781		10.1074/jbc.M610518200	http://dx.doi.org/10.1074/jbc.M610518200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158100	hybrid			2022-12-27	WOS:000244482000059
J	Van Themsche, C; Mathieu, I; Parent, S; Asselin, E				Van Themsche, Celine; Mathieu, Isabelle; Parent, Sophie; Asselin, Eric			Transforming growth factor-beta 3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of X-linked inhibitor of apoptosis and protein kinase C-dependent induction of matrix metalloproteinase-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; SIGNAL-TRANSDUCTION; CANCER-CELLS; IN-VITRO; EXPRESSION; INVASION; ADENOCARCINOMA; ANGIOGENESIS; ACTIVATION	dTumor cells often acquire intrinsic resistance to the growth inhibitory and pro-apoptotic effects of transforming growth factor-beta (TGF-beta); moreover, TGF-beta can confer invasive properties to established tumor cells. In the present study, we show that TGF-beta isoforms (TGF-beta 1, TGF-beta 2, and TGF-beta 3) trigger proper Smad signaling in human endometrial carcinoma cell lines and efficiently inhibit cellular proliferation. These cells, however, exhibit a high degree of resistance to TGF-beta pro-apoptotic effects; we found that this resistant phenotype would be acquired through up-regulation of X-linked inhibitor of apoptosis protein (XIAP) levels. In addition, using RNA interference and pharmacological inhibitors, we show that TGF-beta increases cellular invasiveness via two distinct signaling pathways in endometrial carcinoma cells: phosphatidylinositol 3-kinase/AKT-dependent up-regulation of XIAP and protein kinase C-dependent induction of matrix-metalloproteinase-9 (MMP-9) expression. Additionally, these findings were correlated with clinical observations showing abundant TGF-beta immunoreactivity in human endometrial carcinoma tumors in vivo, extending from the epithelial compartment to the stroma upon acquisition of an invasive phenotype (gradually from grades I to III). Collectively our results describe for the first time a role for TGF-beta 3 in tumor invasiveness.	Univ Quebec, Dept Biol Chem, Trois Rivieres, PQ G9A 5H7, Canada	University of Quebec; University of Quebec Trois Rivieres	Asselin, E (corresponding author), Univ Quebec, Dept Biol Chem, Trois Rivieres, PQ G9A 5H7, Canada.	eric.asselin@uqtr.ca						Aglund K, 2004, GYNECOL ONCOL, V94, P699, DOI 10.1016/j.ygyno.2004.06.028; Alabert C, 2006, ONCOGENE, V25, P3387, DOI 10.1038/sj.onc.1209385; Arends MJ, 1999, HISTOPATHOLOGY, V35, P174, DOI 10.1046/j.1365-2559.1999.00756.x; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Farina AR, 1998, INT J CANCER, V75, P721; GOLD LI, 1994, CANCER RES, V54, P2347; Gold LI, 1999, SEMIN REPROD ENDOCR, V17, P73, DOI 10.1055/s-2007-1016214; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Javelaud D, 2005, ONCOGENE, V24, P7624, DOI 10.1038/sj.onc.1208900; Jin X, 2004, BRIT J CANCER, V91, P1808, DOI 10.1038/sj.bjc.6602214; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Leivonen SK, 2006, ONCOGENE, V25, P2588, DOI 10.1038/sj.onc.1209291; Maliekal TT, 2003, ONCOGENE, V22, P4889, DOI 10.1038/sj.onc.1206806; Parekh TV, 2002, CANCER RES, V62, P2778; Park DW, 2003, CANCER LETT, V195, P185, DOI 10.1016/S0304-3835(03)00131-9; Perlino E, 1998, BRIT J CANCER, V77, P1260, DOI 10.1038/bjc.1998.211; Qian SW, 1999, GROWTH FACTORS, V17, P63, DOI 10.3109/08977199909001063; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Schrantz N, 1999, ONCOGENE, V18, P3511, DOI 10.1038/sj.onc.1202718; Shigeoka Y, 2004, J CANCER RES CLIN, V130, P146, DOI 10.1007/s00432-003-0520-0; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Shooner C, 2005, REPROD BIOL ENDOCRIN, V3, P1, DOI 10.1186/1477-7827-3-20; Watanabe Y, 2003, CLIN CANCER RES, V9, P6497; Woo JH, 2004, ONCOGENE, V23, P1845, DOI 10.1038/sj.onc.1207307; Yabushita H, 2000, J Obstet Gynaecol Res, V26, P163; Yu Q, 2000, GENE DEV, V14, P163; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200	30	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4794	4802		10.1074/jbc.M608497200	http://dx.doi.org/10.1074/jbc.M608497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17150964	hybrid			2022-12-27	WOS:000244482000061
J	Nolting, A; Ferraro, T; D'hoedt, D; Stocker, M				Nolting, Andreas; Ferraro, Teresa; D'hoedt, Dieter; Stocker, Martin			An amino acid outside the pore region influences apamin sensitivity in small conductance Ca2+-activated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; SK CHANNELS; AFTERHYPERPOLARIZATION CURRENTS; MOLECULAR DETERMINANTS; FUNCTIONAL EXPRESSION; SYNAPTIC-TRANSMISSION; PURKINJE NEURONS; VOLTAGE-SENSOR; HEK-293 CELLS; ION CHANNELS	Small conductance calcium-activated potassium channels (SK, K-Ca) are a family of voltage-independent K+ channels with a distinct physiology and pharmacology. The bee venom toxin apamin inhibits exclusively the three cloned SK channel subtypes (SK1, SK2, and SK3) with different affinity, highest for SK2, lowest for SK1, and intermediate for SK3 channels. The high selectivity of apamin made it a valuable toot to study the molecular makeup and function of native SK channels. Three amino acids located in the outer vestibule of the pore are of particular importance for the different apamin sensitivities of SK channels. Chimeric SK1 channels, enabling the homomeric expression of the rat SK1 (rSK1) subunit and containing the core domain (S1-S6) of rSK1, are apamin-insensitive. By contrast, channels formed by the human orthologue human SK1 (hSK1) are sensitive to apamin. This finding hinted at the involvement of regions beyond the pore as determinants of apamin sensitivity, because hSK1 and rSK1 have an identical amino acid sequence in the pore region. Here we investigated which parts of the channels outside the pore region are important for apamin sensitivity by constructing chimeras between apamin-insensitive and -sensitive SK channel subunits and by introducing point mutations. We demonstrate that a single amino acid situated in the extracellular loop between the transmembrane segments S3 and S4 has a major impact on apamin sensitivity. Our findings enabled us to convert the hSK1 channel into a channel that was as sensitive for apamin as SK2, the SK channel with the highest sensitivity.	UCL, Dept Pharmacol, Mol Pharmacol Lab, London WC1E 6BT, England	University of London; University College London	Stocker, M (corresponding author), UCL, Dept Pharmacol, Mol Pharmacol Lab, Gower St, London WC1E 6BT, England.	M.Stocker@ucl.ac.uk	Stocker, Martin/C-1844-2008		Wellcome Trust [061198] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andreotti N, 2005, PEPTIDES, V26, P1095, DOI 10.1016/j.peptides.2005.01.022; BANKS BEC, 1979, NATURE, V282, P415, DOI 10.1038/282415a0; Barfod ET, 2001, AM J PHYSIOL-CELL PH, V280, pC836, DOI 10.1152/ajpcell.2001.280.4.C836; Benton DCH, 2003, J PHYSIOL-LONDON, V553, P13, DOI 10.1113/jphysiol.2003.054551; Bond CT, 2005, CURR OPIN NEUROBIOL, V15, P305, DOI 10.1016/j.conb.2005.05.001; Bond CT, 2004, J NEUROSCI, V24, P5301, DOI 10.1523/JNEUROSCI.0182-04.2004; CAPIOD T, 1989, J PHYSIOL-LONDON, V409, P285, DOI 10.1113/jphysiol.1989.sp017497; Cingolani LA, 2002, J NEUROSCI, V22, P4456, DOI 10.1523/JNEUROSCI.22-11-04456.2002; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Cui M, 2002, J MOL BIOL, V318, P417, DOI 10.1016/S0022-2836(02)00095-5; D'hoedt D, 2004, J BIOL CHEM, V279, P12088, DOI 10.1074/jbc.C300382200; Edgerton JR, 2003, J PHYSIOL-LONDON, V548, P53, DOI 10.1113/jphysiol.2002.027854; Elinder F, 2001, J GEN PHYSIOL, V118, P1, DOI 10.1085/jgp.118.1.1; Faber ESL, 2005, NAT NEUROSCI, V8, P635, DOI 10.1038/nn1450; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Fournier C, 2001, BEHAV BRAIN RES, V121, P81, DOI 10.1016/S0166-4328(00)00387-9; Garcia ML, 2001, TOXICON, V39, P739, DOI 10.1016/S0041-0101(00)00214-2; Giangiacomo KM, 2004, TOXICON, V43, P877, DOI 10.1016/j.toxicon.2003.11.029; Glowatzki E, 2000, SCIENCE, V288, P2366, DOI 10.1126/science.288.5475.2366; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; Hallworth NE, 2003, J NEUROSCI, V23, P7525; Hammond RS, 2006, J NEUROSCI, V26, P1844, DOI 10.1523/JNEUROSCI.4106-05.2006; Harvey AL, 1997, GEN PHARMACOL-VASC S, V28, P7, DOI 10.1016/S0306-3623(96)00173-5; Herrera GM, 2002, J PHYSIOL-LONDON, V541, P483, DOI 10.1113/jphysiol.2002.017707; HILLE B, 2001, ION CHANNELS EXCITAB, P143; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUGUES M, 1982, EMBO J, V1, P1039, DOI 10.1002/j.1460-2075.1982.tb01293.x; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Jager H, 2004, TOXICON, V43, P951, DOI 10.1016/j.toxicon.2004.03.025; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Klocker N, 2001, MOL CELL NEUROSCI, V17, P514, DOI 10.1006/mcne.2000.0956; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; Liegeois JF, 2003, CURR MED CHEM, V10, P625, DOI 10.2174/0929867033457908; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Meera P, 2000, P NATL ACAD SCI USA, V97, P5562, DOI 10.1073/pnas.100118597; MESSIER C, 1991, BRAIN RES, V551, P322, DOI 10.1016/0006-8993(91)90950-Z; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Monaghan AS, 2004, J BIOL CHEM, V279, P1003, DOI 10.1074/jbc.M308070200; Ngo-Anh TJ, 2005, NAT NEUROSCI, V8, P642, DOI 10.1038/nn1449; Oliver D, 2000, NEURON, V26, P595, DOI 10.1016/S0896-6273(00)81197-6; Orio P, 2002, NEWS PHYSIOL SCI, V17, P156, DOI 10.1152/nips.01387.2002; Pedarzani P, 2000, J PHYSIOL-LONDON, V527, P283, DOI 10.1111/j.1469-7793.2000.t01-1-00283.x; Pedarzani P, 2002, J BIOL CHEM, V277, P46101, DOI 10.1074/JBC.m206465200; Phillips LR, 2005, NATURE, V436, P857, DOI 10.1038/nature03873; Pribnow D, 1999, MUSCLE NERVE, V22, P742, DOI 10.1002/(SICI)1097-4598(199906)22:6<742::AID-MUS11>3.0.CO;2-1; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; Schetz JA, 1995, CARDIOVASC RES, V30, P755, DOI 10.1016/S0008-6363(95)00114-X; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SCHWINDT PC, 1988, J NEUROPHYSIOL, V59, P424, DOI 10.1152/jn.1988.59.2.424; Shah M, 2000, BRIT J PHARMACOL, V129, P627, DOI 10.1038/sj.bjp.0703111; Shakkottai VG, 2001, J BIOL CHEM, V276, P43145, DOI 10.1074/jbc.M106981200; Stackman RW, 2002, J NEUROSCI, V22, P10163; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; Stocker M, 2004, NAT REV NEUROSCI, V5, P758, DOI 10.1038/nrn1516; Stocker M, 2000, MOL CELL NEUROSCI, V15, P476, DOI 10.1006/mcne.2000.0842; Stocker M, 2004, TOXICON, V43, P933, DOI 10.1016/j.toxicon.2003.12.009; Strobaek D, 2000, BRIT J PHARMACOL, V129, P991, DOI 10.1038/sj.bjp.0703120; STRONG PN, 1990, PHARMACOL THERAPEUT, V46, P137, DOI 10.1016/0163-7258(90)90040-9; Swartz KJ, 1997, NEURON, V18, P675, DOI 10.1016/S0896-6273(00)80307-4; Swartz KJ, 2004, NAT REV NEUROSCI, V5, P905, DOI 10.1038/nrn1559; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; Villalobos C, 2004, J NEUROSCI, V24, P3537, DOI 10.1523/JNEUROSCI.0380-04.2004; Wei AD, 2005, PHARMACOL REV, V57, P463, DOI 10.1124/pr.57.4.9; Wittekindt OH, 2004, MOL PHARMACOL, V65, P788, DOI 10.1124/mol.65.3.788; Wolfart J, 2001, J NEUROSCI, V21, P3443, DOI 10.1523/JNEUROSCI.21-10-03443.2001; Womack MD, 2003, J NEUROSCI, V23, P2600; Wu YL, 2004, BIOPHYS J, V87, P105, DOI 10.1529/biophysj.103.039156; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Xu YF, 2003, J BIOL CHEM, V278, P49085, DOI 10.1074/jbc.M307508200	71	43	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3478	3486		10.1074/jbc.M607213200	http://dx.doi.org/10.1074/jbc.M607213200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17142458	hybrid, Green Accepted			2022-12-27	WOS:000244481900010
J	Nieves-Cintron, M; Amberg, GC; Nichols, CB; Molkentin, JD; Santana, LF				Nieves-Cintron, Madeline; Amberg, Gregory C.; Nichols, C. Blake; Molkentin, Jeffery D.; Santana, Luis F.			Activation of NFATc3 down-regulates the beta 1 subunit of large conductance, calcium-activated K+ channels in arterial smooth muscle and contributes to hypertension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ACCUMULATION; CARDIAC-HYPERTROPHY; RECEPTORS; CURRENTS; CELLS	Large conductance, Ca2+-activated K+ (BK) channels modulate the excitability and contractile state of arterial smooth muscle. Recently, we demonstrated that during hypertension, expression of the accessory beta 1 subunit was decreased relative to the pore-forming alpha subunit of the BK channel. Reduced beta 1 subunit expression resulted in BK channels with impaired function due to lowered sensitivity to Ca2+. Here, we tested the hypothesis that activation of the calcineurin/NFATc3 signaling pathway down-regulates beta 1 expression during angiotensin II-induced hypertension. Consistent with this hypothesis, we found that in vivo administration of angiotensin II-activated calcineurin/NFATc3 signaling in arterial smooth muscle. During angiotensin II infusion, arterial smooth muscle BK channel function was decreased in wild type (WT) but not in NFATc3 null (NFATc3(-/-)) mice. Accordingly, beta 1 expression was decreased in WT but not in NFATc3(-/-) arteries. Angiotensin II-induced down-regulation of the beta 1 subunit required Ca2+ influx via L-type Ca2+ channels. However, in the absence of angiotensin II, moderate elevation of [Ca2+](i) alone was not sufficient to activate NFAT transcriptional activity and, thus, decrease beta 1 subunit expression. Importantly, angiotensin II infusion increased systemic blood pressure to a lower extent in NFATc3(-/-) than in WT mice, indicating that this transcription factor is required for the development of severe hypertension during chronic angiotensin II signaling activation. We conclude that activation of calcineurin and NFATc3 during sustained angiotensin II signaling down-regulates the expression of the beta 1 subunit of the BK channel, which in turn contributes to arterial dysfunction and the development of hypertension.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Childrens Hosp, Med Ctr Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	University of Washington; University of Washington Seattle; Cincinnati Children's Hospital Medical Center	Santana, LF (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.	santana@u.washington.edu		Molkentin, Jeffery/0000-0002-3558-6529; Santana, Luis/0000-0002-4297-8029; Amberg, Gregory/0000-0001-6094-1185	NHLBI NIH HHS [HL077115, HL085870] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085870, R01HL077115] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amberg GC, 2004, J BIOL CHEM, V279, P47326, DOI 10.1074/jbc.M408789200; Amberg GC, 2003, J CLIN INVEST, V112, P717, DOI 10.1172/JC1200318684; Amberg GC, 2003, CIRC RES, V93, P965, DOI 10.1161/01.RES.0000100068.43006.36; Bayguinov O, 2001, AM J PHYSIOL-CELL PH, V281, pC1512, DOI 10.1152/ajpcell.2001.281.5.C1512; Bosc LVG, 2004, J BIOL CHEM, V279, P10702, DOI 10.1074/jbc.M312920200; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Bueno OF, 2004, CIRC RES, V94, P91, DOI 10.1161/01.RES.0000107197.99679.77; Cox DH, 2000, J GEN PHYSIOL, V116, P411, DOI 10.1085/jgp.116.3.411; Crowley SD, 2006, P NATL ACAD SCI USA, V103, P17985, DOI 10.1073/pnas.0605545103; Gomez MF, 2003, J BIOL CHEM, V278, P46847, DOI 10.1074/jbc.M304765200; Gomez MF, 2002, J BIOL CHEM, V277, P37756, DOI 10.1074/jbc.M203596200; Hagen BM, 2003, AM J PHYSIOL-CELL PH, V285, pC1270, DOI 10.1152/ajpcell.00153.2003; HARDER DR, 1985, CIRC RES, V57, P319, DOI 10.1161/01.RES.57.2.319; Hayabuchi Y, 2001, AM J PHYSIOL-HEART C, V281, pH2480, DOI 10.1152/ajpheart.2001.281.6.H2480; Kleppisch T, 1996, AM J PHYSIOL-HEART C, V271, pH2462, DOI 10.1152/ajpheart.1996.271.6.H2462; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; Kubo M, 1997, J PHYSIOL-LONDON, V503, P489, DOI 10.1111/j.1469-7793.1997.489bg.x; Maravall M, 2000, BIOPHYS J, V78, P2655, DOI 10.1016/S0006-3495(00)76809-3; Meera P, 1996, FEBS LETT, V385, P127; Navedo MF, 2006, J GEN PHYSIOL, V127, P611, DOI 10.1085/jgp.200609519; Navedo MF, 2005, P NATL ACAD SCI USA, V102, P11112, DOI 10.1073/pnas.0500360102; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Ni YG, 2006, CIRCULATION, V114, P1159, DOI 10.1161/CIRCULATIONAHA.106.637124; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; Rossow CF, 2004, CIRC RES, V94, P1340, DOI 10.1161/01.RES.0000128406.08418.34; Rossow CF, 2006, CIRC RES, V98, P1306, DOI 10.1161/01.RES.0000222028.92993.10; Shipston MJ, 1996, J PHYSIOL-LONDON, V493, P665, DOI 10.1113/jphysiol.1996.sp021413; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Tanaka Y, 1997, J PHYSIOL-LONDON, V502, P545, DOI 10.1111/j.1469-7793.1997.545bj.x; Wellman GC, 2001, AM J PHYSIOL-HEART C, V281, pH2559, DOI 10.1152/ajpheart.2001.281.6.H2559; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Yang L, 2005, J BIOL CHEM, V280, P207, DOI 10.1074/jbc.M410509200	32	93	96	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3231	3240		10.1074/jbc.M608822200	http://dx.doi.org/10.1074/jbc.M608822200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148444	hybrid			2022-12-27	WOS:000243793900050
J	Sanchez-Laorden, BL; Jimenez-Cervantes, C; Garcia-Borron, JC				Sanchez-Laorden, Berta L.; Jimenez-Cervantes, Celia; Garcia-Borron, Jose C.			Regulation of human melanocortin 1 receptor signaling and trafficking by Thr-308 and Ser-316 and its alteration in variant alleles associated with red hair and skin cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; HORMONE-RECEPTOR; MELANOMA-CELLS; RISK PHENOTYPES; SUN SENSITIVITY; RAB GTPASES; DNA-DAMAGE; DESENSITIZATION; INTERNALIZATION; GENE	The melanocortin 1 receptor (MC1R), a G protein-coupled receptor (GPCR) positively coupled to adenylyl cyclase, is a key regulator of melanocyte proliferation and differentiation and a determinant of pigmentation, skin phototype, and skin cancer risk. MC1R activation stimulates melanogenesis and increases the ratio of black, strongly photoprotective eumelanins to yellowish and poorly photoprotective pheomelanin pigments. Desensitization and internalization are key regulatory mechanisms of GPCR signaling. Agonist-induced desensitization usually depends on phosphorylation by a GPCR kinase (GRK) followed by receptor internalization in endocytic vesicles. We have shown that MC1R desensitization is mediated by two GRKs expressed in melanocytes and melanoma cells, GRK2 and GRK6. Here we show that in contrast with this dual specificity for desensitization, GRK6 but not GRK2 mediated MC1R internalization. Mutagenesis studies suggested that the targets of GRK6 are two residues located in the MC1R cytosolic C terminus, Thr-308 and Ser-316. A T308D/ S316D mutant mimicking their phosphorylated state was constitutively desensitized and associated with endosomes, whereas a T308A/ S316A mutant was resistant to desensitization and internalization. We studied the desensitization and internalization of three variant MC1R forms associated with red hair and increased skin cancer risk: R151C, R160W, and D294H. These variants showed a less efficient desensitization. Moreover, D294H was resistant to internalization, thus accounting for its abnormally high surface expression. Co-expression of variant and wild type MC1R modified its desensitization and internalization behavior. These data suggest that MC1R might be regulated by novel mechanisms including differential effects of GRKs and altered desensitization rates of certain allelic combinations.	Univ Murcia, Sch Med, Dept Biochem & Mol Biol, Espinardo 30100, Spain	University of Murcia	Garcia-Borron, JC (corresponding author), Univ Murcia, Sch Med, Dept Biochem & Mol Biol, Espinardo 30100, Spain.	gborron@um.es	Sanchez-Laorden, Berta/T-2177-2017; Jimenez-Cervantes, Celia/H-1953-2015; Garcia-Borron, Jose Carlos/H-2247-2015	Sanchez-Laorden, Berta/0000-0002-6499-6332; Jimenez-Cervantes, Celia/0000-0002-5821-9510; Garcia-Borron, Jose Carlos/0000-0002-9192-588X				Ali BR, 2004, J CELL SCI, V117, P6401, DOI 10.1242/jcs.01542; Audet N, 2005, J BIOL CHEM, V280, P7808, DOI 10.1074/jbc.M411695200; Beaumont KA, 2005, HUM MOL GENET, V14, P2145, DOI 10.1093/hmg/ddi219; Bishop JAN, 2005, DRUG TODAY, V41, P193, DOI 10.1358/dot.2005.41.3.892524; Bohm M, 2005, J BIOL CHEM, V280, P5795, DOI 10.1074/jbc.M406334200; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Duffy DL, 2004, HUM MOL GENET, V13, P447, DOI 10.1093/hmg/ddh043; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Garcia-Borron JC, 2005, PIGM CELL RES, V18, P393, DOI 10.1111/j.1600-0749.2005.00278.x; Garcia-Borron JC, 2002, PIGM CELL RES, V15, P162, DOI 10.1034/j.1600-0749.2002.02012.x; Gardner B, 2001, MOL PHARMACOL, V59, P310, DOI 10.1124/mol.59.2.310; Gaudreau R, 2002, J BIOL CHEM, V277, P31567, DOI 10.1074/jbc.M202723200; Healy E, 2000, LANCET, V355, P1072, DOI 10.1016/S0140-6736(00)02042-0; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Iyer V, 2006, BRIT J PHARMACOL, V147, P249, DOI 10.1038/sj.bjp.0706551; Jimenez-Cervantes C, 2001, FEBS LETT, V508, P44, DOI 10.1016/S0014-5793(01)03025-3; Jimenez-Cervantes C, 2001, J INVEST DERMATOL, V117, P156, DOI 10.1046/j.0022-202x.2001.01393.x; Jones BW, 2005, J BIOL CHEM, V280, P38346, DOI 10.1074/jbc.M502918200; Kadekaro AL, 2005, CANCER RES, V65, P4292, DOI 10.1158/0008-5472.CAN-04-4535; Kadekaro AL, 2003, PIGM CELL RES, V16, P434, DOI 10.1034/j.1600-0749.2003.00088.x; KONG GH, 1994, J BIOL CHEM, V269, P13084; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Luttrell LM, 2002, J CELL SCI, V115, P455; Martin NP, 2003, J BIOL CHEM, V278, P45954, DOI 10.1074/jbc.M308285200; Martinez-Esparza M, 2001, INT J BIOCHEM CELL B, V33, P971, DOI 10.1016/S1357-2725(01)00068-1; Mas JS, 2003, PIGM CELL RES, V16, P540, DOI 10.1034/j.1600-0749.2003.00073.x; Mas JS, 2002, EUR J BIOCHEM, V269, P6133, DOI 10.1046/j.1432-1033.2002.03329.x; ORLOW SJ, 1990, J CELL PHYSIOL, V142, P129, DOI 10.1002/jcp.1041420116; PAO CS, 2002, SCI STKE, pE42; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rees JL, 2004, AM J HUM GENET, V75, P739, DOI 10.1086/425285; Ringholm A, 2004, J INVEST DERMATOL, V123, P917, DOI 10.1111/j.0022-202X.2004.23444.x; Roberts DW, 2006, PIGM CELL RES, V19, P76, DOI 10.1111/j.1600-0749.2005.00286.x; Sanchez-Laorden BL, 2006, J INVEST DERMATOL, V126, P172, DOI 10.1038/sj.jid.5700036; Sanchez-Mas J, 2005, MOL ENDOCRINOL, V19, P1035, DOI 10.1210/me.2004-0227; Sanchez-Mas J, 2004, PIGM CELL RES, V17, P386, DOI 10.1111/j.1600-0749.2004.00160.x; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Smith R, 1998, J INVEST DERMATOL, V111, P119, DOI 10.1046/j.1523-1747.1998.00252.x; Sturm RA, 2003, PIGM CELL RES, V16, P266, DOI 10.1034/j.1600-0749.2003.00041.x; Sturm RA, 2003, ANN NY ACAD SCI, V994, P348, DOI 10.1111/j.1749-6632.2003.tb03199.x; Sturm RA, 2002, MELANOMA RES, V12, P405, DOI 10.1097/00008390-200209000-00001; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; Vance KW, 2004, PIGM CELL RES, V17, P318, DOI 10.1111/j.1600-0749.2004.00164.x; Virador V, 2001, PIGM CELL RES, V14, P289, DOI 10.1034/j.1600-0749.2001.140410.x; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Wong WS, 1996, INT J BIOCHEM CELL B, V28, P1223, DOI 10.1016/S1357-2725(96)00074-X	49	48	50	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3241	3251		10.1074/jbc.M606865200	http://dx.doi.org/10.1074/jbc.M606865200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17130136	hybrid			2022-12-27	WOS:000243793900051
J	Esteve, PO; Chin, HG; Pradhan, S				Esteve, Pierre-Olivier; Chin, Hang Gyeong; Pradhan, Sriharsa			Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; DNA CYTOSINE-5 METHYLTRANSFERASES; TRANSCRIPTION FACTOR SP1; TUMOR-SUPPRESSOR P53; DE-NOVO METHYLATION; COLORECTAL-CANCER; HUMAN MAINTENANCE; PROMOTER REGION; CPG ISLANDS; EXPRESSION	Human maintenance DNA cytosine methyltransferase (DNMT1) regulates gene expression in a methylation-dependent and -independent manner. Anti-apoptotic survivin gene down-regulation is mediated by p53 recruitment of DNMT1 to its promoter. Survivin inhibits programmed cell death, regulates cell division, and is expressed in cancer cells. The survivin gene promoter is CG-rich containing several Sp1 canonical, Sp1-like, cell cycle-dependent element/cell cycle gene homology region, and p53-binding sites. Here we demonstrate that Sp1 transcription factor(s) play a role in transcriptional activation of the survivin promoter in Drosophila and human cells. Sp1 inhibition in vivo by mithramycin A leads to down-regulation of a luciferase reporter driven by the human survivin promoter in transfected cells. Mithramycin A or Sp1-specific short interfering RNA down-regulated the endogenous survivin gene expression, confirming Sp1 as the primary determinant for transcriptional activation. Furthermore, immobilized DNMT1 ligand bound to seven consensus amino acids corresponding to the N-terminal region of the Sp class of transcription factors in a phage display analysis. In the co-immunoprecipitation assay, the endogenous Sp1 or Sp3 pulled down DNMT1 and methyltransferase activity. Similarly, a glutathione S-transferase pull-down assay between DNMT1 and Sp1 demonstrates a direct interaction between the two proteins. Fluorescent fusions of DNMT1 and Sp1 co-localized in the mammalian nucleus, thus supporting binary complex formation between both the proteins. The kinetics of survivin promoter occupancy via chromatin immunoprecipitation following doxorubicin treatment show the presence of Sp1 and gradual accumulation of transcriptional repressors p53, DNMT1, histone methyltransferase G9a, and HDAC1 onto the promoter along with histone H3K9me2. These data suggest that the Sp1 transcription factor acts as a platform for recruitment of transcriptional repressors.	New England Biolabs Inc, Ipswich, MA 01938 USA	New England Biolabs	Pradhan, S (corresponding author), New England Biolabs Inc, 240 Cty Rd, Ipswich, MA 01938 USA.	pradhan@neb.com						Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Di Croce L, 2005, HUM MOL GENET, V14, pR77, DOI 10.1093/hmg/ddi109; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Geiman TM, 2004, NUCLEIC ACIDS RES, V32, P2716, DOI 10.1093/nar/gkh589; GIGLIONI B, 1989, BIOCHEM BIOPH RES CO, V164, P149, DOI 10.1016/0006-291X(89)91695-1; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Islam A, 2000, MED PEDIATR ONCOL, V35, P550, DOI 10.1002/1096-911X(20001201)35:6<550::AID-MPO12>3.0.CO;2-Y; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jair KW, 2006, CANCER RES, V66, P682, DOI 10.1158/0008-5472.CAN-05-1980; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Koutsodontis G, 2005, BIOCHEM J, V389, P443, DOI 10.1042/BJ20041980; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; LANS MS, 1994, J BIOL CHEM, V269, P14170; Le Gac G, 2006, J BIOL CHEM, V281, P24161, DOI 10.1074/jbc.M603724200; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li FZ, 1999, CANCER RES, V59, P3143; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIAO WC, 1994, GENE, V146, P183, DOI 10.1016/0378-1119(94)90291-7; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; Pradhan S, 2003, CLIN IMMUNOL, V109, P6, DOI 10.1016/S1521-6616(03)00204-3; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Song J, 2001, J BIOL CHEM, V276, P19897, DOI 10.1074/jbc.M010658200; Szepeshazi K, 2002, CANCER RES, V62, P781; Williams NS, 2003, CLIN CANCER RES, V9, P931; Yamamoto K, 2004, LEUKEMIA RES, V28, P1203, DOI 10.1016/j.leukres.2004.03.020; You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844; Zhang T, 2001, CANCER RES, V61, P8664	56	91	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2615	2625		10.1074/jbc.M606203200	http://dx.doi.org/10.1074/jbc.M606203200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17124180	hybrid			2022-12-27	WOS:000243593200054
J	Gonzalez-Gutierrez, G; Miranda-Laferte, E; Neely, A; Hidalgo, P				Gonzalez-Gutierrez, Giovanni; Miranda-Laferte, Erick; Neely, Alan; Hidalgo, Patricia			The Src homology 3 domain of the beta-subunit of voltage-gated calcium channels promotes endocytosis via dynamin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; POTASSIUM CHANNEL; SH3 DOMAINS; COMPLEX; MODULATION; CONTAINS; BINDING	High voltage-gated calcium channels enable calcium entry into cells in response to membrane depolarization. Association of the auxiliary beta-subunit to the alpha-interaction-domain in the pore-forming alpha(1)-subunit is required to form functional channels. The beta-subunit belongs to the membrane-associated guanylate kinase class of scaffolding proteins containing a Src homology 3 and a guanylate kinase domain. Although the latter is responsible for the high affinity binding to the alpha-interaction domain, the functional significance of the Src homology 3 domain remains elusive. Here, we show that injection of isolated beta-subunit Src homology 3 domain into Xenopus laevis oocytes expressing the alpha(1)-subunit reduces the number of channels in the plasma membrane. This effect is reverted by coexpressing alpha(1) with a dominant-negative mutant of dynamin, a GTPase involved in receptor-mediated endocytosis. Full-length beta-subunit also down-regulates voltage-gated calcium channels but only when lacking the alpha-interaction domain. Moreover, isolated Src homology 3 domain and the full-length beta-subunit were found to interact in vitro with dynamin and to internalize the distantly related Shaker potassium channel. These results demonstrate that the beta-subunit regulates the turnover of voltage-gated calcium channels and other proteins in the cell membrane. This effect is mediated by dynamin and depends on the association state of the beta-subunit to the alpha(1)-pore-forming subunit. Our findings define a novel function for the beta-subunit through its Src homology 3 domain and establish a link between voltage-gated calcium channel activity and the cell endocytic machinery.	Hannover Med Sch, Abt Neurophysiol, D-30625 Hannover, Germany; Univ Valparaiso, Ctr Neurociencia Valparaiso, Valparaiso 2349400, Chile	Hannover Medical School; Universidad de Valparaiso	Hidalgo, P (corresponding author), Hannover Med Sch, Abt Neurophysiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	hidalgo.patricia@mh-hannover.de	Tuluc, Petronel/C-2527-2011; Neely, Alan/A-8715-2009; Hidalgo, Patricia/I-7506-2013	Hidalgo, Patricia/0000-0002-4162-6590; Gonzalez-Gutierrez, Giovanni/0000-0002-1044-943X; Neely, Alan/0000-0002-6007-2159				Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Bezanilla F, 1998, METHOD ENZYMOL, V293, P331; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; Cohen RM, 2005, AM J PHYSIOL-HEART C, V288, pH2363, DOI 10.1152/ajpheart.00348.2004; Dzhura I, 2003, BIOPHYS J, V85, P274, DOI 10.1016/S0006-3495(03)74473-7; Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hidalgo P, 2006, J BIOL CHEM, V281, P24104, DOI 10.1074/jbc.M605930200; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Maltez JM, 2005, NAT STRUCT MOL BIOL, V12, P372, DOI 10.1038/nsmb909; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Neely A, 2004, J BIOL CHEM, V279, P21689, DOI 10.1074/jbc.M312675200; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; Opatowsky Y, 2003, J BIOL CHEM, V278, P52323, DOI 10.1074/jbc.M303564200; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Takahashi SX, 2005, J GEN PHYSIOL, V126, P365, DOI 10.1085/jgp.200509354; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; Zeng WZ, 2002, AM J PHYSIOL-RENAL, V283, pF630, DOI 10.1152/ajprenal.00378.2001	29	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2156	2162		10.1074/jbc.M609071200	http://dx.doi.org/10.1074/jbc.M609071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17110381	hybrid			2022-12-27	WOS:000243593200006
J	Renaudo, A; L'Hoste, S; Guizouarn, H; Borgese, F; Soriani, O				Renaudo, Adrien; L'Hoste, Sebastien; Guizouarn, Helene; Borgese, Franck; Soriani, Olivier			Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl-channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JURKAT T-LYMPHOCYTES; POTASSIUM CHANNELS; CHLORIDE CONDUCTANCE; MOLECULAR-CLONING; DEPENDENT KINASES; STEROL ISOMERASE; IN-VIVO; VOLUME; PROLIFERATION; DEATH	The sigma-1 receptor is an intracellular protein characterized as a tumor biomarker whose function remains mysterious. We demonstrate herein for the first time that highly selective sigma ligands inhibit volume-regulated chloride channels (VRCC) in small cell lung cancer and T-leukemia cells. Sigma ligands and VRCC blockers provoked a cell cycle arrest underlined by p27 accumulation. In stably sigma-1 receptor-transfected HEK cells, the proliferation rate was significantly lowered by sigma ligands when compared with control cells. Sigma ligands produced a strong inhibition of VRCC in HEK-transfected cells but not in control HEK. Surprisingly, the activation rate of VRCC was dramatically delayed in HEK-transfected cells in the absence of ligands, indicating that sigma-1 receptors per se modulate cell regulating volume processes in physiological conditions. Volume measurements in hypotonic conditions revealed indeed that the regulatory volume decrease was delayed in HEK-transfected cells and virtually abolished in the presence of igmesine in both HEK-tranfected and T-leukemic cells. Moreover, HEK-transfected cells showed a significant resistance to staurosporine-induced apoptosis volume decrease, indicating that sigma-1 receptors protect cancer cells from apoptosis. Altogether, our results show for the first time that sigma-1 receptors modulate "cell destiny" through VRCC and cell volume regulation.	Univ Nice Sophia Antipolis, UNSA, UMR 6548,CNRS, Fac Sci,Lab Physiol Cellulaire & Mol Syst Integre, F-06108 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Soriani, O (corresponding author), Univ Nice Sophia Antipolis, UNSA, UMR 6548,CNRS, Fac Sci,Lab Physiol Cellulaire & Mol Syst Integre, Batiment Sci Nat,3eme Etage,28 Ave Valrose, F-06108 Nice 2, France.	soriani@unice.fr		BORGESE, Franck/0000-0001-7718-2111; soriani, olivier/0000-0001-9485-3992				Alonso G, 2000, NEUROSCIENCE, V97, P155, DOI 10.1016/S0306-4522(00)00014-2; Aydar E, 2002, NEURON, V34, P399, DOI 10.1016/S0896-6273(02)00677-3; Aydar E, 2006, CANCER LETT, V242, P245, DOI 10.1016/j.canlet.2005.11.011; DEUTSCH C, 1988, RENAL PHYSIOL BIOCH, V11, P260; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Ghiani CA, 1999, J NEUROSCI, V19, P5380; Hanner M, 1996, P NATL ACAD SCI USA, V93, P8072, DOI 10.1073/pnas.93.15.8072; Hayashi T, 2004, CNS DRUGS, V18, P269, DOI 10.2165/00023210-200418050-00001; Helix N, 2003, J MEMBRANE BIOL, V196, P83, DOI 10.1007/s00232-003-0627-x; JAKAB M, 1903, CELL PHYSIOL BIOCHEM, V12, P235; Jbilo O, 1997, J BIOL CHEM, V272, P27107, DOI 10.1074/jbc.272.43.27107; JIRSCH JD, 1994, AM J PHYSIOL, V267, pC688, DOI 10.1152/ajpcell.1994.267.3.C688; John CS, 1999, CANCER RES, V59, P4578; Kawamura K, 2005, ANN NUCL MED, V19, P701; Lang F, 1998, CELL PHYSIOL BIOCHEM, V8, P285, DOI 10.1159/000016290; Lang F, 1999, HERZ, V24, P232, DOI 10.1007/BF03044966; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Mammoto A, 2004, J BIOL CHEM, V279, P26323, DOI 10.1074/jbc.M402725200; Marin M, 2005, BIOCHEM BIOPH RES CO, V334, P1266, DOI 10.1016/j.bbrc.2005.07.010; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Mei JF, 2001, BIOCHEM PHARMACOL, V62, P349, DOI 10.1016/S0006-2952(01)00666-9; Monnet FP, 2006, J PHARMACOL SCI, V100, P93, DOI 10.1254/jphs.CR0050032; Morin-Surun MP, 1999, P NATL ACAD SCI USA, V96, P8196, DOI 10.1073/pnas.96.14.8196; NILIUS B, 1994, PFLUG ARCH EUR J PHY, V428, P364, DOI 10.1007/BF00724520; Nilius B, 2001, J PHYSIOL-LONDON, V532, P581, DOI 10.1111/j.1469-7793.2001.0581e.x; Ouadid-Ahidouch H, 1999, FEBS LETT, V459, P15, DOI 10.1016/S0014-5793(99)01121-7; Pardo LA, 2005, J MEMBRANE BIOL, V205, P115, DOI 10.1007/s00232-005-0776-1; Renaudo A, 2004, J PHARMACOL EXP THER, V311, P1105, DOI 10.1124/jpet.104.072413; Roger S, 2004, BBA-BIOMEMBRANES, V1667, P190, DOI 10.1016/j.bbamem.2004.10.002; ROMAN FJ, 1990, J PHARM PHARMACOL, V42, P439, DOI 10.1111/j.2042-7158.1990.tb06588.x; ROSS PE, 1994, BIOPHYS J, V66, P169, DOI 10.1016/S0006-3495(94)80754-4; Rouzaire-Dubois B, 2000, PFLUG ARCH EUR J PHY, V440, P881, DOI 10.1007/s004240000371; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shuba YM, 2000, AM J PHYSIOL-CELL PH, V279, pC1144, DOI 10.1152/ajpcell.2000.279.4.C1144; Simony-Lafontaine J, 2000, BRIT J CANCER, V82, P1958; Soriani O, 1998, J PHARMACOL EXP THER, V286, P163; Soriani O, 1999, J PHARMACOL EXP THER, V289, P321; Soriani O, 1999, AM J PHYSIOL-ENDOC M, V277, pE73, DOI 10.1152/ajpendo.1999.277.1.E73; Spruce BA, 2004, CANCER RES, V64, P4875, DOI 10.1158/0008-5472.CAN-03-3180; Storey NM, 2003, J BIOL CHEM, V278, P33319, DOI 10.1074/jbc.M300443200; Su TP, 2003, CURR MED CHEM, V10, P2073, DOI 10.2174/0929867033456783; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; VAN WA, 2004, J NUCL MED, V45, P1939; VILNER BJ, 1995, CANCER RES, V55, P408; Wang LW, 2002, J CELL PHYSIOL, V193, P110, DOI 10.1002/jcp.10156; Wheeler KT, 2000, BRIT J CANCER, V82, P1223, DOI 10.1054/bjoc.1999.1067; Wondergem N, 2001, J PHYSIOL-LONDON, V532, P661, DOI 10.1111/j.1469-7793.2001.0661e.x; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; Xu B, 1996, AM J PHYSIOL-CELL PH, V271, pC2037, DOI 10.1152/ajpcell.1996.271.6.C2037; Zheng YJ, 2003, J CELL PHYSIOL, V194, P376, DOI 10.1002/jcp.10218	51	77	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2259	2267		10.1074/jbc.M607915200	http://dx.doi.org/10.1074/jbc.M607915200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121836	hybrid			2022-12-27	WOS:000243593200017
J	Long, YC; Glund, S; Garcia-Roves, PM; Zierath, JR				Long, Yun Chau; Glund, Stephan; Garcia-Roves, Pablo M.; Zierath, Juleen R.			Calcineurin regulates skeletal muscle metabolism via coordinated changes in gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; OXIDATIVE-METABOLISM; CONTRACTILE ACTIVITY; AMP KINASE; GLUCOSE; STIMULATION; BIOGENESIS; INSULIN; FIBERS; STATE	The metabolic property of skeletal muscle adapts in response to an increased physiological demand by altering substrate utilization and gene expression. The calcium-regulated serine/threonine protein phosphatase calcineurin has been implicated in the transduction of motor neuron signals to alter gene expression programs in skeletal muscle. We utilized transgenic mice that overexpress an activated form of calcineurin in skeletal muscle (MCK-CnA*) to investigate the impact of calcineurin activation on metabolic properties of skeletal muscle. Activation of calcineurin increased glucose incorporation into glycogen and lipid oxidation in skeletal muscle. Activated calcineurin suppressed skeletal muscle glucose oxidation and increased lactate release. The enhancement in lipid oxidation was supported by increased expression of genes for lipid metabolism and mitochondrial oxidative phosphorylation. In a reciprocal fashion, several genes of glycolysis were down-regulated, whereas pyruvate dehydrogenase kinase 4 was markedly induced. This expression pattern was associated with decreased glucose utilization and enhanced glycogen storage. The peroxisome proliferator-activated receptors (PPARs) and PPAR gamma coactivator 1 alpha (PGC1 alpha) are transcription regulators for the expression of metabolic and mitochondrial genes. Consistent with changes in the gene-regulatory program, calcineurin promoted the expression of PPAR alpha, PPAR delta, and PPAR gamma coactivator 1 alpha in skeletal muscle. These results provide evidence that calcineurin-mediated skeletal muscle reprogramming induces the expression of several transcription regulators that coordinate changes in the expression of genes for lipid and glucose metabolism, which in turn alters energy substrate utilization in skeletal muscle.	Karolinska Inst, Sect Integrat Physiol, Dept Mol Med & Surg, S-17177 Stockholm, Sweden	Karolinska Institutet	Zierath, JR (corresponding author), Karolinska Inst, Sect Integrat Physiol, Dept Mol Med & Surg, von Eulers Vag 4,4th Floor, S-17177 Stockholm, Sweden.	Juleen.Zierath@ki.se	Roves, Pablo Garcia/A-7113-2015; Garcia-Roves, Pablo M./X-4585-2018	Garcia-Roves, Pablo M./0000-0002-8371-2067; Zierath, Juleen/0000-0001-6891-7497				ANDRES R, 1956, J CLIN INVEST, V35, P671, DOI 10.1172/JCI103324; Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002; Barnes BR, 2005, DIABETES, V54, P3484, DOI 10.2337/diabetes.54.12.3484; Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Dunn SE, 2001, J BIOL CHEM, V276, P45243, DOI 10.1074/jbc.M105445200; Finck BN, 2005, CELL METAB, V1, P133, DOI 10.1016/j.cmet.2005.01.006; Garcia-Roves PM, 2006, AM J PHYSIOL-ENDOC M, V290, pE1172, DOI 10.1152/ajpendo.00633.2005; Garnier A, 2005, FASEB J, V19, P43, DOI 10.1096/fj.04-2173com; Hamilton MT, 1998, AM J PHYSIOL-ENDOC M, V275, pE1016, DOI 10.1152/ajpendo.1998.275.6.E1016; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; Hughes SM, 1998, CURR BIOL, V8, pR892, DOI 10.1016/S0960-9822(07)00554-4; KELLEY DE, 1990, AM J PHYSIOL, V258, pE923, DOI 10.1152/ajpendo.1990.258.6.E923; KONG XM, 1994, J BIOL CHEM, V269, P12963; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Long YC, 2005, DIABETOLOGIA, V48, P2354, DOI 10.1007/s00125-005-1962-5; Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Norrbom J, 2004, J APPL PHYSIOL, V96, P189, DOI 10.1152/japplphysiol.00765.2003; Nuhr M, 2003, EUR J APPL PHYSIOL, V89, P202, DOI 10.1007/s00421-003-0792-8; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Pette D, 1999, MUSCLE NERVE, V22, P666, DOI 10.1002/(SICI)1097-4598(199906)22:6<666::AID-MUS3>3.0.CO;2-Z; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Ryder JW, 2003, J BIOL CHEM, V278, P44298, DOI 10.1074/jbc.M304510200; Schaeffer PJ, 2004, J BIOL CHEM, V279, P39593, DOI 10.1074/jbc.M403649200; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; THERIAULT R, 1994, J APPL PHYSIOL, V77, P1885, DOI 10.1152/jappl.1994.77.4.1885; Tsao TS, 2001, FASEB J, V15, P958, DOI 10.1096/fj.00-0381; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Winder WW, 2001, J APPL PHYSIOL, V91, P1017, DOI 10.1152/jappl.2001.91.3.1017; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	37	63	65	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1607	1614		10.1074/jbc.M609208200	http://dx.doi.org/10.1074/jbc.M609208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17107952	hybrid, Green Published			2022-12-27	WOS:000243451300012
J	Meadows, NA; Sharma, SM; Faulkner, GJ; Ostrowski, MC; Hume, DA; Cassady, AI				Meadows, Nicholas A.; Sharma, Sudarshana M.; Faulkner, Geoffrey J.; Ostrowski, Michael C.; Hume, David A.; Cassady, Alan I.			The expression of Clcn7 and Ostm1 in osteoclasts is coregulated by microphthalmia transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MAST-CELLS; RESISTANT ACID-PHOSPHATASE; NF-KAPPA-B; MUTANT MICE; IMPAIRED EXPRESSION; GENE-EXPRESSION; BONE-RESORPTION; FACTOR MITF; OSTEOPETROSIS; MOUSE	Microphthalmia transcription factor (MITF) regulates osteoclast function by controling the expression of genes, including tartrate-resistant acid phosphatase (TRAP) and cathepsin K in response to receptor activator of nuclear factor-kappa B ligand (RANKL)-induced signaling. To identify novel MITF target genes, we have overexpressed MITF in the murine macrophage cell line RAW264.7 subclone 4 (RAW/C4) and examined the gene expression profile after sRANKL-stimulated osteoclastogenesis. Microarray analysis identified a set of genes superinduced by MITF overexpression, including Clcn7 (chloride channel 7) and Ostm1 (osteopetrosis-associated transmembrane protein 1). Using electrophoretic mobility shift assays, we identified two MITF-binding sites (M-boxes) in the Clcn7 promoter and a single M-box in the Ostm1 promoter. An anti-MITF antibody supershifted DNA-protein complexes for promoter sites in both genes, whereas MITF binding was abolished by mutation of these sites. The Clcn7 promoter was transactivated by coexpression of MITF in reporter gene assays. Mutation of one Clcn7 M-box prevented MITF transactivation, but mutation of the second MITF-binding site only reduced basal activity. Chromatin immunoprecipitation assays confirmed that the two Clcn7 MITF binding and responsive regions in vitro bind MITF in genomic DNA. The expression of Clcn7 is repressed in the dominant negative mutant Mitf mouse, mi/mi, indicating that the dysregulated bone resorption seen in these mice can be attributed in part to transcriptional repression of Clcn7. MITF regulation of the TRAP, cathepsin K, Clcn7, and Ostm1 genes, which are critical for osteoclast resorption, suggests that the role of MITF is more significant than previously perceived and that MITF may be a master regulator of osteoclast function and bone resorption.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Cooperat Res Ctr Chron Inflammatory Dis, St Lucia, Qld 4072, Australia; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University of Queensland; University System of Ohio; Ohio State University	Cassady, AI (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	I.Cassady@imb.uq.edu.au	Sharma, Sudarshana Mangalore/AAI-2475-2019; Hume, David A/C-7695-2013; Cassady, Alan/AAY-2962-2021; Faulkner, Geoffrey J/M-3168-2014; Ostrowski, Michael/H-3108-2011	Cassady, Alan/0000-0001-8585-5427; Faulkner, Geoffrey J/0000-0001-5769-4494; Ostrowski, Michael/0000-0003-2948-6297; Sharma, Sudarshana/0000-0002-9745-0061; Hume, David/0000-0002-2615-1478	NIAMS NIH HHS [R01 AR044719] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044719] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adachi S, 2000, J IMMUNOL, V164, P855, DOI 10.4049/jimmunol.164.2.855; Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; Amiel J, 1998, CLIN DYSMORPHOL, V7, P17; Baxter LL, 2003, GENE EXPR PATTERNS, V3, P703, DOI 10.1016/j.modgep.2003.07.002; Campos-Xavier AB, 2003, HUM GENET, V112, P186, DOI 10.1007/s00439-002-0861-9; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; Cassady AI, 2003, J BONE MINER RES, V18, P1901, DOI 10.1359/jbmr.2003.18.10.1901; Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842; Du JY, 2003, AM J PATHOL, V163, P333, DOI 10.1016/S0002-9440(10)63657-7; Ferguson CA, 1997, PIGM CELL RES, V10, P127, DOI 10.1111/j.1600-0749.1997.tb00474.x; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Ge Y, 2001, AM J PATHOL, V158, P281, DOI 10.1016/S0002-9440(10)63967-3; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GLOWACKI J, 1989, BONE MINER, V5, P271, DOI 10.1016/0169-6009(89)90005-6; Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654; GRAVES L, 1990, J CELL PHYSIOL, V145, P102, DOI 10.1002/jcp.1041450115; HALLEEN JM, 1998, BONE NY, V23, pW108; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002-9440(10)63712-1; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ito A, 2003, BLOOD, V101, P2601, DOI 10.1182/blood-2002-07-2265; Ito A, 1998, BLOOD, V91, P3210, DOI 10.1182/blood.V91.9.3210.3210_3210_3221; Jippo T, 1999, BLOOD, V93, P1942, DOI 10.1182/blood.V93.6.1942.406k08_1942_1950; Jippo T, 1997, BLOOD, V90, P2601, DOI 10.1182/blood.V90.7.2601.2601_2601_2608; Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576; Kim DK, 1998, BLOOD, V92, P1973, DOI 10.1182/blood.V92.6.1973.418k23_1973_1980; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P304; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P295; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Miki R, 2001, P NATL ACAD SCI USA, V98, P2199, DOI 10.1073/pnas.041605498; Mitic N, 2005, ARCH BIOCHEM BIOPHYS, V439, P154, DOI 10.1016/j.abb.2005.05.013; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; Morii E, 1997, BLOOD, V90, P3057, DOI 10.1182/blood.V90.8.3057; Morii E, 2001, BLOOD, V97, P2038, DOI 10.1182/blood.V97.7.2038; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Murakami H, 2005, PIGM CELL RES, V18, P265, DOI 10.1111/j.1600-0749.2005.00234.x; Murakami M, 2003, BIOCHEM BIOPH RES CO, V311, P4, DOI 10.1016/j.bbrc.2003.09.148; Nomura S, 2001, J BONE MINER METAB, V19, P183, DOI 10.1007/s007740170040; Oddie GW, 2000, BONE, V27, P575, DOI 10.1016/S8756-3282(00)00368-9; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ramirez A, 2004, HUM MUTAT, V23, P471, DOI 10.1002/humu.20028; Rehli M, 1999, J IMMUNOL, V162, P1559; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; So H, 2003, J BIOL CHEM, V278, P24209, DOI 10.1074/jbc.M302940200; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; Turque N, 1996, EMBO J, V15, P3338, DOI 10.1002/j.1460-2075.1996.tb00699.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Wu M, 2000, GENE DEV, V14, P301; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200	61	62	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1891	1904		10.1074/jbc.M608572200	http://dx.doi.org/10.1074/jbc.M608572200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17105730	hybrid			2022-12-27	WOS:000243451300040
J	Oka, T; Ihara, S; Fukui, Y				Oka, Tsutomu; Ihara, Sayoko; Fukui, Yasuhisa			Cooperation of DEF6 with activated rac in regulating cell morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; RHO-GTPASES; ACTIN POLYMERIZATION; PROTEIN; CDC42; PATHWAYS; SWAP-70; BINDING; IDENTIFICATION; TRANSFORMATION	Rho-family GTPases have been implicated in actin remodeling and subsequent morphologic changes in various cells. DEF6, a pleckstrin homology domain-containing protein, has been reported to regulate Rho- family GTPases as a guanine nucleotide exchange factor. Here, we demonstrate that DEF6 also has the property of cooperating with activated Rac1. DEF6 bound selectively to Rac1 loaded with GTP. The interaction is mediated by the effector domain of Rac1. Overexpression of GFP-DEF6 together with constitutively active Rac1 in COS-7 cells significantly changed their cell shape; this was not seen in the absence of activated Rac1. This effect of DEF6 on cellular morphology was shown to be independent of its guanine nucleotide exchange activity. Because DEF6 does not contain any sequences previously known to interact with Rac, we explored the domain necessary for the binding. The amino-terminal portion and central parts of DEF6 were required for the binding. Finally, we succeeded in creating mutants of DEF6 with point mutations in the amino-terminal portion, which abrogate the binding to activated Rac1. These mutants did not exhibit the morphologic change in COS-7 cells when they were co-expressed with activated Rac1. These results suggest that DEF6 not only activates Rho- family GTPases but also cooperates with activated Rac1 to exert its cellular function.	Univ Tokyo, Grad Sch Agr & Life Sci, Div Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Fukui, Y (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Div Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	ayfukui@mail.ecc.u-tokyo.ac.jp	Fukui, Yasuhisa/E-8806-2010					Benard V, 2002, METHOD ENZYMOL, V345, P349; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; del Pozo MA, 2003, J IMMUNOL, V170, P41, DOI 10.4049/jimmunol.170.1.41; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; Fanzo JC, 2006, J CLIN INVEST, V116, P703, DOI 10.1172/JCI24096; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Gupta S, 2003, J BIOL CHEM, V278, P43541, DOI 10.1074/jbc.M308960200; Gupta S, 2003, HUM IMMUNOL, V64, P389, DOI 10.1016/S0198-8859(03)00024-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hotfilder M, 1999, BRIT J HAEMATOL, V106, P335, DOI 10.1046/j.1365-2141.1999.01551.x; Ihara S, 2006, J CELL SCI, V119, P500, DOI 10.1242/jcs.02767; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Mavrakis KJ, 2004, EXP CELL RES, V294, P335, DOI 10.1016/j.yexcr.2003.12.004; Meller N, 2005, J CELL SCI, V118, P4937, DOI 10.1242/jcs.02671; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SAWANO A, 2000, NUCLEIC ACIDS RES, V28, P78, DOI DOI 10.1093/NAR/28.16.E78; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; Shirai T, 1998, BBA-MOL CELL RES, V1402, P292, DOI 10.1016/S0167-4889(98)00014-7; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; Tanaka Y, 2003, IMMUNITY, V18, P403, DOI 10.1016/S1074-7613(03)00054-2; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; VAN AL, 1997, GENE DEV, V11, P2295; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324	35	30	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					2011	2018		10.1074/jbc.M605153200	http://dx.doi.org/10.1074/jbc.M605153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121847	hybrid			2022-12-27	WOS:000243451300052
J	Vanderford, NL; Andrali, SS; Ozcan, S				Vanderford, Nathan L.; Andrali, Sreenath S.; Ozcan, Sabire			Glucose induces MafA expression in pancreatic beta cell lines via the hexosamine biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; O-GLCNAC TRANSFERASE; N-ACETYLGLUCOSAMINE; CHRONIC EXPOSURE; BINDING-ACTIVITY; TRANSGENIC MICE; KEY REGULATOR; RIN-5F CELLS; SECRETION; GLYCOSYLATION	MafA is a basic leucine zipper transcription factor that regulates gene expression in both the neuroretina and pancreas. Within the pancreas, MafA is exclusively expressed in the beta cells and is involved in insulin gene transcription, insulin secretion, and beta cell survival. The expression of the mafA gene within beta cells is known to increase in response to high glucose levels by an unknown mechanism. In this study, we demonstrate that pyruvate, which is produced by glycolysis from glucose, is not sufficient to induce mafA gene expression compared with high glucose. This suggests that the signal for MafA induction is independent of ATP levels and that a metabolic event occurring upstream of pyruvate production leads to the induction of MafA. Furthermore, insulin secretion mediated by high glucose is not important for MafA expression. However, the addition of glucosamine to beta cell lines stimulates MafA expression in the absence of high glucose, and inhibition of the hexosamine biosynthetic pathway in the presence of high glucose abolishes MafA induction. Moreover, we demonstrate that the expression of UDP-N-acetylglucosaminyl transferase, the enzyme mediating O-linked glycosylation of cytosolic and nuclear proteins, is essential for glucose-dependent MafA expression. Consistent with this observation, inhibition of N-acetylglucosaminidase, the enzyme involved in the removal of the O-GlcNAc modification from proteins, with O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino-N-phenylcarbamate stimulates MafA expression under low glucose conditions. The presented data suggest that MafA expression mediated by high glucose requires flux through the hexosamine biosynthetic pathway and the O- linked glycosylation of an unknown protein(s) by UDP-N-acetylglucosaminyl transferase.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky	Ozcan, S (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 741 S Limestone St, Lexington, KY 40536 USA.	sozcan@uky.edu			NCRR NIH HHS [P20 RR020171, P20 RR20171] Funding Source: Medline; NIDDK NIH HHS [R01 DK067581, 5R21DK065730-02, 5R01DK067581-02, R01 DK067581-02, R21 DK065730-02, R21 DK065730] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065730, R01DK067581] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto Y, 2000, DIABETOLOGIA, V43, P1239, DOI 10.1007/s001250051519; Akimoto Yoshihiro, 2005, Medical Molecular Morphology, V38, P84, DOI 10.1007/s00795-004-0264-1; ALEXANDERBRIDGES M, 1992, MOL CELL BIOCHEM, V109, P99; Andrali SS, 2005, BIOCHEM BIOPH RES CO, V337, P149, DOI 10.1016/j.bbrc.2005.09.026; Buse MG, 2006, AM J PHYSIOL-ENDOC M, V290, pE1, DOI 10.1152/ajpendo.00329.2005; Cooksey RC, 2006, AM J PHYSIOL-ENDOC M, V290, pE334, DOI 10.1152/ajpendo.00265.2005; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Finlin BS, 2005, J BIOL CHEM, V280, P41864, DOI 10.1074/jbc.M414261200; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Goldberg HJ, 2006, ENDOCRINOLOGY, V147, P222, DOI 10.1210/en.2005-0523; Gronning LM, 2006, AM J PHYSIOL-ENDOC M, V290, pE599, DOI 10.1152/ajpendo.00242.2005; Harmon JS, 2005, J BIOL CHEM, V280, P11107, DOI 10.1074/jbc.M410345200; Harmon JS, 1998, DIABETES, V47, P900, DOI 10.2337/diabetes.47.6.900; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; Josefsen K, 1999, DIABETOLOGIA, V42, P195, DOI 10.1007/s001250051139; Kajihara M, 2003, BIOCHEM BIOPH RES CO, V312, P831, DOI 10.1016/j.bbrc.2003.10.196; Kaneto H, 2005, J BIOL CHEM, V280, P15047, DOI 10.1074/jbc.M412013200; Kataoka K, 2004, J MOL ENDOCRINOL, V32, P9, DOI 10.1677/jme.0.0320009; Kataoka K, 2002, J BIOL CHEM, V277, P36825, DOI 10.1074/jbc.M206756200; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Lam NT, 2004, J MOL ENDOCRINOL, V32, P415, DOI 10.1677/jme.0.0320415; Leibiger IB, 2002, FEBS LETT, V532, P1, DOI 10.1016/S0014-5793(02)03627-X; LeRoith D, 2002, AM J MED, V113, p3S; LeRoith D., 2000, DIABETES MELLITUS FU; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Love, 2005, SCI STKE, V2005, DOI DOI 10.1126/STKE.3122005RE13; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; Matsuoka T, 2004, P NATL ACAD SCI USA, V101, P2930, DOI 10.1073/pnas.0306233101; McClain DA, 2002, J DIABETES COMPLICAT, V16, P72, DOI 10.1016/S1056-8727(01)00188-X; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mosley AL, 2004, J BIOL CHEM, V279, P54241, DOI 10.1074/jbc.M410379200; Mosley AL, 2004, MOL ENDOCRINOL, V18, P2279, DOI 10.1210/me.2003-0463; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; Nishimura W, 2006, DEV BIOL, V293, P526, DOI 10.1016/j.ydbio.2006.02.028; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; Ohsugi M, 2004, DIABETES, V53, P1496, DOI 10.2337/diabetes.53.6.1496; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; Petersen HV, 2002, FEBS LETT, V528, P241, DOI 10.1016/S0014-5793(02)03318-5; Poitout V, 2006, J NUTR, V136, P873, DOI 10.1093/jn/136.4.873; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; Poitout V, 1996, ANNU REV MED, V47, P69; Raum JC, 2006, MOL CELL BIOL, V26, P5735, DOI 10.1128/MCB.00249-06; Reza HM, 2004, DEV DYNAM, V229, P440, DOI 10.1002/dvdy.10467; Roderigo-Milne H, 2002, BIOCHEM BIOPH RES CO, V296, P589, DOI 10.1016/S0006-291X(02)00913-0; Rumberger JM, 2003, J BIOL CHEM, V278, P28547, DOI 10.1074/jbc.M302793200; SENER A, 1984, EUR J BIOCHEM, V144, P223, DOI 10.1111/j.1432-1033.1984.tb08453.x; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Tang JP, 2000, DIABETES, V49, P1492, DOI 10.2337/diabetes.49.9.1492; Ueki K, 2006, NAT GENET, V38, P583, DOI 10.1038/ng1787; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Vosseller K, 2001, BIOCHIMIE, V83, P575, DOI 10.1016/S0300-9084(01)01295-0; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Wells L, 2003, CELL MOL LIFE SCI, V60, P222, DOI 10.1007/s000180300017; Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0; WELSH M, 1985, J BIOL CHEM, V260, P3590; Zachara NE, 2006, BBA-MOL CELL BIOL L, V1761, P599, DOI 10.1016/j.bbalip.2006.04.007; ZAWALICH WS, 1977, J BIOL CHEM, V252, P8519; Zhang C, 2005, MOL CELL BIOL, V25, P4969, DOI 10.1128/MCB.25.12.4969-4976.2005; Zhao L, 2005, J BIOL CHEM, V280, P11887, DOI 10.1074/jbc.M409475200; Zraika S, 2002, ARCH BIOCHEM BIOPHYS, V405, P275, DOI 10.1016/S0003-9861(02)00397-1	72	45	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1577	1584		10.1074/jbc.M605064200	http://dx.doi.org/10.1074/jbc.M605064200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17142462	Green Accepted, hybrid			2022-12-27	WOS:000243451300009
J	Daleke, DL				Daleke, David L.			Phospholipid flippases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							P-TYPE ATPASES; PUTATIVE AMINOPHOSPHOLIPID TRANSLOCASE; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; TRANSMEMBRANE MOVEMENT; TRANSBILAYER MOVEMENT; LABELED PHOSPHOLIPIDS; LIPID ASYMMETRY; INNER MEMBRANE; FLIP-FLOP		Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Bloomington, IN 47405 USA; Indiana Univ, Sch Med, Med Sci Program, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Daleke, DL (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Bloomington, IN 47405 USA.	daleked@indiana.edu	Daleke, David/T-3123-2019					Abe-Dohmae S, 2004, J BIOL CHEM, V279, P604, DOI 10.1074/jbc.M309888200; Alder-Baerens N, 2006, MOL BIOL CELL, V17, P1632, DOI 10.1091/mbc.E05-10-0912; Alder-Baerens N, 2005, J BIOL CHEM, V280, P26321, DOI 10.1074/jbc.M413993200; BACKER JM, 1987, NATURE, V327, P341, DOI 10.1038/327341a0; Balasubramanian K, 2003, ANNU REV PHYSIOL, V65, P701, DOI 10.1146/annurev.physiol.65.092101.142459; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Bretscher M.S., 1974, CELL SURFACE DEV, P17; Buton X, 1996, J BIOL CHEM, V271, P6651, DOI 10.1074/jbc.271.12.6651; Buton X, 2002, BIOCHEMISTRY-US, V41, P13106, DOI 10.1021/bi020385t; Carlton VEH, 2004, ANN MED, V36, P606, DOI 10.1080/07853890410018916; DALEKE DL, 1989, J CELL BIOL, V108, P1375, DOI 10.1083/jcb.108.4.1375; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; Daleke DL, 2000, BBA-MOL CELL BIOL L, V1486, P108, DOI 10.1016/S1388-1981(00)00052-4; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Dekkers DWC, 2000, BIOCHEM J, V350, P531, DOI 10.1042/0264-6021:3500531; Devaux PF, 2006, CHEM PHYS LIPIDS, V141, P119, DOI 10.1016/j.chemphyslip.2006.02.007; Dhar MS, 2004, J NUTR, V134, P799, DOI 10.1093/jn/134.4.799; Ding JT, 2000, J BIOL CHEM, V275, P23378, DOI 10.1074/jbc.M910319199; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Gall WE, 2002, CURR BIOL, V12, P1623, DOI 10.1016/S0960-9822(02)01148-X; Graham TR, 2004, TRENDS CELL BIOL, V14, P670, DOI 10.1016/j.tcb.2004.10.008; Halleck MS, 1999, PHYSIOL GENOMICS, V1, P139, DOI 10.1152/physiolgenomics.1999.1.3.139; Halleck MS, 2002, J BIOL CHEM, V277, P9736, DOI 10.1074/jbc.M200240200; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hanson PK, 2003, J BIOL CHEM, V278, P36041, DOI 10.1074/jbc.M305263200; Helenius J, 2002, SEMIN CELL DEV BIOL, V13, P171, DOI 10.1016/S1084-9521(02)00045-9; Helenius J, 2002, NATURE, V415, P447, DOI 10.1038/415447a; Hrafnsdottir S, 2000, J BACTERIOL, V182, P4198, DOI 10.1128/JB.182.15.4198-4206.2000; Hua ZL, 2002, MOL BIOL CELL, V13, P3162, DOI 10.1091/mbc.E02-03-0172; Kamp D, 1998, BBA-BIOMEMBRANES, V1372, P91, DOI 10.1016/S0005-2736(98)00049-2; Kato U, 2002, J BIOL CHEM, V277, P37855, DOI 10.1074/jbc.M205564200; Katoh Y, 2004, ONCOL REP, V12, P939; KAWASHIMA Y, 1987, J BIOL CHEM, V262, P16495; Kol MA, 2004, BIOCHEMISTRY-US, V43, P2673, DOI 10.1021/bi036200f; KORNBERG RD, 1971, BIOCHEMISTRY-US, V10, P1111; LEIER I, 1994, J BIOL CHEM, V269, P27807; Lyles Jill V, 2003, Methods Mol Biol, V228, P257, DOI 10.1385/1-59259-400-X:257; Meguro M, 2001, NAT GENET, V28, P19, DOI 10.1038/ng0501-19; MORIYAMA Y, 1991, ARCH BIOCHEM BIOPHYS, V286, P252, DOI 10.1016/0003-9861(91)90037-J; Natarajan P, 2004, P NATL ACAD SCI USA, V101, P10614, DOI 10.1073/pnas.0404146101; Nichols JW, 2002, SEMIN CELL DEV BIOL, V13, P179, DOI 10.1016/S1084-9521(02)00046-0; Nurmi EL, 2003, MOL PSYCHIATR, V8, P624, DOI [10.1038/sj.mp.4001283, 10.1038/sj.mp.4001361]; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; Paterson JK, 2006, BIOCHEMISTRY-US, V45, P5367, DOI 10.1021/bi052359b; Paulusma CC, 2005, BBA-MOL BASIS DIS, V1741, P11, DOI 10.1016/j.bbadis.2005.04.006; Pohl A, 2005, BBA-MOL CELL BIOL L, V1733, P29, DOI 10.1016/j.bbalip.2004.12.007; Pomorski T, 2004, J CELL SCI, V117, P805, DOI 10.1242/jcs.01055; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; Raggers RJ, 1999, J CELL SCI, V112, P415; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; ROTHMAN JE, 1977, P NATL ACAD SCI USA, V74, P1821, DOI 10.1073/pnas.74.5.1821; Rush JS, 2004, BIOCHEMISTRY-US, V43, P7643, DOI 10.1021/bi036083o; Saito K, 2004, MOL BIOL CELL, V15, P3418, DOI 10.1091/mbc.E03-11-0829; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Smriti, 2002, YEAST, V19, P303, DOI 10.1002/yea.818; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Vishwakarma RA, 2005, CHEM COMMUN, P453, DOI 10.1039/b413196g; Vishwakarma RA, 2005, ORG BIOMOL CHEM, V3, P1275, DOI 10.1039/b500300h; Voelker DR, 2004, BIOCHEM CELL BIOL, V82, P156, DOI 10.1139/o03-075; Wang N, 2003, J BIOL CHEM, V278, P42906, DOI 10.1074/jbc.M307831200; Watkins WE, 2002, BIOL CHEM, V383, P1435, DOI 10.1515/BC.2002.162; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Wicky S, 2004, MOL CELL BIOL, V24, P7402, DOI 10.1128/MCB.24.17.7402-7418.2004; Williamson P, 2002, BBA-MOL CELL BIOL L, V1585, P53, DOI 10.1016/S1388-1981(02)00324-4; Woehlecke H, 2003, BIOCHEM J, V376, P489, DOI 10.1042/BJ20030886; Zwaal RFA, 2005, CELL MOL LIFE SCI, V62, P971, DOI 10.1007/s00018-005-4527-3	72	185	187	1	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					821	825		10.1074/jbc.R600035200	http://dx.doi.org/10.1074/jbc.R600035200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17130120	hybrid			2022-12-27	WOS:000243295200002
J	Nielsen, MJ; Petersen, SV; Jacobsen, C; Thirup, S; Enghild, JJ; Graversen, JH; Moestrup, SK				Nielsen, Marianne Jensby; Petersen, Steen Vang; Jacobsen, Christian; Thirup, Soren; Enghild, Jan Johannes; Graversen, Jonas Heilskov; Moestrup, Sren Kragh			A unique loop extension in the serine protease domain of haptoglobin is essential for CD163 recognition of the haptoglobin-hemoglobin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOME LYTIC FACTOR; SCAVENGER RECEPTOR; HUMAN SERUM; BINDING; POLYMORPHISM; SPECIFICITY	Haptoglobin and haptoglobin-related protein are homologous hemoglobin-binding proteins consisting of a complement control repeat (alpha-chain) and a serine protease domain (alpha-chain). Haptoglobin-hemoglobin complex formation promotes high affinity binding of hemoglobin to the macrophage scavenger receptor CD163 leading to endocytosis and degradation of the haptoglobin-hemoglobin complex. In contrast, complex formation between haptoglobin-related protein and hemoglobin does not promote high affinity interaction with CD163. To define structural components of haptoglobin important for CD163 recognition, we exploited this functional difference to design and analyze recombinant haptoglobin/haptoglobin-related protein chimeras complexed to hemoglobin. These data revealed that only the alpha-chain of haptoglobin is involved in receptor recognition. Substitution of 4 closely spaced amino acid residues of the haptoglobin alpha-chain (valine 259, glutamate 261, lysine 262, and threonine 264) abrogated the high affinity receptor binding. The 4 residues are encompassed by a part of the primary structure not present in other serine protease domain proteins. Structural modeling based on the well characterized serine protease domain fold suggests that this sequence represents a loop extension unique for haptoglobin and haptoglobin-related protein. A synthetic peptide representing the haptoglobin loop sequence exhibited a pronounced inhibitory effect on receptor binding of haptoglobin-hemoglobin.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Moestrup, SK (corresponding author), Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark.	skm@biokemi.au.dk	Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Vang Petersen, Steen/0000-0002-9338-911X; Graversen, Jonas Heilskov/0000-0002-2411-9933; Thirup, Soren/0000-0002-0061-7137; Graversen, Jonas Heilskov/0000-0001-7119-2108; Enghild, Jan Johannes/0000-0001-9292-9172	Lundbeck Foundation [R7-2006-752] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden)		BENSI G, 1985, EMBO J, V4, P119, DOI 10.1002/j.1460-2075.1985.tb02325.x; Czapinska H, 1999, EUR J BIOCHEM, V260, P571, DOI 10.1046/j.1432-1327.1999.00160.x; Delanghe JR, 2002, CLIN CHEM LAB MED, V40, P212, DOI 10.1515/CCLM.2002.035; Drain J, 2001, J BIOL CHEM, V276, P30254, DOI 10.1074/jbc.M010198200; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; KUROSKY A, 1980, P NATL ACAD SCI-BIOL, V77, P3388, DOI 10.1073/pnas.77.6.3388; Langlois MR, 1996, CLIN CHEM, V42, P1589; Liau CY, 2003, J CHROMATOGR B, V790, P209, DOI 10.1016/S1570-0232(03)00128-4; Madsen M, 2004, J BIOL CHEM, V279, P51561, DOI 10.1074/jbc.M409629200; MAEDA N, 1985, J BIOL CHEM, V260, P6698; Melamed-Frank M, 2001, BLOOD, V98, P3693, DOI 10.1182/blood.V98.13.3693; Nielsen MJ, 2006, BLOOD, V108, P2846, DOI 10.1182/blood-2006-05-022327; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; Raper J, 1999, INFECT IMMUN, V67, P1910; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; Schaer DJ, 2006, BLOOD, V107, P373, DOI 10.1182/blood-2005-03-1014; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shiflett AM, 2005, J BIOL CHEM, V280, P32578, DOI 10.1074/jbc.M503510200; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; Tomlinson S, 1997, MOL BIOCHEM PARASIT, V86, P117, DOI 10.1016/S0166-6851(97)90013-X; WEJMAN JC, 1984, J MOL BIOL, V174, P319, DOI 10.1016/0022-2836(84)90341-3; Wicher KB, 2004, P NATL ACAD SCI USA, V101, P14390, DOI 10.1073/pnas.0405692101	24	58	60	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1072	1079		10.1074/jbc.M605684200	http://dx.doi.org/10.1074/jbc.M605684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17102136	hybrid			2022-12-27	WOS:000243295200031
J	Perlow-Poehnelt, RA; Likhterov, I; Wang, LH; Scicchitano, DA; Geacintov, NE; Broyde, S				Perlow-Poehnelt, Rebecca A.; Likhterov, Ilya; Wang, Lihua; Scicchitano, David A.; Geacintov, Nicholas E.; Broyde, Suse			Increased flexibility enhances misincorporation - Temperature effects on nucleotide incorporation opposite a bulky carcinogen-DNA adduct by a Y-family DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZO<A>PYRENE DIOL EPOXIDE; CRICK HYDROGEN-BONDS; I KLENOW FRAGMENT; LESION-BYPASS; ESCHERICHIA-COLI; SEQUENCE CONTEXT; TRANSLESIONAL SYNTHESIS; DEOXYGUANOSINE ADDUCTS; CRYSTAL-STRUCTURES; ACTIVE-SITE	The Y-family DNA polymerase Dpo4, from the thermophilic crenarchaeon Sulfolobus solfataricus P2, offers a valuable opportunity to investigate the effect of conformational flexibility on the bypass of bulky lesions because of its ability to function efficiently at a wide range of temperatures. Combined molecular modeling and experimental kinetic studies have been carried out for 10S-(+)-trans-anti-[BP]-N-2-dG((+)-ta-[BP]G), a lesion derived from the covalent reaction of a benzo[a] pyrene metabolite with guanine in DNA, at 55 degrees C and results compared with an earlier study at 37 degrees C ( Perlow- Poehnelt, R. A., Likhterov, I., Scicchitano, D. A., Geacintov, N. E., and Broyde, S. (2004) J. Biol. Chem. 279, 36951-36961). The experimental results show that there is more overall nucleotide insertion opposite (+)-ta-[BP]G due to particularly enhanced mismatch incorporation at 55 degrees C compared with 37 degrees C. The molecular dynamics simulations suggest that mismatched nucleotide insertion opposite (+)-ta-[BP]G is increased at 55 degrees C compared with 37 degrees C because the higher temperature shifts the preference of the damaged base from the anti to the syn conformation, with the carcinogen on the more open major groove side. The mismatched dNTP structures are less distorted when the damaged base is syn than when it is anti, at the higher temperature. However, with the normal partner dCTP, the anti conformation with close to Watson-Crick alignment remains more favorable. The molecular dynamics simulations are consistent with the k(cat) values for nucleotide incorporation opposite the lesion studied, providing structural interpretation of the experimental observations. The observed temperature effect suggests that conformational flexibility plays a role in nucleotide incorporation and bypass fidelity opposite (+)-ta-[BP]G by Dpo4.	NYU, Dept Biol, New York, NY 10003 USA; NYU, Dept Chem, New York, NY 10003 USA	New York University; New York University	Broyde, S (corresponding author), 100 Washington Sq E,1009 Silver Ctr, New York, NY 10003 USA.	broyde@nyu.edu			NCI NIH HHS [CA099194, CA28038] Funding Source: Medline; NIEHS NIH HHS [ES10581] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028038, R01CA099194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010581] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alekseyev YO, 2000, BIOCHEMISTRY-US, V39, P10431, DOI 10.1021/bi000552u; Avkin S, 2004, J BIOL CHEM, V279, P53298, DOI 10.1074/jbc.M409155200; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boudsocq F, 2002, DNA REPAIR, V1, P343, DOI 10.1016/S1568-7864(02)00019-8; Boudsocq F, 2001, NUCLEIC ACIDS RES, V29, P4607, DOI 10.1093/nar/29.22.4607; Bresson A, 2002, EMBO J, V21, P3881, DOI 10.1093/emboj/cdf363; CHANDANI S, 2006, IN PRESS J MOL GRAPH; CHENG SC, 1989, CHEM RES TOXICOL, V2, P334, DOI 10.1021/tx00011a011; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P15334, DOI 10.1021/bi00046a043; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Duvauchelle JB, 2002, NUCLEIC ACIDS RES, V30, P2061, DOI 10.1093/nar/30.9.2061; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Fernandes A, 1998, BIOCHEMISTRY-US, V37, P10164, DOI 10.1021/bi980401f; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; Frank EG, 2002, NUCLEIC ACIDS RES, V30, P5284, DOI 10.1093/nar/gkf643; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; GEACINTOV NE, 1991, CARCINOGENESIS, V12, P2099, DOI 10.1093/carcin/12.11.2099; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; Gonzalez M, 2002, BIOESSAYS, V24, P141, DOI 10.1002/bies.10040; Hanrahan CJ, 1997, CHEM RES TOXICOL, V10, P369, DOI 10.1021/tx9601925; Hsu GW, 2005, J BIOL CHEM, V280, P3764, DOI 10.1074/jbc.M411276200; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; JELINSKY SA, 1995, BIOCHEMISTRY-US, V34, P13545, DOI 10.1021/bi00041a034; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kokoska RJ, 2003, J BIOL CHEM, V278, P50537, DOI 10.1074/jbc.M308515200; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Lenne-Samuel N, 2000, MOL MICROBIOL, V38, P299, DOI 10.1046/j.1365-2958.2000.02116.x; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; Lipinski LJ, 1998, INT J ONCOL, V13, P269; MAO B, 1995, CARCINOGENESIS, V16, P357, DOI 10.1093/carcin/16.2.357; MEEHAN T, 1979, NATURE, V277, P410, DOI 10.1038/277410a0; Morales JC, 2000, BIOCHEMISTRY-US, V39, P12979, DOI 10.1021/bi001578o; Morales JC, 1999, J AM CHEM SOC, V121, P2323, DOI 10.1021/ja983502+; Moriya M, 1996, BIOCHEMISTRY-US, V35, P16646, DOI 10.1021/bi9608875; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Perlow RA, 2003, J MOL BIOL, V327, P797, DOI 10.1016/S0022-2836(03)00187-6; Perlow RA, 2002, J MOL BIOL, V322, P291, DOI 10.1016/S0022-2836(02)00751-9; Perlow RA, 2001, J MOL BIOL, V309, P519, DOI 10.1006/jmbi.2001.4674; Perlow-Poehnelt RA, 2004, J BIOL CHEM, V279, P36951, DOI 10.1074/jbc.M404332200; Pirogov N, 1998, CHEM RES TOXICOL, V11, P381, DOI 10.1021/tx980006q; Potapova O, 2006, BIOCHEMISTRY-US, V45, P890, DOI 10.1021/bi051792i; Rechkoblit O, 2006, PLOS BIOL, V4, P25, DOI 10.1371/journal.pbio.0040011; Rechkoblit O, 1999, BIOCHEMISTRY-US, V38, P11834, DOI 10.1021/bi990614k; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; RODRIGUEZ H, 1993, CARCINOGENESIS, V14, P373, DOI 10.1093/carcin/14.3.373; RODRIGUEZ H, 1995, MUTAT RES-FUND MOL M, V326, P29, DOI 10.1016/0027-5107(95)00149-D; Rothwell PJ, 2005, ADV PROTEIN CHEM, V71, P401, DOI 10.1016/S0065-3233(04)71011-6; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Seo KY, 2006, DNA REPAIR, V5, P515, DOI 10.1016/j.dnarep.2005.12.009; Seo KY, 2005, MUTAGENESIS, V20, P441, DOI 10.1093/mutage/gei061; Shen X, 2002, J BIOL CHEM, V277, P5265, DOI 10.1074/jbc.M109575200; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P4615, DOI 10.1021/bi00068a019; Shukla R, 1997, BIOCHEMISTRY-US, V36, P13263, DOI 10.1021/bi971195z; Shukla R, 1999, CARCINOGENESIS, V20, P261, DOI 10.1093/carcin/20.2.261; Simhadri S, 2002, MUTAT RES-FUND MOL M, V508, P137, DOI 10.1016/S0027-5107(02)00211-7; Steitz TA, 2004, PHILOS T R SOC B, V359, P17, DOI 10.1098/rstb.2003.1374; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Xie XM, 1999, BIOCHEMISTRY-US, V38, P2956, DOI 10.1021/bi9825605; Zang H, 2005, CHEM RES TOXICOL, V18, P389, DOI 10.1021/tx049683c; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhao B, 2006, NUCLEIC ACIDS RES, V34, P417, DOI 10.1093/nar/gkj446; Zhuang P, 2001, BIOCHEMISTRY-US, V40, P6660, DOI 10.1021/bi010005o	77	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1397	1408		10.1074/jbc.M606769200	http://dx.doi.org/10.1074/jbc.M606769200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17090533	hybrid			2022-12-27	WOS:000243295200065
J	Chen, K; Cases, O; Rebrin, I; Wu, WH; Gallaher, TK; Seif, I; Shih, JC				Chen, Kevin; Cases, Olivier; Rebrin, Igor; Wu, Weihua; Gallaher, Timothy K.; Seif, Isabelle; Shih, Jean Chen			Forebrain-specific expression of monoamine oxidase a reduces neurotransmitter levels, restores the brain structure, and rescues aggressive behavior in monoamine oxidase A-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SOMATOSENSORY CORTEX; TRANSGENIC MICE; MOLECULAR-BASIS; POINT MUTATION; SEROTONIN; GENE; NOREPINEPHRINE; LOCALIZATION; ACCUMULATION; IMPULSIVITY	Previous studies have established that abrogation of monoamine oxidase (MAO) A expression leads to a neurochemical, morphological, and behavioral specific phenotype with increased levels of serotonin (5-HT), norepinephrine, and dopamine, loss of barrel field structure in mouse somatosensory cortex, and an association with increased aggression in adults. Forebrain-specific MAO A transgenic mice were generated from MAO A knock-out (KO) mice by using the promoter of calcium-dependent kinase II alpha (CaMKII alpha). The presence of human MAO A transgene and its expression were verified by PCR of genomic DNA and reverse transcription-PCR of mRNA and Western blot, respectively. Significant MAO A catalytic activity, autoradiographic labeling of 5-HT, and immunocytochemistry of MAO A were found in the frontal cortex, striatum, and hippocampus but not in the cerebellum of the forebrain transgenic mice. Also, compared with MAO A KO mice, lower levels of 5-HT, norepinephrine, and DA and higher levels of MAO A metabolite 5-hydroxyin-doleacetic acid were found in the forebrain regions but not in the cerebellum of the transgenic mice. These results suggest that MAO A is specifically expressed in the forebrain regions of transgenic mice. This forebrain-specific differential expression resulted in abrogation of the aggressive phenotype. Furthermore, the disorganization of the somatosensory cortex barrel field structure associated with MAO A KO mice was restored and became morphologically similar to wild type. Thus, the lack of MAO A in the forebrain of MAO A KO mice may underlie their phenotypes.	Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA; Hop Robert Debre, INSERM, U676, F-75019 Paris, France; Inst Curie, UMR 146, F-91405 Orsay, France	University of Southern California; University of Southern California; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Shih, JC (corresponding author), Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Rm 518,1985 Zonal Ave, Los Angeles, CA 90089 USA.	jcshih@hsc.usc.edu	Chen, Kevin/GYU-8963-2022; cases, olivier/G-4882-2017	cases, olivier/0000-0002-5678-7362	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039085, R01MH067968] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH067968, R37 MH39085, R37 MH039085-23, R37 MH039085, R01 MH067968-05] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; BRUNNER HG, 1993, AM J HUM GENET, V52, P1032; Cases O, 1996, NEURON, V16, P297, DOI 10.1016/S0896-6273(00)80048-3; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; Cases O, 1998, J NEUROSCI, V18, P6914; CESURA AM, 1990, MOL PHARMACOL, V37, P358; Chen K, 2004, J BIOL CHEM, V279, P39645, DOI 10.1074/jbc.M405550200; Chen K, 1996, J NEUROCHEM, V66, P797; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; GRIMSBY J, 1990, J NEUROCHEM, V55, P1166, DOI 10.1111/j.1471-4159.1990.tb03121.x; GRIMSBY J, 1997, NAT GENET, V17, P1; JOHNSTON JP, 1968, BIOCHEM PHARMACOL, V17, P1285, DOI 10.1016/0006-2952(68)90066-X; Kim JJ, 1997, P NATL ACAD SCI USA, V94, P5929, DOI 10.1073/pnas.94.11.5929; Kim-Cohen J, 2006, MOL PSYCHIATR, V11, P903, DOI 10.1038/sj.mp.4001851; Knoll J, 1972, Adv Biochem Psychopharmacol, V5, P393; LAN NC, 1989, GENOMICS, V4, P552, DOI 10.1016/0888-7543(89)90279-6; Lenders JWM, 1996, J CLIN INVEST, V97, P1010, DOI 10.1172/JCI118492; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Meyer-Lindenberg A, 2006, P NATL ACAD SCI USA, V103, P6269, DOI 10.1073/pnas.0511311103; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MITOMA J, 1992, J BIOCHEM-TOKYO, V111, P20, DOI 10.1093/oxfordjournals.jbchem.a123712; Mossner R, 2006, NEUROSCI LETT, V401, P49, DOI 10.1016/j.neulet.2006.02.081; Ou XM, 2006, P NATL ACAD SCI USA, V103, P10923, DOI 10.1073/pnas.0601515103; Packer MA, 2005, CELL MOL BIOL, V51, P269, DOI 10.1170/T627; Passamonti L, 2006, BIOL PSYCHIAT, V59, P334, DOI 10.1016/j.biopsych.2005.07.027; Rebrin I, 2001, J BIOL CHEM, V276, P29499, DOI 10.1074/jbc.M100431200; Rebsam A, 2005, J NEUROSCI, V25, P706, DOI 10.1523/JNEUROSCI.4191-04.2005; Sabol SZ, 1998, HUM GENET, V103, P273, DOI 10.1007/s004390050816; Shih JC, 1999, BRAIN RES, V835, P104, DOI 10.1016/S0006-8993(99)01478-X; SHIH JC, 1991, NEUROPSYCHOPHARMACOL, V4, P1; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Thorpe LW, 1987, J HISTOCHEM CYTOCHEM, V35, P23, DOI 10.1177/35.1.3025289; Vitalis T, 1998, J COMP NEUROL, V393, P169, DOI 10.1002/(SICI)1096-9861(19980406)393:2<169::AID-CNE3>3.0.CO;2-0; Wang HB, 2004, NAT NEUROSCI, V7, P635, DOI 10.1038/nn1248	38	37	38	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					115	123		10.1074/jbc.M609830200	http://dx.doi.org/10.1074/jbc.M609830200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17090537	Green Accepted, hybrid			2022-12-27	WOS:000243166500014
J	Chen, Y; Hayashida, A; Bennett, AE; Hollingshead, SK; Park, PW				Chen, Ye; Hayashida, Atsuko; Bennett, Allison E.; Hollingshead, Susan K.; Park, Pyong Woo			Streptococcus pneumoniae sheds syndecan-1 ectodomains through ZmpC, a metalloproteinase virulence factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; NECROSIS-FACTOR-ALPHA; A1 PROTEASE GENE; PSEUDOMONAS-AERUGINOSA; STAPHYLOCOCCUS-AUREUS; FACTOR RECEPTOR; PNEUMOLYSIN; PROTEINS; BINDING; INTERLEUKIN-6	Several microbial pathogens stimulate the ectodomain shedding of host cell surface proteins to promote their pathogenesis. We reported previously that Pseudomonas aeruginosa and Staphylococcus aureus activate the ectodomain shedding of syndecan-1 and that syndecan-1 shedding promotes P. aeruginosa pathogenesis in mouse models of lung and burned skin infections. However, it remains to be determined whether activation of syndecan-1 shedding is a virulence mechanism broadly used by pathogens. Here we show that Streptococcus pneumoniae stimulates syndecan-1 shedding in cell culture-based assays. S. pneumoniae-induced syndecan-1 shedding was repressed by peptide hydroxamate inhibitors of metalloproteinases but not by inhibitors of intracellular signaling pathways previously found to be essential for syndecan-1 shedding caused by P. aeruginosa, S. aureus, or other shedding agonists. A 170-kDa protein fraction with a peptide hydroxamate-sensitive shedding activity was purified by ammonium sulfate precipitation, DEAE chromatography, and size exclusion chromatography. Mass spectrometry analyses revealed that the 170-kDa fraction is composed of ZmpB and ZmpC, two metalloproteinase virulence factors of S. pneumoniae. Both the purified 170-kDa ZmpB/ ZmpC fraction and unfractionated S. pneumoniae culture supernatant generated syndecan-1 ectodomains that are smaller than those released by endogenous shedding. Further, a mutant S. pneumoniae strain deficient in zmpC, but not zmpB, lost its capacity to stimulate syndecan-1 shedding. These data demonstrate that S. pneumoniae directly sheds syndecan-1 ectodomains through the action of ZmpC.	Baylor Coll Med, Infect Dis Sect, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Alabama System; University of Alabama Birmingham	Park, PW (corresponding author), Baylor Coll Med, Infect Dis Sect, Dept Med, 1 baylor Plaza,Rm N1319, Houston, TX 77030 USA.	pwpark@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073725, R01HL069050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007041, R01AI053749] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL069050, HL73725, R01 HL073725, HL69050] Funding Source: Medline; NIAID NIH HHS [AI053749, T32AI07041] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Balachandran P, 2002, INFECT IMMUN, V70, P2526, DOI 10.1128/IAI.70.5.2526-2534.2002; Balachandran P, 2001, J BACTERIOL, V183, P3108, DOI 10.1128/JB.183.10.3108-3116.2001; Bender MH, 2006, MOL MICROBIOL, V61, P526, DOI 10.1111/j.1365-2958.2006.05256.x; Berge M, 2001, MOL MICROBIOL, V39, P1651, DOI 10.1046/j.1365-2958.2001.02359.x; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Berry AM, 2000, INFECT IMMUN, V68, P133, DOI 10.1128/IAI.68.1.133-140.2000; BERRY AM, 1989, INFECT IMMUN, V57, P2037, DOI 10.1128/IAI.57.7.2037-2042.1989; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Blue CE, 2003, INFECT IMMUN, V71, P4925, DOI 10.1128/IAI.71.9.4925-4935.2003; Briles DE, 2003, J INFECT DIS, V188, P339, DOI 10.1086/376571; Chiavolini D, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471-2180-3-14; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Fritchley SJ, 2000, CLIN EXP IMMUNOL, V120, P247, DOI 10.1046/j.1365-2249.2000.01178.x; Hava D, 2002, MOL MICROBIOL, V45, P1389, DOI 10.1046/j.1365-2958.2002.03106.x; Haynes A, 2005, INFECT IMMUN, V73, P7914, DOI 10.1128/IAI.73.12.7914-7921.2005; Hollingshead SK, 2001, CURR OPIN MICROBIOL, V4, P71, DOI 10.1016/S1369-5274(00)00167-3; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lau PCY, 2002, J MICROBIOL METH, V49, P193, DOI 10.1016/S0167-7012(01)00369-4; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Mattsson E, 1996, INFECT IMMUN, V64, P4351, DOI 10.1128/IAI.64.10.4351-4355.1996; Oggioni MR, 2003, MOL MICROBIOL, V49, P795, DOI 10.1046/j.1365-2958.2003.03596.x; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Park PW, 2004, J BIOL CHEM, V279, P251, DOI 10.1074/jbc.M308537200; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Park PW, 2000, J BIOL CHEM, V275, P3057, DOI 10.1074/jbc.275.5.3057; Poulsen K, 1996, INFECT IMMUN, V64, P3957, DOI 10.1128/IAI.64.10.3957-3966.1996; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; Sarrazin S, 2005, J BIOL CHEM, V280, P37558, DOI 10.1074/jbc.M507729200; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schmidtchen A, 2001, MOL MICROBIOL, V39, P708, DOI 10.1046/j.1365-2958.2001.02251.x; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Sung CK, 2001, APPL ENVIRON MICROB, V67, P5190, DOI 10.1128/AEM.67.11.5190-5196.2001; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; Vollmer P, 1996, INFECT IMMUN, V64, P3646, DOI 10.1128/IAI.64.9.3646-3651.1996; Walev I, 2000, J LEUKOCYTE BIOL, V68, P865; Walev I, 1996, P NATL ACAD SCI USA, V93, P7882, DOI 10.1073/pnas.93.15.7882; Wani JH, 1996, INFECT IMMUN, V64, P3967, DOI 10.1128/IAI.64.10.3967-3974.1996; Weiser JN, 2003, P NATL ACAD SCI USA, V100, P4215, DOI 10.1073/pnas.0637469100; Xu J, 2005, J IMMUNOL, V174, P5758, DOI 10.4049/jimmunol.174.9.5758	45	53	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					159	167		10.1074/jbc.M608542200	http://dx.doi.org/10.1074/jbc.M608542200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17098735	hybrid			2022-12-27	WOS:000243166500019
J	Kriska, T; Marathe, GK; Schmidt, JC; McIntyre, TM; Girotti, AW				Kriska, Tamas; Marathe, Gopal K.; Schmidt, Jacob C.; McIntyre, Thomas M.; Girotti, Albert W.			Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SERUM PARAOXONASE; DENSITY-LIPOPROTEIN OXIDATION; HUMAN-PLASMA; LIPID HYDROPEROXIDES; PURIFIED HUMAN; HUMAN CORONARY; PON1; ATHEROSCLEROSIS; MICE; PEROXIDATION	Phospholipid hydroperoxide (PLOOH) degrading activity of high density lipoprotein (HDL)-derived paraoxonase-1 (PON1) was investigated, using peroxidized 1-palmitoyl-2-oleoyl phosphatidylcholine (PCOOH) as substrate and high performance thin layer chromatography for quantitative peroxide analysis. Incubation of PCOOH with PON1 resulted in decay of the latter and reciprocal buildup of oleic acid hydroperoxide (OAOOH) at rates unaffected by GSH or other reductants. A serine esterase inhibitor blocked this activity and a recombinant PON1 was devoid of it, raising the possibility that the activity represents platelet-activating factor acetylhydrolase (PAF-AH), an esterase that co-purifies with PON1 from HDL. This was verified by showing that a recombinant PAF-AH recapitulates the ability of natural PON1 to hydrolyze PCOOH and release OAOOH while having essentially no effect on parental PC. Furthermore, recombinant PAF-AH and natural PON1 were shown to have similar K-m values for PCOOH hydrolysis. Finally, we found that recombinant PAF-AH, but not PON1, catalyzes PLOOH hydrolysis in peroxidized low density lipoprotein. We conclude from this study that PON1 is neither a PLOOH peroxidase nor hydrolase and that the phospholipase A(2)-like activity previously attributed to PON1 in natural enzyme preparations was actually due to novel PLOOH hydrolytic activity of contaminating PAF-AH.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Cleveland Clinic Foundation; Medical College of Wisconsin	McIntyre, TM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, NE-10,9500 Euclid Ave, Cleveland, OH 44195 USA.	mcintyt@ccf.org; agirotti@mcw.edu	Girotti, Albert/AAF-6910-2020	Marathe, Gopal/0000-0002-0025-6677	NCI NIH HHS [CA72630] Funding Source: Medline; NHLBI NIH HHS [HL44513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072630] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aharoni A, 2004, P NATL ACAD SCI USA, V101, P482, DOI 10.1073/pnas.2536901100; Ahmed Z, 2002, BIOCHEM BIOPH RES CO, V290, P391, DOI 10.1006/bbrc.2001.6150; Ahmed Z, 2001, J BIOL CHEM, V276, P24473, DOI 10.1074/jbc.M010459200; Aviram M, 2000, CIRCULATION, V101, P2510, DOI 10.1161/01.CIR.101.21.2510; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradshaw G, 2005, P NATL ACAD SCI USA, V102, P11029, DOI 10.1073/pnas.0502677102; Brushia RJ, 2001, J LIPID RES, V42, P951; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; Cao HB, 1999, J LIPID RES, V40, P133; CHUNG BH, 1980, J LIPID RES, V21, P284; Draganov DI, 2005, J LIPID RES, V46, P1239, DOI 10.1194/jlr.M400511-JLR200; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESWORTHY RS, 1993, ARCH BIOCHEM BIOPHYS, V307, P29, DOI 10.1006/abbi.1993.1555; FRANKEL EN, 1984, PROG LIPID RES, V23, P197, DOI 10.1016/0163-7827(84)90011-0; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; Girotti AW, 1998, J LIPID RES, V39, P1529; GIROTTI AW, 1985, ARCH BIOCHEM BIOPHYS, V236, P238, DOI 10.1016/0003-9861(85)90623-X; HALLIWELL B, 1989, FREE RADICAL BIO MED, V7, P645, DOI 10.1016/0891-5849(89)90145-7; Harel M, 2004, NAT STRUCT MOL BIOL, V11, P412, DOI 10.1038/nsmb767; HASSETT C, 1991, BIOCHEMISTRY-US, V30, P10141, DOI 10.1021/bi00106a010; Jarvik GP, 2000, ARTERIOSCL THROM VAS, V20, P2441, DOI 10.1161/01.ATV.20.11.2441; Kell PJ, 2003, J PHARMACOL EXP THER, V307, P1163, DOI 10.1124/jpet.103.055392; Kempen EC, 2001, ANAL BIOCHEM, V297, P183, DOI 10.1006/abio.2001.5325; Khersonsky O, 2006, J BIOL CHEM, V281, P7649, DOI 10.1074/jbc.M512594200; Khersonsky O, 2005, BIOCHEMISTRY-US, V44, P6371, DOI 10.1021/bi047440d; Korytowski W, 1999, ANAL BIOCHEM, V270, P123, DOI 10.1006/abio.1999.4070; Korytowski W, 2005, ANAL BIOCHEM, V343, P136, DOI 10.1016/j.ab.2005.04.005; Kriska T, 2004, ANAL BIOCHEM, V327, P97, DOI 10.1016/j.ab.2003.12.021; KUO CL, 1995, DRUG METAB DISPOS, V23, P935; Mackness B, 2003, CIRCULATION, V107, P2775, DOI 10.1161/01.CIR.0000070954.00271.13; Mackness M, 2004, FREE RADICAL BIO MED, V37, P1317, DOI 10.1016/j.freeradbiomed.2004.07.034; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; Mackness MI, 2000, CURR OPIN LIPIDOL, V11, P383, DOI 10.1097/00041433-200008000-00007; Marathe GK, 2003, J BIOL CHEM, V278, P3937, DOI 10.1074/jbc.M211126200; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Oda MN, 2002, BIOCHEM BIOPH RES CO, V290, P921, DOI 10.1006/bbrc.2001.6295; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Rodrigo L, 2001, BIOCHEM J, V354, P1, DOI 10.1042/0264-6021:3540001; Rosenblat M, 2006, J BIOL CHEM, V281, P7657, DOI 10.1074/jbc.M512595200; Rozenberg O, 2003, ARTERIOSCL THROM VAS, V23, P461, DOI 10.1161/01.ATV.0000060462.35946.B3; Serrato M, 1995, J CLIN INVEST, V96, P3005, DOI 10.1172/JCI118373; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Stafforini DM, 2006, J BIOL CHEM, V281, P4616, DOI 10.1074/jbc.M507340200; STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Teiber JF, 2004, J LIPID RES, V45, P2260, DOI 10.1194/jlr.M400213-JLR200; Teiber JF, 2003, BIOCHEM PHARMACOL, V66, P887, DOI 10.1016/S0006-2952(03)00401-5; THOMAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1045, P252, DOI 10.1016/0005-2760(90)90128-K; Tjoelker LW, 2000, BBA-MOL CELL BIOL L, V1488, P102, DOI 10.1016/S1388-1981(00)00114-1; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; Tward A, 2002, CIRCULATION, V106, P484, DOI 10.1161/01.CIR.0000023623.87083.4F; Vila A, 2004, BIOCHEMISTRY-US, V43, P12592, DOI 10.1021/bi0491200; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359	62	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					100	108		10.1074/jbc.M608135200	http://dx.doi.org/10.1074/jbc.M608135200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17090529	hybrid			2022-12-27	WOS:000243166500012
J	Mare, L; Trinchera, M				Mare, Lydia; Trinchera, Marco			Comparative analysis of retroviral and native promoters driving expression of beta 1,3-galactosyltransferase beta 3Gal-T5 in human and mouse tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPOSABLE ELEMENTS; UDP-GALACTOSE; DNA-SEQUENCE; CELLS; INTESTINE; CLONING; COLON; ADENOCARCINOMAS; TRANSCRIPTION; SYNTHASE	beta 1,3-Galactosyltransferase beta 3Gal-T5 is highly expressed in the colons of humans and certain primates due to a retroviral long terminal repeat (LTR) acting as a strong promoter. Because this promoter is inactive in other human tissues or mice, we attempted to understand how adoption of a retrotransposon allowed the gene to acquire tissue-specific expression. We identified three novel 5'-UTRs of beta 3Gal-T5 mRNA, types A, B, and C, and found widespread expression of the type A transcript at much lower levels than the LTR transcript, the expression of which is restricted to organs of the gastrointestinal tract. Expression of the type C 5'-UTR transcript was mostly restricted to the ileum, where it was expressed at high levels. We cloned the 5'-flanking regions of both types A and B 5'-UTRs,found deletion constructs functionally active as promoters, and identified CCAAT-binding factor (CBF) and hepatocyte nuclear factor 1 (HNF-1) as the principal nuclear factors controlling the promoters of types A and B 5'-UTR transcripts, respectively. The CCAAT-binding factor binding site and the entire downstream sequence driving the expression of type A transcripts in humans are structurally and functionally conserved in mice, where they constitute a unique beta 3Gal-T5 promoter that appears to be the ancestral promoter of the gene. The HNF-1 binding motif of the second human promoter is identical to the HNF-1/Cdx binding motif of the LTR promoter but is in the antisense orientation, resulting in much lower binding affinity and promoter strength. These data may explain the successful insertion of the transposon during evolution.	Univ Insubria, Sch Med, Dept Biomed Sci Expt & Clin, I-21100 Varese, Italy	University of Insubria	Mare, L (corresponding author), DSBSC, Via JH Dunant 5, I-21100 Varese, Italy.	marco.trinchera@uninsubria.it						Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Angstrom J, 2004, GLYCOBIOLOGY, V14, P1, DOI 10.1093/glycob/cwh003; BAECKSTROM D, 1994, J BIOL CHEM, V269, P14430; Bardoni A, 1999, FEBS LETT, V451, P75, DOI 10.1016/S0014-5793(99)00547-5; Britten R, 2006, P NATL ACAD SCI USA, V103, P1798, DOI 10.1073/pnas.0510007103; Britten RJ, 1996, P NATL ACAD SCI USA, V93, P9374, DOI 10.1073/pnas.93.18.9374; Bry L, 1996, P NATL ACAD SCI USA, V93, P1161, DOI 10.1073/pnas.93.3.1161; Dunn CA, 2005, GENE, V364, P2, DOI 10.1016/j.gene.2005.05.045; Dunn CA, 2003, P NATL ACAD SCI USA, V100, P12841, DOI 10.1073/pnas.2134464100; Dupuy F, 2002, MOL BIOL EVOL, V19, P815, DOI 10.1093/oxfordjournals.molbev.a004138; Feschotte C, 2002, NAT REV GENET, V3, P329, DOI 10.1038/nrg793; Harduin-Lepers A, 2005, GLYCOBIOLOGY, V15, P805, DOI 10.1093/glycob/cwi063; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Isshiki S, 2003, J BIOL CHEM, V278, P36611, DOI 10.1074/jbc.M302681200; Jordan IK, 2003, TRENDS GENET, V19, P68, DOI 10.1016/S0168-9525(02)00006-9; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Mare L, 2004, EUR J BIOCHEM, V271, P186, DOI 10.1046/j.1432-1033.2003.03919.x; Pletcher MT, 2001, GENOMICS, V74, P45, DOI 10.1006/geno.2001.6533; Salvini R, 2001, J BIOL CHEM, V276, P3564, DOI 10.1074/jbc.M006662200; Samuelson J, 2005, P NATL ACAD SCI USA, V102, P1548, DOI 10.1073/pnas.0409460102; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; van de Lagemaat LN, 2003, TRENDS GENET, V19, P530, DOI 10.1016/j.tig.2003.08.004; Watanabe H, 2004, NATURE, V429, P382, DOI 10.1038/nature02564; WU GD, 1994, J BIOL CHEM, V269, P17080; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x; Zhou DP, 2000, J BIOL CHEM, V275, P22631, DOI 10.1074/jbc.C000263200; Zhu D, 2003, FEBS LETT, V538, P163, DOI 10.1016/S0014-5793(03)00168-6	28	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					49	57		10.1074/jbc.M606666200	http://dx.doi.org/10.1074/jbc.M606666200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17107959	hybrid, Green Published			2022-12-27	WOS:000243166500006
J	Wang, H; Gilner, JB; Bautch, VL; Wang, DZ; Wainwright, BJ; Kirby, SL; Patterson, C				Wang, Hong; Gilner, Jennifer B.; Bautch, Victoria L.; Wang, Da-Zhi; Wainwright, Brandon J.; Kirby, Suzanne L.; Patterson, Cam			Wnt2 coordinates the commitment of mesoderm to hematopoietic, endothelial, and cardiac lineages embryoid bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL DIFFERENTIATION; IN-VITRO DIFFERENTIATION; GROWTH-FACTOR; YOLK-SAC; BETA-CATENIN; DEFINITIVE HEMATOPOIESIS; COMMON PRECURSOR; PROGENITOR CELLS; GENE FAMILY; MOUSE	Our recent gene expression profiling analyses demonstrated that Wnt2 is highly expressed in Flk1(+) cells, which serve as common progenitors of endothelial cells, blood cells, and mural cells. In this report, we characterize the role of Wnt2 in mesoderm development during embryonic stem (ES) cell differentiation by creating ES cell lines in which Wnt2 was deleted. Wnt2(-/-) embryoid bodies (EBs) generated increased numbers of Flk1(+) cells and blast colony-forming cells compared with wild-type EBs, and had higher Flk1 expression at comparable stages of differentiation. Although Flk1(+) cells were increased, we found that endothelial cell and terminal cardiomyocyte differentiation was impaired, but hematopoietic cell differentiation was enhanced and smooth muscle cell differentiation was unchanged in Wnt2(-/-) Ells. Later stage Wnt2(-/-) EBs had either lower or undetectable expression of endothelial and cardiac genes compared with wild-type EBs. Consistently, vascular plexi were poorly formed and neither beating cardiomyocytes nor alpha-actinin-staining cells were detectable in later stage Wnt2(-/-) EBs. In contrast, hematopoietic cell gene expression was upregulated, and the number of hematopoietic progenitor colonies was significantly enhanced in Wnt2(-/-) EBs. Our data indicate that Wnt2 functions at multiple stages of development during ES cell differentiation and during the commitment and diversification of mesoderm: as a negative regulator for hemangioblast differentiation and hematopoiesis but alternatively as a positive regulator for endothelial and terminal cardiomyocyte differentiation.	Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA; Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Queensland	Patterson, C (corresponding author), Univ N Carolina, Div Cardiol, 8200 Med Biomol Res Bldg, Chapel Hill, NC 27599 USA.	cpatters@med.unc.edu	Gilner, Jennifer/V-1185-2019	Gilner, Jennifer/0000-0002-8996-2972; Wainwright, Brandon/0000-0003-0406-2092	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL069768, K08HL003658, R01HL061656, R01HL072347] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61656, HL 072347, HL 03658] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Blankesteijn WM, 2000, AM J PATHOL, V157, P877, DOI 10.1016/S0002-9440(10)64601-9; Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157; Chan RJ, 2003, BLOOD, V102, P2074, DOI 10.1182/blood-2003-04-1171; Choi K, 1998, DEVELOPMENT, V125, P725; Dale TC, 1998, BIOCHEM J, V329, P209; Davenport TG, 2003, DEVELOPMENT, V130, P2263, DOI 10.1242/dev.00431; Drab M, 1997, FASEB J, V11, P905, DOI 10.1096/fasebj.11.11.9285489; Easwaran V, 2003, CANCER RES, V63, P3145; Eichmann A, 1997, P NATL ACAD SCI USA, V94, P5141, DOI 10.1073/pnas.94.10.5141; Goodwin A. M., 2002, Angiogenesis, V5, P1, DOI 10.1023/A:1021563510866; HAAR JL, 1971, ANAT REC, V170, P199, DOI 10.1002/ar.1091700206; He X, 2003, DEV CELL, V4, P791, DOI 10.1016/S1534-5807(03)00165-5; Howe LR, 1999, CANCER RES, V59, P1572; Ishikawa T, 2001, DEVELOPMENT, V128, P25; Keller GA, 2001, HEAMTOPOIETIC STEM C, P209; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Koyanagi M, 2005, J BIOL CHEM, V280, P16838, DOI 10.1074/jbc.M500323200; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Marvin MJ, 2001, GENE DEV, V15, P316, DOI 10.1101/gad.855501; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; Monkley SJ, 1996, DEVELOPMENT, V122, P3343; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; Moser M, 2003, MOL CELL BIOL, V23, P5664, DOI 10.1128/MCB.23.16.5664-5679.2003; Motoike T, 2003, GENESIS, V35, P153, DOI 10.1002/gene.10175; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Terami H, 2004, BIOCHEM BIOPH RES CO, V325, P968, DOI 10.1016/j.bbrc.2004.10.103; Tzahor E, 2001, GENE DEV, V15, P255, DOI 10.1101/gad.871501; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; Wang H, 2006, CIRC RES, V98, P1331, DOI 10.1161/01.RES.0000220650.26555.1d; WANG R, 1992, DEVELOPMENT, V114, P303; Wobus A M, 2002, Methods Mol Biol, V185, P127; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yamashita JK, 2005, FASEB J, V19, P1534, DOI 10.1096/fj.04-3540fje; Zhang XB, 2001, CANCER RES, V61, P6050	43	62	66	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					782	791		10.1074/jbc.M606610200	http://dx.doi.org/10.1074/jbc.M606610200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17098737	Green Published, hybrid			2022-12-27	WOS:000243166500083
J	Guil, S; Rodriguez-Castro, M; Aguilar, F; Villasevil, EM; Anton, LC; Del Val, M				Guil, Sara; Rodriguez-Castro, Marta; Aguilar, Francisco; Villasevil, Eugenia M.; Anton, Luis C.; Del Val, Margarita			Need for tripeptidyl-peptidase II in major histocompatibility complex class I viral antigen processing when proteasomes are detrimental	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; T-LYMPHOCYTE EPITOPES; ENDOPLASMIC-RETICULUM; PROTEIN-DEGRADATION; CELL RESPONSES; BETA-SUBUNITS; GENERATION; AMINOPEPTIDASE; PRECURSORS; MOLECULES	CD8(+) T lymphocytes recognize infected cells that display virus-derived antigenic peptides complexed with major histocompatibility complex class I molecules. Peptides are mainly byproducts of cellular protein turnover by cytosolic proteasomes. Cytosolic tripeptidyl-peptidase II (TPPII) also participates in protein degradation. Several peptidic epitopes unexpectedly do not require proteasomes, but it is unclear which proteases generate them. We studied antigen processing of influenza virus nucleoprotein epitope NP147-155, an archetype epitope that is even destroyed by a proteasome-mediated mechanism. TPPII, with the assistance of endoplasmic reticulum trimming metallo-aminopeptidases, probably ERAAP (endoplasmic reticulum aminopeptidase associated with antigen processing), was crucial for nucleoprotein epitope generation both in the presence of functional proteasomes and when blocked by lactacystin, as shown with specific chemical inhibitors and gene silencing. Different protein contexts and subcellular targeting all allowed epitope processing by TPPII as well as trimming. The results show the plasticity of the cell's assortment of proteases for providing ligands for recognition by antiviral CD8(+) T cells. Our observations identify for the first time a set of proteases competent for antigen processing of an epitope that is susceptible to destruction by proteasomes.	Inst Salud Carlos III, Unidad Inmunol Viral, Ctr Nacl Microbiol, E-28220 Madrid, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain	Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Del Val, M (corresponding author), Inst Salud Carlos III, Unidad Inmunol Viral, Ctr Nacl Microbiol, Ctra Pozuelo Km 2, E-28220 Madrid, Spain.	mdval@isciii.es	Antón, Luis C/C-4740-2013; Del Val, Margarita/E-4769-2010	Antón, Luis C/0000-0001-9665-011X; Del Val, Margarita/0000-0001-6769-4279				ABASTADO JP, 1987, J EXP MED, V166, P327, DOI 10.1084/jem.166.2.327; Anton LC, 1998, J IMMUNOL, V160, P4859; Bacik I, 1997, J EXP MED, V186, P479, DOI 10.1084/jem.186.4.479; BALOW RM, 1986, J BIOL CHEM, V261, P2409; Benham AM, 1998, J IMMUNOL, V161, P83; BRADSHAW RA, 2004, HDB PROTEOLYTIC ENZY, P911; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; Chen WS, 2000, IMMUNITY, V12, P83, DOI 10.1016/S1074-7613(00)80161-2; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; DICK LR, 1994, J IMMUNOL, V152, P3884; Dick TP, 1998, J BIOL CHEM, V273, P25637, DOI 10.1074/jbc.273.40.25637; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; EISENLOHR LC, 1992, CELL, V71, P963, DOI 10.1016/0092-8674(92)90392-P; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Gil-Torregrosa BC, 1998, J EXP MED, V188, P1105, DOI 10.1084/jem.188.6.1105; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Johnstone C, 2004, J GEN VIROL, V85, P3229, DOI 10.1099/vir.0.80219-0; Kloetzel PM, 2004, NAT IMMUNOL, V5, P661, DOI 10.1038/ni1090; Levy F, 2002, J IMMUNOL, V169, P4161, DOI 10.4049/jimmunol.169.8.4161; Lopez D, 2000, J IMMUNOL, V164, P5070, DOI 10.4049/jimmunol.164.10.5070; Lopez D, 2001, J IMMUNOL, V167, P4238, DOI 10.4049/jimmunol.167.8.4238; Luckey CJ, 1998, J IMMUNOL, V161, P112; Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9; Princiotta MF, 2001, P NATL ACAD SCI USA, V98, P513, DOI 10.1073/pnas.021132398; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Reits E, 2004, IMMUNITY, V20, P495, DOI 10.1016/S1074-7613(04)00074-3; Reits E, 2003, IMMUNITY, V18, P97, DOI 10.1016/S1074-7613(02)00511-3; Rock KL, 2004, NAT IMMUNOL, V5, P670, DOI 10.1038/ni1089; Rose C, 1996, NATURE, V380, P403, DOI 10.1038/380403a0; Samino Y, 2004, J BIOL CHEM, V279, P1151, DOI 10.1074/jbc.M305343200; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Tanioka T, 2003, J BIOL CHEM, V278, P32275, DOI 10.1074/jbc.M305076200; Tomkinson B, 1999, TRENDS BIOCHEM SCI, V24, P355, DOI 10.1016/S0968-0004(99)01435-8; Tscharke DC, 2006, J VIROL, V80, P6318, DOI 10.1128/JVI.00427-06; Vines D, 1998, BBA-PROTEIN STRUCT M, V1384, P233, DOI 10.1016/S0167-4838(98)00012-0; Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897; Wherry EJ, 2006, J IMMUNOL, V176, P2249, DOI 10.4049/jimmunol.176.4.2249; Wong P, 2003, ANNU REV IMMUNOL, V21, P29, DOI 10.1146/annurev.immunol.21.120601.141114; YellenShaw AJ, 1997, J IMMUNOL, V158, P3227; Yewdell JW, 2003, NAT REV IMMUNOL, V3, P952, DOI 10.1038/nri1250; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; York IA, 2006, J IMMUNOL, V177, P1434, DOI 10.4049/jimmunol.177.3.1434; ZHOU XZ, 1994, EUR J IMMUNOL, V24, P1863, DOI 10.1002/eji.1830240822	50	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39925	39934		10.1074/jbc.M608522200	http://dx.doi.org/10.1074/jbc.M608522200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17088258	Green Published, hybrid			2022-12-27	WOS:000243033900020
J	Cnop, M; Ladriere, L; Hekerman, P; Ortis, F; Cardozo, AK; Dogusan, Z; Flamez, D; Boyce, M; Yuan, JY; Eizirik, DL				Cnop, Miriam; Ladriere, Laurence; Hekerman, Paul; Ortis, Fernanda; Cardozo, Alessandra K.; Dogusan, Zeynep; Flamez, Daisy; Boyce, Michael; Yuan, Junying; Eizirik, Decio L.			Selective inhibition of eukaryotic translation initiation factor 2 alpha dephosphorylation potentiates fatty acid-induced endoplasmic reticulum stress and causes pancreatic beta-cell dysfunction and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; INSULIN-PRODUCING CELLS; FACTOR-KAPPA-B; MONOCYTE CHEMOATTRACTANT PROTEIN-1; WOLCOTT-RALLISON-SYNDROME; MESSENGER-RNA; ER STRESS; GLUCOSE-HOMEOSTASIS; PROMOTES SURVIVAL; ISLET CELLS	Free fatty acids cause pancreatic beta-cell apoptosis and may contribute to beta-cell loss in type 2 diabetes via the induction of endoplasmic reticulum stress. Reductions in eukaryotic translation initiation factor (eIF) 2 alpha phosphorylation trigger P-cell failure and diabetes. Salubrinal selectively inhibits eIF2 alpha dephosphorylation, protects other cells against endoplasmic reticulum stress-mediated apoptosis, and has been proposed as a beta-cell protector. Unexpectedly, salubrinal induced apoptosis in primary beta-cells, and it potentiated the deleterious effects of oleate and palmitate. Salubrinal induced a marked eIF2 alpha phosphorylation and potentiated the inhibitory effects of free fatty acids on protein synthesis and insulin release. The synergistic activation of the PERK-eIF2 alpha branch of the endoplasmic reticulum stress response, but not of the IRE1 and activating transcription factor-6 pathways, led to a marked induction of activating transcription factor-4 and the pro-apoptotic transcription factor CHOP. Our findings demonstrate that excessive eIF2 alpha phosphorylation is poorly tolerated by beta-cells and exacerbates free fatty acid-induced apoptosis. This modifies the present paradigm regarding the beneficial role of eIF2 alpha phosphorylation in beta-cells and must be taken into consideration when designing therapies to protect beta-cells in type 2 diabetes.	Free Univ Brussels, Erasmus Sch Med, Expt Med Lab, B-1070 Brussels, Belgium; Erasme Univ Hosp, Div Endocrinol, B-1070 Brussels, Belgium; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Harvard University; Harvard Medical School	Cnop, M (corresponding author), Free Univ Brussels, Erasmus Sch Med, Expt Med Lab, CP-618,Route Lennik 808, B-1070 Brussels, Belgium.	mcnop@ulb.ac.be	Ortis, Fernanda/M-7190-2019; Longo, Kenneth A/A-5631-2010; Ortis, Fernanda/K-7917-2014	Cnop, Miriam/0000-0002-5112-1692; Ortis, Fernanda/0000-0002-9551-2839; DOGUSAN, ZEYNEP/0000-0002-1506-669X; Boyce, Michael/0000-0002-2729-4876; Kupper Cardozo, Alessandra/0000-0001-7143-3696				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Cardozo AK, 2005, DIABETES, V54, P452, DOI 10.2337/diabetes.54.2.452; Chen MC, 2001, DIABETOLOGIA, V44, P325, DOI 10.1007/s001250051622; Cnop M, 2005, DIABETES, V54, pS97, DOI 10.2337/diabetes.54.suppl_2.S97; Cnop M, 2001, DIABETES, V50, P1771, DOI 10.2337/diabetes.50.8.1771; Cnop M, 2002, BIOCHEM PHARMACOL, V63, P1281, DOI 10.1016/S0006-2952(02)00860-2; Darville MI, 1998, DIABETOLOGIA, V41, P1101, DOI 10.1007/s001250051036; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; EIZIRIK DL, 1991, AUTOIMMUNITY, V10, P107, DOI 10.3109/08916939109004814; Eldor R, 2006, P NATL ACAD SCI USA, V103, P5072, DOI 10.1073/pnas.0508166103; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Heimberg H, 2001, DIABETES, V50, P2219, DOI 10.2337/diabetes.50.10.2219; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Karaskov E, 2006, ENDOCRINOLOGY, V147, P3398, DOI 10.1210/en.2005-1494; Kessel D, 2006, BIOCHEM BIOPH RES CO, V346, P1320, DOI 10.1016/j.bbrc.2006.06.056; Kharroubi I, 2006, DIABETOLOGIA, V49, P2350, DOI 10.1007/s00125-006-0366-5; Kharroubi I, 2004, ENDOCRINOLOGY, V145, P5087, DOI 10.1210/en.2004-0478; Korth MJ, 1996, GENE, V170, P181, DOI 10.1016/0378-1119(95)00883-7; Kutlu B, 2003, DIABETES, V52, P348, DOI 10.2337/diabetes.52.2.348; Ladiges WC, 2005, DIABETES, V54, P1074, DOI 10.2337/diabetes.54.4.1074; LECLERCQMEYER V, 1985, ENDOCRINOLOGY, V116, P1168, DOI 10.1210/endo-116-3-1168; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LING Z, 1994, DIABETOLOGIA, V37, P15; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Maedler K, 2003, DIABETES, V52, P726, DOI 10.2337/diabetes.52.3.726; Mann JI, 2002, LANCET, V360, P783, DOI 10.1016/S0140-6736(02)09901-4; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Oakes SA, 2006, CURR MOL MED, V6, P99, DOI 10.2174/156652406775574587; Ortis F, 2006, MOL ENDOCRINOL, V20, P1867, DOI 10.1210/me.2005-0268; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Pirot P, 2006, DIABETOLOGIA, V49, P1229, DOI 10.1007/s00125-006-0214-7; Porte D, 2001, DIABETES, V50, pS160, DOI 10.2337/diabetes.50.2007.S160; Rasschaert J, 2005, J BIOL CHEM, V280, P33984, DOI 10.1074/jbc.M502213200; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Scheuner D, 2005, NAT MED, V11, P757, DOI 10.1038/nm1259; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Schroder M, 2006, CURR MOL MED, V6, P5, DOI 10.2174/156652406775574569; Senee V, 2004, DIABETES, V53, P1876, DOI 10.2337/diabetes.53.7.1876; Smith WW, 2005, HUM MOL GENET, V14, P3801, DOI 10.1093/hmg/ddi396; VALVERDE I, 1988, ENDOCRINOLOGY, V122, P1443, DOI 10.1210/endo-122-4-1443; Wang HY, 2005, J CELL SCI, V118, P3905, DOI 10.1242/jcs.02513; Wang Y, 2000, J BIOL CHEM, V275, P27013; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	58	250	262	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3989	3997		10.1074/jbc.M607627200	http://dx.doi.org/10.1074/jbc.M607627200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158450	hybrid, Green Published			2022-12-27	WOS:000244481900063
J	Koshiba, T; Hashii, T; Kawabata, SI				Koshiba, Takumi; Hashii, Tornoyuki; Kawabata, Shun-ichiro			A structural perspective on the interaction between lipopolysaccharide and Factor C, a receptor involved in recognition of Gram-negative bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE ZYMOGEN; INNATE IMMUNITY; DROSOPHILA; HEMOCYTES; PROTEINS; ACTIVATION; ENDOTOXIN	The recognition of broadly conserved microorganism components known as pathogen-associated molecular patterns is an essential step in initiating the innate immune response. In the horseshoe crab, stimulation of hemocytes with lipopolysaccharide (LPS) causes the activation of its innate immune response, and Factor C, a serine protease zymogen, plays an important role in this event. Here, we report that Factor C associates with LPS on the hemocyte surface and directly recognizes Gram-negative bacteria. Structure-function analyses reveal that the LPS binding site is present in the N-terminal cysteine-rich (Cys-rich) region of the molecule and that it contains a tripeptide sequence consisting of an aromatic residue flanked by two basic residues that is conserved in other mammalian LPS-recognizing proteins. Moreover, we have demonstrated that the Cys-rich region specifically binds to LPS on Gram-negative bacteria and that mutations in the tripeptide motif abrogate its association with both LPS and Gram-negative bacteria, underscoring the importance of the tripeptide in LPS interaction. Although the innate immune response to LPS in the horseshoe crab is distinct from that of mammals, it appears to rely on structural features that are conserved among LPS-recognizing proteins from diverse species.	Kyushu Univ, Fac Sci, Dept Biol, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Kawabata, SI (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	skawascb@mbox.nc.kyushu-u.ac.jp	Koshiba, Takumi/A-3996-2013	Koshiba, Takumi/0000-0001-8535-5043				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Ariki S, 2004, P NATL ACAD SCI USA, V101, P953, DOI 10.1073/pnas.0306904101; ARMSTRONG PB, 1985, BLOOD CELLS MARINE I, P77; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Inamori K, 2004, IMMUNOL REV, V198, P106, DOI 10.1111/j.0105-2896.2004.0131.x; Iwanaga S, 1998, J BIOCHEM, V123, P1; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Koshiba T, 2003, J BIOL CHEM, V278, P7573, DOI 10.1074/jbc.M211154200; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kurata S, 2006, IMMUNOBIOLOGY, V211, P237, DOI 10.1016/j.imbio.2005.10.016; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; MIURA Y, 1992, J BIOCHEM-TOKYO, V112, P476, DOI 10.1093/oxfordjournals.jbchem.a123924; MUTA T, 1991, J BIOL CHEM, V266, P6554; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1988, EUR J BIOCHEM, V176, P89, DOI 10.1111/j.1432-1033.1988.tb14254.x; Pristovsek P, 2005, J MED CHEM, V48, P1666, DOI 10.1021/jm049217k; ROWLEY AF, 1981, INVERTEBRATE BLOOD C, V2, P421; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stuart LM, 2005, IMMUNITY, V22, P539, DOI 10.1016/j.immuni.2005.05.002; Tan NS, 2000, FASEB J, V14, P1801, DOI 10.1096/fj.99-0866com; Trexler M, 2000, EUR J BIOCHEM, V267, P5751, DOI 10.1046/j.1432-1327.2000.01641.x	25	44	48	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3962	3967		10.1074/jbc.M609198200	http://dx.doi.org/10.1074/jbc.M609198200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17135239	hybrid			2022-12-27	WOS:000244481900060
J	Kuo, CL; Isogai, Z; Keene, DR; Hazeki, N; Ono, RN; Sengle, G; Bachinger, HP; Sakai, LY				Kuo, Chiu-Liang; Isogai, Zenzo; Keene, Douglas R.; Hazeki, Noriko; Ono, Robert N.; Sengle, Gerhard; Bachinger, Hans Peter; Sakai, Lynn Y.			Effects of fibrillin-1 degradation on microfibril ultrastructure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIVE-TISSUE MICROFIBRILS; FACTOR-LIKE DOMAINS; MARFAN-SYNDROME; EXTRACELLULAR MICROFIBRILS; RICH MICROFIBRILS; VITREOUS-HUMOR; ORGANIZATION; CALCIUM; MATRIX; CONSEQUENCES	Current models of the elastic properties and structural organization of fibrillin-containing microfibrils are based primarily on microscopic analyses of microfibrils liberated from connective tissues after digestion with crude collagenase. Results presented here demonstrate that this digestion resulted in the cleavage of fibrillin-1 and loss of specific immunoreactive epitopes. The proline-rich region and regions near the second 8-cysteine domain in fibrillin-1 were easily cleaved by crude collagenase. Other sites that may also be cleaved during microfibril digestion and extraction were identified. In contrast to collagenase-digested microfibrils, guanidine-extracted microfibrils contained all fibrillin-1 epitopes recognized by available antibodies. The ultrastructure of guanidine-extracted microfibrils differed markedly from that of collagenase-digested microfibrils. Fibrillin-1 filaments splayed out, extending beyond the width of the periodic globular beads. Both guanidine-extracted and collagenase-digested microfibrils were subjected to extensive digestion by crude collagenase. Collagenase digestion of guanidine-extracted microfibrils removed the outer filaments, revealing a core structure. In contrast to microfibrils extracted from tissues, cell culture microfibrils could be digested into short units containing just a few beads. These data suggest that additional cross-links stabilize the long beaded microfibrils in tissues. Based on the microfibril morphologies observed after these experiments, on the crude collagenase cleavage sites identified in fibrillin-1, and on known antibody binding sites in fibrillin-1, a model is proposed in which fibrillin-1 molecules are staggered in microfibrils. This model further suggests that the N-terminal half of fibrillin-1 is asymmetrically exposed in the outer filaments, whereas the C-terminal half of fibrillin-1 is present in the interior of the microfibril.	Shriners Hosp Children, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Sakai, LY (corresponding author), Shriners Hosp Children, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	LYS@SHCC.org	Isogai, Zenzo/AAD-3690-2022		NIAMS NIH HHS [AR46811] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046811] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arteaga-Solis E, 2001, J CELL BIOL, V154, P275, DOI 10.1083/jcb.200105046; Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; Cain SA, 2006, PROTEOMICS, V6, P111, DOI 10.1002/pmic.200401340; Charbonneau NL, 2003, J BIOL CHEM, V278, P2740, DOI 10.1074/jbc.M209201200; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; Davis EC, 2002, J STRUCT BIOL, V139, P65, DOI 10.1016/S1047-8477(02)00559-2; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Gregory KE, 2005, J BIOL CHEM, V280, P27970, DOI 10.1074/jbc.M504270200; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; Haston JL, 2003, J BIOL CHEM, V278, P41189, DOI 10.1074/jbc.M212854200; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; Keene DR, 1997, J HISTOCHEM CYTOCHEM, V45, P1069, DOI 10.1177/002215549704500805; Kielty CM, 1998, ANAL BIOCHEM, V255, P108, DOI 10.1006/abio.1997.2442; KIELTY CM, 1995, J CELL SCI, V108, P1317; KIELTY CM, 1991, J CELL SCI, V99, P797; KIELTY CM, 1994, J CELL BIOL, V124, P997, DOI 10.1083/jcb.124.6.997; KIELTY CM, 1993, FEBS LETT, V336, P323, DOI 10.1016/0014-5793(93)80829-J; Lee SSJ, 2004, STRUCTURE, V12, P717, DOI 10.1016/j.str.2004.02.023; LIU W, 1996, HUM MOL GENET, V10, P1581; Liu WG, 1996, HUM MOL GENET, V5, P1581, DOI 10.1093/hmg/5.10.1581; Lu YH, 2005, J MOL BIOL, V349, P73, DOI 10.1016/j.jmb.2005.03.066; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Putnam EA, 1996, AM J MED GENET, V62, P233, DOI 10.1002/(SICI)1096-8628(19960329)62:3<233::AID-AJMG7>3.0.CO;2-U; Qian RQ, 1997, BIOCHEMISTRY-US, V36, P15841, DOI 10.1021/bi971036f; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Reinhardt DP, 1997, J BIOL CHEM, V272, P7368, DOI 10.1074/jbc.272.11.7368; REN ZX, 1991, J STRUCT BIOL, V106, P57, DOI 10.1016/1047-8477(91)90062-2; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sherratt MJ, 2003, J MOL BIOL, V332, P183, DOI 10.1016/S0022-2836(03)00829-5; Vollbrandt T, 2004, J BIOL CHEM, V279, P32924, DOI 10.1074/jbc.M405239200; WRIGHT DW, 1988, J ULTRA MOL STRUCT R, V100, P224, DOI 10.1016/0889-1605(88)90039-0; Yuan XM, 1997, EMBO J, V16, P6659, DOI 10.1093/emboj/16.22.6659	41	51	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4007	4020		10.1074/jbc.M606370200	http://dx.doi.org/10.1074/jbc.M606370200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158461	hybrid			2022-12-27	WOS:000244481900065
J	Stenmark, P; Kursula, P; Flodin, S; Graslund, S; Landry, R; Nordlund, P; Schuler, H				Stenmark, Pal; Kursula, Petri; Flodin, Susanne; Graslund, Susanne; Landry, Robert; Nordlund, Par; Schuler, Herwig			Crystal structure of human inosine triphosphatase - Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHOHYDROLASE DEFICIENCY; JAPANESE POPULATION; GENETIC-BASIS; ITPA GENE; REFINEMENT; IDENTIFICATION; POLYMORPHISMS; EXPRESSION; DOMAIN	Inosine triphosphatase (ITPA) is a ubiquitous key regulator of cellular non-canonical nucleotide levels. It breaks down inosine and xanthine nucleotides generated by deamination of purine bases. Its enzymatic action prevents accumulation of ITP and reduces the risk of incorporation of potentially mutagenic inosine nucleotides into nucleic acids. Here we describe the crystal structure of human ITPA in complex with its prime substrate ITP, as well as the apoenzyme at 2.8 and 1.1 angstrom, respectively. These structures show for the first time the site of substrate and Mg2+ coordination as well as the conformational changes accompanying substrate binding in this class of enzymes. Enzyme substrate interactions induce an extensive closure of the nucleotide binding grove, resulting in tight interactions with the base that explain the high substrate specificity of ITPA for inosine and xanthine over the canonical nucleotides. One of the dimer contact sites is made up by a loop that is involved in coordinating the metal ion in the active site. We predict that the ITPA deficiency mutation P32T leads to a shift of this loop that results in a disturbed affinity for nucleotides and/or a reduced catalytic activity in both monomers of the physiological dimer.	Karolinska Inst, Struct Genom Consortium, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Toronto, Struct Genom Consortium, Toronto, ON M5S 1A8, Canada	Karolinska Institutet; University of Toronto; Structural Genomics Consortium	Nordlund, P (corresponding author), Karolinska Inst, Struct Genom Consortium, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	Par.Nordlund@ki.se; schueler@mdc-berlin.de	Kursula, Petri/K-1058-2012; Gräslund, Susanne/ABB-6339-2020; Kursula, Petri/AAF-4563-2020; Schuler, Herwig/E-5751-2011	Kursula, Petri/0000-0001-8529-3751; Kursula, Petri/0000-0001-8529-3751; Schuler, Herwig/0000-0003-4059-3501; Stenmark, Pal/0000-0003-4777-3417; Graslund, Susanne/0000-0003-0077-8333	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Behmanesh M, 2005, DNA RES, V12, P39, DOI 10.1093/dnares/12.1.39; Berg J. M., 2002, BIOCHEMISTRY-US, P698; Cao HN, 2002, J HUM GENET, V47, P620, DOI 10.1007/s100380200095; Derijks LJJ, 2006, ALIMENT PHARM THER, V24, P715, DOI 10.1111/j.1365-2036.2006.02980.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Galperin MY, 2006, MOL MICROBIOL, V59, P5, DOI 10.1111/j.1365-2958.2005.04950.x; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; HOLMES SL, 1979, CLIN CHIM ACTA, V97, P143, DOI 10.1016/0009-8981(79)90410-8; Hwang KY, 1999, NAT STRUCT BIOL, V6, P691; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kursula P., 2004, J APPL CRYSTALLOGR, V37, P347; Kursula P, 2006, ACTA CRYSTALLOGR F, V62, P613, DOI 10.1107/S1744309106018136; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Lin SR, 2001, J BIOL CHEM, V276, P18695, DOI 10.1074/jbc.M011084200; Maeda T, 2005, MOL GENET METAB, V85, P271, DOI 10.1016/j.ymgme.2005.03.011; Marinaki AM, 2004, NUCLEOS NUCLEOT NUCL, V23, P1399, DOI 10.1081/NCN-200027641; Marsh S, 2004, J HUM GENET, V49, P579, DOI 10.1007/s10038-004-0183-y; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Page R, 2004, METHODS, V34, P373, DOI 10.1016/j.ymeth.2004.03.026; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shichijo S, 2003, INT J MOL MED, V12, P895; Shipkova M, 2006, CLIN CHEM, V52, P240, DOI 10.1373/clinchem.2005.059501; Sumi S, 2002, HUM GENET, V111, P360, DOI 10.1007/s00439-002-0798-z; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; VANDERHEIDEN BS, 1979, J CELL PHYSIOL, V98, P41, DOI 10.1002/jcp.1040980106; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Zheng JM, 2005, STRUCTURE, V13, P1511, DOI 10.1016/j.str.2005.07.007	32	37	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3182	3187		10.1074/jbc.M609838200	http://dx.doi.org/10.1074/jbc.M609838200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17138556	hybrid			2022-12-27	WOS:000243793900044
J	Wang, S; Zhang, C; Nordeen, SK; Shapiro, DJ				Wang, Stanley; Zhang, Chen; Nordeen, Steven K.; Shapiro, David J.			In vitro fluorescence anisotropy analysis of the interaction of full-length SRC1a with estrogen receptors alpha and beta supports an active displacement model for coregulator utilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RESPONSE ELEMENT SEQUENCE; SMALL-MOLECULE INHIBITORS; NUCLEAR-RECEPTOR; PEPTIDE ANTAGONISTS; COACTIVATOR INTERACTIONS; TRANSCRIPTIONAL COACTIVATORS; REGULATED TRANSCRIPTION; ALLOSTERIC MODULATION; SELECTIVE INHIBITORS	Binding of full-length P160 coactivators to hormone response element-steroid receptor complexes has been difficult to investigate in vitro. Here, we report a new application of our recently described fluorescence anisotropy microplate assay to investigate binding and dissociation of full-length steroid receptor coactivator-1a (SRC1a) from full-length estrogen receptor alpha (ER alpha) or estrogen receptor beta(ER beta) bound to a fluorescein-labeled (fl) estrogen response element (ERE). SRC1a exhibited slightly higher affinity binding to flERE(.)ER beta than to flERE(.)ER beta. Binding of SRC1a to flERE(.)ER alpha and to flERE(.)ER alpha was 17 beta-estradiol (E-2)-dependent and was nearly absent when ICI 182,780, raloxifene, or 4- hydroxytamoxifen were bound to the ERs. SRC1a binds to flERE E-.(2)-ER alpha and flERE(.)E(2)-ER beta complexes with a t(1/2) of 15 - 20 s. Short LXXLL-containing nuclear receptor (NR) box peptides from P160 coactivators competed much better for SRC1a binding to flERE(.)E(2)-ER than an NR box peptide from TRAP220. However, similar to 40-250-fold molar excess of the P160 NR box peptides was required to inhibit SRC1a binding by 50%. This suggests that whereas the NR box region is a primary site of interaction between SRC1a and (EREE2)-E-.-ER additional contacts between the coactivator and the ligand-receptor-DNA complex make substantial contributions to overall affinity. Increasing amounts of NR box peptides greatly enhanced the rate of dissociation of SRC1a from preformed flERE(.)E(2)-ER complexes. The data support a model in which coactivator exchange is facilitated by active displacement and is not simply the result of passive dissociation and replacement. It also shows that an isolated coactivator exhibits an inherent capacity for rapid exchange.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Colorado, Dept Pathol, Denver, CO 80202 USA; Hlth Sci Ctr, Aurora, CO 80045 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Colorado System; University of Colorado Denver	Shapiro, DJ (corresponding author), 600 S Mathews Ave, Urbana, IL 61801 USA.	djshapir@uiuc.edu	Zhang, Chen/K-3978-2014		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062362, R01DK071909] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16720] Funding Source: Medline; NIDDK NIH HHS [DK-071909, DK/HD62362] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Arnold LA, 2005, J BIOL CHEM, V280, P43048, DOI 10.1074/jbc.M506693200; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Becker M, 2002, EMBO REP, V3, P1188, DOI 10.1093/embo-reports/kvf244; Bramlett KS, 2002, MOL GENET METAB, V76, P225, DOI 10.1016/S1096-7192(02)00043-4; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Chang CY, 2005, MOL ENDOCRINOL, V19, P2478, DOI 10.1210/me.2005-0072; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Cheskis BJ, 2003, J BIOL CHEM, V278, P13271, DOI 10.1074/jbc.M211031200; Cogliano V, 2005, LANCET ONCOL, V6, P552, DOI 10.1016/S1470-2045(05)70273-4; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Edwards DP, 2000, J MAMMARY GLAND BIOL, V5, P307, DOI 10.1023/A:1009503029176; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Galande AK, 2004, J PEPT RES, V63, P297, DOI 10.1111/j.1399-3011.2004.00152.x; Geistlinger TR, 2004, CHEM BIOL, V11, P273, DOI 10.1016/j.chembiol.2004.01.016; Geistlinger TR, 2003, J AM CHEM SOC, V125, P6852, DOI 10.1021/ja0348391; Glass CK, 2000, GENE DEV, V14, P121; Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469; Hall JM, 2000, MOL ENDOCRINOL, V14, P2010, DOI 10.1210/me.14.12.2010; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Katzenellenbogen BS, 2000, J STEROID BIOCHEM, V74, P279, DOI 10.1016/S0960-0760(00)00104-7; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; Klinge CM, 2004, J MOL ENDOCRINOL, V33, P387, DOI 10.1677/jme.1.01541; Klinge CM, 2001, MOL CELL ENDOCRINOL, V174, P151, DOI 10.1016/S0303-7207(01)00382-3; Krieg AJ, 2004, J BIOL CHEM, V279, P5025, DOI 10.1074/jbc.M307076200; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leduc AM, 2003, P NATL ACAD SCI USA, V100, P11273, DOI 10.1073/pnas.1934759100; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Liu JW, 2003, MOL ENDOCRINOL, V17, P346, DOI 10.1210/me.2002-0331; Loven MA, 2001, J BIOL CHEM, V276, P45282, DOI 10.1074/jbc.M106211200; Loven MA, 2001, MOL CELL ENDOCRINOL, V181, P151, DOI 10.1016/S0303-7207(01)00491-9; Luconi M, 2002, J STEROID BIOCHEM, V80, P369, DOI 10.1016/S0960-0760(02)00041-9; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mao CJ, 2006, ANAL BIOCHEM, V350, P222, DOI 10.1016/j.ab.2005.12.010; Margeat E, 2003, J MOL BIOL, V326, P77, DOI 10.1016/S0022-2836(02)01355-4; Margeat E, 2001, J MOL BIOL, V306, P433, DOI 10.1006/jmbi.2000.4418; McDonnell DP, 2000, J STEROID BIOCHEM, V74, P327, DOI 10.1016/S0960-0760(00)00109-6; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Ozers MS, 2005, MOL ENDOCRINOL, V19, P25, DOI 10.1210/me.2004-0256; Ozers MS, 1997, J BIOL CHEM, V272, P30405, DOI 10.1074/jbc.272.48.30405; Rodriguez AL, 2004, J MED CHEM, V47, P600, DOI 10.1021/jm030404c; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shupnik MA, 2002, J NEUROENDOCRINOL, V14, P85, DOI 10.1046/j.0007-1331.2001.00744.x; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001; Thackray VG, 2002, BIOTECHNIQUES, V32, P260, DOI 10.2144/02322bm05; Thenot S, 1999, MOL ENDOCRINOL, V13, P2137, DOI 10.1210/me.13.12.2137; Toogood PL, 2002, J MED CHEM, V45, P1543, DOI 10.1021/jm010468s; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wang SY, 2004, BIOTECHNIQUES, V37, P807, DOI 10.2144/04375RR01; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Windahl SH, 2002, TRENDS ENDOCRIN MET, V13, P195, DOI 10.1016/S1043-2760(02)00594-5; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang CC, 1999, MOL ENDOCRINOL, V13, P632, DOI 10.1210/me.13.4.632; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	73	5	5	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2765	2775		10.1074/jbc.M607531200	http://dx.doi.org/10.1074/jbc.M607531200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135255	hybrid			2022-12-27	WOS:000243793900003
J	Yang, WS; Rozan, LM; McDonald, ER; Navaraj, A; Liu, JJ; Matthew, EM; Wang, WG; Dicker, DT; El-Deiry, WS				Yang, Wensheng; Rozan, Laura M.; McDonald, E. Robert, III; Navaraj, Arunasalam; Liu, Jue Judy; Matthew, Elizabeth M.; Wang, Wenge; Dicker, David T.; El-Deiry, Wafik S.			CARPs are ubiquitin Ligases that promote MDM2-independent p53 and phospho-p53(ser20) degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	13th International P53 Workshop	MAY 24, 2006	New York, NY				NEGATIVE REGULATOR; PROTEIN LIGASE; RING FINGER; MDM2; GROWTH	Caspase 8/10-associated RING proteins (CARPs) are a recently described family of protein ubiquitin ligases that interact with and negatively regulate death receptor-mediated apoptosis. Because CARPs are overexpressed in cancer and their silencing reduces cell viability and sensitizes tumor cells to chemotherapeutic agents, we investigated their relationship to p53 tumor suppressor signaling. p53 is a major determinant of chemosensitivity, and its levels are increased following DNA damage through N-terminal phosphorylation and inhibition of degradation. Although p53 is well known to be negatively regulated by several ubiquitin ligases including MDM2, none are known to target phosphorylated p53 for degradation. CARPs physically interact with and ubiquitinate p53, targeting it for degradation in the absence of MDM2. Serine 20-phosphorylated p53 is also ubiquitinated by CARPs. CARP silencing stimulates p53 expression and promotes downstream effects, including transcriptional activation and tumor suppression.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Dept Med Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Abramson Comprehens Canc Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Dept Med Hematol Oncol, 415 Curie Blvd,CRB 437A, Philadelphia, PA 19104 USA.	wafik@mail.med.upenn.edu		Wang, Edward/0000-0001-9509-6735; El-Deiry, Wafik/0000-0002-9577-8266	NCI NIH HHS [CA97100, CA98101, CA105008, CA75138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097100, P01CA075138, P01CA098101, U54CA105008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Boutell C, 2003, J BIOL CHEM, V278, P36596, DOI 10.1074/jbc.M300776200; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; Olivier Magali, 2004, IARC Sci Publ, P247; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; XIA ZP, 2005, SCI STKE 2005, P7	20	61	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3273	3281		10.1074/jbc.M610793200	http://dx.doi.org/10.1074/jbc.M610793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	130IS	17121812	hybrid			2022-12-27	WOS:000243793900054
J	Schnaith, A; Kashkar, H; Leggio, SA; Addicks, K; Kronke, M; Krut, O				Schnaith, Annabelle; Kashkar, Hamid; Leggio, Sonja A.; Addicks, Klaus; Kroenke, Martin; Krut, Oleg			Staphylococcus aureus subvert autophagy for induction of caspase-independent host cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; DEFENSE-MECHANISM; EPITHELIAL-CELLS; APOPTOSIS; VIRULENCE; INVASION; NECROSIS; PATHWAY; INTERNALIZATION; MACROPHAGES	Staphylococcus aureus is a common bacterial etiology of serious infectious diseases. S. aureus can invade various types of non-professional phagocytes to produce host cell death. Weshow here that shortly after invasion of HeLa cells S. aureus transit to autophago-somes was characterized by double membranes and co-localization with LC3. S. aureus were not able to replicate and produce cell death in autophagy-deficient atg5(-/-) mouse embryonic fibroblasts. S. aureus-containing autophagosomes do not acidify nor do they acquire lysosome-associated membrane protein-2, indicating that S. aureus inhibits autophagosome maturation and fusion with lysosomes. Eventually, S. aureus escape from autophagosomes into the cytoplasm, which results in caspase-independent host cell death. S. aureus strains deficient for agr, a global regulator of S. aureus virulence, were not targeted by autophagy and did not produce host-cell death. Autophagy induction by rapamycin restored both replication and cytotoxicity of agr-deficient S. aureus strains, indicating that an agr-regulated factor(s) is required for autophagy-mediated cytotoxicity. The results of this study suggest that rapid induction of autophagy is essential for S. aureus replication, escape into the cytoplasm, and host cell killing.	Univ Cologne, Inst Med Microbiol Immunol & Hyg, D-50935 Cologne, Germany; Univ Cologne, Ctr Mol Med Cologne, D-50935 Cologne, Germany; Univ Cologne, Dept Anat, D-50935 Cologne, Germany	University of Cologne; University of Cologne; University of Cologne	Krut, O (corresponding author), Univ Cologne, Inst Med Microbiol Immunol & Hyg, Goldenfels Str 19-21, D-50935 Cologne, Germany.	oleg.krut@uni-koeln.de		LEGGIO, Samuele/0000-0002-2180-0109				Almeida RA, 1996, J DAIRY SCI, V79, P1021, DOI 10.3168/jds.S0022-0302(96)76454-8; Baran J, 2001, INFECT IMMUN, V69, P1287, DOI 10.1128/IAI.69.3.1287-1297.2001; Bayles KW, 1998, INFECT IMMUN, V66, P336, DOI 10.1128/IAI.66.1.336-342.1998; Beron W, 2002, INFECT IMMUN, V70, P5816, DOI 10.1128/IAI.70.10.5816-5821.2002; BONIFACIO JS, 2000, CURRENT PROTOCOLS CE; Comerci DJ, 2001, CELL MICROBIOL, V3, P159, DOI 10.1046/j.1462-5822.2001.00102.x; Delrue RM, 2001, CELL MICROBIOL, V3, P487, DOI 10.1046/j.1462-5822.2001.00131.x; Deretic V, 2006, CELL MICROBIOL, V8, P719, DOI 10.1111/j.1462-5822.2006.00705.x; Dorn BR, 2002, CELL MICROBIOL, V4, P1, DOI 10.1046/j.1462-5822.2002.00164.x; Dorn BR, 2001, INFECT IMMUN, V69, P5698, DOI 10.1128/IAI.69.9.5698-5708.2001; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Haslinger B, 2003, CELL MICROBIOL, V5, P729, DOI 10.1046/j.1462-5822.2003.00317.x; Haslinger-Loffler B, 2005, CELL MICROBIOL, V7, P1087, DOI 10.1111/j.1462-5822.2005.00533.x; Joshi AD, 2001, CELL MICROBIOL, V3, P99, DOI 10.1046/j.1462-5822.2001.00093.x; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kahl BC, 2000, INFECT IMMUN, V68, P5385, DOI 10.1128/IAI.68.9.5385-5392.2000; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865; Krut O, 2003, INFECT IMMUN, V71, P2716, DOI 10.1128/IAI.71.5.2716-2723.2003; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lee J C, 1995, Methods Mol Biol, V47, P209; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Luhrmann A, 2000, Methods Cell Sci, V22, P329, DOI 10.1023/A:1017963401560; Menzies BE, 1998, INFECT IMMUN, V66, P5994, DOI 10.1128/IAI.66.12.5994-5998.1998; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; Nuzzo I, 2000, FEMS IMMUNOL MED MIC, V27, P235, DOI 10.1111/j.1574-695X.2000.tb01435.x; OGAWA SK, 1985, INFECT IMMUN, V50, P218, DOI 10.1128/IAI.50.1.218-224.1985; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Petti Cathy A., 2003, Cardiology Clinics, V21, P219, DOI 10.1016/S0733-8651(03)00030-4; Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P5711; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Rich KA, 2003, CELL MICROBIOL, V5, P455, DOI 10.1046/j.1462-5822.2003.00292.x; RIKIHISA Y, 1984, ANAT REC, V208, P319, DOI 10.1002/ar.1092080302; Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043; Rzomp KA, 2003, INFECT IMMUN, V71, P5855, DOI 10.1128/IAI.71.10.5855-5870.2003; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Sinha B, 2005, THROMB HAEMOSTASIS, V94, P266, DOI 10.1160/TH05-04-0235; Sturgill-Koszycki S, 2000, J EXP MED, V192, P1261, DOI 10.1084/jem.192.9.1261; SULLIVAN MA, 1984, GENE, V29, P21, DOI 10.1016/0378-1119(84)90161-6; Vieira OV, 2002, BIOCHEM J, V366, P689, DOI 10.1042/BJ20020691; Walker DH, 1997, LAB INVEST, V76, P129; Wesson CA, 1998, INFECT IMMUN, V66, P5238, DOI 10.1128/IAI.66.11.5238-5243.1998	52	207	217	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2695	2706		10.1074/jbc.M609784200	http://dx.doi.org/10.1074/jbc.M609784200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135247	hybrid			2022-12-27	WOS:000243593200062
J	Esumi, N; Kachi, S; Campochiaro, PA; Zack, DJ				Esumi, Noriko; Kachi, Shu; Campochiaro, Peter A.; Zack, Donald J.			VMD2 promoter requires two proximal E-box sites for its activity in vivo and is regulated by the MITF-TFE family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL-PIGMENT EPITHELIUM; MICROPHTHALMIA TRANSCRIPTION FACTOR; LOOP-HELIX PROTEIN; RECESSIVE RETINITIS-PIGMENTOSA; OCULAR GENE-TRANSFER; MACULAR DYSTROPHY; FUNDUS-ALBIPUNCTATUS; BINDING PROTEIN; NEURAL CREST; RPE65 GENE	The retinal pigment epithelium (RPE) is crucial for the function and survival of retinal photoreceptors. VMD2 encodes bestrophin, an oligomeric chloride channel that is preferentially expressed in the RPE and, when mutated, causes Best macular dystrophy. Previously, we defined the VMD2 upstream region from -253 to +38 bp as being sufficient to direct RPE-specific expression in the eye, and we suggested microphthalmia-associated transcription factor (MITF) as a possible positive regulator. Here we show that in transgenic mice the -154 to +38 bp region is sufficient for RPE expression, and mutation of two E-boxes, 1 and 2, within this region leads to loss of promoter activity. Ayeast one-hybrid screen using bait containing E-box 1 identified clones encoding MITF, TFE3, and TFEB, and chromatin immunoprecipitation with antibodies against these proteins enriched the VMD2 proximal promoter. Analysis using in vivo electroporation with constructs containing mutation of each E-box indicated that expression in native RPE requires both E-boxes, yet in vitro DNA binding studies suggested that MITF binds well to E-box 1 but only minimally to E-box 2. MITF knockdown by small interfering RNA ( siRNA) in cell culture revealed a strong correlation between MITF and VMD2 mRNA levels. Sequential transfection of a luciferase construct with expression vectors following MITF siRNA revealed that TFE3 and TFEB can also transactivate the VMD2 promoter. Taken together, we suggest that VMD2 is regulated by the MITF-TFE family through two E-boxes, with E-box 1 required for a direct interaction of MITF-TFE factors and E-box 2 for binding of the as yet unidentified factor(s).	Johns Hopkins Univ, Sch Med, Guerrieri Ctr Genet Engn & Mol Ophthalmol, Wilmer Eye Inst, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Genet & Mol Biol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Esumi, N (corresponding author), Johns Hopkins Univ, Sch Med, Guerrieri Ctr Genet Engn & Mol Ophthalmol, Wilmer Eye Inst, 600 N Wolfe St,832 Maumenee Bldg, Baltimore, MD 21287 USA.	nesumi@jhmi.edu		Zack, Don/0000-0002-7966-1973	NEI NIH HHS [R01 EY016398] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY016398] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGATEP R, 1998, TECHNICAL TIPS ONLIN, V1, P66; Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; Bakall B, 2003, INVEST OPHTH VIS SCI, V44, P3622, DOI 10.1167/iovs.03-0030; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BEERMANN F, 1992, P NATL ACAD SCI USA, V89, P2809, DOI 10.1073/pnas.89.7.2809; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BOK D, 1993, J CELL SCI, P189; Boulanger A, 2000, J BIOL CHEM, V275, P31274, DOI 10.1074/jbc.M003441200; Boulanger A, 2002, CURR EYE RES, V24, P368, DOI 10.1076/ceyr.24.5.368.8523; Bumsted KM, 2000, INVEST OPHTH VIS SCI, V41, P903; Calomme C, 2004, J VIROL, V78, P13848, DOI 10.1128/JVI.78.24.13848-13864.2004; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; Chen SM, 2000, METHOD ENZYMOL, V316, P590; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; Davis IJ, 2006, CANCER CELL, V9, P473, DOI 10.1016/j.ccr.2006.04.021; Esumi N, 2004, J BIOL CHEM, V279, P19064, DOI 10.1074/jbc.M309881200; Felbor U, 1997, AM J HUM GENET, V60, P57; FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1115; Gaggioli C, 2003, PIGM CELL RES, V16, P374, DOI 10.1034/j.1600-0749.2003.00057.x; Goding CR, 2000, GENE DEV, V14, P1712; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Hallsson JH, 2000, GENETICS, V155, P291; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; HERO I, 1991, INVEST OPHTH VIS SCI, V32, P2622; Hertwig P., 1942, ZEITSCHR INDUKT ABSTAMM U VERERBUNGSL, V80, P220, DOI 10.1007/BF01741984; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Horsford DJ, 2005, DEVELOPMENT, V132, P177, DOI 10.1242/dev.01571; Hou L, 2000, DEVELOPMENT, V127, P5379; Huan CM, 2006, NAT IMMUNOL, V7, P1082, DOI 10.1038/ni1378; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; Kachi S, 2005, GENE THER, V12, P843, DOI 10.1038/sj.gt.3302475; Kachi S, 2006, GENE THER, V13, P798, DOI 10.1038/sj.gt.3302700; Katsanis N, 2001, CLIN GENET, V59, P424, DOI 10.1034/j.1399-0004.2001.590607.x; Kennedy BN, 1998, J BIOL CHEM, V273, P5591, DOI 10.1074/jbc.273.10.5591; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; Kuiper RP, 2004, NUCLEIC ACIDS RES, V32, P2315, DOI 10.1093/nar/gkh571; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P304; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097; Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517; Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064; Martinez-Morales JR, 2003, J BIOL CHEM, V278, P21721, DOI 10.1074/jbc.M301708200; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; Miller AJ, 2004, CANCER RES, V64, P509, DOI 10.1158/0008-5472.CAN-03-2440; Morimura H, 1999, NAT GENET, V23, P393, DOI 10.1038/70496; Morimura H, 1999, INVEST OPHTH VIS SCI, V40, P1000; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Nakamura M, 2000, INVEST OPHTH VIS SCI, V41, P3925; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; Nicoletti A, 1998, INVEST OPHTH VIS SCI, V39, P637; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; OGDEN TE, 2001, RETINA BASIC SCI INH, V1, P104; PACKER SO, 1967, J EXP ZOOL, V165, P21, DOI 10.1002/jez.1401650103; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Qian J, 2005, NUCLEIC ACIDS RES, V33, P3479, DOI 10.1093/nar/gki658; Rowan S, 2004, DEVELOPMENT, V131, P5139, DOI 10.1242/dev.01300; Sidman RL, 1996, INVEST OPHTH VIS SCI, V37, P1097; SMITH SB, 1992, EXP EYE RES, V55, P903, DOI 10.1016/0014-4835(92)90017-M; Smith SD, 2000, J MED GENET, V37, P446, DOI 10.1136/jmg.37.6.446; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; Steingrimsson E, 1998, DEVELOPMENT, V125, P4607; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; STONE EM, 1992, NAT GENET, V1, P246, DOI 10.1038/ng0792-246; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TIETZ W, 1963, AM J HUM GENET, V15, P259; Tsunenari T, 2003, J BIOL CHEM, V278, P41114, DOI 10.1074/jbc.M306150200; Vachtenheim J, 2001, J INVEST DERMATOL, V117, P1505, DOI 10.1046/j.0022-202x.2001.01563.x; Verastegui C, 2000, MOL ENDOCRINOL, V14, P449, DOI 10.1210/me.14.3.449; Vetrini F, 2004, MOL CELL BIOL, V24, P6550, DOI 10.1128/mcb.24.15.6550-6559.2004; Villavicencio EH, 2002, GENESIS, V32, P247, DOI 10.1002/gene.10078; Weilbaecher KN, 1998, J EXP MED, V187, P775, DOI 10.1084/jem.187.5.775; WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; Yardley J, 2004, INVEST OPHTH VIS SCI, V45, P3683, DOI 10.1167/iovs.04-0550; Yasumoto K, 1997, J BIOL CHEM, V272, P503; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; ZACK DJ, 1993, METH NEUROSCI, V15, P331; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505; ZINGG JM, 1994, NUCLEIC ACIDS RES, V22, P2234, DOI 10.1093/nar/22.12.2234	91	36	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1838	1850		10.1074/jbc.M609517200	http://dx.doi.org/10.1074/jbc.M609517200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17085443	hybrid			2022-12-27	WOS:000243451300035
J	Meng, XB; Yue, JY; Liu, ZH; Shen, ZY				Meng, Xiangbing; Yue, Jingyin; Liu, Zhihe; Shen, Zhiyuan			Abrogation of the transactivation activity of p53 by BCCIP down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; PROTEIN; ACTIVATION; KINASE; DAMAGE; BRCA2; GENE; INHIBITION; EXPRESSION; MUTATIONS	The tumor suppression function of p53 is mostly conferred by its transactivation activity, which is inactivated by p53 mutations in similar to 50% of human cancers. In cancers harboring wild type p53, the p53 transactivation activity may be compromised by other mechanisms. Identifying the mechanisms by which wild type p53 transactivation activity can be abrogated may provide insights into the molecular etiology of cancers harboring wild type p53. In this report, we show that BCCIP, a BRCA2 and CDKN1A- interacting protein, is required for the transactivation activity of wild type p53. In p53 wild type cells, BCCIP knock down by RNA interference diminishes the transactivation activity of p53 without reducing the p53 protein level, inhibits the binding of p53 to the promoters of p53 target genes p21 and HDM2, and reduces the tetrameric formation of p53. These data demonstrate a critical role of BCCIP in maintaining the transactivation activity of wild type p53 and further suggest down-regulation of BCCIP as a novel mechanism to impair the p53 function in cells harboring wild type p53.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ 08903 USA; Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of New Mexico	Shen, ZY (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, New Brunswick, NJ 08903 USA.	shenzh@umdnj.edu		meng, xiangbing/0000-0002-9612-6438; Shen, Zhiyuan/0000-0003-2834-0309	NCI NIH HHS [R01 CA115488-04, R01 CA115488-02, R01 CA115488-03, CA115488, R01 CA115488-01, R01 CA115488] Funding Source: Medline; NIEHS NIH HHS [ES08353, R29 ES008353, R01 ES008353] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008353, R01ES008353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hanson S, 2005, ONCOGENE, V24, P1641, DOI 10.1038/sj.onc.1208351; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KASTAN MB, 1991, CANCER RES, V51, P6304; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Liu YG, 2004, CANCER BIOL THER, V3, P1102, DOI 10.4161/cbt.3.11.1189; Lu HM, 2005, MOL CELL BIOL, V25, P1949, DOI 10.1128/MCB.25.5.1949-1957.2005; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Meng XB, 2004, CELL CYCLE, V3, P1457, DOI 10.4161/cc.3.11.1213; Meng XB, 2004, CELL CYCLE, V3, P343; Meng XB, 2004, J BIOL CHEM, V279, P6098, DOI 10.1074/jbc.M306794200; Meng XB, 2003, GENE, V302, P139, DOI 10.1016/S0378-1119(02)01098-3; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; Robles AI, 2002, ONCOGENE, V21, P6898, DOI 10.1038/sj.onc.1205563; Takimoto R, 2001, P NATL ACAD SCI USA, V98, P781, DOI 10.1073/pnas.98.3.781; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	28	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1570	1576		10.1074/jbc.M607520200	http://dx.doi.org/10.1074/jbc.M607520200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17135243	Green Accepted, hybrid			2022-12-27	WOS:000243451300008
J	Subramanian, S; Boder, ET; Discher, DE				Subramanian, Shyamsundar; Boder, Eric T.; Discher, Dennis E.			Phylogenetic divergence of CD47 interactions with human signal regulatory protein alpha reveals locus of species specificity - Implications for the binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; ABERRANT N-GLYCOSYLATION; T-CELL-ACTIVATION; RED-BLOOD-CELLS; SIRP-ALPHA; NEUTROPHIL TRANSMIGRATION; IMMUNOGLOBULIN DOMAIN; ADHESION MOLECULE; HIGH-AFFINITY; MEMBRANE	Cell-cell interactions between ubiquitously expressed integrin-associated protein (CD47) and its counterreceptor signal regulatory protein (SIRP alpha) on phagocytes regulate a wide range of adhesive signaling processes, including the inhibition of phagocytosis as documented in mice. We show that CD47-SIRP alpha binding interactions are different between mice and humans, and we exploit phylogenetic divergence to identify the species-specific binding locus on the immunoglobulin domain of human CD47. All of the studies are conducted in the physiological context of membrane protein display on Chinese hamster ovary (CHO) cells. Novel quantitative flow cytometry analyses with CD47-green fluorescent protein and soluble human SIRP alpha as a probe show that neither human CD47 nor SIRP alpha requires glycosylation for interaction. Human CD47-expressing CHO cells spread rapidly on SIRP alpha-coated glass surfaces, correlating well with the spreading of primary human T cells. In contrast, CHO cells expressing mouse CD47 spread minimally and show equally weak binding to soluble human SIRP alpha. Further phylogenetic analyses and multisite substitutions of the CD47 Ig domain show that human to cow mutation of a cluster of seven residues on adjacent strands near the middle of the domain decreases the association constant for human SIRP alpha to about one-third that of human CD47. Direct tests of cell-cell adhesion between human monocytes and CD47-displaying CHO cells affirm the species specificity as well as the importance of the newly identified binding locus in cell-cell interactions.	Univ Penn, Biophys Engn Lab, Philadelphia, PA 19104 USA	University of Pennsylvania	Discher, DE (corresponding author), Univ Penn, Mol & Cell Biophys Lab, 112 Towne Bldg,220 S 33rd St, Philadelphia, PA 19104 USA.	discher@seas.upenn.edu	Boder, Eric T./E-9635-2015	Boder, Eric T./0000-0003-4095-5680; discher, dennis/0000-0001-6163-2229	PHS HHS [R01, R21] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Arndt PA, 2004, BRIT J HAEMATOL, V125, P412, DOI 10.1111/j.1365-2141.2004.04911.x; Babic I, 2000, J IMMUNOL, V164, P3652, DOI 10.4049/jimmunol.164.7.3652; Blazar BR, 2001, J EXP MED, V194, P541, DOI 10.1084/jem.194.4.541; Boulbitch A, 2001, BIOPHYS J, V81, P2743, DOI 10.1016/S0006-3495(01)75917-6; Breithaupt C, 2003, P NATL ACAD SCI USA, V100, P9446, DOI 10.1073/pnas.1133443100; Brooke G, 2004, J IMMUNOL, V173, P2562, DOI 10.4049/jimmunol.173.4.2562; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Bruce LJ, 2003, BLOOD, V101, P4180, DOI 10.1182/blood-2002-09-2824; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Darbha R, 2004, BIOCHEMISTRY-US, V43, P1410, DOI 10.1021/bi035323x; de Vries HE, 2002, J IMMUNOL, V168, P5832, DOI 10.4049/jimmunol.168.11.5832; Discher DE, 1996, BIOPHYS J, V71, P1680, DOI 10.1016/S0006-3495(96)79424-9; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Fleire SJ, 2006, SCIENCE, V312, P738, DOI 10.1126/science.1123940; Fujimoto TT, 2003, J BIOL CHEM, V278, P26655, DOI 10.1074/jbc.M302194200; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Furusawa T, 1998, J BIOCHEM-TOKYO, V123, P101; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Granovsky M, 2000, NAT MED, V6, P306; Guo HB, 2002, CANCER RES, V62, P6837; Hao L, 2006, P NATL ACAD SCI USA, V103, P3192, DOI 10.1073/pnas.0511280103; Hatherley D, 2004, EUR J IMMUNOL, V34, P1688, DOI 10.1002/eji.200425080; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lee SJE, 2002, TRENDS IMMUNOL, V23, P492, DOI 10.1016/S1471-4906(02)02285-8; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; LINDBERG FP, 1994, J BIOL CHEM, V269, P1567; Liu Y, 2004, J IMMUNOL, V172, P2578, DOI 10.4049/jimmunol.172.4.2578; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; MAWBY WJ, 1994, BIOCHEM J, V304, P525, DOI 10.1042/bj3040525; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Midelfort KS, 2006, PROTEIN SCI, V15, P324, DOI 10.1110/ps.051842406; Miyashita M, 2004, MOL BIOL CELL, V15, P3950, DOI 10.1091/mbc.E04-01-0019; Mouro-Chanteloup I, 2003, BLOOD, V101, P338, DOI 10.1182/blood-2002-04-1285; Ogura T, 2004, J BIOL CHEM, V279, P13711, DOI 10.1074/jbc.M310276200; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Olsson M, 2005, BLOOD, V105, P3577, DOI 10.1182/blood-2004-08-2980; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; Parthasarathy R, 2006, BIOTECHNOL BIOENG, V93, P159, DOI 10.1002/bit.20684; Piccio L, 2005, BLOOD, V105, P2421, DOI 10.1182/blood-2004-07-2823; Rebres RA, 2005, J CELL PHYSIOL, V205, P182, DOI 10.1002/jcp.20379; Rebres RA, 2001, J BIOL CHEM, V276, P34607, DOI 10.1074/jbc.M106107200; Reinhold MI, 1999, INT IMMUNOL, V11, P707, DOI 10.1093/intimm/11.5.707; REINHOLD MI, 1995, J CELL SCI, V108, P3419; Schwartz JCD, 2001, NATURE, V410, P604, DOI 10.1038/35069112; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Subramanian S, 2006, BLOOD, V107, P2548, DOI 10.1182/blood-2005-04-1463; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thoumine O, 2005, BIOPHYS J, V89, pL40, DOI 10.1529/biophysj.105.071688; van Beek EM, 2005, J IMMUNOL, V175, P7781, DOI 10.4049/jimmunol.175.12.7781; Vernon-Wilson EF, 2000, EUR J IMMUNOL, V30, P2130; Yamamoto H, 2000, CANCER RES, V60, P134	57	50	61	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1805	1818		10.1074/jbc.M603923200	http://dx.doi.org/10.1074/jbc.M603923200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17098740	hybrid			2022-12-27	WOS:000243451300032
J	Piermarini, PM; Kim, EY; Boron, WF				Piermarini, Peter M.; Kim, Eugene Y.; Boron, Walter F.			Evidence against a direct interaction between intracellular carbonic anhydrase II and pure C-terminal domains of SLC4 bicarbonate transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGER; BINDING-SITE; FUNCTIONAL INTERACTION; SECONDARY STRUCTURE; CO2 PERMEABILITY; MEMBRANE DOMAIN; ERYTHROCYTE; PROTEIN; METABOLON; BAND-3	Based on solid-phase binding assays with enzyme- linked immunosorbent assay detection, previous investigators suggested that intracellular carbonic anhydrase II (CA II) interacts at high affinity with the C-terminal (Ct) domains of SLC4 bicarbonate-transport proteins, expressed as glutathione S-transferase (GST) fusion proteins, to form functional HCO3- metabolons. Here we re-evaluated this protein- protein interaction using two solid-phase binding assays. We first compared the ability of the Ct domain of three SLC4 transporters, SLC4-A1 (AE1), SLC4-A4 (NBCe1), and SLC4-A8 (NDCBE), to bind immobilized CA II, using enzyme- linked immunosorbent assay detection. We found that when expressed as GST fusion proteins, all three bind to CAII (K-d 300-600 nM) better than does pure GST. However, we detected no binding of pure SLC4-Ct peptides to immobilized CA II. Second, we reversed assay orientation by immobilizing the SLC4-Ct fusion proteins or peptides. We found that more CA II binds to GST than to any of the three GST-SLC4-Ct fusion proteins. Furthermore, we detected no binding of CAII to any of the immobilized pure SLC4-Ct peptides. Finally, we used surface plasmon resonance to detect possible rapid interactions between CA II and the pure peptides. Although we detected acetazolamide binding to immobilized CA II and specific antibodies binding to immobilized SLC4-Ct peptides, we detected no binding of CA II to immobilized SLC4-Ct or vice versa. Thus, although an HCO3 metabolon may exist, CA II cannot bind directly to pure SLC4-Ct peptides and can bind to GST-SLC4-Ct fusion proteins only when the CA II is immobilized and the fusion protein is soluble, and not vice versa.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Piermarini, PM (corresponding author), Cornell Univ, Coll Vet Med, T4-018,Vet Res Tower, Ithaca, NY 14853 USA.	pmp26@cornell.edu	Piermarini, Peter/AAO-5666-2021; Boron, Walter/ABI-1564-2020	Boron, Walter/0000-0003-4741-7287; Piermarini, Peter/0000-0003-1020-5774	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030344, R01DK030344, F32DK067771, T32DK007259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018400] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-30344, R37 DK030344-28, R37 DK030344, DK067771, DK07259] Funding Source: Medline; NINDS NIH HHS [NS-18400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarez BV, 2005, EMBO J, V24, P2499, DOI 10.1038/sj.emboj.7600736; Bevensee MO, 2000, AM J PHYSIOL-CELL PH, V278, pC1200, DOI 10.1152/ajpcell.2000.278.6.C1200; BRION LP, 1988, ANAL BIOCHEM, V175, P289, DOI 10.1016/0003-2697(88)90391-0; Cannon MJ, 2004, ANAL BIOCHEM, V330, P98, DOI 10.1016/j.ab.2004.02.027; Cooper GJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1481, DOI 10.1152/ajpcell.1998.275.6.C1481; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Elder I, 2004, ARCH BIOCHEM BIOPHYS, V421, P283, DOI 10.1016/j.abb.2003.11.006; Endeward V, 2006, FASEB J, V20, P1974, DOI 10.1096/fj.04-3300com; Gagnon DG, 2005, BBA-BIOMEMBRANES, V1712, P173, DOI 10.1016/j.bbamem.2005.04.007; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gross E, 2002, J PHYSIOL-LONDON, V544, P679, DOI 10.1113/jphysiol.2002.029777; Gross E, 2001, J PHYSIOL-LONDON, V537, P659; Li HC, 2004, J BIOL CHEM, V279, P43190, DOI 10.1074/jbc.M405780200; Li XJ, 2002, J BIOL CHEM, V277, P36085, DOI 10.1074/jbc.M111952200; Li XJ, 2006, BIOCHEMISTRY-US, V45, P2414, DOI 10.1021/bi051132d; Loiselle FB, 2004, AM J PHYSIOL-CELL PH, V286, pC1423, DOI 10.1152/ajpcell.00382.2003; Loiselle FB, 2003, MOL MEMBR BIOL, V20, P307, DOI 10.1080/0968768031000122520; Lu J, 2006, J BIOL CHEM, V281, P19241, DOI 10.1074/jbc.M602181200; MAREN TH, 1992, MOL PHARMACOL, V41, P419; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Nicolas V, 2006, TRANSFUS CLIN BIOL, V13, P23, DOI 10.1016/j.tracli.2006.02.019; Park M, 2004, MOL CELL, V16, P331, DOI 10.1016/j.molcel.2004.09.030; Popov M, 1999, BIOCHEM J, V339, P269, DOI 10.1042/0264-6021:3390269; Przybylski D, 2002, PROTEINS, V46, P197, DOI 10.1002/prot.10029; Pushkin A, 2004, J PHYSIOL-LONDON, V559, P55, DOI 10.1113/jphysiol.2004.065110; Pushkin A, 2003, AM J PHYSIOL-CELL PH, V284, pC667, DOI 10.1152/ajpcell.00225.2002; Reithmeier RAF, 2001, BLOOD CELL MOL DIS, V27, P85, DOI 10.1006/bcmd.2000.0353; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schroder HC, 2004, BIOCHEM J, V381, P665, DOI 10.1042/BJ20040463; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Sterling D, 2002, AM J PHYSIOL-CELL PH, V283, pC1522, DOI 10.1152/ajpcell.00115.2002; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; Tanner MJA, 2002, CURR OPIN HEMATOL, V9, P133, DOI 10.1097/00062752-200203000-00009; Toye AM, 2004, J CELL SCI, V117, P1399, DOI 10.1242/jcs.00974; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Vince JW, 2000, BIOCHEMISTRY-US, V39, P13344, DOI 10.1021/bi0015111; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; WAINWRIGHT SD, 1990, BIOCHEM J, V272, P265, DOI 10.1042/bj2720265; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211; WHITNEY PL, 1974, ANAL BIOCHEM, V57, P467, DOI 10.1016/0003-2697(74)90102-X	41	59	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1409	1421		10.1074/jbc.M608261200	http://dx.doi.org/10.1074/jbc.M608261200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17090540	hybrid			2022-12-27	WOS:000243295200066
J	Beyl, S; Timin, EN; Hohaus, A; Stary, A; Kudrnac, M; Guy, RH; Hering, S				Beyl, Stanislav; Timin, Eugen N.; Hohaus, Annette; Stary, Anna; Kudrnac, Michaela; Guy, Robert H.; Hering, Steffen			Probing the architecture of an L-type calcium channel with a charged phenylalkylamine - Evidence for a widely open pore and drug trapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DETERMINANTS; RETINAL DISORDER; BLOCK; MUSCLE; INACTIVATION; ANTAGONISTS; ACTIVATION; DEPENDENCE; MEMBRANE; CURRENTS	Voltage-gated calcium channels are in a closed conformation at rest and open temporarily when the membrane is depolarized. To gain insight into the molecular architecture of Ca(v)1.2, we probed the closed and open conformations with the charged phenylalkylamine (-)devapamil ((-)qD888). To elucidate the access pathway of (-)D888 to its binding pocket from the intracellular side, we used mutations replacing a highly conserved Ile-781 by threonine/proline in the pore-lining segment IIS6 of Ca(v)1.2 (1). The shifted channel gating of these mutants (by 30 - 40 mV in the hyperpolarizing direction) enabled us to evoke currents with identical kinetics at different potentials and thus investigate the effect of the membrane potentials on the drug access per se. We show here that under these conditions the development of channel block by (-)qD888 is not affected by the transmembrane voltage. Recovery from block at rest was, however, accelerated at more hyperpolarized voltages. These findings support the conclusion that Ca(v)1.2 must be opening widely to enable free access of the charged (-)D888 molecule to its binding site, whereas drug dissociation from the closed channel conformation is restricted by bulky channel gates. The functional data indicating a location of a trapped (-)D888 molecule close to the central pore region are supported by a homology model illustrating that the closed Ca(v)1.2 is able to accommodate a large cation such as (-)D888.	Univ Vienna, Inst Pharmacol & Toxicol, A-1090 Vienna, Austria; Univ Vienna, Inst Theoret Chem, A-1090 Vienna, Austria; NCI, NIH, Cell Biol Lab, Bethesda, MD 20892 USA	University of Vienna; University of Vienna; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hering, S (corresponding author), Univ Vienna, Inst Pharmacol & Toxicol, Althanstr 14, A-1090 Vienna, Austria.	steffen.hering@univie.ac.at	Stary-Weinzinger, Anna/A-3629-2014	Stary-Weinzinger, Anna/0000-0002-9202-0484	NATIONAL CANCER INSTITUTE [Z01BC010721, ZIABC010721] Funding Source: NIH RePORTER; Austrian Science Fund FWF [P 15914] Funding Source: Medline; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Austrian Science Fund FWF(Austrian Science Fund (FWF)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Berjukov S, 1996, BRIT J PHARMACOL, V119, P1197, DOI 10.1111/j.1476-5381.1996.tb16022.x; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Catterall WA, 2005, PHARMACOL REV, V57, P411, DOI 10.1124/pr.57.4.5; Dilmac N, 2004, MOL PHARMACOL, V66, P1236, DOI 10.1124/mol.104.000893; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hemara-Wahanui A, 2005, P NATL ACAD SCI USA, V102, P7553, DOI 10.1073/pnas.0501907102; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Hering S, 2002, TRENDS PHARMACOL SCI, V23, P509, DOI 10.1016/S0165-6147(02)02104-1; Hering S, 1998, TRENDS PHARMACOL SCI, V19, P439, DOI 10.1016/S0165-6147(98)01258-9; HESCHELER J, 1982, PFLUG ARCH EUR J PHY, V393, P287, DOI 10.1007/BF00581411; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Hohaus A, 2005, J BIOL CHEM, V280, P38471, DOI 10.1074/jbc.M507013200; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; KHODOROV BI, 1975, BRAIN RES, V84, P541, DOI 10.1016/0006-8993(75)90771-4; MATHIAS RT, 1990, BIOPHYS J, V58, P759, DOI 10.1016/S0006-3495(90)82418-8; MCDONALD TF, 1984, J PHYSIOL-LONDON, V352, P217, DOI 10.1113/jphysiol.1984.sp015288; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANGUINETTI MC, 1984, CIRC RES, V55, P336, DOI 10.1161/01.RES.55.3.336; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; UEHARA A, 1985, J GEN PHYSIOL, V85, P621, DOI 10.1085/jgp.85.5.621	26	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3864	3870		10.1074/jbc.M609153200	http://dx.doi.org/10.1074/jbc.M609153200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17138559	Green Accepted, hybrid			2022-12-27	WOS:000244481900050
J	Nagashima, T; Shimodaira, H; Ide, K; Nakakuki, T; Tani, Y; Takahashi, K; Yumoto, N; Hatakeyama, M				Nagashima, Takeshi; Shimodaira, Hidetoshi; Ide, Kaori; Nakakuki, Takashi; Tani, Yukitaka; Takahashi, Kaoru; Yumoto, Noriko; Hatakeyama, Mariko			Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; EARLY GENE-PRODUCTS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; EPITHELIAL-CELLS; KAPPA-B; AKT; HEREGULIN	ErbB receptor ligands, epidermal growth factor (EGF) and heregulin (HRG), induce dose-dependent transient and sustained intracellular signaling, proliferation, and differentiation of MCF-7 breast cancer cells, respectively. In an effort to delineate the ligand-specific cell determination mechanism, we investigated time course gene expressions induced by EGF and HRG that induce distinct cellular phenotypes in MCF-7 cells. To analyze independently the effects of ligand dosage and time for gene expression, we developed a statistical method for estimating the two effects. Our results indicated that signal transduction pathways convey quantitative properties of the dose-dependent activation of ErbB receptor to early transcription. The results also implied that moderate changes in the expression levels of a number of genes, not the predominant regulation of a few specific genes, might cooperatively work at the early stage of the transcription for determining cell fate. However, the EGF- and HRG-induced distinct signal durations resulted in the ligand-oriented biphasic induction of proteins after 20 min. The selected gene list and HRG-induced prolonged signaling suggested that transcriptional feedback to the intracellular signaling results in a graded to biphasic response in the cell determination process and that each ErbB receptor is inextricably responsible for the control of amplitude and duration of cellular biochemical reactions.	RIKEN Genom Sci Ctr, Cellular Syst Biol Team, Computat & Expt Syst Biol Grp, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Tokyo Inst Technol, Dept Math & Comp Sci, Meguro Ku, Tokyo 1528552, Japan	RIKEN; Tokyo Institute of Technology	Hatakeyama, M (corresponding author), RIKEN Genom Sci Ctr, Cellular Syst Biol Team, Computat & Expt Syst Biol Grp, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	marikoh@gsc.riken.jp	Shimodaira, Hidetoshi/B-9127-2008; Okada, Mariko/N-6933-2015	Shimodaira, Hidetoshi/0000-0002-3371-7724; 				Amin DN, 2005, EXP CELL RES, V309, P12, DOI 10.1016/j.yexcr.2005.04.034; Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carricaburu V, 2003, P NATL ACAD SCI USA, V100, P9867, DOI 10.1073/pnas.1734038100; Das S, 2005, J BIOL CHEM, V280, P23748, DOI 10.1074/jbc.M412837200; Davy A, 2004, GENE DEV, V18, P572, DOI 10.1101/gad.1171704; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Greenberg CC, 2003, J BIOL CHEM, V278, P30835, DOI 10.1074/jbc.M303846200; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hollander MC, 2003, ONCOGENE, V22, P3827, DOI 10.1038/sj.onc.1206567; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Klinghoffer RA, 2001, MOL CELL, V7, P343, DOI 10.1016/S1097-2765(01)00182-4; Levkowitz G, 1996, ONCOGENE, V12, P1117; Li WQ, 2004, J BIOL CHEM, V279, P37398, DOI 10.1074/jbc.M405730200; MacKeigan JP, 2005, MOL CELL BIOL, V25, P4676, DOI 10.1128/MCB.25.11.4676-4682.2005; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Matsuda S, 1996, ONCOGENE, V12, P705; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Pandey SK, 2002, ENDOCRINOLOGY, V143, P375, DOI 10.1210/en.143.2.375; Ram TG, 2000, J CELL PHYSIOL, V183, P301, DOI 10.1002/(SICI)1097-4652(200006)183:3<301::AID-JCP2>3.0.CO;2-W; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Semino CE, 2006, EXP CELL RES, V312, P289, DOI 10.1016/j.yexcr.2005.10.029; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Thottassery JV, 2004, CANCER RES, V64, P4637, DOI 10.1158/0008-5472.CAN-03-2645; Tullai JW, 2004, J BIOL CHEM, V279, P20167, DOI 10.1074/jbc.M309260200; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Uyemura T, 2005, BIOPHYS J, V88, P3720, DOI 10.1529/biophysj.104.053330; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wenner CE, 2003, J CELL PHYSIOL, V196, P42, DOI 10.1002/jcp.10243; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Xu WP, 2003, CANCER RES, V63, P7777; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000	52	121	123	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4045	4056		10.1074/jbc.M608653200	http://dx.doi.org/10.1074/jbc.M608653200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17142811	hybrid			2022-12-27	WOS:000244481900068
J	Singh, P; Zheng, L; Chavez, V; Qiu, JZ; Shen, BH				Singh, Purnima; Zheng, Li; Chavez, Valerie; Qiu, Junzhuan; Shen, Binghui			Concerted action of exonuclease and gap-dependent endonuclease activities of FEN-1 contributes to the resolution of triplet repeat sequences (CTG)(n)- and (GAA)(n)-derived secondary structures formed during maturation of Okazaki fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FLAP ENDONUCLEASE-1; SACCHAROMYCES-CEREVISIAE; FRIEDREICHS-ATAXIA; TRINUCLEOTIDE REPEATS; IN-VITRO; MISMATCH REPAIR; DNA-SEQUENCES; HUMAN-DISEASE; STICKY DNA; EXPANSION	There is much evidence to indicate that FEN-1 efficiently cleaves single-stranded DNA flaps but is unable to process double-stranded flaps or flaps adopting secondary structures. However, the absence of Fen1 in yeast results in a significant increase in trinucleotide repeat (TNR) expansion. There are then two possibilities. One is that TNRs do not always form stable secondary structures or that FEN-1 has an alternative approach to resolve the secondary structures. In the present study, we test the hypothesis that concerted action of exonuclease and gap-dependent endonuclease activities of FEN-1 play a role in the resolution of secondary structures formed by (CTG)(n) and (GAA)(n) repeats. Employing a yeast FEN-1 mutant, E176A, which is deficient in exonuclease (EXO) and gap endonuclease (GEN) activities but retains almost all of its flap endonuclease (FEN) activity, we show severe defects in the cleavage of various TNR intermediate substrates. Precise knock-in of this point mutation causes an increase in both the expansion and fragility of a (CTG), tract in vivo. Taken together, our biochemical and genetic analyses suggest that although FEN activity is important for single-stranded flap processing, EXO and GEN activities may contribute to the resolution of structured flaps. A model is presented to explain how the concerted action of EXO and GEN activities may contribute to resolving structured flaps, thereby preventing their expansion in the genome.	City Hope Natl Med Ctr, Dept Radiat Biol, Duarte, CA 91010 USA; Beckman Res Inst, Duarte, CA 91010 USA	City of Hope; City of Hope; Beckman Research Institute of City of Hope	Shen, BH (corresponding author), City Hope Natl Med Ctr, Dept Radiat Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	bshen@coh.org		Shen, Binghui/0000-0002-4408-407X; Singh, Purnima/0000-0002-4968-7398	NATIONAL CANCER INSTITUTE [R01CA073764, R01CA085344] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA085344, R01 CA073764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Callahan JL, 2003, MOL CELL BIOL, V23, P7849, DOI 10.1128/MCB.23.21.7849-7860.2003; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; Cleary JD, 2003, CYTOGENET GENOME RES, V100, P25, DOI 10.1159/000072837; Frank G, 2001, J BIOL CHEM, V276, P36295, DOI 10.1074/jbc.M103397200; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gacy AM, 1998, MOL CELL, V1, P583, DOI 10.1016/S1097-2765(00)80058-1; GACY AM, 1995, CELL, V81, P533; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Heidenfelder BL, 2003, J BIOL CHEM, V278, P2425, DOI 10.1074/jbc.M210643200; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Krasilnikova MM, 2004, MOL CELL BIOL, V24, P2286, DOI 10.1128/MCB.24.6.2286-2295.2004; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Liu R, 2006, NUCLEIC ACIDS RES, V34, P1772, DOI 10.1093/nar/gkl106; Liu Y, 2004, MOL CELL BIOL, V24, P4049, DOI 10.1128/MCB.24.9.4049-4064.2004; Liu Y, 2003, J BIOL CHEM, V278, P13728, DOI 10.1074/jbc.M212061200; Mariappan SVS, 1999, J MOL BIOL, V285, P2035, DOI 10.1006/jmbi.1998.2435; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; McMurray CT, 1999, P NATL ACAD SCI USA, V96, P1823, DOI 10.1073/pnas.96.5.1823; Miret JJ, 1998, P NATL ACAD SCI USA, V95, P12438, DOI 10.1073/pnas.95.21.12438; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Negritto MC, 2001, MOL CELL BIOL, V21, P2349, DOI 10.1128/MCB.21.7.2349-2358.2001; Parrish JZ, 2003, EMBO J, V22, P3451, DOI 10.1093/emboj/cdg320; Pollard LM, 2004, NUCLEIC ACIDS RES, V32, P5962, DOI 10.1093/nar/gkh933; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; Ruggiero BL, 2004, J BIOL CHEM, V279, P23088, DOI 10.1074/jbc.M313170200; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; Schweitzer JK, 1999, GENETICS, V152, P953; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Sharma R, 2002, HUM MOL GENET, V11, P2175, DOI 10.1093/hmg/11.18.2175; Shen BH, 2005, BIOESSAYS, V27, P717, DOI 10.1002/bies.20255; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Subramanian J, 2005, GENETICS, V171, P427, DOI 10.1534/genetics.105.042861; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Toth G, 2000, GENOME RES, V10, P967, DOI 10.1101/gr.10.7.967; Vetcher AA, 2004, J BIOL CHEM, V279, P6434, DOI 10.1074/jbc.M309595200; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wells RD, 1998, J BIOL CHEM, V273, P19532, DOI 10.1074/jbc.273.31.19532; Zheng L, 2005, EMBO REP, V6, P83, DOI 10.1038/sj.embor.7400313	54	49	52	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3465	3477		10.1074/jbc.M606582200	http://dx.doi.org/10.1074/jbc.M606582200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17138563	hybrid			2022-12-27	WOS:000244481900009
J	Yang, F; Hu, W; Xu, HM; Li, CM; Xia, B; Jin, CW				Yang, Fan; Hu, Wei; Xu, Huimin; Li, Congmin; Xia, Bin; Jin, Changwen			Solution structure and backbone dynamics of an endopeptidase HycI from Escherichia coli - Implications for mechanism of the [NiFe] hydrogenase maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; TORSION ANGLE DYNAMICS; C-TERMINAL EXTENSION; N-15 NMR RELAXATION; MODEL-FREE APPROACH; LARGE SUBUNIT; C-13/N-15-ENRICHED PROTEINS; AZOTOBACTER-VINELANDII; ROTATIONAL DIFFUSION; NICKEL INCORPORATION	[NiFe] hydrogenases are metalloenzymes involved in many biological processes concerning the metabolism of hydrogen. The maturation of the large subunit of these hydrogenases requires the cleavage of a peptide at the C terminus by an endopeptidase before the final formation of the [NiFe] metallocenter. HycI is an endopeptidase of the M52 family and responsible for the C-terminal cleavage of the large subunit of hydrogenase 3 in Escherichia coli. Although extensive studies were performed, the molecular mechanism of recognition and cleavage of hydrogenase 3 remains elusive. Herein, we report the solution structure of E. coli HycI determined by high resolution nuclear magnetic resonance spectroscopy. This is the first solution structure of the apo form of endopeptidase of the M52 family reported thus far. The overall structure is similar to the crystal structure of holo-HybD in the same family. However, significant diversity was observed between the two structures. Especially, HycI shows an open conformation at the putative nickel-binding site, whereas HybD adopts a closed conformation. In addition, we performed backbone dynamic studies to probe the motional properties of the apo form of HycI. Furthermore, the metal ion titration experiments provide insightful information on the substrate recognition and cleavage processes. Taken together, our current structural, biochemical, and dynamic studies extend the knowledge of the M52 family proteins and provide novel insights into the biological function of HycI.	Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China; Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China	Peking University; Peking University; Peking University	Jin, CW (corresponding author), Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China.	changwen@pku.edu.cn	Yang, Fan/GYU-4249-2022; Hu, Wei/ABH-1470-2021; Zhu, Ren-Yuan/V-8966-2019	Hu, Wei/0000-0002-0392-6939; Zhu, Ren-Yuan/0000-0003-3091-7461; Yang, Fan/0000-0002-0841-8933				Andrews SC, 1997, MICROBIOL-SGM, V143, P3633, DOI 10.1099/00221287-143-11-3633; Atkinson RA, 2004, PROG NUCL MAG RES SP, V44, P141, DOI 10.1016/j.pnmrs.2004.01.001; BALLANTINE SP, 1985, J BACTERIOL, V163, P454, DOI 10.1128/JB.163.2.454-459.1985; BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Drapal N, 1998, BIOCHEMISTRY-US, V37, P2941, DOI 10.1021/bi9720078; Duggan BM, 2001, J BIOMOL NMR, V19, P321, DOI 10.1023/A:1011227824104; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fritsche E, 1999, J MOL BIOL, V288, P989, DOI 10.1006/jmbi.1999.2719; Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771; Gerstein M, 2004, CURR OPIN CHEM BIOL, V8, P14, DOI 10.1016/j.cbpa.2003.12.006; GOLLIN DJ, 1992, FEBS LETT, V309, P371, DOI 10.1016/0014-5793(92)80809-U; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARKLEY JL, 1971, J CHEM PHYS, V55, P3604, DOI 10.1063/1.1676626; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Massanz C, 1997, EUR J BIOCHEM, V245, P441, DOI 10.1111/j.1432-1033.1997.t01-3-00441.x; MENON AL, 1994, J BACTERIOL, V176, P291, DOI 10.1128/JB.176.2.291-295.1994; Mittermaier A, 2006, SCIENCE, V312, P224, DOI 10.1126/science.1124964; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; ROSSMANN R, 1995, EUR J BIOCHEM, V227, P545, DOI 10.1111/j.1432-1033.1995.tb20422.x; ROSSMANN R, 1994, EUR J BIOCHEM, V220, P377, DOI 10.1111/j.1432-1033.1994.tb18634.x; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; SAWERS RG, 1985, J BACTERIOL, V164, P1324, DOI 10.1128/JB.164.3.1324-1331.1985; Theodoratou E, 2000, ARCH MICROBIOL, V173, P110, DOI 10.1007/s002039900116; Theodoratou E, 2005, BIOCHEM SOC T, V33, P108, DOI 10.1042/BST0330108; Theodoratou E, 2000, EUR J BIOCHEM, V267, P1995, DOI 10.1046/j.1432-1327.2000.01202.x; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Zhang M, 2003, BIOCHIMIE, V85, P575, DOI 10.1016/S0300-9084(03)00091-9	45	17	18	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3856	3863		10.1074/jbc.M609263200	http://dx.doi.org/10.1074/jbc.M609263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150961	Green Submitted, hybrid			2022-12-27	WOS:000244481900049
J	Pyott, SJ; Meredith, AL; Fodor, AA; Vazquez, AE; Yamoah, EN; Aldrich, RW				Pyott, Sonja J.; Meredith, Andrea L.; Fodor, Anthony A.; Vazquez, Ana E.; Yamoah, Ebenezer N.; Aldrich, Richard W.			Cochlear function in mice lacking the BK channel alpha, beta 1, or beta 4 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER HAIR-CELLS; CA2+-ACTIVATED K+ CHANNEL; ACTIVATED POTASSIUM CHANNELS; INDUCED HEARING-LOSS; GUINEA-PIG COCHLEA; ADRENAL CHROMAFFIN CELLS; LARGE-CONDUCTANCE; MOUSE COCHLEA; BETA-SUBUNIT; TARGETED DISRUPTION	Large conductance voltage- and calcium- activated potassium (BK) channels are important for regulating many essential cellular functions, from neuronal action potential shape and firing rate to smooth muscle contractility. In amphibians, reptiles, and birds, BK channels mediate the intrinsic frequency tuning of the cochlear hair cell by an electrical resonance mechanism. In contrast, inner hair cells of the mammalian cochlea are extrinsically tuned by accessory structures of the cochlea. Nevertheless, BK channels are present in inner hair cells and encode a fast activating outward current. To understand the role of the BK channel alpha and beta subunits in mammalian inner hair cells, we analyzed the morphology, physiology, and function of these cells from mice lacking the BK channel alpha (Slo(-/-)) and also the beta 1 and beta 4 subunits (beta 1/4(-/-)). beta 1/4(-/-) mice showed normal subcellular localization, developmental acquisition, and expression of BK channels. beta 1/4(-/-) mice showed normal cochlear function as indicated by normal auditory brainstem responses and distortion product otoacoustic emissions. Slo(-/-) mice also showed normal cochlear function despite the absence of the BK alpha subunit and the absence of fast activating outward current from the inner hair cells. Moreover, microarray analyses revealed no compensatory changes in transcripts encoding ion channels or transporters in the cochlea from Slo(-/-) mice. Slo(-/-) mice did, however, show increased resistance to noise- induced hearing loss. These findings reveal the fundamentally different contribution of BK channels to nonmammalian and mammalian hearing and suggest that BK channels should be considered a target in the prevention of noise-induced hearing loss.	Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ N Carolina, Dept Bioinformat Comp Sci, Charlotte, NC 28233 USA; Univ Calif Davis, Dept Otolaryngol, Ctr Neurosci, Davis, CA 95616 USA; Univ Texas, Neurobiol Sect, Austin, TX 78712 USA	Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore; University of North Carolina; University of North Carolina Charlotte; University of California System; University of California Davis; University of Texas System; University of Texas Austin	Pyott, SJ (corresponding author), Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, 720 Rutland Ave,Traylor 521, Baltimore, MD 21205 USA.	spyott@jhmi.edu	Pyott, Sonja/AAW-8789-2020	Pyott, Sonja/0000-0001-7750-2437; Meredith, Andrea/0000-0003-1061-2302	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC007592] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC03828, DC07592] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Armstrong CE, 2001, J PHYSIOL-LONDON, V536, P49, DOI 10.1111/j.1469-7793.2001.00049.x; BERGLUND AM, 1991, J COMP NEUROL, V306, P393, DOI 10.1002/cne.903060304; Brandle U, 2001, HEARING RES, V161, P23, DOI 10.1016/S0378-5955(01)00323-9; Brandt A, 2003, J NEUROSCI, V23, P10832; Brenner R, 2005, NAT NEUROSCI, V8, P1752, DOI 10.1038/nn1573; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; Chen ZY, 2002, JARO-J ASSOC RES OTO, V3, P140, DOI 10.1007/s101620020029; Davis RR, 2001, HEARING RES, V155, P82, DOI 10.1016/S0378-5955(01)00250-7; Erway LC, 1996, HEARING RES, V93, P181, DOI 10.1016/0378-5955(95)00226-X; Fettiplace R, 1999, ANNU REV PHYSIOL, V61, P809, DOI 10.1146/annurev.physiol.61.1.809; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; Hafidi A, 2005, NEUROSCIENCE, V130, P475, DOI 10.1016/j.neuroscience.2004.09.038; Helyer RJ, 2005, AUDIOL NEURO-OTOL, V10, P22, DOI 10.1159/000081545; Henderson D, 2006, EAR HEARING, V27, P1, DOI 10.1097/01.aud.0000191942.36672.f3; Hildebrand MS, 2005, HEARING RES, V200, P102, DOI 10.1016/j.heares.2004.08.018; Hu H, 2001, J NEUROSCI, V21, P9585, DOI 10.1523/JNEUROSCI.21-24-09585.2001; Jimenez AM, 1999, HEARING RES, V138, P91, DOI 10.1016/S0378-5955(99)00154-9; Jimenez AM, 2001, JARO, V2, P233; Johnson KR, 1997, HEARING RES, V114, P83, DOI 10.1016/S0378-5955(97)00155-X; Kimitsuki T, 2003, HEARING RES, V180, P85, DOI 10.1016/S0378-5955(03)00109-6; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KROS CJ, 1990, J PHYSIOL-LONDON, V421, P263, DOI 10.1113/jphysiol.1990.sp017944; Kros CJ, 1998, NATURE, V394, P281, DOI 10.1038/28401; Kros CJ, 1996, COCHLEA, P318; Langer P, 2003, J COMP NEUROL, V455, P198, DOI 10.1002/cne.10471; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; Marcotti W, 2004, J PHYSIOL-LONDON, V557, P613, DOI 10.1113/jphysiol.2003.060137; Marcotti W, 2003, J PHYSIOL-LONDON, V548, P383, DOI 10.1113/jphysiol.2002.034801; MARTIN GK, 2001, ASS RES OTOLARYNGOLO; Meera P, 2000, P NATL ACAD SCI USA, V97, P5562, DOI 10.1073/pnas.100118597; Meredith AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200; Meredith AL, 2006, NAT NEUROSCI, V9, P1041, DOI 10.1038/nn1740; Morris KA, 2005, JARO-J ASSOC RES OTO, V6, P75, DOI 10.1007/s10162-004-5046-x; Muller M, 2005, HEARING RES, V202, P63, DOI 10.1016/j.heares.2004.08.011; Nelson AB, 2003, NEURON, V40, P609, DOI 10.1016/S0896-6273(03)00641-X; Nenov AP, 1996, HEARING RES, V101, P149, DOI 10.1016/S0378-5955(96)00143-8; Oliver D, 2006, J NEUROSCI, V26, P6181, DOI 10.1523/JNEUROSCI.1047-06.2006; Oliver D, 2003, J NEUROSCI, V23, P2141; Pattillo JM, 2001, NEUROSCIENCE, V102, P229, DOI 10.1016/S0306-4522(00)00453-X; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; Pyott SJ, 2004, J NEUROSCI, V24, P9469, DOI 10.1523/JNEUROSCI.3162-04.2004; Ramanathan K, 1999, SCIENCE, V283, P215, DOI 10.1126/science.283.5399.215; Remillard CV, 2004, AM J PHYSIOL-LUNG C, V286, pL49, DOI 10.1152/ajplung.00041.2003; Rusch A, 2001, J NEUROSCI, V21, P9792, DOI 10.1523/JNEUROSCI.21-24-09792.2001; Ruttiger L, 2004, P NATL ACAD SCI USA, V101, P12922, DOI 10.1073/pnas.0402660101; Sausbier M, 2005, CIRCULATION, V112, P60, DOI 10.1161/01.CIR.0000156448.74296.FE; Shao LR, 1999, J PHYSIOL-LONDON, V521, P135, DOI 10.1111/j.1469-7793.1999.00135.x; SHEN KZ, 1994, PFLUG ARCH EUR J PHY, V426, P440, DOI 10.1007/BF00388308; Simmler MC, 2000, NAT GENET, V24, P139, DOI 10.1038/72793; Skinner LJ, 2003, J NEUROPHYSIOL, V90, P320, DOI 10.1152/jn.01155.2002; SOLARO CR, 1995, J NEUROSCI, V15, P6110; Tang XD, 2001, J GEN PHYSIOL, V117, P253, DOI 10.1085/jgp.117.3.253; Thurm H, 2005, J PHYSIOL-LONDON, V569, P137, DOI 10.1113/jphysiol.2005.094680; Uebele VN, 2000, J BIOL CHEM, V275, P23211, DOI 10.1074/jbc.M910187199; Van De Water TR, 2004, OTOL NEUROTOL, V25, P627, DOI 10.1097/00129492-200407000-00035; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; von Kriegstein K, 1999, EUR J NEUROSCI, V11, P1335, DOI 10.1046/j.1460-9568.1999.00542.x; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Wang Y, 2002, JARO, V3, P248, DOI 10.1007/s101620020028; Werner ME, 2005, J PHYSIOL-LONDON, V567, P545, DOI 10.1113/jphysiol.2005.093823; Xia XM, 1999, J NEUROSCI, V19, P5255, DOI 10.1523/jneurosci.19-13-05255.1999; Yu SP, 2003, PROG NEUROBIOL, V70, P363, DOI 10.1016/S0301-0082(03)00090-X; Zheng JL, 1997, J NEUROSCI, V17, P8270; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9	65	65	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3312	3324		10.1074/jbc.M608726200	http://dx.doi.org/10.1074/jbc.M608726200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135251	hybrid			2022-12-27	WOS:000243793900058
J	Rouhier, N; Kauffmann, B; Tete-Favier, F; Palladino, P; Gans, P; Branlant, G; Jacquot, JP; Boschi-Muller, S				Rouhier, Nicolas; Kauffmann, Brice; Tete-Favier, Frederique; Palladino, Pasquale; Gans, Pierre; Branlant, Guy; Jacquot, Jean-Pierre; Boschi-Muller, Sandrine			Functional and structural aspects of poplar cytosolic and plastidial type A methionine sulfoxide reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-BOUND METHIONINE; ESCHERICHIA-COLI; NEISSERIA-MENINGITIDIS; THIOREDOXIN REDUCTASE; ARABIDOPSIS-THALIANA; CATALYTIC MECHANISM; OXIDATIVE STRESS; POTENTIAL ROLE; PEPTIDE; EXPRESSION	The genome of Populus trichocarpa contains five methionine sulfoxide reductase A genes. Here, both cytosolic (cMsrA) and plastidial (pMsrA) poplar MsrAs were analyzed. The two recombinant enzymes are active in the reduction of methionine sulfoxide with either dithiothreitol or poplar thioredoxin as a reductant. In both enzymes, five cysteines, at positions 46, 81, 100, 196, and 202, are conserved. Biochemical and enzymatic analyses of the cysteine-mutated MsrAs support a catalytic mechanism involving three cysteines at positions 46, 196, and 202. Cys(46) is the catalytic cysteine, and the two C-terminal cysteines, Cys(196) and Cys(202), are implicated in the thioredoxin-dependent recycling mechanism. Inspection of the pMsrA x-ray three-dimensional structure, which has been determined in this study, strongly suggests that contrary to bacterial and Bos taurus MsrAs, which also contain three essential Cys, the last C-terminal Cys(202), but not Cys(196), is the first recycling cysteine that forms a disulfide bond with the catalytic Cys(46). Then Cys(202) forms a disulfide bond with the second recycling cysteine Cys(196) that is preferentially reduced by thioredoxin. In agreement with this assumption, Cys(202) is located closer to Cys(46) compared with Cys(196) and is included in a (202)CYG(204) signature specific for most plant MsrAs. The tyrosine residue corresponds to the one described to be involved in substrate binding in bacterial and B. taurus MsrAs. In these MsrAs, the tyrosine residue belongs to a similar signature as found in plant MsrAs but with the first C-terminal cysteine instead of the last C-terminal cysteine.	Nancy Univ, UMR 1136, INRA,Fac Sci & Tech, UHP,IFR 110, F-54506 Vandoeuvre Les Nancy, France; Nancy Univ, UMR 7036,Fac Sci & Tech, CNRS,Grp Biocristallog, UHP,LCM3B, F-54506 Vandoeuvre Les Nancy, France; UJF Jean Pierre Ebel, CNRS, CEA, Lab Resonance Magnet Nucl,Inst Biol Struct, F-38027 Grenoble 1, France; Nancy Univ, UMR 7567,Fac Sci & Tech, CNRS,Grp Enzymol Mol, UHP,Lab MAEM, F-54506 Vandoeuvre Les Nancy, France	INRAE; Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Universite de Lorraine; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Rouhier, N (corresponding author), Nancy Univ, UMR 1136, INRA,Fac Sci & Tech, UHP,IFR 110, BP 239, F-54506 Vandoeuvre Les Nancy, France.	nrouhier@scbiol.uhp-nancy.fr	Palladino, Pasquale/G-3749-2012; Jacquot, Jean-Pierre/A-1571-2012; Palladino, Pasquale/AAC-9967-2019; Favier, Frederique/B-3090-2013; Kauffmann, Brice/L-6029-2015	Palladino, Pasquale/0000-0002-3869-5085; Jacquot, Jean-Pierre/0000-0003-4975-8587; Palladino, Pasquale/0000-0002-3869-5085; Favier, Frederique/0000-0003-3249-997X; Kauffmann, Brice/0000-0002-2932-3255; Boschi, Sandrine/0000-0001-8962-4749; Rouhier, Nicolas/0000-0002-2036-7884				Antoine M, 2003, J BIOL CHEM, V278, P45352, DOI 10.1074/jbc.M307471200; Bechtold U, 2004, PLANT CELL, V16, P908, DOI 10.1105/tpc.015818; Behm M, 2000, PLANT PHYSIOL BIOCH, V38, P363, DOI 10.1016/S0981-9428(00)00760-9; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; Boschi-Muller S, 2005, BBA-PROTEINS PROTEOM, V1703, P231, DOI 10.1016/j.bbapap.2004.09.016; Boschi-Muller S, 2001, PROTEIN SCI, V10, P2272, DOI 10.1110/ps.10701; BROT N, 1981, P NATL ACAD SCI-BIOL, V78, P2155, DOI 10.1073/pnas.78.4.2155; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dos Santos CV, 2005, PLANT PHYSIOL, V138, P909, DOI 10.1104/pp.105.062430; Gao J, 1998, BIOPHYS J, V74, P1115, DOI 10.1016/S0006-3495(98)77830-0; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; Gustavsson N, 2002, PLANT J, V29, P545, DOI 10.1046/j.1365-313X.2002.029005545.x; HARNDAHL U, 2001, BIOCHIM BIOPHYS ACTA, V1545, P27; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; In O, 2005, PLANTA, V220, P941, DOI 10.1007/s00425-004-1410-7; Jacquot JP, 1997, FEBS LETT, V400, P293, DOI 10.1016/S0014-5793(96)01407-X; JACQUOT JP, 1994, J MOL BIOL, V235, P1357, DOI 10.1006/jmbi.1994.1091; Kauffmann B, 2005, BBA-PROTEINS PROTEOM, V1703, P249, DOI 10.1016/j.bbapap.2004.09.008; Khor HK, 2004, J BIOL CHEM, V279, P19486, DOI 10.1074/jbc.M310045200; Kumar RA, 2002, J BIOL CHEM, V277, P37527, DOI 10.1074/jbc.M203496200; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Lowther WT, 2000, BIOCHEMISTRY-US, V39, P13307, DOI 10.1021/bi0020269; Lowther WT, 2002, NAT STRUCT BIOL, V9, P348, DOI 10.1038/nsb783; Olry A, 2002, J BIOL CHEM, V277, P12016, DOI 10.1074/jbc.M112350200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Romero HM, 2004, PLANT PHYSIOL, V136, P3784, DOI 10.1104/pp.104.046656; Sadanandom A, 1996, PLANT J, V10, P235, DOI 10.1046/j.1365-313X.1996.10020235.x; Sadanandom A, 2000, PLANT PHYSIOL, V123, P255, DOI 10.1104/pp.123.1.255; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; Sun HY, 1999, BIOCHEMISTRY-US, V38, P105, DOI 10.1021/bi981295k; Taggart C, 2000, J BIOL CHEM, V275, P27258; Taylor AB, 2003, J BACTERIOL, V185, P4119, DOI 10.1128/JB.185.14.4119-4126.2003; Tete-Favier F, 2000, STRUCTURE, V8, P1167, DOI 10.1016/S0969-2126(00)00526-8; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G	37	55	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3367	3378		10.1074/jbc.M605007200	http://dx.doi.org/10.1074/jbc.M605007200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135266	hybrid, Green Published			2022-12-27	WOS:000243793900063
J	Watson, AA; Brown, J; Harlos, K; Eble, JA; Walter, TS; O'Callaghan, CA				Watson, Aleksandra A.; Brown, James; Harlos, Karl; Eble, Johannes A.; Walter, Thomas S.; O'Callaghan, Christopher A.			The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE-LECTIN; ALPHA(2)BETA(1) INTEGRIN; LIGAND RECOGNITION; MOLECULAR GRAPHICS; GLYCOPROTEIN IB; NKG2D; RHODOCYTIN; PROGRAM; CELLS; MODEL	The human C-type lectin-like molecule CLEC-2 is expressed on the surface of platelets and signaling through CLEC-2 causes platelet activation and aggregation. CLEC-2 is a receptor for the platelet-aggregating snake venom protein rhodocytin. It is also a newly identified co-receptor for human immunodeficiency virus type 1 (HIV-1). An endogenous ligand has not yet been identified. We have solved the crystal structure of the extracellular domain of CLEC-2 to 1.6-angstrom-resolution, and identified the key structural features involved in ligand binding. A semi-helical loop region and flanking residues dominate the surface that is available for ligand binding. The precise distribution of hydrophobic and electrostatic features in this loop will determine the nature of any endogenous ligand with which it can interact. Major ligand-induced conformational change in CLEC-2 is unlikely as its overall fold is compact and robust. However, ligand binding could induce a tilt of a 3-10 helical portion of the long loop region. Mutational analysis and surface plasmon resonance binding studies support these observations. This study provides a framework for understanding the effects of rhodocytin venom binding on CLEC-2 and for understanding the nature of likely endogenous ligands and will provide a basis for rational design of drugs to block ligand binding.	Univ Oxford, Oxford OX3 7BN, England; Univ Oxford, Div Struct Biol, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, Div Struct Biol, Oxford Prot Prod Facil, Oxford OX3 7BN, England; Munster Univ Hosp, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Munster	O'Callaghan, CA (corresponding author), Univ Oxford, Henry Wellcome Bldg Mol Physiol,Roosevelt Dr, Oxford OX3 7BN, England.	chrisoc@ccmp.ox.ac.uk	Walter, Thomas S/S-5104-2019; Walter, Thomas/S-8636-2017	Walter, Thomas S/0000-0002-0030-7235; Walter, Thomas/0000-0002-0030-7235	MRC [G0500365, G116/165] Funding Source: UKRI; Medical Research Council [G0500365, G116/165] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adachi Y, 2004, INFECT IMMUN, V72, P4159, DOI 10.1128/IAI.72.7.4159-4171.2004; Barrett CP, 2004, ACTA CRYSTALLOGR D, V60, P2280, DOI 10.1107/S0907444904019171; Bergmeier W, 2001, J BIOL CHEM, V276, P25121, DOI 10.1074/jbc.M103892200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chaipan C, 2006, J VIROL, V80, P8951, DOI 10.1128/JVI.00136-06; Claude JB, 2004, NUCLEIC ACIDS RES, V32, pW606, DOI 10.1093/nar/gkh400; Colonna M, 2000, EUR J IMMUNOL, V30, P697; Comeau SR, 2004, BIOINFORMATICS, V20, P45, DOI 10.1093/bioinformatics/btg371; Dam J, 2003, NAT IMMUNOL, V4, P1213, DOI 10.1038/ni1006; Dodson E, 1996, ACTA CRYSTALLOGR D, V52, P228, DOI 10.1107/S0907444995010638; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kantardjieff KA, 2003, PROTEIN SCI, V12, P1865, DOI 10.1110/ps.0350503; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McFarland BJ, 2003, IMMUNITY, V19, P803, DOI 10.1016/S1074-7613(03)00320-0; McFarland BJ, 2003, STRUCTURE, V11, P411, DOI 10.1016/S0969-2126(03)00047-9; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Natarajan K, 2000, BIOCHEMISTRY-US, V39, P14779, DOI 10.1021/bi0018180; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Callaghan CA, 2003, STRUCTURE, V11, P360, DOI 10.1016/S0969-2126(03)00055-8; O'Callaghan CA, 2001, IMMUNITY, V15, P201, DOI 10.1016/S1074-7613(01)00187-X; Ohki I, 2005, STRUCTURE, V13, P905, DOI 10.1016/j.str.2005.03.016; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Radaev S, 2002, J IMMUNOL, V169, P6279, DOI 10.4049/jimmunol.169.11.6279; Radaev S, 2001, IMMUNITY, V15, P1039, DOI 10.1016/S1074-7613(01)00241-2; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shin Y, 1998, BIOCHEM BIOPH RES CO, V245, P741, DOI 10.1006/bbrc.1998.8516; Sobanov Y, 2001, EUR J IMMUNOL, V31, P3493, DOI 10.1002/1521-4141(200112)31:12<3493::AID-IMMU3493>3.0.CO;2-9; Suzuki-Inoue K, 2006, BLOOD, V107, P542, DOI 10.1182/blood-2005-05-1994; Suzuki-Inoue K, 2001, J BIOL CHEM, V276, P1643, DOI 10.1074/jbc.M006191200; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Watson AA, 2005, ACTA CRYSTALLOGR F, V61, P1094, DOI 10.1107/S1744309105037991; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Zelensky AN, 2003, PROTEINS, V52, P466, DOI 10.1002/prot.10626; 1999, SE ASIAN J TROP M S1, V30, P1	46	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3165	3172		10.1074/jbc.M610383200	http://dx.doi.org/10.1074/jbc.M610383200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17132623	hybrid			2022-12-27	WOS:000243793900042
J	Pelegrin, P; Surprenant, A				Pelegrin, Pablo; Surprenant, Annmarie			Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1 beta release through a dye uptake-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P2X(7) RECEPTOR; PERMEABILITY; ACTIVATION; SECRETION; CHANNEL; FAMILY; PORE; IL-1	Pannexin-1 is a recently identified membrane protein that can act as a nonselective pore permeable to dyes such as ethidium when ectopically expressed. Blockade of pannexin-1 in macrophage endogenously expressing the ATP-gated P2X(7) receptor (P2X(7)R) blocks the initial dye uptake, but not the ionic current, and also blocks processing and release of interleukin-1 beta (IL-1 beta) in response to P2X(7)R activation. These results suggest that pannexin-1 may be a hemichannel activated by the P2X(7)R to provide the conduit for dye uptake and downstream signaling to processing and release of IL-1 beta. We have pursued this hypothesis by measuring dye uptake and IL-1 beta processing and release in mouse J774 macrophage in response to P2X(7)R activation and to maitotoxin and nigericin, two agents considered to evoke IL-1 beta release via the same mechanism. The experiments were carried out over time periods during which no lactate dehydrogenase was released from cells to examine only noncytolytic pathways. P2X(7)R activation evoked dye uptake that could be separated into two components by pannexin-1 inhibition: an initial rapid phase and a slower pannexin-1-independent phase. Maitotoxin-evoked dye uptake was unaltered by pannexin-1 inhibition. Nigericin did not induce dye uptake. Inhibition of pannexin-1 blocked caspase-1 and IL-1 beta processing and release in response to all three stimuli. Thus, although pannexin-1 is required for IL-1 beta release in response to maitotoxin, nigericin, and ATP, a mechanism distinct from pannexin-1 hemichannel activation must underlie the former two processes.	Univ Sheffield, Western Bank, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Surprenant, A (corresponding author), Univ Sheffield, Western Bank, Dept Biomed Sci, Addison Bldg, Sheffield S10 2TN, S Yorkshire, England.	a.surprenant@shef.ac.uk	Pelegrin, Pablo/M-2007-2014	Pelegrin, Pablo/0000-0002-9688-1804	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bao L, 2004, FEBS LETT, V572, P65, DOI 10.1016/j.febslet.2004.07.009; Baraldi PG, 2004, CURR TOP MED CHEM, V4, P1707, DOI 10.2174/1568026043387223; Baranova A, 2004, GENOMICS, V83, P706, DOI 10.1016/j.ygeno.2003.09.025; Bruzzone R, 2005, J NEUROCHEM, V92, P1033, DOI 10.1111/j.1471-4159.2004.02947.x; Bruzzone R, 2003, P NATL ACAD SCI USA, V100, P13644, DOI 10.1073/pnas.2233464100; Chaytor AT, 1998, J PHYSIOL-LONDON, V508, P561, DOI 10.1111/j.1469-7793.1998.561bq.x; Dhein S, 2004, CARDIOVASC RES, V62, P287, DOI 10.1016/j.cardiores.2004.01.019; Dinarello CA, 2005, J EXP MED, V201, P1355, DOI 10.1084/jem.20050640; Estacion M, 2001, BMC Physiol, V1, P2, DOI 10.1186/1472-6793-1-2; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Gudipaty L, 2003, AM J PHYSIOL-CELL PH, V285, pC286, DOI 10.1152/ajpcell.00070.2003; Hult M, 1998, FEBS LETT, V441, P25, DOI 10.1016/S0014-5793(98)01515-4; Jiang LH, 2005, AM J PHYSIOL-CELL PH, V289, pC1295, DOI 10.1152/ajpcell.00253.2005; Kahlenberg JM, 2004, AM J PHYSIOL-CELL PH, V286, pC1100, DOI 10.1152/ajpcell.00494.2003; la Sala A, 2003, J LEUKOCYTE BIOL, V73, P339, DOI 10.1189/jlb.0802418; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Martinez-Francois JR, 2002, J PHYSIOL-LONDON, V538, P79, DOI 10.1113/jphysiol.2001.013036; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC755, DOI 10.1152/ajpcell.1999.277.4.C755; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC766, DOI 10.1152/ajpcell.1999.277.4.C766; Vanden Abeele F, 2006, J CELL BIOL, V174, P535, DOI 10.1083/jcb.200601115; Verhoef PA, 2004, MOL PHARMACOL, V66, P909, DOI 10.1124/mol.66.4.909; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Warny M, 1999, AM J PHYSIOL-CELL PH, V276, pC717, DOI 10.1152/ajpcell.1999.276.3.C717; Watanabe N, 1998, CYTOKINE, V10, P645, DOI 10.1006/cyto.1998.0341	29	251	260	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2386	2394		10.1074/jbc.M610351200	http://dx.doi.org/10.1074/jbc.M610351200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121814	hybrid			2022-12-27	WOS:000243593200030
J	Trasak, C; Zenner, G; Vogel, A; Yuksekdag, G; Rost, R; Haase, I; Fischer, M; Israel, L; Imhof, A; Linder, S; Schleicher, M; Aepfelbacher, M				Trasak, Claudia; Zenner, Gerhardt; Vogel, Annette; Yueksekdag, Guelnihal; Rost, Rene; Haase, Ilka; Fischer, Markus; Israel, Lars; Imhof, Axel; Linder, Stefan; Schleicher, Michael; Aepfelbacher, Martin			Yersinia protein kinase YopO is activated by a novel G-actin binding process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SER/THR KINASE; F-ACTIN; VIRULENCE; ENTEROCOLITICA; POLYMERIZATION; DYNAMICS; EFFECTOR; MOTILITY; GTPASES; SYSTEM	Pathogenic bacteria of the genus Yersinia employ a type III secretion system to inject effector proteins (Yops) into host cells. The Yops down-regulate host cell functions through unique biochemical activities. YopO, a serine/threonine kinase required for Yersinia virulence, is activated by host cell actin via an unknown process. Here we show that YopO kinase is activated by formation of a 1:1 complex with monomeric (G) actin but is unresponsive to filamentous (F) actin. Two separate G-actin binding sites, one in the N-terminal kinase region (amino acids 89 - 440) and one in the C-terminal guanine nucleotide dissociation inhibitor-like region (amino acids 441 - 729) of YopO, were identified. Actin binding to both of these sites was necessary for effective autophosphorylation of YopO on amino acids Ser-90 and Ser-95. A S90A/S95A YopO mutant was strongly reduced in substrate phosphorylation, suggesting that autophosphorylation activates YopO kinase activity. In cells the kinase activity of YopO regulated rounding/arborization and was specifically required for inhibition of Yersinia YadA-dependent phagocytosis. Thus, YopO kinase is activated by a novel G-actin binding process, and this appears to be crucial for its anti-host cell functions.	Univ Klinikum Eppendorf, Inst Med Mikrobiol Virol & Hyg, D-20246 Hamburg, Germany; Univ Munich, Adolf Butenandt Inst Zellbiol, D-80336 Munich, Germany; Univ Munich, Max Von Pettenkofer Inst Med Microbiol, D-80336 Munich, Germany; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Munich, Prot Labor, D-80336 Munich, Germany; Univ Munich, Inst Prophylaxe Kreislaufkrankheiten, D-80336 Munich, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Munich; Technical University of Munich; University of Munich; University of Munich	Aepfelbacher, M (corresponding author), Univ Klinikum Eppendorf, Inst Med Mikrobiol Virol & Hyg, Martinistr 52, D-20246 Hamburg, Germany.	m.aepfelbacher@uke.uni-hamburg.de	Fischer, Markus/AFT-1856-2022; Imhof, Axel/AAU-5313-2021; Fischer, Markus J./G-9477-2012	Fischer, Markus/0000-0001-7243-4199; Imhof, Axel/0000-0003-2993-8249; Rost, Rene/0000-0002-5393-0370				Aepfelbacher M, 2001, INT J MED MICROBIOL, V291, P269, DOI 10.1078/1438-4221-00130; Barz C, 2000, FEBS LETT, V482, P139, DOI 10.1016/S0014-5793(00)02045-7; Bonaldi T, 2004, PROTEOMICS, V4, P1382, DOI 10.1002/pmic.200300743; Braun V, 2004, EMBO J, V23, P4166, DOI 10.1038/sj.emboj.7600427; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Dukuzumuremyi JM, 2000, J BIOL CHEM, V275, P35281, DOI 10.1074/jbc.M003009200; EICHINGER L, 1991, J CELL BIOL, V112, P665, DOI 10.1083/jcb.112.4.665; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; Gouin E, 2005, CURR OPIN MICROBIOL, V8, P35, DOI 10.1016/j.mib.2004.12.013; Grosdent N, 2002, INFECT IMMUN, V70, P4165, DOI 10.1128/IAI.70.8.4165-4176.2002; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; HEESEMANN J, 1983, J BACTERIOL, V155, P761, DOI 10.1128/JB.155.2.761-767.1983; Juris SJ, 2000, P NATL ACAD SCI USA, V97, P9431, DOI 10.1073/pnas.170281997; Juris SJ, 2006, FEBS LETT, V580, P179, DOI 10.1016/j.febslet.2005.11.071; Juris SJ, 2002, CELL MICROBIOL, V4, P201, DOI 10.1046/j.1462-5822.2002.00182.x; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Letzelter M, 2006, EMBO J, V25, P3223, DOI 10.1038/sj.emboj.7601202; Merrifield CJ, 2004, TRENDS CELL BIOL, V14, P352, DOI 10.1016/j.tcb.2004.05.008; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Philimonenko VV, 2004, NAT CELL BIOL, V6, P1165, DOI 10.1038/ncb1190; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Prehna G, 2006, CELL, V126, P869, DOI 10.1016/j.cell.2006.06.056; ROGGENKAMP A, 1995, MOL MICROBIOL, V16, P1207, DOI 10.1111/j.1365-2958.1995.tb02343.x; Shao F, 2002, CELL, V109, P575, DOI 10.1016/S0092-8674(02)00766-3; Soares L, 2004, NAT IMMUNOL, V5, P45, DOI 10.1038/ni1017; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Viboud GI, 2001, EMBO J, V20, P5373, DOI 10.1093/emboj/20.19.5373; Visa N, 2005, EMBO REP, V6, P218, DOI 10.1038/sj.embor.7400362; von Pawel-Rammingen U, 2000, MOL MICROBIOL, V36, P737, DOI 10.1046/j.1365-2958.2000.01898.x; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; Wiedemann A, 2001, CELL MICROBIOL, V3, P693, DOI 10.1046/j.1462-5822.2001.00149.x; Wiley DJ, 2006, MICROB PATHOGENESIS, V40, P234, DOI 10.1016/j.micpath.2006.02.001; Winder SJ, 2005, J CELL SCI, V118, P651, DOI 10.1242/jcs.01670; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Zumbihl R, 1999, J BIOL CHEM, V274, P29289, DOI 10.1074/jbc.274.41.29289	37	45	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2268	2277		10.1074/jbc.M610071200	http://dx.doi.org/10.1074/jbc.M610071200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121817	hybrid			2022-12-27	WOS:000243593200018
J	Tremblay, LO; Kovacs, EN; Daniels, E; Wong, NK; Sutton-Smith, M; Morris, HR; Dell, A; Marcinkiewicz, E; Seidah, NG; McKerlie, C; Herscovics, A				Tremblay, Linda O.; Kovacs, Erzsebet Nagy; Daniels, Eugene; Wong, Nyet Kui; Sutton-Smith, Mark; Morris, Howard R.; Dell, Anne; Marcinkiewicz, Edwige; Seidah, Nabil G.; McKerlie, Colin; Herscovics, Annette			Respiratory distress and neonatal lethality in mice lacking Golgi alpha 1,2-mannosidase IB involved in N-glycan maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ALPHA-MANNOSIDASE-II; ENDOPLASMIC-RETICULUM; LUNG DEVELOPMENT; MOLECULAR-BASIS; SACCHAROMYCES-CEREVISIAE; CONGENITAL DISORDERS; GENETIC-CONTROL; IN-VIVO; GLYCOSYLATION	There are three mammalian Golgi alpha 1,2-mannosidases, encoded by different genes, that form Man(5)GlcNAc(2) from Man(8-9)GlcNAc(2) for the biosynthesis of hybrid and complex N-glycans. Northern blot analysis and in situ hybridization indicate that the three paralogs display distinct developmental and tissue-specific expression. The physiological role of Golgi alpha 1,2-mannosidase IB was investigated by targeted gene ablation. The null mice have normal gross appearance at birth, but they display respiratory distress and die within a few hours. Histology of fetal lungs the day before birth indicate some delay in development, whereas neonatal lungs show extensive pulmonary hemorrhage in the alveolar region. No significant histopathological changes occur in other tissues. No remarkable ultrastructural differences are detected between wild type and null lungs. The membranes of a subset of bronchiolar epithelial cells are stained with lectins from Phaseolus vulgaris (leukoagglutinin and erythroagglutinin) and Datura stramonium in wild type lungs, but this staining disappears in lungs from null mice. Mass spectrometry of N-glycans from different tissues shows no significant changes in global N-glycans of null mice. Therefore, only a few glycoproteins required for normal lung function depend on alpha 1,2-mannosidase IB for maturation. There are no apparent differences in the expression of several lung epithelial cell and endothelial cell markers between null and wild type mice. The alpha 1,2-mannosidase IB null phenotype differs from phenotypes caused by ablation of other enzymes in N-glycan biosynthesis and from other mouse gene disruptions that affect pulmonary development and function.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3G 1Y6, Canada; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England; Clin Res Inst Montreal, Lab Biochem Neuroendocrinol, Montreal, PQ H2W 1R7, Canada; Univ Toronto, Hosp Sick Children, Program Lung Biol Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada	McGill University; McGill University; Imperial College London; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Herscovics, A (corresponding author), 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	annette.herscovics@mcgill.ca	Wong, Nyet-Kui/E-6927-2010; Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; McKerlie, Colin/0000-0002-2232-0967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akama TO, 2002, SCIENCE, V295, P124, DOI 10.1126/science.1065570; Akama TO, 2006, P NATL ACAD SCI USA, V103, P8983, DOI 10.1073/pnas.0603248103; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BERGER TM, 2000, J PERINATOL, V5, P295; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; Cardoso WV, 2000, DEV DYNAM, V219, P121, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1053>3.3.CO;2-8; Chui D, 1997, CELL, V90, P157, DOI 10.1016/S0092-8674(00)80322-0; Chui D, 2001, P NATL ACAD SCI USA, V98, P1142, DOI 10.1073/pnas.98.3.1142; COLE VA, 1973, PEDIATRICS, V51, P175; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; deMello Daphne E, 2004, Semin Neonatol, V9, P311, DOI 10.1016/j.siny.2003.12.001; Dyke NC, 1997, GENOMICS, V41, P155, DOI 10.1006/geno.1997.4663; Essalmani R, 2006, MOL CELL BIOL, V26, P354, DOI 10.1128/MCB.26.1.354-361.2006; Freeze HH, 2005, CURR OPIN STRUC BIOL, V15, P490, DOI 10.1016/j.sbi.2005.08.010; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Hato M, 2006, MOL CELL PROTEOMICS, V5, P2146, DOI 10.1074/mcp.M600213-MCP200; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; Herscovics A, 2001, BIOCHIMIE, V83, P757, DOI 10.1016/S0300-9084(01)01319-0; Hogan B, 1994, MANIPULATING MOUSE E; Igdoura SA, 1999, EUR J CELL BIOL, V78, P441, DOI 10.1016/S0171-9335(99)80071-5; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; Ioffe E, 1996, P NATL ACAD SCI USA, V93, P11041, DOI 10.1073/pnas.93.20.11041; Jaeken J, 2004, CURR OPIN PEDIATR, V16, P434, DOI 10.1097/01.mop.0000133636.56790.4a; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; LAL A, 1994, J BIOL CHEM, V269, P9872; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; LIPARI F, 1995, BIOCHEM BIOPH RES CO, V209, P322, DOI 10.1006/bbrc.1995.1506; Lobsanov YD, 2002, J BIOL CHEM, V277, P5620, DOI 10.1074/jbc.M110243200; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; Ohtsubo K, 2005, CELL, V123, P1307, DOI 10.1016/j.cell.2005.09.041; Priatel JJ, 1997, GLYCOBIOLOGY, V7, P45, DOI 10.1093/glycob/7.1.45; Rezkalla M A, 1995, S D J Med, V48, P79; Roth-Kleiner M, 2003, BIOL NEONATE, V84, P83, DOI 10.1159/000071009; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; Sutton-Smith M, 2000, TETRAHEDRON-ASYMMETR, V11, P363, DOI 10.1016/S0957-4166(99)00581-9; Tempel W, 2004, J BIOL CHEM, V279, P29774, DOI 10.1074/jbc.M403065200; Tremblay LO, 2000, J BIOL CHEM, V275, P31655, DOI 10.1074/jbc.M004935200; Tremblay LO, 1998, GLYCOBIOLOGY, V8, P585, DOI 10.1093/glycob/8.6.585; Tremblay LO, 1999, GLYCOBIOLOGY, V9, P1073, DOI 10.1093/glycob/9.10.1073; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; WASSERMAN PM, 1993, METHODS ENZYMOLOGY G, V225; Wong NK, 2003, J BIOL CHEM, V278, P28619, DOI 10.1074/jbc.M302741200	47	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2558	2566		10.1074/jbc.M608661200	http://dx.doi.org/10.1074/jbc.M608661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121831	hybrid			2022-12-27	WOS:000243593200048
J	Poon, DKY; Withers, SG; McIntosh, LP				Poon, David K. Y.; Withers, Stephen G.; McIntosh, Lawrence P.			Direct demonstration of the flexibility of the glycosylated proline-threonine linker in the Cellulomonas fimi xylanase Cex through NMR spectroscopic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; STREPTOMYCES-LIVIDANS GLYCOSYLATES; CARBOHYDRATE-BINDING MODULES; RESIDUAL DIPOLAR COUPLINGS; OVINE SUBMAXILLARY MUCIN; CELLOBIOHYDROLASE-I; TRICHODERMA-REESEI; ESCHERICHIA-COLI; FUNCTIONAL DOMAINS; CONFORMATIONAL FLEXIBILITY	The modular xylanase Cex ( or CfXyn10A) from Cellulomonas fimi consists of an N-terminal catalytic domain and a C-terminal cellulose- binding domain, joined by a glycosylated proline-threonine ( PT) linker. To characterize the conformation and dynamics of the Cex linker and the consequences of its modification, we have used NMR spectroscopy to study full-length Cex in its nonglycosylated ( similar to 47 kDa) and glycosylated ( similar to 51 kDa) forms. The PT linker lacks any predominant structure in either form as indicated by random coil amide chemical shifts. Furthermore, heteronuclear H-1-N-15 nuclear Overhauser effect relaxation measurements demonstrate that the linker is flexible on the ns-to-ps time scale and that glycosylation partially dampens this flexibility. The catalytic and cellulose- binding domains also exhibit identical amide chemical shifts whether in isolation or in the context of either unmodified or glycosylated full-length Cex. Therefore, there are no noncovalent interactions between the two domains of Cex or between either domain and the linker. This conclusion is supported by the distinct N-15 relaxation properties of the two domains, as well as their differential alignment within a magnetic field by Pf1 phage particles. These data demonstrate that the PT linker is a flexible tether, joining the structurally independent catalytic and cellulose-binding domains of Cex in an ensemble of conformations; however, more extended forms may predominate because of restrictions imparted by the alternating proline residues. This supports the postulate that the binding-domain anchors Cex to the surface of cellulose, whereas the linker provides flexibility for the catalytic domain to hydrolyze nearby hemicellulose ( xylan) chains.	Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Prot Engn Network Ctr Excellence, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	McIntosh, LP (corresponding author), Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintosh@chem.ubc.ca						ABUJA PM, 1988, EUR BIOPHYS J BIOPHY, V15, P339, DOI 10.1007/BF00254721; ABUJA PM, 1988, BIOCHEM BIOPH RES CO, V156, P180, DOI 10.1016/S0006-291X(88)80821-0; ARGOS P, 1990, J MOL BIOL, V211, P943, DOI 10.1016/0022-2836(90)90085-Z; BEGUIN P, 1994, FEMS MICROBIOL REV, V13, P25, DOI 10.1016/0168-6445(94)90099-X; BHANDARI DG, 1986, EUR J BIOCHEM, V160, P349, DOI 10.1111/j.1432-1033.1986.tb09978.x; Black GW, 1996, BIOCHEM J, V319, P515, DOI 10.1042/bj3190515; Black GW, 1997, J BIOTECHNOL, V57, P59, DOI 10.1016/S0168-1656(97)00089-8; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Braddock DT, 2001, J AM CHEM SOC, V123, P8634, DOI 10.1021/ja016234f; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; COUTINHO JB, 1993, FEMS MICROBIOL LETT, V113, P211, DOI 10.1111/j.1574-6968.1993.tb06516.x; Coutinho PM, 1999, ROY SOC CH, P3; Creagh AL, 1996, P NATL ACAD SCI USA, V93, P12229, DOI 10.1073/pnas.93.22.12229; Daragan VA, 1997, PROG NUCL MAG RES SP, V31, P63, DOI 10.1016/S0079-6565(97)00006-X; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dosset P, 2001, J BIOMOL NMR, V20, P223, DOI 10.1023/A:1011206132740; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fujimoto Z, 2000, J MOL BIOL, V300, P575, DOI 10.1006/jmbi.2000.3877; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; George RA, 2002, PROTEIN ENG, V15, P871, DOI 10.1093/protein/15.11.871; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; GILBERT HJ, 1993, J GEN MICROBIOL, V139, P187, DOI 10.1099/00221287-139-2-187; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GILKES NR, 1993, INT J BIOL MACROMOL, V15, P347, DOI 10.1016/0141-8130(93)90052-N; GILKES NR, 1988, J BIOL CHEM, V263, P10401; Goddard T. D., 1999, SPARKY 3; GRAHAM RW, 1995, GENE, V158, P51, DOI 10.1016/0378-1119(95)00165-3; HALL J, 1995, BIOCHEM J, V309, P749, DOI 10.1042/bj3090749; Hansen MR, 2000, METHOD ENZYMOL, V317, P220; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Jervis EJ, 1997, J BIOL CHEM, V272, P24016, DOI 10.1074/jbc.272.38.24016; Kanelis V, 2000, J BIOMOL NMR, V16, P253, DOI 10.1023/A:1008355012528; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; LANGSFORD ML, 1987, FEBS LETT, V225, P163, DOI 10.1016/0014-5793(87)81150-X; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MACLEOD AM, 1994, BIOCHEMISTRY-US, V33, P6371, DOI 10.1021/bi00186a042; MACLEOD AM, 1992, GENE, V121, P143, DOI 10.1016/0378-1119(92)90173-M; McLean BW, 2000, PROTEIN ENG, V13, P801, DOI 10.1093/protein/13.11.801; MILLER R, 1995, P 6 INT C BIOT PULP; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Nikolova PV, 1997, BIOCHEMISTRY-US, V36, P1381, DOI 10.1021/bi962367f; ONEILL GP, 1986, GENE, V44, P331, DOI 10.1016/0378-1119(86)90198-8; ONG E, 1993, BIOTECHNOL BIOENG, V42, P401, DOI 10.1002/bit.260420402; ONG E, 1994, J BACTERIOL, V176, P999, DOI 10.1128/JB.176.4.999-1008.1994; Pell G, 2004, J BIOL CHEM, V279, P11777, DOI 10.1074/jbc.M311947200; PILZ I, 1990, BIOCHEM J, V271, P277, DOI 10.1042/bj2710277; POON DKY, 2006, IN PRESS BIOCHEMISTR; RADFORD SE, 1989, J BIOL CHEM, V264, P767; Receveur V, 2002, J BIOL CHEM, V277, P40887, DOI 10.1074/jbc.M205404200; Sakon J, 1997, NAT STRUCT BIOL, V4, P810, DOI 10.1038/nsb1097-810; SHEN H, 1991, J BIOL CHEM, V266, P11335; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; Shoseyov O, 2006, MICROBIOL MOL BIOL R, V70, P283, DOI 10.1128/MMBR.00028-05; Skrynnikov NR, 2000, J BIOMOL NMR, V18, P239, DOI 10.1023/A:1026501101716; SRISODSUK M, 1993, J BIOL CHEM, V268, P20756; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; TOMME P, 1995, J BACTERIOL, V177, P4356, DOI 10.1128/jb.177.15.4356-4363.1995; VANTILBEURGH H, 1986, FEBS LETT, V204, P223, DOI 10.1016/0014-5793(86)80816-X; Violot S, 2005, J MOL BIOL, V348, P1211, DOI 10.1016/j.jmb.2005.03.026; von Ossowski I, 2005, BIOPHYS J, V88, P2823, DOI 10.1529/biophysj.104.050146; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011; Yang DW, 1999, J BIOMOL NMR, V13, P3, DOI 10.1023/A:1008329230975; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	66	53	58	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					2091	2100		10.1074/jbc.M609670200	http://dx.doi.org/10.1074/jbc.M609670200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121820	hybrid			2022-12-27	WOS:000243451300060
J	Harris, TE; Huffman, TA; Chi, A; Shabanowitz, J; Hunt, DF; Kumar, A; Lawrence, JC				Harris, Thurl E.; Huffman, Todd A.; Chi, An; Shabanowitz, Jeffrey; Hunt, Donald F.; Kumar, Anil; Lawrence, John C., Jr.			Insulin controls subcellular localization and multisite phosphorylation of the phosphatidic acid phosphatase, lipin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TARGET; ADIPOSE-TISSUE; PHOSPHOLIPID BIOSYNTHESIS; PROTEIN; PHOSPHOHYDROLASE; RAPAMYCIN; MUTATION; PATHWAY; BINDING; GENE	Brain, liver, kidney, heart, and skeletal muscle from fatty liver dystrophy (fld/fld) mice, which do not express lipin 1 (lipin), contained much less Mg2+-dependent phosphatidic acid phosphatase (PAP) activity than tissues from wild type mice. Lipin harboring the fld(2j) (Gly(84) -> Arg) mutation exhibited relatively little PAP activity. These results indicate that lipin is a major PAP in vivo and that the loss of PAP activity contributes to the fld phenotype. PAP activity was readily detected in immune complexes of lipin from 3T3-L1 adipocytes, where the protein was found both as a microsomal form and a soluble, more highly phosphorylated, form. Fifteen phosphorylation sites were identified by mass spectrometric analyses. Insulin increased the phosphorylation of multiple sites and promoted a gel shift that was due in part to phosphorylation of Ser(106). In contrast, epinephrine and oleic acid promoted dephosphorylation of lipin. The PAP-specific activity of lipin was not affected by the hormones or by dephosphorylation of lipin with protein phosphatase 1. However, the ratio of soluble to microsomal lipin was markedly increased in response to insulin and decreased in response to epinephrine and oleic acid. The results suggest that insulin and epinephrine control lipin primarily by changing localization rather than intrinsic PAP activity.	Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Lawrence, JC (corresponding author), Univ Virginia, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	jcl3p@virginia.edu	Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368	NIDDK NIH HHS [DK28312, DK52753] Funding Source: Medline; NIGMS NIH HHS [GM37573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312, R01DK052753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRINDLEY DN, 1984, PROG LIPID RES, V23, P115, DOI 10.1016/0163-7827(84)90001-8; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Elabbadi N, 2005, BIOCHIMIE, V87, P437, DOI 10.1016/j.biochi.2005.01.003; Elabbadi N, 2002, LIPIDS, V37, P69, DOI 10.1007/s11745-002-0865-7; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; FARESE RV, 1982, J BIOL CHEM, V257, P4042; Finck BN, 2006, CELL METAB, V4, P199, DOI 10.1016/j.cmet.2006.08.005; Han GS, 2006, J BIOL CHEM, V281, P9210, DOI 10.1074/jbc.M600425200; Harris TE, 2006, EMBO J, V25, P1659, DOI 10.1038/sj.emboj.7601047; Harris Thurl E, 2003, Sci STKE, V2003, pre15; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huffman TA, 2002, P NATL ACAD SCI USA, V99, P1047, DOI 10.1073/pnas.022634399; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; LANGNER CA, 1991, J BIOL CHEM, V266, P11955; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Martin SE, 2000, ANAL CHEM, V72, P4266, DOI 10.1021/ac000497v; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; MOLLER F, 1977, BIOCHIM BIOPHYS ACTA, V486, P359, DOI 10.1016/0005-2760(77)90032-7; MOLLER F, 1982, BIOCHIM BIOPHYS ACTA, V711, P521, DOI 10.1016/0005-2760(82)90068-6; O'Hara L, 2006, J BIOL CHEM, V281, P34537, DOI 10.1074/jbc.M606654200; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Phan J, 2004, J BIOL CHEM, V279, P29558, DOI 10.1074/jbc.M403506200; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; PITTNER RA, 1985, BIOCHEM J, V230, P525, DOI 10.1042/bj2300525; Reue K, 1996, J LIPID RES, V37, P1387; Reue K, 2000, J LIPID RES, V41, P1067; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Santos-Rosa H, 2005, EMBO J, V24, P1931, DOI 10.1038/sj.emboj.7600672; Satow R, 2002, BIOCHEM BIOPH RES CO, V295, P85, DOI 10.1016/S0006-291X(02)00641-1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Stace CL, 2006, BBA-MOL CELL BIOL L, V1761, P913, DOI 10.1016/j.bbalip.2006.03.006; Tange Y, 2002, J CELL SCI, V115, P4375, DOI 10.1242/jcs.00135; TAYLOR SJ, 1986, BIOCHEM J, V239, P275, DOI 10.1042/bj2390275; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073	43	168	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					277	286		10.1074/jbc.M609537200	http://dx.doi.org/10.1074/jbc.M609537200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17105729	hybrid			2022-12-27	WOS:000243166500032
J	Oinuma, I; Katoh, H; Negishi, M				Oinuma, Izumi; Katoh, Hironori; Negishi, Manabu			R-Ras controls axon specification upstream of glycogen synthase kinase-3 beta through integrin-linked kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; GTPASE-ACTIVATING PROTEIN; NEURONAL POLARITY; PHOSPHOINOSITIDE 3-KINASE; HIPPOCAMPAL-NEURONS; CELL-MIGRATION; GSK-3-BETA; ESTABLISHMENT; GROWTH; PHOSPHORYLATION	The initial event in establishing a polarized neuron is the specification of a single axon. Spatially regulated glycogen synthase kinase-3 beta (GSK-3 beta) activity is critical for specifying axon-dendrite fate; however, the upstream signaling of GSK-3 beta in the determination of neuronal polarity still remains obscure. Here, we found that, in cultured hippocampal neurons, the small GTPase R-Ras selectively localized in a single neurite of stage 2 neurons and that its activity increased after plating and peaked between stages 2 and 3. Ectopic expression of R-Ras induced global inactivation of GSK-3 beta and formation of multiple axons, whereas knockdown of endogenous R-Ras by RNA interference blocked GSK-3 beta inactivation and axon formation. GSK-3p inactivation and axon formation by R-Ras required integrin-linked kinase (ILK), and subcellular localization of ILK was strictly regulated by R-Ras-mediated phosphatidylinositol 3-kinase activity. In addition, membrane targeting of ILK was sufficient to inactivate GSK-3 beta and to form multiple axons. Our study demonstrates a novel role of R-Ras and ILK upstream of GSK-3 beta in the regulation of neuronal polarity.	Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan.	mnegishi@pharm.kyoto-u.ac.jp		Katoh, Hironori/0000-0002-8191-8117				Bradke F, 1997, NEURON, V19, P1175, DOI 10.1016/S0896-6273(00)80410-9; Bradke F, 2000, CURR OPIN NEUROBIOL, V10, P574, DOI 10.1016/S0959-4388(00)00124-0; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHANDBORN NH, 2006, J CELL SCI, V119, P951; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Esch T, 1999, J NEUROSCI, V19, P6417; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GOSLIN K, 1990, J NEUROSCI, V10, P588; GOSLIN K, 1989, J CELL BIOL, V108, P1507, DOI 10.1083/jcb.108.4.1507; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ishii T, 2003, J BIOL CHEM, V278, P26970, DOI 10.1074/jbc.M304113200; Ivins JK, 2000, J NEUROSCI, V20, P6551, DOI 10.1523/JNEUROSCI.20-17-06551.2000; Jiang H, 2005, NAT NEUROSCI, V8, P544, DOI 10.1038/nn0505-544; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; LEIN PJ, 1992, DEV BRAIN RES, V69, P191, DOI 10.1016/0165-3806(92)90159-T; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Menager C, 2004, J NEUROCHEM, V89, P109, DOI 10.1046/j.1471-4159.2004.02302.x; Mills J, 2003, J NEUROSCI, V23, P1638; Niewmierzycka A, 2005, J NEUROSCI, V25, P7022, DOI 10.1523/JNEUROSCI.1695-05.2005; Oertli B, 2000, ONCOGENE, V19, P4961, DOI 10.1038/sj.onc.1203876; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Oinuma I, 2006, J CELL BIOL, V173, P601, DOI 10.1083/jcb.200508204; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Shi SH, 2004, CURR BIOL, V14, P2025, DOI 10.1016/j.cub.2004.11.009; Suire S, 2002, CURR BIOL, V12, P1068, DOI 10.1016/S0960-9822(02)00933-8; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; Wiggin GR, 2005, DEV CELL, V8, P803, DOI 10.1016/j.devcel.2005.05.007; Wozniak MA, 2005, MOL BIOL CELL, V16, P84, DOI 10.1091/mbc.E04-04-0277; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Yoshimura T, 2006, BIOCHEM BIOPH RES CO, V340, P62, DOI 10.1016/j.bbrc.2005.11.147; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	39	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					303	318		10.1074/jbc.M607979200	http://dx.doi.org/10.1074/jbc.M607979200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17107957	hybrid			2022-12-27	WOS:000243166500035
J	Pongratz, RL; Kibbey, RG; Shulman, GI; Cline, GW				Pongratz, Rebecca L.; Kibbey, Richard G.; Shulman, Gerald I.; Cline, Gary W.			Cytosolic and mitochondrial malic enzyme isoforms differentially control insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR ISOTOPOMER ANALYSIS; PANCREATIC-ISLETS; CELL MITOCHONDRIA; METHYL SUCCINATE; MALONYL-COA; METABOLISM; PYRUVATE; GLUCOSE; PHOSPHATE; SHUTTLE	In islet beta-cells and INS-1 cells both the high activity of malic enzyme and the correlation of insulin secretion rates with pyruvate carboxylase (PC) flux suggest that a pyruvate-malate cycle is functionally relevant to insulin secretion. Expression of the malic enzyme isoforms in INS-1 cells and rat islets was measured, and small interfering RNA was used to selectively reduce isoform mRNA expression in INS-1 cells to evaluate its impact on insulin secretion. The cytosolic NADP(+)-specific isoform (ME1) was the most abundant, with the mitochondrial isoforms NAD(+)-preferred (ME2) expressed at similar to 50%, and the NADP(+)-specific (ME3) at similar to 10% compared with ME1. Selective reduction (89 +/- 2%) of cytosolic ME1 mRNA expression and enzyme activity significantly reduced glucose (15mm: 41 +/- 6%, p < 0.01) and amino acid (4 mm glutamine 10 mm leucine: 39 +/- 6%, p < 0.01)-stimulated insulin secretion. Selective small interfering RNA reduction (51 +/- 6%) of mitochondrial ME2 mRNA expression did not impact glucose-induced insulin secretion, but decreased amino acid-stimulated insulin secretion by 25 +/- 4% (p < 0.01). Modeling of the metabolism of [U-C-13] glucose by its isotopic distribution in glutamate indicates a second pool of pyruvate distinct from glycolytically derived pyruvate in INS-1 cells. ME1 knockdown decreased flux of both pools of pyruvate through PC. In contrast, ME2 knockdown affected only PC flux of the pyruvate derived from glutamate metabolism. These results suggest a physiological basis for two metabolically and functionally distinct pyruvate cycles. The cycling of pyruvate by ME1 generates cytosolic NADPH, whereas mitochondrial ME2 responds to elevated amino acids and serves to supply sufficient pyruvate for increased Krebs cycle flux when glucose is limiting.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Cline, GW (corresponding author), POB 208020, New Haven, CT 06520 USA.	gary.cline@yale.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NIDDK NIH HHS [R01 DK040936, R01 DK71071, R01DK-40936, U24 DK-59635] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936, U24DK059635, R01DK071071] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT SJH, 1979, BIOCHEM J, V184, P697, DOI 10.1042/bj1840697; Bakken IJ, 1997, NEUROREPORT, V8, P1567, DOI 10.1097/00001756-199705060-00004; Brun T, 1996, DIABETES, V45, P190, DOI 10.2337/diabetes.45.2.190; Cline GW, 2004, J BIOL CHEM, V279, P44370, DOI 10.1074/jbc.M311842200; Dabrowski M, 2003, J PHYSIOL-LONDON, V550, P357, DOI 10.1113/jphysiol.2003.041715; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Ivarsson R, 2005, DIABETES, V54, P2132, DOI 10.2337/diabetes.54.7.2132; Kowluru A, 2001, DIABETOLOGIA, V44, P89, DOI 10.1007/s001250051584; Li CH, 2003, J BIOL CHEM, V278, P2853, DOI 10.1074/jbc.M210577200; Liu YQ, 2002, J BIOL CHEM, V277, P39163, DOI 10.1074/jbc.M207157200; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P201, DOI 10.1006/abbi.1993.1028; MacDonald MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE1, DOI 10.1152/ajpendo.00218.2004; MACDONALD MJ, 1993, METABOLISM, V42, P1229, DOI 10.1016/0026-0495(93)90118-8; MACDONALD MJ, 1992, HORM METAB RES, V24, P158, DOI 10.1055/s-2007-1003284; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MACDONALD MJ, 1985, DIABETES, V34, P246, DOI 10.2337/diabetes.34.3.246; MacDonald MJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE302, DOI 10.1152/ajpendo.00041.2002; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MANDELLA RD, 1975, J BIOL CHEM, V250, P5877; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; MOREADITH RW, 1984, J BIOL CHEM, V259, P6215; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; SUMEGI B, 1990, BIOCHEMISTRY-US, V29, P9106, DOI 10.1021/bi00491a002; Wollheim CB, 2002, DIABETES, V51, pS37, DOI 10.2337/diabetes.51.2007.S37	31	108	114	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					200	207		10.1074/jbc.M602954200	http://dx.doi.org/10.1074/jbc.M602954200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17102138	hybrid			2022-12-27	WOS:000243166500024
J	Serrano, R; Martin, H; Casamayor, A; Arino, J				Serrano, Raquel; Martin, Humberto; Casamayor, Antonio; Arino, Joaquin			Signaling alkaline pH stress in the yeast Saccharomyces cerevisiae through the Wsc1 cell surface sensor and the Slt2 MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GENOME-WIDE ANALYSIS; TRANSCRIPTIONAL RESPONSE; INTEGRITY PATHWAY; GENE-EXPRESSION; WALL STRESS; ENVIRONMENTAL-CHANGES; TRANSDUCTION PATHWAY; CANDIDA-ALBICANS; PLASMA-MEMBRANE	Alkalinization of the external environment represents a stress situation for Saccharomyces cerevisiae. Adaptation to this circumstance involves the activation of diverse response mechanisms, the components of which are still largely unknown. We show here that mutation of members of the cell integrity Pkc1/Slt2 MAPK module, as well as upstream and downstream elements of the system, confers sensitivity to alkali. Alkalinization resulted in fast and transient activation of the Slt2 MAPK, which depended on the integrity of the kinase module and was largely abolished by sorbitol. Lack of Wsc1, removal of specific extracellular and intracellular domains, or substitution of Tyr(303) in this putative membrane stress sensor rendered cells sensitive to alkali and considerably decreased alkali-induced Slt2 activation. In contrast, constitutive activation of Slt2 by the bck1-20 allele increased pH tolerance in the wsc1 mutant. DNA microarray analysis revealed that several genes encoding cell wall proteins, such as GSC2/FKS2, DFG5, SKT5, and CRH1, were induced, at least in part, by high pH in an Slt2-dependent manner. We observed that dfg5, skt5, and particularly dfg5 skt5 cells were alkali- sensitive. Therefore, our results show that an alkaline environment imposes a stress condition on the yeast cell wall. We propose that the Slt2-mediated MAPK pathway plays an important role in the adaptive response to this insult and that Wsc1 participates as an essential cell-surface pH sensor. Moreover, these results provide a new example of the complexity of the response of budding yeast to the alkalinization of the environment.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Vet, E-08193 Barcelona, Spain; Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, E-28040 Madrid, Spain	Autonomous University of Barcelona; Complutense University of Madrid	Arino, J (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Vet, E-08193 Barcelona, Spain.	Joaquin.Arino@uab.es	Casamayor, Antonio/C-2509-2017; Martín, Humberto/Z-3423-2019; Brieva, Humberto Martin/E-9254-2016; Casamayor, Antonio/A-3190-2012; Arino, Joaquin/D-3756-2011	Martín, Humberto/0000-0002-6736-3602; Brieva, Humberto Martin/0000-0002-6736-3602; Casamayor, Antonio/0000-0003-2788-7329; Arino, Joaquin/0000-0002-6774-2987; Arino Carmona, Joaquin/0000-0002-0390-4270				Agarwal AK, 2003, J BIOL CHEM, V278, P34998, DOI 10.1074/jbc.M306291200; Alberola TM, 2004, INT MICROBIOL, V7, P199; Alepuz PM, 1997, MOL MICROBIOL, V26, P91, DOI 10.1046/j.1365-2958.1997.5531917.x; ASAMS A, 1997, METHODS YEAST GENETI; Bensen ES, 2004, MOL MICROBIOL, V54, P1335, DOI 10.1111/j.1365-2958.2004.04350.x; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Boorsma A, 2004, YEAST, V21, P413, DOI 10.1002/yea.1109; Castrejon F, 2006, EUKARYOT CELL, V5, P507, DOI 10.1128/EC.5.3.507-517.2006; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Claret S, 2005, EUKARYOT CELL, V4, P1375, DOI 10.1128/EC.4.8.1375-1386.2005; Cullen PJ, 2000, GENETICS, V155, P1005; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; Garcia R, 2004, J BIOL CHEM, V279, P15183, DOI 10.1074/jbc.M312954200; Garcia-Rodriguez LJ, 2005, FEBS LETT, V579, P6186, DOI 10.1016/j.febslet.2005.10.001; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Groll AH, 2001, EXPERT OPIN INV DRUG, V10, P1545, DOI 10.1517/13543784.10.8.1545; Gualtieri T, 2004, YEAST, V21, P1107, DOI 10.1002/yea.1155; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Harrison JC, 2004, J BIOL CHEM, V279, P2616, DOI 10.1074/jbc.M306110200; Herrero J, 2003, NUCLEIC ACIDS RES, V31, P3461, DOI 10.1093/nar/gkg591; Imai K, 2005, J BIOL CHEM, V280, P8275, DOI 10.1074/jbc.M409428200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacoby JJ, 1998, MOL GEN GENET, V258, P148, DOI 10.1007/s004380050717; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lamb TM, 2003, MOL CELL BIOL, V23, P677, DOI 10.1128/MCB.23.2.677-686.2003; Lamb TM, 2001, J BIOL CHEM, V276, P1850, DOI 10.1074/jbc.M008381200; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; Lodder AL, 1999, GENETICS, V152, P1487; Lommel M, 2004, MOL CELL BIOL, V24, P46, DOI 10.1128/MCB.24.1.46-57.2004; MacIsaac KD, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-113; Martin H, 2005, MOL MICROBIOL, V58, P6, DOI 10.1111/j.1365-2958.2005.04822.x; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; Penalva MA, 2002, MICROBIOL MOL BIOL R, V66, P426, DOI 10.1128/MMBR.66.3.426-446.2002; Penalva MA, 2004, ANNU REV MICROBIOL, V58, P425, DOI 10.1146/annurev.micro.58.030603.123715; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; Platara M, 2006, J BIOL CHEM, V281, P36632, DOI 10.1074/jbc.M606483200; Qi MS, 2005, J CELL SCI, V118, P3569, DOI 10.1242/jcs.02470; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Reinoso-Martin C, 2003, EUKARYOT CELL, V2, P1200, DOI 10.1128/EC.2.6.1200-1210.2003; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Ruepp A, 2004, NUCLEIC ACIDS RES, V32, P5539, DOI 10.1093/nar/gkh894; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Serrano R, 2002, MOL MICROBIOL, V46, P1319, DOI 10.1046/j.1365-2958.2002.03246.x; Serrano R, 2004, J BIOL CHEM, V279, P19698, DOI 10.1074/jbc.M313746200; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; SIKORSKI RS, 1989, GENETICS, V122, P19; Torres J, 2002, J BIOL CHEM, V277, P43495, DOI 10.1074/jbc.M205408200; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; VANDERREST ME, 1995, MICROBIOL REV, V59, P304, DOI 10.1128/MMBR.59.2.304-322.1995; Vay HA, 2004, MICROBIOL-SGM, V150, P3281, DOI 10.1099/mic.0.27264-0; Viladevall L, 2004, J BIOL CHEM, V279, P43614, DOI 10.1074/jbc.M403606200; Vilella F, 2005, J BIOL CHEM, V280, P9149, DOI 10.1074/jbc.M411062200; Willer T, 2003, CURR OPIN STRUC BIOL, V13, P621, DOI 10.1016/j.sbi.2003.09.003; Winkler A, 2002, EUKARYOT CELL, V1, P163, DOI 10.1128/EC.1.2.163-173.2002; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xu WJ, 2004, MOL BIOL CELL, V15, P5528, DOI 10.1091/mbc.E04-08-0666; Zakrzewska A, 2005, EUKARYOT CELL, V4, P703, DOI 10.1128/EC.4.4.703-715.2005; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013	66	90	94	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39785	39795		10.1074/jbc.M604497200	http://dx.doi.org/10.1074/jbc.M604497200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17088254	hybrid			2022-12-27	WOS:000243033900006
J	Ragas, A; Roussel, L; Puzo, G; Riviere, M				Ragas, Aude; Roussel, Lucie; Puzo, Germain; Riviere, Michel			The Mycobacterium tuberculosis cell-surface glycoprotein Apa as a potential adhesin to colonize target cells via the innate immune system pulmonary C-type lectin surfactant protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; HUMAN DENDRITIC CELLS; MYO-INOSITOL ANCHOR; CARBOHYDRATE RECOGNITION; ATTENUATED STRAINS; MASS-SPECTROMETRY; MANNOSE RECEPTOR; IL-12 PRODUCTION; ANTIGEN COMPLEX; BOVIS BCG	Tuberculosis is still a major health problem, and understanding the mechanism by which Mycobacterium tuberculosis (Mtb) invades and colonizes its host target cells remains an important issue for the control of infection. The innate immune system C-type lectins (C-TLs), including the human pulmonary surfactant protein A (PSP-A), have been recently identified as determinant players in the early recognition of the invading pathogen and in mounting the host defense response. Although the antigenic lipoglycan mannosylated lipoarabinomannan is currently considered to be the major C-TL target on the mycobacterial surface, the recognition by some C-TLs of the only mycobacterial species composing the "Mtb complex" indicates that mannosylated lipoarabinomannan cannot account alone for this specificity. Thus, we searched for the mycobacterial molecules targeted by human PSP-A, focusing our attention on the Mtb surface glycoproteins. We developed an original functional proteomic approach based on a lectin blot assay using crude human bronchoalveolar lavage fluid as a source of physiological PSP-A. Combined with selective cell-surface protein extraction and mass spectrometry peptide mapping, this strategy allowed us to identify the Apa (alanine-and proline-rich antigenic) glycoprotein as new potential target for PSP-A. This result was supported by direct binding of PSP-A to purified Apa. Moreover, EDTA addition or deglycosylation of purified Apa samples completely abolished the interaction, demonstrating that the interaction is calcium- and mannose-dependent, as expected. Finally, we provide convincing evidence that Apa, formerly considered as mainly secreted, is associated with the cell wall for a sufficiently long time to aid in the attachment of PSP-A. Because, to date, Apa seems to be restricted to the Mtb complex strains, we propose that it may account for the selective recognition of those strains by PSP-A and other immune system C-TLs containing homologous functional domains.	CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse 4, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Riviere, M (corresponding author), CNRS, Inst Pharmacol & Biol Struct, 205 Narbonne, F-31077 Toulouse 4, France.	Michel.Riviere@ipbs.fr						Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Dobos KM, 1996, J BACTERIOL, V178, P2498, DOI 10.1128/jb.178.9.2498-2506.1996; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Ferguson JS, 1999, J IMMUNOL, V163, P312; Garapin AC, 2001, VACCINE, V19, P2830, DOI 10.1016/S0264-410X(01)00012-3; Gatfield J, 2003, ADV IMMUNOL, V81, P45, DOI 10.1016/S0065-2776(03)81002-7; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; GILLERON M, 2001, GLYCANS CELL INTERAC, P113; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Horn C, 1999, J BIOL CHEM, V274, P32023, DOI 10.1074/jbc.274.45.32023; Ibango HB, 2006, LANCET INFECT DIS, V6, P522, DOI 10.1016/S1473-3099(06)70552-7; Johansson U, 2001, IMMUNOL LETT, V77, P63, DOI 10.1016/S0165-2478(01)00190-0; Jouanguy E, 1999, CURR OPIN IMMUNOL, V11, P346, DOI 10.1016/S0952-7915(99)80055-7; Kumar P, 2003, INFECT IMMUN, V71, P1929, DOI 10.1128/IAI.71.4.1929-1937.2003; LAQUEYRERIE A, 1995, INFECT IMMUN, V63, P4003, DOI 10.1128/IAI.63.10.4003-4010.1995; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; Michell SL, 2003, J BIOL CHEM, V278, P16423, DOI 10.1074/jbc.M207959200; Monsarrat B, 1999, GLYCOBIOLOGY, V9, P335, DOI 10.1093/glycob/9.4.335; Nguyen L, 2005, TRENDS CELL BIOL, V15, P269, DOI 10.1016/j.tcb.2005.03.009; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; ORTALOMAGNE A, 1995, MICROBIOL-UK, V141, P1609, DOI 10.1099/13500872-141-7-1609; Pasula R, 1997, AM J RESP CELL MOL, V17, P209, DOI 10.1165/ajrcmb.17.2.2469; Pitarque S, 2005, BIOCHEM J, V392, P615, DOI 10.1042/BJ20050709; Romain F, 1999, INFECT IMMUN, V67, P5567, DOI 10.1128/IAI.67.11.5567-5572.1999; Schlesinger LS, 1996, J IMMUNOL, V157, P4568; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; Sharon N, 2006, BBA-GEN SUBJECTS, V1760, P527, DOI 10.1016/j.bbagen.2005.12.008; Sidobre S, 2002, BIOCHEM J, V365, P89, DOI 10.1042/BJ20011659; Sidobre S, 2000, J BIOL CHEM, V275, P2415, DOI 10.1074/jbc.275.4.2415; Ting LM, 1999, J IMMUNOL, V163, P3898; VanderVen BC, 2005, SCIENCE, V309, P941, DOI 10.1126/science.1114347; VENISSE A, 1993, J BIOL CHEM, V268, P12401; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x	37	86	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5133	5142		10.1074/jbc.M610183200	http://dx.doi.org/10.1074/jbc.M610183200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17158455	hybrid			2022-12-27	WOS:000244482300007
J	Valcourt, U; Merle, B; Gineyts, E; Viguet-Carrin, S; Delmas, PD; Garnero, P				Valcourt, Ulrich; Merle, Blandine; Gineyts, Evelyne; Viguet-Carrin, Stephanie; Delmas, Pierre D.; Garnero, Patrick			Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; MAILLARD REACTION-PRODUCTS; OSTEOBLAST-LIKE CELLS; END-PRODUCTS; I COLLAGEN; CROSS-LINKING; BIOMECHANICAL PROPERTIES; RECEPTOR; AGE; EXPRESSION	Type I collagen, the major organic component of bone matrix, undergoes a series of post-translational modifications that occur with aging, such as the non-enzymatic glycation. This spontaneous reaction leads to the formation of advanced glycation end products (AGEs), which accumulate in bone tissue and affect its structural and mechanical properties. We have investigated the role of matrix AGEs on bone resorption mediated by mature osteoclasts and the effects of exogenous AGEs on osteoclastogenesis. Using in vitro resorption assays performed on control- and AGE-modified bone and ivory slices, we showed that the resorption process was markedly inhibited when mature osteoclasts were seeded on slices containing matrix pentosidine, a well characterized AGE. More specifically, the total area resorbed per slice, and the area degraded per resorption lacuna created by osteoclasts, were significantly decreased in AGE-containing slices. This inhibition of bone resorption was confirmed by a marked reduction of the release of type I collagen fragments generated by the collagenolytic enzymes secreted by osteoclasts in the culture medium of AGE-modified mineralized matrices. This effect is likely to result from decreased solubility of collagen molecules in the presence of AGEs, as documented by the reduction of pepsin-mediated digestion of AGE-containing collagen. We found that AGE-modified BSA totally inhibited osteoclastogenesis in vitro, most likely by impairing the commitment of osteoclast progenitors into pre-osteoclastic cells. Although the mechanisms remain unknown, AGEs might interfere with osteoclastic differentiation and activity through their interaction with specific cell-surface receptors, because we showed that both osteoclast progenitors and mature osteoclasts expressed different AGEs receptors, including receptor for AGEs (RAGEs). These results suggest that AGEs decreased osteoclast-induced bone resorption, by altering not only the structural integrity of bone matrix proteins but also the osteoclastic differentiation process. We suggest that AGEs may play a role in the alterations of bone remodeling associated with aging and diabetes.	INSERM, Res Unit 403, F-69437 Lyon 03, France; Univ Lyon 1, F-69437 Lyon 03, France; Synarc, Mol Markers, F-69003 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Synarc	Valcourt, U (corresponding author), Univ Lyon 1, Inst Biol & Chim Prot, CNRS, UMR 5086,IFR128 Biosci Lyon Gerland, F-69367 Lyon 07, France.	u.valcourt@ibcp.fr	VALCOURT, Ulrich/ABB-3943-2021	VALCOURT, Ulrich/0000-0002-1727-4409; Merle, Blandine/0000-0001-8794-9523				ACHARYA AS, 1991, J PROTEIN CHEM, V10, P345, DOI 10.1007/BF01025633; Alikhani ZB, 2005, J BIOL CHEM, V280, P12087, DOI 10.1074/jbc.M406313200; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; Bhatwadekar AD, 2005, J CLIN LAB ANAL, V19, P11, DOI 10.1002/jcla.20048; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Candido R, 2003, CIRC RES, V92, P785, DOI 10.1161/01.RES.0000065620.39919.20; Chen AC, 2002, ARTHRITIS RHEUM, V46, P3212, DOI 10.1002/art.10627; Cortizo AM, 2003, MOL CELL BIOCHEM, V250, P1, DOI 10.1023/A:1024934008982; DeGroot J, 2001, ARTHRITIS RHEUM, V44, P2562, DOI 10.1002/1529-0131(200111)44:11<2562::AID-ART437>3.0.CO;2-1; DeGroot J, 2004, CURR OPIN PHARMACOL, V4, P301, DOI 10.1016/j.coph.2004.01.007; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Foged NT, 1996, J BONE MINER RES, V11, P226; Garnero P, 2006, BONE, V38, P300, DOI 10.1016/j.bone.2005.09.014; Garnero P, 2003, BONE, V32, P20, DOI 10.1016/S8756-3282(02)00922-5; GRANT ME, 1968, BIOCHEM J, V108, P587, DOI 10.1042/bj1080587; Hein G, 2006, ANN RHEUM DIS, V65, P101, DOI 10.1136/ard.2004.034348; Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002-9440(10)63712-1; Hernandez CJ, 2005, BONE, V37, P825, DOI 10.1016/j.bone.2005.07.019; Hoebertz A, 2003, METH MOLEC MED, V80, P53; Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002-9440(10)62269-9; Katayama Y, 1997, BONE, V21, P237, DOI 10.1016/S8756-3282(97)00128-2; Katayama Y, 1996, J BONE MINER RES, V11, P931, DOI 10.1002/jbmr.5650110709; Kume S, 2005, J BONE MINER RES, V20, P1647, DOI 10.1359/JBMR.050514; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Lu HF, 2003, ENDOCRINOLOGY, V144, P346, DOI 10.1210/en.2002-220072; McCarthy AD, 2004, INT J BIOCHEM CELL B, V36, P840, DOI 10.1016/j.biocel.2003.09.006; McCarthy AD, 2001, ACTA DIABETOL, V38, P113, DOI 10.1007/s005920170007; McCarthy AD, 1999, ACTA DIABETOL, V36, P45, DOI 10.1007/s005920050144; McCarthy AD, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-16; Mercer N, 2004, MOL CELL BIOCHEM, V266, P17, DOI 10.1023/B:MCBI.0000049128.71095.ac; Merle B, 2003, J CELL BIOCHEM, V90, P424, DOI 10.1002/jcb.10625; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; Miyata T, 1997, J AM SOC NEPHROL, V8, P260; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; Obrenovich Mark E, 2005, Sci Aging Knowledge Environ, V2005, ppe3, DOI 10.1126/sageke.2005.4.pe3; Ohgami N, 2002, J DIABETES COMPLICAT, V16, P56, DOI 10.1016/S1056-8727(01)00208-2; Ohgami N, 2001, J BIOL CHEM, V276, P13348, DOI 10.1074/jbc.M011613200; Pokharna HK, 2000, J SURG RES, V94, P35, DOI 10.1006/jsre.2000.6000; Ramasamy R, 2005, GLYCOBIOLOGY, V15, p16R, DOI 10.1093/glycob/cwi053; Raynal C, 1996, ENDOCRINOLOGY, V137, P2347, DOI 10.1210/en.137.6.2347; Reddy GK, 2004, EXP DIABESITY RES, V5, P143, DOI 10.1080/15438600490277860; Saito M, 1997, ANAL BIOCHEM, V253, P26, DOI 10.1006/abio.1997.2350; Saito M, 2006, OSTEOPOROSIS INT, V17, P986, DOI 10.1007/s00198-006-0087-0; Sajithlal GB, 1998, BBA-MOL BASIS DIS, V1407, P215, DOI 10.1016/S0925-4439(98)00043-X; Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04-06-0522; Santana RB, 2003, DIABETES, V52, P1502, DOI 10.2337/diabetes.52.6.1502; Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223-003-0023-7; SELL DR, 1989, J BIOL CHEM, V264, P21597; SELL DR, 1989, CONNECT TISSUE RES, V19, P77, DOI 10.3109/03008208909016816; SERRE CM, 1995, J BONE MINER RES, V10, P1158; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; TAKESHITA N, 1995, LIFE SCI, V56, P1095, DOI 10.1016/0024-3205(95)00046-9; Thorpe SR, 2003, AMINO ACIDS, V25, P275, DOI 10.1007/s00726-003-0017-9; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Valcourt U, 2002, J BIOL CHEM, V277, P33545, DOI 10.1074/jbc.M202086200; Valencia JV, 2004, ANAL BIOCHEM, V324, P68, DOI 10.1016/j.ab.2003.09.013; Vashishth D, 2001, BONE, V28, P195, DOI 10.1016/S8756-3282(00)00434-8; Verzijl N, 2000, BIOCHEM J, V350, P381, DOI 10.1042/0264-6021:3500381; Verzijl N, 2002, ARTHRITIS RHEUM, V46, P114, DOI 10.1002/1529-0131(200201)46:1<114::AID-ART10025>3.0.CO;2-P; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200; Viguet-Carrin S, 2006, BONE, V39, P1073, DOI 10.1016/j.bone.2006.05.013; Vlassara H, 2001, DIABETES-METAB RES, V17, P436, DOI 10.1002/dmrr.233; Wang X, 2002, BONE, V31, P1, DOI 10.1016/S8756-3282(01)00697-4; Wu XJ, 2005, J BONE MINER RES, V20, P107, DOI 10.1359/JBMR.041022	66	137	147	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5691	5703		10.1074/jbc.M610536200	http://dx.doi.org/10.1074/jbc.M610536200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17142454	hybrid			2022-12-27	WOS:000244482300066
J	Burnett, JC; Ruthel, G; Stegmann, CM; Panchal, RG; Nguyen, TL; Hermone, AR; Stafford, RG; Lane, DJ; Kenny, TA; McGrath, CF; Wipf, P; Stahl, AM; Schmidt, JJ; Gussio, R; Brunger, AT; Bavari, S				Burnett, James C.; Ruthel, Gordon; Stegmann, Christian M.; Panchal, Rekha G.; Nguyen, Tam L.; Hermone, Ann R.; Stafford, Robert G.; Lane, Douglas J.; Kenny, Tara A.; McGrath, Connor F.; Wipf, Peter; Stahl, Andrea M.; Schmidt, James J.; Gussio, Rick; Brunger, Axel T.; Bavari, Sina			Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN TYPE-A; NEUROTOXIN SEROTYPE; ZINC ENDOPEPTIDASE; NEUROTRANSMITTER RELEASE; COMMON PHARMACOPHORE; CRYSTAL-STRUCTURE; PROTEASE ACTIVITY; POISONOUS POISON; IDENTIFICATION; PROTEINS	An efficient research strategy integrating empirically guided, structure-based modeling and chemoinformatics was used to discover potent small molecule inhibitors of the botulinum neurotoxin serotype A light chain. First, a modeled binding mode for inhibitor 2-mercapto-3-phenylpropionyl-RATKML (K-i = 330 nM) was generated, and required the use of a molecular dynamic conformer of the enzyme displaying the reorientation of surface loops bordering the substrate binding cleft. These flexible loops are conformationally variable in x-ray crystal structures, and the model predicted that they were pivotal for providing complementary binding surfaces and solvent shielding for the pseudo-peptide. The docked conformation of 2-mercapto-3-phenylpropionyl-RATKML was then used to refine our pharmacophore for botulinum serotype A light chain inhibition. Data base search queries derived from the pharmacophore were employed to mine small molecule (non-peptidic) inhibitors from the National Cancer Institute's Open Repository. Four of the inhibitors possess K, values ranging from 3.0 to 10.0 mu m. Of these, NSC 240898 is a promising lead for therapeutic development, as it readily enters neurons, exhibits no neuronal toxicity, and elicits dose-dependent protection of synaptosomal-associated protein (of 25 kDa) in a primary culture of embryonic chicken neurons. Isothermal titration calorimetry showed that the interaction between NSC 240898 and the botulinum A light chain is largely entropy-driven, and occurs with a 1:1 stoichiometry and a dissociation constant of 4.6 mu M.	Stanford Univ, Sch Med, HHMI, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Stanford Synchrotron Radiat Lab, Stanford, CA 94305 USA; NCI Frederick, Informat Technol Branch, Dev Therapeut Program, Ft Detrick, MD 21702 USA; USA, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA; SAIC Frederick, Target Struct Based Drug Discovery Grp, Frederick, MD USA; Univ Pittsburgh, Combinatorial Chem Ctr, Pittsburgh, PA 15260 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Science Applications International Corporation (SAIC); SAIC-Frederick; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Brunger, AT (corresponding author), Stanford Univ, Sch Med, HHMI, 318 Campus Dr,Rm E300, Stanford, CA 94305 USA.	brunger@stanford.edu; sina.bavari@us.army.mil	Bavari, Sina/L-3642-2019; Wipf, Peter/AAG-1771-2021; Ruthel, Gordon/GYU-9133-2022; Panchal, Rekha/None	Bavari, Sina/0000-0001-8424-5635; Wipf, Peter/0000-0001-7693-5863; Brunger, Axel/0000-0001-5121-2036; Panchal, Rekha/0000-0001-8621-9078; Ruthel, Gordon/0000-0001-9193-5589	NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Anne C, 2005, CHEMBIOCHEM, V6, P1375, DOI 10.1002/cbic.200400398; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; Boldt GE, 2006, ORG LETT, V8, P1729, DOI 10.1021/ol0603211; Boldt GE, 2006, CHEM COMMUN, P3063, DOI 10.1039/b603099h; BORDERS CL, 1994, PROTEIN SCI, V3, P541; Breidenbach MA, 2004, NATURE, V432, P925, DOI 10.1038/nature03123; Burnett JC, 2005, NAT REV DRUG DISCOV, V4, P281, DOI 10.1038/nrd1694; Burnett JC, 2005, BIOORGAN MED CHEM, V13, P333, DOI 10.1016/j.bmc.2004.10.026; Burnett JC, 2003, BIOCHEM BIOPH RES CO, V310, P84, DOI 10.1016/j.bbrc.2003.08.112; Cheng CA, 2006, AM J HEALTH-SYST PH, V63, P225, DOI 10.2146/sp/06001; Clarke SC, 2005, BRIT J BIOMED SCI, V62, P40, DOI 10.1080/09674845.2005.11732685; Cote TR, 2005, J AM ACAD DERMATOL, V53, P407, DOI 10.1016/j.jaad.2005.06.011; Dong M, 2006, SCIENCE, V312, P592, DOI 10.1126/science.1123654; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; Giannakakou P, 2000, P NATL ACAD SCI USA, V97, P2904, DOI 10.1073/pnas.040546297; Josko Deborah, 2004, Clin Lab Sci, V17, P30; Kuhn TB, 2003, METHOD CELL BIOL, V71, P67, DOI 10.1016/S0091-679X(03)01005-7; Kukreja R, 2005, J BIOL CHEM, V280, P39346, DOI 10.1074/jbc.M508463200; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Lipozencic Jasna, 2006, Acta Dermatovenerol Croat, V14, P60; Marks James D, 2004, Anesthesiol Clin North Am, V22, P509, DOI 10.1016/j.atc.2004.05.010; Merino I, 2006, BIOORGAN MED CHEM, V14, P3583, DOI 10.1016/j.bmc.2006.01.015; Meunier FA, 2003, MOL CELL NEUROSCI, V22, P454, DOI 10.1016/S1044-7431(02)00016-7; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; Montecucco C, 2005, CURR OPIN PHARMACOL, V5, P274, DOI 10.1016/j.coph.2004.12.006; Nguyen TL, 2005, J MED CHEM, V48, P6107, DOI 10.1021/jm050502t; Paddle BM, 2003, J APPL TOXICOL, V23, P139, DOI 10.1002/jat.903; Park JG, 2006, BIOORGAN MED CHEM, V14, P395, DOI 10.1016/j.bmc.2005.08.018; Roe RR, 1999, J MOL MODEL, V5, P134, DOI 10.1007/s008940050113; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHIAVO G, 1994, J BIOL CHEM, V269, P20213; Schmidt JJ, 1995, J PROTEIN CHEM, V14, P703, DOI 10.1007/BF01886909; Schmidt JJ, 2003, APPL ENVIRON MICROB, V69, P297, DOI 10.1128/AEM.69.1.297-303.2003; Schmidt JJ, 2002, FEBS LETT, V532, P423, DOI 10.1016/S0014-5793(02)03738-9; Schmidt JJ, 1998, FEBS LETT, V435, P61, DOI 10.1016/S0014-5793(98)01041-2; Schmidt JJ, 1997, J PROTEIN CHEM, V16, P19, DOI 10.1023/A:1026386710428; Segel I.H., 1975, ENZYME KINETICS; Segelke B, 2004, P NATL ACAD SCI USA, V101, P6888, DOI 10.1073/pnas.0400584101; Singh BR, 2000, NAT STRUCT BIOL, V7, P617, DOI 10.1038/77900; Smith TJ, 2005, INFECT IMMUN, V73, P5450, DOI 10.1128/IAI.73.9.5450-5457.2005; Sukonpan C, 2004, J PEPT RES, V63, P181, DOI 10.1111/j.1399-3011.2004.00124.x; Swaminathan S, 2004, MOVEMENT DISORD, V19, pS17, DOI 10.1002/mds.20005	46	87	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					5004	5014		10.1074/jbc.M608166200	http://dx.doi.org/10.1074/jbc.M608166200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17092934	hybrid, Green Accepted			2022-12-27	WOS:000244482000083
J	Mei, G; Di Venere, A; Gasperi, V; Nicolai, E; Masuda, KR; Finazzi-Agro, A; Cravatt, BF; Maccarrone, M				Mei, Giampiero; Di Venere, Almerinda; Gasperi, Valeria; Nicolai, Eleonora; Masuda, Kim R.; Finazzi-Agro, Alessandro; Cravatt, Benjamin F.; Maccarrone, Mauro			Closing the gate to the active site - Effect of the inhibitor methoxyarachidonyl fluorophosphonate on the conformation and membrane binding of fatty acid amide hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANANDAMIDE; TARGET	Fatty acid amide hydrolase (FAAH) is a dimeric, membrane-bound enzyme that degrades neuromodulatory fatty acid amides and esters and is expressed in mammalian brain and peripheral tissues. The cleavage of 30 amino acids from each subunit creates an FAAH variant that is soluble and homogeneous in detergent-containing buffers, opening the avenue to the in vitro mechanistic and structural studies. Here we have studied the stability of FAAH as a function of guanidinium hydrochloride concentration and of hydrostatic pressure. The unfolding transition was observed to be complex and required a fitting procedure based on a three-state process with a monomeric intermediate. The first transition was characterized by dimer dissociation, with a free energy change of approximate to 11 kcal/mol that accounted for approximate to 80% of the total stabilization energy. This process was also paralleled by a large change in the solvent-accessible surface area, because of the hydration occurring both at the dimeric interface and within the monomers. As a consequence, the isolated subunits were found to be much less stable (Delta G approximate to 3 kcal/mol). The addition of methoxyarachidonyl fluorophosphonate, an irreversible inhibitor of FAAH activity, enhanced the stability of the dimer by approximate to 2 kcal/mol, toward denaturant- and pressure-induced unfolding. FAAH inhibition by methoxyarachidonyl fluorophosphonate also reduced the ability of the protein to bind to the membranes. These findings suggest that local conformational changes at the level of the active site might induce a tighter interaction between the subunits of FAAH, affecting the enzymatic activity and the interaction with membranes.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Roma Tor Vergata, INFM, I-00133 Rome, Italy; Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; European Ctr Brain Res, Ist Ric & Cura, S Lucia Fdn, I-00143 Rome, Italy; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Chem, La Jolla, CA 92037 USA	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Rome Tor Vergata; University of Teramo; IRCCS Santa Lucia; Scripps Research Institute; Scripps Research Institute	Mei, G (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Montpellier 1, I-00133 Rome, Italy.	mei@med.uniroma2.it; mmaccarrone@unite.it	Gasperi, Valeria/AAN-9210-2021; Nicolai, Eleonora/AAR-4554-2020; gasperi, valeria/AGO-4500-2022	Nicolai, Eleonora/0000-0003-1415-9808; gasperi, valeria/0000-0003-3200-8093; Di Venere, Almerinda/0000-0002-9493-0270				Bari M, 2006, MINI-REV MED CHEM, V6, P257, DOI 10.2174/138955706776073466; Battista N, 2004, CURR NEUROVASC RES, V1, P129, DOI 10.2174/1567202043480107; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Chebrou H, 1996, BBA-PROTEIN STRUCT M, V1298, P285, DOI 10.1016/S0167-4838(96)00145-8; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Cravatt BF, 2003, CURR OPIN CHEM BIOL, V7, P469, DOI 10.1016/S1367-5931(03)00079-6; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; FONTANA A, 1995, PROSTAG LEUKOTR ESS, V53, P301, DOI 10.1016/0952-3278(95)90130-2; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P3; Li WF, 2005, BIOTECHNOL ADV, V23, P271, DOI 10.1016/j.biotechadv.2005.01.002; Maccarrone M, 2003, J BIOL CHEM, V278, P32726, DOI 10.1074/jbc.M302123200; Maccarrone M, 2006, CURR PHARM DESIGN, V12, P759, DOI 10.2174/138161206775474279; Maccarrone M, 2001, BIOCHEMISTRY-US, V40, P6819, DOI 10.1021/bi010187m; Marianayagam NJ, 2004, TRENDS BIOCHEM SCI, V29, P618, DOI 10.1016/j.tibs.2004.09.006; May C, 2000, EUR J BIOCHEM, V267, P1100, DOI 10.1046/j.1432-1327.2000.01105.x; McKinney MK, 2005, ANNU REV BIOCHEM, V74, P411, DOI 10.1146/annurev.biochem.74.082803.133450; Mei G, 2005, FEBS J, V272, P16, DOI 10.1111/j.1432-1033.2004.04407.x; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Patricelli MP, 1998, BIOCHEMISTRY-US, V37, P15177, DOI 10.1021/bi981733n; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Royer CA, 2002, BBA-PROTEIN STRUCT M, V1595, P201, DOI 10.1016/S0167-4838(01)00344-2; SILVA JL, 1993, ANNU REV PHYS CHEM, V50, P245; Sipe JC, 2002, P NATL ACAD SCI USA, V99, P8394, DOI 10.1073/pnas.082235799; THOMSON JA, 1989, J BIOL CHEM, V264, P11614	26	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3829	3836		10.1074/jbc.M605653200	http://dx.doi.org/10.1074/jbc.M605653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158103	hybrid			2022-12-27	WOS:000244481900046
J	O'Brien, EM; Gomes, DA; Sehgal, S; Nathanson, MH				O'Brien, Elizabeth M.; Gomes, Dawidson A.; Sehgal, Sona; Nathanson, Michael H.			Hormonal regulation of nuclear permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; PROTEIN-KINASE-C; PORE COMPLEX; VASOPRESSIN RECEPTOR; TRANSCRIPTION FACTOR; CYTOSOLIC CALCIUM; CA2+ SPIKES; CELLS; ACTIVATION; TRANSPORT	Transport into the nucleus is critical for regulation of gene transcription and other intranuclear events. Passage of molecules into the nucleus depends in part upon their size and the presence of appropriate targeting sequences. However, little is known about the effects of hormones or their second messengers on transport across the nuclear envelope. We used localized two-photon activation of a photoactivatable green fluorescent protein to investigate whether hormones, via their second messengers, could alter nuclear permeability. Vasopressin and other hormones that increase cytosolic Ca2+ and activate protein kinase C increased permeability across the nuclear membrane of SKHep1 liver cells in a rapid unidirectional manner. An increase in cytosolic Ca2+ was both necessary and sufficient for this process. Furthermore, localized photorelease of caged Ca2+ near the nuclear envelope resulted in a local increase in nuclear permeability. Neither activation nor inhibition of protein kinase C affected nuclear permeability. These findings provide evidence that hormones linking to certain G protein-coupled receptors increase nuclear permeability via cytosolic Ca2+. Short term regulation of nuclear permeability may provide a novel mechanism by which such hormones permit transcription factors and other regulatory molecules to enter the nucleus, thereby regulating gene transcription in target cells.	Yale Univ, Sch Med, Sect Digest Dis, Dept Med, New Haven, CT 06520 USA	Yale University	Nathanson, MH (corresponding author), Yale Univ, Sch Med, Sect Digest Dis, Dept Med, 1 Gilbert St,Rm TAC S241D, New Haven, CT 06520 USA.	michael.nathanson@yale.edu	Gomes, Dawidson Assis/O-1372-2013	Gomes, Dawidson Assis/0000-0001-7714-991X; O'Brien, Elizabeth/0000-0003-4648-8358	NIDDK NIH HHS [DK07356, T32 DK007356, R01 DK045710-06A2, DK57751, DK34989, DK45710, R01 DK045710, P30 DK034989-169004, P01 DK057751, T32 DK007356-27, P01 DK057751-01A1, P30 DK034989] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, R01DK045710, T32DK007356, P01DK057751, R29DK045710] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; Belov GA, 2004, J VIROL, V78, P10166, DOI 10.1128/JVI.78.18.10166-10177.2004; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; Brasier AR, 2000, MOL CELL BIOCHEM, V212, P155, DOI 10.1023/A:1007133710837; Brown EB, 1999, BIOPHYS J, V76, P489, DOI 10.1016/S0006-3495(99)77217-6; Buchholz I, 2004, J MEMBRANE BIOL, V199, P135, DOI 10.1007/s00232-004-0684-9; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; CHENOY SK, 2005, SCI STJE, pCM14; Craske ML, 2005, J CELL BIOL, V170, P1147, DOI 10.1083/jcb.200503118; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Dyachok O, 2006, NATURE, V439, P349, DOI 10.1038/nature04410; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fox JL, 1997, BIOCHEM J, V326, P491, DOI 10.1042/bj3260491; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hirata K, 1998, P NATL ACAD SCI USA, V95, P8381, DOI 10.1073/pnas.95.14.8381; Howell JL, 2002, BIOTECHNIQUES, V32, P80, DOI 10.2144/02321st04; Ito K, 1997, EMBO J, V16, P242, DOI 10.1093/emboj/16.2.242; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; Leite MF, 2003, P NATL ACAD SCI USA, V100, P2975, DOI 10.1073/pnas.0536590100; Leite MF, 2002, GASTROENTEROLOGY, V122, P415, DOI 10.1053/gast.2002.30982; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Markou T, 2004, J MOL CELL CARDIOL, V37, P1001, DOI 10.1016/j.yjmcc.2004.08.002; Minagawa N, 2005, J BIOL CHEM, V280, P33637, DOI 10.1074/jbc.M503210200; Moore-Nichols D, 2002, BIOPHYS J, V83, P1421, DOI 10.1016/S0006-3495(02)73913-1; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; Nicou Alexandra, 2003, FASEB Journal, V17, P1901; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; Pante N, 2002, MOL BIOL CELL, V13, P425, DOI 10.1091/mbc.01-06-0308; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Potter SM, 1996, CURR BIOL, V6, P1595, DOI 10.1016/S0960-9822(02)70782-3; Pusl T, 2002, J BIOL CHEM, V277, P27517, DOI 10.1074/jbc.M203002200; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; Shahin V, 2005, J CELL SCI, V118, P2881, DOI 10.1242/jcs.02429; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Thevananther S, 2004, HEPATOLOGY, V39, P393, DOI 10.1002/hep.20075; THORGATE R, 2006, CALCIUM BINDING PROT, V1, P36; Thorogate R, 2004, J CELL SCI, V117, P5923, DOI 10.1242/jcs.01510; Wei XB, 2003, BIOPHYS J, V84, P1317, DOI 10.1016/S0006-3495(03)74947-9; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551	51	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4210	4217		10.1074/jbc.M606300200	http://dx.doi.org/10.1074/jbc.M606300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158097	Green Accepted, hybrid			2022-12-27	WOS:000244481900084
J	An, JJ; Rhee, Y; Kim, SH; Kim, DM; Han, DH; Hwang, JH; Jin, YJ; Cha, BS; Baik, JH; Lee, WT; Lim, SK				An, Juan Ji; Rhee, Yumie; Kim, Se Hwa; Kim, Dol Mi; Han, Dong-He; Hwang, Jung Hee; Jin, Young-Jun; Cha, Bong Soo; Baik, Ja-Hyun; Lee, Won Tae; Lim, Sung-Kil			Peripheral effect of alpha-melanocyte-stimulating hormone on fatty acid oxidation in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACETYL-COA CARBOXYLASE; RECEPTOR ANTAGONIST HS014; MOLECULAR-CLONING; MALONYL-COA; CARNITINE PALMITOYLTRANSFERASE; INSULIN SENSITIVITY; OBESITY; EXPRESSION; LEPTIN	To study the peripheral effects of melanocortin on fuel homeostasis in skeletal muscle, we assessed palmitate oxidation and AMP kinase activity in alpha-melanocyte-stimulating hormone (alpha-MSH)-treated muscle cells. After alpha-MSH treatment, carnitine palmitoyltransferase-1 and fatty acid oxidation (FAO) increased in a dose-dependent manner. A strong melanocortin agonist, NDP-MSH, also stimulated FAO in primary culture muscle cells and C2C12 cells. However, [Glu(6)]alpha-MSH-ND, which has ample MC4R and MC3R agonistic activity, stimulated FAO only at high concentrations (10(-5) M). JKC-363, a selective MC4R antagonist, did not suppress alpha-MSH-induced FAO. Meanwhile, SHU9119, which has both antagonistic activity on MC3R and MC4R and agonistic activity on both MC1R and MC5R, increased the effect of alpha-MSH on FAO in both C2C12 and primary muscle cells. Small interference RNA against MC5R suppressed the alpha-MSH-induced FAO effectively. cAMP analogues mimicked the effect of alpha-MSH on FAO, and the effects of both alpha-MSH and cAMP analogue-mediated FAO were antagonized by a protein kinase A inhibitor (H89) and a cAMP antagonist ((R-p)-cAMP). Acetyl-CoA carboxylase activity was suppressed by alpha-MSH and cAMP analogues by phosphorylation through AMP-activated protein kinase activation in C2C12 cells. Taken together, these results suggest that alpha-MSH increases FAO in skeletal muscle, in which MC5R may play a major role. Furthermore, these results suggest that alpha-MSH-induced FAO involves cAMP-protein kinase A-mediated AMP-activated protein kinase activation.	Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Endocrine Res Inst, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea 21 Project Med Sci, Seoul 120752, South Korea; Yanbian Univ, Coll Med, Affiliated Hosp, Dept Internal Med,Div Endocrinol, Yanji 133000, Peoples R China; Affiliated Hosp, Binzhou Med Coll, Dept Internal Med, Div Endocrinol, Shandong 256600, Peoples R China; Korea Univ, Sch Life Sci & Biotechnol, Seoul 136713, South Korea; Yonsei Univ, Dept Biochem, Seoul 120749, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yanbian University; Binzhou Medical University; Korea University; Yonsei University	Lim, SK (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, 134 Shinchon Dong, Seoul 120752, South Korea.	lsk@yumc.yonsei.ac.kr	Rhee, Yumie/L-8020-2019	Rhee, Yumie/0000-0003-4227-5638; Cha, Bong-Soo/0000-0003-0542-2854				Boone AN, 1999, BIOCHEM J, V341, P347, DOI 10.1042/0264-6021:3410347; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; CATANIA A, 1993, ENDOCR REV, V14, P564, DOI 10.1210/er.14.5.564; Chagnon YC, 1997, MOL MED, V3, P663, DOI 10.1007/BF03401705; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Chen WB, 1997, CELL, V91, P789, DOI 10.1016/S0092-8674(00)80467-5; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; Cone RD, 1999, TRENDS ENDOCRIN MET, V10, P211, DOI 10.1016/S1043-2760(99)00153-8; DANIELS MP, 1990, J CELL SCI, V97, P615; Djouadi F, 2003, MOL GENET METAB, V78, P112, DOI 10.1016/S1096-7192(03)00017-9; Dyck JRB, 1999, EUR J BIOCHEM, V262, P184, DOI 10.1046/j.1432-1327.1999.00371.x; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Ferrannini E, 1998, ENDOCR REV, V19, P477, DOI 10.1210/edrv.19.4.0336; Forbes S, 2001, P NATL ACAD SCI USA, V98, P4233, DOI 10.1073/pnas.071054298; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Goodpaster BH, 1997, DIABETES, V46, P1579, DOI 10.2337/diabetes.46.10.1579; Grill HJ, 1998, J NEUROSCI, V18, P10128; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hoggard N, 2004, J MOL ENDOCRINOL, V32, P145, DOI 10.1677/jme.0.0320145; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kask A, 1999, NEUROREPORT, V10, P707, DOI 10.1097/00001756-199903170-00009; Kishi K, 2000, BIOCHEM BIOPH RES CO, V276, P16, DOI 10.1006/bbrc.2000.3417; LABBE O, 1994, BIOCHEMISTRY-US, V33, P4543, DOI 10.1021/bi00181a015; Lee EJ, 2001, EUR J BIOCHEM, V268, P582, DOI 10.1046/j.1432-1327.2001.01900.x; Li SZ, 1999, EUR J BIOCHEM, V265, P430, DOI 10.1046/j.1432-1327.1999.00763.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mizuno TM, 1998, DIABETES, V47, P294, DOI 10.2337/diabetes.47.2.294; Norman D, 2003, MOL CELL ENDOCRINOL, V200, P99, DOI 10.1016/S0303-7207(02)00410-0; PAGLIASSOTTI MJ, 1995, OBES RES, V3, P459, DOI 10.1002/j.1550-8528.1995.tb00175.x; Pan DA, 1997, DIABETES, V46, P983, DOI 10.2337/diabetes.46.6.983; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SAGGERSON D, 1992, ADV ENZYME REGUL, V32, P285; SAGGERSON ED, 1981, FEBS LETT, V129, P229, DOI 10.1016/0014-5793(81)80171-8; Schioth HB, 1999, NEUROPEPTIDES, V33, P191, DOI 10.1054/npep.1999.0760; SIMONEAU JA, 1995, FASEB J, V9, P273, DOI 10.1096/fasebj.9.2.7781930; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; Velasco G, 1998, J BIOL CHEM, V273, P21497, DOI 10.1074/jbc.273.34.21497; WINDER WW, 1990, AM J PHYSIOL, V259, pE266, DOI 10.1152/ajpendo.1990.259.2.E266; Winder WW, 1997, J APPL PHYSIOL, V82, P219, DOI 10.1152/jappl.1997.82.1.219; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Yamagishi SI, 2001, J BIOL CHEM, V276, P25096, DOI 10.1074/jbc.M007383200; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; Zemel MB, 2000, NUTR REV, V58, P177, DOI 10.1111/j.1753-4887.2000.tb01857.x	50	45	47	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2862	2870		10.1074/jbc.M603454200	http://dx.doi.org/10.1074/jbc.M603454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17127674	hybrid			2022-12-27	WOS:000243793900012
J	Krishnamurthy, K; Wang, GH; Silva, J; Condie, BG; Bieberich, E				Krishnamurthy, Kannan; Wang, Guanghu; Silva, Jeane; Condie, Brian G.; Bieberich, Erhard			Ceramide regulates atypical PKC zeta lambda-mediated cell polarity in primitive Ectoderm cells - A novel function of sphingolipids in morphogenesis.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ZETA; EMBRYONIC STEM-CELLS; SERINE PALMITOYLTRANSFERASE; DIFFERENTIATION; APOPTOSIS; COMPLEX; SURVIVAL; MOUSE; CAVITATION; ACTIVATION	In mammals, the primitive ectoderm is an epithelium of polarized cells that differentiates into all embryonic tissues. Our study shows that in primitive ectoderm cells, the sphingolipid ceramide was elevated and co-distributed with the small GTPase Cdc42 and cortical F-actin at the apicolateral cell membrane. Pharmacological or RNA interference-mediated inhibition of ceramide biosynthesis enhanced apoptosis and impaired primitive ectoderm formation in embryoid bodies differentiated from mouse embryonic stem cells. Primitive ectoderm formation was restored by incubation with ceramide or a ceramide analog. Ceramide depletion prevented plasma membrane translocation of PKC zeta/lambda, its interaction with Cdc42, and phosphorylation of GSK-3 beta, a substrate of PKC zeta/lambda. Recombinant PKC zeta formed a complex with the polarity protein Par6 and Cdc42 when bound to ceramide containing lipid vesicles. Our data suggest a novel mechanism by which a ceramide-induced, apicolateral polarity complex with PKC zeta/lambda regulates primitive ectoderm cell polarity and morphogenesis.	Med Coll Georgia, Inst Mol Med & Genet, Sch Med, Augusta, GA 30912 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA	University System of Georgia; Augusta University; University System of Georgia; University of Georgia	Bieberich, E (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Sch Med, 1120 15th St,Rm CB-2803, Augusta, GA 30912 USA.	ebieberich@mail.mcg.edu		Silva, PhD, MPA, EdS, EdD, MB(ASCP)CM, Jeane/0000-0003-3368-3963	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046835] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS046835] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bieberich E, 2000, J BIOL CHEM, V275, P177, DOI 10.1074/jbc.275.1.177; Bieberich E, 2004, GLYCOCONJUGATE J, V21, P315, DOI 10.1023/B:GLYC.0000046274.35732.47; Bieberich E, 2003, J CELL BIOL, V162, P469, DOI 10.1083/jcb.200212067; Bieberich E, 2004, J CELL BIOL, V167, P723, DOI 10.1083/jcb.200405144; Bieberich E, 2002, CANCER LETT, V181, P55, DOI 10.1016/S0304-3835(02)00049-6; Bieberich E, 2001, J BIOL CHEM, V276, P44396, DOI 10.1074/jbc.M107239200; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Chen F, 2000, CURR BIOL, V10, P758, DOI 10.1016/S0960-9822(00)00571-6; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; Cowart LA, 2002, J LIPID RES, V43, P2042, DOI 10.1194/jlr.M200241-JLR200; Dasgupta S, 2001, J LIPID RES, V42, P301; Desbaillets I, 2000, EXP PHYSIOL, V85, P645, DOI 10.1017/S0958067000021047; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Frey RS, 2006, J BIOL CHEM, V281, P16128, DOI 10.1074/jbc.M508810200; Hanada K, 2000, BIOCHEM PHARMACOL, V59, P1211, DOI 10.1016/S0006-2952(00)00251-3; Hojjati MR, 2005, BBA-MOL CELL BIOL L, V1737, P44, DOI 10.1016/j.bbalip.2005.08.006; Kim SK, 2000, NAT CELL BIOL, V2, pE143, DOI 10.1038/35019620; Li L, 2004, DEVELOPMENT, V131, P5277, DOI 10.1242/dev.01415; Li Shaohua, 2006, V329, P113; Liu XF, 2004, MOL CELL BIOL, V24, P6665, DOI 10.1128/mcb.24.15.6665-6675.2004; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Marasas WFO, 2004, J NUTR, V134, P711, DOI 10.1093/jn/134.4.711; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Rodda SJ, 2002, INT J DEV BIOL, V46, P449; Soloff RS, 2004, J IMMUNOL, V173, P3250, DOI 10.4049/jimmunol.173.5.3250; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Waes JG, 2005, BIRTH DEFECTS RES A, V73, P487, DOI 10.1002/bdra.20148; Wang GH, 2005, J BIOL CHEM, V280, P26415, DOI 10.1074/jbc.M501492200; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; Westmoreland JJ, 2001, BIOCHEM BIOPH RES CO, V284, P674, DOI 10.1006/bbrc.2001.5031; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142	36	38	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3379	3390		10.1074/jbc.M607779200	http://dx.doi.org/10.1074/jbc.M607779200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17105725	hybrid			2022-12-27	WOS:000243793900064
J	Vortherms, TA; Mosier, PD; Westkaemper, RB; Roth, BL				Vortherms, Timothy A.; Mosier, Philip D.; Westkaemper, Richard B.; Roth, Bryan L.			Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity - Studies with salvinorin A and the kappa-opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE D2 RECEPTOR; BINDING-SITE CREVICES; SALVIA-DIVINORUM; TRANSMEMBRANE SEGMENT; MOLECULAR-MECHANISMS; SEROTONIN RECEPTORS; AGONIST; ACCESSIBILITY; RESIDUES; DOMAINS	Salvinorin A, the active component of the hallucinogenic sage Salvia divinorum, is an apparently selective and highly potent kappa-opioid receptor (KOR) agonist. Salvinorin A is unique among ligands for peptidergic G protein-coupled receptors in being nonnitrogenous and lipid-like in character. To examine the molecular basis for the subtype-selective binding of salvinorin A, we utilized an integrated approach using chimeric opioid receptors, site-directed mutagenesis, the substituted cysteine accessibility method, and molecular modeling and dynamics studies. We discovered that helix 2 is required for salvinorin A binding to KOR and that two residues (Val-108(2.53) and Val-118(2.63)) confer subtype selectivity. Intriguingly, molecular modeling studies predicted that these loci exhibit an indirect effect on salvinorin A binding, presumably through rotation of helix 2. Significantly, and in agreement with our in silico predictions, substituted cysteine accessibility method analysis of helix 2 comparing KOR and the delta-opioid receptor, which has negligible affinity for salvinorin A, revealed that residues known to be important for salvinorin A binding exhibit a differential pattern of water accessibility. These findings imply that differences in the helical orientation of helix 2 are critical for the selectivity of salvinorin A binding to KOR and provide a structurally novel basis for ligand selectivity.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA; Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Virginia Commonwealth University	Roth, BL (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, CB 7365,8032 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.	bryan_roth@med.unc.edu	Roth, Bryan L/F-3928-2010		NHLBI NIH HHS [5T32HL007653-17] Funding Source: Medline; NIDA NIH HHS [R01 DA018151-01A2, R01 DA018151, 1F32DA022188-01, R01DA017204] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F32DA022188, R01DA018151, R01DA017204] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Chavkin C, 2004, J PHARMACOL EXP THER, V308, P1197, DOI 10.1124/jpet.103.059394; CHEN Y, 1993, BIOCHEM J, V295, P625, DOI 10.1042/bj2950625; Eguchi M, 2004, MED RES REV, V24, P182, DOI 10.1002/med.10059; Harding WW, 2005, J MED CHEM, V48, P4765, DOI 10.1021/jm048963m; Javitch JA, 2000, BIOCHEMISTRY-US, V39, P12190, DOI 10.1021/bi001069m; Javitch JA, 1998, BIOCHEMISTRY-US, V37, P998, DOI 10.1021/bi972241y; JONES G, 1995, CURR OPIN BIOTECH, V6, P652, DOI 10.1016/0958-1669(95)80107-3; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kane BE, 2006, FEBS J, V273, P1966, DOI 10.1111/j.1742-4658.2006.05212.x; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Munro TA, 2005, J MED CHEM, V48, P345, DOI 10.1021/jm049438q; Nichols DE, 2004, PHARMACOL THERAPEUT, V101, P131, DOI 10.1016/j.pharmthera.2003.11.002; Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399; Setola V, 2005, MOL PHARMACOL, V68, P20, DOI 10.1124/mol.104.009266; Shapiro DA, 2000, MOL PHARMACOL, V58, P877, DOI 10.1124/mol.58.5.877; Shapiro DA, 2002, J BIOL CHEM, V277, P11441, DOI 10.1074/jbc.M111675200; Sharma SK, 2001, J MED CHEM, V44, P2073, DOI 10.1021/jm010095v; Sheffler DJ, 2003, TRENDS PHARMACOL SCI, V24, P107, DOI 10.1016/S0165-6147(03)00027-0; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Shi L, 2001, BIOCHEMISTRY-US, V40, P12339, DOI 10.1021/bi011204a; SIEBERT DJ, 1994, J ETHNOPHARMACOL, V43, P53, DOI 10.1016/0378-8741(94)90116-3; VALDES LJ, 1983, J ETHNOPHARMACOL, V7, P287, DOI 10.1016/0378-8741(83)90004-1; VALDES LJ, 1994, J PSYCHOACTIVE DRUGS, V26, P277, DOI 10.1080/02791072.1994.10472441; Watson B, 1996, NEUROBIOL DIS, V3, P87, DOI 10.1006/nbdi.1996.0009; Xu W, 2000, BIOCHEMISTRY-US, V39, P13904, DOI 10.1021/bi001099p; Xu W, 2005, BIOCHEMISTRY-US, V44, P16014, DOI 10.1021/bi050938a; Xu W, 2001, BIOCHEMISTRY-US, V40, P8018, DOI 10.1021/bi002490d; Yan F, 2005, BIOCHEMISTRY-US, V44, P8643, DOI 10.1021/bi050490d	33	27	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3146	3156		10.1074/jbc.M609264200	http://dx.doi.org/10.1074/jbc.M609264200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17121830	hybrid			2022-12-27	WOS:000243793900040
J	Weitz, D; Harder, D; Casagrande, F; Fotiadis, D; Obrdlik, P; Kelety, B; Daniel, H				Weitz, Dietmar; Harder, Daniel; Casagrande, Fabio; Fotiadis, Dimitrios; Obrdlik, Petr; Kelety, Bela; Daniel, Hannelore			Functional and structural characterization of a prokaryotic peptide transporter with features similar to mammalian PEPT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; DIPEPTIDE TRANSPORTER; H+/PEPTIDE COTRANSPORTER; CHARGE TRANSLOCATION; IDENTIFICATION; SUBSTRATE; PURIFICATION; RECOGNITION; PHYSIOLOGY; HISTIDINE	The ydgR gene of Escherichia coli encodes a protein of the proton-dependent oligopeptide transporter (POT) family. We cloned YdgR and overexpressed the His-tagged fusion protein in E. coli BL21 cells. Bacterial growth inhibition in the presence of the toxic phosphonopeptide alafosfalin established YgdR functionality. Transport was abolished in the presence of the proton ionophore carbonyl cyanide p-chlorophenylhydrazone, suggesting a proton-coupled transport mechanism. YdgR transports selectively only di- and tripeptides and structurally related peptidomimetics (such as aminocephalosporins) with a substrate recognition pattern almost identical to the mammalian peptide transporter PEPT1. The YdgR protein was purified to homogeneity from E. coli membranes. Blue native-polyacrylamide gel electrophoresis and transmission electron microscopy of detergent-solubilized YdgR suggest that it exists in monomeric form. Transmission electron microscopy revealed a crown-like structure with a diameter of similar to 8 nm and a central density. These are the first structural data obtained from a proton-dependent peptide transporter, and the YgdR protein seems an excellent model for studies on substrate and inhibitor interactions as well as on the molecular architecture of cell membrane peptide transporters.	Tech Univ Munich, Dept Food & Nutr, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany; Univ Basel, Biozentrum, ME Muller Inst Struct Biol, CH-4056 Basel, Switzerland; Iongate Biosci GmbH, D-65926 Frankfurt, Germany	Technical University of Munich; University of Basel	Daniel, H (corresponding author), Tech Univ Munich, Dept Food & Nutr, Mol Nutr Unit, Forum 5, D-85350 Freising Weihenstephan, Germany.	daniel@wzw.tum.de	Daniel, Hannelore/B-8982-2009	Harder, Daniel/0000-0003-4226-9748				Bolger MB, 1998, J PHARM SCI-US, V87, P1286, DOI 10.1021/js980090u; Brandsch M, 2004, EUR J PHARM SCI, V21, P53, DOI 10.1016/S0928-0987(03)00142-8; Chen XZ, 2000, BIOCHEM BIOPH RES CO, V272, P726, DOI 10.1006/bbrc.2000.2851; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Covitz KMY, 1998, BIOCHEMISTRY-US, V37, P15214, DOI 10.1021/bi981128k; Daniel H, 2004, PFLUG ARCH EUR J PHY, V447, P610, DOI 10.1007/s00424-003-1101-4; Daniel H, 2004, ANNU REV PHYSIOL, V66, P361, DOI 10.1146/annurev.physiol.66.032102.144149; DEKKER JP, 1988, BIOCHIM BIOPHYS ACTA, V936, P307, DOI 10.1016/0005-2728(88)90006-0; Dieck ST, 1999, GLIA, V25, P10, DOI 10.1002/(SICI)1098-1136(19990101)25:1<10::AID-GLIA2>3.0.CO;2-Y; Doring F, 1996, J PHYSIOL-LONDON, V497, P773; Doring F, 1998, J BIOL CHEM, V273, P23211, DOI 10.1074/jbc.273.36.23211; Fei YJ, 1997, BIOCHEMISTRY-US, V36, P452, DOI 10.1021/bi962058p; Fei YJ, 1998, BIOCHEM BIOPH RES CO, V246, P39, DOI 10.1006/bbrc.1998.8566; Ganapathy ME, 1998, BIOCHEM BIOPH RES CO, V246, P470, DOI 10.1006/bbrc.1998.8628; Geibel S, 2006, J BIOMOL SCREEN, V11, P262, DOI 10.1177/1087057105285110; GIBSON MM, 1984, J BACTERIOL, V160, P122, DOI 10.1128/JB.160.1.122-130.1984; Goh EB, 2004, J BACTERIOL, V186, P4019, DOI 10.1128/JB.186.12.4019-4024.2004; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; HIGGINS CF, 1986, METHOD ENZYMOL, V125, P365; Meyer-Lipp K, 2004, BIOCHEMISTRY-US, V43, P12606, DOI 10.1021/bi0489053; Otto C, 1996, AM J PHYSIOL, V271, P210; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; STEINER HY, 1995, MOL MICROBIOL, V16, P825, DOI 10.1111/j.1365-2958.1995.tb02310.x; Tamai I, 1998, J PHARM SCI-US, V87, P1542, DOI 10.1021/js980186o; Terada T, 1996, FEBS LETT, V394, P196, DOI 10.1016/0014-5793(96)00952-0; Terada T, 2004, CURR DRUG METAB, V5, P85, DOI 10.2174/1389200043489153; Theis S, 2002, MOL PHARMACOL, V61, P214, DOI 10.1124/mol.61.1.214; Theis S, 2001, PROTEIN EXPRES PURIF, V22, P436, DOI 10.1006/prep.2001.1455; Yeung AK, 1998, BIOCHEM BIOPH RES CO, V250, P103, DOI 10.1006/bbrc.1998.9283; Zhuang JP, 1999, J STRUCT BIOL, V125, P63, DOI 10.1006/jsbi.1998.4059; Zuber D, 2005, BBA-BIOENERGETICS, V1709, P240, DOI 10.1016/j.bbabio.2005.07.009	32	61	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2832	2839		10.1074/jbc.M604866200	http://dx.doi.org/10.1074/jbc.M604866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17158458	hybrid			2022-12-27	WOS:000243793900009
J	Fujiwara, Y; Osborne, DA; Walker, MD; Wang, DA; Bautista, DA; Liliom, K; Van Brocklyn, JR; Parrill, AL; Tigyi, G				Fujiwara, Yuko; Osborne, Daniel A.; Walker, Michelle D.; Wang, De-an; Bautista, Debra A.; Liliom, Karoly; Van Brocklyn, James R.; Parrill, Abby L.; Tigyi, Gabor			Identification of the hydrophobic ligand binding pocket of the S1P(1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SPHINGOSINE 1-PHOSPHATE RECEPTOR-1; SITE-DIRECTED MUTAGENESIS; FORCE-FIELD; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; AGONIST; CALCIUM; FTY720; EDG1	Sphingosine 1-phosphate (S1P), a naturally occurring sphingolipid mediator and also a second messenger with growth factor-like actions in almost every cell type, is an endogenous ligand of five G protein-coupled receptors (GPCRs) in the endothelial differentiation gene family. The lack of GPCR crystal structures sets serious limitations to rational drug design and in silico searches for subtype-selective ligands. Here we report on the experimental validation of a computational model of the ligand binding pocket of the S1P(1) GPCR surrounding the aliphatic portion of S1P. The extensive mutagenesis-based validation confirmed 18 residues lining the hydrophobic ligand binding pocket, which, combined with the previously validated three head group-interacting residues, now complete the mapping of the S1P ligand recognition site. We identified six mutants (L3.43G/L3.44G, L3.43E/L3.44E, L5.52A, F5.48G, V6.40L, and F6.44G) that maintained wild type [P-32]S1P binding with abolished ligand-dependent activation by S1P. These data suggest a role for these amino acids in the conformational transition of S1P(1) to its activated state. Three aromatic mutations (F5.48Y, F6.44G, and W6.48A) result in differential activation, by S1P or SEW2871, indicating that structural differences between the two agonists can partially compensate for differences in the amino acid side chain. The now validated ligand binding pocket provided us with a pharmacophore model, which was used for in silico screening of the NCI, National Institutes of Health, Developmental Therapeutics chemical library, leading to the identification of two novel nonlipid agonists of S1P(1).	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA; Univ Memphis, Computat Res Mat Inst, Memphis, TN 38152 USA; Eastern Kentucky Univ, Dept Chem, Richmond, KY 40475 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43250 USA; Hungarian Acad Sci, Inst Enzymol, Budapest, Hungary	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Memphis; University System of Ohio; Ohio State University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences	Tigyi, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu	Liliom, Karoly/A-6563-2011; Van Brocklyn, Jim/A-9733-2010	Liliom, Karoly/0000-0002-7177-6872; Parrill, Abby/0000-0003-1658-8497	NCI NIH HHS [R01 CA092160, R01 CA092160-09, CA92160] Funding Source: Medline; NHLBI NIH HHS [R01 HL061469, HL61469] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092160] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bautista DL, 2000, J MOL STRUC-THEOCHEM, V529, P219, DOI 10.1016/S0166-1280(00)00549-2; Blaker M, 2000, MOL PHARMACOL, V58, P399, DOI 10.1124/mol.58.2.399; Brinkmann V, 2004, AM J TRANSPLANT, V4, P1019, DOI 10.1111/j.1600-6143.2004.00476.x; Brinkmann V, 2002, CURR OPIN IMMUNOL, V14, P569, DOI 10.1016/S0952-7915(02)00374-6; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; BUENEMANN M, 1996, EMBO J, V15, P5524; Chae SS, 2004, J CLIN INVEST, V114, P1082, DOI 10.1172/JCI200422716; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Cinamon G, 2004, NAT IMMUNOL, V5, P713, DOI 10.1038/ni1083; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Di Paolo E, 1999, PEPTIDES, V20, P1187, DOI 10.1016/S0196-9781(99)00122-9; Escrieut C, 2002, J BIOL CHEM, V277, P7546, DOI 10.1074/jbc.M108563200; Gao ZG, 2002, J BIOL CHEM, V277, P19056, DOI 10.1074/jbc.M110960200; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler MH, 2003, J BIOL CHEM, V278, P27737, DOI 10.1074/jbc.C300147200; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X; Heringdorf DMZ, 2003, FEBS LETT, V554, P443, DOI 10.1016/S0014-5793(03)01219-5; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; Inagaki Y, 2005, BIOCHEM J, V389, P187, DOI 10.1042/BJ20050046; Itagaki K, 2003, J BIOL CHEM, V278, P27540, DOI 10.1074/jbc.M301763200; Jo EJ, 2005, CHEM BIOL, V12, P703, DOI 10.1016/j.chembiol.2005.04.019; Konvicka K, 1998, BIOPHYS J, V75, P601, DOI 10.1016/S0006-3495(98)77551-4; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Liliom K, 2001, BIOCHEM J, V355, P189, DOI 10.1042/0264-6021:3550189; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; McAllister SD, 2004, J BIOL CHEM, V279, P48024, DOI 10.1074/jbc.M406648200; Meini S, 2004, BIOCHEM PHARMACOL, V67, P601, DOI 10.1016/j.bcp.2003.09.034; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Parrill AL, 2004, SEMIN CELL DEV BIOL, V15, P467, DOI 10.1016/j.semcdb.2004.05.006; Parrill AL, 2000, J BIOL CHEM, V275, P39379, DOI 10.1074/jbc.M007680200; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016/S1388-1981(04)00023-X; Tigyi G, 2003, PROG LIPID RES, V42, P498, DOI 10.1016/S0163-7827(03)00035-3; Wang DA, 2001, J BIOL CHEM, V276, P49213, DOI 10.1074/jbc.M107301200; Yamamura S, 1997, BIOCHEMISTRY-US, V36, P10751, DOI 10.1021/bi970926s; Yang Y, 2000, BIOCHEMISTRY-US, V39, P14900, DOI 10.1021/bi001684q	43	48	54	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2374	2385		10.1074/jbc.M609648200	http://dx.doi.org/10.1074/jbc.M609648200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17114791	hybrid, Green Accepted			2022-12-27	WOS:000243593200029
J	Ki, SH; Choi, MJ; Lee, CH; Kim, SG				Ki, Sung Hwan; Choi, Min Jung; Lee, Chang Ho; Kim, Sang Geon			G alpha(12) specifically regulates COX-2 induction by sphingosine 1-phosphate - Role for JNK-dependent ubiquitination and degradation of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; LIGASE ITCH; C/EBP-BETA; TNF-ALPHA; ACTIVATION; RECEPTOR; CYCLOOXYGENASE-2; CELLS; PHOSPHORYLATION; KINASE	Cyclooxygenase-2 (COX-2) plays a critical role in vasodilatation and local inflammatory responses during platelet aggregation and thrombosis. Sphingosine 1-phosphate (S1P), a sphingolipid released from activated platelets, stimulates COX-2 induction and activates G-protein-coupled receptors coupled to G alpha family members. In this study, we investigated whether G alpha(12) family regulates COX-2 induction by S1P and investigated the molecular basis of this COX-2 regulation. Gene knock-out and chemical inhibitor experiments revealed that the S1P induction of COX-2 requires G alpha(12) but not G alpha(13), G alpha(q), or G alpha(i/o). The specific role of G alpha(12) in COX-2 induction by S1P was verified by promoter luciferase assay, G alpha(12) transfection, and knockdown experiments. Experiments using siRNAs specifically directed against S1P(1-5) showed that S1P(1), S1P(3), and S1P(5) are necessary for the full activation of COX-2 induction. Gel shift, immunocytochemistry, chromatin immuno-precipitation, and NF-kappa B site mutation analyses revealed the role of NF-kappa B inCOX-2 gene transcription by S1P. G alpha(12) deficiency did not affect S1P-mediated I kappa B alpha phosphorylation but abrogated I kappa B alpha ubiquitination and degradation. Moreover, the inhibition of S1P activation of JNK abolished I kappa B alpha ubiquitination. Consistently, JNK transfection restored the ability of S1P to degrade I kappa B alpha during G alpha(12) deficiency. S1P injection induced COX-2 in the lungs and livers of mice and increased plasma prostaglandin E-2, and these effects were prevented by G alpha(12) deficiency. Our data indicate that, of the G alpha proteins coupled to S1P receptors, G alpha(12) specifically regulates NF-kappa B-mediated COX-2 induction by S1P downstream of S1P(1), S1P(3), and S1P(5), in a process mediated by the JNK-dependent ubiquitination and degradation of I kappa B alpha.	Seoul Natl Univ, Coll Pharm, Natl Res Lab, Seoul 151742, South Korea; Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Hanyang Univ, Dept Pharmacol, Seoul 133791, South Korea; Hanyang Univ, Inst Biomed Sci, Seoul 133791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Hanyang University; Hanyang University	Kim, SG (corresponding author), Seoul Natl Univ, Coll Pharm, Natl Res Lab, Sillim Dong, Seoul 151742, South Korea.	sgk@snu.ac.kr						APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Boguslawski G, 2002, EXP CELL RES, V274, P264, DOI 10.1006/excr.2002.5472; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Deutschman DH, 2003, AM HEART J, V146, P62, DOI 10.1016/S0002-8703(03)00118-2; Dhanasekaran N, 1998, ONCOGENE, V17, P1329, DOI 10.1038/sj.onc.1202170; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Kang KW, 2003, J BIOL CHEM, V278, P17368, DOI 10.1074/jbc.M300471200; Ki SH, 2005, MOL CELL BIOL, V25, P4150, DOI 10.1128/MCB.25.10.4150-4165.2005; Kim JI, 2003, J BIOL CHEM, V278, P31731, DOI 10.1074/jbc.M300625200; Maeda T, 2003, PROG RETIN EYE RES, V22, P417, DOI 10.1016/S1350-9462(03)00017-X; Moers A, 2003, NAT MED, V9, P1418, DOI 10.1038/nm943; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Ohashi K, 2001, INT J CLIN PHARM RES, V21, P85; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pan MH, 2000, BIOCHEM PHARMACOL, V60, P1665, DOI 10.1016/S0006-2952(00)00489-5; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; Siehler S, 2001, J BIOL CHEM, V276, P48733, DOI 10.1074/jbc.M011072200; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; Sol VVD, 2005, J IMMUNOL, V174, P2825, DOI 10.4049/jimmunol.174.5.2825; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Srinivas H, 2005, MOL CELL BIOL, V25, P1054, DOI 10.1128/MCB.25.3.1054-1069.2005; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yatomi Y, 1997, J BIOCHEM, V121, P969	42	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1938	1947		10.1074/jbc.M606080200	http://dx.doi.org/10.1074/jbc.M606080200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17098744	hybrid			2022-12-27	WOS:000243451300044
J	Schottler, MA; Flugel, C; Thiele, W; Bock, R				Schoettler, Mark Aurel; Fluegel, Claudia; Thiele, Wolfram; Bock, Ralph			Knock-out of the plastid-encoded PetL subunit results in reduced stability and accelerated leaf age-dependent loss of the cytochrome b(6)f complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; CHLAMYDOMONAS-REINHARDTII; BF COMPLEX; THYLAKOID MEMBRANE; ELECTRON-TRANSPORT; STATE TRANSITIONS; PHOTOSYSTEM-I; ATP-SYNTHASE; CHLOROPLAST; PHOTOSYNTHESIS	The cytochrome-b(6)f complex, a key component of the photosynthetic electron transport chain, contains a number of very small protein subunits whose functions are not well defined. Here we have investigated the function of the 31-amino acid PetL subunit encoded in the chloroplast genome in all higher plants. Chloroplast-transformed pet L knock-out tobacco plants display no obvious phenotype, suggesting that PetL is not essential for cytochrome b(6)f complex biogenesis and function (Fiebig, A., Stegemann, S., and Bock, R. (2004) Nucleic Acids Res. 32, 3615-3622). We show here that, whereas young mutant leaves accumulate comparable amounts of cytochrome b(6)f complex and have an identical assimilation capacity as wild type leaves, both cytochrome b(6)f complex contents and assimilation capacities of mature and old leaves are strongly reduced in the mutant, indicating that the cytochrome b(6)f complex is less stable than in the wild type. Reduced complex stability was also confirmed by in vitro treatments of isolated thylakoids with chaotropic reagents. Adaptive responses observed in the knockout mutants, such as delayed down-regulation of plastocyanin contents, indicate that plants can sense the restricted electron flux to photosystem I yet cannot compensate the reduced stability of the cytochrome b(6)f complex by adaptive up-regulation of complex synthesis. We propose that efficient cytochrome b(6)f complex biogenesis occurs only in young leaves and that the capacity for de novo synthesis of the complex is very low in mature and aging leaves. Gene expression analysis indicates that the ontogenetic down-regulation of cytochrome b(6)f complex biogenesis occurs at the post-transcriptional level.	Max Planck Inst Mol Pflanzenphysiol, D-14476 Potsdam, Germany	Max Planck Society	Schottler, MA (corresponding author), Max Planck Inst Mol Pflanzenphysiol, Muhlenberg 1, D-14476 Potsdam, Germany.	schoettler@mpimp-golm.mpg.de	Bock, Ralph/B-4352-2009	Bock, Ralph/0000-0001-7502-6940; Schottler, Mark Aurel/0000-0003-3210-0260				Allen JF, 2004, TRENDS PLANT SCI, V9, P130, DOI 10.1016/j.tplants.2004.01.009; ANDERSON JM, 1992, PHOTOSYNTH RES, V34, P341, DOI 10.1007/BF00029810; ANDERSON JM, 1988, AUST J PLANT PHYSIOL, V15, P11, DOI 10.1071/PP9880011; Anderson JM, 1997, PHOTOSYNTH RES, V53, P215, DOI 10.1023/A:1005856615915; BERTHOLD DA, 1995, J BIOL CHEM, V270, P29293, DOI 10.1074/jbc.270.49.29293; Bonardi V, 2005, NATURE, V437, P1179, DOI 10.1038/nature04016; Breyton C, 1997, J BIOL CHEM, V272, P21892, DOI 10.1074/jbc.272.35.21892; Brown NJ, 2005, PLANT J, V43, P541, DOI 10.1111/j.1365-313X.2005.02474.x; Choquet Y, 2003, PLANT CELL, V15, P1443, DOI 10.1105/tpc.011692; Choquet Y, 2001, BIOCHEM SOC T, V29, P421, DOI 10.1042/BST0290421; Cramer WA, 2005, PHOTOSYNTH RES, V85, P133, DOI 10.1007/s11120-004-2149-5; Eberhard S, 2002, PLANT J, V31, P149, DOI 10.1046/j.1365-313X.2002.01340.x; Fernie AR, 2004, CURR OPIN PLANT BIOL, V7, P254, DOI 10.1016/j.pbi.2004.03.007; Fiebig A, 2004, NUCLEIC ACIDS RES, V32, P3615, DOI 10.1093/nar/gkh695; Gong XS, 2001, J BIOL CHEM, V276, P24365, DOI 10.1074/jbc.M010721200; Gupta R, 2002, P NATL ACAD SCI USA, V99, P15806, DOI 10.1073/pnas.222550399; Hager M, 1999, EMBO J, V18, P5834, DOI 10.1093/emboj/18.21.5834; Hauska G., 1996, OXYGENIC PHOTOSYNTHE, P377; Hope AB, 2000, BBA-BIOENERGETICS, V1456, P5, DOI 10.1016/S0005-2728(99)00101-2; Joliot P, 1998, BIOCHEMISTRY-US, V37, P10404, DOI 10.1021/bi980546m; Kaneko T, 1996, DNA Res, V3, P109; Kirchhoff H, 2002, BIOCHEMISTRY-US, V41, P4872, DOI 10.1021/bi011650y; Kirchhoff H, 2004, BBA-BIOENERGETICS, V1659, P63, DOI 10.1016/j.bbabio.2004.08.004; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; Lamkemeyer P, 2006, PLANT J, V45, P968, DOI 10.1111/j.1365-313X.2006.02665.x; Lennartz K, 2006, PLANT J, V45, P101, DOI 10.1111/j.1365-313X.2005.02605.x; Lennartz K, 2001, PLANT CELL, V13, P2539, DOI 10.1105/tpc.13.11.2539; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; Maiwald D, 2003, PLANT PHYSIOL, V133, P191, DOI 10.1104/pp.103.024190; Majeran W, 2000, PLANT CELL, V12, P137; Metzger SU, 1997, BBA-BIOENERGETICS, V1319, P233, DOI 10.1016/S0005-2728(96)00164-8; Monde RA, 2000, MOL GEN GENET, V263, P610, DOI 10.1007/s004380051208; Monde RA, 2000, PLANT J, V21, P61, DOI 10.1046/j.1365-313x.2000.00653.x; NELSON N, 1972, J BIOL CHEM, V247, P1817; Ostersetzer O, 1997, PLANT CELL, V9, P957, DOI 10.1105/tpc.9.6.957; Page MLD, 2004, J BIOL CHEM, V279, P32474, DOI 10.1074/jbc.M404285200; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Raghavendra AS, 2003, TRENDS PLANT SCI, V8, P546, DOI 10.1016/j.tplants.2003.09.015; Sacksteder CA, 2000, P NATL ACAD SCI USA, V97, P14283, DOI 10.1073/pnas.97.26.14283; Schneider D, 2001, J BIOL CHEM, V276, P16780, DOI 10.1074/jbc.M009503200; Schottler MA, 2004, PLANT PHYSIOL, V136, P4265, DOI 10.1104/pp.104.052324; Sherameti I, 2004, PLANT J, V38, P578, DOI 10.1111/j.1365-313X.2004.02069.x; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; Whitelegge JP, 2002, MOL CELL PROTEOMICS, V1, P816, DOI 10.1074/mcp.M200045-MCP200; Zhang HM, 2001, J BIOL CHEM, V276, P38159; Zito F, 2002, J BIOL CHEM, V277, P12446, DOI 10.1074/jbc.M110914200	48	51	54	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					976	985		10.1074/jbc.M606436200	http://dx.doi.org/10.1074/jbc.M606436200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17114182	hybrid			2022-12-27	WOS:000243295200020
J	Gao, X; Sadana, R; Dessauer, CW; Patel, TB				Gao, Xianlong; Sadana, Rachna; Dessauer, Carmen W.; Patel, Tarun B.			Conditional stimulation of type V and VI adenylyl cyclases by G protein beta gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINUS DOMAIN; RECEPTOR KINASE; SF9 CELLS; INHIBITION; IDENTIFICATION; EXPRESSION; DIVERSITY; PHOSPHORYLATION; ACTIVATION; REGIONS	In a yeast two-hybrid screen of mouse brain cDNA library, using the N-terminal region of human type V adenylyl cyclase (hACV) as bait, we identified G protein beta 2 subunit as an interacting partner. Additional yeast two-hybrid assays showed that the G beta(1), subunit also interacts with the N-terminal segments of hACV and human type VI adenylyl cyclase (hACVI). In vitro adenylyl cyclase (AC) activity assays using membranes of SO cells expressing hACV or hACVI showed that G beta gamma subunits enhance the activity of these enzymes provided either G alpha(s) or forskolin is present. Deletion of residues 77-151, but not 1-76, in the N-terminal region of hACVI obliterated the ability of G,67 subunits to conditionally stimulate the enzyme. Likewise, activities of the recombinant, engineered, soluble forms of ACV and ACVI, which lack the N termini, were not enhanced by G beta gamma subunits. Transfection of the C terminus of G protein receptor kinase 2 to sequester endogenous G beta gamma subunits attenuated the ability of isoproterenol to increase cAMP accumulation in COS-7 cells overexpressing hACVI even when G(i) was inactivated by pertussis toxin. Therefore, we conclude that the N termini of human hACV and hACVI are necessary for interactions with, and regulation by, G beta gamma subunits both in vitro and in intact cells. Moreover, G beta gamma subunits derived from a source(s) other than G(i) are necessary for the full activation of hACVI by isoproterenol in intact cells.	Loyola Univ, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, Maywood, IL 60153 USA; Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	Loyola University Chicago; University of Texas System; University of Texas Health Science Center Houston	Patel, TB (corresponding author), Loyola Univ, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, 2160 S 1st Ave, Maywood, IL 60153 USA.	tpatel7@lumc.edu	Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NHLBI NIH HHS [HL59679] Funding Source: Medline; NIGMS NIH HHS [R01 GM060419-07, GM073181, R01 GM060419, GM060419] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060419, R01GM073181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bayewitch ML, 1998, FASEB J, V12, P1019, DOI 10.1096/fasebj.12.11.1019; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; Chen-Goodspeed M, 2005, J BIOL CHEM, V280, P1808, DOI 10.1074/jbc.M409172200; Chou JL, 2004, J BIOL CHEM, V279, P46271, DOI 10.1074/jbc.M407206200; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; Diel S, 2006, J BIOL CHEM, V281, P288, DOI 10.1074/jbc.M511045200; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Gao XL, 2005, MOL PHARMACOL, V67, P42, DOI 10.1124/mol.104.005355; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; Kao YY, 2004, J BIOL CHEM, V279, P34440, DOI 10.1074/jbc.M401952200; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lai HL, 1999, MOL PHARMACOL, V56, P644, DOI 10.1124/mol.56.3.644; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Muller S, 1996, J BIOL CHEM, V271, P11781, DOI 10.1074/jbc.271.20.11781; Patel TB, 2001, GENE, V269, P13, DOI 10.1016/S0378-1119(01)00448-6; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; PREMONT RT, 1994, METHOD ENZYMOL, V238, P116; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Salim S, 2003, J BIOL CHEM, V278, P15842, DOI 10.1074/jbc.M210663200; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Scholich K, 1997, P NATL ACAD SCI USA, V94, P9602, DOI 10.1073/pnas.94.18.9602; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Smith MS, 1998, ANN EMERG MED, V32, P65, DOI 10.1016/S0196-0644(98)70101-5; Steiner D, 2006, CELL SIGNAL, V18, P62, DOI 10.1016/j.cellsig.2005.03.014; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WATSON PA, 1994, J BIOL CHEM, V269, P28893; Weitmann S, 2001, BIOCHEMISTRY-US, V40, P10853, DOI 10.1021/bi011176w; Wittpoth C, 1999, P NATL ACAD SCI USA, V96, P9551, DOI 10.1073/pnas.96.17.9551; WU ZL, 1993, J BIOL CHEM, V268, P23766; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Zhong JM, 2001, J PHYSIOL-LONDON, V531, P105, DOI 10.1111/j.1469-7793.2001.0105j.x	49	36	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					294	302		10.1074/jbc.M607522200	http://dx.doi.org/10.1074/jbc.M607522200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17110384	hybrid			2022-12-27	WOS:000243166500034
J	Gavilano, LB; Coleman, NP; Bowen, SW; Siminszky, B				Gavilano, Lily B.; Coleman, Nicholas P.; Bowen, Steven W.; Siminszky, Balazs			Functional analysis of nicotine demethylase genes reveals insights into the evolution of modern tobacco	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORNICOTINE; EXPRESSION; TABACUM; TOMENTOSIFORMIS; SYLVESTRIS; CONVERSION; INCREASES; RESPONSES; ORIGIN; GENOME	Tobacco (Nicotiana tabacum L.) is a natural allotetraploid derived from the interspecific hybridization between ancestral Nicotiana sylvestris and Nicotiana tomentosiformis. The majority of cultivated tobacco differs from both of its progenitor species in that tobacco typically contains nicotine as the primary alkaloid, in contrast to its two progenitors that accumulate nornicotine in the senescing leaves. However, most, if not all, tobacco cultivars possess an unstable mutation, commonly referred to as the conversion locus, that when activated mediates the conversion of a large percentage of nicotine to nornicotine in the senescing leaf. We have recently identified CYP82E4, a tobacco nicotine N-demethylase gene whose expression was highly induced during senescence in plants that have converted, and CYP82E3, a closely related homolog that exhibited no nicotine N-demethylase activity. In this study, domain swapping and site-directed mutagenesis studies identified a single amino acid change that fully restored nicotine N-demethylase activity to CYP82E3. An examination of the N. tomentosiformis orthologs of CYP82E3 and CYP82E4 revealed that both are functional nicotine N-demethylase genes in N. tomentosiformis. Collectively, our results suggest that a single base pair mutation in CYP82E3 and transcriptional suppression of CYP82E4 played important roles in the evolution of the alkaloid profile characteristic of modern tobacco.	Univ Kentucky, Dept Plant & Soil Sci, Lexington, KY 40546 USA; N Carolina State Univ, Dept Crop Sci, Raleigh, NC 27695 USA	University of Kentucky; University of North Carolina; North Carolina State University	Siminszky, B (corresponding author), Univ Kentucky, Dept Plant & Soil Sci, 1405 Veterans Dr, Lexington, KY 40546 USA.	balazs@uky.edu						BALDWIN IT, 1994, J CHEM ECOL, V20, P2139, DOI 10.1007/BF02066250; BALDWIN IT, 1993, J CHEM ECOL, V19, P1143, DOI 10.1007/BF00987376; BALDWIN IT, 1988, OECOLOGIA, V75, P367, DOI 10.1007/BF00376939; Bogani P, 1997, MOL PHYLOGENET EVOL, V7, P62, DOI 10.1006/mpev.1996.0356; Brogan AP, 2005, P NATL ACAD SCI USA, V102, P10433, DOI 10.1073/pnas.0504721102; BURK LG, 1958, TOBACCO SCI, V2, P139; Dickerson TJ, 2002, P NATL ACAD SCI USA, V99, P15084, DOI 10.1073/pnas.222561699; Gavilano LB, 2006, J AGR FOOD CHEM, V54, P9071, DOI 10.1021/jf0610458; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOODSPEED T. H., 1954, Chronica botanica, V16, P1; GRIFFITH RB, 1955, SCIENCE, V121, P343, DOI 10.1126/science.121.3140.343; Halitschke R, 2003, PLANT J, V36, P794, DOI 10.1046/j.1365-313X.2003.01921.x; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; HECHT SS, 1989, CANCER SURV, V8, P273; HUESING J, 1989, J CHEM ECOL, V15, P1203, DOI 10.1007/BF01014823; Katz J, 2005, J PERIODONTOL, V76, P1171, DOI 10.1902/jop.2005.76.7.1171; Laue G, 2000, PLANTA, V210, P510, DOI 10.1007/s004250050038; MANN T. J., 1964, CROP SCI, V4, P349, DOI 10.2135/cropsci1964.0011183X000400040003x; METCALF R.A., 1992, DESTRUCTIVE USEFUL I; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Murad L, 2002, AM J BOT, V89, P921, DOI 10.3732/ajb.89.6.921; Paquette SM, 2000, DNA CELL BIOL, V19, P307, DOI 10.1089/10445490050021221; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; Ren N, 2001, GENOME, V44, P559, DOI 10.1139/gen-44-4-559; Riah O, 1997, NAT PROD LETT, V11, P37, DOI 10.1080/10575639708043755; Riechers DE, 1999, PLANT MOL BIOL, V41, P387, DOI 10.1023/A:1006342018991; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; SAITOH F, 1985, PHYTOCHEMISTRY, V24, P477, DOI 10.1016/S0031-9422(00)80751-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELF LS, 1964, J INSECT PHYSIOL, V10, P907, DOI 10.1016/0022-1910(64)90081-2; SIEGLER EH, 1946, J ECON ENTOMOL, V39, P673, DOI 10.1093/jee/39.5.673; Siminszky B, 2005, P NATL ACAD SCI USA, V102, P14919, DOI 10.1073/pnas.0506581102; SISSON VA, 1990, BEITR TABAKFORSCH, V14, P327, DOI 10.2478/cttr-2013-0610; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WERNSMAN. E. A, 1968, Tobacco Science, V12, P226; YAMAMOTO I, 1968, AGR BIOL CHEM TOKYO, V32, P1341, DOI 10.1080/00021369.1968.10859236; Yukawa M, 2006, MOL GENET GENOMICS, V275, P367, DOI 10.1007/s00438-005-0092-6	38	23	51	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					249	256		10.1074/jbc.M609512200	http://dx.doi.org/10.1074/jbc.M609512200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17102129	hybrid			2022-12-27	WOS:000243166500029
J	Yamaguchi, Y; Ota, K; Ito, T				Yamaguchi, Yoshihiro; Ota, Kazuhisa; Ito, Takashi			A novel Cdc42-interacting domain of the yeast polarity establishment protein Bem1 - Implications for modulation of mating pheromone signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-TYPE GTPASES; INTERACTION MAP; BUDDING YEAST; CELL POLARITY; PC MOTIF; CDC42; BINDING; MUTANTS; REGION	In Saccharomyces cerevisiae, the Rho-type small GTPase Cdc42 is activated by its guanine-nucleotide exchange factor Cdc24 to polarize the cell for budding and mating. A multidomain protein Bem1 interacts not only with Cdc42 but also with Cdc24 and the effectors of Cdc42, including the p21-activated kinase Ste20, to function as a scaffold for cell polarity establishment. Although Bem1 interacts with Cdc24 and Ste20 via its PB1 and the second SH3 domains (SH3b), respectively, it is unclear how Bem1 binds Cdc42. Here we show that a region comprising the SH3b and its C-terminal flanking segment termed CI (SH3b-CI) directly interacts, with Cdc42. A dual-bait reverse two-hybrid approach revealed that the CI is critical to the interaction: N253D substitution in the CI abolishes the binding of the SH3b-CI to Cdc42 but not to the proline-rich region of Ste20, whereas W192K substitution in the SH3b has the opposite effect. Nevertheless, the SH3b-CI interacts with Ste20 proline-rich region and Cdc42 in a mutually exclusive manner. The N253D substitution renders cellular growth temperature-sensitive and suppresses mating. The W192K-induced mating defect is exacerbated by the N253D substitution and suppressed by increasing the dosage of Ste20 provided that the CI is intact. Intriguingly, Cdc42 can mediate an indirect interaction of the SH3b-CI to the CRIB domain of Ste20. These results suggest that the SH3b and the CI collaborate in tethering of Ste20 to Bem1 to ensure efficient mating pheromone signaling.	Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol, Kashiwa, Chiba 2778561, Japan; Japan Sci & Technol Agcy, Inst Bioinformat Rs & Dev, Tokyo 1020081, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Ito, T (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol, 5-1-5 Kashiwanoha, Kashiwa, Chiba 2778561, Japan.	ito@k.u-tokyo.ac.jp		Ito, Takashi/0000-0001-6097-2803				Adams A, 1997, METHODS YEAST GENETI; Bender L, 1996, J CELL BIOL, V133, P879, DOI 10.1083/jcb.133.4.879; Bose I, 2001, J BIOL CHEM, V276, P7176, DOI 10.1074/jbc.M010546200; Butty AC, 2002, EMBO J, V21, P1565, DOI 10.1093/emboj/21.7.1565; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; Chang F, 2003, NAT CELL BIOL, V5, P294, DOI 10.1038/ncb0403-294; Drees BL, 2001, J CELL BIOL, V154, P549, DOI 10.1083/jcb.200104057; Elion EA, 2001, J CELL SCI, V114, P3967; Endo M, 2003, J BIOL CHEM, V278, P843, DOI 10.1074/jbc.M209714200; Ferrell JE, 2003, MOL CELL, V11, P289, DOI 10.1016/S1097-2765(03)00055-8; France YE, 2006, J CELL SCI, V119, P876, DOI 10.1242/jcs.02849; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Gladfelter AS, 2001, MOL BIOL CELL, V12, P1239, DOI 10.1091/mbc.12.5.1239; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Gulli MP, 2000, MOL CELL, V6, P1155, DOI 10.1016/S1097-2765(00)00113-1; Han BK, 2005, GENE DEV, V19, P2606, DOI 10.1101/gad.1361505; Irazoqui JE, 2004, J CELL SCI, V117, P2169, DOI 10.1242/jcs.00953; Irazoqui JE, 2003, NAT CELL BIOL, V5, P1062, DOI 10.1038/ncb1068; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Kubota H, 2001, J BIOL CHEM, V276, P17591, DOI 10.1074/jbc.M011793200; Lamson RE, 2002, MOL CELL BIOL, V22, P2939, DOI 10.1128/MCB.22.9.2939-2951.2002; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; Matsui Y, 1996, J CELL BIOL, V133, P865, DOI 10.1083/jcb.133.4.865; Miura F, 2001, FEBS LETT, V505, P103, DOI 10.1016/S0014-5793(01)02792-2; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Wedlich-Soldner R, 2004, J CELL BIOL, V166, P889, DOI 10.1083/jcb.200405061; Wheatley E, 2005, BIOCHEM J, V388, P177, DOI 10.1042/BJ20041838; Winters MJ, 2005, MOL CELL BIOL, V25, P2177, DOI 10.1128/MCB.25.6.2177-2190.2005; Xu H, 2006, J BIOL CHEM, V281, P27158, DOI 10.1074/jbc.M605592200; Yoshinaga S, 2003, EMBO J, V22, P4888, DOI 10.1093/emboj/cdg475; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728	34	33	33	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					29	38		10.1074/jbc.M609308200	http://dx.doi.org/10.1074/jbc.M609308200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17090539	hybrid			2022-12-27	WOS:000243166500004
J	Myslinski, E; Gerard, MA; Krol, A; Carbon, P				Myslinski, Evelyne; Gerard, Marie-Aline; Krol, Alain; Carbon, Philippe			A genome scale location analysis of human Staf/ZNF143-binding sites suggests a widespread role for human Staf/ZNF143 in mammalian promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE TRANSFER-RNA; TRANSCRIPTION ACTIVATING FACTOR; SMALL NUCLEAR-RNA; ZINC-FINGER; GENE-TRANSCRIPTION; POLYMERASE-III; START SITES; EXPRESSION; BINDING; ZNF143	Staf was originally identified as the transcriptional activator of Xenopus tRNA(Sec) and small nuclear (sn) RNA-type genes. Recently, transcription of seven human (h) protein coding genes was reported to be activated by the human ortholog hStaf/ZNF143. Here we have used a combined in silico and biochemical approach to identify 1175 conserved hStaf/ZNF143-binding sites (SBS) distributed in 938 promoters of four mammalian genomes. The SBS shows a significant positional preference and occurs mostly within 200 bp upstream of the transcription start site. Chromatin immunoprecipitation assays with 295 of the promoters established that 90% contain bona fide SBS. By extrapolating the values of this mapping to the full sizes of the mammalian genomes, we can infer the existence of at least 2500 SBS distributed in 2000 promoters. This unexpected large number strongly suggests that SBS constitutes one of the most widespread transcription factor-binding sites in mammalian promoters. Furthermore, we demonstrated that the presence of the SBS alone is sufficient to direct expression of a luciferase reporter gene, suggesting that hStaf/ZNF143 can recruit per se the transcription machinery.	Univ Strasbourg 1, Inst Biol Mol & Cellulaire, UPR CNRS Architecture & React ARN, F-67084 Strasbourg, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Carbon, P (corresponding author), Univ Strasbourg 1, Inst Biol Mol & Cellulaire, UPR CNRS Architecture & React ARN, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	P.Carbon@ibmc.u-strasbg.fr						Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6; Barski OA, 2004, GENOMICS, V83, P119, DOI 10.1016/S0888-7543(03)00213-1; Blais A, 2005, GENE DEV, V19, P1499, DOI 10.1101/gad.1325605; Caiafa P, 2005, J CELL BIOCHEM, V94, P257, DOI 10.1002/jcb.20325; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Di Leva F, 2004, J BIOL CHEM, V279, P7734, DOI 10.1074/jbc.M308140200; Grossman CE, 2004, J BIOL CHEM, V279, P12190, DOI 10.1074/jbc.M307039200; Ishiguchi H, 2004, INT J CANCER, V111, P900, DOI 10.1002/ijc.20358; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Kubota H, 2000, J BIOL CHEM, V275, P28641, DOI 10.1074/jbc.M005009200; Mach CM, 2002, J BIOL CHEM, V277, P4853, DOI 10.1074/jbc.M108308200; Myslinski E, 2001, NUCLEIC ACIDS RES, V29, P2502, DOI 10.1093/nar/29.12.2502; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; Myslinski E, 2004, GENE, V330, P149, DOI 10.1016/j.gene.2004.01.021; MYSLINSKI E, 1992, NUCLEIC ACIDS RES, V20, P203, DOI 10.1093/nar/20.2.203; RAGOUSSIS J, 1992, GENOMICS, V14, P673, DOI 10.1016/S0888-7543(05)80167-3; Saur D, 2002, J BIOL CHEM, V277, P25798, DOI 10.1074/jbc.M109802200; Schaub M, 1999, J BIOL CHEM, V274, P24241, DOI 10.1074/jbc.274.34.24241; Schaub M, 1999, J BIOL CHEM, V274, P25042, DOI 10.1074/jbc.274.35.25042; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Schuster C, 1998, MOL CELL BIOL, V18, P2650, DOI 10.1128/MCB.18.5.2650; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; Suzuki Y, 2002, NUCLEIC ACIDS RES, V30, P328, DOI 10.1093/nar/30.1.328; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; Trinklein ND, 2004, GENOME RES, V14, P62, DOI 10.1101/gr.1982804; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yamashita R, 2006, NUCLEIC ACIDS RES, V34, pD86, DOI 10.1093/nar/gkj129	31	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39953	39962		10.1074/jbc.M608507200	http://dx.doi.org/10.1074/jbc.M608507200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17092945	hybrid			2022-12-27	WOS:000243033900023
J	Hsu, MH; Savas, U; Griffin, KJ; Johnson, EF				Hsu, Mei-Hui; Savas, Uzen; Griffin, Keith J.; Johnson, Eric F.			Regulation of human cytochrome P4504F2 expression by sterol regulatory element-binding protein and lovastatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; X-LINKED ADRENOLEUKODYSTROPHY; ACID OMEGA-HYDROXYLASE; COENZYME-A REDUCTASE; HEPG2 CELLS; ARACHIDONIC-ACID; HUMAN LIVER; 20-HYDROXYEICOSATETRAENOIC ACID; TRANSCRIPTIONAL REGULATION; TARGETED DISRUPTION	This report provides the first evidence that human P450 4172 (CYP4F2) is induced by statins, which are widely used to treat hypercholesterolemia. Real time PCR and immunoblots indicate that lovastatin treatment increases expression of the endogenous CYP4F2 gene in human primary hepatocytes and HepG2 cells. The effects of lovastatin on gene expression are often mediated through sterol regulatory element-binding proteins (SREBPs). Immunoblots indicate that lovastatin-treated human hepatocytes display increased proteolytic processing of SREBP-2. In HepG2 cells, co-administration of a potent suppressor of SREBP-2 activation, 25-hydroxycholesterol, inhibits CYP4F2 mRNA induction by lovastatin. HepG2 cells transfected with an expression vector for the active nuclear form of SREBP-1a (nSREBP-1a) also display elevated endogenous CYP4F2 expression. Luciferase reporters containing the CYP4F2 proximal promoter are transactivated by nSREBPs (-1a, -1c, and -2) or a dominant positive form of the SREBP cleavage-activating protein (SCAP), which facilitates activation of endogenous SREBPs. Lovastatin-induced reporter expression is inhibited by overexpressed Insig-1, which prevents proteolytic activation of endogenous SREBPs. Electrophoretic mobility shift assays with in vitro translated nSREBP-1a identified two SREBP binding sites at -169/-152 and -109/-92, relative to the CYP4F2 transcription start site. Mutations in each site abolish SREBP binding. Chromatin immunoprecipitation experiments indicate that more SREBP-1 is associated with the CYP4F2 promoter after overexpression of nSREBP-1a. Transfection studies and mutagenesis indicate that the -109/-92 region is the primary site responsible for the effects of statins. Collectively, these results demonstrate that SREBPs transactivate CYP4F2 transcription and that CYP4F2 induction by statins is mediated by SREBP-2.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA	Scripps Research Institute	Johnson, EF (corresponding author), Mail Drop MEM255,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Johnson@scripps.edu			NICHD NIH HHS [HD004445] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD004445] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004445] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; Capdevila JH, 2001, BIOCHEM BIOPH RES CO, V285, P571, DOI 10.1006/bbrc.2001.5167; Capdevila JH, 2000, J LIPID RES, V41, P163; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; Christmas P, 2001, J BIOL CHEM, V276, P38166; Cui XM, 2001, J PHARMACOL EXP THER, V296, P542; Datta S, 2005, J BIOL CHEM, V280, P3338, DOI 10.1074/jbc.M411222200; Gainer JV, 2005, CIRCULATION, V111, P63, DOI 10.1161/01.CIR.0000151309.82473.59; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Holla VR, 2001, P NATL ACAD SCI USA, V98, P5211, DOI 10.1073/pnas.081627898; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; JIANG GJ, 1993, J BIOL CHEM, V268, P12818; Kawashima H, 1997, ARCH BIOCHEM BIOPHYS, V347, P148, DOI 10.1006/abbi.1997.0342; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; Kocarek TA, 1996, DRUG METAB DISPOS, V24, P1197; Komen JC, 2006, FEBS LETT, V580, P3794, DOI 10.1016/j.febslet.2006.05.069; Lasker JM, 2000, J BIOL CHEM, V275, P4118, DOI 10.1074/jbc.275.6.4118; Latasa MJ, 2003, MOL CELL BIOL, V23, P5896, DOI 10.1128/MCB.23.16.5896-5907.2003; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Liu JW, 2003, ARTERIOSCL THROM VAS, V23, P90, DOI 10.1161/01.ATV.0000046229.77566.E5; Mayer B, 2005, HYPERTENSION, V46, P766, DOI 10.1161/01.HYP.0000182658.04299.15; McPherson R, 2004, BIOCHEM CELL BIOL, V82, P201, DOI 10.1139/o03-090; MOLOWA DT, 1989, BIOCHEM J, V260, P731, DOI 10.1042/bj2600731; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; Nagai M, 2002, BIOCHEM BIOPH RES CO, V295, P74, DOI 10.1016/S0006-291X(02)00623-X; Nakagawa K, 2006, J CLIN INVEST, V116, P1696, DOI 10.1172/JCI27546; Nishimura M, 2003, YAKUGAKU ZASSHI, V123, P369; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Okita RT, 2001, CURR DRUG METAB, V2, P265; PALMER CNA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P161, DOI 10.1016/0167-4781(93)90285-L; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Powell PK, 1998, J PHARMACOL EXP THER, V285, P1327; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sanders RJ, 2006, J BIOL CHEM, V281, P13180, DOI 10.1074/jbc.M513481200; Scharnagl H, 2001, BIOCHEM PHARMACOL, V62, P1545, DOI 10.1016/S0006-2952(01)00790-0; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Singh I, 1998, NEW ENGL J MED, V339, P702, DOI 10.1056/NEJM199809033391012; Sontag TJ, 2002, J BIOL CHEM, V277, P25290, DOI 10.1074/jbc.M201466200; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Xiong SB, 2000, P NATL ACAD SCI USA, V97, P3948, DOI 10.1073/pnas.040574197; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; Zhang XL, 2000, ARCH BIOCHEM BIOPHYS, V378, P364, DOI 10.1006/abbi.2000.1836	50	27	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5225	5236		10.1074/jbc.M608176200	http://dx.doi.org/10.1074/jbc.M608176200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17142457	hybrid			2022-12-27	WOS:000244482300017
J	Roy, S; Tenniswood, M				Roy, Somdutta; Tenniswood, Martin			Site-specific acetylation of p53 directs selective transcription complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITORS; PROSTATE-CANCER CELLS; DNA-DAMAGE; POSTTRANSLATIONAL MODIFICATIONS; GENE; EXPRESSION; PCAF; ACTIVATION; APOPTOSIS; PROMOTER	Histone deacetylase (HDAC) inhibitors are being investigated as possible adjuvant therapies for a number of diseases, including cancer. In addition to stabilization of acetylated histones, HDAC inhibitors stabilize the acetylation of a number of transcription factors, including p53. This study investigates the action of two HDAC inhibitors, CG-1521 and trichostatin A, which stabilize Ac-Lys-373 p53 and Ac-Lys-382 p53, respectively, in LNCaP prostate cancer cells. Real-time PCR demonstrates that CG-1521 induces p21 transcription whereas trichostatin A does not alter the steady state level of p21 mRNA. Co-immunoprecipitation demonstrates that the selective acetylation of p53 directs the recruitment of mutually exclusive coactivator complexes on the p53 response elements in the p21 promoter. Furthermore, the co-activator complexes initiate the recruitment of the components of the basal transcription apparatus to the basal promoter with markedly different outcomes because only Ac-Lys-373 p53 promotes the assembly of the basal transcriptional apparatus on the p21 promoter. These data highlight the profound effects of post-translational modification, including acetylation, on the function of p53. The data also suggest a novel and critically important role for protein acetylation/deacetylation in the assembly of active transcription processes that may be as important as classical phosphorylation/dephosphorylation.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA	University of Notre Dame	Tenniswood, M (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.	tenniswood.1@nd.edu		Tenniswood, Martin/0000-0001-7896-4019				Appella E, 2000, PATHOL BIOL, V48, P227; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fu MF, 2004, J BIOL CHEM, V279, P29436, DOI 10.1074/jbc.M313466200; GERSHEY EL, 1968, J BIOL CHEM, V243, P5018; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Halkidou K, 2004, EUR UROL, V45, P382, DOI 10.1016/j.eururo.2003.10.005; Hammond EM, 2006, MOL CELL BIOL, V26, P3492, DOI 10.1128/MCB.26.9.3492-3504.2006; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Li JP, 2005, ONCOGENE, V24, P5510, DOI 10.1038/sj.onc.1208693; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Narayanan BA, 2003, INT J CANCER, V104, P204, DOI 10.1002/ijc.10932; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980; Prives C, 1999, J PATHOL, V187, P112; Roy S, 2005, CELL DEATH DIFFER, V12, P482, DOI 10.1038/sj.cdd.4401581; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saramaki A, 2006, NUCLEIC ACIDS RES, V34, P543, DOI 10.1093/nar/gkj460; Soucek K, 2006, PROSTATE, V66, P954, DOI 10.1002/pros.20416; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	31	59	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4765	4771		10.1074/jbc.M609588200	http://dx.doi.org/10.1074/jbc.M609588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17121856	hybrid			2022-12-27	WOS:000244482000058
J	Balasubramanian, S; Fam, SR; Hall, RA				Balasubramanian, Srividya; Fam, Sami R.; Hall, Randy A.			GABA(B) receptor association with the PDZ scaffold Mupp1 alters receptor stability and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN PROTEIN-1 MUPP1; B-RECEPTOR; KINASE-ACTIVITY; PHOSPHORYLATION; INTERACTS; ALCOHOL; TRAFFICKING; COMPLEXES; BACLOFEN; SUBUNITS	gamma-Aminobutyric acid, type B (GABA(B)) receptors are heterodimeric G protein-coupled receptors that mediate slow inhibitory synaptic transmission in the central nervous system. To identify novel interacting partners that might regulate GABAB receptor (GABA(B)R) functionality, we screened the GABA(B)R2 carboxyl terminus against a recently created proteomic array of 96 distinct PDZ (PSD-95/Dlg/ZO-1 homology) domains. The screen identified three specific PDZ domains that exhibit interactions with GABABR2: Mupp1 PDZ13, PAPIN PDZ1, and Erbin PDZ. Biochemical analysis confirmed that full-length Mupp1 and PAPIN interact with GABABR2 in cells. Disruption of the GABABR2 interaction with PDZ scaffolds by a point mutation to the carboxyl terminus of the receptor dramatically decreased receptor stability and attenuated the duration of GABAB receptor signaling. The effects of mutating the GABABR2 carboxyl terminus on receptor stability and signaling were mimicked by small interference RNA knockdown of endogenous Mupp1. These findings reveal that GABA, receptor stability and signaling can be modulated via GABABR2 interactions with the PDZ scaffold protein Mupp1, which may contribute to cell-specific regulation of GABA, receptors in the central nervous system.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Hall, RA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 5113 Rollins Res Ctr,1510 Clifton Rd, Atlanta, GA 30322 USA.	rhall@pharm.emory.edu		Hall, Randy/0000-0002-8318-8728	NINDS NIH HHS [NS45644] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045644] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Addolorato G, 2000, ALCOHOL CLIN EXP RES, V24, P67, DOI 10.1097/00000374-200001000-00011; Addolorato G, 2002, ALCOHOL ALCOHOLISM, V37, P504, DOI 10.1093/alcalc/37.5.504; Balasubramanian S, 2004, J BIOL CHEM, V279, P18840, DOI 10.1074/jbc.M313470200; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; Bowery NG, 2006, CURR OPIN PHARMACOL, V6, P37, DOI 10.1016/j.coph.2005.10.002; Bowery NG, 2002, PHARMACOL REV, V54, P247, DOI 10.1124/pr.54.2.247; Brock C, 2005, MOL BIOL CELL, V16, P5572, DOI 10.1091/mbc.E05-05-0400; Burman KJ, 2003, BRAIN RES, V970, P35, DOI 10.1016/S0006-8993(02)04269-5; Chen ZJ, 2006, J BIOL CHEM, V281, P12414, DOI 10.1074/jbc.M508651200; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Colombo G, 2004, NEUROTOX RES, V6, P403, DOI 10.1007/BF03033315; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Couve A, 2004, J BIOL CHEM, V279, P13934, DOI 10.1074/jbc.M311737200; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Deguchi M, 2000, J BIOL CHEM, V275, P29875, DOI 10.1074/jbc.M005384200; Dev KK, 2004, NAT REV DRUG DISCOV, V3, P1047, DOI 10.1038/nrd1578; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Enna SJ, 2004, BIOCHEM PHARMACOL, V68, P1541, DOI 10.1016/j.bcp.2004.06.037; Fairfax BP, 2004, J BIOL CHEM, V279, P12565, DOI 10.1074/jbc.M311389200; Fam SR, 2005, P NATL ACAD SCI USA, V102, P8042, DOI 10.1073/pnas.0408818102; Fehr C, 2002, J NEUROSCI, V22, P3730; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; GODFREY PP, 1988, EUR J PHARMACOL, V152, P185, DOI 10.1016/0014-2999(88)90854-0; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Harris BZ, 2001, J CELL SCI, V114, P3219; Havlickova M, 2002, MOL PHARMACOL, V62, P343, DOI 10.1124/mol.62.2.343; He JQ, 2006, J BIOL CHEM, V281, P2820, DOI 10.1074/jbc.M509503200; Jeansonne B, 2003, CELL MOL BIOL, V49, P13; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kimber WA, 2002, BIOCHEM J, V361, P525, DOI 10.1042/0264-6021:3610525; Krapivinsky G, 2004, NEURON, V43, P563, DOI 10.1016/j.neuron.2004.08.003; Mancini A, 2000, FEBS LETT, V482, P54, DOI 10.1016/S0014-5793(00)02036-6; Margeta-Mitrovic M, 1999, J COMP NEUROL, V405, P299, DOI 10.1002/(SICI)1096-9861(19990315)405:3<299::AID-CNE2>3.0.CO;2-6; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Pagano A, 2001, J NEUROSCI, V21, P1189; Parker LL, 2003, J BIOL CHEM, V278, P21576, DOI 10.1074/jbc.M210973200; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shirley RL, 2004, NAT NEUROSCI, V7, P699, DOI 10.1038/nn1271; Sitek B, 2003, BRAIN RES, V970, P178, DOI 10.1016/S0006-8993(03)02338-2; Slattery DA, 2005, J PHARMACOL EXP THER, V312, P290, DOI 10.1124/jpet.104.073536; Torres-Escalante JL, 2004, J NEUROSCI RES, V78, P268, DOI 10.1002/jnr.20247; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; Zaleski MJB, 2001, PSYCHOPHARMACOLOGY, V153, P415, DOI 10.1007/s002130000581	56	68	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4162	4171		10.1074/jbc.M607695200	http://dx.doi.org/10.1074/jbc.M607695200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17145756	hybrid			2022-12-27	WOS:000244481900079
J	Harkewicz, R; Fahy, E; Andreyev, A; Dennis, EA				Harkewicz, Richard; Fahy, Eoin; Andreyev, Alexander; Dennis, Edward A.			Arachidonate-derived dihomoprostaglandin production observed in endotoxin-stimulated macrophage-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						.	ADRENIC ACID; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); SIMULTANEOUS QUANTIFICATION; PROSTAGLANDINS; ELECTROSPRAY; QUANTITATION; EICOSANOIDS; METABOLITES; LIPIDOMICS; LIGAND	Eicosanoids, including the prostaglandins, leukotrienes, hydroxyeicosatetraenoic acids, epoxyeicosatetraenoic acids, and related compounds, are biosynthetic, bioactive mediators derived from arachidonic acid (AA), a 20: 4 (n-6) fatty acid. We have developed a comprehensive and sensitive mass spectral analysis to survey eicosanoid release from endotoxin-stimulated RAW 264.7 macrophage-like cells that is capable of detecting over 70 diverse eicosanoids and eicosanoid metabolites, should they be present. We now address the question: Are biologically significant eicosanoids being overlooked? Herein, we illustrate a general approach to diverse isotope metabolic profiling of labeled exogenous substrates using mass spectrometry (DIM-PLES/MS), demonstrated for one substrate (AA) and its resultant products (eicosanoids). RAW cells were incubated in medium supplemented with deuterium-labeled AA. When the cells are stimulated, two sets of eicosanoids are produced, one from endogenous AA and the other from the supplemented (exogenous) deuterium-labeled form. This produces a signature mass spectral "doublet" pattern, allowing for a comprehensive and diverse eicosanoid search requiring no previous knowledge or assumptions as to what these species may be, in contrast to traditional methods. We report herein observing unexpected AA metabolites generated by the cells, some of which may constitute novel bioactive eicosanoids or eicosanoid inactivation metabolites, as well as demonstrating differing metabolic pathways for the generation of isomeric prostaglandins and potential peroxisome proliferator-activated receptor activators. Unexpectedly, we report observing a series of 1a, 1b-dihomologue prostaglandins, products of adrenic acid (22: 4 (n-6)), resulting from the two-carbon elongation of AA by the RAW cells.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biochem, La Jolla, CA 92093 USA; San Diego Supercomp Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Dennis, EA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	edennis@ucsd.edu	Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140; Andreyev, Alexander Y./0000-0002-9246-9943	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM069338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2005, CELL, V121, P511, DOI 10.1016/j.cell.2005.04.020; Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; BERGSTROM S, 1962, J BIOL CHEM, V237, P3005; CAGEN LM, 1980, LIFE SCI, V26, P765, DOI 10.1016/0024-3205(80)90281-7; CAGEN LM, 1979, PROSTAGLANDINS, V18, P617, DOI 10.1016/0090-6980(79)90028-5; CAMPBELL WB, 1985, BIOCHIM BIOPHYS ACTA, V837, P67, DOI 10.1016/0005-2760(85)90086-4; Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200; FISCHER C, 1982, ADV LIPID RES, V19, P185; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Kempen EC, 2001, ANAL BIOCHEM, V297, P183, DOI 10.1006/abio.2001.5325; Kingsley PJ, 2005, ANAL BIOCHEM, V343, P203, DOI 10.1016/j.ab.2005.05.005; Kita Y, 2005, ANAL BIOCHEM, V342, P134, DOI 10.1016/j.ab.2005.03.048; Kita Y, 2005, BIOCHEM BIOPH RES CO, V330, P898, DOI 10.1016/j.bbrc.2005.03.055; Lee SH, 2005, PROSTAG OTH LIPID M, V77, P141, DOI 10.1016/j.prostaglandins.2004.01.009; Lu Y, 2005, J LIPID RES, V46, P790, DOI 10.1194/jlr.D400020-JLR200; Margalit A, 1996, ANAL BIOCHEM, V235, P73, DOI 10.1006/abio.1996.0093; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; Murphy RC, 2005, ANAL BIOCHEM, V346, P1, DOI 10.1016/j.ab.2005.04.042; Nithipatikom K, 2003, J CHROMATOGR B, V785, P135, DOI 10.1016/S1570-0232(02)00906-6; Pedrioli PGA, 2004, NAT BIOTECHNOL, V22, P1459, DOI 10.1038/nbt1031; Powell WS, 2003, J CLIN INVEST, V112, P828, DOI 10.1172/JCI200319796; RAETZ CRH, 2005, J LIPID RES, V46, P969; Smith WL, 2002, PROSTAG OTH LIPID M, V68-9, P115, DOI 10.1016/S0090-6980(02)00025-4; SPRECHER H, 1982, J BIOL CHEM, V257, P3912; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Takabatake M, 2002, PROSTAG LEUKOTR ESS, V67, P51, DOI 10.1054/plef.2002.0381; WANTANABE K, 2002, OTHER LIPID MEDIAT, V68, P401; Yang PY, 2002, ANAL BIOCHEM, V308, P168, DOI 10.1016/S0003-2697(02)00218-X; ZIRROLLI JA, 1990, J AM SOC MASS SPECTR, V1, P325, DOI 10.1016/1044-0305(90)85009-B	29	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2899	2910		10.1074/jbc.M610067200	http://dx.doi.org/10.1074/jbc.M610067200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135246	Green Published, hybrid			2022-12-27	WOS:000243793900016
J	Ye, S; Wu, X; Wei, L; Tang, DM; Sun, P; Bartlam, M; Rao, ZH				Ye, Sheng; Wu, Xiao'ai; Wei, Lei; Tang, Danming; Sun, Ping; Bartlam, Mark; Rao, Zihe			An insight into the mechanism of human cysteine dioxygenase - Key roles of the thioether-bonded tyrosine-cysteine cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; CRYSTAL-STRUCTURE; STRUCTURAL ORGANIZATION; PROTEASOME SYSTEM; PROTEIN; IRON; SULFINATE; OXIDASE; NEUROTOXICITY; PURIFICATION	Cysteine dioxygenase is a non-heme mononuclear iron metalloenzyme that catalyzes the oxidation of cysteine to cysteine sulfinic acid with addition of molecular dioxygen. This irreversible oxidative catabolism of cysteine initiates several important metabolic pathways related to diverse sulfurate compounds. Cysteine dioxygenase is therefore very important for maintaining the proper hepatic concentration of intracellular free cysteine. Mechanisms for mouse and rat cysteine dioxygenases have recently been reported based on their crystal structures in the absence of substrates, although there is still a lack of direct evidence. Here we report the first crystal structure of human cysteine dioxygenase in complex with its substrate L-cysteine to 2.7 angstrom, together with enzymatic activity and metal content assays of several single point mutants. Our results provide an insight into a new mechanism of cysteine thiol dioxygenation catalyzed by cysteine dioxygenase, which is tightly associated with a thioether-bonded tyrosine-cysteine cofactor involving Tyr-157 and Cys-93. This cross-linked protein-derived cofactor plays several key roles different from those in galactose oxidase. This report provides a new potential target for therapy of diseases related to human cysteine dioxygenase, including neurodegenerative and autoimmune diseases.	Tsinghua Univ, Tsinghua IBP Joint Res Grp Struct Biol, Beijing 100084, Peoples R China; Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Rao, ZH (corresponding author), Tsinghua Univ, Tsinghua IBP Joint Res Grp Struct Biol, Beijing 100084, Peoples R China.	raozh@xtal.tsinghua.edu.cn	Rao, Zihe/HCH-6944-2022	Bartlam, Mark/0000-0001-5173-5080				Adams M, 2005, J BIOL CHEM, V280, P28675, DOI 10.1074/jbc.M501034200; ANDINE P, 1991, J NEUROCHEM, V57, P230, DOI 10.1111/j.1471-4159.1991.tb02120.x; BAGLEY PJ, 1995, ANAL BIOCHEM, V227, P40, DOI 10.1006/abio.1995.1250; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRADLEY H, 1994, J RHEUMATOL, V21, P1192; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chai SC, 2005, J BIOL CHEM, V280, P9865, DOI 10.1074/jbc.M413733200; Chai SC, 2006, J BIOL CHEM, V281, P15774, DOI 10.1074/jbc.M601269200; Cresenzi CL, 2003, J NUTR, V133, P2697, DOI 10.1093/jn/133.9.2697; Dominy JE, 2006, BIOCHEM J, V394, P267, DOI 10.1042/BJ20051510; Dominy JE, 2006, J BACTERIOL, V188, P5561, DOI 10.1128/JB.00291-06; Dunwell JM, 2004, PHYTOCHEMISTRY, V65, P7, DOI 10.1016/j.phytochem.2003.08.016; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; EMERY P, 1992, BRIT J RHEUMATOL, V31, P449; EWETZ L, 1966, BIOCHIM BIOPHYS ACTA, V128, P296, DOI 10.1016/0926-6593(66)90176-7; GORDON C, 1992, LANCET, V339, P25, DOI 10.1016/0140-6736(92)90144-R; Guthikonda Sasidhar, 2006, Curr Atheroscler Rep, V8, P100, DOI 10.1007/s11883-006-0046-4; HEAFIELD MT, 1990, NEUROSCI LETT, V110, P216, DOI 10.1016/0304-3940(90)90814-P; HEAFIELD MTE, 1992, CURR OPIN NEUROL NEU, V5, P288; Hirschberger LL, 2001, GENE, V277, P153, DOI 10.1016/S0378-1119(01)00691-6; Hwang J, 2000, SCIENCE, V287, P122, DOI 10.1126/science.287.5450.122; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; Itoh S, 1997, INORG CHEM, V36, P1407, DOI 10.1021/ic961144a; JOHNSON JM, 1985, BIOCHEMISTRY-US, V24, P1579, DOI 10.1021/bi00328a001; Knight JA, 2001, ADV CLIN CHEM, V35, P1, DOI 10.1016/S0065-2423(01)35014-X; LEHMANN A, 1993, EUR J NEUROSCI, V5, P1398, DOI 10.1111/j.1460-9568.1993.tb00926.x; Marx JJM, 1996, ACTA HAEMATOL-BASEL, V95, P49; McCoy JG, 2006, P NATL ACAD SCI USA, V103, P3084, DOI 10.1073/pnas.0509262103; Montine TJ, 1997, EXP NEUROL, V148, P26, DOI 10.1006/exnr.1997.6662; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; Obeid R, 2006, FEBS LETT, V580, P2994, DOI 10.1016/j.febslet.2006.04.088; Okeley NM, 2000, CHEM BIOL, V7, pR159, DOI 10.1016/S1074-5521(00)00140-X; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pang H, 2004, J BIOL CHEM, V279, P1491, DOI 10.1074/jbc.M310022200; Perera R, 2003, P NATL ACAD SCI USA, V100, P3641, DOI 10.1073/pnas.0737142100; POOLE RK, 1979, BIOCHEM J, V184, P555, DOI 10.1042/bj1840555; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; Shimada M, 1998, AMINO ACIDS, V15, P143, DOI 10.1007/BF01345287; Simmons CR, 2006, J BIOL CHEM, V281, P18723, DOI 10.1074/jbc.M601555200; Simmons CR, 2006, PROTEIN EXPRES PURIF, V47, P74, DOI 10.1016/j.pep.2005.10.025; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Stipanuk MH, 2002, J NUTR, V132, P3369, DOI 10.1093/jn/132.11.3369; Stipanuk MH, 2004, AM J PHYSIOL-ENDOC M, V286, pE439, DOI 10.1152/ajpendo.00336.2003; Straganz GD, 2006, CHEMBIOCHEM, V7, P1536, DOI 10.1002/cbic.200600152; Tsuboyama N, 1996, GENE, V181, P161, DOI 10.1016/S0378-1119(96)00496-9; Undas A, 2005, THROMB HAEMOSTASIS, V94, P907, DOI 10.1160/TH05-05-0313; Wu DF, 2003, ALCOHOL RES HEALTH, V27, P277; YAMAGUCHI K, 1987, METHOD ENZYMOL, V143, P395; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zhu XW, 2005, J LIPID RES, V46, P1303, DOI 10.1194/jlr.M400401-JLR200	51	136	139	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3391	3402		10.1074/jbc.M609337200	http://dx.doi.org/10.1074/jbc.M609337200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135237	hybrid			2022-12-27	WOS:000243793900065
J	Spiegel, S; Milstien, S				Spiegel, Sarah; Milstien, Sheldon			Functions of the multifaceted family of sphingosine kinases and some close relatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CERAMIDE KINASE; LYSOPHOSPHATIDIC ACID; CELL-MIGRATION; DEPENDENT TRANSLOCATION; PLASMA-MEMBRANE; POOR SURVIVAL; LIPID KINASE; IN-VIVO; 1-PHOSPHATE; SPHINGOSINE-1-PHOSPHATE		Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA; NIMH, Bethesda, MD 20892 USA	Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.	sspiegel@vcu.edu			Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [CA61774] Funding Source: Medline; NIAID NIH HHS [AI50094] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R37GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH001039] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ando T, 2006, ONCOL REP, V15, P1551; Bektas M, 2005, J CELL BIOL, V169, P801, DOI 10.1083/jcb.200407123; Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; French KJ, 2006, J PHARMACOL EXP THER, V318, P596, DOI 10.1124/jpet.106.101345; French KJ, 2003, CANCER RES, V63, P5962; Gomez-Munoz A, 2006, BBA-BIOMEMBRANES, V1758, P2049, DOI 10.1016/j.bbamem.2006.05.011; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hinkovska-Galcheva V, 2005, J BIOL CHEM, V280, P26612, DOI 10.1074/jbc.M501359200; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046; Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200; Liang H, 2003, GENE DEV, V17, P2636, DOI 10.1101/gad.1140503; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Milstien S, 2006, CANCER CELL, V9, P148, DOI 10.1016/j.ccr.2006.02.025; Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103; Mitsutake S, 2005, J BIOL CHEM, V280, P40436, DOI 10.1074/jbc.M501962200; Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005; Okada T, 2005, J BIOL CHEM, V280, P36318, DOI 10.1074/jbc.M504507200; Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200; PAYNE SG, 2006, IN PRESS BLOOD; Pettus BJ, 2005, MOL PHARMACOL, V68, P330, DOI 10.1124/mol.104.008722; Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Roviezzo F, 2004, P NATL ACAD SCI USA, V101, P11170, DOI 10.1073/pnas.0401439101; Rovina P, 2006, BIOCHEM J, V400, P255, DOI 10.1042/BJ20060316; Sanna MG, 2006, NAT CHEM BIOL, V2, P434, DOI 10.1038/nchembio804; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Stahelin RV, 2005, J BIOL CHEM, V280, P43030, DOI 10.1074/jbc.M507574200; Subramanian P, 2005, J BIOL CHEM, V280, P17601, DOI 10.1074/jbc.M414173200; Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200; Sukocheva O, 2006, J CELL BIOL, V173, P301, DOI 10.1083/jcb.200506033; Sutherland CM, 2006, J BIOL CHEM, V281, P11693, DOI 10.1074/jbc.M601042200; Taha TA, 2005, FASEB J, V19, P482, DOI 10.1096/fj.05-4412fje; Tanaka M, 2004, FEBS LETT, V571, P197, DOI 10.1016/j.febslet.2004.06.083; Tedesco-Silva H, 2005, TRANSPLANTATION, V79, P1553, DOI 10.1097/01.TP.0000121761.02129.A6; Tuson M, 2004, AM J HUM GENET, V74, P128, DOI 10.1086/381055; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; Venkataraman K, 2006, BIOCHEM J, V397, P461, DOI 10.1042/BJ20060251; Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023; Waggoner DW, 2004, J BIOL CHEM, V279, P38228, DOI 10.1074/jbc.M405932200	50	164	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2125	2129		10.1074/jbc.R600028200	http://dx.doi.org/10.1074/jbc.R600028200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135245	hybrid			2022-12-27	WOS:000243593200002
J	Izquierdo, JM; Valcarcel, J				Izquierdo, Jose M.; Valcarcel, Juan			Fas-activated serine/threonine kinase (FAST K) synergizes with TIA-1/TIAR proteins to regulate fas alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; MEDIATED APOPTOSIS; BINDING PROTEINS; 5'-SPLICE SITES; IMMUNE-SYSTEM; TIAR	The factors and mechanisms that mediate the effects of intracellular signaling cascades on alternative pre-mRNA splicing are poorly understood. TIA-1 (T-cellintracellular antigen1) and TIAR (TIA-1-related) proteins regulate alternative pre-mRNA splicing by promoting the use of suboptimal 5' splice sites followed by uridine-rich intronic enhancer sequences. These proteins promote, for example, inclusion of Fas receptor exon 6, which leads to an mRNA encoding a pro-apoptotic form of the receptor at the expense of the form that skips exon 6, which encodes an anti-apoptotic form. Fas-activated serine/threonine kinase (FAST K) is known to interact with and phosphorylate TIA-1. Here we have tested the possibility that FAST K influences alternative pre-mRNA splicing by affecting the activity of TIA-1/TIAR. Depletion of FAST K form Jurkat cells leads to skipping of exon 6 from endogenous Fas transcripts. Conversely, FAST K overexpression enhances exon 6 inclusion of Fas reporters transfected in HeLa cells. Consistent with the possibility that the effects of FAST K are mediated by changes in the function of TIA-1/TIAR, the effects of FAST K overexpression (i) are largely suppressed by depletion of TIA-1 and TIAR and (ii) are significantly compromised by mutation of a TIA-1/TIAR-responsive enhancer present downstream of exon 6 5' splice site. Furthermore, in vitro phosphorylation of TIA-1 by FAST K results in enhanced U1 snRNP recruitment. Interestingly, this enhancement is not due to increased binding of TIA-1 to the pre-mRNA. Taken together, the results connect Fas signaling with the activity of splicing factors that modulate Fas alternative splicing, suggesting the existence of an autoregulatory loop that could serve to amplify Fas responses.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, Modulo CV,Lab 230, Madrid 28049, Spain; Univ Pompeu Fabra, Barcelona 08003, Spain; ICREA, Barcelona 08003, Spain; Ctr Regulacio Genom, Barcelona 08003, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Pompeu Fabra University; ICREA; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG)	Izquierdo, JM (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, Modulo CV,Lab 230, Madrid 28049, Spain.	jmizquierdo@cbm.uam.es	Valcarcel, Juan/O-9814-2014	Valcarcel, Juan/0000-0001-5398-3571	ICREA Funding Source: Custom	ICREA(ICREA)		Beck ARP, 1996, NUCLEIC ACIDS RES, V24, P3829, DOI 10.1093/nar/24.19.3829; Bidere N, 2006, ANNU REV IMMUNOL, V24, P321, DOI 10.1146/annurev.immunol.24.021605.090513; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Forch P, 2002, EMBO J, V21, P6882, DOI 10.1093/emboj/cdf668; Izquierdo JM, 2005, MOL CELL, V19, P475, DOI 10.1016/j.molcel.2005.06.015; Izquierdo JM, 2006, GENE DEV, V20, P1679, DOI 10.1101/gad.1449106; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Le Guienr C, 2001, J BIOL CHEM, V276, P40638, DOI 10.1074/jbc.M105642200; LIU CD, 1995, BIOCHEM J, V310, P957, DOI 10.1042/bj3100957; McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754; Roesler J, 2005, BLOOD, V106, P1652, DOI 10.1182/blood-2004-08-3104; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; Zhang T, 2005, J CELL SCI, V118, P5453, DOI 10.1242/jcs.02669; Zhu H, 2003, MOL CELL BIOL, V23, P5959, DOI 10.1128/MCB.23.17.5959-5971.2003; Zuccato E, 2004, J BIOL CHEM, V279, P16980, DOI 10.1074/jbc.M313439200	22	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1539	1543		10.1074/jbc.C600198200	http://dx.doi.org/10.1074/jbc.C600198200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17135269	hybrid			2022-12-27	WOS:000243451300004
J	Kamei, H; Saito, T; Ozawa, M; Fujita, Y; Asada, A; Bibb, JA; Saido, TC; Sorimachi, H; Hisanaga, S				Kamei, Hirotsugu; Saito, Taro; Ozawa, Mirai; Fujita, Yuichi; Asada, Akiko; Bibb, James A.; Saido, Takaomi C.; Sorimachi, Hiroyuki; Hisanaga, Shin-ichi			Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25 by site-specific phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; TYROSINE PHOSPHORYLATION; TAU; SUBUNIT; DEGRADATION; PROTEASOME; TRUNCATION; PROTEINS; PROTECTS; TARGET	Cdk5 is a proline-directed Ser/Thr protein kinase predominantly expressed in postmitotic neurons together with its activator, p35. N-terminal truncation of p35 to p25 by calpain results in deregulation of Cdk5 and contributes to neuronal cell death associated with several neurodegenerative diseases. Previously we reported that p35 occurred as a phosphoprotein, phospho-p35 levels changed with neuronal maturation, and that phosphorylation of p35 affected its vulnerability to calpain cleavage. Here, we identify the p35 residues Ser(8) and Thr(138) as the major sites of phosphorylation by Cdk5. Mutagenesis of these sites to unphosphorylatable Ala increased susceptibility to calpain in cultured cells and neurons while changing them to phosphomimetic glutamate-attenuated cleavage. Furthermore, phosphorylation state-specific antibodies to these sites revealed that Thr(138) was dephosphorylated in adult rat, although both Ser(8) and Thr(138) were phosphorylated in prenatal brains. In cultured neurons, inhibition of protein phosphatases converted phosho-Ser(8) p35 to dual phospho-Ser(8)/Thr(138) p35 and conferred resistance to calpain cleavage. These results suggest phosphorylation of Thr138 predominantly defines the susceptibility of p35 to calpain-dependent cleavage and that dephosphorylation of this site is a critical determinant of Cdk5-p25-induced cell death associated with neurodegeneration.	Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol Sci, Hachioji, Tokyo 1920397, Japan; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA; RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan	Tokyo Metropolitan University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; RIKEN; Tokyo Metropolitan Institute of Medical Science	Hisanaga, S (corresponding author), Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol Sci, 1-1 Minami Osawa, Hachioji, Tokyo 1920397, Japan.	hisanaga-shinichi@c.metro-u.ac.jp	Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015; Sorimachi, Hiroyuki/Q-6956-2017; Sorimachi, Hiroyuki/C-6448-2009	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903; Sorimachi, Hiroyuki/0000-0001-9509-6727; Sorimachi, Hiroyuki/0000-0001-9509-6727				Bi RF, 2000, J BIOL CHEM, V275, P26477, DOI 10.1074/jbc.M003763200; Cheung ZH, 2006, NEURON, V50, P13, DOI 10.1016/j.neuron.2006.02.024; Ching YP, 2000, GENE, V242, P285, DOI 10.1016/S0378-1119(99)00499-0; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Fischer A, 2005, NEURON, V48, P825, DOI 10.1016/j.neuron.2005.10.033; Fischer A, 2002, J NEUROSCI, V22, P3700; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Hamdane M, 2005, J CELL SCI, V118, P1291, DOI 10.1242/jcs.01724; Hashiguchi M, 2002, J BIOL CHEM, V277, P44525, DOI 10.1074/jbc.M207426200; Hisanaga S, 2003, NEUROSIGNALS, V12, P221, DOI 10.1159/000074624; Kerokoski P, 2001, BIOCHEM BIOPH RES CO, V280, P998, DOI 10.1006/bbrc.2001.4240; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Nicolas G, 2002, MOL CELL BIOL, V22, P3527, DOI 10.1128/MCB.22.10.3527-3536.2002; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; O'Hare MJ, 2005, J NEUROSCI, V25, P8954, DOI 10.1523/JNEUROSCI.2899-05.2005; Ohshima T, 2005, J NEUROCHEM, V94, P917, DOI 10.1111/j.1471-4159.2005.03233.x; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Saito T, 1998, BIOCHEM BIOPH RES CO, V252, P775, DOI 10.1006/bbrc.1998.9739; Saito T, 2003, J NEUROSCI, V23, P1189, DOI 10.1523/JNEUROSCI.23-04-01189.2003; Sakaue F, 2005, J BIOL CHEM, V280, P31522, DOI 10.1074/jbc.M504792200; Shelton SB, 2004, J NEUROCHEM, V88, P1313, DOI 10.1111/j.1471-4159.2003.02328.x; Smith PD, 2006, J NEUROSCI, V26, P440, DOI 10.1523/JNEUROSCI.2875-05.2006; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; Takasaki A, 1999, J BIOL CHEM, V274, P11848, DOI 10.1074/jbc.274.17.11848; Tang D, 1996, Prog Cell Cycle Res, V2, P205; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Tokuoka H, 2000, J CELL SCI, V113, P1059; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Tsai LH, 2004, BBA-PROTEINS PROTEOM, V1697, P137, DOI 10.1016/j.bbapap.2003.11.019; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; UCHIDA T, 1994, FEBS LETT, V355, P35, DOI 10.1016/0014-5793(94)01163-X; Wang HM, 2005, BIOCHEM BIOPH RES CO, V333, P496, DOI 10.1016/j.bbrc.2005.05.143; Wang J, 2003, NAT NEUROSCI, V6, P1039, DOI 10.1038/nn1119; Wei FY, 2005, J NEUROCHEM, V93, P502, DOI 10.1111/j.1471-4159.2005.03058.x; Zhang J, 2003, DEV BRAIN RES, V142, P105, DOI 10.1016/S0165-3806(03)00057-9; Zhang JW, 2002, J NEUROCHEM, V81, P307, DOI 10.1046/j.1471-4159.2002.00824.x; Zhu YS, 2005, J NEUROCHEM, V94, P1535, DOI 10.1111/j.1471-4159.2005.03301.x	45	54	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1687	1694		10.1074/jbc.M610541200	http://dx.doi.org/10.1074/jbc.M610541200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121855	hybrid			2022-12-27	WOS:000243451300020
J	von Stetten, D; Seibeck, S; Michael, N; Scheerer, P; Mroginski, MA; Murgida, DH; Krauss, N; Heyn, MP; Hildebrandt, P; Borucki, B; Lamparter, T				von Stetten, David; Seibeck, Sven; Michael, Norbert; Scheerer, Patrick; Mroginski, Maria Andrea; Murgida, Daniel H.; Krauss, Norbert; Heyn, Maarten P.; Hildebrandt, Peter; Borucki, Berthold; Lamparter, Tilman			Highly conserved residues Asp-197 and His-250 in Agp1 phytochrome control the proton affinity of the chromophore and Pfr formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; AGROBACTERIUM-TUMEFACIENS; CPH1 PHYTOCHROME; PEA PHYTOCHROME; CYANOBACTERIAL; PROTEIN; DEPROTONATION; BINDING; SPECTROSCOPY; ATTACHMENT	The mutants H250A and D197A of Agp1 phytochrome from Agrobacterium tumefaciens were prepared and investigated by different spectroscopic and biochemical methods. Asp-197 and His-250 are highly conserved amino acids and are part of the hydrogen-bonding network that involves the chromophore. Both substitutions cause a destabilization of the protonated chromophore in the Pr state as revealed by resonance Raman and UV-visible absorption spectroscopy. Titration experiments demonstrate a lowering of the pK(a) from 11.1 ( wild type) to 8.8 in H250A and 7.2 in D197A. Photoconversion of the mutants does not lead to the Pfr state. H250A is arrested in a meta-Rc-like state in which the chromophore is deprotonated. For H250A and the wild-type protein, deprotonation of the chromophore in meta-Rc is coupled to the release of a proton to the external medium, whereas the subsequent proton re-uptake, linked to the formation of the Pfr state in the wild- type protein, is not observed for H250A. No transient proton exchange with the external medium occurs in D197A, suggesting that Asp-197 may be the proton release group. Both mutants do not undergo the photoinduced protein structural changes that in the wild- type protein are detectable by size exclusion chromatography. These conformational changes are, therefore, attributed to the meta-Rc -> Pfr transition and most likely coupled to the transient proton re- uptake. The present results demonstrate that Asp-197 and His-250 are essential for stabilizing the protonated chromophore structure in the parent Pr state, which is required for the primary photochemical process, and for the complete photo-induced conversion to the Pfr state.	Tech Univ Berlin, Inst Chem, D-10623 Berlin, Germany; Free Univ Berlin, Inst Phys Expt, Fachbereich Phys, D-14195 Berlin, Germany; Free Univ Berlin, Pflanzenphysiol, D-14195 Berlin, Germany; Charite Univ Med Berlin, Inst Biochem, Prot Strukturforsch, D-10117 Berlin, Germany	Technical University of Berlin; Free University of Berlin; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hildebrandt, P (corresponding author), Tech Univ Berlin, Inst Chem, Sekretariat PC14,Str 17 Juni 135, D-10623 Berlin, Germany.	hildebrandt@chem.tu-berlin.de; borucki@physik.fu-berlin.de; lamparte@zedat.fu-berlin.de	Lamparter, Tilman/E-4421-2013; Hildebrandt, Peter/J-5658-2014; Murgida, Daniel H./F-2350-2018	Lamparter, Tilman/0000-0003-4327-9737; Hildebrandt, Peter/0000-0003-1030-5900; Scheerer, Patrick/0000-0001-5028-2075; Krauss, Norbert/0000-0002-7128-4632; von Stetten, David/0000-0001-7906-9788; Murgida, Daniel H./0000-0001-5173-0183				Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; Bhoo SH, 1997, J AM CHEM SOC, V119, P11717, DOI 10.1021/ja972875s; Borucki B, 2005, J BIOL CHEM, V280, P34358, DOI 10.1074/jbc.M505493200; Borucki B, 2003, BIOCHEMISTRY-US, V42, P13684, DOI 10.1021/bi035511n; Borucki B, 2003, BIOCHEMISTRY-US, V42, P8780, DOI 10.1021/bi034315d; Borucki B, 2006, PHOTOCH PHOTOBIO SCI, V5, P553, DOI 10.1039/b603846h; Christie JM, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P277, DOI 10.1002/352760510X.ch13; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; EILFELD P, 1985, Z NATURFORSCH C, V40, P109; Foerstendorf H, 1996, BIOCHEMISTRY-US, V35, P10793, DOI 10.1021/bi960960r; Hahn J, 2006, FEBS J, V273, P1415, DOI 10.1111/j.1742-4658.2006.05164.x; Hildebrandt P, 1999, RRD PHYS CHEM, V3, P63; Inomata K, 2005, J BIOL CHEM, V280, P24491, DOI 10.1074/jbc.M504710200; Karniol B, 2005, BIOCHEM J, V392, P103, DOI 10.1042/BJ20050826; KNEIP C, 2004, BIOCHEMISTRY-US, V16, P15185; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamparter T, 2004, FEBS LETT, V573, P1, DOI 10.1016/j.febslet.2004.07.050; Lamparter T, 2004, BIOCHEMISTRY-US, V43, P3659, DOI 10.1021/bi035693l; Lamparter T, 2002, P NATL ACAD SCI USA, V99, P11628, DOI 10.1073/pnas.152263999; MATYSIK J, 1995, BIOCHEMISTRY-US, V34, P10497, DOI 10.1021/bi00033a023; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIZUTANI Y, 1991, BIOCHEMISTRY-US, V30, P10693, DOI 10.1021/bi00108a013; MIZUTANI Y, 1994, BIOCHEMISTRY-US, V33, P153, DOI 10.1021/bi00167a020; Mroginski MA, 2004, J AM CHEM SOC, V126, P16734, DOI 10.1021/ja043959l; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; Scheerer P, 2006, J STRUCT BIOL, V153, P97, DOI 10.1016/j.jsb.2005.11.002; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; Strauss HM, 2005, BIOCHEMISTRY-US, V44, P8244, DOI 10.1021/bi050457r; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOKUTOMI S, 1988, PHOTOCHEM PHOTOBIOL, V47, P439, DOI 10.1111/j.1751-1097.1988.tb02748.x; Tu SL, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P121, DOI 10.1002/352760510X.ch6; van Thor JJ, 2001, BIOCHEMISTRY-US, V40, P11460, DOI 10.1021/bi002651d; Wagner JR, 2005, NATURE, V438, P325, DOI 10.1038/nature04118; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Zhang XN, 1997, BIOPHYS J, V73, P1516, DOI 10.1016/S0006-3495(97)78183-9	37	96	98	1	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					2116	2123		10.1074/jbc.M608878200	http://dx.doi.org/10.1074/jbc.M608878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121858	Green Published, hybrid			2022-12-27	WOS:000243451300062
J	Yokota, K; Shibata, H; Kurihara, I; Kobayashi, S; Suda, N; Murai-Takeda, A; Saito, I; Kitagawa, H; Kato, S; Saruta, T; Itoh, H				Yokota, Kenichi; Shibata, Hirotaka; Kurihara, Isao; Kobayashi, Sakiko; Suda, Noriko; Murai-Takeda, Ayano; Saito, Ikuo; Kitagawa, Hirochika; Kato, Shigeaki; Saruta, Takao; Itoh, Hiroshi			Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-I; MODIFIER-1 SUMO-1 MODIFICATION; NUCLEAR RECEPTOR; GLUCOCORTICOID-RECEPTOR; ANDROGEN RECEPTOR; DEPENDENT TRANSCRIPTION; PROTEIN INHIBITOR; INTERACTING PROTEIN-3; PROGESTERONE-RECEPTOR; INDUCTION PROPERTIES	Molecular mechanisms underlying mineralocorticoid receptor ( MR)-mediated gene expression are not fully understood. Various transcription factors are post-translationally modified by small ubiquitin-related modifier-1 ( SUMO-1). We investigated the role of the SUMO-1-conjugating enzyme Ubc9 in MR transactivation. Yeast two-hybrid, GST-pulldown, and coimmunoprecipitation assays showed that Ubc9 interacted with N-terminal MR-( 1-670). Endogenous Ubc9 is associated with stably expressing MR in 293-MR cells. Transient transfection assays in COS-1 cells showed that Ubc9 increased MR transactivation of reporter constructs containing MRE, ENaC, or MMTV promoter in a hormone-sensitive manner. Moreover, reduction of Ubc9 protein levels by small interfering RNA attenuated hormonal activation of a reporter construct as well as an endogenous target gene by MR. A sumoylation-inactive mutant Ubc9( C93S) similarly interacted with MR and potentiated aldosterone-dependent MR transactivation. An MR mutant in which four lysine residues within sumoylation motifs were mutated into arginine ( K89R/K399R/K494R/K953R) failed to be sumoylated, but Ubc9 similarly enhanced transactivation by the mutant MR, indicating that sumoylation activity is dispensable for coactivation capacity of Ubc9. Coexpression of Ubc9 and steroid receptor coactivator-1 ( SRC-1) synergistically enhanced MR- mediated transactivation in transient transfection assays. Indeed, chromatin immunoprecipitation assays demonstrated that endogenous MR, Ubc9, and SRC-1 were recruited to an endogenous ENaC gene promoter in a largely aldosterone-dependent manner. Coimmunoprecipitation assays showed a complex of MR, Ubc9, and SRC-1 in mammalian cells, and the endogenous proteins were colocalized in the nuclei of the mouse collecting duct cells. These findings support a physiological role of Ubc9 as a transcriptional MR coactivator, beyond the known SUMO E2-conjugating enzyme.	Keio Univ, Sch Med, Dept Internal Med, Tokyo 1608582, Japan; Keio Univ, Ctr Hlth, Tokyo 1608582, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan	Keio University; Keio University; University of Tokyo	Shibata, H (corresponding author), Keio Univ, Sch Med, Dept Internal Med, Tokyo 1608582, Japan.	hiro-405@cb3.so-net.ne.jp						Abdel-Hafiz H, 2002, J BIOL CHEM, V277, P33950, DOI 10.1074/jbc.M204573200; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Chen WY, 2004, J BIOL CHEM, V279, P38730, DOI 10.1074/jbc.M405006200; Cho SY, 2005, MOL ENDOCRINOL, V19, P290, DOI 10.1210/me.2004-0134; Floyd ZE, 2004, OBES RES, V12, P921, DOI 10.1038/oby.2004.112; Funder JW, 2003, EXPERT OPIN INV DRUG, V12, P1963, DOI 10.1517/eoid.12.12.1963.21998; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Gross M, 2004, ONCOGENE, V23, P3059, DOI 10.1038/sj.onc.1207443; Haller H., 2003, NEPHRON PHYSIOL, V94, P47; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hultman ML, 2005, MOL ENDOCRINOL, V19, P1460, DOI 10.1210/me.2004-0537; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaul S, 2002, J BIOL CHEM, V277, P12541, DOI 10.1074/jbc.M112330200; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Kobayashi S, 2004, ENDOCR RES, V30, P617, DOI 10.1081/ERC-200043789; Kobayashi S, 2004, J MOL ENDOCRINOL, V32, P69, DOI 10.1677/jme.0.0320069; Komatsu T, 2004, MOL ENDOCRINOL, V18, P2451, DOI 10.1210/me.2004-0173; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, J BIOL CHEM, V277, P17781, DOI 10.1074/jbc.M106354200; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kurihara I, 2005, J BIOL CHEM, V280, P6721, DOI 10.1074/jbc.M411820200; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Le Menuet D, 2004, MOL CELL ENDOCRINOL, V217, P127, DOI 10.1016/j.mce.2003.10.045; Lee MB, 2005, MOL CELL BIOL, V25, P1879, DOI 10.1128/MCB.25.5.1879-1890.2005; Li Y, 2005, MOL CELL, V19, P367, DOI 10.1016/j.molcel.2005.06.026; Lu ZH, 2006, EXP CELL RES, V312, P1865, DOI 10.1016/j.yexcr.2006.02.017; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mick VE, 2001, MOL ENDOCRINOL, V15, P575, DOI 10.1210/me.15.4.575; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; ONATE SA, 1995, SCIENCE, V270, P1354; Pascual-Le Tallec L, 2003, MOL ENDOCRINOL, V17, P2529, DOI 10.1210/me.2003-0299; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sentis S, 2005, MOL ENDOCRINOL, V19, P2671, DOI 10.1210/me.2005-0042; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tian S, 2002, BIOCHEM J, V367, P907, DOI 10.1042/BJ20021085; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Yamashita D, 2004, GENES CELLS, V9, P1017, DOI 10.1111/j.1365-2443.2004.00786.x; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1	59	61	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1998	2010		10.1074/jbc.M607741200	http://dx.doi.org/10.1074/jbc.M607741200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17105732	hybrid			2022-12-27	WOS:000243451300051
J	Begum, NA; Izumi, N; Nishikori, M; Nagaoka, H; Shinkura, R; Honjo, T				Begum, Nasim A.; Izumi, Nakako; Nishikori, Momoko; Nagaoka, Hitoshi; Shinkura, Reiko; Honjo, Tasuku			Requirement of non-canonical activity of uracil DNA glycosylase for class switch recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MISMATCH REPAIR PROTEIN; CYTIDINE DEAMINASE AID; BASE EXCISION-REPAIR; SOMATIC HYPERMUTATION; B-CELLS; MICE DEFICIENT; CIRCULAR DNA; ANTIBODY DIVERSIFICATION; REGION RECOMBINATION	Activation-induced cytidine deaminase (AID) and uracil DNA glycosylase (UNG) are required for class switch recombination (CSR). AID is involved in the DNA cleavage step of CSR, but the precise role of UNG is not yet understood. Mutations and deletions are footprints of abortive DNA cleavage in the immunoglobulin switch region in splenic B cells stimulated to undergo CSR. However, a UNG deficiency did not reduce the number of such footprints, indicating UNG is dispensable for the DNA cleavage step. Mutagenesis experiments revealed that the role of UNG in CSR depends on its WXXF motif This motif is also essential for the interaction of UNG with the HIV viral peptide Vpr, which recruits UNG to the HIV particle. Furthermore, exogenous Vpr had a dominant-negative effect on CSR. These results suggest that UNG is recruited to the CSR machinery through its WXXF motif by a Vpr-like host factor and plays a novel non-canonical role in a CSR step that follows DNA cleavage.	Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Honjo, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Sakyo Ku, Kyoto 6068501, Japan.	honjo@mfour.med.kyoto-u-ac.jp	Honjo, Tasuku/N-4470-2016	Begum, Nasim/0000-0001-7177-188X				Begum NA, 2004, P NATL ACAD SCI USA, V101, P13003, DOI 10.1073/pnas.0405219101; Begum NA, 2004, SCIENCE, V305, P1160, DOI 10.1126/science.1098444; Bottaro A, 1998, INT IMMUNOL, V10, P799, DOI 10.1093/intimm/10.6.799; BouHamdan M, 1998, J BIOL CHEM, V273, P8009, DOI 10.1074/jbc.273.14.8009; Cascalho M, 1998, SCIENCE, V279, P1207, DOI 10.1126/science.279.5354.1207; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Chen RX, 2004, J BIOL CHEM, V279, P28419, DOI 10.1074/jbc.M403875200; Chen XC, 2001, P NATL ACAD SCI USA, V98, P13860, DOI 10.1073/pnas.241524898; De Silva FS, 2003, J VIROL, V77, P159, DOI 10.1128/JVI.77.1.159-166.2003; Delbos F, 2005, J EXP MED, V201, P1191, DOI 10.1084/jem.20050292; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Dudley DD, 2002, P NATL ACAD SCI USA, V99, P9984, DOI 10.1073/pnas.152333499; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; Ehrenstein MR, 1999, EMBO J, V18, P3484, DOI 10.1093/emboj/18.12.3484; Ehrenstein MR, 2001, P NATL ACAD SCI USA, V98, P14553, DOI 10.1073/pnas.241525998; Endres M, 2004, J CLIN INVEST, V113, P1711, DOI 10.1172/JCI200420926; Gearhart PJ, 2001, NAT REV IMMUNOL, V1, P187, DOI 10.1038/35105009; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Ho PJ, 2001, BLOOD, V97, P490, DOI 10.1182/blood.V97.2.490; Honjo T, 2005, NAT IMMUNOL, V6, P655, DOI 10.1038/ni1218; Honjo T, 2004, IMMUNITY, V20, P659, DOI 10.1016/j.immuni.2004.05.011; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; Jiang YL, 2002, J BIOL CHEM, V277, P15385, DOI 10.1074/jbc.M200634200; Kim N, 1999, J EXP MED, V190, P21, DOI 10.1084/jem.190.1.21; Ko R, 2005, DNA REPAIR, V4, P1421, DOI 10.1016/j.dnarep.2005.08.006; Krokan HE, 2002, ONCOGENE, V21, P8935, DOI 10.1038/sj.onc.1205996; Lahdesmaki A, 2004, J BIOL CHEM, V279, P16479, DOI 10.1074/jbc.M312796200; Li ZQ, 2006, IMMUNITY, V24, P393, DOI 10.1016/j.immuni.2006.02.011; Li ZQ, 2004, GENE DEV, V18, P1, DOI 10.1101/gad.1161904; Lumsden JM, 2004, J EXP MED, V200, P1111, DOI 10.1084/jem.20041074; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; Manis JP, 2002, IMMUNITY, V16, P607, DOI 10.1016/S1074-7613(02)00306-0; Mansky LM, 2000, J VIROL, V74, P7039, DOI 10.1128/JVI.74.15.7039-7047.2000; Martin A, 2002, NAT REV IMMUNOL, V2, P605, DOI 10.1038/nri858; Martomo SA, 2004, J EXP MED, V200, P61, DOI 10.1084/jem.20040691; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nagaoka H, 2005, P NATL ACAD SCI USA, V102, P2022, DOI 10.1073/pnas.0409491102; Neuberger MS, 2003, TRENDS BIOCHEM SCI, V28, P305, DOI 10.1016/S0968-0004(03)00111-7; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Pan-Hammarstrom Q, 2005, J EXP MED, V201, P189, DOI 10.1084/jem.20040772; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Phung QH, 1998, J EXP MED, V187, P1745, DOI 10.1084/jem.187.11.1745; Priet S, 2005, MOL CELL, V17, P479, DOI 10.1016/j.molcel.2005.01.016; Rada C, 2004, MOL CELL, V16, P163, DOI 10.1016/j.molcel.2004.10.011; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Reina-San-Martin B, 2005, P NATL ACAD SCI USA, V102, P1590, DOI 10.1073/pnas.0406289102; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Schrader CE, 2005, J EXP MED, V202, P561, DOI 10.1084/jem.20050872; Schrader CE, 2003, EMBO J, V22, P5893, DOI 10.1093/emboj/cdg550; Schrader CE, 2003, J EXP MED, V197, P1377, DOI 10.1084/jem.20022190; Schrader CE, 1999, J EXP MED, V190, P323, DOI 10.1084/jem.190.3.323; Schrader CE, 2002, J EXP MED, V195, P367, DOI 10.1084/jem.20011877; Seki M, 2005, EMBO REP, V6, P1143, DOI 10.1038/sj.embor.7400582; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Stanitsa ES, 2006, J BIOL CHEM, V281, P3439, DOI 10.1074/jbc.M511239200; Stivers JT, 2004, SCIENCE, V306, p2042A, DOI 10.1126/science.1104396; STUDEBAKER AW, 2003, THESIS OHIO STATE U; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0; Wiesendanger M, 2000, J EXP MED, V191, P579, DOI 10.1084/jem.191.3.579; Wilson TM, 2005, J EXP MED, V201, P637, DOI 10.1084/jem.20042066; WINTER E, 1987, EMBO J, V6, P1663, DOI 10.1002/j.1460-2075.1987.tb02415.x	70	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					731	742		10.1074/jbc.M607439200	http://dx.doi.org/10.1074/jbc.M607439200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17090531	hybrid			2022-12-27	WOS:000243166500078
J	Fang, YL; Kolmakova-Partensky, L; Miller, C				Fang, Yiling; Kolmakova-Partensky, Ludmila; Miller, Christopher			A bacterial arginine-agmatine exchange transporter involved in extreme acid resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROKARYOTIC K+ CHANNEL; CLC CHLORIDE CHANNELS; ESCHERICHIA-COLI; FUNCTIONAL RECONSTITUTION; TORPEDO ELECTROPLAX; STOICHIOMETRY; PURIFICATION; ANTIPORTER; MEMBRANE; STATE	The arginine-dependent extreme acid resistance response of Escherichia coli operates by decarboxylating arginine. AdiC, a membrane antiporter, catalyzes arginine influx coupled to efflux of the decarboxylation product agmatine, effectively exporting a proton in each turnover. Using the adiC coding sequence under control of a tetracycline promoter in an E. coli vector, we expressed and purified the transport-protein with a yield of similar to 10 mg/liter bacterial culture. Glutaraldehyde cross-linking experiments indicate that the protein is a homodimer in detergent micelles and lipid membranes. Purified AdiC reconstituted into liposomes exchanges arginine and agmatine in a strictly coupled, electrogenic fashion. Kinetic analysis yields K-m similar to 80 mu m for Arg, in the same range as its dissociation constant determined by isothermal titration calorimetry.	Brandeis Univ, Dept Biochem, Howard Hughes Med Inst, Waltham, MA 02468 USA	Brandeis University; Howard Hughes Medical Institute	Miller, C (corresponding author), Brandeis Univ, Dept Biochem, Howard Hughes Med Inst, 415 South St, Waltham, MA 02468 USA.	cmiller@brandeis.edu						Accardi A, 2004, J GEN PHYSIOL, V123, P109, DOI 10.1085/jgp.200308935; BLETHEN SL, 1968, J BIOL CHEM, V243, P1671; Castanie-Cornet MP, 1999, J BACTERIOL, V181, P3525, DOI 10.1128/JB.181.11.3525-3535.1999; Dutzler R, 2003, SCIENCE, V300, P108, DOI 10.1126/science.1082708; Foster JW, 2004, NAT REV MICROBIOL, V2, P898, DOI 10.1038/nrmicro1021; Geertsma ER, 2005, J MOL BIOL, V350, P102, DOI 10.1016/j.jmb.2005.04.047; GOLDBERG AFX, 1991, J MEMBRANE BIOL, V124, P199, DOI 10.1007/BF01994354; Gong S, 2003, J BACTERIOL, V185, P4402, DOI 10.1128/JB.185.15.4402-4409.2003; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; HICKMAN RK, 1988, J BACTERIOL, V170, P1715, DOI 10.1128/jb.170.4.1715-1720.1988; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; Iyer R, 2003, J BACTERIOL, V185, P6556, DOI 10.1128/JB.185.22.6556-6561.2003; Iyer R, 2002, NATURE, V419, P715, DOI 10.1038/nature01000; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; LAI FA, 1989, J BIOL CHEM, V264, P16776; Maduke M, 1999, J GEN PHYSIOL, V114, P713, DOI 10.1085/jgp.114.5.713; MALONEY PC, 1994, J EXP BIOL, V196, P471; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; Nimigean CM, 2004, J GEN PHYSIOL, V124, P203, DOI 10.1085/jgp.200409133; Richard H, 2004, J BACTERIOL, V186, P6032, DOI 10.1128/jb.186.18.6032-6041.2004; ROTH GJ, 1980, J BIOL CHEM, V255, P1301; Saier M H Jr, 1999, J Mol Microbiol Biotechnol, V1, P257; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; SKERRA A, 1994, GENE, V151, P131, DOI 10.1016/0378-1119(94)90643-2; Yernool D, 2003, BIOCHEMISTRY-US, V42, P12981, DOI 10.1021/bi030161q	28	54	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					176	182		10.1074/jbc.M610075200	http://dx.doi.org/10.1074/jbc.M610075200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17099215	hybrid			2022-12-27	WOS:000243166500021
J	Tian, E; Ten Hagen, KG				Tian, E.; Ten Hagen, Kelly G.			A UDP-GaINAc : polypeptide N-acetylgalactosaminyltransferase is required for epithelial tube formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA TRACHEAL SYSTEM; ZONULA ADHERENS FORMATION; SEPTATE JUNCTIONS; APICAL MEMBRANE; CELL POLARITY; CAENORHABDITIS-ELEGANS; SIZE CONTROL; EXPRESSION; CRUMBS; MORPHOGENESIS	Epithelial tubes are essential for the proper function of a diverse array of eukaryotic organs. Here we present a novel class of genes required for maintaining epithelial cell shape, polarity, and paracellular barrier function in the Drosophila embryonic tracheal system. Mutations in one member of the UDP-GaINAc:polypeptide N-acetylgalactosaminyltransferase family (pgant3SA) are recessive lethal and result in tracheal tubes that are irregular in diameter and morphology. Further analysis of the pgant35A mutants reveals diminished levels of the apical determinant Crbs and the luminal marker 2A12, concomitant with increased staining in cytoplasmic vesicles within tracheal cells. GalNAc-containing glycoproteins are severely diminished along the apical region of the tracheal system as well. Tracheal cells become irregular in size and shape, and septate junction proteins are mislocalized to a more apical position. Most notably, paracellular barrier function is lost in the tracheal system of the mutants. Overexpression of wild type pgant35A under control of the trachea-specific breathless (btl) promoter results in partial rescue of the lethality. We propose a model where pgant35A is required to establish proper apical composition of tracheal cells by influencing apical delivery of proteins/glycoproteins. Disruption of the normal apical content results in altered cell morphology and loss of paracellular barrier function. These studies demonstrate a previously unrecognized requirement for mucin-type O-glycosylation in epithelial tube integrity and have obvious implications for epithelial morphogenesis in higher eukaryotes, since a unique ortholog to pgant35A exists in mammals.	NIDCR, Dev Glycobiol Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ten Hagen, KG (corresponding author), NIDCR, Dev Glycobiol Unit, NIH, Bldg 30,Rm 4A400,30 Convent Dr,MSC 4370, Bethesda, MD 20892 USA.	Kelly.Tenhagen@nih.gov			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000713] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Araujo SJ, 2005, DEV BIOL, V288, P179, DOI 10.1016/j.ydbio.2005.09.031; Avichezer D, 1997, INT J CANCER, V72, P119, DOI 10.1002/(SICI)1097-0215(19970703)72:1<119::AID-IJC17>3.3.CO;2-5; Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Behr M, 2003, DEV CELL, V5, P611, DOI 10.1016/S1534-5807(03)00275-2; Beitel GJ, 2000, DEVELOPMENT, V127, P3271; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cabernard C, 2004, J APPL PHYSIOL, V97, P2347, DOI 10.1152/japplphysiol.00435.2004; Devine WP, 2005, P NATL ACAD SCI USA, V102, P17014, DOI 10.1073/pnas.0506676102; Dubreuil RR, 1997, MOL BIOL CELL, V8, P1933, DOI 10.1091/mbc.8.10.1933; Funes M, 2006, J BIOL CHEM, V281, P19310, DOI 10.1074/jbc.M603225200; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hang HC, 2005, BIOORGAN MED CHEM, V13, P5021, DOI 10.1016/j.bmc.2005.04.085; HARTENSTEIN V, 1993, ATLAS DROSOPHILA DEV, P2; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Klebes A, 2000, CURR BIOL, V10, P76, DOI 10.1016/S0960-9822(99)00277-8; Lamb RS, 1998, MOL BIOL CELL, V9, P3505, DOI 10.1091/mbc.9.12.3505; LEE JK, 1993, J CELL BIOL, V123, P1797, DOI 10.1083/jcb.123.6.1797; Liebl FLW, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-44; Llimargas M, 2004, DEVELOPMENT, V131, P181, DOI 10.1242/dev.00917; Lubarsky B, 2003, CELL, V112, P19, DOI 10.1016/S0092-8674(02)01283-7; Luschnig S, 2006, CURR BIOL, V16, P186, DOI 10.1016/j.cub.2005.11.072; Medina E, 2002, J CELL BIOL, V158, P941, DOI 10.1083/jcb.200203080; Myat MM, 2005, DEV DYNAM, V232, P617, DOI 10.1002/dvdy.20293; Myat MM, 2002, CELL, V111, P879, DOI 10.1016/S0092-8674(02)01140-6; Ohshiro T, 1997, DEVELOPMENT, V124, P3975; Potter BA, 2006, AM J PHYSIOL-CELL PH, V290, pC1, DOI 10.1152/ajpcell.00333.2005; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200; Shiga Y, 1996, DEV GROWTH DIFFER, V38, P99; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Tachibana K, 2006, GLYCOBIOLOGY, V16, P46, DOI 10.1093/glycob/cwj038; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Ten Hagen KG, 2002, J BIOL CHEM, V277, P22616, DOI 10.1074/jbc.M201807200; Ten Hagen KG, 2003, J BIOL CHEM, V278, P35039, DOI 10.1074/jbc.M303836200; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; Tian E, 2006, GLYCOBIOLOGY, V16, P83, DOI 10.1093/glycob/cwj051; Tonning A, 2005, DEV CELL, V9, P423, DOI 10.1016/j.devcel.2005.07.012; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Wu VM, 2004, CURR OPIN CELL BIOL, V16, P493, DOI 10.1016/j.ceb.2004.07.008; Wu VM, 2004, J CELL BIOL, V164, P313, DOI 10.1083/jcb.200309134; Xia LJ, 2004, J CELL BIOL, V164, P451, DOI 10.1083/jcb.200311112; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Young WW, 2003, GLYCOBIOLOGY, V13, P549, DOI 10.1093/glycob/cwg062; Zarnescu DC, 1999, J CELL BIOL, V146, P1075, DOI 10.1083/jcb.146.5.1075	49	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					606	614		10.1074/jbc.M606268200	http://dx.doi.org/10.1074/jbc.M606268200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17098739	hybrid			2022-12-27	WOS:000243166500066
J	Jepson, BJN; Mohan, S; Clarke, TA; Gates, AJ; Cole, JA; Butler, CS; Butt, JN; Hemmings, AM; Richardson, DJ				Jepson, Brian J. N.; Mohan, Sudesh; Clarke, Thomas A.; Gates, Andrew J.; Cole, Jeffrey A.; Butler, Clive S.; Butt, Julea N.; Hemmings, Andrew M.; Richardson, David J.			Spectropotentiometric and structural analysis of the periplasmic nitrate reductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C NITRITE REDUCTASE; CRYSTAL-STRUCTURE; DESULFOVIBRIO-DESULFURICANS; PARACOCCUS-PANTOTROPHUS; CYTOCHROME; RESOLUTION; REVEALS; MO(V); DMSO; DEHYDROGENASE	The Escherichia coli NapA (periplasmic nitrate reductase) contains a [4Fe-4S] cluster and a Mo-bis-molybdopterin guanine dinucleotide cofactor. The NapA holoenzyme associates with a di-heme c-type cytochrome redox partner (NapB). These proteins have been purified and studied by spectropotentiometry, and the structure of NapA has been determined. In contrast to the well characterized heterodimeric NapAB systems of alpha-proteobacteria, such as Rhodobactersphaeroides and Paracoccuspantotrophus, the gamma-proteobacterial E. coli NapA and NapB proteins purify independently and not as a tight heterodimeric complex. This relatively weak interaction is reflected in dissociation constants of 15 and 32 mu M determined for oxidized and reduced NapAB complexes, respectively. The surface electrostatic potential of E. coli NapA in the apparent NapB binding region is markedly less polar and anionic than that of the alpha-proteobacterial NapA, which may underlie the weaker binding of NapB. The molybdenum ion coordination sphere of E coli NapA includes two molybdopterin guanine dinucleotide dithiolenes, a protein-derived cysteinyl ligand and an oxygen atom. The Mo-O bond length is 2.6 angstrom, which is indicative of a water ligand. The potential range over which the Mo6+ state is reduced to the Mo5+ state in either NapA (between +100 and -100 mV) or the NapAB complex (-150 to -350 mV) is much lower than that reported for R. sphaeroides NapA (midpoint potential Mo6+/5+ > +350 mV) and the form of the Mo5+ EPR signal is quite distinct. In E. coli NapA or NapAB, the Mo5+ state could not be further reduced to Mo4+. We then propose a catalytic cycle for E. coli NapA in which nitrate binds to the Mo5+ ion and where a stable des-oxo Mo6+ species may participate.	Univ E Anglia, Ctr Met Prot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci, Norwich NR4 7TJ, Norfolk, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Newcastle Univ, Inst Cell & Mol Biosci, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of East Anglia; University of East Anglia; University of East Anglia; University of Birmingham; Newcastle University - UK	Hemmings, AM (corresponding author), Univ E Anglia, Ctr Met Prot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.	a.hemmings@uea.ac.uk; d.richardson@uea.ac.uk	Gates, Andrew J/F-8218-2011; Richardson, David J/E-2275-2011; HEMMINGS, ANDREW MICHAEL/E-5517-2011; clarke, tom/D-1837-2009; Butt, Julea/E-2133-2011	Gates, Andrew J/0000-0002-4594-5038; HEMMINGS, ANDREW MICHAEL/0000-0003-3053-3134; clarke, tom/0000-0002-6234-1914; Butt, Julea/0000-0002-9624-5226	Biotechnology and Biological Sciences Research Council [B18695] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; ANGROVE H, 2002, J BIOL CHEM, V277, P23374; Arnoux P, 2003, NAT STRUCT BIOL, V10, P928, DOI 10.1038/nsb994; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; BENNETT B, 1994, EUR J BIOCHEM, V226, P789, DOI 10.1111/j.1432-1033.1994.00789.x; BERKS BC, 1994, EUR J BIOCHEM, V220, P117, DOI 10.1111/j.1432-1033.1994.tb18605.x; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; BOYTINGTON JC, 1997, SCIENCE, V275, P1305; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETON J, 1994, FEBS LETT, V345, P76, DOI 10.1016/0014-5793(94)00445-5; Brige A, 2002, BIOCHEMISTRY-US, V41, P4827, DOI 10.1021/bi012144b; Brondijk THC, 2002, MOL MICROBIOL, V44, P245, DOI 10.1046/j.1365-2958.2002.02875.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURSAKOV S, 1995, ANAEROBE, V1, P55, DOI 10.1016/S1075-9964(95)80444-7; Butler CS, 2002, BIOCHEM J, V363, P817, DOI 10.1042/0264-6021:3630817; Butler CS, 1999, BIOCHEMISTRY-US, V38, P9000, DOI 10.1021/bi990402n; Butt JN, 2002, BIOELECTROCHEMISTRY, V56, P17, DOI 10.1016/S1567-5394(02)00049-X; Clarke TA, 2004, J BIOL CHEM, V279, P41333, DOI 10.1074/jbc.M407604200; Czjzek M, 1998, J MOL BIOL, V284, P435, DOI 10.1006/jmbi.1998.2156; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; Dobbin PS, 1999, BIOCHEM J, V342, P439, DOI 10.1042/0264-6021:3420439; Ellington MJK, 2002, J BACTERIOL, V184, P4767, DOI 10.1128/JB.184.17.4767-4774.2002; Elliott SJ, 2004, BIOCHEMISTRY-US, V43, P799, DOI 10.1021/bi035869j; Frangioni B, 2004, J AM CHEM SOC, V126, P1328, DOI 10.1021/ja0384072; Gangeswaran R, 1996, BIOCHEM J, V317, P103, DOI 10.1042/bj3170103; Gonzalez PJ, 2006, J BIOL INORG CHEM, V11, P609, DOI 10.1007/s00775-006-0110-0; Gwyer JD, 2004, BIOCHEMISTRY-US, V43, P15086, DOI 10.1021/bi049085x; Heffron K, 2001, BIOCHEMISTRY-US, V40, P3117, DOI 10.1021/bi002452u; Hettmann T, 2003, BIOCHEM BIOPH RES CO, V310, P40, DOI 10.1016/j.bbrc.2003.08.114; Hille R, 2002, TRENDS BIOCHEM SCI, V27, P360, DOI 10.1016/S0968-0004(02)02107-2; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Jepson BJN, 2006, BIOCHEM SOC T, V34, P122, DOI 10.1042/BST0340122; Jepson BJN, 2004, J BIOL CHEM, V279, P32212, DOI 10.1074/jbc.M402669200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jormakka M, 2002, SCIENCE, V295, P1863, DOI 10.1126/science.1068186; Jormakka M, 2004, STRUCTURE, V12, P95, DOI 10.1016/j.str.2003.11.020; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Lim BS, 2001, J AM CHEM SOC, V123, P1920, DOI 10.1021/ja003546u; Marietou A, 2005, FEMS MICROBIOL LETT, V248, P217, DOI 10.1016/j.femsle.2005.05.042; McAlpine AS, 1998, J MOL BIOL, V275, P613, DOI 10.1006/jmbi.1997.1513; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Potter L, 2001, ADV MICROB PHYSIOL, V45, P51, DOI 10.1016/S0065-2911(01)45002-8; Potter LC, 1999, BIOCHEM J, V344, P77, DOI 10.1042/0264-6021:3440077; REES DC, 1985, P NATL ACAD SCI USA, V82, P3082, DOI 10.1073/pnas.82.10.3082; RICHARDSON DJ, 1990, EUR J BIOCHEM, V194, P263, DOI 10.1111/j.1432-1033.1990.tb19452.x; Richardson DJ, 2001, CELL MOL LIFE SCI, V58, P165, DOI 10.1007/PL00000845; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; SHEN BH, 1994, J BIOL CHEM, V269, P8564; Stolz JF, 2002, CHEMBIOCHEM, V3, P198, DOI 10.1002/1439-7633(20020301)3:2/3<198::AID-CBIC198>3.0.CO;2-C; Thomas G, 1999, FEMS MICROBIOL LETT, V174, P167, DOI 10.1111/j.1574-6968.1999.tb13564.x; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	54	87	90	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6425	6437		10.1074/jbc.M607353200	http://dx.doi.org/10.1074/jbc.M607353200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17130127	hybrid			2022-12-27	WOS:000244867200050
J	Schubert, C; Schalk-Hihi, C; Struble, GT; Ma, HC; Petrounia, IP; Brandt, B; Deckman, IC; Patch, RJ; Player, MR; Spurlino, JC; Springer, BA				Schubert, Carsten; Schalk-Hihi, Celine; Struble, Geoffrey T.; Ma, Hong-Chang; Petrounia, Ioanna P.; Brandt, Benjamin; Deckman, Ingrid C.; Patch, Raymond J.; Player, Mark R.; Spurlino, John C.; Springer, Barry A.			Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUXTAMEMBRANE DOMAIN; STI-571 INHIBITION; FMS ONCOGENE; MACROPHAGE; CSF-1; BINDING; PROTEIN; MURINE; AUTOINHIBITION; PHOSPHORYLATION	The cFMS proto-oncogene encodes for the colony-stimulating factor-1 receptor, a receptor-tyrosine kinase responsible for the differentiation and maturation of certain macrophages. Upon binding its ligand colony-stimulating factor-1 cFMS autophosphorylates, dimerizes, and induces phosphorylation of downstream targets. We report the novel crystal structure of unphosphorylated cFMS in complex with two members of different classes of drug-like protein kinase inhibitors. cFMS exhibits a typical bi-lobal kinase fold, and its activation loop and DFG motif are found to be in the canonical inactive conformation. Both ATP competitive inhibitors are bound in the active site and demonstrate a binding mode similar to that of STI-571 bound to cABL. The DFG motif is prevented from switching into the catalytically competent conformation through interactions with the inhibitors. Activation of cFMS is also inhibited by the juxtamembrane domain, which interacts with residues of the active site and prevents formation of the activated kinase. Together the structures of cFMS provide further insight into the autoinhibition of receptor-tyrosine kinases via their respective juxtamembrane domains; additionally the binding mode of two novel classes of kinase inhibitors will guide the design of novel molecules targeting macrophage-related diseases.	Johnson & Johnson Pharmaceut Res & Dev LLC, Struct Biol, Exton, PA 19341 USA	Johnson & Johnson; Johnson & Johnson USA	Schubert, C (corresponding author), Johnson & Johnson Pharmaceut Res & Dev LLC, Struct Biol, 665 Stockton Dr, Exton, PA 19341 USA.	cschuber@prdus.jnj.com		Spurlino, John/0000-0003-1308-2570				ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Bischof RJ, 2000, CLIN EXP IMMUNOL, V119, P361; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campbell IK, 2000, J LEUKOCYTE BIOL, V68, P144; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Feng X, 2002, ENDOCRINOLOGY, V143, P4868, DOI 10.1210/en.2002-220467; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Hubbard SR, 2002, FRONT BIOSCI, V7, pD330, DOI 10.2741/hubbard; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joos H, 1996, J BIOL CHEM, V271, P24476, DOI 10.1074/jbc.271.40.24476; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; Kluger HM, 2004, CLIN CANCER RES, V10, P173, DOI 10.1158/1078-0432.CCR-0699-3; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Nagar B, 2002, CANCER RES, V62, P4236; Novak U, 1996, ONCOGENE, V13, P2607; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; Pierce AC, 2002, PROTEINS, V49, P567, DOI 10.1002/prot.10259; Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETTENMIER CW, 1988, J CELL SCI, P27; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; Schalk-Hihi C, 2007, J BIOL CHEM, V282, P4085, DOI 10.1074/jbc.M608182200; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2	33	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4094	4101		10.1074/jbc.M608183200	http://dx.doi.org/10.1074/jbc.M608183200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17132624	hybrid			2022-12-27	WOS:000244481900073
J	Mahalingam, Y; Gallagher, JT; Couchman, JR				Mahalingam, Yashithra; Gallagher, John T.; Couchman, John R.			Cellular adhesion responses to the heparin-binding (HepII) domain of fibronectin require heparan sulfate with specific properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDECAN-4; PROTEOGLYCANS; BIOSYNTHESIS; RECEPTOR; IDENTIFICATION; LOCALIZATION; FIBROBLASTS; PEPTIDES; SEQUENCE; MUTANTS	Cell surface heparan sulfate (HS) proteoglycans are required in development and postnatal repair. Important classes of ligands for HS include growth factors and extracellular matrix macromolecules. For example, the focal adhesion component syndecan-4 interacts with the III12-14 region of fibronectin (HepII domain) through its HS chains. The fine structure of HS is critical to growth factor responses, and whether this extends to matrix ligands is unknown but is suggested from in vitro experiments. Cell attachment to HepII showed that heparin oligosaccharides of >= 14 sugar residues were required for optimal inhibition. The presence of N-sulfated glucosamine in the HS was essential, whereas 2-O-sulfation of uronic acid or 6-O-sulfation of glucosamine had marginal effects. In the more complex response of focal adhesion formation through syndecan-4, N-sulfates were again required and also glucosamine 6-O-sulfate. The significance of polymer N-sulfation and sulfated domains in HS was confirmed by studies with mutant Chinese hamster ovary cells where heparan sulfation was compromised. Finally, focal adhesion formation was absent in fibroblasts synthesizing short HS chains resulting from a gene trap mutation in one of the two major glucosaminoglycan polymerases (EXT1). Several separate, specific properties of cell surface HS are therefore required in cell adhesion responses to the fibronectin HepII domain.	Imperial Coll London, Div Biomed Sci, London SW7 2AZ, England; Univ Manchester, Canc Res UK, Dept Med Oncol, Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England	Imperial College London; Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Couchman, JR (corresponding author), Imperial Coll London, Div Biomed Sci, Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	j.couchman@imperial.ac.uk			Wellcome Trust [065940] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; Busse M, 2003, J BIOL CHEM, V278, P41333, DOI 10.1074/jbc.M308314200; Cornelison DDW, 2004, GENE DEV, V18, P2231, DOI 10.1101/gad.1214204; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; ESKO JD, 1987, J BIOL CHEM, V262, P12189; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; HAUGEN PK, 1992, J NEUROSCI, V12, P2597; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; JOHANSSON S, 1985, J BIOL CHEM, V260, P1557; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; Lim ST, 2003, J BIOL CHEM, V278, P13795, DOI 10.1074/jbc.M208300200; Lyon M, 2000, J BIOL CHEM, V275, P4599, DOI 10.1074/jbc.275.7.4599; MCCARTHY JB, 1986, J CELL BIOL, V102, P179, DOI 10.1083/jcb.102.1.179; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; MOULD AP, 1990, J BIOL CHEM, V265, P4020; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Rawson JM, 2005, CURR BIOL, V15, P833, DOI 10.1016/j.cub.2005.03.039; Sachchidanand, 2002, J BIOL CHEM, V277, P50629, DOI 10.1074/jbc.M208956200; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; SINGER II, 1984, J CELL BIOL, V98, P2091, DOI 10.1083/jcb.98.6.2091; Stringer SE, 2003, GLYCOBIOLOGY, V13, P97, DOI 10.1093/glycob/cwg006; Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7; Tkachenko E, 2005, CIRC RES, V96, P488, DOI 10.1161/01.RES.0000159708.71142.c8; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; Whitelock JM, 2005, CHEM REV, V105, P2745, DOI 10.1021/cr010213m; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Yamada S, 2004, J BIOL CHEM, V279, P32134, DOI 10.1074/jbc.M312624200; YONEDA J, 1995, EXP CELL RES, V217, P169, DOI 10.1006/excr.1995.1076; Yuguchi Y, 2005, INT J BIOL MACROMOL, V35, P19, DOI 10.1016/j.ijbiomac.2004.11.003	53	56	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3221	3230		10.1074/jbc.M604938200	http://dx.doi.org/10.1074/jbc.M604938200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17130131	hybrid			2022-12-27	WOS:000243793900049
J	Schwarzer, D; Stummeyer, K; Gerardy-Schahn, R; Muhlenhoff, M				Schwarzer, David; Stummeyer, Katharina; Gerardy-Schahn, Rita; Muehlenhoff, Martina			Characterization of a novel intramolecular chaperone domain conserved in endosialidases and other bacteriophage tail spike and fiber proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P22 TAILSPIKE PROTEIN; ESCHERICHIA-COLI K1; CAPSULAR POLYSACCHARIDE; CRYSTAL-STRUCTURE; POLYSIALIC ACID; KINETIC STABILITY; BACILLUS-SUBTILIS; EVOLUTION; CLEAVAGE; CLONING	Folding and assembly of endosialidases, the trimeric tail spike proteins of Escherichia coli K1-specific bacteriophages, crucially depend on their C-terminal domain (CTD). Homologous CTDs were identified in phage proteins belonging to three different protein families: neck appendage proteins of several Bacillus phages, L-shaped tail fibers of coliphage T5, and K5 lyases, the tail spike proteins of phages infecting E. coli K5. By analyzing a representative of each family, we show that in all cases, the CTD is cleaved off after a strictly conserved serine residue and alanine substitution prevented cleavage. Further structural and functional analyses revealed that (i) CTDs are autonomous domains with a high alpha-helical content; (ii) proteolytically released CTDs assemble into hexamers, which are most likely dimers of trimers; (iii) highly conserved amino acids within the CTD are indispensable for CTD-mediated folding and complex formation; (iv) CTDs can be exchanged between proteins of different families; and (v) proteolytic cleavage is essential to stabilize the native protein complex. Data obtained for full-length and proteolytically processed endosialidase variants suggest that release of the CTD increases the unfolding barrier, trapping the mature trimer in a kinetically stable conformation. In summary, we characterize the CTD as a novel C-terminal chaperone domain, which assists folding and assembly of unrelated phage proteins.	Hannover Med Sch, Abt Zellulare Chem, Zentrum Biochem, D-30625 Hannover, Germany	Hannover Medical School	Muhlenhoff, M (corresponding author), Hannover Med Sch, Abt Zellulare Chem, Zentrum Biochem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	muehlenhoff.martina@mh-hannover.de	Schwarzer, David/C-1939-2012					Ackermann HW, 1999, ADV VIRUS RES, V51, P135; Ali SA, 2003, BIOPHYS J, V85, P2606, DOI 10.1016/S0006-3495(03)74683-9; Botstein D, 1980, Ann N Y Acad Sci, V354, P484, DOI 10.1111/j.1749-6632.1980.tb27987.x; Burda MR, 1999, EUR J BIOCHEM, V265, P771, DOI 10.1046/j.1432-1327.1999.00782.x; CARRASCOSA JL, 1976, EUR J BIOCHEM, V66, P229, DOI 10.1111/j.1432-1033.1976.tb10512.x; Casjens SR, 2005, CURR OPIN MICROBIOL, V8, P451, DOI 10.1016/j.mib.2005.06.014; Clarke BR, 2000, J BACTERIOL, V182, P3761, DOI 10.1128/JB.182.13.3761-3766.2000; CONWAY JF, 1995, J MOL BIOL, V253, P86, DOI 10.1006/jmbi.1995.0538; Cunningham EL, 1999, P NATL ACAD SCI USA, V96, P11008, DOI 10.1073/pnas.96.20.11008; DICKSON RC, 1973, J MOL BIOL, V79, P633, DOI 10.1016/0022-2836(73)90068-5; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; Gage MJ, 2003, PROTEIN SCI, V12, P2732, DOI 10.1110/ps.03150303; GERARDYSCHAHN R, 1995, MOL MICROBIOL, V16, P441, DOI 10.1111/j.1365-2958.1995.tb02409.x; GROSS RJ, 1977, J CLIN MICROBIOL, V6, P548; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HELLER K, 1979, J BACTERIOL, V139, P32, DOI 10.1128/JB.139.1.32-38.1979; KALIMAN AV, 1995, FEBS LETT, V366, P46, DOI 10.1016/0014-5793(95)00482-O; Kanamaru S, 2002, NATURE, V415, P553, DOI 10.1038/415553a; Kreisberg JF, 2002, PROTEIN SCI, V11, P820, DOI 10.1110/ps.3440102; KWIATKOWSKI B, 1983, J VIROL, V45, P367, DOI 10.1128/JVI.45.1.367-374.1983; KWIATKOWSKI B, 1982, J VIROL, V43, P697, DOI 10.1128/JVI.43.2.697-704.1982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYING H, 1990, INFECT IMMUN, V58, P222, DOI 10.1128/IAI.58.1.222-227.1990; Lindberg AA, 1977, SURFACE CARBOHYDRATE, P289; Manning M, 2004, BIOCHEMISTRY-US, V43, P11248, DOI 10.1021/bi0491898; MARVIK OJ, 1994, VIROLOGY, V205, P51, DOI 10.1006/viro.1994.1619; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; Miller ES, 2003, MICROBIOL MOL BIOL R, V67, P86, DOI 10.1128/MMBR.67.1.86-156.2003; Miroshnikov KA, 1998, PROTEIN ENG, V11, P329, DOI 10.1093/protein/11.4.329; Miyake K, 1997, J FERMENT BIOENG, V84, P90, DOI 10.1016/S0922-338X(97)82793-6; Muhlenhoff M, 2003, J BIOL CHEM, V278, P12634, DOI 10.1074/jbc.M212048200; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Papanikolopoulou K, 2004, J BIOL CHEM, V279, P8991, DOI 10.1074/jbc.M311791200; PELKONEN S, 1989, J VIROL, V63, P4409, DOI 10.1128/JVI.63.10.4409-4416.1989; Peterson C, 2001, J STRUCT BIOL, V135, P18, DOI 10.1006/jsbi.2001.4375; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; SARFF LD, 1975, LANCET, V1, P1099; Scholl D, 2001, J VIROL, V75, P2509, DOI 10.1128/JVI.75.6.2509-2515.2001; SMITH HW, 1982, J GEN MICROBIOL, V128, P307; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 2004, METHOD ENZYMOL, V383, P318; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STIRM S, 1971, J VIROL, V8, P330, DOI 10.1128/JVI.8.3.330-342.1971; Stummeyer K, 2005, NAT STRUCT MOL BIOL, V12, P90, DOI 10.1038/nsmb874; Stummeyer K, 2006, MOL MICROBIOL, V60, P1123, DOI 10.1111/j.1365-2958.2006.05173.x; Tao YZ, 1998, CELL, V95, P431, DOI 10.1016/S0092-8674(00)81773-0; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; TOSI ME, 1975, J VIROL, V16, P1282, DOI 10.1128/JVI.16.5.1282-1295.1975; van Raaij MJ, 2001, J MOL BIOL, V314, P1137, DOI 10.1006/jmbi.2000.5204; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; Wang JB, 2005, VIROLOGY, V332, P45, DOI 10.1016/j.virol.2004.10.049; Wang SF, 2003, VIROLOGY, V314, P1, DOI 10.1016/S0042-6822(03)00375-1; Weigele PR, 2003, J BACTERIOL, V185, P4022, DOI 10.1128/JB.185.14.4022-4030.2003; Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002; Zhang YM, 2000, NAT BIOTECHNOL, V18, P1314, DOI 10.1038/82449	55	54	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2821	2831		10.1074/jbc.M609543200	http://dx.doi.org/10.1074/jbc.M609543200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17158460	hybrid			2022-12-27	WOS:000243793900008
J	Yamamoto, N; Matsubara, E; Maeda, S; Minagawa, H; Takashima, A; Maruyama, W; Michikawa, M; Yanagisawa, K				Yamamoto, Naoki; Matsubara, Etsuro; Maeda, Sumihiro; Minagawa, Hirohisa; Takashima, Akihiko; Maruyama, Wakako; Michikawa, Makoto; Yanagisawa, Katsuhiko			A ganglioside-induced toxic soluble A beta assembly - Its enhanced formation from A beta bearing the Arctic mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P75 NEUROTROPHIN RECEPTOR; ATOMIC-FORCE MICROSCOPY; LONG-TERM POTENTIATION; GROWTH-FACTOR RECEPTOR; ALZHEIMERS-DISEASE; CEREBRAL-HEMORRHAGE; AMYLOID OLIGOMERS; TRANSGENIC MICE; NERVOUS-SYSTEM; MOUSE MODELS	The mechanism underlying plaque-independent neuronal death in Alzheimer disease ( AD), which is probably responsible for early cognitive decline in AD patients, remains unclarified. Here, we show that a toxic soluble A beta assembly (TA beta) is formed in the presence of liposomes containing GM1 ganglioside more rapidly and to a greater extent from a hereditary variant-type ("Arctic") A beta than from wild-type A beta. TA beta is also formed from soluble A beta through incubation with natural neuronal membranes prepared from aged mouse brains in a GM1 ganglioside-dependent manner. An oligomer-specific antibody (anti-Oligo) significantly suppresses TA beta toxicity. Biophysical and structural analyses by atomic force microscopy and size exclusion chromatography revealed that TA beta is spherical with diameters of 10 - 20 nm and molecular masses of 200 - 300 kDa. TA beta induces neuronal death, which is abrogated by the small interfering RNA-mediated knockdown of nerve growth factor receptors, including TrkA and p75 neurotrophin receptor. Our results suggest that soluble A beta assemblies, such as TA beta, can cause plaque-independent neuronal death that favorably occurs in nerve growth factor-dependent neurons in the cholinergic basal forebrain in AD.	Natl Ctr Geriatr & Gerontol, Dept Alzheimers Dis Res, Natl Inst Longev Sci, Morioka, Obu 4748522, Japan; Natl Ctr Geriatr & Gerontol, Dept Geriatr Med, Natl Inst Longev Sci, Morioka, Obu 4748522, Japan; Japan Soc Promot Sci, Tokyo 1028472, Japan; RIKEN, Brain Sci Inst, Lab Alzheimers Dis, Wako, Saitama 3510198, Japan	National Center for Geriatrics & Gerontology; National Center for Geriatrics & Gerontology; Japan Society for the Promotion of Science; RIKEN	Yanagisawa, K (corresponding author), Natl Ctr Geriatr & Gerontol, Dept Alzheimers Dis Res, Natl Inst Longev Sci, 36-3 Gengo, Morioka, Obu 4748522, Japan.	katuhiko@nils.go.jp	Maeda, Sumihiro/W-9146-2019					Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Bothwell M, 1996, SCIENCE, V272, P506, DOI 10.1126/science.272.5261.506; Brocca P, 1998, BIOPHYS J, V74, P309, DOI 10.1016/S0006-3495(98)77788-4; Cheng IH, 2004, NAT MED, V10, P1190, DOI 10.1038/nm1123; Chong YH, 2006, J BIOL CHEM, V281, P20315, DOI 10.1074/jbc.M601016200; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Costantini C, 2005, EXP CELL RES, V311, P126, DOI 10.1016/j.yexcr.2005.09.004; Costantini C, 2005, J MOL NEUROSCI, V25, P141, DOI 10.1385/JMN:25:2:141; Coulson EJ, 2006, J NEUROCHEM, V98, P654, DOI 10.1111/j.1471-4159.2006.03905.x; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Grabowski TJ, 2001, ANN NEUROL, V49, P697, DOI 10.1002/ana.1009; Gylys KH, 2007, NEUROBIOL AGING, V28, P8, DOI 10.1016/j.neurobiolaging.2005.10.018; HANSMA HG, 1995, BIOPHYS J, V68, P1672, DOI 10.1016/S0006-3495(95)80343-7; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hayashi H, 2004, J NEUROSCI, V24, P4894, DOI 10.1523/JNEUROSCI.0861-04.2004; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kuner P, 1998, J NEUROSCI RES, V54, P798, DOI 10.1002/(SICI)1097-4547(19981215)54:6<798::AID-JNR7>3.3.CO;2-K; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lad SP, 2003, CNS NEUROL DISORD-DR, V2, P315, DOI 10.2174/1568007033482724; Lad SP, 2003, J BIOL CHEM, V278, P24808, DOI 10.1074/jbc.M212270200; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Lee MS, 2006, J CELL BIOCHEM, V99, P88, DOI 10.1002/jcb.20830; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Malaplate-Armand C, 2006, NEUROBIOL DIS, V23, P178, DOI 10.1016/j.nbd.2006.02.010; Mamidipudi V, 2002, J NEUROSCI RES, V68, P373, DOI 10.1002/jnr.10244; Melchor JP, 2000, J NEUROCHEM, V74, P2209, DOI 10.1046/j.1471-4159.2000.0742209.x; Molander-Melin M, 2005, J NEUROCHEM, V92, P171, DOI 10.1111/j.1471-4159.2004.02849.x; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Oddo S, 2006, J BIOL CHEM, V281, P1599, DOI 10.1074/jbc.M507892200; Ohno M, 2006, EUR J NEUROSCI, V23, P251, DOI 10.1111/j.1460-9568.2005.04551.x; Perini G, 2002, J EXP MED, V195, P907, DOI 10.1084/jem.20011797; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; RABIZADEH S, 1994, P NATL ACAD SCI USA, V91, P10703, DOI 10.1073/pnas.91.22.10703; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; SCHROEDER F, 1988, BIOCHIM BIOPHYS ACTA, V946, P85, DOI 10.1016/0005-2736(88)90460-9; Terry R., 1999, ALZHEIMER DIS, V2nd Edn, P187; Tsukamoto E, 2003, J NEUROSCI RES, V73, P627, DOI 10.1002/jnr.10703; Walsh DM, 2005, J NEUROSCI, V25, P2455, DOI 10.1523/JNEUROSCI.4391-04.2005; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Whalen BM, 2005, NEUROBIOL DIS, V20, P254, DOI 10.1016/j.nbd.2005.03.007; WOOLE NJ, 1989, NEUROSCIENCE, V30, P143, DOI 10.1016/0306-4522(89)90360-6; WOOLF NJ, 1989, NEUROSCI LETT, V96, P277, DOI 10.1016/0304-3940(89)90391-1; Yaar M, 2002, J BIOL CHEM, V277, P7720, DOI 10.1074/jbc.M110929200; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yamamoto N, 2004, FEBS LETT, V569, P135, DOI 10.1016/j.febslet.2004.05.037; Yamamoto N, 2004, J NEUROCHEM, V90, P62, DOI 10.1111/j.1471-4159.2004.02459.x; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Zhang Y, 2003, J NEUROSCI, V23, P7385	69	63	66	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2646	2655		10.1074/jbc.M606202200	http://dx.doi.org/10.1074/jbc.M606202200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135262	hybrid			2022-12-27	WOS:000243593200057
J	Arita, K; Hashimoto, H; Igari, K; Akaboshi, M; Kutsuna, S; Sato, M; Shimizu, T				Arita, Kyouhei; Hashimoto, Hiroshi; Igari, Kumiko; Akaboshi, Mayuko; Kutsuna, Shinsuke; Sato, Mamoru; Shimizu, Toshiyuki			Structural and biochemical characterization of a cyanobacterium circadian clock-modifier protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ANTIBIOTIC-RESISTANCE; KAIC PHOSPHORYLATION; CRYSTAL-STRUCTURE; TRANSCRIPTIONAL REGULATOR; MOLECULAR REPLACEMENT; GENE-EXPRESSION; SYSTEM; RHYTHM; OSCILLATION; PCC-7942	Circadian clocks are self-sustained biochemical oscillators. The oscillator of cyanobacteria comprises the products of three kai genes (kaiA, kaiB, and kaiC). The autophosphorylation cycle of KaiC oscillates robustly in the cell with a 24-h period and is essential for the basic timing of the cyanobacterial circadian clock. Recently, period extender (pex), mutants of which show a short period phenotype, was classified as a resetting-related gene. In fact, pex mRNA and the pex protein (Pex) increase during the dark period, and a pex mutant subjected to diurnal light-dark cycles shows a 3-h advance in rhythm phase. Here, we report the x-ray crystallographic analysis and biochemical characterization of Pex from cyanobacterium Synechococcus elongatus PCC 7942. The molecule has an (alpha+beta) structure with a winged-helix motif and is indicated to function as a dimer. The subunit arrangement in the dimer is unique and has not been seen in other winged-helix proteins. Electrophoresis mobility shift assay using a 25-base pair complementary oligonucleotide incorporating the kaiA upstream sequence demonstrates that Pex has an affinity for the double-stranded DNA. Furthermore, mutation analysis shows that Pex uses the wing region to recognize the DNA. The in vivo rhythm assay of Pex shows that the constitutive expression of the pex gene harboring the mutation that fails to bind to DNA lacks the period-prolongation activity in the pex-deficient Synechococcus, suggesting that Pex is a DNA-binding transcription factor.	Yokohama City Univ, Int Grad Sch Arts & Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Yokohama City Univ, Grad Sch Arts & Sci, Kanazawa Ku, Yokohama, Kanagawa 2360027, Japan	Yokohama City University; Yokohama City University	Shimizu, T (corresponding author), Yokohama City Univ, Int Grad Sch Arts & Sci, Tsurumi Ku, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	shimizu@tsurumi.yokohama-cu.ac.jp	Arita, Kyohei/AAJ-6402-2020	Arita, Kyohei/0000-0002-9762-8405; Hashimoto, Hiroshi/0000-0003-1503-6789				Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Aoki S, 1997, J BACTERIOL, V179, P5751, DOI 10.1128/jb.179.18.5751-5755.1997; Barthelmebs L, 2000, J BACTERIOL, V182, P6724, DOI 10.1128/JB.182.23.6724-6731.2000; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bunning E, 1973, PHYSL CLOCK; BUSSIERE DE, 1995, CELL, V80, P651; CHEN TH, 1991, PLANT PHYSIOL, V97, P55, DOI 10.1104/pp.97.1.55; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; DeLano W.L, PYMOL MOL GRAPHICS S; Dunlap J.C., 2004, CHRONOBIOLOGY BIOL T; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Garcia-Castellanos R, 2003, J BIOL CHEM, V278, P39897, DOI 10.1074/jbc.M307199200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki H, 2002, P NATL ACAD SCI USA, V99, P15788, DOI 10.1073/pnas.222467299; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kageyama H, 2003, J BIOL CHEM, V278, P2388, DOI 10.1074/jbc.M208899200; Kitayama Y, 2003, EMBO J, V22, P2127, DOI 10.1093/emboj/cdg212; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; Kutsuna S, 2005, MOL MICROBIOL, V57, P1474, DOI 10.1111/j.1365-2958.2005.04781.x; Kutsuna S, 1998, J BACTERIOL, V180, P2167, DOI 10.1128/JB.180.8.2167-2174.1998; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU Y, 1995, GENE DEV, V9, P1469, DOI 10.1101/gad.9.12.1469; Mori T, 1996, P NATL ACAD SCI USA, V93, P10183, DOI 10.1073/pnas.93.19.10183; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakahira Y, 2004, P NATL ACAD SCI USA, V101, P881, DOI 10.1073/pnas.0307411100; Nakajima M, 2005, SCIENCE, V308, P414, DOI 10.1126/science.1108451; Nikaido H, 1998, CURR OPIN MICROBIOL, V1, P516, DOI 10.1016/S1369-5274(98)80083-0; Nishiwaki T, 2004, P NATL ACAD SCI USA, V101, P13927, DOI 10.1073/pnas.0403906101; Onai M, 2004, J BACTERIOL, V186, P4972, DOI 10.1128/JB.186.15.4972-4977.2004; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Schmitz O, 2000, SCIENCE, V289, P765, DOI 10.1126/science.289.5480.765; Takahashi Y, 2004, MOL MICROBIOL, V52, P837, DOI 10.1111/j.1365-2958.2004.04021.x; Takai N, 2006, J BIOL RHYTHM, V21, P235, DOI 10.1177/0748730406289400; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tomita J, 2005, SCIENCE, V307, P251, DOI 10.1126/science.1102540; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Xu Y, 2004, P NATL ACAD SCI USA, V101, P13933, DOI 10.1073/pnas.0404768101	44	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1128	1135		10.1074/jbc.M608148200	http://dx.doi.org/10.1074/jbc.M608148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17098741	hybrid			2022-12-27	WOS:000243295200037
J	Harris, M; Firsov, D; Vuagniaux, G; Stutts, MJ; Rossier, BC				Harris, Michael; Firsov, Dmitri; Vuagniaux, Gregoire; Stutts, M. Jackson; Rossier, Bernard C.			A novel neutrophil elastase inhibitor prevents elastase activation and surface cleavage of the epithelial sodium channel expressed in Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; LUNG-DISEASE; MUCUS CLEARANCE; NA+ TRANSPORT; CELL LINE; LIQUID; DYSFUNCTION; MECHANISM; AMILORIDE; SALINE	The amiloride-sensitive epithelial sodium channel (ENaC) constitutes a limiting step in sodium reabsorption across distal airway epithelium and controlling mucociliary clearance. ENaC is activated by serine proteases secreted in the extracellular milieu. In cystic fibrosis lungs, high concentrations of secreted neutrophil elastase (NE) are observed. hNE could activate ENaC and contribute to further decreased mucociliary clearance. The aims of this study were (i) to test the ability of an engineered human neutrophil elastase inhibitor (EPI-hNE4) to specifically inhibit the elastase activation of ENaC-mediated amiloride-sensitive currents (I-Na) and (ii) to examine the effect of elastase on cell surface expression of ENaC and its cleavage pattern (exogenous proteolysis). Oocytes were exposed to hNE (10-100 mu g/ml) and/or trypsin (10 mu g/ml) for 2-5 min in the presence or absence of EPI-hNE4 (0.7 mu m). hNE activated I-Na 3.6-fold (p < 0.001) relative to non-treated hENaC-injected oocytes. EPI-hNE4 fully inhibited hNE-activated I-Na but had no effect on trypisin- or prostasin-activated I-Na. The co-activation of I-Na by hNE and trypsin was not additive. Biotinylation experiments revealed that cell surface gamma ENaC (but not alpha or beta ENaC) exposed to hNE for 2 min was cleaved (as a 67-kDa fragment) and correlated with increased INa. The elastase-induced exogenous proteolysis pattern is distinct from the endogenous proteolysis pattern induced upon preferential assembly, suggesting a causal relationship between gamma ENaC cleavage and ENaC activation, taking place at the plasma membrane.	Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Debiopharm SA, CH-1000 Lausanne, Switzerland; Univ N Carolina, Chapel Hill, NC 27599 USA	University of Lausanne; Debiopharm; University of North Carolina; University of North Carolina Chapel Hill	Rossier, BC (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, 27,Rue Bugnon, CH-1005 Lausanne, Switzerland.	Bernard.Rossier@unil.ch						AMITANI R, 1991, AM J RESP CELL MOL, V4, P26, DOI 10.1165/ajrcmb/4.1.26; BIRRER P, 1994, AM J RESP CRIT CARE, V150, P207, DOI 10.1164/ajrccm.150.1.7912987; Boucher RC, 2003, PFLUG ARCH EUR J PHY, V445, P495, DOI 10.1007/s00424-002-0955-1; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Bridges RJ, 2001, AM J PHYSIOL-LUNG C, V281, pL16, DOI 10.1152/ajplung.2001.281.1.L16; Caldwell RA, 2005, AM J PHYSIOL-LUNG C, V288, pL813, DOI 10.1152/ajplung.00435.2004; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; Delacourt C, 2002, AM J RESP CELL MOL, V26, P290, DOI 10.1165/ajrcmb.26.3.4611; Donaldson SH, 2006, NEW ENGL J MED, V354, P241, DOI 10.1056/NEJMoa043891; Guggino WB, 1999, CELL, V96, P607, DOI 10.1016/S0092-8674(00)80570-X; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kerem E, 1999, NEW ENGL J MED, V341, P156, DOI 10.1056/NEJM199907153410304; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Matalon S, 2002, J APPL PHYSIOL, V93, P1852, DOI 10.1152/japplphysiol.01241.2001; Michlig S, 2005, J BIOL CHEM, V280, P38264, DOI 10.1074/jbc.M506308200; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; Planes C, 2005, AM J PHYSIOL-LUNG C, V288, pL1099, DOI 10.1152/ajplung.00332.2004; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Rossier Bernard C, 2004, Proc Am Thorac Soc, V1, P4, DOI 10.1513/pats.2306007; Sood N, 2003, AM J RESP CRIT CARE, V167, P158, DOI 10.1164/rccm.200204-293OC; Tong ZY, 2004, AM J PHYSIOL-LUNG C, V287, pL928, DOI 10.1152/ajplung.00160.2004; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	27	84	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					58	64		10.1074/jbc.M605125200	http://dx.doi.org/10.1074/jbc.M605125200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17090546	Green Published, hybrid			2022-12-27	WOS:000243166500007
J	Langeslag, M; Clark, K; Moolenaar, WH; van Leeuwen, FN; Jalink, K				Langeslag, Michiel; Clark, Kristopher; Moolenaar, Wouter H.; van Leeuwen, Frank N.; Jalink, Kees			Activation of TRPM7 channels by phospholipase C-coupled receptor agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; CATION CHANNEL; FLUORESCENT INDICATOR; POLYVALENT CATIONS; KINASE-ACTIVITY; CELL-ADHESION; MIC CHANNELS; LIVING CELLS; CYCLIC-AMP; PROTEIN	TRPM7 is a ubiquitously expressed nonspecific cation channel that has been implicated in cellular Mg2+ homeostasis. We have recently shown that moderate overexpression of TRPM7 in neuroblastoma N1E-115 cells elevates cytosolic Ca2+ levels and enhances cell-matrix adhesion. Furthermore, activation of TRPM7 by phospholipase C (PLC)-coupled receptor agonists caused a further increase in intracellular Ca2+ levels and augmented cell adhesion and spreading in a Ca2+-dependent manner (1). Regulation of the TRPM7 channel is not well understood, although it has been reported that PIP2 hydrolysis closes the channel. Here we have examined the regulation of TRPM7 by PLC-coupled receptor agonists such as bradykinin, lysophosphatidic acid, and thrombin. Using FRET assays for second messengers, we have shown that the TRPM7-dependent Ca2+ increase closely correlates with activation of PLC. Under noninvasive "perforated patch clamp" conditions, we have found similar activation of TRPM7 by PLC-coupled receptor agonists. Although we could confirm that, under whole-cell conditions, the TRPM7 currents were significantly inhibited following PLC activation, this PLC-dependent inhibition was only observed when [Mg2+](i) was reduced below physiological levels. Thus, under physiological ionic conditions, TRPM7 currents were activated rather than inhibited by PLC-activating receptor agonists.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Tumor Immunol, NL-6500 HB Nijmegen, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Radboud University Nijmegen	Jalink, K (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	K.Jalink@NKI.nl	van Leeuwen, Frank/AAQ-6799-2020	van Leeuwen, Frank/0000-0003-1107-6513; Langeslag, Michiel/0000-0003-4883-7339; Jalink, Kees/0000-0001-7019-3440				Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Albert O, 1999, LIFE SCI, V64, P859, DOI 10.1016/S0024-3205(99)00007-7; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; Balla T, 2001, CURR PHARM DESIGN, V7, P475, DOI 10.2174/1381612013397906; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clark K, 2006, EMBO J, V25, P290, DOI 10.1038/sj.emboj.7600931; COGGAN JS, 1995, AM J PHYSIOL-CELL PH, V269, pC841, DOI 10.1152/ajpcell.1995.269.4.C841; DEMUESE P, 2006, J GEN PHYSIOL, V127, P421; Gwanyanya A, 2006, AM J PHYSIOL-CELL PH, V291, pC627, DOI 10.1152/ajpcell.00074.2006; HANANO T, 2004, J PHARM SCI; Hanke S, 2001, MOL CELL BIOL, V21, P8452, DOI 10.1128/MCB.21.24.8452-8460.2001; Honda A, 2001, P NATL ACAD SCI USA, V98, P2437, DOI 10.1073/pnas.051631298; Horowitz LF, 2005, J GEN PHYSIOL, V126, P243, DOI 10.1085/jgp.200509309; JALINK K, 1990, J BIOL CHEM, V265, P12232; Kerschbaum HH, 2003, BIOPHYS J, V84, P2293, DOI 10.1016/S0006-3495(03)75035-8; Kim BJ, 2005, GASTROENTEROLOGY, V129, P1504, DOI 10.1053/j.gastro.2005.08.016; Kozak JA, 2005, J GEN PHYSIOL, V126, P499, DOI 10.1085/jgp.200509324; Kozak JA, 2003, BIOPHYS J, V84, P922, DOI 10.1016/S0006-3495(03)74909-1; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Liu BY, 2005, J NEUROSCI, V25, P1674, DOI 10.1523/JNEUROSCI.3632-04.2005; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; Matsushita M, 2005, J BIOL CHEM, V280, P20793, DOI 10.1074/jbc.M413671200; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nilius B, 2006, EMBO J, V25, P467, DOI 10.1038/sj.emboj.7600963; Ponsioen B, 2004, EMBO REP, V5, P1176, DOI 10.1038/sj.embor.7400290; Postma FR, 2001, CURR BIOL, V11, P121, DOI 10.1016/S0960-9822(01)00030-6; Postma FR, 1996, EMBO J, V15, P63, DOI 10.1002/j.1460-2075.1996.tb00334.x; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RASMUSSEN U, 1978, ACTA PHARM SUEC, V15, P133; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Schmitz C, 2005, J BIOL CHEM, V280, P37763, DOI 10.1074/jbc.M509175200; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Su LT, 2006, J BIOL CHEM, V281, P11260, DOI 10.1074/jbc.M512885200; Takezawa R, 2004, P NATL ACAD SCI USA, V101, P6009, DOI 10.1073/pnas.0307565101; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Voets T, 2004, J BIOL CHEM, V279, P19, DOI 10.1074/jbc.M311201200; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345; Zhang Z, 2005, J BIOL CHEM, V280, P39185, DOI 10.1074/jbc.M506965200	41	99	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					232	239		10.1074/jbc.M605300200	http://dx.doi.org/10.1074/jbc.M605300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17095511	hybrid, Green Published			2022-12-27	WOS:000243166500027
J	Xicluna, J; Lacombe, B; Dreyer, I; Alcon, C; Jeanguenin, L; Sentenac, H; Thibaud, JB; Cherel, I				Xicluna, Jerome; Lacombe, Benoit; Dreyer, Ingo; Alcon, Carine; Jeanguenin, Linda; Sentenac, Herve; Thibaud, Jean-Baptiste; Cherel, Isabelle			Increased functional diversity of plant K+ channels by preferential heteromerization of the Shaker-like subunits AKT2 and KAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-GATED CHANNELS; POTASSIUM-CHANNEL; GUARD-CELLS; SURFACE EXPRESSION; ALPHA-SUBUNITS; BETA-SUBUNITS; ION CHANNELS; ARABIDOPSIS; STOICHIOMETRY; PHLOEM	Assembly of plant Shaker subunits as heterotetramers, increasing channel functional diversity, has been reported. Here we focus on a new interaction, between AKT2 and KAT2 subunits. The assembly as AKT2/KAT2 heterotetramers is demonstrated by (i) a strong signal in two-hybrid tests with intracytoplasmic C-terminal regions, (ii) the effect of KAT2 on AKT2 subunit targeting in tobacco cells, (iii) the complete inhibition of AKT2 currents by co-expression with a dominant-negative KAT2 subunit in Xenopus oocytes, and reciprocally, and (iv) the appearance, upon co-expression of wild-type AKT2 and KAT2 subunits, of new channel functional properties that cannot be explained by the co-existence of two kinds of homotetrameric channels. In particular, the instantaneous current, characteristic of AKT2, displayed new functional features when compared with those of AKT2 homotetramers: activation by external acidification (instead of inhibition) and weak inhibition by calcium. Single channel current measurements in oocytes co-expressing AKT2 and KAT2 revealed a strong preference for incorporation of subunits into heteromultimers and a diversity of individual channels. In planta, these new channels, which may undergo specific regulations, are likely to be formed in guard cells and in the phloem, where they could participate in the control of membrane potential and potassium fluxes.	Univ Montpellier 2, INRA, Lab Biochim & Physiol Mol Plantes, UMR Agro Montpellier 5004,CNRS, F-34060 Montpellier 1, France	INRAE; Institut Agro; Montpellier SupAgro; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Cherel, I (corresponding author), Univ Montpellier 2, INRA, Lab Biochim & Physiol Mol Plantes, UMR Agro Montpellier 5004,CNRS, Pl Viala, F-34060 Montpellier 1, France.	cherel@ensam.inra.fr	Lacombe, Benoit/B-1202-2013; Dreyer, Ingo/N-4747-2014	Dreyer, Ingo/0000-0002-2781-0359; THIBAUD, Jean-Baptiste/0000-0002-0824-6465; Sentenac, Herve/0000-0003-3641-4822; Lacombe, Benoit/0000-0001-9924-3093; Cherel, Isabelle/0000-0001-8007-7099				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baizabal-Aguirre VM, 1999, J MEMBRANE BIOL, V167, P119, DOI 10.1007/s002329900476; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BLATT MR, 1992, J GEN PHYSIOL, V99, P615, DOI 10.1085/jgp.99.4.615; Butt AD, 1997, J PLANT PHYSIOL, V150, P652, DOI 10.1016/S0176-1617(97)80279-9; CAO YW, 1995, PLANT PHYSIOL, V109, P1093, DOI 10.1104/pp.109.3.1093; Cherel I, 2002, PLANT CELL, V14, P1133, DOI 10.1105/tpc.000943; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; Deeken R, 2002, PLANTA, V216, P334, DOI 10.1007/s00425-002-0895-1; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dreyer I, 2004, BIOPHYS J, V87, P858, DOI 10.1529/biophysj.103.037671; Dreyer I, 2001, FEBS LETT, V505, P233, DOI 10.1016/S0014-5793(01)02832-0; Dreyer I, 1997, BIOPHYS J, V72, P2143, DOI 10.1016/S0006-3495(97)78857-X; Ehrhardt T, 1997, FEBS LETT, V409, P166, DOI 10.1016/S0014-5793(97)00502-4; Fang ZW, 1998, PLANT MOL BIOL, V37, P597, DOI 10.1023/A:1005913629485; Fink M, 1996, J BIOL CHEM, V271, P26341, DOI 10.1074/jbc.271.42.26341; Geiger D, 2002, PLANT CELL, V14, P1859, DOI 10.1105/tpc.003244; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; He YJ, 2000, P NATL ACAD SCI USA, V97, P895, DOI 10.1073/pnas.97.2.895; Hosy E, 2005, PLANT METHODS, V1, DOI 10.1186/1746-4811-1-14; Hosy E, 2003, P NATL ACAD SCI USA, V100, P5549, DOI 10.1073/pnas.0733970100; Hugnot JP, 1996, EMBO J, V15, P3322, DOI 10.1002/j.1460-2075.1996.tb00697.x; Ichida AM, 1997, PLANT CELL, V9, P1843, DOI 10.1105/tpc.9.10.1843; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Ivashikina N, 2005, J GEN PHYSIOL, V125, P483, DOI 10.1085/jgp.200409211; Ivashikina N, 2003, PLANT J, V36, P931, DOI 10.1046/j.1365-313X.2003.01931.x; Ketchum KA, 1996, FEBS LETT, V378, P19, DOI 10.1016/0014-5793(95)01417-9; Kwak JM, 2001, PLANT PHYSIOL, V127, P473, DOI 10.1104/pp.010428; Lacombe B, 1998, J MEMBRANE BIOL, V166, P91, DOI 10.1007/s002329900451; Lacombe B, 2000, FEBS LETT, V466, P351, DOI 10.1016/S0014-5793(00)01093-0; Lacombe B, 2000, PLANT CELL, V12, P837, DOI 10.1105/tpc.12.6.837; Leonhardt N, 2004, PLANT CELL, V16, P596, DOI 10.1105/tpc.019000; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Liu DT, 1998, NEURON, V21, P235, DOI 10.1016/S0896-6273(00)80530-9; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Marten I, 1999, P NATL ACAD SCI USA, V96, P7581, DOI 10.1073/pnas.96.13.7581; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; Michard E, 2005, J GEN PHYSIOL, V126, P605, DOI 10.1085/jgp.200509413; Michard E, 2005, PLANT J, V44, P783, DOI 10.1111/j.1365-313X.2005.02566.x; Obrdlik P, 2004, P NATL ACAD SCI USA, V101, P12242, DOI 10.1073/pnas.0404467101; Pilot G, 2003, PLANT MOL BIOL, V51, P773, DOI 10.1023/A:1022597102282; Pilot G, 2003, J MOL EVOL, V56, P418, DOI 10.1007/s00239-002-2413-2; Pilot G, 2001, J BIOL CHEM, V276, P3215, DOI 10.1074/jbc.M007303200; Reintanz B, 2002, P NATL ACAD SCI USA, V99, P4079, DOI 10.1073/pnas.052677799; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Roelfsema MRG, 1997, PLANTA, V202, P18, DOI 10.1007/s004250050098; Roelfsema MRG, 2001, PLANT J, V26, P1, DOI 10.1046/j.1365-313x.2001.01000.x; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Salinas M, 1997, J BIOL CHEM, V272, P24371, DOI 10.1074/jbc.272.39.24371; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHROEDER JI, 1987, P NATL ACAD SCI USA, V84, P4108, DOI 10.1073/pnas.84.12.4108; Schwake M, 2000, J BIOL CHEM, V275, P13343, DOI 10.1074/jbc.275.18.13343; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Shammat IM, 1999, NEURON, V23, P809, DOI 10.1016/S0896-6273(01)80038-6; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Szyroki A, 2001, P NATL ACAD SCI USA, V98, P2917, DOI 10.1073/pnas.051616698; TANG HX, 1995, PLANT PHYSIOL, V109, P327, DOI 10.1104/pp.109.1.327; Tombola F, 2006, ANNU REV CELL DEV BI, V22, P23, DOI 10.1146/annurev.cellbio.21.020404.145837; Urbach S, 2000, PLANT J, V23, P527, DOI 10.1046/j.1365-313x.2000.00828.x; van Huizen R, 1999, FEBS LETT, V457, P107, DOI 10.1016/S0014-5793(99)01021-2; Very AA, 2003, ANNU REV PLANT BIOL, V54, P575, DOI 10.1146/annurev.arplant.54.031902.134831; Weitz D, 2002, NEURON, V36, P881, DOI 10.1016/S0896-6273(02)01098-X; Xu J, 1998, TRENDS CARDIOVAS MED, V8, P229, DOI 10.1016/S1050-1738(98)00011-5; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; Zhang XA, 1999, PLANT PHYSIOL, V121, P995, DOI 10.1104/pp.121.3.995; Zheng J, 2002, NEURON, V36, P891, DOI 10.1016/S0896-6273(02)01099-1; Zhong HN, 2003, P NATL ACAD SCI USA, V100, P5509, DOI 10.1073/pnas.0931279100; Zimmermann S, 2001, PLANT J, V28, P517, DOI 10.1046/j.1365-313X.2001.01177.x	71	54	61	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					486	494		10.1074/jbc.M607607200	http://dx.doi.org/10.1074/jbc.M607607200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17085433	hybrid, Green Published			2022-12-27	WOS:000243166500054
J	Yu, LG; Andrews, N; Zhao, Q; McKean, D; Williams, JF; Connor, LJ; Gerasimenko, OV; Hilkens, J; Hirabayashi, J; Kasai, K; Rhodes, JM				Yu, Lu-Gang; Andrews, Nigel; Zhao, Qicheng; McKean, Daniel; Williams, Jennifer F.; Connor, Lucy J.; Gerasimenko, Oleg V.; Hilkens, John; Hirabayashi, Jun; Kasai, Kenichi; Rhodes, Jonathan M.			Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; HUMAN BREAST; ALTERED GLYCOSYLATION; CARCINOMA CELLS; EPISIALIN MUC1; MESSENGER-RNA; TUMOR-CELLS; TF ANTIGEN; IN-VITRO; EXPRESSION	Patients with metastatic cancer commonly have increased serum galectin-3 concentrations, but it is not known whether this has any functional implications for cancer progression. We report that MUC1, a large transmembrane mucin protein that is overexpressed and aberrantly glycosylated in epithelial cancer, is a natural ligand for galectin-3. Recombinant galectin-3 at concentrations (0.2-1.0 mu g/ml) similar to those found in the sera of patients with metastatic cancer increased adhesion of MUC1-expressing human breast (ZR-75-1) and colon (HT29-5F7) cancer cells to human umbilical vein endothelial cells (HUVEC) by 111% (111 +/- 21%, mean S.D.) and 93% (93 +/- 17%), respectively. Recombinant galectin-3 also increased adhesion to HUVEC of MUC1 transfected HCA1.7+ human breast epithelial cells that express MUC1 bearing the oncofetal Thomsen-Friedenreich antigen (Gal beta 1,3GalNAc-alpha (TF)) but did not affect adhesion of MUC1-negative HCA1.7- cells. MUC1-transfected, Ras-transformed, canine kidney epithelial-like (MDE9.2+) cells, bearing MUC1 that predominantly carries sialyl-TF, only demonstrated an adhesive response to galectin-3 after sialidase pretreatment. Furthermore, galectin-3-mediated adhesion of HCA1.7+ to HUVEC was reduced by O-glycanase pretreatment of the cells to remove TF. Recombinant galectin-3 caused focal disappearance of cell surface MUC1 in HCA1.7+ cells, suggesting clustering of MUC1. Co-incubation with antibodies against E-Selectin or CD44H, but not integrin-beta 1, ICAM-1 or VCAM-1, largely abolished the epithelial cell adhesion to HUVEC induced by galectin-3. Thus, galectin-3, by interacting with cancer-associated MUC1 via TF, promotes cancer cell adhesion to endothelium by revealing epithelial adhesion molecules that are otherwise concealed by MUC1. This suggests a critical role for circulating galectin-3 in cancer metastasis and highlights the functional importance of altered cell surface glycosylation in cancer progression.	Univ Liverpool, Sch Clin Sci, Henry Wellcome Lab Mol & Cellular Gastroenterol, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Sch Biomed Sci, Physiol Lab, Liverpool L69 3BX, Merseyside, England; Netherlands Canc Inst, Div Tumour Biol, NL-1066 CX Amsterdam, Netherlands; Teikyo Univ, Dept Biol Chem, Kanagawa 1990195, Japan	University of Liverpool; University of Liverpool; Netherlands Cancer Institute; Teikyo University	Yu, LG (corresponding author), Univ Liverpool, Sch Clin Sci, Henry Wellcome Lab Mol & Cellular Gastroenterol, Liverpool L69 3BX, Merseyside, England.	lgyu@liv.ac.uk	Gerasimenko, Oleg/A-6622-2010; Rhodes, Jonathan M/C-2496-2009	Gerasimenko, Oleg/0000-0003-2573-8258; Hilkens, John/0000-0002-0932-7793				Ahmad N, 2004, J BIOL CHEM, V279, P10841, DOI 10.1074/jbc.M312834200; Baldus SE, 2000, CANCER-AM CANCER SOC, V88, P1536, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1536::AID-CNCR6>3.3.CO;2-N; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BECKER JW, 1989, P NATL ACAD SCI USA, V86, P1088, DOI 10.1073/pnas.86.3.1088; BHAVANANDAN VP, 1976, BIOCHEM BIOPH RES CO, V70, P738, DOI 10.1016/0006-291X(76)90654-9; Burchell J, 1999, GLYCOBIOLOGY, V9, P1307, DOI 10.1093/glycob/9.12.1307; Burdick MM, 2006, J BIOL CHEM, V281, P13899, DOI 10.1074/jbc.M513617200; CAMPBELL BJ, 1995, J CLIN INVEST, V95, P571, DOI 10.1172/JCI117700; Campbell BJ, 2001, GLYCOCONJUGATE J, V18, P851, DOI 10.1023/A:1022240107040; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Dalziel M, 2001, J BIOL CHEM, V276, P11007, DOI 10.1074/jbc.M006523200; Engelmann K, 2005, GLYCOBIOLOGY, V15, P1111, DOI 10.1093/glycob/cwi099; Glinsky VV, 2001, CANCER RES, V61, P4851; Glinsky VV, 2003, CANCER RES, V63, P3805; Glinsky VV, 2000, CANCER RES, V60, P2584; Gorelik E, 2001, CANCER METAST REV, V20, P245, DOI 10.1023/A:1015535427597; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; Hughes RC, 2001, BIOCHIMIE, V83, P667; Iurisci I, 2000, CLIN CANCER RES, V6, P1389; Jothy S, 2003, CLIN EXP METASTAS, V20, P195, DOI 10.1023/A:1022931016285; Khaldoyanidi SK, 2003, J BIOL CHEM, V278, P4127, DOI 10.1074/jbc.M209590200; Kim YJ, 1997, GLYCOCONJUGATE J, V14, P569, DOI 10.1023/A:1018580324971; Kondo K, 1998, CANCER RES, V58, P2014; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; Leteurtre E, 2004, BIOL CELL, V96, P145, DOI 10.1016/j.biolcel.2003.12.005; LIGTENBERG MJL, 1991, NUCLEIC ACIDS RES, V19, P297, DOI 10.1093/nar/19.2.297; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; LIU FT, 2000, BIOICH BIOPHYS ACTA, V1572, P263; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; McDermott KM, 2001, INT J CANCER, V94, P783, DOI 10.1002/ijc.1554; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; Muller AM, 2002, EXP MOL PATHOL, V73, P171, DOI 10.1006/exmp.2002.2446; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; Ono M, 2003, GLYCOCONJUGATE J, V20, P71, DOI 10.1023/B:GLYC.0000018019.22070.7d; Price EA, 1996, INT J CANCER, V65, P513, DOI 10.1002/(SICI)1097-0215(19960208)65:4<513::AID-IJC20>3.0.CO;2-9; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Reddish MA, 1997, GLYCOCONJUGATE J, V14, P549, DOI 10.1023/A:1018576224062; Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3; Takenaka Y, 2002, GLYCOCONJUGATE J, V19, P543, DOI 10.1023/B:GLYC.0000014084.01324.15; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4; Truant S, 2003, INT J CANCER, V104, P683, DOI 10.1002/ijc.11011; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yu LG, 1997, INT J CANCER, V73, P424, DOI 10.1002/(SICI)1097-0215(19971104)73:3<424::AID-IJC18>3.3.CO;2-C; Yu LG, 2002, J BIOL CHEM, V277, P24538, DOI 10.1074/jbc.M203550200; Zou J, 2005, CARCINOGENESIS, V26, P309, DOI 10.1093/carcin/bgh329	55	229	243	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					773	781		10.1074/jbc.M606862200	http://dx.doi.org/10.1074/jbc.M606862200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17090543	hybrid			2022-12-27	WOS:000243166500082
J	Lee, TH; Seng, S; Li, HC; Kennel, SJ; Avraham, HK; Avraham, S				Lee, Tae-Hee; Seng, Seyha; Li, Huchun; Kennel, Stephen J.; Avraham, Hava Karsenty; Avraham, Shalom			Integrin regulation by vascular endothelial growth factor in human brain microvascular endothelial cells - Role of alpha(6)beta(1) integrin in angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-6-BETA-4 INTEGRIN; TUMOR ANGIOGENESIS; TRANSENDOTHELIAL MIGRATION; ALPHA(2)BETA(1) INTEGRINS; SIGNAL-TRANSDUCTION; FACTOR VEGF; EXPRESSION; PERMEABILITY; ACTIVATION; RECEPTORS	The precise role of vascular endothelial growth factor ( VEGF) in regulating integrins in brain microvascular endothelial cells is unknown. Here, we analyzed VEGF effects on integrin expression and activation in human brain microvascular endothelial cells ( HBMECs). Using human cDNA arrays and ribonuclease ( RNase) protection assays, we observed that VEGF up-regulated the mRNA expression of alpha(6) integrin in HBMECs. VEGF significantly increased alpha(6)beta(1) integrin expression, but not alpha(6)beta(4) integrin expression in these cells. Specific down- regulation of beta(6) integrin expression by small interfering RNA ( siRNA) oligonucleotides inhibited both the capillary morphogenesis of HBMECs and their adhesion and migration. Additionally, VEGF treatment resulted in activation of alpha(6)beta(1) integrins in HBMECs. Functional blocking of alpha(6) integrin with its specific antibody inhibited the VEGF- induced adhesion and migration as well as in vivo angiogenesis, and markedly suppressed tumor angiogenesis and breast carcinoma growth in vivo. Thus, VEGF can modulate angiogenesis via increased expression and activation of alpha(6)beta(1) integrins, which may promote VEGF- driven tumor angiogenesis in vivo.	Harvard Univ, Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; United States Department of Energy (DOE); Oak Ridge National Laboratory	Avraham, S (corresponding author), Harvard Univ, Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle,3rd Floor, Boston, MA 02115 USA.	savraham@bidmc.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [R01CA096805] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080699] Funding Source: NIH RePORTER; NCI NIH HHS [CA096805] Funding Source: Medline; NHLBI NIH HHS [HL80699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; Brekken RA, 2000, CANCER RES, V60, P5117; BROWN LF, 1995, J IMMUNOL, V154, P2801; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Byzova TV, 1998, J CELL BIOL, V143, P2081, DOI 10.1083/jcb.143.7.2081; Cai J, 2003, DIABETES, V52, P2959, DOI 10.2337/diabetes.52.12.2959; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Colognato H, 2002, NAT CELL BIOL, V4, P833, DOI 10.1038/ncb865; COSTANTINI RM, 1990, CANCER RES, V50, P6107; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; DAVIS GE, 1995, EXP CELL RES, V216, P113, DOI 10.1006/excr.1995.1015; Davis TL, 2001, J BIOL CHEM, V276, P26099, DOI 10.1074/jbc.M102811200; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; FALCIONI R, 1986, CANCER RES, V46, P5772; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Hynes RO, 1997, THROMB HAEMOSTASIS, V78, P83; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Rabinovitz I, 2001, MOL BIOL CELL, V12, P4030, DOI 10.1091/mbc.12.12.4030; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Senger DR, 1996, AM J PATHOL, V149, P293; Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	43	53	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40450	40460		10.1074/jbc.M607525200	http://dx.doi.org/10.1074/jbc.M607525200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17085437	hybrid			2022-12-27	WOS:000243033900075
J	Takeda, M; Ogino, S; Umemoto, R; Sakakura, M; Kajiwara, M; Sugahara, KN; Hayasaka, H; Miyasaka, M; Terasawa, H; Shimada, I				Takeda, Mitsuhiro; Ogino, Shinji; Umemoto, Ryo; Sakakura, Masayoshi; Kajiwara, Masahiro; Sugahara, Kazuki N.; Hayasaka, Haruko; Miyasaka, Masayuki; Terasawa, Hiroaki; Shimada, Ichio			Ligand-induced structural changes of the CD44 hyaluronan-binding domain revealed by NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; CELL-MIGRATION; TUMOR-CELLS; LINK MODULE; CLEAVAGE; PROTEINS; OLIGOSACCHARIDES; SPECTROSCOPY; CALMODULIN; DYNAMICS	CD44, a major cell surface receptor for hyaluronan (HA), contains a functional domain responsible for HA binding at its N terminus (residues 21-178). Accumulating evidence indicates that proteolytic cleavage of CD44 in its extracellular region (residues 21-268) leads to enhanced tumor cell migration and invasion. Hence, understanding the mechanisms underlying the CD44 proteolytic cleavage is important for understanding the mechanism of CD44-mediated tumor progression. Here we present the NMR structure of the HA-binding domain of CD44 in its HA-bound state. The structure is composed of the Link module (residues 32-124) and an extended lobe (residues 21-31 and 125-152). Interestingly, a comparison of its unbound and HA-bound structures revealed that rearrangement of the beta-strands in the extended lobe (residues 143-148) and disorder of the structure in the following C-terminal region (residues 153-169) occurred upon HA binding, which is consistent with the results of trypsin proteolysis studies of the CD44 HA-binding domain. The order-to-disorder transition of the C-terminal region by HA binding may be involved in the CD44-mediated cell migration.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Biol Informat Consortium, Japan Biol Informat Res Ctr, Chuo Ku, Tokyo 1040032, Japan; Meiji Pharmaceut Univ, Dept Med Chem, Kiyose, Tokyo 2048588, Japan; Osaka Univ, Grad Sch Med, Lab Immunodynam, Dept Immunol & Microbiol, Suita, Osaka 5650871, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan	University of Tokyo; Meiji Pharmaceutical University; Osaka University; National Institute of Advanced Industrial Science & Technology (AIST)	Shimada, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	shimada@iw-nmr.f.u-tokyo.ac.jp	Miyasaka, Masayuki/AAM-6343-2020	Umemoto, Ryo/0000-0003-2866-7168				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Banerji S, 1998, PROTEIN EXPRES PURIF, V14, P371, DOI 10.1006/prep.1998.0971; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GODDARD TD, 2001, SPARKY3; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kawano Y, 2000, J BIOL CHEM, V275, P29628, DOI 10.1074/jbc.M002440200; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Nagano O, 2004, CANCER SCI, V95, P930, DOI 10.1111/j.1349-7006.2004.tb03179.x; Nakamura H, 2004, CANCER RES, V64, P876, DOI 10.1158/0008-5472.CAN-03-3502; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Sugahara KN, 2006, J BIOL CHEM, V281, P5861, DOI 10.1074/jbc.M506740200; Sugahara KN, 2003, J BIOL CHEM, V278, P32259, DOI 10.1074/jbc.M300347200; Takahashi H, 2000, NAT STRUCT BIOL, V7, P220; Takeda M, 2003, J BIOL CHEM, V278, P43550, DOI 10.1074/jbc.M308199200; Tawada A, 2002, GLYCOBIOLOGY, V12, P421, DOI 10.1093/glycob/cwf048; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2	30	52	60	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40089	40095		10.1074/jbc.M608425200	http://dx.doi.org/10.1074/jbc.M608425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17085435	hybrid			2022-12-27	WOS:000243033900038
J	Brandman, R; Disatnik, MH; Churchill, E; Mochly-Rosen, D				Brandman, Relly; Disatnik, Marie-Helene; Churchill, Eric; Mochly-Rosen, Daria			Peptides derived from the C2 domain of protein kinase C epsilon (epsilon PKC) modulate epsilon PKC activity and identify potential protein-protein interaction surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-PKC; CARDIAC PROTECTION; CORTICAL-NEURONS; ACTIVATION; TRANSLOCATION; ISOZYMES; ISCHEMIA; DOMAIN; BETA; ETHANOL	Peptides derived from protein kinase C (PKC) modulate its activity by interfering with critical protein-protein interactions within PKC and between PKC and PKC-binding proteins (Souroujon, M. C., and Mochly-Rosen, D. (1998) Nat. Biotechnol, 16, 919-924). We previously demonstrated that the C2 domain of PKC plays a critical role in these interactions. By focusing on epsilon PKC and using a rational approach, we then identified one C2-derived peptide that acts as an isozyme-selective activator and another that acts as a selective inhibitor of epsilon PKC. These peptides were used to identify the role of epsilon PKC in protection from cardiac and brain ischemic damage, in prevention of complications from diabetes, in reducing pain, and in protecting transplanted hearts. The efficacy of these two peptides led us to search for additional C2-derived peptides with PKC-modulating activities. Here we report on the activity of a series of 5-9-residue peptides that are derived from regions that span the length of the C2 domain of epsilon PKC. These peptides were tested for their effect on PKC activity in cells in vivo and in an ex vivo model of acute ischemic heart disease. Most of the peptides acted as activators of PKC, and a few peptides acted as inhibitors. PKC-dependent myristoylated alanine-rich C kinase substrate phosphorylation in epsilon PKC knock-out cells revealed that only a subset of the peptides were selective for epsilon PKC over other PKC isozymes. These epsilon PKC-selective peptides were also protective of the myocardium from ischemic injury, an epsilon PKC-dependent function (Liu, G. S., Cohen, M. V., Mochly-Rosen, D., and Downey, J. M. (1999) J. Mal. CelL Cardiol. 31, 1937-1948), and caused selective translocation of epsilon PKC over other isozymes when injected systemically into mice. Examination of the structure of the C2 domain from epsilon PKC revealed that peptides with similar activities clustered into discrete regions within the domain. We propose that these regions represent surfaces of protein-protein interactions within epsilon PKC and/or between epsilon PKC and other partner proteins; some of these interactions are unique to epsilon PKC, and others are common to other PKC isozymes.	Stanford Univ, Sch Med, Dept Chem & Syst Biol, CCSR, Stanford, CA 94305 USA	Stanford University	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Chem & Syst Biol, CCSR, Rm 3145A,269 Campus Dr, Stanford, CA 94305 USA.	mochly@stanford.edu		Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Aley KO, 2000, J NEUROSCI, V20, P4680, DOI 10.1523/JNEUROSCI.20-12-04680.2000; Allard JB, 2005, CURR PROTEIN PEPT SC, V6, P125, DOI 10.2174/1389203053545417; Begley R, 2004, BIOCHEM BIOPH RES CO, V318, P949, DOI 10.1016/j.bbrc.2004.04.121; Braun MU, 2003, J MOL CELL CARDIOL, V35, P895, DOI 10.1016/S0022-2828(03)00142-1; Bright R, 2005, STROKE, V36, P2781, DOI 10.1161/01.STR.0000189996.71237.f7; Bright R, 2004, J NEUROSCI, V24, P6880, DOI 10.1523/JNEUROSCI.4474-03.2004; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chen CH, 1999, P NATL ACAD SCI USA, V96, P12784, DOI 10.1073/pnas.96.22.12784; Chen L, 2001, CHEM BIOL, V8, P1123, DOI 10.1016/S1074-5521(01)00076-X; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Churchill EN, 2005, CIRC RES, V97, P78, DOI 10.1161/01.RES.0000173896.32522.6e; Critz SD, 2005, VASC PHARMACOL, V42, P201, DOI 10.1016/j.vph.2005.02.007; Dawn B, 2002, ANN NY ACAD SCI, V962, P18, DOI 10.1111/j.1749-6632.2002.tb04053.x; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Disatnik MH, 2004, J CELL SCI, V117, P4469, DOI 10.1242/jcs.01309; Disatnik MH, 2002, J CELL SCI, V115, P2151; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; HONDEGHEM LM, 1978, AM J PHYSIOL, V235, pH574, DOI 10.1152/ajpheart.1978.235.5.H574; Inagaki K, 2005, J MOL CELL CARDIOL, V39, P203, DOI 10.1016/j.yjmcc.2005.05.014; Inagaki K, 2005, CIRCULATION, V111, P44, DOI 10.1161/01.CIR.0000151614.22282.F1; Inagaki K, 2003, CIRCULATION, V108, P869, DOI 10.1161/01.CIR.0000081943.93653.73; Inagaki K, 2002, J MOL CELL CARDIOL, V34, P1377, DOI 10.1006/jmcc.2002.2089; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; JOHNSON JA, 1995, CIRC RES, V76, P654, DOI 10.1161/01.RES.76.4.654; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kishore U, 2004, TRENDS IMMUNOL, V25, P551, DOI 10.1016/j.it.2004.08.006; Kohout SC, 2002, BIOCHEMISTRY-US, V41, P11411, DOI 10.1021/bi026041k; Koponen S, 2003, J NEUROCHEM, V86, P442, DOI 10.1046/j.1471-4159.2003.01846.x; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; Lange-Asschenfeldt C, 2004, J CEREBR BLOOD F MET, V24, P636, DOI 10.1097/01.WCB.0000121235.42748.BF; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Li HF, 2005, BRIT J PHARMACOL, V144, P301, DOI 10.1038/sj.bjp.0706033; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Malhotra A, 2005, AM J PHYSIOL-HEART C, V289, pH1343, DOI 10.1152/ajpheart.01200.2004; Morgan A, 2005, BIOCHEM SOC T, V33, P1341, DOI 10.1042/BST0331341; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Ochoa WF, 2001, J MOL BIOL, V311, P837, DOI 10.1006/jmbi.2001.4910; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; Res I, 2005, PHYS BIOL, V2, pS36, DOI 10.1088/1478-3975/2/2/S04; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Saurin AT, 2002, CARDIOVASC RES, V55, P672, DOI 10.1016/S0008-6363(02)00325-5; Schechtman D, 2002, METHOD ENZYMOL, V345, P470; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shumilla JA, 2005, J PAIN, V6, P535, DOI 10.1016/j.jpain.2005.03.005; SMITH BL, 1992, BIOCHEM BIOPH RES CO, V188, P1235, DOI 10.1016/0006-291X(92)91363-U; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Sweitzer SM, 2004, PAIN, V110, P281, DOI 10.1016/j.pain.2004.04.004; Sweitzer SM, 2004, J PHARMACOL EXP THER, V309, P616, DOI 10.1124/jpet.103.060350; Tanaka M, 2004, CIRCULATION, V110, pII194, DOI 10.1161/01.CIR.0000138389.22905.62; Vondriska TM, 2001, AM J PHYSIOL-HEART C, V280, pH1434, DOI 10.1152/ajpheart.2001.280.4.H1434; Wang J, 2004, NEUROPHARMACOLOGY, V47, P136, DOI 10.1016/j.neuropharm.2004.03.009; Xiao GQ, 2003, BIOCHEM BIOPH RES CO, V306, P1019, DOI 10.1016/S0006-291X(03)01095-7; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	63	58	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4113	4123		10.1074/jbc.M608521200	http://dx.doi.org/10.1074/jbc.M608521200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17142835	hybrid			2022-12-27	WOS:000244481900075
J	Iorga, B; Adamek, N; Geeves, MA				Iorga, Bogdan; Adamek, Nancy; Geeves, Michael A.			The slow skeletal muscle isoform of myosin shows kinetic features common to smooth and non-muscle myosins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ISOFORMS; DICTYOSTELIUM-DISCOIDEUM; SHORTENING VELOCITY; ACTOMYOSIN SUBFRAGMENT-1; NUCLEOTIDE-BINDING; PHOSPHATE RELEASE; FORCE GENERATION; ADP DISSOCIATION; MOLECULAR MOTOR; RABBIT	Fast and slow mammalian muscle myosins differ in the heavy chain sequences (MHC-2, MHC-1) and muscles expressing the two isoforms contract at markedly different velocities. One role of slow skeletal muscles is to maintain posture with low ATP turnover, and MHC-1 expressed in these muscles is identical to heavy chain of the,beta-myosin of cardiac muscle. Few studies have addressed the biochemical kinetic properties of the slow MHC-1 isoform. We report here a detailed analysis of the MHC-1 isoform of the rabbit compared with MHC-2 and focus on the mechanism of ADP release. We show that MHC-1, like some non-muscle myosins, shows a biphasic dissociation of actin-myosin by ATP. Most of the actin-myosin dissociates at up to similar to 1000 s(-1), a very similar rate constant to MHC-2, but 10-15% of the complex must go through a slow isomerization (similar to 20 s(-1)) before ATP can dissociate it. Similar slow isomerizations were seen in the displacement of ADP from actinmyosin(.)ADP and provide evidence of three closely related actinmyosin(.)ADP complexes, a complex in rapid equilibrium with free ADP, a complex from which ADP is released at the rate required to define the maximum shortening velocity of slow muscle fibers (similar to 20 s(-1)), and a third complex that releases ADP too slowly (similar to 6 s(-1)) to be on the main ATPase pathway. The role of these actin-myosin(.)ADP complexes in the mechanochemistry of slow muscle contraction is discussed in relation to the load dependence of ADP release.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Univ Montpellier 1, CNRS, UMR 5121, F-34000 Montpellier, France; Univ Cologne, Fac Med, Dept Vegetat Physiol, D-50931 Cologne, Germany	University of Kent; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Cologne	Geeves, MA (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.	m.a.geeves@kent.ac.uk	Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898	Wellcome Trust [070021] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIGNER S, 1993, EUR J BIOCHEM, V211, P367, DOI 10.1111/j.1432-1033.1993.tb19906.x; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; Barsotti RJ, 1996, NAT STRUCT BIOL, V3, P737, DOI 10.1038/nsb0996-737; Batra R, 1999, BIOCHEMISTRY-US, V38, P6126, DOI 10.1021/bi982251e; Batters C, 2004, EMBO J, V23, P1433, DOI 10.1038/sj.emboj.7600169; Bottinelli R, 2001, PFLUG ARCH EUR J PHY, V443, P6, DOI 10.1007/s004240100700; Canepari M, 1999, EXP PHYSIOL, V84, P803, DOI 10.1111/j.1469-445X.1999.00350.x; Capitanio M, 2006, P NATL ACAD SCI USA, V103, P87, DOI 10.1073/pnas.0506830102; Conibear PB, 1999, J MUSCLE RES CELL M, V20, P727, DOI 10.1023/A:1005696017544; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; Fujita-Becker S, 2005, J BIOL CHEM, V280, P6064, DOI 10.1074/jbc.M412473200; Geeves MA, 2000, J BIOL CHEM, V275, P21624, DOI 10.1074/jbc.M000342200; Geeves MA, 2005, ADV PROTEIN CHEM, V71, P161, DOI 10.1016/S0065-3233(04)71005-0; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Goodson HV, 2006, P NATL ACAD SCI USA, V103, P3498, DOI 10.1073/pnas.0600045103; Hannemann DE, 2005, BIOCHEMISTRY-US, V44, P8826, DOI 10.1021/bi0473509; Iorga B, 2004, J MUSCLE RES CELL M, V25, P367, DOI 10.1007/s10974-004-0812-2; JANMOT C, 1994, FEBS LETT, V353, P13, DOI 10.1016/0014-5793(94)01002-1; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; MILLAR NC, 1983, FEBS LETT, V160, P141, DOI 10.1016/0014-5793(83)80954-5; MILLAR NC, 1990, J BIOL CHEM, V265, P20234; MILLAR NC, 1992, AM J PHYSIOL, V262, pC1239, DOI 10.1152/ajpcell.1992.262.5.C1239; Nyitrai M, 2006, J MOL BIOL, V355, P432, DOI 10.1016/j.jmb.2005.10.063; Nyitrai M, 2004, PHILOS T R SOC B, V359, P1867, DOI 10.1098/rstb.2004.1560; Pellegrino MA, 2003, J PHYSIOL-LONDON, V546, P677, DOI 10.1113/jphysiol.2002.027375; Reggiani C, 2000, NEWS PHYSIOL SCI, V15, P26; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Robblee JP, 2005, BIOCHEMISTRY-US, V44, P10238, DOI 10.1021/bi050232g; Rosenfeld SS, 2005, J BIOL CHEM, V280, P6072, DOI 10.1074/jbc.M412717200; Rosenfeld SS, 2000, J BIOL CHEM, V275, P25418, DOI 10.1074/jbc.M002685200; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Sellers J. R., 1999, MYOSINS; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Sellers JR, 1996, J MUSCLE RES CELL M, V17, P7, DOI 10.1007/BF00140320; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SLEEP JA, 1980, BIOCHEMISTRY-US, V19, P1276, DOI 10.1021/bi00548a002; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tikunov BA, 2001, J APPL PHYSIOL, V90, P1927, DOI 10.1152/jappl.2001.90.5.1927; TRAYER HR, 1985, FEBS LETT, V180, P170, DOI 10.1016/0014-5793(85)81065-6; Veigel C, 2003, NAT CELL BIOL, V5, P980, DOI 10.1038/ncb1060; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; Weiss S, 2001, J BIOL CHEM, V276, P45902, DOI 10.1074/jbc.M107434200; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0	51	31	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3559	3570		10.1074/jbc.M608191200	http://dx.doi.org/10.1074/jbc.M608191200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17130133	hybrid			2022-12-27	WOS:000244481900018
J	Barrows, BD; Haslam, SM; Bischof, LJ; Morris, HR; Dell, A; Aroian, RV				Barrows, Brad D.; Haslam, Stuart M.; Bischof, Larry J.; Morris, Howard R.; Dell, Anne; Aroian, Raffi V.			Resistance to Bacillus thuringiensis toxin in Caenorhabditis elegans from loss of fucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-MANNOSE 4,6-DEHYDRATASE; C-ELEGANS; N-GLYCANS; IN-VITRO; BT; GDP-D-MANNOSE-4,6-DEHYDRATASE; IDENTIFICATION; RECONSTITUTION; GLYCOSYLATION; TRANSPORT	A mutation in the Caenorhabditis elegans bre-1 gene was isolated in a screen for Bacillus thuringiensis toxin-resistant (bre) mutants to the Cry5B crystal toxin made by B. thuringiensis. bre-1 mutant animals are different from the four other cloned bre mutants in that their level of resistance is noticeably lower. bre-1 animals also display a significantly reduced brood size at 25 C. Here we cloned the bre-1 gene and characterized the bre-1 mutant phenotype. bre-1 encodes a protein with significant homology to a GDP-mannose 4,6-dehydratase, which catalyzes the first step in the biosynthesis of GDP-fucose from GDP-mannose. Injection of GDP-fucose but not fucose into C. elegans intestinal cells rescues bre-1 mutant phenotypes. Thus, C. elegans lacks a functional fucose salvage pathway. Furthermore, we demonstrate that bre-1 mutant animals are defective in production of fucosylated glycolipids and that bre-1 mutant animals make quantitatively reduced levels of glycolipid receptors for Cry5B. We finally show that bre-1 mutant animals, although viable, show a lack of fucosylated N-and O-glycans, based on mass spectrometric evidence. Thus, C. elegans can survive with little fucose and can develop resistance to crystal toxin by loss of a monosaccharide biosynthetic pathway.	Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Imperial Coll, Fac Nat Sci, Div Mol Biosci, London SW7 2AZ, England; MSCAN Res & Training Ctr, Ascot SL5 7PZ, Berks, England	University of California System; University of California San Diego; Imperial College London	Aroian, RV (corresponding author), Univ Calif San Diego, Sect Cell & Dev Biol, 9500 Gilman Dr,Dept 0349,Bonner Hall 4430, La Jolla, CA 92093 USA.	raroian@ucsd.edu		Barrows, Brad/0000-0003-4069-525X				Betz FS, 2000, REGUL TOXICOL PHARM, V32, P156, DOI 10.1006/rtph.2000.1426; Bischof Larry J., 2006, V351, P139; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; BRENNER S, 1974, GENETICS, V77, P71; Cappello M, 2006, P NATL ACAD SCI USA, V103, P15154, DOI 10.1073/pnas.0607002103; Coyne MJ, 2005, SCIENCE, V307, P1778, DOI 10.1126/science.1106469; Dell A, 1999, BBA-GEN SUBJECTS, V1473, P196, DOI 10.1016/S0304-4165(99)00179-8; DELL A, 1994, METHOD ENZYMOL, V230, P108; *DION CORP, 1993, 20 DION CORP, P1; FINNEY D J, 1971, P333; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Griffitts JS, 2005, BIOESSAYS, V27, P614, DOI 10.1002/bies.20239; Griffitts JS, 2001, SCIENCE, V293, P860, DOI 10.1126/science.1062441; Griffitts JS, 2005, SCIENCE, V307, P922, DOI 10.1126/science.1104444; Griffitts JS, 2003, J BIOL CHEM, V278, P45594, DOI 10.1074/jbc.M308142200; Haslam SM, 2003, BIOCHIMIE, V85, P25, DOI 10.1016/S0300-9084(03)00041-5; Haslam SM, 2002, BIOCHEM SOC SYMP, V69, P117; Huffman DL, 2004, P NATL ACAD SCI USA, V101, P10995, DOI 10.1073/pnas.0404073101; JAMES C, 2005, GLOBAL STATUS COMMER; JONAS AJ, 1990, BIOCHEM J, V272, P323, DOI 10.1042/bj2720323; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kotze AC, 2005, INT J PARASITOL, V35, P1013, DOI 10.1016/j.ijpara.2005.03.010; Marroquin LD, 2000, GENETICS, V155, P1693; Morelle W, 2000, GLYCOBIOLOGY, V10, P941, DOI 10.1093/glycob/10.9.941; Palmer RW, 1996, ONDERSTEPOORT J VET, V63, P289; Pastuszak I, 1998, J BIOL CHEM, V273, P30165, DOI 10.1074/jbc.273.46.30165; Pimenta AD, 2003, MICROBES INFECT, V5, P1177, DOI 10.1016/j.micinf.2003.09.002; Rhomberg S, 2006, FEBS J, V273, P2244, DOI 10.1111/j.1742-4658.2006.05239.x; Roos C, 2002, J BIOL CHEM, V277, P3168, DOI 10.1074/jbc.m107927200; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P348; Smith PL, 2002, J CELL BIOL, V158, P801, DOI 10.1083/jcb.200203125; Somoza JR, 2000, STRUCTURE, V8, P123, DOI 10.1016/S0969-2126(00)00088-5; Sturla L, 1998, FEBS LETT, V429, P274, DOI 10.1016/S0014-5793(98)00615-2; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Thomson JA, 2002, J NUTR, V132, p3441S, DOI 10.1093/jn/132.11.3441S; van Die I, 1999, FEBS LETT, V463, P189, DOI 10.1016/S0014-5793(99)01508-2; Wei JZ, 2003, P NATL ACAD SCI USA, V100, P2760, DOI 10.1073/pnas.0538072100; Whalon ME, 2003, ARCH INSECT BIOCHEM, V54, P200, DOI 10.1002/arch.10117; Wicks SR, 2001, NAT GENET, V28, P160, DOI 10.1038/88878; WIESE TJ, 1994, J BIOL CHEM, V269, P22705	40	39	49	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3302	3311		10.1074/jbc.M606621200	http://dx.doi.org/10.1074/jbc.M606621200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135259	hybrid			2022-12-27	WOS:000243793900057
J	Gao, L; Wang, JK; Sekhar, KR; Yin, HY; Yared, NF; Schneider, SN; Sasi, S; Dalton, TP; Anderson, ME; Chan, JY; Morrow, JD; Freeman, ML				Gao, Ling; Wang, Jiakun; Sekhar, Konjeti R.; Yin, Huiyong; Yared, Nicholas F.; Schneider, Scott N.; Sasi, Soumya; Dalton, Timothy P.; Anderson, Mark E.; Chan, Jefferson Y.; Morrow, Jason D.; Freeman, Michael L.			Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY MASS-SPECTROMETRY; TRANSCRIPTION FACTOR NRF2; CUL3-BASED E3 LIGASE; IN-VIVO; DOCOSAHEXAENOIC ACID; LIPID-PEROXIDATION; RESPONSE ELEMENT; PROTEASOMAL DEGRADATION; EICOSAPENTAENOIC ACID; GENE-EXPRESSION	Consumption of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can mitigate the progression of diseases in which oxidative stress represents a common underlying biochemical process. Nrf2-regulated gene expression regulates detoxification of reactive oxygen species. EPA and DHA were subjected to an in vitro free radical oxidation process that models in vivo conditions. Oxidized n-3 fatty acids reacted directly with the negative regulator of Nrf2, Keap1, initiating Keap1 dissociation with Cullin3, thereby inducing Nrf2-directed gene expression. Liquid chromatography-tandem mass spectrometry analyses of oxidized EPA demonstrated the presence of novel cyclopentenone-containing molecules termed J(3)-isoprostanes in vitro and in vivo and were shown to induce Nrf2-directed gene expression. These experiments provide a biochemical basis for the hypothesis that formation of J-ring compounds generated from oxidation of EPA and DHA in vivo can reach concentrations high enough to induce Nrf2-based cellular defense systems.	Vanderbilt Univ, Sch Med, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Div Clin Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Ctr Environm Genet, Cincinnati, OH 45267 USA; Univ Iowa, Carver Coll Med, Dept Med, Iowa City, IA 52242 USA; Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Iowa; University of California System; University of California Irvine	Morrow, JD (corresponding author), Vanderbilt Univ, Sch Med, Dept Med & Pharmacol, Div Clin Pharmacol, 526 RRB,23rd & Pierce Ave, Nashville, TN 37232 USA.	jason.morrow@vanderbilt.edu; michael.freeman@vanderbilt.edu		yin, hui yong/0000-0001-7049-1560; Konjeti, Sekhar/0000-0003-2930-0739; Freeman, Michael/0000-0003-1881-366X	NATIONAL CANCER INSTITUTE [R55CA038079, T32CA093240, P01CA077839, R01CA104590, R01CA038079] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062494, R01HL070250, P01HL046681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657, R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012463, P01ES013125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA093240, CA77839, CA38079, CA104590, R01 CA104590] Funding Source: Medline; NHLBI NIH HHS [HL070250, HL62494, HL046681] Funding Source: Medline; NIDDK NIH HHS [DK26657, DK48831] Funding Source: Medline; NIEHS NIH HHS [ES012463, ES13125] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Bhattacharya A, 2007, J NUTR BIOCHEM, V18, P23, DOI 10.1016/j.jnutbio.2006.02.005; Calviello G, 1999, NUTR CANCER, V34, P206, DOI 10.1207/S15327914NC3402_12; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; Chen Jiawei, 2004, Indian Heart J, V56, P163; Cho HY, 2006, ANTIOXID REDOX SIGN, V8, P76, DOI 10.1089/ars.2006.8.76; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Fam SS, 2002, J BIOL CHEM, V277, P36076, DOI 10.1074/jbc.M205638200; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Galvez J, 2006, FITOTERAPIA, V77, P515, DOI 10.1016/j.fitote.2006.05.029; Gao L, 2006, J BIOL CHEM, V281, P14092, DOI 10.1074/jbc.M601035200; Grundt H, 2003, EUR J CLIN NUTR, V57, P793, DOI 10.1038/sj.ejcn.1601730; Harrison N, 2005, CURR MED RES OPIN, V21, P95, DOI 10.1185/030079904X17956; Hirayama A, 2003, FREE RADICAL BIO MED, V34, P1236, DOI 10.1016/S0891-5849(03)00073-X; Hong F, 2005, J BIOL CHEM, V280, P31768, DOI 10.1074/jbc.M503346200; Iraz M, 2005, ANN CLIN LAB SCI, V35, P169; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; Kerwin JL, 1996, J MASS SPECTROM, V31, P184, DOI 10.1002/(SICI)1096-9888(199602)31:2<184::AID-JMS283>3.0.CO;2-2; Kerwin JL, 1996, ANAL BIOCHEM, V237, P56, DOI 10.1006/abio.1996.0200; Kinsella BT, 1997, J PHARMACOL EXP THER, V281, P957; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Li XC, 2004, ACTA CRYSTALLOGR D, V60, P2346, DOI 10.1107/S0907444904024825; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Lo SC, 2006, MOL CELL BIOL, V26, P1235, DOI 10.1128/MCB.26.4.1235-1244.2006; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; Ma Q, 2006, AM J PATHOL, V168, P1960, DOI 10.2353/ajpath.2006.051113; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Moreira PL, 2005, DRUG NEWS PERSPECT, V18, P13, DOI 10.1358/dnp.2005.18.1.877164; Mori TA, 2000, REDOX REP, V5, P45, DOI 10.1179/rer.2000.5.1.45; Morrow JD, 1998, ARCH BIOCHEM BIOPHYS, V353, P160, DOI 10.1006/abbi.1998.0645; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; Musiek ES, 2005, J BIOL CHEM, V280, P35562, DOI 10.1074/jbc.M504785200; Nalsen C, 2006, J NUTR, V136, P1222; Palozza P, 1996, AM J CLIN NUTR, V64, P297, DOI 10.1093/ajcn/64.3.297; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Reich EE, 2000, BIOCHEMISTRY-US, V39, P2376, DOI 10.1021/bi992000l; Roberts LJ, 2004, CHEM PHYS LIPIDS, V128, P173, DOI 10.1016/j.chemphyslip.2003.09.016; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; Sacktor N, 2004, J NEUROIMMUNOL, V157, P176, DOI 10.1016/j.jneuroim.2004.08.037; SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002; Sarsilmaz M, 2003, PROSTAG LEUKOTR ESS, V69, P253, DOI 10.1016/S0952-3278(03)00107-8; Scholz H, 2003, CARDIOVASC RES, V59, P945, DOI 10.1016/S0008-6363(03)00538-8; Sekhar KR, 2003, CANCER RES, V63, P5636; Shibata T, 2003, J BIOL CHEM, V278, P26046, DOI 10.1074/jbc.M303690200; Smi CK, 2004, DEV BRAIN RES, V152, P11, DOI [10.1016/j.devbrainres.2004.05.004, 10.1016/j.debrainres.2004.05.004]; Soccio M, 2005, EUR J CLIN INVEST, V35, P305, DOI 10.1111/j.1365-2362.2005.01500.x; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Vericel E, 2003, J THROMB HAEMOST, V1, P566, DOI 10.1046/j.1538-7836.2003.00076.x; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Waugh RJ, 1997, FREE RADICAL BIO MED, V23, P943, DOI 10.1016/S0891-5849(97)00133-0; Woods Margo N, 2005, Nutr Clin Care, V8, P24; Wu JT, 2005, NAT CELL BIOL, V7, P1014, DOI 10.1038/ncb1301; Yin HY, 2005, J BIOL CHEM, V280, P26600, DOI 10.1074/jbc.M503088200; Yin HY, 2003, ANAL BIOCHEM, V313, P319, DOI 10.1016/S0003-2697(02)00621-8; Young G, 2005, REPROD NUTR DEV, V45, P1, DOI 10.1051/rnd:2005001; Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang R, 2005, NAT MED, V11, P409, DOI 10.1038/nm1215; Zhu M, 2001, BIOCHEM BIOPH RES CO, V289, P212, DOI 10.1006/bbrc.2001.5944	70	213	220	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2529	2537		10.1074/jbc.M607622200	http://dx.doi.org/10.1074/jbc.M607622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17127771	hybrid			2022-12-27	WOS:000243593200045
J	Hinzpeter, A; Fritsch, J; Borot, F; Trudel, S; Vieu, DL; Brouillard, F; Baudouin-Legros, M; Clain, J; Edelman, A; Ollero, M				Hinzpeter, Alexandre; Fritsch, Janine; Borot, Florence; Trudel, Stephanie; Vieu, Diane-Lore; Brouillard, Franck; Baudouin-Legros, Maryvonne; Clain, Jerome; Edelman, Aleksander; Ollero, Mario			Membrane cholesterol content modulates ClC-2 gating and sensitivity to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDIOPATHIC GENERALIZED EPILEPSIES; REGULATED ANION CURRENT; CIC-2 CHLORIDE CHANNEL; LIPID RAFTS; EPITHELIAL-CELLS; ACTIN CYTOSKELETON; RECEPTOR FUNCTION; PLASMA-MEMBRANE; K+ CHANNELS; LOCALIZATION	ClC-2 is a broadly expressed member of the voltage-gated ClC chloride channel family. In this study, we aimed to evaluate the role of the membrane lipid environment in ClC-2 function, and in particular the effect of cholesterol and ClC-2 distribution in membrane microdomains. Detergent-resistant and detergent-soluble microdomains (DSM) were isolated from stably transfected HEK293 cells by a discontinuous OptiPrep gradient. ClC-2 was found concentrated in detergent-insoluble membranes in basal conditions and relocalized to DSM upon cholesterol depletion by methyl-beta-cyclodextrin. As assessed by patch clamp recordings, relocalization was accompanied by acceleration of the activation kinetics of the channel. A similar distribution and activation pattern were obtained when cells were treated with the oxidant tert-butyl hydroperoxide and after ATP depletion. In both cases activation was prevented by cholesterol enrichment of cells. We conclude that the cholesterol environment regulates ClC-2 activity, and we provide evidence that the increase in ClC-2 activity in response to acute oxidative or metabolic stress involves relocalization of this channel to DSM.	Univ Paris 05, Fac Med Rene Descartes, INSERM U806, F-75015 Paris, France; Univ Paris 05, Fac Med Rene Descartes, Inst Federat Rech 94, Proteom Core Facil, F-75015 Paris, France; Univ Paris 05, Fac Pharm, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Fritsch, J (corresponding author), Fac Med Necker Enfants Malad, INSERM U806, 156 Rue Vaugirard, F-75015 Paris, France.	fritsch@necker.fr	Ollero, Mario/AAJ-3545-2020; Ollero, Mario/Q-6147-2018	Clain, Jerome/0000-0002-0232-5058; Ollero, Mario/0000-0003-3590-706X; Hinzpeter, Alexandre/0000-0001-6920-7761				Ahmed N, 2000, BIOCHEM J, V352, P789, DOI 10.1042/0264-6021:3520789; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Bali MZ, 2001, AM J PHYSIOL-CELL PH, V280, pC1588, DOI 10.1152/ajpcell.2001.280.6.C1588; Barbuti A, 2004, CIRC RES, V94, P1325, DOI 10.1161/01.RES.0000127621.54132.AE; Bell SP, 2006, BIOCHEMISTRY-US, V45, P6773, DOI 10.1021/bi0523815; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Camilleri M, 2006, AM J PHYSIOL-GASTR L, V290, pG942, DOI 10.1152/ajpgi.00264.2005; Catalan M, 2004, GASTROENTEROLOGY, V126, P1104, DOI 10.1053/j.gastro.2004.01.010; Cuppoletti J, 2004, AM J PHYSIOL-CELL PH, V287, pC1173, DOI 10.1152/ajpcell.00528.2003; de Santiago JA, 2005, J GEN PHYSIOL, V126, P591, DOI 10.1085/jgp.200509310; Dhani SU, 2003, J BIOL CHEM, V278, P16262, DOI 10.1074/jbc.M209828200; Duan D, 2000, CIRC RES, V86, pE63, DOI 10.1161/01.RES.86.4.e63; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Fritsch J, 1996, J PHYSIOL-LONDON, V490, P115, DOI 10.1113/jphysiol.1996.sp021130; Furukawa T, 2002, J PHYSIOL-LONDON, V540, P883; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Haug K, 2003, NAT GENET, V33, P527, DOI 10.1038/ng1121; Hinzpeter A, 2006, AM J PHYSIOL-CELL PH, V290, pC45, DOI 10.1152/ajpcell.00209.2005; Huber SM, 2004, J BIOL CHEM, V279, P41444, DOI 10.1074/jbc.M407618200; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jeulin C, 2005, AM J PHYSIOL-LUNG C, V289, pL636, DOI 10.1152/ajplung.00351.2004; Kabouridis PS, 2006, MOL MEMBR BIOL, V23, P49, DOI 10.1080/09687860500453673; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kowalski MP, 2004, J IMMUNOL, V172, P418, DOI 10.4049/jimmunol.172.1.418; Levitan I, 2000, J GEN PHYSIOL, V115, P405, DOI 10.1085/jgp.115.4.405; Li HD, 2004, J BIOL CHEM, V279, P19893, DOI 10.1074/jbc.M400525200; Li Y, 2005, BIOPHYS J, V88, P3936, DOI 10.1529/biophysj.104.055012; Lim CH, 2006, ACTA PHYSIOL, V187, P295, DOI 10.1111/j.1748-1716.2006.01534.x; Lipecka J, 2002, AM J PHYSIOL-CELL PH, V282, pC805, DOI 10.1152/ajpcell.00291.2001; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Martens JR, 2004, TRENDS PHARMACOL SCI, V25, P16, DOI 10.1016/j.tips.2003.11.007; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Niemeyer MI, 2004, PHYSIOL GENOMICS, V19, P74, DOI 10.1152/physiolgenomics.00070.2004; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Palmada M, 2004, BIOCHEM BIOPH RES CO, V321, P1001, DOI 10.1016/j.bbrc.2004.07.064; Pena-Muzenmayer G, 2005, J CELL SCI, V118, P4243, DOI 10.1242/jcs.02525; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P10315, DOI 10.1021/bi025943i; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Romanenko VG, 2004, BIOPHYS J, V87, P3850, DOI 10.1529/biophysj.104.043273; Romanenko VG, 2004, J GEN PHYSIOL, V123, P77, DOI 10.1085/jgp.200308882; Rubin D, 2004, ARCH BIOCHEM BIOPHYS, V431, P224, DOI 10.1016/j.abb.2004.08.007; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Shaw AR, 2003, CURR OPIN MOL THER, V5, P294; Shigematsu S, 2003, J BIOL CHEM, V278, P10683, DOI 10.1074/jbc.M208563200; Sik A, 2000, NEUROSCIENCE, V101, P51, DOI 10.1016/S0306-4522(00)00360-2; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sleer LS, 2001, ATHEROSCLEROSIS, V159, P49, DOI 10.1016/S0021-9150(01)00486-5; Staley K, 1996, NEURON, V17, P543, DOI 10.1016/S0896-6273(00)80186-5; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Trouet D, 2001, BIOCHEM BIOPH RES CO, V284, P461, DOI 10.1006/bbrc.2001.4995; Trouet D, 1999, J PHYSIOL-LONDON, V520, P113, DOI 10.1111/j.1469-7793.1999.t01-1-00113.x; Wong W, 2004, J BIOL CHEM, V279, P444, DOI 10.1074/jbc.M304675200; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Ying M, 2003, TRAFFIC, V4, P772, DOI 10.1034/j.1600-0854.2003.00134.x; Zeidner G, 2001, J BIOL CHEM, V276, P35564, DOI 10.1074/jbc.M105189200; Zuniga L, 2004, J PHYSIOL-LONDON, V555, P671, DOI 10.1113/jphysiol.2003.060046	62	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2423	2432		10.1074/jbc.M608251200	http://dx.doi.org/10.1074/jbc.M608251200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17110372	hybrid			2022-12-27	WOS:000243593200033
J	Mellgren, RL; Zhang, WL; Miyake, K; McNeil, PL				Mellgren, Ronald L.; Zhang, Wenli; Miyake, Katsuya; McNeil, Paul L.			Calpain is required for the rapid, calcium-dependent repair of wounded plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-SUBUNIT; CALPASTATIN; INHIBITION; GROWTH; DISRUPTION; PROTEINS; ACTIN; PROTEOLYSIS; MUTATIONS; VIMENTIN	Mammalian cells require extracellular calcium ion to undergo rapid plasma membrane repair seconds after mechanical damage. Utilizing transformed fibroblasts from calpain small subunit knock-out (Capns1(-/-)) mouse embryos, we now show that the heterodimeric, typical subclass of calpains is required for calcium-mediated survival after plasma membrane damage caused by scraping a cell monolayer. Survival of scrape-damaged Capns1(-/-) cells was unaffected by calcium in the scraping medium, whereas more Capns1(-/-) cells survived when calcium was present. Calcium-mediated survival was increased when Capns1(-/-) cells were scraped in the presence of purified m- or mu-calpain. Survival rates of scraped Capns1(-/-), HFL-1, or Chinese hamster ovary cells were decreased by the calpain inhibitor, calpeptin, or the highly specific calpain inhibitor protein, calpastatin. Capns1(-/-) cells failed to reseal following laser-induced membrane disruption, demonstrating that their decreased survival after scraping resulted, at least in part, from failed membrane repair. Proteomic and immunologic analyses demonstrated that the known calpain substrates talin and vimentin were exposed at the cell surface and processed by calpain following cell scraping. Autoproteolytic activation of calpain at the scrape site was evident at the earliest time point analyzed and appeared to precede proteolysis of talin and vimentin. The results indicate that conventional calpains are required for calcium-facilitated survival after plasma membrane damage and may act by localized remodeling of the cortical cytoskeleton at the injury site.	Univ Toledo, Coll Med, Dept Physiol Pharmacol Metab & Cardiovasc Sci, Toledo, OH 43606 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA	University System of Ohio; University of Toledo; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Mellgren, RL (corresponding author), Univ Toledo, Coll Med, Dept Physiol Pharmacol Metab & Cardiovasc Sci, Mail Stop 1008,Hlth Sci Campus,3000 Arlington Ave, Toledo, OH 43606 USA.	rmellgren@meduohio.edu						Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Bansal D, 2004, TRENDS CELL BIOL, V14, P206, DOI 10.1016/j.tcb.2004.03.001; Benink HA, 2005, J CELL BIOL, V168, P429, DOI 10.1083/jcb.200411109; Botion LM, 2001, ENDOCRINOLOGY, V142, P5069, DOI 10.1210/en.142.12.5069; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; DAYTON WR, 1976, BIOCHEMISTRY-US, V15, P2159, DOI 10.1021/bi00655a020; DEMARTINO GN, 1986, J BIOL CHEM, V261, P2047; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Dourdin N, 1997, EXP CELL RES, V235, P385, DOI 10.1006/excr.1997.3684; FISCHER S, 1986, BIOL CHEM H-S, V367, P1147, DOI 10.1515/bchm3.1986.367.2.1147; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; FUKUI I, 1989, BIOCHEM BIOPH RES CO, V162, P559, DOI 10.1016/0006-291X(89)92347-4; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Godell CM, 1997, P NATL ACAD SCI USA, V94, P4751, DOI 10.1073/pnas.94.9.4751; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hao LY, 2000, BIOCHEM BIOPH RES CO, V279, P756, DOI 10.1006/bbrc.2000.4040; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; LEE TL, 1993, J CELL SCI, V105, P167; Mayer C, 2004, EUR J CELL BIOL, V83, P709, DOI 10.1078/0171-9335-00394; McNeil AK, 2006, J BIOL CHEM, V281, P35202, DOI 10.1074/jbc.M606406200; McNeil PL, 2005, NAT REV MOL CELL BIO, V6, P499, DOI 10.1038/nrm1665; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; McNeil PL, 2003, P NATL ACAD SCI USA, V100, P4592, DOI 10.1073/pnas.0736739100; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MELLGREN RL, 1989, BIOCHIM BIOPHYS ACTA, V999, P71, DOI 10.1016/0167-4838(89)90032-0; Miyake K, 2001, J CELL SCI, V114, P3487; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; Palecek SP, 1998, J CELL SCI, V111, P929; PAWAR S, 1995, J CELL PHYSIOL, V165, P556, DOI 10.1002/jcp.1041650314; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Schoenwaelder SM, 1999, J BIOL CHEM, V274, P14359, DOI 10.1074/jbc.274.20.14359; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WANG KKW, 1999, CALPAIN PHARM TOXICO, P77; Xu Y, 2002, J BIOL CHEM, V277, P21474, DOI 10.1074/jbc.M111689200; YAMAMOTO S, 1992, ARTHRITIS RHEUM-US, V35, P1309, DOI 10.1002/art.1780351111; Yoo S, 2003, J NEUROSCI RES, V74, P541, DOI 10.1002/jnr.10771; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825	43	94	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2567	2575		10.1074/jbc.M604560200	http://dx.doi.org/10.1074/jbc.M604560200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121849	hybrid			2022-12-27	WOS:000243593200049
J	Cortes-Hernandez, P; Vazquez-Memije, ME; Garcia, JJ				Cortes-Hernandez, Paulina; Vazquez-Memije, Martha E.; Garcia, Jose J.			ATP6 homoplasmic mutations inhibit and destabilize the human F1F0-ATP synthase without preventing enzyme assembly and oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-DNA MUTATION; ESCHERICHIA-COLI; LEIGH-SYNDROME; MTDNA MUTATION; MAMMALIAN MITOCHONDRIA; T8993G MUTATION; PROTEIN IF1; GENE; ATPASE; SUBUNIT	The molecular pathogenic mechanism of the human mitochondrial diseases neurogenic ataxia and retinitis pigmentosa and maternally inherited Leigh syndrome was determined in cultured human cells harboring homoplasmic T8993G/T8993C point mutations in the mitochondrial ATP6 gene, which encodes subunit 6 of the F1F0-ATP synthase. Immunoprecipitation and blue native electrophoresis showed that F1F0-ATP synthase assembles correctly in homoplasmic mutant mitochondria. The mutants exhibited a tendency to have an increased sensitivity to subsaturating amounts of oligomycin; this provided further evidence for complete assembly and tight coupling between the F-1 and F-0 sectors. Furthermore, human ATP synthase dimers and higher homo-oligomers were observed for the first time, and it was demonstrated that the mutant enzymes retain enough structural integrity to oligomerize. A reproducible increase in the proportion of oligomeric-to-monomeric enzyme was found for the T8993G mutant suggesting that F1F0 oligomerization is regulated in vivo and that it can be modified in pathological conditions. Despite correct assembly, the T8993G mutation produced a 60% inhibition in ATP synthesis turnover. In vitro denaturing conditions showed F1F0 instability conferred by the mutations, although this instability did not produce enzyme disassembly in the conditions used for determination of ATP synthesis. Taken together, the data show that the primary molecular pathogenic mechanism of these deleterious human mitochondrial mutations is functional inhibition in a correctly assembled ATP synthase. Structural instability may play a role in the progression of the disease under potentially denaturing conditions, as discussed.	Inst Nacl Cardiol Ignacio Chavez, Dept Biochem, Mexico City 14080, DF, Mexico; Inst Nacl Cardiol Ignacio Chavez, Dept Genet, Ctr Med Nacl Siglo 21, Mexico City 14080, DF, Mexico; Inst Nacl Cardiol Ignacio Chavez, Cardiovasc Dis Genom & Proteom Study Grp, Mexico City 14080, DF, Mexico	National Institute of Cardiology - Mexico; National Institute of Cardiology - Mexico; National Institute of Cardiology - Mexico	Garcia, JJ (corresponding author), Inst Nacl Cardiol Ignacio Chavez, Dept Biochem, Juan Badiano 1 Sec 16, Mexico City 14080, DF, Mexico.	jjgarcia_trejo@yahoo.com	Cortes-Hernandez, Paulina/ABC-1133-2020; Cortes-Hernandez, Paulina/GLQ-5915-2022	Cortes-Hernandez, Paulina/0000-0001-8226-1703; 				Aggeler R, 2002, J BIOL CHEM, V277, P33906, DOI 10.1074/jbc.M204538200; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Baracca A, 2000, J BIOL CHEM, V275, P4177, DOI 10.1074/jbc.275.6.4177; Bravo C, 2004, J BIOENERG BIOMEMBR, V36, P257, DOI 10.1023/B:JOBB.0000031977.99479.ea; Carrozzo R, 2006, ANN NEUROL, V59, P265, DOI 10.1002/ana.20729; Carrozzo R, 2004, J NEUROCHEM, V90, P490, DOI 10.1111/j.1471-4159.2004.02505.x; Carrozzo R, 2000, NEUROL SCI, V21, pS983, DOI 10.1007/s100720070016; Carrozzo R, 2001, NEUROLOGY, V56, P687, DOI 10.1212/WNL.56.5.687; DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; FRYER A, 1994, ARCH DIS CHILD, V71, P419, DOI 10.1136/adc.71.5.419; Fujii T, 1998, PEDIATR NEUROL, V18, P275, DOI 10.1016/S0887-8994(97)00187-2; Garcia J.J., 2002, RECENT RES DEV HUMAN, P127; Garcia JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075; Garcia JJ, 2006, BIOCHEMISTRY-US, V45, P12695, DOI 10.1021/bi060339j; HARTZOG PE, 1993, J BIOL CHEM, V268, P12250; HOLT IJ, 1990, AM J HUM GENET, V46, P428; HOUSTEK J, 1995, BBA-MOL BASIS DIS, V1271, P349, DOI 10.1016/0925-4439(95)00063-A; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; Krause F, 2005, BIOCHEM BIOPH RES CO, V329, P583, DOI 10.1016/j.bbrc.2005.02.010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; Majander A, 1997, FEBS LETT, V412, P351, DOI 10.1016/S0014-5793(97)00757-6; Minauro-Sanmiguel F, 2005, P NATL ACAD SCI USA, V102, P12356, DOI 10.1073/pnas.0503893102; Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200; Ogilvie I, 1999, FEBS LETT, V453, P179, DOI 10.1016/S0014-5793(99)00605-5; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Santorelli FM, 1996, PEDIATR RES, V39, P914, DOI 10.1203/00006450-199605000-00028; SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612; SANTORELLI FM, 1994, NEUROLOGY, V44, P972, DOI 10.1212/WNL.44.5.972; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schon EA, 2001, SEMIN CELL DEV BIOL, V12, P441, DOI 10.1006/scdb.2001.0281; Sgarbi G, 2006, BIOCHEM J, V395, P493, DOI 10.1042/BJ20051748; TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390; TATUCH Y, 1992, AM J HUM GENET, V50, P852; TRAUTSCHOLD ILW, 1995, METHODS ENZYMATIC AN; Vazquez-Memije ME, 1998, J INHERIT METAB DIS, V21, P829, DOI 10.1023/A:1005418718299; VAZQUEZMEMIJE ME, 2002, RECENT RES DEV HUMAN, P127; Vik SB, 2000, BBA-BIOENERGETICS, V1458, P457, DOI 10.1016/S0005-2728(00)00094-3	41	58	58	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1051	1058		10.1074/jbc.M606828200	http://dx.doi.org/10.1074/jbc.M606828200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17121862	hybrid			2022-12-27	WOS:000243295200028
J	Friedman, J; Meharenna, YT; Wilks, A; Poulos, TL				Friedman, Jonathan; Meharenna, Yergalem T.; Wilks, Angela; Poulos, Thomas L.			Diatomic ligand discrimination by the heme oxygenases from Neisseria meningitidis and Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; CRYSTAL-STRUCTURES; CORYNEBACTERIUM-DIPHTHERIAE; IRON SOURCES; CO BINDING; MYOGLOBIN; O-2; GENE; DEGRADATION; HEMOGLOBIN	Heme oxygenases have an increased binding affinity for O-2 relative to CO. Such discrimination is critical to the function of HO enzymes because one of the main products of heme catabolism is CO. Kinetic studies of mammalian and bacterial HO proteins reveal a significant decrease in the dissociation rate of O-2 relative to other heme proteins such as myoglobin. Here we report the kinetic rate constants for the binding of O-2 and CO by the heme oxygenases from Neisseria meningitidis (nmHO) and Pseudomonas aeruginosa (paHO). A combination of stopped flow kinetic and laser flash photolysis experiments reveal that nmHO and paHO both maintain a similar degree of ligand discrimination as mammalian HO-1 and the HO from Corynebacterium diphtheriae. However, in addition to the observed decrease in dissociation rate for O-2 by both nmHO and paHO, kinetic analyses show an increase in dissociation rate for CO by these two enzymes. The crystal structures of nmHO and paHO both contain significant differences from the mammalian HO-1 and bacterial C. diphtheriae HO structures, which suggests a structural basis for ligand discrimination in nmHO and paHO.	Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Chem & Struct Biol, Irvine, CA 92697 USA; Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University System of Maryland; University of Maryland Baltimore	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA.	poulos@uci.edu						Andrews SC, 2003, FEMS MICROBIOL REV, V27, P215, DOI 10.1016/S0168-6445(03)00055-X; Bruggemann H, 2004, ARCH MICROBIOL, V182, P259, DOI 10.1007/s00203-004-0721-1; Caignan GA, 2002, J AM CHEM SOC, V124, P14879, DOI 10.1021/ja0274960; COLLMAN JP, 1976, P NATL ACAD SCI USA, V73, P3333, DOI 10.1073/pnas.73.10.3333; Cornejo J, 1998, PLANT J, V15, P99, DOI 10.1046/j.1365-313X.1998.00186.x; Davis SJ, 1999, P NATL ACAD SCI USA, V96, P6541, DOI 10.1073/pnas.96.11.6541; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; Farres J, 2005, BIOCHEMISTRY-US, V44, P4125, DOI 10.1021/bi047389d; Friedman J, 2004, BIOCHEMISTRY-US, V43, P5239, DOI 10.1021/bi049687g; Friedman J, 2003, J BIOL CHEM, V278, P34654, DOI 10.1074/jbc.M302985200; Ghosh A, 1996, J PHYS CHEM-US, V100, P6363, DOI 10.1021/jp953543h; Jain R, 2003, J BIOL INORG CHEM, V8, P1, DOI 10.1007/s00775-002-0405-8; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; Krzywda S, 1998, BIOCHEMISTRY-US, V37, P15896, DOI 10.1021/bi9812470; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Migita CT, 1998, J BIOL CHEM, V273, P945, DOI 10.1074/jbc.273.2.945; Paiva-Silva GO, 2006, P NATL ACAD SCI USA, V103, P8030, DOI 10.1073/pnas.0602224103; Ratliff M, 2001, J BACTERIOL, V183, P6394, DOI 10.1128/JB.183.21.6394-6403.2001; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; Shikama K, 2006, PROG BIOPHYS MOL BIO, V91, P83, DOI 10.1016/j.pbiomolbio.2005.04.001; Sigfridsson E, 2002, J INORG BIOCHEM, V91, P101, DOI 10.1016/S0162-0134(02)00426-9; Sigfridsson E, 1999, J BIOL INORG CHEM, V4, P99, DOI 10.1007/s007750050293; Skaar EP, 2004, J BIOL CHEM, V279, P436, DOI 10.1074/jbc.M307952200; Skaar EP, 2006, J BACTERIOL, V188, P1071, DOI 10.1128/JB.188.3.1071-1080.2006; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; Spiro TG, 2001, ACCOUNTS CHEM RES, V34, P137, DOI 10.1021/ar000108j; Spiro TG, 2001, CURR OPIN CHEM BIOL, V5, P715, DOI 10.1016/S1367-5931(01)00271-X; Sugishima M, 2003, BIOCHEMISTRY-US, V42, P9898, DOI 10.1021/bi027268i; Tani F, 2003, CHEM-EUR J, V9, P862, DOI 10.1002/chem.200390096; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Unno M, 2004, J BIOL CHEM, V279, P21055, DOI 10.1074/jbc.M400491200; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; Wandersman C, 2004, ANNU REV MICROBIOL, V58, P611, DOI 10.1146/annurev.micro.58.030603.123811; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; Zhang XH, 2004, EUR J BIOCHEM, V271, P1713, DOI 10.1111/j.1432-1033.2004.04077.x; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	40	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1066	1071		10.1074/jbc.M609112200	http://dx.doi.org/10.1074/jbc.M609112200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17095508	hybrid			2022-12-27	WOS:000243295200030
J	Song, JJ; An, JY; Kwon, YT; Lee, YJ				Song, Jae J.; An, Jee Young; Kwon, Yong Tae; Lee, Yong J.			Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance - Involvement of Bcl-xL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRAIL-INDUCED APOPTOSIS; OVARIAN-CANCER CELLS; PROTEIN-KINASE; DR5/TRAIL-RECEPTOR-2 GENE; BAD PHOSPHORYLATION; BCL-X(L) EXPRESSION; DEATH RECEPTORS; FAMILY-MEMBERS; ACTIVATION	Previous studies have shown that repeated application of TRAIL induces acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Using human prostate adenocarcinoma DU-145 and human pancreatic carcinoma MiaPaCa-2 cells as a model, we now demonstrate for the first time that two states of acquired TRAIL resistance can be developed after TRAIL treatment. Data from survival assay and Western blot analysis show that acquired TRAIL resistance was developed within 1 day and gradually decayed within 6 days after TRAIL treatment in both cell lines. After TRAIL treatment, the level of Bcl-xL increased and reached a maximum within 2 days and gradually decreased in both cell lines. Bcl-xL-mediated development of acquired TRAIL resistance was suppressed by knockdown of Bcl-xL expression. Protein interaction assay revealed that during the development of TRAIL resistance, Bcl-xL dissociated from Bad and then associated with Bax. Overexpression of mutant-type Bad (S136A), which prevents this dissociation, partially suppressed the development of acquired TRAIL resistance. Thus, our results suggest that (a) dissociation of Bad from Bcl-xL and (b) an increase in the intracellular level of Bcl-xL are responsible for development of acquired TRAIL resistance.	Univ Pittsburgh, Dept Surg & Pharmacol, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Pharm, Ctr Pharmacogent, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, 5117 Ctr Ave,Rm 1-46C, Pittsburgh, PA 15213 USA.	leeyj@upmc.edu		Song, Jae/0000-0001-8183-9550	NCI NIH HHS [CA96989, CA95191, CA121395] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095191, R01CA096989, R03CA121395] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Austin CD, 2006, P NATL ACAD SCI USA, V103, P10283, DOI 10.1073/pnas.0604044103; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burow ME, 1998, CANCER RES, V58, P4940; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dairaku N, 2004, J LAB CLIN MED, V143, P143, DOI 10.1016/j.lab.2003.11.003; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Eggert A, 2001, CANCER RES, V61, P1314; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Glasgow JN, 2001, NEUROCHEM RES, V26, P647, DOI 10.1023/A:1010987220034; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hayakawa J, 2000, CANCER RES, V60, P5988; Hetman M, 2000, J NEUROSCI, V20, P2567; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Jeng YM, 2002, CANCER LETT, V181, P205, DOI 10.1016/S0304-3835(02)00051-4; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kondo S, 1998, ONCOGENE, V17, P2585, DOI 10.1038/sj.onc.1202194; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SH, 1999, CANCER RES, V59, P5683; Lee SH, 2001, ONCOGENE, V20, P399, DOI 10.1038/sj.onc.1204103; Lee YJ, 2004, CLIN CANCER RES, V10, P1894, DOI 10.1158/1078-0432.CCR-03-0136; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; Marinari B, 2004, P NATL ACAD SCI USA, V101, P6098, DOI 10.1073/pnas.0308688101; Morel J, 2005, J BIOL CHEM, V280, P15709, DOI 10.1074/jbc.M414469200; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Oliver CL, 2004, CLIN CANCER RES, V10, P7757, DOI 10.1158/1078-0432.CCR-04-0551; Ozes ON, 1999, NATURE, V401, P82; Pai SI, 1998, CANCER RES, V58, P3513; Park WS, 2001, GASTROENTEROLOGY, V121, P1219, DOI 10.1053/gast.2001.28663; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Ray S, 2005, APOPTOSIS, V10, P1411, DOI 10.1007/s10495-005-2490-y; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sclabas GM, 2003, J GASTROINTEST SURG, V7, P37, DOI 10.1016/S1091-255X(02)00088-4; Secchiero P, 2003, CIRCULATION, V107, P2250, DOI 10.1161/01.CIR.0000062702.60708.C4; Secchiero P, 2004, CELL MOL LIFE SCI, V61, P1965, DOI 10.1007/s00018-004-4197-6; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Seol DW, 2001, CANCER RES, V61, P1138; Shin MS, 2001, CANCER RES, V61, P4942; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Thomas LR, 2004, J BIOL CHEM, V279, P32780, DOI 10.1074/jbc.M401680200; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Yang XH, 2001, CANCER RES, V61, P348; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zauli G, 2005, J CELL PHYSIOL, V202, P900, DOI 10.1002/jcp.20202; Zhang L, 2002, GENE THER, V9, P1262, DOI 10.1038/sj.gt.3301797; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang MC, 2003, BIOCHEM PHARMACOL, V66, P93, DOI 10.1016/S0006-2952(03)00248-X; Zheng TS, 2001, NAT CELL BIOL, V3, pE43, DOI 10.1038/35055145	69	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					319	328		10.1074/jbc.M608065200	http://dx.doi.org/10.1074/jbc.M608065200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17110373	hybrid			2022-12-27	WOS:000243166500036
J	Balasubramanian, S; Eckert, RL				Balasubramanian, Sivaprakasam; Eckert, Richard L.			Curcumin suppresses AP1 transcription factor-dependent differentiation and activates apoptosis in human epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INVOLUCRIN PROMOTER; NF-KAPPA-B; GREEN TEA POLYPHENOL; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED TUMOR PROMOTION; PROTEIN-KINASE-C; CELL-PROLIFERATION; GENE-EXPRESSION; PROTEASOMAL DEGRADATION; DERIVATIVES INHIBIT; DIETARY CURCUMIN	The diet-derived cancer preventive agent, curcumin, inhibits skin cancer cell proliferation and tumor formation. However, its effect on normal human keratinocyte differentiation, proliferation, and apoptosis has not been adequately studied. Involucrin (hINV) is a marker of keratinocyte differentiation and a useful model for the study of chemopreventive agent action. We show that curcumin suppresses the differentiation agent-dependent activation of hINV gene expression and that an AP1 transcription factor DNA binding site in the hINV gene is required for this regulation. A protein kinase C, Ras, MEKK1, MEK3 signaling cascade controls hINV expression by regulating AP1 factor level. Curcumin treatment inhibits the novel protein kinase C-, Ras-, and MEKK1-dependent activation of hINV promoter activity and reduces the differentiation agent-dependent increase in AP1 factor level and DNA binding. This reduction requires proteasome function. In addition, curcumin treatment reduces cell number, which is associated with a reduced cyclin and cdk1 levels. Curcumin treatment also suppresses the Bcl-xL level, leading to reduced mitochondrial membrane potential and increased cleavage of procaspases and poly(ADP-ribose) polymerase. These studies provide important insights regarding the mechanism whereby curcumin acts as a chemopreventive agent in normal human epidermis.	Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, 2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu			NATIONAL CANCER INSTITUTE [R01CA092201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750, R01AR046494] Funding Source: NIH RePORTER; NCI NIH HHS [CA92201] Funding Source: Medline; NIAMS NIH HHS [AR046494, AR39750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Acquaviva C, 2001, ONCOGENE, V20, P7563, DOI 10.1038/sj.onc.1204880; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Aggarwal BB, 2003, ANTICANCER RES, V23, P363; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Balasubramanian S, 2005, ONCOGENE, V24, P4257, DOI 10.1038/sj.onc.1208586; Balasubramanian S, 2005, CARCINOGENESIS, V26, P1100, DOI 10.1093/carcin/bgi048; Balasubramanian S, 2004, J BIOL CHEM, V279, P24007, DOI 10.1074/jbc.M314331200; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Berse M, 2004, J MOL BIOL, V343, P361, DOI 10.1016/j.jmb.2004.08.043; Cho JW, 2005, EXP MOL MED, V37, P186, DOI 10.1038/emm.2005.25; Choudhuri T, 2005, J BIOL CHEM, V280, P20059, DOI 10.1074/jbc.M410670200; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; Crish JF, 2002, ONCOGENE, V21, P738, DOI 10.1038/sj.onc.1205038; Dikshit P, 2006, NEUROTOX RES, V9, P29, DOI 10.1007/BF03033305; Dikshit P, 2006, BIOCHEM BIOPH RES CO, V342, P1323, DOI 10.1016/j.bbrc.2006.02.104; Eckert RL, 2006, MOL NUTR FOOD RES, V50, P123, DOI 10.1002/mnfr.200500125; Eckert RL, 2004, J INVEST DERMATOL, V123, P13, DOI 10.1111/j.0022-202X.2004.22723.x; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Gafner S, 2004, PHYTOCHEMISTRY, V65, P2849, DOI 10.1016/j.phytochem.2004.08.008; Grandjean-Laquerriere A, 2002, CYTOKINE, V18, P168, DOI 10.1006/cyto.2002.0888; Hahm ER, 2004, BIOCHEM BIOPH RES CO, V321, P337, DOI 10.1016/j.bbrc.2004.06.119; Hahm ER, 2002, CANCER LETT, V184, P89, DOI 10.1016/S0304-3835(02)00170-2; Hour TC, 2002, PROSTATE, V51, P211, DOI 10.1002/pros.10089; Huang MT, 1997, CARCINOGENESIS, V18, P83, DOI 10.1093/carcin/18.1.83; HUANG MT, 1995, CARCINOGENESIS, V16, P2493, DOI 10.1093/carcin/16.10.2493; Jana NR, 2004, J BIOL CHEM, V279, P11680, DOI 10.1074/jbc.M310369200; Jost M, 1999, J INVEST DERMATOL, V112, P443, DOI 10.1046/j.1523-1747.1999.00543.x; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; KAKAR SS, 1994, CANCER LETT, V87, P85, DOI 10.1016/0304-3835(94)90413-8; Kawasaki H, 2003, ONCOGENE, V22, P6839, DOI 10.1038/sj.onc.1206903; Krishnaswamy K, 1998, NUTR CANCER, V30, P163, DOI 10.1080/01635589809514657; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Limtrakul P, 1997, CANCER LETT, V116, P197, DOI 10.1016/S0304-3835(97)00187-0; Limtrakul PN, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-1; LU YP, 1994, CARCINOGENESIS, V15, P2363, DOI 10.1093/carcin/15.10.2363; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Park CH, 2005, J BIOCHEM MOL BIOL, V38, P474; Prusty BK, 2005, INT J CANCER, V113, P951, DOI 10.1002/ijc.20668; Rinaldi AL, 2002, CANCER RES, V62, P5451; Santibanez JF, 2000, NUTR CANCER, V37, P49, DOI 10.1207/S15327914NC3701_6; Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010; Shishodia S, 2003, CARCINOGENESIS, V24, P1269, DOI 10.1093/carcin/bgg078; Singletary K, 1998, CARCINOGENESIS, V19, P1039, DOI 10.1093/carcin/19.6.1039; STONER GD, 1995, J CELL BIOCHEM, P169; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Wyke SM, 2004, BRIT J CANCER, V91, P1742, DOI 10.1038/sj.bjc.6602165; Yan CH, 2005, MOL CANCER THER, V4, P233	57	74	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2007	282	9					6707	6715		10.1074/jbc.M606003200	http://dx.doi.org/10.1074/jbc.M606003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	145LS	17148446	hybrid			2022-12-27	WOS:000244867200080
J	Hajek, P; Chomyn, A; Attardi, G				Hajek, Petr; Chomyn, Anne; Attardi, Giuseppe			Identification of a novel mitochondrial complex containing mitofusin 2 and stomatin-like protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; OUTER-MEMBRANE; INNER MEMBRANE; FUSION; MORPHOLOGY; CELLS; PROHIBITINS; PROTEASE; GTPASE; OPA1	A reverse genetics approach was utilized to discover new proteins that interact with the mitochondrial fusion mediator mitofusin 2 (Mfn2) and that may participate in mitochondrial fusion. In particular, in vivo formaldehyde cross-linking of whole HeLa cells and immunoprecipitation with purified Mfn2 antibodies of SDS cell lysates were used to detect an similar to 42-kDa protein. This protein was identified by liquid chromatography and tandem mass spectrometry as stomatin-like protein 2 (Stoml2), previously described as a peripheral plasma membrane protein of unknown function associated with the cytoskeleton of erythrocytes (Wang, Y., and Morrow, J. S. (2000) 1. Biol. Chem. 275, 8062-8071). Immunoblot analysis with anti-Stoml2 antibodies showed that Stoml2 could be immurroprecipitated specifically with Mfn2 antibody either from formaldehyde-cross-linked and SDS-lysed cells or from cells lysed with digitonin. Subsequent immunocytochemistry and cell fractionation experiments fully supported the conclusion that Stoml2 is indeed a mitochondrial protein. Furthermore, demonstration of mitochondrial membrane potential-dependent import of Stoml2 accompanied by proteolytic processing, together with the results of sublocalization experiments, suggested that Stoml2 is associated with the inner mitochondrial membrane and faces the intermembrane space. Notably, formaldehyde cross-linking revealed a "ladder" of high molecular weight protein species, indicating the presence of high molecular weight Stoml2-Mfn2 hetero-oligomers. Knockdown of Stoml2 by the short interfering RNA approach showed a reduction of the mitochondrial membrane potential, without, however, any obvious changes in mitochondrial morphology.	CALTECH, Div Biol 15629, Pasadena, CA 91125 USA	California Institute of Technology	Attardi, G (corresponding author), CALTECH, Div Biol 15629, 1200 E Calif Blvd, Pasadena, CA 91125 USA.	attardi@caltech.edu			NIGMS NIH HHS [GM11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen KH, 2004, NAT CELL BIOL, V6, P872, DOI 10.1038/ncb1161; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; Da Cruz S, 2003, J BIOL CHEM, V278, P41566, DOI 10.1074/jbc.M304940200; FernandezSilva P, 1997, EMBO J, V16, P1066, DOI 10.1093/emboj/16.5.1066; Fritz S, 2001, J CELL BIOL, V152, P683, DOI 10.1083/jcb.152.4.683; Griffin EE, 2006, J BIOL CHEM, V281, P16599, DOI 10.1074/jbc.M601847200; Hajek P, 2001, J BIOL CHEM, V276, P606, DOI 10.1074/jbc.M007871200; Herlan M, 2004, J CELL BIOL, V165, P167, DOI 10.1083/jcb.200403022; Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200; Ishihara N, 2004, J CELL SCI, V117, P6535, DOI 10.1242/jcs.01565; Ishihara N, 2006, EMBO J, V25, P2966, DOI 10.1038/sj.emboj.7601184; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; MADDEN EA, 1987, ANAL BIOCHEM, V163, P350, DOI 10.1016/0003-2697(87)90235-1; MARIOTTINI P, 1986, J BIOL CHEM, V261, P3355; McQuibban GA, 2003, NATURE, V423, P537, DOI 10.1038/nature01633; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nagase T., 1996, DNA RES, V3; Neuspiel M, 2005, J BIOL CHEM, V280, P25060, DOI 10.1074/jbc.M501599200; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Owczarek CM, 2001, CYTOGENET CELL GENET, V92, P196, DOI 10.1159/000056902; Pich S, 2005, HUM MOL GENET, V14, P1405, DOI 10.1093/hmg/ddi149; Piper PW, 2002, AGING CELL, V1, P149, DOI 10.1046/j.1474-9728.2002.00018.x; Reifschneider NH, 2006, J PROTEOME RES, V5, P1117, DOI 10.1021/pr0504440; Rojo M, 2002, J CELL SCI, V115, P1663; Santel A, 2003, J CELL SCI, V116, P2763, DOI 10.1242/jcs.00479; Santel A, 2001, J CELL SCI, V114, P867; Sanz MA, 2003, J BIOL CHEM, V278, P32091, DOI 10.1074/jbc.M304877200; Schmitt S, 2006, PROTEOMICS, V6, P72, DOI 10.1002/pmic.200402084; Sesaki H, 2004, J BIOL CHEM, V279, P28298, DOI 10.1074/jbc.M401363200; Sesaki H, 2003, MOL BIOL CELL, V14, P2342, DOI 10.1091/mbc.E02-12-0788; Sesaki H, 2001, J CELL BIOL, V152, P1123, DOI 10.1083/jcb.152.6.1123; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snyers L, 1999, FEBS LETT, V449, P101, DOI 10.1016/S0014-5793(99)00417-2; Steglich G, 1999, MOL CELL BIOL, V19, P3435; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TANG WJY, 1993, METHOD CELL BIOL, V37, P95, DOI 10.1016/S0091-679X(08)60245-9; Tatsuta T, 2005, MOL BIOL CELL, V16, P248, DOI 10.1091/mbc.e04-09-0807; Wang YJ, 2000, J BIOL CHEM, V275, P8062, DOI 10.1074/jbc.275.11.8062	51	84	92	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2007	282	8					5670	5681		10.1074/jbc.M608168200	http://dx.doi.org/10.1074/jbc.M608168200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CZ	17121834	hybrid, Green Accepted			2022-12-27	WOS:000244482300064
J	Fang, Z; Park, CK; Li, HY; Kim, HY; Park, SH; Jung, SJ; Kim, JS; Monteil, A; Oh, SB; Miller, RJ				Fang, Zhi; Park, Chul-Kyu; Li, Hai Ying; Kim, Hyun Yeong; Park, Seong-Hae; Jung, Sung Jun; Kim, Joong Soo; Monteil, Arnaud; Oh, Seog Bae; Miller, Richard J.			Molecular basis of Ca(V)2.3 calcium channels in rat nociceptive neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CA2+ CHANNELS; ALPHA(1) SUBUNITS; SENSORY NEURONS; PAIN; CELL; RECEPTOR; CURRENTS; MECHANISMS; AXOTOMY	Ca(v)2.3 calcium channels play an important role in pain transmission in peripheral sensory neurons. Six Ca(v)23 isoforms resulting from different combinations of three inserts (inserts I and II in the II-III loop and insert III in the carboxyl-terminal region) have been identified in different mammalian tissues. To date, however, Ca(v)23 isoforms unique to primary sensory neurons have not been identified. In this study, we determined Cav2.3 isoforms expressed in the rat trigeminal ganglion neurons. Whole tissue reverse transcription (RT)-PCR analyses revealed that only two isoforms, Ca(v)2.3a and Ca(v)23e, are present in TG neurons. Using single cell RT-PCR, we found that Ca(v)23e is the major isoform, whereas Ca(v)2.3e expression is highly restricted to small (< 16 mu m) isolectin B4-negative and tyrosine kinase A-positive neurons. Ca(v)23e was also preferentially detected in neurons expressing the nociceptive marker, transient receptor potential vanilloid 1. Single cell RT-PCR following calcium imaging and whole-cell patch clamp recordings provided evidence of an association between an R-type calcium channel component and Ca(v)2.3e expression. Our results suggest that Ca(v)2.3e in sensory neurons may be a potential target for the treatment of pain.	Seoul Natl Univ, Dept Physiol, Sch Dent & Dent Res Inst, Seoul 110749, South Korea; Seoul Natl Univ, Program Mol & Cellular Neurosci, Seoul 110749, South Korea; Kangwon Natl Univ, Dept Physiol, Coll Med, Chunchon 200710, South Korea; Inst Genom Fonct, Dept Physiol, CNRS UMR 5203, F-34396 Montpellier 5, France; Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA	Seoul National University (SNU); Seoul National University (SNU); Kangwon National University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Northwestern University; Feinberg School of Medicine	Oh, SB (corresponding author), Seoul Natl Univ, Dept Physiol, Sch Dent & Dent Res Inst, Seoul 110749, South Korea.	odolbae@snu.ac.kr	Monteil, Arnaud/G-3113-2012; OH, Seog Bae/AAQ-2478-2020	Monteil, Arnaud/0000-0003-1632-7318; 	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013141] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA013141-06A2, R01 DA013141] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bell TJ, 2004, NEURON, V41, P127, DOI 10.1016/S0896-6273(03)00801-8; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Bradbury EJ, 1998, MOL CELL NEUROSCI, V12, P256, DOI 10.1006/mcne.1998.0719; Brown SP, 2004, J NEUROSCI, V24, P5623, DOI 10.1523/JNEUROSCI.0918-04.2004; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Dietrich D, 2003, NEURON, V39, P483, DOI 10.1016/S0896-6273(03)00430-6; DUNLAP K, 1994, SCIENCE, V266, P828, DOI 10.1126/science.7973643; Foehring RC, 2000, J NEUROPHYSIOL, V84, P2225, DOI 10.1152/jn.2000.84.5.2225; Ikeda M, 2003, LIFE SCI, V73, P1175, DOI 10.1016/S0024-3205(03)00414-4; ISHIBASHI H, 1995, NEUROREPORT, V6, P1621, DOI 10.1097/00001756-199508000-00008; Ji RR, 2001, NEUROBIOL DIS, V8, P1, DOI 10.1006/nbdi.2000.0360; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Lambert RC, 1998, J NEUROSCI, V18, P8605; Lee SC, 2002, P NATL ACAD SCI USA, V99, P3276, DOI 10.1073/pnas.052697799; McCleskey EW, 1999, ANNU REV PHYSIOL, V61, P835, DOI 10.1146/annurev.physiol.61.1.835; Michael GJ, 1997, J NEUROSCI, V17, P8476; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Murakami M, 2004, BRAIN RES, V1024, P122, DOI 10.1016/j.brainres.2004.07.066; Murakami M, 2001, BRAIN RES, V903, P231, DOI 10.1016/S0006-8993(01)02427-1; Murray SS, 2003, J ANAT, V202, P227, DOI 10.1046/j.1469-7580.2003.00151.x; NAGY JI, 1982, NEUROSCIENCE, V7, P89, DOI 10.1016/0306-4522(82)90155-5; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; Pereverzev A, 2002, MOL CELL NEUROSCI, V21, P352, DOI 10.1006/mcne.2002.1179; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Piedras-Renteria ES, 1998, P NATL ACAD SCI USA, V95, P7760, DOI 10.1073/pnas.95.13.7760; Saegusa H, 2000, P NATL ACAD SCI USA, V97, P6132, DOI 10.1073/pnas.100124197; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; Schramm M, 1999, NEUROSCIENCE, V92, P565, DOI 10.1016/S0306-4522(99)00013-5; Sessle Barry J, 2002, J Dent Educ, V66, P108; Silbert SC, 2003, J NEUROSCI, V23, P34; Snider WD, 1998, NEURON, V20, P629, DOI 10.1016/S0896-6273(00)81003-X; Stucky CL, 1999, J NEUROSCI, V19, P6497; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tottene A, 2000, J NEUROSCI, V20, P171, DOI 10.1523/JNEUROSCI.20-01-00171.2000; Vajna R, 1998, EUR J BIOCHEM, V257, P274, DOI 10.1046/j.1432-1327.1998.2570274.x; Vanegas H, 2000, PAIN, V85, P9, DOI 10.1016/S0304-3959(99)00241-9; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Wilson SM, 2000, J NEUROSCI, V20, P8566; Yaksh TL, 2006, J PAIN, V7, pS13, DOI 10.1016/j.jpain.2005.09.007; Yang BH, 2003, J DENT RES, V82, P781, DOI 10.1177/154405910308201004; Yusaf SP, 2001, NEUROSCI LETT, V311, P137, DOI 10.1016/S0304-3940(01)02038-9; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	45	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4757	4764		10.1074/jbc.M605248200	http://dx.doi.org/10.1074/jbc.M605248200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17145762	Green Accepted, hybrid			2022-12-27	WOS:000244482000057
J	Frugier, G; Coussen, F; Giraud, MF; Odessa, MF; Emerit, MB; Boue-Grabot, E; Garret, M				Frugier, Guillaume; Coussen, Francoise; Giraud, Marie-France; Odessa, Marie-Francoise; Emerit, Michel B.; Boue-Grabot, Eric; Garret, Maurice			A gamma 2(R43Q) mutation, linked to epilepsy in humans, alters GABA(A) receptor assembly and modifies subunit composition on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID TYPE-A; CHILDHOOD ABSENCE EPILEPSY; FEBRILE SEIZURES; INHIBITORY SYNAPSES; EXPRESSION; GAMMA-2-SUBUNIT; TRAFFICKING; MODEL; OVEREXPRESSION; LOCALIZATION	Genetic defects leading to epilepsy have been identified in gamma 2 GABA(A) receptor subunit. A gamma 2(R43Q) substitution is linked to childhood absence epilepsy and febrile seizure, and a gamma 2(K289M) mutation is associated with generalized epilepsy with febrile seizures plus. To understand the effect of these mutations, surface targeting of GABAA receptors was analyzed by subunit-specific immunofluorescent labeling of living cells. We first transfected hippocampal neurons in culture with recombinant gamma 2 constructs and showed that the gamma 2(R43Q) mutation prevented surface expression of the subunit, unlike gamma 2(K289M) substitution. Several gamma 2-subunit constructs, bearing point mutations within the Arg-43 domain, were expressed in COS-7 cells with alpha 3- and beta 3-subunits. R43Q and R43A substitutions dramatically reduced surface expression of the gamma 2-subunit, whereas R43K, P44A, and D39A substitutions had a lesser, but still significant, impact and K289M substitution had no effect. Whereas the mutant gamma 2(R43Q) was retained within intracellular compartments, alpha beta complexes were still targeted at the cell membrane. Coimmunoprecipitation experiments showed that gamma 2(R43Q) was able to associate with alpha 3- or beta 3-subunits, although the stoichiometry of the complex with alpha 3 was altered. Our data show that gamma 2(R43Q) is not a dominant negative and that the mutation leads to a modification of GABAA receptor subunit composition on the cell surface that impairs the synaptic targeting in neurons. This study reveals an involvement of the gamma 2-Arg-43 domain in the control of receptor assembly that may be relevant to the effect of the heterozygous gamma 2(R43Q) mutation leading to childhood absence epilepsy and febrile seizure.	Univ Bordeaux 2, CNRS, UMR 5543, Neurophysiol Lab, F-33076 Bordeaux, France; Inst F Magendie, UMR 5091, F-33077 Bordeaux, France; CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Inst Natl Sante & Rech Med, U288, F-75013 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Garret, M (corresponding author), Univ Bordeaux 2, CNRS, UMR 5543, Neurophysiol Lab, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	maurice.garret@u-bordeaux2.fr	Boué-Grabot, Eric/AAQ-2061-2020; Scheffer, Ingrid/G-1668-2013	Boué-Grabot, Eric/0000-0003-2187-9037; Emerit, Michel Boris/0000-0003-4824-535X; Scheffer, Ingrid/0000-0002-2311-2174				Alldred MJ, 2005, J NEUROSCI, V25, P594, DOI 10.1523/JNEUROSCI.4011-04.2005; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; Bianchi MT, 2002, J NEUROSCI, V22, P5321; Bollan K, 2003, J BIOL CHEM, V278, P4747, DOI 10.1074/jbc.M210229200; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Boue-Grabot E, 2004, J BIOL CHEM, V279, P52517, DOI 10.1074/jbc.M410223200; Boue-Grabot E, 2004, J BIOL CHEM, V279, P6967, DOI 10.1074/jbc.M307772200; Bowser DN, 2002, P NATL ACAD SCI USA, V99, P15170, DOI 10.1073/pnas.212320199; Connolly CN, 1999, MOL CELL NEUROSCI, V13, P259, DOI 10.1006/mcne.1999.0746; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Cossart R, 2005, TRENDS NEUROSCI, V28, P108, DOI 10.1016/j.tins.2004.11.011; Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885; Coussen F, 2002, J NEUROSCI, V22, P6426, DOI 10.1523/jneurosci.22-15-06426.2002; Crestani F, 1999, NAT NEUROSCI, V2, P833, DOI 10.1038/12207; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; EUGENE E, 2006, FENS, V3; Feng HJ, 2006, J NEUROSCI, V26, P1499, DOI 10.1523/JNEUROSCI.2913-05.2006; Fritschy JM, 2003, PHARMACOL THERAPEUT, V98, P299, DOI 10.1016/S0163-7258(03)00037-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; Hales TG, 2005, MOL CELL NEUROSCI, V29, P120, DOI 10.1016/j.mcn.2005.01.002; Hanchar HJ, 2005, NAT NEUROSCI, V8, P339, DOI 10.1038/nn1398; Jacobs C, 2003, MOL CELL ENDOCRINOL, V209, P71, DOI 10.1016/j.mce.2003.07.002; Jaskolski F, 2004, J NEUROSCI, V24, P2506, DOI 10.1523/JNEUROSCI.5116-03.2004; Jin P, 2004, J BIOL CHEM, V279, P14179, DOI 10.1074/jbc.M313411200; KAIN SR, 1994, BIOTECHNIQUES, V17, P982; Kananura C, 2002, ARCH NEUROL-CHICAGO, V59, P1137, DOI 10.1001/archneur.59.7.1137; Kang JQ, 2006, J NEUROSCI, V26, P2590, DOI 10.1523/JNEUROSCI.4243-05.2006; Kang JQ, 2004, J NEUROSCI, V24, P8672, DOI 10.1523/JNEUROSCI.2717-04.2004; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; Korpi ER, 2006, PHARMACOL THERAPEUT, V109, P12, DOI 10.1016/j.pharmthera.2005.05.009; Li HF, 2006, NEUROPHARMACOLOGY, V51, P121, DOI 10.1016/j.neuropharm.2006.03.003; Luscher B, 2004, PHARMACOL THERAPEUT, V102, P195, DOI 10.1016/j.pharmthera.2004.04.003; Maljevic S, 2006, ANN NEUROL, V59, P983, DOI 10.1002/ana.20874; Milligan CJ, 2004, J NEUROSCI, V24, P7241, DOI 10.1523/JNEUROSCI.1979-04.2004; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Noebels JL, 2003, ANNU REV NEUROSCI, V26, P599, DOI 10.1146/annurev.neuro.26.010302.081210; O'Mara M, 2005, BIOPHYS J, V88, P3286, DOI 10.1529/biophysj.104.051664; Sancar F, 2004, J BIOL CHEM, V279, P47034, DOI 10.1074/jbc.M403388200; Semyanov A, 2004, TRENDS NEUROSCI, V27, P262, DOI 10.1016/j.tins.2004.03.005; TAN HO, 2005, 2005 ABSTR VIEW IT P; Taylor AB, 2006, J NEUROSCI, V26, P1154, DOI 10.1523/JNEUROSCI.4424-05.2006; Thomas P, 2005, NAT NEUROSCI, V8, P889, DOI 10.1038/nn1483; Thompson SA, 2002, NEUROPHARMACOLOGY, V43, P662, DOI 10.1016/S0028-3908(02)00162-4; Toulme E, 2006, MOL PHARMACOL, V69, P576, DOI 10.1124/mol.105.018812; VANGUNSTEREN WF, 1996, GROMOS 96 MANUAL USE; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49; Wanamaker CP, 2003, ANN NY ACAD SCI, V998, P66, DOI 10.1196/annals.1254.009	50	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3819	3828		10.1074/jbc.M608910200	http://dx.doi.org/10.1074/jbc.M608910200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148443	hybrid			2022-12-27	WOS:000244481900045
J	Xia, DR; Srinivas, H; Ahn, YH; Sethi, G; Sheng, XY; Yung, WKA; Xia, QH; Chiao, PJ; Kim, H; Brown, PH; Wistuba, II; Aggarwal, BB; Kurie, JM				Xia, Dianren; Srinivas, Harish; Ahn, Young-Ho; Sethi, Gautam; Sheng, Xiaoyang; Yung, W. K. Alfred; Xia, Qianghua; Chiao, Paul J.; Kim, Heetae; Brown, Powel H.; Wistuba, Ignacio I.; Aggarwal, Bharat B.; Kurie, Jonathan M.			Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; TUMOR-SUPPRESSOR; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; MICE LACKING; GENE; INHIBITION; JNK; MUTATIONS; APOPTOSIS	Mitogen-activated protein kinase kinase-4 (MKK4/SEK1) cooperates with phosphatidylinositol 3-kinase to maintain the survival of non-small cell lung cancer (NSCLC) cells, but the biochemical basis of this phenomenon has not been elucidated. Here we used genetic approaches to modulate MKK4 expression in mouse embryo fibroblasts (MEF cells) and NSCLC cells to identify prosurvival signals downstream of MKK4. Relative to wild-type MEF cells, MKK4-null MEF cells were highly susceptible to apoptosis by LY294002, paclitaxel, or serum starvation. MKK4 promoted the survival of MEF cells by decreasing the expression of phosphatase and tensin homologue deleted from chromosome 10 (PTEN). MKK4 inhibited PTEN transcription by activating NF kappa B, a transcriptional suppressor of PTEN. MKK4 was required for nuclear translocation of RelA/p65 and processing of the NF kappa B2 precursor (p100) into the mature form (p52). Studies on a panel of NSCLC cell lines revealed a subset with high MKK4/high NF kappa B/low PTEN that was relatively resistant to apoptosis. Thus, MKK4 promotes cell survival by activating phosphatidylinositol 3-kinase through an NF kappa B/PTEN-dependent pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Kurie, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jkurie@mdanderson.org	Sethi, Gautam/F-2372-2011; Aggarwal, Bharat B/G-3388-2013	Sethi, Gautam/0000-0002-8677-8475; 	NCI NIH HHS [P50 CA070907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bost F, 1999, MOL CELL BIOL, V19, P1938; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Lee HY, 2003, J BIOL CHEM, V278, P23630, DOI 10.1074/jbc.M300997200; Lee HY, 2002, CLIN CANCER RES, V8, P2970; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Massion PP, 2002, CANCER RES, V62, P3636; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1999, DEVELOPMENT, V126, P505; OHSHIMA S, 1994, VIRCHOWS ARCH, V424, P129; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Sheng XY, 2002, BIOCHEM BIOPH RES CO, V292, P422, DOI 10.1006/bbrc.2002.6662; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Su Gloria H, 2002, Hum Mutat, V19, P81, DOI 10.1002/humu.9002; Tas F, 2005, MED ONCOL, V22, P353, DOI 10.1385/MO:22:4:353; Teng DHF, 1997, CANCER RES, V57, P4177; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Wang L, 2004, ONCOGENE, V23, P5978, DOI 10.1038/sj.onc.1207802; Watanabe T, 2002, DEV BIOL, V250, P332, DOI 10.1006/dbio.2002.0781; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yoshida BA, 1999, CANCER RES, V59, P5483; Zhang WZ, 2002, AM J PHYSIOL-RENAL, V283, pF904, DOI 10.1152/ajprenal.00156.2002	39	79	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3507	3519		10.1074/jbc.M610141200	http://dx.doi.org/10.1074/jbc.M610141200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158870	hybrid			2022-12-27	WOS:000244481900013
J	Grabulovski, D; Kaspar, M; Neri, D				Grabulovski, Dragan; Kaspar, Manuela; Neri, Dario			A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRA DOMAIN-B; ED-B; FIBRONECTIN ISOFORM; RECOMBINANT ANTIBODY; PHAGE-DISPLAY; SH3 DOMAINS; IDENTIFICATION; ANGIOGENESIS; EXPRESSION; DELIVERY	The generation of novel binding molecules based on protein frameworks ("scaffolds") represents an emerging field in protein engineering, with the potential to replace antibodies for many research and clinical applications. Here, we describe the design, construction, characterization, and use of a novel human Fyn SH3 phage library, containing 1.2 x 10(9) individual clone members. We also present the isolation and in vitro characterization of Fyn SH3-derived proteins binding to the extra-domain B of fibronectin, a marker of angiogenesis. One specific binding clone, named D3, was further evaluated and showed a remarkable ability to stain vascular structures in tumor sections. Furthermore, quantitative biodistribution studies in tumor-bearing mice revealed the ability of D3 to selectively accumulate in the tumor. In contrast to human scFv antibody fragments administered to mice, neither Fyn SH3 WT nor the D3 mutant was immunogenic in mice after four intravenous injections. The extra-domain B binding D3 protein opens new biomedical opportunities for the in vivo imaging of solid tumors and for the delivery of toxic agents to the tumoral vasculature.	ETH, Inst Pharmaceut Sci, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Neri, D (corresponding author), ETH, Inst Pharmaceut Sci, Dept Chem & Appl Biosci, Wolfgang Pauli Str 10,HCI G396, CH-8093 Zurich, Switzerland.	dario.neri@pharma.ethz.ch	Neri, Dario/P-4368-2016	Neri, Dario/0000-0001-5234-7370				Balza E, 2006, CLIN CANCER RES, V12, P2575, DOI 10.1158/1078-0432.CCR-05-2448; Berndorff D, 2005, CLIN CANCER RES, V11, p7053S, DOI 10.1158/1078-0432.CCR-1004-0015; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Binz HK, 2005, CURR OPIN BIOTECH, V16, P459, DOI 10.1016/j.copbio.2005.06.005; Birchler MT, 2003, LARYNGOSCOPE, V113, P1231, DOI 10.1097/00005537-200307000-00023; Borsi L, 2003, BLOOD, V102, P4384, DOI 10.1182/blood-2003-04-1039; Borsi L, 2002, INT J CANCER, V102, P75, DOI 10.1002/ijc.10662; Brack SS, 2006, CLIN CANCER RES, V12, P3200, DOI 10.1158/1078-0432.CCR-05-2804; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; Carnemolla B, 1996, INT J CANCER, V68, P397, DOI 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.3.CO;2-D; CARNEMOLLA B, 1992, J BIOL CHEM, V267, P24689; Castellani P, 2002, AM J PATHOL, V161, P1695, DOI 10.1016/S0002-9440(10)64446-X; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; COOKE M P, 1989, New Biologist, V1, P66; Dennis MS, 2002, J BIOL CHEM, V277, P35035, DOI 10.1074/jbc.M205854200; Ettorre A, 2006, PROTEOMICS, V6, P4496, DOI 10.1002/pmic.200600162; Filimonov VV, 1999, BIOPHYS CHEM, V77, P195, DOI 10.1016/S0301-4622(99)00025-3; Halin C, 2002, NAT BIOTECHNOL, V20, P264, DOI 10.1038/nbt0302-264; Harrison JL, 1996, METHOD ENZYMOL, V267, P83; HAUPTMANN S, 1995, LAB INVEST, V73, P172; Hey T, 2005, TRENDS BIOTECHNOL, V23, P514, DOI 10.1016/j.tibtech.2005.07.007; Hiipakka M, 1999, J MOL BIOL, V293, P1097, DOI 10.1006/jmbi.1999.3225; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; KACZMAREK J, 1994, INT J CANCER, V59, P11, DOI 10.1002/ijc.2910590104; Karkkainen S, 2006, EMBO REP, V7, P186, DOI 10.1038/sj.embor.7400596; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; Menrad A, 2005, EXPERT OPIN THER TAR, V9, P491, DOI 10.1517/14728222.9.3.491; Mirick GR, 2004, Q J NUCL MED MOL IM, V48, P251; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; Musacchio A, 2003, ADV PROTEIN CHEM, V61, P211; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; Nygren PA, 1997, CURR OPIN STRUC BIOL, V7, P463, DOI 10.1016/S0959-440X(97)80108-X; Panni S, 2002, J BIOL CHEM, V277, P21666, DOI 10.1074/jbc.M109788200; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Resh MD, 1998, INT J BIOCHEM CELL B, V30, P1159, DOI 10.1016/S1357-2725(98)00089-2; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; Smith G, 1998, TRENDS BIOCHEM SCI, V23, P457, DOI 10.1016/S0968-0004(98)01323-1; Tomlinson IM, 2004, NAT BIOTECHNOL, V22, P521, DOI 10.1038/nbt0504-521; Viti F, 2000, METHOD ENZYMOL, V326, P480; Vogel W, 2003, INT J MOL MED, V12, P831; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x	41	60	108	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3196	3204		10.1074/jbc.M609211200	http://dx.doi.org/10.1074/jbc.M609211200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17130124	hybrid			2022-12-27	WOS:000243793900046
J	Jang, YJ; Ji, JH; Choi, YC; Ryu, CJ; Ko, SY				Jang, Young-Joo; Ji, Jae-Hoon; Choi, Young-Chul; Ryu, Chun Jeih; Ko, Seon-Yle			Regulation of polo-like kinase 1 by DNA damage in mitosis - Inhibition of mitotic PLK-1 By protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE; OKADAIC ACID; CHECKPOINT; PHOSPHORYLATION; SPINDLE; CYTOKINESIS; CHROMOSOMES; CENTROSOMES; PROGRESSION	DNA damage triggers multiple checkpoint pathways to arrest cell cycle progression. Polo-like kinase 1 (Plk1) is an important regulator of several events during mitosis. In addition to Plk1 functions in cell cycle, Plk1 is involved in DNA damage checkpoint in G(2) phase. Normally, ataxia telangiectasia-mutated kinase (ATM) is a key enzyme involved in G(2) phase cell cycle arrest following DNA damage, and inhibition of Plk1 by DNA damage during G(2) occurs in a ATM/ATR-dependent manner. However, it is still unclear how Plk1 is regulated in response to DNA damage in mitosis in which Plk1 is already activated. Here, we show that treatment of mitotic cells with doxorubicin and gamma-irradiation inhibits Plk1 activity through dephosphorylation of Plk1, and cells were arrested in G(2) phase. Treatments of the phosphatase inhibitors and siRNA experiments suggested that PP2A pathway might be involved in regulating mitotic Plk1 activity in mitotic DNA damage. Finally, we propose a novel pathway, which is connected between ATM/ATR/Chk and protein phosphatase-Plk1 in DNA damage response in mitosis.	Dankook Univ, Sch Dent, Biochem Lab, Cheonnan Si 330714, Chungnam, South Korea; Dankook Univ, Dept Mol Biol, Seoul 140714, South Korea; Bioneer Corp, Gene2Drug Res Ctr, Taejon 306220, South Korea; Sejong Univ, Dept Biosci & Biotechnol, Seoul 143747, South Korea	Dankook University; Dankook University; Sejong University	Jang, YJ (corresponding author), Dankook Univ, Sch Dent, Biochem Lab, 29 Anseo Dong, Cheonnan Si 330714, Chungnam, South Korea.	yjjang@dku.edu						Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen ZH, 2003, MOL CANCER THER, V2, P543; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Choi YC, 1996, DNA CELL BIOL, V15, P495, DOI 10.1089/dna.1996.15.495; Chow JPH, 2003, MOL BIOL CELL, V14, P3989, DOI 10.1091/mbc.E03-03-0168; Douglas P, 2001, J BIOL CHEM, V276, P18992, DOI 10.1074/jbc.M011703200; Dozier C, 2004, BIOL CELL, V96, P509, DOI 10.1016/j.biolcel.2004.04.010; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Ghosh S, 1996, EXP CELL RES, V227, P165, DOI 10.1006/excr.1996.0262; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jang YJ, 2004, BIOCHEM BIOPH RES CO, V325, P257, DOI 10.1016/j.bbrc.2004.10.023; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; ROBERGE M, 1994, CANCER RES, V54, P6115; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Wianny F, 1998, CHROMOSOMA, V107, P430, DOI 10.1007/s004120050327; Zhao RY, 2005, CELL RES, V15, P143, DOI 10.1038/sj.cr.7290279; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	39	49	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2473	2482		10.1074/jbc.M605480200	http://dx.doi.org/10.1074/jbc.M605480200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121863	hybrid			2022-12-27	WOS:000243593200039
J	McElhinny, SAN; Stith, CM; Burgers, PMJ; Kunkel, TA				McElhinny, Stephanie A. Nick; Stith, Carrie M.; Burgers, Peter M. J.; Kunkel, Thomas A.			Inefficient proofreading and biased error rates during inaccurate DNA synthesis by a mutant derivative of Saccharomyces cerevisiae DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKAZAKI FRAGMENT MATURATION; ACTIVE-SITE; REPLICATION FIDELITY; MISMATCH REPAIR; MOTIF-A; YEAST; ALPHA; COMPLEX	DNA polymerase delta(pol delta) is a high fidelity eukaryotic enzyme that participates in DNA repair and is essential for DNA replication. Toward the goal of dissecting its multiple biological functions, here we describe the biochemical properties of Saccharomyces cerevisiae pol delta with a methionine replacing conserved leucine 612 at the polymerase active site. Compared with wild type pol delta, L612M pol delta has normal processivity and slightly higher polymerase specific activity. L612M pol delta also has normal 3' exonuclease activity, yet it is impaired in partitioning mismatches to the exonuclease active site, thereby reducing DNA synthesis fidelity. Error rates in vitro for L612M pol delta are elevated for both base substitutions and single base deletions but in a highly biased manner. For each of the six possible pairs of reciprocal mismatches that could arise during replication of complementary DNA strands to account for any particular base substitution in vivo (e.g. T-dGMP or A-dCMP for T to C transitions), L612M pol delta error rates are substantially higher for one mismatch than the other. These results provide a biochemical explanation for our observation, which confirms earlier genetic studies, that a haploid pol3-L612M S. cerevisiae strain has an elevated spontaneous mutation rate that is likely due to reduced replication fidelity in vivo.	NIEHS, Mol Genet Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Washington University (WUSTL)	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Burgers, Peter M/AAW-6621-2021; Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [R01 GM032431, GM32431] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albertson TM, 2006, CURR BIOL, V16, pR209, DOI 10.1016/j.cub.2006.02.031; Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bebenek K, 2004, ADV PROTEIN CHEM, V69, P137; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Beechem JM, 1998, BIOCHEMISTRY-US, V37, P10144, DOI 10.1021/bi980074b; da Silva EF, 2002, J BIOL CHEM, V277, P40640, DOI 10.1074/jbc.M203315200; Fortune JM, 2005, J BIOL CHEM, V280, P29980, DOI 10.1074/jbc.M505236200; Fortune JM, 2006, NUCLEIC ACIDS RES, V34, P4335, DOI 10.1093/nar/gkl403; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Garcia-Diaz M, 2006, TRENDS BIOCHEM SCI, V31, P206, DOI 10.1016/j.tibs.2006.02.004; Garg P, 2005, CRIT REV BIOCHEM MOL, V40, P115, DOI 10.1080/10409230590935433; Goldsby RE, 2002, P NATL ACAD SCI USA, V99, P15560, DOI 10.1073/pnas.232340999; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Jin YH, 2003, J BIOL CHEM, V278, P1626, DOI 10.1074/jbc.M209803200; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Li L, 2005, GENETICS, V170, P569, DOI 10.1534/genetics.104.040295; McElhinny SAN, 2006, CELL CYCLE, V5, P958, DOI 10.4161/cc.5.9.2736; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; Minnick DT, 2002, P NATL ACAD SCI USA, V99, P1194, DOI 10.1073/pnas.032457899; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niimi A, 2004, MOL CELL BIOL, V24, P2734, DOI 10.1128/MCB.24.7.2734-2746.2004; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Pavlov YI, 2001, GENETICS, V159, P47; Pavlov YI, 2006, CURR BIOL, V16, P202, DOI 10.1016/j.cub.2005.12.002; Pavlov YI, 2003, CURR BIOL, V13, P744, DOI 10.1016/S0960-9822(03)00284-7; Pavlov YI, 2002, MOL CELL, V10, P207, DOI 10.1016/S1097-2765(02)00567-1; REHAKRANTZ LJ, 1994, J BIOL CHEM, V269, P5635; Shcherbakova PV, 2003, J BIOL CHEM, V278, P43770, DOI 10.1074/jbc.M306893200; TRAN HT, 1995, MOL CELL BIOL, V15, P5607; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; Venkatesan RN, 2006, J BIOL CHEM, V281, P4486, DOI 10.1074/jbc.M510245200; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Zhong XJ, 2006, NUCLEIC ACIDS RES, V34, P4731, DOI 10.1093/nar/gkl465	37	66	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2324	2332		10.1074/jbc.M609591200	http://dx.doi.org/10.1074/jbc.M609591200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121822	Green Accepted, hybrid			2022-12-27	WOS:000243593200024
J	Sunyach, C; Cisse, MA; da Costa, CA; Checler, F				Sunyach, Claire; Cisse, Moustapha Alfa; da Costa, Cristine Alves; Checler, Frederic			The C-terminal products of cellular prion protein processing, C1 and C2, exert distinct influence on p53-dependent staurosporine-induced caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEK293 HUMAN-CELLS; N-TERMINUS; WILD-TYPE; CLEAVAGE; NEURONS; RECEPTOR; PRP; P53; OVEREXPRESSION; EXPRESSION	The cellular prion protein ( PrPc) undergoes various endoproteolytic attacks within its N-terminal domain, leading to the production of C-terminal fragments ( C) tethered to the plasma membrane and soluble N-terminal peptides ( N). One of these cleavages occurs at position 110/111, thereby generating C1 and N1 products. We have reported that disintegrins ADAM-10, -9, and -17 participate either directly or indirectly to this proteolytic event. An alternative proteolytic event taking place around residue 90 yields C2 and N2 fragments. The putative function of these proteolytic fragments remained to be established. We have set up two novel human embryonic kidney 293 cell lines stably overexpressing either C1 or C2. Weshow that C1 potentiates staurosporine-induced caspase-3 activation through a p53-dependent mechanism. Thus, C1 positively controls p53 transcription and mRNA levels and increases p53-like immunoreactivity and activity. C1-induced caspase-3 activation remained unaffected by the blockade of endocytosis in HEK 293 cells and was abolished in p53-deficient fibroblasts. Conversely, overexpression of the C2 fragment did not significantly sensitize HEK 293 cells to apoptotic stimuli and did not modify p53 mRNA levels or activity. Therefore, the nature of the proteolytic cleavage taking place on PrPc yielded C-terminal catabolites with distinct function and could be seen as a switch mechanism controlling the function of the PrPc in cell survival.	Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, CNRS, UMR6097,Equipe Labellisee,Fdn Rech Med, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Checler, F (corresponding author), Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, CNRS, UMR6097,Equipe Labellisee,Fdn Rech Med, 660 Route Lucioles, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr	CISSE, Moustapha/AAM-1022-2021; da Costa, Cristine Alves/G-8075-2011; Checler, Frederic/C-1241-2009	da Costa, Cristine Alves/0000-0002-7777-005X; Checler, Frederic/0000-0003-2098-1750; Vincent, Bruno/0000-0003-3876-2118; CISSE, Moustapha/0000-0003-3890-9183				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Brown DR, 2002, J NEUROCHEM, V82, P209, DOI 10.1046/j.1471-4159.2002.01004.x; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Cisse MA, 2005, J BIOL CHEM, V280, P40624, DOI 10.1074/jbc.M506069200; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; Diarra-Mehrpour M, 2004, CANCER RES, V64, P719, DOI 10.1158/0008-5472.CAN-03-1735; Du JP, 2005, INT J CANCER, V113, P213, DOI 10.1002/ijc.20570; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; GINSBERG D, 1990, ONCOGENE, V5, P1285; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; Jimenez-Huete A, 1998, AM J PATHOL, V153, P1561, DOI 10.1016/S0002-9440(10)65744-6; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kanaani J, 2005, J NEUROCHEM, V95, P1373, DOI 10.1111/j.1471-4159.2005.03469.x; Laffont-Proust I, 2005, FEBS LETT, V579, P6333, DOI 10.1016/j.febslet.2005.10.013; Li AM, 2005, J BIOL CHEM, V280, P17430, DOI 10.1074/jbc.C500058200; Mange A, 2002, FEBS LETT, V514, P159, DOI 10.1016/S0014-5793(02)02338-4; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Nunziante M, 2003, J BIOL CHEM, V278, P3726, DOI 10.1074/jbc.M206313200; Paitel E, 2004, J BIOL CHEM, V279, P612, DOI 10.1074/jbc.M310453200; Paitel E, 2003, J BIOL CHEM, V278, P10061, DOI 10.1074/jbc.M211580200; Paitel E, 2002, J NEUROCHEM, V83, P1208, DOI 10.1046/j.1471-4159.2002.01234.x; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Roucou X, 2005, CELL DEATH DIFFER, V12, P783, DOI 10.1038/sj.cdd.4401629; Roucou X, 2005, J MOL MED, V83, P3, DOI 10.1007/s00109-004-0605-5; Roucou X, 2004, J NEUROSCI RES, V75, P153, DOI 10.1002/jnr.10864; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Santuccione A, 2005, J CELL BIOL, V169, P341, DOI 10.1083/jcb.200409127; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344; Sunyach C, 2005, J NEUROCHEM, V92, P1399, DOI 10.1111/j.1471-4159.2004.02989.x; Taylor DR, 2005, J CELL SCI, V118, P5141, DOI 10.1242/jcs.02627; Vincent B, 2000, J BIOL CHEM, V275, P35612, DOI 10.1074/jbc.M004628200; Vincent B, 2001, J BIOL CHEM, V276, P37743; Weissmann C, 2005, CELL, V122, P165, DOI 10.1016/j.cell.2005.07.001	39	66	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1956	1963		10.1074/jbc.M609663200	http://dx.doi.org/10.1074/jbc.M609663200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121821	hybrid			2022-12-27	WOS:000243451300046
J	Milenkovic, VM; Rivera, A; Horling, F; Weber, BHF				Milenkovic, Vladimir M.; Rivera, Andrea; Horling, Franziska; Weber, Bernhard H. F.			Insertion and topology of normal and mutant bestrophin-1 in the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITELLIFORM MACULAR DYSTROPHY; CHLORIDE CHANNELS; SIGNAL SEQUENCE; RETINAL DEGENERATION; INTERNAL SIGNAL; BEST-DISEASE; PROTEIN; FAMILY; GENE; VMD2	The vitelliform macular dystrophy type 2 (VMD2) gene mutated in Best macular dystrophy encodes a 585-amino acid putative transmembrane protein termed bestrophin-1. The vast majority of known disease-associated alterations are of the missense type, which cluster near predicted transmembrane domains (TMDs). To investigate bestrophin-1 membrane topology and to assess consequences of point mutations on membrane integration, we have analyzed the insertion of putative TMDs into the endoplasmic reticulum (ER) membrane. Out of six potential TMDs, our data suggest a topological model of bestrophin-1 with four transmembrane-spanning segments and one large cytoplasmatic loop between putative TMD2 and TMD5. Consequently, a relatively hydrophobic segment containing putative TMD3 (aa 130-149) and TMD4 (aa 179-201) is located within the cytoplasm. Furthermore, we show that three out of 18 disease-associated alterations investigated (I73N, Y85H, F281del) reveal measurable effects on membrane insertion suggesting that defective membrane integration of bestrophin-1 may represent a potential disease mechanism for a small subset of Best macular dystrophy-related mutations.	Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany; Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany	University of Regensburg; University of Regensburg	Weber, BHF (corresponding author), Univ Regensburg, Inst Human Genet, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	bweb@klinik.uni-regensburg.de		Weber, Bernhard H.F./0000-0002-8808-7723				Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986; Arden G B, 1962, Br J Ophthalmol, V46, P449, DOI 10.1136/bjo.46.8.449; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fischmeister R, 2005, J PHYSIOL-LONDON, V562, P477, DOI 10.1113/jphysiol.2004.075622; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; Hartzell C, 2005, PHYSIOLOGY, V20, P292, DOI 10.1152/physiol.00021.2005; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Kramer F, 2004, CYTOGENET GENOME RES, V105, P107, DOI 10.1159/000078016; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LINGAPPA VR, 1979, NATURE, V281, P117, DOI 10.1038/281117a0; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097; Marmorstein AD, 2004, INVEST OPHTH VIS SCI, V45, P3733, DOI 10.1167/iovs.04-0307; Marmorstein LY, 2006, J GEN PHYSIOL, V127, P577, DOI 10.1085/jgp.200509473; Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517; Monne M, 2005, FEBS J, V272, P28, DOI 10.1111/j.1432-1033.2004.04394.x; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Partridge AW, 2004, PROTEINS, V54, P648, DOI 10.1002/prot.10611; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Qu ZQ, 2006, J NEUROSCI, V26, P5411, DOI 10.1523/JNEUROSCI.5500-05.2006; Qu ZQ, 2004, J GEN PHYSIOL, V124, P371, DOI 10.1085/jgp.200409108; Qu ZQ, 2003, J BIOL CHEM, V278, P49563, DOI 10.1074/jbc.M308414200; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schneider D, 2002, FEBS LETT, V532, P231, DOI 10.1016/S0014-5793(02)03687-6; Stohr H, 2002, EUR J HUM GENET, V10, P281, DOI 10.1038/sj.ejhg.5200796; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Tsunenari T, 2003, J BIOL CHEM, V278, P41114, DOI 10.1074/jbc.M306150200; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; White K, 2000, HUM MUTAT, V15, P301, DOI 10.1002/(SICI)1098-1004(200004)15:4<301::AID-HUMU1>3.0.CO;2-N; Yardley J, 2004, INVEST OPHTH VIS SCI, V45, P3683, DOI 10.1167/iovs.04-0550	41	65	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1313	1321		10.1074/jbc.M607383200	http://dx.doi.org/10.1074/jbc.M607383200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17110374	hybrid			2022-12-27	WOS:000243295200057
J	Priller, C; Dewachter, I; Vassallo, N; Paluch, S; Pace, C; Kretzschmar, HA; Van Leuven, F; Herms, J				Priller, Christina; Dewachter, Ilse; Vassallo, Neville; Paluch, Sandra; Pace, Claudia; Kretzschmar, Hans A.; Van Leuven, Fred; Herms, Jochen			Mutant presenilin 1 alters synaptic transmission in cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; LONG-TERM POTENTIATION; FAMILIAL ALZHEIMERS-DISEASE; TRANSGENIC MICE; GAMMA-SECRETASE; APP; BETA; PLASTICITY; SYNAPSES; RELEASE	Mutations in presenilins are the major cause of familial Alzheimer disease, but the precise pathogenic mechanism by which presenilin (PS) mutations cause synaptic dysfunction leading to memory loss and neurodegeneration remains unclear. Using autaptic hippocampal cultures from transgenic mice expressing human PS1 with the A246E mutation, we demonstrate that mutant PS1 significantly depressed the amplitude of evoked alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and N-methyl-D-aspartate receptor-mediated synaptic currents. Analysis of the spontaneous miniature synaptic activity revealed a lower frequency of miniature currents but normal miniature amplitude. Both alterations could be rescued by the application of a gamma-secretase blocker. On the other hand, the application of synthetic soluble A beta(42) in wild-type neurons induced the PS1 mutant phenotype on synaptic strength. Together, these findings strongly suggest that the expression of mutant PS1 in cultured neurons depresses synaptic transmission by causing a physical reduction in the number of synapses. This hypothesis is consistent with morphometic and semiquantitative immunohistochemical analysis, revealing a decrease in synaptophysin-positive puncta in PS1 mutant hippocampal neurons.	Univ Munich, Dept Neuropathol, D-81377 Munich, Germany; Expt Genet Grp, B-3000 Louvain, Belgium; Univ Malta, Dept Physiol & Biochem, Msida, Malta	University of Munich; University of Malta	Herms, J (corresponding author), Univ Munich, Dept Neuropathol, Feodor Lynen Str 23, D-81377 Munich, Germany.	jochen.herms@med.uni-muenchen.de	Dewachter, Ilse/AAZ-5661-2020; Herms, Jochen/D-3518-2011	Dewachter, Ilse/0000-0001-7202-515X; Vassallo, Neville/0000-0002-8985-5587				Almeida CG, 2005, NEUROBIOL DIS, V20, P187, DOI 10.1016/j.nbd.2005.02.008; Barrow PA, 2000, NEUROBIOL DIS, V7, P119, DOI 10.1006/nbdi.1999.0276; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Braak E, 1997, ACTA NEUROPATHOL, V93, P323, DOI 10.1007/s004010050622; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chang EH, 2006, P NATL ACAD SCI USA, V103, P3410, DOI 10.1073/pnas.0507313103; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Cohen-Cory S, 2002, SCIENCE, V298, P770, DOI 10.1126/science.1075510; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dewachter I, 2000, J NEUROSCI, V20, P6452, DOI 10.1523/JNEUROSCI.20-17-06452.2000; Fitzjohn SM, 2001, J NEUROSCI, V21, P4691, DOI 10.1523/JNEUROSCI.21-13-04691.2001; Gong B, 2004, J CLIN INVEST, V114, P1624, DOI 10.1172/JCI200422831; Gureviciene I, 2004, NEUROBIOL DIS, V15, P188, DOI 10.1016/j.nbd.2003.11.011; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Herms J, 2003, J BIOL CHEM, V278, P2484, DOI 10.1074/jbc.M206769200; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Huang SM, 2006, J BIOL CHEM, V281, P17941, DOI 10.1074/jbc.M601372200; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Krebs B, 2006, J HISTOCHEM CYTOCHEM, V54, P559, DOI 10.1369/jhc.5A6818.2006; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Larson J, 1999, BRAIN RES, V840, P23, DOI 10.1016/S0006-8993(99)01698-4; Leissring MA, 1999, J NEUROCHEM, V72, P1061, DOI 10.1046/j.1471-4159.1999.0721061.x; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Marjaux E, 2004, NEURON, V42, P189, DOI 10.1016/S0896-6273(04)00218-1; MASLIAH E, 1990, AM J PATHOL, V137, P1293; MASLIAH E, 1990, J HISTOCHEM CYTOCHEM, V38, P837, DOI 10.1177/38.6.2110586; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Murayama O, 1999, NEUROSCI LETT, V265, P61, DOI 10.1016/S0304-3940(99)00187-1; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; Parent A, 1999, NEUROBIOL DIS, V6, P56, DOI 10.1006/nbdi.1998.0207; Parent AT, 2005, J NEUROSCI, V25, P1540, DOI 10.1523/JNEUROSCI.3850-04.2005; Priller C, 2006, J NEUROSCI, V26, P7212, DOI 10.1523/JNEUROSCI.1450-06.2006; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Roder S, 2003, NEUROSCIENCE, V120, P705, DOI 10.1016/S0306-4522(03)00381-6; Roselli F, 2005, J NEUROSCI, V25, P11061, DOI 10.1523/JNEUROSCI.3034-05.2005; ROSENMUND C, 1995, J NEUROPHYSIOL, V73, P427, DOI 10.1152/jn.1995.73.1.427; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Schneggenburger R, 1999, NEURON, V23, P399, DOI 10.1016/S0896-6273(00)80789-8; Schneider I, 2001, J BIOL CHEM, V276, P11539, DOI 10.1074/jbc.M010977200; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Trinchese F, 2004, ANN NEUROL, V55, P801, DOI 10.1002/ana.20101; Vetrivel KS, 2005, J BIOL CHEM, V280, P25892, DOI 10.1074/jbc.M503570200; Zaman SH, 2000, NEUROBIOL DIS, V7, P54, DOI 10.1006/nbdi.1999.0271	49	31	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1119	1127		10.1074/jbc.M605066200	http://dx.doi.org/10.1074/jbc.M605066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17088253	hybrid			2022-12-27	WOS:000243295200036
J	Ruiz-Gomez, A; Mellstrom, B; Tornero, D; Morato, E; Savignac, M; Holguin, H; Aurrekoetxea, K; Gonzalez, P; Gonzalez-Garcia, C; Cena, V; Mayor, F; Naranjo, JR				Ruiz-Gomez, Ana; Mellstrom, Britt; Tornero, Daniel; Morato, Esperanza; Savignac, Magali; Holguin, Helena; Aurrekoetxea, Koldo; Gonzalez, Paz; Gonzalez-Garcia, Carmen; Cena, Valenti; Mayor, Federico, Jr.; Naranjo, Jose R.			G protein-coupled receptor kinase 2-mediated phosphorylation of downstream regulatory element antagonist modulator regulates membrane trafficking of Kv4.2 potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR KINASE; CALCIUM-BINDING PROTEIN; DENDRITIC K+ CHANNELS; EXPRESSION; TRANSIENT; NEURONS; DREAM; BETA; GENE; PKA	Downstream regulatory element antagonist modulator (DREAM)/ potassium channel interacting protein (KChIP3) is a multifunctional protein of the neuronal calcium sensor subfamily of Ca2+-binding proteins with specific roles in different cell compartments. In the nucleus, DREAM acts as a Ca2+-dependent transcriptional repressor, and outside the nucleus DREAM interacts with Kv4 potassium channels, regulating their trafficking to the cell membrane and their gating properties. In this study we characterized the interaction of DREAM with GRK6 and GRK2, members of the G protein-coupled receptor kinase family of proteins, and their phosphorylation of DREAM. Ser-95 was identified as the site phosphorylated by GRK2. This phosphorylation did not modify the repressor activity of DREAM. Mutation of Ser-95 to aspartic acid, however, blocked DREAM-mediated membrane expression of the Kv4.2 potassium channel without affecting channel tetramerization. Treatment with the calcineurin inhibitors FK506 and cyclosporin A also blocked DREAM-mediated Kv4.2 channel trafficking and calcineurin de-phosphorylated GRK2-phosphorylated DREAM in vitro. Our results indicate that these two Ca2+-dependent posttranslational events regulate the activity of DREAM on Kv4.2 channel function.	CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Univ Autonoma Madrid, CSIC, Dept Biol Mol, E-28049 Madrid, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Castilla La Mancha, Unidad Asociada Neurodeath, CSIC, Albacete 02006, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Castilla-La Mancha	Naranjo, JR (corresponding author), CSIC, Ctr Nacl Biotecnol, C Darwin 3, E-28049 Madrid, Spain.	naranjo@cnb.uam.es	Cena, Valentin/L-1751-2017; Tornero, Daniel/N-2049-2014; Mayor, Federico/N-7644-2016; Ruiz-Gómez, Ana/H-2092-2015; NARANJO, Jose R/K-1950-2014; Ruiz-Gomez, Ana/ABF-3079-2021; Savignac, Magali/K-1757-2014	Cena, Valentin/0000-0001-8928-3681; Tornero, Daniel/0000-0002-4812-4091; Ruiz-Gómez, Ana/0000-0002-1646-3072; NARANJO, Jose R/0000-0002-0270-3469; Mayor Menendez, Federico/0000-0003-1434-8449; Morato Lopez, Esperanza/0000-0003-4768-895X				Adams JP, 2000, J NEUROCHEM, V75, P2277, DOI 10.1046/j.1471-4159.2000.0752277.x; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; Boekhoff I, 1997, EUR J CELL BIOL, V72, P151; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Cant SH, 2005, MOL BIOL CELL, V16, P3088, DOI 10.1091/mbc.E04-10-0877; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Freedman NJ, 2002, J BIOL CHEM, V277, P48261, DOI 10.1074/jbc.M204431200; Freeman JLR, 2002, BIOCHEMISTRY-US, V41, P12850, DOI 10.1021/bi020145d; Frick A, 2004, NAT NEUROSCI, V7, P126, DOI 10.1038/nn1178; Guo WN, 2002, CIRC RES, V90, P586, DOI 10.1161/01.RES.0000012664.05949.E0; Guo WN, 1999, J PHYSIOL-LONDON, V521, P587, DOI 10.1111/j.1469-7793.1999.00587.x; Hasdemir B, 2005, J CELL BIOL, V171, P459, DOI 10.1083/jcb.200506005; Hoffman DA, 1999, J NEUROPHYSIOL, V81, P408, DOI 10.1152/jn.1999.81.1.408; Hoffman DA, 1998, J NEUROSCI, V18, P3521; Hu HJ, 2003, J NEUROPHYSIOL, V90, P1671, DOI 10.1152/jn.00340.2003; Iacovelli L, 1999, FASEB J, V13, P1; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; Johnson LR, 2004, MOL CELL BIOL, V24, P10169, DOI 10.1128/MCB.24.23.10169-10179.2004; Kabbani N, 2002, J NEUROSCI, V22, P8476; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; Kunjilwar K, 2004, J BIOL CHEM, V279, P54542, DOI 10.1074/jbc.M409721200; Ledo F, 2002, EMBO J, V21, P4583, DOI 10.1093/emboj/cdf440; Ledo F, 2000, MOL CELL BIOL, V20, P9120, DOI 10.1128/MCB.20.24.9120-9126.2000; Levay K, 1998, BIOCHEMISTRY-US, V37, P13650, DOI 10.1021/bi980998z; Lilliehook C, 2002, MOL CELL NEUROSCI, V19, P552, DOI 10.1006/mcne.2001.1096; Link WA, 2004, J NEUROSCI, V24, P5346, DOI 10.1523/JNEUROSCI.1460-04.2004; Malin SA, 2000, J NEUROSCI, V20, P5191, DOI 10.1523/JNEUROSCI.20-14-05191.2000; Mellstrom B, 2002, MOL CELL NEUROSCI, V19, P417, DOI 10.1006/mcne.2001.1092; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; Penela P, 2006, CARDIOVASC RES, V69, P46, DOI 10.1016/j.cardiores.2005.09.011; Penela P, 2003, CELL SIGNAL, V15, P973, DOI 10.1016/S0898-6568(03)00099-8; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pronin AN, 1998, J BIOL CHEM, V273, P31510, DOI 10.1074/jbc.273.47.31510; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Rivas M, 2004, J BIOL CHEM, V279, P33114, DOI 10.1074/jbc.M403526200; Ruiz-Gomez A, 2000, J BIOL CHEM, V275, P29724, DOI 10.1074/jbc.M001864200; Sallese M, 2000, BBA-MOL CELL RES, V1498, P112, DOI 10.1016/S0167-4889(00)00088-4; Sanz C, 2001, EMBO J, V20, P2286, DOI 10.1093/emboj/20.9.2286; Schrader LA, 2006, AM J PHYSIOL-CELL PH, V290, pC852, DOI 10.1152/ajpcell.00358.2005; Schrader LA, 2002, J NEUROSCI, V22, P10123; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Song WJ, 1998, J NEUROSCI, V18, P3124; Strang C, 2003, J BIOL CHEM, V278, P31361, DOI 10.1074/jbc.M304268200; Takimoto K, 2002, J BIOL CHEM, V277, P26904, DOI 10.1074/jbc.M203651200; Tkatch T, 2000, J NEUROSCI, V20, P579, DOI 10.1523/JNEUROSCI.20-02-00579.2000; Watanabe S, 2002, P NATL ACAD SCI USA, V99, P8366, DOI 10.1073/pnas.122210599; Willets JM, 2003, TRENDS PHARMACOL SCI, V24, P626, DOI 10.1016/j.tips.2003.10.003; Yoshida N, 2003, EUR J BIOCHEM, V270, P1154, DOI 10.1046/j.1432-1033.2003.03465.x; Yuan LL, 2002, J NEUROSCI, V22, P4860, DOI 10.1523/JNEUROSCI.22-12-04860.2002	56	47	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1205	1215		10.1074/jbc.M607166200	http://dx.doi.org/10.1074/jbc.M607166200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17102134	hybrid			2022-12-27	WOS:000243295200046
J	Pan, YP; Nussinov, R				Pan, Yongping; Nussinov, Ruth			Structural basis for p53 binding-induced DNA bending	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; CORE DOMAIN; COOPERATIVE BINDING; CRYSTAL-STRUCTURE; RESPONSE ELEMENT; CONSENSUS DNA; RECOGNITION; SITE; COMPLEX; TETRAMERIZATION	Specific p53 binding-induced DNA bending has important biological implications such as transcription activation. However, the detailed structures of the bent DNA and the p53-DNA complex are still unavailable, hampering our understanding of the mechanism for p53-induced DNA bending and its consequent biological significance. To gain insight into the p53 binding-induced DNA bending, we performed molecular dynamics simulations on DNA segments with the consensus sequence for p53-specific binding, half site DNA-p53 complexes, and full site DNA-p53 complexes. We show that each DNA-bound p53 core domain caused a local DNA conformational change within the quarter site; upon the binding of the p53 dimer, there was an apparent DNA bending at the center of the half site; when bound with two p53 dimers, the full site DNAs with two different sequences bent 20 and 35 degrees, respectively. These results are in agreement with experimental observations. Our simulations demonstrate that the two p53 dimers favored a staggered conformation in which they make favorable interactions at the interface. This dimer-dimer interface organization necessitated conformational changes in the DNA, leading to the bending at the center of the full site, which in turn is dependent on the DNA sequence. Overall, our results provide the detailed atomic model for the DNA-p53 tetramer complex and delineate the roles of DNA-p53, p53 dimer-dimer interactions, and DNA sequence in specific p53 binding-induced DNA conformational changes.	NCI, SAIC Frederick Inc, Ctr Canc Res Nanobiol Program, NIH, Frederick, MD 21702 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Tel Aviv University; Sackler Faculty of Medicine	Nussinov, R (corresponding author), Bldg 469,Rm 151, Frederick, MD 21702 USA.	ruthn@ncifcrf.gov		Nussinov, Ruth/0000-0002-8115-6415	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010441] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Balagurumoorthy P, 2002, BIOPHYS CHEM, V101, P611, DOI 10.1016/S0301-4622(02)00169-2; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Ceskova P, 2006, J MOL BIOL, V357, P442, DOI 10.1016/j.jmb.2005.12.026; Cherny DI, 1999, J MOL BIOL, V294, P1015, DOI 10.1006/jmbi.1999.3299; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Dehner A, 2005, ANGEW CHEM INT EDIT, V44, P5247, DOI 10.1002/anie.200501887; DURELL SR, 1998, P 10 CONV ALB JUN 17, P277; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Ho WC, 2006, J BIOL CHEM, V281, P20494, DOI 10.1074/jbc.M603634200; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KASTAN MB, 1991, CANCER RES, V51, P6304; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Lebrun A, 2001, PROTEIN ENG, V14, P233, DOI 10.1093/protein/14.4.233; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ma BY, 2005, P NATL ACAD SCI USA, V102, P3988, DOI 10.1073/pnas.0500215102; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; NADEAU JG, 1989, P NATL ACAD SCI USA, V86, P2622, DOI 10.1073/pnas.86.8.2622; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Rippin TM, 2002, J MOL BIOL, V319, P351, DOI 10.1016/S0022-2836(02)00326-1; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; Sun XZ, 2003, ANTIOXID REDOX SIGN, V5, P655, DOI 10.1089/152308603770310338; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071	39	29	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					691	699		10.1074/jbc.M605908200	http://dx.doi.org/10.1074/jbc.M605908200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17085447	hybrid			2022-12-27	WOS:000243166500074
J	Yao, D; Kieselbach, T; Komenda, J; Promnares, K; Prieto, MAH; Tichy, M; Vermaas, W; Funk, C				Yao, Danny; Kieselbach, Thomas; Komenda, Josef; Promnares, Kamoltip; Prieto, Miguel A. Hernandez; Tichy, Martin; Vermaas, Wim; Funk, Christiane			Localization of the small CAB-like proteins in photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; ASSISTED-LASER-DESORPTION/IONIZATION; LIGHT-INDUCIBLE POLYPEPTIDES; THYLAKOID MEMBRANES; HARVESTING COMPLEX; SEQUENCE DATABASES; CRYSTAL-STRUCTURE; STRESS PROTEINS; GENE FAMILY; BINDING	The cyanobacterial small CAB-like proteins (SCPs) consist of one-helix proteins that resemble transmembrane regions of the light-harvesting proteins of plants. To determine whether these proteins are associated with protein complexes in the thylakoid membrane, an abundant member of the SCP family, ScpD, was marked with a His tag, and proteins co-isolating with His-tagged ScpD were identified. These proteins included the major Photosystem (PS) II components as well as FtsH, which is involved in degradation of the PSII complex. To ascertain specific interaction between ScpD and the PSII complex, the His-tagged protein fraction was subjected to two-dimensional blue native/SDS-PAGE. Again, PSII components were co-isolated with ScpD-His, and ScpD-His was found to interact most strongly with CP47. ScpD association was most prominent with the monomeric form of PSII, suggesting ScpD association with PSII that is repaired. Using antibodies that recognize both ScpC and ScpD, we found the ScpC protein, which is very similar in primary structure to ScpD, to also co-isolate with the PSII complex. In contrast, ScpE did not co-isolate with a major protein complex in thylakoids. A fourth member of the SCP family, ScpB, could not be immunodetected, but was found by mass spectrometry in samples co-isolating with ScpD-His. Therefore, ScpB may be associated with ScpD as well. No association between SCPs and PSI could be demonstrated. On the basis of these and other data presented, we suggest that members of the SCP family can associate with damaged PSII and can serve as a temporary pigment reservoir while PSII components are being replaced.	Umea Univ, Dept Biochem, SE-90187 Umea, Sweden; Umea Univ, Umea Plant Sci Ctr, SE-90187 Umea, Sweden; Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynth, Tempe, AZ 85287 USA; Univ S Bohemia, Inst Phys Biol, Nove Hrady 37333, Czech Republic; Acad Sci, Inst Microbiol, Lab Photosynth, Trebon 37981, Czech Republic	Umea University; Umea University; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; University of South Bohemia Ceske Budejovice; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Funk, C (corresponding author), Umea Univ, Dept Biochem, SE-90187 Umea, Sweden.	Christiane.Funk@chem.umu.se	Funk, Christiane/AAO-6041-2021; Kieselbach, Thomas/O-6023-2015; Hernandez-Prieto, Miguel/AAU-3837-2020; Komenda, Josef/H-4083-2014; Promnares, Kamoltip/S-6106-2019; Tichy, Martin/B-6545-2008	Funk, Christiane/0000-0002-7897-4038; Kieselbach, Thomas/0000-0001-5577-2938; Komenda, Josef/0000-0003-4588-0382; Tichy, Martin/0000-0003-2814-1959; Hernandez-Prieto, Miguel Angel/0000-0001-7950-1526				Adamska I, 2001, ADV PHOTOSYNTH, V11, P487; Adamska I, 1999, EUR J BIOCHEM, V260, P453, DOI 10.1046/j.1432-1327.1999.00178.x; Aro EM, 2005, J EXP BOT, V56, P347, DOI 10.1093/jxb/eri041; Bhaya D, 2002, FEMS MICROBIOL LETT, V215, P209, DOI 10.1111/j.1574-6968.2002.tb11393.x; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1357, DOI 10.1002/elps.11501401209; Bricker TM, 1998, BBA-BIOENERGETICS, V1409, P50, DOI 10.1016/S0005-2728(98)00148-0; Demmig-Adams B., 2005, PHOTOPROTECTION PHOT, P145; Durnford DG, 1999, J MOL EVOL, V48, P59, DOI 10.1007/PL00006445; ErmakovaGerdes S, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL I, P483; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; FUNK C, 1994, FEBS LETT, V342, P261, DOI 10.1016/0014-5793(94)80513-X; Funk C, 1999, BIOCHEMISTRY-US, V38, P9397, DOI 10.1021/bi990545+; Funk C, 2001, ADV PHOTOSYNTH, V11, P453; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; HAO LM, 2001, P 12 INT C PHOT, pS31; Havaux M, 2003, BBA-BIOENERGETICS, V1557, P21, DOI 10.1016/S0005-2728(02)00391-2; He QF, 2001, J BIOL CHEM, V276, P306, DOI 10.1074/jbc.M008686200; Heddad M, 2000, P NATL ACAD SCI USA, V97, P3741, DOI 10.1073/pnas.050391397; Heddad M, 2002, COMP FUNCT GENOM, V3, P504, DOI 10.1002/cfg.221; Ikeuchi M, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P297; Jansson S, 2000, PLANT MOL BIOL, V42, P345, DOI 10.1023/A:1006365213954; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; Kern J, 2005, PHOTOSYNTH RES, V84, P153, DOI 10.1007/s11120-004-7077-x; Klimmek F, 2006, PLANT PHYSIOL, V140, P793, DOI 10.1104/pp.105.073304; Komenda J, 2004, J BIOL CHEM, V279, P48620, DOI 10.1074/jbc.M405725200; Komenda J, 2002, EUR J BIOCHEM, V269, P610, DOI 10.1046/j.0014-2956.2001.02693.x; Kouril R, 2005, FEBS LETT, V579, P3253, DOI 10.1016/j.febslet.2005.03.051; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Kussmann M, 1997, J MASS SPECTROM, V32, P593; Lagarde D, 2000, APPL ENVIRON MICROB, V66, P64, DOI 10.1128/AEM.66.1.64-72.2000; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Lindell D, 2004, P NATL ACAD SCI USA, V101, P11013, DOI 10.1073/pnas.0401526101; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mikami K, 2002, MOL MICROBIOL, V46, P905, DOI 10.1046/j.1365-2958.2002.03202.x; Mullineaux CW, 2005, J EXP BOT, V56, P389, DOI 10.1093/jxb/eri064; Nixon PJ, 2005, J EXP BOT, V56, P357, DOI 10.1093/jxb/eri021; Norling B, 1998, FEBS LETT, V436, P189, DOI 10.1016/S0014-5793(98)01123-5; Ohta N, 2003, DNA RES, V10, P67, DOI 10.1093/dnares/10.2.67; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Rakhimberdieva MG, 2004, FEBS LETT, V574, P85, DOI 10.1016/j.febslet.2004.07.087; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; RIED JL, 1987, GENE, V57, P239, DOI 10.1016/0378-1119(87)90127-2; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sobotka R, 2005, J BIOL CHEM, V280, P31595, DOI 10.1074/jbc.M505976200; Standfuss R, 2005, EMBO J, V24, P919, DOI 10.1038/sj.emboj.7600585; Sullivan MB, 2005, PLOS BIOL, V3, P790, DOI 10.1371/journal.pbio.0030144; Teramoto H, 2004, PLANT CELL PHYSIOL, V45, P1221, DOI 10.1093/pcp/pch157; Thidholm E, 2002, FEBS LETT, V513, P217, DOI 10.1016/S0014-5793(02)02314-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vavilin D, 2005, BBA-BIOENERGETICS, V1708, P91, DOI 10.1016/j.bbabio.2004.12.011; VERMAAS WFJ, 1990, CURRENT RES PHOTOSYN, V1, P231; Wilson A, 2006, PLANT CELL, V18, P992, DOI 10.1105/tpc.105.040121; Xu H, 2004, J BIOL CHEM, V279, P27971, DOI 10.1074/jbc.M403307200; Xu H, 2002, PLANT MOL BIOL, V49, P149, DOI 10.1023/A:1014900806905; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	62	78	80	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					267	276		10.1074/jbc.M605463200	http://dx.doi.org/10.1074/jbc.M605463200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17105726	hybrid			2022-12-27	WOS:000243166500031
J	Pierrot, N; Santos, SF; Feyt, C; Morel, M; Brion, JP; Octave, JN				Pierrot, Nathalie; Santos, Susana Ferrao; Feyt, Christine; Morel, Marina; Brion, Jean-Pierre; Octave, Jean-Noel			Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-beta accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; TRANSGENIC MICE; CDK5; APP; NEURONS; PATHOLOGY; ACTIVATOR; BRAIN	Intraneuronal accumulation of hyperphosphorylated protein tau in paired helical filaments together with amyloid-beta peptide (A beta) deposits confirm the clinical diagnosis of Alzheimer disease. A common cellular mechanism leading to the production of these potent toxins remains elusive. Here we show that, in cultured neurons, membrane depolarization induced a calcium-mediated transient phosphorylation of both microtubule-associated protein tau and amyloid precursor protein (APP), followed by a dephosphorylation of these proteins. Phosphorylation was mediated by glycogen synthase kinase 3 and cyclin-dependent kinase 5 protein kinases, while calcineurin was responsible for dephosphorylation. Following the transient phosphorylation of APP, intraneuronal A beta accumulated and induced neurotoxicity. Phosphorylation of APP on Thr-668 was indispensable for intraneuronal accumulation of A beta. Our data demonstrate that an increase in cytosolic calcium concentration induces modifications of neuronal metabolism of APP and tau, similar to those found in Alzheimer disease.	Univ Catholique Louvain, Lab Expt Pharmacol, B-1200 Brussels, Belgium; Univ Libre Bruxelles, Lab Histol & Neuropathol, B-1070 Brussels, Belgium	Universite Catholique Louvain; Universite Libre de Bruxelles	Octave, JN (corresponding author), Univ Catholique Louvain, Lab Expt Pharmacol, 54 Ave Hippocrate, B-1200 Brussels, Belgium.	octave@nchm.ucl.ac.be	Santos, Sidney/B-6064-2013; Brion, Jean-Pierre/C-6467-2009; Santos, Susana Ferrao/AAE-4102-2019	Brion, Jean-Pierre/0000-0002-1917-775X; Santos, Susana Ferrao/0000-0001-6029-6235				Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; Aplin AE, 1996, J NEUROCHEM, V67, P699; Bennett DA, 2004, ARCH NEUROL-CHICAGO, V61, P378, DOI 10.1001/archneur.61.3.378; Boutajangout A, 2004, NEUROBIOL DIS, V15, P47, DOI 10.1016/j.nbd.2003.09.007; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; BRION JP, 1985, J SUBMICR CYTOL PATH, V17, P89; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; COLLINS F, 1989, BRAIN RES, V502, P99, DOI 10.1016/0006-8993(89)90465-4; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Imahori K, 1997, J BIOCHEM, V121, P179; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kerokoski P, 2004, NEUROSCI LETT, V368, P181, DOI 10.1016/j.neulet.2004.07.007; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Koch Horst J., 2005, Current Drug Targets - CNS and Neurological Disorders, V4, P499, DOI 10.2174/156800705774322021; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Liu F, 2003, FEBS LETT, V547, P193, DOI 10.1016/S0014-5793(03)00714-2; Macq AF, 1998, J BIOL CHEM, V273, P28931, DOI 10.1074/jbc.273.44.28931; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Mattson MP, 2001, J MOL NEUROSCI, V17, P205, DOI 10.1385/JMN:17:2:205; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Miguel-Hidalgo JJ, 2002, BRAIN RES, V958, P210, DOI 10.1016/S0006-8993(02)03731-9; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Paglini G, 2001, EUR J BIOCHEM, V268, P1528, DOI 10.1046/j.1432-1033.2001.02023.x; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Pierrot N, 2004, J NEUROCHEM, V88, P1140, DOI 10.1046/j.1471-4159.2003.02227.x; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Ryder J, 2003, BIOCHEM BIOPH RES CO, V312, P922, DOI 10.1016/j.bbrc.2003.11.014; Sato T, 2006, BIOCHEMISTRY-US, V45, P5503, DOI 10.1021/bi052485f; Schonheit B, 2004, NEUROBIOL AGING, V25, P697, DOI 10.1016/j.neurobioalging.2003.09.009; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sergeant N, 2002, J NEUROCHEM, V81, P663, DOI 10.1046/j.1471-4159.2002.00901.x; Shea Thomas B., 1999, J Alzheimers Dis, V1, P353; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Tu HP, 2006, CELL, V126, P981, DOI 10.1016/j.cell.2006.06.059; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119; Zoia CP, 2005, NEUROBIOL AGING, V26, P825, DOI 10.1016/j.neurobiolaging.2004.07.007; Zou K, 2002, J NEUROSCI, V22, P4833, DOI 10.1523/JNEUROSCI.22-12-04833.2002	57	82	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39907	39914		10.1074/jbc.M606015200	http://dx.doi.org/10.1074/jbc.M606015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17085446	hybrid			2022-12-27	WOS:000243033900018
J	Qi, W; Yu, HT				Qi, Wei; Yu, Hongtao			KEN-box-dependent degradation of the Bub1 spindle checkpoint kinase by the anaphase-promoting complex/cyclosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; KINETOCHORE LOCALIZATION; ASSEMBLY CHECKPOINT; BUDDING YEAST; MITOTIC EXIT; CENP-E; PROTEOLYSIS; MITOSIS; PHOSPHORYLATION; CDC20	The spindle checkpoint is a cell cycle surveillance mechanism that ensures the fidelity of chromosome segregation during mitosis and meiosis. Bub1 is a protein serine-threonine kinase that plays multiple roles in chromosome segregation and the spindle checkpoint. In response to misaligned chromosomes, Bub1 directly inhibits the ubiquitin ligase activity of the anaphase-promoting complex or cyclosome (APC/C) by phosphorylating its activator Cdc20. The protein level and the kinase activity of Bub1 are regulated during the cell cycle; they peak in mitosis and are low in G(1)/S phase. Here we show that Bub1 is degraded during mitotic exit and that degradation of Bub1 is mediated by APC/C in complex with its activator Cdh1 (APC/C-Cdh1). Overexpression of Cdh1 reduces the protein levels of ectopically expressed Bub1, whereas depletion of Cdh1 by RNA interference increases the level of the endogenous Bub1 protein. Bub1 is ubiquitinated by immunopurified APC/C-Cdh1 in vitro. We further identify two KEN-box motifs on Bub1 that are required for its degradation in vivo and ubiquitination in vitro. A Bub1 mutant protein with both KEN-boxes mutated is stable in cells but fails to elicit a cell cycle phenotype, indicating that degradation of Bub1 by APC/C-Cdh1 is not required for mitotic exit. Nevertheless, our study clearly demonstrates that Bub1, an APC/C inhibitor, is also an APC/C substrate. The antagonistic relationship between Bub1 and APC/C may help to prevent the premature accumulation of Bub1 during G(1).	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, HT (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	hongtao.yu@utsouthwestern.edu	Pillay, Nischalan/F-9536-2012	Yu, Hongtao/0000-0002-8861-049X; Qi, Wei/0000-0003-0813-5316	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061542] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61542] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araki M, 2005, GENE DEV, V19, P2458, DOI 10.1101/gad.1361905; Bernard P, 1998, J CELL BIOL, V143, P1775, DOI 10.1083/jcb.143.7.1775; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Chen RH, 2004, EMBO J, V23, P3113, DOI 10.1038/sj.emboj.7600308; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Farr KA, 1998, MOL CELL BIOL, V18, P2738, DOI 10.1128/MCB.18.5.2738; Gillett ES, 2004, J CELL BIOL, V164, P535, DOI 10.1083/jcb.200308100; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Johnson VL, 2004, J CELL SCI, V117, P1577, DOI 10.1242/jcs.01006; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Palframan WJ, 2006, SCIENCE, V313, P680, DOI 10.1126/science.1127205; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; Qi W, 2006, MOL BIOL CELL, V17, P3705, DOI 10.1091/mbc.E06-03-0240; Schwab MS, 2001, CURR BIOL, V11, P141, DOI 10.1016/S0960-9822(01)00045-8; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Tanaka K, 1998, MOL CELLS, V8, P503; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 2001, J CELL SCI, V114, P4385; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Yamaguchi S, 2003, EMBO J, V22, P1075, DOI 10.1093/emboj/cdg100; Yu HT, 2005, CELL CYCLE, V4, P262; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	36	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3672	3679		10.1074/jbc.M609376200	http://dx.doi.org/10.1074/jbc.M609376200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158872	hybrid			2022-12-27	WOS:000244481900029
J	Cannavo, E; Gerrits, B; Marra, G; Schlapbach, R; Jiricny, J				Cannavo, Elda; Gerrits, Bertran; Marra, Giancarlo; Schlapbach, Ralph; Jiricny, Josef			Characterization of the interactome of the human MutL homologues MLH1, PMS1, and PMS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH-REPAIR; CHROMATIN REMODELING COMPLEX; FANCONI-ANEMIA; HUMAN-CELLS; C-MYC; ONCOGENIC TRANSFORMATION; DIRECT ASSOCIATION; MASS-SPECTROMETRY; HELICASE BRIP1; PROTEIN HMLH1	Postreplicative mismatch repair (MMR) involves the concerted action of at least 20 polypeptides. Although the minimal human MMR system has recently been reconstituted in vitro, genetic evidence from different eukaryotic organisms suggests that some steps of the MMR process may be carried out by more than one protein. Moreover, MMR proteins are involved also in other pathways of DNA metabolism, but their exact role in these processes is unknown. In an attempt to gain novel insights into the function of MMR proteins in human cells, we searched for interacting partners of the MutL homologues MLH1 and PMS2 by tandem affinity purification and of PMS1 by large scale immunoprecipitation. In addition to proteins known to interact with the MutL homologues during MMR, mass spectrometric analyses identified a number of other polypeptides, some of which bound to the above proteins with very high affinity. Whereas some of these interactors may represent novel members of the mismatch repairosome, others appear to implicate the MutL homologues in biological processes ranging from intracellular transport through cell signaling to cell morphology, recombination, and ubiquitylation.	Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; Univ Zurich, Funct Genom Ctr Zurich, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich	Jiricny, J (corresponding author), Univ Zurich, Inst Mol Canc Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	jiricny@imcr.unizh.ch	Schlapbach, Ralph/R-8234-2016	Schlapbach, Ralph/0000-0002-7488-4262				Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bratt A, 2005, J BIOL CHEM, V280, P34859, DOI 10.1074/jbc.M503915200; Brieger A, 2005, MOL CARCINOGEN, V43, P51, DOI 10.1002/mc.20081; Cannavo E, 2005, CANCER RES, V65, P10759, DOI 10.1158/0008-5472.CAN-05-2528; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Cejka P, 2003, EMBO J, V22, P2245, DOI 10.1093/emboj/cdg216; Chen PC, 2005, CANCER RES, V65, P8662, DOI 10.1158/0008-5472.CAN-05-0742; Cho SG, 2001, MOL CELL BIOL, V21, P8398, DOI 10.1128/MCB.21.24.8398-8413.2001; Ciotta C, 1998, J MOL BIOL, V276, P705, DOI 10.1006/jmbi.1997.1559; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Dziembowski A, 2004, FEBS LETT, V556, P1, DOI 10.1016/S0014-5793(03)01357-7; El-Shemerly M, 2005, CANCER RES, V65, P3604, DOI 10.1158/0008-5472.CAN-04-4069; Ernkvist M, 2006, FEBS J, V273, P2000, DOI 10.1111/j.1742-4658.2006.05216.x; Feng Y, 2003, CANCER RES, V63, P8726; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Garcia V, 2000, NUCLEIC ACIDS RES, V28, P1692, DOI 10.1093/nar/28.8.1692; Gingras AC, 2005, J PHYSIOL-LONDON, V563, P11, DOI 10.1113/jphysiol.2004.080440; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Her CT, 2002, DNA REPAIR, V1, P719, DOI 10.1016/S1568-7864(02)00079-4; Hoffmann ER, 2004, CYTOGENET GENOME RES, V107, P232, DOI 10.1159/000080601; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Irminger-Finger I, 2006, NAT REV CANCER, V6, P382, DOI 10.1038/nrc1878; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; Jiricny J, 2006, CELL, V126, P239, DOI 10.1016/j.cell.2006.07.003; Jonsson ZO, 2004, MOL CELL, V16, P465, DOI 10.1016/j.molcel.2004.09.033; Kadyrov FA, 2006, CELL, V126, P297, DOI 10.1016/j.cell.2006.05.039; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kinch LN, 2005, NUCLEIC ACIDS RES, V33, P3598, DOI 10.1093/nar/gki676; Kondo E, 2001, NUCLEIC ACIDS RES, V29, P1695, DOI 10.1093/nar/29.8.1695; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Lipkin SM, 2002, NAT GENET, V31, P385, DOI 10.1038/ng931; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Neuberger MS, 2005, NAT REV IMMUNOL, V5, P171, DOI 10.1038/nri1553; Nielsen FC, 2004, ONCOGENE, V23, P1457, DOI 10.1038/sj.onc.1207265; Owen BAL, 2005, NAT STRUCT MOL BIOL, V12, P663, DOI 10.1038/nsmb965; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Pedrazzi G, 2001, NUCLEIC ACIDS RES, V29, P4378, DOI 10.1093/nar/29.21.4378; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Raschle M, 2002, J BIOL CHEM, V277, P21810, DOI 10.1074/jbc.M108787200; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SCHAR P, 1998, NUCL ACID M, V12, P199; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Sourisseau T, 2006, MOL CELL BIOL, V26, P2387, DOI 10.1128/MCB.26.6.2387-2398.2006; Stojic L, 2004, GENE DEV, V18, P1331, DOI 10.1101/gad.294404; Sugawara N, 2004, P NATL ACAD SCI USA, V101, P9315, DOI 10.1073/pnas.0305749101; Trojan J, 2002, GASTROENTEROLOGY, V122, P211, DOI 10.1053/gast.2002.30296; Tronchere H, 2003, CELL MOL LIFE SCI, V60, P2084, DOI 10.1007/s00018-003-3062-3; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wang Y, 2000, GENE DEV, V14, P927; Wei K, 2002, TRENDS MOL MED, V8, P346, DOI 10.1016/S1471-4914(02)02359-6; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Wu XS, 2003, MOL CELL BIOL, V23, P3320, DOI 10.1128/MCB.23.9.3320-3328.2003; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhang YB, 2005, CELL, V122, P693, DOI 10.1016/j.cell.2005.06.027	74	111	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2976	2986		10.1074/jbc.M609989200	http://dx.doi.org/10.1074/jbc.M609989200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148452	hybrid, Green Accepted			2022-12-27	WOS:000243793900024
J	Fiser, R; Masin, J; Basler, M; Krusek, J; Spulakova, V; Konopasek, I; Sebo, P				Fiser, Radovan; Masin, Jiri; Basler, Marek; Krusek, Jan; Spulakova, Veronika; Konopasek, Ivo; Sebo, Peter			Third activity of Bordetella adenylate cyclase (AC) toxin-hemolysin - Membrane translocation of AC domain polypeptide promotes calcium influx into CD11b(+) monocytes independently of the catalytic and hemolytic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL EPITOPES; CALMODULIN-BINDING; INVASIVE ACTIVITY; PERTUSSIS TOXIN; FATTY-ACYLATION; ALPHA-HEMOLYSIN; TARGET-CELLS; IDENTIFICATION; CYTOTOXICITY; RECEPTORS	The Bordetella adenylate cyclase toxin-hemolysin (CyaA) targets phagocytes expressing the alpha(M)beta(2) integrin (CD11b/CD18), permeabilizes their membranes by forming small cation-selective pores, and delivers into cells a calmodulin-activated adenylate cyclase (AC) enzyme that dissipates cytosolic ATP into cAMP. We describe here a third activity of CyaA that yields elevation of cytosolic calcium concentration ([Ca2+](i)) in target cells. The CyaA-mediated [Ca2+](i) increase in CD11b(+) J774A. 1 monocytes was inhibited by extracellular La3+ ions but not by nifedipine, SK&F 96365, flunarizine, 2-aminoethyl diphenyl-borinate, or thapsigargin, suggesting that influx of Ca2+ into cells was not because of receptor signaling or opening of conventional calcium channels by cAMP. Compared with intact CyaA, a CyaA-AC(-) toxoid unable to generate cAMP promoted a faster, albeit transient, elevation of [Ca2+](i). This was not because of cell permeabilization by the CyaA hemolysin pores, because a mutant exhibiting a strongly enhanced pore-forming activity (CyaA-E509K/E516K), but unable to deliver the AC domain into cells, was also unable to elicit a [Ca2+](i) increase. Further mutations interfering with AC translocation into cells, such as proline substitutions of glutamate residues 509 or 570 or deletion of the AC domain as such, reduced or ablated the [Ca2+](i)-elevating capacity of CyaA. Moreover, structural alterations within the AC domain, because of insertion of various oligopeptides, differently modulated the kinetics and extent of Ca2+ influx elicited by the respective AC(-) toxoids. Hence, the translocating AC polypeptide itself appears to participate in formation of a novel type of membrane path for calcium ions, contributing to action of CyaA in an unexpected manner.	Acad Sci Czech Republ, Lab Mol Biol Bacterial Pathogens, Inst Microbiol, CZ-14220 Prague 4, Czech Republic; Acad Sci Czech Republ, Inst Physiol, Dept Cellular Neurophysiol, CZ-14220 Prague 4, Czech Republic; Charles Univ Prague, Fac Sci, Dept Genet & Microbiol, CZ-12844 Prague 2, Czech Republic	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Charles University Prague	Sebo, P (corresponding author), Acad Sci Czech Republ, Lab Mol Biol Bacterial Pathogens, Inst Microbiol, CZ-14220 Prague 4, Czech Republic.	sebo@biomed.cas.cz	SEBO, Peter/N-2043-2019; Fiser, Radovan/E-4908-2012; Masin, Jiri/H-3125-2014; SEBO, Peter/F-7423-2011; Krusek, Jan/B-6341-2012; Basler, Marek/A-3559-2012; Konopásek, Ivo/AAE-9034-2021	SEBO, Peter/0000-0002-9755-7715; Fiser, Radovan/0000-0003-4516-0086; SEBO, Peter/0000-0002-9755-7715; Krusek, Jan/0000-0002-4820-0947; Basler, Marek/0000-0001-5414-2088; Konopásek, Ivo/0000-0002-6824-5974				Azenabor AA, 2004, BIOL CHEM, V385, P67, DOI 10.1515/BC.2004.009; Bagley KC, 2002, J LEUKOCYTE BIOL, V72, P962; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; Basar T, 1999, J BIOL CHEM, V274, P10777, DOI 10.1074/jbc.274.16.10777; Basler M, 2006, INFECT IMMUN, V74, P2207, DOI 10.1128/IAI.74.4.2207-2214.2006; Bassinet L, 2004, INFECT IMMUN, V72, P5530, DOI 10.1128/IAI.72.9.5530-5533.2004; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; Bennett DL, 1998, BIOCHEM J, V329, P349; BENZ R, 1994, J BIOL CHEM, V269, P27231; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Boyd AP, 2005, J IMMUNOL, V175, P730, DOI 10.4049/jimmunol.175.2.730; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; CARONI P, 1981, J BIOL CHEM, V256, P3263; CHEN CF, 1988, SCIENCE, V239, P1024, DOI 10.1126/science.2449730; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; Delvig AA, 1999, EUR J IMMUNOL, V29, P2414, DOI 10.1002/(SICI)1521-4141(199908)29:08<2414::AID-IMMU2414>3.0.CO;2-P; Dib K, 2000, FRONT BIOSCI-LANDMRK, V5, pD438, DOI 10.2741/Pathology; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; El-Azami-El-Idrissi M, 2003, J BIOL CHEM, V278, P38514, DOI 10.1074/jbc.M304387200; Fong KP, 2006, CELL MICROBIOL, V8, P1753, DOI 10.1111/j.1462-5822.2006.00746.x; FRIEDMAN RL, 1987, INFECT IMMUN, V55, P135, DOI 10.1128/IAI.55.1.135-140.1987; Gao ZY, 2002, BIOCHEM J, V368, P397, DOI 10.1042/BJ20020999; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GOODWIN MS, 1990, INFECT IMMUN, V58, P3445, DOI 10.1128/IAI.58.10.3445-3447.1990; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; Gray M, 1998, J BIOL CHEM, V273, P18260, DOI 10.1074/jbc.273.29.18260; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HANSKI E, 1985, J BIOL CHEM, V260, P5526; Harvill ET, 1999, INFECT IMMUN, V67, P1493, DOI 10.1128/IAI.67.3.1493-1500.1999; Heveker N, 1997, EUR J BIOCHEM, V243, P643, DOI 10.1111/j.1432-1033.1997.00643.x; HEWLETT E, 1976, J BACTERIOL, V127, P890, DOI 10.1128/JB.127.2.890-898.1976; HEWLETT EL, 1983, CLIN RES, V31, pA365; Hewlett EL, 2006, MOL MICROBIOL, V59, P447, DOI 10.1111/j.1365-2958.2005.04958.x; IWAKI M, 1995, MOL MICROBIOL, V17, P1015, DOI 10.1111/j.1365-2958.1995.mmi_17061015.x; Karimova G, 1998, P NATL ACAD SCI USA, V95, P12532, DOI 10.1073/pnas.95.21.12532; KHELEF N, 1993, INFECT IMMUN, V61, P4064, DOI 10.1128/IAI.61.10.4064-4071.1993; KHELEF N, 1995, FEMS MICROBIOL LETT, V134, P27, DOI 10.1016/0378-1097(95)00375-F; Koschinski A, 2006, FASEB J, V20, P973, DOI 10.1096/fj.05-4561fje; Kumar P, 2002, INFECT IMMUN, V70, P4997, DOI 10.1128/IAI.70.9.4997-5007.2002; LADANT D, 1988, J BIOL CHEM, V263, P2612; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Masin J, 2005, BIOCHEMISTRY-US, V44, P12759, DOI 10.1021/bi050459b; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; Nhieu GT, 2004, BIOL CELL, V96, P93, DOI 10.1016/j.biocel.2003.10.006; Njamkepo E, 2000, J CELL PHYSIOL, V183, P91, DOI 10.1002/(SICI)1097-4652(200004)183:1<91::AID-JCP11>3.0.CO;2-S; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Osicka R, 2000, INFECT IMMUN, V68, P247; Osickova A, 1999, J BIOL CHEM, V274, P37644; OTERO AS, 1995, J BIOL CHEM, V270, P9695, DOI 10.1074/jbc.270.17.9695; PEARSON RD, 1987, J IMMUNOL, V139, P2749; Persechini A, 2002, TRENDS CARDIOVAS MED, V12, P32, DOI 10.1016/S1050-1738(01)00144-X; Rhodes CR, 2001, ARCH BIOCHEM BIOPHYS, V395, P169, DOI 10.1006/abbi.2001.2553; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROSE T, 1995, J BIOL CHEM, V270, P26370, DOI 10.1074/jbc.270.44.26370; Ross PJ, 2004, INFECT IMMUN, V72, P1568, DOI 10.1128/IAI.72.3.1568-1579.2004; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; Schlecht G, 2004, J IMMUNOL, V173, P6089, DOI 10.4049/jimmunol.173.10.6089; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; Shen YQ, 2002, EMBO J, V21, P6721, DOI 10.1093/emboj/cdf681; Skinner LJ, 2003, J NEUROPHYSIOL, V90, P320, DOI 10.1152/jn.01155.2002; SZABO G, 1994, J BIOL CHEM, V269, P22496; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; Valeva A, 2005, J BIOL CHEM, V280, P36657, DOI 10.1074/jbc.M507690200; Vojtova J, 2006, CURR OPIN MICROBIOL, V9, P69, DOI 10.1016/j.mib.2005.12.011; Weingart CL, 2000, INFECT IMMUN, V68, P1735, DOI 10.1128/IAI.68.3.1735-1739.2000; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	72	60	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2808	2820		10.1074/jbc.M609979200	http://dx.doi.org/10.1074/jbc.M609979200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148436	hybrid			2022-12-27	WOS:000243793900007
J	Guilluy, C; Rolli-Derkinderen, M; Tharaux, PL; Melino, G; Pacaud, P; Loirand, G				Guilluy, Christophe; Rolli-Derkinderen, Malvyne; Tharaux, Pierre-Louis; Melino, Gerry; Pacaud, Pierre; Loirand, Gervaise			Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; PROTEIN-KINASE AKT; INHIBITION; APOPTOSIS; TRANSPORTER; HYPOXIA; GTPASES; GROWTH; PHOSPHORYLATION; TRANSLOCATION	The small G protein RhoA plays a major role in several vascular processes and cardiovascular disorders. Here we analyze the mechanisms of RhoA regulation by serotonin (5-HT) in arterial smooth muscle. 5-HT (0.1-10 mu M) induced activation of RhoA followed by RhoA depletion at 24-72 h. Inhibition of 5-HT1 receptors reduced the early phase of RhoA activation but had no effect on 5-HT-induced delayed RhoA activation and depletion, which were suppressed by the 5-HT transporter inhibitor fluoxetine and the transglutaminase inhibitor monodansylcadaverin and in type 2 transglutaminase-deficient smooth muscle cells. Coimmunoprecipitations demonstrated that 5-HT associated with RhoA both in vitro and in vivo. This association was calcium-dependent and inhibited by fluoxetine and monodansylcadaverin. 5-HT promotes the association of RhoA with the E3 ubiquitin ligase Smurf1, and 5-HT-induced Rho Adepletion was inhibited by the proteasome inhibitor MG132 and the RhoA inhibitor Tat-C3. Simvastatin, the Rho kinase inhibitor Y-27632, small interfering RNA-mediated RhoA gene silencing, and long-term 5-HT stimulation induced Akt activation. In contrast, inhibition of 5-HT-mediated RhoA degradation by MG132 prevented 5-HT-induced Akt activation. Long-term 5-HT stimulation also led to the inhibition of the RhoA/Rho kinase component of arterial contraction. Our data provide evidence that 5-HT, internalized through the 5-HT transporter, is transamidated to RhoA by transglutaminase. Transamidation of RhoA leads to RhoA activation and enhanced proteasomal degradation, which in turn is responsible for Akt activation and contraction inhibition. The observation of transamidation of 5-HT to RhoA in pulmonary artery of hypoxic rats suggests that this process could participate in pulmonary artery remodeling and hypertension.	Univ Nantes, Inst Thorax, Fac Sci, INSERM,U533, F-44322 Nantes 3, France; Hop Tenon, INSERM, U702, F-75970 Paris, France; Univ Roma Tor Vergata, Biochem Lab, I-00133 Rome, Italy; INSERM, U771, CNRS, UMR 6214,Fac Med, F-49045 Angers, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Rome Tor Vergata; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers	Pacaud, P (corresponding author), Univ Nantes, Inst Thorax, Fac Sci, INSERM,U533, 2 Rue Houssiniere,BP 92208, F-44322 Nantes 3, France.	pierre.pacaud@univ-nantes.fr; gervaise.loirand@univ-nantes.fr	Loirand, Gervaise/K-1834-2014; guilluy, christophe/C-6002-2014; Tharaux, Pierre-Louis/A-9155-2009; Pacaud, Pierre/D-6392-2015; Guilluy, Christophe/Z-1015-2019; Rolli-Derkinderen, Malvyne/K-2406-2015	Loirand, Gervaise/0000-0002-2306-3931; guilluy, christophe/0000-0003-1141-0809; Tharaux, Pierre-Louis/0000-0002-6062-5905; Guilluy, Christophe/0000-0003-1141-0809; 	Medical Research Council [MC_U132670600] Funding Source: Medline; MRC [MC_U132670600] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Amerongen GPV, 2001, ARTERIOSCL THROM VAS, V21, P300, DOI 10.1161/01.ATV.21.3.300; Backlund PS, 1997, J BIOL CHEM, V272, P33175, DOI 10.1074/jbc.272.52.33175; Bai HZ, 1999, CIRC RES, V85, P229, DOI 10.1161/01.RES.85.3.229; Caputo I, 2004, AMINO ACIDS, V26, P381, DOI 10.1007/s00726-004-0083-7; Dale GL, 2002, NATURE, V415, P175, DOI 10.1038/415175a; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Denoyelle C, 2003, CELL SIGNAL, V15, P327, DOI 10.1016/S0898-6568(02)00124-9; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Eddahibi S, 1999, CIRC RES, V84, P329, DOI 10.1161/01.RES.84.3.329; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fanburg BL, 1997, AM J PHYSIOL-LUNG C, V272, pL795, DOI 10.1152/ajplung.1997.272.5.L795; Fanburg BL, 2000, J CLIN INVEST, V105, P1521, DOI 10.1172/JCI10230; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Guibert C, 1996, AM J PHYSIOL-LUNG C, V271, pL450, DOI 10.1152/ajplung.1996.271.3.L450; Guijarro C, 1998, CIRC RES, V83, P490, DOI 10.1161/01.RES.83.5.490; Guilluy C, 2005, BRIT J PHARMACOL, V146, P1010, DOI 10.1038/sj.bjp.0706408; Higaki M, 1999, ARTERIOSCL THROM VAS, V19, P2127, DOI 10.1161/01.ATV.19.9.2127; Hixon ML, 2000, J CLIN INVEST, V106, P1011, DOI 10.1172/JCI8252; Jernigan NL, 2004, AM J PHYSIOL-LUNG C, V287, pL1220, DOI 10.1152/ajplung.00196.2004; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Laufs U, 2000, CIRC RES, V87, P526, DOI 10.1161/01.RES.87.7.526; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; LEE SL, 1994, AM J PHYSIOL, V266, pL46, DOI 10.1152/ajplung.1994.266.1.L46; LEE SL, 1994, AM J PHYSIOL, V266, pL53, DOI 10.1152/ajplung.1994.266.1.L53; LEE SL, 1989, J CELL PHYSIOL, V138, P145, DOI 10.1002/jcp.1041380120; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Liu YL, 2006, AM J RESP CELL MOL, V34, P182, DOI 10.1165/rcmb.2005-0163OC; Liu YL, 2004, CIRC RES, V95, P579, DOI 10.1161/01.RES.0000141428.53262.a4; Loirand G, 2006, CIRC RES, V98, P322, DOI 10.1161/01.RES.0000201960.04223.3c; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Ming XF, 2002, MOL CELL BIOL, V22, P8467, DOI 10.1128/MCB.22.24.8467-8477.2002; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NEMECEK GM, 1986, P NATL ACAD SCI USA, V83, P674, DOI 10.1073/pnas.83.3.674; Rebsamen MC, 2002, CIRC RES, V91, P17, DOI 10.1161/01.RES.0000025269.60668.0F; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rikitake Y, 2005, CIRC RES, V97, P1232, DOI 10.1161/01.RES.0000196564.18314.23; Rolli-Derkinderen M, 2005, CIRC RES, V96, P1152, DOI 10.1161/01.RES.0000170084.88780.ea; Sauzeau V, 2003, CIRC RES, V93, P630, DOI 10.1161/01.RES.0000093220.90027.D9; Sauzeau V, 2001, CIRC RES, V88, P1102, DOI 10.1161/hh1101.092034; Schmidt G, 1998, J BIOL CHEM, V273, P13669, DOI 10.1074/jbc.273.22.13669; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Shibata R, 2003, J CARDIOVASC PHARM, V42, pS43, DOI 10.1097/00005344-200312001-00011; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; Skaletz-Rorowski A, 2003, CARDIOVASC RES, V57, P253, DOI 10.1016/S0008-6363(02)00618-1; Szasz R, 2002, BLOOD, V100, P2827, DOI 10.1182/blood-2002-02-0354; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; Walther DJ, 2003, CELL, V115, P851, DOI 10.1016/S0092-8674(03)01014-6; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang YX, 2005, CIRCULATION, V111, P2219, DOI 10.1161/01.CIR.0000163544.17221.BE; Weiss RH, 1999, J AM SOC NEPHROL, V10, P1880; Wolfrum S, 2004, ARTERIOSCL THROM VAS, V24, P1842, DOI 10.1161/01.ATV.0000142813.33538.82; Worth NF, 2001, ANN NY ACAD SCI, V947, P316; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9	57	90	93	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2918	2928		10.1074/jbc.M604195200	http://dx.doi.org/10.1074/jbc.M604195200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17142836	hybrid			2022-12-27	WOS:000243793900018
J	Matsumoto, ML; Narzinski, K; Nikiforovich, GV; Baranski, TJ				Matsumoto, Marissa L.; Narzinski, Kirk; Nikiforovich, Gregory V.; Baranski, Thomas J.			A comprehensive structure-function map of the intracellular surface of the human C5a receptor - II. Elucidation of G protein specificity determinants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-ACTIVATED RHODOPSIN; VASOPRESSIN V-2 RECEPTOR; DISULFIDE BOND FORMATION; STATE TERTIARY STRUCTURE; COVALENT CROSS-LINKING; BETA-GAMMA-SUBUNITS; AMINO-ACID-RESIDUES; C-TERMINAL TAIL; ALPHA-SUBUNIT; COUPLING SELECTIVITY	Within any given cell many G protein-coupled receptors are expressed in the presence of multiple G proteins, yet most receptors couple to a specific subset of G proteins to elicit their programmed response. Numerous studies demonstrate that the carboxyl-terminal five amino acids of the G alpha subunits are a major determinant of specificity, however the receptor determinants of specificity are less clear. We have used a collection of 133 functional mutants of the C5a receptor obtained in a mutagenesis screen targeting the intracellular loops and the carboxyl terminus ( Matsumoto, M. L., Narzinski, K., Kiser, P. D., Nikiforovich, G. V., and Baranski, T. J. ( 2007) J. Biol. Chem. 282, 3105 3121) to investigate how specificity is encoded. Each mutant, originally selected for its ability to signal through a nearly full-length G alpha(i) in yeast, was tested to see whether it could activate three versions of chimeric G alpha subunits consisting of Gpa1 fused to the carboxyl-terminal five amino acids of G alpha(i), G alpha(q), or G alpha(s) in yeast. Surprisingly the carboxyl- terminal tail of the C5a receptor is the most important specificity determinant in that nearly all mutants in this region showed a gain in coupling to G alpha(q) and/or G alpha(s). More than half of the receptors mutated in the second intracellular loop also demonstrated broadened G protein coupling. Given a lack of selective advantage for this broadened signaling in the initial screen, we propose a model in which the carboxyl- terminal tail acts together with the intracellular loops to generate a specificity filter for receptor-G protein interactions that functions primarily to restrict access of incorrect G proteins to the receptor.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Baranski, TJ (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.	baranski@wustl.edu		Matsumoto, Marissa/0000-0002-5353-1097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068460, R01GM063720] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63720-01, GM068460] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdulaev NG, 2005, J BIOL CHEM, V280, P38071, DOI 10.1074/jbc.M505259200; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; Anderson LL, 2005, J BIOL CHEM, V280, P31019, DOI 10.1074/jbc.M503690200; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; Bolon DN, 2005, P NATL ACAD SCI USA, V102, P12724, DOI 10.1073/pnas.0506124102; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Cai KW, 2001, BIOCHEMISTRY-US, V40, P12479, DOI 10.1021/bi010747h; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DAYOFF MO, 1978, ATLAS PROTEIN SEQUEN, P345; Duvernay MT, 2004, J BIOL CHEM, V279, P30741, DOI 10.1074/jbc.M313881200; Erlenbach I, 1998, J BIOL CHEM, V273, P26549, DOI 10.1074/jbc.273.41.26549; Erlenbach I, 2001, J BIOL CHEM, V276, P29382, DOI 10.1074/jbc.M103203200; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; Estall JL, 2005, J BIOL CHEM, V280, P22124, DOI 10.1074/jbc.M500078200; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; Gibson SK, 2006, P NATL ACAD SCI USA, V103, P212, DOI 10.1073/pnas.0509763102; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; Kim JM, 2005, BIOCHEMISTRY-US, V44, P2284, DOI 10.1021/bi048328i; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Klein-Seetharaman J, 2001, BIOCHEMISTRY-US, V40, P12472, DOI 10.1021/bi010746p; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Krause G, 2000, MOL PHARMACOL, V57, P232; Kuhn B, 2002, N-S ARCH PHARMACOL, V365, P231, DOI 10.1007/s00210-001-0512-z; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Malmberg A, 2000, J NEUROCHEM, V75, P1283, DOI 10.1046/j.1471-4159.2000.751283.x; MATSUMOTO ML, 1997, J BIOL CHEM, V282, P3105; Miller KJ, 2004, CNS NEUROL DISORD-DR, V3, P357, DOI 10.2174/1568007043337003; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Nasman J, 1997, J BIOL CHEM, V272, P9703; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; Olah ME, 1997, J BIOL CHEM, V272, P337; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pankevych H, 2003, J BIOL CHEM, V278, P30283, DOI 10.1074/jbc.M212918200; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; Ridge KD, 2006, J BIOL CHEM, V281, P7635, DOI 10.1074/jbc.M509851200; Robert J, 2005, J BIOL CHEM, V280, P2300, DOI 10.1074/jbc.M410655200; Robillard L, 2000, CELL SIGNAL, V12, P673, DOI 10.1016/S0898-6568(00)00118-2; SCHNEIDER H, 1994, FEBS LETT, V351, P281, DOI 10.1016/0014-5793(94)00878-7; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; Thielen A, 2005, FEBS LETT, V579, P5227, DOI 10.1016/j.febslet.2005.08.043; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1990, MOL PHARMACOL, V38, P872; Wettschureck N, 2005, PHYSIOL REV, V85, P1159, DOI 10.1152/physrev.00003.2005; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t	67	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3122	3133		10.1074/jbc.M607683200	http://dx.doi.org/10.1074/jbc.M607683200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17090530	hybrid			2022-12-27	WOS:000243793900038
J	Averna, M; Stifanese, R; De Tullio, R; Passalacqua, M; Defranchi, E; Salamino, F; Melloni, E; Pontremoli, S				Averna, Monica; Stifanese, Roberto; De Tullio, Roberta; Passalacqua, Mario; Defranchi, Enrico; Salamino, Franca; Melloni, Edon; Pontremoli, Sandro			Regulation of calpain activity in rat brain with altered Ca2+ homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEINASE; ISCHEMIC NEURONAL DEATH; SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; SKELETAL-MUSCLE; HUMAN-ERYTHROCYTES; NA+-CA2+ EXCHANGE; CALPASTATIN FORMS; MOUSE MODEL; CALCIUM	Activation of calpain occurs as an early event in correlation with an increase in [Ca2+](i) induced in rat brain upon treatment with a high salt diet for a prolonged period of time. The resulting sequential events have been monitored in the brain of normal and hypertensive rats of the Milan strain, diverging for a constitutive alteration in the level of [Ca2+](i) found to be present in nerve cells of hypertensive animals. After 2 weeks of treatment, the levels of the plasma membrane Ca2+-ATPase and of native calpastatin are profoundly decreased. These degradative processes, more pronounced in the brain of hypertensive rats, are progressively and efficiently compensated in the brain of both rat strains by different incoming mechanisms. Along with calpastatin degradation, 15-kDa still-active inhibitory fragments are accumulated, capable of efficiently replacing the loss of native inhibitor molecules. A partial return to a more efficient control of Ca2+ homeostasis occurs in parallel, assured by an early increase in the expression of Ca2+-ATPase and of calpastatin, both producing, after 12 weeks of a high salt (sodium) diet, the restoration of almost original levels of the Ca2+ pump and of significant amounts of native inhibitor molecules. Thus, conservative calpastatin fragmentation, associated with an increased expression of Ca2+-ATPase and of the calpain natural inhibitor, has been demonstrated to occur in vivo in rat brain. This represents a sequential adaptive response capable of overcoming the effects of calpain activation induced by a moderate long term elevation of [Ca2+](i).	Univ Genoa, DIMES, Biochem Sect, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy	University of Genoa; University of Genoa	Pontremoli, S (corresponding author), Univ Genoa, DIMES, Biochem Sect, Viale Benedetto XV, I-16132 Genoa, Italy.	pontremoli@unige.it	AVERNA, MONICA/R-5719-2019; Passalacqua, Mario/W-1973-2019	AVERNA, MONICA/0000-0002-9463-7533; Passalacqua, Mario/0000-0003-2779-6259				Averna M, 2001, J BIOL CHEM, V276, P38426, DOI 10.1074/jbc.M101936200; Aviv A, 1996, AM J HYPERTENS, V9, P703, DOI 10.1016/0895-7061(95)00447-5; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Barnoy S, 2007, INT J BIOCHEM CELL B, V39, P253, DOI 10.1016/j.biocel.2006.08.008; Bartoli M, 2006, J BIOL CHEM, V281, P39672, DOI 10.1074/jbc.M608803200; Betts R, 2004, BIOCHEMISTRY-US, V43, P2596, DOI 10.1021/bi0359832; Betts R, 2003, J BIOL CHEM, V278, P7800, DOI 10.1074/jbc.M208350200; Bianchi G., 1984, HDB HYPERTENSION, V4, P328; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Blomgren K, 1999, J BIOL CHEM, V274, P14046, DOI 10.1074/jbc.274.20.14046; Brandenburg K, 2002, EUR J BIOCHEM, V269, P5414, DOI 10.1046/j.1432-1033.2002.03225.x; Byrom FB, 1938, J PHYSIOL-LONDON, V93, P301, DOI 10.1113/jphysiol.1938.sp003641; Camins A, 2006, CNS DRUG REV, V12, P135, DOI 10.1111/j.1527-3458.2006.00135.x; Castejon MS, 1999, MUSCLE NERVE, V22, P905, DOI 10.1002/(SICI)1097-4598(199907)22:7<905::AID-MUS14>3.3.CO;2-N; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Crocker SJ, 2003, J NEUROSCI, V23, P4081; Dainese E, 2002, J BIOL CHEM, V277, P40296, DOI 10.1074/jbc.M204471200; De Tullio R, 1998, FEBS LETT, V422, P113, DOI 10.1016/S0014-5793(97)01588-3; De Tullio R, 2003, BIOCHEM J, V375, P689, DOI 10.1042/BJ20030706; De Tullio R, 2000, FEBS LETT, V475, P17, DOI 10.1016/S0014-5793(00)01613-6; Duguez S, 2006, FEBS J, V273, P3427, DOI 10.1111/j.1742-4658.2006.05351.x; Dutt P, 2002, BIOCHEM J, V367, P263, DOI 10.1042/BJ20020485; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Higuchi M, 2005, J BIOL CHEM, V280, P15229, DOI 10.1074/jbc.M500939200; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Iwamoto T, 2004, NAT MED, V10, P1193, DOI 10.1038/nm1118; Kawamura M, 2005, BRAIN RES, V1037, P59, DOI 10.1016/j.brainres.2004.12.050; Kent MP, 2004, J ANIM SCI, V82, P794; Kinbara K, 1998, BIOCHEM PHARMACOL, V56, P415; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; Limaye PB, 2006, HEPATOLOGY, V44, P379, DOI 10.1002/hep.21250; MartinezZaguilan R, 1996, CELL CALCIUM, V19, P337, DOI 10.1016/S0143-4160(96)90074-3; Melloni E, 1998, FEBS LETT, V431, P55, DOI 10.1016/S0014-5793(98)00724-8; MELLONI E, 1982, BIOCHEM BIOPH RES CO, V106, P731, DOI 10.1016/0006-291X(82)91772-7; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; Moldoveanu T, 2004, J MOL BIOL, V343, P1313, DOI 10.1016/j.jmb.2004.09.016; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; MURACHI T, 1989, BIOCHEM INT, V18, P263; Nakajima T, 2001, BBA-GENE STRUCT EXPR, V1519, P55, DOI 10.1016/S0167-4781(01)00212-3; NAKAMURA M, 1989, BIOCHEMISTRY-US, V28, P449, DOI 10.1021/bi00428a007; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; PALEJWALA S, 1992, P NATL ACAD SCI USA, V89, P4202, DOI 10.1073/pnas.89.9.4202; PONTREMOLI S, 1988, J BIOL CHEM, V263, P1915; PONTREMOLI S, 1991, ARCH BIOCHEM BIOPHYS, V288, P646, DOI 10.1016/0003-9861(91)90247-G; Rami A, 2003, NEUROBIOL DIS, V13, P75, DOI 10.1016/S0969-9961(03)00018-4; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Raynaud F, 2006, FEBS J, V273, P3437, DOI 10.1111/j.1742-4658.2006.05352.x; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; Sorimachi Y, 1997, J BIOCHEM-TOKYO, V122, P743; Squier MKT, 1999, J CELL PHYSIOL, V178, P311, DOI 10.1002/(SICI)1097-4652(199903)178:3<311::AID-JCP5>3.3.CO;2-K; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Tompa P, 2002, J BIOL CHEM, V277, P9022, DOI 10.1074/jbc.C100700200; Tsuji T, 1998, NEUROSCI LETT, V248, P109, DOI 10.1016/S0304-3940(98)00348-6; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5; WANG LF, 1994, BIOCHEM MOL BIOL INT, V33, P245; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; Yoshikawa Y, 2005, AM J PHYSIOL-HEART C, V288, pH1690, DOI 10.1152/ajpheart.00666.2004; Zeitz O, 2002, CIRC RES, V90, P988, DOI 10.1161/01.RES.0000018625.25212.1E; Zhang J, 2002, AM J PHYSIOL-HEART C, V283, pH2692, DOI 10.1152/ajpheart.00260.2002	71	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2656	2665		10.1074/jbc.M606919200	http://dx.doi.org/10.1074/jbc.M606919200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135258	hybrid			2022-12-27	WOS:000243593200058
J	Chemin, J; Nargeot, J; Lory, P				Chemin, Jean; Nargeot, Joel; Lory, Philippe			Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; ENDOGENOUS CANNABINOID ANANDAMIDE; CA2+-ACTIVATED K+ CHANNELS; RAT VENTRICULAR MYOCYTES; SMOOTH-MUSCLE CELLS; ARACHIDONIC-ACID; CA2+ CHANNELS; SYNAPTIC-TRANSMISSION; VANILLOID RECEPTORS; LARGE-CONDUCTANCE	Anandamide, originally described as an endocannabinoid, is the main representative molecule of a new class of signaling lipids including endocannabinoids and N-acyl-related molecules, eicosanoids, and fatty acids. Bioactive lipids regulate neuronal excitability by acting on G-protein-coupled receptors (such as CB1) but also directly modulate various ionic conductances including voltage-activated T-type calcium channels (T-channels). However, little is known about the properties and the specificity of this new class of molecules on their various targets. In this study, we have investigated the chemical determinants involved in anandamide-induced inhibition of the three cloned T-channels: Ca(V)3.1, Ca(V)3.2, and Ca(V)3.3. We show that both the hydroxyl group and the alkyl chain of anandamide are key determinants of its effects on T-currents. As follows, T-currents are also inhibited by fatty acids. Inhibition of the three Ca(V)3 currents by anandamide and arachidonic acid does not involve enzymatic metabolism and occurs in cell-free inside-out patches. Inhibition of T-currents by fatty acids and N-acyl ethanolamides depends on the degree of unsaturation but not on the alkyl chain length and consequently is not restricted to eicosanoids. Inhibition increases for polyunsaturated fatty acids comprising 18 - 22 carbons when cis-double bonds are close to the carboxyl group. Therefore the major natural (food-supplied) and mammalian endogenous fatty acids including gamma-linolenic acid, mead acid, and arachidonic acid as well as the fully polyunsaturated omega 3-fatty acids that are enriched in fish oil eicosapentaenoic and docosahexaenoic acids are potent inhibitors of T-currents, which possibly contribute to their physiological functions.	Univ Montpellier I, Dept Physiol, Inst Genom Fonct,INSERM U661, CNRS,UMR 5203, F-34094 Montpellier, France; Univ Montpellier 2, F-34094 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier	Chemin, J (corresponding author), Univ Montpellier I, Dept Physiol, Inst Genom Fonct,INSERM U661, CNRS,UMR 5203, 141 Rue Cardonille, F-34094 Montpellier, France.	jean.chemin@igf.cnrs.fr		Nargeot, Joel/0000-0003-2893-5636; LORY, philippe/0000-0002-1638-7604; chemin, jean/0000-0002-6089-5964				ABE K, 1989, ANN NY ACAD SCI, V559, P259; Alger BE, 2002, PROG NEUROBIOL, V68, P247; Anderson MP, 2005, P NATL ACAD SCI USA, V102, P1743, DOI 10.1073/pnas.0409644102; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; Bazan NG, 2003, J LIPID RES, V44, P2221, DOI 10.1194/jlr.R300013-JLR200; Bijlenga P, 2000, P NATL ACAD SCI USA, V97, P7627, DOI 10.1073/pnas.97.13.7627; Bourinet E, 2005, EMBO J, V24, P315, DOI 10.1038/sj.emboj.7600515; Bradshaw HB, 2005, BRIT J PHARMACOL, V144, P459, DOI 10.1038/sj.bjp.0706093; Chemin J, 2002, J NEUROSCI, V22, P6856; Chemin J, 2002, J PHYSIOL-LONDON, V540, P3, DOI 10.1113/jphysiol.2001.013269; Chemin J, 2001, EMBO J, V20, P7033, DOI 10.1093/emboj/20.24.7033; Chemin J, 2001, EUR J NEUROSCI, V14, P1678, DOI 10.1046/j.0953-816x.2001.01796.x; Chemin J, 2001, BIOPHYS J, V80, P1238, DOI 10.1016/S0006-3495(01)76100-0; Chemin J, 2006, CELL CALCIUM, V40, P121, DOI 10.1016/j.ceca.2006.04.015; Chen C, 2005, PROSTAG OTH LIPID M, V77, P65, DOI 10.1016/j.prostaglandins.2005.07.001; Danthi SJ, 2005, BIOCHEM BIOPH RES CO, V327, P485, DOI 10.1016/j.bbrc.2004.12.033; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2000, PROSTAG OTH LIPID M, V61, P43, DOI 10.1016/S0090-6980(00)00054-X; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; HAGIWARA N, 1988, J PHYSIOL-LONDON, V395, P233, DOI 10.1113/jphysiol.1988.sp016916; HONORE E, 1994, P NATL ACAD SCI USA, V91, P1937, DOI 10.1073/pnas.91.5.1937; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Kim D, 2003, SCIENCE, V302, P117, DOI 10.1126/science.1088886; Kim D, 2001, NEURON, V31, P35, DOI 10.1016/S0896-6273(01)00343-9; KIRBER MT, 1992, FEBS LETT, V297, P24, DOI 10.1016/0014-5793(92)80319-C; Leaf A, 2003, PHARMACOL THERAPEUT, V98, P355, DOI 10.1016/S0163-7258(03)00039-1; Lory P, 2006, CELL CALCIUM, V40, P135, DOI 10.1016/j.ceca.2006.04.017; Maingret F, 2001, EMBO J, V20, P47, DOI 10.1093/emboj/20.1.47; Mangoni ME, 2006, CIRC RES, V98, P1422, DOI 10.1161/01.RES.0000225862.14314.49; Mariot P, 2002, J BIOL CHEM, V277, P10824, DOI 10.1074/jbc.M108754200; Movahed P, 2005, J BIOL CHEM, V280, P38496, DOI 10.1074/jbc.M507429200; Nicholson RA, 2003, BRAIN RES, V978, P194, DOI 10.1016/S0006-8993(03)02808-7; Nikonenko I, 2005, MOL PHARMACOL, V68, P84, DOI 10.1124/mol.104.010066; NUSS HB, 1993, CIRC RES, V73, P777, DOI 10.1161/01.RES.73.4.777; Oliver D, 2004, SCIENCE, V304, P265, DOI 10.1126/science.1094113; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; Oz M, 2000, EUR J PHARMACOL, V404, P13, DOI 10.1016/S0014-2999(00)00396-4; Oz M, 2006, PHARMACOL THERAPEUT, V111, P114, DOI 10.1016/j.pharmthera.2005.09.009; Park KA, 2005, TRENDS PHARMACOL SCI, V26, P571, DOI 10.1016/j.tips.2005.09.010; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; Randall MD, 2002, PHARMACOL THERAPEUT, V95, P191, DOI 10.1016/S0163-7258(02)00258-9; Rossier MF, 1996, ENDOCRINOLOGY, V137, P4817, DOI 10.1210/en.137.11.4817; Sade H, 2006, AM J PHYSIOL-CELL PH, V290, pC77, DOI 10.1152/ajpcell.00482.2004; Schuel H, 2005, BIOL REPROD, V73, P1078, DOI 10.1095/biolreprod.105.043273; SHEETZ MP, 1976, J CELL BIOL, V70, P247, DOI 10.1083/jcb.70.1.247; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; SHIMADA T, 1992, J GEN PHYSIOL, V100, P27, DOI 10.1085/jgp.100.1.27; SIESJO BK, 1989, ANN NY ACAD SCI, V559, P323; Talavera K, 2004, J GEN PHYSIOL, V124, P225, DOI 10.1085/jgp.200409050; Todorovic SM, 2001, NEURON, V31, P75, DOI 10.1016/S0896-6273(01)00338-5; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; van der Stelt M, 2005, PROSTAG OTH LIPID M, V77, P111, DOI 10.1016/j.prostaglandins.2004.09.007; van der Stelt M, 2005, EMBO J, V24, P3026, DOI 10.1038/sj.emboj.7600784; VanderVusse GJ, 1997, PROSTAG LEUKOTR ESS, V57, P85, DOI 10.1016/S0952-3278(97)90497-X; Veldhuis WB, 2003, J NEUROSCI, V23, P4127; Vreugdenhil M, 1996, P NATL ACAD SCI USA, V93, P12559, DOI 10.1073/pnas.93.22.12559; Xiao YF, 2006, AM J PHYSIOL-CELL PH, V290, pC362, DOI 10.1152/ajpcell.00296.2005; Xiao YF, 1997, P NATL ACAD SCI USA, V94, P4182, DOI 10.1073/pnas.94.8.4182; XIAO YF, 1995, P NATL ACAD SCI USA, V92, P11000, DOI 10.1073/pnas.92.24.11000; Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200; Zhang Y, 2000, AM J PHYSIOL-HEART C, V278, pH184, DOI 10.1152/ajpheart.2000.278.1.H184; Zhong XL, 2006, HUM MOL GENET, V15, P1497, DOI 10.1093/hmg/ddl068; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	70	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2314	2323		10.1074/jbc.M610033200	http://dx.doi.org/10.1074/jbc.M610033200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121818	hybrid			2022-12-27	WOS:000243593200023
J	Stuhlmeier, KM				Stuhlmeier, Karl M.			The anti-rheumatic gold salt aurothiomalate suppresses interleukin-1 beta-induced hyaluronan accumulation by blocking HAS1 transcription and by acting as a COX-2 transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NEUTROPHIL-DEPENDENT CYTOTOXICITY; HUMAN ENDOTHELIAL-CELLS; RHEUMATOID-ARTHRITIS; INFLAMMATORY ARTHRITIS; SODIUM AUROTHIOMALATE; SYNOVIAL FIBROBLASTS; DENDRITIC CELLS; ACTIVATION; SYNTHASES	Gold compounds are among the oldest disease-modifying drugs and are still widely used today for treating rheumatoid arthritis. Despite decades of use, little is known about the mode of action of this class of drugs. Here we have demonstrated that aurothiomalate (AuTM) suppresses hyaluronan accumulation by blocking interleukin (IL)-1 beta-induced hyaluronan synthase-1 transcription. We have further demonstrated that, in fibroblast-like synoviocytes (FLSs), AuTM acts as a specific COX-2 transcriptional repressor in that IL-1 beta-induced COX-2 transcription is blocked, whereas COX-1 transcription and translation is unaffected. As a consequence, PGE2 levels released by FLS are dose-dependently reduced in cells exposed to AuTM. Of similar importance is the demonstration that AuTM does block NF kappa B-DNA interaction. In addition, two other transcription factors implicated in inflammatory events, namely AP-1 and STAT3, are blocked as well. The effect on NF kappa B likely explains the inhibition of COX-2 as well as that of HAS1, as both are genes that depend on the activation of NF kappa B. Interestingly, AuTM does not interfere with IL-1 beta-induced I kappa B alpha degradation, in most cases a prerequisite for subsequent NF kappa B activation. Furthermore, evidence is presented that, in FLS, AuTM blocks NF kappa B-DNA interaction neither by binding to NF kappa B binding sites nor by interacting with activated NF kappa B proteins. Taken together, AuTM treatment of FLS blocks two of the most important pro-inflammatory events that are associated with rheumatoid arthritis. AuTM blocks the release of PGE2 and prevents the activation of NF kappa B, therefore blocking IL-1 beta-induced hyaluronan accumulation and likely a series of other pro-inflammatory NF kappa B-dependent genes.	Ludwig Boltzmann Inst Rheumatol & Balneol, A-1100 Vienna, Austria	Ludwig Boltzmann Institute	Stuhlmeier, KM (corresponding author), Ludwig Boltzmann Inst Rheumatol & Balneol, Kurbadstr 10, A-1100 Vienna, Austria.	karlms@excite.com						AONUMA K, 1992, INT J HEMATOL, V55, P265; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bratt J, 2000, J INVEST MED, V48, P395; Bratt J, 2000, CLIN EXP IMMUNOL, V120, P79, DOI 10.1046/j.1365-2249.2000.01190.x; BROWN RA, 1992, J PHARM PHARMACOL, V44, P467, DOI 10.1111/j.2042-7158.1992.tb03648.x; CAMPBELL JM, 1992, ANN RHEUM DIS, V51, P969, DOI 10.1136/ard.51.8.969; CASTOR CW, 1966, ARTHRITIS RHEUM, V9, P783, DOI 10.1002/art.1780090606; Clohisy JC, 2003, J IMMUNOL, V171, P5547, DOI 10.4049/jimmunol.171.10.5547; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; EngstromLaurent A, 1997, J INTERN MED, V242, P57, DOI 10.1046/j.1365-2796.1997.00174.x; Feldherr CM, 2002, BIOTECHNIQUES, V32, P1288, DOI 10.2144/02326st04; Feldmann M, 2002, ANN RHEUM DIS, V61, P13; Forestier J, 1934, LANCET, V2, P646; GOLDBERG RL, 1981, J PHARMACOL EXP THER, V218, P395; GRAUDAL H, 1988, Z RHEUMATOL, V47, P347; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Haslinger B, 2001, CELL TISSUE RES, V305, P79, DOI 10.1007/s004410100409; HENDERSON EB, 1991, ANN RHEUM DIS, V50, P196, DOI 10.1136/ard.50.3.196; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Jeon KI, 2000, J IMMUNOL, V164, P5981, DOI 10.4049/jimmunol.164.11.5981; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kataoka K, 2001, J BIOL CHEM, V276, P34074, DOI 10.1074/jbc.M105383200; Kryachko ES, 2005, NANO LETT, V5, P735, DOI 10.1021/nl050194m; KUTTAN R, 1987, Indian Journal of Physiology and Pharmacology, V31, P245; Larabee JL, 2005, CHEM RES TOXICOL, V18, P1943, DOI 10.1021/tx0501435; Laurent TC, 1996, ANN MED, V28, P241, DOI 10.3109/07853899609033126; Laurent TC, 1995, ACTA ORTHOP SCAND, V66, P116, DOI 10.3109/17453679509157665; Lehman AJ, 2005, ARTHRITIS RHEUM-US, V52, P1360, DOI 10.1002/art.21018; Li HX, 2004, P NATL ACAD SCI USA, V101, P14036, DOI 10.1073/pnas.0406115101; MADHOK R, 1993, J RHEUMATOL, V20, P630; Matt T, 2002, ACTA MED AUST, V29, P77, DOI 10.1046/j.1563-2571.2002.02010.x; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Meldrum KK, 2003, CIRC RES, V92, P293, DOI 10.1161/01.RES.0000057754.35180.99; MullerLadner U, 1996, AM J PATHOL, V149, P1607; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Pap T, 2000, ARTHRITIS RES, V2, P361, DOI 10.1186/ar113; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Rockey DC, 1998, HEPATOLOGY, V27, P86, DOI 10.1002/hep.510270115; Roth A, 2005, ARTHRITIS RES THER, V7, pR677, DOI 10.1186/ar1725; Smith AD, 1999, J NUTR, V129, P194, DOI 10.1093/jn/129.1.194; Soares MP, 2001, IMMUNOL REV, V184, P275, DOI 10.1034/j.1600-065x.2001.1840124.x; Stoyanov JV, 2003, J BIOL CHEM, V278, P1407, DOI 10.1074/jbc.C200580200; Stuhlmeier KM, 1996, EUR J IMMUNOL, V26, P1417, DOI 10.1002/eji.1830260703; Stuhlmeier KM, 2005, J BIOL CHEM, V280, P42766, DOI 10.1074/jbc.M503374200; Stuhlmeier KM, 2005, J IMMUNOL, V174, P7376, DOI 10.4049/jimmunol.174.11.7376; Stuhlmeier KM, 2004, J BIOL CHEM, V279, P8753, DOI 10.1074/jbc.M303945200; Stuhlmeier KM, 2004, RHEUMATOLOGY, V43, P164, DOI 10.1093/rheumatology/keh014; STUHLMEIER KM, 2006, IN PRESS BIOCH BIOPH; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; Wang JY, 2002, P NATL ACAD SCI USA, V99, P14362, DOI 10.1073/pnas.222536599; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEST DC, 1989, CIBA F SYMP, V143, P187; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Wilkinson TS, 2006, J CELL PHYSIOL, V206, P378, DOI 10.1002/jcp.20468	56	18	18	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2250	2258		10.1074/jbc.M605011200	http://dx.doi.org/10.1074/jbc.M605011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17085450	hybrid			2022-12-27	WOS:000243593200016
J	Datta-Mannan, A; Witcher, DR; Tang, Y; Watkins, J; Wroblewski, VJ				Datta-Mannan, Amita; Witcher, Derrick R.; Tang, Ying; Watkins, Jeffry; Wroblewski, Victor J.			Monoclonal antibody clearance - Impact of modulating the interaction of IgG with the neonatal Fc receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-RELATED RECEPTOR; NECROSIS-FACTOR-ALPHA; SERUM HALF-LIVES; CRYSTAL-STRUCTURE; BINDING; SITE; COMPLEX; MICE; IDENTIFICATION; RESOLUTION	The neonatal Fc receptor (FcRn) plays a critical role in regulating IgG homeostasis in vivo. There are mixed reports on whether modification of the interaction with FcRn can be used as an engineering strategy to improve the pharmacokinetic and pharmacodynamic properties of monoclonal antibodies. We tested whether the T250Q/M428L mutations, which improved the pharmacokinetics of humanized IgGs in the rhesus monkey, would translate to a pharmacokinetic benefit in both cynomolgus monkeys and mice when constructed on a different humanized IgG framework (anti-tumor necrosis factor-alpha (TNF alpha)). The T250Q/M428L anti-TNF alpha variant displayed an similar to 40-fold increase in binding affinity to cynomolgus monkey FcRn (C-FcRn) at pH 6.0, with maintenance of the pH binding dependence. We also constructed another anti-TNF alpha variant (P257I/Q311I) whose binding kinetics with the C-FcRn was similar to that of the T250Q/M428L variant. The binding affinity of the T250Q/M428L variant for murine FcRn was increased similar to 500-fold, with maintenance of pH dependence. In contrast to the interaction with C-FcRn, this interaction was driven mainly by a decrease in the rate of dissociation. Despite the improved in vitro binding properties of the anti-TNF alpha T250Q/M428L and P257I/Q311I variants to C-FcRn, the pharmacokinetic profiles of these molecules were not differentiated from the wild-type antibody in cynomolgus monkeys after intravenous administration. When administered intravenously to mice, the T250Q/M428L anti-TNF alpha variant displayed improved pharmacokinetics, characterized by an similar to 2-fold slower clearance than the wildtype antibody. The discrepancy between these data and previously reported benefits in rhesus monkeys and the inability of these mutations to translate to improved kinetics across species may be related to a number of factors. We propose extending consideration to differences in the absolute IgG-FcRn affinity, the kinetics of the IgG/FcRn interaction, and differences in the relative involvement of this pathway in the context of other factors influencing the disposition or elimination of monoclonal antibodies.	Lilly Corp Ctr, Lilly Res Labs, Dept Drug Disposit Dev Commercializat, Indianapolis, IN 46285 USA; Lilly Corp Ctr, Lilly Res Labs, Dept Biotechnol Discovery Res, Indianapolis, IN 46285 USA; Appl Mol Evolut, Discovery Res, San Diego, CA 92121 USA	Eli Lilly; Eli Lilly	Wroblewski, VJ (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Dept Drug Disposit Dev Commercializat, Indianapolis, IN 46285 USA.	wroblewski_victor@lilly.com						BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; Christianson GJ, 1997, J IMMUNOL, V159, P4781; Cianga P, 2003, HUM IMMUNOL, V64, P1152, DOI 10.1016/j.humimm.2003.08.025; Cianga P, 1999, EUR J IMMUNOL, V29, P2515, DOI 10.1002/(SICI)1521-4141(199908)29:08&lt;2515::AID-IMMU2515&gt;3.0.CO;2-D; Dall'Acqua WF, 2002, J IMMUNOL, V169, P5171, DOI 10.4049/jimmunol.169.9.5171; Dall'Acqua WF, 2006, J BIOL CHEM, V281, P23514, DOI 10.1074/jbc.M604292200; Datta-Mannan A, 2007, DRUG METAB DISPOS, V35, P86, DOI 10.1124/dmd.106.011734; Firan M, 2001, INT IMMUNOL, V13, P993, DOI 10.1093/intimm/13.8.993; Ghetie V, 1997, NAT BIOTECHNOL, V15, P637, DOI 10.1038/nbt0797-637; Ghetie V, 1997, IMMUNOL TODAY, V18, P592, DOI 10.1016/S0167-5699(97)01172-9; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; Gurbaxani B, 2006, MOL IMMUNOL, V43, P1462, DOI 10.1016/j.molimm.2005.07.032; Hinton PR, 2006, J IMMUNOL, V176, P346, DOI 10.4049/jimmunol.176.1.346; Hinton PR, 2004, J BIOL CHEM, V279, P6213, DOI 10.1074/jbc.C300470200; ISRAEL EJ, 1995, J IMMUNOL, V154, P6246; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kim JK, 1999, EUR J IMMUNOL, V29, P2819, DOI 10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; Kim SJ, 2005, MOL CELLS, V20, P17; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Martin WL, 1999, BIOCHEMISTRY-US, V38, P12639, DOI 10.1021/bi9913505; Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1; Medesan C, 1998, EUR J IMMUNOL, V28, P2092, DOI 10.1002/(SICI)1521-4141(199807)28:07<2092::AID-IMMU2092>3.0.CO;2-E; Medesan C, 1996, EUR J IMMUNOL, V26, P2533, DOI 10.1002/eji.1830261038; Ober RJ, 2004, P NATL ACAD SCI USA, V101, P11076, DOI 10.1073/pnas.0402970101; Ober RJ, 2004, J IMMUNOL, V172, P2021, DOI 10.4049/jimmunol.172.4.2021; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; RAGHAVAN M, 1994, IMMUNITY, V1, P303, DOI 10.1016/1074-7613(94)90082-5; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; RAPONI G, 1993, INFECT IMMUN, V61, P3976, DOI 10.1128/IAI.61.9.3976-3980.1993; Reuben S, 2003, NEUROL INDIA, V51, P487; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; Vaccaro C, 2005, NAT BIOTECHNOL, V23, P1283, DOI 10.1038/nbt1143; Vaughn DE, 1998, STRUCTURE, V6, P63, DOI 10.1016/S0969-2126(98)00008-2; Vaughn DE, 1997, J MOL BIOL, V274, P597, DOI 10.1006/jmbi.1997.1388; Verdier F, 1995, TOXICOLOGY, V105, P81, DOI 10.1016/0300-483X(95)03127-2; WALLACE KH, 1980, BIOCHEM J, V188, P9, DOI 10.1042/bj1880009; Wani MA, 2006, P NATL ACAD SCI USA, V103, P5084, DOI 10.1073/pnas.0600548103; Ward ES, 2003, INT IMMUNOL, V15, P187, DOI 10.1093/intimm/dxg018; West AP, 2000, BIOCHEMISTRY-US, V39, P9698, DOI 10.1021/bi000749m	43	118	208	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1709	1717		10.1074/jbc.M607161200	http://dx.doi.org/10.1074/jbc.M607161200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17135257	hybrid			2022-12-27	WOS:000243451300022
J	Handattu, SP; Garber, DW; Horn, DC; Hughes, DW; Berno, B; Bain, AD; Mishra, VK; Palgunachari, MN; Datta, G; Anantharamaiah, GM; Epand, RM				Handattu, Shaila P.; Garber, David W.; Horn, Dawn C.; Hughes, Donald W.; Berno, Bob; Bain, Alex D.; Mishra, Vinod K.; Palgunachari, Mayakonda N.; Datta, Geeta; Anantharamaiah, G. M.; Epand, Richard M.			ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; E-NULL MICE; BIOLOGICAL-ACTIVITY; CHOLESTEROL EFFLUX; HDL; D-4F; PARAOXONASE-1; OXIDATION; PROTECTS	Two homologous apoA-I mimetic peptides, 3F-2 and 3F(14), differ in their in vitro antiatherogenic properties ( Epand, R. M., Epand, R. F., Sayer, B. G., Datta, G., Chaddha, M., and Anantharamaiah, G. M. ( 2004) J. Biol. Chem. 279, 51404 - 51414). In the present work, we demonstrate that the peptide 3F-2, which has more potent anti- inflammatory activity in vitro when administered intraperitoneally to female apoE null mice ( 20 mu g/mouse/day) for 6 weeks, inhibits atherosclerosis ( lesion area 15,800 +/- 1000 mu m(2), n = 29), whereas 3F(14) does not ( lesion area 20,400 +/- 1000 mu m(2), n = 26) compared with control saline administered ( 19,900 +/- 1400 mu m(2), n = 22). Plasma distribution of the peptides differs in that 3F-2 preferentially associates with high density lipoprotein, whereas 3F(14) preferentially associates with apoB-containing particles. After intraperitoneal injection of C-14-labeled peptides, 3F(14) reaches a higher maximal concentration and has a longer half-time of elimination than 3F-2. A study of the effect of these peptides on the motional and organizational properties of phospholipid bilayers, using several NMR methods, demonstrates that the two peptides insert to different extents into membranes. 3F-2 with aromatic residues at the center of the nonpolar face partitions closer to the phospholipid head group compared with 3F(14). In contrast, only 3F(14) affects the terminal methyl group of the acyl chain, decreasing the H-2 order parameter and at the same time also decreasing the molecular motion of this methyl group. This dual effect of 3F(14) can be explained in terms of the cross-sectional shape of the amphipathic helix. These results support the proposal that the molecular basis for the difference in the biological activities of the two peptides lies with their different interactions with membranes.	UAB Med Ctr, Dept Med, Birmingham, AL 35294 USA; UAB Med Ctr, Dept Biochem, Birmingham, AL 35294 USA; UAB Med Ctr, Dept Mol Genet, Birmingham, AL 35294 USA; UAB Med Ctr, Atherosclerosis Res Unit, Birmingham, AL 35294 USA; McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Chem, Hamilton, ON L8N 3Z5, Canada	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; McMaster University; McMaster University	Garber, DW (corresponding author), UAB Med Ctr, Dept Med, Birmingham, AL 35294 USA.	dgarber@uab.edu; epand@mcmaster.ca	Mishra, Vinod/S-1151-2019; , Richard/R-2316-2019	Mishra, Vinod/0000-0002-4527-1512; , Richard/0000-0002-9602-9558	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 34343, P01 HL034343] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ansell B, 2004, CIRCULATION, V110, P117; Asztalos BF, 2003, AM J CARDIOL, V91, p12E, DOI 10.1016/S0002-9149(02)03383-0; AUERBACH BJ, 1992, ANAL BIOCHEM, V201, P375, DOI 10.1016/0003-2697(92)90354-A; Ballantyne CM, 2004, J AM COLL CARDIOL, V44, P1436, DOI 10.1016/S0735-1097(04)01449-4; Castellani LW, 1997, J CLIN INVEST, V100, P464, DOI 10.1172/JCI119554; CHUNG J, 1979, J BIOL CHEM, V254, P7456; Datta G, 2004, J BIOL CHEM, V279, P26509, DOI 10.1074/jbc.M314276200; Datta G, 2001, J LIPID RES, V42, P1096; Epand RM, 2004, J BIOL CHEM, V279, P51404, DOI 10.1074/jbc.M408581200; Gaidukov L, 2005, BIOCHEMISTRY-US, V44, P11843, DOI 10.1021/bi050862i; Garber DW, 2000, J LIPID RES, V41, P1020; Garber DW, 2001, J LIPID RES, V42, P545; Garin MCB, 2006, J LIPID RES, V47, P515, DOI 10.1194/jlr.M500281-JLR200; Gowri MS, 1999, ARTERIOSCL THROM VAS, V19, P2226, DOI 10.1161/01.ATV.19.9.2226; Handwerger S, 1999, AM J PHYSIOL-ENDOC M, V276, pE384, DOI 10.1152/ajpendo.1999.276.2.E384; HERZFELD J, 1980, J CHEM PHYS, V73, P6021, DOI 10.1063/1.440136; Kontush A, 2006, NAT CLIN PRACT CARD, V3, P144, DOI 10.1038/ncpcardio0500; Mackness MI, 2000, CURR OPIN LIPIDOL, V11, P383, DOI 10.1097/00041433-200008000-00007; Meyers CD, 2005, CURR OPIN CARDIOL, V20, P307; Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1426, DOI 10.1161/01.ATV.0000167412.98221.1a; Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1325, DOI 10.1161/01.ATV.0000165694.39518.95; Navab M, 2005, ANN MED, V37, P173, DOI 10.1080/07853890510007322; Navab M, 2004, CIRCULATION, V109, P3215, DOI 10.1161/01.CIR.0000134275.90823.87; Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1932, DOI 10.1161/01.ATV.0000174589.70190.e2; Ng CJ, 2005, FREE RADICAL BIO MED, V38, P153, DOI 10.1016/j.freeradbiomed.2004.09.035; Ou ZJ, 2003, CIRCULATION, V107, P1520, DOI 10.1161/01.CIR.0000061949.17174.B6; Rosenblat M, 2006, J BIOL CHEM, V281, P7657, DOI 10.1074/jbc.M512595200; SEELIG J, 1978, BIOCHEMISTRY-US, V17, P3310, DOI 10.1021/bi00609a021; Shah PK, 2005, TRENDS CARDIOVAS MED, V15, P291, DOI 10.1016/j.tcm.2005.09.003; Van Lenten BJ, 2002, CIRCULATION, V106, P1127, DOI 10.1161/01.CIR.0000030182.35880.3E	30	32	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1980	1988		10.1074/jbc.M606231200	http://dx.doi.org/10.1074/jbc.M606231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17114186	hybrid			2022-12-27	WOS:000243451300049
J	Maier, W; Schemm, R; Grewer, C; Laube, B				Maier, Wolfgang; Schemm, Rudolf; Grewer, Christof; Laube, Bodo			Disruption of interdomain interactions in the glutamate binding pocket affects differentially agonist affinity and efficacy of N-methyl-D-aspartate receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; NMDA RECEPTORS; MOLECULAR DETERMINANTS; TETRAMERIC STRUCTURE; SUBUNIT; MECHANISMS; SITE; AMPA; DISCRIMINATION; MUTATIONS	In ionotropic glutamate receptors, agonist binding occurs in a conserved clam shell-like domain composed of the two lobes D1 and D2. Docking of glutamate into the binding cleft promotes rotation in the hinge region of the two lobes, resulting in closure of the binding pocket, which is thought to represent a prerequisite for channel gating. Here, we disrupted D1D2 interlobe interactions in the NR2A subunit of N-methyl-D-aspartate (NMDA) receptors through systematic mutation of individual residues and studied the influence on the activation kinetics of currents from NR1/NR2 NMDA receptors heterologously expressed in HEK cells. We show that the mutations affect differentially glutamate binding and channel gating, depending on their location within the binding domain, mainly by altering k(off) and k(cl), respectively. Whereas impaired stability of glutamate in its binding site is the only effect of mutations on one side of the ligand binding pocket, close to the hinge region, alterations in gating are the predominant consequence of mutations on the opposite side, at the entrance of the binding pocket. A mutation increasing D1D2 interaction at the entrance of the pocket resulted in an NMDA receptor with an increased open probability as demonstrated by single channel and whole cell kinetic analysis. Thus, the results indicate that agonist-induced binding domain closure is itself a complex process, certain aspects of which are coupled either to binding or to gating. Specifically, we propose that late steps of domain closure, in kinetic terms, represent part of channel gating.	Max Planck Inst Brain Res, D-60528 Frankfurt, Germany; Max Planck Inst Biophys, D-60438 Frankfurt, Germany; Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA	Max Planck Society; Max Planck Society; University of Miami	Laube, B (corresponding author), Tech Univ Darmstadt, Dept Biol, AG Cellular Neurophysiol, Schnittspahnstr 3, D-64287 Darmstadt, Germany.	laube@bio.tu-darmstadt.de						Abele R, 2000, J BIOL CHEM, V275, P21355, DOI 10.1074/jbc.M909883199; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Banke TG, 2003, NAT NEUROSCI, V6, P144, DOI 10.1038/nn1000; Canepari M, 2001, J NEUROSCI METH, V112, P29, DOI 10.1016/S0165-0270(01)00451-4; Chen NS, 1999, J NEUROSCI, V19, P6844, DOI 10.1523/JNEUROSCI.19-16-06844.1999; Chen PE, 2005, MOL PHARMACOL, V67, P1470, DOI 10.1124/mol.104.008185; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Dingledine R, 1999, PHARMACOL REV, V51, P7; Erreger K, 2005, J NEUROSCI, V25, P7858, DOI 10.1523/JNEUROSCI.1613-05.2005; Erreger K, 2005, J PHYSIOL-LONDON, V563, P345, DOI 10.1113/jphysiol.2004.080028; Furukawa H, 2005, NATURE, V438, P185, DOI 10.1038/nature04089; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; Inanobe A, 2005, NEURON, V47, P71, DOI 10.1016/j.neuron.2005.05.022; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Laube B, 2004, NEUROPHARMACOLOGY, V47, P994, DOI 10.1016/j.neuropharm.2004.07.041; Laube B, 2000, J PHYSIOL-LONDON, V522, P215, DOI 10.1111/j.1469-7793.2000.t01-1-00215.x; Laube B, 1998, J NEUROSCI, V18, P2954; Maier W, 2005, J NEUROSCI METH, V142, P1, DOI 10.1016/j.jneumeth.2004.07.006; MATSUBARA N, 1992, BIOCHEMISTRY-US, V31, P5477, DOI 10.1021/bi00139a009; Mayer ML, 2005, NEURON, V45, P539, DOI 10.1016/j.neuron.2005.01.031; Mayer ML, 2004, ANNU REV PHYSIOL, V66, P161, DOI 10.1146/annurev.physiol.66.050802.084104; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; Morrison J, 2002, PHOTOCH PHOTOBIO SCI, V1, P960, DOI 10.1039/b206155d; Nanao MH, 2005, P NATL ACAD SCI USA, V102, P1708, DOI 10.1073/pnas.0409573102; Papageorgiou G, 2000, TETRAHEDRON, V56, P8197, DOI 10.1016/S0040-4020(00)00745-6; Popescu G, 2003, NAT NEUROSCI, V6, P476, DOI 10.1038/nn1044; Robert A, 2005, J NEUROSCI, V25, P3752, DOI 10.1523/JNEUROSCI.0188-05.2005; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; STERN P, 1994, J PHYSIOL-LONDON, V476, P391, DOI 10.1113/jphysiol.1994.sp020140; Weston MC, 2006, J NEUROSCI, V26, P7650, DOI 10.1523/JNEUROSCI.1519-06.2006; Williams G, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-153; Wittekindt B, 2001, NEUROPHARMACOLOGY, V41, P753, DOI 10.1016/S0028-3908(01)00112-5	37	20	20	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1863	1872		10.1074/jbc.M608156200	http://dx.doi.org/10.1074/jbc.M608156200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17105731	hybrid			2022-12-27	WOS:000243451300037
J	Stack, CM; Lowther, J; Cunningham, E; Donnelly, S; Gardiner, DL; Trenholme, KR; Skinner-Adams, TS; Teuscher, F; Grembecka, J; Mucha, A; Kafarski, P; Lua, L; Bell, A; Dalton, JP				Stack, Colin M.; Lowther, Jonathan; Cunningham, Eithne; Donnelly, Sheila; Gardiner, Donald L.; Trenholme, Katharine R.; Skinner-Adams, Tina S.; Teuscher, Franka; Grembecka, Jolanta; Mucha, Artur; Kafarski, Pawel; Lua, Linda; Bell, Angus; Dalton, John P.			Characterization of the Plasmodium falciparum M17 leucyl aminopeptidase - A protease involved in amino acid regulation with potential for antimalarial drug development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS LEUCINE AMINOPEPTIDASE; MALARIA PARASITES; CYSTEINE PROTEASE; BOVINE LENS; HEMOGLOBIN DEGRADATION; ERYTHROCYTIC STAGES; DIGESTIVE VACUOLE; CHABAUDI CHABAUDI; FOOD VACUOLE; LIFE-CYCLE	Amino acids generated from the catabolism of hemoglobin by intra-erythrocytic malaria parasites are not only essential for protein synthesis but also function in maintaining an osmotically stable environment, and creating a gradient by which amino acids that are rare or not present in hemoglobin are drawn into the parasite from host serum. We have proposed that a Plasmodium falciparum M17 leucyl aminopeptidase ( PfLAP) generates and regulates the internal pool of free amino acids and therefore represents a target for novel antimalarial drugs. This enzyme has been expressed in insect cells as a functional 320kDa homo-hexamer that is optimally active at neutral or alkaline pH, is dependent on metal ions for activity, and exhibits a substrate preference for N-terminally exposed hydrophobic amino acids, particularly leucine. PfLAP is produced by all stages in the intra-erythrocytic developmental cycle of malaria but was most highly expressed by trophozoites, a stage at which hemoglobin degradation and parasite protein synthesis are elevated. The enzyme was located by immunohistochemical methods and by transfecting malaria cells with a PfLAP-green fluorescent protein construct, to the cytosolic compartment of the cell at all developmental stages, including segregated merozoites. Amino acid dipeptide analogs, such as bestatin and its derivatives, are potent inhibitors of the protease and also block the growth of P. falciparum malaria parasites in culture. This study provides a biochemical basis for the antimalarial activity of aminopeptidase inhibitors. Availability of functionally active recombinant PfLAP, coupled with a simple enzymatic readout, will aid medicinal chemistry and/or high throughput approaches for the future design/discovery of new antimalarial drugs.	Univ Technol Sydney, Inst Biotechnol Infect Dis, Level 6,Bldg 4,Corner Thomas & Harris St, Sydney, NSW 2007, Australia; Univ Dublin, Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland; Queensland Inst Med Res, Malaria Biol Lab, Australian Ctr Int & Trop Hlth & Nutr, Brisbane, Qld 4006, Australia; Univ Queensland, Cent Med Div, St Lucia, Qld 4072, Australia; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Wroclaw Univ Technol, Inst Organ Chem Biochem & Biotechnol, PL-50370 Wroclaw, Poland; Univ Queensland, Inst Mol Sci, SRC Prot Express Facil, St Lucia, Qld 4072, Australia	University of Technology Sydney; Trinity College Dublin; QIMR Berghofer Medical Research Institute; University of Queensland; University of Virginia; Wroclaw University of Science & Technology; University of Queensland	Dalton, JP (corresponding author), Univ Technol Sydney, Inst Biotechnol Infect Dis, Level 6,Bldg 4,Corner Thomas & Harris St, Sydney, NSW 2007, Australia.	john.dalton@uts.edu.au	Donnelly, Sheila/H-7733-2014; Skinner-Adams, Tina S/A-9798-2012; Dalton, John/K-4457-2014; Trenholme, Katharine/C-9244-2013; Lua, Linda/B-4879-2010; Kafarski, Paweł/AAA-9112-2019; Stack, Colin M/D-4601-2009; Gardiner, Don/G-4717-2010	Skinner-Adams, Tina S/0000-0001-7011-3850; Lua, Linda/0000-0002-9756-7083; Bell, Angus/0000-0002-0578-8656; Mucha, Artur/0000-0002-6421-1371; Stack, Colin/0000-0002-7539-7677; Donnelly, Sheila/0000-0003-2005-3698				ABE F, 1989, CANCER IMMUNOL IMMUN, V28, P29; Allary M, 2002, PARASITOLOGY, V125, P1, DOI 10.1017/S0031182002001828; ANDERS RF, 1983, P NATL ACAD SCI-BIOL, V80, P6652, DOI 10.1073/pnas.80.21.6652; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Becker K, 2004, TRENDS PARASITOL, V20, P590, DOI 10.1016/j.pt.2004.09.004; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Breman JG, 2001, AM J TROP MED HYG, V64, pIV, DOI 10.4269/ajtmh.2001.64.iv; CHARET P, 1980, ANN PARASIT HUM COMP, V55, P359, DOI 10.1051/parasite/1980554359; CURLEY GP, 1994, J EUKARYOT MICROBIOL, V41, P119, DOI 10.1111/j.1550-7408.1994.tb01483.x; DePristo MA, 2006, GENE, V378, P19, DOI 10.1016/j.gene.2006.03.023; Eksi S, 2004, MOL MICROBIOL, V53, P243, DOI 10.1111/j.1365-2958.2004.04108.x; Florent I, 1998, MOL BIOCHEM PARASIT, V97, P149, DOI 10.1016/S0166-6851(98)00143-1; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Gardiner DL, 2006, J BIOL CHEM, V281, P1741, DOI 10.1074/jbc.M508955200; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gavigan CS, 2001, MOL BIOCHEM PARASIT, V117, P37, DOI 10.1016/S0166-6851(01)00327-9; GYANG FN, 1982, MOL BIOCHEM PARASIT, V5, P263, DOI 10.1016/0166-6851(82)90034-2; Hawthorne PL, 2004, MOL BIOCHEM PARASIT, V136, P181, DOI 10.1016/j.molbiopara.2004.03.013; HUBER W, 1993, ACTA TROP, V55, P257, DOI 10.1016/0001-706X(93)90083-N; IWAKI S, 1986, J BIOCHEM-TOKYO, V99, P1317, DOI 10.1093/oxfordjournals.jbchem.a135599; KIM HD, 1993, P NATL ACAD SCI USA, V90, P5006, DOI 10.1073/pnas.90.11.5006; Kirk K, 2001, LANCET, pS41; Klemba M, 2004, J BIOL CHEM, V279, P43000, DOI 10.1074/jbc.M408123200; Kolakovich KA, 1997, MOL BIOCHEM PARASIT, V87, P123, DOI 10.1016/S0166-6851(97)00062-5; Krugliak M, 2002, MOL BIOCHEM PARASIT, V119, P249, DOI 10.1016/S0166-6851(01)00427-3; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Larrinaga G, 2005, NEUROSCI LETT, V383, P136, DOI 10.1016/j.neulet.2005.03.061; Le Roch KG, 2004, GENOME RES, V14, P2308, DOI 10.1101/gr.2523904; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Lew VL, 2004, BLOOD CELL MOL DIS, V32, P353, DOI 10.1016/j.bcmd.2004.01.006; Liu J, 2006, P NATL ACAD SCI USA, V103, P8840, DOI 10.1073/pnas.0601876103; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martins TM, 2006, ACTA TROP, V97, P212, DOI 10.1016/j.actatropica.2005.11.001; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; Mehlin C, 2006, MOL BIOCHEM PARASIT, V148, P144, DOI 10.1016/j.molbiopara.2006.03.011; Morty RE, 2002, J BIOL CHEM, V277, P26057, DOI 10.1074/jbc.M202779200; Nankya-Kitaka MF, 1998, PARASITOL RES, V84, P552, DOI 10.1007/s004360050447; OLAYA P, 1991, BIOCHIM BIOPHYS ACTA, V1096, P217, DOI 10.1016/0925-4439(91)90008-W; Olson JE, 1999, BIOORGAN MED CHEM, V7, P633, DOI 10.1016/S0968-0896(99)00004-8; Omara-Opyene AL, 2004, J BIOL CHEM, V279, P54088, DOI 10.1074/jbc.M409605200; Peterson DS, 2002, MOL BIOCHEM PARASIT, V122, P119, DOI 10.1016/S0166-6851(02)00079-8; Ramjee MK, 2006, BIOCHEM J, V399, P47, DOI 10.1042/BJ20060422; ROSENTHAL PJ, 1995, EXP PARASITOL, V80, P272, DOI 10.1006/expr.1995.1033; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; Rosenthal PJ, 2004, INT J PARASITOL, V34, P1489, DOI 10.1016/j.ijpara.2004.10.003; Rosenthal PJ, 2003, J EXP BIOL, V206, P3735, DOI 10.1242/jeb.00589; Rosenthal PJ, 2002, CURR OPIN HEMATOL, V9, P140, DOI 10.1097/00062752-200203000-00010; SCHORLEMMER HU, 1983, CANCER RES, V43, P4148; Scornik OA, 1997, DRUG METAB DISPOS, V25, P798; Scornik OA, 2001, CURR DRUG METAB, V2, P67, DOI 10.2174/1389200013338748; Sekine K, 2001, INT J CANCER, V94, P485, DOI 10.1002/ijc.1492; Shenai BR, 2003, ANTIMICROB AGENTS CH, V47, P154, DOI 10.1128/AAC.47.1.154-160.2003; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Singh N, 2006, EXP PARASITOL, V112, P187, DOI 10.1016/j.exppara.2005.10.007; Skinner-Adams T, 1999, ANTIMICROB AGENTS CH, V43, P1304, DOI 10.1128/AAC.43.5.1304; Skinner-Adams TS, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-19; Spielmann T, 2006, INT J PARASITOL, V36, P1245, DOI 10.1016/j.ijpara.2006.06.017; STIRLING CJ, 1989, EMBO J, V8, P1623, DOI 10.1002/j.1460-2075.1989.tb03547.x; STRATER N, 1998, HDB PROTEOLYTIC ENZY, P1382; Sullivan JS, 1996, AM J TROP MED HYG, V55, P344, DOI 10.4269/ajtmh.1996.55.344; TAYLOR A, 1984, J BIOL CHEM, V259, P4757; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; Tonkin CJ, 2004, MOL BIOCHEM PARASIT, V137, P13, DOI 10.1016/j.molbiopara.2004.05.009; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; UMEZAWA H, 1980, BIOTECHNOL BIOENG, V22, P99; UMEZAWA H, 1976, J ANTIBIOT, V29, P857, DOI 10.7164/antibiotics.29.857; VANDERJAGT DL, 1987, BIOCHEM PHARMACOL, V36, P3285, DOI 10.1016/0006-2952(87)90646-0; VANDERJAGT DL, 1984, MOL BIOCHEM PARASIT, V10, P45, DOI 10.1016/0166-6851(84)90017-3; WILSON RJM, 1994, INFECT AGENT DIS, V3, P29	72	105	108	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					2069	2080		10.1074/jbc.M609251200	http://dx.doi.org/10.1074/jbc.M609251200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17107951	hybrid			2022-12-27	WOS:000243451300058
J	Boot, RG; Verhoek, M; Donker-Koopman, W; Strijland, A; van Marle, J; Overkleeft, HS; Wennekes, T; Aerts, JMFG				Boot, Rolf G.; Verhoek, Marri; Donker-Koopman, Wilma; Strijland, Anneke; van Marle, Jan; Overkleeft, Hermen S.; Wennekes, Tom; Aerts, Johannes M. F. G.			Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BETA-GLUCOSIDASE; GAUCHER-DISEASE; N-BUTYLDEOXYNOJIRIMYCIN; HUMAN-LIVER; MOLECULAR-CLONING; GLUCOCEREBROSIDASE; BIOSYNTHESIS; PURIFICATION; EXPRESSION; PROTEINS	The primary catabolic pathway for glucosylceramide is catalyzed by the lysosomal enzyme glucocerebrosidase that is defective in Gaucher disease patients. A distinct non-lysosomal glucosylceramidase has been described but its identity remained enigmatic for years. We here report that the non-lysosomal glucosylceramidase is identical to the earlier described bile acid beta-glucosidase, being beta-glucosidase 2 (GBA2). Expressed GBA2 is identical to the native non-lysosomal glucosylceramidase in various enzymatic features such as substrate specificity and inhibitor sensitivity. Expression of GBA2 coincides with increased non-lysosomal glucosylceramidase activity, and GBA2-targeted RNA interference reduces endogenous non-lysosomal glucosylceramidase activity in cells. GBA2 is found to be located at or close to the cell surface, and its activity is linked to sphingomyelin generation. Hydrophobic deoxynojirimycins are extremely potent inhibitors for GBA2. In mice pharmacological inhibition of GBA2 activity is associated with impaired spermatogenesis, a phenomenon also very recently reported for GBA2 knock- out mice (Yildiz, Y., Matern, H., Thompson, B., Allegood, J. C., Warren, R. L., Ramirez, D. M., Hammer, R. E., Hamra, F. K., Matern, S., and Russell, D. W. (2006) J. Clin. Invest. 116, 2985-2994). In conclusion, GBA2 plays a role in cellular glucosylceramide metabolism.	Univ Amsterdam, Acad Med Ctr, Dept Biochem Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cell Biol, NL-1105 AZ Amsterdam, Netherlands; Leiden Univ, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University - Excl LUMC	Boot, RG (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Biochem Med, K1-11,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	r.g.boot@amc.uva.nl	Wennekes, Tom/ABD-1448-2021; Wennekes, Tom/H-8271-2012; Aerts, Johannes/A-1028-2009	Wennekes, Tom/0000-0002-2368-7728; Wennekes, Tom/0000-0002-2368-7728; Aerts, Johannes/0000-0001-8168-2565; Boot, Rolf/0000-0002-7031-3390; Overkleeft, Herman/0000-0001-6976-7005				Aerts JMFG, 2006, J INHERIT METAB DIS, V29, P449, DOI 10.1007/s10545-006-0272-5; AMORY JK, 2007, IN PRESS HUM REPROD; Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BERNOTAS RC, 1991, TETRAHEDRON LETT, V32, P161, DOI 10.1016/0040-4039(91)80843-U; BEUTLER E, 2001, METABOLIC MOL BASES, P3635; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BULLER HA, 1989, AM J PHYSIOL, V257, pG616, DOI 10.1152/ajpgi.1989.257.4.G616; Cipolla L, 2002, J CHEM SOC PERK T 1, P2161, DOI 10.1039/b206623h; Cox T, 2000, LANCET, V355, P1481, DOI 10.1016/S0140-6736(00)02161-9; DANIELS LB, 1981, J BIOL CHEM, V256, P3004; Elstein D, 2004, J INHERIT METAB DIS, V27, P757, DOI 10.1023/B:BOLI.0000045756.54006.17; GIGG R, 1983, J CARBOHYD CHEM, V1, P331; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1; Ito S, 2002, BBA-GENE STRUCT EXPR, V1576, P341, DOI 10.1016/S0167-4781(02)00281-6; Kireev AS, 2006, J ORG CHEM, V71, P5694, DOI 10.1021/jo0607562; Kolter T, 2005, ANNU REV CELL DEV BI, V21, P81, DOI 10.1146/annurev.cellbio.21.122303.120013; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; MATERN H, 1992, FEBS LETT, V314, P183, DOI 10.1016/0014-5793(92)80970-R; Matern H, 2001, J BIOL CHEM, V276, P37929; Matern H, 1997, J BIOL CHEM, V272, P11261; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Overkleeft HS, 1998, J BIOL CHEM, V273, P26522, DOI 10.1074/jbc.273.41.26522; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Sprenger RR, 2004, ELECTROPHORESIS, V25, P156, DOI 10.1002/elps.200305675; STOTZ H, 1990, THESIS U BONN BONN; Trajkovic-Bodennec S, 2004, BLOOD CELL MOL DIS, V33, P77, DOI 10.1016/j.bcmd.2004.03.001; van der Spoel AC, 2002, P NATL ACAD SCI USA, V99, P17173, DOI 10.1073/pnas.262586099; VANWEELY S, 1991, BIOCHIM BIOPHYS ACTA, V1096, P301, DOI 10.1016/0925-4439(91)90066-I; VANWEELY S, 1993, BIOCHIM BIOPHYS ACTA, V1181, P55, DOI 10.1016/0925-4439(93)90090-N; Yildiz Y, 2006, J CLIN INVEST, V116, P2985, DOI 10.1172/JCI29224	32	139	147	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1305	1312		10.1074/jbc.M610544200	http://dx.doi.org/10.1074/jbc.M610544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17105727	Green Published, hybrid			2022-12-27	WOS:000243295200056
J	Gough, DJ; Sabapathy, K; Ko, EYN; Arthur, HA; Schreiber, RD; Trapani, JA; Clarke, CJP; Johnstone, RW				Gough, Daniel J.; Sabapathy, Kanaga; Ko, Enoch Yi-No; Arthur, Helen A.; Schreiber, Robert D.; Trapani, Joseph A.; Clarke, Christopher J. P.; Johnstone, Ricky W.			A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; REGULATORY FACTOR-I; NF-KAPPA-B; IFN-GAMMA; PROTEIN-KINASE; BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; STAT1-INDEPENDENT PATHWAYS; SER-727 PHOSPHORYLATION; SERINE PHOSPHORYLATION	The biological effects of interferon gamma(IFN gamma) are mediated by interferon-stimulated genes (ISGs), many of which are activated downstream of Janus kinase (JAK)/signal transducer and activator of transcription 1 (STAT1) signaling. Herein we have shown that IFN gamma rapidly activated AP-1 DNA binding that required c-Jun but was independent of JAK1 and STAT1. IFN gamma-induced c-Jun phosphorylation and AP-1 DNA binding required the MEK1/2 and ERK1/2 signaling pathways, whereas the JNK1/2 and p38 mitogen-activated protein kinase pathways were dispensable. The induction of several ISGs, including ifi-205 and iNOS, was impaired in IFN gamma-treated c-Jun(-/-) cells, but others, such as IP-10 and SOCS3, were unaffected, and chromatin immunoprecipitation demonstrated that c-Jun binds to the iNOS promoter following treatment with IFN gamma. Thus, IFN gamma induced JAK1- and STAT1-independent activation of the ERK mitogen-activated protein kinase pathway, phosphorylation of c-Jun, and activation of AP-1 DNA binding, which are important for the induction of a subset of ISGs. This represents a novel signal transduction pathway induced by IFN gamma that proceeds in parallel with conventional JAK/STAT signaling to activate ISGs.	Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia; Univ Melbourne, Parkville, Vic 3054, Australia; Natl Canc Ctr, Singapore 169610, Singapore; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Peter Maccallum Cancer Center; University of Melbourne; National Cancer Centre Singapore (NCCS); Washington University (WUSTL)	Clarke, CJP (corresponding author), Peter MacCallum Canc Ctr, St Andrews Pl, Melbourne, Vic 3002, Australia.	chris.clarke@petermac.org; ricky.johnstone@petermac.org	Schreiber, Robert D/A-1276-2013; Schreiber, Robert/Q-7550-2019; Johnstone, Ricky w/H-3748-2014	Schreiber, Robert D/0000-0001-6311-0432; Johnstone, Ricky w/0000-0001-7053-9237; Gough, Daniel/0000-0001-6479-1735; Trapani, Joseph/0000-0003-0983-1532; Gough, Daniel/0000-0001-5725-8668; Schreiber, Robert/0000-0003-1590-2341				Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Blair LA, 2002, J BIOL CHEM, V277, P359, DOI 10.1074/jbc.M109819200; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Choudhury GG, 2004, J BIOL CHEM, V279, P27399, DOI 10.1074/jbc.M403530200; Clarke CJP, 2003, J CELL BIOCHEM, V89, P80, DOI 10.1002/jcb.10475; Croce M, 2003, ONCOGENE, V22, P7848, DOI 10.1038/sj.onc.1207054; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Deb A, 2001, J IMMUNOL, V166, P6170, DOI 10.4049/jimmunol.166.10.6170; Deb DK, 2003, J IMMUNOL, V171, P267, DOI 10.4049/jimmunol.171.1.267; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Giroux M, 2003, J IMMUNOL, V171, P4187, DOI 10.4049/jimmunol.171.8.4187; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Jaramillo M, 2004, J IMMUNOL, V172, P5734, DOI 10.4049/jimmunol.172.9.5734; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kleinert H, 2004, EUR J PHARMACOL, V500, P255, DOI 10.1016/j.ejphar.2004.07.030; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Mitrasinovic OM, 2001, J BIOL CHEM, V276, P30142, DOI 10.1074/jbc.M104265200; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Nguyen VAT, 2000, BIOCHEM J, V349, P427, DOI 10.1042/0264-6021:3490427; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Rahmsdorf HJ, 1996, J MOL MED, V74, P725, DOI 10.1007/s001090050077; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Ramsauer K, 2002, P NATL ACAD SCI USA, V99, P12859, DOI 10.1073/pnas.192264999; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Roy SK, 2000, J BIOL CHEM, V275, P12626, DOI 10.1074/jbc.275.17.12626; Roy SK, 2002, P NATL ACAD SCI USA, V99, P7945, DOI 10.1073/pnas.122075799; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sato M, 2001, CYTOKINE GROWTH F R, V12, P133, DOI 10.1016/S1359-6101(00)00032-0; Shiraishi A, 1997, J IMMUNOL, V159, P3549; Shresta S, 2005, J IMMUNOL, V175, P3946, DOI 10.4049/jimmunol.175.6.3946; Sizemore N, 2004, P NATL ACAD SCI USA, V101, P7994, DOI 10.1073/pnas.0401593101; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sun DX, 2006, NAT IMMUNOL, V7, P375, DOI 10.1038/ni1308; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; Varinou L, 2003, IMMUNITY, V19, P793, DOI 10.1016/S1074-7613(03)00322-4; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xiao WH, 2001, J BIOL CHEM, V276, P23275, DOI 10.1074/jbc.M010047200; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Xiong HB, 2003, J BIOL CHEM, V278, P2271, DOI 10.1074/jbc.M209583200; Xu Y, 2004, J BIOL CHEM, V279, P41319, DOI 10.1074/jbc.M404174200; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	53	47	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					938	946		10.1074/jbc.M607674200	http://dx.doi.org/10.1074/jbc.M607674200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17105733	hybrid			2022-12-27	WOS:000243295200016
J	Dandapani, SV; Sugimoto, H; Matthews, BD; Kolb, RJ; Sinha, S; Gerszten, RE; Zhou, J; Ingber, DE; Kalluri, R; Pollak, MR				Dandapani, Savita V.; Sugimoto, Hikaru; Matthews, Benjamin D.; Kolb, Robert J.; Sinha, Sumita; Gerszten, Robert E.; Zhou, Jing; Ingber, Donald E.; Kalluri, Raghu; Pollak, Martin R.			alpha-actinin-4 is required for normal podocyte adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL SEGMENTAL GLOMERULOSCLEROSIS; LINKED KINASE ILK; CONGENITAL NEPHROTIC SYNDROME; CELL-SUBSTRATE INTERACTION; BETA-1 CYTOPLASMIC DOMAIN; INTEGRIN SUBUNIT BETA-1; DENYS-DRASH-SYNDROME; ALPHA-ACTININ; DIABETIC-NEPHROPATHY; CD2-ASSOCIATED PROTEIN	Mutations in the alpha-actinin-4 gene ACTN4 cause an autosomal dominant human kidney disease. Mice deficient in alpha-actinin-4 develop a recessive phenotype characterized by kidney failure, proteinuria, glomerulosclerosis, and retraction of glomerular podocyte foot processes. However, the mechanism by which alpha-actinin-4 deficiency leads to glomerular disease has not been defined. Here, we examined the effect of alpha-actinin-4 deficiency on the adhesive properties of podocytes in vivo and in a cell culture system. In alpha-actinin-4-deficient mice, we observed a decrease in the number of podocytes per glomerulus compared with wild-type mice as well as the presence of podocyte markers in the urine. Podocyte cell lines generated from alpha-actinin-4-deficient mice were less adherent than wild-type cells to glomerular basement membrane (GBM) components collagen IV and laminin 10 and 11. We also observed markedly reduced adhesion of alpha-actinin-4-deficient podocytes under increasing shear stresses. This adhesion deficit was restored by transfecting cells with alpha-actinin-4-GFP. We tested the strength of the integrin receptor-mediated linkages to the cytoskeleton by applying force to microbeads bound to integrin using magnetic pulling cytometry. Beads bound to alpha-actinin-4-deficient podocytes showed greater displacement in response to an applied force than those bound to wild-type cells. Consistent with integrin-dependent alpha-actinin-4-mediated adhesion, phosphorylation of beta 1-integrins on alpha-actinin-4-deficient podocytes is reduced. We rescued the phosphorylation deficit by transfecting alpha-actinin-4 into a-actinin-4-deficient podocytes. These results suggest that alpha-actinin-4 interacts with integrins and strengthens the podocyte-GBM interaction thereby stabilizing glomerular architecture and preventing disease.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Renal, Dept Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Matrix Biol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02129 USA; Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Pollak, MR (corresponding author), 4 Blackfan Circle, Boston, MA 02115 USA.	mpollak@rics.bwh.harvard.edu	Ingber, Donald E/AAC-5894-2019; Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059588, R01DK066017] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65584] Funding Source: Medline; NIDDK NIH HHS [R01 DK059588, DK066017, R01 DK059588-08, DK55001] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER S, 1992, AM J PHYSIOL, V262, pF697; ADLER S, 1992, AM J PHYSIOL, V262, pF770, DOI 10.1152/ajprenal.1992.262.5.F770; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; BARDEESY N, 1994, GENOMICS, V21, P663, DOI 10.1006/geno.1994.1333; Barreuther MF, 1996, EXP CELL RES, V222, P10, DOI 10.1006/excr.1996.0002; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; Bijian K, 2005, CONTRIB NEPHROL, V148, P8, DOI 10.1159/000086039; Bois PRJ, 2005, MOL CELL BIOL, V25, P6112, DOI 10.1128/MCB.25.14.6112-6122.2005; Chin AC, 2003, P NATL ACAD SCI USA, V100, P11104, DOI 10.1073/pnas.1831452100; Demmer L, 1999, J AM SOC NEPHROL, V10, P2215; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Duffield JS, 2000, J IMMUNOL, V164, P2110, DOI 10.4049/jimmunol.164.4.2110; Duffield JS, 2001, AM J PATHOL, V159, P1397, DOI 10.1016/S0002-9440(10)62526-6; Durvasula RV, 2004, KIDNEY INT, V65, P30, DOI 10.1111/j.1523-1755.2004.00362.x; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Ferletta M, 1999, J CELL SCI, V112, P1; Goode NP, 2004, NEPHROL DIAL TRANSPL, V19, P844, DOI 10.1093/ndt/gfg620; Hamano Y, 2002, J BIOL CHEM, V277, P31154, DOI 10.1074/jbc.M204806200; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Henriquez JP, 2002, J CELL SCI, V115, P2041; Ichikawa I, 1996, PEDIATR NEPHROL, V10, P374; Kagami Shoji, 2004, Journal of Medical Investigation, V51, P1, DOI 10.2152/jmi.51.1; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kelly DF, 2005, J STRUCT BIOL, V149, P290, DOI 10.1016/j.jsb.2004.11.010; Kelly KJ, 2003, J AM SOC NEPHROL, V14, P128, DOI 10.1097/01.ASN.0000040596.23073.01; Kelly KJ, 2001, J CLIN INVEST, V108, P1291, DOI 10.1172/JCI13018; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kim YH, 2001, KIDNEY INT, V60, P957, DOI 10.1046/j.1523-1755.2001.060003957.x; Kos CH, 2003, J CLIN INVEST, V111, P1683, DOI 10.1172/JCI200317988; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Kreidberg JA, 2000, AM J PHYSIOL-RENAL, V279, pF233, DOI 10.1152/ajprenal.2000.279.2.F233; Kretzler M, 2002, MICROSC RES TECHNIQ, V57, P247, DOI 10.1002/jemt.10083; Krishnamurti U, 1996, LAB INVEST, V74, P650; Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523-1755.1998.00044.x; Kriz W, 1997, Adv Nephrol Necker Hosp, V27, P1; Lai Xiao-xi, 2004, Beijing Da Xue Xue Bao Yi Xue Ban, V36, P131; Marshall CB, 2006, NEPHRON EXP NEPHROL, V102, P39, DOI 10.1159/000088400; Matsusaka T, 2005, J AM SOC NEPHROL, V16, P1013, DOI 10.1681/ASN.2004080720; Matthews BD, 2004, BIOCHEM BIOPH RES CO, V313, P758, DOI 10.1016/j.bbrc.2003.12.005; Mayer G, 2003, J CELL SCI, V116, P1763, DOI 10.1242/jcs.00394; Michaud JL, 2003, J AM SOC NEPHROL, V14, P1200, DOI 10.1097/01.ASN.0000059864.88610.5E; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Mulrooney JP, 2001, J CELL SCI, V114, P2525; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; Nilsson S, 2006, EXP CELL RES, V312, P844, DOI 10.1016/j.yexcr.2005.12.001; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163; Patari A, 2003, DIABETES, V52, P2969, DOI 10.2337/diabetes.52.12.2969; Patek CE, 2003, HUM MOL GENET, V12, P2379, DOI 10.1093/hmg/ddg240; Pedchenko VK, 2005, DIABETES, V54, P2952, DOI 10.2337/diabetes.54.10.2952; Petermann AT, 2004, NEPHRON EXP NEPHROL, V98, pE114, DOI 10.1159/000081555; Petermann AT, 2003, KIDNEY INT, V64, P1222, DOI 10.1046/j.1523-1755.2003.00217.x; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Reiser J, 2005, NAT GENET, V37, P739, DOI 10.1038/ng1592; Reiser J, 2004, J BIOL CHEM, V279, P34827, DOI 10.1074/jbc.M401973200; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Sanden SK, 2003, J AM SOC NEPHROL, V14, P2484, DOI 10.1097/01.ASN.0000089829.45296.7C; Schiffer M, 2004, J BIOL CHEM, V279, P37004, DOI 10.1074/jbc.M403534200; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Shirato I, 2001, CONTRIB NEPHROL, V134, P69; Smoyer WE, 1997, AM J PHYSIOL-RENAL, V273, pF150, DOI 10.1152/ajprenal.1997.273.1.F150; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; SUN XM, 1992, ANAL BIOCHEM, V204, P351, DOI 10.1016/0003-2697(92)90251-2; Susztak K, 2006, DIABETES, V55, P225, DOI 10.2337/diabetes.55.1.225; Tsukaguchi H, 2002, J CLIN INVEST, V110, P1659, DOI 10.1172/JCI200216242; WEIBEL ER, 1962, J APPL PHYSIOL, V17, P343, DOI 10.1152/jappl.1962.17.2.343; Weins A, 2005, J AM SOC NEPHROL, V16, P3694, DOI 10.1681/ASN.2005070706; Wennerberg K, 1998, J CELL SCI, V111, P1117; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; Wharram BL, 2005, J AM SOC NEPHROL, V16, P2941, DOI 10.1681/ASN.2005010055; White KE, 2004, NEPHROL DIAL TRANSPL, V19, P1437, DOI 10.1093/ndt/gfh129; Wiggins JE, 2005, J AM SOC NEPHROL, V16, P2953, DOI 10.1681/ASN.2005050488; Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215; Wolf G, 2003, LANCET, V362, P1746, DOI 10.1016/S0140-6736(03)14856-8; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1981, HISTOCHEM J, V13, P681, DOI 10.1007/BF01002719; Yamaji S, 2004, J CELL BIOL, V165, P539, DOI 10.1083/jcb.200308141; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yao J, 2004, PLOS BIOL, V2, P787, DOI 10.1371/journal.pbio.0020167; Yo Y, 2003, NEPHRON EXP NEPHROL, V93, P92, DOI 10.1159/000069551; Zamir E, 2001, J CELL SCI, V114, P3577; Zhang WW, 2006, J PHYSIOL-LONDON, V572, P659, DOI 10.1113/jphysiol.2006.106518	90	93	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					467	477		10.1074/jbc.M605024200	http://dx.doi.org/10.1074/jbc.M605024200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17082197	Green Published, hybrid			2022-12-27	WOS:000243166500052
J	Dyczynska, E; Sun, DQ; Yi, HQ; Sehara-Fujisawa, A; Blobel, CP; Zolkiewska, A				Dyczynska, Emilia; Sun, Danqiong; Yi, Haiqing; Sehara-Fujisawa, Atsuko; Blobel, Carl P.; Zolkiewska, Anna			Proteolytic processing of Delta-like 1 by ADAM proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEASE DISINTEGRIN ADAM12; CELL-CELL ADHESION; MYOGENIC DIFFERENTIATION; GAMMA-SECRETASE; POSTNATAL MYOGENESIS; ALPHA-SECRETASE; NOTCH LIGANDS; RESERVE CELLS; DELTA; ACTIVATION	Delta-like 1 (Dll1) is a mammalian ligand for Notch receptors. Interactions between Dll1 and Notch in trans activate the Notch pathway, whereas Dll1 binding to Notch in cis inhibits Notch signaling. Dll1 undergoes proteolytic processing in its extracellular domain by ADAM10. In this work we demonstrate that Dll1 represents a substrate for several other members of the ADAM family. In co-transfected cells, Dll1 is constitutively cleaved by ADAM12, and the N-terminal fragment of Dll1 is released to medium. ADAM12-mediated cleavage of Dll1 is cell density-dependent, takes place in cis orientation, and does not require the presence of the cytoplasmic domain of ADAM12. Full-length Dll1, but not its N- or C-terminal proteolytic fragment, co-immunoprecipitates with ADAM 12. By using a Notch reporter construct, we show that Dll1 processing by ADAM12 increases Notch signaling in a cell-autonomous manner. Furthermore, ADAM9 and ADAM17 have the ability to process Dll1. In contrast, ADAM15 does not cleave Dll1, although the two proteins still co-immunoprecipitate with each other. Asn353 present in the catalytic motif of ADAM12 and other Dll1-processing ADAMs, but absent in ADAM15, is necessary for Dll1 cleavage. Dll1 cleavage is reduced in ADAM9/12/15(-/-) mouse embryonic fibroblasts (MEFs), suggesting that the endogenous ADAM9 and/or ADAM12 present in wild type MEFs contribute to Dll1 processing. Finally, the endogenous Dll1 present in primary mouse myoblasts undergoes cleavage in confluent, differentiating myoblast cultures, and this cleavage is decreased by ADAM12 small interfering RNAs. Our findings expand the role of ADAM proteins in the regulation of Notch signaling.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; Kyoto Univ, Inst Frontier Med Sci, Dept Growth Regulat, Kyoto 6068507, Japan; Cornell Univ, Weill Med Coll, Hosp Special Surg, Arthritis & Tissue Degenerat Program, New York, NY 10021 USA	Kansas State University; Kyoto University; Cornell University	Zolkiewska, A (corresponding author), Kansas State Univ, Dept Biochem, 141 Chalmers Hall, Manhattan, KS 66506 USA.	zolkiea@ksu.edu	Solomon, Emilia/AAH-9319-2021	Solomon, Emilia/0000-0003-0265-9792	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065528, R01GM064750] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR017708, P20 RR017708-030010] Funding Source: Medline; NIGMS NIH HHS [R01 GM065528-03, R01 GM065528-02, R01 GM064750, GM065528, R01 GM065528, GM64750, R01 GM065528-04, R01 GM065528-01A2] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bland CE, 2003, J BIOL CHEM, V278, P13607, DOI 10.1074/jbc.C300016200; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cao Y, 2003, MOL CELL BIOL, V23, P6725, DOI 10.1128/MCB.23.19.6725-6738.2003; Cao Y, 2002, J BIOL CHEM, V277, P26403, DOI 10.1074/jbc.M110814200; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Dahlqvist C, 2003, DEVELOPMENT, V130, P6089, DOI 10.1242/dev.00834; Delfini MC, 2000, DEVELOPMENT, V127, P5213; Franklin JL, 1999, CURR BIOL, V9, P1448, DOI 10.1016/S0960-9822(00)80114-1; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hayward SD, 2004, SEMIN CANCER BIOL, V14, P387, DOI 10.1016/j.semcancer.2004.04.018; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kadesch T, 2004, CURR OPIN GENET DEV, V14, P506, DOI 10.1016/j.gde.2004.07.007; Katsube KI, 2005, INT J DEV BIOL, V49, P369, DOI 10.1387/ijdb.041950kk; Kitzmann M, 2006, J CELL PHYSIOL, V208, P538, DOI 10.1002/jcp.20688; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kurisaki T, 2003, MOL CELL BIOL, V23, P55, DOI 10.1128/MCB.23.1.55-61.2003; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; Kwon C, 2005, P NATL ACAD SCI USA, V102, P18986, DOI 10.1073/pnas.0509535102; Ladi E, 2005, J CELL BIOL, V170, P983, DOI 10.1083/jcb.200503113; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Luo D, 2005, SEMIN CELL DEV BIOL, V16, P612, DOI 10.1016/j.semcdb.2005.07.002; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Martin J, 2002, J BIOL CHEM, V277, P33683, DOI 10.1074/jbc.M200988200; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Peng RS, 2000, J VIROL, V74, P379, DOI 10.1128/JVI.74.1.379-389.2000; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Sakamoto K, 2002, DEV BIOL, V241, P313, DOI 10.1006/dbio.2001.0517; Sapir A, 2005, DEVELOPMENT, V132, P123, DOI 10.1242/dev.01546; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shinin V, 2006, NAT CELL BIOL, V8, P677, DOI 10.1038/ncb1425; Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100; STOCKER W, 1995, PROTEIN SCI, V4, P823; Wittenberger T, 1999, EMBO J, V18, P1915, DOI 10.1093/emboj/18.7.1915; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yi HQ, 2005, J BIOL CHEM, V280, P23475, DOI 10.1074/jbc.M413550200; Zhao P, 2004, DEV DYNAM, V229, P380, DOI 10.1002/dvdy.10457	51	103	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					436	444		10.1074/jbc.M605451200	http://dx.doi.org/10.1074/jbc.M605451200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17107962	hybrid, Green Accepted			2022-12-27	WOS:000243166500049
J	Yin, HY; Gao, L; Tai, HH; Murphey, LJ; Porter, NA; Morrow, JD				Yin, Huiyong; Gao, Ling; Tai, Hsin-Hsiung; Murphey, Laine J.; Porter, Ned A.; Morrow, Jason D.			Urinary prostaglandin F-2 alpha is generated from the isoprostane pathway and not the cyclooxygenase in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; BICYCLO ENDOPEROXIDES; ALZHEIMERS-DISEASE; MASS-SPECTROMETRY; OXIDATIVE STRESS; LUNG-CANCER; PRODUCTS; QUANTIFICATION; AUTOXIDATION; F-2-ISOPROSTANES	Prostaglandins (PGs) derived from the enzymatic oxidation of arachidonic acid by the cyclooxygenases (COXs) are potent lipid mediators involved in human physiology and pathophysiology. Structurally similar compounds, the isoprostanes (IsoPs), are generated from the free radical-catalyzed oxidation of arachidonic acid independent of COX. IsoPs exhibit significant bioactivity and play a role in the pathogenesis of diseases associated with oxidant injury. As one of the major PGs, prostaglandin F-2 alpha (PGF(2 alpha)) is present in human urine in significant concentrations and is presumed to be derived from COX activity. We determined, however, that levels of putative PGF(2 alpha) in urine cannot be suppressed by nonsteroidal anti-inflammatory agents, suggesting that it is generated via another mechanism(s). An important difference between COX-derived PGF(2 alpha) and the IsoPs is that the former is an optically pure compound, whereas IsoPs are racemic. Utilizing a rodent model of oxidative stress, we now show that significant amounts of compounds identical in all respects to PGF(2 alpha) and its enantiomer, ent-PGF(2 alpha), are formed in equal amounts esterified in tissue phospholipids, suggesting that these compounds are derived via the IsoP pathway. Further, employing liquid chromatography/mass spectrometry, the vast majority of putative PGF(2 alpha) in human urine is derived from the free radical-initiated peroxidation of arachidonate independent of COX and is composed of PGF(2 alpha) and its enantiomer, although the latter compound is similar to 2-fold more abundant. Thus, quantification of urinary PGF(2 alpha) actually reflects oxidative stress status as opposed to COX activity. Indeed, levels of this compound are elevated in urine from cigarette smokers and in humans with hypercholesterolemia, two conditions associated with oxidant stress. The elucidation that urinary PGF(2 alpha) in humans is derived from the IsoP pathway has implications regarding PG formation and inhibition in vivo.	Vanderbilt Univ, Div Clin Pharmacol, Dept Med, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Chem, Ctr Mol Toxicol, Nashville, TN 37232 USA; Vanderbilt Univ, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA; Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Kentucky	Morrow, JD (corresponding author), Vanderbilt Univ, Div Clin Pharmacol, Dept Med, Sch Med, 532 RRB,23rd & Pierce Aves, Nashville, TN 37232 USA.	Jason.morrow@vanderbilt.edu		yin, hui yong/0000-0001-7049-1560	NCI NIH HHS [CA77839] Funding Source: Medline; NCRR NIH HHS [RR00095] Funding Source: Medline; NHLBI NIH HHS [HL17921] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIEHS NIH HHS [P30 ES000267, ES00267] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL017921, R01HL017921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basu S, 1999, BIOCHEM BIOPH RES CO, V254, P764, DOI 10.1006/bbrc.1998.9956; Carey FA, 1990, ADV ORGANIC CHEM A, P194; CATELLA F, 1986, AM J MED, V81, P23, DOI 10.1016/0002-9343(86)90905-8; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; Dannhardt G, 2001, EUR J MED CHEM, V36, P109, DOI 10.1016/S0223-5234(01)01197-7; Ding YF, 2005, CARCINOGENESIS, V26, P65, DOI 10.1093/carcin/bgh277; FROELICH JC, 1975, J CLIN INVEST, V55, P763; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gao L, 2003, J BIOL CHEM, V278, P28479, DOI 10.1074/jbc.M303984200; GRANSTRO.E, 1971, J BIOL CHEM, V246, P7470; GRANSTROM E, 1969, J AM CHEM SOC, V91, P3398, DOI 10.1021/ja01040a067; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Havrilla CM, 2000, J AM CHEM SOC, V122, P8042, DOI 10.1021/ja001180f; Kadiiska MB, 2005, FREE RADICAL BIO MED, V38, P698, DOI 10.1016/j.freeradbiomed.2004.09.017; Kadiiska MB, 2005, FREE RADICAL BIO MED, V38, P711, DOI 10.1016/j.freeradbiomed.2004.10.024; Marnett LJ, 2000, CURR OPIN CHEM BIOL, V4, P545, DOI 10.1016/S1367-5931(00)00130-7; McAdam BF, 2005, CIRCULATION, V112, P1024, DOI 10.1161/CIRCULATIONAHA.105.542696; McAdam BF, 2000, J CLIN INVEST, V105, P1473, DOI 10.1172/JCI9523; Montine KS, 2004, CHEM PHYS LIPIDS, V128, P117, DOI 10.1016/j.chemphyslip.2003.10.010; Montine TJ, 1998, ANN NEUROL, V44, P410, DOI 10.1002/ana.410440322; Montine TJ, 2005, AM J PATHOL, V166, P1283, DOI 10.1016/S0002-9440(10)62347-4; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; Morrow JD, 2005, ARTERIOSCL THROM VAS, V25, P279, DOI 10.1161/01.ATV.0000152605.64964.c0; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; Murphey LJ, 2004, ANAL BIOCHEM, V334, P266, DOI 10.1016/j.ab.2004.08.019; OCONNOR DE, 1981, J AM CHEM SOC, V103, P223, DOI 10.1021/ja00391a056; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; Schweer H, 1997, J MASS SPECTROM, V32, P1362, DOI 10.1002/(SICI)1096-9888(199712)32:12<1362::AID-JMS606>3.3.CO;2-E; Smyth EM, 2006, GOODMAN GILMANS PHAR, P653; Stafforini DM, 2006, J BIOL CHEM, V281, P4616, DOI 10.1074/jbc.M507340200; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Taber DF, 2000, TETRAHEDRON, V56, P5991, DOI 10.1016/S0040-4020(00)00531-7; Wubert J, 1997, ANAL CHEM, V69, P2143, DOI 10.1021/ac9611430; Yin HY, 2005, J CHROMATOGR B, V827, P157, DOI 10.1016/j.jchromb.2005.03.038; Yin HY, 2005, ANTIOXID REDOX SIGN, V7, P170, DOI 10.1089/ars.2005.7.170; Yin HY, 2004, J BIOL CHEM, V279, P3766, DOI 10.1074/jbc.M307137200; Yin HY, 2003, J BIOL CHEM, V278, P16720, DOI 10.1074/jbc.M300604200; Yin HY, 2002, J AM CHEM SOC, V124, P7745, DOI 10.1021/ja0201092	40	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					329	336		10.1074/jbc.M608975200	http://dx.doi.org/10.1074/jbc.M608975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17107953	hybrid			2022-12-27	WOS:000243166500037
J	Burkhart, BA; Kennett, SB; Archer, TK				Burkhart, Barbara A.; Kennett, Sarah B.; Archer, Trevor K.			Osmotic stress-dependent repression is mediated by histone H3 phosphorylation and chromatin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRANSFORMED MOUSE FIBROBLASTS; B-INDUCED PHOSPHORYLATION; GLUCOCORTICOID-RECEPTOR; CHROMOSOME CONDENSATION; MITOTIC PHOSPHORYLATION; SER-10 PHOSPHORYLATION; BETAINE TRANSPORTER; KIDNEY-CELLS; IN-VIVO	Histone H3 phosphorylation has been linked to various environmental stress responses and specific chromatin structure. The role of H3 phosphorylation in the osmotic stress response was investigated on the mouse mammary tumor virus (MMTV) promoter in different chromatin configurations. Hormone-dependent transcription from the MMTV promoter is repressed by osmotic stress when the promoter is integrated and has a normal chromatin structure. However, when the MMTV promoter is transiently transfected, the chromatin structure is less organized, and hormone induction is not affected by osmotic stress. On the integrated MMTV promoter, phosphorylation of histone H3 serine 10 and 28 increases in response to osmotic stress, but the transient promoter shows no change. Hormone-dependent glucocorticoid receptor binding is reduced on the repressed promoter, and elevated H3 phosphorylation is temporally correlated with maximal MMTV repression Additionally, the protein kinase C inhibitor rottlerin, but not other kinase inhibitors, blocks both histone H3 phosphorylation and osmotic repression of MMTV transcription. Glucocorticoid receptor binding is inversely correlated with H3 phosphorylation, suggesting that displacement of the glucocorticoid receptor from the promoter is due to H3 phosphorylation and is the mechanism for the osmotic repression of hormone-dependent transcription.	Interagcy Oncol Task Force Food & Drug Adm, Ctr Biol Evaluat & Res, NIH, Bethesda, MD 20892 USA; NCI, NIH, Bethesda, MD 20892 USA; NIEHS, Lab Mol Carcinogenesis, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Archer, TK (corresponding author), Interagcy Oncol Task Force Food & Drug Adm, Ctr Biol Evaluat & Res, NIH, Bethesda, MD 20892 USA.	archer1@niehs.nih.gov	Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071006, ZIAES071006] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bell LM, 2000, J BIOL CHEM, V275, P25262, DOI 10.1074/jbc.M002076200; Bhattacharjee RN, 2006, VIROLOGY, V346, P1, DOI 10.1016/j.virol.2005.12.034; BODE AM, 2005, SCI STKE, pRE4; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; DeManno DA, 1999, MOL ENDOCRINOL, V13, P91, DOI 10.1210/me.13.1.91; Deroo BJ, 2001, ONCOGENE, V20, P3039, DOI 10.1038/sj.onc.1204328; Dihazi H, 2005, MOL CELL PROTEOMICS, V4, P1445, DOI 10.1074/mcp.M400184-MCP200; Ding HF, 1997, MOL CELL BIOL, V17, P5843, DOI 10.1128/MCB.17.10.5843; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Fryer CJ, 2000, J BIOL CHEM, V275, P17771, DOI 10.1074/jbc.M908729199; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; He ZW, 2003, J BIOL CHEM, V278, P10588, DOI 10.1074/jbc.M208581200; Hebbar PB, 2003, CHROMOSOMA, V111, P495, DOI 10.1007/s00412-003-0232-x; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Hsiao PW, 2002, BIOCHEM CELL BIOL, V80, P343, DOI 10.1139/O02-082; Huang W, 2004, J LIPID RES, V45, P1519, DOI 10.1194/jlr.M400088-JLR200; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; Lim JH, 2004, MOL CELL, V15, P573, DOI 10.1016/j.molcel.2004.08.006; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; Michea L, 2000, AM J PHYSIOL-RENAL, V278, pF209, DOI 10.1152/ajprenal.2000.278.2.F209; Mizuno H, 2001, GENES CELLS, V6, P261, DOI 10.1046/j.1365-2443.2001.00418.x; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Proft M, 2004, CELL, V118, P351, DOI 10.1016/j.cell.2004.07.016; Prymakowska-Bosak M, 2001, MOL CELL BIOL, V21, P5169, DOI 10.1128/MCB.21.15.5169-5178.2001; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Schmitt A, 2002, FEBS LETT, V518, P23, DOI 10.1016/S0014-5793(02)02630-3; Sheikh-Hamad D, 2004, AM J PHYSIOL-RENAL, V287, pF1102, DOI 10.1152/ajprenal.00225.2004; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strelkov IS, 2002, CANCER RES, V62, P75; Trieschmann L, 1998, P NATL ACAD SCI USA, V95, P5468, DOI 10.1073/pnas.95.10.5468; Trotter KW, 2004, MOL CELL BIOL, V24, P3347, DOI 10.1128/MCB.24.8.3347-3358.2004; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; Zhao HY, 2002, AM J PHYSIOL-RENAL, V282, pF710, DOI 10.1152/ajprenal.00303.2001; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhu F, 2004, CARCINOGENESIS, V25, P1847, DOI 10.1093/carcin/bgh202; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V278, pC102, DOI 10.1152/ajpcell.2000.278.1.C102	44	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4400	4407		10.1074/jbc.M609041200	http://dx.doi.org/10.1074/jbc.M609041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158874	hybrid			2022-12-27	WOS:000244482000020
J	Cifuentes-Rojas, C; Pavia, P; Hernandez, A; Osterwisch, D; Puerta, C; Cruz-Reyes, J				Cifuentes-Rojas, Catherine; Pavia, Paula; Hernandez, Alfredo; Osterwisch, Daniel; Puerta, Concepcion; Cruz-Reyes, Jorge			Substrate determinants for RNA editing and editing complex interactions at a site for full-round U insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI MITOCHONDRIA; PRECURSOR MESSENGER-RNA; BINDING PROTEIN GBP21; IN-VITRO; LEISHMANIA-TARENTOLAE; EXORIBONUCLEASE ACTIVITY; BAND IV; DELETION; GRNA; DNA	Multisubunit RNA editing complexes catalyze uridylate insertion/deletion RNA editing directed by complementary guide RNAs (gRNAs). Editing in trypanosome mitochondria is transcript-specific and developmentally controlled, but the molecular mechanisms of substrate specificity remain unknown. Here we used a minimal A6 pre-mRNA/gRNA substrate to define functional determinants for full-round insertion and editing complex interactions at the editing site 2 (ES2). Editing begins with pre-mRNA cleavage within an internal loop flanked by upstream and downstream duplexes with gRNA. We found that substrate recognition around the internal loop is sequence-independent and that completely artificial duplexes spanning a single helical turn are functional. Furthermore, after our report of cross-linking interactions at the deletion ES1 (35), we show for the first time editing complex contacts at an insertion ES. Our studies using site-specific ribose 2' substitutions defined 2'-hydroxyls within the (a) gRNA loop region and (b) flanking helixes that markedly stimulate both pre-mRNA cleavage and editing complex interactions at ES2. Modification of the downstream helix affected scissile bond specificity. Notably, a single 2'-hydroxyl at ES2 is essential for cleavage but dispensable for editing complex cross-linking. This study provides new insights on substrate recognition during full-round editing, including the relevance of secondary structure and the first functional association of specific (pre-mRNA and gRNA) riboses with both endonuclease cleavage and cross-linking activities of editing complexes at an ES. Importantly, most observed cross-linking interactions are both conserved and relatively stable at ES2 and ES1 in hybrid substrates. However, they were also detected as transient low-stability contacts in a non-edited transcript.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Pontificia Univ Javeriana, Lab Parasitol Mol, Bogota, Colombia	Texas A&M University System; Texas A&M University College Station; Pontificia Universidad Javeriana	Cruz-Reyes, J (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, 2128 TAMU, College Stn, TX 77843 USA.	cruzrey@tamu.edu	Cruz-Reyes, Jorge/GQP-1338-2022; Hernandez, Alfredo/AAV-5584-2021; Puerta, Concepcion J/AAG-4912-2019; Hernandez, Alfredo J/ABC-8311-2020	Hernandez, Alfredo J/0000-0002-0903-8932; Puerta Bula, Concepcion Judith/0000-0002-3449-3961; Cruz-Reyes, Jorge/0000-0003-0545-1508	NIGMS NIH HHS [GM067130] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067130] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen TE, 1998, MOL CELL BIOL, V18, P6014, DOI 10.1128/MCB.18.10.6014; Aphasizhev R, 2003, RNA, V9, P62, DOI 10.1261/rna.2134303; Aphasizhev R, 2003, EMBO J, V22, P913, DOI 10.1093/emboj/cdg083; Arnott S, 1970, Prog Biophys Mol Biol, V21, P265, DOI 10.1016/0079-6107(70)90027-1; Blaszczyk J, 2001, STRUCTURE, V9, P1225, DOI 10.1016/S0969-2126(01)00685-2; Blom D, 2001, NUCLEIC ACIDS RES, V29, P2950, DOI 10.1093/nar/29.14.2950; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; Brecht M, 2005, MOL CELL, V17, P621, DOI 10.1016/j.molcel.2005.01.018; Carnes J, 2005, P NATL ACAD SCI USA, V102, P16614, DOI 10.1073/pnas.0506133102; Cifuentes-Rojas C, 2005, NUCLEIC ACIDS RES, V33, P6610, DOI 10.1093/nar/gki943; Cruz-Reyes J, 1998, NUCLEIC ACIDS RES, V26, P3634, DOI 10.1093/nar/26.16.3634; Cruz-Reyes J, 1998, MOL CELL, V1, P401, DOI 10.1016/S1097-2765(00)80040-4; Cruz-Reyes J, 2002, MOL CELL BIOL, V22, P4652, DOI 10.1128/MCB.22.13.4652-4660.2002; Cruz-Reyes J, 2001, MOL CELL BIOL, V21, P884, DOI 10.1128/MCB.21.3.884-892.2001; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; Ernst NL, 2003, MOL CELL, V11, P1525, DOI 10.1016/S1097-2765(03)00185-0; Gan JH, 2006, CELL, V124, P355, DOI 10.1016/j.cell.2005.11.034; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; Huang CE, 2001, EMBO J, V20, P4694, DOI 10.1093/emboj/20.17.4694; Hudson BP, 2004, NAT STRUCT MOL BIOL, V11, P257, DOI 10.1038/nsmb738; Igo RP, 2000, MOL CELL BIOL, V20, P8447, DOI 10.1128/MCB.20.22.8447-8457.2000; Igo RP, 2002, MOL CELL BIOL, V22, P1567, DOI 10.1128/MCB.22.5.1567-1576.2002; Igo RP, 2002, EUKARYOT CELL, V1, P112, DOI 10.1128/EC.1.1.112-118.2002; Kabb AL, 2001, NUCLEIC ACIDS RES, V29, P2575, DOI 10.1093/nar/29.12.2575; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; Kang XD, 2005, P NATL ACAD SCI USA, V102, P1017, DOI 10.1073/pnas.0409275102; Kapushoc ST, 1999, RNA, V5, P656, DOI 10.1017/S1355838299982250; Koslowsky Donna J, 2004, RNA Biol, V1, P28; Lawson SD, 2001, RNA, V7, P1793, DOI 10.1017/S135583820101055X; Leung SS, 1999, NUCLEIC ACIDS RES, V27, P778, DOI 10.1093/nar/27.3.778; Madison-Antenucci S, 1998, EMBO J, V17, P6368, DOI 10.1093/emboj/17.21.6368; Madison-Antenucci S, 2002, CELL, V108, P435, DOI 10.1016/S0092-8674(02)00653-0; Madison-Antenucci S, 2001, MOL CELL, V7, P879, DOI 10.1016/S1097-2765(01)00231-3; McManus MT, 2001, RNA, V7, P167, DOI 10.1017/S1355838201002072; Messias AC, 2004, ACCOUNTS CHEM RES, V37, P279, DOI 10.1021/ar030034m; Miller MM, 2006, RNA, V12, P1292, DOI 10.1261/rna.2331506; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Missel A, 1997, MOL CELL BIOL, V17, P4895, DOI 10.1128/MCB.17.9.4895; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; Muller UF, 2001, EMBO J, V20, P1394, DOI 10.1093/emboj/20.6.1394; Nandakumar J, 2004, MOL CELL, V16, P211, DOI 10.1016/j.molcel.2004.09.022; Noy A, 2005, J AM CHEM SOC, V127, P4910, DOI 10.1021/ja043293v; Oppegard LM, 2000, J BIOL CHEM, V275, P33911, DOI 10.1074/jbc.M003002200; Pai RD, 2003, RNA, V9, P469, DOI 10.1261/rna.2175703; Panigrahi AK, 2003, RNA, V9, P484, DOI 10.1261/rna.2194603; Panigrahi AK, 2001, MOL CELL BIOL, V21, P380, DOI 10.1128/MCB.21.2.380-389.2001; Panigrahi AK, 2006, RNA, V12, P1038, DOI 10.1261/rna.45506; Pelletier M, 2003, RNA, V9, P457, DOI 10.1261/rna.2160803; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; Sacharidou A, 2006, RNA, V12, P1219, DOI 10.1261/rna.2295706; Salavati R, 2006, RNA, V12, P819, DOI 10.1261/rna.2244106; Schnaufer A, 2003, MOL CELL, V12, P307, DOI 10.1016/S1097-2765(03)00286-7; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; Simpson L, 2004, RNA, V10, P159, DOI 10.1261/rna.5170704; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Stefl R, 2005, EMBO REP, V6, P33, DOI 10.1038/sj.embor.7400325; Stuart KD, 2005, TRENDS BIOCHEM SCI, V30, P97, DOI 10.1016/j.tibs.2004.12.006; Tian B, 2004, NAT REV MOL CELL BIO, V5, P1013, DOI 10.1038/nrm1528; Trotter JR, 2005, MOL CELL, V20, P403, DOI 10.1016/j.molcel.2005.09.016; Vanhamme L, 1998, J BIOL CHEM, V273, P21825, DOI 10.1074/jbc.273.34.21825; Vondruskova E, 2005, J BIOL CHEM, V280, P2429, DOI 10.1074/jbc.M405933200; WANG AHJ, 1982, NATURE, V299, P601, DOI 10.1038/299601a0; Yu LE, 2006, RNA, V12, P1050, DOI 10.1261/rna.3406; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	68	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4265	4276		10.1074/jbc.M605554200	http://dx.doi.org/10.1074/jbc.M605554200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158098	hybrid			2022-12-27	WOS:000244482000006
J	Larose, S; Laterreur, N; Ghazal, G; Gagnon, J; Wellinger, RJ; Abou Elela, S				Larose, Stephanie; Laterreur, Nancy; Ghazal, Ghada; Gagnon, Jules; Wellinger, Raymund J.; Abou Elela, Sherif			RNase III-dependent regulation of yeast telomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; SUBSTRATE RECOGNITION; EST GENES; DNA; DEGRADATION; RNT1P; PROTEINS; CLEAVAGE; IDENTIFICATION	In bakers' yeast, in vivo telomerase activity requires a ribonucleoprotein (RNP) complex with at least four associated proteins (Est2p, Est1p, Est3p, and Cdc13p) and one RNA species (Tlc1). The function of telomerase in maintaining chromosome ends, called telomeres, is tightly regulated and linked to the cell cycle. However, the mechanisms that regulate the expression of individual components of telomerase are poorly understood. Here we report that yeast RNase III (Rnt1p), a double-stranded RNA-specific endoribonuclease, regulates the expression of telomerase subunits and is required for maintaining normal telomere length. Deletion or inactivation of RNT1 induced the expression of Est1, Est2, Est3, and Tlc1 RNAs and increased telomerase activity, leading to elongation of telomeric repeat tracts. In silico analysis of the different RNAs coding for the telomerase subunits revealed a canonical Rnt1p cleavage site near the 3' end of Est1 mRNA. This predicted structure was cleaved by Rnt1p and its disruption abolished cleavage in vitro. Mutation of the Rnt1p cleavage signal in vivo impaired the cell cycle-dependent degradation of Est1 mRNA without affecting its steady-state level. These results reveal a new mechanism that influences telomeres length by controlling the expression of the telomerase subunits.	Univ Sherbrooke, Fac Med, Dept Microbiol & Infect, RNA Grp, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Abou Elela, S (corresponding author), 3001 12 Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	sherif.abou.elela@usherbrooke.ca	Wellinger, Raymund/K-3207-2019	Wellinger, Raymund/0000-0001-6670-2759; Abou Elela, Sherif/0000-0002-0630-3294				ABOUELELA S, 1998, EMBO J, V17, P3738, DOI DOI 10.1093/EMB0J/17.13.3738); Boule JB, 2005, NATURE, V438, P57, DOI 10.1038/nature04091; Brachmann CB, 1998, YEAST, V14, P115; Catala M, 2004, MOL BIOL CELL, V15, P3015, DOI 10.1091/mbc.E04-03-0183; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; CHANFREU G, 2000, P NATL ACAD SCI USA, V97, P1342; Chapon C, 1997, RNA, V3, P1337; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; Dahlseid JN, 2003, EUKARYOT CELL, V2, P134, DOI 10.1128/EC.2.1.134-142.2003; Danin-Kreiselman M, 2003, MOL CELL, V11, P1279, DOI 10.1016/S1097-2765(03)00137-0; Das B, 2003, MOL CELL BIOL, V23, P5502, DOI 10.1128/MCB.23.16.5502-5515.2003; di Fagagna FD, 2004, GENE DEV, V18, P1781, DOI 10.1101/gad.1214504; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; ENGELKE DR, 1990, ANAL BIOCHEM, V191, P396, DOI 10.1016/0003-2697(90)90238-5; Evans SK, 2000, J CELL SCI, V113, P3357; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; Ge DL, 2005, CURR BIOL, V15, P140, DOI 10.1016/j.cub.2004.12.001; Ghazal G, 2005, MOL CELL BIOL, V25, P2981, DOI 10.1128/MCB.25.8.2981-2994.2005; Gill T, 2004, MOL CELL BIOL, V24, P945, DOI 10.1128/MCB.24.3.945-953.2004; Giorgi C, 2001, EMBO J, V20, P6856, DOI 10.1093/emboj/20.23.6856; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Guthrie C, 1991, GUIDE YEAST GENETICS; HENIKOFF S, 1987, GENETICS, V117, P711; Hug N, 2006, CHROMOSOMA, V115, P413, DOI 10.1007/s00412-006-0067-3; Lamontagne B, 2004, J MOL BIOL, V338, P401, DOI 10.1016/j.jmb.2004.02.059; Lamontagne B, 2003, J MOL BIOL, V327, P985, DOI 10.1016/S0022-2836(03)00231-6; Lamontagne B., 2001, PURIFICATION CHARACT; Larrivee M, 2004, GENE DEV, V18, P1391, DOI 10.1101/gad.1199404; Lebars I, 2001, EMBO J, V20, P7250, DOI 10.1093/emboj/20.24.7250; LeBel C, 2005, J CELL SCI, V118, P2785, DOI 10.1242/jcs.02394; LeBel Catherine, 2006, Methods Mol Biol, V313, P265; Lee A, 2005, MOL CELL, V19, P39, DOI 10.1016/j.molcel.2005.05.021; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Marcand S, 2000, CURR BIOL, V10, P487, DOI 10.1016/S0960-9822(00)00450-4; Nagel R, 2000, RNA, V6, P1142, DOI 10.1017/S1355838200000431; Osterhage JL, 2006, NAT STRUCT MOL BIOL, V13, P720, DOI 10.1038/nsmb1125; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Rose MD., 1990, METHODS YEAST GENETI; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Snow BE, 2003, CURR BIOL, V13, P698, DOI 10.1016/S0960-9822(03)00210-0; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Taggart AKP, 2003, CURR OPIN CELL BIOL, V15, P275, DOI 10.1016/S0955-0674(03)00040-1; Taggart AKP, 2002, SCIENCE, V297, P1023, DOI 10.1126/science.1074968; Teo SH, 2001, EMBO REP, V2, P197, DOI 10.1093/embo-reports/kve038; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tremblay A, 2002, MOL CELL BIOL, V22, P4792, DOI 10.1128/MCB.22.13.4792-4802.2002; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Yang D, 2000, CURR BIOL, V10, P1191, DOI 10.1016/S0960-9822(00)00732-6; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zer C, 2005, J BIOL CHEM, V280, P28997, DOI 10.1074/jbc.M505913200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	57	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4373	4381		10.1074/jbc.M607145200	http://dx.doi.org/10.1074/jbc.M607145200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158880	hybrid			2022-12-27	WOS:000244482000017
J	Besse, A; Lamothe, B; Campos, AD; Webster, WK; Maddineni, U; Lin, SC; Wu, H; Darnay, BG				Besse, Arnaud; Lamothe, Betty; Campos, Alejandro D.; Webster, William K.; Maddineni, Upendra; Lin, Su-Chang; Wu, Hao; Darnay, Bryant G.			TAK1-dependent signaling requires functional interaction with TAB2/TAB3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; KINASE KINASE KINASE; OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; NFATC1 INDUCTION; RAW264.7 CELLS; TAK1; TRAF6; PROTEIN	Transforming growth factor beta-activated kinase 1 (TAX1), a member of the MAPKKK family, was initially described to play an essential role in the transforming growth factor beta-signaling pathway, but recent evidence has emerged implicating TAK1 in the interleukin (IL)-1 and tumor necrosis factor (TNF) pathways. Notably, two homologous proteins, TAB2 and TAB3, have been identified as adaptors linking TAK1 to the upstream adaptors TRAFs. However, it remains unclear whether the interaction between TAB2/TAB3 and TAK1 is necessary for its kinase activation and subsequent activation of the IKK and MAPK pathways. Here, we characterized the TAB2/TAB3-binding domain in TAK1 and further examined the requirement of this interaction for IL-1, TNF, and RANKL signaling. Through deletion mapping experiments, we demonstrated that the binding motif for TAB2/TAB3 is a non-contiguous region located within the last C-terminal 100 residues of TAK1. However, residues 479-553 of TAK1. appear to be necessary and sufficient for TAB2/TAB3 interaction. Conversely, residues 574-693 of TAB2 were shown to interact with TAK1. A green fluorescent protein fusion protein containing the last 100 residues of TAK1 (TAK1-C100) abolished the interaction of endogenous TAB2/TAB3 with TAK1, the phosphorylation of TAK1, and prevented the activation of IKK and MAPK induced by IL-1, TNF, and RANKL. Furthermore, TAK1-C100 blocked RANKL-induced nuclear accumulation of NFATc1 and consequently osteoclast differentiation consistent with the ability of a catalytically inactive TAK1 to block RANKL-mediated signaling. Significantly, our study provides evidence that the TAB2/TAB3 interaction with TAK1 is crucial for the activation of signaling cascades mediated by IL-1, TNF, and RANKL.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	University of Texas System; UTMD Anderson Cancer Center; Cornell University	Darnay, BG (corresponding author), Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	bdarnay@mdanderson.org	Lin, SC/G-4666-2010; Lin, Su-Chang/F-2899-2016	Lin, Su-Chang/0000-0003-0687-3139	NCI NIH HHS [CA16672SAF, P30 CA016672] Funding Source: Medline; NIAID NIH HHS [R01 AI045937, R01-AI 45937] Funding Source: Medline; NIAMS NIH HHS [R01 AR053540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chen ZJ, 2006, CELL DEATH DIFFER, V13, P687, DOI 10.1038/sj.cdd.4401869; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Israel A, 2006, TRENDS IMMUNOL, V27, P395, DOI 10.1016/j.it.2006.07.003; Jin G, 2004, P NATL ACAD SCI USA, V101, P2028, DOI 10.1073/pnas.0307314101; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kishida S, 2005, GENES CELLS, V10, P447, DOI 10.1111/j.1365-2443.2005.00852.x; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kitamura T, 1998, INT J HEMATOL, V67, P351; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; LAMOTHE B, 2006, IN PRESS J BIOL CHEM; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Sanjo H, 2003, MOL CELL BIOL, V23, P1231, DOI 10.1128/MCB.23.4.1231-1238.2003; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109-004-0612-6; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Wald D, 2001, EUR J IMMUNOL, V31, P3747, DOI 10.1002/1521-4141(200112)31:12<3747::AID-IMMU3747>3.0.CO;2-E; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	47	107	114	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3918	3928		10.1074/jbc.M608867200	http://dx.doi.org/10.1074/jbc.M608867200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158449	Green Accepted, hybrid			2022-12-27	WOS:000244481900056
J	Danek, EI; Tcherkezian, J; Triki, I; Meriane, M; Lamarche-Vane, N				Danek, Eric Ian; Tcherkezian, Joseph; Triki, Ibtissem; Meriane, Mayya; Lamarche-Vane, Nathalie			Glycogen synthase kinase-3 phosphorylates CdGAP at a consensus ERK 1 regulatory site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; GTPASE-ACTIVATING PROTEIN; RHO GTPASES; GENE-EXPRESSION; GSK-3; CYTOKINESIS; INHIBITION; PATHWAY; LINK; RAC	Rho GTPases regulate a multitude of cellular processes from cytoskeletal reorganization to gene transcription and are negatively regulated by GTPase-activating proteins (GAPs). Cdc42 GTPase-activating protein (CdGAP) is a ubiquitously expressed GAP for Rac1 and Cdc42. In this study, we set out to identify CdGAP-binding partners and, using a yeast two-hybrid approach, glycogen synthase kinase 3 alpha (GSK-3 alpha) was identified as a partner for CdGAP. GSK-3 exists in two isoforms, alpha and beta, and is involved in regulating many cellular functions from insulin response to tumorigenesis. We show that GSK-3 alpha and -beta interact with CdGAP in mammalian cells. We also demonstrate that GSK-3 phosphorylates CdGAP both in vitro and in vivo on Thr-776, which we have previously shown to be an ERK 1/2 phosphorylation site involved in CdGAP regulation. We report that the mRNA and protein levels of CdGAP are increased upon serum stimulation and that GSK-3 activity is necessary for the up-regulation of the protein levels of CdGAP but not for the increase in mRNA. We conclude that GSK-3 is an important regulator of CdGAP and that regulation of CdGAP protein levels by serum presents a novel mechanism for cells to control Cdc42/Rac1 GTPase signaling pathways.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	McGill University	Lamarche-Vane, N (corresponding author), McGill Univ, Dept Anat & Cell Biol, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.	nathalie.lamarche@mcgill.ca						Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; Benitah SA, 2004, BBA-REV CANCER, V1705, P121, DOI 10.1016/j.bbcan.2004.10.002; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; LaLonde DP, 2006, CURR BIOL, V16, P1375, DOI 10.1016/j.cub.2006.05.057; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Ligeti E, 2006, METHOD ENZYMOL, V406, P104, DOI 10.1016/S0076-6879(06)06009-5; Litovchick L, 2004, MOL CELL BIOL, V24, P8970, DOI 10.1128/MCB.24.20.8970-8980.2004; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; Stryer L., 1988, BIOCHEMISTRY-US, P187; Su L, 2003, J CELL BIOL, V163, P571, DOI 10.1083/jcb.200308007; Tcherkezian J, 2005, MOL CELL BIOL, V25, P6314, DOI 10.1128/MCB.25.15.6314-6329.2005; Tcherkezian J, 2006, BIOL CELL, V98, P445, DOI 10.1042/BC20050101; Trivedi N, 2005, J CELL SCI, V118, P993, DOI 10.1242/jcs.01697; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yin L, 2006, SCIENCE, V311, P1002, DOI 10.1126/science.1121613; YU JS, 1994, J NEUROCHEM, V62, P1596	35	7	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3624	3631		10.1074/jbc.M610073200	http://dx.doi.org/10.1074/jbc.M610073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158447	hybrid			2022-12-27	WOS:000244481900024
J	Lamothe, B; Besse, A; Campos, AD; Webster, WK; Wu, H; Darnay, BG				Lamothe, Betty; Besse, Arnaud; Campos, Alejandro D.; Webster, William K.; Wu, Hao; Darnay, Bryant G.			Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; DEFECTIVE INTERLEUKIN-1; TRAF6-DEFICIENT MICE; POLYUBIQUITIN CHAIN; CRYSTAL-STRUCTURE; UBIQUITIN LIGASE; TRAF6; NEMO; REQUIRES; PATHWAY	Tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) is a key mediator in proximal signaling of the interleukin-1/Toll-like receptor and the TNF receptor superfamily. Analysis of TRAF6-deficient mice revealed a fundamental role of TRAF6 in osteoclastogenesis; however, the molecular mechanism underlying TRAF6 signaling in this biological process is not understood. Recent biochemical evidence has indicated that TRAF6 possesses ubiquitin ligase activity that controls the activation of IKK and NF-kappa B. Because these studies are primarily based on cell-free systems, the role of the ubiquitin ligase activity of TRAF6 and its auto-ubiquitination to initiate the NF-kappa B pathway in vivo remain elusive. Here we show that an intact RING domain of TRAF6 in conjunction with the E2 enzyme Ubc13/Uev1A is necessary for Lys-63-linked auto-ubiquitination of TRAF6 and for its ability to activate IKK and NF-kappa B. Furthermore, a RING mutant of TRAF6 abolishes its ability to induce receptor activator of NF-kappa B-independent osteoclast differentiation and nuclear accumulation of the transcription factor NFATc1. Notably, we map the auto-ubiquitination site of TRAF6 to a single Lys residue, which if mutated renders TRAF6 unable to activate transforming growth factor-beta-activated kinase 1 and IKK and to cause spontaneous osteoclast differentiation. Additionally, we provide biochemical and in vivo evidence that TRAF6 serves as an E3 to directly ubiquitinate NEMO. Reconstituting TRAF6-deficent cells with various TRAF6 mutants, we clearly demonstrate the requirement for the TRAF6 RING domain and site-specific auto-ubiquitination of TRAF6 to activate IKK in response to interleukin-1. These data establish a signaling cascade in which regulated site-specific Lys-63-linked TRAF6 auto-ubiquitination is the critical upstream mediator of IKK.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Cornell Univ, Dept Biochem, Weill Med Coll, New York, NY 10021 USA	University of Texas System; UTMD Anderson Cancer Center; Cornell University	Darnay, BG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	bdarnay@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053540] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672DAF, P30 CA016672] Funding Source: Medline; NIAID NIH HHS [R01 AI045937, R01-AI 45937] Funding Source: Medline; NIAMS NIH HHS [R01 AR053540-04, R01 AR053540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; Burns KA, 2004, CURR BIOL, V14, pR1040, DOI 10.1016/j.cub.2004.11.040; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Chung JY, 2002, J CELL SCI, V115, P679; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Gao M, 2005, MOL CELL, V19, P581, DOI 10.1016/j.molcel.2005.08.017; Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564; Kadono Y, 2005, EMBO REP, V6, P171, DOI 10.1038/sj.embor.7400345; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kitamura T, 1998, INT J HEMATOL, V67, P351; Kobayashi T, 2004, MICROBES INFECT, V6, P1333, DOI 10.1016/j.micinf.2004.09.001; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Wooff J, 2004, FEBS LETT, V566, P229, DOI 10.1016/j.febslet.2004.04.038; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	35	279	289	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4102	4112		10.1074/jbc.M609503200	http://dx.doi.org/10.1074/jbc.M609503200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17135271	Green Accepted, hybrid			2022-12-27	WOS:000244481900074
J	Krejci, P; Masri, B; Salazar, L; Farrington-Rock, C; Prats, H; Thompson, LM; Wilcox, WR				Krejci, Pavel; Masri, Bernard; Salazar, Lisa; Farrington-Rock, Claire; Prats, Herve; Thompson, Leslie Michels; Wilcox, William R.			Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; SIGNALING PATHWAY; FACTOR RECEPTOR-3; TYROSINE KINASE; PC12 CELLS; TRANSCRIPTIONAL ACTIVATION; POTENT INHIBITORS; ENDOTHELIAL-CELLS; FGF RECEPTORS	Fibroblast growth factors (FGFs) inhibit chondrocyte proliferation via the Erk MAP kinase pathway. Here, we explored the role of protein kinase C in FGF signaling in chondrocytes. Erk activity in FGF2-treated RCS (rat chondrosarcoma) chondrocytes or human primary chondrocytes was abolished by the protein kinase C inhibitor bisindolylmaleimide I (Bis I). Bis I inhibited FGF2-induced activation of MEK, Raf-1, and Ras members of Erk signaling module but not the FGF2-induced tyrosine phosphorylation of Frs2 or the kinase activity of FGFR3, demonstrating that it targets the Erk cascade immediately upstream of Ras. Indeed, Bis I abolished the FGF2-mediated association of Shp2 tyrosine phosphatase with Frs2 and Gab1 adaptor proteins necessary for proper Ras activation. We also determined which PKC isoform is involved in FGF2-mediated activation of Erk. When both conventional and novel PKCs expressed by RCS chondrocytes ( PKC alpha, -gamma, -delta, and -is an element of) were down-regulated by phorbol ester, cells remained responsive to FGF2 with Erk activation, and this activation was sensitive to Bis I. Moreover, treatment with PKC lambda/xi pseudosubstrate lead to significant reduction of FGF2-mediated activation of Erk, suggesting involvement of an atypical PKC.	Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA; Inst Louis Bugnard, INSERM, U589, F-31403 Toulouse, France; Univ Calif Irvine, Dept Psychiat, Irvine, CA 92697 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA	Cedars Sinai Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Krejci, P (corresponding author), Cedars Sinai Med Ctr, Inst Med Genet, 8700 Beverly Blvd,SSB-3, Los Angeles, CA 90048 USA.	pavel.krejci@cshs.org	Krejčí, Pavel/I-4285-2014; Masri, Bernard/N-9856-2018	Masri, Bernard/0000-0002-4027-2604; Prats, Herve/0000-0002-4861-2167; Krejci, Pavel/0000-0003-0618-9134	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022657] Funding Source: NIH RePORTER; NICHD NIH HHS [5P01-HD22657] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; Agazie YM, 2003, ONCOGENE, V22, P6909, DOI 10.1038/sj.onc.1206798; Aikawa T, 2001, J BIOL CHEM, V276, P29347, DOI 10.1074/jbc.M101859200; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; Cho JY, 2004, P NATL ACAD SCI USA, V101, P609, DOI 10.1073/pnas.2237184100; Cross MJ, 2002, MOL BIOL CELL, V13, P2881, DOI 10.1091/mbc.E02-02-0103; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hanafusa H, 2004, J BIOL CHEM, V279, P22992, DOI 10.1074/jbc.M312498200; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; Kampfer S, 2001, J BIOL CHEM, V276, P42834, DOI 10.1074/jbc.M102047200; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; KLEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Krejci P, 2005, J CELL SCI, V118, P5089, DOI 10.1242/jcs.02618; Krejci P, 2004, EXP CELL RES, V297, P152, DOI 10.1016/j.yexcr.2004.03.011; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Legeai-Mallet L, 2004, BONE, V34, P26, DOI 10.1016/j.bone.2003.09.002; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; MARQUARDT B, 1994, ONCOGENE, V9, P3213; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Monsonego-Ornan E, 2002, FEBS LETT, V528, P83, DOI 10.1016/S0014-5793(02)03255-6; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Nowroozi N, 2005, HUM MOL GENET, V14, P1529, DOI 10.1093/hmg/ddi161; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; PRESTA M, 1989, J CELL BIOL, V109, P1877, DOI 10.1083/jcb.109.4.1877; Raucci A, 2004, J BIOL CHEM, V279, P1747, DOI 10.1074/jbc.M310384200; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Skaletz-Rorowski A, 2005, CARDIOVASC RES, V67, P142, DOI 10.1016/j.cardiores.2005.03.009; Skaletz-Rorowski A, 1999, ARTERIOSCL THROM VAS, V19, P1608, DOI 10.1161/01.ATV.19.7.1608; Strack V, 2002, BIOCHEMISTRY-US, V41, P603, DOI 10.1021/bi011327v; SZALLASI Z, 1995, MOL PHARMACOL, V47, P258; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UBERALL F, 1994, CELL SIGNAL, V6, P285, DOI 10.1016/0898-6568(94)90033-7; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Yasoda A, 2004, NAT MED, V10, P80, DOI 10.1038/nm971; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	57	31	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2929	2936		10.1074/jbc.M606144200	http://dx.doi.org/10.1074/jbc.M606144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145761	hybrid			2022-12-27	WOS:000243793900019
J	Matsumoto, ML; Narzinski, K; Kiser, PD; Nikiforovich, GV; Baranski, TJ				Matsumoto, Marissa L.; Narzinski, Kirk; Kiser, Philip D.; Nikiforovich, Gregory V.; Baranski, Thomas J.			A comprehensive structure-function map of the intracellular surface of the human C5a receptor - I. Identification of critical residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE SUBSTITUTION MUTANTS; PROTEIN-COUPLED RECEPTORS; LIGHT-ACTIVATED RHODOPSIN; HYDROPHOBIC AMINO-ACID; COVALENT CROSS-LINKING; CONNECTING HELIX-C; ANAPHYLATOXIN RECEPTOR; MUSCARINIC RECEPTOR; TRANSDUCIN ACTIVATION; TRANSMEMBRANE HELICES	G protein-coupled receptors are one of the largest protein families in nature; however, the mechanisms by which they activate G proteins are still poorly understood. To identify residues on the intracellular face of the human C5a receptor that are involved in G protein activation, we performed a genetic analysis of each of the three intracellular loops and the carboxyl-terminal tail of the receptor. Amino acid substitutions were randomly incorporated into each loop, and functional receptors were identified in yeast. The third intracellular loop contains the largest number of preserved residues ( positions resistant to amino acid substitutions), followed by the second loop, the first loop, and lastly the carboxyl terminus. Surprisingly, complete removal of the carboxyl-terminal tail did not impair C5a receptor signaling. When mapped onto a three-dimensional structural model of the inactive state of the C5a receptor, the preserved residues reside on one half of the intracellular surface of the receptor, creating a potential activation face. Together these data provide one of the most comprehensive functional maps of the intracellular surface of any G protein-coupled receptor to date.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Baranski, TJ (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.	baranski@wustl.edu		Matsumoto, Marissa/0000-0002-5353-1097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063720, R01GM068460] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; Acharya S, 1996, J BIOL CHEM, V271, P25406, DOI 10.1074/jbc.271.41.25406; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Auger GA, 2004, IMMUNOLOGY, V112, P590, DOI 10.1111/j.1365-2567.2004.01919.x; Ballon DR, 2006, CELL, V126, P1079, DOI 10.1016/j.cell.2006.07.030; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Braun L, 2003, J BIOL CHEM, V278, P4277, DOI 10.1074/jbc.M210120200; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; Chen QJ, 1996, MOL CELL BIOL, V16, P247; Christophe T, 2000, J BIOL CHEM, V275, P1656, DOI 10.1074/jbc.275.3.1656; Conner AC, 2006, J BIOL CHEM, V281, P1644, DOI 10.1074/jbc.M510064200; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, P345; DUNFIELD LG, 1978, J PHYS CHEM-US, V82, P2609, DOI 10.1021/j100513a014; Duvernay MT, 2004, J BIOL CHEM, V279, P30741, DOI 10.1074/jbc.M313881200; Erlenbach I, 1998, J BIOL CHEM, V273, P26549, DOI 10.1074/jbc.273.41.26549; Erlenbach I, 2001, J BIOL CHEM, V276, P29382, DOI 10.1074/jbc.M103203200; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; Estall JL, 2005, J BIOL CHEM, V280, P22124, DOI 10.1074/jbc.M500078200; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FAUCHERE JL, 1988, INT J PEPT PROT RES, V32, P269; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Floyd DH, 2003, J BIOL CHEM, V278, P35354, DOI 10.1074/jbc.M305607200; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; GIANNINI E, 1995, J IMMUNOL, V154, P4055; Hagemann IS, 2006, J BIOL CHEM, V281, P36783, DOI 10.1074/jbc.M607686200; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; Jastrzebska B, 2006, J BIOL CHEM, V281, P11917, DOI 10.1074/jbc.M600422200; Kim JM, 2005, BIOCHEMISTRY-US, V44, P2284, DOI 10.1021/bi048328i; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Klco JM, 2006, J BIOL CHEM, V281, P12010, DOI 10.1074/jbc.M600548200; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Klco JM, 2003, J BIOL CHEM, V278, P35345, DOI 10.1074/jbc.M305606200; Klein C, 1998, NAT BIOTECHNOL, V16, P1334, DOI 10.1038/4310; Klein-Seetharaman J, 1999, BIOCHEMISTRY-US, V38, P7938, DOI 10.1021/bi990013t; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Krause G, 2000, MOL PHARMACOL, V57, P232; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Marion S, 2006, J BIOL CHEM, V281, P2932, DOI 10.1074/jbc.M508074200; Matsumoto ML, 2007, J BIOL CHEM, V282, P3122, DOI 10.1074/jbc.M607683200; Miller KJ, 2004, CNS NEUROL DISORD-DR, V3, P357, DOI 10.2174/1568007043337003; MORO O, 1993, J BIOL CHEM, V268, P22273; Naik N, 1997, J CELL SCI, V110, P2381; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; NEMETHY G, 1983, J PHYS CHEM-US, V87, P1883, DOI 10.1021/j100234a011; Nikiforovich GV, 2005, BIOPHYS J, V89, P3780, DOI 10.1529/biophysj.105.070722; Nikiforovich GV, 2005, J PEPT RES, V66, P236, DOI 10.1111/j.1399-3011.2005.00293.x; Nikiforovich GV, 2003, BIOCHEMISTRY-US, V42, P9110, DOI 10.1021/bi034586o; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pankevych H, 2003, J BIOL CHEM, V278, P30283, DOI 10.1074/jbc.M212918200; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; Robert J, 2005, J BIOL CHEM, V280, P2300, DOI 10.1074/jbc.M410655200; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Smit MJ, 1996, J BIOL CHEM, V271, P7574, DOI 10.1074/jbc.271.13.7574; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Thielen A, 2005, FEBS LETT, V579, P5227, DOI 10.1016/j.febslet.2005.08.043; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t	82	15	15	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3105	3121		10.1074/jbc.M607679200	http://dx.doi.org/10.1074/jbc.M607679200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135254	hybrid			2022-12-27	WOS:000243793900037
J	Holmes, RK; Koning, FA; Bishop, KN; Malim, MH				Holmes, Rebecca K.; Koning, Fransje A.; Bishop, Kate N.; Malim, Michael H.			APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation - Comparisons with APOBEC3G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HEPATITIS-B-VIRUS; CD4(+) T-CELLS; URACIL DNA GLYCOSYLASE; RNA EDITING ENZYME; VIF PROTEIN; CYTIDINE DEAMINASE; IN-VIVO; ALU RETROTRANSPOSITION; ANTIVIRAL ACTIVITY	APOBEC3F (apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1-like protein 3F) is a cytidine deaminase that, like APOBEC3G, is able to restrict the replication of HIV-1/Delta vif. Initial studies revealed high numbers of mutations in the cDNA of viruses produced in the presence of these proteins, suggesting that cytidine deamination underpinned the inhibition of infection. However, we have recently shown that catalytically inactive APOBEC3G proteins, derived through mutation of the C-terminal cytidine deaminase motif, still exert a substantial antiviral effect. Here, we have generated a panel of APOBEC3F mutant proteins and show that the C-terminal cytidine deaminase motif is essential for catalytic activity and that catalytic activity is not necessary for the antiviral effect of APOBEC3F. Furthermore, we demonstrate that the antiviral activities of wild-type and catalytically inactive APOBEC3F and APOBEC3G proteins correspond well with reductions in the accumulation of viral reverse transcription products. Additional comparisons between APOBEC3F and APOBEC3G suggest that the loss of deaminase activity is more detrimental to APOBEC3G function than to APOBEC3F function, as reflected by perturbations to the suppression of reverse transcript accumulation as well as antiviral activity. Taken together, these data suggest that both APOBEC3F and APOBEC3G are able to function as antiviral factors in the absence of cytidine deamination, that this editing-independent activity is an important aspect of APOBEC protein-mediated antiviral phenotypes, but that APOBEC3F may be a better model in which to study it.	Kings Coll London, Sch Med, Dept Infect Dis, London SE1 9RT, England	University of London; King's College London	Malim, MH (corresponding author), Kings Coll London, Sch Med, Dept Infect Dis, London SE1 9RT, England.	michael.malim@kcl.ac.uk		Malim, Michael/0000-0002-7699-2064; Koning, Frits/0000-0002-4007-5715	MRC [G0401570] Funding Source: UKRI; Medical Research Council [G0401570] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Bishop KN, 2006, J VIROL, V80, P8450, DOI 10.1128/JVI.00839-06; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Bogerd HP, 2006, P NATL ACAD SCI USA, V103, P8780, DOI 10.1073/pnas.0603313103; Bogerd HP, 2006, NUCLEIC ACIDS RES, V34, P89, DOI 10.1093/nar/gkj416; Butler SL, 2002, J VIROL, V76, P3739, DOI 10.1128/JVI.76.8.3739-3747.2002; Chen H, 2006, CURR BIOL, V16, P480, DOI 10.1016/j.cub.2006.01.031; Chiu YL, 2006, P NATL ACAD SCI USA, V103, P15588, DOI 10.1073/pnas.0604524103; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Cullen BR, 2006, J VIROL, V80, P1067, DOI 10.1128/JVI.80.3.1067-1076.2006; Doehle BP, 2005, VIROLOGY, V339, P281, DOI 10.1016/j.virol.2005.06.005; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Hache G, 2005, J BIOL CHEM, V280, P10920, DOI 10.1074/jbc.M500382200; Harris RS, 2003, NAT IMMUNOL, V4, P641, DOI 10.1038/ni0703-641; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; HULME AE, 2006, IN PRESS GENE AMST; Janini M, 2001, J VIROL, V75, P7973, DOI 10.1128/JVI.75.17.7973-7986.2001; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kaiser SM, 2006, J VIROL, V80, P875, DOI 10.1128/JVI.80.2.875-882.2006; Kieffer TL, 2005, J VIROL, V79, P1975, DOI 10.1128/JVI.79.3.1975-1980.2005; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Liu BD, 2005, J VIROL, V79, P9579, DOI 10.1128/JVI.79.15.9579-9587.2005; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Muckenfuss H, 2006, J BIOL CHEM, V281, P22161, DOI 10.1074/jbc.M601716200; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Noguchi C, 2005, HEPATOLOGY, V41, P626, DOI 10.1002/hep.20580; Priet S, 2005, MOL CELL, V17, P479, DOI 10.1016/j.molcel.2005.01.016; Rose KM, 2005, AIDS RES HUM RETROV, V21, P611, DOI 10.1089/aid.2005.21.611; Rosler C, 2005, HEPATOLOGY, V42, P301, DOI 10.1002/hep.20801; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1997, J VIROL, V71, P5259, DOI 10.1128/JVI.71.7.5259-5267.1997; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; Stenglein MD, 2006, J BIOL CHEM, V281, P16837, DOI 10.1074/jbc.M602367200; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Suspene R, 2005, P NATL ACAD SCI USA, V102, P8321, DOI 10.1073/pnas.0408223102; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Yu Q, 2004, J BIOL CHEM, V279, P53379, DOI 10.1074/jbc.M408802200; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zennou V, 2006, VIROLOGY, V349, P31, DOI 10.1016/j.virol.2005.12.035; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	58	250	251	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2587	2595		10.1074/jbc.M607298200	http://dx.doi.org/10.1074/jbc.M607298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121840	hybrid			2022-12-27	WOS:000243593200051
J	Okada, T; Suzuki, H; Wada, K; Kumagai, H; Fukuyama, K				Okada, Toshihiro; Suzuki, Hideyuki; Wada, Kei; Kumagai, Hidehiko; Fukuyama, Keiichi			Crystal structure of the gamma-glutamyltranspeptidase precursor protein from Escherichia coli - Structural changes autocatalytic processing and implications for the maturation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEPHALOSPORIN ACYLASE; CATALYTIC MECHANISM; GLUTATHIONE; GENE; K-12; AUTOPROTEOLYSIS; ACTIVATION; EXPRESSION; CLONING	gamma-Glutamyltranspeptidase (GGT) is an extracellular enzyme that plays a key role in glutathione metabolism. The mature GGT is a heterodimer consisting of L- and S-subunits that is generated by posttranslational cleavage of the peptide bond between Gln-390 and Thr-391 in the precursor protein. Thr-391, which becomes the N-terminal residue of the S-subunit, acts as the active residue in the catalytic reaction. The crystal structure of a mutant GGT, T391A, that is unable to undergo autocatalytic processing, has been determined at 2.55-angstrom resolution. Structural comparison of the precursor protein and mature GGT demonstrates that the structures of the core regions in the two proteins are unchanged, but marked differences are found near the active site. In particular, in the precursor, the segment corresponding to the C-terminal region of the L-subunit occupies the site where the loop (residues 438-449) forms the lid of the gamma-glutamyl group-binding pocket in the mature GGT. This result demonstrates that, upon cleavage of the N-terminal peptide bond of Thr-391, the newly produced C terminus (residues 375-390) flips out, allowing the 438-449 segment to form the gamma-glutamyl group-binding pocket. The electron density map for the T391A protein also identified a water molecule near the carbonyl carbon atom of Gln-390. The spatial arrangement around the water and Thr-391 relative to the scissile peptide bond appears suitable for the initiation of autocatalytic processing, as in other members of the N-terminal nucleophile hydrolase superfamily.	Osaka Univ, Grad Sch Sci, Dept Biol Sci, Toyonaka, Osaka 5600043, Japan; Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Sakyo Ku, Kyoto 6068502, Japan; Ishikawa Prefectural Univ 6, Res Inst Bioresources & Biotechnol, Nonoichi, Ishikawa 9218836, Japan	Osaka University; Kyoto University	Fukuyama, K (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol Sci, Toyonaka, Osaka 5600043, Japan.	fukuyama@bio.sci.osaka-u.ac.jp		Wada, Kei/0000-0001-7631-4151				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boanca G, 2006, J BIOL CHEM, V281, P19029, DOI 10.1074/jbc.M603381200; DeLano W.L, PYMOL MOL GRAPHICS S; Ditzel L, 1998, J MOL BIOL, V279, P1187, DOI 10.1006/jmbi.1998.1818; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; HANIGAN MH, 1993, BIOCHEMISTRY-US, V32, P6302, DOI 10.1021/bi00075a026; HASHIMOTO W, 1995, J BIOCHEM-TOKYO, V118, P75, DOI 10.1093/oxfordjournals.jbchem.a124894; HASHIMOTO W, 1992, BIOCHEM BIOPH RES CO, V189, P173, DOI 10.1016/0006-291X(92)91540-7; Ikeda Y, 2005, METHOD ENZYMOL, V401, P408, DOI 10.1016/S0076-6879(05)01025-6; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kim Y, 2002, J BIOL CHEM, V277, P2823, DOI 10.1074/jbc.M108888200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee YS, 1998, J BACTERIOL, V180, P4576, DOI 10.1128/JB.180.17.4576-4582.1998; Li Y, 1999, EUR J BIOCHEM, V262, P713, DOI 10.1046/j.1432-1327.1999.00417.x; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Mehdi K, 1997, MICROBIOL-UK, V143, P1885, DOI 10.1099/00221287-143-6-1885; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Okada T, 2006, P NATL ACAD SCI USA, V103, P6471, DOI 10.1073/pnas.0511020103; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SUZUKI H, 1988, BIOCHEM BIOPH RES CO, V150, P33, DOI 10.1016/0006-291X(88)90482-2; Suzuki H, 2002, J BIOL CHEM, V277, P43536, DOI 10.1074/jbc.M207680200; SUZUKI H, 1986, J BACTERIOL, V168, P1325, DOI 10.1128/jb.168.3.1325-1331.1986; SUZUKI H, 1993, J BACTERIOL, V175, P6038, DOI 10.1128/JB.175.18.6038-6040.1993; Taniguchi N, 1998, ADV ENZYMOL RAMB, V72, P239; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; VANPOELJE PD, 1990, BIOCHEMISTRY-US, V29, P132, DOI 10.1021/bi00453a016; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yoon J, 2004, J BIOL CHEM, V279, P341, DOI 10.1074/jbc.M309281200	31	71	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2433	2439		10.1074/jbc.M607490200	http://dx.doi.org/10.1074/jbc.M607490200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135273	Green Submitted, hybrid			2022-12-27	WOS:000243593200034
J	Hinton, TM; Coldwell, MJ; Carpenter, GA; Morley, SJ; Pain, VM				Hinton, Tracey M.; Coldwell, Mark J.; Carpenter, Gillian A.; Morley, Simon J.; Pain, Virginia M.			Functional analysis of individual binding activities of the scaffold protein eIF4G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION-FACTOR; FACTOR 4G EIF4G; CAP-INDEPENDENT TRANSLATION; 40S RIBOSOMAL-SUBUNIT; AMINO-ACID-SEQUENCE; FACTOR 4E EIF4E; MESSENGER-RNA; POLY(A)-BINDING PROTEIN; FACTOR 4B; IN-VITRO	Eukaryotic initiation factor (eIF) 4G is an integral member of the translation initiation machinery. The molecule serves as a scaffold for several other initiation factors, including eIF4E, eIF4AI, the eIF3 complex, and poly(A)-binding protein (PABP). Previous work indicates that complexes between these proteins exhibit enhanced mRNA cap-binding and RNA helicase activities relative to the respective individual proteins, eIF4E and eIF4A. The eIF4G-PABP interaction has been implicated in enhancing the formation of 48 S and 80 S initiation complexes and ribosome recycling through mRNA circularization. The eIF3-eIF4GI interaction is believed to forge the link between the 40 S subunit and the mRNA. Here we have investigated the behavior in vitro and in intact cells of eIF4GIf molecules lacking either the PABP-binding site, the eIF3-binding site, the middle domain eIF4A-binding site, or the C-terminal segment that includes the second eIF4A-binding site. Although in some cases the mutant forms were recruited more slowly, all of these eIF4G variants could form complexes with eIF4E, enter 48 S complexes and polysomes in vivo and in vitro, and partially rescue translation in cells targeted with eIF4GI short interfering RNA. In the reticulocyte lysate, eIF4G unable to interact directly with PABP showed little impairment in its ability to support translation, whereas loss of either of the eIF4A-binding sites or the eIF3-binding site resulted in a marked decrease in activity. We conclude that there is considerable redundancy in the mechanisms forming initiation complexes in mammalian cells, such that many individual interactions have regulatory rather than essential roles.	Univ Sussex, Sch Life Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England	University of Sussex	Pain, VM (corresponding author), Univ Sussex, Sch Life Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England.	v.m.pain@sussex.ac.uk	Hinton, Tracey M/G-9324-2011	Hinton, Tracey M/0000-0002-3667-6841	Wellcome Trust [67517, 58915, 56778, 40800] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ali IK, 2001, EMBO J, V20, P4233, DOI 10.1093/emboj/20.15.4233; Berset C, 2003, RNA, V9, P871, DOI 10.1261/rna.5380903; Bradley CA, 2002, J BIOL CHEM, V277, P12559, DOI 10.1074/jbc.M111134200; Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Bushell M, 2001, J BIOL CHEM, V276, P23922, DOI 10.1074/jbc.M100384200; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; Coldwell MJ, 2006, MOL CELL BIOL, V26, P8448, DOI 10.1128/MCB.01248-06; Coldwell MJ, 2004, J CELL SCI, V117, P2545, DOI 10.1242/jcs.01106; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; DARNBROUGH C, 1973, J MOL BIOL, V76, P379; De Quinto SL, 2001, RNA, V7, P1213, DOI 10.1017/S1355838201010433; Fraser CS, 2004, J BIOL CHEM, V279, P8946, DOI 10.1074/jbc.M312745200; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gebauer F, 2003, MOL CELL, V11, P1397, DOI 10.1016/S1097-2765(03)00176-X; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Harris TE, 2006, EMBO J, V25, P1659, DOI 10.1038/sj.emboj.7601047; HELSER TL, 1981, MOL CELL BIOL, V1, P51, DOI 10.1128/MCB.1.1.51; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jivotovskaya AV, 2006, MOL CELL BIOL, V26, P1355, DOI 10.1128/MCB.26.4.1355-1372.2006; Kahvejian A, 2005, GENE DEV, V19, P104, DOI 10.1101/gad.1262905; Keiper BD, 1997, NUCLEIC ACIDS RES, V25, P395, DOI 10.1093/nar/25.2.395; Korneeva NL, 2005, J BIOL CHEM, V280, P1872, DOI 10.1074/jbc.M406168200; Korneeva NL, 2000, J BIOL CHEM, V275, P41369, DOI 10.1074/jbc.M007525200; Lamphear BJ, 1996, BIOCHEMISTRY-US, V35, P15726, DOI 10.1021/bi961864t; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LeFebvre AK, 2006, J BIOL CHEM, V281, P22917, DOI 10.1074/jbc.M605418200; LEVIN DH, 1973, J BIOL CHEM, V248, P6416; Lomakin IB, 2000, MOL CELL BIOL, V20, P6019, DOI 10.1128/MCB.20.16.6019-6029.2000; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1996, RNA, V2, P38; Morino S, 2000, MOL CELL BIOL, V20, P468, DOI 10.1128/MCB.20.2.468-477.2000; Morley SJ, 2002, J BIOL CHEM, V277, P32855, DOI 10.1074/jbc.C200376200; Naegele S, 2004, J BIOL CHEM, V279, P46023, DOI 10.1074/jbc.M404945200; Niepel M, 1999, FEBS LETT, V462, P79, DOI 10.1016/S0014-5793(99)01514-8; Novoa I, 1999, MOL CELL BIOL, V19, P2445; Oberer M, 2005, GENE DEV, V19, P2212, DOI 10.1101/gad.1335305; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; Park HS, 2004, EMBO J, V23, P1381, DOI 10.1038/sj.emboj.7600140; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; Peng J, 2005, RNA, V11, P1131, DOI 10.1261/rna.2470905; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Prevot D, 2003, EMBO J, V22, P1909, DOI 10.1093/emboj/cdg175; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; Svitkin YV, 2001, RNA, V7, P1743; Valasek L, 2004, MOL CELL BIOL, V24, P9437, DOI 10.1128/MCB.24.21.9437-9455.2004; von der Haar T, 2000, J BIOL CHEM, V275, P30551, DOI 10.1074/jbc.M004565200; Wakiyama M, 2000, CURR BIOL, V10, P1147, DOI 10.1016/S0960-9822(00)00701-6; YAN RQ, 1992, J BIOL CHEM, V267, P23226; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Zakowicz H, 2005, RNA, V11, P261, DOI 10.1261/rna.7191905	63	48	50	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1695	1708		10.1074/jbc.M602780200	http://dx.doi.org/10.1074/jbc.M602780200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17130132	hybrid			2022-12-27	WOS:000243451300021
J	Vallentin, A; Mochly-Rosen, D				Vallentin, Alice; Mochly-Rosen, Daria			RBCK1, a protein kinase C beta I (PKC beta I)-interacting protein, regulates PKC beta-dependent function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-HYPERTROPHY; SCAFFOLD PROTEIN; HEART-FAILURE; INTRACELLULAR RECEPTOR; ANCHORING PROTEINS; REPERFUSION INJURY; BINDING-PROTEINS; DOWN-REGULATION; EPSILON-PKC; RACK1	RBCK1 ((RBC) under barC protein interacting with P (K) under barC (1) under bar) has originally been identified as a protein kinase C beta I (PKC beta I)-binding partner by a two-hybrid screen and as one of the gene transcripts that increases during adult cardiac hypertrophy. To address whether RBCK1 and PKC beta I functions are interconnected, we used cultured neonatal myocytes where we previously found that the activity of PKC beta I is required for an increase in cell size, also called hypertrophy. In this study, we showed that acute treatment of cardiac myocytes with phenylephrine, a prohypertrophic stimulant, transiently increased the association of RBCK1 with PKC beta I within 1 min. A prolonged phenylephrine treatment also resulted in an increase of the interaction of the two proteins. Endogenous RBCK1 protein levels increased upon phenylephrine-induced hypertrophy. Further, adenovirus-based RBCK1 overexpression in the absence of phenylephrine increased cardiac cell size. This RBCK1-mediated hypertrophy required PKC beta activity, since the increase in cell size was inhibited when the RBCK1-expressing cells were treated with PKC beta-selective antagonists, supporting our previous observation that both PKC beta I and PKC beta II are required for hypertrophy. Unexpectedly, RBCK1-induced increased cell size was inhibited by phenylephrine. This effect correlated with a decrease in the level of both PKC beta isoforms. Most importantly, RNA interference for RBCK1 significantly inhibited the increase in cell size of cardiac myocytes following phenylephrine treatment. Our results suggest that RBCK1 binds PKC beta I and is a key regulator of PKC beta I function in cells and that, together with PKC beta II, the three proteins are essential for developmental hypertrophy of cardiac myocytes.	Stanford Univ, Sch Med, Dept Chem & Syst Biol, CCSR, Stanford, CA 94305 USA	Stanford University	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Chem & Syst Biol, CCSR, Rm 3145A,269 Campus Dr, Stanford, CA 94305 USA.	mochly@stanford.edu		Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL076675] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076675] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Bowman JC, 1997, J CLIN INVEST, V100, P2189, DOI 10.1172/JCI119755; Bright R, 2004, J NEUROSCI, V24, P6880, DOI 10.1523/JNEUROSCI.4474-03.2004; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Chen L, 2001, CHEM BIOL, V8, P1123, DOI 10.1016/S1074-5521(01)00076-X; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Friddle CJ, 2000, P NATL ACAD SCI USA, V97, P6745, DOI 10.1073/pnas.100127897; GU X, 1994, CIRC RES, V75, P926, DOI 10.1161/01.RES.75.5.926; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; Inagaki K, 2005, CIRCULATION, V111, P44, DOI 10.1161/01.CIR.0000151614.22282.F1; Inagaki K, 2003, CIRCULATION, V108, P2304, DOI 10.1161/01.CIR.0000101682.24138.36; Inagaki K, 2002, J MOL CELL CARDIOL, V34, P1377, DOI 10.1006/jmcc.2002.2089; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jalili T, 2003, J NUTR, V133, P358, DOI 10.1093/jn/133.2.358; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lee HW, 1997, MOL PHARMACOL, V51, P439; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; National Institutes of Health, 1996, GUID CAR US LAB AN; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schechtman D, 2002, METHOD ENZYMOL, V345, P470; Sengupta J, 2004, NAT STRUCT MOL BIOL, V11, P957, DOI 10.1038/nsmb822; Shimkets RA, 1999, NAT BIOTECHNOL, V17, P798, DOI 10.1038/11743; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; Simpson PC, 1999, CIRCULATION, V99, P334, DOI 10.1161/01.CIR.99.3.334; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; STUMPO DJ, 1994, J BIOL CHEM, V269, P21184; Tatematsu K, 1998, BIOCHEM BIOPH RES CO, V247, P392, DOI 10.1006/bbrc.1998.8795; Tatematsu K, 2005, J BIOL CHEM, V280, P22937, DOI 10.1074/jbc.M413476200; Tokunaga C, 1998, BIOCHEM BIOPH RES CO, V244, P353, DOI 10.1006/bbrc.1998.8270; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Wang JW, 2003, AM J PHYSIOL-HEART C, V284, pH2277, DOI 10.1152/ajpheart.00142.2002; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Yamanaka K, 2003, NAT CELL BIOL, V5, P336, DOI 10.1038/ncb952; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909	57	18	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1650	1657		10.1074/jbc.M601710200	http://dx.doi.org/10.1074/jbc.M601710200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121852	hybrid			2022-12-27	WOS:000243451300016
J	Harder, CJ; Meng, A; Rippstein, P; McBride, HM; McPherson, R				Harder, Christopher J.; Meng, Andrew; Rippstein, Peter; McBride, Heidi M.; McPherson, Ruth			SR-BI undergoes cholesterol-stimulated transcytosis to the bile canaliculus in polarized WIF-B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; RECEPTOR CLASS-B; SELECTIVE LIPID UPTAKE; SCAVENGER RECEPTOR; PLASMA-MEMBRANE; IN-VIVO; HEPATIC EXPRESSION; SECRETION; HDL; TRANSPORT	The scavenger receptor BI (SR-BI) is highly expressed in hepatocytes, where it mediates the uptake of lipoprotein cholesterol, promotes the secretion of cholesterol into bile, and protects against atherosclerosis. Despite a strong correlation between the hepatic expression of SR-BI and biliary cholesterol secretion, little is known about SR-BI trafficking in response to changes in sterol availability. Using a well characterized polarized hepatocyte cell model, WIF-B, we determine that in cholesterol-depleted cells, SR-BI is extensively located on the basolateral surface, where it can access circulating lipoproteins. However, in response to cholesterol loading, SR-BI undergoes a slow transcytosis to the apical bile canaliculus independently of lipoprotein binding and new protein synthesis. In cholesterol-replete WIF-B cells, SR-BI that resides on the canalicular membrane is dynamically associated with defined microdomains and does not rapidly recycle to and from the subapical or basolateral regions. Taken together, these data demonstrate that hepatic SR-BI transcytosis is regulated by cholesterol and suggest that SR-BI has a stationary function on the bile canaliculus.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute	McPherson, R (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada.	rmcpherson@ottawaheart.ca	McBride, Heidi M./ABD-5774-2021	McBride, Heidi M./0000-0003-4666-2280				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Assanasen C, 2005, J CLIN INVEST, V115, P969, DOI 10.1172/JCI23858; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BAUCHART D, 1989, J LIPID RES, V30, P1499; Burgos PV, 2004, P NATL ACAD SCI USA, V101, P3845, DOI 10.1073/pnas.0400295101; Camarota LM, 2004, J BIOL CHEM, V279, P27599, DOI 10.1074/jbc.M402946200; DELAMATRE JG, 1990, J LIPID RES, V31, P191; Eckhardt ERM, 2006, J BIOL CHEM, V281, P4348, DOI 10.1074/jbc.M513154200; Eckhardt ERM, 2004, J BIOL CHEM, V279, P14372, DOI 10.1074/jbc.M313793200; Geuken E, 2005, HEPATOLOGY, V42, P1166, DOI 10.1002/hep.20886; GHOSH RN, 1994, J CELL SCI, V107, P2177; Goodwin JS, 2005, METHODS, V37, P154, DOI 10.1016/j.ymeth.2005.05.013; Harder CJ, 2006, J LIPID RES, V47, P492, DOI 10.1194/jlr.M500444-JLR200; Ihrke G, 1998, J CELL BIOL, V141, P115, DOI 10.1083/jcb.141.1.115; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; KAMBOURIS AM, 1990, ARTERIOSCLEROSIS, V10, P582, DOI 10.1161/01.ATV.10.4.582; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Lewis GF, 2005, CIRC RES, V96, P1221, DOI 10.1161/01.RES.0000170946.56981.5c; Mardones P, 2003, J BIOL CHEM, V278, P7884, DOI 10.1074/jbc.M211627200; Mardones P, 2001, J LIPID RES, V42, P170; Miquel JF, 2003, GUT, V52, P1017, DOI 10.1136/gut.52.7.1017; Nakagawa A, 2004, DEV GROWTH DIFFER, V46, P283; Nieland TJF, 2005, BBA-MOL CELL BIOL L, V1734, P44, DOI 10.1016/j.bbalip.2005.02.007; Nyasae LK, 2003, MOL BIOL CELL, V14, P2689, DOI 10.1091/mbc.E02-12-0816; Parathath S, 2004, J BIOL CHEM, V279, P41310, DOI 10.1074/jbc.M404952200; Peng Y, 2004, MOL BIOL CELL, V15, P384, DOI 10.1091/mbc.e03-06-0445; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; Rhainds D, 2004, J CELL SCI, V117, P3095, DOI 10.1242/jcs.01182; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Sai Y, 1999, J CELL SCI, V112, P4535; SCHELL MJ, 1992, J CELL BIOL, V119, P1173, DOI 10.1083/jcb.119.5.1173; SCHWARTZ CC, 1978, SCIENCE, V200, P62, DOI 10.1126/science.204996; Sehayek E, 2003, J LIPID RES, V44, P1605, DOI 10.1194/jlr.M200488-JLR200; SHANKS MR, 1994, J CELL SCI, V107, P813; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Stangl H, 2002, J ENDOCRINOL, V175, P663, DOI 10.1677/joe.0.1750663; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; VAN EM, 2003, J BIOL CHEM, V278, P23699; Williams DL, 2002, J LIPID RES, V43, P544; Wustner D, 2005, J BIOL CHEM, V280, P6766, DOI 10.1074/jbc.M413238200; Wustner D, 2004, J LIPID RES, V45, P427, DOI 10.1194/jlr.M300440-JLR200; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; Zhang YZ, 2005, J CLIN INVEST, V115, P2870, DOI 10.1172/JCI25327	45	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1445	1455		10.1074/jbc.M604627200	http://dx.doi.org/10.1074/jbc.M604627200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17105723	hybrid			2022-12-27	WOS:000243295200069
J	Isken, A; Holzschuh, J; Lampert, JM; Fischer, L; Oberhauser, V; Palczewski, K; von Lintig, J				Isken, Andrea; Holzschuh, Jochen; Lampert, Johanna M.; Fischer, Lara; Oberhauser, Vitus; Palczewski, Krzysztof; von Lintig, Johannes			Sequestration of retinyl esters is essential for retinoid signaling in the zebrafish embryo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-METABOLIZING ENZYME; VITAMIN-A; MOLECULAR-IDENTIFICATION; POSTERIOR AXIS; LECITHIN; ACYLTRANSFERASE; HINDBRAIN; PATTERN; MOUSE; GENE	For vertebrate development, vitamin A (all-trans retinol) is required in quantitative different amounts and spatiotemporal distribution for the production of retinoic acid, a nuclear hormone receptor ligand, and 11-cis retinal, the chromophore of visual pigments. We show here for zebrafish that embryonic retinoid homeostasis essentially depends on the activity of a lecithin: retinol acyltransferase (Lratb). During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (raldh2), the key enzyme for retinoic acid synthesis. Blocking retinyl ester formation by a targeted knock down of Lratb results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects. Thus, we provide evidence that a balanced competition between Lratb and Raldh2 for yolk vitamin A defines embryonic compartments either for retinyl ester or retinoic acid synthesis. This homeostatic mechanism dynamically adjusts embryonic retinoic acid levels for gene regulation, concomitantly sequestering excess yolk vitamin A in the form of retinyl esters for the establishment of larval vision later during development.	Univ Freiburg, Dept Neurobiol, Inst Biol 1, D-79104 Freiburg, Germany; Univ Freiburg, Dept Dev Biol, Inst Biol 1, D-79104 Freiburg, Germany; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	University of Freiburg; University of Freiburg; Case Western Reserve University	von Lintig, J (corresponding author), Univ Freiburg, Dept Neurobiol, Inst Biol 1, Hauptstr 1, D-79104 Freiburg, Germany.	lintig@biologie.uni-freiburg.de		von Lintig, Johannes/0000-0002-2079-2143				Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Begemann G, 2001, DEVELOPMENT, V128, P3081; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Emoto Y, 2005, DEV BIOL, V278, P415, DOI 10.1016/j.ydbio.2004.11.023; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Grandel H, 2002, DEVELOPMENT, V129, P2851; Hamade A, 2006, DEV BIOL, V289, P127, DOI 10.1016/j.ydbio.2005.10.019; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Kudoh T, 2002, DEVELOPMENT, V129, P4335; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; Lampert JM, 2003, DEVELOPMENT, V130, P2173, DOI 10.1242/dev.00437; Liu LM, 2005, J BIOL CHEM, V280, P40226, DOI 10.1074/jbc.M509643200; LIVREA MA, 2000, VITAMIN A RETINOIDS; Moise AR, 2005, J BIOL CHEM, V280, P27815, DOI 10.1074/jbc.M503520200; Mondal MS, 2001, FEBS LETT, V489, P14, DOI 10.1016/S0014-5793(00)02428-5; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Niederreither K, 2002, NAT GENET, V31, P84, DOI 10.1038/ng876; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Nornes S, 1998, MECH DEVELOP, V77, P185, DOI 10.1016/S0925-4773(98)00156-7; O'Byrne SM, 2005, J BIOL CHEM, V280, P35647, DOI 10.1074/jbc.M507924200; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; RANDOLPH RK, 1991, J BIOL CHEM, V266, P16453; Reifers F, 1998, DEVELOPMENT, V125, P2381; ROSS AC, 2003, J NUTR, V133, P291; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Weinberg ES, 1996, DEVELOPMENT, V122, P271; Westerfield M, 1994, ZEBRAFISH BOOK; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x; Zolfaghari R, 2000, J LIPID RES, V41, P2024	40	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1144	1151		10.1074/jbc.M609109200	http://dx.doi.org/10.1074/jbc.M609109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17098734	hybrid			2022-12-27	WOS:000243295200039
J	Karakiulakis, G; Papakonstantinou, E; Aletras, AJ; Tamm, M; Roth, M				Karakiulakis, George; Papakonstantinou, Eleni; Aletras, Alexios J.; Tamm, Michael; Roth, Michael			Cell type-specific effect of hypoxia and platelet-derived growth factor-BB on extracellular matrix turnover and its consequences for lung remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; OBSTRUCTIVE PULMONARY-DISEASE; P38 MAP KINASE; TISSUE INHIBITOR; FIBROBLAST-GROWTH; ACTIVATING-FACTOR; PROLIFERATION; EXPRESSION; ASTHMA; COPD	Hypoxia is associated with extracellular matrix remodeling in several inflammatory lung diseases, such as fibrosis, chronic obstructive pulmonary disease, and asthma. In a human cell culture model, we assessed whether extracellular matrix modification by hypoxia and platelet-derived growth factor (PDGF) involves the action of matrix metalloproteinases (MMPs) and thereby affects cell proliferation. Expression of MMP and its activity were assessed by zymography and enzyme-linked immunosorbent assay in human lung fibroblasts and pulmonary vascular smooth muscle cells (VSMCs), and synthesis of soluble collagen type I was assessed by enzyme-linked immunosorbent assay. In both cell types, hypoxia up-regulated the expression of MMP-1, -2, and -9 precursors without subsequent activation. MMP-13 was increased by hypoxia only in fibroblasts. PDGF-BB inhibited the synthesis and secretion of all hypoxia-dependent MMP via Erk1/2 mitogen-activated protein (MAP) kinase activation. Hypoxia and PDGF-BB induced synthesis of soluble collagen type I via Erk1/2 and p38 MAP kinase. Hypoxia-induced cell proliferation was blocked by antibodies to PDGF-BB or by inhibition of Erk1/2 but not by the inhibition of MMP or p38 MAP kinase in fibroblasts. In VSMCs, hypoxia-induced proliferation involved Erk1/2 and p38 MAP kinases and was further increased by fibroblast-conditioned medium or soluble collagen type I via Erk1/2. In conclusion, hypoxia controls tissue remodeling and proliferation in a cell type-specific manner. Furthermore, fibroblasts may affect proliferation of VSMC indirectly by inducing the synthesis of soluble collagen type I.	Univ Basel Hosp, CH-4031 Basel, Switzerland; Univ Patras, Dept Chem, Biochem Lab, GR-26110 Patras, Greece; Aristotle Univ Thessaloniki, Sch Med, Dept Pharmacol, GR-54124 Thessaloniki, Greece; Woolcock Inst Med Res, Sydney, NSW 2050, Australia	University of Basel; University of Patras; Aristotle University of Thessaloniki; University of Sydney; Woolcock Institute of Medical Research	Roth, M (corresponding author), Univ Basel Hosp, Petersgraben 4, CH-4031 Basel, Switzerland.	Michaelr@med.usyd.edu.au	Roth, Michael/H-8657-2019	Roth, Michael/0000-0002-8139-2821; Karakiulakis, George/0000-0001-5438-2874				Akahane T, 2004, BIOCHEM BIOPH RES CO, V324, P440, DOI 10.1016/j.bbrc.2004.09.063; Arnesen S, 2004, CONNECT TISSUE RES, V45, P238, DOI 10.1080/03008200490888424; Beeh KM, 2003, RESP MED, V97, P634, DOI 10.1053/rmed.2003.1493; Blaschke F, 2002, BIOCHEM BIOPH RES CO, V296, P890, DOI 10.1016/S0006-291X(02)02033-8; Cha HS, 2003, CLIN EXP RHEUMATOL, V21, P593; Corbel M, 2003, CLIN EXP ALLERGY, V33, P696, DOI 10.1046/j.1365-2222.2003.01581.x; Culpitt SV, 2005, RESP MED, V99, P703, DOI 10.1016/j.rmed.2004.10.022; Das M, 2001, J BIOL CHEM, V276, P15631, DOI 10.1074/jbc.M010690200; Gao ZY, 2005, J BIOL CHEM, V280, P9375, DOI 10.1074/jbc.M413081200; Gebb SA, 2003, ADV EXP MED BIOL, V543, P117; Gerasimovskaya EV, 2002, J BIOL CHEM, V277, P44638, DOI 10.1074/jbc.M203012200; Haque NS, 2004, BLOOD, V103, P1296, DOI 10.1182/blood-2002-05-1480; Hofbauer KH, 2003, EUR J BIOCHEM, V270, P4515, DOI 10.1046/j.1432-1033.2003.03846.x; Holguin F, 2005, CHEST, V128, P2005, DOI 10.1378/chest.128.4.2005; Ihn H, 2005, J INVEST DERMATOL, V125, P247, DOI 10.1111/j.0022-202X.2005.23766.x; Jiang YL, 2006, ACTA BIOCH BIOPH SIN, V38, P29, DOI 10.1111/j.1745-7270.2006.00123.x; Karakiulakis G, 1998, INVAS METAST, V17, P158; Kingsley K, 2002, BIOCHEM BIOPH RES CO, V293, P1000, DOI 10.1016/S0006-291X(02)00331-5; Koong AC, 2000, CANCER RES, V60, P883; Krejci P, 2005, J CELL SCI, V118, P5089, DOI 10.1242/jcs.02618; Kroon Marielle E., 2002, Angiogenesis, V5, P257, DOI 10.1023/A:1024540701634; Leufgen H, 2005, J CELL PHYSIOL, V204, P146, DOI 10.1002/jcp.20289; Li Sheng-qing, 2004, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V20, P723; Marx J, 2004, SCIENCE, V303, P1454, DOI 10.1126/science.303.5663.1454; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Miyamoto H, 2004, PANCREAS, V28, P38, DOI 10.1097/00006676-200401000-00006; Mottet D, 2003, J CELL PHYSIOL, V194, P30, DOI 10.1002/jcp.10176; Munshi HG, 2004, J BIOL CHEM, V279, P39042, DOI 10.1074/jbc.M404958200; Papakonstantinou E, 2000, AM J PHYSIOL-LUNG C, V279, pL825, DOI 10.1152/ajplung.2000.279.5.L825; Papakonstantinou E, 2003, CYTOKINE, V24, P25, DOI 10.1016/S1043-4666(03)00253-9; Phipps P, 2003, THORAX, V58, P81, DOI 10.1136/thorax.58.1.81; Preston IR, 2006, AM J PHYSIOL-LUNG C, V290, pL367, DOI 10.1152/ajplung.00114.2005; Rahman I, 2005, CELL BIOCHEM BIOPHYS, V43, P167, DOI 10.1385/CBB:43:1:167; Rice AB, 2002, AM J RESP CELL MOL, V27, P759, DOI 10.1165/rcmb.2002-0070OC; Rose F, 2002, FASEB J, V16, P1660, DOI 10.1096/fj.02-0420fje; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; Sarjeant JM, 2003, ARTERIOSCL THROM VAS, V23, P2172, DOI 10.1161/01.ATV.0000100404.05459.39; Scano G, 2006, CURR OPIN PULM MED, V12, P18, DOI 10.1097/01.mcp.0000199003.46038.82; Segura-Valdez L, 2000, CHEST, V117, P684, DOI 10.1378/chest.117.3.684; Sublett JL, 2005, CURR ALLERGY ASTHM R, V5, P445, DOI 10.1007/s11882-005-0024-x; Sweet David G, 2005, Treat Respir Med, V4, P347, DOI 10.2165/00151829-200504050-00006; Syggelos SA, 2001, J RHEUMATOL, V28, P1319; Tamm M, 1998, AM J RESP CELL MOL, V19, P653, DOI 10.1165/ajrcmb.19.4.3058; Vestbo J, 2006, THORAX, V61, P86, DOI 10.1136/thx.2005.046227; Yuantai Wan, 2005, Indian J Gastroenterol, V24, P100; Yun AJ, 2004, MED HYPOTHESES, V62, P852, DOI 10.1016/S0306-9877(03)00322-0; Zhong J, 2006, J CELL PHYSIOL, V207, P540, DOI 10.1002/jcp.20605	47	61	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					908	915		10.1074/jbc.M602178200	http://dx.doi.org/10.1074/jbc.M602178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17099219	hybrid			2022-12-27	WOS:000243295200013
J	Emerald, BS; Chen, Y; Zhu, T; Zhu, Z; Lee, KO; Gluckman, PD; Lobie, PE				Emerald, B. Starling; Chen, Yong; Zhu, Tao; Zhu, Zhe; Lee, Kok-Onn; Gluckman, Peter D.; Lobie, Peter E.			alpha CP1 mediates stabilization of hTERT mRNA by autocrine human growth hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELOMERASE CATALYTIC SUBUNIT; CELL-PROLIFERATION; DIRECT ACTIVATION; HUMAN ENDOMETRIUM; GENE-EXPRESSION; PROTEIN; IDENTIFICATION; INHIBITION; STABILITY; ESTROGEN	We herein demonstrate that autocrine human growth hormone production in human mammary carcinoma cells results in increased telomerase activity as a result of specific up-regulation of telomerase catalytic subunit (human telomerase reverse transcriptase (hTERT)) mRNA and protein. This increase in hTERT gene expression is not due to increased transcriptional activation of the hTERT promoter but is the result of increased stability of hTERT mRNA exerted by CU-rich cis-regulatory sequences present in the T-untranslated region of TERT mRNA. Autocrine human growth hormone up-regulates two poly(C)-binding proteins, alpha CP1 and alpha CP2, which bind to these cis-regulatory elements and stabilize hTERT mRNA. We have therefore demonstrated that post-transcriptional modulation of the level of hTERT mRNA is one mechanism for regulation of cellular telomerase activity.	Univ Auckland, Liggins Inst, Auckland, New Zealand; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland, New Zealand; Natl Univ Singapore, Dept Med, Singapore 117609, Singapore; Inst Mol & Cellular Biol, Singapore 117609, Singapore	University of Auckland; University of Auckland; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave,Private bag 92019, Auckland, New Zealand.	p.lobie@auckland.ac.nz	Lee, Kok-Onn/E-9874-2011; David, Starling Emerald Bright/R-6034-2019	Lee, Kok-Onn/0000-0002-3040-1185; David, Starling Emerald Bright/0000-0001-6875-2258				Bachand F, 1999, J BIOL CHEM, V274, P38027, DOI 10.1074/jbc.274.53.38027; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Eberhardt W, 2002, J BIOL CHEM, V277, P33518, DOI 10.1074/jbc.M202008200; Funke B, 1996, NUCLEIC ACIDS RES, V24, P3821, DOI 10.1093/nar/24.19.3821; Graichen R, 2002, J BIOL CHEM, V277, P26662, DOI 10.1074/jbc.M109931200; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Grzybowska EA, 2001, BIOCHEM BIOPH RES CO, V288, P291, DOI 10.1006/bbrc.2001.5738; GUYETTE WA, 1979, CELL, V17, P1013, DOI 10.1016/0092-8674(79)90340-4; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; KEITH WN, 2002, EXPERT REV MOL MED, P1; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kimura A, 2004, ONCOGENE, V23, P4505, DOI 10.1038/sj.onc.1207582; Klapper W, 1998, BBA-GENE STRUCT EXPR, V1442, P120, DOI 10.1016/S0167-4781(98)00155-9; Kyo S, 1999, CANCER RES, V59, P5917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; LU DL, 1993, ENDOCRINOLOGY, V132, P235, DOI 10.1210/en.132.1.235; Maida Y, 2002, ONCOGENE, V21, P4071, DOI 10.1038/sj.onc.1205509; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Mignone F, 2005, NUCLEIC ACIDS RES, V33, pD141, DOI 10.1093/nar/gki021; Mukhina S, 2006, ENDOCRINOLOGY, V147, P1819, DOI 10.1210/en.2005-1082; Mukhina S, 2004, P NATL ACAD SCI USA, V101, P15166, DOI 10.1073/pnas.0405881101; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Newbury SF, 2006, BIOCHEM SOC T, V34, P30, DOI 10.1042/BST0340030; OHLSSON C, 1993, ENDOCRINOLOGY, V133, P2897, DOI 10.1210/en.133.6.2897; Pantaleon M, 1997, P NATL ACAD SCI USA, V94, P5125, DOI 10.1073/pnas.94.10.5125; Raccurt M, 2002, J ENDOCRINOL, V175, P307, DOI 10.1677/joe.0.1750307; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Sbracia M, 2004, AM J REPROD IMMUNOL, V51, P112, DOI 10.1046/j.8755-8920.2003.00127.x; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Stefanovic B, 1999, MOL CELL BIOL, V19, P4334; Sun W, 1999, CANCER RES, V59, P6118; Szepeshazi K, 2001, ENDOCRINOLOGY, V142, P4371, DOI 10.1210/en.142.10.4371; Tanaka M, 1998, AM J PATHOL, V153, P1985, DOI 10.1016/S0002-9440(10)65712-4; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; Wang ZR, 2000, EMBO J, V19, P295, DOI 10.1093/emboj/19.2.295; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; Wright WE, 1996, DEV GENET, V18, P173; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zaffaroni N, 2002, EUR J CANCER, V38, P1792, DOI 10.1016/S0959-8049(02)00139-9; Zhu T, 2005, CANCER RES, V65, P317; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3	58	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					680	690		10.1074/jbc.M600224200	http://dx.doi.org/10.1074/jbc.M600224200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17085453	hybrid			2022-12-27	WOS:000243166500073
J	Feniouk, BA; Suzuki, T; Yoshida, M				Feniouk, Boris A.; Suzuki, Toshiharu; Yoshida, Masasuke			Regulatory interplay between proton motive force, ADP, phosphate, and subunit epsilon in bacterial ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; TIGHTLY BOUND ADP; ENERGY-DEPENDENT TRANSFORMATION; ESCHERICHIA-COLI F1-ATPASE; F-1-ATPASE BINDS ATP; C-TERMINAL DOMAIN; COUPLING FACTOR-I; CATALYTIC SITE; F0F1-ATP SYNTHASE; PARACOCCUS-DENITRIFICANS	ATP synthase couples transmembrane proton transport, driven by the proton motive force (pmf), to the synthesis of ATP from ADP and inorganic phosphate (P-i). In certain bacteria, the reaction is reversed and the enzyme generates pmf, working as a proton-pumping ATPase. The ATPase activity of bacterial enzymes is prone to inhibition by both ADP and the C-terminal domain of subunit epsilon. We studied the effects of ADP, P-i,pmf, and the C-terminal domain of subunit E on the ATPase activity of thermophilic Bacillus PS3 and Escherichia coli ATP synthases. We found that pmf relieved ADP inhibition during steady-state ATP hydrolysis, but only in the presence of P-i. The C-terminal domain of subunit epsilon in the Bacillus PS3 enzyme enhanced ADP inhibition by counteracting the effects of pmf. It appears that these features allow the enzyme to promptly respond to changes in the ATP:ADP ratio and in pmf levels in order to avoid potentially wasteful ATP hydrolysis in vivo.	Japan Sci & Technol Corp, Exploratory Res Adv Technol, ATP Syst Project, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Japan Science & Technology Agency (JST); Tokyo Institute of Technology	Yoshida, M (corresponding author), Japan Sci & Technol Corp, Exploratory Res Adv Technol, ATP Syst Project, Midori Ku, 5800-3 Nagatsuta, Yokohama, Kanagawa 2260026, Japan.	myoshida@res.titech.ac.jp	Feniouk, Boris/F-2380-2012	Feniouk, Boris/0000-0003-0474-7411				AFLALO C, 1983, FEBS LETT, V154, P175, DOI 10.1016/0014-5793(83)80898-9; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; Altendorf K, 2000, J EXP BIOL, V203, P19; BALTSCHEFFSKY M, 1979, CATION FLUX BIOMEMBR, P209; Boyer PD, 2002, FEBS LETT, V512, P29, DOI 10.1016/S0014-5793(02)02293-7; Boyer PD, 2002, J BIOL CHEM, V277, P39045, DOI 10.1074/jbc.X200001200; Capaldi RA, 2000, BBA-BIOENERGETICS, V1458, P263, DOI 10.1016/S0005-2728(00)00078-5; Capaldi RA, 2000, J EXP BIOL, V203, P29; CARMELI C, 1972, BIOCHIM BIOPHYS ACTA, V267, P86, DOI 10.1016/0005-2728(72)90140-5; Cipriano DJ, 2006, J BIOL CHEM, V281, P501, DOI 10.1074/jbc.M509986200; CRECZYNSKIPASA TB, 1994, FEBS LETT, V350, P195, DOI 10.1016/0014-5793(94)00762-4; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DUNHAM KR, 1981, J BIOL CHEM, V256, P212; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; Feniouk BA, 2005, FEBS LETT, V579, P5114, DOI 10.1016/j.febslet.2005.08.030; Feniouk BA, 2005, BBA-BIOENERGETICS, V1706, P184, DOI 10.1016/j.bbabio.2004.10.010; Feniouk BA, 2006, BBA-BIOENERGETICS, V1757, P326, DOI 10.1016/j.bbabio.2006.03.022; Fischer S, 2000, J BIOL CHEM, V275, P30157, DOI 10.1074/jbc.275.39.30157; FISCHER S, 1994, EUR J BIOCHEM, V225, P167, DOI 10.1111/j.1432-1033.1994.00167.x; FITIN AF, 1979, BIOCHEM BIOPH RES CO, V86, P434, DOI 10.1016/0006-291X(79)90884-2; Galkin MA, 1999, FEBS LETT, V448, P123, DOI 10.1016/S0014-5793(99)00347-6; GRABER P, 1977, BIOCHIM BIOPHYS ACTA, V461, P426, DOI 10.1016/0005-2728(77)90231-6; Hara KY, 2001, J BIOL CHEM, V276, P23969, DOI 10.1074/jbc.M009303200; Hirono-Hara Y, 2005, P NATL ACAD SCI USA, V102, P4288, DOI 10.1073/pnas.0406486102; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; Iino R, 2005, J BIOL CHEM, V280, P40130, DOI 10.1074/jbc.M506160200; Ishmukhametov RR, 2005, BBA-BIOENERGETICS, V1706, P110, DOI 10.1016/j.bbabio.2004.09.012; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JUNGE W, 1987, P NATL ACAD SCI USA, V84, P7084, DOI 10.1073/pnas.84.20.7084; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kato-Yamada Y, 1999, J BIOL CHEM, V274, P33991, DOI 10.1074/jbc.274.48.33991; Kato-Yamada Y, 2005, FEBS LETT, V579, P6875, DOI 10.1016/j.febslet.2005.11.036; Kato-Yamada Y, 2003, J BIOL CHEM, V278, P36013, DOI 10.1074/jbc.M306140200; Keis S, 2006, J BACTERIOL, V188, P3796, DOI 10.1128/JB.00040-06; Konno H, 2006, EMBO J, V25, P4596, DOI 10.1038/sj.emboj.7601348; KUKI M, 1988, J BIOL CHEM, V263, P17437; Masaike T, 2006, BIOCHEM BIOPH RES CO, V342, P800, DOI 10.1016/j.bbrc.2006.02.017; MCCARTHY JEG, 1983, EUR J BIOCHEM, V132, P425, DOI 10.1111/j.1432-1033.1983.tb07380.x; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MINKOV IB, 1979, BIOCHEM BIOPH RES CO, V89, P1300, DOI 10.1016/0006-291X(79)92150-8; Mitome N, 2002, EUR J BIOCHEM, V269, P53, DOI 10.1046/j.0014-2956.2002.02623.x; Nakamoto RK, 2000, BBA-BIOENERGETICS, V1458, P289, DOI 10.1016/S0005-2728(00)00081-5; Nakanishi-Matsui M, 2006, J BIOL CHEM, V281, P4126, DOI 10.1074/jbc.M510090200; NISHIMURA M, 1962, BIOCHIM BIOPHYS ACTA, V59, P177; Nowak KF, 2004, BIOCHEMISTRY-US, V43, P3273, DOI 10.1021/bi035820d; Nowak KF, 2002, BIOCHEMISTRY-US, V41, P15130, DOI 10.1021/bi026594v; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; ROVERI OA, 1980, BIOCHIM BIOPHYS ACTA, V589, P241, DOI 10.1016/0005-2728(80)90041-9; SHERMAN PA, 1984, EUR J BIOCHEM, V139, P367, DOI 10.1111/j.1432-1033.1984.tb08015.x; SMITH LT, 1983, J BIOL CHEM, V258, P887; STROTMANN H, 1976, FEBS LETT, V61, P194, DOI 10.1016/0014-5793(76)81036-8; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; Suzuki T, 2002, J BIOL CHEM, V277, P13281, DOI 10.1074/jbc.M111210200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; TURINA P, 1992, J BIOL CHEM, V267, P11057; Vik SB, 2000, J BIOENERG BIOMEMBR, V32, P485, DOI 10.1023/A:1005664908066; Vinogradov AD, 2000, J EXP BIOL, V203, P41; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; Xiong H, 1998, BIOCHEMISTRY-US, V37, P16423, DOI 10.1021/bi981522i; YOSHIDA M, 1983, J BIOL CHEM, V258, P4407; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; Zharova TV, 2004, J BIOL CHEM, V279, P12319, DOI 10.1074/jbc.M311397200; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027	71	75	83	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					764	772		10.1074/jbc.M606321200	http://dx.doi.org/10.1074/jbc.M606321200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17092944	hybrid			2022-12-27	WOS:000243166500081
J	Kume, S; Haneda, M; Kanasaki, K; Sugimoto, T; Araki, S; Isshiki, K; Isono, M; Uzu, T; Guarente, L; Kashiwagi, A; Koya, D				Kume, Shinji; Haneda, Masakazu; Kanasaki, Keizo; Sugimoto, Toshiro; Araki, Shin-ichi; Isshiki, Keiji; Isono, Motohide; Uzu, Takashi; Guarente, Leonard; Kashiwagi, Atsunori; Koya, Daisuke			SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; KAPPA-B; TRANSCRIPTION FACTORS; SURVIVAL; PROTEIN; P53; ACETYLATION; DEGRADATION; STABILITY; RECEPTOR	SIRT1, a class III histone deacetylase, is considered a key regulator of cell survival and apoptosis through its interaction with nuclear proteins. In this study, we have examined the likelihood and role of the interaction between SIRT1 and Smad7, which mediates transforming growth factor beta(TGF beta)-induced apoptosis in renal glomerular mesangial cells. Immunoprecipitation analysis revealed that SIRT1 directly interacts with the N terminus of Smad7. Furthermore, SIRT1 reversed acetyl-transferase (p300)-mediated acetylation of two lysine residues (Lys-64 and -70) on Smad7. In mesangial cells, the Smad7 expression level was reduced by SIRT1 overexpression and increased by SIRT1 knockdown. SIRT1-mediated deacetylation of Smad7 enhanced Smad ubiquitination regulatory factor 1 (Smurf1)-mediated ubiquitin proteasome degradation, which contributed to the low expression of Smad7 in SIRT1-overexpressing mesangial cells. Stimulation by TGF beta or overexpression of Smad7 induced mesangial cell apoptosis, as assessed by morphological apoptotic changes (nuclear condensation) and biological apoptotic markers (cleavages of caspase3 and poly(ADP-ribose) polymerase). However, TGF beta failed to induce apoptosis in Smad7 knockdown mesangial cells, indicating that Smad7 mainly mediates TGF beta-induced apoptosis of mesangial cells. Finally, SIRT1 overexpression attenuated both Smad7- and TGF beta-induced mesangial cell apoptosis, whereas SIRT1 knockdown enhanced this apoptosis. We have concluded that Smad7 is a new target molecule for SIRT1 and SIRT1 attenuates TGF beta-induced mesangial cell apoptosis through acceleration of Smad7 degradation. Our results suggest that up-regulation of SIRT1 deacetylase activity is a potentially useful therapeutic strategy for prevention of TGF beta-related kidney disease through its effect on cell survival.	Kanazawa Med Univ, Div Endocrinol & Metab, Kanazawa, Ishikawa 9200293, Japan; Shiga Univ Med Sci, Dept Med, Otsu, Shiga 5202192, Japan; Asahikawa Med Coll, Dept Med 2, Asahikawa, Hokkaido 0788510, Japan; MIT, Dept Biol, Cambridge, MA 02139 USA	Kanazawa Medical University; Shiga University of Medical Science; Asahikawa Medical College; Massachusetts Institute of Technology (MIT)	Koya, D (corresponding author), Kanazawa Med Univ, Div Endocrinol & Metab, Kanazawa, Ishikawa 9200293, Japan.	koya05l6@kanazawa-med.ac.jp	Koya, Daisuke/J-3257-2014; Kashiwagi, Atsunori/H-8712-2019					Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Guarente L, 2000, GENE DEV, V14, P1021; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Kanasaki K, 2003, J AM SOC NEPHROL, V14, P863, DOI 10.1097/01.ASN.0000057544.95569.EC; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lallemand F, 2001, ONCOGENE, V20, P879, DOI 10.1038/sj.onc.1204167; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Okado T, 2002, KIDNEY INT, V62, P1178, DOI 10.1046/j.1523-1755.2002.00583.x; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; Simonsson M, 2005, J BIOL CHEM, V280, P21797, DOI 10.1074/jbc.M503134200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	32	188	205	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					151	158		10.1074/jbc.M605904200	http://dx.doi.org/10.1074/jbc.M605904200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17098745	hybrid			2022-12-27	WOS:000243166500018
J	Perez-Jimenez, R; Garcia-Manyes, S; Ainavarapu, RK; Fernandez, JM				Perez-Jimenez, Raul; Garcia-Manyes, Sergi; Ainavarapu, Rama Koti; Fernandez, Julio M.			Mechanical unfolding pathways of the enhanced yellow fluorescent protein revealed by single molecule force spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSCOPY; MUTATIONS; STABILITY; VARIANTS; DYNAMICS; MODULES; LENGTH	We used single molecule force spectroscopy to characterize the mechanical stability of the enhanced yellow fluorescent protein (EYFP) (a mutant form of the green fluorescent protein (GFP)) and two of its circularly permutated variants. In all three constructs, we found two main unfolding peaks; the first corresponds to a transition state placed close to the termini and the second to a transition state placed halfway through the molecule. We attribute the second transition state to the shear rupture of the beta 1- and beta 6-strands, which we verified by introducing a point mutation in this region. Although both unfolding peaks were observed in all three EYFP variants, their relative frequency of occurrence varied. Our results demonstrated that the mechanical unfolding pathways in EYFP could be deciphered through the use of circular permutation.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Fernandez, JM (corresponding author), Columbia Univ, Dept Biol Sci, 1011A Fairchild Ctr,1212 Amsterdam Ave,MC 2449, New York, NY 10027 USA.	jfernandez@columbia.edu	Ainavarapu, Sri Rama Koti/D-1231-2011; Perez-Jimenez, Raul/C-3085-2017	Ainavarapu, Sri Rama Koti/0000-0002-1646-2731; Perez-Jimenez, Raul/0000-0001-7094-6799; Garcia-Manyes, Sergi/0000-0001-5140-2606	NHLBI NIH HHS [HL61228, HL66030] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066030, R01HL061228] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ainavarapu RK, 2007, BIOPHYS J, V92, P225, DOI 10.1529/biophysj.106.091561; Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; Cao Y, 2006, ANGEW CHEM INT EDIT, V45, P642, DOI 10.1002/anie.200502623; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P11288, DOI 10.1073/pnas.96.20.11288; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Dietz H, 2004, P NATL ACAD SCI USA, V101, P16192, DOI 10.1073/pnas.0404549101; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Fukuda H, 2000, BIOCHEMISTRY-US, V39, P12025, DOI 10.1021/bi000543l; Gao M, 2002, J MOL BIOL, V323, P939, DOI 10.1016/S0022-2836(02)01001-X; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Li HB, 2000, NAT STRUCT BIOL, V7, P1117; Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; Marszalek PE, 1999, NATURE, V402, P100, DOI 10.1038/47083; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Topell S, 1999, FEBS LETT, V457, P283, DOI 10.1016/S0014-5793(99)01044-3; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0; Wang T, 2005, ULTRAMICROSCOPY, V105, P90, DOI 10.1016/j.ultramic.2005.06.022; Wang T, 2004, JPN J APPL PHYS 1, V43, P5520, DOI 10.1143/JJAP.43.5520; Wang T, 2005, COLLOID SURFACE B, V40, P183, DOI 10.1016/j.colsurfb.2004.10.012; West DK, 2006, BIOPHYS J, V90, P287, DOI 10.1529/biophysj.105.071035; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	25	67	68	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40010	40014		10.1074/jbc.M609890200	http://dx.doi.org/10.1074/jbc.M609890200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17082195	hybrid			2022-12-27	WOS:000243033900029
J	Radom, CT; Banerjee, A; Verdine, GL				Radom, Christopher T.; Banerjee, Anirban; Verdine, Gregory L.			Structural characterization of human 8-oxoguanine DNA glycosylase variants bearing active site mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVELY DAMAGED DNA; BASE EXCISION-REPAIR; BIOCHEMICAL EXPLORATION; SUBSTRATE RECOGNITION; FPG PROTEIN; ENZYME; CLONING; 7,8-DIHYDRO-8-OXOGUANINE; MUTAGENESIS; SYSTEM	The human 8-oxoguanine DNA glycosylase (hOGG1) protein is responsible for initiating base excision DNA repair of the endogenous mutagen 8-oxoguanine. Like nearly all DNA glycosylases, hOGG1 extrudes its substrate from the DNA helix and inserts it into an extrahelical enzyme active site pocket lined with residues that participate in lesion recognition and catalysis. Structural analysis has been performed on mutant versions of hOGG1 having changes in catalytic residues but not on variants having altered 7,8-dihydro-8-oxoguanine (oxoG) contact residues. Here we report high resolution structural analysis of such recognition variants. We found that Ala substitution at residues that contact the phosphate 5' to the lesion (H270A mutation) and its Watson-Crick face (Q315A mutation) simply removed key functionality from the contact interface but otherwise had no effect on structure. Ala substitution at the only residue making an oxoG-specific contact (G42A mutation) introduced torsional stress into the DNA contact surface of hOGG1, but this was overcome by local interactions within the folded protein, indicating that this oxoG recognition motif is "hardwired." Introduction of a side chain intended to sterically obstruct the active site pocket (Q315F mutation) led to two different structures, one of which (Q315F*(149)) has the oxoG lesion in an exosite flanking the active site and the other of which (Q315F*(292)) has the oxoG inserted nearly completely into the lesion recognition pocket. The latter structure offers a view of the latest stage in the base extrusion pathway yet observed, and its lack of catalytic activity demonstrates that the transition state for displacement of the lesion base is geometrically demanding.	Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cell Biol, Cambridge, MA 02138 USA; Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard University; Dana-Farber Cancer Institute	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.	gregory_verdine@harvard.edu	Banerjee, Anirban/AAC-4286-2020	Banerjee, Anirban/0000-0002-9314-2862; banerjee, anirban/0000-0003-1494-6801	NCI NIH HHS [CA100742, R01 CA100742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Banerjee A, 2005, NATURE, V434, P612, DOI 10.1038/nature03458; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P15020, DOI 10.1073/pnas.0603644103; Bjoras M, 2002, J MOL BIOL, V317, P171, DOI 10.1006/jmbi.2002.5400; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W.L, PYMOL MOL GRAPHICS S; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Fromme JC, 2004, NATURE, V427, P652, DOI 10.1038/nature02306; Fromme JC, 2003, J BIOL CHEM, V278, P51543, DOI 10.1074/jbc.M307768200; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Hsu GW, 2004, NATURE, V431, P217, DOI 10.1038/nature02908; Krokan HE, 1997, BIOCHEM J, V325, P1; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MACMILLAN AM, 1991, TETRAHEDRON, V47, P2603, DOI 10.1016/S0040-4020(01)81793-2; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; Norman DPG, 2003, BIOCHEMISTRY-US, V42, P1564, DOI 10.1021/bi026823d; Norman DPG, 2001, J AM CHEM SOC, V123, P359, DOI 10.1021/ja003144m; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P104; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; TCHOU J, 1994, J BIOL CHEM, V269, P15318; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; van der Kemp PA, 2004, NUCLEIC ACIDS RES, V32, P570, DOI 10.1093/nar/gkh224; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; WOLFE SA, 1995, CHEM BIOL, V2, P213, DOI 10.1016/1074-5521(95)90271-6; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Zharkov DO, 2005, MUTAT RES-FUND MOL M, V577, P24, DOI 10.1016/j.mrfmmm.2005.03.011; Zharkov DO, 2002, EMBO J, V21, P789, DOI 10.1093/emboj/21.4.789	41	62	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9182	9194		10.1074/jbc.M608989200	http://dx.doi.org/10.1074/jbc.M608989200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17114185	hybrid			2022-12-27	WOS:000245780300065
J	Baniwal, SK; Chan, KY; Scharf, KD; Nover, L				Baniwal, Sanjeev K.; Chan, Kwan Yu; Scharf, Klaus-Dieter; Nover, Lutz			Role of heat stress transcription factor HsfA5 as specific repressor of HsfA4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-DISTRIBUTION; ACTIVATOR FUNCTION; NUCLEAR IMPORT; TOMATO; GENES; ARABIDOPSIS; EXPRESSION; IDENTIFICATION; PROTEINS; SYSTEM	Unlike other eukaryotes, plants possess a complex family of heat stress transcription factors (Hsfs) with usually more than 20 members. Among them, Hsfs A4 and A5 form a group distinguished from other Hsfs by structural features of their oligomerization domains and by a number of conserved signature sequences. We show that A4 Hsfs are potent activators of heat stress gene expression, whereas A5 Hsfs act as specific repressors of HsfA4 activity. The oligomerization domain of HsfA5 alone is necessary and sufficient to exert this effect. Due to the high specificity of the oligomerization domains, other class A Hsfs are not affected. Pull-down assay and yeast two-hybrid interaction tests demonstrate that the tendency to form HsfA4/A5 heterooligomers is stronger than the formation of homooligomers. The specificity of interaction between Hsfs A4 and A5 was confirmed by bimolecular fluorescence complementation experiments. The major role of the representatives of the HsfA4/A5 group, which are not involved in the conventional heat stress response, may reside in cell type-specific functions connected with the control of cell death triggered by pathogen infection and/or reactive oxygen species.	Goethe Univ Frankfurt, Bioctr, Dept Mol Cell Biol, D-60438 Frankfurt, Germany	Goethe University Frankfurt	Nover, L (corresponding author), Goethe Univ Frankfurt, Bioctr, Dept Mol Cell Biol, Max Von Laue Str 9, D-60438 Frankfurt, Germany.	nover@cellbiology.uni-frankfurt.de						Almoguera C, 2002, J BIOL CHEM, V277, P43866, DOI 10.1074/jbc.M207330200; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baniwal SK, 2004, J BIOSCIENCES, V29, P471, DOI 10.1007/BF02712120; Bharti K, 2000, PLANT J, V22, P355, DOI 10.1046/j.1365-313x.2000.00746.x; Bharti K, 2004, PLANT CELL, V16, P1521, DOI 10.1105/tpc.019927; Boscheinen O, 1997, MOL GEN GENET, V255, P322, DOI 10.1007/s004380050503; Busch W, 2005, PLANT J, V41, P1, DOI 10.1111/j.1365-313X.2004.02272.x; CZARNECKA E, 1985, P NATL ACAD SCI USA, V82, P3726, DOI 10.1073/pnas.82.11.3726; Czarnecka-Verner E, 2004, PLANT MOL BIOL, V56, P57, DOI 10.1007/s11103-004-2307-3; Davletova S, 2005, PLANT CELL, V17, P268, DOI 10.1105/tpc.104.026971; Doring P, 2000, PLANT CELL, V12, P265, DOI 10.1105/tpc.12.2.265; Heerklotz D, 2001, MOL CELL BIOL, V21, P1759, DOI 10.1128/MCB.21.5.1759-1768.2001; Kirschner M, 2000, PLANT J, V24, P397, DOI 10.1046/j.1365-313x.2000.00887.x; Kotak S, 2004, PLANT J, V39, P98, DOI 10.1111/j.1365-313X.2004.02111.x; Lohmann C, 2004, MOL GENET GENOMICS, V271, P11, DOI 10.1007/s00438-003-0954-8; Lyck R, 1997, PLANTA, V202, P117, DOI 10.1007/s004250050110; Miller G, 2006, ANN BOT-LONDON, V98, P279, DOI 10.1093/aob/mcl107; Mishra SK, 2002, GENE DEV, V16, P1555, DOI 10.1101/gad.228802; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nakai A, 1999, CELL STRESS CHAPERON, V4, P86, DOI 10.1054/csac.1998.0002; NOVER L, 1987, ENZYME MICROB TECH, V9, P130, DOI 10.1016/0141-0229(87)90066-4; Nover L, 2001, CELL STRESS CHAPERON, V6, P177, DOI 10.1379/1466-1268(2001)006<0177:AATHST>2.0.CO;2; PELHAM HRB, 1982, EMBO J, V1, P1473, DOI 10.1002/j.1460-2075.1982.tb01340.x; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Port M, 2004, PLANT PHYSIOL, V135, P1457, DOI 10.1104/pp.104.042820; Prandl R, 1998, MOL GEN GENET, V258, P269, DOI 10.1007/s004380050731; Prieto-Dapena P, 2006, PLANT PHYSIOL, V142, P1102, DOI 10.1104/pp.106.087817; Sambrook J., 2001, MOL CLONING LAB MANU, Vthird edition; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; Scharf KD, 1998, MOL CELL BIOL, V18, P2240, DOI 10.1128/MCB.18.4.2240; Scharf KD, 2001, CELL STRESS CHAPERON, V6, P225, DOI 10.1379/1466-1268(2001)006<0225:TEFOAT>2.0.CO;2; Schramm F, 2006, PLANT MOL BIOL, V60, P759, DOI 10.1007/s11103-005-5750-x; Siddique M, 2003, CELL STRESS CHAPERON, V8, P381, DOI 10.1379/1466-1268(2003)008<0381:THSPHR>2.0.CO;2; TOPFER R, 1988, NUCLEIC ACIDS RES, V16, P8725, DOI 10.1093/nar/16.17.8725; TREUTER E, 1993, MOL GEN GENET, V240, P113, DOI 10.1007/BF00276890; Voellmy R, 2004, CELL STRESS CHAPERON, V9, P122, DOI 10.1379/CSC-14R.1; Walter M, 2004, PLANT J, V40, P428, DOI 10.1111/j.1365-313X.2004.02219.x; Yamanouchi U, 2002, P NATL ACAD SCI USA, V99, P7530, DOI 10.1073/pnas.112209199	39	104	116	6	34	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3605	3613		10.1074/jbc.M609545200	http://dx.doi.org/10.1074/jbc.M609545200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17150959	hybrid			2022-12-27	WOS:000244481900022
J	Munshi, UM; Kim, J; Nagashima, K; Hurley, JH; Freed, EO				Munshi, Utpal M.; Kim, Jaewon; Nagashima, Kunio; Hurley, James H.; Freed, Eric O.			An Alix fragment potently inhibits HIV-1 budding - Characterization of binding to retroviral YPXL late domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS-ANEMIA VIRUS; RECEPTOR DOWN-REGULATION; PROTEIN-SORTING PATHWAY; MULTIVESICULAR-BODY; SACCHAROMYCES-CEREVISIAE; PARTICLE-PRODUCTION; GAG PROTEIN; LIFE-CYCLE; ESCRT-I; UBIQUITIN	The retroviral structural protein, Gag, contains small peptide motifs known as late domains that promote efficient virus release from the infected cell. In addition to the well characterized PTAP late domain, the p6 region of HIV-1 Gag contains a binding site for the host cell protein Alix. To better understand the functional role of the Gag/Alix interaction, we overexpressed an Alix fragment composed of residues 364-716 (Alix 364-716) and examined the effect on release of wild type (WT) and Alix binding site mutant HIV-1. We observed that Alix 364-716 expression significantly inhibited WT virus release and Gag processing and that mutation of the Alix binding site largely relieved this inhibition. Furthermore, Alix 364-716 expression induced a severe defect on WT but not mutant particle morphology. Intriguingly, the impact of Alix 364-716 expression on HIV-1 release and Gag processing was markedly different from that induced by mutation of the Alix binding site in p6. The association of Alix 364-716 with HIV-1 and equine infectious anemia virus late domains was quantitatively evaluated by isothermal titration calorimetry and surface plasmon resonance techniques, and the effects of mutations in these viral sequences on Alix 364-716 binding was determined. This study identifies a novel Alix-derived dominant negative inhibitor of HIV-1 release and Gag processing and provides quantitative information on the interaction between Alix and viral late domains.	NCI Frederick, HIV Drug Resistance Program, Virus Cell Interact Sect, Frederick, MD 21702 USA; NIDDK, Mol Biol Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; NCI, SAIC Frederick, Res Technol Program, Image Anal Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Freed, EO (corresponding author), NCI Frederick, HIV Drug Resistance Program, Virus Cell Interact Sect, Bldg 535,Rm 108, Frederick, MD 21702 USA.	efreed@nih.gov			Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036125] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander L, 2000, J VIROL, V74, P4361, DOI 10.1128/JVI.74.9.4361-4376.2000; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Bieniasz PD, 2006, VIROLOGY, V344, P55, DOI 10.1016/j.virol.2005.09.044; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bouamr F, 2003, J VIROL, V77, P11882, DOI 10.1128/JVI.77.22.11882-11895.2003; Bowers K, 2005, BBA-MOL CELL RES, V1744, P438, DOI 10.1016/j.bbamcr.2005.04.004; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Chen CP, 2005, J BIOL CHEM, V280, P40474, DOI 10.1074/jbc.M509317200; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Demirov DG, 2004, VIRUS RES, V106, P87, DOI 10.1016/j.virusres.2004.08.007; Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002; FREED EO, 1994, J VIROL, V68, P5311, DOI 10.1128/JVI.68.8.5311-5320.1994; Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Goila-Gaur R, 2003, J VIROL, V77, P6507, DOI 10.1128/JVI.77.11.6507-6519.2003; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Joshi A, 2006, J VIROL, V80, P7939, DOI 10.1128/JVI.00355-06; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; Kim JW, 2005, DEV CELL, V8, P937, DOI 10.1016/j.devcel.2005.04.001; Martin-Serrano J, 2005, J CELL BIOL, V168, P89, DOI 10.1083/jcb.200408155; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Ono A, 2000, J VIROL, V74, P2855, DOI 10.1128/JVI.74.6.2855-2866.2000; Patnaik A, 2002, J VIROL, V76, P2641, DOI 10.1128/JVI.76.6.2641-2647.2002; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Schmidt MHH, 2004, MOL CELL BIOL, V24, P8981, DOI 10.1128/MCB.24.20.8981-8993.2004; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Shehu-Xhilaga M, 2004, J VIROL, V78, P724, DOI 10.1128/JVI.78.2.724-732.2004; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Trioulier Y, 2004, J BIOL CHEM, V279, P2046, DOI 10.1074/jbc.M309243200; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Vincent O, 2003, MOL CELL BIOL, V23, P1647, DOI 10.1128/MCB.23.5.1647-1655.2003; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Wang HT, 2004, J VIROL, V78, P1503, DOI 10.1128/JVI.78.3.1503-1512.2004; Yuan B, 1999, EMBO J, V18, P4700, DOI 10.1093/emboj/18.17.4700	51	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3847	3855		10.1074/jbc.M607489200	http://dx.doi.org/10.1074/jbc.M607489200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17158451	hybrid			2022-12-27	WOS:000244481900048
J	Stojadinovic, O; Lee, B; Vouthounis, C; Vukelic, S; Pastar, I; Blumenberg, M; Brem, H; Tomic-Canic, M				Stojadinovic, Olivera; Lee, Brian; Vouthounis, Constantinos; Vukelic, Sasa; Pastar, Irena; Blumenberg, Miroslav; Brem, Harold; Tomic-Canic, Marjana			Novel genomic effects of glucocorticoids in epidermal keratinocytes - Inhibition of apoptosis, interferon-gamma pathway, and wound healing along with promotion of terminal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NEGATIVE CROSS-TALK; TRANSCRIPTIONAL PROGRAM; ANTIINFLAMMATORY ACTION; MEDIATED REPRESSION; HUMAN FIBROBLASTS; ACTIN-FILAMENTS; REGULATED GENES; DOWN-REGULATION; ARP2/3 COMPLEX	Glucocorticoids (GCs) have a long history of use as therapeutic agents for numerous skin diseases. Surprisingly, their specific molecular effects are largely unknown. To characterize GC action in epidermis, we compared the transcriptional profiles of primary human keratinocytes untreated and treated with dexamethasone (DEX) for 1, 4, 24, 48, and 72 h using large scale microarray analyses. The majority of genes were found to be regulated only after 24 h and remained regulated throughout treatment. In addition to regulation of the expected pro-inflammatory genes, we found that GCs regulate cell fate, tissue remodeling, cell motility, differentiation, and metabolism. GCs suppress the expression of essentially all IFN gamma-regulated genes, including IFN gamma receptor and STAT-1, an effect that was previously unknown. GCs also block STAT-1 activation and nuclear translocation. Unexpectedly, GCs induce the expression of anti-apoptotic genes and repress pro-apoptotic ones, preventing Uv-induced keratinocyte apoptosis. Consequently, treatment with GCs blocked UV-induced apoptosis of keratinocytes. GCs have profound effect on wound healing by inhibiting cell motility and the expression of the proangiogenic factor, vascular endothelial growth factor. They play an important role in tissue remodeling and scar formation by suppressing the expression of TGF beta 1 and 2 and MMP1, -2,-9, and -10 and inducing TIMP-2. Finally, GCs promote terminal epidermal differentiation while simultaneously inhibiting early stage differentiation. These results provide new insights into the beneficial and adverse effects of GCs in the epidermis, defining the participating genes and mechanisms that coordinate the cellular responses important for GC-based therapies.	Cornell Univ, Hosp Special Surg, Dept Dermatol,Tissue Repair Lab, Weill Med Coll,Tissue Engn Regenerat & Repair Pro, New York, NY 10021 USA; NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; Columbia Univ Coll Phys & Surg, Wound Healing Program, Dept Surg, New York, NY 10034 USA	Cornell University; New York University; Columbia University	Tomic-Canic, M (corresponding author), Cornell Univ, Hosp Special Surg, Dept Dermatol,Tissue Repair Lab, Weill Med Coll,Tissue Engn Regenerat & Repair Pro, 535 E 70th St, New York, NY 10021 USA.	tomicm@hss.edu	Pastar, Irena/AAD-3626-2020	Blumenberg, Miroslav/0000-0002-8672-7774; Pastar, Irena/0000-0003-0197-6198	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR008029] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM008443] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45974] Funding Source: Medline; NIDDK NIH HHS [DK59424] Funding Source: Medline; NINR NIH HHS [NR08029] Funding Source: Medline; NLM NIH HHS [LM008443] Funding Source: Medline; PHS HHS [T3207190] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adcock IM, 1999, BRIT J PHARMACOL, V127, P1003, DOI 10.1038/sj.bjp.0702613; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Autio P, 1996, AM J RESP CRIT CARE, V153, P1172, DOI 10.1164/ajrccm.153.3.8630563; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Banno T, 2005, J BIOL CHEM, V280, P18973, DOI 10.1074/jbc.M411758200; Banno T, 2003, ANTIVIR THER, V8, P541; BAUMANN L, 1999, FITZPATRICKS DERMATO, V2, P2713; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Bruscoli S, 2006, EUR J PHARMACOL, V529, P63, DOI 10.1016/j.ejphar.2005.10.053; Byers Hugh Randolph, 1992, Journal of Dermatology (Tokyo), V19, P847; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Caramori Gaetano, 2005, Current Drug Targets - Inflammation and Allergy, V4, P455, DOI 10.2174/1568010054526331; Chen W, 2005, WOUND REPAIR REGEN, V13, P68, DOI 10.1111/j.1067-1927.2005.130109.x; Christoffolete MA, 2006, ENDOCRINOLOGY, V147, P1735, DOI 10.1210/en.2005-1300; Chrysis D, 2005, ENDOCRINOLOGY, V146, P1391, DOI 10.1210/en.2004-1152; Crochemore C, 2005, MOL PSYCHIATR, V10, P790, DOI 10.1038/sj.mp.4001679; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; Das A, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-36; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Doucas V, 2000, P NATL ACAD SCI USA, V97, P11893, DOI 10.1073/pnas.220413297; EKBLOM M, 1993, J CELL BIOL, V123, P1037, DOI 10.1083/jcb.123.4.1037; Fassler R, 1996, EXP CELL RES, V222, P111, DOI 10.1006/excr.1996.0014; Fehm H L, 1979, Pathobiol Annu, V9, P225; Flanagan LA, 2001, J CELL BIOL, V155, P511, DOI 10.1083/jcb.200105148; Gazel A, 2003, J INVEST DERMATOL, V121, P1459, DOI 10.1111/j.1523-1747.2003.12611.x; Hammer S, 2004, J CELL BIOCHEM, V91, P840, DOI 10.1002/jcb.10766; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Hu XY, 2003, J IMMUNOL, V170, P4833, DOI 10.4049/jimmunol.170.9.4833; Huynh DP, 1996, CELL GROWTH DIFFER, V7, P1551; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jho SH, 2001, J BIOL CHEM, V276, P45914, DOI 10.1074/jbc.M103144200; Kondo S, 1999, J INVEST DERM SYMP P, V4, P177, DOI 10.1038/sj.jidsp.5640205; Koster MI, 2006, DEV BIOL, V289, P253, DOI 10.1016/j.ydbio.2005.10.041; KUPPER TS, 1990, J INVEST DERMATOL, V94, pS146, DOI 10.1111/1523-1747.ep12876130; Lee B, 2005, J MOL BIOL, V345, P1083, DOI 10.1016/j.jmb.2004.11.027; LEE B, 2002, MOL MECH ACTION STER, P1; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Machuca C, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-9; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; Newman JC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r81; Perez P, 2001, FASEB J, V15, P2030, DOI 10.1096/fj.00-0772fje; Planey SL, 2003, CANCER RES, V63, P172; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Quinkler M, 2003, J CLIN ENDOCR METAB, V88, P2384, DOI 10.1210/jc.2003-030138; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; Reichardt HM, 2000, Z RHEUMATOL, V59, P1; Richardson DW, 2003, INFLAMM RES, V52, P39, DOI 10.1007/s000110300012; Runnebaum IB, 2005, CLIN CANCER RES, V11, P6325, DOI 10.1158/1078-0432.CCR-05-0182; SARNSTRAND B, 1982, J INVEST DERMATOL, V79, P412, DOI 10.1111/1523-1747.ep12530360; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Steinhoff M, 2001, CURR OPIN ALLERGY CL, V1, P469, DOI 10.1097/00130832-200110000-00014; Stojadinovic O, 2005, AM J PATHOL, V167, P59, DOI 10.1016/S0002-9440(10)62953-7; Szell M, 2004, J INVEST DERMATOL, V123, P537, DOI 10.1111/j.0022-202X.2004.23224.x; Totino PRR, 2006, CELL BIOL INT, V30, P133, DOI 10.1016/j.cellbi.2005.09.002; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Vidal VPI, 2005, CURR BIOL, V15, P1340, DOI 10.1016/j.cub.2005.06.064; Wang J, 2005, J BIOL CHEM, V280, P37725, DOI 10.1074/jbc.M507976200; Wanke I, 2004, TOXICOLOGY, V204, P141, DOI 10.1016/j.tox.2004.06.020; Watson Cheryl S, 2005, EMBO Rep, V6, P116; Wicke C, 2000, ARCH SURG-CHICAGO, V135, P1265, DOI 10.1001/archsurg.135.11.1265; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Wu WS, 2006, J INVEST DERMATOL, V126, P1264, DOI 10.1038/sj.jid.5700274; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yudt MR, 2001, MOL ENDOCRINOL, V15, P1093, DOI 10.1210/me.15.7.1093; Zhao XD, 2006, INT J CANCER, V118, P643, DOI 10.1002/ijc.21400; Zhou JG, 2005, STEROIDS, V70, P407, DOI 10.1016/j.steroids.2005.02.006	74	140	145	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4021	4034		10.1074/jbc.M606262200	http://dx.doi.org/10.1074/jbc.M606262200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17095510	hybrid			2022-12-27	WOS:000244481900066
J	Welburn, JPI; Tucker, JA; Johnson, T; Lindert, L; Morgan, M; Willis, A; Noble, MEM; Endicott, JA				Welburn, Julie P. I.; Tucker, Julie A.; Johnson, Tim; Lindert, Lisa; Morgan, Marc; Willis, Antony; Noble, Martin E. M.; Endicott, Jane A.			How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; PROTEIN-KINASE; STRUCTURAL BASIS; P34CDC2 KINASE; HUMAN CDC25A; DNA-DAMAGE; HUMAN MYT1; ACTIVATION; FISSION; CDK2	Inhibition of cyclin-dependent kinase 1 (CDK1) activity by Tyr-15 phosphorylation directly regulates entry into mitosis and is an important element in the control of the unperturbed cell cycle. Active site phosphorylation of other members of the CDK family that regulate cell cycle progression instates checkpoints that are fundamental to eukaryotic cell cycle regulation. Kinetic and crystallographic analyses of CDK2-cyclin A complexes reveal that this inhibitory mechanism operates through steric blockade of peptide substrate binding and through the creation of an environment that favors a non-productive conformation of the terminal group of ATP. By contrast, tyrosine phosphorylation of CDK2 alters neither its Km for ATP nor its significant intrinsic ATPase activity. Tyr-15-phosphorylated CDK2 retains trace protein phosphorylation activity that should be considered in quantitative and qualitative cell cycle models.	Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; AstraZeneca, Macclesfield SK10 4TF, Cheshire, England; Calif Polytech State Univ San Luis Obispo, Dept Biochem & Chem, San Luis Obispo, CA 93407 USA	University of Oxford; University of Oxford; University of Oxford; University of Oxford; AstraZeneca; California State University System; California Polytechnic State University San Luis Obispo	Endicott, JA (corresponding author), Univ Oxford, Mol Biophys Lab, Rex Richards Bldg,S Parks Rd, Oxford OX1 3QU, England.	jane.endicott@biop.ox.ac.uk	Tucker, Julie/AAT-1513-2021	Noble, Martin/0000-0002-3595-9807; Endicott, Jane/0000-0003-4868-0116; Morgan, Rhodri/0000-0002-9760-3638; Tucker, Julie/0000-0002-6119-676X	Wellcome Trust [065956] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abrieu A, 1998, J CELL SCI, V111, P1751; Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartova I, 2004, PROTEIN SCI, V13, P1449, DOI 10.1110/ps.03578504; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ENDICOTT JA, 1994, PROTEIN ENG, V7, P243, DOI 10.1093/protein/7.2.243; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Iavarone A, 1997, NATURE, V387, P417; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Prowse CN, 2001, J BIOL CHEM, V276, P99, DOI 10.1074/jbc.M008137200; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Stevenson LM, 2002, BIOCHEMISTRY-US, V41, P8528, DOI 10.1021/bi025812h; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	60	72	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3173	3181		10.1074/jbc.M609151200	http://dx.doi.org/10.1074/jbc.M609151200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17095507	hybrid			2022-12-27	WOS:000243793900043
J	Bihani, T; Chicas, A; Lo, CPK; Lin, AW				Bihani, Teeru; Chicas, Agustin; Lo, Crystal Pui-Kwan; Lin, Athena W.			Dissecting the senescence-like program in tumor cells activated by Ras signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OF-FUNCTION MUTATIONS; REPLICATIVE SENESCENCE; PREMATURE SENESCENCE; CELLULAR SENESCENCE; GROWTH ARREST; HUMAN CANCER; DNA-DAMAGE; RB FAMILY; P53; GENE	Activated Ras signaling can induce a permanent growth arrest in osteosarcoma cells. Here, we report that a senescence-like growth inhibition is also achieved in human carcinoma cells upon the transduction of H-Ras(V12). Ras-induced tumor senescence can be recapitulated by the transduction of activated, but not wild-type, MEK. The ability for H-Ras(V12) to suppress tumor cell growth is drastically compromised in cells that harbor endogenous activating ras mutations. Notably, growth inhibition of tumor cells containing ras mutations can be achieved through the introduction of activated MEK. Tumor senescence induced by Ras signaling can occur in the absence of p16 or Rb and is not interrupted by the inactivation of Rb, p107, or p130 via short hairpin RNA or the transduction with HPV16 E7. In contrast, inactivation of p21 via short hairpin RNA disrupts Ras-induced tumor senescence. In summary, this study uncovers a senescence-like program activated by Ras signaling to inhibit cancer cell growth. This program appears to be intact in cancer cells that do not harbor ras mutations. Moreover, cancer cells that carry ras mutations remain susceptible to tumor senescence induced by activated MEK. These novel findings can potentially lead to the development of innovative cancer intervention.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; SUNY Buffalo, Roswell Pk Canc Inst, Program Mol Pharmacol & Canc Therapeut, Grad Div, Buffalo, NY 14263 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Cold Spring Harbor Laboratory	Lin, AW (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	athena.lin@roswellpark.org			NCI NIH HHS [CA16056, T32 CA09072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009072, P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Benanti JA, 2004, CELL CYCLE, V3, P715; Bihani T, 2004, CELL CYCLE, V3, P1201; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Child ES, 2006, CELL CYCLE, V5, P1313, DOI 10.4161/cc.5.12.2863; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2005, CELL CYCLE, V4, P1722, DOI 10.4161/cc.4.12.2260; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng QD, 2004, J BIOL CHEM, V279, P1050, DOI 10.1074/jbc.M308644200; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dlamini Zodwa, 2005, Future Oncol, V1, P339, DOI 10.1517/14796694.1.3.339; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gewirtz DA, 2000, BREAST CANCER RES TR, V62, P223, DOI 10.1023/A:1006414422919; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; HOLLIDAY R, 1986, EXP CELL RES, V166, P543, DOI 10.1016/0014-4827(86)90499-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIAO M, 1994, AM J PATHOL, V145, P702; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; Kramer DL, 2001, CANCER RES, V61, P7754; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee S, 2003, CURR OPIN GENET DEV, V13, P90, DOI 10.1016/S0959-437X(02)00014-X; Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Linke SP, 1997, CANCER RES, V57, P1171; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Mason DX, 2004, ONCOGENE, V23, P9238, DOI 10.1038/sj.onc.1208172; McKenna WG, 2003, ONCOGENE, V22, P5866, DOI 10.1038/sj.onc.1206699; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Moasser MM, 2002, BREAST CANCER RES TR, V73, P135, DOI 10.1023/A:1015209123900; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Paddison PJ, 2004, NAT METHODS, V1, P163, DOI 10.1038/nmeth1104-163; Prasad KAN, 1997, CELL PROLIFERAT, V30, P81; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Roninson IB, 2003, CANCER RES, V63, P2705; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Shay JW, 1997, J CLIN PATHOL, V50, P799, DOI 10.1136/jcp.50.10.799; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; te Poele RH, 2002, CANCER RES, V62, P1876; Terao Y, 2001, INT J CANCER, V94, P257, DOI 10.1002/ijc.1448; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Viktorsson K, 2005, ADV CANCER RES, V94, P143, DOI 10.1016/S0065-230X(05)94004-9; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Warnberg F, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1395; Wei WY, 2003, EMBO REP, V4, P1061, DOI 10.1038/sj.embor7400001; WEINBERG RA, 1992, CANCER SURV, V12, P43; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	86	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2666	2675		10.1074/jbc.M608127200	http://dx.doi.org/10.1074/jbc.M608127200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17135242	hybrid			2022-12-27	WOS:000243593200059
J	Borgono, CA; Michael, IP; Shaw, JLV; Luo, LY; Ghosh, MC; Soosaipillai, A; Grass, L; Katsaros, D; Diamandis, EP				Borgono, Carla A.; Michael, Iacovos P.; Shaw, Julie L. V.; Luo, Liu-Ying; Ghosh, Manik C.; Soosaipillai, Antoninus; Grass, Linda; Katsaros, Dionyssios; Diamandis, Eleftherios P.			Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; CORNEUM CHYMOTRYPTIC ENZYME; MOLECULAR-WEIGHT KININOGEN; HUMAN-PLASMA KALLIKREIN; HUMAN STRATUM-CORNEUM; SUBSTRATE-SPECIFICITY; OVARIAN-CANCER; GENE FAMILY; BIOCHEMICAL-CHARACTERIZATION; PLASMINOGEN-ACTIVATOR	Human tissue kallikrein 14 (KLK14) is a novel extracellular serine protease. Clinical data link KLK14 expression to several diseases, primarily cancer; however, little is known of its (patho)-physiological role. To functionally characterize KLK14, we expressed and purified recombinant KLK14 in mature and proenzyme forms and determined its expression pattern, specificity, regulation, and in vitro substrates. By using our novel immunoassay, the normal and/or diseased skin, breast, prostate, and ovary contained the highest concentration of KLK14. Serum KLK14 levels were significantly elevated in prostate cancer patients compared with healthy males. KLK14 displayed trypsin-like specificity with high selectivity for P1-Arg over Lys. KLK14 activity could be regulated as follows: 1) by autolytic cleavage leading to enzymatic inactivation; 2) by the inhibitory serpins alpha(1)-antitrypsin, alpha(2)-antiplasmin, antithrombin III, and alpha 1-antichymotrypsin with second order rate constants (k(+2)/K-i) of 49.8, 23.8, 1.48, and 0.224 mu M-1 min(-1), respectively, as well as plasminogen activator inhibitor-1; and 3) by citrate and zinc ions, which exerted stimulatory and inhibitory effects on KLK14 activity, respectively. We also expanded the in vitro target repertoire of KLK14 to include collagens I-IV, fibronectin, laminin, kininogen, fibrinogen, plasminogen, vitronectin, and insulin-like growth factor-binding proteins 2 and 3. Our results indicate that KLK14 may be implicated in several facets of tumor progression, including growth, invasion, and angiogenesis, as well as in arthritic disease via deterioration of cartilage. These findings may have clinical implications for the management of cancer and other disorders in which KLK14 activity is elevated.	Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada; Univ Turin, Dept Gynecol, Gynecol Oncol Unit, I-10126 Turin, Italy	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Turin	Diamandis, EP (corresponding author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	ediamandis@mtsinai.on.ca	Michael, Iacovos P/C-8695-2016	Michael, Iacovos P/0000-0001-7674-1233; Diamandis, Eleftherios/0000-0002-1589-820X				Angelo PF, 2006, J BIOL CHEM, V281, P3116, DOI 10.1074/jbc.M510096200; Bayes A, 2004, BIOL CHEM, V385, P517, DOI 10.1515/BC.2004.061; Bernett MJ, 2002, J BIOL CHEM, V277, P24562, DOI 10.1074/jbc.M202392200; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bix G, 2005, TRENDS CELL BIOL, V15, P52, DOI 10.1016/j.tcb.2004.11.008; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; Borgono CA, 2004, MOL CANCER RES, V2, P257; Borgono CA, 2003, CANCER RES, V63, P9032; Borgono CA, 2003, INT J CANCER, V106, P605, DOI 10.1002/ijc.11296; Bourgeois L, 1997, J BIOL CHEM, V272, P29590, DOI 10.1074/jbc.272.47.29590; Brattsand M, 2005, J INVEST DERMATOL, V124, P198, DOI 10.1111/j.0022-202X.2004.23547.x; Brattsand M, 1999, J BIOL CHEM, V274, P30033, DOI 10.1074/jbc.274.42.30033; BRAUN PJ, 1988, THROMB RES, V50, P273, DOI 10.1016/0049-3848(88)90228-9; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; CHRISTOPOULOS TK, 1992, ANAL CHEM, V64, P342, DOI 10.1021/ac00028a004; COFFEY JW, 1976, J BIOL CHEM, V251, P5280; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; Diamandis EP, 1998, TRENDS ENDOCRIN MET, V9, P310, DOI 10.1016/S1043-2760(98)00082-4; Edman P, 1970, Mol Biol Biochem Biophys, V8, P211; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Felber LM, 2005, BIOL CHEM, V386, P291, DOI 10.1515/BC.2005.035; Felber LM, 2006, FEBS J, V273, P2505, DOI 10.1111/j.1742-4658.2006.05257.x; Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Franzke CW, 1996, J BIOL CHEM, V271, P21886, DOI 10.1074/jbc.271.36.21886; Fritzsche F, 2006, BRIT J CANCER, V94, P540, DOI 10.1038/sj.bjc.6602956; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HANSSON L, 1994, J BIOL CHEM, V269, P19420; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Heidtmann HH, 1999, BRIT J CANCER, V81, P1269, DOI 10.1038/sj.bjc.6692167; Homandberg GA, 1996, ARCH BIOCHEM BIOPHYS, V334, P325, DOI 10.1006/abbi.1996.0461; Hooper JD, 2001, GENOMICS, V73, P117, DOI 10.1006/geno.2000.6490; Hsieh MC, 2000, BBA-PROTEIN STRUCT M, V1481, P75, DOI 10.1016/S0167-4838(00)00116-3; Hsieh MC, 2002, BIOCHEMISTRY-US, V41, P2990, DOI 10.1021/bi0117450; Huang XY, 2001, BIOCHEMISTRY-US, V40, P11734, DOI 10.1021/bi010364j; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; KAVANAGH JP, 1985, J REPROD FERTIL, V75, P35; Kishi T, 2006, BIOL CHEM, V387, P723, DOI 10.1515/BC.2006.091; KITZ R, 1962, J BIOL CHEM, V237, P3245; Klatt AR, 2001, J BIOL CHEM, V276, P17267, DOI 10.1074/jbc.M100587200; Komatsu N, 2005, J INVEST DERMATOL, V125, P1182, DOI 10.1111/j.0022-202X.2005.23933.x; Komatsu N, 2003, J INVEST DERMATOL, V121, P542, DOI 10.1046/j.1523-1747.2003.12363.x; Komatsu N, 2006, J INVEST DERMATOL, V126, P925, DOI 10.1038/sj.jid.5700146; Komatsu N, 2006, J INVEST DERMATOL, V126, P2338, DOI 10.1038/sj.jid.5700379; Lovgren J, 1999, EUR J BIOCHEM, V262, P781, DOI 10.1046/j.1432-1327.1999.00433.x; Lovgren J, 1997, BIOCHEM BIOPH RES CO, V238, P549, DOI 10.1006/bbrc.1997.7333; Luo LY, 2006, CLIN CANCER RES, V12, P742, DOI 10.1158/1078-0432.CCR-05-1696; Luo LY, 2001, CLIN CHEM, V47, P237; Magklara A, 2003, BIOCHEM BIOPH RES CO, V307, P948, DOI 10.1016/S0006-291X(03)01271-3; Malm J, 2000, PROSTATE, V45, P132, DOI 10.1002/1097-0045(20001001)45:2<132::AID-PROS7>3.0.CO;2-3; Matsumura M, 2005, PROSTATE, V62, P1, DOI 10.1002/pros.20101; Michael IP, 2006, J BIOL CHEM, V281, P12743, DOI 10.1074/jbc.M600326200; Michael IP, 2005, J BIOL CHEM, V280, P14628, DOI 10.1074/jbc.M408132200; Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538-7836.2005.01365.x; Obiezu CV, 2006, BIOL CHEM, V387, P749, DOI 10.1515/BC.2006.094; Obiezu CV, 2005, CLIN CHEM, V51, P1432, DOI 10.1373/clinchem.2005.049692; Oikonomopoulou K, 2006, J BIOL CHEM, V281, P32095, DOI 10.1074/jbc.M513138200; Page MJ, 2005, J THROMB HAEMOST, V3, P2401, DOI 10.1111/j.1538-7836.2005.01456.x; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Petralki CD, 2006, BIOL CHEM, V387, P653, DOI 10.1515/BC.2006.084; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; Rehault S, 2001, EUR J BIOCHEM, V268, P2960, DOI 10.1046/j.1432-1327.2001.02185.x; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCHAPIRA M, 1981, BIOCHEMISTRY-US, V20, P2738, DOI 10.1021/bi00513a006; SCHAPIRA M, 1982, BIOCHEMISTRY-US, V21, P567, DOI 10.1021/bi00532a024; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; Shipway A, 2004, BIOCHEM BIOPH RES CO, V324, P953, DOI 10.1016/j.bbrc.2004.09.123; Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027; Sotiropoulou G, 2003, ONCOL RES, V13, P381; Stanton H, 2002, BIOCHEM J, V364, P181, DOI 10.1042/bj3640181; Stefansson K, 2006, BIOL CHEM, V387, P761, DOI 10.1515/BC.2006.095; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; VILLOUTREIX BO, 1994, PROTEIN SCI, V3, P2033, DOI 10.1002/pro.5560031116; WATT KWK, 1986, P NATL ACAD SCI USA, V83, P3166, DOI 10.1073/pnas.83.10.3166; WU HL, 1987, P NATL ACAD SCI USA, V84, P8793, DOI 10.1073/pnas.84.24.8793; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620; Yousef GM, 2003, PROSTATE, V56, P287, DOI 10.1002/pros.10263; Yousef GM, 2003, CANCER RES, V63, P3958; Yousef GM, 2003, AM J CLIN PATHOL, V119, P346, DOI 10.1309/0UA57MNAYV0MCE9U; Yousef GM, 2002, BRIT J CANCER, V87, P1287, DOI 10.1038/sj.bjc.6600623; Yousef GM, 2001, CANCER RES, V61, P3425; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184	86	95	99	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2405	2422		10.1074/jbc.M608348200	http://dx.doi.org/10.1074/jbc.M608348200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17110383	hybrid			2022-12-27	WOS:000243593200032
J	Kitano, K; Yoshihara, N; Hakoshima, T				Kitano, Ken; Yoshihara, Nozomi; Hakoshima, Toshio			Crystal structure of the HRDC domain of human Werner syndrome protein, WRN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECQ; DOUBLE-STRAND BREAKS; DNA HELICASES; SYNDROME GENE; P53-MEDIATED APOPTOSIS; HOLLIDAY JUNCTIONS; MOLECULAR-BASIS; EXONUCLEASE; BINDING; BLOOMS	Werner syndrome is a human premature aging disorder characterized by chromosomal instability. The disease is caused by the functional loss of WRN, a member of the RecQ-helicase family that plays an important role in DNA metabolic pathways. WRN contains four structurally folded domains comprising an exonuclease, a helicase, a winged-helix, and a helicase-and-ribonuclease D/C-terminal (HRDC) domain. In contrast to the accumulated knowledge pertaining to the biochemical functions of the three N-terminal domains, the function of C-terminal HRDC remains unknown. In this study, the crystal structure of the human WRN HRDC domain has been determined. The domain forms a bundle of alpha-helices similar to those of Saccharomyces cerevisiae Sgs1 and Escherichia coli RecQ. Surprisingly, the extra ten residues at each of the N and C termini of the domain were found to participate in the domain architecture by forming an extended portion of the first helix alpha 1, and a novel looping motif that traverses straight along the domain surface, respectively. The motifs combine to increase the domain surface of WRN HRDC, which is larger than that of Sgs1 and E. coli. In WRN HRDC, neither of the proposed DNA-binding surfaces in Sgs1 or E. coli is conserved, and the domain was shown to lack DNA-binding ability in vitro. Moreover, the domain was shown to be thermostable and resistant to protease digestion, implying independent domain evolution in WRN. Coupled with the unique long linker region in WRN, the WRN HRDC may be adapted to play a distinct function in WRN that involves protein-protein interactions.	Nara Inst Sci & Technol, Struct Biol Lab, Ikoma, Nara 6300192, Japan	Nara Institute of Science & Technology	Kitano, K (corresponding author), Nara Inst Sci & Technol, Struct Biol Lab, 8916-5 Takayama, Ikoma, Nara 6300192, Japan.	kkitano@is.naist.jp; hakosima@bs.naist.jp						Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Baynton K, 2003, J BIOL CHEM, V278, P36476, DOI 10.1074/jbc.M303885200; Bennett RJ, 2004, CRIT REV BIOCHEM MOL, V39, P79, DOI 10.1080/10409230490460756; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bernstein DA, 2005, STRUCTURE, V13, P1173, DOI 10.1016/j.str.2005.04.018; Bernstein DA, 2003, NUCLEIC ACIDS RES, V31, P2778, DOI 10.1093/nar/gkg376; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Bohr VA, 2005, MUTAT RES-FUND MOL M, V577, P252, DOI 10.1016/j.mrfmmm.2005.03.021; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hu JS, 2005, P NATL ACAD SCI USA, V102, P18379, DOI 10.1073/pnas.0509380102; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Jasiak AJ, 2006, MOL CELL, V23, P71, DOI 10.1016/j.molcel.2006.05.013; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Killoran MP, 2006, NUCLEIC ACIDS RES, V34, P4098, DOI 10.1093/nar/gkl538; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lebel M, 2001, CELL MOL LIFE SCI, V58, P857, DOI 10.1007/s00018-001-8398-y; Lee JW, 2005, MECH AGEING DEV, V126, P79, DOI 10.1016/j.mad.2004.09.011; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Liu Z, 1999, STRUCTURE, V7, P1557, DOI 10.1016/S0969-2126(00)88346-X; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Matsumoto T, 1997, HUM GENET, V100, P123, DOI 10.1007/s004390050477; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Miyazaki Satoshi, 2002, Journal of Structural and Functional Genomics, V2, P37, DOI 10.1023/A:1014418700858; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Moser MJ, 1999, HUM MUTAT, V13, P271, DOI 10.1002/(SICI)1098-1004(1999)13:4<271::AID-HUMU2>3.0.CO;2-Q; Navarro CL, 2006, HUM MOL GENET, V15, pR151, DOI 10.1093/hmg/ddl214; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Oshima J, 2002, CANCER RES, V62, P547; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Perry JJP, 2006, NAT STRUCT MOL BIOL, V13, P414, DOI 10.1038/nsmb1088; Plank JL, 2006, P NATL ACAD SCI USA, V103, P11118, DOI 10.1073/pnas.0604873103; SALK D, 1982, HUM GENET, V62, P1, DOI 10.1007/BF00295598; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shen JC, 2001, MECH AGEING DEV, V122, P921, DOI 10.1016/S0047-6374(01)00248-2; Spillare EA, 2006, ONCOGENE, V25, P2119, DOI 10.1038/sj.onc.1209242; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Wu L, 2005, EMBO J, V24, P2679, DOI 10.1038/sj.emboj.7600740; Yan H, 2005, J CELL BIOL, V171, P217, DOI 10.1083/jcb.200502077; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zhang XD, 2006, J BIOL CHEM, V281, P12655, DOI 10.1074/jbc.M513089200; Zuo YH, 2005, STRUCTURE, V13, P973, DOI 10.1016/j.str.2005.04.015	56	47	49	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2717	2728		10.1074/jbc.M610142200	http://dx.doi.org/10.1074/jbc.M610142200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17148451	hybrid			2022-12-27	WOS:000243593200064
J	Qu, XP; Perez-Canadillas, JM; Agrawal, S; De Baecke, J; Cheng, HL; Varani, G; Moore, C				Qu, Xiangping; Perez-Canadillas, Jose-Manuel; Agrawal, Shipra; De Baecke, Julia; Cheng, Hailing; Varani, Gabriele; Moore, Claire			The C-terminal domains of vertebrate CstF-64 and its yeast orthologue Rna15 form a new structure critical for mRNA 3 '-end processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES TRANSCRIPTION TERMINATION; POLYADENYLATION FACTOR SUBUNIT; CLEAVAGE FACTOR-IA; SACCHAROMYCES-CEREVISIAE; POLYMERASE-II; LYSINE-4 METHYLATION; ELONGATION COMPLEX; PROTEIN COMPLEXES; COACTIVATOR PC4; ELEVATED LEVELS	Yeast Rna15 and its vertebrate orthologue CstF-64 play critical roles in mRNA 3'-end processing and in transcription termination downstream of poly( A) sites. These proteins contain N- terminal domains that recognize the poly( A) site, but little is known about their highly conserved C-terminal regions. Here we show by NMR that the C-terminal domains of CstF-64 and Rna15 fold into a three-helix bundle with an uncommon topological arrangement. The structure defines a cluster of evolutionary conserved yet exposed residues we show to be essential for the interaction between Pcf11 and Rna15. Furthermore, we demonstrate that this interaction is critical for the function of Rna15 in 3'-end processing but dispensable for transcription termination. The C-terminal domain of the Rna15 homologue Pti1 contains critical sequence alterations within this region that are predicted to prevent Pcf11 interaction, providing an explanation for the distinct functions of these two closely related proteins in the 3'-end formation of RNA polymerase II transcripts. These results define the role of the C-terminal half of Rna15 and provide insight into the network of protein/protein interactions responsible for assembly of the 3'-end processing apparatus.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Tufts Univ, Dept Mol Microbiol, Sch Med, Boston, MA 02111 USA; Sackler Grad Sch Biomed Sci, Boston, MA 02111 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Tufts University	Varani, G (corresponding author), Univ Washington, Dept Chem, Bagley Hall, Seattle, WA 98195 USA.	varani@chem.washington.edu; Claire.moore@tufts.edu	Perez-Canadillas, Jose M/J-5748-2013; Pérez-Cañadillas, Jose Manuel/AAN-1864-2020	Perez-Canadillas, Jose M/0000-0002-8266-5502; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064440] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM041752, GM64440] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amrani N, 1997, MOL CELL BIOL, V17, P1102, DOI 10.1128/MCB.17.3.1102; Amrani N, 1997, MOL CELL BIOL, V17, P3694, DOI 10.1128/MCB.17.7.3694; Aranda A, 2001, MOL CELL, V7, P1003, DOI 10.1016/S1097-2765(01)00235-0; Barilla D, 2001, P NATL ACAD SCI USA, V98, P445, DOI 10.1073/pnas.021545298; Barnard DC, 2004, CELL, V119, P641, DOI 10.1016/j.cell.2004.10.029; Bentley DL, 2005, CURR OPIN CELL BIOL, V17, P251, DOI 10.1016/j.ceb.2005.04.006; Beyer K, 1997, J BIOL CHEM, V272, P26769, DOI 10.1074/jbc.272.42.26769; Birse CE, 1998, SCIENCE, V280, P298, DOI 10.1126/science.280.5361.298; Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; Brodsky AS, 2000, RNA, V6, P1737, DOI 10.1017/S1355838200001059; Buratowski S, 2005, CURR OPIN CELL BIOL, V17, P257, DOI 10.1016/j.ceb.2005.04.003; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; Canadillas JMP, 2003, EMBO J, V22, P2821, DOI 10.1093/emboj/cdg259; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; Cheng HL, 2004, MOL CELL BIOL, V24, P2932, DOI 10.1128/MCB.24.7.2932-2943.2004; Chennathukuzhi VM, 2001, MOL REPROD DEV, V58, P460, DOI 10.1002/1098-2795(20010401)58:4&lt;460::AID-MRD15&gt;3.0.CO;2-F; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Deka P, 2005, J MOL BIOL, V347, P719, DOI 10.1016/j.jmb.2005.01.046; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dheur S, 2003, EMBO J, V22, P2831, DOI 10.1093/emboj/cdg253; Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4; Dichtl E, 2004, RNA, V10, P965, DOI 10.1261/rna.7090104; Dominski Z, 2005, CELL, V123, P37, DOI 10.1016/j.cell.2005.08.002; Duvel K, 1999, NUCLEIC ACIDS RES, V27, P4751, DOI 10.1093/nar/27.24.4751; Edmonds M, 2002, PROG NUCLEIC ACID RE, V71, P285, DOI 10.1016/S0079-6603(02)71046-5; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Goddard T. D., 2005, SPARKY 3; Gross S, 2001, P NATL ACAD SCI USA, V98, P6080, DOI 10.1073/pnas.101046598; Gross S, 2001, MOL CELL BIOL, V21, P8045, DOI 10.1128/MCB.21.23.8045-8055.2001; Guntert P, 2003, PROG NUCL MAG RES SP, V43, P105, DOI 10.1016/S0079-6565(03)00021-9; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hammell CM, 2002, MOL CELL BIOL, V22, P6441, DOI 10.1128/MCB.22.18.6441-6457.2002; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; Hatton LS, 2000, NUCLEIC ACIDS RES, V28, P520, DOI 10.1093/nar/28.2.520; He XY, 2003, GENE DEV, V17, P1030, DOI 10.1101/gad.1075203; Henry NL, 1996, J BIOL CHEM, V271, P21842, DOI 10.1074/jbc.271.36.21842; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Huber Z, 2005, ANN NY ACAD SCI, V1061, P163, DOI 10.1196/annals.1336.017; Kessler MM, 1996, J BIOL CHEM, V271, P27167, DOI 10.1074/jbc.271.43.27167; Kim M, 2004, EMBO J, V23, P354, DOI 10.1038/sj.emboj.7600053; Kim M, 2004, NATURE, V432, P517, DOI 10.1038/nature03041; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; Kolev NG, 2005, GENE DEV, V19, P2583, DOI 10.1101/gad.1371105; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Kyburz A, 2003, NUCLEIC ACIDS RES, V31, P3936, DOI 10.1093/nar/gkg478; Lei EP, 2002, GENE DEV, V16, P2761, DOI 10.1101/gad.1032902; Libri D, 2002, MOL CELL BIOL, V22, P8254, DOI 10.1128/MCB.22.23.8254-8266.2002; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; Luna R, 2005, MOL CELL, V18, P711, DOI 10.1016/j.molcel.2005.05.001; Luo WF, 2006, GENE DEV, V20, P954, DOI 10.1101/gad.1409106; Luo WF, 2004, CELL, V119, P911, DOI 10.1016/j.cell.2004.11.041; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; MANDART E, 1995, MOL CELL BIOL, V15, P6979; Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MinvielleSebastia L, 1997, P NATL ACAD SCI USA, V94, P7897, DOI 10.1073/pnas.94.15.7897; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; Nedea E, 2003, J BIOL CHEM, V278, P33000, DOI 10.1074/jbc.M304454200; Noble CG, 2004, NUCLEIC ACIDS RES, V32, P3364, DOI 10.1093/nar/gkh664; Pantoja-Uceda David, 2006, V340, P27; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; Sadowski M, 2003, EMBO J, V22, P2167, DOI 10.1093/emboj/cdg200; Saguez C, 2005, CURR OPIN CELL BIOL, V17, P287, DOI 10.1016/j.ceb.2005.04.009; Santiveri CM, 2002, J AM CHEM SOC, V124, P14903, DOI 10.1021/ja0278537; Shell SA, 2005, J BIOL CHEM, V280, P39950, DOI 10.1074/jbc.M508848200; Skaar DA, 2002, MOL CELL, V10, P1429, DOI 10.1016/S1097-2765(02)00731-1; Steinmetz EJ, 2001, NATURE, V413, P327, DOI 10.1038/35095090; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Torchet C, 2002, MOL CELL, V9, P1285, DOI 10.1016/S1097-2765(02)00544-0; Walsh EP, 2002, BIOCHEMISTRY-US, V41, P2409, DOI 10.1021/bi015815e; Werten S, 1999, J BIOL CHEM, V274, P3693, DOI 10.1074/jbc.274.6.3693; West S, 2004, NATURE, V432, P522, DOI 10.1038/nature03035; Wu WH, 1999, GENETICS, V153, P643; Yao YL, 2002, J EXP BOT, V53, P2277, DOI 10.1093/jxb/erf073; Ye KQ, 2005, STRUCTURE, V13, P1375, DOI 10.1016/j.str.2005.06.017; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907; Zhang ZQ, 2006, MOL CELL, V21, P65, DOI 10.1016/j.molcel.2005.11.002; Zhang ZQ, 2005, GENE DEV, V19, P1572, DOI 10.1101/gad.1296305; Zhao J, 1997, J BIOL CHEM, V272, P10831; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhelkovsky A, 2006, RNA, V12, P435, DOI 10.1261/rna.2267606	88	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					2101	2115		10.1074/jbc.M609981200	http://dx.doi.org/10.1074/jbc.M609981200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17116658	Green Published, hybrid			2022-12-27	WOS:000243451300061
J	Szollosi, A; Nenquin, M; Aguilar-Bryan, L; Bryan, J; Henquin, JC				Szollosi, Andras; Nenquin, Myriam; Aguilar-Bryan, Lydia; Bryan, Joseph; Henquin, Jean-Claude			Glucose stimulates Ca2+ influx and insulin secretion in 2-week-old beta-cells lacking ATP-sensitive K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC CA2+; AMPLIFYING PATHWAYS; FUNCTIONAL-ROLE; KNOCKOUT MICE; IN-VITRO; MOUSE; CALCIUM; RELEASE; CAMP; HYPERINSULINISM	In adult beta-cells glucose-induced insulin secretion involves two mechanisms (a) a KATP channel-dependent Ca2+ influx and rise of cytosolic [Ca2+] c and (b) a KATP channel-independent amplification of secretion without further increase of [Ca2+](c). Mice lacking the high affinity sulfonylurea receptor (Sur1KO), and thus KATP channels, have been developed as a model of congenital hyperinsulinism. Here, we compared [Ca2+] c and insulin secretion in overnight cultured islets from 2-week-old normal and Sur1KO mice. Control islets proved functionally mature: the magnitude and biphasic kinetics of [Ca2+] c and insulin secretion changes induced by glucose, and operation of the amplifying pathway, were similar to adult islets. Sur1KO islets perifused with 1 mm glucose showed elevation of both basal [Ca2+](c) and insulin secretion. Stimulation with 15 mm glucose produced a transient drop of [Ca2+](c) followed by an overshoot and a sustained elevation, accompanied by a monophasic, 6-fold increase in insulin secretion. Glucose also increased insulin secretion when [Ca2+](c) was clamped by KCl. When Sur1KO islets were cultured in 5 instead of 10 mm glucose, [Ca2+] c and insulin secretion were unexpectedly low in 1 mm glucose and increased following a biphasic time course upon stimulation by 15 mm glucose. This KATP channel-independent first phase [Ca2+](c) rise was attributed to a Na+-, Cl--, and Na+-pump-independent depolarization of beta-cells, leading to Ca2+ influx through voltage-dependent calcium channels. Glucose indeed depolarized Sur1KO islets under these conditions. It is suggested that unidentified potassium channels are sensitive to glucose and subserve the acute and long-term metabolic control of [Ca2+](c) in beta-cells without functional K-ATP channels.	Catholic Univ Louvain, Fac Med, Unit Endocrinol & Metab, B-1200 Brussels, Belgium; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Universite Catholique Louvain; Baylor College of Medicine; Baylor College of Medicine	Henquin, JC (corresponding author), Catholic Univ Louvain, Fac Med, Unit Endocrinol & Metab, UCL 55-30,Ave Hippocrate 55, B-1200 Brussels, Belgium.	henquin@endo.ucl.ac.be	Szollosi, Andras/P-4278-2019; Szollosi, Andras/J-5097-2013	Szollosi, Andras/0000-0002-5570-4609; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052771] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52771] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aizawa T, 2002, DIABETES, V51, pS96, DOI 10.2337/diabetes.51.2007.S96; Ashcroft FM, 2005, J CLIN INVEST, V115, P2047, DOI 10.1172/JCI25495; BLISS CR, 1992, AM J PHYSIOL, V263, pE890, DOI 10.1152/ajpendo.1992.263.5.E890; BRAUNER T, 1984, BIOCHIM BIOPHYS ACTA, V771, P208, DOI 10.1016/0005-2736(84)90535-2; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Doliba NM, 2004, AM J PHYSIOL-ENDOC M, V286, pE834, DOI 10.1152/ajpendo.00292.2003; Dufer M, 2004, DIABETOLOGIA, V47, P488, DOI 10.1007/s00125-004-1348-0; Dunne MJ, 2004, PHYSIOL REV, V84, P239, DOI 10.1152/physrev.00022.2003; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; EPPS DE, 1994, CHEM PHYS LIPIDS, V69, P137, DOI 10.1016/0009-3084(94)90035-3; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; GarciaBarrado MJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE426, DOI 10.1152/ajpendo.1996.271.3.E426; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; Gilon P, 2002, DIABETES, V51, pS144, DOI 10.2337/diabetes.51.2007.S144; GILON P, 1994, DIABETOLOGIA, V37, P1007, DOI 10.1007/BF00400464; Giurgea I, 2004, J CLIN ENDOCR METAB, V89, P925, DOI 10.1210/jc.2003-030941; Glaser B, 2000, ARCH DIS CHILD-FETAL, V82, pF79, DOI 10.1136/fn.82.2.F79; Goforth PB, 2002, J GEN PHYSIOL, V120, P307, DOI 10.1085/jgp.20028581; GRILL V, 1981, DIABETES, V30, P56, DOI 10.2337/diab.30.1.56; Grimberg A, 2001, DIABETES, V50, P322, DOI 10.2337/diabetes.50.2.322; Haspel D, 2005, DIABETOLOGIA, V48, P913, DOI 10.1007/s00125-005-1720-8; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; HELLMAN B, 1974, BIOCHEM J, V138, P33, DOI 10.1042/bj1380033; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Henquin JC, 2006, DIABETES, V55, P441, DOI 10.2337/diabetes.55.02.06.db05-1051; HENQUIN JC, 1982, J PHYSIOL-LONDON, V332, P529, DOI 10.1113/jphysiol.1982.sp014429; HENQUIN JC, 1984, ENDOCRINOLOGY, V115, P1125, DOI 10.1210/endo-115-3-1125; HERMANS MP, 1986, BIOCHIM BIOPHYS ACTA, V889, P262, DOI 10.1016/0167-4889(86)90112-6; Huopio H, 2002, AM J PHYSIOL-ENDOC M, V283, pE207, DOI 10.1152/ajpendo.00047.2002; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Jonas JC, 1998, DIABETES, V47, P1266, DOI 10.2337/diabetes.47.8.1266; Kanno T, 2002, J PHYSIOL-LONDON, V545, P501, DOI 10.1113/jphysiol.2002.031344; Kasai H, 2002, DIABETES, V51, pS19, DOI 10.2337/diabetes.51.2007.S19; Kato S, 1996, J CLIN INVEST, V97, P2417, DOI 10.1172/JCI118688; Komatsu M, 2002, DIABETES, V51, pS29, DOI 10.2337/diabetes.51.2007.S29; Langheinrich U, 1997, J PHYSIOL-LONDON, V502, P397, DOI 10.1111/j.1469-7793.1997.397bk.x; MacDonald PE, 2005, PHILOS T R SOC B, V360, P2211, DOI 10.1098/rstb.2005.1762; Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a; Malik-Hall M, 2000, BRIT J PHARMACOL, V129, P1431, DOI 10.1038/sj.bjp.0703233; Matschinsky FM, 2006, DIABETES, V55, P1; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Nakazaki M, 2002, DIABETES, V51, P3440, DOI 10.2337/diabetes.51.12.3440; Nenquin M, 2004, J BIOL CHEM, V279, P32316, DOI 10.1074/jbc.M402076200; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; SEHLIN J, 1978, AM J PHYSIOL, V235, pE501, DOI 10.1152/ajpendo.1978.235.5.E501; Seino S, 2000, DIABETES, V49, P311, DOI 10.2337/diabetes.49.3.311; Shiota C, 2002, J BIOL CHEM, V277, P37176, DOI 10.1074/jbc.M206757200; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; Straub SG, 2002, DIABETES-METAB RES, V18, P451, DOI 10.1002/dmrr.329; Straub SG, 2001, DIABETES, V50, P329, DOI 10.2337/diabetes.50.2.329; Tamarina NA, 2003, DIABETES, V52, P2000, DOI 10.2337/diabetes.52.8.2000; Van Eylen F, 1998, DIABETES, V47, P1873, DOI 10.2337/diabetes.47.12.1873; Yajima H, 1999, DIABETES, V48, P1006, DOI 10.2337/diabetes.48.5.1006; Zhang M, 2005, J GEN PHYSIOL, V126, P353, DOI 10.1085/jgp.200509312	56	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1747	1756		10.1074/jbc.M609875200	http://dx.doi.org/10.1074/jbc.M609875200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17138557	hybrid			2022-12-27	WOS:000243451300026
J	Tian, GL; Lai, LC; Guo, H; Lin, Y; Butchbach, MER; Chang, YM; Lin, CLG				Tian, Guilian; Lai, Liching; Guo, Hong; Lin, Yuan; Butchbach, Matthew E. R.; Chang, Yueming; Lin, Chien-Liang Glenn			Translational control of glial glutamate transporter EAAT2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; AMINO-ACID TRANSPORTER; MOTOR-NEURON DEGENERATION; NF-KAPPA-B; SPINAL-CORD; HUMAN BRAIN; RAT-BRAIN; ALZHEIMERS-DISEASE; MOLECULAR-CLONING; GENE-EXPRESSION	Glutamate is the major excitatory neurotransmitter in the central nervous system. Its activity is carefully modulated in the synaptic cleft by glutamate transporters. The glial glutamate transporter EAAT2 is the main mediator of glutamate clearance. Reduced EAAT2 function could lead to accumulation of extracellular glutamate, resulting in a form of cell death known as excitotoxicity. In amyotrophic lateral sclerosis and Alzheimer disease, EAAT2 protein levels are significantly decreased in affected areas. EAAT2 mRNA levels, however, remain constant, indicating that alterations in EAAT2 expression are due to disturbances at the post-transcriptional level. In the present study, we found that some EAAT2 transcripts contained 5'-untranslated regions (5'-UTRs) greater than 300 nucleotides. The mRNAs that bear long 5'-UTRs are often regulated at the translational level. We tested this possibility initially in a primary astrocyte line that constantly expressed an EAAT2 transcript containing the 565-nt 5'-UTR and found that translation of this transcript was regulated by many extracellular factors, including corticosterone and retinol. Moreover, many disease-associated insults affected the efficiency of translation of this transcript. Importantly, this translational regulation of EAAT2 occurred in vivo (i.e. both in primary cortical neurons-astrocytes mixed cultures and in mice). These results indicate that expression of EAAT2 protein is highly regulated at the translational level and also suggest that translational regulation may play an important role in the differential EAAT2 protein expression under normal and disease conditions.	Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Lin, CLG (corresponding author), Ohio State Univ, Dept Neurosci, 4198 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	lin.492@osu.edu	lin, yuan/E-6062-2011; Lin, Chien-liang G/E-3513-2011	Butchbach, Matthew/0000-0003-2912-6400	NIMH NIH HHS [MH59805] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abe K, 2003, NEUROSCI RES, V45, P25, DOI 10.1016/S0168-0102(02)00190-6; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Bendotti C, 2001, J NEUROCHEM, V79, P737, DOI 10.1046/j.1471-4159.2001.00572.x; Bristol LA, 1996, ANN NEUROL, V39, P676, DOI 10.1002/ana.410390519; Brown RH, 1997, ARCH NEUROL-CHICAGO, V54, P1246, DOI 10.1001/archneur.1997.00550220050013; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Butchbach MER, 2004, J BIOL CHEM, V279, P34388, DOI 10.1074/jbc.M403938200; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; Day DA, 1998, J ENDOCRINOL, V157, P361, DOI 10.1677/joe.0.1570361; Dunlop J, 2003, J NEUROSCI, V23, P1688; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Figiel M, 2000, J NEUROSCI, V20, P3596, DOI 10.1523/JNEUROSCI.20-10-03596.2000; Figiel M, 2003, EXP NEUROL, V183, P124, DOI 10.1016/S0014-4886(03)00134-1; Gegelashvili G, 1997, J NEUROCHEM, V69, P2612; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Guo H, 2003, HUM MOL GENET, V12, P2519, DOI 10.1093/hmg/ddg267; Guo H, 2002, MOL CELL NEUROSCI, V21, P546, DOI 10.1006/mcne.2002.1198; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Harris ME, 1996, J NEUROCHEM, V67, P277; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Ikonomidou C, 1996, J NEUROPATH EXP NEUR, V55, P211, DOI 10.1097/00005072-199602000-00010; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kim SY, 2003, J NEUROCHEM, V86, P1458, DOI 10.1046/j.1471-4159.2003.01958.x; Knudsen S, 1999, BIOINFORMATICS, V15, P356, DOI 10.1093/bioinformatics/15.5.356; Lauderback CM, 2001, J NEUROCHEM, V78, P413, DOI 10.1046/j.1471-4159.2001.00451.x; Li S, 1997, J NEUROPATH EXP NEUR, V56, P901, DOI 10.1097/00005072-199708000-00008; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; Liu ZQ, 2004, AM J PHYSIOL-ENDOC M, V287, pE275, DOI 10.1152/ajpendo.00457.2003; Masliah E, 2000, EXP NEUROL, V163, P381, DOI 10.1006/exnr.2000.7386; Masliah E, 1996, ANN NEUROL, V40, P759, DOI 10.1002/ana.410400512; Meier CA, 1997, J RECEPT SIGNAL TR R, V17, P319, DOI 10.3109/10799899709036612; Meyer T, 1997, NEUROREPORT, V8, P775, DOI 10.1097/00001756-199702100-00039; Meyer T, 1998, NEUROSCI LETT, V241, P68, DOI 10.1016/S0304-3940(97)00973-7; Munch C, 2000, MOL BRAIN RES, V80, P244, DOI 10.1016/S0169-328X(00)00139-X; Munch C, 2002, J NEUROCHEM, V82, P594, DOI 10.1046/j.1471-4159.2002.01012.x; Munch C, 2001, J NEUROL NEUROSUR PS, V71, P675, DOI 10.1136/jnnp.71.5.675; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; Rodriguez-Kern A, 2003, NEUROCHEM INT, V43, P363, DOI 10.1016/S0197-0186(03)00023-8; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROTHSTEIN JD, 1990, ANN NEUROL, V28, P18, DOI 10.1002/ana.410280106; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Rozyczka J, 2005, MOL BRAIN RES, V133, P157, DOI 10.1016/j.molbrainres.2004.09.021; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; Schluter K, 2002, EUR J NEUROSCI, V16, P836, DOI 10.1046/j.1460-9568.2002.02130.x; SHASHIDHARAN P, 1994, BRAIN RES, V662, P245, DOI 10.1016/0006-8993(94)90819-2; SHASHIDHARAN P, 1993, BIOCHIM BIOPHYS ACTA, V1216, P161, DOI 10.1016/0167-4781(93)90057-K; SHASHIDHARAN P, 1994, BBA-BIOMEMBRANES, V1191, P393, DOI 10.1016/0005-2736(94)90192-9; Siddique T, 1996, HUM MOL GENET, V5, P1465, DOI 10.1093/hmg/5.Supplement_1.1465; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Su ZZ, 2003, P NATL ACAD SCI USA, V100, P1955, DOI 10.1073/pnas.0136555100; Swanson RA, 1997, J NEUROSCI, V17, P932; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; UtsunomiyaTate N, 1997, FEBS LETT, V416, P312, DOI 10.1016/S0014-5793(97)01232-5; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zelenaia O, 2000, MOL PHARMACOL, V57, P667, DOI 10.1124/mol.57.4.667; Zschocke J, 2005, J BIOL CHEM, V280, P34924, DOI 10.1074/jbc.M502581200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	63	65	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1727	1737		10.1074/jbc.M609822200	http://dx.doi.org/10.1074/jbc.M609822200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17138558	hybrid			2022-12-27	WOS:000243451300024
J	Smethurst, PA; Onley, DJ; Jarvis, GE; O'Connor, MN; Knight, CG; Herr, AB; Ouwehand, WH; Farndale, RW				Smethurst, Peter A.; Onley, David J.; Jarvis, Gavin E.; O'Connor, Marie N.; Knight, C. Graham; Herr, Andrew B.; Ouwehand, Willem H.; Farndale, Richard W.			Structural basis for the platelet-collagen interaction - The smallest motif within collagen that recognizes and activates platelet glycoprotein VI contains two glycine-proline-hydroxyproline triplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLY-PRO-HYP; TYROSINE PHOSPHORYLATION; CRYSTAL-STRUCTURE; RECEPTOR; BINDING; SEQUENCE; PEPTIDE; GPVI; ALPHA(2)BETA(1); AFFINITY	Collagen-related peptide is a selective agonist for the platelet collagen receptor Glycoprotein VI. The triple helical peptide contains ten GPO triplets/strand (single letter amino acid nomenclature, where O is hydroxyproline) and so over-represents GPO compared with native collagen sequence. To investigate the ability of Glycoprotein VI to recognize GPO triplets in a setting more representative of the collagens, we synthesized a set of triple helical peptides containing fewer GPO triplets, varying their number and spacing within an inert (GPP)(n) backbone. The adhesion of recombinant human Glycoprotein VI ectodomain, like that of human platelets, to these peptides increased with their GPO content, and platelet adhesion was abolished by the specific anti-Glycoprotein VI-blocking antibody, 10B12. Platelet aggregation and protein tyrosine phosphorylation were induced only by cross-linked peptides and only those that contained two or more GPO triplets. Such peptides were less potent than cross-linked collagen-related peptide. Our data suggest that both the sequences GPOGPO and GPO center dot center dot center dot center dot center dot center dot center dot center dot center dot GPO represent functional Glycoprotein VI recognition motifs within collagen. Furthermore, we propose that the (GPO)(4) motif can support simultaneous binding of two glycoprotein VI molecules, in either a parallel or anti-parallel stacking arrangement, which could play an important role in activation of signaling.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Cambridge, Dept Haematol, Cambridge CB2 2XY, England; Natl Blood Serv, Cambridge CB2 2PT, England; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Cambridge; University of Cambridge; University System of Ohio; University of Cincinnati	Farndale, RW (corresponding author), Univ Cambridge, Dept Biochem, Downing Site, Cambridge CB2 1QW, England.	rwf10@cam.ac.uk	Jarvis, Gavin/A-1903-2013; Herr, Andrew/R-3049-2019	Herr, Andrew/0000-0002-3598-3399; Jarvis, Gavin/0000-0003-4362-1133	MRC [G0601378, G0400701] Funding Source: UKRI; Medical Research Council [G0601378, G0400701] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Achison M, 2001, J BIOL CHEM, V276, P3167, DOI 10.1074/jbc.M007186200; Achison M, 1996, BLOOD COAGUL FIBRIN, V7, P149, DOI 10.1097/00001721-199603000-00009; Asselin J, 1999, BIOCHEM J, V339, P413, DOI 10.1042/0264-6021:3390413; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; BELL GI, 1974, NATURE, V248, P430, DOI 10.1038/248430a0; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Berisio R, 2002, PROTEIN SCI, V11, P262, DOI 10.1110/ps.32602; Boyington JC, 2002, MOL IMMUNOL, V38, P1007, DOI 10.1016/S0161-5890(02)00030-5; Clemetson KJ, 1999, HAEMOSTASIS, V29, P16; COLLER BS, 1989, BLOOD, V74, P182; Farndale RW, 2004, J THROMB HAEMOST, V2, P561, DOI 10.1111/j.1538-7836.2004.00665.x; Farndale RW, 2003, BIOCHEM SOC SYMP, V70, P81, DOI 10.1042/bss0700081; Feng JW, 2005, IMMUNITY, V22, P427, DOI 10.1016/j.immuni.2005.02.005; Feng YB, 1996, J AM CHEM SOC, V118, P10351, DOI 10.1021/ja961260c; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; HORII K, 2006, BLOOD; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joutsi-Korhonen L, 2003, BLOOD, V101, P4372, DOI 10.1182/blood-2002-08-2591; Kehrel B, 1998, BLOOD, V91, P491; Knight C Graham, 2004, Methods Mol Biol, V273, P349; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Lebbink RJ, 2006, J EXP MED, V203, P1419, DOI 10.1084/jem.20052554; Massberg S, 2003, J EXP MED, V197, P41, DOI 10.1084/jem.20020945; Miura Y, 2002, J BIOL CHEM, V277, P46197, DOI 10.1074/jbc.M204029200; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; MORTON LF, 1987, BIOCHEM J, V248, P483, DOI 10.1042/bj2480483; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; O'Connor MN, 2006, J BIOL CHEM, V281, P33505, DOI 10.1074/jbc.M606480200; O'Connor MN, 2006, J THROMB HAEMOST, V4, P869, DOI 10.1111/j.1538-7836.2005.01764.x; Onley DJ, 2000, J BIOL CHEM, V275, P24560, DOI 10.1074/jbc.M004111200; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ruehl M, 2002, J BIOL CHEM, V277, P26872, DOI 10.1074/jbc.M202335200; Smethurst PA, 2004, BLOOD, V103, P903, DOI 10.1182/blood-2003-01-0308; Van Lier M, 2005, J THROMB HAEMOST, V3, P2514; Watson SP, 2005, J THROMB HAEMOST, V3, P1752, DOI 10.1111/j.1538-7836.2005.01429.x; Zong YN, 2005, EMBO J, V24, P4224, DOI 10.1038/sj.emboj.7600888	38	89	94	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1296	1304		10.1074/jbc.M606479200	http://dx.doi.org/10.1074/jbc.M606479200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17085439	hybrid			2022-12-27	WOS:000243295200055
J	Boanca, G; Sand, A; Okada, T; Suzuki, H; Kumagai, H; Fukuyama, K; Barycki, JJ				Boanca, Gina; Sand, Aaron; Okada, Toshihiro; Suzuki, Hideyuki; Kumagai, Hidehiko; Fukuyama, Keiichi; Barycki, Joseph J.			Autoprocessing of Helicobacter pylori gamma-glutamyltranspeptidase leads to the formation of a threonine-threonine catalytic dyad	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERASE TRANSPEPTIDASE; ESCHERICHIA-COLI; IDENTIFICATION; NUCLEOPHILE; MECHANISM; RESIDUES; SYSTEM; ACID	Helicobacter pylori gamma-glutamyltranspeptidase (HpGT) is a glutathione-degrading enzyme that has been shown to be a virulence factor in infection. It is expressed as a 60-kDa inactive precursor that must undergo autocatalytic processing to generate a 40-kDa/20-kDa heterodimer with full gamma-glutamyl amide bond hydrolase activity. The new N terminus of the processed enzyme, Thr-380, is the catalytic nucleophile in both the autoprocessing and enzymatic reactions, indicating that HpGT is a member of the N-terminal nucleophile hydrolase superfamily. To further investigate activation as a result of autoprocessing, the structure of HpGT has been determined to a resolution of 1.9 angstrom. The refined model contains two 40-kDa/20-kDa heterodimers in the asymmetric unit and has structural features comparable with other N-terminal nucleophile hydrolases. Autoprocessing of HpGT leads to a large conformational change, with the loop preceding the catalytic Thr-380 moving > 35 angstrom, thus relieving steric constraints that likely limit substrate binding. In addition, cleavage of the proenzyme results in the formation of a threonine-threonine dyad comprised of Thr-380 and a second conserved threonine residue, Thr-398. The hydroxyl group of Thr-398 is located equidistant from the a-amino group and hydroxyl side chain of Thr-380. Mutation of Thr-398 to an alanine results in an enzyme that is fully capable of autoprocessing but is devoid of enzymatic activity. Substrate docking studies in combination with homology modeling studies of the human homologue reveal additional mechanistic details of enzyme maturation and activation, substrate recognition, and catalysis.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Osaka Univ, Dept Biol Sci, Toyonaka, Osaka 5600043, Japan; Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Sakyo Ku, Kyoto 6068502, Japan; Ishikawa Prefectural Univ, Res Inst Bioresources & Biotechnol, Nonoichi, Ishikawa 9218836, Japan	University of Nebraska System; University of Nebraska Lincoln; Osaka University; Kyoto University; Ishikawa Prefecture University	Barycki, JJ (corresponding author), Univ Nebraska, Dept Biochem, 1901 Vine St, Lincoln, NE 68588 USA.	jbarycki2@unl.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077289] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR-17675, P20 RR017675, RR07707] Funding Source: Medline; NIGMS NIH HHS [1R01GM0077289-01, R01 GM077289] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT WA, 1983, J BIOL CHEM, V258, P6193; ALLISON RD, 1985, METHOD ENZYMOL, V113, P419; Bates PA, 2001, PROTEINS, P39; Boanca G, 2006, J BIOL CHEM, V281, P19029, DOI 10.1074/jbc.M603381200; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Castonguay R, 2003, BIOCHEMISTRY-US, V42, P11504, DOI 10.1021/bi035064b; Chevalier C, 1999, MOL MICROBIOL, V31, P1359, DOI 10.1046/j.1365-2958.1999.01271.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; HASHIMOTO W, 1995, J BIOCHEM-TOKYO, V118, P75, DOI 10.1093/oxfordjournals.jbchem.a124894; Ikeda Y, 2005, METHOD ENZYMOL, V401, P408, DOI 10.1016/S0076-6879(05)01025-6; IKEDA Y, 1993, J BIOL CHEM, V268, P3980; IKEDA Y, 1995, J BIOL CHEM, V270, P12471, DOI 10.1074/jbc.270.21.12471; IKEDA Y, 1995, J BIOL CHEM, V270, P22223, DOI 10.1074/jbc.270.38.22223; Ikeda Y, 1996, J BIOCHEM-TOKYO, V119, P1166; Inoue M, 2000, BIOCHEMISTRY-US, V39, P7764, DOI 10.1021/bi000220p; Keillor JW, 2005, METHOD ENZYMOL, V401, P449, DOI 10.1016/S0076-6879(05)01027-X; Kinlough CL, 2005, METHOD ENZYMOL, V401, P426, DOI 10.1016/S0076-6879(05)01026-8; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McGovern KJ, 2001, INFECT IMMUN, V69, P4168, DOI 10.1128/IAI.69.6.4168-4173.2001; Menard A, 2001, BIOCHEMISTRY-US, V40, P12678, DOI 10.1021/bi011234d; Michalska K, 2005, J BIOL CHEM, V280, P28484, DOI 10.1074/jbc.M504501200; Minami H, 2003, FEMS MICROBIOL LETT, V224, P169, DOI 10.1016/S0378-1097(03)00456-7; Oinonen C, 2000, PROTEIN SCI, V9, P2329, DOI 10.1110/ps.9.12.2329; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Okada T, 2006, P NATL ACAD SCI USA, V103, P6471, DOI 10.1073/pnas.0511020103; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; RODGERS DW, 1994, STRUCTURE, V2, P1135, DOI 10.1016/S0969-2126(94)00116-2; Suzuki H, 2002, J BIOL CHEM, V277, P43536, DOI 10.1074/jbc.M207680200; SUZUKI H, 1986, J BACTERIOL, V168, P1325, DOI 10.1128/jb.168.3.1325-1331.1986; Taniguchi N, 1998, ADV ENZYMOL RAMB, V72, P239; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TATE SS, 1985, METHOD ENZYMOL, V113, P400	35	65	67	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					534	541		10.1074/jbc.M607694200	http://dx.doi.org/10.1074/jbc.M607694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17107958	hybrid			2022-12-27	WOS:000243166500059
J	Feng, YF; Zhao, HB; Luderer, HF; Epple, H; Faccio, R; Ross, FP; Teitelbaum, SL; Longmore, GD				Feng, Yunfeng; Zhao, Haibo; Luderer, Hilary F.; Epple, Holly; Faccio, Roberta; Ross, F. Patrick; Teitelbaum, Steven L.; Longmore, Gregory D.			The LIM protein, LIMD1, regulates AP-1 activation through an interaction with TRAF6 to influence osteoclast development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; C-JUN; DEFECTIVE INTERLEUKIN-1; AJUBA; INDUCTION; FHL2; DIFFERENTIATION; OSTEOPETROSIS; RANKL; GENE	Increasingly a number of proteins important in the regulation of bone osteoclast development have been shown primarily influence osteoclastogenesis under conditions of physiologic or pathologic stress. Why basal osteoclastogenesis is normal and how these proteins regulate stress osteoclastogenic responses, as opposed to basal osteoclastogenesis, is unclear. LIM proteins of the Ajuba/Zyxin family localize to cellular sites of cell adhesion where they contribute to the regulation of cell adhesion and migration, translocate into the nucleus where they can affect cell fate, but are also found in the cytoplasm where their function is largely unknown. We show that one member of this LIM protein family, Limd1, is uniquely up-regulated during osteoclast differentiation and interacts with Traf6, a critical cytosolic regulator of RANK-L-regulated osteoclast development. Limd1 positively affects the capacity of Traf6 to activate AP-1, and Limd1(-/-) osteoclast precursor cells are defective in the activation of AP-1 and thus induction of NFAT2. Limd1(-/-) mice, although having normal basal bone osteoclast numbers and bone density, are resistant to physiological and pathologic osteoclastogenic stimuli. These results implicate Limd1 as a potentially important regulator of osteoclast development under conditions of stress.	Washington Univ, Sch Med, Div Hematol, Dept Med, St Louis, MO 63110 USA; Washington Univ, Dept Cell Biol, St Louis, MO 63110 USA; Washington Univ, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Dept Orthoped Surg, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Longmore, GD (corresponding author), Washington Univ, Sch Med, Div Hematol, Dept Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	glongmor@im.wustl.edu	Zhao, Haibo/ABG-9729-2021	Teitelbaum, Steven/0000-0002-4054-6679; ZHAO, HAIBO/0000-0003-0836-7555; Feng, Yunfeng/0000-0001-9150-7795	NCI NIH HHS [CA75315] Funding Source: Medline; NIAMS NIH HHS [AR048853, AR032788, AR048812, AR046523, AR046852] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048812, R01AR046523, R01AR032788, R37AR046523, R01AR048853, R01AR046852] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Aya K, 2005, J CLIN INVEST, V115, P1848, DOI 10.1172/JCI23763; Bai ST, 2005, J CLIN INVEST, V115, P2742, DOI 10.1172/JCI24921; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Chaisson ML, 2004, J BIOL CHEM, V279, P54841, DOI 10.1074/jbc.M406392200; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Duran A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534-5807(03)00403-9; Feng YF, 2005, MOL CELL BIOL, V25, P4010, DOI 10.1128/MCB.25.10.4010-4022.2005; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; Gunther T, 2005, EMBO J, V24, P3049, DOI 10.1038/sj.emboj.7600773; Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Kadono Y, 2005, EMBO REP, V6, P171, DOI 10.1038/sj.embor.7400345; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Kanungo J, 2000, MOL BIOL CELL, V11, P3299, DOI 10.1091/mbc.11.10.3299; Kiss H, 1999, HUM GENET, V105, P552, DOI 10.1007/s004390051144; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Laurin N, 2002, AM J HUM GENET, V70, P1582, DOI 10.1086/340731; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Marie H, 2003, J BIOL CHEM, V278, P1220, DOI 10.1074/jbc.M205391200; Matsumoto I, 2002, NAT IMMUNOL, V3, P360, DOI 10.1038/ni772; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; Reddy SV, 2004, CRIT REV EUKAR GENE, V14, P255, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.20; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sharp TV, 2004, P NATL ACAD SCI USA, V101, P16531, DOI 10.1073/pnas.0407123101; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644; Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004; Thompson JB, 2000, PETROLOGY+, V8, P303; Wagner EF, 2003, ANN RHEUM DIS, V62, P83, DOI 10.1136/ard.62.suppl_2.ii83; Wilson SG, 2003, AM J HUM GENET, V72, P144, DOI 10.1086/345819; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	48	40	46	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					39	48		10.1074/jbc.M607399200	http://dx.doi.org/10.1074/jbc.M607399200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17092936	hybrid			2022-12-27	WOS:000243166500005
J	Wullaert, A; Verstrepen, L; Van Huffel, S; Adib-Conquy, M; Cornelis, S; Kreike, M; Haegman, M; El Bakkouri, K; Sanders, M; Verhelst, K; Carpentier, I; Cavaillon, JM; Heyninck, K; Beyaert, R				Wullaert, Andy; Verstrepen, Lynn; Van Huffel, Sofie; Adib-Conquy, Minou; Cornelis, Sigrid; Kreike, Marja; Haegman, Mira; El Bakkouri, Karim; Sanders, Matthew; Verhelst, Kelly; Carpentier, Isabelle; Cavaillon, Jean-Marc; Heyninck, Karen; Beyaert, Rudi			LIND/ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; FINGER PROTEIN A20; GENE-EXPRESSION; ENDOTOXIN TOLERANCE; INTERLEUKIN-1 RECEPTOR; A20-BINDING INHIBITOR; NEGATIVE REGULATION; IMMUNE-RESPONSES; LIVER-FAILURE; CELL-DEATH	Recognition of lipopolysaccharide (LPS) by Toll-like receptor (TLR)4 initiates an intracellular signaling pathway leading to the activation of nuclear factor-kappa B (NF-kappa B). Although LPS-induced activation of NF-kappa B is critical to the induction of an efficient immune response, excessive or prolonged signaling from TLR4 can be harmful to the host. Therefore, the NF-kappa B signal transduction pathway demands tight regulation. In the present study, we describe the human protein Listeria INDuced (LIND) as a novel A20-binding inhibitor of NF-kappa B activation (ABIN) that is related to ABIN-1 and -2 and, therefore, is further referred to as ABIN-3. Similar to the other ABINs, ABIN-3 binds to A20 and inhibits NF-kappa B activation induced by tumor necrosis factor, interleukin-1, and 12-O-tetradecanoylphorbol-13-acetate. However, unlike the other ABINs, constitutive expression of ABIN-3 could not be detected in different human cells. Treatment of human monocytic cells with LPS strongly induced ABIN-3 mRNA and protein expression, suggesting a role for ABIN-3 in the LPS/TLR4 pathway. Indeed, ABIN-3 overexpression was found to inhibit NF-kappa B-dependent gene expression in response to LPS/TLR4 at a level downstream of TRAF6 and upstream of IKK beta. NF-kappa B inhibition was mediated by the ABIN-homology domain 2 and was independent of A20 binding. Moreover, in vivo adenoviral gene transfer of ABIN-3 in mice reduced LPS-induced NF-kappa B activity in the liver, thereby partially protecting mice against LPS/D-(+)-galactosamine-induced mortality. Taken together, these results implicate ABIN-3 as a novel negative feedback regulator of LPS-induced NF-kappa B activation.	Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Zwijnaarde, Belgium; Inst Pasteur, Cytokines & Inflammat Unit, F-75724 Paris 15, France	Flanders Institute for Biotechnology (VIB); Ghent University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Beyaert, R (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Zwijnaarde, Belgium.	rudi.beyaert@dmbr.ugent.be	Beyaert, Rudi/B-2589-2009; Wullaert, Andy/D-2975-2018; Bakkouri, Karim El/C-2992-2009; Wullaert, Andy/R-1924-2019; El Bakkouri, Karim/H-9253-2018	Wullaert, Andy/0000-0001-5012-654X; Wullaert, Andy/0000-0001-5012-654X; El Bakkouri, Karim/0000-0001-9102-9877; Haegman, Mira/0000-0002-4883-312X; Beyaert, Rudi/0000-0002-5704-582X				Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Brint EK, 2004, NAT IMMUNOL, V5, P373, DOI 10.1038/ni1050; Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cavaillon JM, 2003, J ENDOTOXIN RES, V9, P101, DOI 10.1179/096805103125001487; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cusson-Hermance N, 2005, J BIOL CHEM, V280, P36560, DOI 10.1074/jbc.M506831200; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; Fitzgerald KA, 2004, MICROBES INFECT, V6, P1361, DOI 10.1016/j.micinf.2004.08.015; FREUDENBERG MA, 1986, INFECT IMMUN, V51, P891, DOI 10.1128/IAI.51.3.891-895.1986; Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001; Heyninck K, 2003, BIOCHEM PHARMACOL, V66, P1409, DOI 10.1016/S0006-2952(03)00491-X; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Heyninck K, 2003, FEBS LETT, V536, P135, DOI 10.1016/S0014-5793(03)00041-3; Heyninck K, 1999, ANTICANCER RES, V19, P2863; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Janssens S, 2002, CURR BIOL, V12, P467, DOI 10.1016/S0960-9822(02)00712-1; Kerfoot SM, 2004, J IMMUNOL, V173, P7070, DOI 10.4049/jimmunol.173.11.7070; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Klinkenberg M, 2001, FEBS LETT, V498, P93, DOI 10.1016/S0014-5793(01)02504-2; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Michelsen KS, 2004, CIRC RES, V95, pE96; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Ogushi I, 2003, HEPATOLOGY, V38, P335, DOI 10.1053/jhep.2003.50298; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Papoutsopoulou S, 2006, NAT IMMUNOL, V7, P606, DOI 10.1038/ni1334; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Staege H, 2001, IMMUNOGENETICS, V53, P105, DOI 10.1007/s002510100306; Van Huffel S, 2001, J BIOL CHEM, V276, P30216, DOI 10.1074/jbc.M100048200; Volpe F, 1997, FEBS LETT, V419, P41, DOI 10.1016/S0014-5793(97)01426-9; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Wullaert A, 2005, HEPATOLOGY, V42, P381, DOI 10.1002/hep.20785	46	61	68	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					81	90		10.1074/jbc.M607481200	http://dx.doi.org/10.1074/jbc.M607481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17088249	hybrid			2022-12-27	WOS:000243166500010
J	Zargari, A; Boban, M; Heessen, S; Andreasson, C; Thyberg, J; Ljungdahl, PO				Zargari, Arezou; Boban, Mirta; Heessen, Stijn; Andreasson, Claes; Thyberg, Johan; Ljungdahl, Per O.			Inner nuclear membrane proteins Asi1, Asi2, and Asi3 function in concert to maintain the latent properties of transcription factors Stp1 and Stp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMIN-B RECEPTOR; ENDOPROTEOLYTIC ACTIVATION; SSY1P-PTR3P-SSY5P SENSOR; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; BUDDING YEAST; AMINO-ACIDS; GENE; ENVELOPE; PERMEASE	In yeast the homologous transcription factors Stp1 and Stp2 are synthesized as latent cytoplasmic precursors with N-terminal regulatory domains. In response to extracellular amino acids the regulatory domains are endoproteolytically excised by the plasma membrane-localized SPS sensor. The processed forms of Stp1 and Stp2 efficiently enter the nucleus and induce expression of amino acid permease genes. We recently reported that the inner nuclear membrane protein Asi1 is required to prevent unprocessed forms of Stp1 and Stp2, which ectopically enter the nucleus, from binding SPS sensor-regulated promoters. Here we show that Asi3, an Asi1 homolog, and Asi2 are integral proteins of the inner nuclear membrane that function in concert with Asi1. In cells lacking any of the three Asi proteins, unprocessed full-length forms of Stp1 and Stp2 constitutively induce SPS sensor-regulated genes. Our results demonstrate that the Asi proteins ensure the fidelity of SPS sensor signaling by maintaining the dormant, or repressed state, of gene expression in the absence of inducing signals. This study documents additional components of a novel mechanism controlling transcription in eukaryotic cells.	Karolinska Inst, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Ludwig Institute for Cancer Research; Karolinska Institutet	Ljungdahl, PO (corresponding author), Box 240, S-17177 Stockholm, Sweden.	plju@icr.ki.se	Ljungdahl, Per O/M-5258-2013	Ljungdahl, Per O/0000-0002-6625-3540; Andreasson, Claes/0000-0001-8948-0685				Abdel-Sater F, 2004, MOL CELL BIOL, V24, P9771, DOI 10.1128/MCB.24.22.9771-9785.2004; Andreasson C, 2004, MOL CELL BIOL, V24, P7503, DOI 10.1128/MCB.24.17.7503-7513.2004; Andreasson C, 2004, YEAST, V21, P193, DOI 10.1002/yea.1052; Andreasson C, 2002, GENE DEV, V16, P3158, DOI 10.1101/gad.239202; ANDREASSON C, 2006, GENES DEV, V20; Andrulis ED, 2002, MOL CELL BIOL, V22, P8292, DOI 10.1128/MCB.22.23.8292-8301.2002; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Aza-Blanc P, 1999, TRENDS GENET, V15, P458, DOI 10.1016/S0168-9525(99)01869-7; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Boban M, 2006, J CELL BIOL, V173, P695, DOI 10.1083/jcb.200601011; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Burke D., 2000, METHODS YEAST GENETI; CARDENAS ME, 1990, J CELL SCI, V96, P439; Casolari JM, 2005, GENE DEV, V19, P1188, DOI 10.1101/gad.1307205; Casolari JM, 2004, CELL, V117, P427, DOI 10.1016/S0092-8674(04)00448-9; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; de Boer M, 2000, NUCLEIC ACIDS RES, V28, P974; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Forsberg H, 2001, CURR GENET, V40, P91, DOI 10.1007/s002940100244; Forsberg H, 2001, MOL CELL BIOL, V21, P814, DOI 10.1128/MCB.21.3.814-826.2001; Forsberg H, 2001, GENETICS, V158, P973; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Gartenberg MR, 2004, CELL, V119, P955, DOI 10.1016/j.cell.2004.11.008; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilstring CF, 2000, J BIOL CHEM, V275, P31488, DOI 10.1074/jbc.M005047200; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hetzer MW, 2005, ANNU REV CELL DEV BI, V21, P347, DOI 10.1146/annurev.cellbio.21.090704.151152; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Iraqui I, 1999, MOL CELL BIOL, V19, P989; Ishii K, 2002, CELL, V109, P551, DOI 10.1016/S0092-8674(02)00756-0; Ivorra' C, 2006, GENE DEV, V20, P307, DOI 10.1101/gad.349506; Jorgensen MU, 1998, YEAST, V14, P103, DOI 10.1002/(SICI)1097-0061(19980130)14:2<103::AID-YEA203>3.0.CO;2-C; King MC, 2006, NATURE, V442, P1003, DOI 10.1038/nature05075; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Klasson H, 1999, MOL CELL BIOL, V19, P5405; Lin F, 2005, HUM MOL GENET, V14, P437, DOI 10.1093/hmg/ddi040; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Muchir A, 2004, PHYSIOLOGY, V19, P309, DOI 10.1152/physiol.00022.2004; Nielsen PS, 2001, MOL GEN GENET, V264, P613, DOI 10.1007/s004380000347; Osada SI, 2003, DEVELOPMENT, V130, P1783, DOI 10.1242/dev.00401; Pan D, 2005, J BIOL CHEM, V280, P15992, DOI 10.1074/jbc.M411234200; PEMBERTON LF, 1995, P NATL ACAD SCI USA, V92, P1187, DOI 10.1073/pnas.92.4.1187; Persson B, 1996, PROTEIN SCI, V5, P363; Schirmer EC, 2005, TRENDS BIOCHEM SCI, V30, P551, DOI 10.1016/j.tibs.2005.08.003; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Schmid M, 2006, MOL CELL, V21, P379, DOI 10.1016/j.molcel.2005.12.012; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; SMITH S, 1993, J CELL BIOL, V120, P631, DOI 10.1083/jcb.120.3.631; Somech R, 2005, PEDIATR RES, V57, p8R, DOI 10.1203/01.PDR.0000159566.54287.6C; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; Taddei A, 2004, ANNU REV GENET, V38, P305, DOI 10.1146/annurev.genet.37.110801.142705; Worman HJ, 2006, BBA-MOL CELL BIOL L, V1761, P626, DOI 10.1016/j.bbalip.2006.02.010	58	45	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					594	605		10.1074/jbc.M609201200	http://dx.doi.org/10.1074/jbc.M609201200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17085444	hybrid			2022-12-27	WOS:000243166500065
J	Portier, BP; Taglialatela, G				Portier, Bryce Patrick; Taglialatela, Giulio			Bcl-2 localized at the nuclear compartment induces apoptosis after transient overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; FACTOR-KAPPA-B; ENDOPLASMIC-RETICULUM; CELL-DEATH; OXIDATIVE-STRESS; CYTOCHROME-C; PC12 CELLS; EXPRESSION; INHIBITION; BAX	Bcl-2 is the best characterized member of a large family of proteins that regulate apoptosis. Although it is established that Bcl-2 localized at the mitochondria functions as an anti- apoptotic protein, the function of Bcl-2 at the nucleus remains unclear. Recently we showed that nuclear compartment-associated Bcl-2 inhibits transcription factor activation. Based on this observation, we hypothesized that presence of Bcl-2 at the nucleus may induce rather than protect cells from apoptosis. Here we investigated the putative apoptotic role of nuclear compartment- associated Bcl-2. Additionally, we examined the role of the Bcl-2 BH4 domain in mediating binding to FKBP38, the Bcl-2 mitochondrial chaperone. Our results demonstrate a novel, pro-apoptotic function for nuclear Bcl-2 and identify the Bcl-2 BH4 domain as a key regulator in mediating Bcl-2/FKBP38 binding. These results indicate that Bcl-2 has a dual role as both a protector and a killer and that the ability to switch roles depends on Bcl-2 subcellular localization.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Taglialatela, G (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA.	gtaglial@utmb.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011255, F30NS049759] Funding Source: NIH RePORTER; NINDS NIH HHS [1F30NS049759-01A1, NS11255] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bruckheimer E M, 1998, Adv Biochem Eng Biotechnol, V62, P75, DOI 10.1007/BFb0102306; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Distelhorst CW, 1996, ONCOGENE, V12, P2051; Ferrer I, 1998, EXP BRAIN RES, V121, P167, DOI 10.1007/s002210050448; FISHER G, 2003, REV PHYSL BIOCH PHAR, V148, P105; GERMAIN M, 2003, SCI STKE, pPE10; HACKER G, 1995, CURR BIOL, V5, P622, DOI 10.1016/S0960-9822(95)00126-6; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Honkaniemi J, 1996, MOL BRAIN RES, V42, P79, DOI 10.1016/S0169-328X(96)00121-0; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Kang CB, 2005, FEBS LETT, V579, P1469, DOI 10.1016/j.febslet.2005.01.053; Kaufmann JA, 2003, J NEUROCHEM, V87, P981, DOI 10.1046/j.1471-4159.2003.02092.x; Kaufmann JA, 2001, J NEUROCHEM, V76, P1099, DOI 10.1046/j.1471-4159.2001.00118.x; Kaufmann JA, 2002, NEUROREPORT, V13, P1917, DOI 10.1097/00001756-200210280-00017; Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang Y, 2002, MOL PHARMACOL, V61, P142, DOI 10.1124/mol.61.1.142; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Maroto R, 1997, J NEUROCHEM, V69, P514; Massaad CA, 2004, J BIOL CHEM, V279, P54470, DOI 10.1074/jbc.M407659200; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Portier BP, 2006, J NEUROSCI METH, V155, P134, DOI 10.1016/j.jneumeth.2006.01.024; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Taglialatela G, 1998, NEUROREPORT, V9, P489, DOI 10.1097/00001756-199802160-00024; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	43	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40493	40502		10.1074/jbc.M606181200	http://dx.doi.org/10.1074/jbc.M606181200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17090549	hybrid			2022-12-27	WOS:000243033900079
J	Shin, JH; Santangelo, TJ; Xie, YW; Reeve, JN; Kelman, Z				Shin, Jae-Ho; Santangelo, Thomas J.; Xie, Yunwei; Reeve, John N.; Kelman, Zvi			Archaeal minichromosome maintenance (MCM) helicase can unwind DNA bound by archaeal histones and transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; REPLICATION; PROTEINS; EUKARYAL	Protein-DNA complexes must be disassembled to facilitate DNA replication. Replication forks contain a helicase that unwinds the duplex DNA at the front of the fork. The minichromosome maintenance helicase from the archaeon Methanothermobacter thermautotrophicus required only ATP to unwind DNA bound into complexes by the M. thermautotrophicus archaeal histone HMtA2, transcription repressor TrpY, or into a transcription pre-initiation complex by M. thermautotrophicus TATA-box-binding protein, transcription factor B, and RNA polymerase. In contrast, the minichromosome maintenance helicase was unable to unwind DNA bound by this archaeal RNA polymerase in a stalled transcript-elongating complex.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	Ohio State University	Kelman, Z (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.	kelman@umbi.umd.edu	Santangelo, Tom/L-8206-2019	Santangelo, Tom/0000-0003-4559-3244	NIGMS NIH HHS [GM073336-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM073336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alilat M, 1999, J MOL BIOL, V291, P815, DOI 10.1006/jmbi.1999.2988; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Bailey KA, 1999, NUCLEIC ACIDS RES, V27, P532, DOI 10.1093/nar/27.2.532; Bartlett MS, 2004, J BIOL CHEM, V279, P5894, DOI 10.1074/jbc.M311429200; Boule JB, 2005, NATURE, V438, P57, DOI 10.1038/nature04091; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Chen YJ, 2005, J MOL BIOL, V346, P389, DOI 10.1016/j.jmb.2004.11.076; Darcy TJ, 1999, J BACTERIOL, V181, P4424, DOI 10.1128/JB.181.14.4424-4429.1999; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; EGGLESTON AK, 1995, J BIOL CHEM, V270, P2024, DOI 10.1074/jbc.270.5.2024; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; Grabowski B, 2003, ANNU REV MICROBIOL, V57, P487, DOI 10.1146/annurev.micro.57.030502.090709; Holland L, 2002, EUR J BIOCHEM, V269, P5192, DOI 10.1046/j.1432-1033.2002.03224.x; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kornberg A., 1992, DNA REPLICATION; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mirkin EV, 2005, MOL CELL BIOL, V25, P888, DOI 10.1128/MCB.25.3.888-895.2005; Pereira SL, 1997, P NATL ACAD SCI USA, V94, P12633, DOI 10.1073/pnas.94.23.12633; Reeve JN, 2003, MOL MICROBIOL, V48, P587, DOI 10.1046/j.1365-2958.2003.03439.x; Renfrow MB, 2004, J BIOL CHEM, V279, P2825, DOI 10.1074/jbc.M311433200; Santangelo TJ, 2006, J MOL BIOL, V355, P196, DOI 10.1016/j.jmb.2005.10.062; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Stano NM, 2005, NATURE, V435, P370, DOI 10.1038/nature03615; Veaute X, 2005, EMBO J, V24, P180, DOI 10.1038/sj.emboj.7600485; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; Xie YM, 2004, J BACTERIOL, V186, P3492, DOI 10.1128/JB.186.11.3492-3498.2004; Xie YW, 2005, J BACTERIOL, V187, P6419, DOI 10.1128/JB.187.18.6419-6429.2005; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713; Yankulov K, 1999, MOL CELL BIOL, V19, P6154	36	17	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4908	4915		10.1074/jbc.M606847200	http://dx.doi.org/10.1074/jbc.M606847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17158792	hybrid			2022-12-27	WOS:000244482000073
J	Thakur, KG; Joshi, AM; Gopal, B				Thakur, Krishan Gopal; Joshi, Anagha Madhusudan; Gopal, B.			Structural and biophysical studies on two promoter recognition domains of the extra-cytoplasmic function cr factor from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-SIGMA FACTOR; CRYSTAL-STRUCTURE; EXPRESSION; SEQUENCE	sigma factors are transcriptional regulatory proteins that bind to the RNA polymerase and dictate gene expression. The extracytoplasmic function (ECF) sigma factors govern the environment dependent regulation of transcription. ECF sigma factors have two domains sigma(2) and sigma(4) that recognize the -10 and -35 promoter elements. However, unlike the primary sigma factor sigma(4), the ECF sigma factors lack sigma(3), a region that helps in the recognition of the extended -10 element and sigma(1.1), a domain involved in the autoinhibition of sigma(A) in the absence of core RNA polymerase. Mycobacterium tuberculosis sigma(C) is an ECF sigma factor that is essential for the pathogenesis and virulence of M. tuberculosis in the mouse and guinea pig models of infection. However, unlike other ECF sigma factors, sigma c does not appear to have a regulatory anti- or factor located in the same operon. We also note that M. tuberculosis sigma c differs from the canonical ECF sigma factors as it has an N-terminal domain comprising of 126 amino acids that precedes the sigma(C)(2) and sigma(C)(4) domains. In an effort to understand the regulatory mechanism of this protein, the crystal structures of the sigma(C)(2) and sigma(C)(4) domains of sigma(C) were determined. These promoter recognition domains are structurally similar to the corresponding domains of sigma(A) despite the low sequence similarity. Fluorescence experiments using the intrinsic tryptophan residues of sigma(C)(2) as well as surface plasmon resonance measurements reveal that the sigma(C)(2) and sigma(C), domains interact with each other. Mutational analysis suggests that the Pribnow box-binding region of sigma(C)(2) is involved in this interdomain interaction. Interaction between the promoter recognition domains in M. tuberculosis sigma(C) are thus likely to regulate the activity of this protein even in the absence of an anti-sigma factor.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Gopal, B (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	bgopal@mbu.iisc.ernet.in	Thakur, Krishan/B-6480-2012; Gopal, Balasubramanian/ABG-3754-2021; Gopal, Balasubramanian/K-4566-2012	Joshi, Anagha/0000-0003-1184-3305; Thakur, Krishan/0000-0003-4500-2133	Wellcome Trust [078994] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arai M, 2004, NUCLEIC ACIDS RES, V32, pW390, DOI 10.1093/nar/gkh380; Beaucher J, 2002, MOL MICROBIOL, V45, P1527, DOI 10.1046/j.1365-2958.2002.03135.x; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Campbell EA, 2003, MOL CELL, V11, P1067, DOI 10.1016/S1097-2765(03)00148-5; Campbell EA, 2002, CELL, V108, P795, DOI 10.1016/S0092-8674(02)00662-1; Camus JC, 2002, MICROBIOL-SGM, V148, P2967, DOI 10.1099/00221287-148-10-2967; Costanzo A, 2006, J BACTERIOL, V188, P4627, DOI 10.1128/JB.01981-05; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002; Golovanov AP, 2004, J AM CHEM SOC, V126, P8933, DOI 10.1021/ja049297h; Hahn MY, 2005, J BACTERIOL, V187, P7062, DOI 10.1128/JB.187.20.7062-7071.2005; Helmann JD, 2002, ADV MICROB PHYSIOL, V46, P47; Karls RK, 2006, MICROBIOL-SGM, V152, P1591, DOI 10.1099/mic.0.28591-0; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Manganelli R, 2002, MOL MICROBIOL, V45, P365, DOI 10.1046/j.1365-2958.2002.03005.x; Manganelli R, 1999, MOL MICROBIOL, V31, P715, DOI 10.1046/j.1365-2958.1999.01212.x; Manganelli R, 2001, MOL MICROBIOL, V41, P423, DOI 10.1046/j.1365-2958.2001.02525.x; Manganelli R, 2004, J BACTERIOL, V186, P895, DOI 10.1128/JB.186.4.895-902.2004; Murakami KS, 2003, CURR OPIN STRUC BIOL, V13, P31, DOI 10.1016/S0959-440X(02)00005-2; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Prilusky J, 2005, BIOINFORMATICS, V21, P3435, DOI 10.1093/bioinformatics/bti537; Raman S, 2004, J BACTERIOL, V186, P6605, DOI 10.1128/JB.186.19.6605-6616.2004; Sambrook J., 2001, MOL CLONING LAB MANU; Shenoy AR, 2003, ANAL BIOCHEM, V319, P335, DOI 10.1016/S0003-2697(03)00286-0; Song TS, 2003, MOL MICROBIOL, V50, P949, DOI 10.1046/j.1365-2958.2003.03739.x; Sorenson MK, 2004, MOL CELL, V14, P127, DOI 10.1016/S1097-2765(04)00150-9; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Strong M, 2003, NUCLEIC ACIDS RES, V31, P7099, DOI 10.1093/nar/gkg924; Sun RG, 2004, MOL MICROBIOL, V52, P25, DOI 10.1111/j.1365-2958.2003.03958.x; Thakur KG, 2005, ACTA CRYSTALLOGR F, V61, P779, DOI 10.1107/S1744309105022669; Tomsic M, 2001, J BIOL CHEM, V276, P31891, DOI 10.1074/jbc.M105027200; von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005; Waagmeester A, 2005, TRENDS MICROBIOL, V13, P505, DOI 10.1016/j.tim.2005.08.009	33	24	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2007	282	7					4711	4718		10.1074/jbc.M606283200	http://dx.doi.org/10.1074/jbc.M606283200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CX	17145760	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000244482000052
J	Liang, MH; Chuang, DM				Liang, Min-Huei; Chuang, De-Maw			Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL REGULATION; NUCLEAR ACCUMULATION; NEGATIVE REGULATOR; CELL-SURVIVAL; LITHIUM; TYROSINE; PHOSPHORYLATION; INHIBITION; INSULIN; 3-BETA	Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase consisting of two isoforms, alpha and beta. The activities of GSK-3 are regulated negatively by serine phosphorylation but positively by tyrosine phosphorylation. GSK-3 inactivation has been proposed as a mechanism to promote neuronal survival. We used GSK-3 isoform-specific small interfering RNAs, dominant-negative mutants, or pharmacological inhibitors to search for functions of the two GSK-3 isoforms in regulating neuronal survival in cultured cortical neurons in response to glutamate insult or during neuronal maturation/aging. Surprisingly, RNA interference-induced depletion of either isoform was sufficient to block glutamate-induced excitotoxicity, and the resulting neuroprotection was associated with enhanced N-terminal serine phosphorylation in both GSK-3 isoforms. However, GSK-3 beta depletion was more effective than GSK-3 alpha depletion in suppressing spontaneous neuronal death in extended culture. This phenomenon is likely due to selective and robust inhibition of GSK-3 beta activation resulting from GSK-3 beta Ser(9) dephosphorylation during the course of spontaneous neuronal death. GSK-3 alpha silencing resulted in reduced tyrosine phosphorylation of GSK-3 beta, suggesting that tyrosine phosphorylation is also a critical autoregulatory event. Interestingly, GSK-3 inhibitors caused a rapid and long-lasting increase in GSK-3 alpha Ser(21) phosphorylation levels, followed by a delayed increase in GSK-3 beta Ser(9) phosphorylation and a decrease in GSK-3 alpha Tyr(279) and GSK-3 beta Tyr(216) phosphorylation, thus implying additional levels of GSK-3 autoregulation. Taken together, our results underscore important similarities and dissimilarities of GSK-3 alpha and GSK-3 beta in the roles of cell survival as well as their distinct modes of regulation. The development of GSK-3 isoform-specific inhibitors seems to be warranted for treating GSK-3-mediated pathology.	NIMH, Mol Neurobiol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Chuang, DM (corresponding author), NIMH, Mol Neurobiol Sect, Bldg 10,Room 4C-206,10 Ctr Dr,MSC 1363, Bethesda, MD 20892 USA.	chuang@mail.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002468, Z01MH002468, Z01MH002698] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Apostol BL, 2006, HUM MOL GENET, V15, P273, DOI 10.1093/hmg/ddi443; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; Cruz JC, 2004, CURR OPIN NEUROBIOL, V14, P390, DOI 10.1016/j.conb.2004.05.002; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; GOODE N, 1992, J BIOL CHEM, V267, P16878; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Hartigan JA, 2001, BIOCHEM BIOPH RES CO, V284, P485, DOI 10.1006/bbrc.2001.4986; Hashimoto R, 2002, J NEUROCHEM, V80, P589, DOI 10.1046/j.0022-3042.2001.00728.x; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hetman M, 2000, J NEUROSCI, V20, P2567; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; HOSHI M, 1995, J BIOCHEM-TOKYO, V118, P683, DOI 10.1093/oxfordjournals.jbchem.a124965; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Iitaka C, 2005, J BIOL CHEM, V280, P29397, DOI 10.1074/jbc.M503526200; Iwahana E, 2004, EUR J NEUROSCI, V19, P2281, DOI 10.1111/j.0953-816X.2004.03322.x; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Jope RS, 2002, MOL PSYCHIATR, V7, pS35, DOI 10.1038/sj.mp.4001017; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Liang MH, 2006, J BIOL CHEM, V281, P30479, DOI 10.1074/jbc.M607468200; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Lucas FR, 1998, J CELL SCI, V111, P1351; Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x; Manji HK, 1999, BIOL PSYCHIAT, V46, P929, DOI 10.1016/S0006-3223(99)00165-1; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Muly EC, 2004, CEREB CORTEX, V14, P1398, DOI 10.1093/cercor/bhh101; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; O'Brien WT, 2004, J NEUROSCI, V24, P6791, DOI 10.1523/JNEUROSCI.4753-03.2004; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Rowe Michael K., 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404008385; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; Spittaels K, 2002, NEUROSCIENCE, V113, P797, DOI 10.1016/S0306-4522(02)00236-1; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Su Y, 2004, BIOCHEMISTRY-US, V43, P6899, DOI 10.1021/bi035627j; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Szatmari E, 2005, J BIOL CHEM, V280, P37526, DOI 10.1074/jbc.M502699200; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Terry-Lorenzo RT, 2005, MOL BIOL CELL, V16, P2349, DOI 10.1091/mbc.E04-12-1054; Wang Q, 2006, ONCOGENE, V25, P43, DOI 10.1038/sj.onc.1209004; WANG QM, 1994, BIOCHEMISTRY-US, V33, P143, DOI 10.1021/bi00167a018; WANG QM, 1994, J BIOL CHEM, V269, P14566; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yin L, 2006, SCIENCE, V311, P1002, DOI 10.1126/science.1121613; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zmijewski JW, 2004, AGING CELL, V3, P309, DOI 10.1111/j.1474-9728.2004.00117.x	63	124	130	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3904	3917		10.1074/jbc.M605178200	http://dx.doi.org/10.1074/jbc.M605178200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17148450	hybrid			2022-12-27	WOS:000244481900055
J	Hewitson, KS; Lienard, BMR; McDonough, MA; Clifton, IJ; Butler, D; Soares, AS; Oldham, NJ; McNeill, LA; Schofield, CJ				Hewitson, Kirsty S.; Lienard, Benoit M. R.; McDonough, Michael A.; Clifton, Ian J.; Butler, Danica; Soares, Alexie S.; Oldham, Neil J.; McNeill, Luke A.; Schofield, Christopher J.			Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL COMPLEX-III; CRYSTAL-STRUCTURE; HIF-ALPHA; HISTONE DEMETHYLATION; FUMARATE HYDRATASE; NITRIC-OXIDE; TCA CYCLE; OXYGEN; PROLYL; PROTEIN	In humans both the levels and activity of the alpha-subunit of the hypoxia-inducible transcription factor (HIF-alpha) are regulated by its post-translation hydroxylation as catalyzed by iron-and 2-oxoglutarate (2OG)-dependent prolyl and asparaginyl hydroxylases (PHD1-3 and factor-inhibiting HIF (FIH), respectively). One consequence of hypoxia is the accumulation of tricarboxylic acid cycle intermediates (TCAIs). In vitro assays were used to assess non-2OG TCAIs as inhibitors of purified PHD2 and FIH. Under the assay conditions, no significant FIH inhibition was observed by the TCAIs or pyruvate, but fumarate, succinate, and isocitrate inhibited PHD2. Mass spectrometric analyses under nondenaturing conditions were used to investigate the binding of TCAIs to PHD2 and supported the solution studies. X-ray crystal structures of FIH in complex with Fe(II) and fumarate or succinate revealed similar binding modes for each in the 2OG co-substrate binding site. The in vitro results suggest that the cellular inhibition of PHD2, but probably not FIH, by fumarate and succinate may play a role in the Warburg effect providing that appropriate relative concentrations of the components are achieved under physiological conditions.	Univ Oxford, Dept Chem, Oxford OX1 3TA, England; ReOx Ltd, Magdalen Ctr, Oxford OX4 4GA, England; Brookhaven Natl Labs, Dept Biol, Upton, NY 11973 USA	University of Oxford; United States Department of Energy (DOE); Brookhaven National Laboratory	Schofield, CJ (corresponding author), Univ Oxford, Dept Chem, Mansfield Rd, Oxford OX1 3TA, England.	kirsty.hewitson@reox.co.uk; christopher.schofield@chemistry.oxford.ac.uk	McDonough, Michael A/G-2744-2013; McDonough, Michael/N-8913-2019; Soares, Alexei S/F-4800-2014	McDonough, Michael A/0000-0003-4664-6942; McDonough, Michael/0000-0003-4664-6942; Soares, Alexei S/0000-0002-6565-8503; Schofield, Christopher/0000-0002-0290-6565; Oldham, Neil/0000-0001-8024-4563	Biotechnology and Biological Sciences Research Council [BBS/B/07683] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Agani FH, 2002, AM J PHYSIOL-CELL PH, V283, pC178, DOI 10.1152/ajpcell.00381.2001; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Baysal BE, 2003, TRENDS ENDOCRIN MET, V14, P453, DOI 10.1016/j.tem.2003.08.004; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Blasiak LC, 2006, NATURE, V440, P368, DOI 10.1038/nature04544; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024; Clifton IJ, 2006, J INORG BIOCHEM, V100, P644, DOI 10.1016/j.jinorgbio.2006.01.024; Dann CE, 2005, BIOCHEM BIOPH RES CO, V338, P639, DOI 10.1016/j.bbrc.2005.08.140; Doege K, 2005, BLOOD, V106, P2311, DOI 10.1182/blood-2005-03-1138; Dubus A, 2001, CELL MOL LIFE SCI, V58, P835, DOI 10.1007/PL00000904; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirota K, 2005, BIOCHEM BIOPH RES CO, V338, P610, DOI 10.1016/j.bbrc.2005.08.193; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; HOLME E, 1975, BIOCHEMISTRY-US, V14, P4999, DOI 10.1021/bi00693a033; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Kietzmann T, 2005, SEMIN CELL DEV BIOL, V16, P474, DOI 10.1016/j.semcdb.2005.03.010; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; Knowles HJ, 2003, CANCER RES, V63, P1764; Koukourakis MI, 2005, CLIN EXP METASTAS, V22, P25, DOI 10.1007/s10585-005-2343-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; Lee HJ, 2001, J MOL BIOL, V308, P937, DOI 10.1006/jmbi.2001.4649; Lu HS, 2005, J BIOL CHEM, V280, P41928, DOI 10.1074/jbc.M508718200; McDonough MA, 2005, J AM CHEM SOC, V127, P7680, DOI 10.1021/ja050841b; McDonough MA, 2006, P NATL ACAD SCI USA, V103, P9814, DOI 10.1073/pnas.0601283103; McNeill LA, 2005, MOL BIOSYST, V1, P321, DOI 10.1039/b511249b; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Muller I, 2005, J BIOL CHEM, V280, P5716, DOI 10.1074/jbc.M410840200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Percy MJ, 2006, P NATL ACAD SCI USA, V103, P654, DOI 10.1073/pnas.0508423103; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pollard PJ, 2003, ANN MED, V35, P632, DOI 10.1080/07853890310018458; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schofield CJ, 2005, BIOCHEM BIOPH RES CO, V338, P617, DOI 10.1016/j.bbrc.2005.08.111; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Valegard K, 2004, NAT STRUCT MOL BIOL, V11, P95, DOI 10.1038/nsmb712; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Welford RWD, 2003, J BIOL CHEM, V278, P10157, DOI 10.1074/jbc.M211058200; Wilmouth RC, 2002, STRUCTURE, V10, P93, DOI 10.1016/S0969-2126(01)00695-5; Yu B, 2006, NATURE, V439, P879, DOI 10.1038/nature04561; Zhang ZH, 1997, BIOCHEMISTRY-US, V36, P15999, DOI 10.1021/bi971823c; Zhang ZH, 2002, FEBS LETT, V517, P7, DOI 10.1016/S0014-5793(02)02520-6; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	66	170	177	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3293	3301		10.1074/jbc.M608337200	http://dx.doi.org/10.1074/jbc.M608337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135241	hybrid			2022-12-27	WOS:000243793900056
J	Li, M; Chevalier-Larsen, ES; Merry, DE; Diamond, MI				Li, Mei; Chevalier-Larsen, Erica S.; Merry, Diane E.; Diamond, Marc I.			Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; EXPANDED POLYGLUTAMINE; PROTEIN AGGREGATION; SCA1 MICE; HUNTINGTIN; DISEASE; NUCLEAR; INCLUSIONS; FRAGMENT; BRAIN	In polyglutamine diseases such as X-linked spinobulbar muscular atrophy (SBMA), it is unknown whether the toxic form of the protein is an insoluble or soluble aggregate or a monomer. We have addressed this question by studying a full-length androgen receptor (AR) mouse model of SBMA. We used biochemistry and atomic force microscopy to immunopurify oligomers soluble after ultracentrifugation that are comprised of a single similar to 50-kDa N-terminal polyglutamine-containing AR fragment. AR oligomers appeared several weeks prior to symptom onset, were distinct and temporally dissociated from intranuclear inclusions, and disappeared rapidly after castration, which halts disease. This is the first demonstration of soluble AR oligomers in vivo and suggests that they underlie neurodegeneration in SBMA.	Univ Calif San Francisco, Dept Neurol, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	University of California System; University of California San Francisco; Jefferson University; University of Pennsylvania	Diamond, MI (corresponding author), Univ Calif San Francisco, Dept Neurol, Dept Cellular & Mol Pharmacol, GH-SS72B,600 16th St, San Francisco, CA 94143 USA.	marc.diamond@ucsf.edu			NINDS NIH HHS [R01 NS032214] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032214] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi H, 2005, BRAIN, V128, P659, DOI 10.1093/brain/awh381; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Chevalier-Larsen ES, 2004, J NEUROSCI, V24, P4778, DOI 10.1523/JNEUROSCI.0808-04.2004; Cowan KJ, 2003, HUM MOL GENET, V12, P1377, DOI 10.1093/hmg/ddg151; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Diaz-Hernandez M, 2004, J NEUROSCI, V24, P9361, DOI 10.1523/JNEUROSCI.2365-04.2004; Goti D, 2004, J NEUROSCI, V24, P10266, DOI 10.1523/JNEUROSCI.2734-04.2004; HARDING AE, 1982, J NEUROL NEUROSUR PS, V45, P1012, DOI 10.1136/jnnp.45.11.1012; Hazeki N, 2000, BIOCHEM BIOPH RES CO, V277, P386, DOI 10.1006/bbrc.2000.3682; Hoffner G, 2005, J NEUROCHEM, V95, P125, DOI 10.1111/j.1471-4159.2005.03348.x; Iuchi S, 2003, P NATL ACAD SCI USA, V100, P2409, DOI 10.1073/pnas.0437660100; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Li H, 1999, HUM MOL GENET, V8, P1227, DOI 10.1093/hmg/8.7.1227; Li I, 1998, AM J PATHOL, V153, P695, DOI 10.1016/S0002-9440(10)65612-X; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Merry DE, 1998, HUM MOL GENET, V7, P693, DOI 10.1093/hmg/7.4.693; Mukai H, 2005, P NATL ACAD SCI USA, V102, P10887, DOI 10.1073/pnas.0409283102; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Simeoni S, 2000, HUM MOL GENET, V9, P133, DOI 10.1093/hmg/9.1.133; Sopher BL, 2004, NEURON, V41, P687, DOI 10.1016/S0896-6273(04)00082-0; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; WALCOTT JL, 2002, J BIOL CHEM; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Yoo SY, 2003, NEURON, V37, P383, DOI 10.1016/S0896-6273(02)01190-X; Zhou H, 2003, J CELL BIOL, V163, P109, DOI 10.1083/jcb.200306038; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	40	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3157	3164		10.1074/jbc.M609972200	http://dx.doi.org/10.1074/jbc.M609972200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17121819	hybrid			2022-12-27	WOS:000243793900041
J	Lin, H; Chen, MC; Chiu, CY; Song, YM; Lin, SY				Lin, Ho; Chen, Mei-Chih; Chiu, Chih-Yuan; Song, Yuh-Min; Lin, Shih-Yi			Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; PREOPERATIVE DIAGNOSIS; ALZHEIMERS-DISEASE; INDUCED APOPTOSIS; P35; TRANSCRIPTION; EXPRESSION; PATHWAY; CANCER; P25	The biological behaviors of thyroid cancer are varied, and the pathological mechanisms remain unclear. Some reports indicated an apparent aggregation of amyloid accompanying medullary thyroid carcinoma (MTC). Amyloid aggregation in neurodegeneration leads to hyperactivation of Cdk5 and subsequent neuronal death. Based on the connection with amyloid, the role of Cdk5 in MTC is worthy of investigation. Initially, the expression of Cdk5 and its activator, p35, in MTC cell lines was identified. Cdk5 inhibition by specific inhibitors or short interfering RNA decreased the proliferation of MTC cell lines, which reveals the importance of Cdk5 in MTC cell growth. Although p35 cleavage has been considered as an important element in neurodegeneration, it seems that p35 cleavage was not a major cause in Cdk5 activity-dependent MTC cell proliferation because neither Cdk5 activity nor cell growth was affected by the inhibition of p35 cleavage. Clearance of amyloid by antibody neutralization indicated that MTC cell proliferation was supported by calcitonin-derived extracellular amyloid and subsequent Her2 and Cdk5 activation. Significantly, the STAT3 pathway was involved in Cdk5-dependent proliferation of MTC cells through Ser-727 phosphorylation. In addition, Cdk5 inhibition reduced nuclear distributions of both the Cdk5-p35 complex and phospho-STAT3 in MTC cells. Finally, Cdk5 inhibition retarded tumor formation in vivo accompanying the reduction of phospho-STAT3. Our findings suggest the first demonstration of a novel and specific role for Cdk5 kinase in supporting the proliferation of the medullary thyroid carcinoma cells and could shed light on a new field for diagnosis and therapy of thyroid cancer.	Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; Taichung Vet Gen Hosp, Biochem Sect, Dept Med Labs, Taichung 40705, Taiwan; Taichung Vet Gen Hosp, Div Endocrinol & Metab, Taichung 40705, Taiwan; Natl Yang Ming Univ, Dept Physiol, Taipei 11221, Taiwan	National Chung Hsing University; Taichung Veterans General Hospital; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University	Lin, H (corresponding author), Natl Chung Hsing Univ, Dept Life Sci, 250 Kuo Kuang Rd, Taichung 40227, Taiwan.	hlin@dragon.nchu.edu.tw		Lin, Ho/0000-0001-7849-9137				Alevizaki M, 2001, EUR J ENDOCRINOL, V145, P585, DOI 10.1530/eje.0.1450585; Alvarez A, 2001, EXP CELL RES, V264, P266, DOI 10.1006/excr.2001.5152; Bojunga J, 2004, CLIN ENDOCRINOL, V61, P523, DOI 10.1111/j.1365-2265.2004.02131.x; Bugalho MJGB, 2000, EUR J ENDOCRINOL, V143, P335, DOI 10.1530/eje.0.1430335; Chen F, 2004, CANCER RES, V64, P5425, DOI 10.1158/0008-5472.CAN-04-0806; Chen F, 1999, EXP CELL RES, V249, P422, DOI 10.1006/excr.1999.4522; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Fu AKY, 2004, P NATL ACAD SCI USA, V101, P6728, DOI 10.1073/pnas.0307606100; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Halliday BE, 1998, DIAGN CYTOPATHOL, V18, P270, DOI 10.1002/(SICI)1097-0339(199804)18:4<270::AID-DC4>3.3.CO;2-2; HUANG SN, 1968, CANCER, V21, P302, DOI 10.1002/1097-0142(196802)21:2<302::AID-CNCR2820210220>3.0.CO;2-R; Khurana R, 2004, ENDOCRINOLOGY, V145, P5465, DOI 10.1210/en.2004-0780; Leboulleux S, 2004, CLIN ENDOCRINOL, V61, P299, DOI 10.1111/j.1365-2265.2004.02037.x; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li BS, 2003, J BIOL CHEM, V278, P35702, DOI 10.1074/jbc.M302004200; Li HB, 2004, BIOCHEM J, V381, P257, DOI 10.1042/BJ20040515; Lin H, 2004, J BIOL CHEM, V279, P29302, DOI 10.1074/jbc.M403664200; LIN H, 2007, IN PRESS CELL DEATH; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Menacho IP, 2005, CANCER RES, V65, P1729, DOI 10.1158/0008-5472.CAN-04-2363; MEYER JS, 1968, CANCER, V21, P406, DOI 10.1002/1097-0142(196803)21:3<406::AID-CNCR2820210310>3.0.CO;2-6; Musa FRM, 1998, J ANDROL, V19, P657; Musa FRM, 2000, J ANDROL, V21, P392; Nguyen KC, 2002, J ALZHEIMERS DIS, V4, P123, DOI 10.3233/JAD-2002-4207; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; O'Hare MJ, 2005, J NEUROSCI, V25, P8954, DOI 10.1523/JNEUROSCI.2899-05.2005; Park JI, 2003, MOL CELL BIOL, V23, P543, DOI 10.1128/MCB.23.2.543-554.2003; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Reches M, 2002, J BIOL CHEM, V277, P35475, DOI 10.1074/jbc.M206039200; Sandal T, 2002, J BIOL CHEM, V277, P20783, DOI 10.1074/jbc.M112248200; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Takano T, 1999, CANCER RES, V59, P4542; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; Xie HQ, 1997, J NEUROCHEM, V69, P1020; Yoo BC, 2001, NATURE, V411, P763, DOI 10.1038/35081146; Zabel M, 1997, HISTOL HISTOPATHOL, V12, P283	41	86	90	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2776	2784		10.1074/jbc.M607234200	http://dx.doi.org/10.1074/jbc.M607234200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17145757	hybrid			2022-12-27	WOS:000243793900004
J	Polgar, N; Fogelgren, B; Shipley, JM; Csiszar, K				Polgar, Noemi; Fogelgren, Ben; Shipley, J. Michael; Csiszar, Katalin			Lysyl oxidase interacts with hormone placental lactogen and synergistically promotes breast epithelial cell proliferation and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; RECEPTOR MESSENGER-RNA; PROLACTIN RECEPTOR; FIBROGENIC CELLS; CANCER; PROTEIN; EXPRESSION; CARCINOMA; GENE; ACTIVATION	Lysyl oxidase (LOX), an extracellular amine oxidase, catalyzes the cross-linking of collagen and elastin. LOX has been also shown to play an essential role in promoting the invasive and metastatic potential of breast tumor cells. However, the LOX-interacting factors in these processes are not known. In this study, we identified placental lactogen (PL), a member of the growth hormone/ prolactin hormone family, as a LOX-interacting partner using yeast two-hybrid screens. PL is normally only expressed in placental syncytiotrophoblasts, but PL genes are amplified and expressed in a high percentage of invasive ductal breast carcinomas. We confirmed LOX-PL interactions using far Western and solid phase binding assays. In activity assays, PL was not a substrate or inhibitor of LOX. We further demonstrated that PL is expressed in breast tumor epithelial cells and detected LOX-PL interactions by coimmunoprecipitation in invasive breast cancer cells. In MCF-10A normal breast epithelial cells stably expressing LOX, PL, or both, LOX had no effect on cell proliferation, PL alone increased proliferation by 49%, and coexpression of LOX and PL led to a 121% increase in cell proliferation. Unlike in tumor cells, LOX did not induce a more migratory phenotype in MCF-10A cells; nor did PL. However, their coexpression resulted in a 240% increase in cell migration, suggesting that these interactions may be highly relevant to the transition of epithelial cells toward a migratory phenotype during the development and progression of breast carcinoma and a significant role for LOX-PL interactions in epithelial cell behavior.	Univ Hawaii, John A Burns Sch Med, Cardiovasc Res Ctr, Honolulu, HI 96822 USA; Univ Hawaii, John A Burns Sch Med, Dept Anat Biochem & Physiol, Honolulu, HI 96813 USA; Washington Univ, Div Pulm & Crit Care Med, St Louis, MO 63110 USA	University of Hawaii System; University of Hawaii System; Washington University (WUSTL)	Csiszar, K (corresponding author), Univ Hawaii, John A Burns Sch Med, Cardiovasc Res Ctr, 1960 East West Rd,Biomed T311, Honolulu, HI 96822 USA.	Kcsiszar@aol.com	Polgar, Noemi/B-3948-2013	Polgar, Noemi/0000-0002-8400-162X	NCRR NIH HHS [G12RR003096] Funding Source: Medline; NIAMS NIH HHS [AR47713] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [S11AR047713] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Barrera-Saldana HA, 1998, GENE, V211, P11, DOI 10.1016/S0378-1119(98)00092-4; BARRERASALDANA HA, 1983, J BIOL CHEM, V258, P3787; BARRERASALDANA HA, 1982, J BIOL CHEM, V257, P2399; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; Bhatavdekar JM, 2000, EUR J SURG ONCOL, V26, P540, DOI 10.1053/ejso.2000.0943; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; Chilton BS, 2005, CURR TOP DEV BIOL, V68, P1, DOI 10.1016/S0070-2153(05)68001-5; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DECOUVELAERE C, 1995, CELL GROWTH DIFFER, V6, P477; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fogelgren B, 2005, J BIOL CHEM, V280, P24690, DOI 10.1074/jbc.M412979200; Gebre-Medhin M, 2001, AM J PATHOL, V158, P1217, DOI 10.1016/S0002-9440(10)64071-0; GOLEMIS E, 2002, PROTEIN PROTEIN INTE, P37; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; He QP, 2003, NEUROBIOL DIS, V12, P25, DOI 10.1016/S0969-9961(02)00006-2; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HILL DJ, 1985, J CELL PHYSIOL, V125, P337, DOI 10.1002/jcp.1041250224; HOLTKAMP W, 1984, INT J CANCER, V34, P323, DOI 10.1002/ijc.2910340307; HORNE CHW, 1976, LANCET, V2, P279; JANSEN MK, 2006, IN PRESS MATRIX BIOL; Jung ST, 2003, PROTEIN EXPRES PURIF, V31, P240, DOI 10.1016/S1046-5928(03)00217-1; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KELLY PA, 1976, ENDOCRINOLOGY, V99, P765, DOI 10.1210/endo-99-3-765; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; Kirschmann DA, 2000, CANCER RES, V60, P3359; Kirschmann DA, 2002, CANCER RES, V62, P4478; Latham C, 2001, CANCER GENET CYTOGEN, V127, P16, DOI 10.1016/S0165-4608(00)00427-1; Lazarus HM, 1995, MATRIX BIOL, V14, P727, DOI 10.1016/S0945-053X(05)80015-0; Li WD, 2003, J CELL BIOCHEM, V88, P152, DOI 10.1002/jcb.10304; Li WD, 1997, P NATL ACAD SCI USA, V94, P12817, DOI 10.1073/pnas.94.24.12817; LOWMAN HB, 1991, J BIOL CHEM, V266, P10982; MACLEOD JN, 1992, J BIOL CHEM, V267, P14219; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; Meng JP, 2004, CANCER RES, V64, P5677, DOI 10.1158/0008-5472.CAN-04-1019; MOULD P, 2000, EXTRACELLULAR MATRIX; Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265; NELSON JM, 1988, P SOC EXP BIOL MED, V188, P346; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Payne SL, 2006, J CELL BIOCHEM, V98, P827, DOI 10.1002/jcb.20792; Peirce SK, 2001, J ENDOCRINOL, V171, pR1, DOI 10.1677/joe.0.171R001; Peterson FC, 2004, PROTEIN ENG DES SEL, V17, P417, DOI 10.1093/protein/gzh051; RESENDEZPEREZ D, 1990, NUCLEIC ACIDS RES, V18, P4665, DOI 10.1093/nar/18.16.4665; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; SCHNEIDER AB, 1979, J BIOL CHEM, V254, P3782; SCHNEIDER AB, 1975, ENDOCRINOLOGY, V97, P1364, DOI 10.1210/endo-97-6-1364; SCHNEIDER AB, 1977, BIOCHIM BIOPHYS ACTA, V493, P69, DOI 10.1016/0005-2795(77)90260-4; SCIARRA JJ, 1968, AM J OBSTET GYNECOL, V101, P413, DOI 10.1016/0002-9378(68)90075-6; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; Takeda T, 1997, J ENDOCRINOL, V153, pR1, DOI 10.1677/joe.0.153R001; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; WALKER WH, 1991, ENDOCR REV, V12, P316, DOI 10.1210/edrv-12-4-316; Walsh STR, 2006, J MOL BIOL, V358, P773, DOI 10.1016/j.jmb.2006.02.038; WELSCH CW, 1977, CANCER RES, V37, P2257; Zhu T, 2005, CANCER RES, V65, P317; Ziegler J, 1997, ANAL BIOCHEM, V250, P257, DOI 10.1006/abio.1997.2248	61	19	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3262	3272		10.1074/jbc.M609407200	http://dx.doi.org/10.1074/jbc.M609407200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17130123	hybrid			2022-12-27	WOS:000243793900053
J	Pasupuleti, M; Walse, B; Nordahl, EA; Morgelin, M; Malmsten, M; Schmidtchen, A				Pasupuleti, Mukesh; Walse, Bjorn; Nordahl, Emma Andersson; Morgelin, Matthias; Malmsten, Martin; Schmidtchen, Artur			Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPONENT C3; EVOLUTION; INNATE; CATHELICIDINS; DIVERGENCE; INSIGHTS	The human anaphylatoxin peptide C3a, generated during complement activation, exerts antimicrobial effects. Phylogenetic analysis, sequence analyses, and structural modeling studies paired with antimicrobial assays of peptides from known C3a sequences showed that, in particular in vertebrate C3a, crucial structural determinants governing antimicrobial activity have been conserved during the evolution of C3a. Thus, regions of the ancient C3a from Carcinoscorpius rotundicauda as well as corresponding parts of human C3a exhibited helical structures upon binding to bacterial lipopolysaccharide permeabilized liposomes and were antimicrobial against Gram-negative and Gram-positive bacteria. Human C3a and C4a (but not C5a) were antimicrobial, in concert with the separate evolutionary development of the chemotactic C5a. Thus, the results demonstrate that, notwithstanding a significant sequence variation, functional and structural constraints imposed on C3a during evolution have preserved critical properties governing antimicrobial activity.	Lund Univ, Biomed Ctr, Sect Dermatol & Venerol, Dept Clin Sci, SE-22184 Lund, Sweden; Lund Univ, Biomed Ctr, Sect Clin & Expt Infect Dis, Dept Clin Sci, SE-22184 Lund, Sweden; Uppsala Univ, Dept Pharm, SE-75123 Uppsala, Sweden	Lund University; Lund University; Uppsala University	Schmidtchen, A (corresponding author), Lund Univ, Biomed Ctr, Sect Dermatol & Venerol, Dept Clin Sci, Tornavagen 10, SE-22184 Lund, Sweden.	artur.schmidtchen@med.lu.se	Pasupuleti, Mukesh/AAD-9977-2020; Pasupuleti, Mukesh/H-7605-2013; Pasupuleti, Mukesh/AAF-4066-2020; Schmidtchen, Artur/F-9507-2015	Pasupuleti, Mukesh/0000-0001-6337-6257; Walse, Bjorn/0000-0003-1513-9040				Alper CA, 1998, EXP CLIN IMMUNOGENET, V15, P203, DOI 10.1159/000019074; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HUBER R, 1980, H-S Z PHYSIOL CHEM, V361, P1389, DOI 10.1515/bchm2.1980.361.2.1389; HUGLI TE, 1990, CURR TOP MICROBIOL, V153, P181; Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; Kerr AR, 2005, INFECT IMMUN, V73, P4245, DOI 10.1128/IAI.73.7.4245-4252.2005; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Lehrer RI, 2002, CURR OPIN HEMATOL, V9, P18, DOI 10.1097/00062752-200201000-00004; Maxwell AI, 2003, MOL IMMUNOL, V40, P413, DOI 10.1016/S0161-5890(03)00160-3; Nonaka M, 2004, MOL IMMUNOL, V40, P897, DOI 10.1016/j.molimm.2003.10.009; Nordahl EA, 2004, P NATL ACAD SCI USA, V101, P16879, DOI 10.1073/pnas.0406678101; Pinto MR, 2003, J IMMUNOL, V171, P5521, DOI 10.4049/jimmunol.171.10.5521; Poirot O, 2004, NUCLEIC ACIDS RES, V32, pW37, DOI 10.1093/nar/gkh382; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Semple CAM, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-5-r31; Sunyer JO, 2005, VET IMMUNOL IMMUNOP, V108, P77, DOI 10.1016/j.vetimm.2005.07.009; Tennessen JA, 2005, J MOL EVOL, V61, P445, DOI 10.1007/s00239-004-0330-2; Tennessen JA, 2005, J EVOLUTION BIOL, V18, P1387, DOI 10.1111/j.1420-9101.2005.00925.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomasinsig L, 2005, CURR PROTEIN PEPT SC, V6, P23, DOI 10.2174/1389203053027520; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WILLIAMSON MP, 1990, BIOCHEMISTRY-US, V29, P2895, DOI 10.1021/bi00464a002; Yount NY, 2006, BIOPOLYMERS, V84, P435, DOI 10.1002/bip.20543; Zarkadis IK, 2001, DEV COMP IMMUNOL, V25, P745, DOI 10.1016/S0145-305X(01)00034-9; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zelezetsky I, 2006, BBA-BIOMEMBRANES, V1758, P1436, DOI 10.1016/j.bbamem.2006.03.021; Zelezetsky I, 2006, J BIOL CHEM, V281, P19861, DOI 10.1074/jbc.M511108200; Zhang XL, 1997, PROTEINS, V28, P261, DOI 10.1002/(SICI)1097-0134(199706)28:2<261::AID-PROT13>3.0.CO;2-G; Zhu Y, 2005, EMBO J, V24, P382, DOI 10.1038/sj.emboj.7600533	31	49	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2520	2528		10.1074/jbc.M607848200	http://dx.doi.org/10.1074/jbc.M607848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17132627	hybrid, Green Submitted			2022-12-27	WOS:000243593200044
J	Wu, CY; Bird, AJ; Winge, DR; Eide, DJ				Wu, Chang-Yi; Bird, Amanda J.; Winge, Dennis R.; Eide, David J.			Regulation of the yeast TSA1 peroxiredoxin by ZAP1 is an adaptive response to the oxidative stress of zinc deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; GENE-EXPRESSION; CELLULAR ZINC; PROTEIN; DAMAGE; FINGERS; DOMAIN; MITOCHONDRIAL	Zinc deficiency is a potential risk factor for disease in humans because it leads to increased oxidative stress and DNA damage. We show here that the yeast Saccharomyces cerevisiae also experiences oxidative stress when zinc-deficient, and we have identified one mechanism yeast cells use to defend themselves against this stress. The Zap1p transcription factor is a central player in the response of yeast to zinc deficiency. To identify genes important for growth in low zinc, DNA microarrays were used to identify genes directly regulated by Zap1p. We found that the TSA1 gene is one such Zap1p target whose expression is increased under zinc deficiency. TSA1 encodes a cytosolic thioredoxin-dependent peroxidase responsible for degrading hydrogen peroxide and organic hydroperoxides. Consistent with its regulation by Zap1p, we showed that tsa1 Delta mutants have a growth defect in low zinc that can be suppressed by zinc but not by other metals. Anaerobic conditions also suppressed the tsa1 Delta low zinc growth defect indicating that oxidative stress is the likely cause of the poor growth. Consistent with this hypothesis, we demonstrated that zinc deficiency causes increased reactive oxygen species in wild type cells and that this increase is further exacerbated in tsa1 Delta mutants. The role of this regulation by Zap1p in limiting oxidative stress in low zinc was confirmed when the Zap1p-binding site was specifically mutated in the chromosomal TSA1 promoter. Thus, we conclude that TSA1 induction by Zap1p is an adaptive response to deal with the increased oxidative stress caused by zinc deficiency.	Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA	University of Wisconsin System; University of Wisconsin Madison; Utah System of Higher Education; University of Utah	Eide, DJ (corresponding author), Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr, Madison, WI 53706 USA.	eide@nutrisci.wisc.edu	Bird, Amanda Jane/ABD-2295-2021; Winge, Dennis/G-3611-2010	Bird, Amanda Jane/0000-0002-1846-7050; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56285] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames BN, 2002, NAT REV CANCER, V2, P694, DOI 10.1038/nrc886; Andreini C, 2006, J PROTEOME RES, V5, P196, DOI 10.1021/pr050361j; Bird A, 2000, J BIOL CHEM, V275, P16160, DOI 10.1074/jbc.M000664200; Bird AJ, 2004, EMBO J, V23, P1123, DOI 10.1038/sj.emboj.7600122; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; Bird AJ, 2003, EMBO J, V22, P5137, DOI 10.1093/emboj/cdg484; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY TM, 1990, FREE RADICAL BIO MED, V8, P281, DOI 10.1016/0891-5849(90)90076-U; BURKE JP, 1985, P SOC EXP BIOL MED, V179, P187; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; Demasi APD, 2006, FEBS J, V273, P805, DOI 10.1111/j.1742-4658.2006.05116.x; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; Eide DJ, 2003, J NUTR, V133, p1532S, DOI 10.1093/jn/133.5.1532S; Ellis CD, 2005, J BIOL CHEM, V280, P28811, DOI 10.1074/jbc.M505500200; Evans-Galea MV, 2003, BIOCHEMISTRY-US, V42, P1053, DOI 10.1021/bi0263199; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hambidge M, 2000, J NUTR, V130, p1344S, DOI 10.1093/jn/130.5.1344S; Han SH, 2005, J BIOL CHEM, V280, P29017, DOI 10.1074/jbc.M505881200; He XJ, 2005, MOL MICROBIOL, V58, P1454, DOI 10.1111/j.1365-2958.2005.04917.x; Herbig A, 2005, MOL MICROBIOL, V57, P834, DOI 10.1111/j.1365-2958.2005.04734.x; Ho E, 2004, J NUTR BIOCHEM, V15, P572, DOI 10.1016/j.jnutbio.2004.07.005; Ho E, 2003, J NUTR, V133, P2543, DOI 10.1093/jn/133.8.2543; Ho E, 2002, P NATL ACAD SCI USA, V99, P16770, DOI 10.1073/pnas.222679399; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang ME, 2005, MOL CELL, V17, P709, DOI 10.1016/j.molcel.2005.02.008; Huang ME, 2003, P NATL ACAD SCI USA, V100, P11529, DOI 10.1073/pnas.2035018100; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Kersting MC, 2006, J BIOL CHEM, V281, P13110, DOI 10.1074/jbc.M601612200; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MacDiarmid CW, 2003, J BIOL CHEM, V278, P15065, DOI 10.1074/jbc.M300568200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; Maret W, 2003, J NUTR, V133, p1460S, DOI 10.1093/jn/133.5.1460S; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OTEIZA PI, 1995, J NUTR, V125, P823; Powell SR, 2000, J NUTR, V130, p1447S, DOI 10.1093/jn/130.5.1447S; Prasad AS, 1993, BIOCH ZINC, P219; Rand JD, 2006, MOL BIOL CELL, V17, P387, DOI 10.1091/mbc.E05-06-0520; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Rutherford JC, 2005, J BIOL CHEM, V280, P10135, DOI 10.1074/jbc.M413731200; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; VANDEPUTTE C, 1994, CELL BIOL TOXICOL, V10, P415, DOI 10.1007/BF00755791; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; YU W, 1994, J BIOL CHEM, V269, P21010; Yuan DS, 2000, GENETICS, V156, P45; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	53	58	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2184	2195		10.1074/jbc.M606639200	http://dx.doi.org/10.1074/jbc.M606639200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121842	hybrid			2022-12-27	WOS:000243593200009
J	Khaire, N; Muller, R; Blau-Wasser, R; Eichinger, L; Schleicher, M; Rief, M; Holak, TA; Noegel, AA				Khaire, Nandkumar; Mueller, Rolf; Blau-Wasser, Rosemarie; Eichinger, Ludwig; Schleicher, Michael; Rief, Matthias; Holak, Tad A.; Noegel, Angelika A.			Filamin-regulated F-actin assembly is essential for morphogenesis and controls phototaxis in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MOVEMENT; STRUCTURAL BASIS; PROTEIN; MIGRATION; ABP-120; TRANSDUCTION; CHEMOTAXIS; MUTATIONS; MOTILITY; LACKING	Dictyostelium strains lacking the F-actin cross-linking protein filamin (ddFLN) have a severe phototaxis defect at the multicellular slug stage. Filamins are rod-shaped homodimers that cross-link the actin cytoskeleton into highly viscous, orthogonal networks. Each monomer chain of filamin is comprised of an F-actin-binding domain and a rod domain. In rescue experiments only intact filamin re-established correct phototaxis in filamin minus mutants, whereas C-terminally truncated filamin proteins that had lost the dimerization domain and molecules lacking internal repeats but retaining the dimerization domain did not rescue the phototaxis defect. Deletion of individual rod repeats also changed their subcellular localization, and mutant filamins in general were less enriched at the cell cortex as compared with the full-length protein and were increasingly present in the cytoplasm. For correct phototaxis ddFLN is only required at the tip of the slug because expression under control of the cell type-specific extracellular-matrix protein A (ecmA) promoter and mixing experiments with wild type cells supported phototactic orientation. Likewise, in chimeric slugs wild type cells were primarily found at the tip of the slug, which acts as an organizer in Dictyostelium morphogenesis.	Univ Cologne, Fac Med, Inst Biochem 1, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Zentrum Mol Med Koln, D-50931 Cologne, Germany; Univ Munich, Inst Zellbiol, D-80336 Munich, Germany; Tech Univ Munich, Phys Dept E22, D-85747 Garching, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Cologne; University of Cologne; University of Munich; Technical University of Munich; Max Planck Society	Noegel, AA (corresponding author), Univ Cologne, Fac Med, Inst Biochem 1, Ctr Biochem, Stelzmann Str 52, D-50931 Cologne, Germany.	noegel@uni-koeln.de	Eichinger, Ludwig/AAJ-8895-2021	Eichinger, Ludwig/0000-0003-1594-6117				BRINK M, 1990, J CELL BIOL, V111, P1477, DOI 10.1083/jcb.111.4.1477; Chisholm RL, 2004, NAT REV MOL CELL BIO, V5, P531, DOI 10.1038/nrm1427; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; COX D, 1995, J CELL BIOL, V128, P819, DOI 10.1083/jcb.128.5.819; DARCY PK, 1994, MICROBIOL-UK, V140, P1619, DOI 10.1099/13500872-140-7-1619; Dormann D, 1996, DEVELOPMENT, V122, P761; Dormann D, 2001, DEVELOPMENT, V128, P4535; EARLY AE, 1993, DEVELOPMENT, V118, P353; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Eichinger L, 1996, BIOPHYS J, V70, P1054, DOI 10.1016/S0006-3495(96)79651-0; Escalante R, 1997, MOL BIOL CELL, V8, P1763, DOI 10.1091/mbc.8.9.1763; ESCALANTE R, 1995, DEV BIOL, V171, P262, DOI 10.1006/dbio.1995.1278; Feng YY, 2004, NAT CELL BIOL, V6, P1034, DOI 10.1038/ncb1104-1034; Fisher P.R., 1984, Modern Cell Biology, V3, P197; Fisher PR, 1997, CURR BIOL, V7, P889, DOI 10.1016/S0960-9822(06)00379-4; Fisher PR, 1997, BIOESSAYS, V19, P397, DOI 10.1002/bies.950190507; Fucini P, 1997, NAT STRUCT BIOL, V4, P223, DOI 10.1038/nsb0397-223; Fucini P, 1999, J MOL BIOL, V291, P1017, DOI 10.1006/jmbi.1999.3046; Furuike S, 2001, FEBS LETT, V498, P72, DOI 10.1016/S0014-5793(01)02497-8; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; Gloss A, 2003, MOL BIOL CELL, V14, P2716, DOI 10.1091/mbc.E02-12-0827; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Graf R, 2000, J CELL SCI, V113, P1747; HARTWIG JH, 1994, PROTEIN PROFILE, V1, P711; Krakow D, 2004, NAT GENET, V36, P405, DOI 10.1038/ng1319; Li GC, 2001, DEVELOPMENT, V128, P3473; Maeda Y., 1997, DICTYOSTELIUM MODEL; McCoy AJ, 1999, NAT STRUCT BIOL, V6, P836; Noegel AA, 2004, MOL BIOL CELL, V15, P934, DOI 10.1091/mbc.E03-05-0269; NOEGEL AA, 1989, J CELL BIOL, V109, P607, DOI 10.1083/jcb.109.2.607; Pang KM, 1998, CURR BIOL, V8, P405, DOI 10.1016/S0960-9822(98)70159-9; POFF KL, 1973, EXP CELL RES, V82, P236, DOI 10.1016/0014-4827(73)90266-8; Pudas R, 2005, STRUCTURE, V13, P111, DOI 10.1016/j.str.2004.10.014; Robertson SP, 2003, NAT GENET, V33, P487, DOI 10.1038/ng1119; Robertson SP, 2005, CURR OPIN GENET DEV, V15, P301, DOI 10.1016/j.gde.2005.04.001; SCHAGGER H, 1994, PRACTICAL GUIDE MEMB, P84; Schwaiger I, 2005, EMBO REP, V6, P46, DOI 10.1038/sj.embor.7400317; Schwaiger I, 2004, NAT STRUCT MOL BIOL, V11, P81, DOI 10.1038/nsmb705; SIMPSON PA, 1984, J CELL BIOL, V99, P287, DOI 10.1083/jcb.99.1.287; Sokol NS, 2003, DEV BIOL, V260, P260, DOI 10.1016/S0012-1606(03)00248-3; Stocker S, 1999, MOL BIOL CELL, V10, P161, DOI 10.1091/mbc.10.1.161; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Wallraff E, 1997, J EXP BIOL, V200, P3213; Weening KE, 2003, DEV BIOL, V255, P373, DOI 10.1016/S0012-1606(02)00077-5; Weijer CJ, 2004, CURR OPIN GENET DEV, V14, P392, DOI 10.1016/j.gde.2004.06.006; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; Wilkins A, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r68; Wilkins A, 2000, GENE DEV, V14, P1407; WILLIAMS KL, 1976, GENETICS, V82, P287; WU L, 1995, DEV BIOL, V171, P149, DOI 10.1006/dbio.1995.1267; YAMAZXAKI M, 2003, J MUSC RES, V23, P525	51	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1948	1955		10.1074/jbc.M610262200	http://dx.doi.org/10.1074/jbc.M610262200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17121815	hybrid			2022-12-27	WOS:000243451300045
J	Olferiev, M; Masuda, E; Tanaka, S; Blank, MC; Pricop, L				Olferiev, Mikhail; Masuda, Emi; Tanaka, Shizuko; Blank, Marissa C.; Pricop, Luminita			The role of activating protein 1 in the transcriptional regulation of the human FCGR2B promoter mediated by the -343 G -> C polymorphism associated with systemic lupus erythematosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RIIB; ALTERS RECEPTOR EXPRESSION; CELL-LINE; B-CELLS; RHEUMATOID-ARTHRITIS; IIIB POLYMORPHISMS; AUTOIMMUNE-DISEASE; HUMAN MONOCYTES; FACTOR YY1; GENE	The inhibitory receptor Fc gamma RIIb is a negative regulator of antibody production and inflammatory responses. The -343 G -> C polymorphism in the human FCGR2B promoter is associated with systemic lupus erythematosus. The -343 C mutant promoter has decreased transcriptional activity. In the present study, we show that the transcriptional change correlates with quantitative differences in the interaction of the activating protein 1 complex with the mutant FCGR2B promoter. Promoter pulldown and chromatin immunoprecipitation assays demonstrated binding of c-Jun to the FCGR2B promoter. Phosphorylation of c-Jun was accompanied by transactivation of both FCGR2B promoter variants, whereas dephosphorylation of c-Jun by an inhibitor of c-Jun N-terminal kinase, markedly decreased the promoter activities. The -343 G -> C substitution enabled the specific interaction of the transcription factor Yin-Yang 1 with the mutant FCGR2B promoter. Yin-Yang 1 competed with activating protein 1 for binding at the -343 site, and contributed to the repression of the mutant FCGR2B promoter activity. This mechanism could be responsible for the decreased expression of Fc gamma RIIb associated with the -343 C/C homozygous FCGR2B genotype in lupus patients. These findings provide a rationale for the transcriptional defect mediated by the -343 C/C FCGR2B promoter polymorphism associated with systemic lupus erythematosus, and add to our understanding of the complex transcriptional regulation of the human FCGR2B promoter.	Hosp Special Surg, Div Res, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Rheumatol, New York, NY 10021 USA; Weill Grad Sch Med Sci, Program Immunol, New York, NY 10021 USA	Cornell University; Cornell University	Pricop, L (corresponding author), Hosp Special Surg, Div Res, 535 E 70th St, New York, NY 10021 USA.	pricopl@hss.edu	Olferiev, Mikhail/L-5213-2019		NCRR NIH HHS [C06-RR12538-01] Funding Source: Medline; NIAMS NIH HHS [AR49765] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR012538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049765] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Belostocki K, 2005, CLIN IMMUNOL, V117, P78, DOI 10.1016/j.clim.2005.07.001; Blank MC, 2005, HUM GENET, V117, P220, DOI 10.1007/s00439-005-1302-3; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bolland S, 2002, J EXP MED, V195, P1167, DOI 10.1084/jem.20020165; Cameron AJM, 2002, IMMUNOL LETT, V83, P171, DOI 10.1016/S0165-2478(02)00118-9; Cerutti A, 1998, J IMMUNOL, V160, P2145; Chu ZT, 2004, TISSUE ANTIGENS, V63, P21, DOI 10.1111/j.1399-0039.2004.00142.x; ENGELHARDT W, 1990, MOL IMMUNOL, V27, P379, DOI 10.1016/0161-5890(90)90051-Z; Estienne V, 2002, FASEB J, V16, P1087, DOI 10.1096/fj.01-0998hyp; Floto RA, 2005, NAT MED, V11, P1056, DOI 10.1038/nm1288; Grammer AC, 2004, ARTHRITIS RES THER, V6, P28, DOI 10.1186/ar1155; Han ZN, 1999, J PHARMACOL EXP THER, V291, P124; Hayakawa J, 2004, MOL CELL, V16, P521, DOI 10.1016/j.molcel.2004.10.024; Holzberg D, 2003, J BIOL CHEM, V278, P40213, DOI 10.1074/jbc.M304058200; Jiang Y, 2000, IMMUNOGENETICS, V51, P429, DOI 10.1007/s002510050641; Kyogoku C, 2002, ARTHRITIS RHEUM, V46, P1242, DOI 10.1002/art.10257; Kyogoku C, 2002, GENES IMMUN, V3, P488, DOI 10.1038/sj.gene.6363921; Liu Y, 2005, J LEUKOCYTE BIOL, V77, P767, DOI 10.1189/jlb.0904532; Luan JJ, 1996, J IMMUNOL, V157, P4707; Mackay M, 2006, J EXP MED, V203, P2157, DOI 10.1084/jem.20051503; McGaha TL, 2005, SCIENCE, V307, P590, DOI 10.1126/science.1105160; NAMBU M, 1989, J IMMUNOL, V143, P4158; Nishimura T, 2001, INT IMMUNOL, V13, P1075, DOI 10.1093/intimm/13.8.1075; Pricop L, 2001, J IMMUNOL, V166, P531, DOI 10.4049/jimmunol.166.1.531; Pritchard NR, 2000, CURR BIOL, V10, P227, DOI 10.1016/S0960-9822(00)00344-4; Rudge EU, 2002, J EXP MED, V195, P1079, DOI 10.1084/jem.20011435; Schett G, 2000, ARTHRITIS RHEUM, V43, P2501, DOI 10.1002/1529-0131(200011)43:11<2501::AID-ANR18>3.0.CO;2-K; Setterblad N, 1997, IMMUNOGENETICS, V46, P318, DOI 10.1007/s002510050278; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Siriboonrit U, 2003, TISSUE ANTIGENS, V61, P374, DOI 10.1034/j.1399-0039.2003.00047.x; Stefanescu RN, 2004, J CLIN IMMUNOL, V24, P315, DOI 10.1023/B:JOCI.0000029105.47772.04; Su KH, 2004, J IMMUNOL, V172, P7192, DOI 10.4049/jimmunol.172.11.7192; Su KH, 2004, J IMMUNOL, V172, P7186, DOI 10.4049/jimmunol.172.11.7186; Yao YL, 1998, NUCLEIC ACIDS RES, V26, P3776, DOI 10.1093/nar/26.16.3776; Ye JP, 1996, MOL CELL BIOL, V16, P4744	36	19	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1738	1746		10.1074/jbc.M605808200	http://dx.doi.org/10.1074/jbc.M605808200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17130130	hybrid			2022-12-27	WOS:000243451300025
J	Dago, AE; Wigneshweraraj, SR; Buck, M; Morett, E				Dago, Angel Ernesto; Wigneshweraraj, Siva R.; Buck, Martin; Morett, Enrique			A role for the conserved GAFTGA motif of AAA plus transcription activators in sensing promoter DNA conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEINS; BACTERIAL RNA-POLYMERASE; ESCHERICHIA-COLI; JAW DOMAIN; REGION I; SIGMA(54); COMPLEX; COMMUNICATION; ISOMERIZATION; SEQUENCES	Transcription from sigma(54)-dependent bacterial promoters can be regarded as a second paradigm for bacterial gene transcription. The initial sigma(54)-RNA polymerase (RNAP)center dot promoter complex, the closed complex, is transcriptionally silent. The transcriptionally proficient sigma(54)-RNAP center dot promoter complex, the open complex, is formed upon remodeling of the closed complex by actions of a specialized activator protein that belongs to the AAA ((A) under bar TPases (a) under bar ssociated with various cellular (a) under bar ctivities) protein family in an ATP hydrolysis-dependent reaction. The integrity of a highly conserved signature motif in the AAA activator (known as the GAFTGA motif) is important for the remodeling activity of the AAA activator and for open complex formation. We now provide evidence that the invariant threonine residue of the GAFTGA motif plays a role in sensing the DNA downstream of the sigma(54)-RNAP-binding site and in coupling this information to sigma(54)-RNAP via the conserved regulatory Region I domain of sigma(54) during open complex formation.	Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Ingn Celular & Biocatalisis, Cuernavaca 62210, Morelos, Mexico; Univ London Imperial Coll Sci Technol & Med, Fac Life Sci, Div Biol, London SW7 2AZ, England	Universidad Nacional Autonoma de Mexico; Imperial College London	Buck, M (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Ingn Celular & Biocatalisis, AP 510-3, Cuernavaca 62210, Morelos, Mexico.	m.buck@imperial.ac.uk; emorett@ibt.unam.mx	Morett, Enrique/G-3401-2013	Wigneshweraraj, Sivaramesh/0000-0002-1418-4029; Morett, Enrique/0000-0001-5723-0032	Biotechnology and Biological Sciences Research Council [BBS/B/03351] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Bordes P, 2004, MOL MICROBIOL, V54, P489, DOI 10.1111/j.1365-2958.2004.04280.x; Burrows PC, 2004, EMBO J, V23, P4253, DOI 10.1038/sj.emboj.7600406; Cannon W, 2003, J BIOL CHEM, V278, P19815, DOI 10.1074/jbc.M301296200; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Casaz P, 1997, P NATL ACAD SCI USA, V94, P12145, DOI 10.1073/pnas.94.22.12145; Casaz P, 1999, J MOL BIOL, V285, P507, DOI 10.1006/jmbi.1998.2328; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; De Carlo S, 2006, GENE DEV, V20, P1485, DOI 10.1101/gad.1418306; Gallegos MT, 1999, J BIOL CHEM, V274, P25285, DOI 10.1074/jbc.274.36.25285; Gaytan P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf083; Gonzalez V, 1998, MOL MICROBIOL, V28, P55, DOI 10.1046/j.1365-2958.1998.00772.x; Grande RA, 1999, J MOL BIOL, V294, P291, DOI 10.1006/jmbi.1999.3232; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; Jovanovic G, 1999, J MOL BIOL, V285, P469, DOI 10.1006/jmbi.1998.2263; Rappas M, 2005, SCIENCE, V307, P1972, DOI 10.1126/science.1105932; Schumacher J, 2006, J STRUCT BIOL, V156, P190, DOI 10.1016/j.jsb.2006.01.006; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; Wigneshweplaraj SR, 2005, PROG NUCLEIC ACID RE, V79, P339, DOI 10.1016/S0079-6603(04)79007-8; Wigneshweraraj SR, 2006, J MOL BIOL, V359, P1182, DOI 10.1016/j.jmb.2006.04.063; Wigneshweraraj SR, 2000, EMBO J, V19, P3038, DOI 10.1093/emboj/19.12.3038; Wigneshweraraj SR, 2005, J BIOL CHEM, V280, P36176, DOI 10.1074/jbc.M506416200; Wigneshweraraj SR, 2004, EMBO J, V23, P4264, DOI 10.1038/sj.emboj.7600407; Wigneshweraraj SR, 2003, METHOD ENZYMOL, V370, P646; Wigneshweraraj SR, 2001, J MOL BIOL, V306, P681, DOI 10.1006/jmbi.2000.4393; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	27	18	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1087	1097		10.1074/jbc.M608715200	http://dx.doi.org/10.1074/jbc.M608715200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17090527	hybrid			2022-12-27	WOS:000243295200033
J	Yu, Y; Fan, JJ; Hui, YQ; Rouzer, CA; Marnett, LJ; Klein-Szanto, AJ; FitzGerald, GA; Funk, CD				Yu, Ying; Fan, Jinjin; Hui, Yiqun; Rouzer, Carol A.; Marnett, Lawrence J.; Klein-Szanto, Andres J.; FitzGerald, Garret A.; Funk, Colin D.			Targeted cyclooxygenase gene (Ptgs) exchange reveals discriminant isoform functionality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE-H SYNTHASE-1; ARACHIDONIC-ACID; INFLAMMATORY RESPONSE; SELECTIVE-INHIBITION; MOLECULAR-BIOLOGY; MICE; PROSTACYCLIN; MOUSE; COX-2; DISRUPTION	The prostaglandin G/H synthase enzymes, commonly termed COX-1 and COX-2, differ markedly in their responses to regulatory stimuli and their tissue expression patterns. COX-1 is the dominant source of "housekeeping" prostaglandins, whereas COX-2 synthesizes prostaglandins of relevance to pain, inflammation, and mitogenesis. Despite these distinctions, the two enzymes are remarkably conserved, and their subcellular distributions overlap considerably. To address the functional interchangeability of the two isozymes, mice in which COX-1 is expressed under COX-2 regulatory elements were created by a gene targeting "knock- in" strategy. In macrophages from these mice, COX-1 was shown to be lipopolysaccharide- inducible in a manner analogous to COX-2 in wild-type macrophages. However, COX- 1 failed to substitute effectively for COX-2 in lipopolysaccharide-induced prostaglandin E-2 synthesis at low concentrations of substrate and in the metabolism of the endocannabinoid 2-arachidonylglycerol. The marked depression of the major urinary metabolite of prostacyclin in COX-2 null mice was only partially rescued by COX-1 knock-in, whereas the main urinary metabolite of prostaglandin E-2 was rescued totally. Replacement with COX-1 partially rescued the impact of COX-2 deletion on reproductive function. The renal pathology consequent to COX- 2 deletion was delayed but not prevented, whereas the corresponding peritonitis was unaltered. Insertion of COX-1 under the regulatory sequences that drive COX-2 expression indicated that COX-1 can substitute for some COX-2 actions and rescue only some of the consequences of gene disruption. Manipulation of COX-2 also revealed a preference for coupling with distinct downstream prostaglandin synthases in vivo. These mice will provide a valuable reagent with which to elucidate the distinct roles of the COX enzymes in mammalian biology.	Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA; Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA	Queens University - Canada; Queens University - Canada; University of Pennsylvania; Pennsylvania Medicine; Vanderbilt University; Fox Chase Cancer Center	Funk, CD (corresponding author), Queens Univ, Dept Physiol, Botterell Hall,Rm 433, Kingston, ON K7L 3N6, Canada.	funkc@post.queensu.ca	FitzGerald, Garret A/A-4222-2010; Funk, Colin D/A-9518-2010	yu, ying/0000-0002-6476-1752; Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431, R01GM063130] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62250] Funding Source: Medline; NIGMS NIH HHS [GM063130, GM15431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; CATELLA F, 1987, THROMB RES, V47, P647, DOI 10.1016/0049-3848(87)90103-4; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540; Chulada PC, 1996, ARCH BIOCHEM BIOPHYS, V330, P301, DOI 10.1006/abbi.1996.0257; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Gross GA, 1998, P NATL ACAD SCI USA, V95, P11875, DOI 10.1073/pnas.95.20.11875; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Huang JC, 2004, HUM REPROD, V19, P2907, DOI 10.1093/humrep/deh520; Huang JC, 2004, HUM REPROD, V19, P2900, DOI 10.1093/humrep/deh524; Huang JC, 2004, HUM REPROD, V19, P1856, DOI 10.1093/humrep/deh352; Juranek I, 1999, BBA-MOL CELL BIOL L, V1436, P509, DOI 10.1016/S0005-2760(98)00159-3; Kawada N, 2005, HYPERTENSION, V45, P1131, DOI 10.1161/01.HYP.0000166141.69081.80; Kozak KR, 2004, CURR PHARM DESIGN, V10, P659, DOI 10.2174/1381612043453081; Kulmacz RJ, 1998, FEBS LETT, V430, P154, DOI 10.1016/S0014-5793(98)00657-7; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Loftin CD, 2001, P NATL ACAD SCI USA, V98, P1059, DOI 10.1073/pnas.031573498; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; MONCADA S, 1977, THROMB RES, V11, P323, DOI 10.1016/0049-3848(77)90185-2; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; Reese J, 2001, ENDOCRINOLOGY, V142, P3198, DOI 10.1210/en.142.7.3198; Reuter BK, 1996, J CLIN INVEST, V98, P2076, DOI 10.1172/JCI119013; Rouzer CA, 2005, J BIOL CHEM, V280, P26690, DOI 10.1074/jbc.M501021200; Schmassmann A, 1998, BRIT J PHARMACOL, V123, P795, DOI 10.1038/sj.bjp.0701672; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; Sigthorsson G, 2002, GASTROENTEROLOGY, V122, P1913, DOI 10.1053/gast.2002.33647; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Swinney DC, 1997, J BIOL CHEM, V272, P12393, DOI 10.1074/jbc.272.19.12393; Takeda H, 2003, CANCER RES, V63, P4872; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tiano HF, 2002, CANCER RES, V62, P3395; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wang HB, 2004, J BIOL CHEM, V279, P10649, DOI 10.1074/jbc.M312203200; Wu KK, 2005, BIOCHEM BIOPH RES CO, V338, P45, DOI 10.1016/j.bbrc.2005.08.021; Yokoyama C, 2002, CIRCULATION, V106, P2397, DOI 10.1161/01.CIR.0000034733.93020.BC; Yu Y, 2005, J CLIN INVEST, V115, P986, DOI 10.1172/JCI23683; Yu Y, 2006, NAT MED, V12, P699, DOI 10.1038/nm1412	49	41	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1498	1506		10.1074/jbc.M609930200	http://dx.doi.org/10.1074/jbc.M609930200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17110378	hybrid			2022-12-27	WOS:000243295200074
J	Buteau, J; Shlien, A; Foisy, S; Accili, D				Buteau, Jean; Shlien, Adam; Foisy, Sylvain; Accili, Domenico			Metabolic diapause in pancreatic beta-cells expressing a gain-of-function mutant of the forkhead protein Foxo1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PREMATURE SENESCENCE; TYPE-2 DIABETES-MELLITUS; INSULIN-SECRETION; GLUCOSE-CONCENTRATIONS; GTP-CYCLOHYDROLASE; ABNORMAL PATTERNS; HUMAN ISLETS; LIFE-SPAN; GLICLAZIDE; APOPTOSIS	Diabetes is associated with decreased pancreatic beta-cell function and mass. It is unclear whether diabetes treatment should aim at restoring beta-cell performance/mass or at inducing "beta-cell rest" to prevent further deterioration. The transcription factor Foxo1 protects beta-cells against oxidative stress induced by hyperglycemia and prevents beta-cell replication in insulin-resistant states. Here we show that these combined effects are associated with a concerted repression of genes involved in glycolysis, nitric-oxide synthesis, G protein-coupled receptor signaling, and ion transport. Conversely, Foxo1 increases expression of several neurotransmitter receptors and fails to regulate target genes predicted from Caenorhabditis elegans and Drosophila studies. Functional analyses show decreased glucose utilization and insulin secretion in beta-cells overexpressing Foxo1. We propose the definition of "metabolic diapause" for the changes induced by Foxo1 to protect beta-cells against oxidative stress. The data provide genetic underpinning for the concept of beta-cell rest as a treatment goal in diabetes.	Columbia Univ, Med Ctr, Berrie Diabet Ctr, Dept Med, New York, NY 10032 USA; Diploide Net, Montreal, PQ H4E 2W9, Canada	Columbia University	Accili, D (corresponding author), Berrie Res Pavil 1150 St Nicholas Ave, New York, NY 10032 USA.	da230@columbia.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064819] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK64819] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 2004, DIABETES, V53, P1633, DOI 10.2337/diabetes.53.7.1633; Alp NJ, 2003, J CLIN INVEST, V112, P725, DOI 10.1172/JCI200317786; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Baggio LL, 2006, ANNU REV MED, V57, P265, DOI 10.1146/annurev.med.57.110104.115624; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Buteau J, 2006, DIABETES, V55, P1190, DOI 10.2337/db05-0825; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; CORBETT JA, 1993, AUTOIMMUNITY, V15, P145, DOI 10.3109/08916939309043889; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; De Luca M, 2003, NAT GENET, V34, P429, DOI 10.1038/ng1218; De Luca M, 2001, EXP GERONTOL, V36, P1663, DOI 10.1016/S0531-5565(01)00146-2; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Dong H, 2006, DIABETOLOGIA, V49, P697, DOI 10.1007/s00125-005-0123-1; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004; Ferrannini E, 1998, ENDOCR REV, V19, P477, DOI 10.1210/edrv.19.4.0336; Grill V, 2001, DIABETES, V50, pS122, DOI 10.2337/diabetes.50.2007.S122; Hansen JB, 2004, CURR MED CHEM, V11, P1595, DOI 10.2174/0929867043365026; HAVRANKOVA J, 1978, NATURE, V272, P827, DOI 10.1038/272827a0; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Hollingdal M, 2005, DIABETIC MED, V22, P1408, DOI 10.1111/j.1464-5491.2005.01652.x; HORVATH TL, 2006, INT J OBES LOND S1, V30, P30; HOSKER JP, 1989, METABOLISM, V38, P767, DOI 10.1016/0026-0495(89)90064-4; Hui HX, 2003, ENDOCRINOLOGY, V144, P1444, DOI 10.1210/en.2002-220897; Juhl CB, 2001, DIABETES, V50, P1778, DOI 10.2337/diabetes.50.8.1778; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kitamura T, 2006, NAT MED, V12, P534, DOI 10.1038/nm1392; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; LANG DA, 1981, DIABETES, V30, P435, DOI 10.2337/diabetes.30.5.435; Lauro D, 1998, NAT GENET, V20, P294, DOI 10.1038/3112; LEAHY JL, 1994, DIABETES, V43, P173, DOI 10.2337/diabetes.43.2.173; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Levy J, 1998, DIABETIC MED, V15, P290, DOI 10.1002/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M; Martinez SC, 2006, DIABETES, V55, P1581, DOI 10.2337/db05-0678; Matthews DR, 1997, METABOLISM, V46, P5, DOI 10.1016/S0026-0495(97)90309-7; McElwee JJ, 2006, MECH AGEING DEV, V127, P458, DOI 10.1016/j.mad.2006.01.006; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Naka K, 2004, J BIOL CHEM, V279, P2030, DOI 10.1074/jbc.M309457200; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Okamoto H, 2004, J CLIN INVEST, V114, P214, DOI 10.1172/JCI200421645; Okamoto H, 2006, J CLIN INVEST, V116, P775, DOI 10.1172/JCI24967; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; POLONSKY KS, 1988, NEW ENGL J MED, V318, P1231, DOI 10.1056/NEJM198805123181903; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Ritzel RA, 2004, J CLIN ENDOCR METAB, V89, P795, DOI 10.1210/jc.2003-031120; Roche E, 1998, DIABETES, V47, P1086, DOI 10.2337/diabetes.47.7.1086; Schuit F, 2002, DIABETES, V51, pS326, DOI 10.2337/diabetes.51.2007.S326; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SHAPIRO ET, 1989, J CLIN ENDOCR METAB, V69, P571, DOI 10.1210/jcem-69-3-571; Sheng GQ, 2006, NAT MED, V12, P526, DOI 10.1038/nm1382; Stickings P, 2002, NITRIC OXIDE-BIOL CH, V7, P289, DOI 10.1016/S1089-8603(02)00122-2; Toussaint O, 2002, BIOCHEM PHARMACOL, V64, P1007, DOI 10.1016/S0006-2952(02)01170-X; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; VIVEROS OH, 1981, SCIENCE, V213, P349, DOI 10.1126/science.7017928; Weir GC, 2004, DIABETES, V53, pS16, DOI 10.2337/diabetes.53.suppl_3.S16; Wrede CE, 2002, J BIOL CHEM, V277, P49676, DOI 10.1074/jbc.M208756200; Yoshikawa H, 2004, AM J PHYSIOL-ENDOC M, V287, pE1202, DOI 10.1152/ajpendo.00255.2004; Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200	63	79	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					287	293		10.1074/jbc.M606118200	http://dx.doi.org/10.1074/jbc.M606118200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17107961	hybrid			2022-12-27	WOS:000243166500033
J	Nelson, SW; Benkovic, SJ				Nelson, Scott W.; Benkovic, Stephen J.			The T4 phage UvsW protein contains both DNA unwinding and strand annealing activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FORK; SRS2 HELICASE; BREAK REPAIR; BACTERIOPHAGE-T4; RECOMBINATION; BINDING; MECHANISM; SUBSTRATE; ALLELES; GENE	UvsW protein belongs to the SF2 helicase family and is one of three helicases found in T4 phage. UvsW governs the transition from origin-dependent to origin-independent replication through the dissociation of R-loops located at the T4 origins of replication. Additionally, in vivo evidence indicates that UvsW plays a role in recombination-dependent replication and/or DNA repair. Here, the biochemical properties of UvsW helicase are described. UvsW is a 3' to 5' helicase that unwinds a wide variety of substrates, including those resembling stalled replication forks and recombination intermediates. UvsW also contains a potent single-strand DNA annealing activity that is enhanced by ATP hydrolysis but does not require it. The annealing activity is inhibited by the non-hydrolysable ATP analog (adenosine 5'-O-(thiotriphosphate)), T4 single-stranded DNA-binding protein (gp32), or a small 8.8-kDa polypeptide (UvsW.1). Fluorescence resonance energy transfer experiments indicate that UvsW and UvsW. I form a complex, suggesting that the UvsW helicase may exist as a heterodimer in vivo. Fusion of UvsW and UvsW.1 results in a 68-kDa protein having nearly identical properties as the UvsW-UvsW.1 complex, indicating that the binding locus of UvsW.1 is close to the C terminus of UvsW. The biochemical properties of UvsW are similar to the RecQ protein family and suggest that the annealing activity of these helicases may also be modulated by protein-protein interactions. The dual activities of UvsW are well suited for the DNA repair pathways described for leading strand lesion bypass and synthesis-dependent strand annealing.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.	sjb1@psu.edu			NIGMS NIH HHS [GM13306] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; Bachrati CZ, 2006, METHOD ENZYMOL, V409, P86, DOI 10.1016/S0076-6879(05)09005-1; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Bennett RJ, 2004, CRIT REV BIOCHEM MOL, V39, P79, DOI 10.1080/10409230490460756; CarlesKinch K, 1997, EMBO J, V16, P4142, DOI 10.1093/emboj/16.13.4142; Cheok CF, 2005, NUCLEIC ACIDS RES, V33, P3932, DOI 10.1093/nar/gki712; Chong SR, 1998, NUCLEIC ACIDS RES, V26, P5109, DOI 10.1093/nar/26.22.5109; CONKLING MA, 1984, GENETICS, V107, P505; de Jager M, 2001, NUCLEIC ACIDS RES, V29, P1317, DOI 10.1093/nar/29.6.1317; DERR LK, 1990, MOL GEN GENET, V222, P257, DOI 10.1007/BF00633826; DERR LK, 1990, J MOL BIOL, V214, P643, DOI 10.1016/0022-2836(90)90283-R; Dudas KC, 2001, MOL CELL BIOL, V21, P2706, DOI 10.1128/MCB.21.8.2706-2715.2001; Eoff RL, 2006, NAT STRUCT MOL BIOL, V13, P242, DOI 10.1038/nsmb1055; Garcia PL, 2004, EMBO J, V23, P2882, DOI 10.1038/sj.emboj.7600301; George JW, 1996, GENETICS, V143, P1507; HAMLETT NV, 1975, VIROLOGY, V63, P539, DOI 10.1016/0042-6822(75)90326-8; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; Kantake N, 2002, P NATL ACAD SCI USA, V99, P15327, DOI 10.1073/pnas.252633399; Kreuzer KN, 2005, ANNU REV MICROBIOL, V59, P43, DOI 10.1146/annurev.micro.59.030804.121255; Li N, 2002, MOL MICROBIOL, V43, P1079, DOI 10.1046/j.1365-2958.2002.02809.x; Machwe A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-1; Macris MA, 2005, BIOCHEM SOC T, V33, P1447, DOI 10.1042/BST0331447; Macris MA, 2006, DNA REPAIR, V5, P172, DOI 10.1016/j.dnarep.2005.09.005; McIlwraith MJ, 2001, NUCLEIC ACIDS RES, V29, P4509, DOI 10.1093/nar/29.22.4509; Miller ES, 2003, MICROBIOL MOL BIOL R, V67, P86, DOI 10.1128/MMBR.67.1.86-156.2003; MOSIG G, 1995, FEMS MICROBIOL REV, V17, P83, DOI 10.1111/j.1574-6976.1995.tb00190.x; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; RANEY KD, 1995, J BIOL CHEM, V270, P22236, DOI 10.1074/jbc.270.38.22236; Schrock RD, 1996, J BIOL CHEM, V271, P16678, DOI 10.1074/jbc.271.28.16678; Sharma S, 2005, J BIOL CHEM, V280, P28072, DOI 10.1074/jbc.M500264200; Sickmier EA, 2004, STRUCTURE, V12, P583, DOI 10.1016/j.str.2004.02.016; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Tuteja N, 2004, EUR J BIOCHEM, V271, P1849, DOI 10.1111/j.1432-1033.2004.04094.x; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WAKEM LP, 1984, VIROLOGY, V137, P338, DOI 10.1016/0042-6822(84)90226-5; Woodworth DL, 1996, GENETICS, V143, P1081; Yang JS, 2003, J BIOL CHEM, V278, P49828, DOI 10.1074/jbc.M307406200; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	40	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					407	416		10.1074/jbc.M608153200	http://dx.doi.org/10.1074/jbc.M608153200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17092935	hybrid			2022-12-27	WOS:000243166500046
J	Schalk-Hihi, C; Ma, HC; Struble, GT; Bayoumy, S; Williams, R; Devine, E; Petrounia, IP; Mezzasalma, T; Zeng, L; Schubert, C; Grasberger, B; Springer, BA; Deckman, IC				Schalk-Hihi, Celine; Ma, Hong-Chang; Struble, Geoffrey T.; Bayoumy, Shariff; Williams, Robyn; Devine, Eric; Petrounia, Ioanna P.; Mezzasalma, Tara; Zeng, Lee; Schubert, Carsten; Grasberger, Bruce; Springer, Barry A.; Deckman, Ingrid C.			Protein engineering of the colony-stimulating factor-1 receptor kinase domain for structural studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL TAIL; GROWTH-FACTOR; TYROSINE KINASE; CRYSTAL-STRUCTURE; CSF-1 RECEPTOR; CELL-PROLIFERATION; CARBOXYL-TERMINUS; INSULIN-RECEPTOR; V-FMS; PHOSPHATIDYLINOSITOL 3-KINASE	A parallel approach to designing crystallization constructs for the c-FMS kinase domain was implemented, resulting in proteins suitable for structural studies. Sequence alignment and limited proteolysis were used to identify and eliminate unstructured and surface-exposed domains. A small library of chimeras was prepared in which the kinase insert domain of FMS was replaced with the kinase insert domain of previously crystallized receptor-tyrosine kinases. Characterization of the newly generated FMS constructs by enzymology and thermoshift assays demonstrated similar activities and compound binding to the FMS full-length cytoplasmic domain. Two chimeras were evaluated for crystallization in the presence and absence of a variety of ligands resulting in crystal structures, and leading to a successful structure-based drug design project for this important inflammation target.	Johnson & Johnson Pharmaceut Res & Dev LLC, Struct Biol, Exton, PA 19341 USA	Johnson & Johnson; Johnson & Johnson USA	Schalk-Hihi, C (corresponding author), Johnson & Johnson Pharmaceut Res & Dev LLC, Struct Biol, 665 Stockton Dr, Exton, PA 19341 USA.	cschalkh@prdus.jnj.com						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING PJ, 1986, P NATL ACAD SCI USA, V83, P7800, DOI 10.1073/pnas.83.20.7800; Bucher MH, 2002, ACTA CRYSTALLOGR D, V58, P392, DOI 10.1107/S0907444901021187; Campbell IK, 2000, J LEUKOCYTE BIOL, V68, P144; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Dhawan J, 1996, SOMAT CELL MOLEC GEN, V22, P363, DOI 10.1007/BF02369893; Foehr ED, 2001, J BIOL CHEM, V276, P37529, DOI 10.1074/jbc.M103234200; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Hsu PY, 2003, ARCH BIOCHEM BIOPHYS, V416, P38, DOI 10.1016/S0003-9861(03)00287-X; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jahn T, 2002, ONCOGENE, V21, P4508, DOI 10.1038/sj.onc.1205559; Kapust RB, 2002, BIOCHEM BIOPH RES CO, V294, P949, DOI 10.1016/S0006-291X(02)00574-0; Kirma N, 2004, CANCER RES, V64, P4162, DOI 10.1158/0008-5472.CAN-03-2971; LI W, 1991, CELL REGUL, V2, P641, DOI 10.1091/mbc.2.8.641; Liu KJ, 2004, INT J ONCOL, V24, P581; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Marron MB, 2000, J BIOL CHEM, V275, P39741, DOI 10.1074/jbc.M007189200; Matulis D, 2005, BIOCHEMISTRY-US, V44, P5258, DOI 10.1021/bi048135v; McGlynn H, 1998, LEUKEMIA RES, V22, P365, DOI 10.1016/S0145-2126(98)00006-X; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; Meyer RD, 2004, ONCOGENE, V23, P5523, DOI 10.1038/sj.onc.1207712; Meyer RD, 2004, J BIOL CHEM, V279, P735, DOI 10.1074/jbc.M305575200; MEZZASALMA TM, 2007, IN PRESS J BIOMOL SC; Mitrasinovic OM, 2001, J BIOL CHEM, V276, P30142, DOI 10.1074/jbc.M104265200; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Munshi S, 2003, ACTA CRYSTALLOGR D, V59, P1725, DOI 10.1107/S0907444903015415; Munshi S, 2002, J BIOL CHEM, V277, P38797, DOI 10.1074/jbc.M205580200; Murphy GM, 2000, AM J PATHOL, V157, P895, DOI 10.1016/S0002-9440(10)64603-2; Niu XL, 2002, J BIOL CHEM, V277, P31768, DOI 10.1074/jbc.M203995200; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; Piccinini G, 2002, J BIOL CHEM, V277, P22231, DOI 10.1074/jbc.M111145200; RAJAGOPALAN M, 1995, BIOCHEM BIOPH RES CO, V211, P714, DOI 10.1006/bbrc.1995.1871; Rajavashisth T, 1998, J CLIN INVEST, V101, P2702, DOI 10.1172/JCI119891; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; Schubert C, 2007, J BIOL CHEM, V282, P4094, DOI 10.1074/jbc.M608183200; SEEDORF K, 1992, MOL CELL BIOL, V12, P4347, DOI 10.1128/MCB.12.10.4347; SHERR CJ, 1988, J CELL BIOCHEM, V38, P179, DOI 10.1002/jcb.240380305; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Shirai T, 1999, J MOL BIOL, V287, P369, DOI 10.1006/jmbi.1999.2603; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Till JH, 2002, STRUCTURE, V10, P1187, DOI 10.1016/S0969-2126(02)00814-6; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; Wada T, 1997, KIDNEY INT, V52, P934, DOI 10.1038/ki.1997.415; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296	57	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4085	4093		10.1074/jbc.M608182200	http://dx.doi.org/10.1074/jbc.M608182200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17132625	hybrid			2022-12-27	WOS:000244481900072
J	Greenwald, J; Hoegy, F; Nader, M; Journet, L; Mislin, GLA; Graumann, PL; Schalk, IJ				Greenwald, Jason; Hoegy, Francoise; Nader, Mirella; Journet, Laure; Mislin, Gaeetan L. A.; Graumann, Peter L.; Schalk, Isabelle J.			Real time fluorescent resonance energy transfer visualization of ferric pyoverdine uptake in pseudomonas aeruginosa - A role for ferrous iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE RECEPTOR; FERRIPYOVERDINE RECEPTOR; ESCHERICHIA-COLI; SIDEROPHORE; FPVA; MECHANISM; TONB; TRANSPORT; IDENTIFICATION; OXIDOREDUCTASE	To acquire iron, Pseudomonas aeruginosa secretes a major fluorescent siderophore, pyoverdine (PvdI), that chelates iron and shuttles it into the cells via the specific outer membrane transporter, FpvAI. We took advantage of the fluorescence properties of PvdI and its metal chelates as well as the efficient FRET between donor tryptophans in FpvAI and PvdI to follow the fate of the siderophore during iron uptake. Our findings with PvdI-Ga and PvdI-Cr uptake indicate that iron reduction is required for the dissociation of PvdI-Fe, that a ligand exchange for iron occurs, and that this dissociation occurs in the periplasm. We also observed a delay between PvdI-Fe dissociation and the rebinding of PvdI to FpvAI, underlining the kinetic independence of metal release and siderophore recycling. Meanwhile, PvdI is not modified but recycled to the medium, still competent for iron chelation and transport. Finally, in vivo fluorescence microscopy revealed patches of PvdI, suggesting that uptake occurs via macromolecular assemblies on the cell surface.	Univ Strasbourg 1, ESBS, UMR 7175 LC1, Inst Gilbert Laustriat,CNRS, F-67413 Illkirch Graffenstaden, Strasbourg, France; Univ Freiburg, Inst Mikrobiol, D-79104 Freiburg, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Freiburg	Schalk, IJ (corresponding author), Univ Strasbourg 1, ESBS, UMR 7175 LC1, Inst Gilbert Laustriat,CNRS, Blvd Sebastien Brant,BP 10412, F-67413 Illkirch Graffenstaden, Strasbourg, France.	schalk@esbs.u-strasbg.fr		Graumann, Peter/0000-0002-8033-5171; Journet, Laure/0000-0002-5847-2962				ALBRECHTGARY AM, 1994, INORG CHEM, V33, P6391, DOI 10.1021/ic00104a059; ANKENBAUER R, 1986, J BACTERIOL, V167, P7, DOI 10.1128/jb.167.1.7-11.1986; Boukhalfa H, 2002, BIOMETALS, V15, P325, DOI 10.1023/A:1020218608266; Braun V, 2003, FRONT BIOSCI-LANDMRK, V8, pS1409, DOI 10.2741/1232; Buchanan SK, 1999, CURR OPIN STRUC BIOL, V9, P455, DOI 10.1016/S0959-440X(99)80064-5; Budzikiewicz H, 1997, Z NATURFORSCH C, V52, P713; Clement E, 2004, BIOCHEMISTRY-US, V43, P7954, DOI 10.1021/bi049768c; Cobessi D, 2005, J MOL BIOL, V352, P893, DOI 10.1016/j.jmb.2005.08.004; Cobessi D, 2005, J MOL BIOL, V347, P121, DOI 10.1016/j.jmb.2005.01.021; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; de Chial M, 2003, MICROBIOL-SGM, V149, P821, DOI 10.1099/mic.0.26136-0; DEAN CR, 1993, MOL MICROBIOL, V8, P1095, DOI 10.1111/j.1365-2958.1993.tb01654.x; DEMANGE P, 1990, BIOL MET, V3, P155; ECKER DJ, 1983, J BACTERIOL, V155, P616, DOI 10.1128/JB.155.2.616-622.1983; EMERY T, 1980, J NUCL MED, V21, P935; Ferguson AD, 1998, PROTEIN SCI, V7, P1636, DOI 10.1002/pro.5560070719; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Folschweiller N, 2002, BIOCHEMISTRY-US, V41, P14591, DOI 10.1021/bi0259711; Ghysels B, 2004, MICROBIOL-SGM, V150, P1671, DOI 10.1099/mic.0.27035-0; HALLE F, 1992, EUR J BIOCHEM, V209, P613, DOI 10.1111/j.1432-1033.1992.tb17327.x; HALLE F, 1992, EUR J BIOCHEM, V209, P621, DOI 10.1111/j.1432-1033.1992.tb17328.x; Koster W, 2001, RES MICROBIOL, V152, P291, DOI 10.1016/S0923-2508(01)01200-1; LANGMAN L, 1972, J BACTERIOL, V112, P1142, DOI 10.1128/JB.112.3.1142-1149.1972; LEONG J, 1976, J BACTERIOL, V126, P823, DOI 10.1128/JB.126.2.823-830.1976; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Mascarenhas J, 2002, EMBO J, V21, P3108, DOI 10.1093/emboj/cdf314; Matzanke BF, 2004, BIOCHEMISTRY-US, V43, P1386, DOI 10.1021/bi0357661; MATZANKE BF, 1997, IRON TRANPORT MICROB; Meyer JM, 2002, APPL ENVIRON MICROB, V68, P2745, DOI 10.1128/AEM.68.6.2745-2753.2002; Mielczarek E V, 1990, Biol Met, V3, P34, DOI 10.1007/BF01141175; Mies KA, 2006, BIOMETALS, V19, P115, DOI 10.1007/s10534-005-4342-1; Moeck GS, 1998, MOL MICROBIOL, V28, P675, DOI 10.1046/j.1365-2958.1998.00817.x; Poole K, 2003, FRONT BIOSCI-LANDMRK, V8, pD661, DOI 10.2741/1051; Poole K, 1996, MICROBIOL-UK, V142, P1449, DOI 10.1099/13500872-142-6-1449; POOLE K, 1993, J BACTERIOL, V175, P4597, DOI 10.1128/JB.175.15.4597-4604.1993; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; Ravel J, 2003, TRENDS MICROBIOL, V11, P195, DOI 10.1016/S0966-842X(03)00076-3; Royt P W, 1990, Biol Met, V3, P28, DOI 10.1007/BF01141174; SCHALK I, 2004, PSEUDOMONAS MOL BIOL, V4; Schalk IJ, 1999, BIOCHEMISTRY-US, V38, P9357, DOI 10.1021/bi990421x; Schalk IJ, 2004, MOL MICROBIOL, V54, P14, DOI 10.1111/j.1365-2958.2004.04241.x; Schalk IJ, 2002, BIOCHEMISTRY-US, V41, P1663, DOI 10.1021/bi0157767; Schalk IJ, 2001, MOL MICROBIOL, V39, P351, DOI 10.1046/j.1365-2958.2001.02207.x; Takase H, 2000, INFECT IMMUN, V68, P1834, DOI 10.1128/IAI.68.4.1834-1839.2000; Voulhoux R, 2006, J BACTERIOL, V188, P3317, DOI 10.1128/JB.188.9.3317-3323.2006; Yue WW, 2003, J MOL BIOL, V332, P353, DOI 10.1016/S0022-2836(03)00855-6	46	81	82	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					2987	2995		10.1074/jbc.M609238200	http://dx.doi.org/10.1074/jbc.M609238200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17148441	hybrid			2022-12-27	WOS:000243793900025
J	Valnickova, Z; Thogersen, IB; Potempa, J; Enghild, JJ				Valnickova, Zuzana; Thogersen, Ida B.; Potempa, Jan; Enghild, Jan J.			Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; PROCARBOXYPEPTIDASE-B; 3-DIMENSIONAL STRUCTURE; ENDOPLASMIC-RETICULUM; PROTEOLYTIC CLEAVAGE; PURIFICATION; PROTEIN; ASSAY; PLASMINOGEN; COAGULATION	Thrombin-activable fibrinolysis inhibitor ( TAFI) is a carboxypeptidase found in human plasma, presumably as an inactive zymogen. The current dogma is that proteolytic activation by thrombin/thrombomodulin generates the active enzyme (TAFIa), which down-regulates fibrinolysis by removing C-terminal lysine residues from partially degraded fibrin. In this study, we have shown that the zymogen exhibits continuous and stable carboxypeptidase activity against large peptide substrates, and we suggest that the activity down-regulates fibrinolysis in vivo.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Aarhus Univ, Ctr Insoluble Prot Struct, Dept Biol Mol, DK-8000 Aarhus C, Denmark; Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Microbiol, PL-30387 Krakow, Poland; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Aarhus University; Aarhus University; Jagiellonian University; University System of Georgia; University of Georgia	Enghild, JJ (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	jje@mb.au.dk	Potempa, Jan/AAA-6850-2021	Enghild, Jan Johannes/0000-0001-9292-9172	NIDCR NIH HHS [DE09761] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arolas JL, 2005, J BIOL CHEM, V280, P3441, DOI 10.1074/jbc.M411086200; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; Campbell W, 2001, IMMUNOL REV, V180, P162, DOI 10.1034/j.1600-065X.2001.1800114.x; CAMPBELL W, 1989, BIOCHEM BIOPH RES CO, V162, P933, DOI 10.1016/0006-291X(89)90762-6; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EATON DL, 1991, J BIOL CHEM, V266, P21833; ENGHILD JJ, 1993, BIOCHEM J, V291, P933, DOI 10.1042/bj2910933; FOLK JE, 1960, J BIOL CHEM, V235, P2272; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; HENDRIKS D, 1985, CLIN CHEM, V31, P1936; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; Kowarik M, 2002, MOL CELL, V10, P769, DOI 10.1016/S1097-2765(02)00685-8; LACKO AG, 1970, BIOCHEMISTRY-US, V9, P4680; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; Marx PF, 2004, CURR MED CHEM, V11, P2335, DOI 10.2174/0929867043364586; MOLINA MA, 1992, GENE, V116, P129, DOI 10.1016/0378-1119(92)90508-M; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; Pereira PJB, 2002, J MOL BIOL, V321, P537, DOI 10.1016/S0022-2836(02)00648-4; Petrescu AJ, 2004, GLYCOBIOLOGY, V14, P103, DOI 10.1093/glycob/cwh008; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; REECK GR, 1972, BIOCHEMISTRY-US, V11, P3947, DOI 10.1021/bi00771a018; Reverter D, 1997, FEBS LETT, V420, P7, DOI 10.1016/S0014-5793(97)01476-2; SAKODA M, 1976, J BIOCHEM-TOKYO, V80, P547, DOI 10.1093/oxfordjournals.jbchem.a131310; Stromqvist M, 2001, THROMB HAEMOSTASIS, V85, P12, DOI 10.1055/s-0037-1612656; Valnickova Z, 2006, BIOCHEMISTRY-US, V45, P1525, DOI 10.1021/bi051956v; Valnickova Z, 1998, J BIOL CHEM, V273, P27220, DOI 10.1074/jbc.273.42.27220; Valnickova Z, 1996, J BIOL CHEM, V271, P12937, DOI 10.1074/jbc.271.22.12937; Walker JB, 2003, J BIOL CHEM, V278, P8913, DOI 10.1074/jbc.M205006200; WANG W, 1994, J BIOL CHEM, V269, P15937	35	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3066	3076		10.1074/jbc.M606559200	http://dx.doi.org/10.1074/jbc.M606559200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17138567	hybrid			2022-12-27	WOS:000243793900033
J	Wesley, UV; Bove, PF; Hristova, M; McCarthy, S; van der Vliet, A				Wesley, Umadevi V.; Bove, Peter F.; Hristova, Milena; McCarthy, Sean; van der Vliet, Albert			Airway epithelial cell migration and wound repair by ATP-mediated activation of dual oxidase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; EXTRACELLULAR ATP; MUCIN SECRETION; REACTIVE OXYGEN; DIFFERENTIAL REGULATION; ERK ACTIVATION; P2Y RECEPTORS; NADPH OXIDASE; HOST-DEFENSE; IN-VITRO	The airway epithelium is continuously subjected to environmental pollutants, airborne pathogens, and allergens and relies on several intrinsic mechanisms to maintain barrier integrity and to promote epithelial repair processes following injury. Here, we report a critical role for dual oxidase 1 (Duox1), a newly identified NADPH oxidase homolog within the tracheobronchial epithelium, in airway epithelial cell migration and repair following injury. Activation of Duox1 during epithelial injury is mediated by cellular release of ATP, which signals through purinergic receptors expressed on the epithelial cell surface. Purinergic receptor stimulation by extracellular ATP is a critical determinant of epithelial cell migration and repair following injury and is associated with activation of extracellular signal-regulated kinases (ERK1/2) and matrix metalloproteinase-9 (MMP-9). Stimulation of these integral features of epithelial cell migration and repair processes was found to require the activation of Duox1. Our findings demonstrate a novel role for Duox1 in the tracheobronchial epithelium, in addition to its proposed role in antimicrobial host defense, by participating in epithelial repair processes to maintain epithelial integrity and barrier function in the face of environmental stress.	Univ Vermont, Dept Pathol, Burlington, VT 05405 USA; Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA	University of Vermont; University of Vermont	van der Vliet, A (corresponding author), Univ Vermont, Dept Pathol, D205 Given Bldg,89 Beaumont Ave, Burlington, VT 05405 USA.	Albert.van-der-Vliet@uvm.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074295, R01HL068865, R01HL085646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007122] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL074295, HL068865, R01 HL085646] Funding Source: Medline; NIEHS NIH HHS [T32ES07122] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmad S, 2005, FREE RADICAL BIO MED, V39, P213, DOI 10.1016/j.freeradbiomed.2005.03.009; BOVE PF, 2006, IN PRESS AM J RESP C; Chen Y, 2001, AM J RESP CELL MOL, V25, P409, DOI 10.1165/ajrcmb.25.4.4413; Conway JD, 2003, AM J PHYSIOL-LUNG C, V284, pL945, DOI 10.1152/ajplung.00410.2002; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; Dignass AU, 1998, EUR J CLIN INVEST, V28, P554; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Erjefalt JS, 1997, THORAX, V52, P1010, DOI 10.1136/thx.52.11.1010; Forteza R, 2005, AM J RESP CELL MOL, V32, P462, DOI 10.1165/rcmb.2004-0302OC; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; Grasberger H, 2006, J BIOL CHEM, V281, P18269, DOI 10.1074/jbc.C600095200; Gurjar MV, 2001, AM J PHYSIOL-HEART C, V281, pH2568, DOI 10.1152/ajpheart.2001.281.6.H2568; Ha EM, 2005, SCIENCE, V310, P847, DOI 10.1126/science.1117311; Harper RW, 2005, FEBS LETT, V579, P4911, DOI 10.1016/j.febslet.2005.08.002; Joseph SM, 2004, BRIT J PHARMACOL, V142, P1002, DOI 10.1038/sj.bjp.0705865; Klepeis VE, 2004, J CELL BIOCHEM, V93, P1115, DOI 10.1002/jcb.20258; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Legrand C, 1999, J CELL BIOL, V146, P517, DOI 10.1083/jcb.146.2.517; Li QA, 2006, MOL CELL BIOL, V26, P140, DOI 10.1128/MCB.26.1.140-154.2006; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Matsubayashi Y, 2004, CURR BIOL, V14, P731, DOI 10.1016/j.cub.2004.03.060; McNamara N, 2001, P NATL ACAD SCI USA, V98, P9086, DOI 10.1073/pnas.161290898; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Morand S, 2003, ENDOCRINOLOGY, V144, P1241, DOI 10.1210/en.2002-220981; Mukhin YV, 2004, J BIOL CHEM, V279, P1845, DOI 10.1074/jbc.M304907200; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Okada SF, 2006, J BIOL CHEM, V281, P22992, DOI 10.1074/jbc.M603019200; Okamoto T, 2002, AM J RESP CELL MOL, V27, P463, DOI 10.1165/rcmb.2002-0039OC; OToole EA, 1996, DERMATOL SURG, V22, P525, DOI 10.1111/j.1524-4725.1996.tb00368.x; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Pines A, 2005, NUCLEIC ACIDS RES, V33, P4379, DOI 10.1093/nar/gki751; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Schwarzer C, 2004, J BIOL CHEM, V279, P36454, DOI 10.1074/jbc.M404983200; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; Shao MXG, 2005, P NATL ACAD SCI USA, V102, P767, DOI 10.1073/pnas.0408932102; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Wesley UV, 2005, CANCER RES, V65, P1325, DOI 10.1158/0008-5472.CAN-04-1852; Wu RF, 2005, J CELL BIOL, V171, P893, DOI 10.1083/jcb.200507004; Yang LL, 2004, J CELL BIOCHEM, V91, P938, DOI 10.1002/jcb.10774; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	45	120	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2007	282	5					3213	3220		10.1074/jbc.M606533200	http://dx.doi.org/10.1074/jbc.M606533200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130IS	17135261	hybrid			2022-12-27	WOS:000243793900048
J	de Jong, RM; Bazzacco, P; Poelarends, GJ; Johnson, WH; Kim, YJ; Burks, EA; Serrano, H; Thunnissen, AMWH; Whitman, CP; Dijkstra, BW				de Jong, Rene M.; Bazzacco, Paola; Poelarends, Gerrit J.; Johnson, William H., Jr.; Kim, Yoon Jae; Burks, Elizabeth A.; Serrano, Hector; Thunnissen, Andy-Mark W. H.; Whitman, Christian P.; Dijkstra, Bauke W.			Crystal structures of native and inactivated cis-3-chloroacrylic acid dehalogenase - Structural basis for substrate specificity and inactivation by (R)-oxirane-2-carboxylate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONATE SEMIALDEHYDE DECARBOXYLASE; PROGRAM; MECHANISM; 1,3-DICHLOROPROPENE; DEGRADATION; ENZYMES; PRODUCE	The bacterial degradation pathways for the nematocide 1,3-dichloropropene rely on hydrolytic dehalogenation reactions catalyzed by cis- and trans-3-chloroacrylic acid dehalogenases (cis-CaaD and CaaD, respectively). X-ray crystal structures of native cis- CaaD and cis- CaaD inactivated by (R)-oxirane-2-carboxylate were elucidated. They locate four known catalytic residues (Pro-1, Arg-70, Arg-73, and Glu-114) and two previously unknown, potential catalytic residues (His-28 and Tyr-103'). The Y103F and H28A mutants of these latter two residues displayed reductions in cis- CaaD activity confirming their importance in catalysis. The structure of the inactivated enzyme shows covalent modification of the Pro-1 nitrogen atom by (R)-2-hydroxypropanoate at the C3 position. The interactions in the complex implicate Arg-70 or a water molecule bound to Arg-70 as the proton donor for the epoxide ring-opening reaction and Arg-73 and His-28 as primary binding contacts for the carboxylate group. This proposed binding mode places the (R)-enantiomer, but not the (S)-enantiomer, in position to covalently modify Pro-1. The absence of His-28 ( or an equivalent) in CaaD could account for the fact that CaaD is not inactivated by either enantiomer. The cis- CaaD structures support a mechanism in which Glu-114 and Tyr-103' activate a water molecule for addition to C3 of the substrate and His-28, Arg-70, and Arg-73 interact with the C1 carboxylate group to assist in substrate binding and polarization. Pro-1 provides a proton at C2. The involvement of His-28 and Tyr-103' distinguishes the cis- CaaD mechanism from the otherwise parallel CaaD mechanism. The two mechanisms probably evolved independently as the result of an early gene duplication of a common ancestor.	Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biochem, NL-9747 AG Groningen, Netherlands	University of Texas System; University of Texas Austin; University of Groningen; University of Groningen	Dijkstra, BW (corresponding author), Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA.	B.W.Dijkstra@rug.nl	Thunnissen, Andy-Mark/A-1777-2010; Dijkstra, Bauke W./H-4308-2019	Thunnissen, Andy-Mark/0000-0002-1915-9850; Dijkstra, Bauke W./0000-0001-9731-6586; Poelarends, Gerrit/0000-0002-6917-6368	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065324] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07784] Funding Source: Medline; NIGMS NIH HHS [GM 65324] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2005, BIOCHEMISTRY-US, V44, P14818, DOI 10.1021/bi051383m; Almrud JJ, 2002, BIOCHEMISTRY-US, V41, P12010, DOI 10.1021/bi020271h; Azurmendi HF, 2004, BIOCHEMISTRY-US, V43, P4082, DOI 10.1021/bi030241u; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; de Jong RM, 2004, J BIOL CHEM, V279, P11546, DOI 10.1074/jbc.M311966200; HARAYAMA S, 1989, J BACTERIOL, V171, P6251, DOI 10.1128/jb.171.11.6251-6258.1989; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KJELDGAARD M, 1998, ACTA CRYSTALLOGR D, V54, P1119; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petit Y, 1998, ORG SYNTH, V75, P37; Poelarends GJ, 2004, BIOORG CHEM, V32, P376, DOI 10.1016/j.bioorg.2004.05.006; Poelarends GJ, 2004, BIOCHEMISTRY-US, V43, P7187, DOI 10.1021/bi049823h; Poelarends GJ, 2004, BIOCHEMISTRY-US, V43, P759, DOI 10.1021/bi0355948; Poelarends GJ, 2003, J BIOL CHEM, V278, P48674, DOI 10.1074/jbc.M306706200; Poelarends GJ, 1998, APPL ENVIRON MICROB, V64, P2931; Poelarends GJ, 2001, J BACTERIOL, V183, P4269, DOI 10.1128/JB.183.14.4269-4277.2001; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SPARNINS VL, 1974, J BACTERIOL, V120, P159, DOI 10.1128/JB.120.1.159-167.1974; Subramanya HS, 1996, BIOCHEMISTRY-US, V35, P792, DOI 10.1021/bi951732k; Taylor AB, 1999, BIOCHEMISTRY-US, V38, P7444, DOI 10.1021/bi9904048; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; Wang SC, 2003, BIOCHEMISTRY-US, V42, P8762, DOI 10.1021/bi034598+; Whitman CP, 2002, ARCH BIOCHEM BIOPHYS, V402, P1, DOI 10.1016/S0003-9861(02)00052-8	33	31	31	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2007	282	4					2440	2449		10.1074/jbc.M608134200	http://dx.doi.org/10.1074/jbc.M608134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127NM	17121835	Green Published, hybrid			2022-12-27	WOS:000243593200035
J	Bienert, GP; Moller, ALB; Kristiansen, KA; Schulz, A; Moller, IM; Schjoerring, JK; Jahn, TP				Bienert, Gerd P.; Moller, Anders L. B.; Kristiansen, Kim A.; Schulz, Alexander; Moller, Ian M.; Schjoerring, Jan K.; Jahn, Thomas P.			Specific aquaporins facilitate the diffusion of hydrogen peroxide across membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER CHANNELS AQUAPORINS; REACTIVE OXYGEN; OXIDATIVE STRESS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; H2O2; CELL; TRANSPORT; YEAST; PLANT	The metabolism of aerobic organisms continuously produces reactive oxygen species. Although potentially toxic, these compounds also function in signaling. One important feature of signaling compounds is their ability to move between different compartments, e. g. to cross membranes. Here we present evidence that aquaporins can channel hydrogen peroxide (H2O2). Twenty-four aquaporins from plants and mammals were screened in five yeast strains differing in sensitivity toward oxidative stress. Expression of human AQP8 and plant Arabidopsis TIP1;1 and TIP1; 2 in yeast decreased growth and survival in the presence of H2O2. Further evidence for aquaporin-mediated H2O2 diffusion was obtained by a fluorescence assay with intact yeast cells using an intracellular reactive oxygen species-sensitive fluorescent dye. Application of silver ions (Ag+), which block aquaporin-mediated water diffusion in a fast kinetics swelling assay, also reversed both the aquaporin-dependent growth repression and the H2O2-induced fluorescence. Our results present the first molecular genetic evidence for the diffusion of H2O2 through specific members of the aquaporin family.	Univ Copenhagen, Fac Life Sci, Dept Agr Sci, Plant & Soil Sci Lab, DK-1871 Frederiksberg C, Denmark; Univ Copenhagen, Fac Life Sci, Dept Plant Biol, DK-1871 Frederiksberg C, Denmark	University of Copenhagen; University of Copenhagen	Jahn, TP (corresponding author), Univ Copenhagen, Fac Life Sci, Dept Agr Sci, Plant & Soil Sci Lab, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	tpj@kvl.dk	Schulz, Alexander/A-3357-2013; Schjoerring, Jan K./M-4044-2019; Schjoerring, Jan K./A-5387-2009	Schulz, Alexander/0000-0001-6796-3598; Schjoerring, Jan K./0000-0002-2852-3298; Schjoerring, Jan K./0000-0002-2852-3298; Bienert, Gerd/0000-0001-9345-4666				Amara P, 2001, PROTEIN SCI, V10, P1927, DOI 10.1110/ps.14201; Ampilogova YN, 2006, RUSS J PLANT PHYSL+, V53, P622, DOI 10.1134/S1021443706050050; Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Ardanaz N, 2006, EXP BIOL MED, V231, P237; ARDON M, 1965, OXYGEN, P82; Barrieu F, 1998, PLANT PHYSIOL, V117, P1153, DOI 10.1104/pp.117.4.1153; Beitz E, 2006, P NATL ACAD SCI USA, V103, P269, DOI 10.1073/pnas.0507225103; BERGMEYER HU, 1955, BIOCHEM Z, V327, P255; Bienert GP, 2006, BBA-BIOMEMBRANES, V1758, P994, DOI 10.1016/j.bbamem.2006.02.015; Bonhivers M, 1998, J BIOL CHEM, V273, P27565, DOI 10.1074/jbc.273.42.27565; Branco MR, 2004, J BIOL CHEM, V279, P6501, DOI 10.1074/jbc.M311818200; Bright J, 2006, PLANT J, V45, P113, DOI 10.1111/j.1365-313X.2005.02615.x; Cai H, 2005, CARDIOVASC RES, V68, P26, DOI 10.1016/j.cardiores.2005.06.021; Calamita G, 2005, J BIOL CHEM, V280, P17149, DOI 10.1074/jbc.C400595200; Chelikani P, 2004, CELL MOL LIFE SCI, V61, P192, DOI 10.1007/s00018-003-3206-5; Chelikani P, 2003, J BIOL CHEM, V278, P31290, DOI 10.1074/jbc.M304076200; Couee I, 2006, J EXP BOT, V57, P449, DOI 10.1093/jxb/erj027; Coury LA, 1999, J BACTERIOL, V181, P4437, DOI 10.1128/JB.181.14.4437-4440.1999; Daniels MJ, 1996, PLANT CELL, V8, P587, DOI 10.1105/tpc.8.4.587; Dirmeier R, 2002, J BIOL CHEM, V277, P34773, DOI 10.1074/jbc.M203902200; Fetter K, 2004, PLANT CELL, V16, P215, DOI 10.1105/tpc.017194; Foyer CH, 2003, PHYSIOL PLANTARUM, V119, P355, DOI 10.1034/j.1399-3054.2003.00223.x; Geigenberger P, 2005, J EXP BOT, V56, P1469, DOI 10.1093/jxb/eri178; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Halliwell B, 1999, FREE RADICAL BIO MED, P105, DOI DOI 10.1093/ACPR0F:0S0/9780198717478.003.0005; Henzler T, 2000, J EXP BOT, V51, P2053, DOI 10.1093/jexbot/51.353.2053; Henzler T, 2004, PLANT CELL ENVIRON, V27, P1184, DOI 10.1111/j.1365-3040.2004.01226.x; Hubert JF, 2005, BIOL CELL, V97, P675, DOI 10.1042/BC20040125; Ishibashi K, 1997, BIOCHEM BIOPH RES CO, V237, P714, DOI 10.1006/bbrc.1997.7219; Jahn TP, 2004, FEBS LETT, V574, P31, DOI 10.1016/j.febslet.2004.08.004; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Kozono D, 2003, J BIOL CHEM, V278, P10649, DOI 10.1074/jbc.M212418200; Laize V, 2000, YEAST, V16, P897, DOI 10.1002/1097-0061(200007)16:10<897::AID-YEA583>3.0.CO;2-T; Laize V, 1999, BIOCHEM BIOPH RES CO, V257, P139, DOI 10.1006/bbrc.1999.0425; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Liszkay A, 2004, PLANT PHYSIOL, V136, P3114, DOI 10.1104/pp.104.044784; Liu K, 2006, BIOL CELL, V98, P153, DOI 10.1042/BC20050026; Ma S, 2004, PLANT J, V40, P845, DOI 10.1111/j.1365-313X.2004.02265.x; Makino N, 2004, BBA-GEN SUBJECTS, V1673, P149, DOI 10.1016/j.bbagen.2004.04.011; MATHAI JC, 1994, J BIOL CHEM, V269, P17784; Moller IM, 2001, ANNU REV PLANT PHYS, V52, P561, DOI 10.1146/annurev.arplant.52.1.561; MOLLER IM, 2007, IN PRESS ANN REV PLA; Munhoz DC, 2004, J BIOL CHEM, V279, P35219, DOI 10.1074/jbc.M313773200; Niemietz CM, 2002, FEBS LETT, V531, P443, DOI 10.1016/S0014-5793(02)03581-0; Pelle E, 2005, J INVEST DERMATOL, V124, P793, DOI 10.1111/j.0022-202X.2005.23661.x; Pletjushkina OY, 2006, BIOCHEMISTRY-MOSCOW+, V71, P60, DOI 10.1134/S0006297906010093; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Seaver LC, 2001, J BACTERIOL, V183, P7182, DOI 10.1128/JB.183.24.7182-7189.2001; Shin R, 2004, P NATL ACAD SCI USA, V101, P8827, DOI 10.1073/pnas.0401707101; Sousa-Lopes A, 2004, FEBS LETT, V578, P152, DOI 10.1016/j.febslet.2004.10.090; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; Waghray M, 2005, FASEB J, V19, P854, DOI 10.1096/fj.04-2882fje; Wellner RB, 2000, PFLUG ARCH EUR J PHY, V441, P49, DOI 10.1007/s004240000396; Wong CM, 2002, J BIOL CHEM, V277, P5385, DOI 10.1074/jbc.M106846200; Yang BX, 2006, J BIOL CHEM, V281, P16202, DOI 10.1074/jbc.M601864200; Yang BX, 2005, AM J PHYSIOL-CELL PH, V288, pC1161, DOI 10.1152/ajpcell.00564.2004; Ye Q, 2006, PLANT CELL ENVIRON, V29, P459, DOI 10.1111/j.1365-3040.2005.01423.x; Zardoya R, 2005, BIOL CELL, V97, P397, DOI 10.1042/BC20040134	58	891	924	7	149	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1183	1192		10.1074/jbc.M603761200	http://dx.doi.org/10.1074/jbc.M603761200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17105724	hybrid			2022-12-27	WOS:000243295200044
J	Fujimura, N; Vacik, T; Machon, O; Vlcek, C; Scalabrin, S; Speth, M; Diep, DB; Krauss, S; Kozmik, Z				Fujimura, Naoko; Vacik, Tomas; Machon, Ondrej; Vlcek, Cestmir; Scalabrin, Simone; Speth, Martin; Diep, Dzung Bao; Krauss, Stefan; Kozmik, Zbynek			Wnt-mediated down-regulation of Sp1 target genes by a transcriptional repressor Sp5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; NEGATIVE REGULATOR; GENOMIC STRUCTURE; PROMOTER REGION; BINDING-SITES; RECEPTOR GENE; CYCLIN D1; EXPRESSION; PATHWAY; IDENTIFICATION	Wnt/beta-catenin signaling regulates many processes during vertebrate development. To study transcriptional targets of canonical Wnt signaling, we used the conditional Cre/loxP system in mouse to ectopically activate beta-catenin during central nervous system development. We show that the activation of Wnt/beta-catenin signaling in the embryonic mouse telencephalon results in the up-regulation of Sp5 gene, which encodes a member of the Sp1 transcription factor family. A proximal promoter of Sp5 gene is highly evolutionarily conserved and contains five TCF/LEF binding sites that mediate direct regulation of Sp5 expression by canonical Wnt signaling. We provide evidence that Sp5 works as a transcriptional repressor and has three independent repressor domains, called R1, R2, and R3, respectively. Furthermore, we show that the repression activity of R1 domain is mediated through direct interaction with a transcriptional corepressor mSin3a. Finally, our data strongly suggest that Sp5 has the same DNA binding specificity as Sp1 and represses Sp1 target genes such as p21. We conclude that Sp5 transcription factor mediates the downstream responses to Wnt/beta-catenin signaling by directly repressing Sp1 target genes.	Acad Sci Czech Republic, Inst Mol Genet, Prague 14220 4, Czech Republic; Univ Udine, Dept Math & Comp Sci, I-33100 Udine, Italy; Natl Hosp Norway, Inst Microbiol, N-0349 Oslo, Norway	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of Udine; University of Oslo; National Hospital Norway	Kozmik, Z (corresponding author), Acad Sci Czech Republic, Inst Mol Genet, Videnska 1083, Prague 14220 4, Czech Republic.	kozmik@img.cas.cz	Kozmik, Zbynek/I-8807-2014; Vlcek, Cestmir/I-8820-2014; Diệp, Dzũng/ABG-9262-2020; Vacik, Tomas/G-2355-2017; Kozmik, Zbynek/G-3581-2014; Diep, Dzung B./AAK-1419-2021; Machon, Ondrej/G-3587-2014; Vacik, Tomas/G-3533-2014	Vacik, Tomas/0000-0003-0797-7757; Kozmik, Zbynek/0000-0002-5850-2105; Diep, Dzung/0000-0001-7661-5501; Krauss, Stefan/0000-0001-6992-8091				Ahn J, 2005, BIOCHEM BIOPH RES CO, V338, P1435, DOI 10.1016/j.bbrc.2005.10.107; AINO H, 1995, GENE, V164, P301, DOI 10.1016/0378-1119(95)00391-I; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Avila J, 1998, GENE, V208, P221, DOI 10.1016/S0378-1119(97)00661-6; Backman M, 2005, DEV BIOL, V279, P155, DOI 10.1016/j.ydbio.2004.12.010; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; BELANGER C, 1991, NUCLEIC ACIDS RES, V19, P4341, DOI 10.1093/nar/19.16.4341; Bierie B, 2003, ONCOGENE, V22, P3875, DOI 10.1038/sj.onc.1206426; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bros M, 2003, J IMMUNOL, V171, P1825, DOI 10.4049/jimmunol.171.4.1825; Chen YX, 2006, BIOCHEM BIOPH RES CO, V340, P758, DOI 10.1016/j.bbrc.2005.12.068; Cheng LP, 2004, FEBS LETT, V565, P195, DOI 10.1016/j.febslet.2004.03.097; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Collins M, 1996, NUCLEIC ACIDS RES, V24, P3661, DOI 10.1093/nar/24.19.3661; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Ding W, 2004, AM J PHYSIOL-LUNG C, V287, pL52, DOI 10.1152/ajplung.00430.2003; Ellenrieder V, 2002, EMBO J, V21, P2451, DOI 10.1093/emboj/21.10.2451; Galceran J, 2000, DEVELOPMENT, V127, P469; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harrison SM, 2000, DEV BIOL, V227, P358, DOI 10.1006/dbio.2000.9878; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Imaki H, 2003, CANCER RES, V63, P4607; Iwata Y, 1999, BIOCHEM BIOPH RES CO, V261, P381, DOI 10.1006/bbrc.1999.1037; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Kaczynski J, 2001, J BIOL CHEM, V276, P36749, DOI 10.1074/jbc.M105831200; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kawakami Y, 2004, DEVELOPMENT, V131, P4763, DOI 10.1242/dev.01331; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Klenova EM, 1998, J BIOL CHEM, V273, P26571, DOI 10.1074/jbc.273.41.26571; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Lee SMK, 2000, DEVELOPMENT, V127, P457; Li CG, 2000, BBA-GENE STRUCT EXPR, V1490, P213, DOI 10.1016/S0167-4781(99)00183-9; Li X, 2002, SCIENCE, V297, P1180; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Machon O, 2005, MOL CELL NEUROSCI, V30, P388, DOI 10.1016/j.mcn.2005.08.003; Machon O, 2002, NEUROSCIENCE, V112, P951, DOI 10.1016/S0306-4522(02)00053-2; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; MISKIMINS WK, 1986, J CELL BIOL, V103, P1781, DOI 10.1083/jcb.103.5.1781; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morkel M, 2003, DEVELOPMENT, V130, P6283, DOI 10.1242/dev.00859; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Nakajima T, 2000, J HUM GENET, V45, P212, DOI 10.1007/s100380070029; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Okubo Tadashi, 2004, J Biol, V3, P11, DOI 10.1186/jbiol3; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; Randall J, 1997, AM J PHYSIOL-CELL PH, V273, pC1267, DOI 10.1152/ajpcell.1997.273.4.C1267; Rappa G, 2004, NEUROSCIENCE, V124, P823, DOI 10.1016/j.neuroscience.2003.11.030; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Soccio RE, 2005, J BIOL CHEM, V280, P19410, DOI 10.1074/jbc.M501778200; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Spatuzza C, 2004, J BIOL CHEM, V279, P42535, DOI 10.1074/jbc.M401860200; Takahashi M, 2005, INT J ONCOL, V27, P1483; Tallafuss A, 2001, DEVELOPMENT, V128, P4021; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Treichel D, 2003, GENE DEV, V17, P2630, DOI 10.1101/gad.274103; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van den Bout CJ, 2002, MECH DEVELOP, V110, P179, DOI 10.1016/S0925-4773(01)00597-4; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Weidenfeld J, 2002, J BIOL CHEM, V277, P21061, DOI 10.1074/jbc.M111702200; Weidinger G, 2005, CURR BIOL, V15, P489, DOI 10.1016/j.cub.2005.01.041; WENGER RH, 1993, J BIOL CHEM, V268, P23345; WILGENBUS KK, 1994, GENOMICS, V19, P326, DOI 10.1006/geno.1994.1065; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Ziegler S, 2005, FEBS J, V272, P1600, DOI 10.1111/j.1742-4658.2005.04581.x	77	60	64	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1225	1237		10.1074/jbc.M605851200	http://dx.doi.org/10.1074/jbc.M605851200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17090534	hybrid			2022-12-27	WOS:000243295200048
J	Nurmi, SM; Autero, M; Raunio, AK; Gahmberg, CG; Fagerholm, SC				Nurmi, Susanna M.; Autero, Matti; Raunio, Anna K.; Gahmberg, Carl G.; Fagerholm, Susanna C.			Phosphorylation of the LFA-1 integrin beta 2-chain on Thr-758 leads to adhesion, Rac-1/Cdc42 activation, and stimulation of CD69 expression in human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LEUKOCYTE ADHESION; CYTOPLASMIC DOMAIN; CYTOSKELETAL REGULATION; AVIDITY REGULATION; TYROSINE KINASE; IN-VIVO; LYMPHOCYTES; CD18; AFFINITY	Phosphorylation of the leukocyte function-associated antigen-1 (LFA-1) integrin beta 2-chain on Thr-758 occurs after T cell receptor stimulation and leads to 14-3-3 recruitment to the integrin, actin cytoskeleton reorganization, and increased adhesion. Here, we have investigated the signaling effects of beta 2 integrin Thr-758 phosphorylation. A penetratin-coupled phospho-Thr-758-beta 2 peptide (mimicking the part of the integrin beta-chain surrounding Thr-758) stimulated adhesion of human T cells to the LFA-1 ligand intercellular adhesion molecule-1 (ICAM-1). Additionally, the peptide activated the small GTPases Rac-1 and Cdc42 in T cells. Constitutively active forms of Rac-1 and Cdc42, but not Rho, could compensate for the reduction of cell adhesion to ICAM-1 caused by the T758A mutation in the beta 2 integrin. Additionally, the active GTPases salvaged the cell-spreading defect of T758A integrin-transfected cells on coated ICAM-1. A dominant negative form of Cdc42, on the other hand, significantly reduced wild-type beta 2 integrin-mediated cell adhesion and spreading. In a T cell stimulation system, the pThr-758 penetratin peptide acted in a similar manner to coated ICAM-1 to increase T cell receptor-induced CD69 expression. These results show that Thr-758-phosphorylated LFA-1 is upstream of Rac-1/Cdc42, cell adhesion, and costimulatory activation of human T cells, thus identifying phosphorylation of Thr-758 in beta 2 as a proximal element in LFA-1 signaling.	Univ Helsinki, Div Biochem, Fac Biosci, FIN-00014 Helsinki, Finland	University of Helsinki	Fagerholm, SC (corresponding author), Univ Helsinki, Div Biochem, Fac Biosci, FIN-00014 Helsinki, Finland.	susanna.fagerholm@helsinki.fi	Gahmberg, Carl/AAE-1876-2019; Raunio, Anna/G-6919-2018	Raunio, Anna/0000-0003-0356-7048; Gahmberg, Carl/0000-0001-9892-9296; Fagerholm, Susanna Carola/0000-0002-0354-8763				Bialkowska K, 2003, J BIOL CHEM, V278, P33342, DOI 10.1074/jbc.M301217200; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Cairo CW, 2006, IMMUNITY, V25, P297, DOI 10.1016/j.immuni.2006.06.012; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Fagerholm S, 2002, J BIOL CHEM, V277, P1728, DOI 10.1074/jbc.M106856200; Fagerholm S, 2002, EUR J IMMUNOL, V32, P1670, DOI 10.1002/1521-4141(200206)32:6<1670::AID-IMMU1670>3.0.CO;2-M; Fagerholm SC, 2005, J CELL BIOL, V171, P705, DOI 10.1083/jcb.200504016; Fagerholm SC, 2004, TRENDS BIOCHEM SCI, V29, P504, DOI 10.1016/j.tibs.2004.07.005; Fagerholm SC, 2001, FEBS LETT, V491, P131, DOI 10.1016/S0014-5793(01)02182-2; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; Geginat J, 1999, J IMMUNOL, V162, P5085; HARLOW E, 1988, ANTIBODIES LABORATOR, P82; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; Hilden TJ, 2003, J IMMUNOL, V170, P4170, DOI 10.4049/jimmunol.170.8.4170; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Kotovuori A, 1999, J IMMUNOL, V162, P6613; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; Ni HT, 1999, J IMMUNOL, V162, P5183; NORTAMO P, 1988, SCAND J IMMUNOL, V28, P537, DOI 10.1111/j.1365-3083.1988.tb01485.x; Perez OD, 2003, NAT IMMUNOL, V4, P1083, DOI 10.1038/ni984; Rodriguez-Fernandez JL, 2001, J BIOL CHEM, V276, P40518, DOI 10.1074/jbc.M102896200; Sanchez-Martin L, 2004, J BIOL CHEM, V279, P16194, DOI 10.1074/jbc.M400905200; Sims TN, 2002, IMMUNOL REV, V186, P100, DOI 10.1034/j.1600-065X.2002.18610.x; Smith A, 2005, J CELL BIOL, V170, P141, DOI 10.1083/jcb.200412032; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Valmu L, 1999, BIOCHEM J, V339, P119, DOI 10.1042/0264-6021:3390119; Valmu L, 1999, EUR J IMMUNOL, V29, P2107, DOI 10.1002/(SICI)1521-4141(199907)29:07<2107::AID-IMMU2107>3.0.CO;2-T; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Vartiainen M, 2000, MOL CELL BIOL, V20, P1772, DOI 10.1128/MCB.20.5.1772-1783.2000; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Wiedemann AS, 2006, J CELL BIOL, V172, P1069, DOI 10.1083/jcb.200508075	38	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					968	975		10.1074/jbc.M608524200	http://dx.doi.org/10.1074/jbc.M608524200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17107954	hybrid			2022-12-27	WOS:000243295200019
J	Wang, HS; Gong, B; Vadakkan, KI; Toyoda, H; Kaang, BK; Zhuo, M				Wang, Hansen; Gong, Bo; Vadakkan, Kunjumon I.; Toyoda, Hiroki; Kaang, Bong-Kiun; Zhuo, Min			Genetic evidence for adenylyl cyclase 1 as a target for preventing neuronal excitotoxicity mediated by N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ADENYLYL CYCLASES; LONG-TERM-POTENTIATION; CEREBELLAR GRANULE NEURONS; ELEMENT-BINDING PROTEIN; CELL-DEATH; BEHAVIORAL SENSITIZATION; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; CORTICAL-NEURONS; NITRIC-OXIDE	The excessive activation of N-methyl-D-aspartate (NMDA) receptors by glutamate results in neuronal excitotoxicity. cAMP is a key second messenger and contributes to NMDA receptor-dependent synaptic plasticity. Adenylyl cyclases 1 (AC1) and 8 (AC8) are the two major calcium-stimulated ACs in the central nervous system. Previous studies demonstrate AC1 and AC8 play important roles in synaptic plasticity, memory, and persistent pain. However, little is known about the possible roles of these two ACs in glutamate-induced neuronal excitotoxicity. Here, we report that genetic deletion of AC1 significantly attenuated neuronal death induced by glutamate in primary cultures of cortical neurons, whereas AC8 deletion did not produce a significant effect. AC1, but not AC8, contributes to intracellular cAMP production following NMDA receptor activation by glutamate in cultured cortical neurons. AC1 is involved in the dynamic modulation of cAMP-response element-binding protein activity in neuronal excitotoxicity. To explore the possible roles of AC1 in cell death in vivo, we studied neuronal excitotoxicity induced by an intracortical injection of NMDA. Cortical lesions induced by NMDA were significantly reduced in AC1 but not in AC8 knock-out mice. Our findings provide direct evidence that AC1 plays an important role in neuronal excitotoxicity and may serve as a therapeutic target for preventing excitotoxicity in stroke and neurodegenerative diseases.	Univ Toronto, Fac Med, Dept Physiol, Toronto, ON M5S 1A8, Canada; Seoul Natl Univ, Coll Nat Sci, Dept Biol Sci, Seoul 151742, South Korea	University of Toronto; Seoul National University (SNU)	Zhuo, M (corresponding author), Univ Toronto, Fac Med, Dept Physiol, 1 Kings Coll Circle,Med Sci Bldg,Rm 3342, Toronto, ON M5S 1A8, Canada.	min.zhuo@utoronto.ca	Vadakkan, Kunjumon/A-3254-2008; Zhuo, Min/A-2072-2008; Gong, Bo/E-6820-2011; wang, hansen/I-2510-2019	Vadakkan, Kunjumon/0000-0002-2721-6931; Zhuo, Min/0000-0001-9062-3241; Gong, Bo/0000-0001-6028-1818; wang, hansen/0000-0003-4414-3372; Toyoda, Hiroki/0000-0002-9907-7176	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042722] Funding Source: NIH RePORTER; NINDS NIH HHS [NS42722] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Auberson YP, 2002, BIOORG MED CHEM LETT, V12, P1099, DOI 10.1016/S0960-894X(02)00074-4; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Baker LP, 1998, J BIOL CHEM, V273, P17469, DOI 10.1074/jbc.273.28.17469; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Beck J, 2003, J NEUROSCI, V23, P5061; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; HAHN JS, 1988, P NATL ACAD SCI USA, V85, P6556, DOI 10.1073/pnas.85.17.6556; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Jiang XY, 2005, J NEUROCHEM, V94, P713, DOI 10.1111/j.1471-4159.2005.03200.x; Leavitt BR, 2006, J NEUROCHEM, V96, P1121, DOI 10.1111/j.1471-4159.2005.03605.x; Lee B, 2005, J NEUROSCI, V25, P1137, DOI 10.1523/JNEUROSCI.4288-04.2005; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; Li WM, 2005, J BIOL CHEM, V280, P18179, DOI 10.1074/jbc.M411085200; Liauw J, 2005, J NEUROPHYSIOL, V94, P878, DOI 10.1152/jn.01205.2004; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Maas JW, 2005, J NEUROSCI, V25, P4118, DOI 10.1523/JNEUROSCI.4273-04.2005; Maas JW, 2005, J NEUROSCI, V25, P2376, DOI 10.1523/JNEUROSCI.4940-04.2005; Mabuchi T, 2001, J NEUROSCI, V21, P9204, DOI 10.1523/JNEUROSCI.21-23-09204.2001; MacDonald JF, 2006, TRENDS NEUROSCI, V29, P75, DOI 10.1016/j.tins.2005.12.001; Massey PV, 2004, J NEUROSCI, V24, P7821, DOI 10.1523/JNEUROSCI.1697-04.2004; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Nielsen MD, 1996, J BIOL CHEM, V271, P33308, DOI 10.1074/jbc.271.52.33308; Perez-Garcia G, 2006, BEHAV BRAIN RES, V169, P83, DOI 10.1016/j.bbr.2005.12.013; Perez-Garcia GS, 2005, BEHAV BRAIN RES, V163, P136, DOI 10.1016/j.bbr.2005.04.014; Petegnief V, 2003, J BIOL CHEM, V278, P29552, DOI 10.1074/jbc.M300661200; Poser S, 2003, J NEUROSCI, V23, P4420; Riccio A, 2002, NAT NEUROSCI, V5, P389, DOI 10.1038/nn0502-389; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Sunahara Roger K, 2002, Mol Interv, V2, P168, DOI 10.1124/mi.2.3.168; Toyoda H, 2005, EUR J NEUROSCI, V22, P485, DOI 10.1111/j.1460-9568.2005.04236.x; VILLACRES EC, 1995, J BIOL CHEM, V270, P14352, DOI 10.1074/jbc.270.24.14352; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Wang HB, 2003, MOL PHARMACOL, V63, P463, DOI 10.1124/mol.63.3.463; Wang YS, 2004, J BIOL CHEM, V279, P41267, DOI 10.1074/jbc.C400199200; Wei F, 2006, J NEUROSCI, V26, P851, DOI 10.1523/JNEUROSCI.3292-05.2006; Wei F, 2002, NEURON, V36, P713, DOI 10.1016/S0896-6273(02)01019-X; Wong ST, 1999, NEURON, V23, P787, DOI 10.1016/S0896-6273(01)80036-2; Wu LJ, 2005, J NEUROSCI, V25, P11107, DOI 10.1523/JNEUROSCI.1678-05.2005; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3; Yu SP, 2000, P NATL ACAD SCI USA, V97, P9360, DOI 10.1073/pnas.97.17.9360; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3; Zhang YM, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-13; Zhao MG, 2005, NEURON, V47, P859, DOI 10.1016/j.neuron.2005.08.014; Zhuang SY, 2005, NEUROPHARMACOLOGY, V48, P1086, DOI 10.1016/j.neuropharm.2005.01.005; Zipfel GJ, 1999, NEW ENGL J MED, V341, P1543, DOI 10.1056/NEJM199911113412011	63	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1507	1517		10.1074/jbc.M607291200	http://dx.doi.org/10.1074/jbc.M607291200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17121841	hybrid			2022-12-27	WOS:000243295200075
J	Zhao, YQ; Gaidarov, I; Keen, JH				Zhao, Yanqiu; Gaidarov, Ibragim; Keen, James H.			Phosphoinositide 3-kinase C2 alpha links clathrin to microtubule-dependent movement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II PHOSPHOINOSITIDE 3-KINASE; TRANS-GOLGI NETWORK; MEDIATED ENDOCYTOSIS; EARLY ENDOSOMES; COATED PITS; IN-VIVO; MEMBRANE TRAFFICKING; ORGANELLE TRANSPORT; ACTIN CYTOSKELETON; ALPHA-ISOFORM	Phosphoinositide 3-kinase C2 alpha(PI3K-C2 alpha) is a type II PI-3-kinase that has been implicated in several important membrane transport and signaling processes. We previously found that overexpression of PI3K-C2 alpha inhibits clathrin-mediated membrane trafficking and induces proliferation of novel clathrin-coated structures within the cytoplasm. Using fluorescently tagged fusions of PI3K-C2 alpha and clathrin, we explored the behavior of these structures in intact cells. Both proteins are present in the structures, and using rapid image acquisition and fluorescence photoactivation probes, we find that they exhibit localized, rapid mobility (5-20 mu m/s). The movement is microtubule-based as revealed by use of inhibitors, and PI3K-C2 alpha accumulates on microtubules rapidly and reversibly following cytoplasmic acidification, which also blocks movement. Dynactin mediates the movement of these clathrin-PI3K-C2 alpha structures, since disruption of dynactin function by overexpression of its p50 subunit also inhibits movement. Finally, immunoprecipitation experiments reveal an interaction between endogenous PI3K-C2 alpha and dynactin subunits. Together, these results reveal a molecular linkage between PI3K-C2 alpha and the microtubule motor machinery, with implications for membrane trafficking in intact cells.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Keen, JH (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Biochem & Mol Biol, 233 S 10th St,BLSB 915, Philadelphia, PA 19107 USA.	jim.keen@mail.jci.tju.edu			NIGMS NIH HHS [GM-49217] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049217] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1977, NATURE, V270, P695, DOI 10.1038/270695a0; ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Denarier E, 1998, P NATL ACAD SCI USA, V95, P6055, DOI 10.1073/pnas.95.11.6055; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Eckley DM, 1999, J CELL BIOL, V147, P307, DOI 10.1083/jcb.147.2.307; Edeling MA, 2006, NAT REV MOL CELL BIO, V7, P32, DOI 10.1038/nrm1786; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Enns CA, 2001, TRAFFIC, V2, P167, DOI 10.1034/j.1600-0854.2001.020303.x; Gaidarov I, 2005, J BIOL CHEM, V280, P40766, DOI 10.1074/jbc.M507731200; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; HAMMALVAREZ SF, 1994, P NATL ACAD SCI USA, V91, P7812, DOI 10.1073/pnas.91.16.7812; Haucke V, 2005, BIOCHEM SOC T, V33, P1285, DOI 10.1042/BST0331285; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; Hughes AC, 2004, MOL BRAIN RES, V128, P182, DOI 10.1016/j.molbrainres.2004.06.016; Hussain NK, 2003, J BIOL CHEM, V278, P28823, DOI 10.1074/jbc.M300995200; Kaksonen M, 2005, CELL, V123, P305, DOI 10.1016/j.cell.2005.09.024; Keyel PA, 2004, J BIOL CHEM, V279, P13190, DOI 10.1074/jbc.M312717200; King SJ, 2003, MOL BIOL CELL, V14, P5089, DOI 10.1091/mbc.E03-01-0025; Ktori C, 2003, BIOCHEM BIOPH RES CO, V306, P139, DOI 10.1016/S0006-291X(03)00933-1; Kural C, 2005, SCIENCE, V308, P1469, DOI 10.1126/science.1108408; Lakadamyali M, 2006, CELL, V124, P997, DOI 10.1016/j.cell.2005.12.038; Luby-Phelps K, 2000, INT REV CYTOL, V192, P189; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 2005, CELL, V121, P593, DOI 10.1016/j.cell.2005.03.015; Meunier FA, 2005, MOL BIOL CELL, V16, P4841, DOI 10.1091/mbc.E05-02-0171; Newpher TM, 2005, DEV CELL, V9, P87, DOI 10.1016/j.devcel.2005.04.014; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Orzech E, 2001, J BIOL CHEM, V276, P31340, DOI 10.1074/jbc.M101054200; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; PFEFFER SR, 1983, J CELL BIOL, V97, P40, DOI 10.1083/jcb.97.1.40; Puertollano R, 2003, MOL BIOL CELL, V14, P1545, DOI 10.1091/mbc.02-07-0109; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Rappoport JZ, 2003, TRAFFIC, V4, P460, DOI 10.1034/j.1600-0854.2003.00100.x; Reilein A, 2005, J CELL BIOL, V171, P845, DOI 10.1083/jcb.200505071; Roth MG, 2006, NAT REV MOL CELL BIO, V7, P63, DOI 10.1038/nrm1783; Royle SJ, 2005, NATURE, V434, P1152, DOI 10.1038/nature03502; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Seetharam RN, 2005, CELL MOTIL CYTOSKEL, V60, P96, DOI 10.1002/cm.20048; So CW, 2000, LEUKEMIA, V14, P594, DOI 10.1038/sj.leu.2401692; Sonee M, 1998, AM J PHYSIOL-CELL PH, V275, pC1630, DOI 10.1152/ajpcell.1998.275.6.C1630; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Subtil A, 1997, J CELL SCI, V110, P2441; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Vonderheit A, 2005, PLOS BIOL, V3, P1225, DOI 10.1371/journal.pbio.0030233; Warner AK, 2006, TRAFFIC, V7, P205, DOI 10.1111/j.1600-0854.2005.00377.x; Yarar D, 2005, MOL BIOL CELL, V16, P964, DOI 10.1091/mbc.e04-09-0774; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947	55	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1249	1256		10.1074/jbc.M606998200	http://dx.doi.org/10.1074/jbc.M606998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17110375	hybrid			2022-12-27	WOS:000243295200050
J	Engel, PL; Kobayashi, T; Biesiadecki, B; Davis, J; Tikunova, S; Wu, S; Solaro, RJ				Engel, Patti L.; Kobayashi, Tornoyoshi; Biesiadecki, Brandon; Davis, Jonathan; Tikunova, Svetlana; Wu, Steven; Solaro, R. John			Identification of a region of troponin I important in signaling cross-bridge-dependent activation of cardiac myofilaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NH2-TERMINAL VARIABLE REGION; CA2+ SENSITIVITY; SARCOPLASMIC-RETICULUM; LENGTH DEPENDENCE; CALCIUM-BINDING; THIN-FILAMENTS; MUSCLE; EXPRESSION; PHOSPHORYLATION; LEVOSIMENDAN	Force generating strong cross-bridges are required to fully activate cardiac thin filaments, but the molecular signaling mechanism remains unclear. Evidence demonstrating differential extents of cross-bridge-dependent activation of force, especially at acidic pH, in myofilaments in which slow skeletal troponin I (ssTnI) replaced cardiac TnI (cTnI) indicates the significance of a His in ssTnI that is an homologous Ala in cTnI. We compared cross-bridge-dependent activation in myofilaments regulated by cTnI, ssTnI, cTnI(A66H), or ssTnI(H34A). A drop from pH 7.0 to 6.5 induced enhanced cross-bridge-dependent activation in cTnI myofilaments, but depressed activation in cTrLI(A66H) myofilaments. This same drop in pH depressed cross-bridge-dependent activation in both ssTnI myofilaments and ssTnI(H34A) myofilaments. Compared with controls, cTnI(A66H) myofilaments were desensitized to Ca2+, whereas there was no difference in the Ca2+-force relationship between ssTnI and ssTnI(H34A) myofilaments. The mutations in cTnI and ssTnI did not affect Ca2+ dissociation rates from cTnC at pH 7.0 or 6.5. However, at pH 6.5, cTnI(A66H) had lower affinity for cTnT than cTnI. We also probed cross-bridge-dependent activation in myofilaments regulated by cTnI(Q56A). Myofilaments containing cTnI(Q56A) demonstrated cross-bridge-dependent activation that was similar to controls containing cTnI at pH 7.0 and an enhanced cross-bridge-dependent activation at pH 6.5. We conclude that a localized N-terminal region of TnI comprised of amino acids 33-80, which interacts with C-terminal regions of cTnC and cTnT, is of particular significance in transducing signaling of thin filament activation by strong cross-bridges.	Univ Illinois, Coll Med, Dept Physiol & Biophys, Cardiovasc Res Ctr, Chicago, IL 60612 USA; Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University System of Ohio; Ohio State University	Solaro, RJ (corresponding author), 909 S Wolcott Ave, Chicago, IL 60612 USA.	solarorj@uic.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062426, T32HL007692, R37HL022231] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL 07692, R37 HL 22231, P01 HL 62426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arteaga GM, 2005, AM J PHYSIOL-HEART C, V289, pH2183, DOI 10.1152/ajpheart.00520.2005; Arteaga GM, 2000, J PHYSIOL-LONDON, V526, P541, DOI 10.1111/j.1469-7793.2000.t01-1-00541.x; Biesiadecki BJ, 2004, J BIOL CHEM, V279, P13825, DOI 10.1074/jbc.M314225200; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; Burkart EM, 2003, J BIOL CHEM, V278, P11265, DOI 10.1074/jbc.M210712200; Butters CA, 1997, J BIOL CHEM, V272, P13196, DOI 10.1074/jbc.272.20.13196; Campbell K, 1997, BIOPHYS J, V72, P254, DOI 10.1016/S0006-3495(97)78664-8; Chandra M, 1999, J MOL CELL CARDIOL, V31, P867, DOI 10.1006/jmcc.1999.0928; Dargis R, 2002, J BIOL CHEM, V277, P34662, DOI 10.1074/jbc.C200419200; EDES I, 1995, CIRC RES, V77, P107, DOI 10.1161/01.RES.77.1.107; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; Ferrieres G, 2000, FEBS LETT, V479, P99, DOI 10.1016/S0014-5793(00)01881-0; Gasmi-Seabrook GMC, 1999, BIOCHEMISTRY-US, V38, P8313, DOI 10.1021/bi9902642; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; GODT RE, 1982, J GEN PHYSIOL, V80, P279, DOI 10.1085/jgp.80.2.279; Gomes AV, 2004, J BIOL CHEM, V279, P49579, DOI 10.1074/jbc.M407340200; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GUO XD, 1994, J BIOL CHEM, V269, P15210; Kass DA, 2006, CIRCULATION, V113, P305, DOI 10.1161/CIRCULATIONAHA.105.542407; Ke YB, 2004, CIRC RES, V94, P194, DOI 10.1161/01.RES.0000111522.02730.56; Kobayashi T, 2005, ANNU REV PHYSIOL, V67, P39, DOI 10.1146/annurev.physiol.67.040403.114025; Kobayashi T, 2005, J MOL CELL CARDIOL, V38, P213, DOI 10.1016/j.yjmcc.2004.10.014; Layland J, 2005, CARDIOVASC RES, V66, P12, DOI 10.1016/j.cardiores.2004.12.022; Layland J, 2005, FASEB J, V19, P1137, DOI 10.1096/fj.04-2519fje; MacGowan GA, 2001, AM J PHYSIOL-HEART C, V280, pH835, DOI 10.1152/ajpheart.2001.280.2.H835; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; Morimoto S, 2001, BIOCHEM BIOPH RES CO, V282, P811, DOI 10.1006/bbrc.2001.4647; Moss RL, 2004, CIRC RES, V94, P1290, DOI 10.1161/01.RES.0000127125.61647.4F; MOSS RL, 1991, J PHYSIOL-LONDON, V440, P273, DOI 10.1113/jphysiol.1991.sp018708; Mukhopadhyay S, 2005, J BIOL CHEM, V280, P538, DOI 10.1074/jbc.M409537200; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; Ogut O, 1996, BIOCHEMISTRY-US, V35, P16581, DOI 10.1021/bi961712y; PAN BS, 1987, J BIOL CHEM, V262, P7839; Papp Z, 2002, J PHYSIOL-LONDON, V543, P177, DOI 10.1113/jphysiol.2002.022145; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; Perry SV, 2001, J MUSCLE RES CELL M, V22, P5, DOI 10.1023/A:1010303732441; SHINER JS, 1982, P NATL ACAD SCI-BIOL, V79, P4637, DOI 10.1073/pnas.79.15.4637; Solaro RJ, 2002, HDB PHYSL 2, P264; Sorsa T, 2004, MOL CELL BIOCHEM, V266, P87, DOI 10.1023/B:MCBI.0000049141.37823.19; Sorsa T, 2004, EUR J PHARMACOL, V486, P1, DOI 10.1016/j.ejphar.2003.12.006; Sumandea MP, 2003, J BIOL CHEM, V278, P35135, DOI 10.1074/jbc.M306325200; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; Swartz DR, 1999, AM J PHYSIOL-HEART C, V276, pH1460, DOI 10.1152/ajpheart.1999.276.5.H1460; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Urboniene D, 2005, CIRC RES, V97, P70, DOI 10.1161/01.RES.0000173849.68636.1e; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; Wang J, 1998, BIOCHEMISTRY-US, V37, P14519, DOI 10.1021/bi9812322; WANG YP, 1995, J MOL CELL CARDIOL, V27, P1235, DOI 10.1016/S0022-2828(05)82385-5; Westfall MV, 1997, P NATL ACAD SCI USA, V94, P5444, DOI 10.1073/pnas.94.10.5444; WOLFF MR, 1995, CIRC RES, V76, P154, DOI 10.1161/01.RES.76.1.154; Wolska BM, 1999, CIRC RES, V84, P745; Wolska BM, 2001, J PHYSIOL-LONDON, V536, P863, DOI 10.1111/j.1469-7793.2001.00863.x	54	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					183	193		10.1074/jbc.M512337200	http://dx.doi.org/10.1074/jbc.M512337200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17099250	hybrid			2022-12-27	WOS:000243166500022
